{"id": "batch_req_5ZY18VThUWurpxjbzBSNJdKQ", "custom_id": "1_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "09d715bd3bbaaaf5d54dfb5569657408", "body": {"id": "chatcmpl-9St51YPQ1ScEjOopZ7VprYUVmKpKE", "object": "chat.completion", "created": 1716671939, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abemaciclib is an important medication in the treatment of certain types of cancer, particularly hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Here are some key points you should know about Abemaciclib:\n\n### Mechanism of Action\n- **CDK4/6 Inhibitor**: Abemaciclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). These kinases are involved in cell cycle regulation, and their inhibition can lead to reduced proliferation of cancer cells.\n\n### Indications\n- **Breast Cancer**: It is primarily used in combination with endocrine therapy (such as an aromatase inhibitor or fulvestrant) for the treatment of HR+, HER2- advanced or metastatic breast cancer. It can also be used as monotherapy in certain cases where patients have progressed on prior endocrine therapy and chemotherapy.\n\n### Administration\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_gR7ok7iIA2JHG5mn9vw0fDEf", "custom_id": "2_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9f6c5af237b47cee7eb0cc9743f58533", "body": {"id": "chatcmpl-9St533kyVIg8YDxpRYQ9Myruwi9yU", "object": "chat.completion", "created": 1716671941, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abiraterone acetate is a medication used primarily in the treatment of prostate cancer. Here are some key points you should know about it:\n\n### Indications:\n- **Prostate Cancer**: Abiraterone is used in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC).\n\n### Mechanism of Action:\n- **Androgen Biosynthesis Inhibitor**: Abiraterone works by inhibiting CYP17A1, an enzyme critical for androgen production. This reduces androgen levels, which can help slow the growth of prostate cancer cells that rely on these hormones.\n\n### Administration:\n- **Oral Medication**: Abiraterone is taken orally, typically once daily.\n- **Fasting Requirement**: It should be taken on an empty stomach, at least one hour before or two hours after a meal, as food can significantly increase its absorption and potentially lead to increased side"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_vBg7KAVI3VLTc3h2oKpXciov", "custom_id": "3_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "5c78f54bd9418b70f52fe0b48f2dec12", "body": {"id": "chatcmpl-9St53zgWsI7Gf3QCr5pLr9bWChR6j", "object": "chat.completion", "created": 1716671941, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Acalabrutinib is a medication used primarily in the treatment of certain types of blood cancers. Here are some key points you should know about it:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL)**: Acalabrutinib is approved for the treatment of adult patients with CLL.\n2. **Mantle Cell Lymphoma (MCL)**: It is also approved for the treatment of adult patients with MCL who have received at least one prior therapy.\n\n### Mechanism of Action:\n- **Bruton Tyrosine Kinase (BTK) Inhibitor**: Acalabrutinib works by inhibiting BTK, a protein that plays a crucial role in the survival and proliferation of B-cells. By inhibiting BTK, acalabrutinib helps to reduce the growth and survival of malignant B-cells.\n\n### Administration:\n- **Oral Medication**: Acalabrutinib is taken orally,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_lteShv2ovMuLsTyUgSVH5GAh", "custom_id": "4_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c7e64928ad84fdcb4519a182d7f16a8b", "body": {"id": "chatcmpl-9St555ZA4qUGHlvNsnPsxAQO1FqJb", "object": "chat.completion", "created": 1716671943, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aclarubicin, also known as aclacinomycin A, is an anthracycline antibiotic used primarily in the treatment of certain types of cancer, particularly hematologic malignancies such as acute myeloid leukemia (AML). Here are some key points you should know about Aclarubicin:\n\n### Mechanism of Action\n- **DNA Intercalation**: Aclarubicin intercalates into DNA, disrupting the function of topoisomerase II, an enzyme crucial for DNA replication and transcription.\n- **Inhibition of RNA Synthesis**: It also inhibits RNA synthesis, which can lead to apoptosis (programmed cell death) in rapidly dividing cancer cells.\n\n### Indications\n- **Acute Myeloid Leukemia (AML)**: Aclarubicin is often used in combination with other chemotherapeutic agents for the treatment of AML.\n- **Other Hematologic Malignancies**: It may also be used in other types of leukemia and lymphomas,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_sctoQrpqLQscgEx7PFGQk5aD", "custom_id": "5_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "54a2cd21cb519563414e4b99dbec3b45", "body": {"id": "chatcmpl-9St5AYlWJTh6PTzVK313BYIdRxwjO", "object": "chat.completion", "created": 1716671948, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab emtansine, also known as T-DM1 and marketed under the brand name Kadcyla, is an antibody-drug conjugate used in the treatment of HER2-positive breast cancer. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Antibody Component (Trastuzumab)**: Targets the HER2 receptor, a protein overexpressed in some breast cancers, and inhibits its signaling pathways. It also mediates antibody-dependent cellular cytotoxicity (ADCC).\n- **Cytotoxic Component (DM1)**: A derivative of maytansine, a potent microtubule inhibitor, which disrupts cell division and induces cell death. DM1 is linked to trastuzumab via a stable linker, allowing targeted delivery to HER2-positive cells.\n\n### Indications\n- **Metastatic Breast Cancer**: Approved for patients with HER2-positive metastatic breast cancer who have previously received trastuzumab and a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_A4vwRcDsLoBgIzslbartrjHU", "custom_id": "6_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3428a483879e8c53ee2a74060422d436", "body": {"id": "chatcmpl-9St5AAnjb3n8qqbVBtAqe712stvgQ", "object": "chat.completion", "created": 1716671948, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Afatinib is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about Afatinib as a physician:\n\n### Mechanism of Action\n- **Tyrosine Kinase Inhibitor (TKI):** Afatinib is an irreversible inhibitor of the ErbB family of tyrosine kinases, which includes EGFR (epidermal growth factor receptor), HER2, and HER4. By inhibiting these receptors, Afatinib disrupts signaling pathways that promote cancer cell proliferation and survival.\n\n### Indications\n- **NSCLC:** Afatinib is approved for the first-line treatment of patients with metastatic NSCLC whose tumors have non-resistant EGFR mutations. It is also used in patients with squamous cell carcinoma of the lung who have progressed after platinum-based chemotherapy.\n\n### Administration\n- **Oral Medication:** Afatinib is administered orally, typically once daily. It should be taken on"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_rqqKveOdVdeBJbNJFWPJ6CmA", "custom_id": "7_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3122da1825c8724287b87fc892f48ad4", "body": {"id": "chatcmpl-9St5BMR4npFieDQLvTWKsjnIXH3YR", "object": "chat.completion", "created": 1716671949, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aldesleukin, also known by its brand name Proleukin, is a recombinant form of interleukin-2 (IL-2), a cytokine that plays a crucial role in the activation and proliferation of T-cells, which are essential for the immune response. Here are some key points you should know about Aldesleukin:\n\n### Indications\n- **Metastatic Renal Cell Carcinoma (RCC):** Aldesleukin is primarily used for the treatment of metastatic RCC.\n- **Metastatic Melanoma:** It is also approved for the treatment of metastatic melanoma.\n\n### Mechanism of Action\n- **Immune Activation:** Aldesleukin stimulates the growth and activity of T-cells and natural killer (NK) cells, enhancing the body's immune response against cancer cells.\n\n### Administration\n- **Route:** It is administered intravenously.\n- **Dosing Schedule:** The dosing regimen can be complex and typically involves multiple cycles of treatment with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_gl1hhj9mWhlERc8FtpzHA9QP", "custom_id": "8_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a9fd98f7f3cbe89acb190960aa7635a2", "body": {"id": "chatcmpl-9St5FkObgFmxKdaNl3C4fbSAIokYr", "object": "chat.completion", "created": 1716671953, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alectinib is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK) mutations. Here are some key points you should know about Alectinib:\n\n### Mechanism of Action\n- **ALK Inhibitor**: Alectinib is a tyrosine kinase inhibitor that specifically targets and inhibits the activity of the ALK protein, which can drive cancer cell growth in certain types of NSCLC.\n\n### Indications\n- **NSCLC**: It is indicated for the treatment of patients with ALK-positive metastatic NSCLC. It is often used in cases where the cancer has progressed despite other treatments or as a first-line therapy.\n\n### Administration\n- **Oral Medication**: Alectinib is administered orally, typically in capsule form.\n- **Dosage**: The standard dosage is 600 mg taken twice daily with food.\n\n### Efficacy\n- **Clinical Trials**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_8Pcwkh5qwMBMTLL0xyb0rq1g", "custom_id": "9_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e0520cba2450a4556c42474031e7e158", "body": {"id": "chatcmpl-9St5FrAbisCXHGGXs5FW5imxfWii0", "object": "chat.completion", "created": 1716671953, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alemtuzumab is a monoclonal antibody used primarily in the treatment of certain types of cancers and autoimmune diseases. Here are some key points you should know about Alemtuzumab:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL):** Alemtuzumab is approved for the treatment of B-cell chronic lymphocytic leukemia.\n2. **Multiple Sclerosis (MS):** It is also used in the treatment of relapsing forms of multiple sclerosis, typically in patients who have had an inadequate response to two or more other medications.\n\n### Mechanism of Action:\n- Alemtuzumab targets CD52, a protein present on the surface of mature lymphocytes. By binding to CD52, Alemtuzumab induces antibody-dependent cell-mediated cytolysis, leading to the depletion of these lymphocytes.\n\n### Administration:\n- **Route:** It is administered via intravenous infusion.\n- **Dosing:** The dosing regimen can vary depending on the condition"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_h4YEbQZTi8cvOhyMi4X7KgVb", "custom_id": "10_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "bc377e84d872e09da93c8bb7b57ea1fd", "body": {"id": "chatcmpl-9St5JwoIgWGrGwU33AiwjCwDR5RXy", "object": "chat.completion", "created": 1716671957, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "All-trans retinoic acid (ATRA), also known as tretinoin, is a derivative of vitamin A and is used in various medical treatments. Here are some key points you should know about ATRA:\n\n### Clinical Uses:\n1. **Acute Promyelocytic Leukemia (APL):**\n   - ATRA is a cornerstone in the treatment of APL, a subtype of acute myeloid leukemia. It induces differentiation of the immature leukemic cells into mature blood cells.\n   - It is often used in combination with other chemotherapeutic agents like arsenic trioxide or anthracyclines.\n\n2. **Dermatology:**\n   - ATRA is widely used in the treatment of acne vulgaris. It helps to reduce the formation of comedones and promotes the turnover of epithelial cells.\n   - It is also used in the treatment of photoaging and hyperpigmentation disorders.\n\n### Mechanism of Action:\n- ATRA binds to nuclear receptors (retino"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_WkBi5vowoebtUj4Bh3hZBP9t", "custom_id": "11_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "fe1a5fde2c13d959f9d5a3e122ea9980", "body": {"id": "chatcmpl-9St5LwzVq1TiPpuQAk9lVvZhcYYSI", "object": "chat.completion", "created": 1716671959, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Altretamine, also known by its brand name Hexalen, is an antineoplastic agent used primarily in the treatment of ovarian cancer. Here are some key points you should know about Altretamine:\n\n### Indications:\n- **Ovarian Cancer**: Altretamine is typically used for the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy.\n\n### Mechanism of Action:\n- **Cytotoxic Agent**: Altretamine is an alkylating agent that interferes with the function of DNA and RNA, leading to cell death. The exact mechanism is not fully understood, but it is believed to involve the formation of covalent bonds with DNA, causing cross-linking and strand breakage.\n\n### Administration:\n- **Oral Medication**: Altretamine is administered orally, usually in capsule form.\n- **Dosage**: The typical dosage is 260 mg/m\u00b2/day, divided into four doses, for 14 or 21 consecutive days"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_uEXdbzNRwKYaZP0WNawZlnvH", "custom_id": "12_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "952ac1028c7b45d96863443fa277b29f", "body": {"id": "chatcmpl-9St5LjxQKzkBnjawEXCyscG7NPqkp", "object": "chat.completion", "created": 1716671959, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aminoglutethimide is a medication that has been used primarily as an adrenocortical steroid synthesis inhibitor. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Inhibition of Steroid Synthesis**: Aminoglutethimide inhibits the enzyme aromatase, which is involved in the conversion of androgens to estrogens. It also inhibits the enzyme P450scc (cholesterol side-chain cleavage enzyme), which is crucial for the synthesis of all steroid hormones.\n- **Reduction of Cortisol Production**: By inhibiting these enzymes, aminoglutethimide reduces the production of cortisol, aldosterone, and sex steroids.\n\n### Indications\n- **Cushing's Syndrome**: It has been used to treat Cushing's syndrome by reducing cortisol production.\n- **Breast Cancer**: Historically, it was used in the treatment of hormone-sensitive breast cancer to reduce estrogen levels, although it has largely"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_jcgsnP0I8TR2EuIY9LrPiOnx", "custom_id": "13_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d3fe9b1ea1d163ae981e2b22b6351115", "body": {"id": "chatcmpl-9St5OwhA9XF8kHPuI6NazWMSTJt1U", "object": "chat.completion", "created": 1716671962, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amrubicin is an anthracycline derivative used primarily in the treatment of small cell lung cancer (SCLC) and other types of lung cancer. Here are some key points you should know about Amrubicin:\n\n### Mechanism of Action\n- **Topoisomerase II Inhibition**: Amrubicin works by inhibiting topoisomerase II, an enzyme crucial for DNA replication and repair. This leads to DNA strand breaks and ultimately cell death.\n- **Anthracycline Class**: As an anthracycline, it shares some properties with other drugs in this class, such as doxorubicin, but has a different toxicity profile.\n\n### Indications\n- **Small Cell Lung Cancer (SCLC)**: Amrubicin is primarily used for the treatment of SCLC, particularly in patients who have relapsed or are refractory to first-line chemotherapy.\n- **Non-Small Cell Lung Cancer (NSCLC)**: It has also been studied for use in NS"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_SvHMLKrsV2E5fxEMPLVhG2A1", "custom_id": "14_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b4aa43bee8cac027b167305fc8c0cd9f", "body": {"id": "chatcmpl-9St5iVElS32iB9brw8Pi4n03kf6lB", "object": "chat.completion", "created": 1716671982, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amsacrine is an antineoplastic agent used primarily in the treatment of certain types of cancer, particularly acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Here are some key points you should know about Amsacrine:\n\n### Mechanism of Action\n- **DNA Intercalation**: Amsacrine intercalates into DNA, disrupting the DNA structure and inhibiting the synthesis of DNA and RNA.\n- **Topoisomerase II Inhibition**: It also inhibits topoisomerase II, an enzyme crucial for DNA replication and repair, leading to DNA strand breaks and apoptosis in rapidly dividing cells.\n\n### Indications\n- **Acute Lymphoblastic Leukemia (ALL)**: Often used in combination with other chemotherapeutic agents.\n- **Acute Myeloid Leukemia (AML)**: Used in induction and consolidation therapy.\n\n### Administration\n- **Intravenous (IV) Infusion**: Amsacrine"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_XPKjQ3Fciyg55NoyQvrkJ0bm", "custom_id": "15_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d8471dd1584c7f8b539ed13e72eb2a5c", "body": {"id": "chatcmpl-9St5kRbMtXwQa4XMbPWm3lw0x9b0m", "object": "chat.completion", "created": 1716671984, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Anastrozole is a medication primarily used in the treatment of breast cancer. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Aromatase Inhibitor**: Anastrozole works by inhibiting the enzyme aromatase, which is involved in the synthesis of estrogen. By reducing estrogen levels, it helps to slow or stop the growth of estrogen receptor-positive breast cancer cells.\n\n### Indications\n- **Breast Cancer**: It is commonly prescribed for postmenopausal women with hormone receptor-positive breast cancer, either as adjuvant therapy (after surgery) or for metastatic disease.\n- **Prevention**: It may also be used in high-risk postmenopausal women to reduce the risk of developing breast cancer.\n\n### Dosage and Administration\n- **Standard Dose**: The typical dose is 1 mg taken orally once daily.\n- **Duration**: Treatment duration can vary but often continues for 5 years or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_0OYXnUGRaaUQyfjVI2qeIq2A", "custom_id": "16_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6c8a010711c23af46a406cd5944a9251", "body": {"id": "chatcmpl-9St5ntmaQzMnDbF4VZICeFpnCSSXy", "object": "chat.completion", "created": 1716671987, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Apalutamide is an androgen receptor inhibitor used primarily in the treatment of prostate cancer. Here are some key points you should know about Apalutamide:\n\n### Indications:\n1. **Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC):** Apalutamide is approved for use in patients with nmCRPC.\n2. **Metastatic Castration-Sensitive Prostate Cancer (mCSPC):** It is also indicated for patients with mCSPC.\n\n### Mechanism of Action:\n- Apalutamide works by binding to androgen receptors and inhibiting the action of androgens (male hormones), which can stimulate the growth of prostate cancer cells.\n\n### Dosage and Administration:\n- The typical dosage is 240 mg (four 60 mg tablets) taken orally once daily.\n- It can be taken with or without food.\n- Patients should continue androgen deprivation therapy (ADT) during treatment.\n\n### Side Effects:\nCommon side"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_IQiGkrNolvKolfgGWdHA8mGt", "custom_id": "17_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "66c58f8c2dd3e57e2f6e05458edbe5e4", "body": {"id": "chatcmpl-9St5tju1nKgKrR5TuN575Gwf2Mo4W", "object": "chat.completion", "created": 1716671993, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Apatinib is a tyrosine kinase inhibitor that specifically targets the vascular endothelial growth factor receptor-2 (VEGFR-2). It is primarily used in the treatment of certain types of cancer, particularly advanced or metastatic gastric cancer. Here are some key points you should know about Apatinib:\n\n### Mechanism of Action\n- **VEGFR-2 Inhibition**: Apatinib inhibits VEGFR-2, which plays a crucial role in tumor angiogenesis. By blocking this receptor, Apatinib reduces the blood supply to the tumor, thereby inhibiting its growth.\n\n### Indications\n- **Gastric Cancer**: Apatinib is mainly indicated for the treatment of advanced or metastatic gastric cancer, especially in patients who have failed to respond to standard chemotherapy.\n- **Other Cancers**: Research is ongoing to evaluate its efficacy in other types of cancers, such as non-small cell lung cancer, colorectal cancer, and hepatocellular carcinoma.\n\n### Dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_TfzIV2xx9fqJIkNY5geVqVDv", "custom_id": "18_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6ff8d282f366ad67c0512651c94db1be", "body": {"id": "chatcmpl-9St5wGtZCBYaVCYc3jhA9ff1blCVR", "object": "chat.completion", "created": 1716671996, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Arsenic trioxide (As2O3) is a chemotherapeutic agent primarily used in the treatment of acute promyelocytic leukemia (APL). Here are some key points you should know about it:\n\n### Indications:\n- **Acute Promyelocytic Leukemia (APL):** Arsenic trioxide is particularly effective in patients with APL, especially those who have relapsed or are refractory to other treatments like all-trans retinoic acid (ATRA) and anthracyclines.\n\n### Mechanism of Action:\n- **Induces Apoptosis:** Arsenic trioxide induces apoptosis in malignant cells.\n- **Promotes Differentiation:** It promotes the differentiation of promyelocytes into mature granulocytes.\n- **Inhibits Angiogenesis:** It has anti-angiogenic properties, which can help in reducing tumor growth.\n\n### Administration:\n- **Intravenous Infusion:** Arsenic trioxide is administered as an intravenous infusion. The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_84Vh7YanTJ5XS7Aums5BjaZd", "custom_id": "19_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b81066bd1ccc535802b5ab303771073d", "body": {"id": "chatcmpl-9St60tcdM9HS3VmDZ3DXqJvgX32JE", "object": "chat.completion", "created": 1716672000, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asparaginase is an enzyme used primarily in the treatment of acute lymphoblastic leukemia (ALL). Here are some key points you should know about Asparaginase:\n\n### Mechanism of Action\n- **Enzyme Function**: Asparaginase catalyzes the hydrolysis of asparagine to aspartic acid and ammonia.\n- **Cancer Cell Impact**: Many cancer cells, particularly lymphoblasts in ALL, are unable to synthesize asparagine due to low levels of asparagine synthetase. Asparaginase depletes extracellular asparagine, leading to inhibition of protein synthesis and apoptosis in these cells.\n\n### Indications\n- **Primary Use**: Asparaginase is primarily used in combination chemotherapy regimens for the treatment of acute lymphoblastic leukemia (ALL).\n- **Other Uses**: It may also be used in some cases of non-Hodgkin lymphoma.\n\n### Forms and Administration\n- **Types**: There are"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_dTVLQjyP4P0QkUr4er1Oe4ln", "custom_id": "20_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "75874363d20df978a5497b0f9cbe62f8", "body": {"id": "chatcmpl-9St605pQw18rKF1BnzkEJAnXlybLU", "object": "chat.completion", "created": 1716672000, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asparaginase Erwinia chrysanthemi, also known as Erwinia asparaginase, is an enzyme used primarily in the treatment of acute lymphoblastic leukemia (ALL). Here are some key points you should know about it:\n\n### Indications:\n- **Acute Lymphoblastic Leukemia (ALL):** It is used as part of a multi-agent chemotherapeutic regimen for patients with ALL, particularly those who have developed hypersensitivity to E. coli-derived asparaginase products.\n\n### Mechanism of Action:\n- **Enzyme Activity:** Asparaginase Erwinia chrysanthemi works by hydrolyzing asparagine, an amino acid necessary for the growth of leukemic cells. By depleting asparagine, it inhibits protein synthesis in these cells, leading to cell death.\n\n### Administration:\n- **Route:** It is typically administered intramuscularly (IM) or intravenously (IV).\n- **Dosage:** The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ptaF0Nls5oUC21n0YYCz371z", "custom_id": "21_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "4bc66734c8a6d041bf27c61bc8810fc7", "body": {"id": "chatcmpl-9St6AJVuvhbvOZzz9dVjgKL6uIJmC", "object": "chat.completion", "created": 1716672010, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Atezolizumab is a monoclonal antibody used in cancer immunotherapy. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **PD-L1 Inhibition**: Atezolizumab targets and binds to the programmed death-ligand 1 (PD-L1) on tumor cells and tumor-infiltrating immune cells. By blocking PD-L1, it prevents the interaction with PD-1 and B7.1 receptors on T cells, thereby enhancing T-cell activation and proliferation, which helps the immune system to attack cancer cells.\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC)**: Used as a first-line treatment in combination with other agents or as a monotherapy in certain cases.\n- **Small Cell Lung Cancer (SCLC)**: Approved for use in combination with chemotherapy.\n- **Urothelial Carcinoma**: Used for locally advanced or metastatic urothelial carcinoma.\n- **Triple"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ZQDm8hnKmFvWowvRSmeCZhJD", "custom_id": "22_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "304014518486d61048223ba2bcfe8e24", "body": {"id": "chatcmpl-9St6KUzGtHwQJJq9VPq12xacjis9S", "object": "chat.completion", "created": 1716672020, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Avelumab is a human monoclonal antibody used in cancer immunotherapy. Here are some key points you should know about Avelumab:\n\n### Mechanism of Action\n- **PD-L1 Inhibition**: Avelumab targets and inhibits the programmed death-ligand 1 (PD-L1). By blocking PD-L1, Avelumab helps restore the immune system's ability to recognize and attack cancer cells.\n\n### Indications\n- **Merkel Cell Carcinoma (MCC)**: Avelumab is approved for the treatment of metastatic Merkel cell carcinoma.\n- **Urothelial Carcinoma**: It is also approved for the treatment of locally advanced or metastatic urothelial carcinoma in patients who have disease progression during or following platinum-containing chemotherapy.\n- **Renal Cell Carcinoma (RCC)**: Avelumab, in combination with axitinib, is approved for the first-line treatment of advanced renal cell carcinoma.\n\n### Administration\n- **Intr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ryw1CTAH7PxTSFv6iaafp0fA", "custom_id": "23_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "53515b92bd500d870c6753823d24fccd", "body": {"id": "chatcmpl-9St6UsoANdBQ4QNOdkSkv5b6ifvio", "object": "chat.completion", "created": 1716672030, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Axicabtagene ciloleucel, marketed under the brand name Yescarta, is a type of chimeric antigen receptor (CAR) T-cell therapy. It is used in the treatment of certain types of non-Hodgkin lymphoma (NHL), specifically relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Here are some key points you should know about this therapy:\n\n### Mechanism of Action\n- **CAR T-Cell Therapy**: Axicabtagene ciloleucel involves modifying a patient's own T cells to express a chimeric antigen receptor (CAR) that targets the CD19 antigen found on the surface of B cells, including malignant B cells.\n- **Targeting CD19**: The modified T cells are then infused back into the patient, where they seek out and destroy CD19-expressing cells.\n\n### Indications\n- **FDA Approval**: It is approved for the treatment of adult patients with rel"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_jhDfJc83Qs7A2ADXm8T8XPlQ", "custom_id": "24_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "43aba08693cad0f8c3cde8d33d9b078e", "body": {"id": "chatcmpl-9St6VPJIpRou2oii8xWwFw3YZMDuu", "object": "chat.completion", "created": 1716672031, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Axitinib is a tyrosine kinase inhibitor (TKI) that is primarily used in the treatment of advanced renal cell carcinoma (RCC). Here are some key points you should know about Axitinib:\n\n### Mechanism of Action\n- **Target**: Axitinib selectively inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), which play a crucial role in tumor angiogenesis.\n- **Effect**: By inhibiting these receptors, Axitinib reduces the blood supply to the tumor, thereby inhibiting its growth.\n\n### Indications\n- **Primary Use**: Axitinib is approved for the treatment of advanced renal cell carcinoma, particularly in patients who have received prior systemic therapy.\n\n### Dosage and Administration\n- **Starting Dose**: The typical starting dose is 5 mg taken orally twice daily.\n- **Adjustments**: Dose adjustments may be necessary based on individual tolerance and side effects. The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_pwqPEisYFO2qxfXgcgARECH3", "custom_id": "25_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c86c324eb1974e0b2727f51cd2377190", "body": {"id": "chatcmpl-9St6XDnS79wRWFeyBphTbdPIf3lGG", "object": "chat.completion", "created": 1716672033, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azacitidine is a chemotherapeutic agent used primarily in the treatment of myelodysplastic syndromes (MDS), a group of bone marrow disorders. Here are some key points you should know about Azacitidine:\n\n### Mechanism of Action\n- **Hypomethylating Agent**: Azacitidine is a nucleoside analog of cytidine. It incorporates into DNA and RNA, inhibiting DNA methyltransferase, leading to hypomethylation of DNA. This can reactivate tumor suppressor genes and induce cellular differentiation and apoptosis.\n- **Cytotoxic Effects**: It also has direct cytotoxic effects on abnormal hematopoietic cells in the bone marrow.\n\n### Indications\n- **Myelodysplastic Syndromes (MDS)**: Approved for the treatment of various subtypes of MDS, including refractory anemia, chronic myelomonocytic leukemia (CMMoL), and others.\n- **Acute Myeloid Leukemia (AML)**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_j1hRrpGHl0aYxZ5vJRnrqNN9", "custom_id": "26_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2e390c3eb8dca89f7fbf2c539aa4d885", "body": {"id": "chatcmpl-9St6eOk49z0GxZys9Kc3R0j4qa4PZ", "object": "chat.completion", "created": 1716672040, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bacillus Calmette-Gu\u00e9rin (BCG) is a live attenuated strain of Mycobacterium bovis, primarily used as a vaccine against tuberculosis (TB). Here are some key points you should know about BCG as a physician:\n\n### 1. **Indications and Usage:**\n   - **Tuberculosis Prevention:** BCG is primarily used to prevent tuberculosis, especially in countries with a high prevalence of TB. It is most effective in preventing severe forms of TB in children, such as miliary TB and TB meningitis.\n   - **Bladder Cancer Treatment:** BCG is also used as an intravesical therapy for non-muscle invasive bladder cancer. It helps to stimulate the immune system to attack cancer cells.\n\n### 2. **Administration:**\n   - **Vaccine:** The BCG vaccine is usually administered intradermally, typically in the upper arm. It is often given to newborns or young children in countries where TB is common"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_gSktu18UvplizOe9WyUVsMNW", "custom_id": "27_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "398705f5906d1e3d1ef41c6a9c0dac68", "body": {"id": "chatcmpl-9St6gDQLxn7dq3t8NijQupAfVguKT", "object": "chat.completion", "created": 1716672042, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bavituximab is a monoclonal antibody that has been investigated for its potential use in cancer therapy. Here are some key points you should know about Bavituximab:\n\n1. **Mechanism of Action**: Bavituximab targets phosphatidylserine (PS), a phospholipid that is normally located on the inner leaflet of the cell membrane but becomes exposed on the outer leaflet in tumor blood vessels and on the surface of tumor cells. By binding to PS, Bavituximab is thought to help the immune system recognize and attack tumor cells.\n\n2. **Therapeutic Use**: Bavituximab has been primarily studied in the context of oncology, particularly for its potential to treat various types of cancer, including non-small cell lung cancer (NSCLC), breast cancer, and hepatocellular carcinoma. It has been evaluated both as a monotherapy and in combination with other treatments such as chemotherapy and radiation therapy.\n\n3. **Clinical Trials"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_jmvxaSKweTBiLdJxq6Fg0W7h", "custom_id": "28_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "5b228bd45b53fb56e40c075d18db3494", "body": {"id": "chatcmpl-9St6gxvBN4OLTuaC0xLFZqwWNrDTz", "object": "chat.completion", "created": 1716672042, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belinostat is a histone deacetylase (HDAC) inhibitor used in the treatment of certain types of cancer. Here are some key points you should know about Belinostat:\n\n### Indications:\n- **Peripheral T-cell Lymphoma (PTCL):** Belinostat is primarily approved for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).\n\n### Mechanism of Action:\n- **HDAC Inhibition:** Belinostat inhibits histone deacetylases, leading to an accumulation of acetylated histones and proteins. This results in altered gene expression, cell cycle arrest, and apoptosis of cancer cells.\n\n### Administration:\n- **Intravenous Infusion:** Belinostat is administered as an intravenous infusion, typically over 30 minutes.\n- **Dosing Schedule:** The standard dosing regimen is 1,000 mg/m\u00b2 once daily on days 1-5 of a 21-day cycle.\n\n### Side Effects:\n- **Common Ad"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_P2cFS3NqQJ2YHLR16OLMWlOX", "custom_id": "29_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "70a5a62d80c7323e0c5a2a2e35679205", "body": {"id": "chatcmpl-9St6kcDYRLWDvPWOBZFnidpm6xUtd", "object": "chat.completion", "created": 1716672046, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belotecan is a chemotherapeutic agent that belongs to the class of topoisomerase I inhibitors. It is a semi-synthetic derivative of camptothecin, a natural alkaloid extracted from the Chinese tree Camptotheca acuminata. Here are some key points you should know about Belotecan:\n\n### Mechanism of Action\n- **Topoisomerase I Inhibition**: Belotecan works by inhibiting the enzyme topoisomerase I, which is essential for DNA replication. By stabilizing the DNA-topoisomerase I complex, it prevents the relegation of single-strand breaks, leading to DNA damage and cell death.\n\n### Indications\n- **Cancer Treatment**: Belotecan is primarily used in the treatment of various cancers, including small cell lung cancer (SCLC) and ovarian cancer. Its use may be considered in other malignancies as well, depending on clinical trials and emerging evidence.\n\n### Administration\n- **Intravenous"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_P2ROcyFheGCQNvILCivya5Kt", "custom_id": "30_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "dd59ea3c8bf6ed4911ef1e92c69420e3", "body": {"id": "chatcmpl-9St6nUFlUNUntpr4J19AzYgKRnpUq", "object": "chat.completion", "created": 1716672049, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bendamustine is a chemotherapy medication used primarily in the treatment of certain types of cancer, including chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL). Here are some key points you should know about Bendamustine:\n\n### Mechanism of Action\n- **Alkylating Agent**: Bendamustine is an alkylating agent that works by causing cross-linking of DNA strands, leading to cell death. It has a unique mechanism that combines properties of both alkylating agents and purine analogs.\n\n### Indications\n- **Chronic Lymphocytic Leukemia (CLL)**: Approved for the treatment of CLL.\n- **Non-Hodgkin's Lymphoma (NHL)**: Specifically indicated for indolent B-cell NHL that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.\n\n### Administration\n- **Intravenous"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_LLIPYRKNsV0PHCme6lWfM56I", "custom_id": "31_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3ec2842b77b0ef1eac915d1df0a314cd", "body": {"id": "chatcmpl-9St6m16MtyUfuoFMf8D1mv1IkLTVd", "object": "chat.completion", "created": 1716672048, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bevacizumab, marketed under the brand name Avastin, is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A). Here are some key points you should know about Bevacizumab:\n\n### Mechanism of Action\n- **VEGF Inhibition**: Bevacizumab binds to VEGF-A, preventing it from interacting with its receptors (VEGFR-1 and VEGFR-2) on the surface of endothelial cells. This inhibition reduces angiogenesis (the formation of new blood vessels), which is crucial for tumor growth and metastasis.\n\n### Indications\n- **Cancer Treatment**: Bevacizumab is used in the treatment of various cancers, including:\n  - Metastatic colorectal cancer\n  - Non-small cell lung cancer (NSCLC)\n  - Glioblastoma\n  - Metastatic renal cell carcinoma\n  - Cervical cancer\n  - Ovarian cancer\n- **Ophthalmology**: Off-label"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_GBv9l1Lx5J0vHsT0k0oqGZWC", "custom_id": "32_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a4c924ba29716c13e28852bea40fb0ac", "body": {"id": "chatcmpl-9St6nhuwTML1wsnn0xyjMz4sYXgao", "object": "chat.completion", "created": 1716672049, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bexarotene is a synthetic retinoid that selectively activates retinoid X receptors (RXRs). It is primarily used in the treatment of cutaneous T-cell lymphoma (CTCL), particularly in patients who are refractory to at least one prior systemic therapy. Here are some key points you should know about Bexarotene:\n\n### Mechanism of Action\n- **RXR Activation**: Bexarotene binds to and activates RXRs, which are nuclear receptors that regulate gene expression. This activation influences cell differentiation, proliferation, and apoptosis.\n\n### Indications\n- **Cutaneous T-cell Lymphoma (CTCL)**: Approved for the treatment of CTCL in patients who have not responded to at least one prior systemic therapy.\n\n### Administration\n- **Oral Formulation**: Bexarotene is available in capsule form and is taken orally.\n- **Topical Formulation**: There is also a gel formulation for topical application in localized CTCL"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_8Scoz3fygvS4HLC0owCpyuom", "custom_id": "33_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c90af863baff2a2c0624d64e21623b3d", "body": {"id": "chatcmpl-9St6oFhLHlLoKqox40d0iRr16Jkj0", "object": "chat.completion", "created": 1716672050, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bicalutamide is a non-steroidal anti-androgen medication primarily used in the treatment of prostate cancer. Here are some key points you should know about Bicalutamide:\n\n### Mechanism of Action\n- **Anti-Androgen**: Bicalutamide works by binding to androgen receptors, thereby inhibiting the action of androgens (male hormones) like testosterone. This helps to slow the growth of androgen-dependent prostate cancer cells.\n\n### Indications\n- **Prostate Cancer**: It is commonly used in combination with a luteinizing hormone-releasing hormone (LHRH) analog or surgical castration for the treatment of advanced prostate cancer.\n- **Monotherapy**: In some cases, it may be used as monotherapy for patients with locally advanced prostate cancer.\n\n### Dosage\n- **Standard Dose**: The typical dose is 50 mg once daily, but this can vary based on the specific clinical scenario and patient response.\n- **Administration**: It is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_vhpB1ARrKiDi3ufGFq4Gy4EH", "custom_id": "34_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6efc127eb707b09ab0a33aedf2a18b17", "body": {"id": "chatcmpl-9St6ogbWx852tDxIm4fFxfFu2QiCx", "object": "chat.completion", "created": 1716672050, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Binimetinib is a medication used in the treatment of certain types of cancer. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Binimetinib** is a MEK inhibitor. It specifically targets and inhibits the activity of MEK1 and MEK2, which are part of the MAPK/ERK pathway. This pathway is often dysregulated in various cancers, leading to uncontrolled cell proliferation.\n\n### Indications\n- **Melanoma**: Binimetinib is commonly used in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.\n- **Other Cancers**: Research is ongoing to evaluate its efficacy in other cancers with similar pathway dysregulations.\n\n### Administration\n- **Dosage**: The typical dosage is 45 mg taken orally twice daily. However, the exact dosage may vary based on specific patient factors and combination"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_0pGGQAsbmjNY23iG8Uo9rhPY", "custom_id": "35_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "511bd2bdd9fc07de8c8b9a993a5350d3", "body": {"id": "chatcmpl-9St6rV1E4dbmbSygraDO4UHDurwS5", "object": "chat.completion", "created": 1716672053, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bleomycin is an antineoplastic antibiotic used primarily in the treatment of various cancers, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer, ovarian cancer, and certain types of head and neck cancers. Here are some key points you should know about Bleomycin:\n\n### Mechanism of Action\n- **DNA Interaction**: Bleomycin binds to DNA and causes strand breaks, leading to inhibition of DNA synthesis and cell death. It generates free radicals that damage the DNA.\n\n### Administration\n- **Routes**: It can be administered intravenously, intramuscularly, subcutaneously, or intrapleurally.\n- **Dosing**: The dosage varies depending on the type of cancer being treated, the patient's body surface area, and the specific treatment protocol.\n\n### Pharmacokinetics\n- **Metabolism**: Bleomycin is metabolized by the enzyme bleomycin hydrolase, which is present in various tissues but is notably"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_eoxv4GjCV1R9DTcK3E9Auhu4", "custom_id": "36_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "417b1112e93887053a8b50c0533da78a", "body": {"id": "chatcmpl-9St6tkFU7Frgw3bVtYpfPs6DHMjRZ", "object": "chat.completion", "created": 1716672055, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blinatumomab is a bispecific T-cell engager (BiTE) antibody construct used in the treatment of certain types of blood cancers, specifically B-cell precursor acute lymphoblastic leukemia (ALL). Here are some key points you should know about Blinatumomab:\n\n### Mechanism of Action\n- **Bispecific Antibody**: Blinatumomab is designed to bind to both CD19, a protein expressed on the surface of B-cell leukemia cells, and CD3, a protein on T-cells. This dual binding brings T-cells into close proximity with the cancer cells, facilitating the T-cells' ability to recognize and kill the cancer cells.\n\n### Indications\n- **Acute Lymphoblastic Leukemia (ALL)**: Blinatumomab is primarily indicated for the treatment of adults and children with B-cell precursor ALL that is in relapse or refractory.\n- **Minimal Residual Disease (MRD)**: It is also used in patients with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_sAzuGJ18rZSVAOgUXGj0Y1TU", "custom_id": "37_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9c0d2f03c1c64634e134df1862ff7104", "body": {"id": "chatcmpl-9St6uF6HIWgGZA0Booa7pqYd3jxXr", "object": "chat.completion", "created": 1716672056, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bortezomib is a proteasome inhibitor used primarily in the treatment of multiple myeloma and mantle cell lymphoma. Here are some key points you should know about Bortezomib:\n\n### Mechanism of Action\n- **Proteasome Inhibition**: Bortezomib inhibits the 26S proteasome, a complex responsible for degrading ubiquitinated proteins. This inhibition leads to an accumulation of proteins within the cell, causing cell cycle arrest and apoptosis, particularly in cancer cells.\n\n### Indications\n- **Multiple Myeloma**: Bortezomib is often used in combination with other agents such as dexamethasone, lenalidomide, or melphalan.\n- **Mantle Cell Lymphoma**: It is used for patients who have received at least one prior therapy.\n\n### Administration\n- **Routes**: Bortezomib can be administered intravenously (IV) or subcutaneously (SC). The sub"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_SxO5x2BIynPk9U1OKNXbtPju", "custom_id": "38_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "27c8516dc16ad4cd95aa298c0419a502", "body": {"id": "chatcmpl-9St6xWSKR35RDFFaYUJXbDhPdmFC7", "object": "chat.completion", "created": 1716672059, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bosutinib is a tyrosine kinase inhibitor (TKI) used primarily in the treatment of chronic myeloid leukemia (CML). Here are some key points you should know about Bosutinib:\n\n### Indications:\n- **Chronic Myeloid Leukemia (CML):** Bosutinib is indicated for the treatment of adult patients with newly diagnosed chronic phase CML and for those with chronic, accelerated, or blast phase CML with resistance or intolerance to prior therapy.\n\n### Mechanism of Action:\n- **Tyrosine Kinase Inhibition:** Bosutinib inhibits the BCR-ABL kinase, which is produced by the Philadelphia chromosome abnormality in CML. It also inhibits other kinases such as SRC family kinases, which may contribute to its efficacy.\n\n### Dosage and Administration:\n- **Starting Dose:** The typical starting dose is 400 mg once daily for newly diagnosed chronic phase CML and 500 mg once daily for patients with resistance or intolerance to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_bX1RYW5yzuHCEKW0tby5mIj3", "custom_id": "39_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a054f8f0db5aeb07c472abaf6b884e9f", "body": {"id": "chatcmpl-9St6xu1l7dARaOGKgstJG9CoKG25N", "object": "chat.completion", "created": 1716672059, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brentuximab vedotin is an antibody-drug conjugate (ADC) used primarily in the treatment of certain types of lymphoma. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Antibody Component**: Brentuximab vedotin consists of a chimeric monoclonal antibody (brentuximab) that targets CD30, a protein expressed on the surface of certain lymphoma cells.\n- **Drug Component**: It is conjugated to a cytotoxic agent, monomethyl auristatin E (MMAE), which disrupts microtubules and induces cell cycle arrest and apoptosis.\n- **Internalization and Release**: Upon binding to CD30, the ADC is internalized by the cancer cell, and MMAE is released, leading to cell death.\n\n### Indications\n- **Classical Hodgkin Lymphoma (cHL)**: For patients who have relapsed or are refractory after autologous"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ApvLxl8XMBF2Mh4lEAJAXNVr", "custom_id": "40_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "19d31398cda251f372781b90da97c5e3", "body": {"id": "chatcmpl-9St72kq746zM1GEquXebNtdhU28cA", "object": "chat.completion", "created": 1716672064, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brigatinib is a targeted cancer therapy used primarily in the treatment of non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK) mutations. Here are some key points you should know about Brigatinib:\n\n### Mechanism of Action\n- **ALK Inhibition**: Brigatinib is a tyrosine kinase inhibitor that targets ALK, a protein involved in the growth and spread of cancer cells. By inhibiting ALK, Brigatinib can help to slow or stop the progression of cancer.\n- **Additional Targets**: Brigatinib also inhibits other kinases, including ROS1, FLT3, and IGF-1R, which may contribute to its efficacy.\n\n### Indications\n- **ALK-Positive NSCLC**: Brigatinib is approved for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib, another ALK inhibitor.\n\n### Dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_62UYrYkjPRaBoe0zNHzqOGRS", "custom_id": "41_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "75c52bfca0268c546aeaf0cfd33e4d66", "body": {"id": "chatcmpl-9St771CTfJHv3K4Q9colfPEvoxrn1", "object": "chat.completion", "created": 1716672069, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Busulfan is an alkylating agent used primarily in the treatment of chronic myelogenous leukemia (CML) and as a conditioning regimen prior to hematopoietic stem cell transplantation (HSCT). Here are some key points you should know about Busulfan:\n\n### Mechanism of Action\n- **Alkylating Agent**: Busulfan works by cross-linking DNA strands, which inhibits DNA replication and RNA transcription, leading to cell death. It is particularly effective against rapidly dividing cells.\n\n### Indications\n- **Chronic Myelogenous Leukemia (CML)**: Busulfan is used in the treatment of CML, particularly in patients who are not candidates for other treatments.\n- **Conditioning Regimen for HSCT**: It is used in combination with other chemotherapeutic agents to prepare patients for bone marrow or stem cell transplantation.\n\n### Administration\n- **Oral and Intravenous Forms**: Busulfan can be administered orally or intraven"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_HG0wZRLGMFKoH84olyYpgpBF", "custom_id": "42_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "533ddac9d833de4d8d440ddcdca59da7", "body": {"id": "chatcmpl-9St77nnvhOUf1Iq1fbshUSNuiXkHR", "object": "chat.completion", "created": 1716672069, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cabazitaxel is a chemotherapy medication used primarily in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Here are some key points you should know about Cabazitaxel:\n\n### Mechanism of Action\n- **Taxane Class**: Cabazitaxel is a member of the taxane class of drugs. It works by inhibiting microtubule depolymerization, which disrupts cell division and leads to cell death.\n- **Overcoming Resistance**: It is particularly noted for its ability to overcome resistance to other taxanes like docetaxel, making it useful in patients who have progressed despite prior chemotherapy.\n\n### Indications\n- **mCRPC**: Cabazitaxel is approved for use in patients with metastatic castration-resistant prostate cancer who have previously been treated with a docetaxel-containing regimen.\n\n### Administration\n- **Intravenous Infusion**: It is administered as an intravenous infusion, typically every three weeks.\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_17vYAQzuorYbNMD0lbEDA7ib", "custom_id": "43_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "75122ac00a8003feac0459b7d172b875", "body": {"id": "chatcmpl-9St78Yk03dTkgVoeYb407j2OHIJjM", "object": "chat.completion", "created": 1716672070, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cabozantinib is a tyrosine kinase inhibitor used primarily in the treatment of certain types of cancer. Here are some key points you should know about it:\n\n### Indications:\n1. **Renal Cell Carcinoma (RCC):** Cabozantinib is approved for the treatment of advanced renal cell carcinoma.\n2. **Hepatocellular Carcinoma (HCC):** It is also indicated for patients with hepatocellular carcinoma who have been previously treated with sorafenib.\n3. **Medullary Thyroid Cancer (MTC):** Cabozantinib is used for the treatment of progressive, metastatic medullary thyroid cancer.\n\n### Mechanism of Action:\n- Cabozantinib inhibits multiple tyrosine kinases, including MET, VEGFR, and AXL, which are involved in tumor growth, angiogenesis, and metastatic progression.\n\n### Administration:\n- It is available in oral tablet form and should be taken on an empty stomach (at"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_GURpepKwe0hvPYcrcB3Hm7i0", "custom_id": "44_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f032abee126865dde8f7b58838bf1c4b", "body": {"id": "chatcmpl-9St79pIM7sYz7WGEgmgd6nh8zmpEW", "object": "chat.completion", "created": 1716672071, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Calaspargase pegol-mknl (brand name: Asparlas) is an asparagine-specific enzyme used in the treatment of acute lymphoblastic leukemia (ALL). Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Enzyme Activity**: Calaspargase pegol is a modified form of L-asparaginase, an enzyme that depletes asparagine, an amino acid essential for the survival and proliferation of leukemic cells. By breaking down asparagine, it starves the leukemia cells, which rely on external sources of this amino acid.\n\n### Indications\n- **Acute Lymphoblastic Leukemia (ALL)**: It is primarily indicated for the treatment of ALL in pediatric and young adult patients, typically as part of a multi-agent chemotherapy regimen.\n\n### Administration\n- **Dosage and Schedule**: The dosing regimen can vary, but it is often administered intravenously. The specific dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_F1adgu4rDn2F44YtkYiDHzr1", "custom_id": "45_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "168dbfcbb89eea044fae3f10fbe2d909", "body": {"id": "chatcmpl-9St7BG2GzXvEpIbg7hqKCyuzjw9lI", "object": "chat.completion", "created": 1716672073, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Capecitabine is an oral chemotherapeutic agent used primarily in the treatment of various cancers, including colorectal cancer and breast cancer. Here are some key points you should know about Capecitabine:\n\n### Mechanism of Action\n- **Prodrug**: Capecitabine is a prodrug that is metabolized in the body to 5-fluorouracil (5-FU), a pyrimidine analog that interferes with DNA synthesis.\n- **Selective Activation**: It is designed to be selectively activated in tumor tissues, which can potentially reduce systemic toxicity.\n\n### Indications\n- **Colorectal Cancer**: Often used as first-line therapy for metastatic colorectal cancer.\n- **Breast Cancer**: Used in metastatic breast cancer, particularly in patients who have not responded to other treatments like anthracyclines and taxanes.\n- **Other Cancers**: Sometimes used off-label for other types of cancer, such as gastric cancer.\n\n### Administration\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_iou0OTZaH1TDpQnx359Wk8tO", "custom_id": "46_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "683668adbf3530102f80bf55278c7f06", "body": {"id": "chatcmpl-9St7KesTi3k3bhAmITlxCauMSo17q", "object": "chat.completion", "created": 1716672082, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carboplatin is a chemotherapy medication used primarily to treat various types of cancer, including ovarian, lung, head and neck, and brain cancers. Here are some key points you should know about Carboplatin:\n\n### Mechanism of Action\n- **Platinum-Based Agent**: Carboplatin is a platinum-containing compound that causes cross-linking of DNA, which interferes with DNA repair and replication, leading to cell death.\n- **Cell Cycle Non-Specific**: It affects cells at all stages of the cell cycle, making it effective against rapidly dividing cancer cells.\n\n### Indications\n- **Ovarian Cancer**: Often used as first-line treatment or in recurrent cases.\n- **Lung Cancer**: Used in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).\n- **Other Cancers**: Also used in head and neck cancers, brain tumors, and as part of combination therapy for various malignancies.\n\n### Administration\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_g54IS2nZYSjjyt0nCE6ALdev", "custom_id": "47_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "eb11d2d79c5a6e70a1dcc0fbd04a39d4", "body": {"id": "chatcmpl-9St7K4BuZIbRYVUo4TBVRdQgOao8p", "object": "chat.completion", "created": 1716672082, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carfilzomib is a proteasome inhibitor used primarily in the treatment of multiple myeloma, a type of blood cancer. Here are some key points you should know about Carfilzomib:\n\n### Mechanism of Action\n- **Proteasome Inhibition**: Carfilzomib selectively and irreversibly inhibits the chymotrypsin-like activity of the 20S proteasome, leading to an accumulation of polyubiquitinated proteins, which induces apoptosis in cancer cells.\n\n### Indications\n- **Multiple Myeloma**: Carfilzomib is indicated for the treatment of patients with relapsed or refractory multiple myeloma, often in combination with other agents such as dexamethasone, lenalidomide, or daratumumab.\n\n### Administration\n- **Intravenous Infusion**: Carfilzomib is administered via intravenous infusion. The dosing schedule can vary, but it is often given on two consecutive"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_xaWA2h984gv9APxeuXKMwx3v", "custom_id": "48_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f02cdf17d755db5f0ff5fac2b3e4057a", "body": {"id": "chatcmpl-9St7KQSpHyhXZKbXHaBtkimGFy8WE", "object": "chat.completion", "created": 1716672082, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carmustine, also known by its brand name BiCNU, is a chemotherapy agent used primarily in the treatment of certain types of cancer. Here are some key points you should know about Carmustine:\n\n### Mechanism of Action\n- **Alkylating Agent**: Carmustine belongs to the class of alkylating agents. It works by cross-linking DNA strands, thereby inhibiting DNA replication and RNA transcription, leading to cell death.\n- **Nitrosourea Compound**: It is a nitrosourea compound, which allows it to cross the blood-brain barrier, making it effective in treating brain tumors.\n\n### Indications\n- **Brain Tumors**: Primary and metastatic brain tumors, including glioblastoma, medulloblastoma, and astrocytoma.\n- **Hodgkin's Lymphoma**: Often used in combination with other chemotherapy agents.\n- **Non-Hodgkin's Lymphoma**: Similarly used"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_GkXFrf6ZFLzG4iXqj29NNo8S", "custom_id": "49_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c6fca6d3305ca8a9bbad18335dda5d97", "body": {"id": "chatcmpl-9St7LRJNXZw3UAKjGHdlhZH3o9fpi", "object": "chat.completion", "created": 1716672083, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carmustine wafer (polifeprosan 20) is a biodegradable, implantable wafer used in the treatment of certain types of brain tumors, specifically high-grade gliomas such as glioblastoma multiforme. Here are some key points you should know about it:\n\n### Indications:\n- **Primary Use**: Carmustine wafers are primarily used as an adjunct to surgery and radiation in patients with newly diagnosed high-grade malignant glioma.\n- **Recurrent Tumors**: They are also used for patients with recurrent glioblastoma multiforme after surgical resection.\n\n### Mechanism of Action:\n- **Chemotherapy Delivery**: The wafer delivers carmustine (BCNU), a nitrosourea alkylating agent, directly to the tumor site. This localized delivery allows for higher concentrations of the drug at the tumor site while minimizing systemic exposure and associated side effects.\n- **Biodegradability**: The polifeprosan 20 polymer matrix gradually de"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_dsM32urW6Pdy0qUPXyKKPD3S", "custom_id": "50_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "151f092813dc61160fca858dcd2fc133", "body": {"id": "chatcmpl-9St7MFwBk5lSX2fWUqudZkyvk0WCE", "object": "chat.completion", "created": 1716672084, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cediranib is a small-molecule tyrosine kinase inhibitor that primarily targets vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3). It is used in oncology for its anti-angiogenic properties, which means it inhibits the growth of new blood vessels that tumors need to grow and metastasize. Here are some key points you should know about Cediranib:\n\n### Mechanism of Action\n- **VEGFR Inhibition**: Cediranib blocks VEGFR-1, VEGFR-2, and VEGFR-3, which are critical for angiogenesis. By inhibiting these receptors, Cediranib reduces the blood supply to tumors, thereby inhibiting their growth and spread.\n\n### Indications\n- **Ovarian Cancer**: Cediranib has been studied in combination with other agents like olaparib for the treatment of recurrent ovarian cancer.\n- **Other Cancers**: It is also being investigated in clinical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5dKolYhpczDF6eQxYdVBsypp", "custom_id": "51_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "52585a1bd65d923d68e3e0110b0f13e8", "body": {"id": "chatcmpl-9St7NfcgvqpfyvVRvFmmH3GkJpkfk", "object": "chat.completion", "created": 1716672085, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cemiplimab is a monoclonal antibody used in the treatment of certain types of cancer. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Cemiplimab** is a programmed death receptor-1 (PD-1) blocking antibody. It works by inhibiting the interaction between PD-1 on T cells and its ligands, PD-L1 and PD-L2, which are often overexpressed on tumor cells. This inhibition enhances the immune system's ability to recognize and destroy cancer cells.\n\n### Indications\n- **Cutaneous Squamous Cell Carcinoma (CSCC)**: Cemiplimab is approved for the treatment of patients with metastatic or locally advanced CSCC who are not candidates for curative surgery or radiation.\n- **Non-Small Cell Lung Cancer (NSCLC)**: It is also approved for first-line treatment of patients with NSCLC whose tumors have high PD-L1 expression (\u226550%) and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_IPX700FNDPQVyIOfJ02spech", "custom_id": "52_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "fb4156edfd994278781d7fe7b920168b", "body": {"id": "chatcmpl-9St7PzG2hI5PnAXmMBGSkK1A8zCS2", "object": "chat.completion", "created": 1716672087, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ceritinib is a targeted cancer therapy used primarily for the treatment of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. Here are some key points you should know about Ceritinib:\n\n### Mechanism of Action\n- **Targeted Therapy**: Ceritinib is a tyrosine kinase inhibitor that specifically targets and inhibits the activity of the ALK protein, which can be abnormally activated in some cancers, leading to uncontrolled cell growth.\n\n### Indications\n- **NSCLC**: Ceritinib is indicated for the treatment of patients with ALK-positive metastatic NSCLC. It is often used in patients who have progressed on or are intolerant to crizotinib, another ALK inhibitor.\n\n### Administration\n- **Dosage**: The recommended dose is typically 450 mg orally once daily with food. The dose may be adjusted based on patient tolerance and side effects.\n- **Food Interaction**: Taking Ceritinib with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_peb3UiTCSQ7ZYnj5HNVIlUcG", "custom_id": "53_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "01ff12358fd43d5f85fe150c90223a81", "body": {"id": "chatcmpl-9St7U8IG7eb43DEGzaEmsLgwH9zR9", "object": "chat.completion", "created": 1716672092, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR). It is used primarily in the treatment of certain types of cancer. Here are some key points you should know about Cetuximab:\n\n### Indications:\n1. **Colorectal Cancer**: Cetuximab is used for the treatment of metastatic colorectal cancer, particularly in patients whose tumors express EGFR and who have not responded to other treatments.\n2. **Head and Neck Cancer**: It is also used in the treatment of squamous cell carcinoma of the head and neck, either in combination with radiation therapy for locally or regionally advanced disease or as a single agent in patients with recurrent or metastatic disease.\n\n### Mechanism of Action:\n- Cetuximab binds to the extracellular domain of the EGFR, inhibiting the receptor's activation and subsequent downstream signaling pathways that promote cell proliferation, survival, and angiogenesis. This inhibition can lead to reduced tumor growth"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_e7E1OqeN5b8s6C5qqLjXcsdA", "custom_id": "54_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c2fe79373955b2bb3783dc16e71ff0ce", "body": {"id": "chatcmpl-9St7VJCKRbftpsneniGNshWkX6pXp", "object": "chat.completion", "created": 1716672093, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Chidamide is an oral histone deacetylase (HDAC) inhibitor that is used primarily in the treatment of certain types of cancers. Here are some key points you should know about Chidamide:\n\n### Mechanism of Action\n- **Histone Deacetylase Inhibition**: Chidamide inhibits HDAC enzymes, which play a role in modifying chromatin structure and regulating gene expression. By inhibiting these enzymes, Chidamide can induce cell cycle arrest, differentiation, and apoptosis in cancer cells.\n\n### Indications\n- **Peripheral T-cell Lymphoma (PTCL)**: Chidamide is approved for the treatment of relapsed or refractory PTCL.\n- **Other Cancers**: Research is ongoing to explore its efficacy in other malignancies, including breast cancer and non-small cell lung cancer.\n\n### Administration\n- **Oral Administration**: Chidamide is taken orally, which can be more convenient for patients compared to intravenous chemotherapy.\n\n### Dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_xzi2b0A5hrBRhEx5zU0Q5nPc", "custom_id": "55_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9d8613ffb81a1987e01fafcc825d81de", "body": {"id": "chatcmpl-9St7ZWjr0Mj17ZRQap4EY37V2auIy", "object": "chat.completion", "created": 1716672097, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Chlorambucil is an alkylating agent used primarily in the treatment of certain types of cancer. Here are some key points you should know about Chlorambucil:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL)**: Chlorambucil is often used as a first-line treatment.\n2. **Non-Hodgkin's Lymphoma**: It can be used in certain types of non-Hodgkin's lymphoma.\n3. **Hodgkin's Disease**: Occasionally used in the treatment of Hodgkin's disease.\n4. **Waldenstr\u00f6m's Macroglobulinemia**: It may be used in this rare type of cancer.\n5. **Other Conditions**: Sometimes used off-label for other conditions like autoimmune diseases, though this is less common.\n\n### Mechanism of Action:\n- Chlorambucil works by cross-linking DNA strands, which inhibits DNA replication and RNA transcription, leading to cell"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_51wfIk5lZoNXkDoHlALpRm04", "custom_id": "56_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6faf49ed581f18171f16127418d9ebd0", "body": {"id": "chatcmpl-9St7ZZGAh2M4RGPEBjVghBOv4O7Ih", "object": "chat.completion", "created": 1716672097, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cisplatin is a chemotherapy drug that is widely used in the treatment of various types of cancers, including testicular, ovarian, bladder, lung, and head and neck cancers. Here are some key points you should know about Cisplatin:\n\n### Mechanism of Action\n- **DNA Cross-Linking:** Cisplatin forms covalent bonds with DNA, leading to the formation of DNA cross-links. This inhibits DNA replication and transcription, ultimately causing cell death.\n- **Cell Cycle Non-Specific:** It is effective in all phases of the cell cycle, although cells are most vulnerable during the S phase.\n\n### Administration\n- **Intravenous Infusion:** Cisplatin is typically administered via IV infusion. The dosage and schedule depend on the type of cancer being treated, the patient's overall health, and other factors.\n- **Hydration:** Adequate hydration before and after administration is crucial to reduce the risk of nephrotoxicity.\n\n### Side Effects\n- **Nephro"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_N7l8HSlBWXutrpjbrMHjy2At", "custom_id": "57_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "bf5900aaf15377174364bdee8a0c1880", "body": {"id": "chatcmpl-9St7bwBGisxnvysBBGacgrS2UQDFt", "object": "chat.completion", "created": 1716672099, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cladribine is a purine analog used primarily in the treatment of certain hematologic malignancies and multiple sclerosis (MS). Here are some key points you should know about Cladribine:\n\n### Indications:\n1. **Hematologic Malignancies:**\n   - **Hairy Cell Leukemia:** Cladribine is FDA-approved for the treatment of hairy cell leukemia.\n   - **Other Uses:** It has also been used off-label for other hematologic malignancies such as chronic lymphocytic leukemia (CLL) and certain types of non-Hodgkin lymphoma.\n\n2. **Multiple Sclerosis:**\n   - **Relapsing Forms of MS:** Cladribine is approved for the treatment of relapsing forms of multiple sclerosis, including relapsing-remitting MS and active secondary progressive MS.\n\n### Mechanism of Action:\n- Cladribine is a synthetic purine nucleoside analog that interferes with DNA synthesis and repair, leading to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_uBbZ3XvpsbMzT95AP3Rc40FT", "custom_id": "58_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9d106a5b41b21dde54326bb927fe317f", "body": {"id": "chatcmpl-9St7cjPyanl6aICdkQXkJM6wERxGh", "object": "chat.completion", "created": 1716672100, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Clarithromycin is a macrolide antibiotic commonly used to treat various bacterial infections. Here are some key points you should know about it:\n\n### Indications\n- **Respiratory Tract Infections**: Such as pharyngitis, tonsillitis, sinusitis, bronchitis, and pneumonia.\n- **Skin Infections**: Including cellulitis and impetigo.\n- **Helicobacter pylori Eradication**: Often used in combination with other medications for the treatment of H. pylori-associated peptic ulcer disease.\n- **Mycobacterial Infections**: Including Mycobacterium avium complex (MAC) in patients with HIV.\n\n### Mechanism of Action\n- Clarithromycin works by inhibiting bacterial protein synthesis. It binds to the 50S ribosomal subunit, preventing the translocation of peptides.\n\n### Dosage and Administration\n- **Adults**: Typically, 250-500 mg twice daily for 7-14 days,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5fgnvxt0QxGaL2pyBOhsIRFH", "custom_id": "59_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6d2a75811618bef58ac2fe918f615d81", "body": {"id": "chatcmpl-9St7fwDLESKnXYyst8HEidsvoKGf6", "object": "chat.completion", "created": 1716672103, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Clofarabine is a chemotherapeutic agent primarily used in the treatment of certain types of leukemia, particularly acute lymphoblastic leukemia (ALL) in pediatric patients who have not responded to or have relapsed after at least two prior regimens. Here are some key points you should know about Clofarabine:\n\n### Mechanism of Action\n- **Antimetabolite**: Clofarabine is a purine nucleoside analog. It inhibits DNA synthesis by incorporating into DNA and inhibiting DNA polymerase and ribonucleotide reductase, leading to apoptosis of rapidly dividing cells.\n\n### Indications\n- **Pediatric Acute Lymphoblastic Leukemia (ALL)**: Specifically for patients who have relapsed or are refractory after at least two prior regimens.\n- **Other Uses**: It may be used off-label for other hematologic malignancies, but this should be based on clinical judgment and emerging evidence.\n\n### Administration\n- **Intravenous Infusion**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_lSQYFo1rWsLTfq1enBhAYqFT", "custom_id": "60_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6b12040e5523d8fc9fc6e71170b2c196", "body": {"id": "chatcmpl-9St7gRbAhtUuK9SzIVbUOJkIeRtsj", "object": "chat.completion", "created": 1716672104, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cobimetinib is a medication used in the treatment of certain types of cancer, specifically unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Here are some key points you should know about Cobimetinib:\n\n### Mechanism of Action\n- **Target**: Cobimetinib is a selective inhibitor of the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway, specifically targeting MEK1 and MEK2.\n- **Function**: By inhibiting MEK1/2, Cobimetinib helps to block the MAPK/ERK signaling pathway, which is often overactive in certain cancers, leading to uncontrolled cell proliferation.\n\n### Indications\n- **Primary Use**: Cobimetinib is primarily used in combination with vemurafenib, a BRAF inhibitor, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_InGLcZMSt1qov7bkXmU9ZBee", "custom_id": "61_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "931ed667f243b89741f71fc8ea3d7066", "body": {"id": "chatcmpl-9St7iBwXec0p0b9dwXltYahz3wYel", "object": "chat.completion", "created": 1716672106, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Copanlisib is a medication used primarily in the treatment of certain types of cancer, specifically relapsed follicular lymphoma, which is a type of non-Hodgkin lymphoma. Here are some key points you should know about Copanlisib:\n\n### Mechanism of Action\n- **PI3K Inhibitor**: Copanlisib is a selective inhibitor of phosphoinositide 3-kinase (PI3K), particularly the PI3K-\u03b1 and PI3K-\u03b4 isoforms. PI3K is involved in cell growth, proliferation, and survival, and its dysregulation is implicated in various cancers.\n\n### Indications\n- **Relapsed Follicular Lymphoma**: Copanlisib is approved for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies.\n\n### Administration\n- **Intravenous Infusion**: Copanlisib is administered as an intravenous infusion. The typical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_UAMhbkagUoAfKIiQhUsUmVCx", "custom_id": "62_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c400e74e281d0af042072d90ec8e41c2", "body": {"id": "chatcmpl-9St7jr5iEkFG2oD8eM4KKumZsJh48", "object": "chat.completion", "created": 1716672107, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Crizotinib is a targeted therapy used primarily in the treatment of certain types of cancer. Here are key points you should know about Crizotinib:\n\n### Indications:\n1. **Non-Small Cell Lung Cancer (NSCLC):** Crizotinib is primarily used for the treatment of patients with metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK)-positive or ROS1-positive.\n2. **ALK-Positive Inflammatory Myofibroblastic Tumor (IMT):** It is also used in some cases of ALK-positive IMT.\n\n### Mechanism of Action:\n- **Tyrosine Kinase Inhibitor:** Crizotinib inhibits the activity of ALK, ROS1, and MET tyrosine kinases, which are involved in the growth and spread of cancer cells.\n\n### Administration:\n- **Oral Medication:** Crizotinib is administered orally, typically in capsule form.\n- **Dosage:** The standard dose is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_gNu6iczYkmUc6oq9CebtDVA8", "custom_id": "63_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3c2a9bc5f365310fe55603889b156ab3", "body": {"id": "chatcmpl-9St7jZ4FF6XlDzBTVObZzkZtH3lQ7", "object": "chat.completion", "created": 1716672107, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyclophosphamide is a chemotherapeutic and immunosuppressive agent used in the treatment of various cancers and autoimmune diseases. Here are some key points you should know about Cyclophosphamide:\n\n### Mechanism of Action\n- **Alkylating Agent**: Cyclophosphamide is a prodrug that is metabolized in the liver to form active metabolites, including phosphoramide mustard and acrolein. These metabolites cross-link DNA strands, inhibiting DNA replication and transcription, leading to cell death.\n- **Immunosuppressive Effects**: It suppresses the immune system by reducing the number of lymphocytes, which is beneficial in treating autoimmune diseases.\n\n### Indications\n- **Cancer**: Used in the treatment of various cancers, including lymphomas, leukemias, breast cancer, ovarian cancer, and multiple myeloma.\n- **Autoimmune Diseases**: Employed in the management of severe autoimmune conditions such as systemic lupus erythematosus, rheumatoid"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_a4E4fkO29j3Rt98hEIrjRw9a", "custom_id": "64_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "44b398f5696c308b4b86018ace6c6897", "body": {"id": "chatcmpl-9St7jlPmxFbBHZVrM34sgNJ7QdXMh", "object": "chat.completion", "created": 1716672107, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyproterone acetate (CPA) is a synthetic steroidal antiandrogen and progestogen with various clinical applications. Here are some key points you should know about CPA:\n\n### Mechanism of Action\n1. **Antiandrogenic Effects**: CPA blocks androgen receptors, inhibiting the effects of male sex hormones (androgens) like testosterone and dihydrotestosterone (DHT).\n2. **Progestogenic Effects**: CPA has progestogenic activity, which can suppress the secretion of gonadotropins (LH and FSH) from the pituitary gland, leading to reduced production of testosterone in men and ovulation suppression in women.\n\n### Indications\n1. **Prostate Cancer**: Used in the treatment of advanced prostate cancer due to its ability to block androgen receptors and reduce testosterone levels.\n2. **Hirsutism and Acne in Women**: Used to treat conditions like hirsutism, severe acne, and androgenic alopecia by"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_yQVoBQtxN9jatD9NNuTC474u", "custom_id": "65_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6263a3d7076933830f1fb27ac08f3722", "body": {"id": "chatcmpl-9St7jkqtxXn3wCGY3GRA2apEZCM6c", "object": "chat.completion", "created": 1716672107, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cytarabine, also known as Ara-C, is a chemotherapy agent primarily used in the treatment of certain types of leukemia, such as acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL), as well as non-Hodgkin's lymphoma. Here are some key points you should know about Cytarabine:\n\n### Mechanism of Action\n- **Antimetabolite**: Cytarabine is a pyrimidine analog that interferes with DNA synthesis. It gets incorporated into DNA during the S-phase of the cell cycle, inhibiting DNA polymerase and causing chain termination.\n- **Cell Cycle Specificity**: It is most effective against rapidly dividing cells, particularly in the S-phase.\n\n### Indications\n- **Acute Myeloid Leukemia (AML)**: Often used in induction and consolidation therapy.\n- **Acute Lymphocytic Leukemia (ALL)**: Sometimes used in combination with other drugs.\n- **Non-Hodgkin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_10sYYhRWUniqT6qUXwrSQ3Hj", "custom_id": "66_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "eb44beaf1df34349cbc8372d7dd75748", "body": {"id": "chatcmpl-9St7kBw00lJqH0NlZYVH23p0kkkZG", "object": "chat.completion", "created": 1716672108, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cytarabine and daunorubicin liposomal (brand name Vyxeos) is a combination chemotherapy medication used primarily for the treatment of certain types of acute myeloid leukemia (AML). Here are key points you should know about this medication:\n\n### Indications:\n- **Acute Myeloid Leukemia (AML):** Specifically, it is approved for the treatment of newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults.\n\n### Mechanism of Action:\n- **Cytarabine:** An antimetabolite that inhibits DNA synthesis by incorporating into DNA and inhibiting DNA polymerase.\n- **Daunorubicin:** An anthracycline antibiotic that intercalates into DNA, inhibiting topoisomerase II and generating free radicals that damage cellular components.\n\n### Formulation:\n- **Liposomal Delivery:** The liposomal formulation allows for a fixed molar ratio of cytarabine"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_USxIz4qHNBlsz8VrxkBr9fsR", "custom_id": "67_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "5aef621b4312008909989d1f2a65a796", "body": {"id": "chatcmpl-9St7lVrQcOT45GRFLFcC0YoOxkCVJ", "object": "chat.completion", "created": 1716672109, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dabrafenib is a targeted therapy used primarily in the treatment of certain types of cancer. Here are key points you should know about Dabrafenib:\n\n### Indications:\n1. **Melanoma**: Dabrafenib is approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.\n2. **Non-Small Cell Lung Cancer (NSCLC)**: It is also used in combination with trametinib for the treatment of patients with metastatic NSCLC with a BRAF V600E mutation.\n3. **Anaplastic Thyroid Cancer**: In combination with trametinib, it is used for the treatment of locally advanced or metastatic anaplastic thyroid cancer with a BRAF V600E mutation.\n\n### Mechanism of Action:\n- Dabrafenib is a BRAF inhibitor. It works by inhibiting the activity of the BRAF protein with the V600E mutation, which is involved"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_gAWBRaNdSDVKMUBpjbTqPyAG", "custom_id": "68_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3e8d055e58b829c697a399cd398c4a55", "body": {"id": "chatcmpl-9St7mu3TqzPhLGRIvyRPoY7BggkIJ", "object": "chat.completion", "created": 1716672110, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dacarbazine is an antineoplastic agent used primarily in the treatment of certain types of cancer. Here are some key points you should know about Dacarbazine:\n\n### Indications:\n1. **Malignant Melanoma**: Dacarbazine is often used as a single agent or in combination with other drugs.\n2. **Hodgkin's Lymphoma**: It is part of the ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) regimen.\n3. **Soft Tissue Sarcomas**: Occasionally used in combination with other chemotherapeutic agents.\n\n### Mechanism of Action:\n- Dacarbazine is an alkylating agent. It works by methylating guanine at the O6 position, leading to DNA cross-linking and strand breaks, which ultimately inhibits DNA, RNA, and protein synthesis.\n\n### Administration:\n- **Route**: Intravenous (IV) infusion.\n- **Dos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_xw7GSeWkD3z5x77gOSGmBimZ", "custom_id": "69_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "4c1c8c2149af71a3ceefd463d6d78332", "body": {"id": "chatcmpl-9St7nJ3fhN7GqJEDIWWJnbhuiAUPV", "object": "chat.completion", "created": 1716672111, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dacomitinib is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Dacomitinib** is a tyrosine kinase inhibitor (TKI) that targets the epidermal growth factor receptor (EGFR). It binds irreversibly to the EGFR family of receptors, which includes EGFR (HER1), HER2, and HER4, inhibiting their activity and thereby blocking the downstream signaling pathways that promote cancer cell proliferation and survival.\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC)**: Dacomitinib is specifically indicated for the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.\n\n### Dosage and Administration\n- The recommended dose of dacomitinib is **45 mg orally once daily**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_9GPQC0lhdZlGTuEnbsCSWFDX", "custom_id": "70_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "39041cac6d821df2472fc0390cdf7036", "body": {"id": "chatcmpl-9St7n1eRPGIuAgWgNCb7Ulc9q44eU", "object": "chat.completion", "created": 1716672111, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dactinomycin, also known as actinomycin D, is a chemotherapy medication used primarily in the treatment of various types of cancer. Here are some key points you should know about Dactinomycin:\n\n### Mechanism of Action\n- **Intercalation**: Dactinomycin intercalates into DNA, which means it inserts itself between DNA base pairs. This disrupts the DNA structure and inhibits RNA synthesis.\n- **Inhibition of Transcription**: By binding to DNA, it prevents RNA polymerase from transcribing mRNA, thereby inhibiting protein synthesis and leading to cell death.\n\n### Indications\n- **Wilms' Tumor**: Often used in combination with other chemotherapeutic agents.\n- **Rhabdomyosarcoma**: Commonly used in pediatric oncology.\n- **Ewing's Sarcoma**: Part of multi-agent chemotherapy regimens.\n- **Gestational Trophoblastic Neoplasia**: Effective in treating"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_iSbAFn36q8zFtw1lFYTO8qPb", "custom_id": "71_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "48b9e644c0bbec404746677d6860ce8d", "body": {"id": "chatcmpl-9St7o2EbsWqOIC9hcsOVRjoyWGtUj", "object": "chat.completion", "created": 1716672112, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Danazol is a synthetic steroid with a variety of clinical applications, primarily used for its antigonadotropic and anti-estrogenic effects. Here are some key points you should know about Danazol:\n\n### Indications:\n1. **Endometriosis**: Danazol is commonly used to treat endometriosis by creating a hypoestrogenic and hyperandrogenic environment, which helps to atrophy endometrial tissue.\n2. **Fibrocystic Breast Disease**: It can be used to alleviate the symptoms of fibrocystic breast disease.\n3. **Hereditary Angioedema**: Danazol is effective in preventing attacks of hereditary angioedema by increasing the levels of C1 esterase inhibitor.\n\n### Mechanism of Action:\n- Danazol suppresses the pituitary-ovarian axis, leading to decreased secretion of gonadotropins (LH and FSH), which in turn reduces estrogen production.\n- It also has weak androgenic, anabolic,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ulTpv2wz3RmL40KMaho9hDAl", "custom_id": "72_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ce3759ad74033d01c6f348995ec34c8e", "body": {"id": "chatcmpl-9St7o4xDuJYnooOAOs5GZaayNc2X6", "object": "chat.completion", "created": 1716672112, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daratumumab is a monoclonal antibody used primarily in the treatment of multiple myeloma, a type of blood cancer. Here are some key points you should know about Daratumumab:\n\n### Mechanism of Action\n- **Target**: Daratumumab targets CD38, a protein that is highly expressed on the surface of multiple myeloma cells.\n- **Action**: It induces cell death through multiple mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and direct apoptosis.\n\n### Indications\n- **Multiple Myeloma**: Daratumumab is approved for use in various settings of multiple myeloma, including newly diagnosed and relapsed/refractory cases.\n- **Combination Therapy**: It is often used in combination with other agents such as lenalidomide, bortezomib, and dexamethasone.\n\n### Administration\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_8gCayqIEQELEe74ylyd5uGhu", "custom_id": "73_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a311c13ef228e20e65b81390ce109143", "body": {"id": "chatcmpl-9St7pPMKcxMfG4m8SuAQBacA0RVzV", "object": "chat.completion", "created": 1716672113, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Darolutamide is an androgen receptor inhibitor used primarily in the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). Here are some key points you should know about Darolutamide:\n\n### Mechanism of Action\n- **Androgen Receptor Inhibition**: Darolutamide works by inhibiting the action of androgens (male hormones) by binding to androgen receptors, which are critical for the growth and survival of prostate cancer cells.\n\n### Indications\n- **Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)**: Darolutamide is indicated for the treatment of men with nmCRPC, a condition where the prostate cancer has not spread to other parts of the body but continues to progress despite low levels of testosterone.\n\n### Dosage and Administration\n- **Standard Dosage**: The typical dosage is 600 mg (two 300 mg tablets) taken orally twice daily, with or without food.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_mcA1EXTonlLhx8mGzpqonF7G", "custom_id": "74_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ad556ff1549162d8a2fe2c3065402109", "body": {"id": "chatcmpl-9St7qixrHIbycrKpjLXBq4tFbwGgE", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dasatinib is a tyrosine kinase inhibitor (TKI) used primarily in the treatment of certain types of cancer, most notably chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Here are some key points you should know about Dasatinib:\n\n### Mechanism of Action\n- **Target**: Dasatinib inhibits multiple tyrosine kinases, including BCR-ABL, SRC family kinases, c-KIT, EPHA2, and PDGFR\u03b2.\n- **Function**: By inhibiting these kinases, Dasatinib interferes with the signaling pathways that promote cancer cell proliferation and survival.\n\n### Indications\n- **Chronic Myeloid Leukemia (CML)**: Dasatinib is used for the treatment of adults with newly diagnosed Philadelphia chromosome-positive (Ph+) CML in chronic phase.\n- **Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Xd8b0fM0U8UEM7EA7hUyj8HM", "custom_id": "75_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7076c51b98b38e98d8ef2671a17f171b", "body": {"id": "chatcmpl-9St7qQTTi18XVtG4CyUws2LXERwZL", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daunorubicin is an anthracycline antibiotic commonly used in the treatment of various types of cancer, particularly hematologic malignancies such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Here are some key points you should know about Daunorubicin:\n\n### Mechanism of Action\n- **DNA Intercalation**: Daunorubicin intercalates into DNA, disrupting the DNA double helix and inhibiting the synthesis of DNA and RNA.\n- **Topoisomerase II Inhibition**: It inhibits the enzyme topoisomerase II, which is essential for DNA replication and repair, leading to DNA strand breaks.\n- **Free Radical Formation**: Daunorubicin generates free radicals, which can cause oxidative damage to cellular components, including DNA, proteins, and lipids.\n\n### Indications\n- **Acute Myeloid Leukemia (AML)**: Often used in combination with other chemotherapeutic agents"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_BnOKNElNN4OMgOuHqmRUyCvN", "custom_id": "76_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c778411dd0b49436772d8f3862cb8ad6", "body": {"id": "chatcmpl-9St7qvAD7YibPskvGjezVi5GJ8cvM", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daunorubicin liposomal is a chemotherapeutic agent used primarily in the treatment of certain types of cancer, including acute myeloid leukemia (AML). Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Daunorubicin**: It is an anthracycline antibiotic that intercalates DNA, inhibiting the synthesis of nucleic acids and leading to cell death.\n- **Liposomal Formulation**: Encapsulation in liposomes helps to improve the drug's pharmacokinetics and biodistribution, potentially reducing toxicity and enhancing efficacy.\n\n### Indications\n- **Acute Myeloid Leukemia (AML)**: Particularly in newly diagnosed patients.\n- **Other Hematologic Malignancies**: It may be used in other contexts as determined by clinical guidelines and individual patient factors.\n\n### Administration\n- **Intravenous Infusion**: The drug is administered via IV infusion. The specific dosing regimen can vary"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_vJlZQFhMdJPNubAsKIUQlE0u", "custom_id": "77_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c932beff10e220f88e6bda99c7a88713", "body": {"id": "chatcmpl-9St7qa3i38BMjiURwvYCExXrN4aBu", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Decitabine is a nucleoside analog used primarily in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Here are some key points you should know about Decitabine:\n\n### Mechanism of Action\n- **Hypomethylating Agent**: Decitabine incorporates into DNA and inhibits DNA methyltransferase, leading to hypomethylation of DNA. This can reactivate silenced genes that control differentiation and proliferation, potentially restoring normal function to abnormal cells.\n\n### Indications\n- **Myelodysplastic Syndromes (MDS)**: Decitabine is approved for the treatment of MDS, including all subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia).\n- **Acute Myeloid Leukemia (AML)**: It is also used in the treatment of AML, particularly in older adults who are not candidates for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_hyHna9f5ukJcJ5EMDEFQrNoR", "custom_id": "78_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "634ac36ffa5166aba5ff13c8243a1bc0", "body": {"id": "chatcmpl-9St7qOCosFJR0vWml4df07OWJ0WUe", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Degarelix is a medication used primarily in the treatment of advanced prostate cancer. It is a gonadotropin-releasing hormone (GnRH) antagonist, which means it works by directly inhibiting the release of gonadotropins (luteinizing hormone and follicle-stimulating hormone) from the pituitary gland. This leads to a rapid decrease in testosterone production by the testes, which is beneficial in managing prostate cancer, as the growth of prostate cancer cells is often driven by testosterone.\n\nHere are some key points you should know about Degarelix:\n\n### Mechanism of Action\n- **GnRH Antagonist**: Unlike GnRH agonists, which initially cause a surge in testosterone levels before reducing them, Degarelix immediately reduces testosterone levels without an initial surge. This can be advantageous in avoiding a temporary worsening of symptoms.\n\n### Indications\n- **Advanced Prostate Cancer**: Degarelix is indicated for the treatment of patients with advanced prostate cancer.\n\n### Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_gyqtnAtcc927rcSRbksiFMUh", "custom_id": "79_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7aad16d6d099bd3d1de5cb0c5afbbbcd", "body": {"id": "chatcmpl-9St7q7n15M59iSXFIaHSLePJGQYjL", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Denileukin diftitox is a fusion protein used as an antineoplastic agent, primarily for the treatment of certain types of lymphomas. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Fusion Protein**: Denileukin diftitox is a recombinant fusion protein that combines interleukin-2 (IL-2) with diphtheria toxin. \n- **Targeting**: It targets cells that express the IL-2 receptor (CD25), which is often overexpressed in certain types of lymphomas.\n- **Cytotoxicity**: Once bound to the IL-2 receptor, the diphtheria toxin component is internalized, leading to inhibition of protein synthesis and cell death.\n\n### Indications\n- **Cutaneous T-cell Lymphoma (CTCL)**: It is primarily indicated for the treatment of persistent or recurrent CTCL.\n- **Other Lymphomas**: It may also be used off"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_eFEfr0mgfEMP9LslEZMFjpdO", "custom_id": "80_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f327a90f671020cdc038ec919e39af22", "body": {"id": "chatcmpl-9St7q799vW0vvxyqkgnlOErx5Yr9M", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Denosumab is a monoclonal antibody used primarily in the treatment of osteoporosis and certain cancers that affect the bones. Here are some key points you should know about Denosumab:\n\n### Mechanism of Action\n- **RANKL Inhibition**: Denosumab works by inhibiting RANKL (Receptor Activator of Nuclear factor Kappa-\u0392 Ligand), a protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. By inhibiting RANKL, Denosumab decreases bone resorption and increases bone mass and strength.\n\n### Indications\n- **Osteoporosis**: Denosumab is used to treat osteoporosis in postmenopausal women and men at high risk of fractures.\n- **Bone Metastases**: It is also used to prevent skeletal-related events in patients with bone metastases from solid tumors.\n- **Giant Cell Tumor of Bone**: Denosumab is indicated for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_vixkHHHqHv7AQhS4oSs3li1y", "custom_id": "81_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ae22da962ab4e4cd1acc1b87b033c115", "body": {"id": "chatcmpl-9St7qbjBnV2yJWvVnmJdBKOZlHQer", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dexamethasone is a potent synthetic corticosteroid with anti-inflammatory and immunosuppressant properties. Here are some key points you should know about it:\n\n### Pharmacology\n1. **Mechanism of Action**: Dexamethasone works by binding to glucocorticoid receptors, leading to changes in gene expression that reduce inflammation and suppress the immune response.\n2. **Potency**: It is approximately 25-30 times more potent than cortisol and about 6-7 times more potent than prednisone.\n\n### Indications\n1. **Inflammatory Conditions**: Used to treat a variety of inflammatory and autoimmune conditions, such as rheumatoid arthritis, lupus, and inflammatory bowel disease.\n2. **Allergic Reactions**: Effective in managing severe allergic reactions and anaphylaxis.\n3. **Respiratory Conditions**: Used in conditions like asthma and chronic obstructive pulmonary disease (COPD) exacerbations.\n4. **Cerebral Edema**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_L9ggwk8Zj5MPV5OR9Ascmudt", "custom_id": "82_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "72e40a8d8666207a124258053a64c154", "body": {"id": "chatcmpl-9St7qMXMsxtbGXk8QkbzC23gQ63Vr", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dexrazoxane is a medication primarily used to protect the heart from the toxic effects of certain chemotherapy drugs, particularly anthracyclines like doxorubicin and daunorubicin. Here are some key points you should know about Dexrazoxane:\n\n### Indications:\n1. **Cardioprotection**: Dexrazoxane is used to reduce the risk of cardiomyopathy in patients receiving anthracycline chemotherapy.\n2. **Extravasation Management**: It is also used to treat extravasation (leakage) of anthracycline chemotherapy drugs into surrounding tissues, which can cause severe local tissue damage.\n\n### Mechanism of Action:\n- **Cardioprotection**: Dexrazoxane works by chelating iron, which reduces the formation of free radicals that can cause oxidative damage to cardiac cells.\n- **Extravasation**: It helps to mitigate tissue damage by reducing the formation of free radicals and by inhibiting topoisomerase"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_NFIpmyHieiz9hkD7nNZzmhx4", "custom_id": "83_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "182d1ecbe061a1baddf1f01f6e826b4c", "body": {"id": "chatcmpl-9St7qbHk2PSw9zod90G2TVQ6YZHJK", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Diethylstilbestrol (DES) is a synthetic estrogen that was widely prescribed to pregnant women between the 1940s and 1970s to prevent miscarriages, premature labor, and related complications. However, it was later discovered that DES had significant adverse effects, leading to its discontinuation for use in pregnant women. Here are some key points you should know about DES:\n\n### Historical Context\n- **Usage Period**: DES was prescribed from the late 1940s until 1971 in the United States, and its use continued in some other countries for a few more years.\n- **Purpose**: It was believed to reduce the risk of pregnancy complications, although later studies showed it was not effective for this purpose.\n\n### Adverse Effects\n- **DES Daughters**: Women exposed to DES in utero (known as DES daughters) have an increased risk of developing clear cell adenocarcinoma of the vagina and cervix, reproductive tract abnormalities, infertility, and pregnancy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_kyQ19KXeHZ7m08UKhTQncst9", "custom_id": "84_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "bdc148dcb97d2b9207fc0257c64cf59d", "body": {"id": "chatcmpl-9St7qODnf4sTnNK1kCtasCweh58wN", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dinutuximab is a monoclonal antibody used primarily in the treatment of high-risk neuroblastoma, a type of cancer that most commonly affects children. Here are some key points you should know about Dinutuximab:\n\n### Mechanism of Action\n- **Target**: Dinutuximab targets the GD2 ganglioside, a glycolipid found on the surface of neuroblastoma cells and other tumors of neuroectodermal origin.\n- **Action**: By binding to GD2, Dinutuximab induces cell lysis through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).\n\n### Indications\n- **Primary Use**: It is indicated for the treatment of pediatric patients with high-risk neuroblastoma who have achieved at least a partial response to prior first-line multiagent, multimodality therapy.\n- **Combination Therapy**: Often used in combination with other agents such as granulocyte-mac"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Bu5HZcremRvIqezP33sACe2W", "custom_id": "85_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1b6006639682fbc5977c242b420f3d89", "body": {"id": "chatcmpl-9St7qA2fzAMQDXZsKQ33yiHp6aPlm", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Docetaxel is a chemotherapy medication used primarily in the treatment of various cancers, including breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head and neck cancer. Here are some key points you should know about Docetaxel:\n\n### Mechanism of Action\n- **Microtubule Stabilization**: Docetaxel works by stabilizing microtubules, which inhibits cell division and leads to cell death. It binds to tubulin and promotes the assembly of microtubules while inhibiting their disassembly, disrupting the mitotic and interphase cellular functions.\n\n### Indications\n- **Breast Cancer**: Often used in combination with other chemotherapy agents.\n- **Non-Small Cell Lung Cancer (NSCLC)**: Used as a first-line treatment in combination with platinum-based chemotherapy or as a second-line treatment.\n- **Prostate Cancer**: Used in combination with prednisone for metastatic castration-resistant prostate cancer.\n- **Gastric"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_LJWgNm2dGe5ez8gII0Ww9ezQ", "custom_id": "86_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ee721bbc782dbfa044c833b3919d75e1", "body": {"id": "chatcmpl-9St7qMK8Bsla9FpLGyFMKHRtb6kkY", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Doxifluridine, also known as 5'-deoxy-5-fluorouridine (5'-DFUR), is an oral prodrug of the chemotherapeutic agent 5-fluorouracil (5-FU). Here are some key points you should know about Doxifluridine:\n\n### Mechanism of Action\n- **Prodrug Conversion**: Doxifluridine is converted into 5-FU in the body, primarily by the enzyme thymidine phosphorylase. This conversion allows for a more targeted delivery of the active drug to tumor tissues, where thymidine phosphorylase is often overexpressed.\n- **Cytotoxic Effects**: Once converted to 5-FU, it interferes with DNA synthesis and RNA function, leading to cell death. 5-FU is incorporated into RNA and DNA, disrupting their normal function and synthesis.\n\n### Indications\n- **Cancer Treatment**: Doxifluridine is used in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_2gN7xUr9MVb0ZS1uWwDovRUt", "custom_id": "87_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "06267a426dce0c26d309ec5463817d9d", "body": {"id": "chatcmpl-9St7qC0nKGIrR1bhFE0iPaP7dREwu", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Doxorubicin is a chemotherapy medication used to treat various types of cancer. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Intercalation into DNA:** Doxorubicin intercalates between DNA base pairs, disrupting the DNA structure and inhibiting the synthesis of nucleic acids.\n- **Topoisomerase II Inhibition:** It inhibits the enzyme topoisomerase II, which is essential for DNA replication and repair, leading to DNA strand breaks.\n- **Free Radical Formation:** Doxorubicin generates free radicals, which can cause damage to cellular components, including DNA, proteins, and cell membranes.\n\n### Indications\n- **Breast Cancer**\n- **Lymphomas (Hodgkin and non-Hodgkin)**\n- **Leukemias**\n- **Sarcomas**\n- **Bladder Cancer**\n- **Lung Cancer**\n- **Ovarian Cancer**\n\n### Administration\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_yrLs9A0JUf0TTSTS7Pd49V61", "custom_id": "88_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c21191313f2f9835e42ff1fd595f94aa", "body": {"id": "chatcmpl-9St7q8m9jyTEgRhpNW0EGfNPTXL5z", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Durvalumab is a human monoclonal antibody that targets programmed death-ligand 1 (PD-L1). It is used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC) and urothelial carcinoma. Here are some key points you should know about Durvalumab:\n\n### Mechanism of Action\n- **PD-L1 Inhibition**: Durvalumab binds to PD-L1, blocking its interaction with PD-1 and CD80. This inhibition prevents the \"immune checkpoint\" mechanism that tumors use to evade the immune system, thereby enhancing the body's immune response against cancer cells.\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC)**: Durvalumab is approved for the treatment of patients with locally advanced, unresectable NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.\n- **Urothelial Carcinoma**: It is also indicated for the treatment of patients with locally"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_DH4LRAzL0QTJl3YK9JgSpop0", "custom_id": "89_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9365e27f148ebe0ca1f85bf9aa9632a1", "body": {"id": "chatcmpl-9St7qasRbZZnMWoboWaxBAfuykm6N", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dutasteride is a medication primarily used to treat benign prostatic hyperplasia (BPH), which is an enlargement of the prostate gland. Here are some key points you should know about Dutasteride:\n\n### Mechanism of Action\n- **5-Alpha-Reductase Inhibitor**: Dutasteride inhibits both type 1 and type 2 isoforms of the enzyme 5-alpha-reductase. This enzyme converts testosterone to dihydrotestosterone (DHT), a hormone that contributes to prostate growth. By reducing DHT levels, Dutasteride helps to shrink the prostate and alleviate symptoms of BPH.\n\n### Indications\n- **Benign Prostatic Hyperplasia (BPH)**: Dutasteride is used to improve urinary flow and reduce the risk of acute urinary retention and the need for BPH-related surgery.\n- **Off-Label Uses**: It may also be used off-label for conditions like androgenetic alopecia (male pattern baldness),"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_LpGEfwv8A7ALbETaMQvL0yhA", "custom_id": "90_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "54b6ed51f13de3ec1e6b28408c4bf4b2", "body": {"id": "chatcmpl-9St7qq8FTqJUR646CsEg7AbBQXS8U", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Duvelisib is an oral medication used primarily in the treatment of certain types of blood cancers, specifically chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma (FL). Here are some key points you should know about Duvelisib:\n\n### Mechanism of Action\n- **PI3K Inhibitor**: Duvelisib is a dual inhibitor of phosphoinositide 3-kinase (PI3K) delta and gamma isoforms. These enzymes are involved in the signaling pathways that promote the growth, survival, and proliferation of malignant B cells.\n\n### Indications\n- **Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)**: Duvelisib is indicated for the treatment of adult patients with relapsed or refractory CLL or SLL after at least two prior therapies.\n- **Follicular Lymphoma (FL)**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Nqa5LqIZGMe0ufqrKW46yQGr", "custom_id": "91_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "259a0b0532f542746a8622bb9be3ee54", "body": {"id": "chatcmpl-9St7qdPV6GK00qzio7curuU8NGJn9", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Edrecolomab is a monoclonal antibody that was developed for the treatment of certain types of cancer, particularly colorectal cancer. Here are some key points you should know about Edrecolomab:\n\n1. **Mechanism of Action**: Edrecolomab targets the epithelial cell adhesion molecule (EpCAM), which is overexpressed in many epithelial cancers, including colorectal cancer. By binding to EpCAM, Edrecolomab is thought to help the immune system recognize and destroy cancer cells.\n\n2. **Indications**: Edrecolomab was primarily investigated for use in patients with colorectal cancer, particularly in the adjuvant setting (post-surgery) to reduce the risk of cancer recurrence.\n\n3. **Clinical Trials and Efficacy**: Early clinical trials showed some promise, but subsequent studies yielded mixed results. Some trials indicated a potential benefit in terms of disease-free survival, while others did not show a significant advantage over standard treatments.\n\n4. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_KbuPZayJfuS86dMSmqMHhXnF", "custom_id": "92_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c3bb9596583f31daa6022b346b2b1bbc", "body": {"id": "chatcmpl-9St7q0aVjgWmhSeDDBcJDgBNyZSVe", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Elotuzumab is a monoclonal antibody used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Here are some key points you should know about Elotuzumab:\n\n### Mechanism of Action\n- **Target**: Elotuzumab targets SLAMF7 (Signaling Lymphocytic Activation Molecule Family member 7), a protein highly expressed on myeloma cells and natural killer (NK) cells.\n- **Dual Action**: It works by directly activating NK cells and by tagging myeloma cells for destruction by the immune system.\n\n### Indications\n- **Combination Therapy**: Elotuzumab is typically used in combination with other agents such as lenalidomide and dexamethasone or pomalidomide and dexamethasone.\n- **Relapsed/Refractory Multiple Myeloma**: It is indicated for patients who have received one to three prior therapies.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_n96IYq3bnUM0AQop8sOodcMw", "custom_id": "93_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b8894a735323b93e9100e58aa0516d60", "body": {"id": "chatcmpl-9St7rvS6q7YrrueVsWakXkBwDnofs", "object": "chat.completion", "created": 1716672115, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enasidenib is an important medication used in the treatment of certain types of cancer, specifically acute myeloid leukemia (AML). Here are some key points you should know about Enasidenib:\n\n### Mechanism of Action\n- **Target**: Enasidenib is an inhibitor of the isocitrate dehydrogenase 2 (IDH2) enzyme.\n- **Function**: It works by targeting and inhibiting the mutant IDH2 enzyme, which is involved in the production of an oncometabolite called 2-hydroxyglutarate (2-HG). Elevated levels of 2-HG are associated with the development and progression of AML.\n\n### Indications\n- **Primary Use**: Enasidenib is primarily indicated for the treatment of relapsed or refractory AML in patients with an IDH2 mutation.\n- **Testing**: Patients must be tested for the IDH2 mutation before starting treatment with Enasidenib.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_coaQUK8FqlaULB4dhAMN1WDH", "custom_id": "94_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a30fd7e68b1ff3f6a391389099cb1666", "body": {"id": "chatcmpl-9St7rHstDR2er4y2pbz8RjgRy2sqc", "object": "chat.completion", "created": 1716672115, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Encorafenib is a targeted therapy used primarily in the treatment of certain types of cancer, most notably melanoma. Here are some key points you should know about Encorafenib as a physician:\n\n### Mechanism of Action\n- **BRAF Inhibitor**: Encorafenib is a small molecule inhibitor of the BRAF kinase, specifically targeting the BRAF V600E mutation. This mutation leads to uncontrolled cell growth and is present in a subset of cancers.\n- **Pathway**: By inhibiting the BRAF V600E kinase, Encorafenib disrupts the MAPK/ERK signaling pathway, which is involved in cell division and survival.\n\n### Indications\n- **Melanoma**: Encorafenib is approved for use in combination with binimetinib (a MEK inhibitor) for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.\n- **Colorectal Cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_w9Yrhq5l8FBv45y11WWSytW1", "custom_id": "95_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0f400be9ffee2f994e491d7ccca0493c", "body": {"id": "chatcmpl-9St7sc0NwSQD7ixBKiFbWelgxyp69", "object": "chat.completion", "created": 1716672116, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Entrectinib is a targeted cancer therapy that you should be familiar with, especially if you are treating patients with specific types of cancer. Here are some key points you should know:\n\n### Mechanism of Action\n- **Entrectinib** is a tyrosine kinase inhibitor that targets TRK (tropomyosin receptor kinase) fusion proteins, ROS1, and ALK (anaplastic lymphoma kinase).\n- It works by inhibiting the kinase activity of these proteins, which are involved in the growth and proliferation of cancer cells.\n\n### Indications\n- **NTRK Gene Fusion-Positive Solid Tumors**: Entrectinib is approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.\n- **ROS1-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_1yS9we2PfGMDRBlABsJhT3dz", "custom_id": "96_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ca4caee47b0828c6dc79705ff359b550", "body": {"id": "chatcmpl-9St7tSUTWCWMyAKSndvN7i4Xqin88", "object": "chat.completion", "created": 1716672117, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enzalutamide is an oral medication used primarily in the treatment of prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC). Here are some key points you should know about Enzalutamide:\n\n### Mechanism of Action\n- **Androgen Receptor Inhibition**: Enzalutamide is an androgen receptor inhibitor. It works by binding to the androgen receptor, inhibiting androgen receptor nuclear translocation, DNA binding, and coactivator recruitment. This prevents the androgen receptor from stimulating the growth of prostate cancer cells.\n\n### Indications\n- **Metastatic Castration-Resistant Prostate Cancer (mCRPC)**: Enzalutamide is approved for the treatment of mCRPC.\n- **Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)**: It is also approved for patients with nmCRPC.\n\n### Dosage and Administration\n- **Standard Dose**: The typical dose is 160 mg (four "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_EAZIkuB2DMlQOymQLTinK5a5", "custom_id": "97_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "85df5c088ca3bd73b789694f0912319d", "body": {"id": "chatcmpl-9St7uQbwwGCnWzayvRxDwZyTvaF6r", "object": "chat.completion", "created": 1716672118, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Epirubicin is an anthracycline antibiotic that is commonly used as a chemotherapeutic agent. Here are some key points you should know about Epirubicin:\n\n### Mechanism of Action\n- **DNA Intercalation**: Epirubicin intercalates into DNA, disrupting the function of topoisomerase II, an enzyme crucial for DNA replication and transcription.\n- **Free Radical Formation**: It generates free radicals that cause damage to cellular components, including DNA, proteins, and cell membranes.\n\n### Indications\n- **Breast Cancer**: Epirubicin is often used in the treatment of early and advanced breast cancer.\n- **Other Cancers**: It may also be used for other types of cancers, including gastric cancer, ovarian cancer, and lymphomas, depending on the specific clinical scenario.\n\n### Administration\n- **Intravenous (IV)**: Epirubicin is administered intravenously, typically in a hospital or clinical setting.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_lkr9vSaKEJdD3bCuHLuowBb5", "custom_id": "98_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3c6eeccec47a6f66e31388c25b293029", "body": {"id": "chatcmpl-9St7uVUSXyZAqeWWyJDWuCxJMkYz8", "object": "chat.completion", "created": 1716672118, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erdafitinib is a targeted therapy used primarily in the treatment of certain types of cancer, specifically urothelial carcinoma (a type of bladder cancer). Here are some key points you should know about Erdafitinib:\n\n### Mechanism of Action\n- **FGFR Inhibitor**: Erdafitinib is an oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. It targets and inhibits FGFR1, FGFR2, FGFR3, and FGFR4, which are involved in tumor cell proliferation and survival.\n\n### Indications\n- **Urothelial Carcinoma**: Erdafitinib is approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations and has progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_r2TN3Mi3LAeFI9obIs47gHYa", "custom_id": "99_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "8f460d426a4508fef0d299eecebb1aa6", "body": {"id": "chatcmpl-9St7uniaaeFStxDvLn9LALdM1JDM7", "object": "chat.completion", "created": 1716672118, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Eribulin is a chemotherapeutic agent used primarily in the treatment of certain types of cancer. Here are some key points you should know about Eribulin:\n\n### Mechanism of Action\n- **Microtubule Dynamics Inhibition**: Eribulin is a synthetic analog of halichondrin B, a natural product derived from marine sponges. It works by inhibiting the growth phase of microtubules, which are essential for cell division. This leads to the arrest of the cell cycle at the G2/M phase and ultimately induces apoptosis (programmed cell death).\n\n### Indications\n- **Metastatic Breast Cancer**: Eribulin is approved for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.\n- **Liposarcoma**: It is also"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_CKrwzsIGeTDpNjNME1owcbUg", "custom_id": "100_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "abfbcce4f981df30d793600437cc0ebd", "body": {"id": "chatcmpl-9St7vdjEBHdS9gOSL1lZUESPrENmF", "object": "chat.completion", "created": 1716672119, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erlotinib is a tyrosine kinase inhibitor (TKI) that targets the epidermal growth factor receptor (EGFR). It is primarily used in the treatment of certain types of non-small cell lung cancer (NSCLC) and pancreatic cancer. Here are some key points you should know about Erlotinib:\n\n### Indications:\n1. **Non-Small Cell Lung Cancer (NSCLC):**\n   - Erlotinib is used as a first-line treatment for patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.\n   - It is also used as a maintenance treatment for patients with locally advanced or metastatic NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.\n   - Additionally, it can be used for the treatment of locally advanced or metastatic NSCLC after the failure of at least one prior chemotherapy regimen.\n\n2. **Pancreatic Cancer:**\n   - Erlotinib is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_VOct3OWOQUUzYpaMctlYPm2A", "custom_id": "101_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "90a1343582ecee2ecec6de5090676c0f", "body": {"id": "chatcmpl-9St7xy0PB4WLY7W0m9R84Lof6hLwE", "object": "chat.completion", "created": 1716672121, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Estramustine is a chemotherapy medication primarily used in the treatment of prostate cancer. Here are some key points you should know about Estramustine:\n\n### Mechanism of Action\n- **Combination Drug**: Estramustine is a combination of estradiol (a form of estrogen) and nitrogen mustard (a type of alkylating agent). \n- **Dual Action**: It works by disrupting microtubule function, which inhibits cell division, and by exerting estrogenic effects that can help in reducing testosterone levels, which prostate cancer cells often rely on for growth.\n\n### Indications\n- **Prostate Cancer**: It is mainly indicated for the palliative treatment of metastatic or progressive prostate cancer.\n\n### Administration\n- **Oral Form**: Estramustine is typically administered orally in the form of capsules.\n- **Dosage**: The dosage can vary, but it is often given as 14 mg/kg/day in divided doses. It is important to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_amVgI1kgu8mINgfYKXelkFlz", "custom_id": "102_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7f0631cef2dbe7284ebbb4f4c4988291", "body": {"id": "chatcmpl-9St7xOxRZHOuLWCAQ8RIi26ZEfpfo", "object": "chat.completion", "created": 1716672121, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Etoposide is a chemotherapeutic agent used primarily in the treatment of various malignancies. Here are some key points you should know about Etoposide:\n\n### Mechanism of Action\n- **Topoisomerase II Inhibition**: Etoposide works by inhibiting the enzyme topoisomerase II, which is essential for DNA replication and repair. This inhibition leads to DNA strand breaks and ultimately cell death, particularly in rapidly dividing cancer cells.\n\n### Indications\n- **Small Cell Lung Cancer (SCLC)**: Etoposide is commonly used in combination with other chemotherapeutic agents for the treatment of SCLC.\n- **Testicular Cancer**: It is also used in combination regimens for the treatment of testicular cancer.\n- **Other Cancers**: Etoposide may be used off-label for other malignancies, including lymphomas, leukemias, and certain types of sarcomas.\n\n### Administration\n- **Intravenous"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_VsxfeXaGWCSrUfAzwVkHZv1H", "custom_id": "103_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c0e420328b0a7c2a56c008267f6e84e6", "body": {"id": "chatcmpl-9St7z69cuDXfytvQF9PnzAgtnaCw3", "object": "chat.completion", "created": 1716672123, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Everolimus is an immunosuppressant and antineoplastic agent that you might encounter in various clinical settings. Here are some key points you should know about Everolimus:\n\n### Mechanism of Action\n- **mTOR Inhibition**: Everolimus inhibits the mammalian target of rapamycin (mTOR), a kinase involved in cell growth, proliferation, and survival. By inhibiting mTOR, Everolimus can reduce cell proliferation and angiogenesis.\n\n### Indications\n- **Oncology**: Everolimus is used in the treatment of various cancers, including advanced renal cell carcinoma, hormone receptor-positive, HER2-negative breast cancer, pancreatic neuroendocrine tumors, and subependymal giant cell astrocytoma associated with tuberous sclerosis.\n- **Transplantation**: It is also used as an immunosuppressant to prevent organ rejection in kidney and liver transplant recipients.\n\n### Dosage and Administration\n- **Formulations**: Everolimus"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_r7keBDhaWnQmXgblnmIkaPDI", "custom_id": "104_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "db8f5f88ad1e1d5e0f17a726404976e4", "body": {"id": "chatcmpl-9St7zpUpX2z4WWU3vTqWCMhwLxmi0", "object": "chat.completion", "created": 1716672123, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Exemestane is an aromatase inhibitor used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Here are some key points you should know about Exemestane:\n\n### Mechanism of Action\n- **Aromatase Inhibition**: Exemestane works by inhibiting the enzyme aromatase, which is responsible for converting androgens to estrogens. By reducing estrogen levels, it helps to slow the growth of estrogen-dependent breast cancer cells.\n\n### Indications\n- **Breast Cancer**: It is commonly prescribed for postmenopausal women with estrogen receptor-positive (ER+) breast cancer, either as adjuvant therapy following surgery or as a treatment for advanced or metastatic disease.\n- **Prevention**: In some cases, it may be used for the prevention of breast cancer in high-risk postmenopausal women.\n\n### Dosage and Administration\n- **Standard Dose**: The typical dose is 25 mg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_4I0OH52v0ToDwfdED8O0xZMx", "custom_id": "105_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ee7198a2ddc173514718e7c2728566c1", "body": {"id": "chatcmpl-9St80nr1nGr2MFoaGteiZ5sGI1JPF", "object": "chat.completion", "created": 1716672124, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Floxuridine is a chemotherapeutic agent primarily used in the treatment of cancer. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Antimetabolite**: Floxuridine is a pyrimidine analog that interferes with DNA synthesis. It is converted into 5-fluorouracil (5-FU) in the body, which then inhibits thymidylate synthase, an enzyme crucial for DNA replication and repair.\n\n### Indications\n- **Cancer Treatment**: It is mainly used for the treatment of gastrointestinal adenocarcinoma that has metastasized to the liver. It can also be used for other types of cancer as determined by the oncologist.\n- **Regional Chemotherapy**: Often administered via intra-arterial infusion directly to the liver to maximize local drug concentration and minimize systemic toxicity.\n\n### Administration\n- **Intra-arterial Infusion**: Typically delivered through a catheter placed in the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_S3IDINOrX8qdguUqmZ4FrbRR", "custom_id": "106_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ab3d781fe2753e377d7b3561a7781faa", "body": {"id": "chatcmpl-9St80szJQtuOrIOiXvUSa5cH3QlV0", "object": "chat.completion", "created": 1716672124, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fludarabine is a chemotherapy medication primarily used to treat hematologic malignancies, particularly chronic lymphocytic leukemia (CLL). Here are some key points you should know about Fludarabine:\n\n### Mechanism of Action\n- **Antimetabolite**: Fludarabine is a purine analog that interferes with DNA synthesis. It gets incorporated into the DNA of rapidly dividing cells, leading to inhibition of DNA polymerase, ribonucleotide reductase, and DNA primase, ultimately causing cell death.\n\n### Indications\n- **Chronic Lymphocytic Leukemia (CLL)**: It is most commonly used for CLL, especially in patients who have not responded to other treatments.\n- **Other Hematologic Malignancies**: It may also be used off-label for other conditions like non-Hodgkin's lymphoma and acute myeloid leukemia (AML).\n\n### Administration\n- **Intravenous (IV)**: Fludarabine is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_1wL4MUSKfNc7D9jGTdblMeX7", "custom_id": "107_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "533ebad93532f0e38a8b7a0f4d60d0ba", "body": {"id": "chatcmpl-9St80D5unN8FcD2QQU3tLWP8Rosm9", "object": "chat.completion", "created": 1716672124, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fluorouracil (5-FU) is a widely used chemotherapeutic agent, primarily employed in the treatment of various cancers. Here are some key points you should know about Fluorouracil:\n\n### Mechanism of Action\n- **Antimetabolite**: Fluorouracil is a pyrimidine analog that interferes with DNA and RNA synthesis.\n- **Inhibition of Thymidylate Synthase**: It inhibits thymidylate synthase, an enzyme crucial for DNA synthesis, leading to cell death.\n\n### Indications\n- **Cancers Treated**: Commonly used for colorectal, breast, stomach, pancreatic, and head and neck cancers.\n- **Topical Use**: Also used topically for actinic keratosis and superficial basal cell carcinoma.\n\n### Administration\n- **Routes**: Can be administered intravenously or topically.\n- **Regimens**: Often used in combination with other chemotherapeutic agents or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_kTMH7mYIe0BrJEcJmS6Ar4O3", "custom_id": "108_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7400f3383370f5fc1c83e75a545b606b", "body": {"id": "chatcmpl-9St8058XeWdjKx7lgxbE8S3YfZrUi", "object": "chat.completion", "created": 1716672124, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fluoxymesterone is an anabolic steroid with properties similar to testosterone. It is used in various medical conditions, but it also has significant potential for abuse and adverse effects. Here are some key points you should know about Fluoxymesterone:\n\n### Indications:\n1. **Hypogonadism in Males**: It is used to treat males with low testosterone levels due to various causes.\n2. **Delayed Puberty in Males**: It can be prescribed to stimulate puberty in boys with delayed puberty.\n3. **Breast Cancer in Females**: It is sometimes used in the palliative treatment of breast cancer in postmenopausal women.\n\n### Mechanism of Action:\n- Fluoxymesterone works by binding to androgen receptors, leading to increased protein synthesis and decreased protein breakdown. This results in the development and maintenance of male secondary sexual characteristics and muscle mass.\n\n### Dosage and Administration:\n- The dosage varies depending on the condition being treated. For hyp"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_tQHsNnlCfpCvafYUy72SOeSc", "custom_id": "109_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e0d7865828316413b3fa833d9d011a2c", "body": {"id": "chatcmpl-9St818wh9FyQzpiHPen5nfbjpiv0V", "object": "chat.completion", "created": 1716672125, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Flutamide is a nonsteroidal antiandrogen medication primarily used in the treatment of prostate cancer. Here are some key points you should know about Flutamide:\n\n### Mechanism of Action\n- **Antiandrogen**: Flutamide works by inhibiting the action of androgens (male hormones) by binding to androgen receptors. This prevents androgens from stimulating the growth of prostate cancer cells.\n\n### Indications\n- **Prostate Cancer**: It is commonly used in combination with other treatments such as luteinizing hormone-releasing hormone (LHRH) agonists for the management of metastatic prostate cancer.\n- **Off-label Uses**: Occasionally, it may be used off-label for conditions like hirsutism in women, though this is less common.\n\n### Dosage and Administration\n- **Typical Dosage**: The usual dose for prostate cancer is 250 mg taken orally three times a day.\n- **Combination Therapy**: Often used in combination"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_c3b1bKGF0Oz2bGnRTWiBEh2g", "custom_id": "110_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "93bc330b6bace2882fa4a168bc429b4e", "body": {"id": "chatcmpl-9St81QN1g8P8kcKuwDTcmW9Hkir78", "object": "chat.completion", "created": 1716672125, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Folinic acid, also known as leucovorin, is a medication that has several important clinical uses. Here are key points you should know about it:\n\n### Mechanism of Action\n- **Folinic acid** is a form of folate (vitamin B9) that bypasses the need for dihydrofolate reductase, an enzyme that converts folic acid to its active form, tetrahydrofolate.\n- It is used to counteract the effects of folic acid antagonists, such as methotrexate, by providing a source of folate that can be utilized by the body.\n\n### Clinical Uses\n1. **Methotrexate Rescue**:\n   - Folinic acid is used to reduce the toxic effects of high-dose methotrexate therapy in cancer treatment. It \"rescues\" normal cells by providing a source of folate, allowing them to survive while methotrexate continues to target rapidly dividing cancer cells.\n\n2. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_DZahQoKjhY54mM6KFEU8kjLe", "custom_id": "111_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "91cb3c0e2dc262679807f829967aff6f", "body": {"id": "chatcmpl-9St84TT3bFE3Lbz97nPUaHNqDLGSE", "object": "chat.completion", "created": 1716672128, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Formestane is a synthetic steroidal substance that functions as an aromatase inhibitor. It is primarily used in the treatment of estrogen receptor-positive breast cancer in postmenopausal women. Here are some key points you should know about Formestane:\n\n### Mechanism of Action\n- **Aromatase Inhibition**: Formestane inhibits the enzyme aromatase, which is responsible for converting androgens into estrogens. By blocking this conversion, Formestane reduces estrogen levels in the body, which can help slow the growth of estrogen-dependent breast cancer cells.\n\n### Indications\n- **Breast Cancer**: It is used mainly for the treatment of hormone receptor-positive breast cancer in postmenopausal women.\n- **Off-Label Uses**: While not commonly prescribed for other conditions, some off-label uses may exist, but these should be approached with caution and based on clinical judgment.\n\n### Administration\n- **Route**: Formestane is typically administered via"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Q1A0LRNPwBv7Rj23z1Uw96Vm", "custom_id": "112_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "10b730c83d74eb0304ef98e5075e3f29", "body": {"id": "chatcmpl-9St86Kljr3yCFmbSVGdmB7ZnWfvcH", "object": "chat.completion", "created": 1716672130, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Forodesine is a purine nucleoside phosphorylase (PNP) inhibitor that has been investigated primarily for its potential use in treating certain types of hematologic malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL) and T-cell non-Hodgkin's lymphoma (T-NHL). Here are some key points you should know about Forodesine:\n\n### Mechanism of Action\n- **PNP Inhibition**: Forodesine inhibits the enzyme purine nucleoside phosphorylase, which is crucial for the salvage pathway of purine metabolism. This inhibition leads to the accumulation of deoxyguanosine triphosphate (dGTP) in T-cells.\n- **Selective Toxicity**: The accumulation of dGTP is particularly toxic to T-cells, leading to apoptosis. This selective toxicity makes Forodesine a potential therapeutic agent for T-cell malignancies.\n\n### Indications\n- **T-Cell Malignancies"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_jNwQ1Ei03lPZRZy0TuLZftoO", "custom_id": "113_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "8d10df3e39816486f40173cfe0cc765b", "body": {"id": "chatcmpl-9St87YTMpxjFIG7ZgKniaVCLyqBX9", "object": "chat.completion", "created": 1716672131, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fostamatinib is an oral spleen tyrosine kinase (SYK) inhibitor that is primarily used in the treatment of chronic immune thrombocytopenia (ITP) in adults who have had an insufficient response to previous treatments. Here are some key points you should know about Fostamatinib:\n\n### Mechanism of Action\n- **SYK Inhibition**: Fostamatinib inhibits SYK, a key signaling molecule in the immune system that is involved in the activation of various immune cells, including B cells, T cells, and macrophages. By inhibiting SYK, Fostamatinib reduces the destruction of platelets.\n\n### Indications\n- **Chronic Immune Thrombocytopenia (ITP)**: It is indicated for the treatment of adults with chronic ITP who have not responded adequately to other treatments such as corticosteroids, immunoglobulins, or splenectomy.\n\n### Dosage and Administration\n- **Initial Dose"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_3FBGSerMfhKc9wG9Qlkte1SM", "custom_id": "114_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "04b99e1ea54796af472f544b20a0e010", "body": {"id": "chatcmpl-9St89SQDdzlrnU7ock6SBDfaaFMGE", "object": "chat.completion", "created": 1716672133, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fotemustine is a chemotherapeutic agent used primarily in the treatment of certain types of cancer, including malignant melanoma and brain metastases. Here are some key points you should know about Fotemustine:\n\n### Mechanism of Action\n- **Alkylating Agent**: Fotemustine belongs to the nitrosourea class of alkylating agents. It works by adding an alkyl group to the DNA, which leads to DNA cross-linking and strand breaks, ultimately inhibiting DNA replication and transcription, and causing cell death.\n\n### Indications\n- **Malignant Melanoma**: Fotemustine is often used in the treatment of advanced malignant melanoma, particularly when the disease has metastasized to the brain.\n- **Brain Metastases**: It is also used for treating brain metastases from other primary tumors.\n\n### Administration\n- **Intravenous Infusion**: Fotemustine is typically administered via intravenous infusion. The dosing regimen"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_RRRrx8yGyj4VpadPdDKXB7Hb", "custom_id": "115_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c218a583a7dbea7ec9373d95ed6df807", "body": {"id": "chatcmpl-9St8AFN7d5x1HKgsMLpT7GgGnLrjT", "object": "chat.completion", "created": 1716672134, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fulvestrant is a medication used primarily in the treatment of hormone receptor-positive metastatic breast cancer. Here are some key points you should know about Fulvestrant as a physician:\n\n### Mechanism of Action\n- **Estrogen Receptor Antagonist**: Fulvestrant is a selective estrogen receptor degrader (SERD). It binds to estrogen receptors (ER) and accelerates their degradation, thereby reducing the number of estrogen receptors available for estrogen binding.\n- **Inhibition of Tumor Growth**: By degrading estrogen receptors, Fulvestrant inhibits the growth of estrogen-dependent breast cancer cells.\n\n### Indications\n- **Metastatic Breast Cancer**: Fulvestrant is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women.\n- **Combination Therapy**: It is often used in combination with other therapies, such as CDK4/6 inhibitors (e.g., palbociclib) or PI3K inhibitors ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_VZXXDlJgbOlJFU32owqtG0we", "custom_id": "116_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "07d2f54a338da27233b40d132475c13f", "body": {"id": "chatcmpl-9St8AS56mrelyPxi9xyeJcYTh7a6m", "object": "chat.completion", "created": 1716672134, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gefitinib is a tyrosine kinase inhibitor (TKI) that targets the epidermal growth factor receptor (EGFR). It is primarily used in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. Here are some key points you should know about Gefitinib:\n\n### Indications:\n- **Non-Small Cell Lung Cancer (NSCLC):** Gefitinib is indicated for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.\n\n### Mechanism of Action:\n- **EGFR Inhibition:** Gefitinib inhibits the tyrosine kinase activity of the EGFR, which is involved in the signaling pathways that regulate cell proliferation and survival. By blocking this activity, Gefitinib can slow down or stop the growth of cancer cells.\n\n### Administration:\n- **Oral Intake:** Gefitinib is administered orally, typically at a dose of "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_zNkQ9cm7jrx66kcy0ze0Btnf", "custom_id": "117_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "89ea7d8983dbbc966444cd65fc4ee05c", "body": {"id": "chatcmpl-9St8BRcCpMwSs3it2XPH1DiUypvdg", "object": "chat.completion", "created": 1716672135, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gemcitabine is a nucleoside analog used as chemotherapy. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Antimetabolite**: Gemcitabine is a pyrimidine analog that interferes with DNA synthesis. It is incorporated into DNA during replication, leading to chain termination and apoptosis.\n- **Cell Cycle Specificity**: It is most effective in the S-phase of the cell cycle.\n\n### Indications\n- **Cancers Treated**: Gemcitabine is used to treat various types of cancer, including:\n  - Pancreatic cancer\n  - Non-small cell lung cancer (NSCLC)\n  - Bladder cancer\n  - Breast cancer\n  - Ovarian cancer\n  - Soft tissue sarcoma\n\n### Administration\n- **Route**: Intravenous infusion.\n- **Dosing Schedule**: Typically administered on a weekly basis for a few weeks followed by a rest period, but schedules"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_UIZAmOst5gLpXax7XiccSGfg", "custom_id": "118_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "4a4e9445a79f0074e3c9e9a922a6212c", "body": {"id": "chatcmpl-9St8BpQKvXjrLDINbM9lrc7zXmUW3", "object": "chat.completion", "created": 1716672135, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gemtuzumab ozogamicin is an important medication used in the treatment of certain types of acute myeloid leukemia (AML). Here are key points you should know about it:\n\n### Mechanism of Action\n- **Antibody-Drug Conjugate**: Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC). It combines a monoclonal antibody targeting CD33, a protein expressed on the surface of myeloid leukemia cells, with a cytotoxic agent called calicheamicin.\n- **Targeted Therapy**: The monoclonal antibody binds to CD33-positive cells, allowing the cytotoxic agent to be internalized and released inside the cell, leading to DNA damage and cell death.\n\n### Indications\n- **Acute Myeloid Leukemia (AML)**: It is primarily used for the treatment of newly diagnosed and relapsed or refractory CD33-positive AML in adults and pediatric patients.\n\n### Administration\n- **Intravenous"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_lTIA0ZbfLHJEwfVg7i8FJiSw", "custom_id": "119_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "87e6912911b76a2817f0b9e4cd786989", "body": {"id": "chatcmpl-9St8CZo7giS31KvmymBIjrSKPf9X2", "object": "chat.completion", "created": 1716672136, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gilteritinib is a medication used primarily in the treatment of acute myeloid leukemia (AML), particularly in patients who have a specific genetic mutation known as FLT3. Here are some key points you should know about Gilteritinib:\n\n### Mechanism of Action\n- **FLT3 Inhibition**: Gilteritinib is a tyrosine kinase inhibitor that specifically targets FLT3, a receptor tyrosine kinase that is often mutated in AML. These mutations can lead to uncontrolled cell proliferation.\n- **Dual Inhibition**: It inhibits both FLT3-ITD (internal tandem duplication) and FLT3-TKD (tyrosine kinase domain) mutations, which are associated with poor prognosis in AML.\n\n### Indications\n- **Relapsed or Refractory AML**: Gilteritinib is approved for use in adult patients with relapsed or refractory AML who have a FLT3 mutation, as detected by an FDA-approved test.\n\n### Administration\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_n7AJlhPecolJoqXkIo0GMPNb", "custom_id": "120_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "05f578c317dbc06b0aad7c6f05d4aec3", "body": {"id": "chatcmpl-9St8CaVOLW3Icy59Xwd19AAghNbMI", "object": "chat.completion", "created": 1716672136, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Glasdegib is an oral medication used in the treatment of certain types of cancer, specifically acute myeloid leukemia (AML). Here are some key points you should know about Glasdegib:\n\n### Mechanism of Action\n- **Hedgehog Pathway Inhibitor**: Glasdegib works by inhibiting the Hedgehog signaling pathway, which is involved in the regulation of cell growth and differentiation. This pathway is often abnormally activated in cancer cells, contributing to their proliferation and survival.\n\n### Indications\n- **Acute Myeloid Leukemia (AML)**: Glasdegib is approved for use in combination with low-dose cytarabine for the treatment of newly diagnosed AML in adult patients who are 75 years or older or who have comorbidities that preclude the use of intensive induction chemotherapy.\n\n### Administration\n- **Oral Tablet**: Glasdegib is administered orally, typically once daily.\n- **Combination Therapy**: It is used in combination with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_7JBkWJ5VJZO22XZmLyAu2nyp", "custom_id": "121_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0befc182326bab66fb89df26cb7dc8e7", "body": {"id": "chatcmpl-9St8DxMnNrGUUcW0ehCWbE2X6xEFJ", "object": "chat.completion", "created": 1716672137, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Goserelin is a synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH or GnRH) used primarily in the treatment of hormone-sensitive cancers and certain benign gynecological conditions. Here are key points you should know about Goserelin:\n\n### Indications:\n1. **Prostate Cancer**: Used in the management of advanced prostate cancer.\n2. **Breast Cancer**: Indicated for premenopausal women with hormone receptor-positive breast cancer.\n3. **Endometriosis**: Helps in the management of endometriosis by reducing estrogen levels.\n4. **Uterine Fibroids**: Used to shrink fibroids before surgery.\n5. **Assisted Reproductive Technology**: Sometimes used to control ovarian function.\n\n### Mechanism of Action:\n- Goserelin acts as an agonist at the LHRH receptors in the pituitary gland. Initially, it causes a surge in luteinizing hormone (LH) and follicle-st"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_9yS0rLfAGHwwzfSZRJ7tfNi3", "custom_id": "122_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "4fbfc2ef9b7d103a00d2ea93e6ad2e9d", "body": {"id": "chatcmpl-9St8ESXVFI29aob3CIXFNGU0MK10o", "object": "chat.completion", "created": 1716672138, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Histrelin is a synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH) used primarily in the treatment of hormone-sensitive conditions. Here are some key points you should know about Histrelin:\n\n### Indications:\n1. **Central Precocious Puberty (CPP):** Histrelin is used to treat children with CPP to delay the onset of puberty.\n2. **Prostate Cancer:** It is used in the palliative treatment of advanced prostate cancer by reducing testosterone levels.\n\n### Mechanism of Action:\n- Histrelin acts as a GnRH agonist. Initially, it stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a temporary increase in sex hormones (testosterone in males and estrogen in females). However, with continuous administration, it downregulates GnRH receptors in the pituitary gland, leading to decreased secretion of LH and FSH, and subsequently, a significant reduction in sex"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_dmwkRdV0lBHycaOvWHER4yLm", "custom_id": "123_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "918347641730b3f10c8ae36957f342c4", "body": {"id": "chatcmpl-9St8Fca80G9lheqSDowWYZEK9SYiN", "object": "chat.completion", "created": 1716672139, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Hydrocortisone is a corticosteroid medication commonly used to treat a variety of conditions due to its anti-inflammatory and immunosuppressive properties. Here are some key points you should know about hydrocortisone:\n\n### Indications\n1. **Inflammatory Conditions**: Hydrocortisone is used to treat conditions such as arthritis, dermatitis, and inflammatory bowel disease.\n2. **Allergic Reactions**: It can be used to manage severe allergic reactions, including anaphylaxis.\n3. **Adrenal Insufficiency**: It is the drug of choice for replacement therapy in adrenal insufficiency (e.g., Addison's disease).\n4. **Autoimmune Diseases**: Conditions like lupus and multiple sclerosis may be managed with hydrocortisone.\n5. **Respiratory Conditions**: It can be used in asthma and chronic obstructive pulmonary disease (COPD) exacerbations.\n\n### Forms and Administration\n- **Topical**: Creams and ointments for skin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ECfZhWiq4s2jlqDXYaBD6Omi", "custom_id": "124_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3e02a6b5ec2aa04d2539ec408bde6b2c", "body": {"id": "chatcmpl-9St8Frj5S0Km3beMzpyIl9I74tsir", "object": "chat.completion", "created": 1716672139, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Hydroxyurea is a medication with several important clinical applications, and as a physician, there are several key aspects you should be aware of:\n\n### Indications:\n1. **Sickle Cell Disease**: Hydroxyurea is commonly used to reduce the frequency of painful crises and the need for blood transfusions in patients with sickle cell anemia. It works by increasing fetal hemoglobin (HbF) levels, which helps to reduce the sickling of red blood cells.\n2. **Myeloproliferative Disorders**: It is used in the management of certain myeloproliferative disorders, such as chronic myeloid leukemia (CML) and polycythemia vera, to reduce the high cell counts.\n3. **Other Cancers**: Hydroxyurea can be used as part of the treatment regimen for certain cancers, including melanoma, ovarian cancer, and head and neck cancers.\n\n### Mechanism of Action:\n- Hydroxyurea inhibits rib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_xeCP9hVH0yN9lr17uvBbKPL8", "custom_id": "125_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7a37d0fa17688bf00182c9937537c1e8", "body": {"id": "chatcmpl-9St8GBccuPFiK3jVbkErdxYc1y2hG", "object": "chat.completion", "created": 1716672140, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibritumomab tiuxetan is a radioimmunotherapy drug used primarily in the treatment of certain types of non-Hodgkin lymphoma (NHL). Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Monoclonal Antibody**: Ibritumomab is a monoclonal antibody that targets the CD20 antigen found on the surface of B-cells.\n- **Radioisotope**: Tiuxetan is a chelator that binds to a radioactive isotope, typically Yttrium-90 (Y-90) or Indium-111 (In-111). The radioisotope delivers targeted radiation to the cancer cells.\n\n### Indications\n- **Relapsed or Refractory NHL**: It is often used for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin lymphoma.\n- **First-line Consolidation Therapy**: It can also be used as"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_YGX1pL3ofs6R0aAz0bg24TWx", "custom_id": "126_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3fa8eced0694c595637fbdddc974dbed", "body": {"id": "chatcmpl-9St8HzA3Ui6zNiVnssauRj5BdX7Lm", "object": "chat.completion", "created": 1716672141, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibrutinib is a medication used primarily in the treatment of certain types of blood cancers. Here are some key points you should know about it:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL)**: Ibrutinib is often used in both treatment-naive and relapsed/refractory CLL.\n2. **Mantle Cell Lymphoma (MCL)**: Approved for patients who have received at least one prior therapy.\n3. **Waldenstr\u00f6m's Macroglobulinemia (WM)**: Used in the treatment of this rare type of non-Hodgkin lymphoma.\n4. **Marginal Zone Lymphoma (MZL)**: For patients who require systemic therapy and have received at least one prior anti-CD20-based therapy.\n5. **Chronic Graft-Versus-Host Disease (cGVHD)**: For patients who have failed one or more lines of systemic therapy.\n\n### Mechanism of Action"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_zZeFg02LNtDZjsWn98719wpl", "custom_id": "127_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9506520f1012bc36dcb2d4dcc49c40e5", "body": {"id": "chatcmpl-9St8I051pJPeeTJzqBaOtAG5tu1Z8", "object": "chat.completion", "created": 1716672142, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Icotinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used primarily in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. Here are some key points you should know about Icotinib:\n\n1. **Mechanism of Action**: Icotinib selectively inhibits the tyrosine kinase activity of the EGFR, which is often overexpressed or mutated in certain types of cancer, including NSCLC. By inhibiting this pathway, Icotinib can reduce tumor cell proliferation and induce apoptosis.\n\n2. **Indications**: Icotinib is indicated for the treatment of patients with locally advanced or metastatic NSCLC who have specific activating mutations in the EGFR gene. It is often used in patients who have not responded to chemotherapy or as a first-line treatment in those with confirmed EGFR mutations.\n\n3. **Efficacy**: Clinical trials have shown that Icot"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_CqdBQSdRnJpm1ChAPWDo1Ufp", "custom_id": "128_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "bcc86e5894e4c7ca03ad54b4661c5627", "body": {"id": "chatcmpl-9St8ImTibCXBSjooHIvQlJ0IfZ4ax", "object": "chat.completion", "created": 1716672142, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idarubicin is an anthracycline antibiotic used primarily as a chemotherapeutic agent. Here are some key points you should know about Idarubicin:\n\n### Indications:\n- **Acute Myeloid Leukemia (AML):** Idarubicin is commonly used in combination with other chemotherapeutic agents for the treatment of AML in adults.\n- **Acute Lymphoblastic Leukemia (ALL):** It may also be used in certain cases of ALL.\n\n### Mechanism of Action:\n- Idarubicin intercalates into DNA, disrupting the enzyme topoisomerase II, which is essential for DNA replication and repair. This leads to the inhibition of DNA synthesis and induces apoptosis in rapidly dividing cells.\n\n### Administration:\n- **Intravenous (IV) Administration:** Idarubicin is typically administered intravenously. The dosage and schedule depend on the specific treatment protocol and patient factors such as age, weight, and overall health.\n\n### Side Effects:\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_hn2jbI9uW6Qe6DLRTPN7zH7P", "custom_id": "129_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0836c163919714f61465ad13d944a062", "body": {"id": "chatcmpl-9St8JBtxmJ8PjcNSuICWK2BhhcRrK", "object": "chat.completion", "created": 1716672143, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idelalisib is an oral medication used primarily in the treatment of certain types of blood cancers. Here are some key points you should know about Idelalisib:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL)**: Often used in combination with rituximab for patients who have received at least one prior therapy.\n2. **Follicular B-cell non-Hodgkin lymphoma (FL)**: For patients who have received at least two prior systemic therapies.\n3. **Small Lymphocytic Lymphoma (SLL)**: Similar to CLL, used in patients who have received at least one prior therapy.\n\n### Mechanism of Action:\n- Idelalisib is a selective inhibitor of the delta isoform of phosphoinositide 3-kinase (PI3K\u03b4), which is highly expressed in B-cell malignancies. By inhibiting PI3K\u03b4, Idelalisib disrupts signaling pathways that"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_d9JZVTwJxRTvpY5YvIDJ6g9a", "custom_id": "130_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "fb9e1e3fd7bf05059f45fa8a627caf53", "body": {"id": "chatcmpl-9St8K337kTXTYUmb4KjbzOxiqJp6q", "object": "chat.completion", "created": 1716672144, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ifosfamide is an alkylating agent used primarily in the treatment of various cancers, including testicular cancer, sarcomas, lymphomas, and certain types of lung cancer. Here are some key points you should know about Ifosfamide:\n\n### Mechanism of Action\n- **Alkylating Agent**: Ifosfamide works by cross-linking DNA strands, which inhibits DNA replication and transcription, leading to cell death. It is a prodrug that requires activation by hepatic enzymes.\n\n### Indications\n- **Cancer Treatment**: It is used in the treatment of various malignancies, often in combination with other chemotherapeutic agents.\n\n### Administration\n- **Intravenous**: Ifosfamide is typically administered intravenously. The dosage and schedule depend on the type of cancer being treated, the patient's overall health, and other factors.\n\n### Side Effects\n- **Hematologic**: Myelosuppression, leading to leukopenia, thrombocyt"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_8leA1cPM2StxtiFa0CqaaCpC", "custom_id": "131_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "eb61a1765fb311072172cf742564f5f6", "body": {"id": "chatcmpl-9St8KFlpRhtuqGreETjTTduPI8piq", "object": "chat.completion", "created": 1716672144, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imatinib, commonly known by its brand name Gleevec, is a tyrosine kinase inhibitor used primarily in the treatment of certain types of cancer. Here are some key points you should know about Imatinib:\n\n### Indications:\n1. **Chronic Myeloid Leukemia (CML):** Imatinib is most commonly used for the treatment of Philadelphia chromosome-positive (Ph+) CML in chronic, accelerated, or blast crisis phases.\n2. **Acute Lymphoblastic Leukemia (ALL):** It is also used for Ph+ ALL.\n3. **Gastrointestinal Stromal Tumors (GIST):** Imatinib is effective in treating metastatic and/or unresectable malignant GIST.\n4. **Other Indications:** It may also be used for other conditions like myelodysplastic/myeloproliferative diseases, systemic mastocytosis, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_eqxSMa3mG6eGKVNH3NxCjdy6", "custom_id": "132_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1323bc7649135021076b40ea76f311cd", "body": {"id": "chatcmpl-9St8LaNRcCCph4tdk0lOF8IuKlRqz", "object": "chat.completion", "created": 1716672145, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Infigratinib is a targeted therapy used primarily in the treatment of certain types of cancer. Here are some key points you should know about it:\n\n### Indications:\n- **Cholangiocarcinoma**: Infigratinib is approved for the treatment of patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) that has a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.\n\n### Mechanism of Action:\n- **FGFR Inhibitor**: Infigratinib is a tyrosine kinase inhibitor that targets FGFR1, FGFR2, and FGFR3. By inhibiting these receptors, it can interfere with the signaling pathways that promote cancer cell proliferation and survival.\n\n### Administration:\n- **Oral**: Infigratinib is administered orally, typically once daily. The specific dosage and treatment schedule can vary based on the patient's condition and response"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_uCut1vIM37FdnaHxRXhqsSaR", "custom_id": "133_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3747cf09e498950a5a28395312620b88", "body": {"id": "chatcmpl-9St8MUgVTTtdjqCxJhkNJTIHjJZ3b", "object": "chat.completion", "created": 1716672146, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Inotuzumab ozogamicin is a targeted cancer therapy used primarily in the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Here are some key points you should know about this medication:\n\n### Mechanism of Action\n- **Antibody-Drug Conjugate (ADC):** Inotuzumab ozogamicin is an ADC composed of a monoclonal antibody targeting CD22, a cell surface antigen expressed on B-cells, linked to a cytotoxic agent, calicheamicin.\n- **Targeted Delivery:** The monoclonal antibody binds to CD22 on the surface of B-cells, allowing the conjugated calicheamicin to be internalized into the cell.\n- **Cytotoxic Effect:** Once inside the cell, calicheamicin is released, causing DNA breaks and leading to cell death.\n\n### Indications\n- **Relapsed or Refractory B-cell Precursor ALL:** It is specifically indicated for adult"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_UWpyatBGrdXnXQl7WoNjNE9E", "custom_id": "134_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "fd08afa822584743bc2fbf9aeb87a9ac", "body": {"id": "chatcmpl-9St8NgbFRVFsI3yZZJwgzLFpv4IjY", "object": "chat.completion", "created": 1716672147, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon alfa-2a is a type of cytokine used in the treatment of various medical conditions, primarily certain types of cancers and viral infections. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Antiviral Activity**: Interferon alfa-2a inhibits viral replication within host cells.\n- **Antiproliferative Effects**: It can inhibit the growth of tumor cells.\n- **Immunomodulatory Effects**: It enhances the immune system's response to infections and malignancies.\n\n### Indications\n- **Chronic Hepatitis B and C**: It is used to treat chronic viral hepatitis infections.\n- **Certain Cancers**: Including hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.\n- **Other Conditions**: It may also be used for other conditions as determined by a healthcare provider.\n\n### Administration\n- **Route**: Typically administered via subcutaneous or intramuscular injection.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_EwYrGgKqgBHxHqenpFyyJoJZ", "custom_id": "135_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "72a465fb333efd064cda03100786731a", "body": {"id": "chatcmpl-9St8OycDEC2Eeikv4ALmkvHB7saeY", "object": "chat.completion", "created": 1716672148, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon alfa-2b is a type of cytokine in the interferon family, which are proteins that play a crucial role in the immune response. Here are some key points you should know about Interferon alfa-2b:\n\n### Mechanism of Action\n- **Antiviral Activity**: Interferon alfa-2b inhibits viral replication within host cells.\n- **Immunomodulatory Effects**: It enhances the immune system's ability to fight off infections and diseases by increasing the activity of natural killer cells and macrophages.\n- **Antiproliferative Effects**: It can inhibit the growth of certain cancer cells by modulating the expression of specific genes involved in cell proliferation.\n\n### Indications\nInterferon alfa-2b is used to treat a variety of conditions, including:\n- **Chronic Hepatitis B and C**: It helps to reduce viral load and improve liver function.\n- **Certain Cancers**: Such as malignant melanoma, hairy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_yE3p4NMzbIqNYwyHjsnHDnPq", "custom_id": "136_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "bf25a1b0061dc79e6eb85166a2b8eb92", "body": {"id": "chatcmpl-9St8ObxJsAbPqqAq9W5HMxBMx0xFf", "object": "chat.completion", "created": 1716672148, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon gamma-1b (IFN-\u03b31b) is a recombinant form of the naturally occurring protein interferon gamma, which is a cytokine critical for innate and adaptive immunity against viral and intracellular bacterial infections and for tumor control. Here are some key points you should know about Interferon gamma-1b:\n\n### Indications:\n1. **Chronic Granulomatous Disease (CGD):** IFN-\u03b31b is used to reduce the frequency and severity of serious infections in patients with CGD.\n2. **Severe, Malignant Osteopetrosis (SMO):** It is also indicated to delay disease progression in patients with severe, malignant osteopetrosis.\n\n### Mechanism of Action:\n- **Immune Modulation:** IFN-\u03b31b enhances the oxidative metabolism of macrophages, increases the expression of Fc receptors, and enhances antigen presentation. It also activates neutrophils and natural killer (NK) cells, promoting the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_oakO2UZHxSWLvYLJNuzT6euN", "custom_id": "137_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ac2c5d0fed365574f59c34896588cc6b", "body": {"id": "chatcmpl-9St8Oqxv15CQ0V7bNIwpi5aX8eZQO", "object": "chat.completion", "created": 1716672148, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ipilimumab is a monoclonal antibody that is used as an immunotherapy treatment, primarily for certain types of cancer. Here are some key points you should know about Ipilimumab:\n\n### Mechanism of Action\n- **CTLA-4 Inhibition**: Ipilimumab works by targeting CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4), a protein receptor that downregulates the immune system. By inhibiting CTLA-4, Ipilimumab enhances the immune system's ability to attack cancer cells.\n\n### Indications\n- **Melanoma**: Ipilimumab is FDA-approved for the treatment of unresectable or metastatic melanoma.\n- **Other Cancers**: It is also being studied and used in combination with other therapies for various other cancers, including renal cell carcinoma and non-small cell lung cancer.\n\n### Administration\n- **Dosage**: The typical dosage and schedule can vary depending on the specific cancer being"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_GjnfrjJPicTyi07kbDccDwQn", "custom_id": "138_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f23cd8b8be9456030378cc4ebd97e193", "body": {"id": "chatcmpl-9St8Oy9qXyAwKJAvt4AvGPlhwHRPl", "object": "chat.completion", "created": 1716672148, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Irinotecan is a chemotherapy drug used primarily in the treatment of colorectal cancer, but it can also be used for other types of cancer. Here are some key points you should know about Irinotecan:\n\n### Mechanism of Action\n- **Topoisomerase I Inhibitor**: Irinotecan works by inhibiting the enzyme topoisomerase I, which is essential for DNA replication. This inhibition leads to DNA damage and ultimately cell death, particularly in rapidly dividing cancer cells.\n\n### Indications\n- **Colorectal Cancer**: Often used in combination with other chemotherapy agents like 5-fluorouracil (5-FU) and leucovorin (FOLFIRI regimen).\n- **Other Cancers**: May also be used in small cell lung cancer, pancreatic cancer, and other malignancies.\n\n### Administration\n- **Intravenous (IV) Infusion**: Typically administered as an IV infusion. The dosage and schedule depend on the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_IcVCxDhBf7ovkkJS61iRD7yq", "custom_id": "139_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "10e0e25c1eca704fcef417b10c33852a", "body": {"id": "chatcmpl-9St8OoazmsjsL9OvYPYqk54D4AU3G", "object": "chat.completion", "created": 1716672148, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Irinotecan liposome, also known by its brand name Onivyde, is a chemotherapeutic agent used primarily in the treatment of metastatic pancreatic cancer. It is a liposomal formulation of irinotecan, which is a topoisomerase I inhibitor. Here are some key points you should know about Irinotecan liposome:\n\n### Indications:\n- **Metastatic Pancreatic Cancer**: It is approved for use in combination with fluorouracil and leucovorin for patients with metastatic adenocarcinoma of the pancreas whose disease has progressed following gemcitabine-based therapy.\n\n### Mechanism of Action:\n- **Topoisomerase I Inhibition**: Irinotecan inhibits topoisomerase I, an enzyme involved in DNA replication. This inhibition leads to DNA damage and cell death, particularly in rapidly dividing cancer cells.\n- **Liposomal Formulation**: The liposomal encapsulation allows for a more targeted delivery of the drug to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_keNWbDdRPbXZ94fmJp9L4xSB", "custom_id": "140_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "80d998767dddda3f53f26f08ffed4fcb", "body": {"id": "chatcmpl-9St8Orh2if1ScuuONvhXsxvWUCFfT", "object": "chat.completion", "created": 1716672148, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Isatuximab is a monoclonal antibody used in the treatment of multiple myeloma, a type of blood cancer. Here are some key points you should know about Isatuximab:\n\n### Mechanism of Action\n- **Target**: Isatuximab targets CD38, a glycoprotein expressed on the surface of multiple myeloma cells.\n- **Action**: It induces cell death through multiple mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis.\n\n### Indications\n- **Multiple Myeloma**: Isatuximab is typically used in combination with other therapies for patients with relapsed or refractory multiple myeloma. It is often combined with agents like pomalidomide and dexamethasone.\n\n### Administration\n- **Route**: Intravenous infusion.\n- **Dosing Schedule**: The dosing schedule can vary, but it often involves an"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_0WbjHdtbo2mzWIh2mXbjuCRI", "custom_id": "141_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f4c18b44a2b3f069ec94d29527c9963c", "body": {"id": "chatcmpl-9St8PXolQeZ1KXi85jBJ6GRK3AHvF", "object": "chat.completion", "created": 1716672149, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Isotretinoin, commonly known by its former brand name Accutane, is a powerful medication primarily used to treat severe acne, particularly nodular or cystic acne that has not responded to other treatments. Here are some key points you should know about Isotretinoin:\n\n### Mechanism of Action\n- **Reduces Sebum Production:** Isotretinoin significantly decreases the size and activity of sebaceous glands, leading to reduced sebum production.\n- **Anti-inflammatory Effects:** It has anti-inflammatory properties that help reduce acne lesions.\n- **Normalizes Keratinization:** It helps normalize the shedding of skin cells within hair follicles, preventing clogged pores.\n\n### Indications\n- **Severe Nodular Acne:** It is primarily indicated for severe nodular acne.\n- **Recalcitrant Acne:** Used when other treatments, including antibiotics and topical therapies, have failed.\n- **Off-label Uses:** Sometimes used for other skin conditions like rosacea, hidradenitis suppur"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_VPVFn9TlCtvLfKMLmlLD37XD", "custom_id": "142_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "11f02cbcb736262b5947514e6cb80f54", "body": {"id": "chatcmpl-9St8P1hwEDATOrfUFbJ6Ny5Pl0NnX", "object": "chat.completion", "created": 1716672149, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ivosidenib is a medication used primarily in the treatment of certain types of cancer, specifically acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. Here are some key points you should know about Ivosidenib:\n\n### Mechanism of Action\n- **Target**: Ivosidenib is an inhibitor of the IDH1 enzyme. Mutations in IDH1 can lead to the production of an oncometabolite called 2-hydroxyglutarate (2-HG), which contributes to the development and progression of cancer.\n- **Action**: By inhibiting the mutated IDH1 enzyme, Ivosidenib reduces the levels of 2-HG, thereby potentially restoring normal cellular differentiation and reducing the proliferation of cancer cells.\n\n### Indications\n- **Acute Myeloid Leukemia (AML)**: Ivosidenib is indicated for the treatment of adult patients with rel"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Ma6qSSLPr8FnSJxpEDkUi1IW", "custom_id": "143_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c33e16a565781119d1c23e1f9e1a093d", "body": {"id": "chatcmpl-9St8QJPJD1NgQs6sOAndJRTLSQKQ3", "object": "chat.completion", "created": 1716672150, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ixabepilone is a chemotherapeutic agent used primarily in the treatment of metastatic or locally advanced breast cancer, particularly in patients whose tumors are resistant to other treatments. Here are some key points you should know about Ixabepilone:\n\n### Mechanism of Action\n- **Microtubule Stabilization**: Ixabepilone is a microtubule inhibitor that stabilizes microtubules, preventing their disassembly. This disrupts the mitotic process, leading to cell cycle arrest and apoptosis in cancer cells.\n\n### Indications\n- **Breast Cancer**: It is approved for use in metastatic or locally advanced breast cancer, especially in cases where the cancer is resistant to anthracyclines, taxanes, and capecitabine.\n\n### Administration\n- **Intravenous Infusion**: Ixabepilone is administered as an intravenous infusion. The typical dosing schedule is 40 mg/m\u00b2 over 3 hours every 21 days"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_bi3GEhD9HNadVEjO2lKfgBUx", "custom_id": "144_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "45b7533259907a530a7de5e49f0d4676", "body": {"id": "chatcmpl-9St8QxNHxmpElSIJJz7yk7xjNbWjm", "object": "chat.completion", "created": 1716672150, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ixazomib is an oral proteasome inhibitor used primarily in the treatment of multiple myeloma, a type of blood cancer. Here are some key points you should know about Ixazomib:\n\n### Mechanism of Action\n- **Proteasome Inhibition**: Ixazomib inhibits the 20S proteasome, a complex responsible for degrading ubiquitinated proteins. This inhibition leads to an accumulation of proteins within the cell, inducing apoptosis, particularly in cancer cells.\n\n### Indications\n- **Multiple Myeloma**: Ixazomib is approved for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.\n\n### Administration\n- **Oral Route**: Ixazomib is taken orally, typically once a week on days 1, 8, and 15 of a 28-day cycle.\n- **Combination Therapy**: It is usually"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_QEyyLtDENhIeokU6UJvMSKsM", "custom_id": "145_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0737c691c489ab110691cd830f7e8b84", "body": {"id": "chatcmpl-9St8RiXeERLwrkcY5vgsZcesqJNxi", "object": "chat.completion", "created": 1716672151, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ketoconazole is an antifungal medication that is used to treat a variety of fungal infections. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Inhibition of Ergosterol Synthesis**: Ketoconazole works by inhibiting the enzyme lanosterol 14\u03b1-demethylase, which is crucial for the synthesis of ergosterol, an essential component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately cell death.\n\n### Indications\n- **Topical Use**: Ketoconazole is commonly used in topical formulations (creams, shampoos) to treat conditions like seborrheic dermatitis, tinea infections (e.g., athlete's foot, jock itch), and dandruff.\n- **Systemic Use**: Oral ketoconazole can be used for systemic fungal infections, but its use has declined due to the risk of severe side effects and the availability of safer alternatives.\n\n### Dosage and Administration\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_g8mID6RTAl1FStpBJbraixl7", "custom_id": "146_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "43893fe0bcb11942a60494e3c460ab1d", "body": {"id": "chatcmpl-9St8RgWepiM1grjsPouQwHN2R4p3Q", "object": "chat.completion", "created": 1716672151, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lanreotide is a synthetic, long-acting analog of somatostatin, a hormone that inhibits the release of several other hormones. It is primarily used in the treatment of acromegaly and certain types of neuroendocrine tumors. Here are some key points you should know about Lanreotide:\n\n### Indications:\n1. **Acromegaly**: Lanreotide is used to reduce growth hormone and insulin-like growth factor-1 (IGF-1) levels in patients with acromegaly, particularly when surgery or radiotherapy is not an option or has not been fully effective.\n2. **Neuroendocrine Tumors (NETs)**: It is used to treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to control symptoms and slow tumor growth.\n\n### Mechanism of Action:\n- Lanreotide mimics natural somatostatin, binding to somatostatin receptors and inhibiting the secretion of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ONwUshjohvVbS43tw3RIIsDO", "custom_id": "147_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a3a85d2875731fa3fc8f401348901ff2", "body": {"id": "chatcmpl-9St8R7VJI7UJSZCoDng6UxnX8mrSN", "object": "chat.completion", "created": 1716672151, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lansoprazole is a proton pump inhibitor (PPI) commonly used to treat conditions related to excess stomach acid. Here are some key points you should know about Lansoprazole:\n\n### Indications:\n1. **Gastroesophageal Reflux Disease (GERD):** Lansoprazole is effective in reducing symptoms and healing erosive esophagitis.\n2. **Peptic Ulcer Disease:** It helps in the treatment and prevention of gastric and duodenal ulcers.\n3. **Zollinger-Ellison Syndrome:** Used to manage this condition characterized by excessive gastric acid production.\n4. **Helicobacter pylori Eradication:** Often used in combination with antibiotics to treat H. pylori infections.\n\n### Mechanism of Action:\n- Lansoprazole inhibits the H+/K+ ATPase enzyme system (proton pump) in the gastric parietal cells, leading to a significant reduction in gastric acid secretion.\n\n### Dosage and Administration:\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_x8yTYEPBqJcw5hA7qA2A9B74", "custom_id": "148_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "fcf646e32e5ecd18a0ce157ca34832e5", "body": {"id": "chatcmpl-9St8Ry1ONAzvnxVtsPGCcckxwRTYk", "object": "chat.completion", "created": 1716672151, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lapatinib is an oral tyrosine kinase inhibitor used primarily in the treatment of certain types of breast cancer. Here are some key points you should know about Lapatinib:\n\n### Indications:\n1. **HER2-Positive Breast Cancer**: Lapatinib is used in combination with other therapies for patients with advanced or metastatic HER2-positive breast cancer. It is often used in cases where patients have previously received other treatments, such as trastuzumab.\n\n### Mechanism of Action:\n1. **Dual Inhibition**: Lapatinib inhibits both the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2). This dual inhibition helps to block the pathways that promote cancer cell growth and survival.\n\n### Administration:\n1. **Oral Medication**: Lapatinib is taken orally, usually once daily. It should be taken on an empty stomach, either one hour before or one hour after a meal.\n2"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_r9p2VMNLfnLuF1C5SirhCqfC", "custom_id": "149_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "69555c6e5ca7a64370df4252fb91181f", "body": {"id": "chatcmpl-9St8SUlMGJJuNAYwqSEOypes8TfDf", "object": "chat.completion", "created": 1716672152, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Larotrectinib is a targeted cancer therapy that you should be familiar with, especially if you are involved in oncology. Here are some key points you should know:\n\n### Mechanism of Action\n- **Target**: Larotrectinib is a selective inhibitor of tropomyosin receptor kinases (TRK) A, B, and C.\n- **Mechanism**: It works by inhibiting the TRK fusion proteins that result from NTRK gene fusions, which can drive cancer cell growth and survival.\n\n### Indications\n- **Tumor-Agnostic**: Larotrectinib is approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation.\n- **Specific Cancers**: It is used in various cancers, including but not limited to, soft tissue sarcoma, thyroid cancer, lung cancer, and certain pediatric cancers.\n\n### Efficacy\n- **Response Rates**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_os4S66Iu4Ia9txmhuHCB1ESO", "custom_id": "150_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "8c71041655870b9dfeb415a4470d157d", "body": {"id": "chatcmpl-9St8SMz7qrqK8JMnFFDHIjIjWrR4q", "object": "chat.completion", "created": 1716672152, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lenalidomide is an immunomodulatory drug with anti-angiogenic and anti-neoplastic properties, commonly used in the treatment of various hematologic malignancies. Here are some key points you should know about Lenalidomide:\n\n### Indications:\n1. **Multiple Myeloma**: Often used in combination with dexamethasone or other agents.\n2. **Myelodysplastic Syndromes (MDS)**: Particularly effective in patients with deletion 5q cytogenetic abnormality.\n3. **Mantle Cell Lymphoma**: Approved for use in patients whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.\n4. **Follicular Lymphoma and Marginal Zone Lymphoma**: In combination with rituximab.\n\n### Mechanism of Action:\n- **Immunomodulation**: Enhances T-cell and natural killer (NK) cell-mediated cytotoxicity.\n- **Anti"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_dUtA60bvF4WmzSFlDZ6iUZPj", "custom_id": "151_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0ab926c36d6adc9b12bbc615755f883c", "body": {"id": "chatcmpl-9St8SnHaBYJLcLLZXA2t53DXuwuWg", "object": "chat.completion", "created": 1716672152, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lenograstim is a recombinant human granulocyte colony-stimulating factor (G-CSF) used primarily to stimulate the production of white blood cells, particularly neutrophils. Here are some key points you should know about Lenograstim:\n\n### Indications:\n1. **Neutropenia**: Lenograstim is used to treat neutropenia, which can be a side effect of chemotherapy in cancer patients. It helps reduce the duration of neutropenia and the incidence of febrile neutropenia.\n2. **Bone Marrow Transplantation**: It is also used to mobilize peripheral blood progenitor cells (PBPCs) for collection and subsequent autologous or allogeneic transplantation.\n3. **Severe Chronic Neutropenia**: It can be used in patients with severe chronic neutropenia to increase neutrophil counts and reduce the risk of infection.\n\n### Mechanism of Action:\n- Lenograstim acts by binding to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_3lcPkvpotQe0dTqPsc05JpCU", "custom_id": "152_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "70ffe2d4b991572dac1dfcab768bd3a9", "body": {"id": "chatcmpl-9St8SkhDui3JpNcWl4OEWemW7o4wg", "object": "chat.completion", "created": 1716672152, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lenvatinib is a multi-kinase inhibitor used primarily in the treatment of certain types of cancer. Here are some key points you should know about Lenvatinib:\n\n### Indications:\n1. **Thyroid Cancer**: Lenvatinib is approved for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.\n2. **Renal Cell Carcinoma (RCC)**: It is used in combination with everolimus for the treatment of advanced RCC following one prior anti-angiogenic therapy.\n3. **Hepatocellular Carcinoma (HCC)**: Lenvatinib is indicated for the first-line treatment of patients with unresectable HCC.\n4. **Endometrial Carcinoma**: In combination with pembrolizumab, it is used for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_fFqk9nJtO1yTgBEtvrDNJitc", "custom_id": "153_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1f99bde3fe6afb9884e11993f4c9ab4e", "body": {"id": "chatcmpl-9St8S9NrFjhdzlFBVKnpCQWpHktr8", "object": "chat.completion", "created": 1716672152, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Letrozole is a medication that is primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Here are some key points you should know about Letrozole:\n\n### Mechanism of Action\n- **Aromatase Inhibitor**: Letrozole works by inhibiting the enzyme aromatase, which is involved in the synthesis of estrogen. By reducing estrogen levels, it helps to slow or stop the growth of estrogen receptor-positive breast cancer cells.\n\n### Indications\n- **Breast Cancer**: It is commonly prescribed for the adjuvant treatment of hormone receptor-positive early breast cancer, extended adjuvant treatment after 5 years of tamoxifen therapy, and for the treatment of advanced breast cancer.\n- **Fertility Treatment**: Off-label, Letrozole is sometimes used to induce ovulation in women with polycystic ovary syndrome (PCOS) or other ovulatory disorders.\n\n### Dosage and Administration\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_UoyReoU9qk9KWLmvh5A19PP8", "custom_id": "154_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "05d3345a309d204d6a84f12d0d741e2f", "body": {"id": "chatcmpl-9St8S6dfg62PNlUWHrjRM0C3ab8XF", "object": "chat.completion", "created": 1716672152, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Leuprolide is a synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH or LHRH). It is used primarily in the treatment of hormone-responsive cancers such as prostate cancer and breast cancer, as well as in conditions like endometriosis, uterine fibroids, and central precocious puberty. Here are some key points you should know about Leuprolide:\n\n### Mechanism of Action\n- **GnRH Agonist**: Leuprolide acts as a GnRH agonist. Initially, it stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a temporary increase in sex hormones (testosterone and estrogen). However, with continuous administration, it downregulates the GnRH receptors in the pituitary gland, leading to decreased production of LH and FSH, and subsequently, a significant reduction in sex hormone levels.\n\n### Indications\n- **Prostate Cancer**: Used"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_OoVbqzriU5vLTUrT8WTq5ekq", "custom_id": "155_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3052b4e2ee3eca7ddf799736a6a90014", "body": {"id": "chatcmpl-9St8TvdosTsbZCB5Q1r1J6en641aZ", "object": "chat.completion", "created": 1716672153, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Levamisole is a medication that has been used for various purposes, including as an anthelmintic (to treat parasitic worm infections) and as an immunomodulatory agent. Here are some key points you should know about Levamisole:\n\n### Medical Uses:\n1. **Anthelmintic**: Levamisole was originally used to treat parasitic worm infections, particularly those caused by nematodes.\n2. **Immunomodulatory Agent**: It has been used in the past as an adjuvant treatment in colorectal cancer to enhance the immune response. However, its use in this context has largely been discontinued due to the availability of more effective treatments and concerns about side effects.\n\n### Mechanism of Action:\n- **Anthelmintic**: Levamisole works by causing paralysis of the worms, which are then expelled from the body.\n- **Immunomodulatory**: It is believed to modulate the immune system by enhancing the function of T-ly"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_0UF2xouYpwBLdhCROH6yIjV9", "custom_id": "156_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "dca9a7a0987102aaeae250a2c92761cc", "body": {"id": "chatcmpl-9St8TtsvTNpT5QZ9DNwoiwJstl1FK", "object": "chat.completion", "created": 1716672153, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Levoleucovorin is a medication used primarily in oncology and is the active enantiomer of racemic leucovorin (folinic acid). Here are some key points you should know about Levoleucovorin:\n\n### Indications:\n1. **Methotrexate Rescue**: Levoleucovorin is used to diminish the toxic effects of high-dose methotrexate therapy in osteosarcoma and other cancers.\n2. **Colorectal Cancer**: It is used in combination with 5-fluorouracil (5-FU) for the treatment of advanced colorectal cancer.\n3. **Folic Acid Antagonist Overdose**: It can be used to counteract the effects of folic acid antagonists, such as methotrexate, in cases of overdose or accidental exposure.\n\n### Mechanism of Action:\n- Levoleucovorin acts as a folate analog, providing a source of tetrahydrofolate, which is necessary"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_RWgs2ifoV7GM6iqMFugDRJRh", "custom_id": "157_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f9bee11a8abf369b7277a9d19126ea05", "body": {"id": "chatcmpl-9St8TVsB7UlOLNbBnzMDDJ6wuRcnU", "object": "chat.completion", "created": 1716672153, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lomustine, also known by its brand name CeeNU, is an alkylating agent used primarily in the treatment of certain types of cancer. Here are some key points you should know about Lomustine:\n\n### Indications:\n1. **Primary Brain Tumors**: Lomustine is often used in the treatment of primary brain tumors, including gliomas.\n2. **Hodgkin's Lymphoma**: It is sometimes used in combination with other chemotherapy agents for the treatment of Hodgkin's lymphoma, particularly in cases where the disease has relapsed or is refractory to initial treatment.\n3. **Other Cancers**: It may also be used off-label for other types of cancers, such as lung cancer or melanoma, depending on the clinical scenario.\n\n### Mechanism of Action:\n- Lomustine is an alkylating agent that works by cross-linking DNA strands, thereby inhibiting DNA replication and RNA transcription. This leads to cell cycle arrest and apoptosis"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_127OzRhSgmoLBnWMIN61pGWe", "custom_id": "158_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c1719faa8c61b71963c82ff524f0e9eb", "body": {"id": "chatcmpl-9St8UDkFr1M6tEAmMOefNQySwmEdm", "object": "chat.completion", "created": 1716672154, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lorlatinib is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK) or ROS1 gene rearrangements. Here are some key points you should know about Lorlatinib:\n\n### Mechanism of Action\n- **Tyrosine Kinase Inhibitor (TKI):** Lorlatinib is a third-generation ALK and ROS1 TKI. It works by inhibiting the activity of these kinases, which are involved in the growth and spread of cancer cells.\n\n### Indications\n- **ALK-positive NSCLC:** Lorlatinib is indicated for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to one or more ALK TKIs.\n- **ROS1-positive NSCLC:** It is also used for patients with ROS1-positive metastatic NSCLC.\n\n### Dosage and Administration\n- **Oral Administration:** Lorlatinib is taken orally, usually"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_8sqCocVts3T8fS58cnEXKmd1", "custom_id": "159_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "390719cb4c03b5552bc2c6083739c93e", "body": {"id": "chatcmpl-9St8UuxqKA5KHTxIYLgvZqhBWkA68", "object": "chat.completion", "created": 1716672154, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lutetium Lu 177 dotatate (brand name Lutathera) is a radiopharmaceutical used in the treatment of certain types of neuroendocrine tumors (NETs). Here are some key points you should know about it:\n\n### Indications:\n- **Approved Use**: Lutetium Lu 177 dotatate is primarily indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.\n- **Mechanism of Action**: It works by binding to somatostatin receptors, which are often overexpressed in neuroendocrine tumors. Once bound, the radiolabeled compound delivers targeted radiation to the tumor cells, causing DNA damage and cell death.\n\n### Administration:\n- **Dosage**: The typical dosage is 7.4 GBq (200 mCi) administered intravenously every "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_DhzZYXyM6wq61kPy7SVm0vrS", "custom_id": "160_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7fb1bb476de18c3bd5e44b73bc0408f9", "body": {"id": "chatcmpl-9St8UCXJXdSRI7tLJn5Zw5zacKBan", "object": "chat.completion", "created": 1716672154, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tafasitamab is a monoclonal antibody used in the treatment of certain types of B-cell non-Hodgkin lymphoma, particularly relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Here are some key points you should know about Tafasitamab:\n\n### Mechanism of Action\n- **Target**: Tafasitamab targets CD19, a protein expressed on the surface of B-cells.\n- **Action**: By binding to CD19, Tafasitamab induces cell death through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).\n\n### Indications\n- **Primary Use**: Tafasitamab is primarily indicated for the treatment of adult patients with relapsed or refractory DLBCL who are not eligible for autologous stem cell transplant (ASCT).\n- **Combination Therapy**: It is often used in combination with lenalidomide, followed by Tafasitam"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_LkeLoLqM8D4NQsICrJgIrRk6", "custom_id": "161_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "198450ea944c2c161776bd1286559c73", "body": {"id": "chatcmpl-9St8UeAhVbt69pDrCN3RKFkWZyP7u", "object": "chat.completion", "created": 1716672154, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mechlorethamine, also known as nitrogen mustard, is a chemotherapy agent used primarily in the treatment of certain types of cancer. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Alkylating Agent**: Mechlorethamine works by alkylating DNA, which leads to cross-linking of DNA strands, thereby inhibiting DNA replication and transcription. This ultimately results in cell death, particularly in rapidly dividing cells such as cancer cells.\n\n### Indications\n- **Hodgkin's Lymphoma**: Often used as part of combination chemotherapy regimens.\n- **Non-Hodgkin's Lymphoma**: Can be used in certain cases.\n- **Cutaneous T-cell Lymphoma**: Topical formulations are used for skin lesions.\n- **Other Cancers**: Occasionally used in other malignancies, though less common.\n\n### Administration\n- **Intravenous (IV)**: Traditional route for systemic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_isVcWk3B0sz53cqSXXKNN2qW", "custom_id": "162_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1681fbcdbef8795d6994e7eae280b8ef", "body": {"id": "chatcmpl-9St8U2yJmakWgYxHPKbILvSyhxrdj", "object": "chat.completion", "created": 1716672154, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Medroxyprogesterone is a synthetic progestin, a type of hormone similar to the natural hormone progesterone. It is used in various clinical settings, and as a physician, you should be aware of its indications, mechanisms of action, dosing, side effects, and contraindications. Here are some key points:\n\n### Indications\n1. **Contraception**: Medroxyprogesterone acetate (MPA) is used as a long-acting injectable contraceptive (Depo-Provera).\n2. **Menstrual Disorders**: It is used to treat amenorrhea (absence of menstruation) and abnormal uterine bleeding due to hormonal imbalance.\n3. **Endometriosis**: It can help manage pain and other symptoms associated with endometriosis.\n4. **Hormone Replacement Therapy (HRT)**: Used in combination with estrogen to reduce the risk of endometrial hyperplasia in postmenopausal women.\n5. **Cancer**: Sometimes used"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_M87CZOnat94q3gSBPtld4lEy", "custom_id": "163_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "71716972d2504b2979dde86a5d41bb4f", "body": {"id": "chatcmpl-9St8UBq5XG69JVVp3zflDkTdFPeLp", "object": "chat.completion", "created": 1716672154, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Megestrol acetate is a synthetic progestin with various clinical applications. Here are some key points you should know about it:\n\n### Indications:\n1. **Cancer Treatment**: Megestrol is often used in the palliative treatment of advanced breast cancer and endometrial cancer. It can help manage symptoms and potentially slow the progression of these cancers.\n2. **Appetite Stimulation**: It is commonly prescribed to stimulate appetite and promote weight gain in patients with significant weight loss due to chronic illnesses such as cancer, AIDS, or other conditions causing cachexia.\n3. **Hormone Replacement Therapy**: In some cases, it may be used as part of hormone replacement therapy, although this is less common.\n\n### Mechanism of Action:\n- **Progestational Effects**: Megestrol works by mimicking the effects of the natural hormone progesterone. It can alter the hormonal environment, which can be beneficial in hormone-sensitive cancers.\n- **Appetite Stimulation**: The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_IxpxCAKGMwwi3BKodRpnTrXp", "custom_id": "164_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "78642dec433dbf01709fcb50e3763dad", "body": {"id": "chatcmpl-9St8V1W9sFTr3E3EQqFI0WDRBAp7h", "object": "chat.completion", "created": 1716672155, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Melphalan is an alkylating agent used primarily in the treatment of multiple myeloma and ovarian cancer. Here are some key points you should know about Melphalan:\n\n### Mechanism of Action\n- **Alkylating Agent**: Melphalan works by cross-linking DNA strands, which inhibits DNA synthesis and function, leading to cell death. This is particularly effective in rapidly dividing cancer cells.\n\n### Indications\n- **Multiple Myeloma**: Often used in combination with other drugs or as part of high-dose chemotherapy followed by stem cell transplantation.\n- **Ovarian Cancer**: Used in certain cases, particularly when other treatments have failed.\n- **Other Cancers**: Occasionally used off-label for other malignancies, such as melanoma and amyloidosis.\n\n### Administration\n- **Oral and Intravenous**: Available in both oral and IV forms. The choice depends on the specific clinical scenario and patient factors.\n- **Dosing**: D"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_NWeV3bmklppihzN7PND3kNRM", "custom_id": "165_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "58b71e29d8f70dedcc1563ae1d74b564", "body": {"id": "chatcmpl-9St8VvcGobM4ZfLKP61maxQAsiHhw", "object": "chat.completion", "created": 1716672155, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mercaptopurine, also known as 6-mercaptopurine or 6-MP, is an important medication used primarily in the treatment of certain types of cancer and autoimmune diseases. Here are key points you should know about it:\n\n### Indications:\n1. **Acute Lymphoblastic Leukemia (ALL):** Mercaptopurine is commonly used in the maintenance phase of treatment.\n2. **Chronic Myeloid Leukemia (CML):** It can be used as part of the treatment regimen.\n3. **Inflammatory Bowel Disease (IBD):** It is sometimes used off-label for Crohn's disease and ulcerative colitis.\n\n### Mechanism of Action:\n- Mercaptopurine is a purine analog that interferes with DNA and RNA synthesis. It gets incorporated into the DNA and RNA, leading to faulty replication and transcription, which ultimately inhibits the proliferation of rapidly dividing cells, such as cancer cells.\n\n### Dosage and Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_DFAXL7woeelXX8cYYSOhzvvn", "custom_id": "166_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1bffda40dc0b3906076634e65e65499f", "body": {"id": "chatcmpl-9St8VHTAsRDpPLCkNU7OxkABJ5cue", "object": "chat.completion", "created": 1716672155, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mesna (2-mercaptoethane sulfonate sodium) is a medication primarily used to reduce the risk of hemorrhagic cystitis, a potential side effect of certain chemotherapy drugs like cyclophosphamide and ifosfamide. Here are some key points you should know about Mesna:\n\n### Mechanism of Action\n- **Protective Agent**: Mesna works by binding to and inactivating acrolein, a toxic metabolite of cyclophosphamide and ifosfamide, which can cause damage to the bladder lining.\n\n### Indications\n- **Prophylaxis**: It is indicated for the prophylaxis of hemorrhagic cystitis in patients receiving high-dose cyclophosphamide or ifosfamide.\n\n### Administration\n- **Routes**: Mesna can be administered intravenously (IV) or orally.\n- **Dosing Schedule**: The dosing schedule typically involves administration at the same time as the chemotherapy agent and at intervals afterward to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_1BI0YiC4uksQlYwuqP8UoM6I", "custom_id": "167_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "980c5459d201809a115ea88f54c5849d", "body": {"id": "chatcmpl-9St8ViovD58B9fVpBKvb0bCLmx7Lg", "object": "chat.completion", "created": 1716672155, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Methotrexate is a medication with a wide range of uses, primarily in the treatment of certain cancers and autoimmune diseases. Here are some key points you should know about Methotrexate as a physician:\n\n### Mechanism of Action\n- **Antimetabolite and Antifolate**: Methotrexate inhibits dihydrofolate reductase (DHFR), an enzyme involved in the synthesis of tetrahydrofolate. This inhibition leads to a decrease in the synthesis of DNA, RNA, and proteins, which is particularly effective in rapidly dividing cells.\n\n### Indications\n- **Cancer**: Used in the treatment of various cancers, including acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma, breast cancer, and osteosarcoma.\n- **Autoimmune Diseases**: Commonly used in the management of rheumatoid arthritis, psoriasis, and Crohn's disease.\n- **Ectopic Pregnancy**: Used to treat ectopic pregnancies by inhibiting"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_CIxbrsXdA7pjDHS4aOwdSwea", "custom_id": "168_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "028d43b6ed5d2e032e444a6eaf7d9d04", "body": {"id": "chatcmpl-9St8WBRuNZmxyUBv09DouRb2Pw0sI", "object": "chat.completion", "created": 1716672156, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Methoxsalen, also known as 8-methoxypsoralen, is a medication primarily used in combination with ultraviolet A (UVA) light therapy to treat certain skin conditions, such as vitiligo and severe psoriasis. Here are some key points you should know about Methoxsalen:\n\n### Mechanism of Action\n- **Photosensitizer**: Methoxsalen is a photosensitizing agent that, when activated by UVA light, forms cross-links with DNA, leading to a therapeutic effect on skin cells.\n- **Cellular Effects**: It inhibits DNA synthesis and cell proliferation, which is beneficial in conditions characterized by rapid skin cell turnover.\n\n### Indications\n- **Vitiligo**: Used to repigment skin in patients with vitiligo.\n- **Psoriasis**: Employed in the treatment of severe, recalcitrant psoriasis.\n- **Cutaneous T-cell Lymphoma (CTCL)**: Sometimes used in the management"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_gn1BsarKM1bKyuWkvgEYfkEB", "custom_id": "169_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e11e3480c1ee928a8f7d28bb887d4328", "body": {"id": "chatcmpl-9St8WsCMX0QLBl6VzLwfVrEBqXH2d", "object": "chat.completion", "created": 1716672156, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Methylprednisolone is a corticosteroid medication used to suppress the immune system and reduce inflammation. Here are some key points you should know about it:\n\n### Indications:\n1. **Inflammatory and Autoimmune Conditions**: Used to treat conditions like rheumatoid arthritis, lupus, multiple sclerosis, and inflammatory bowel disease.\n2. **Allergic Reactions**: Effective in managing severe allergic reactions and asthma exacerbations.\n3. **Dermatologic Conditions**: Used for severe skin conditions such as psoriasis and eczema.\n4. **Endocrine Disorders**: Can be used in adrenal insufficiency and congenital adrenal hyperplasia.\n5. **Respiratory Conditions**: Employed in the management of chronic obstructive pulmonary disease (COPD) exacerbations.\n6. **Oncology**: Sometimes used in the treatment of certain cancers and to manage chemotherapy-induced nausea and vomiting.\n\n### Mechanism of Action:\n- Methylprednisolone works by mimicking the effects of cortisol, a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_HoAbWyuHxUStWlV6nOojJREm", "custom_id": "170_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "df89fb769b5aa9a2c5c3cd5ec74a6341", "body": {"id": "chatcmpl-9St8WjE75HGxGPhAxepoEj2oxYQdd", "object": "chat.completion", "created": 1716672156, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Midostaurin is a multi-targeted kinase inhibitor used primarily in the treatment of certain types of cancer. Here are some key points you should know about Midostaurin:\n\n### Indications:\n1. **Acute Myeloid Leukemia (AML):**\n   - Midostaurin is used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed AML who are FLT3 mutation-positive, as detected by an FDA-approved test.\n\n2. **Systemic Mastocytosis:**\n   - It is also indicated for the treatment of aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).\n\n### Mechanism of Action:\n- Midostaurin inhibits multiple receptor tyrosine kinases, including FLT3 (FMS-like tyrosine kinase 3), KIT, PDGFR (plate"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ElAgA3ezcgXLUx7xVWsY3yvL", "custom_id": "171_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f39542ea3e6619d41ac434273763e132", "body": {"id": "chatcmpl-9St8XSq5BLBbqtKLpMJDejWDX9iVB", "object": "chat.completion", "created": 1716672157, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mitomycin is an antineoplastic antibiotic that is used primarily in the treatment of various cancers. Here are some key points you should know about Mitomycin:\n\n### Mechanism of Action\n- **DNA Cross-Linking:** Mitomycin works by cross-linking DNA, which inhibits DNA synthesis and function, leading to cell death. It is particularly effective in hypoxic tumor cells.\n- **Alkylation:** It also acts as an alkylating agent, adding alkyl groups to DNA and causing further disruption of DNA function.\n\n### Indications\n- **Gastrointestinal Cancers:** Often used in the treatment of stomach and pancreatic cancers.\n- **Bladder Cancer:** Used intravesically (directly into the bladder) for superficial bladder cancer.\n- **Breast Cancer:** Sometimes used in combination with other chemotherapeutic agents.\n- **Anal Cancer:** Part of the chemoradiation regimen for anal cancer.\n\n### Administration\n- **Intravenous (IV):**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_chzT9HocoDYWKjYhy1kUxZ5r", "custom_id": "172_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "159d66c7337c5876d5b84ce24ead7efd", "body": {"id": "chatcmpl-9St8XXP3HBlRMDtBj7gzKUlv4wGFi", "object": "chat.completion", "created": 1716672157, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mitotane is an adrenolytic medication primarily used in the treatment of adrenocortical carcinoma, a rare cancer of the adrenal cortex. Here are some key points you should know about Mitotane:\n\n### Mechanism of Action\n- **Adrenolytic Activity**: Mitotane selectively destroys adrenal cortex cells, leading to a reduction in cortisol production.\n- **Metabolic Effects**: It alters the peripheral metabolism of steroids and directly suppresses adrenal function.\n\n### Indications\n- **Adrenocortical Carcinoma**: Mitotane is used both for inoperable cases and as adjuvant therapy post-surgery to reduce the risk of recurrence.\n- **Cushing's Syndrome**: Occasionally used off-label for its cortisol-lowering effects.\n\n### Dosage and Administration\n- **Initial Dose**: Typically starts at a lower dose (e.g., 2-6 grams per day) and is gradually increased based on tolerance and therapeutic response.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_XCyjESinG19dKoFQ8Zya4xMe", "custom_id": "173_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a4063149e7c418250a59f21b44d9c915", "body": {"id": "chatcmpl-9St8XEV3XoRIJsB7XqXjljwwfExHL", "object": "chat.completion", "created": 1716672157, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mitoxantrone is an antineoplastic (anti-cancer) agent that is used in the treatment of certain types of cancer and multiple sclerosis (MS). Here are some key points you should know about Mitoxantrone:\n\n### Indications:\n1. **Cancer Treatment:**\n   - Acute myeloid leukemia (AML)\n   - Advanced hormone-refractory prostate cancer\n   - Non-Hodgkin's lymphoma\n   - Breast cancer (especially metastatic breast cancer)\n\n2. **Multiple Sclerosis:**\n   - Secondary progressive MS\n   - Progressive-relapsing MS\n   - Worsening relapsing-remitting MS\n\n### Mechanism of Action:\n- Mitoxantrone is a type II topoisomerase inhibitor. It works by intercalating into DNA and causing crosslinks and strand breaks, which inhibits DNA replication and RNA synthesis. This leads to cell death, particularly in rapidly dividing cells.\n\n### Administration:\n- Mitoxantrone"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_fbIKaMEJ4TaJmjvrHzArVVLH", "custom_id": "174_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b6f4f0feec7aab20108ca635dfc0c237", "body": {"id": "chatcmpl-9St8Xh8Ym9NDF5G6qYNpOZs1Wl8EF", "object": "chat.completion", "created": 1716672157, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mogamulizumab is a monoclonal antibody used in the treatment of certain types of cancer, specifically cutaneous T-cell lymphoma (CTCL) and adult T-cell leukemia/lymphoma (ATLL). Here are some key points you should know about Mogamulizumab:\n\n### Mechanism of Action\n- **Target**: Mogamulizumab targets CCR4 (C-C chemokine receptor type 4), a protein expressed on the surface of some cancer cells, particularly in CTCL and ATLL.\n- **Action**: By binding to CCR4, Mogamulizumab helps the immune system recognize and destroy these cancer cells.\n\n### Indications\n- **Cutaneous T-cell Lymphoma (CTCL)**: Approved for patients with relapsed or refractory CTCL, including mycosis fungoides and S\u00e9zary syndrome.\n- **Adult T-cell Leukemia/Lymphoma (ATLL)**: Used in patients with relapsed or refractory ATLL.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_KgRwp0yGWPYdW91oDcdBJBVI", "custom_id": "175_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b8ebb8af45d12fe9638082a3769c88c3", "body": {"id": "chatcmpl-9St8XtcAKnhX9ecGgZQlqVKHYUOm9", "object": "chat.completion", "created": 1716672157, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Moxetumomab pasudotox is a recombinant immunotoxin used in the treatment of certain types of cancer, specifically hairy cell leukemia (HCL). Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Target**: Moxetumomab pasudotox targets CD22, a cell surface antigen expressed on B-cells.\n- **Structure**: It is a fusion protein combining an anti-CD22 monoclonal antibody fragment with a truncated form of Pseudomonas exotoxin A.\n- **Action**: Upon binding to CD22, the drug is internalized by the cancer cell, where the exotoxin component inhibits protein synthesis, leading to cell death.\n\n### Indications\n- **Hairy Cell Leukemia (HCL)**: It is specifically approved for the treatment of adult patients with relapsed or refractory HCL who have received at least two prior systemic therapies, including treatment with a purine nucleoside"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_r69zdANOgwqONJycgvn7Yxcc", "custom_id": "176_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b63918187da8fd9b6f0ec65d67627547", "body": {"id": "chatcmpl-9St8X0Y5NiZrKnNvFJ3JaHCNQWRVb", "object": "chat.completion", "created": 1716672157, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nadroparin is a low molecular weight heparin (LMWH) used primarily for its anticoagulant properties. Here are some key points you should know about Nadroparin:\n\n### Indications:\n1. **Prophylaxis of Venous Thromboembolism (VTE):** Used to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing surgery or those at risk due to immobilization.\n2. **Treatment of VTE:** Used in the treatment of established DVT and PE.\n3. **Acute Coronary Syndromes (ACS):** Used in the management of unstable angina and non-ST elevation myocardial infarction (NSTEMI).\n4. **Hemodialysis:** Used to prevent clotting in the extracorporeal circuit during hemodialysis.\n\n### Mechanism of Action:\n- Nadroparin enhances the activity of antithrombin III, which inhibits thrombin and factor Xa"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_IvxddPhntuUxdQFJFF0H0qiS", "custom_id": "177_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c73119e3cd878c4aafecb5f7c8265c02", "body": {"id": "chatcmpl-9St8YHOPx3U8bOAiPuOewzNXPo57m", "object": "chat.completion", "created": 1716672158, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Necitumumab is a recombinant human IgG1 monoclonal antibody that targets the epidermal growth factor receptor (EGFR). It is primarily used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC). Here are some key points you should know about Necitumumab:\n\n### Indications:\n- **Non-Small Cell Lung Cancer (NSCLC):** Necitumumab is approved for use in combination with gemcitabine and cisplatin for the first-line treatment of patients with metastatic squamous NSCLC.\n\n### Mechanism of Action:\n- **EGFR Inhibition:** Necitumumab binds to the EGFR, blocking the binding of natural ligands such as EGF and TGF-\u03b1. This inhibition prevents receptor activation and downstream signaling pathways that promote cell proliferation and survival.\n\n### Administration:\n- **Intravenous Infusion:** Necitumumab is administered as an intravenous infusion. The typical dosing schedule involves an initial loading dose followed by maintenance doses"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_KTS48cY9L1oEN8i6O6LtWwF3", "custom_id": "178_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9335787f1a8c85650bc0b58832a78c8c", "body": {"id": "chatcmpl-9St8YVcv2PtVRTWnWlrlizirMX55H", "object": "chat.completion", "created": 1716672158, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nedaplatin is a platinum-based chemotherapeutic agent used primarily in the treatment of various cancers, including head and neck cancer, esophageal cancer, and non-small cell lung cancer. Here are some key points you should know about Nedaplatin:\n\n### Mechanism of Action\n- **DNA Cross-Linking:** Nedaplatin works by forming cross-links with DNA, which inhibits DNA replication and transcription, leading to cell death. This mechanism is similar to other platinum-based drugs like cisplatin and carboplatin.\n\n### Indications\n- **Cancer Types:** It is used in the treatment of various cancers, particularly those that are sensitive to platinum-based chemotherapy, such as head and neck cancer, esophageal cancer, and non-small cell lung cancer.\n\n### Administration\n- **Intravenous Infusion:** Nedaplatin is administered via intravenous infusion. The dosage and schedule depend on the type of cancer being treated, the patient's overall health, and other factors.\n\n### Side Effects\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_2q8yBeHeCRYS3aaq2NombXeQ", "custom_id": "179_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ae5890e1e09789401476772b00164e53", "body": {"id": "chatcmpl-9St8ZXAiz6MtkhRTbDYctkLYzaEJ4", "object": "chat.completion", "created": 1716672159, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nelarabine is a chemotherapy medication used primarily in the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). Here are some key points you should know about Nelarabine:\n\n### Mechanism of Action\n- **Nelarabine** is a prodrug of ara-G (9-\u03b2-D-arabinofuranosylguanine), which is converted into its active form within the body.\n- The active metabolite, ara-GTP, incorporates into DNA, leading to inhibition of DNA synthesis and cell death, particularly in T-lymphoblasts.\n\n### Indications\n- **T-cell Acute Lymphoblastic Leukemia (T-ALL)**: Used in patients who have relapsed or are refractory to other treatments.\n- **T-cell Lymphoblastic Lymphoma (T-LBL)**: Also used in relapsed or refractory cases.\n\n### Administration\n- **Dosage**: Typically"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ix4W4eKjvtVD32niszi95CD9", "custom_id": "180_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "fa59db926444f3e2ed8d41ba1c9c6595", "body": {"id": "chatcmpl-9St8Zr7Lfyv7VvBdBq4lapIvIJNsc", "object": "chat.completion", "created": 1716672159, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Neratinib is an oral tyrosine kinase inhibitor that is used primarily in the treatment of breast cancer. Here are some key points you should know about Neratinib:\n\n### Indications:\n1. **Breast Cancer**: Neratinib is approved for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy. It is also used in combination with capecitabine for the treatment of advanced or metastatic HER2-positive breast cancer in patients who have received two or more prior anti-HER2-based regimens.\n\n### Mechanism of Action:\n- **Tyrosine Kinase Inhibition**: Neratinib irreversibly binds to and inhibits the HER2 and EGFR (epidermal growth factor receptor) tyrosine kinases, which are involved in the proliferation and survival of cancer cells.\n\n### Dosage and Administration:\n- **Extended Adjuvant Setting**: The recommended dose"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Z2VeQd0HeitfmyrCKDgqAJqZ", "custom_id": "181_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1364e8f52b4434ac757db69574cfd6ab", "body": {"id": "chatcmpl-9St8Z7kRqai5apeixaXwfnf3rG0ia", "object": "chat.completion", "created": 1716672159, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nilotinib is a tyrosine kinase inhibitor (TKI) primarily used in the treatment of chronic myeloid leukemia (CML). Here are some key points you should know about Nilotinib:\n\n### Indications:\n- **Chronic Myeloid Leukemia (CML):** Nilotinib is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase.\n- **Resistant or Intolerant CML:** It is also used for patients with chronic or accelerated phase Ph+ CML who are resistant or intolerant to prior therapy, including imatinib.\n\n### Mechanism of Action:\n- Nilotinib works by inhibiting the BCR-ABL tyrosine kinase, which is produced by the Philadelphia chromosome abnormality in CML. This inhibition prevents the proliferation of leukemic cells.\n\n### Dosage and Administration:\n- **Chronic Phase CML:** The typical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_yCVqwmZmyjKjVXxHcTRnnj7Z", "custom_id": "182_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0162e1a0b699ba460227144dc746919f", "body": {"id": "chatcmpl-9St8ZnNKgjbt6xmeivi1HLrPgiWyo", "object": "chat.completion", "created": 1716672159, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nilutamide is a nonsteroidal antiandrogen medication primarily used in the treatment of prostate cancer. Here are some key points you should know about Nilutamide:\n\n### Mechanism of Action\n- **Antiandrogen**: Nilutamide works by blocking androgen receptors, thereby inhibiting the action of androgens (male hormones) like testosterone. This helps to slow the growth of prostate cancer cells, which often rely on androgens for growth.\n\n### Indications\n- **Prostate Cancer**: Nilutamide is typically used in combination with surgical castration (orchiectomy) or other forms of androgen deprivation therapy (ADT) for the treatment of metastatic prostate cancer.\n\n### Dosage and Administration\n- **Initial Dose**: The usual starting dose is 300 mg per day for the first 30 days.\n- **Maintenance Dose**: After the initial period, the dose is typically reduced to 150 mg per day.\n- **Administration**: It is taken"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_KARdOoIgL8HUMfSscWjfvtoW", "custom_id": "183_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "8b214435bd7f8bebc4a51ff7558b1441", "body": {"id": "chatcmpl-9St8Z6skeWkn3tDGYJ2L1ENZ7XfSw", "object": "chat.completion", "created": 1716672159, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nimustine, also known by its chemical name 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU), is a chemotherapeutic agent used primarily in the treatment of certain types of cancer, particularly brain tumors such as gliomas. Here are some key points you should know about Nimustine:\n\n### Mechanism of Action\n- **Alkylating Agent**: Nimustine belongs to the nitrosourea class of alkylating agents. It works by cross-linking DNA strands, which inhibits DNA replication and transcription, leading to cell death.\n- **Lipophilicity**: Its lipophilic nature allows it to cross the blood-brain barrier, making it particularly useful for treating brain tumors.\n\n### Indications\n- **Primary Use**: It is primarily used for the treatment of malignant gliomas, including glioblastoma multiform"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_3ImsJKcE4hb2Wmmpy49cnj5P", "custom_id": "184_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d31353e778e179c9f23a1dc4a1a7d5ed", "body": {"id": "chatcmpl-9St8Zm5UtP5vVfZ07rKEsTUDUttpG", "object": "chat.completion", "created": 1716672159, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nintedanib is a tyrosine kinase inhibitor that is used primarily in the treatment of certain types of lung diseases and cancers. Here are some key points you should know about Nintedanib:\n\n### Indications:\n1. **Idiopathic Pulmonary Fibrosis (IPF):**\n   - Nintedanib is approved for the treatment of IPF, a chronic, progressive lung disease characterized by fibrosis of the lung tissue.\n\n2. **Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD):**\n   - It is also indicated for slowing the rate of decline in pulmonary function in patients with SSc-ILD.\n\n3. **Non-Small Cell Lung Cancer (NSCLC):**\n   - Nintedanib, in combination with docetaxel, is used for the treatment of adult patients with locally advanced, metastatic, or locally recurrent NSCLC of adenocarcinoma tumor histology after first-line chemotherapy.\n\n### Mechanism of Action:\n- Ninted"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Pz5Oc1wV7QStEDVZrE1UGOfz", "custom_id": "185_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f5417bb870033fac228952a5522105c9", "body": {"id": "chatcmpl-9St8ZZrZTcl4IycZKAeWWo8Ee3EoK", "object": "chat.completion", "created": 1716672159, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Niraparib is an oral poly (ADP-ribose) polymerase (PARP) inhibitor used primarily in the treatment of certain types of ovarian cancer. Here are some key points you should know about Niraparib:\n\n### Indications:\n1. **Ovarian Cancer**: Niraparib is approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\n2. **First-Line Maintenance**: It is also used as a first-line maintenance treatment for patients with advanced ovarian cancer who have responded to first-line platinum-based chemotherapy.\n\n### Mechanism of Action:\n- Niraparib inhibits PARP enzymes, which play a role in DNA repair. By inhibiting these enzymes, Niraparib induces synthetic lethality in cancer cells with deficiencies in homologous recombination repair (HRR), such as those with BRCA1/2 mutations.\n\n### Dosage and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_d7s2mytWeQLqRm5PZK1BKVbC", "custom_id": "186_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "21a50434819d1c6b74b9aec0b61a76b5", "body": {"id": "chatcmpl-9St8ZqSoqlvblM7zp3U42MABvp2VM", "object": "chat.completion", "created": 1716672159, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nivolumab is a monoclonal antibody that is used as an immunotherapy treatment for various types of cancer. Here are some key points you should know about Nivolumab:\n\n### Mechanism of Action\n- **Immune Checkpoint Inhibitor**: Nivolumab is a programmed death-1 (PD-1) inhibitor. It works by blocking the PD-1 receptor on T cells, which enhances the immune system's ability to recognize and attack cancer cells.\n\n### Indications\n- **Approved Uses**: Nivolumab is approved for the treatment of several types of cancer, including:\n  - Melanoma\n  - Non-small cell lung cancer (NSCLC)\n  - Renal cell carcinoma (RCC)\n  - Hodgkin lymphoma\n  - Squamous cell carcinoma of the head and neck (SCCHN)\n  - Urothelial carcinoma\n  - Hepatocellular carcinoma (HCC)\n  - Colorectal cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_dbYORrWMbxIbG7mFmmvsD0vg", "custom_id": "187_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2bbff26b6a995682bf8f2a15ac26514f", "body": {"id": "chatcmpl-9St8al96f4lTyazs3RzGnd1NTJ1IT", "object": "chat.completion", "created": 1716672160, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Non-pegylated liposomal doxorubicin is a formulation of the chemotherapeutic agent doxorubicin, encapsulated in liposomes to improve its delivery to cancer cells while reducing systemic toxicity. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Doxorubicin**: It intercalates into DNA, inhibiting topoisomerase II, and generates free radicals, leading to cytotoxicity.\n- **Liposomal Encapsulation**: Enhances drug delivery to tumor cells and reduces exposure to normal tissues.\n\n### Indications\n- **Cancer Types**: Used in various cancers, including breast cancer, ovarian cancer, multiple myeloma, and Kaposi's sarcoma.\n- **Combination Therapy**: Often used in combination with other chemotherapeutic agents or as part of a multi-drug regimen.\n\n### Pharmacokinetics\n- **Distribution**: Liposomal encapsulation alters the pharmacokinetics, leading"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_pf38fwrFbueIXVyllNAZQ4to", "custom_id": "188_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ed4f8051b9530e6e9fb77e4d0dc46345", "body": {"id": "chatcmpl-9St8a5Y78HYZavauM5GvScijTtWis", "object": "chat.completion", "created": 1716672160, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Norethandrolone, also known as norethandrolone or 17\u03b1-ethyl-19-nortestosterone, is a synthetic anabolic-androgenic steroid (AAS) that was developed in the 1950s. Here are some key points you should know about it:\n\n1. **Pharmacology**:\n   - **Mechanism of Action**: Norethandrolone acts by binding to androgen receptors, which leads to increased protein synthesis and muscle growth. It also has progestogenic activity.\n   - **Metabolism**: It is metabolized in the liver and excreted primarily in the urine.\n\n2. **Medical Uses**:\n   - Historically, norethandrolone was used to treat conditions such as anemia, osteoporosis, and cachexia (wasting syndrome). It was also used to promote weight gain and muscle growth in patients with chronic debilitating diseases.\n   - However, its use has largely been discontinued due to the availability of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_IO4gl4FT3URP9pnnMJEAtjsj", "custom_id": "189_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "203e7acec5dfef30ed81ee69e1479390", "body": {"id": "chatcmpl-9St8adXpXHtc1sO5sKizUkzXHownP", "object": "chat.completion", "created": 1716672160, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Obinutuzumab is a monoclonal antibody used primarily in the treatment of certain types of blood cancers, such as chronic lymphocytic leukemia (CLL) and follicular lymphoma. Here are some key points you should know about Obinutuzumab:\n\n### Mechanism of Action\n- **Target**: Obinutuzumab targets the CD20 protein found on the surface of B-cells.\n- **Action**: It works by binding to CD20, leading to B-cell lysis through multiple mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct cell death.\n\n### Indications\n- **Chronic Lymphocytic Leukemia (CLL)**: Often used in combination with chlorambucil for patients who have not received prior treatment.\n- **Follicular Lymphoma**: Used in combination with chemotherapy for patients who have relapsed or are refractory to a rituximab-containing regimen.\n\n### Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_8oSbkuDPOk3R03yCNe3c03Js", "custom_id": "190_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2f406d6c07f4141d8caaee5663ac09ee", "body": {"id": "chatcmpl-9St8a3hYrlq0SfsxW0OghfHofw3tU", "object": "chat.completion", "created": 1716672160, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Octreotide is a synthetic analog of somatostatin, a naturally occurring hormone that inhibits the release of several other hormones and substances in the body. Here are some key points you should know about Octreotide:\n\n### Indications:\n1. **Acromegaly**: Used to reduce growth hormone and IGF-1 levels in patients.\n2. **Neuroendocrine Tumors**: Effective in managing symptoms of carcinoid syndrome and VIPomas by inhibiting hormone secretion.\n3. **Gastrointestinal Bleeding**: Used in the management of variceal bleeding due to its ability to reduce splanchnic blood flow.\n4. **Diarrhea and Flushing**: Helps control severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and vasoactive intestinal peptide-secreting tumors (VIPomas).\n\n### Mechanism of Action:\n- **Inhibition of Hormone Secretion**: Octreotide mimics somatostatin, inhibiting"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_FIf001HAW1mk5Lejk3WkTJyD", "custom_id": "191_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2fc029d10d9bffca832da2df72275deb", "body": {"id": "chatcmpl-9St8aPL3BOKtRJ4Q0ddKmaKQNBSo7", "object": "chat.completion", "created": 1716672160, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Octreotide LAR (Long-Acting Release) is a synthetic analog of somatostatin, a hormone that inhibits the release of several other hormones and substances in the body. It is used primarily in the management of certain medical conditions, particularly those involving hormone-secreting tumors. Here are some key points you should know about Octreotide LAR:\n\n### Indications:\n1. **Acromegaly**: Used to reduce growth hormone and IGF-1 levels in patients who have not responded adequately to surgery or radiotherapy.\n2. **Neuroendocrine Tumors**: Effective in controlling symptoms associated with carcinoid tumors and vasoactive intestinal peptide-secreting tumors (VIPomas).\n3. **Other Uses**: Sometimes used off-label for conditions like severe diarrhea associated with chemotherapy, AIDS-related diarrhea, and certain cases of hypoglycemia.\n\n### Mechanism of Action:\n- Octreotide mimics natural somatostatin but is more potent and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_rBivZjGP4vIAfJksEsyoV89j", "custom_id": "192_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6bc77b5d4bac17fe15b2eabf52f52aab", "body": {"id": "chatcmpl-9St8aB5KymzvY4pq1Kn8AeMzGl7zg", "object": "chat.completion", "created": 1716672160, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ofatumumab is a fully human monoclonal antibody that targets CD20, a protein found on the surface of B cells. It is used primarily in the treatment of certain types of B-cell malignancies and autoimmune diseases. Here are some key points you should know about Ofatumumab:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL):**\n   - Ofatumumab is approved for the treatment of CLL, particularly in patients who are refractory to fludarabine and alemtuzumab.\n   \n2. **Multiple Sclerosis (MS):**\n   - Ofatumumab is also approved for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.\n\n### Mechanism of Action:\n- Ofatumumab binds specifically to the CD20 molecule on the surface of B cells, leading to B-cell lysis through complement-dependent cytotoxicity (CDC) and antibody-dependent"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_EwpsXFSGHuJXewfJCx1RLesN", "custom_id": "193_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e84cdc75845f1b5ce9a7e4ead816d0f4", "body": {"id": "chatcmpl-9St8aP05IFt5jdCcbIVlq4FfkrD61", "object": "chat.completion", "created": 1716672160, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Olaparib is a targeted cancer therapy known as a PARP (poly ADP-ribose polymerase) inhibitor. It is primarily used in the treatment of certain types of cancers, including ovarian, breast, pancreatic, and prostate cancers, particularly those associated with BRCA1 and BRCA2 mutations. Here are some key points you should know about Olaparib:\n\n### Mechanism of Action\n- **PARP Inhibition**: Olaparib inhibits the PARP enzyme, which is involved in DNA repair. By inhibiting PARP, Olaparib prevents cancer cells from repairing their DNA, leading to cell death, especially in cells deficient in homologous recombination repair (HRR) mechanisms, such as those with BRCA mutations.\n\n### Indications\n- **Ovarian Cancer**: Used as maintenance therapy for patients with recurrent ovarian cancer who are in response to platinum-based chemotherapy.\n- **Breast Cancer**: Approved for HER2-negative metastatic breast cancer with germ"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_shUraaJGu1wTuIyVfAjbt7MB", "custom_id": "194_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "33f63aba2a45f0afdf92bbc07b27e0db", "body": {"id": "chatcmpl-9St8atbOsFvyl5RMUiteoX5MHRuV8", "object": "chat.completion", "created": 1716672160, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Olaratumab is a monoclonal antibody that was developed for the treatment of soft tissue sarcoma (STS). It specifically targets the platelet-derived growth factor receptor alpha (PDGFR-\u03b1), which is implicated in the growth and proliferation of certain types of cancer cells.\n\nHere are some key points you should know about Olaratumab:\n\n1. **Mechanism of Action**: Olaratumab binds to PDGFR-\u03b1, inhibiting its activity. This can disrupt the signaling pathways that promote tumor growth and survival.\n\n2. **Indications**: Olaratumab was initially approved in combination with doxorubicin for the treatment of adult patients with STS who cannot be cured with radiotherapy or surgery and for whom treatment with an anthracycline is appropriate.\n\n3. **Clinical Trials and Efficacy**: The approval was based on a phase II clinical trial that showed a significant improvement in overall survival when olaratumab was combined with doxorub"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_BANWfuKEotWB3FLPYkM9e4pP", "custom_id": "195_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f2e87c189d13a837c91b14d3ccf3d890", "body": {"id": "chatcmpl-9St8a8o8Z6rlyGH2drvl1I8ypf5UX", "object": "chat.completion", "created": 1716672160, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Omacetaxine mepesuccinate, also known simply as omacetaxine, is a chemotherapeutic agent used primarily in the treatment of chronic myeloid leukemia (CML). Here are some key points you should know about omacetaxine:\n\n### Mechanism of Action\n- **Protein Synthesis Inhibition**: Omacetaxine works by inhibiting protein synthesis. It binds to the A-site of the ribosome, interfering with the elongation step of protein synthesis, which ultimately leads to apoptosis of cancer cells.\n- **BCR-ABL Independent**: Unlike tyrosine kinase inhibitors (TKIs) used in CML, omacetaxine's mechanism is independent of the BCR-ABL fusion protein, making it effective in cases where there is resistance to TKIs.\n\n### Indications\n- **Chronic Myeloid Leukemia (CML)**: Omacetaxine is indicated for the treatment of adult patients with chronic or accelerated phase C"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_rPaiHSsTvtFwOAD1YK6JBZyY", "custom_id": "196_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1d71484b507d33d7ac126aca3564b77b", "body": {"id": "chatcmpl-9St8aqN3EeLjbH9CYUAvBEBWrbej7", "object": "chat.completion", "created": 1716672160, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Omeprazole is a proton pump inhibitor (PPI) commonly used to treat conditions related to excess stomach acid. Here are some key points you should know about Omeprazole:\n\n### Indications:\n1. **Gastroesophageal Reflux Disease (GERD):** Omeprazole is often prescribed to manage symptoms and heal erosive esophagitis.\n2. **Peptic Ulcer Disease:** It helps in the treatment and prevention of gastric and duodenal ulcers.\n3. **Zollinger-Ellison Syndrome:** Used to manage this condition characterized by excessive gastric acid production.\n4. **Helicobacter pylori Eradication:** Often used in combination with antibiotics to treat H. pylori infections.\n\n### Mechanism of Action:\n- Omeprazole inhibits the H+/K+ ATPase enzyme system (proton pump) in the gastric parietal cells, leading to a significant reduction in gastric acid secretion.\n\n### Dosage and Administration:\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_EWdSeFNSFXxytRpEv9OHqWcH", "custom_id": "197_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f74f2433db2596d0afaa0d7982273e2f", "body": {"id": "chatcmpl-9St8aANIo3ZfA4NILttwnFbsFI4PH", "object": "chat.completion", "created": 1716672160, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Osimertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used primarily in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. Here are some key points you should know about Osimertinib:\n\n### Indications:\n1. **First-line Treatment**: Osimertinib is approved for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.\n2. **Second-line Treatment**: It is also indicated for patients with metastatic EGFR T790M mutation-positive NSCLC, who have progressed on or after EGFR TKI therapy.\n\n### Mechanism of Action:\n- Osimertinib selectively inhibits both EGFR-sensitizing mutations and the T790M resistance mutation, while sparing wild-type EGFR. This selectivity helps in reducing the side effects associated"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ULIO3IheuOgG0rFOEKZg1LQT", "custom_id": "198_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a5beeca99ea9cad2cf4dc6dced904ea0", "body": {"id": "chatcmpl-9St8aYjAJYa0fj70ce6D4enGsBQPt", "object": "chat.completion", "created": 1716672160, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Oxaliplatin is a platinum-based chemotherapeutic agent used primarily in the treatment of colorectal cancer. Here are some key points you should know about Oxaliplatin:\n\n### Mechanism of Action\n- **DNA Crosslinking:** Oxaliplatin forms crosslinks with DNA, which inhibits DNA replication and transcription, leading to cell death.\n- **Platinum Compound:** It is a third-generation platinum compound, differing from cisplatin and carboplatin in its spectrum of activity and toxicity profile.\n\n### Indications\n- **Colorectal Cancer:** It is commonly used in combination with other chemotherapeutic agents like 5-fluorouracil (5-FU) and leucovorin in regimens such as FOLFOX (5-FU, leucovorin, and oxaliplatin) for the treatment of metastatic colorectal cancer and as adjuvant therapy in stage III colon cancer.\n\n### Administration\n- **Intravenous Infusion:** Oxaliplatin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_bOkozfG6PYRCqsYBem1qk8on", "custom_id": "199_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6afb4d44d51c811c9147ef3670098e9e", "body": {"id": "chatcmpl-9St8bi2Xh3nB9zlJGumcKAKM9gsKO", "object": "chat.completion", "created": 1716672161, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Paclitaxel nanoparticle albumin-bound, commonly known as nab-paclitaxel or by its brand name Abraxane, is a formulation of the chemotherapy drug paclitaxel. It is used primarily in the treatment of various cancers, including breast cancer, non-small cell lung cancer, and pancreatic cancer. Here are some key points you should know about nab-paclitaxel:\n\n### Mechanism of Action\n- **Paclitaxel**: It works by stabilizing microtubules, which inhibits cell division and leads to cell death.\n- **Albumin-bound**: The drug is bound to albumin nanoparticles, which enhances its solubility and allows for better delivery to the tumor site. This formulation avoids the need for solvents like Cremophor EL, which are used in conventional paclitaxel and can cause hypersensitivity reactions.\n\n### Indications\n- **Breast Cancer**: Approved for metastatic breast cancer after failure of combination chemotherapy for metastatic disease"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_0ALM2i0imIt44WPsd1z6OjY2", "custom_id": "200_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d3247426a4da008b2417cb1f5f489dcf", "body": {"id": "chatcmpl-9St8aw2hAP4ezQ2pnOXf5kpy1a6Vp", "object": "chat.completion", "created": 1716672160, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Paclitaxel is a chemotherapeutic agent used primarily in the treatment of various cancers, including ovarian, breast, lung, and pancreatic cancers, as well as Kaposi's sarcoma. Here are some key points you should know about Paclitaxel:\n\n### Mechanism of Action\n- **Microtubule Stabilization**: Paclitaxel works by stabilizing microtubules, which inhibits their disassembly. This action disrupts the normal process of cell division, leading to cell death, particularly in rapidly dividing cancer cells.\n\n### Indications\n- **Ovarian Cancer**: Often used as first-line and subsequent therapy.\n- **Breast Cancer**: Used in both adjuvant and metastatic settings.\n- **Non-Small Cell Lung Cancer (NSCLC)**: Typically used in combination with other chemotherapeutic agents.\n- **Pancreatic Cancer**: Used in combination with other drugs like gemcitabine.\n- **Kaposi's Sarcoma"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_8S26V6ruvJvCiU6KpJNwKi5p", "custom_id": "201_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0002937d9ac87d232d3ddaeaf071f537", "body": {"id": "chatcmpl-9St8bDWTTFjUggGLYCOw1Tu6Tldrv", "object": "chat.completion", "created": 1716672161, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pacritinib is an oral kinase inhibitor that primarily targets Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). It is used in the treatment of myelofibrosis, particularly in patients with low platelet counts (thrombocytopenia). Here are some key points you should know about Pacritinib:\n\n1. **Mechanism of Action**: Pacritinib inhibits JAK2 and FLT3, which are involved in the signaling pathways that regulate blood cell production and immune function. By inhibiting these kinases, Pacritinib can reduce the abnormal proliferation of blood cells and alleviate symptoms associated with myelofibrosis.\n\n2. **Indications**: Pacritinib is indicated for the treatment of intermediate or high-risk myelofibrosis, especially in patients with severe thrombocytopenia (platelet counts below 50,000/\u00b5L). It is particularly useful for patients"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_bOoKKaEFCx4mFkj9RHBLJhYO", "custom_id": "202_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "27e6b880c1b772adcf244c9563037f6a", "body": {"id": "chatcmpl-9St8bw8egpDCttwcAH1xHW9WYW9dO", "object": "chat.completion", "created": 1716672161, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Palbociclib is an important medication used primarily in the treatment of certain types of breast cancer. Here are key points you should know about it:\n\n### Mechanism of Action\n- **Class**: Palbociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor.\n- **Function**: It works by inhibiting CDK4 and CDK6, which are proteins involved in cell division. By blocking these proteins, Palbociclib helps to stop the proliferation of cancer cells.\n\n### Indications\n- **Breast Cancer**: It is primarily used in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.\n- **Combination Therapy**: Often used in combination with endocrine therapy such as letrozole (an aromatase inhibitor) or fulvestrant (an estrogen receptor antagonist).\n\n### Administration\n- **Dosage Form**: Oral"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_6KnbZ74Vxjf31XhlLZw9Tsb9", "custom_id": "203_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "bffba5102d6c1471380b30eef31a1d22", "body": {"id": "chatcmpl-9St8bAl2CbrOnqpSViBiuTY31Kz9C", "object": "chat.completion", "created": 1716672161, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panitumumab is a fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFR). It is primarily used in the treatment of metastatic colorectal cancer. Here are some key points you should know about Panitumumab:\n\n### Mechanism of Action\n- **EGFR Inhibition**: Panitumumab binds to the extracellular domain of EGFR, preventing the receptor from activating its downstream signaling pathways, which are involved in cell proliferation and survival.\n\n### Indications\n- **Metastatic Colorectal Cancer**: Panitumumab is indicated for the treatment of patients with wild-type RAS (KRAS and NRAS) metastatic colorectal cancer. It is often used in combination with other chemotherapeutic agents or as a monotherapy in patients who have progressed on other treatments.\n\n### Administration\n- **Intravenous Infusion**: Panitumumab is administered via intravenous infusion, typically every two weeks. The dosage is usually based on the patient's body surface area.\n\n### E"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_heYHX82fpGfNpKe4eyH9Tn2u", "custom_id": "204_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "5ab25a71ada7021502e9aac2e680f4b3", "body": {"id": "chatcmpl-9St8bFeRcbGf0WVCseLaUtCVTSRSJ", "object": "chat.completion", "created": 1716672161, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panobinostat is a histone deacetylase (HDAC) inhibitor used primarily in the treatment of multiple myeloma. Here are some key points you should know about Panobinostat:\n\n### Mechanism of Action\n- **HDAC Inhibition**: Panobinostat inhibits the activity of histone deacetylases, leading to an accumulation of acetylated histones and proteins. This results in altered gene expression, cell cycle arrest, and apoptosis of cancer cells.\n\n### Indications\n- **Multiple Myeloma**: Panobinostat is approved for use in combination with bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior regimens, including bortezomib and an immunomodulatory agent.\n\n### Administration\n- **Oral Administration**: Panobinostat is administered orally.\n- **Dosing Schedule**: The typical dosing schedule involves taking the drug on specific days within"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_JYGRGx570LpCvlrytq6mZ3rr", "custom_id": "205_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0818c934c371cc98eb544de419b2d2c4", "body": {"id": "chatcmpl-9St8bmXaJVKLzsEPTdHTxyJAq5KTB", "object": "chat.completion", "created": 1716672161, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pazopanib is a tyrosine kinase inhibitor used primarily in the treatment of certain types of cancer. Here are some key points you should know about Pazopanib as a physician:\n\n### Indications:\n1. **Renal Cell Carcinoma (RCC):** Pazopanib is approved for the treatment of advanced renal cell carcinoma.\n2. **Soft Tissue Sarcoma (STS):** It is also indicated for the treatment of advanced soft tissue sarcoma in patients who have received prior chemotherapy.\n\n### Mechanism of Action:\n- Pazopanib inhibits multiple tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-\u03b1 and PDGFR-\u03b2), and c-kit, which play roles in tumor growth and angiogenesis.\n\n### Administration:\n- **Dosage:** The typical starting dose is 800 mg orally once daily. It should be taken on"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_2ebjTJK04g96CODigQQcZ5dO", "custom_id": "206_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0d67daa1019d4ade9a9875f152ac0a7d", "body": {"id": "chatcmpl-9St8chJ8ZhpFG4ngqGwNBZqP5Fc59", "object": "chat.completion", "created": 1716672162, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pegaspargase is an important medication used primarily in the treatment of acute lymphoblastic leukemia (ALL). Here are some key points you should know about Pegaspargase:\n\n### Mechanism of Action\n- **Enzyme Activity**: Pegaspargase is a modified form of the enzyme L-asparaginase. It works by breaking down asparagine, an amino acid that is essential for the survival and proliferation of leukemia cells. Normal cells can synthesize asparagine, but leukemia cells cannot, making them particularly vulnerable to asparagine depletion.\n\n### Indications\n- **Acute Lymphoblastic Leukemia (ALL)**: Pegaspargase is used as part of a multi-agent chemotherapy regimen for the treatment of ALL. It is often used in both pediatric and adult patients.\n\n### Administration\n- **Route**: Pegaspargase is administered either intramuscularly (IM) or intravenously (IV).\n- **Dosing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_X4ym8nQxWe25eZINYzHHH0SB", "custom_id": "207_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "47247cdbf39fff42adc1a0e62a4cf619", "body": {"id": "chatcmpl-9St8cDoJ2ncWraWUtDznOeGbXCpTP", "object": "chat.completion", "created": 1716672162, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Peginterferon alfa-2a is a pegylated form of interferon used primarily in the treatment of chronic hepatitis C and hepatitis B infections. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Interferon Activity**: Peginterferon alfa-2a works by binding to specific receptors on the surface of cells, initiating a complex cascade of intracellular events. This leads to the activation of various genes that inhibit viral replication and modulate the immune response.\n- **Pegylation**: The pegylation process involves attaching polyethylene glycol (PEG) to the interferon molecule, which increases its half-life, allowing for less frequent dosing compared to non-pegylated interferons.\n\n### Indications\n- **Chronic Hepatitis C**: Often used in combination with other antiviral medications like ribavirin or direct-acting antivirals (DAAs).\n- **Chronic Hepatitis B**: Used as monotherapy or in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_vheoWeYMY2dZChgXTaiglft7", "custom_id": "208_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "4b6f6de35513107d1198d1a5f518144f", "body": {"id": "chatcmpl-9St8cEDmwupSSpJwmp14VDR7CfFlv", "object": "chat.completion", "created": 1716672162, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Peginterferon alfa-2b is a medication used primarily in the treatment of chronic hepatitis C and certain types of cancer, such as melanoma. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Interferon Activity**: Peginterferon alfa-2b is a pegylated form of interferon alfa-2b. The pegylation process involves attaching polyethylene glycol (PEG) to the interferon molecule, which extends its half-life and allows for less frequent dosing.\n- **Antiviral and Antiproliferative Effects**: It works by modulating the immune response, enhancing the body's ability to fight viral infections and inhibiting the proliferation of cancer cells.\n\n### Indications\n- **Chronic Hepatitis C**: Often used in combination with ribavirin or other antiviral medications.\n- **Melanoma**: Used as an adjuvant therapy for patients with high-risk melanoma after surgical resection.\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_4VEZtUJasXfD2DEuMAl3Ke9d", "custom_id": "209_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7be7bb29c7eb0bd530086313723b0fb2", "body": {"id": "chatcmpl-9St8cYaalU2UbvQ9zV09GX2MM4gLi", "object": "chat.completion", "created": 1716672162, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pegylated liposomal doxorubicin is a formulation of the chemotherapy drug doxorubicin that is encapsulated in liposomes with a polyethylene glycol (PEG) coating. This formulation is designed to improve the drug's pharmacokinetics and reduce its toxicity. Here are some key points you should know about pegylated liposomal doxorubicin:\n\n### Mechanism of Action\n- **Doxorubicin**: It intercalates into DNA, inhibiting topoisomerase II and preventing DNA replication and RNA synthesis, leading to cell death.\n- **Liposomal Encapsulation**: The liposomes help to deliver the drug more selectively to tumor tissues, exploiting the enhanced permeability and retention (EPR) effect seen in tumors.\n\n### Pharmacokinetics\n- **Prolonged Circulation**: The PEG coating helps the liposomes evade the immune system, allowing for prolonged circulation time in the bloodstream.\n- **Targeted Delivery**: The liposomes preferential"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_MpO08EUpoXwfs4HtK1ZQ69yl", "custom_id": "210_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6fccb68c244628025064f42d22e35fb1", "body": {"id": "chatcmpl-9St8c2kEttFoW0B56bZNVmfEN9oFJ", "object": "chat.completion", "created": 1716672162, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pembrolizumab, marketed under the brand name Keytruda, is a monoclonal antibody used in cancer immunotherapy. Here are some key points you should know about Pembrolizumab:\n\n### Mechanism of Action\n- **Immune Checkpoint Inhibitor**: Pembrolizumab targets the programmed cell death protein 1 (PD-1) receptor on T cells. By blocking PD-1, it prevents cancer cells from evading the immune response, thereby enhancing the body's ability to fight cancer.\n\n### Indications\nPembrolizumab is approved for a variety of cancers, including but not limited to:\n- Melanoma\n- Non-Small Cell Lung Cancer (NSCLC)\n- Head and Neck Squamous Cell Carcinoma (HNSCC)\n- Classical Hodgkin Lymphoma\n- Urothelial Carcinoma\n- Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) cancers\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Yg5MnrZxSSJSUs32cHRpBetP", "custom_id": "211_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2fa884c0f8d60aec86421c295e9439a8", "body": {"id": "chatcmpl-9St8cOUw5SRMxQvD1yHo6EayRoygm", "object": "chat.completion", "created": 1716672162, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pemetrexed is a chemotherapy drug used primarily in the treatment of certain types of cancer, including malignant pleural mesothelioma and non-small cell lung cancer (NSCLC). Here are some key points you should know about Pemetrexed:\n\n### Mechanism of Action\n- **Antifolate Agent**: Pemetrexed works by inhibiting several enzymes involved in the folate pathway, including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This inhibition disrupts DNA and RNA synthesis, leading to cell death, particularly in rapidly dividing cancer cells.\n\n### Indications\n- **Malignant Pleural Mesothelioma**: Often used in combination with cisplatin.\n- **Non-Small Cell Lung Cancer (NSCLC)**: Used as a first-line treatment in combination with cisplatin for non-squamous NSCLC, and as a maintenance therapy or second-line treatment for advanced or metastatic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_KXMII8GmFyY7RJFwP0lrCQ7H", "custom_id": "212_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "746351a039b3b51e4fbce674e626de25", "body": {"id": "chatcmpl-9St8cjM9ZS1zUtDzplpKJzQDLcuvT", "object": "chat.completion", "created": 1716672162, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pentostatin, also known by its brand name Nipent, is a chemotherapeutic agent primarily used in the treatment of hairy cell leukemia. Here are some key points you should know about Pentostatin:\n\n### Mechanism of Action\n- **Inhibition of Adenosine Deaminase (ADA):** Pentostatin is a purine analog that inhibits the enzyme adenosine deaminase. This inhibition leads to an accumulation of deoxyadenosine triphosphate, which is toxic to lymphocytes, particularly T and B cells, leading to their apoptosis.\n\n### Indications\n- **Hairy Cell Leukemia:** Pentostatin is FDA-approved for the treatment of hairy cell leukemia.\n- **Other Uses:** It has also been used off-label for other hematologic malignancies, such as chronic lymphocytic leukemia (CLL) and T-cell prolymphocytic leukemia, although these uses are less common.\n\n### Administration\n- **Dosage:** The typical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_jwwpsQp8R78y5wQSIa2y63D0", "custom_id": "213_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e4c06c35d67e8d1930a001e9477a1e6f", "body": {"id": "chatcmpl-9St8ck4XLqKGB2eD4aQPtTHAblQOY", "object": "chat.completion", "created": 1716672162, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pertuzumab is a monoclonal antibody used in the treatment of certain types of breast cancer. Here are some key points you should know about Pertuzumab:\n\n### Mechanism of Action\n- **HER2 Inhibition**: Pertuzumab targets the human epidermal growth factor receptor 2 (HER2). It binds to the extracellular dimerization domain of HER2, preventing the receptor from pairing with other HER family members (HER1, HER3, and HER4). This inhibition disrupts signaling pathways that promote cell growth and survival.\n\n### Indications\n- **HER2-Positive Breast Cancer**: Pertuzumab is primarily used in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic breast cancer. It is also used in the neoadjuvant (pre-surgery) and adjuvant (post-surgery) settings for early-stage HER2-positive breast cancer.\n\n### Administration\n- **Intravenous Infusion**: Pert"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_OrBrDwykayHgeDRCR7asITEQ", "custom_id": "214_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "cc629aef198d87d3d47d781143feb40a", "body": {"id": "chatcmpl-9St8c4A20BAnSYvyjG9gkEIlk5qCl", "object": "chat.completion", "created": 1716672162, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pirarubicin is an anthracycline antibiotic used primarily as a chemotherapeutic agent. Here are some key points you should know about Pirarubicin:\n\n### Mechanism of Action\n- **DNA Intercalation**: Pirarubicin intercalates into DNA, disrupting the function of topoisomerase II, which is essential for DNA replication and transcription.\n- **Free Radical Formation**: It generates free radicals that cause damage to cellular components, including DNA, proteins, and cell membranes.\n\n### Indications\n- **Cancer Treatment**: Pirarubicin is used in the treatment of various cancers, including breast cancer, bladder cancer, and certain types of leukemia and lymphoma.\n\n### Administration\n- **Routes**: It can be administered intravenously or intravesically (directly into the bladder for bladder cancer).\n- **Dosage**: The dosage varies depending on the type of cancer, the patient's condition, and other factors. It is often given in cycles"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_sF2Jb9A1Sdm0VggXp1hwzFCL", "custom_id": "215_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "04336918ca85b33a02ffe848a1dce0dd", "body": {"id": "chatcmpl-9St8dDMTBLHhOuVNy5BEhmorl2MPj", "object": "chat.completion", "created": 1716672163, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pixantrone is a chemotherapeutic agent used primarily in the treatment of certain types of non-Hodgkin lymphoma (NHL), particularly relapsed or refractory aggressive B-cell NHL. Here are some key points you should know about Pixantrone:\n\n### Mechanism of Action\n- **Anthracenedione Derivative**: Pixantrone is structurally related to anthracyclines and anthracenediones but is designed to reduce the cardiotoxicity associated with these agents.\n- **DNA Interaction**: It intercalates into DNA and induces DNA strand breaks, leading to apoptosis of cancer cells. It also inhibits topoisomerase II, an enzyme crucial for DNA replication and repair.\n\n### Indications\n- **Relapsed/Refractory NHL**: Pixantrone is specifically indicated for patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas who have failed two or more lines of prior therapy.\n\n### Administration\n- **Intr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_vY71k3eY17MuqujRAE9ugjdY", "custom_id": "216_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a0ca9448a1ce628d55767da8782ddb79", "body": {"id": "chatcmpl-9St8dwj4pA2rnpffr7nyuz4GUc8OG", "object": "chat.completion", "created": 1716672163, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Plicamycin, also known as mithramycin, is an antineoplastic antibiotic derived from the bacterium *Streptomyces plicatus*. It has been used primarily in the treatment of certain types of cancer and hypercalcemia associated with malignancy. Here are some key points you should know about Plicamycin:\n\n### Indications:\n1. **Testicular Cancer**: Plicamycin has been used in the treatment of testicular cancer, particularly in cases where other treatments have failed.\n2. **Hypercalcemia and Hypercalciuria**: It is also used to manage hypercalcemia and hypercalciuria associated with malignancies, particularly when other treatments are not effective.\n\n### Mechanism of Action:\n- Plicamycin works by binding to DNA and inhibiting RNA synthesis, which interferes with the replication of cancer cells and leads to cell death. It also inhibits bone resorption, which helps in managing hypercalcemia.\n\n### Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_4abV9Mmu7knu3RYjyq8X8Qwe", "custom_id": "217_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "5b62804c976b91f5771cb4d88bd4922a", "body": {"id": "chatcmpl-9St8deOVVDbiQhBLGaOFiLL9N3DE9", "object": "chat.completion", "created": 1716672163, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pomalidomide is an immunomodulatory drug (IMiD) primarily used in the treatment of multiple myeloma, particularly in patients who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of the last therapy. Here are some key points you should know about Pomalidomide:\n\n### Mechanism of Action\n- **Immunomodulation**: Pomalidomide enhances T-cell and natural killer (NK) cell-mediated cytotoxicity.\n- **Anti-angiogenic**: It inhibits the growth of new blood vessels, which is crucial for tumor growth.\n- **Direct Anti-tumor Effect**: It induces apoptosis and inhibits proliferation of myeloma cells.\n\n### Indications\n- **Multiple Myeloma**: As mentioned, it is used in patients with relapsed or refractory multiple myeloma.\n- **Other Investigational Uses"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_fyrkimH0cRid2cHHywM2E7Pp", "custom_id": "218_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c813f36c7c0311692b1e463cc3d2db97", "body": {"id": "chatcmpl-9St8d1FafFu4j5yDqNZFKXh2oSUbP", "object": "chat.completion", "created": 1716672163, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ponatinib is a tyrosine kinase inhibitor (TKI) used primarily in the treatment of certain types of leukemia, specifically chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Here are some key points you should know about Ponatinib:\n\n### Indications:\n1. **Chronic Myeloid Leukemia (CML):**\n   - Indicated for adult patients with T315I-positive CML (chronic, accelerated, or blast phase).\n   - Indicated for adult patients with CML (chronic, accelerated, or blast phase) for whom no other TKI therapy is indicated.\n\n2. **Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL):**\n   - Indicated for adult patients with T315I-positive Ph+ ALL.\n   - Indicated for adult patients with Ph+ ALL for whom no other TKI therapy is indicated.\n\n### Mechanism of Action:\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Qlg7XBxQfJP2mFPAradYhC1U", "custom_id": "219_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "13cccf8754650885dc8fd13592e444f8", "body": {"id": "chatcmpl-9St8drgDQwXSwRtfeaQ0DB2I42drP", "object": "chat.completion", "created": 1716672163, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pralatrexate is a chemotherapeutic agent used primarily in the treatment of peripheral T-cell lymphoma (PTCL), a type of non-Hodgkin lymphoma. Here are some key points you should know about Pralatrexate:\n\n### Mechanism of Action\n- **Folate Analog**: Pralatrexate is a folate analog metabolic inhibitor. It works by inhibiting dihydrofolate reductase (DHFR), an enzyme involved in the synthesis of tetrahydrofolate, which is necessary for DNA synthesis and cell replication.\n- **Selective Uptake**: It has a high affinity for the reduced folate carrier (RFC-1), which allows for selective uptake by cancer cells.\n\n### Indications\n- **Peripheral T-Cell Lymphoma (PTCL)**: Pralatrexate is primarily indicated for the treatment of relapsed or refractory PTCL.\n\n### Administration\n- **Intravenous Infusion**: Pralatrex"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_I6GeDEwtbDiDSCWjPONLCAZa", "custom_id": "220_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2f7143d5a25702c4a6cfa4ead3369076", "body": {"id": "chatcmpl-9St8dEkMF1qEDjV3FjLIRstp7sCrF", "object": "chat.completion", "created": 1716672163, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pravastatin is a medication that belongs to the class of drugs known as statins, which are used primarily to lower cholesterol levels and reduce the risk of cardiovascular disease. Here are some key points you should know about Pravastatin:\n\n### Mechanism of Action\n- **HMG-CoA Reductase Inhibitor**: Pravastatin works by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in the synthesis of cholesterol in the liver. This leads to a decrease in the production of cholesterol and an increase in the uptake of low-density lipoprotein (LDL) cholesterol from the blood.\n\n### Indications\n- **Hypercholesterolemia**: Used to treat high cholesterol levels, particularly elevated LDL cholesterol.\n- **Prevention of Cardiovascular Events**: Indicated for the prevention of cardiovascular events in patients with existing coronary heart disease or those at high risk.\n\n### Dosage\n- **Starting Dose**: Typically, the starting dose"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_bu0HeDUTOssF7DxbnCAvtUZI", "custom_id": "221_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "048dbde8125709fb5b9054515fd7a9b1", "body": {"id": "chatcmpl-9St8dDPp3KO8GqE91AleET26HQ6TP", "object": "chat.completion", "created": 1716672163, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Prednisolone, a corticosteroid medication used to treat a variety of conditions due to its anti-inflammatory and immunosuppressive properties. Here are key points you should know:\n\n### Indications:\n1. **Inflammatory Conditions**: Prednisolone is commonly used to treat conditions such as asthma, rheumatoid arthritis, inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), and systemic lupus erythematosus.\n2. **Allergic Reactions**: It can be used for severe allergic reactions, including anaphylaxis.\n3. **Autoimmune Diseases**: Conditions like multiple sclerosis and autoimmune hepatitis may be managed with Prednisolone.\n4. **Endocrine Disorders**: It is used in adrenal insufficiency (Addison's disease) and congenital adrenal hyperplasia.\n5. **Neoplastic Diseases**: Prednisolone can be part of the treatment regimen for certain cancers, such as"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Z3FVmWcVsxcIypXVkcW56oHT", "custom_id": "222_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "25e5512a39305019abdc0c0568d9cbb2", "body": {"id": "chatcmpl-9St8e1TbN5IWq4vD4FqiNoMbPcaP6", "object": "chat.completion", "created": 1716672164, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's crucial to have a comprehensive understanding of Prednisone, a synthetic corticosteroid drug that is commonly used to treat a variety of inflammatory and autoimmune conditions. Here are some key points you should know:\n\n### Mechanism of Action\n- **Anti-inflammatory and Immunosuppressive Effects**: Prednisone works by mimicking the effects of cortisol, a natural hormone produced by the adrenal glands. It suppresses the immune system and reduces inflammation by inhibiting the release of substances that cause inflammation.\n\n### Indications\n- **Autoimmune Diseases**: Conditions like rheumatoid arthritis, lupus, and multiple sclerosis.\n- **Inflammatory Conditions**: Such as asthma, inflammatory bowel disease (Crohn's disease and ulcerative colitis), and severe allergic reactions.\n- **Other Uses**: It can also be used in the treatment of certain cancers, to prevent organ transplant rejection, and in various other conditions where inflammation is a component.\n\n### Dosage and Administration\n- **Individualized D"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_qNDYmX0pDGdMr2Rk059D8MFA", "custom_id": "223_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0e4ce3560b4a4fb5bea53e275ee475c1", "body": {"id": "chatcmpl-9St8esy9Bff00Y8imG7gEpvdzSybh", "object": "chat.completion", "created": 1716672164, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Procarbazine is an antineoplastic agent used primarily in the treatment of Hodgkin's lymphoma and certain types of brain tumors. Here are some key points you should know about Procarbazine:\n\n### Mechanism of Action\n- **Alkylating Agent**: Procarbazine works by inhibiting DNA, RNA, and protein synthesis. It is classified as an alkylating agent, which means it adds alkyl groups to DNA, leading to DNA strand breaks and apoptosis of cancer cells.\n\n### Indications\n- **Hodgkin's Lymphoma**: Often used as part of combination chemotherapy regimens such as MOPP (mechlorethamine, vincristine, procarbazine, prednisone).\n- **Brain Tumors**: Used in combination with other chemotherapeutic agents for the treatment of certain brain tumors, including gliomas.\n\n### Administration\n- **Oral**: Procarbazine is administered orally, typically in capsule form"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_fprfVKIKld0dcmWoV8rOrZ0N", "custom_id": "224_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b4038b763b4d4b14bba858b43aa2f99d", "body": {"id": "chatcmpl-9St8eF4b7Nq9RaWXgAdst7E9KDJUW", "object": "chat.completion", "created": 1716672164, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Quinine is a medication that has been used for centuries, primarily for the treatment of malaria. Here are some key points you should know about quinine as a physician:\n\n### Mechanism of Action\n- **Antimalarial Activity**: Quinine works by interfering with the parasite's ability to digest hemoglobin, which is essential for its survival in red blood cells. This leads to the accumulation of toxic heme within the parasite, ultimately killing it.\n- **Other Uses**: Quinine has also been used off-label for the treatment of nocturnal leg cramps, although this use is controversial due to potential side effects.\n\n### Indications\n- **Malaria**: Quinine is primarily indicated for the treatment of uncomplicated and severe malaria caused by Plasmodium falciparum, especially in regions where the parasite has developed resistance to other antimalarial drugs.\n- **Leg Cramps**: While it has been used for nocturnal leg cramps, this is not an FDA-approved indication"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Gzf2Vx12sd88Fk8tfsqWXMim", "custom_id": "225_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d6a2bdeaf6ce3e29b4be7c149c020544", "body": {"id": "chatcmpl-9St8eErAscg1oi4mjOLu9sGUAUF6F", "object": "chat.completion", "created": 1716672164, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Quizartinib is a targeted therapy drug that is primarily used in the treatment of acute myeloid leukemia (AML), particularly in patients who have a specific genetic mutation known as FLT3-ITD (FMS-like tyrosine kinase 3 internal tandem duplication). Here are some key points you should know about Quizartinib:\n\n### Mechanism of Action\n- **FLT3 Inhibition**: Quizartinib is a potent and selective inhibitor of the FLT3 receptor tyrosine kinase. FLT3 mutations, particularly FLT3-ITD, are associated with poor prognosis in AML due to their role in promoting the proliferation and survival of leukemic cells.\n\n### Indications\n- **AML with FLT3-ITD Mutation**: Quizartinib is indicated for the treatment of adult patients with relapsed or refractory AML who have the FLT3-ITD mutation.\n\n### Administration\n- **Oral Medication**: Quizartinib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_2Y7YjHmPeK5jy8xEJPGpU8dH", "custom_id": "226_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "8dd221b22748411de71939a87d50bc2d", "body": {"id": "chatcmpl-9St8eQ4JZJkfNOg651hXBAxP0GIrN", "object": "chat.completion", "created": 1716672164, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Radotinib is a second-generation tyrosine kinase inhibitor (TKI) that is primarily used in the treatment of chronic myeloid leukemia (CML), particularly in patients who are resistant or intolerant to first-generation TKIs like imatinib. Here are some key points you should know about Radotinib:\n\n### Mechanism of Action\n- **Target**: Radotinib specifically targets the BCR-ABL1 fusion protein, which is the result of the Philadelphia chromosome abnormality in CML. This protein has constitutive tyrosine kinase activity that drives the proliferation of leukemic cells.\n- **Inhibition**: By inhibiting the BCR-ABL1 kinase, Radotinib helps to reduce the proliferation of leukemic cells and induce apoptosis.\n\n### Indications\n- **Chronic Myeloid Leukemia (CML)**: Radotinib is indicated for the treatment of adult patients with chronic phase (CP) and accelerated phase (AP) CML who"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_9rGRcyD1QC2rDYswLz0Q49H9", "custom_id": "227_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "be9f514e9d73c4dd1fce646ad6080ecc", "body": {"id": "chatcmpl-9St8elDnaiT7XkbbGpNiI0dpaWr4h", "object": "chat.completion", "created": 1716672164, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Raltitrexed is a chemotherapy medication primarily used in the treatment of colorectal cancer. Here are some key points you should know about Raltitrexed as a physician:\n\n### Mechanism of Action\n- **Antimetabolite**: Raltitrexed is a thymidylate synthase inhibitor. It interferes with DNA synthesis by inhibiting the enzyme thymidylate synthase, which is crucial for the synthesis of thymidine, a nucleotide required for DNA replication.\n\n### Indications\n- **Colorectal Cancer**: It is mainly indicated for the treatment of advanced colorectal cancer, particularly in patients who are intolerant to or have contraindications for 5-fluorouracil (5-FU) and leucovorin.\n\n### Administration\n- **Intravenous Infusion**: Raltitrexed is administered as an intravenous infusion. The dosage and schedule depend on the specific treatment protocol and patient factors such as renal function.\n\n### Side Effects\n- **Common"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_6X2WgnSEzKaH8qDtiT3IVG12", "custom_id": "228_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9bf7f3734d06b5ac8dd16d4c2d897f8a", "body": {"id": "chatcmpl-9St8e2N9VVI2UHf7viEvVXq2YeE4T", "object": "chat.completion", "created": 1716672164, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ramucirumab is a monoclonal antibody used as an anti-cancer agent. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Target**: Ramucirumab specifically targets and binds to the extracellular domain of the vascular endothelial growth factor receptor 2 (VEGFR-2).\n- **Action**: By binding to VEGFR-2, it inhibits the binding of VEGF ligands, thereby blocking the receptor's activation and subsequent angiogenesis (formation of new blood vessels), which is crucial for tumor growth and metastasis.\n\n### Indications\n- **Gastric Cancer**: Used as a single agent or in combination with paclitaxel for the treatment of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.\n- **Colorectal Cancer**: Used in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) for metastatic colorectal cancer that"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_PHRWjZuo90S2YoS5OxCdWdWq", "custom_id": "229_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "376f9c5bf175ddfc14a83d134af6a5fb", "body": {"id": "chatcmpl-9St8ezJpmv5yqHSQjpiA395a4r5Lw", "object": "chat.completion", "created": 1716672164, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ranimustine is an alkylating agent used primarily in the treatment of certain types of cancer. Here are some key points you should know about Ranimustine:\n\n1. **Mechanism of Action**: Ranimustine works by alkylating DNA, which leads to the cross-linking of DNA strands, thereby inhibiting DNA replication and transcription. This ultimately results in cell death, particularly in rapidly dividing cancer cells.\n\n2. **Indications**: It is used in the treatment of various malignancies, including:\n   - Malignant lymphoma\n   - Chronic myelogenous leukemia\n   - Multiple myeloma\n   - Brain tumors\n\n3. **Administration**: Ranimustine is typically administered intravenously. The dosage and schedule depend on the type of cancer being treated, the patient's overall health, and their response to the treatment.\n\n4. **Side Effects**: Common side effects include:\n   - Bone marrow suppression (leading to leukopenia, thromb"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_GpMfMwGojCaGbne9MlKWnNMr", "custom_id": "230_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b58c80352885f84448a7d8a943161589", "body": {"id": "chatcmpl-9St8eUk4PqhT5WwY5m1uDgvVlCwKG", "object": "chat.completion", "created": 1716672164, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Regorafenib is an oral multi-kinase inhibitor that is used in the treatment of certain types of cancer. Here are some key points you should know about Regorafenib:\n\n### Indications:\n1. **Colorectal Cancer**: It is used for the treatment of metastatic colorectal cancer (CRC) in patients who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.\n2. **Gastrointestinal Stromal Tumors (GIST)**: It is indicated for patients with locally advanced, unresectable, or metastatic GIST who have been previously treated with imatinib mesylate and sunitinib malate.\n3. **Hepatocellular Carcinoma (HCC)**: It is used for patients with HCC who have been previously treated with sorafenib.\n\n### Mechanism"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_D8HFY4JR4lwwHnMXkgXyhj8m", "custom_id": "231_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a614b1c3a0e061cfe8b8a995a4788ac7", "body": {"id": "chatcmpl-9St8eeip6GCGC0WGQzNvYrDFZrgma", "object": "chat.completion", "created": 1716672164, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ribociclib is a targeted cancer therapy used primarily in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Here are some key points you should know about Ribociclib:\n\n### Mechanism of Action\n- **CDK4/6 Inhibitor**: Ribociclib works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which are crucial for cell cycle progression. By blocking these kinases, Ribociclib helps to halt the proliferation of cancer cells.\n\n### Indications\n- **Combination Therapy**: It is often used in combination with an aromatase inhibitor (like letrozole) or fulvestrant in postmenopausal women, and in pre/perimenopausal women in combination with an aromatase inhibitor and a luteinizing hormone-releasing hormone (LHRH) agonist.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_F4pagukLw4rYAbq1kSLsa6ml", "custom_id": "232_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7d1d06a73a76b0b615a6ebb6f70d4513", "body": {"id": "chatcmpl-9St8eXwqNofnU0IdFAfmWWqLZPxJE", "object": "chat.completion", "created": 1716672164, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rituximab is a monoclonal antibody that targets the CD20 protein found on the surface of B cells. It is used in the treatment of various conditions, primarily those involving B cells. Here are some key points you should know about Rituximab:\n\n### Indications\n1. **Hematologic Malignancies**:\n   - Non-Hodgkin's Lymphoma (NHL)\n   - Chronic Lymphocytic Leukemia (CLL)\n\n2. **Autoimmune Diseases**:\n   - Rheumatoid Arthritis (RA)\n   - Granulomatosis with Polyangiitis (GPA, formerly Wegener's Granulomatosis)\n   - Microscopic Polyangiitis (MPA)\n   - Pemphigus Vulgaris\n\n### Mechanism of Action\n- Rituximab binds to the CD20 antigen on B cells, leading to their destruction through various mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5ss61GevgEPUmGVulylmT5uo", "custom_id": "233_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "5e5a20259c3e139eee70f2d01feecfd7", "body": {"id": "chatcmpl-9St8eBeH3m4rPnSchMmTWs7K86KSa", "object": "chat.completion", "created": 1716672164, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rituximab and hyaluronidase human is a combination medication used primarily in the treatment of certain types of cancer and autoimmune diseases. Here are key points you should know about this combination therapy:\n\n### Rituximab\n1. **Mechanism of Action**: Rituximab is a monoclonal antibody that targets the CD20 antigen on B lymphocytes. It works by binding to CD20, leading to the destruction of B cells through various mechanisms, including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and induction of apoptosis.\n\n2. **Indications**:\n   - Non-Hodgkin's lymphoma (NHL)\n   - Chronic lymphocytic leukemia (CLL)\n   - Rheumatoid arthritis (in combination with methotrexate)\n   - Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA)\n   - Pemphigus vulgaris\n\n3. **Administration**: Traditionally"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_5UNsk35hybi8eOAcfL6eCANk", "custom_id": "234_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "54a02a4b6adaee1f47d01673d6b10b8e", "body": {"id": "chatcmpl-9St8eTnT277OCC47Ya6FsM3B93GFz", "object": "chat.completion", "created": 1716672164, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Romidepsin is a histone deacetylase (HDAC) inhibitor used primarily in the treatment of certain types of cancer, particularly cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). Here are some key points you should know about Romidepsin:\n\n### Mechanism of Action\n- **HDAC Inhibition**: Romidepsin inhibits histone deacetylases, leading to an accumulation of acetylated histones and other proteins. This results in changes in gene expression, cell cycle arrest, and apoptosis of cancer cells.\n\n### Indications\n- **Cutaneous T-Cell Lymphoma (CTCL)**: Approved for patients who have received at least one prior systemic therapy.\n- **Peripheral T-Cell Lymphoma (PTCL)**: Approved for patients who have received at least one prior therapy.\n\n### Administration\n- **Intravenous Infusion**: Romidepsin is administered as an intravenous infusion over"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_tLjxv2ikaSt9C5PqJyzQH7co", "custom_id": "235_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3ff281745d536c3d2c2a3648d467d7be", "body": {"id": "chatcmpl-9St8epGWhQ30njr2CCPmbt8Q27cmA", "object": "chat.completion", "created": 1716672164, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ropeginterferon alfa-2b is a medication used primarily in the treatment of polycythemia vera, a type of blood cancer characterized by the overproduction of red blood cells. Here are some key points you should know about Ropeginterferon alfa-2b:\n\n### Mechanism of Action\n- **Interferon-Based Therapy**: Ropeginterferon alfa-2b is a long-acting, pegylated interferon. It works by modulating the immune system and inhibiting the proliferation of hematopoietic cells, which helps to control the overproduction of red blood cells in polycythemia vera.\n\n### Indications\n- **Polycythemia Vera**: It is specifically approved for the treatment of polycythemia vera in adults, particularly in those who are either intolerant to or have had an inadequate response to hydroxyurea.\n\n### Administration\n- **Subcutaneous Injection**: Ropeginterferon alfa-2"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_HQ4lOxsIOPhtKBheyAjqwE1W", "custom_id": "236_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3dd85fe8a5035b2be2c004d1195ed69b", "body": {"id": "chatcmpl-9St8eXqNhhRW2YhhYGVezQHH9DigZ", "object": "chat.completion", "created": 1716672164, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor used primarily in the treatment of certain types of cancer. Here are some key points you should know about Rucaparib:\n\n### Indications:\n1. **Ovarian Cancer**: Rucaparib is approved for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies.\n2. **Maintenance Therapy**: It is also used as a maintenance treatment for patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\n3. **Prostate Cancer**: Rucaparib is approved for the treatment of patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.\n\n### Mechanism"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_e8OqycXumvVIRZXMb75usWmh", "custom_id": "237_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "63dd8783ec91e107e262104be0e7eaf5", "body": {"id": "chatcmpl-9St8ePUfY4T4Xh05GQPBGIrJjI12a", "object": "chat.completion", "created": 1716672164, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ruxolitinib is a medication that you, as a physician, should be familiar with, especially if you are treating patients with certain hematologic conditions. Here are some key points to know about Ruxolitinib:\n\n### Indications:\n1. **Myelofibrosis**: Ruxolitinib is primarily used to treat intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.\n2. **Polycythemia Vera**: It is also indicated for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.\n3. **Graft-versus-Host Disease (GVHD)**: Ruxolitinib is approved for the treatment of steroid-refractory acute GVHD and chronic GVHD.\n\n### Mechanism of Action:\n- Ruxolit"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_6cS8sxaHC1zDDQPenYou7FGm", "custom_id": "238_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "efa5a4a3b65cc888de8c73d6a5158908", "body": {"id": "chatcmpl-9St8fJMwAaN5hEbs9N36xoz1keerK", "object": "chat.completion", "created": 1716672165, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sacituzumab govitecan is an antibody-drug conjugate (ADC) used in the treatment of certain types of cancer. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Antibody Component**: Sacituzumab govitecan consists of an antibody that targets Trop-2, a protein commonly overexpressed in various epithelial cancers.\n- **Drug Component**: It is conjugated to SN-38, an active metabolite of the chemotherapy drug irinotecan, which inhibits topoisomerase I, leading to DNA damage and cell death.\n\n### Indications\n- **Triple-Negative Breast Cancer (TNBC)**: It is approved for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease.\n- **Urothelial Cancer**: It is also approved for patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_PvZsTBRGlEksATikOZEhSyVx", "custom_id": "239_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "35832073c7e77a54a0293fcf05e9196e", "body": {"id": "chatcmpl-9St8fcb9SOXMnkjaJPJVXslhigvBj", "object": "chat.completion", "created": 1716672165, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sargramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) used primarily to stimulate the production of white blood cells, particularly granulocytes and macrophages. Here are some key points you should know about Sargramostim:\n\n### Indications\n1. **Hematopoietic Recovery**: It is used to accelerate bone marrow recovery following autologous or allogeneic bone marrow transplantation.\n2. **Neutropenia**: It is indicated for the treatment of neutropenia in patients undergoing chemotherapy for acute myeloid leukemia (AML).\n3. **Peripheral Blood Progenitor Cell (PBPC) Mobilization**: It is used to mobilize hematopoietic progenitor cells into the peripheral blood for collection and subsequent autologous transplantation.\n4. **Radiation Syndrome**: It can be used to increase survival in patients exposed to myelosuppressive doses of radiation.\n\n### Mechanism of Action\nSar"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_WBw2TV0DAupU48b8cUwLXPz5", "custom_id": "240_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f6e67341f0503515e96ac4fb3b48234c", "body": {"id": "chatcmpl-9St8fFw8E2yJnzXRIi1TJ2zFqCxLc", "object": "chat.completion", "created": 1716672165, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Selinexor is an oral selective inhibitor of nuclear export (SINE) compound that is used in the treatment of certain types of cancer. Here are some key points you should know about Selinexor:\n\n### Mechanism of Action\n- **Nuclear Export Inhibition**: Selinexor works by inhibiting exportin 1 (XPO1), a protein that transports various molecules, including tumor suppressor proteins, out of the nucleus. By blocking XPO1, Selinexor causes the accumulation of these tumor suppressor proteins in the nucleus, leading to the induction of apoptosis in cancer cells.\n\n### Indications\n- **Multiple Myeloma**: Selinexor is approved for use in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma in patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_JxzgoQIo9hvEvt2oq4oLyWP6", "custom_id": "241_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "4b7d23fe51d8e57d90a196954c7c1a41", "body": {"id": "chatcmpl-9St8fsCXTEgs97zvhXowD5v6KmI8i", "object": "chat.completion", "created": 1716672165, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Selumetinib is a medication that you might find relevant in the context of treating certain types of cancer. Here are some key points you should know about Selumetinib:\n\n### Mechanism of Action\n- **Target**: Selumetinib is a selective inhibitor of MEK1 and MEK2, which are part of the MAPK/ERK pathway. This pathway is often dysregulated in cancers, leading to uncontrolled cell proliferation.\n- **Action**: By inhibiting MEK1/2, Selumetinib can help to reduce tumor growth and proliferation.\n\n### Indications\n- **Neurofibromatosis Type 1 (NF1)**: Selumetinib is FDA-approved for the treatment of pediatric patients aged 2 years and older with symptomatic, inoperable plexiform neurofibromas (PNs) associated with NF1.\n- **Other Cancers**: While its primary approval is for NF1-related PNs, Selumetin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_z1FfuOlSUJY90UcvOmNGMFrU", "custom_id": "242_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "79a2da40b61fb3cfacd7261088eb2e93", "body": {"id": "chatcmpl-9St8fIZ8tqH05LAt4TFFpoeVZDttG", "object": "chat.completion", "created": 1716672165, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Semustine, also known as methyl-CCNU, is a chemotherapeutic agent that belongs to the nitrosourea class of drugs. It is structurally related to lomustine (CCNU) and carmustine (BCNU). Here are some key points you should know about Semustine:\n\n1. **Mechanism of Action**:\n   - Semustine works by alkylating DNA and RNA, leading to the cross-linking of DNA strands, which inhibits DNA replication and transcription. This ultimately results in cell death, particularly in rapidly dividing cancer cells.\n\n2. **Indications**:\n   - Semustine has been used in the treatment of various cancers, including brain tumors, gastrointestinal cancers, and Hodgkin's disease. However, its use has declined due to the development of newer agents with better efficacy and safety profiles.\n\n3. **Administration**:\n   - Semustine is typically administered orally. The dosage and schedule depend on the type of cancer being"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Tql5Xhfsgpbtw1lhmiVJ7W1i", "custom_id": "243_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d4f42993ae61dfc25f643680725bdcce", "body": {"id": "chatcmpl-9St8f4xzupnPNCZb2FpjYH8NJagg8", "object": "chat.completion", "created": 1716672165, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sipuleucel-T (brand name Provenge) is an autologous cellular immunotherapy used to treat certain types of prostate cancer. Here are some key points you should know about it:\n\n### Indications:\n- **Prostate Cancer**: Sipuleucel-T is specifically indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.\n\n### Mechanism of Action:\n- **Immunotherapy**: Sipuleucel-T is designed to stimulate the patient's immune system to attack prostate cancer cells. It involves collecting the patient's own immune cells (specifically dendritic cells), which are then exposed to a protein that is found on most prostate cancer cells (prostatic acid phosphatase, PAP) fused with an immune-stimulating factor (GM-CSF). These activated cells are then reinfused into the patient to help the immune system target and destroy cancer cells.\n\n### Administration:\n- **Personalized Treatment**: The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_QqlPf92VcTSG2OrRPWfT9G0y", "custom_id": "244_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "705265e71c5778c8bcd4053ce43c8a5f", "body": {"id": "chatcmpl-9St8fd9ZYyd32eUA2ZxtOBGZZrgIg", "object": "chat.completion", "created": 1716672165, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sonidegib, also known by its brand name Odomzo, is a medication used primarily in the treatment of advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or in patients who are not candidates for surgery or radiation. Here are some key points you should know about Sonidegib:\n\n### Mechanism of Action\n- **Hedgehog Pathway Inhibitor**: Sonidegib works by inhibiting the Hedgehog signaling pathway, which is crucial for cell growth and differentiation. This pathway is often abnormally activated in basal cell carcinoma.\n\n### Indications\n- **Advanced Basal Cell Carcinoma**: Specifically indicated for patients with locally advanced BCC that has recurred after surgery or radiation, or for those who are not candidates for these treatments.\n\n### Administration\n- **Oral Medication**: Sonidegib is administered orally, typically at a dose of 200 mg once daily.\n- **Fasting**: It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_HBDVNUwjwPjCjFJ3liYD1jw4", "custom_id": "245_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "67c0119ae29628cf9f369c3ffd97bf2b", "body": {"id": "chatcmpl-9St8fVH371wRSwI9zUrjpXmNbQMmh", "object": "chat.completion", "created": 1716672165, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sorafenib is an oral multikinase inhibitor used primarily in the treatment of certain types of cancer. Here are some key points you should know about Sorafenib:\n\n### Indications:\n1. **Hepatocellular Carcinoma (HCC):** Sorafenib is often used as a first-line treatment for advanced HCC.\n2. **Renal Cell Carcinoma (RCC):** It is also indicated for advanced RCC.\n3. **Thyroid Cancer:** Specifically, it is used for differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.\n\n### Mechanism of Action:\nSorafenib inhibits multiple intracellular and cell surface kinases, which are involved in tumor cell signaling, angiogenesis, and apoptosis. Key targets include:\n- RAF kinases (CRAF, BRAF)\n- VEGFR-2, VEGFR-3\n- PDGFR-\u03b2\n- c-KIT\n- FLT-3\n- RET\n\n### Administration:\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_UB9kcvYxSQghQ842ip8HLDHw", "custom_id": "246_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e629727b1703b6d194ffc1759a726d6b", "body": {"id": "chatcmpl-9St8g42JLS1hpWmhSsEBMYn6XFGox", "object": "chat.completion", "created": 1716672166, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Streptozocin (also spelled streptozotocin) is a chemotherapy agent that is primarily used in the treatment of pancreatic neuroendocrine tumors. Here are some key points you should know about Streptozocin:\n\n### Mechanism of Action\n- **Alkylating Agent**: Streptozocin is a nitrosourea compound that works by alkylating DNA, leading to DNA damage and cell death. It is particularly toxic to pancreatic beta cells.\n\n### Indications\n- **Pancreatic Neuroendocrine Tumors**: It is most commonly used for the treatment of metastatic or inoperable pancreatic neuroendocrine tumors.\n- **Experimental Use**: It has also been used experimentally to induce diabetes in animal models due to its selective toxicity to insulin-producing beta cells in the pancreas.\n\n### Administration\n- **Intravenous (IV) Infusion**: Streptozocin is typically administered via IV infusion. The dosing regimen can vary depending"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_JfsZJ6QnkudCymsEcTh3oGZJ", "custom_id": "247_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ddc85cc586be34d43b01e3f76f84e210", "body": {"id": "chatcmpl-9St8gNilhlfRIwDEpn0UxjfNR1gVo", "object": "chat.completion", "created": 1716672166, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sunitinib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that is used primarily in the treatment of certain types of cancer. Here are some key points you should know about Sunitinib:\n\n### Indications\n1. **Renal Cell Carcinoma (RCC)**: Sunitinib is commonly used for the treatment of advanced or metastatic renal cell carcinoma.\n2. **Gastrointestinal Stromal Tumor (GIST)**: It is indicated for the treatment of GIST after disease progression on or intolerance to imatinib mesylate.\n3. **Pancreatic Neuroendocrine Tumors (pNET)**: Sunitinib is also approved for the treatment of progressive, well-differentiated pNET in patients with unresectable, locally advanced, or metastatic disease.\n\n### Mechanism of Action\nSunitinib inhibits multiple RTKs, which are involved in tumor growth, angiogenesis, and metastatic progression."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_orEoqxFZIC830rUbFbYBj2tX", "custom_id": "248_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "83e34ce8750fae928655011c7a520ced", "body": {"id": "chatcmpl-9St8gtbE3ApXZXUpH4QwLWjnKq209", "object": "chat.completion", "created": 1716672166, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tagraxofusp, also known by its brand name Elzonris, is a targeted therapy used primarily in the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematologic malignancy. Here are some key points you should know about Tagraxofusp:\n\n### Mechanism of Action\n- **Tagraxofusp** is a fusion protein consisting of interleukin-3 (IL-3) and a truncated diphtheria toxin (DT). The IL-3 component targets the IL-3 receptor (CD123), which is overexpressed on BPDCN cells, while the diphtheria toxin component induces cell death by inhibiting protein synthesis.\n\n### Indications\n- **Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)**: Tagraxofusp is FDA-approved for the treatment of BPDCN in adult and pediatric patients aged 2 years and older.\n\n### Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_9d3LigE1ijHBh8pQM95X0uZo", "custom_id": "249_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0ca8ebe2e228219d4d833aa63d46c4e6", "body": {"id": "chatcmpl-9St8gGjvWpzLw8yDjyM6tf1oqKgzP", "object": "chat.completion", "created": 1716672166, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Talazoparib is an oral poly (ADP-ribose) polymerase (PARP) inhibitor used primarily in the treatment of certain types of cancer. Here are some key points you should know about Talazoparib:\n\n### Indications:\n1. **Breast Cancer**: Talazoparib is approved for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer.\n\n### Mechanism of Action:\n1. **PARP Inhibition**: Talazoparib inhibits the PARP enzyme, which plays a critical role in DNA repair. By inhibiting PARP, Talazoparib prevents cancer cells from repairing their DNA, leading to cell death, particularly in cells with BRCA1 or BRCA2 mutations.\n\n### Pharmacokinetics:\n1. **Absorption**: Talazoparib is well-absorbed"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_CDx4aFRvgZ1i7KB7Et8gYdWO", "custom_id": "250_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "adea917eb26fe7bc86c138628a9f1654", "body": {"id": "chatcmpl-9St8g7YlVawdaupTRkgp2hy7LytWB", "object": "chat.completion", "created": 1716672166, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Talimogene laherparepvec (T-VEC) is an oncolytic viral therapy used primarily for the treatment of melanoma. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Oncolytic Virus**: T-VEC is a genetically modified herpes simplex virus type 1 (HSV-1) designed to selectively infect and lyse cancer cells.\n- **GM-CSF Expression**: It is engineered to express granulocyte-macrophage colony-stimulating factor (GM-CSF), which helps stimulate an anti-tumor immune response.\n\n### Indications\n- **Melanoma**: T-VEC is approved for the treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.\n\n### Administration\n- **Intralesional Injection**: T-VEC is administered directly into the tumor lesions. The dosing schedule typically starts with an initial dose, followed by a second dose"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Hrk4HRL2ZWYpNhDIFf8V4AUX", "custom_id": "251_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b8a9c157c938835928838eabd13262b8", "body": {"id": "chatcmpl-9St8gUcV1LUJjXDZCR8M0hcDgw0nh", "object": "chat.completion", "created": 1716672166, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tamibarotene is a synthetic retinoid that is primarily used in the treatment of acute promyelocytic leukemia (APL), particularly in patients who are refractory to or have relapsed after treatment with all-trans retinoic acid (ATRA). Here are some key points you should know about Tamibarotene:\n\n### Mechanism of Action\n- **Retinoic Acid Receptor (RAR) Agonist**: Tamibarotene selectively binds to and activates the retinoic acid receptor alpha (RAR\u03b1), which leads to the differentiation and apoptosis of promyelocytic leukemia cells.\n\n### Indications\n- **Acute Promyelocytic Leukemia (APL)**: It is used in the treatment of APL, especially in cases where patients have not responded to or have relapsed after ATRA therapy.\n\n### Administration\n- **Oral Administration**: Tamibarotene is administered orally, typically in the form of tablets.\n\n### Dosage\n- **Standard"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_T9ifoMXolxu20U9a4RknPwCN", "custom_id": "252_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "86201427e4bf53783e03fc4c0b513df3", "body": {"id": "chatcmpl-9St8hmo6yqSeXfUY9JZCwaaYOai3t", "object": "chat.completion", "created": 1716672167, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tamoxifen is a selective estrogen receptor modulator (SERM) that is commonly used in the treatment and prevention of breast cancer. Here are some key points you should know about Tamoxifen as a physician:\n\n### Indications:\n1. **Breast Cancer Treatment**: Tamoxifen is used to treat estrogen receptor-positive (ER+) breast cancer in both premenopausal and postmenopausal women.\n2. **Breast Cancer Prevention**: It is also used to reduce the risk of breast cancer in high-risk women and in those with ductal carcinoma in situ (DCIS) after surgery and radiation.\n\n### Mechanism of Action:\n- Tamoxifen binds to estrogen receptors on breast cancer cells, blocking estrogen from binding and thereby inhibiting the growth-promoting effects of estrogen on these cells.\n\n### Dosage:\n- The typical dose for breast cancer treatment is 20 mg per day, taken orally. The duration of treatment can vary but is often prescribed for 5 to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_cg0rGqj1r1yPVPADyUpV9txR", "custom_id": "253_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7a18d9bd0e8937e58c1c9bef3c48204a", "body": {"id": "chatcmpl-9St8hGTy7xNvkpjwdpxna9g0KexOq", "object": "chat.completion", "created": 1716672167, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tegafur/gimeracil/oteracil, often referred to as S-1, is an oral anticancer medication used primarily in the treatment of various solid tumors, including gastric cancer, colorectal cancer, and pancreatic cancer. Here are some key points you should know about this combination therapy:\n\n### Components and Mechanism of Action:\n1. **Tegafur**: A prodrug of 5-fluorouracil (5-FU), which is a pyrimidine analog that inhibits thymidylate synthase, leading to disruption of DNA synthesis and cell death.\n2. **Gimeracil**: A dihydropyrimidine dehydrogenase (DPD) inhibitor that prevents the degradation of 5-FU, thereby increasing its bioavailability and effectiveness.\n3. **Oteracil**: A modulator that reduces the gastrointestinal toxicity of 5-FU by inhibiting its phosphorylation in the gut.\n\n### Indications:\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_oBZ8skkAKAnsyrsBRX5GVrWD", "custom_id": "254_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "69c97c0a768c12e86e6ec6b13481a18d", "body": {"id": "chatcmpl-9St8hmU86VrgLO1KifHCXhpB1p09U", "object": "chat.completion", "created": 1716672167, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tegafur and uracil are components of a combination chemotherapy drug used primarily in the treatment of certain types of cancer, including colorectal cancer. Here are some key points you should know about this combination:\n\n### Mechanism of Action:\n1. **Tegafur**: Tegafur is a prodrug of 5-fluorouracil (5-FU), an antimetabolite that interferes with DNA synthesis. Once administered, tegafur is metabolized in the liver to 5-FU, which then inhibits thymidylate synthase, an enzyme crucial for DNA replication and repair.\n2. **Uracil**: Uracil is included to enhance the efficacy of tegafur. It competitively inhibits dihydropyrimidine dehydrogenase (DPD), the enzyme responsible for the degradation of 5-FU. By inhibiting DPD, uracil increases the bioavailability and effectiveness of 5-FU.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_eDQEZTXu9haCfS5Wt5K2ucmH", "custom_id": "255_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a8812e010f8747b86a3885a904e63c8c", "body": {"id": "chatcmpl-9St8hpK9Bn3KA0hq6tqKqoCjF3QZk", "object": "chat.completion", "created": 1716672167, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Temozolomide is an oral chemotherapy drug used primarily in the treatment of certain types of brain tumors, such as glioblastoma multiforme and anaplastic astrocytoma. Here are some key points you should know about Temozolomide:\n\n### Mechanism of Action\n- **Alkylating Agent**: Temozolomide is an alkylating agent that works by adding an alkyl group to the DNA of cancer cells, which leads to DNA damage and ultimately cell death. It is particularly effective in cells that are rapidly dividing.\n\n### Indications\n- **Glioblastoma Multiforme**: Often used as a first-line treatment in combination with radiotherapy and as maintenance therapy.\n- **Anaplastic Astrocytoma**: Used for patients with refractory or recurrent disease.\n\n### Administration\n- **Oral Formulation**: Temozolomide is administered orally, which can be more convenient for patients compared to intravenous chemotherapy.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_oiR35GMcHdVla8ksSimzknTs", "custom_id": "256_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e98b62a2382406dac7e336e2dff561ff", "body": {"id": "chatcmpl-9St8hkts19K01GWkZkMgFZLMFSpJc", "object": "chat.completion", "created": 1716672167, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Temsirolimus is an mTOR (mammalian target of rapamycin) inhibitor used primarily in the treatment of advanced renal cell carcinoma (RCC). Here are some key points you should know about Temsirolimus:\n\n### Mechanism of Action\n- **mTOR Inhibition**: Temsirolimus inhibits the mTOR pathway, which is crucial for cell growth, proliferation, and survival. By inhibiting mTOR, Temsirolimus can reduce tumor cell proliferation and angiogenesis.\n\n### Indications\n- **Renal Cell Carcinoma**: It is primarily indicated for the treatment of advanced RCC, particularly in patients with poor prognostic features.\n- **Other Cancers**: Research is ongoing for its use in other types of cancers, but RCC remains the primary approved indication.\n\n### Administration\n- **Intravenous Infusion**: Temsirolimus is administered as an intravenous infusion, typically once a week.\n- **Dosage**: The standard dose"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_7CJg6ZmtcqaH6NqD7sZdPkpQ", "custom_id": "257_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0d4982611311f78fa66a131364bf99ed", "body": {"id": "chatcmpl-9St8h8u4qetwP1bEzAf4m54Xtx4ZK", "object": "chat.completion", "created": 1716672167, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Teniposide is an important chemotherapeutic agent used primarily in the treatment of certain types of cancer. Here are key points you should know about Teniposide:\n\n### Mechanism of Action\n- **Topoisomerase II Inhibitor**: Teniposide works by inhibiting the enzyme topoisomerase II, which is essential for DNA replication and repair. This inhibition leads to DNA strand breaks and ultimately cell death, particularly in rapidly dividing cancer cells.\n\n### Indications\n- **Acute Lymphoblastic Leukemia (ALL)**: Often used in pediatric patients, particularly those who have relapsed or are refractory to other treatments.\n- **Non-Hodgkin's Lymphoma**: Sometimes used in combination with other chemotherapeutic agents.\n- **Other Cancers**: Occasionally used off-label for other malignancies, including certain types of brain tumors and neuroblastoma.\n\n### Administration\n- **Intravenous (IV) Infusion**: Teniposide"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_kI8KvXXRpNkK2hS81pVnDu8b", "custom_id": "258_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "005f6c73e37c393c2abd404bcd0a03d7", "body": {"id": "chatcmpl-9St8i68VMeXnBb2cFB58CdpZ9XL38", "object": "chat.completion", "created": 1716672168, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Thalidomide is a medication with a complex and controversial history, and as a physician, there are several critical aspects you should be aware of:\n\n### Historical Context:\n1. **Teratogenic Effects**: Thalidomide was originally marketed in the late 1950s and early 1960s as a sedative and treatment for morning sickness in pregnant women. However, it was soon discovered to cause severe birth defects, including limb deformities, in thousands of babies worldwide. This led to its withdrawal from the market in many countries and significantly changed drug regulation policies.\n\n### Current Uses:\n2. **Approved Indications**: Despite its past, thalidomide has found a place in modern medicine for specific conditions. It is approved for:\n   - **Multiple Myeloma**: Used in combination with other drugs for the treatment of multiple myeloma.\n   - **Erythema Nodosum Leprosum (ENL)**: A complication of lepro"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_G7WEaNj6hSLc2g5pIkBc8Uji", "custom_id": "259_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7612ce7091ea0e14cf2b636eb28bf0bb", "body": {"id": "chatcmpl-9St8iOVjmn9eYeXAn0PWpju8e4fbo", "object": "chat.completion", "created": 1716672168, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Thioguanine, also known as 6-thioguanine or 6-TG, is a purine analog and antimetabolite used primarily in the treatment of certain types of leukemia, such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Here are some key points you should know about Thioguanine:\n\n### Mechanism of Action\n- **Antimetabolite**: Thioguanine interferes with DNA and RNA synthesis by incorporating into DNA and RNA strands, leading to faulty replication and transcription.\n- **Inhibition of Purine Synthesis**: It inhibits several enzymes involved in the de novo purine synthesis pathway, which is crucial for the proliferation of rapidly dividing cells, such as cancer cells.\n\n### Indications\n- **Acute Myeloid Leukemia (AML)**: Often used in combination with other chemotherapeutic agents.\n- **Acute Lymphoblastic Leukemia (ALL)**: Sometimes used in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_jsxMgRMCLLPiS4I0eKHN0Sik", "custom_id": "260_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6fc9e8150333d7b2d88a804ace44265c", "body": {"id": "chatcmpl-9St8i1jdeW7TNfkryQDZYUyHTbEqI", "object": "chat.completion", "created": 1716672168, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Thiotepa is an alkylating agent used primarily in the treatment of various cancers. Here are some key points you should know about Thiotepa:\n\n### Indications:\n1. **Oncology**: Thiotepa is used in the treatment of several types of cancer, including:\n   - Breast cancer\n   - Ovarian cancer\n   - Bladder cancer\n   - Hodgkin's disease\n   - Non-Hodgkin's lymphoma\n   - Malignant effusions (e.g., pleural, pericardial, and peritoneal effusions)\n\n2. **Bone Marrow Transplantation**: It is also used as part of high-dose chemotherapy regimens in preparation for bone marrow or stem cell transplantation.\n\n### Mechanism of Action:\n- Thiotepa is an alkylating agent that works by cross-linking DNA strands, thereby inhibiting DNA synthesis and function, which leads to cell death. It is cell cycle phase-nonspecific.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_hn7YIG2Gsp9LTgh5BuCIFslA", "custom_id": "261_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e2b5225e28279564c6e32b99b2d229bb", "body": {"id": "chatcmpl-9St8iy5jjnLOdWrs5Jw2a39HvBRTP", "object": "chat.completion", "created": 1716672168, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tisagenlecleucel, marketed under the brand name Kymriah, is a type of CAR-T (chimeric antigen receptor T-cell) therapy. It represents a significant advancement in the treatment of certain types of cancer, particularly hematologic malignancies. Here are some key points you should know about Tisagenlecleucel:\n\n### Indications\n1. **Pediatric and Young Adult Acute Lymphoblastic Leukemia (ALL):**\n   - Approved for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse.\n   \n2. **Adult Relapsed or Refractory Large B-cell Lymphoma:**\n   - Approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.\n\n### Mechan"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_02DhyAh42yQgBrhN5ps9fa6t", "custom_id": "262_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c9386dcc3eed6ce83ed0c0fe8945ad32", "body": {"id": "chatcmpl-9St8idxpWI1OZNA6X3z9cfkLkydOg", "object": "chat.completion", "created": 1716672168, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tivozanib is a medication used primarily in the treatment of renal cell carcinoma (RCC), a type of kidney cancer. Here are some key points you should know about Tivozanib as a physician:\n\n### Mechanism of Action\n- **Tivozanib** is a tyrosine kinase inhibitor (TKI) that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. By blocking these receptors, Tivozanib reduces angiogenesis (the formation of new blood vessels), which is crucial for tumor growth and metastasis.\n\n### Indications\n- **Renal Cell Carcinoma (RCC)**: Tivozanib is approved for the treatment of adult patients with advanced RCC. It is often used in patients who have received prior therapy or as a first-line treatment in some cases.\n\n### Dosage and Administration\n- **Dosage**: The typical dose is 1.34 mg taken orally once daily for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_mUWasjVOLAqXay6lff1t2qMB", "custom_id": "263_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "07c11576105e65e7b540a4e8620ba19a", "body": {"id": "chatcmpl-9St8jO8Lx03yRpSpzCNO1ztU2sA9c", "object": "chat.completion", "created": 1716672169, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Topotecan is a chemotherapeutic agent used primarily in the treatment of certain types of cancer. Here are some key points you should know about Topotecan:\n\n### Mechanism of Action\n- **Topoisomerase I Inhibition**: Topotecan works by inhibiting the enzyme topoisomerase I, which is essential for DNA replication. By stabilizing the topoisomerase I-DNA complex, it prevents the relegation of single-strand breaks, leading to DNA damage and cell death.\n\n### Indications\n- **Small Cell Lung Cancer (SCLC)**: Topotecan is used for the treatment of relapsed small cell lung cancer.\n- **Ovarian Cancer**: It is indicated for metastatic ovarian cancer after disease progression following initial or subsequent chemotherapy.\n- **Cervical Cancer**: In combination with cisplatin, it is used for the treatment of stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Z6yTxAbKcidIwclxWtXNfRt0", "custom_id": "264_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c98eef7005d245303453e3be2a14c5c7", "body": {"id": "chatcmpl-9St8jZzD8xmnFfhkaV0E296AUxh9C", "object": "chat.completion", "created": 1716672169, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Toremifene is a selective estrogen receptor modulator (SERM) that is primarily used in the treatment of hormone-responsive breast cancer. Here are some key points you should know about Toremifene:\n\n### Indications:\n- **Breast Cancer**: Toremifene is mainly indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or unknown tumors.\n\n### Mechanism of Action:\n- **Estrogen Receptor Modulation**: Toremifene binds to estrogen receptors, exerting both estrogenic and anti-estrogenic effects depending on the target tissue. In breast tissue, it acts as an anti-estrogen, inhibiting the proliferation of estrogen-dependent cancer cells.\n\n### Pharmacokinetics:\n- **Absorption**: Toremifene is well-absorbed orally.\n- **Metabolism**: It is extensively metabolized in the liver, primarily by CYP3A4.\n- **Half-life**: The half-life of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_POuzl8jMsjFbBhxfVTA4HE5i", "custom_id": "265_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "95e9466de1cdf4987ac46b39bf5df0f7", "body": {"id": "chatcmpl-9St8jwlzLTD28yz2L2HfTy7g3Qgo5", "object": "chat.completion", "created": 1716672169, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tositumomab and I-131 (Iodine-131) are components of a radioimmunotherapy treatment used primarily for certain types of non-Hodgkin lymphoma (NHL), particularly those that are refractory to standard treatments or have relapsed. Here are key points you should know:\n\n### Mechanism of Action\n- **Tositumomab**: This is a monoclonal antibody that targets the CD20 antigen found on the surface of B-cells, including malignant B-cells in NHL.\n- **I-131**: This is a radioactive isotope of iodine that is conjugated to tositumomab. It delivers targeted radiation to the B-cells, enhancing the cytotoxic effect.\n\n### Indications\n- Primarily used for patients with CD20-positive, follicular non-Hodgkin lymphoma that is refractory to rituximab and chemotherapy or has relapsed after treatment.\n\n### Administration\n- The treatment involves two steps: an initial dos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_r4B90jaIJrWSiqGEklxnr8Do", "custom_id": "266_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "69b3d9ac00734f4c26cdc5c01724934e", "body": {"id": "chatcmpl-9St8jUghz2n1FswmZipyEWMKG0nPG", "object": "chat.completion", "created": 1716672169, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trabectedin is a chemotherapeutic agent used primarily in the treatment of certain types of soft tissue sarcoma and relapsed ovarian cancer. Here are some key points you should know about Trabectedin:\n\n### Mechanism of Action\n- **DNA Interaction**: Trabectedin binds to the minor groove of DNA, causing a bend in the DNA helix. This interaction disrupts the cell cycle and inhibits the transcription process.\n- **Transcription Inhibition**: It interferes with the transcription-coupled nucleotide excision repair (TC-NER) pathway, leading to DNA damage and apoptosis in cancer cells.\n- **Modulation of Tumor Microenvironment**: Trabectedin also affects the tumor microenvironment by modulating the activity of tumor-associated macrophages.\n\n### Indications\n- **Soft Tissue Sarcoma**: Approved for the treatment of patients with advanced soft tissue sarcoma, particularly liposarcoma and leiomyosarcoma, after failure of anthracycline and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_VPJvPorBe0Lqxmu51KJKBoCm", "custom_id": "267_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "94b90d28ba9a37478a0cedfe64632ef7", "body": {"id": "chatcmpl-9St8k3wkIpyIHRdblEkVeAEszGFr4", "object": "chat.completion", "created": 1716672170, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trametinib is a medication used primarily in the treatment of certain types of cancer. Here are some key points you should know about it:\n\n### Indications:\n- **Melanoma**: Trametinib is often used to treat melanoma that has a specific mutation in the BRAF gene (BRAF V600E or V600K mutations). It is frequently used in combination with another drug, dabrafenib, which targets the same pathway.\n- **Non-Small Cell Lung Cancer (NSCLC)**: It can also be used in combination with dabrafenib for the treatment of NSCLC with BRAF V600E mutations.\n- **Other Cancers**: Research is ongoing to determine its efficacy in other cancers with similar mutations.\n\n### Mechanism of Action:\n- **MEK Inhibitor**: Trametinib is a MEK inhibitor, which means it blocks the activity of MEK1 and MEK2 proteins. These proteins are part of the MAPK"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_8O8londT6rNSKjvLadyTr6mF", "custom_id": "268_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f3a760fb7c13902efe21264417b61fec", "body": {"id": "chatcmpl-9St8kpMiVyDRVqriZjykvovq8XLKZ", "object": "chat.completion", "created": 1716672170, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tranexamic acid (TXA) is an antifibrinolytic medication that is widely used to reduce bleeding in various medical contexts. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Antifibrinolytic Agent**: TXA works by inhibiting the activation of plasminogen to plasmin, an enzyme that breaks down fibrin clots. This helps to stabilize clots and reduce bleeding.\n\n### Indications\n- **Surgical Procedures**: Commonly used to reduce bleeding during and after surgeries, including orthopedic, cardiac, and gynecological surgeries.\n- **Trauma**: Administered to trauma patients to reduce hemorrhage and improve survival rates.\n- **Menorrhagia**: Used to treat heavy menstrual bleeding.\n- **Dental Procedures**: Sometimes used in patients with bleeding disorders undergoing dental procedures.\n- **Hereditary Angioedema**: Can be used off-label to prevent attacks.\n\n### Administration\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_gqznsVaV8QzqO1u7Ff1VLocT", "custom_id": "269_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "51188c05d067e7f405df6452d048f8fe", "body": {"id": "chatcmpl-9St8k1psmEelNkbHNlnKewPoc9xfA", "object": "chat.completion", "created": 1716672170, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab, commonly known by its brand name Herceptin, is a monoclonal antibody used primarily in the treatment of HER2-positive breast cancer and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. Here are some key points you should know about Trastuzumab:\n\n### Mechanism of Action\n- **HER2 Targeting**: Trastuzumab specifically targets the human epidermal growth factor receptor 2 (HER2), which is overexpressed in some cancers. By binding to the HER2 receptor, it inhibits the proliferation of cancer cells that overexpress this protein.\n- **Immune System Activation**: It also mediates antibody-dependent cellular cytotoxicity (ADCC), recruiting immune cells to attack the cancer cells.\n\n### Indications\n- **Breast Cancer**: Used in both early-stage and metastatic HER2-positive breast cancer. It can be administered as monotherapy or in combination with other chemotherapeutic agents.\n- **G"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_jVMKPivGbZc8m63cjGXTqWos", "custom_id": "270_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1229342564dbd727c9648ff9b013b5c3", "body": {"id": "chatcmpl-9St8kv7eEo5wk20cITVzs1nYt1saD", "object": "chat.completion", "created": 1716672170, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tremelimumab is a monoclonal antibody that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), an immune checkpoint receptor. By inhibiting CTLA-4, Tremelimumab enhances the immune system's ability to attack cancer cells. Here are some key points you should know about Tremelimumab:\n\n1. **Mechanism of Action**:\n   - Tremelimumab binds to CTLA-4 on T cells, blocking its interaction with its ligands (CD80/CD86). This inhibition prevents the downregulation of T-cell activation, thereby promoting an anti-tumor immune response.\n\n2. **Indications**:\n   - Tremelimumab is primarily investigated and used in the treatment of various cancers, including melanoma, mesothelioma, and hepatocellular carcinoma. It is often studied in combination with other immune checkpoint inhibitors like PD-1/PD-L1 inhibitors.\n\n3. **Administration**:\n   - It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_PWvwcKb8HQFyHcvLgw8lbBM5", "custom_id": "271_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a53273d8001f37db3f85a0c356b6d696", "body": {"id": "chatcmpl-9St2o3KoCbjMAzfct8RPJ8xMcGLhy", "object": "chat.completion", "created": 1716671802, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Treosulfan is a bifunctional alkylating agent used primarily in the context of conditioning regimens for hematopoietic stem cell transplantation (HSCT). Here are some key points you should know about Treosulfan:\n\n### Indications:\n1. **Conditioning Regimen for HSCT**: Treosulfan is often used in combination with other agents (e.g., fludarabine) as part of a conditioning regimen before allogeneic or autologous HSCT. It is particularly useful in patients who are not candidates for more intensive conditioning regimens due to age or comorbidities.\n\n### Mechanism of Action:\n1. **Alkylating Agent**: Treosulfan works by alkylating DNA, leading to cross-linking and strand breaks, which ultimately results in cell death. This mechanism is similar to other alkylating agents like busulfan, but Treosulfan is considered to have a different toxicity profile.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_B2v4JJzbizcOiSAJHU39hKW7", "custom_id": "272_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "837b86b1f756ffc6124291ca1612254d", "body": {"id": "chatcmpl-9St2pyj2SbP3g9KlkTLZnAdGBSrzt", "object": "chat.completion", "created": 1716671803, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trifluridine and tipiracil, marketed under the brand name Lonsurf, is a combination medication used primarily in the treatment of certain types of cancer, specifically metastatic colorectal cancer and metastatic gastric or gastroesophageal junction adenocarcinoma. Here are some key points you should know about this medication:\n\n### Mechanism of Action:\n1. **Trifluridine**: This is a nucleoside analog that gets incorporated into DNA during replication, leading to DNA dysfunction and cell death. It primarily acts as an antineoplastic agent.\n2. **Tipiracil**: This component inhibits thymidine phosphorylase, an enzyme that degrades trifluridine. By inhibiting this enzyme, tipiracil increases the bioavailability of trifluridine.\n\n### Indications:\n- **Metastatic Colorectal Cancer**: For patients who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_lVfgA1hYkwPArb4DEKxsTwfu", "custom_id": "273_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3fd2acbed01f9f8ff0aac3a071835483", "body": {"id": "chatcmpl-9St2r6AtLnXnFSBKRQs9dc8AZIvsH", "object": "chat.completion", "created": 1716671805, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Triptorelin is a synthetic decapeptide agonist analog of gonadotropin-releasing hormone (GnRH or LHRH). It is used primarily in the treatment of hormone-responsive cancers such as prostate cancer, and in some cases, breast cancer, as well as in the management of precocious puberty and endometriosis. Here are some key points you should know about Triptorelin:\n\n### Mechanism of Action\n- **GnRH Agonist**: Triptorelin initially stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. However, with continuous administration, it desensitizes the GnRH receptors, leading to a significant reduction in LH and FSH levels.\n- **Hormone Suppression**: This reduction in LH and FSH subsequently decreases the production of sex hormones (testosterone in men and estrogen in women), which is beneficial in hormone-sensitive conditions.\n\n### Ind"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5KpFhzX7dz4kFX1ne7RwZsgt", "custom_id": "274_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "26b3218f57c3ffaacf595c83e8b72738", "body": {"id": "chatcmpl-9St2sdBymQbypn2kjdLJqpkeuh6XB", "object": "chat.completion", "created": 1716671806, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Valproate, also known as valproic acid or divalproex sodium, is a medication primarily used to treat epilepsy and bipolar disorder, and to prevent migraine headaches. Here are some key points you should know about Valproate:\n\n### Indications:\n1. **Epilepsy**: Used to treat various types of seizures, including absence seizures, complex partial seizures, and generalized tonic-clonic seizures.\n2. **Bipolar Disorder**: Effective in the treatment of manic episodes and for maintenance therapy to prevent mood swings.\n3. **Migraine Prophylaxis**: Used to prevent migraine headaches, though not for acute treatment.\n\n### Mechanism of Action:\nValproate increases the availability of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the brain, which helps to stabilize neuronal activity.\n\n### Dosage and Administration:\n- **Epilepsy**: The dosage is highly individualized based on the patient's age, weight, and response to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_RvLAk7SIrPLSDPTjMywQ7W5N", "custom_id": "275_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d94ec746df58cc73ace814ed0b2ac591", "body": {"id": "chatcmpl-9St2so94ucS9ggFzISJBSG6weqYg2", "object": "chat.completion", "created": 1716671806, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Valrubicin is an anthracycline chemotherapy drug primarily used in the treatment of bladder cancer, specifically for patients with Bacillus Calmette-Gu\u00e9rin (BCG)-refractory carcinoma in situ (CIS) of the bladder who are not candidates for immediate cystectomy. Here are some key points you should know about Valrubicin:\n\n### Mechanism of Action\n- **Anthracycline Antibiotic**: Valrubicin works by intercalating DNA strands, thereby inhibiting the synthesis of DNA and RNA. This leads to the disruption of cell division and induces apoptosis in cancer cells.\n\n### Indications\n- **Bladder Cancer**: It is specifically indicated for intravesical therapy in patients with BCG-refractory CIS of the bladder.\n\n### Administration\n- **Intravesical Instillation**: Valrubicin is administered directly into the bladder via a catheter. This local administration helps to concentrate the drug in the bladder and minimize systemic exposure.\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_qQl0WdstEqkuxpvQ0a44srQK", "custom_id": "276_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9951e8f69c2812a899792ae7c2815db5", "body": {"id": "chatcmpl-9St2tckUO9ATpz5bKJiElk7XNo5f3", "object": "chat.completion", "created": 1716671807, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vandetanib is a medication used primarily in the treatment of certain types of thyroid cancer, specifically medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Here are some key points you should know about Vandetanib:\n\n### Mechanism of Action\n- **Tyrosine Kinase Inhibitor (TKI):** Vandetanib inhibits multiple receptor tyrosine kinases, including VEGFR (vascular endothelial growth factor receptor), EGFR (epidermal growth factor receptor), and RET (rearranged during transfection) proto-oncogene. This inhibition helps to reduce tumor growth and angiogenesis.\n\n### Indications\n- **Medullary Thyroid Cancer (MTC):** Vandetanib is approved for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.\n\n### Administration\n- **Oral Medication:** Vandetanib is administered orally,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_9Rl0PTlFvIoaub8KbcTv2zRc", "custom_id": "277_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7db8e560241a928ea8c528af5de62c3a", "body": {"id": "chatcmpl-9St2ugHwzpVpaMscI7u7CuCZ6XE0x", "object": "chat.completion", "created": 1716671808, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vemurafenib is a targeted therapy used primarily in the treatment of certain types of cancer, most notably metastatic melanoma with a specific mutation in the BRAF gene (BRAF V600E mutation). Here are some key points you should know about Vemurafenib:\n\n### Mechanism of Action\n- **BRAF Inhibition**: Vemurafenib is a BRAF inhibitor. It specifically targets and inhibits the activity of the mutated BRAF V600E protein, which is involved in cell growth and proliferation. By inhibiting this protein, Vemurafenib can slow down or stop the growth of cancer cells.\n\n### Indications\n- **Metastatic Melanoma**: Vemurafenib is approved for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation.\n- **Other Cancers**: It may also be used in other cancers harboring the BRAF V600E mutation, though this is less"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_NNqki4wmgeHLy2YbRKedYVjO", "custom_id": "278_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "72a870a40607508bd77e5dcbeed425d1", "body": {"id": "chatcmpl-9St2uzIkfDOr3iaJ6BoHb44gaJCCG", "object": "chat.completion", "created": 1716671808, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Venetoclax is an oral B-cell lymphoma-2 (BCL-2) inhibitor used primarily in the treatment of certain hematologic malignancies. Here are some key points you should know about Venetoclax:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL):**\n   - Venetoclax is approved for use in patients with CLL or SLL, either as monotherapy or in combination with other agents such as rituximab or obinutuzumab.\n   \n2. **Acute Myeloid Leukemia (AML):**\n   - Venetoclax is also used in combination with hypomethylating agents (e.g., azacitidine or decitabine) or low-dose cytarabine for the treatment of newly diagnosed AML in adults who are 75 years or older, or who have comorbidities precluding the use of intensive induction chemotherapy.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_3cOTj6GWnQwnWh6i5thXYrnD", "custom_id": "279_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "fb94eb30a8b5767cb3f4863352583c45", "body": {"id": "chatcmpl-9St2voamTxplpnyYxRBPqnfv7O1gD", "object": "chat.completion", "created": 1716671809, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vinblastine is a chemotherapy medication used to treat various types of cancer. Here are some key points you should know about Vinblastine as a physician:\n\n### Mechanism of Action\n- **Microtubule Inhibition**: Vinblastine works by inhibiting the formation of microtubules, which are essential for cell division. It binds to tubulin, preventing the assembly of microtubules, thereby arresting cells in the metaphase of mitosis.\n\n### Indications\n- **Hodgkin's Lymphoma**: Often used as part of combination chemotherapy regimens.\n- **Non-Hodgkin's Lymphoma**: Used in various treatment protocols.\n- **Testicular Cancer**: Part of combination therapy.\n- **Breast Cancer**: Sometimes used in specific cases.\n- **Kaposi's Sarcoma**: Particularly in patients with AIDS.\n- **Choriocarcinoma**: Used in certain treatment regimens.\n\n### Administration\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_QOxmH4Iy0SCOc2AUzlC8DeCR", "custom_id": "280_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0f5f9281744bf05650570efd7115f0dd", "body": {"id": "chatcmpl-9St2vnzcMdgHClKZifW2z2qeKZvKg", "object": "chat.completion", "created": 1716671809, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vincristine is a chemotherapy medication used to treat various types of cancer, including leukemia, lymphoma, and certain types of solid tumors. Here are some key points you should know about Vincristine:\n\n### Mechanism of Action\n- **Microtubule Inhibition**: Vincristine works by inhibiting the formation of microtubules, which are essential for cell division. This disruption prevents cancer cells from successfully dividing and proliferating.\n\n### Indications\n- **Hematologic Malignancies**: Commonly used in the treatment of acute lymphoblastic leukemia (ALL), Hodgkin's lymphoma, and non-Hodgkin's lymphoma.\n- **Solid Tumors**: Sometimes used in the treatment of certain solid tumors, such as rhabdomyosarcoma, neuroblastoma, and Wilms' tumor.\n\n### Administration\n- **Intravenous (IV) Only**: Vincristine is administered intravenously. It is crucial to ensure that it is never"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_0k7ZesxFKQuZdZHs8emyHbJl", "custom_id": "281_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d92306d85919ac339af7149ef5e6fc28", "body": {"id": "chatcmpl-9St2wbSCxUgVofKWM7J36HBAsu9wS", "object": "chat.completion", "created": 1716671810, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vincristine liposomal is a formulation of the chemotherapeutic agent vincristine, encapsulated in liposomes to enhance its delivery and reduce toxicity. Here are some key points you should know about it:\n\n### Indications:\n- **Vincristine liposomal** is primarily used in the treatment of certain types of cancer, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL).\n- It may be used in patients who have relapsed or are refractory to standard treatments.\n\n### Mechanism of Action:\n- Vincristine is a vinca alkaloid that inhibits microtubule formation in the mitotic spindle, leading to cell cycle arrest in metaphase and subsequent apoptosis of cancer cells.\n- The liposomal formulation helps in targeted delivery, potentially increasing the drug concentration at the tumor site while reducing systemic exposure and side effects.\n\n### Administration:\n- Vincristine liposomal is administered intravenously.\n- Dosage and schedule depend on the specific cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_9H5vBFArI5obVWsqhaeGcEFb", "custom_id": "282_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "97be2ded3b93ad6324f96b9807b487c4", "body": {"id": "chatcmpl-9St2x0rNT41y8dGbJlOdqQkM5Z69P", "object": "chat.completion", "created": 1716671811, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vindesine is a chemotherapeutic agent that belongs to the vinca alkaloid class of medications. It is derived from the periwinkle plant (Catharanthus roseus) and is used primarily in the treatment of various types of cancer. Here are some key points you should know about Vindesine:\n\n### Mechanism of Action\n- **Microtubule Inhibition**: Vindesine works by inhibiting the assembly of microtubules, which are essential components of the cell's cytoskeleton. This disruption prevents cell division, leading to cell death, particularly in rapidly dividing cancer cells.\n\n### Indications\n- **Hematologic Malignancies**: It is often used in the treatment of acute lymphoblastic leukemia (ALL) and other hematologic cancers.\n- **Solid Tumors**: Vindesine may also be used in the treatment of various solid tumors, including lung cancer, breast cancer, and melanoma.\n\n### Administration\n- **Intravenous (IV)"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Q8pCTQUl3tESVhpgHYyciy05", "custom_id": "283_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "869b37b07eb52e3f22f192937ed94913", "body": {"id": "chatcmpl-9St2xIxa6u9acdCPvEiQybJPZzY3H", "object": "chat.completion", "created": 1716671811, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vinflunine is a chemotherapeutic agent used primarily in the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, particularly after failure of a prior platinum-containing regimen. Here are some key points you should know about Vinflunine:\n\n### Mechanism of Action\n- **Microtubule Inhibition**: Vinflunine is a vinca alkaloid that inhibits microtubule assembly, thereby disrupting mitotic spindle formation and leading to cell cycle arrest and apoptosis.\n\n### Indications\n- **Urothelial Carcinoma**: It is specifically indicated for patients with advanced or metastatic transitional cell carcinoma of the urothelial tract who have previously been treated with a platinum-based chemotherapy regimen.\n\n### Administration\n- **Intravenous Infusion**: Vinflunine is administered via intravenous infusion, typically over 20 minutes.\n- **Dosing**: The recommended dose is often 320 mg/m\u00b2 every 3 weeks, but dosing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_DhhkmMl3avChIHIsELwhDRYl", "custom_id": "284_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b329de664aef829a6152346d2ce2ad94", "body": {"id": "chatcmpl-9St2xHHi8jYB4srUkIH5Anc00lYSC", "object": "chat.completion", "created": 1716671811, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vinorelbine is a chemotherapy medication used primarily in the treatment of non-small cell lung cancer (NSCLC) and metastatic breast cancer. Here are some key points you should know about Vinorelbine:\n\n### Mechanism of Action\n- **Class**: Vinorelbine is a vinca alkaloid.\n- **Action**: It works by inhibiting microtubule formation in the mitotic spindle, thereby preventing cell division and leading to cell death.\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC)**: Often used as a first-line treatment, either alone or in combination with other chemotherapeutic agents.\n- **Metastatic Breast Cancer**: Used particularly in patients who have failed other chemotherapy regimens.\n\n### Administration\n- **Form**: Available in both intravenous (IV) and oral formulations.\n- **Dosage**: The dosage varies based on the specific protocol, patient\u2019s body surface area, and clinical condition. Typically, it is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_gdINcdx2hOVP2KJIrwtFFe52", "custom_id": "285_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "32a2dd061165caa95e6b320e5388ae8c", "body": {"id": "chatcmpl-9St2yljuFgSgl8N17w6DoWBD9F1Hh", "object": "chat.completion", "created": 1716671812, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vismodegib is an important medication used primarily in the treatment of certain types of skin cancer. Here are key points you should know about it:\n\n### Indications:\n- **Basal Cell Carcinoma (BCC):** Vismodegib is primarily indicated for the treatment of adults with metastatic basal cell carcinoma (mBCC) or with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or who are not candidates for surgery or radiation.\n\n### Mechanism of Action:\n- **Hedgehog Pathway Inhibitor:** Vismodegib works by inhibiting the Hedgehog signaling pathway, which is crucial in the development of basal cell carcinoma. It specifically targets and binds to the Smoothened (SMO) receptor, thereby blocking the pathway and inhibiting tumor growth.\n\n### Administration:\n- **Oral Medication:** Vismodegib is administered orally, typically in the form of a capsule. The usual dosage is 150 mg once daily,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_7BlbLyflywYE1JkBBu3kAhGd", "custom_id": "286_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1c53233ed32f8b096af82c6fdc4f70dd", "body": {"id": "chatcmpl-9St2y1tfFTRwimUqj1kU2xpJjE7uV", "object": "chat.completion", "created": 1716671812, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vorinostat, also known by its brand name Zolinza, is a histone deacetylase (HDAC) inhibitor used primarily in the treatment of certain types of cancer. Here are some key points you should know about Vorinostat:\n\n### Indications:\n- **Cutaneous T-cell Lymphoma (CTCL):** Vorinostat is FDA-approved for the treatment of CTCL in patients who have progressive, persistent, or recurrent disease on or following two systemic therapies.\n\n### Mechanism of Action:\n- **HDAC Inhibition:** Vorinostat inhibits the activity of histone deacetylases, leading to an accumulation of acetylated histones and proteins. This results in altered gene expression, cell cycle arrest, and apoptosis of cancer cells.\n\n### Administration:\n- **Oral Formulation:** Vorinostat is administered orally, typically at a dose of 400 mg once daily with food. The dose may be adjusted based on patient tolerance and response.\n\n### Side"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_6iF5u6VuO94VcwsGSVZVoDUR", "custom_id": "287_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1ad24ce4f9aabb15cc9d1188c6c272e6", "body": {"id": "chatcmpl-9St2zu7FtFgRHRNiTA0XuBPjcM4gP", "object": "chat.completion", "created": 1716671813, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zidovudine, also known as AZT (azidothymidine), is an antiretroviral medication used primarily in the treatment of HIV/AIDS. Here are some key points you should know about Zidovudine:\n\n### Mechanism of Action\n- **Nucleoside Reverse Transcriptase Inhibitor (NRTI)**: Zidovudine works by inhibiting the reverse transcriptase enzyme, which is crucial for the replication of HIV. By incorporating itself into the viral DNA, it causes premature chain termination.\n\n### Indications\n- **HIV Treatment**: Zidovudine is used in combination with other antiretroviral agents for the treatment of HIV-1 infection.\n- **Prevention of Maternal-Fetal Transmission**: It is used to reduce the risk of HIV transmission from an HIV-positive mother to her baby during childbirth.\n- **Post-Exposure Prophylaxis (PEP)**: Zidovudine can be part of a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ziaVSXPyc7IyOFhCgzONhXuS", "custom_id": "288_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "97e1882e2adca2d608a1aa89c674594d", "body": {"id": "chatcmpl-9St2zo3g3NXU2IFhnlUyy4KsBerh0", "object": "chat.completion", "created": 1716671813, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ziv-aflibercept, also known as aflibercept or by its brand name Zaltrap, is a recombinant fusion protein used primarily in oncology. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **VEGF Inhibition**: Ziv-aflibercept acts as a decoy receptor for vascular endothelial growth factor (VEGF) and placental growth factor (PlGF). By binding to these growth factors, it prevents them from interacting with their natural receptors on the surface of endothelial cells, thereby inhibiting angiogenesis (the formation of new blood vessels).\n- **Tumor Growth Suppression**: By inhibiting angiogenesis, ziv-aflibercept can reduce the blood supply to tumors, which is essential for their growth and metastasis.\n\n### Indications\n- **Metastatic Colorectal Cancer**: Ziv-aflibercept is approved for use in combination with 5-fluorouracil, leucov"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_214fXYFM7ULCX9TmytUL6mUk", "custom_id": "289_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e62843279b2844d3317061b19ea92466", "body": {"id": "chatcmpl-9St31wcZMIHfGAD53p5I2MPFk4XpJ", "object": "chat.completion", "created": 1716671815, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Capmatinib, marketed under the brand name Tabrecta, is a targeted therapy used primarily in the treatment of non-small cell lung cancer (NSCLC) that has a specific genetic mutation. Here are some key points you should know about Capmatinib:\n\n### Indications:\n- **Non-Small Cell Lung Cancer (NSCLC):** Capmatinib is indicated for the treatment of adult patients with metastatic NSCLC whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.\n\n### Mechanism of Action:\n- **MET Inhibitor:** Capmatinib is a tyrosine kinase inhibitor that targets the MET receptor. The MET gene can be abnormally activated in some cancers, leading to uncontrolled cell growth and proliferation. By inhibiting MET, Capmatinib can help to slow down or stop the growth of cancer cells.\n\n### Administration:\n- **Oral Medication:** Cap"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_3WSOSY5P6ErZPSq4y41vkeaW", "custom_id": "290_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b8ee84a584a8a39dab70756c96524a12", "body": {"id": "chatcmpl-9St32Kyp60AY4VoFmyUsUe4tchn2D", "object": "chat.completion", "created": 1716671816, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enfortumab vedotin (brand name Padcev) is an antibody-drug conjugate (ADC) used in the treatment of certain types of cancer, specifically urothelial carcinoma. Here are some key points you should know about Enfortumab vedotin:\n\n### Mechanism of Action\n- **Antibody-Drug Conjugate**: Enfortumab vedotin consists of an antibody that targets Nectin-4, a protein highly expressed in urothelial carcinoma cells, linked to a cytotoxic agent called monomethyl auristatin E (MMAE).\n- **Targeted Therapy**: The antibody component binds to Nectin-4 on the surface of cancer cells, allowing the ADC to be internalized. Once inside the cell, MMAE is released, disrupting the microtubule network and inducing cell cycle arrest and apoptosis.\n\n### Indications\n- **Urothelial Carcinoma**: Enfortumab vedotin is primarily indicated for the treatment of adult patients"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_T4JZ8G1OdZY7HVMM8UNDYoA4", "custom_id": "291_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "521ffa3b37b60c7b186438068c18e75f", "body": {"id": "chatcmpl-9St32g2q1kvHvBcnUYRzQ96wxZ6bn", "object": "chat.completion", "created": 1716671816, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab deruxtecan, also known by its brand name Enhertu, is an antibody-drug conjugate (ADC) used primarily in the treatment of certain types of cancer. Here are some key points you should know about this medication:\n\n### Mechanism of Action\n1. **Antibody-Drug Conjugate**: Trastuzumab deruxtecan combines a monoclonal antibody (trastuzumab) targeting the HER2 receptor with a topoisomerase I inhibitor (deruxtecan) as the cytotoxic agent.\n2. **Targeting HER2**: The trastuzumab component binds to the HER2 receptor, which is overexpressed in some cancers, leading to internalization of the drug and release of the cytotoxic deruxtecan inside the cancer cells.\n\n### Indications\n1. **HER2-Positive Breast Cancer**: It is approved for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_RyomAyl7sT5qcb7VQ2w3zxPz", "custom_id": "292_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c8e8d376619501ff733a5829dbdc5678", "body": {"id": "chatcmpl-9St33y1DSWtoOxqFP6xy1Bwimwwng", "object": "chat.completion", "created": 1716671817, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abarelix is a synthetic decapeptide and a gonadotropin-releasing hormone (GnRH) antagonist used primarily in the treatment of advanced prostate cancer. Here are some key points you should know about Abarelix:\n\n### Mechanism of Action\n- **GnRH Antagonist**: Abarelix works by directly inhibiting the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. This leads to a rapid decrease in testosterone production by the testes, which is beneficial in treating hormone-sensitive prostate cancer.\n\n### Indications\n- **Advanced Prostate Cancer**: Abarelix is indicated for the palliative treatment of men with advanced symptomatic prostate cancer who are not candidates for other hormonal therapies or who refuse surgical castration.\n\n### Administration\n- **Route**: It is administered via intramuscular injection.\n- **Dosing**: The typical dosing schedule involves an initial loading dose followed by maintenance doses at"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_yciTNEzOLDmK6LkmzFYJhq5k", "custom_id": "293_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "833297e25f106b6b14be374aa38336ae", "body": {"id": "chatcmpl-9St34fRPBGTBRQyQqDa1chTSX3X8j", "object": "chat.completion", "created": 1716671818, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belantamab mafodotin (brand name Blenrep) is a medication used in the treatment of multiple myeloma, a type of blood cancer. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Target**: Belantamab mafodotin is a monoclonal antibody that targets B-cell maturation antigen (BCMA), which is highly expressed on multiple myeloma cells.\n- **Conjugate**: It is conjugated to a cytotoxic agent, monomethyl auristatin F (MMAF), which disrupts microtubules and induces cell cycle arrest and apoptosis.\n\n### Indications\n- **FDA Approval**: It is approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.\n\n### Administration\n- **Route**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Dltub5hwSK9WdMBtFgt1TUuh", "custom_id": "294_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1ff999d3092e981c6f649afba3e3a69c", "body": {"id": "chatcmpl-9St35SIJfLX3MklBy2ivlGXwFBGSD", "object": "chat.completion", "created": 1716671819, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tucatinib is a medication used in the treatment of certain types of breast cancer. Here are some key points you should know about it:\n\n### Indications:\n- **HER2-Positive Breast Cancer**: Tucatinib is specifically indicated for the treatment of HER2-positive breast cancer. It is often used in combination with other therapies, such as trastuzumab and capecitabine, for patients who have received one or more prior anti-HER2-based regimens in the metastatic setting.\n\n### Mechanism of Action:\n- **HER2 Inhibition**: Tucatinib is a tyrosine kinase inhibitor that selectively inhibits the HER2 protein, which is overexpressed in some breast cancers. By inhibiting HER2, tucatinib helps to slow down or stop the growth of cancer cells.\n\n### Administration:\n- **Oral Medication**: Tucatinib is administered orally, typically in the form of tablets. The dosage and schedule depend on the specific treatment regimen and the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_WMG6Ggq3Oiu8wpOg6W6WnNzh", "custom_id": "295_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b11916942bfd04018b9199d7bba32946", "body": {"id": "chatcmpl-9St36imR4FxTKk6yalvNTqo8hHGrj", "object": "chat.completion", "created": 1716671820, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daratumumab and hyaluronidase-fihj is a combination medication used in the treatment of multiple myeloma, a type of blood cancer. Here are some key points you should know about this combination therapy:\n\n### Daratumumab\n1. **Mechanism of Action**: Daratumumab is a monoclonal antibody that targets CD38, a protein highly expressed on the surface of multiple myeloma cells. By binding to CD38, daratumumab induces cell death through various mechanisms, including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and antibody-dependent cellular phagocytosis.\n\n2. **Indications**: Daratumumab is used in various settings for multiple myeloma, including:\n   - As monotherapy for patients who have received at least three prior lines of therapy.\n   - In combination with other agents like lenalidomide, bortezomib, and dexamethasone for newly diagnosed or relapsed/re"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_3tlHyRzSEnJHShKKOITSQQVs", "custom_id": "296_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e66a12735e54a0f4fe4f50955dd1e710", "body": {"id": "chatcmpl-9St36DXFguFhsDrrjLo2xpVj2rlAR", "object": "chat.completion", "created": 1716671820, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alitretinoin is a retinoid, a derivative of vitamin A, used primarily in the treatment of chronic hand eczema that is unresponsive to topical corticosteroids. Here are some key points you should know about Alitretinoin:\n\n### Indications:\n- **Chronic Hand Eczema:** Alitretinoin is specifically indicated for severe chronic hand eczema that has not responded to potent topical corticosteroids.\n\n### Mechanism of Action:\n- **Retinoid Activity:** Alitretinoin modulates cell differentiation and proliferation, and it has anti-inflammatory properties. It binds to retinoid receptors in the skin, influencing gene expression and reducing inflammation and hyperkeratosis.\n\n### Dosage and Administration:\n- **Oral Administration:** Alitretinoin is typically administered orally in capsule form.\n- **Dosage:** The usual dose ranges from 10 mg to 30 mg once daily, depending on the severity of the condition and patient response.\n- **Duration:**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_QAUEzSZd6OaOPs6MWUKcSSSv", "custom_id": "297_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "32afae6e81131a7f678018aa487141dd", "body": {"id": "chatcmpl-9St37CUAJAhntNOmmM5RJHUmm3JNC", "object": "chat.completion", "created": 1716671821, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brexucabtagene autoleucel, marketed under the brand name Tecartus, is a chimeric antigen receptor (CAR) T-cell therapy. It is specifically designed for the treatment of certain types of cancer, particularly relapsed or refractory mantle cell lymphoma (MCL). Here are some key points you should know about this therapy:\n\n### Indications\n- **Mantle Cell Lymphoma (MCL):** Brexucabtagene autoleucel is approved for adult patients with relapsed or refractory MCL who have not responded to or have relapsed after other treatments.\n\n### Mechanism of Action\n- **CAR T-Cell Therapy:** This therapy involves modifying a patient's own T cells to express a CAR that targets the CD19 antigen, which is commonly found on the surface of B cells, including malignant B cells in MCL.\n- **Immune Activation:** Once these modified T cells are infused back into the patient, they can recognize and kill CD"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_9GUGUBxbAskCOfmlDdcBEOGd", "custom_id": "298_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0689aacef99da3b90d39501772b59f6e", "body": {"id": "chatcmpl-9St37i5dyP7MZV5jaYh6vYAGjLyNw", "object": "chat.completion", "created": 1716671821, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alpelisib, marketed under the brand name Piqray, is an oral medication used in the treatment of certain types of breast cancer. Here are some key points you should know about Alpelisib:\n\n### Indications:\n- **Breast Cancer**: Alpelisib is specifically indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced or metastatic breast cancer. It is used in combination with fulvestrant in postmenopausal women and men.\n\n### Mechanism of Action:\n- **PI3K Inhibitor**: Alpelisib is a selective inhibitor of the alpha isoform of phosphatidylinositol-3-kinase (PI3K). The PI3K pathway is often activated in cancers, and mutations in the PIK3CA gene can lead to uncontrolled cell growth. By inhibiting this pathway, Alpelisib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_QmFKCeiMKPY7d1swSkrbDf5i", "custom_id": "299_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "8d08de949b23fd60d22c7471bec2c168", "body": {"id": "chatcmpl-9St37m4wdKyylYoxFq06yP3DA9SJz", "object": "chat.completion", "created": 1716671821, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amonafide is an investigational anticancer agent that has been studied primarily for its potential use in treating various types of cancer, including leukemia and solid tumors. Here are some key points you should know about Amonafide:\n\n1. **Mechanism of Action**: Amonafide is a DNA intercalator and topoisomerase II inhibitor. It works by intercalating into DNA and inhibiting the enzyme topoisomerase II, which is essential for DNA replication and cell division. This leads to DNA damage and apoptosis (programmed cell death) in cancer cells.\n\n2. **Clinical Trials**: Amonafide has been evaluated in several clinical trials, particularly for its use in treating acute myeloid leukemia (AML) and other hematologic malignancies. However, its development has faced challenges, and it has not yet been approved by regulatory agencies like the FDA.\n\n3. **Side Effects**: Common side effects observed in clinical trials include myelosupp"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_gclnGcdnmYQNZb91oJy8VGHN", "custom_id": "300_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d13433deb96eaff629f791d6f1665237", "body": {"id": "chatcmpl-9St37aNh7hFGf8nwFRy745TFAYgBo", "object": "chat.completion", "created": 1716671821, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Amoxicillin, a commonly prescribed antibiotic. Here are key points you should know:\n\n### Pharmacology\n- **Class**: Beta-lactam antibiotic, part of the penicillin family.\n- **Mechanism of Action**: Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death.\n- **Spectrum of Activity**: Effective against a range of Gram-positive and some Gram-negative bacteria. Commonly used for infections caused by Streptococcus species, Haemophilus influenzae, Escherichia coli, and others.\n\n### Indications\n- **Common Uses**: \n  - Upper respiratory tract infections (e.g., pharyngitis, sinusitis)\n  - Otitis media\n  - Lower respiratory tract infections (e.g., bronchitis, pneumonia)\n  - Urinary tract infections\n  - Skin and soft tissue infections\n  - Helicobacter pylori"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5ouXN6d3L4YNu2qdBNQoylWD", "custom_id": "301_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a30e27c15a05ad3ce2b99ecedfa7f081", "body": {"id": "chatcmpl-9St38sZRSt7NY05nKOrPl59K4hG1h", "object": "chat.completion", "created": 1716671822, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aumolertinib, also known by its research code HS-10296, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It is primarily used in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. Here are some key points you should know about Aumolertinib:\n\n### Mechanism of Action\n- **Targeted Therapy**: Aumolertinib selectively inhibits EGFR mutations, including the T790M resistance mutation, which is a common cause of resistance to first- and second-generation EGFR TKIs.\n- **Irreversible Binding**: It forms a covalent bond with the EGFR, leading to sustained inhibition of the receptor's activity.\n\n### Indications\n- **NSCLC**: It is indicated for the treatment of patients with locally advanced or metastatic NSCLC who have EGFR mutations, particularly those who have progressed on or after prior EG"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_FIRNIHgEsB7zmjQ1AvHMl1XT", "custom_id": "302_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "92da55bd3c29487110a6236bebef128e", "body": {"id": "chatcmpl-9St38MesHDKFQFlfpABqion2QWs4z", "object": "chat.completion", "created": 1716671822, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pemigatinib is a targeted therapy drug used primarily in the treatment of certain types of cancer, specifically cholangiocarcinoma (bile duct cancer) that is locally advanced or metastatic and has a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. Here are some key points you should know about Pemigatinib:\n\n### Mechanism of Action\n- **Targeted Therapy**: Pemigatinib is a tyrosine kinase inhibitor that specifically targets FGFR1, FGFR2, and FGFR3. By inhibiting these receptors, it disrupts the signaling pathways that promote tumor cell proliferation and survival.\n\n### Indications\n- **Cholangiocarcinoma**: It is approved for use in patients with previously treated, unresectable, locally advanced, or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement.\n- **Other Cancers**: Research is ongoing to determine its efficacy in other cancers with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_caaOdcANMkXimxUZjNHykj32", "custom_id": "303_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "afbc648c20cc714d59f37d58399e0a56", "body": {"id": "chatcmpl-9St385MIcuQOopf3LFP6MmRJzKGiW", "object": "chat.completion", "created": 1716671822, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ripretinib, marketed under the brand name Qinlock, is a tyrosine kinase inhibitor used primarily for the treatment of advanced gastrointestinal stromal tumors (GIST) that are resistant to other treatments. Here are some key points you should know about Ripretinib:\n\n### Indications:\n- **Gastrointestinal Stromal Tumors (GIST):** Ripretinib is indicated for adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including imatinib.\n\n### Mechanism of Action:\n- **Tyrosine Kinase Inhibition:** Ripretinib works by inhibiting multiple kinases, including KIT and PDGFRA, which are often mutated and overactive in GIST. By inhibiting these kinases, Ripretinib can help to control tumor growth.\n\n### Dosage and Administration:\n- **Standard Dose:** The recommended dose is 150 mg orally once daily, with or without food.\n- **Administration:** Tablets"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_PMbzV5F6Zp80GLrm9dUPEZUN", "custom_id": "304_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b7e81f20dd25b599803d7b87b1119df4", "body": {"id": "chatcmpl-9St38COjtAF4ApjCi9TL0umwO0BBl", "object": "chat.completion", "created": 1716671822, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Selpercatinib, marketed under the brand name Retevmo, is a targeted therapy used primarily in the treatment of certain types of cancers that have specific genetic mutations. Here are some key points you should know about Selpercatinib:\n\n### Indications:\n1. **Non-Small Cell Lung Cancer (NSCLC):** For adult patients with metastatic RET fusion-positive NSCLC.\n2. **Medullary Thyroid Cancer (MTC):** For adult and pediatric patients (12 years and older) with advanced or metastatic RET-mutant MTC who require systemic therapy.\n3. **Thyroid Cancer:** For adult and pediatric patients (12 years and older) with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate).\n\n### Mechanism of Action:\nSelpercatinib is a selective RET kinase inhibitor. RET (rearranged during transfection) is a proto-oncogene that can"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_zlElv0gRcWAhuB1CrMCVP3IV", "custom_id": "305_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2b0e4876d8c5ceb784dfc0289a12f613", "body": {"id": "chatcmpl-9St39ymAq0GGnbAe7t7nsnowvHCeV", "object": "chat.completion", "created": 1716671823, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Decitabine and cedazuridine is a combination medication used in the treatment of certain types of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Here are some key points you should know about this combination therapy:\n\n### Mechanism of Action:\n1. **Decitabine**: It is a hypomethylating agent that incorporates into DNA and inhibits DNA methyltransferase, leading to hypomethylation of DNA and subsequent reactivation of silenced genes that can induce cellular differentiation and apoptosis.\n2. **Cedazuridine**: It is a cytidine deaminase inhibitor that prevents the degradation of decitabine in the gastrointestinal tract and liver, thereby increasing its bioavailability when administered orally.\n\n### Indications:\n- **Myelodysplastic Syndromes (MDS)**: Including previously treated and untreated, de novo and secondary MDS with various subtypes such as refractory anemia, refractory anemia with ringed sideroblasts"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_5pdFpPxfyq9luYxIInE11DfR", "custom_id": "306_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "263a39143bdcb45fdeede666805e09e3", "body": {"id": "chatcmpl-9St39X6VamX5n4Y0rRG8SCGJslWch", "object": "chat.completion", "created": 1716671823, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bismuth subsalicylate is a medication commonly used to treat temporary discomforts of the stomach and gastrointestinal tract, such as diarrhea, indigestion, heartburn, and nausea. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Antimicrobial Action**: Bismuth subsalicylate has antimicrobial properties that can help reduce the number of bacteria in the gastrointestinal tract, including Helicobacter pylori.\n- **Anti-inflammatory**: The salicylate component has anti-inflammatory properties.\n- **Antacid**: It can neutralize stomach acid to some extent.\n- **Protective Coating**: It forms a protective coating on the stomach and intestinal lining, which can help protect against irritants.\n\n### Indications\n- Acute diarrhea, including traveler's diarrhea\n- Indigestion\n- Heartburn\n- Nausea\n- Adjuvant therapy for Helicobacter pylori eradication (in combination with other medications)\n\n### Dos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_cnm7TomUerwRvmNm3q9jcdsU", "custom_id": "307_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "028585f8e0d6221a0a8fc791a43819c4", "body": {"id": "chatcmpl-9St3A6eWefqTWnynEwg7tZJJjokIw", "object": "chat.completion", "created": 1716671824, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Camrelizumab is a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, which is a checkpoint inhibitor used in cancer immunotherapy. Here are some key points you should know about Camrelizumab:\n\n1. **Mechanism of Action**:\n   - Camrelizumab binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1 and PD-L2 ligands. This inhibition releases the \"brakes\" on the immune system, allowing T cells to recognize and attack cancer cells more effectively.\n\n2. **Indications**:\n   - Camrelizumab is primarily used in the treatment of various cancers, including Hodgkin lymphoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and esophageal squamous cell carcinoma (ESCC). Its use may vary based on regulatory approvals in different countries.\n\n3. **Administration**:\n   - It is typically administered via intravenous"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_SvxwFcVUp9M2JF7gfeNhS8hz", "custom_id": "308_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d7ffec40515b905866e26ec3e441e82f", "body": {"id": "chatcmpl-9St3AZ1n6uNHPmeWny0OQv6uik7PG", "object": "chat.completion", "created": 1716671824, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Relugolix is an oral medication that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist. It is used in various clinical settings, primarily for conditions that benefit from the suppression of sex hormones. Here are some key points you should know about Relugolix:\n\n### Indications\n1. **Prostate Cancer**: Relugolix is approved for the treatment of advanced prostate cancer. It works by reducing testosterone levels, which can help slow the growth of prostate cancer cells.\n2. **Uterine Fibroids**: It is also used in combination with estradiol and norethindrone acetate for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.\n\n### Mechanism of Action\n- Relugolix competitively binds to GnRH receptors in the pituitary gland, leading to a rapid decrease in the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_wK2ilfJ7AeLYIJgEwyNJ5uy0", "custom_id": "309_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "120b52a678f010607f5d3dbc8887e179", "body": {"id": "chatcmpl-9St3Axkgqwwd8CocrW7xG6B6V13UX", "object": "chat.completion", "created": 1716671824, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Elacestrant is an investigational oral selective estrogen receptor degrader (SERD) that is being studied for the treatment of hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. Here are some key points you should know about Elacestrant:\n\n1. **Mechanism of Action**: Elacestrant works by binding to the estrogen receptor (ER) and promoting its degradation. This reduces the number of estrogen receptors available to drive the growth of ER-positive breast cancer cells.\n\n2. **Indications**: Elacestrant is primarily being investigated for use in patients with advanced or metastatic HR+/HER2- breast cancer, particularly those who have progressed on prior endocrine therapy.\n\n3. **Clinical Trials**: The efficacy and safety of Elacestrant are being evaluated in clinical trials. One of the notable studies is the EMERALD trial, which is a phase 3 study comparing Elacestrant to standard-of-care endocrine therapy in patients with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_JgfdpU6N7A6d14RhyRyWdxN5", "custom_id": "310_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "eff3b21b95ca24993d8e4086e539a26e", "body": {"id": "chatcmpl-9St3BS6LmyUpOhzepFHwj9htHD8jh", "object": "chat.completion", "created": 1716671825, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trimetrexate is a chemotherapeutic agent and a folate antagonist that is primarily used in the treatment of certain types of cancer and opportunistic infections. Here are some key points you should know about Trimetrexate:\n\n### Mechanism of Action\n- **Folate Antagonist**: Trimetrexate inhibits dihydrofolate reductase (DHFR), an enzyme involved in the synthesis of tetrahydrofolate. This inhibition disrupts DNA synthesis and cell division, particularly affecting rapidly dividing cells.\n\n### Indications\n- **Pneumocystis jirovecii Pneumonia (PCP)**: Trimetrexate is used in combination with leucovorin for the treatment of moderate to severe PCP in patients who are intolerant to or do not respond to standard treatments like trimethoprim-sulfamethoxazole (TMP-SMX).\n- **Cancer**: It has been investigated for use in various cancers, including colorectal cancer, but its"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_XtKGMXksekTIk5hXeMkYi1VN", "custom_id": "311_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "96ceee4fb963181415ec28cdf71251b3", "body": {"id": "chatcmpl-9St3B7fEnFtEpNZZMlQWxiUcU6AsG", "object": "chat.completion", "created": 1716671825, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tepotinib is a targeted cancer therapy, specifically a MET inhibitor, used primarily in the treatment of non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. Here are some key points you should know about Tepotinib:\n\n### Mechanism of Action\n- **MET Inhibition**: Tepotinib selectively inhibits the MET receptor tyrosine kinase, which is involved in various cellular processes including proliferation, survival, and metastasis. In cancers with MET exon 14 skipping mutations, MET signaling is abnormally activated, promoting tumor growth.\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC)**: Tepotinib is indicated for the treatment of adult patients with metastatic NSCLC harboring MET exon 14 skipping alterations.\n\n### Administration\n- **Dosage**: The recommended dose is typically 450 mg orally once daily, with or without food.\n- **Formulation**: Tepotinib is available in tablet form.\n\n### Efficacy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_0Qy27Ecn2BHtgMaXuByDF3QR", "custom_id": "312_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a59658c8a8e497ed59d111fbf6f15dec", "body": {"id": "chatcmpl-9St3BLJq82S1C5IZBidrDwkfEoBSe", "object": "chat.completion", "created": 1716671825, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Futibatinib is a targeted cancer therapy that is primarily used to treat certain types of cancers with specific genetic mutations. Here are some key points you should know about Futibatinib:\n\n### Mechanism of Action\n- **FGFR Inhibition**: Futibatinib is a potent, selective inhibitor of fibroblast growth factor receptors (FGFRs), particularly FGFR1-4. FGFRs are involved in various cellular processes, including cell growth, survival, migration, and differentiation. Mutations or aberrations in FGFRs can lead to uncontrolled cell proliferation and cancer.\n\n### Indications\n- **Cholangiocarcinoma**: Futibatinib has shown efficacy in treating patients with advanced or metastatic cholangiocarcinoma (bile duct cancer) that harbor FGFR2 gene fusions or other rearrangements.\n- **Other Cancers**: Research is ongoing to evaluate its effectiveness in other cancers with FGFR alterations, such as urothelial carcinoma"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ViKJY8DfKNwCFSNDnjMr5Y3W", "custom_id": "313_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2ffd1c4beba5257ec4c3a52da28fc42a", "body": {"id": "chatcmpl-9St3B3RAQEVDuGhEFjS9vQAaPfqeH", "object": "chat.completion", "created": 1716671825, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "The NovoTTF-100A system, now commonly known as Optune, is a medical device used in the treatment of glioblastoma multiforme (GBM), an aggressive type of brain cancer. Here are some key points you should know about Optune:\n\n### Mechanism of Action\n- **Tumor Treating Fields (TTFields):** Optune uses TTFields, which are low-intensity, alternating electric fields that disrupt cancer cell division. These fields interfere with the mitotic process, inhibiting tumor growth and potentially causing cancer cell death.\n\n### Indications\n- **Newly Diagnosed GBM:** Optune is approved for use in combination with temozolomide (TMZ) after surgery and radiation therapy.\n- **Recurrent GBM:** It can also be used as a monotherapy for patients with recurrent GBM who have experienced disease progression after chemotherapy.\n\n### Efficacy\n- **Clinical Trials:** The EF-14 phase III clinical trial demonstrated that"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_VtvLKOYvhLgqF22vx27162hQ", "custom_id": "314_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6f0669151bb9a4e93e8aba1059a46acd", "body": {"id": "chatcmpl-9St3BvvoXcjxY4G8PtNomNuFsv4Kk", "object": "chat.completion", "created": 1716671825, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lisocabtagene maraleucel, also known as liso-cel and marketed under the brand name Breyanzi, is a chimeric antigen receptor (CAR) T-cell therapy. It is used for the treatment of certain types of B-cell lymphomas, including relapsed or refractory large B-cell lymphoma after at least two prior therapies. Here are some key points you should know about this therapy:\n\n### Mechanism of Action\n- **CAR T-Cell Therapy**: Liso-cel involves modifying a patient's own T cells to express a chimeric antigen receptor (CAR) that targets the CD19 protein found on the surface of B cells, including malignant B cells.\n- **Targeting CD19**: By targeting CD19, liso-cel can specifically recognize and kill B cells, including cancerous ones.\n\n### Indications\n- **Relapsed or Refractory Large B-Cell Lymphoma**: It is approved for adult patients with relapsed or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_0kbtgtg0opVrY906towZGgdn", "custom_id": "315_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a127d5aaa5e0cd774d1b2c48459b75b6", "body": {"id": "chatcmpl-9St3CwUa4Vif6LwXOUjwwv7CdaD1O", "object": "chat.completion", "created": 1716671826, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idecabtagene vicleucel, also known by its brand name Abecma, is a chimeric antigen receptor (CAR) T-cell therapy used in the treatment of multiple myeloma. Here are some key points you should know about it:\n\n### Indications:\n- **Multiple Myeloma**: Idecabtagene vicleucel is specifically indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.\n\n### Mechanism of Action:\n- **CAR T-Cell Therapy**: This therapy involves collecting a patient's T cells, genetically modifying them to express a CAR that targets the B-cell maturation antigen (BCMA) on multiple myeloma cells, and then infusing these modified cells back into the patient. The CAR T cells can then recognize and kill the myeloma"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Vk3uHQlSZa9za98dZQBwPGUj", "custom_id": "316_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "8ef415aa03a2c9b108daba56c6f99bef", "body": {"id": "chatcmpl-9St3CHf7wOD1SrYPDR2HoNrZ4Lhzt", "object": "chat.completion", "created": 1716671826, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Avapritinib is a tyrosine kinase inhibitor that is primarily used in the treatment of certain types of cancers, particularly gastrointestinal stromal tumors (GIST) and advanced systemic mastocytosis. Here are some key points you should know about Avapritinib:\n\n### Indications:\n1. **Gastrointestinal Stromal Tumors (GIST):**\n   - Specifically indicated for adult patients with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including the PDGFRA D842V mutation.\n\n2. **Advanced Systemic Mastocytosis:**\n   - Approved for the treatment of adults with advanced systemic mastocytosis, including aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).\n\n### Mechanism of Action:\n- Avapritinib works by inhibiting the activity of certain tyrosine kinases, including KIT and PDGF"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_rE7q6eX6PHgoJKxx9eBe04Yx", "custom_id": "317_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "314b0ba8644bb64a5f28663cb21f8110", "body": {"id": "chatcmpl-9St3Ca0rIbr3OSse0JWbexKgIGai0", "object": "chat.completion", "created": 1716671826, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pexidartinib is a medication that you should be familiar with, especially if you are involved in oncology or the treatment of rare diseases. Here are some key points you should know:\n\n### Indications\n- **Tenosynovial Giant Cell Tumor (TGCT)**: Pexidartinib is primarily indicated for the treatment of adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery. TGCT is a rare, usually non-cancerous tumor that affects the synovium, bursae, and tendon sheaths.\n\n### Mechanism of Action\n- **CSF1R Inhibition**: Pexidartinib is a tyrosine kinase inhibitor that targets the colony-stimulating factor 1 receptor (CSF1R). By inhibiting CSF1R, it reduces the proliferation of cells that contribute to the growth of TGCT.\n\n### Administration\n- **Oral**: P"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_DZMblBaKcBxBybpcqU9jSOLO", "custom_id": "318_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "35287d501a3ea52a8184efc7875f5693", "body": {"id": "chatcmpl-9St3D5vDpp30uPBtNOBpIRWsTm6Ng", "object": "chat.completion", "created": 1716671827, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pralsetinib is a targeted cancer therapy that is primarily used to treat certain types of cancers with specific genetic mutations. Here are some key points you should know about Pralsetinib:\n\n### Mechanism of Action\n- **Targeted Therapy**: Pralsetinib is a tyrosine kinase inhibitor (TKI) that specifically targets rearranged during transfection (RET) gene fusions and mutations. RET is a proto-oncogene that can drive cancer growth when altered.\n- **Inhibition**: By inhibiting RET kinase activity, Pralsetinib can block the signaling pathways that promote cancer cell proliferation and survival.\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC)**: Pralsetinib is approved for the treatment of adult patients with metastatic RET fusion-positive NSCLC.\n- **Thyroid Cancer**: It is also indicated for patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC)"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_4m1aac0StNDm5F4joLWo6Afu", "custom_id": "319_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d197ef5f1582ad376b4d5dc18a1281b5", "body": {"id": "chatcmpl-9St3DUTITGxAih4AJX8wDH4ixtXWU", "object": "chat.completion", "created": 1716671827, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lurbinectedin is a relatively new antineoplastic agent used primarily in the treatment of certain types of cancer. Here are some key points you should know about Lurbinectedin:\n\n### Indications:\n- **Small Cell Lung Cancer (SCLC):** Lurbinectedin is approved for the treatment of adult patients with metastatic small cell lung cancer (SCLC) who have experienced disease progression on or after platinum-based chemotherapy.\n\n### Mechanism of Action:\n- **DNA Binding:** Lurbinectedin binds to the minor groove of DNA, leading to the inhibition of transcription and eventual apoptosis of cancer cells.\n- **Transcription Inhibition:** It interferes with the transcription process, particularly affecting the transcription-coupled nucleotide excision repair (TC-NER) pathway, which is often upregulated in cancer cells.\n\n### Administration:\n- **Intravenous Infusion:** Lurbinectedin is administered as an intravenous infusion, typically over a period of 60 minutes.\n- **Dosing Schedule"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_XaET9Bbc2ugvRbIcVDUdLY60", "custom_id": "320_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "dd18e0f10094f16b3379029c60abe256", "body": {"id": "chatcmpl-9St3D5mp932rzt8RQrJUcGMDL9dkO", "object": "chat.completion", "created": 1716671827, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Metronidazole is an antibiotic and antiprotozoal medication commonly used to treat a variety of infections. Here are some key points you should know about Metronidazole:\n\n### Indications:\n1. **Bacterial Infections**: Effective against anaerobic bacteria, including Bacteroides, Clostridium, and Fusobacterium species.\n2. **Protozoal Infections**: Used to treat infections caused by protozoa such as Trichomonas vaginalis, Giardia lamblia, and Entamoeba histolytica.\n3. **Specific Conditions**: Commonly prescribed for bacterial vaginosis, pelvic inflammatory disease, intra-abdominal infections, and certain types of colitis, including Clostridium difficile-associated diarrhea.\n\n### Mechanism of Action:\n- Metronidazole works by entering the bacterial or protozoal cell and disrupting the DNA synthesis, leading to cell death.\n\n### Dosage and Administration:\n- **Oral**: Available in tablet"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_NUVohVKkEufC4K2qwJkDU4Cp", "custom_id": "321_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "847c80d5bd9acb59b0e8aab5f8c58db5", "body": {"id": "chatcmpl-9St3DvdkDEH6ahr1I9NknEAoBzecG", "object": "chat.completion", "created": 1716671827, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Naxitamab is a monoclonal antibody used in the treatment of certain types of cancer, specifically high-risk neuroblastoma in pediatric patients. Here are some key points you should know about Naxitamab:\n\n### Indications:\n- **Neuroblastoma**: Naxitamab is primarily indicated for the treatment of relapsed or refractory high-risk neuroblastoma in the bone or bone marrow in pediatric patients who have shown at least a partial response to prior therapy.\n\n### Mechanism of Action:\n- **Target**: Naxitamab targets GD2, a disialoganglioside expressed on the surface of neuroblastoma cells and other tumors of neuroectodermal origin.\n- **Action**: By binding to GD2, Naxitamab induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the destruction of cancer cells.\n\n### Administration:\n- **Route**: Naxitamab is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_JaVN7dAvK8M56LGcFwDuNzVN", "custom_id": "322_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "8679be750727b7b4103726688fc4ebe0", "body": {"id": "chatcmpl-9St3Eu5Wfap4QfSR3tha9DYo8S2j4", "object": "chat.completion", "created": 1716671828, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tetracycline is a broad-spectrum antibiotic that is used to treat a variety of bacterial infections. As a physician, you should be aware of several key aspects of this medication:\n\n1. **Mechanism of Action**: Tetracycline works by inhibiting protein synthesis in bacteria. It binds to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain, which ultimately inhibits bacterial growth.\n\n2. **Indications**: Tetracycline is used to treat a wide range of infections, including respiratory tract infections, urinary tract infections, skin infections, sexually transmitted infections (such as chlamydia), and certain types of acne. It is also used in the treatment of diseases like Lyme disease, Rocky Mountain spotted fever, and other rickettsial infections.\n\n3. **Dosage and Administration**: The dosage of tetracycline can vary depending on the type and severity of the infection. It is typically taken orally, and it is important"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_kz0bAupJlQwLT3wXBvc56HMZ", "custom_id": "323_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a54474cd942d3804775d06c12e89cf63", "body": {"id": "chatcmpl-9St3FK00Tat2AGgjACPJGlSOmzzDg", "object": "chat.completion", "created": 1716671829, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tripotassium dicitratobismuthate, commonly known as bismuth subcitrate potassium, is a medication primarily used in the treatment of gastrointestinal disorders, particularly peptic ulcers and Helicobacter pylori infections. Here are some key points you should know about this compound:\n\n### Mechanism of Action\n- **Protective Barrier**: It forms a protective barrier over ulcers and erosions in the gastrointestinal tract, shielding them from stomach acid and pepsin.\n- **Antibacterial Activity**: It has bactericidal properties against Helicobacter pylori, a common cause of peptic ulcers.\n- **Anti-inflammatory**: It may also have mild anti-inflammatory effects, contributing to ulcer healing.\n\n### Indications\n- **Peptic Ulcer Disease**: Used as part of a combination therapy to treat and prevent recurrence of peptic ulcers.\n- **Helicobacter pylori Eradication**: Often included in multi-drug regimens (e.g., with antibiotics and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_hqG40QVuLj4edRXe9nCWhJiY", "custom_id": "324_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "415330c1850e6f791bb8c622143d7ce6", "body": {"id": "chatcmpl-9St3FHkaYL971u9xGm1jo7vdGbLrM", "object": "chat.completion", "created": 1716671829, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belzutifan, also known by its brand name Welireg, is a medication that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of cancer. Here are some key points you should know about Belzutifan:\n\n### Indications\n- **Von Hippel-Lindau (VHL) Disease**: Belzutifan is indicated for adult patients with VHL disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), and who do not require immediate surgery.\n\n### Mechanism of Action\n- **HIF-2\u03b1 Inhibitor**: Belzutifan works by inhibiting hypoxia-inducible factor 2 alpha (HIF-2\u03b1). HIF-2\u03b1 is a transcription factor that plays a crucial role in the response to hypoxia and is implicated in the pathogenesis of VHL"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_YX8UaxQvc92DohPf19rfL1Tp", "custom_id": "325_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6a95f655f8989ed7070e680cf453db21", "body": {"id": "chatcmpl-9St3GnjyQz1fmsMtSaMkpTSpBpSg1", "object": "chat.completion", "created": 1716671830, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amivantamab is a bispecific antibody that targets both the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET) receptor. It is primarily used in the treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations. Here are some key points you should know about Amivantamab:\n\n### Indications:\n- **Non-Small Cell Lung Cancer (NSCLC):** Amivantamab is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.\n\n### Mechanism of Action:\n- **Dual Targeting:** Amivantamab binds to both EGFR and MET receptors, which are involved in the growth and survival of cancer cells. By targeting these receptors, Amivantamab can inhibit tumor growth and induce cancer cell death.\n\n### Administration:\n- **Intravenous Infusion:** Amivantamab is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_PGp82QHUjxzZot3geceNMbfB", "custom_id": "326_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "820503846e0a52d627db16698ae76ead", "body": {"id": "chatcmpl-9St3Gf0DUIxhxLRnDEhSeCLjl1HCQ", "object": "chat.completion", "created": 1716671830, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azacitidine is a nucleoside metabolic inhibitor used primarily in the treatment of certain types of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The oral formulation of azacitidine, known as Onureg (azacitidine tablets), was approved by the FDA for the continued treatment of adult patients with AML who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and who are not able to complete intensive curative therapy.\n\nHere are some key points you should know about oral azacitidine:\n\n### Indications:\n- **Acute Myeloid Leukemia (AML):** Maintenance therapy for adult patients with AML who achieved first CR or CRi following intensive induction chemotherapy.\n\n### Mechanism of Action:\n- Azacitidine incorporates into DNA and RNA, leading to the inhibition of DNA methyltransferase, which results in hypomethylation of DNA and direct cytotoxicity on abnormal hematopo"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_pkINDj4c0DQ2B2WP4ZMYgB75", "custom_id": "327_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b464fbf85e5560a9ed54b17ccc4c6937", "body": {"id": "chatcmpl-9St3GiSkikmaFTEk3nunTj0rz28Kv", "object": "chat.completion", "created": 1716671830, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Colchicine is a medication commonly used in the treatment of gout and familial Mediterranean fever (FMF). Here are some key points you should know about Colchicine as a physician:\n\n### Indications:\n1. **Gout**: Colchicine is used for both acute gout flares and for prophylaxis to prevent recurrent attacks.\n2. **Familial Mediterranean Fever (FMF)**: It helps reduce the frequency of attacks and the risk of amyloidosis.\n3. **Pericarditis**: Sometimes used off-label for the treatment and prevention of recurrent pericarditis.\n\n### Mechanism of Action:\n- Colchicine works by inhibiting microtubule polymerization, which in turn reduces the activity of neutrophils and other inflammatory processes. This helps to decrease inflammation and pain associated with gout and other inflammatory conditions.\n\n### Dosage:\n- **Acute Gout Flare**: Initial dose is typically 1.2 mg followed by 0.6"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Du4HgU8wIdVpcmiTLpY81GaY", "custom_id": "328_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e8176c48bdd61628ff27befce2678f29", "body": {"id": "chatcmpl-9St3HyTH8eyhWoHWTzueynQiGy0Xr", "object": "chat.completion", "created": 1716671831, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dostarlimab is a monoclonal antibody that targets the programmed death receptor-1 (PD-1) pathway, which is a key immune checkpoint in the regulation of immune responses. Here are some key points you should know about Dostarlimab:\n\n### Indications:\n1. **Endometrial Cancer**: Dostarlimab is approved for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.\n2. **Other Cancers**: Research is ongoing to evaluate its efficacy in other types of cancers, particularly those with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR).\n\n### Mechanism of Action:\n- **Immune Checkpoint Inhibition**: Dostarlimab binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1 and PD-L2 ligands. This inhibition releases the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_I50Ee4j1krDz80JThTu7SzLF", "custom_id": "329_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7c790550d1559a0078020ab60cf7ded1", "body": {"id": "chatcmpl-9St3HNUdtUrvwmxXO0OYqFgibxQ3q", "object": "chat.completion", "created": 1716671831, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Serplulimab is a monoclonal antibody that targets PD-1 (programmed cell death protein 1), a checkpoint protein on immune cells. By inhibiting PD-1, Serplulimab can enhance the immune system's ability to recognize and attack cancer cells. Here are some key points you should know about Serplulimab:\n\n1. **Mechanism of Action**: Serplulimab blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade prevents the \"off\" signal that cancer cells use to evade immune detection, thereby promoting an anti-tumor immune response.\n\n2. **Indications**: Serplulimab is primarily investigated for use in various types of cancers, including non-small cell lung cancer (NSCLC), melanoma, and other solid tumors. Its specific indications may vary based on ongoing clinical trials and regulatory approvals.\n\n3. **Clinical Trials**: As of the latest information, Serplulimab"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_AUpyzwMVig1CmH11OjHntOKX", "custom_id": "330_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "fe8c633388c0728cb4f9549b2bbe6da5", "body": {"id": "chatcmpl-9St3I83LRtexHsA9uDKJfLtR5ZTcz", "object": "chat.completion", "created": 1716671832, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sugemalimab is a monoclonal antibody that targets PD-L1 (programmed death-ligand 1), a protein involved in the immune system's ability to recognize and attack cancer cells. It is used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC). Here are some key points you should know about Sugemalimab:\n\n1. **Mechanism of Action**: Sugemalimab works by inhibiting the interaction between PD-L1 and its receptor PD-1 on T cells. This blockade enhances the immune system's ability to detect and destroy cancer cells.\n\n2. **Indications**: Sugemalimab is primarily indicated for the treatment of advanced or metastatic NSCLC. It may be used in combination with chemotherapy or as a monotherapy, depending on the specific clinical scenario and patient characteristics.\n\n3. **Clinical Trials and Efficacy**: Clinical trials have demonstrated that Sugemalimab can improve progression-free survival and overall"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_1mlcpCzuMSvQQNWybdv3P8Ry", "custom_id": "331_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c40934ef237d69c2d6b8e33c0994a4a9", "body": {"id": "chatcmpl-9St3IZlL5Do3Vm2ywwCxOgKLERi5a", "object": "chat.completion", "created": 1716671832, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sirolimus protein-bound particles, also known as nanoparticle albumin-bound (nab) sirolimus, represent a formulation of the immunosuppressive and anti-proliferative drug sirolimus (also known as rapamycin). This formulation is designed to improve the delivery and efficacy of sirolimus, particularly in the context of cancer therapy. Here are some key points you should know:\n\n### Mechanism of Action\n- **Sirolimus**: Sirolimus inhibits the mammalian target of rapamycin (mTOR), a key regulatory kinase involved in cell growth, proliferation, and survival. By inhibiting mTOR, sirolimus can suppress immune responses and inhibit tumor cell proliferation.\n- **Protein-Bound Formulation**: The protein-bound formulation uses albumin nanoparticles to deliver sirolimus more effectively to the target tissues, potentially enhancing its therapeutic effects and reducing systemic toxicity.\n\n### Indications\n- **Cancer Therapy**: Nab-sirolimus is being investigated and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ylcdyGrWbch0WfwR3PEGfiTo", "custom_id": "332_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "dc9158f82648adcbcfff10cf684be26e", "body": {"id": "chatcmpl-9St3IIpb3jnfNSYx0KDff6XHear0W", "object": "chat.completion", "created": 1716671832, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Suramin is a medication that has been used primarily to treat African trypanosomiasis (sleeping sickness) and onchocerciasis (river blindness). Here are some key points you should know about Suramin:\n\n### Mechanism of Action\n- **Trypanosomiasis**: Suramin works by inhibiting enzymes that are essential for the energy metabolism of the parasite Trypanosoma brucei.\n- **Onchocerciasis**: It is less commonly used for this condition now, but it works by killing the microfilariae of Onchocerca volvulus.\n\n### Indications\n- **African Trypanosomiasis**: Particularly effective in the early hemolymphatic stage of the disease caused by Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense.\n- **Onchocerciasis**: Historically used, but now largely replaced by ivermectin due to better efficacy and safety profile.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_QkzMxRzkh5JT3zdV9SAYhkgG", "custom_id": "333_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "58d777d5da6868433b91814b4ae66c7d", "body": {"id": "chatcmpl-9St3IQu6gWxHRF3DwUIuXdhx59Nxa", "object": "chat.completion", "created": 1716671832, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adagrasib is a targeted cancer therapy that has garnered attention for its potential in treating certain types of cancer, particularly non-small cell lung cancer (NSCLC) with specific genetic mutations. Here are some key points you should know about Adagrasib:\n\n### Mechanism of Action\n- **KRAS Inhibition**: Adagrasib is a KRAS G12C inhibitor. KRAS is a gene that encodes a protein involved in cell signaling pathways that control cell growth and division. Mutations in KRAS, particularly the G12C mutation, are common in various cancers and lead to uncontrolled cell growth.\n- **Targeted Therapy**: By specifically inhibiting the KRAS G12C mutant protein, Adagrasib aims to block the aberrant signaling pathways that drive cancer cell proliferation.\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC)**: Adagrasib is primarily being investigated and used for the treatment of NSCLC with the KR"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Qruf9Qx1nSYLC0MwOk6WJrY1", "custom_id": "334_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0367cc6f35d3d88bbbfa64146a283476", "body": {"id": "chatcmpl-9St3Jkb4iDII1LvvKS3RcZa2GCeDP", "object": "chat.completion", "created": 1716671833, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tebentafusp is a bispecific fusion protein that has been developed for the treatment of certain types of cancer, particularly metastatic uveal melanoma, which is a rare and aggressive form of eye cancer. Here are some key points you should know about Tebentafusp:\n\n### Mechanism of Action\n- **Bispecific T-cell Engager (BiTE):** Tebentafusp is designed to engage T-cells and direct them to target and kill cancer cells. It has two binding domains: one that binds to the CD3 receptor on T-cells and another that binds to the gp100 peptide presented by HLA-A*02:01 on melanoma cells.\n- **Immune Activation:** By bringing T-cells into close proximity with melanoma cells, Tebentafusp facilitates the immune-mediated destruction of the cancer cells.\n\n### Indications\n- **Metastatic Uveal Melanoma:** Tebentafusp has shown efficacy in treating metastatic uveal melanoma, a condition for which"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_FKdtjwM9e8rsX38tlzrQ2Bfl", "custom_id": "335_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e3aca489e838af21c414d4f9c85dcc6b", "body": {"id": "chatcmpl-9St3KyYOeoCtiXdIjAFKr1p4T31Aa", "object": "chat.completion", "created": 1716671834, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fedratinib is a medication used primarily in the treatment of myelofibrosis, a type of bone marrow cancer that disrupts the body's normal production of blood cells. Here are some key points you should know about Fedratinib:\n\n### Mechanism of Action\n- **JAK2 Inhibitor**: Fedratinib is a selective inhibitor of Janus kinase 2 (JAK2), which plays a crucial role in the signaling pathways that regulate blood cell production. By inhibiting JAK2, Fedratinib helps to reduce the abnormal proliferation of blood cells.\n\n### Indications\n- **Primary Myelofibrosis (PMF)**: Used in patients with intermediate-2 or high-risk primary myelofibrosis.\n- **Post-Polycythemia Vera Myelofibrosis (PPV-MF)**: For patients who have developed myelofibrosis following polycythemia vera.\n- **Post-Essential Th"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_j84jqNTnYkDzQm90ZHIA1L8B", "custom_id": "336_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "69185c6a054ea6c2d1c60d6b6dc1fd8e", "body": {"id": "chatcmpl-9St3LsBHMadjRPuNglZ6DWaV3z2vR", "object": "chat.completion", "created": 1716671835, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab and hyaluronidase are components of a combination drug used in the treatment of HER2-positive breast cancer. Here are some key points you should know about them:\n\n### Trastuzumab:\n1. **Mechanism of Action**: Trastuzumab is a monoclonal antibody that targets the HER2 receptor, a protein overexpressed in some breast cancers. By binding to HER2, trastuzumab inhibits the proliferation of cancer cells that overexpress this receptor.\n\n2. **Indications**: It is primarily used for HER2-positive breast cancer, both in early-stage and metastatic settings. It can be used as monotherapy or in combination with other chemotherapeutic agents.\n\n3. **Administration**: Traditionally, trastuzumab is administered intravenously. However, subcutaneous formulations are also available, which can be more convenient for patients.\n\n4. **Side Effects**: Common side effects include infusion reactions, cardiotoxicity (e.g., reduced left"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_XcGwWSeKXYVYHmZY8PxmHRte", "custom_id": "337_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "00a2f38cca1d3c50886717b6284a30ac", "body": {"id": "chatcmpl-9St3LWVd31a12SB5F8BxE26TXnjjq", "object": "chat.completion", "created": 1716671835, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zanubrutinib is a medication used primarily in the treatment of certain types of B-cell malignancies, such as mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Here are some key points you should know about Zanubrutinib:\n\n### Mechanism of Action\n- **Bruton\u2019s Tyrosine Kinase (BTK) Inhibitor**: Zanubrutinib is a selective inhibitor of BTK, a key enzyme in the B-cell receptor signaling pathway. By inhibiting BTK, Zanubrutinib disrupts the survival and proliferation of malignant B-cells.\n\n### Indications\n- **Mantle Cell Lymphoma (MCL)**: Approved for adult patients who have received at least one prior therapy.\n- **Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)**: Approved for the treatment of adult patients.\n\n### Dosage and Administration\n- **Oral"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ddyLiivdqRk7Tw9T0aSohBup", "custom_id": "338_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "60b5ac6ffd5efe653c0820346cebcf41", "body": {"id": "chatcmpl-9St3MsQkvpYCcQgrjLz8zI091WsQP", "object": "chat.completion", "created": 1716671836, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Furmonertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is used in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. Here are some key points you should know about Furmonertinib:\n\n1. **Mechanism of Action**: Furmonertinib selectively inhibits EGFR mutations, including the T790M resistance mutation, which is a common mechanism of resistance to first- and second-generation EGFR TKIs.\n\n2. **Indications**: It is primarily indicated for the treatment of patients with EGFR T790M mutation-positive NSCLC who have progressed on or after EGFR TKI therapy.\n\n3. **Efficacy**: Clinical trials have demonstrated that Furmonertinib is effective in shrinking tumors and prolonging progression-free survival in patients with T790M-positive NSCLC.\n\n4. **Administration**: Furmonertinib is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_veOOz0RRBGIAJoeUpBcGHxay", "custom_id": "339_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "573334c77dc338a072e3a753a5f65e6d", "body": {"id": "chatcmpl-9St3MTfxzGUXeTXcvIB58Lj8opXqZ", "object": "chat.completion", "created": 1716671836, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ciltacabtagene autoleucel, also known as cilta-cel and marketed under the brand name Carvykti, is a chimeric antigen receptor (CAR) T-cell therapy used for the treatment of multiple myeloma. Here are some key points you should know about this therapy:\n\n### Indications\n- **Multiple Myeloma**: Cilta-cel is specifically indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.\n\n### Mechanism of Action\n- **CAR T-Cell Therapy**: Cilta-cel involves the genetic modification of a patient's own T cells to express a chimeric antigen receptor (CAR) that targets B-cell maturation antigen (BCMA), a protein highly expressed on multiple myeloma cells. Once these modified T cells are infused back into"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5KfiLJWm6S8f0N0VDweFqaC2", "custom_id": "340_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "76b1d97fe5d04613cf976e57ebf08c10", "body": {"id": "chatcmpl-9St3Nqi4F1fjUJlL7bnmXkeXlkveC", "object": "chat.completion", "created": 1716671837, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asciminib is a medication used in the treatment of chronic myeloid leukemia (CML), specifically for patients who have the Philadelphia chromosome-positive (Ph+) form of the disease. Here are some key points you should know about Asciminib:\n\n### Mechanism of Action\n- **Targeted Therapy**: Asciminib is a tyrosine kinase inhibitor (TKI) that specifically targets the ABL myristoyl pocket (STAMP). This is different from other TKIs that target the ATP-binding site of the BCR-ABL1 protein.\n- **Selective Inhibition**: By targeting the myristoyl pocket, Asciminib can inhibit the BCR-ABL1 protein with potentially fewer off-target effects compared to other TKIs.\n\n### Indications\n- **Chronic Myeloid Leukemia (CML)**: Asciminib is indicated for the treatment of adult patients with Ph+ CML in chronic phase (CP) who have been previously treated with two"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_sUIfGzwSvjA0B2OXv344sdH1", "custom_id": "341_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f4566c163afc2e05c8c1a151cdcd5909", "body": {"id": "chatcmpl-9St3N1sGNjoAIwRInH8WTKAaRHEIJ", "object": "chat.completion", "created": 1716671837, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Loncastuximab tesirine (brand name Zynlonta) is an antibody-drug conjugate (ADC) used in the treatment of certain types of cancer, specifically relapsed or refractory large B-cell lymphoma. Here are some key points you should know about this medication:\n\n### Mechanism of Action\n- **Antibody-Drug Conjugate**: Loncastuximab tesirine consists of a monoclonal antibody (loncastuximab) that targets CD19, a protein commonly found on the surface of B-cells, linked to a cytotoxic agent (tesirine).\n- **Targeted Therapy**: The monoclonal antibody binds to CD19 on the surface of cancerous B-cells, delivering the cytotoxic agent directly to the cancer cells, which helps to minimize damage to normal cells.\n\n### Indications\n- **Relapsed or Refractory Large B-Cell Lymphoma**: It is approved for use in adult patients"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_4GGmfcDJNAMzRB5ojS5sUe14", "custom_id": "342_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1e08baeb3e7e110a2edc5d7352e7e6dd", "body": {"id": "chatcmpl-9St3OsjTNqCQjqzIzsxHEOUWcqLGV", "object": "chat.completion", "created": 1716671838, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tazemetostat is an important medication in the field of oncology, specifically used for the treatment of certain types of cancer. Here are key points you should know about Tazemetostat:\n\n### Mechanism of Action\n- **EZH2 Inhibitor**: Tazemetostat is an inhibitor of the enzyme enhancer of zeste homolog 2 (EZH2). EZH2 is a part of the polycomb repressive complex 2 (PRC2), which plays a role in gene expression through histone methylation. By inhibiting EZH2, Tazemetostat can reduce the methylation of histone H3 at lysine 27 (H3K27), leading to reactivation of tumor suppressor genes and inhibition of cancer cell proliferation.\n\n### Indications\n- **Epithelioid Sarcoma**: Tazemetostat is approved for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelio"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_8ypTlz10SeZbjBkAssdyAw06", "custom_id": "343_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "65cccb70fb0dcca64eb3e734be0e3cb4", "body": {"id": "chatcmpl-9St3Oj1Fp9XqA9Ox7BzoVpWuK44Dl", "object": "chat.completion", "created": 1716671838, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nivolumab and relatlimab are both immune checkpoint inhibitors used in the treatment of various cancers. Here\u2019s a detailed overview of each:\n\n### Nivolumab\n- **Mechanism of Action**: Nivolumab is a monoclonal antibody that targets the programmed death-1 (PD-1) receptor on T cells. By blocking PD-1, nivolumab prevents the interaction with its ligands (PD-L1 and PD-L2), thereby enhancing the immune response against tumor cells.\n- **Indications**: Nivolumab is approved for the treatment of several types of cancer, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, and others.\n- **Administration**: It is typically administered intravenously, with dosing schedules varying based on the type of cancer and combination with other therapies.\n- **Side Effects**: Common side effects include fatigue"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_oQIqN8I9wiJ76FTs9YQFGRBF", "custom_id": "344_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ac6f219476c31e9dd61c76f059bb9b6b", "body": {"id": "chatcmpl-9St3PDfuC3CAljdTYYSkjhPMR7FtF", "object": "chat.completion", "created": 1716671839, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon alfa-2c is a type of interferon, which is a group of signaling proteins made and released by host cells in response to the presence of pathogens such as viruses, bacteria, parasites, and tumor cells. Here are some key points you should know about Interferon alfa-2c:\n\n### Mechanism of Action\n- **Antiviral Activity**: Interferon alfa-2c helps inhibit viral replication within host cells.\n- **Immunomodulatory Effects**: It enhances the immune response by increasing the activity of natural killer cells and macrophages, and by promoting the presentation of antigens to T cells.\n- **Antiproliferative Effects**: It can inhibit the growth of certain cancer cells by modulating the expression of specific genes involved in cell proliferation.\n\n### Indications\nInterferon alfa-2c is used in the treatment of various conditions, including:\n- **Chronic Hepatitis B and C**: It helps reduce viral load"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_LCm41s20ibLDjgYJ6M8CD9qc", "custom_id": "345_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "8604a0fff98ac4bc098a0653b3408672", "body": {"id": "chatcmpl-9St3PfLIi2vWaFGE3qINqaIVho9Il", "object": "chat.completion", "created": 1716671839, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon alfa-n1 is a type of interferon, which is a group of signaling proteins made and released by host cells in response to the presence of pathogens such as viruses, bacteria, parasites, or tumor cells. Here are some key points you should know about Interferon alfa-n1:\n\n### Mechanism of Action\n- **Antiviral Activity**: Interferon alfa-n1 helps inhibit viral replication within host cells.\n- **Immunomodulatory Effects**: It enhances the immune response by increasing the activity of natural killer cells and macrophages, and by promoting the presentation of antigens to T cells.\n- **Antiproliferative Effects**: It can inhibit the growth of certain cancer cells by modulating the expression of specific genes involved in cell proliferation.\n\n### Indications\nInterferon alfa-n1 is used to treat various conditions, including:\n- **Chronic Hepatitis B and C**: It helps reduce viral load and liver inflammation.\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_GlbNu0pblt3PLtRnXURBuedt", "custom_id": "346_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3d586090ec660a336609eaed83e39510", "body": {"id": "chatcmpl-9St3P606B0SF2oLiazdyfb1Pty5R8", "object": "chat.completion", "created": 1716671839, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Margetuximab is a monoclonal antibody used in the treatment of certain types of breast cancer. Here are some key points you should know about it:\n\n1. **Mechanism of Action**: Margetuximab is designed to target the HER2 (human epidermal growth factor receptor 2) protein, which is overexpressed in some breast cancers. It binds to the HER2 receptor, inhibiting the proliferation of cancer cells and mediating antibody-dependent cellular cytotoxicity (ADCC).\n\n2. **Indications**: Margetuximab is typically used in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.\n\n3. **Efficacy**: Clinical trials, such as the SOPHIA study, have shown that margetuximab, in combination with chemotherapy, can improve progression-free survival compared to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_jvDW842zp84WiZpa6e3t8ksv", "custom_id": "347_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d0641553b2b773ee1b2801343ac4f6b6", "body": {"id": "chatcmpl-9St3QcDayr0Bwt9zx5cUx3XzQTuK5", "object": "chat.completion", "created": 1716671840, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sotorasib is a targeted cancer therapy that has garnered attention for its role in treating non-small cell lung cancer (NSCLC) with a specific genetic mutation. Here are some key points you should know about Sotorasib:\n\n### Mechanism of Action\n- **Target**: Sotorasib specifically targets the KRAS G12C mutation, a common driver mutation in various cancers, including NSCLC.\n- **Action**: It works by irreversibly binding to the KRAS G12C protein, inhibiting its function and thereby blocking the downstream signaling pathways that promote cancer cell growth and survival.\n\n### Indications\n- **Primary Use**: Sotorasib is primarily indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy.\n- **Other Potential Uses**: Research is ongoing to explore its efficacy in other KRAS G12C-mutated cancers, such as colorectal cancer and pancreatic cancer.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_CiAuMBAZSjC308x6PIPlbBif", "custom_id": "348_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6e848e8010d0b73e7e7da7ddda5dd790", "body": {"id": "chatcmpl-9St3QUTi1ZjWUC4IHp5UELwaKBAQR", "object": "chat.completion", "created": 1716671840, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Umbralisib is a medication that was used in the treatment of certain types of cancer, specifically relapsed or refractory marginal zone lymphoma (MZL) and follicular lymphoma (FL). It is an oral inhibitor of phosphoinositide 3-kinase (PI3K) delta and casein kinase 1 epsilon (CK1\u03b5), which are enzymes involved in the growth and survival of malignant B-cells.\n\nHere are some key points you should know about Umbralisib:\n\n1. **Mechanism of Action**: Umbralisib inhibits PI3K delta, which is involved in the signaling pathways that promote the growth and survival of B-cells. By inhibiting this enzyme, Umbralisib can help to reduce the proliferation of malignant B-cells. It also inhibits CK1\u03b5, which may contribute to its antitumor activity.\n\n2. **Indications**: Umbralisib was approved for the treatment of adult patients with relapsed or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_h34CQXBOpScBeHmHEll98ZGn", "custom_id": "349_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "91c9d087bc8656dddc6337f2c30bbbaf", "body": {"id": "chatcmpl-9St3QjsWtKWDd9Fv6HRa7Lt48oz7U", "object": "chat.completion", "created": 1716671840, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sintilimab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) pathway, which is a key immune checkpoint in the regulation of immune responses. Here are some key points you should know about Sintilimab:\n\n1. **Mechanism of Action**:\n   - Sintilimab binds to PD-1 receptors on T cells, blocking the interaction with its ligands PD-L1 and PD-L2. This inhibition releases the \"brakes\" on the immune system, allowing T cells to attack cancer cells more effectively.\n\n2. **Indications**:\n   - Sintilimab is primarily used in the treatment of various cancers, including non-small cell lung cancer (NSCLC), classical Hodgkin lymphoma, and other solid tumors. The specific indications can vary based on regulatory approvals in different countries.\n\n3. **Administration**:\n   - It is administered via intravenous infusion. The dosing schedule can vary depending on the specific cancer being treated and the treatment protocol.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_QA9tMpixrSUByq9C32qRv2G7", "custom_id": "350_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7df1afd568a986facc5c6b6d896ae94b", "body": {"id": "chatcmpl-9St3Rkpw4PlwtbB7FfPpQxiAzoqsu", "object": "chat.completion", "created": 1716671841, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pirtobrutinib is a novel medication that you might find relevant in the context of treating certain hematologic malignancies. Here are some key points you should know about it:\n\n1. **Mechanism of Action**: Pirtobrutinib is a highly selective, non-covalent (reversible) inhibitor of Bruton's tyrosine kinase (BTK). BTK is a crucial enzyme in the B-cell receptor signaling pathway, which is important for the survival and proliferation of malignant B cells.\n\n2. **Indications**: Pirtobrutinib is being investigated for use in various B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), and other B-cell non-Hodgkin lymphomas. It is particularly of interest for patients who have developed resistance to or cannot tolerate covalent BTK inhibitors like ibrutinib, acalabrutinib, or zanubrutin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_UCPTyC3f73GE0Ai0zbKHcbRG", "custom_id": "351_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b4483cd7652dcd0e2e158838c5dc0cf8", "body": {"id": "chatcmpl-9St3RBDs76Jk0xbCrqVNzEOuG3Yiu", "object": "chat.completion", "created": 1716671841, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Toripalimab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, which is a checkpoint inhibitor used in cancer immunotherapy. Here are some key points you should know about Toripalimab:\n\n1. **Mechanism of Action**: Toripalimab binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1 and PD-L2 ligands. This inhibition releases the \"brakes\" on the immune system, allowing T cells to recognize and attack cancer cells more effectively.\n\n2. **Indications**: Toripalimab is primarily used for the treatment of various types of cancers, including melanoma, nasopharyngeal carcinoma, and other solid tumors. Its use is often considered in cases where other treatments have failed or are not suitable.\n\n3. **Administration**: Toripalimab is administered via intravenous infusion. The dosing schedule can vary depending on the specific cancer being treated and the patient's"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_OemcxRWyKMLRyC6pb9G1og3t", "custom_id": "352_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0c07578e5e2e0fdc548c7ebce873ec84", "body": {"id": "chatcmpl-9St3SCQn93XJCtSPGXyFMVP1yMydD", "object": "chat.completion", "created": 1716671842, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Teclistamab is a bispecific antibody that has garnered attention in the field of oncology, particularly for its potential in treating multiple myeloma. Here are some key points you should know about Teclistamab:\n\n### Mechanism of Action\n- **Bispecific Antibody**: Teclistamab is designed to bind to two different antigens simultaneously. It targets B-cell maturation antigen (BCMA) on multiple myeloma cells and CD3 on T cells.\n- **Immune Activation**: By binding to both BCMA and CD3, Teclistamab brings T cells into close proximity with myeloma cells, thereby promoting T-cell-mediated killing of the cancer cells.\n\n### Indications\n- **Multiple Myeloma**: Teclistamab is primarily being investigated for the treatment of relapsed or refractory multiple myeloma, particularly in patients who have exhausted other treatment options.\n\n### Clinical Trials and Efficacy\n- **Clinical Trials"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_1U6RzSNt17qPc0lvRFcI5YMp", "custom_id": "353_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a604d3aa1ee5dadcdf483e9642e79d9c", "body": {"id": "chatcmpl-9St3SWgwqdKHSylq9qDsdsK9e6E7w", "object": "chat.completion", "created": 1716671842, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mobocertinib is an oral tyrosine kinase inhibitor (TKI) specifically designed to target epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Here are some key points you should know about Mobocertinib:\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC):** Mobocertinib is primarily indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.\n\n### Mechanism of Action\n- **Targeted Therapy:** Mobocertinib selectively inhibits the activity of EGFR exon 20 insertion mutations, which are less responsive to other EGFR TKIs. By inhibiting these mutations, Mobocertinib can help to slow or stop the growth of cancer cells.\n\n### Administration\n- **Oral Administration:** Mobocertinib is administered orally, typically once daily. The specific dosage and administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_4hNsIisgHG3n6K1i5l2V9hMJ", "custom_id": "354_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a512e91f2d23b407b34fca90ee652ffe", "body": {"id": "chatcmpl-9St3TRVSrRIkEMJt5ia1kQCYQstvE", "object": "chat.completion", "created": 1716671843, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tisotumab vedotin is an antibody-drug conjugate (ADC) used in oncology, specifically for the treatment of certain types of cancer. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Antibody Component**: Tisotumab vedotin consists of a monoclonal antibody that targets tissue factor (TF), a protein commonly overexpressed in various cancers.\n- **Cytotoxic Agent**: The antibody is linked to a cytotoxic agent, monomethyl auristatin E (MMAE), which disrupts microtubules, leading to cell cycle arrest and apoptosis.\n\n### Indications\n- **Cervical Cancer**: Tisotumab vedotin is approved for the treatment of recurrent or metastatic cervical cancer in patients who have progressed on or after chemotherapy.\n- **Other Cancers**: Research is ongoing to evaluate its efficacy in other types of cancer, including ovarian, lung, and bladder cancers.\n\n### Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_3XzOpx7oG9It1EOhRQaMNpb2", "custom_id": "355_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b84f2490db05f59a603b1e7e76864679", "body": {"id": "chatcmpl-9St3Tybi7J57ZaCJ2rAVWtbGoYzHS", "object": "chat.completion", "created": 1716671843, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lanreotide LAR (Long-Acting Release) is a somatostatin analog used primarily in the treatment of certain medical conditions. Here are some key points you should know about Lanreotide LAR:\n\n### Indications:\n1. **Acromegaly**: Lanreotide LAR is used to reduce growth hormone and insulin-like growth factor-1 (IGF-1) levels in patients with acromegaly, particularly when surgery or radiotherapy is not an option or has not been fully effective.\n2. **Neuroendocrine Tumors (NETs)**: It is used for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to control symptoms and tumor growth.\n3. **Thyrotropin-Secreting Pituitary Adenomas**: It may be used off-label for this condition.\n\n### Mechanism of Action:\nLanreotide mimics natural somatostatin, inhibiting the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Rz8UuJEuZbpRVecupHLtE4zu", "custom_id": "356_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "90c86a5383ce67c88da54eb2de156710", "body": {"id": "chatcmpl-9St3UJ8BYrpiEmMkHD566lGAmPmbr", "object": "chat.completion", "created": 1716671844, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pimitespib is a relatively new drug, and as a physician, there are several key aspects you should be aware of:\n\n1. **Mechanism of Action**: Pimitespib is a heat shock protein 90 (HSP90) inhibitor. HSP90 is a molecular chaperone involved in the proper folding, stability, and function of many proteins, including those that drive cancer cell growth and survival. By inhibiting HSP90, pimitespib can disrupt these processes, leading to cancer cell death.\n\n2. **Indications**: Pimitespib is primarily being investigated and used in the treatment of various cancers. It has shown promise in preclinical and clinical studies for certain types of solid tumors and hematologic malignancies. However, its specific indications may vary based on ongoing research and regulatory approvals.\n\n3. **Clinical Trials**: As of the latest information, pimitespib is undergoing clinical trials to determine its efficacy and safety in different cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_fqHE7a3GMrhahPPEakuIEgrB", "custom_id": "357_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0318a8664a1c3cfba07f784bf104c326", "body": {"id": "chatcmpl-9St3UY7NaWJNqyqSxsZhZkuMA2Q1v", "object": "chat.completion", "created": 1716671844, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prednimustine is a chemotherapeutic agent that combines two drugs: prednisolone, a corticosteroid, and chlorambucil, an alkylating agent. Here are some key points you should know about Prednimustine:\n\n### Mechanism of Action\n- **Prednisolone**: It is a corticosteroid that works by suppressing inflammation and modulating the immune response.\n- **Chlorambucil**: It is an alkylating agent that interferes with DNA replication and transcription, leading to cell death, particularly in rapidly dividing cells such as cancer cells.\n\n### Indications\n- Prednimustine is primarily used in the treatment of certain types of cancers, including lymphomas and leukemias. It may be used in other malignancies as well, depending on the specific clinical scenario.\n\n### Administration\n- The dosage and administration schedule can vary based on the type and stage of cancer, as well as the patient's overall health and response to treatment. It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_QO5UeyYAZkhEvcrB7ca1f0rx", "custom_id": "358_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c4006527be341544b5e547232ebc3c82", "body": {"id": "chatcmpl-9St3USzZpwNl1aDV6eeOjDmLNsiZb", "object": "chat.completion", "created": 1716671844, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pipobroman is an antineoplastic agent primarily used in the treatment of certain types of chronic myeloproliferative disorders, such as polycythemia vera and essential thrombocythemia. Here are some key points you should know about Pipobroman:\n\n### Mechanism of Action\n- **Alkylating Agent**: Pipobroman works by alkylating DNA, which interferes with DNA replication and RNA transcription, leading to cell cycle arrest and apoptosis. This is particularly effective in rapidly dividing cells, such as cancer cells.\n\n### Indications\n- **Polycythemia Vera**: A condition characterized by the overproduction of red blood cells.\n- **Essential Thrombocythemia**: A disorder marked by an excessive number of platelets in the blood.\n\n### Dosage and Administration\n- **Individualized Dosing**: The dosage of Pipobroman is typically individualized based on the patient's condition, response to treatment, and tolerance. It is usually"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_xkBLqQFT3XSpu9mwJCMJAUub", "custom_id": "359_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "fe16a22b9b7a8caaf92527ef3dcbb883", "body": {"id": "chatcmpl-9St3Uvqoce8BhHddS9GtBLK09fxqP", "object": "chat.completion", "created": 1716671844, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Polatuzumab vedotin is an antibody-drug conjugate (ADC) used in the treatment of certain types of B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma (DLBCL). Here are some key points you should know about Polatuzumab vedotin:\n\n### Mechanism of Action\n- **Antibody Component**: Polatuzumab vedotin targets CD79b, a protein expressed on the surface of B-cells.\n- **Cytotoxic Component**: It is conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting agent. Once the ADC binds to CD79b, it is internalized by the cell, and MMAE is released, leading to cell cycle arrest and apoptosis.\n\n### Indications\n- **Diffuse Large B-Cell Lymphoma (DLBCL)**: Polatuzumab vedotin is often used in combination with bendamustine and rit"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_zGWL0nGGNGWujWEqUFvRFcPs", "custom_id": "360_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a057eecc2b3f57161c8ee2be3cf013fd", "body": {"id": "chatcmpl-9St3V5Iu0AH4rhU5TLvBvFMMbNrby", "object": "chat.completion", "created": 1716671845, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mirvetuximab soravtansine is an antibody-drug conjugate (ADC) designed for the treatment of certain types of cancer. Here are some key points you should know about it:\n\n1. **Mechanism of Action**: Mirvetuximab soravtansine consists of a monoclonal antibody (mirvetuximab) that targets folate receptor alpha (FR\u03b1), which is often overexpressed in certain cancers, linked to a cytotoxic agent (soravtansine). The antibody binds to FR\u03b1 on the surface of cancer cells, and the conjugate is internalized. Once inside the cell, the cytotoxic agent is released, leading to cell death.\n\n2. **Indications**: It is primarily being investigated for the treatment of FR\u03b1-positive cancers, such as ovarian cancer. Its efficacy and safety are being evaluated in clinical trials, and it may be used in patients with recurrent or refractory disease.\n\n3. **Clinical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_UkoFA76m8ysFaVylvBu86qIH", "custom_id": "361_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "656dd5c7a5bf57ea46af89b0a4333ac5", "body": {"id": "chatcmpl-9St3VcmyYSnVHSq0Bu4nZz1laqTpv", "object": "chat.completion", "created": 1716671845, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mosunetuzumab is a bispecific monoclonal antibody that targets both CD20 on B cells and CD3 on T cells. It is designed to redirect T cells to engage and eliminate CD20-expressing B cells, which is particularly useful in the treatment of certain types of B-cell malignancies, such as non-Hodgkin lymphoma (NHL).\n\nHere are some key points you should know about Mosunetuzumab:\n\n1. **Mechanism of Action**: Mosunetuzumab binds to CD20 on malignant B cells and CD3 on T cells, bringing them into close proximity. This interaction activates the T cells, leading to the targeted killing of the B cells.\n\n2. **Indications**: It is primarily used for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma, including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).\n\n3. **Administration**: Mosunetuzumab is administered intravenously"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_pXaYrxbkoR2URHDjjYA4LeCF", "custom_id": "362_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "250d73b5094a8a29117752a3844f75ae", "body": {"id": "chatcmpl-9St3VyPfdGvF0W0EIeQycTHQw0Bpz", "object": "chat.completion", "created": 1716671845, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nadofaragene firadenovec (also known as rAd-IFN/Syn3) is a gene therapy product used for the treatment of high-grade, Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). Here are some key points you should know about it:\n\n1. **Mechanism of Action**: Nadofaragene firadenovec is a non-replicating adenovirus vector-based gene therapy. It delivers the human interferon alfa-2b gene directly into the bladder urothelium. The expressed interferon alfa-2b has anti-tumor activity, enhancing the immune response against cancer cells.\n\n2. **Indication**: It is specifically indicated for patients with high-grade NMIBC who are unresponsive to BCG therapy. This includes patients with carcinoma in situ (CIS) with or without papillary tumors.\n\n3. **Administration**: The therapy is administered intraves"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_yG0aImkok8uoNZwKEIBn13yV", "custom_id": "363_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ef0574b38287b1637bf900ad62f7d750", "body": {"id": "chatcmpl-9St3WfcwpwDkSKiioItuSQseTDuJB", "object": "chat.completion", "created": 1716671846, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Olutasidenib is a medication that has been under investigation for its potential use in treating certain types of cancer, particularly those with specific genetic mutations. Here are some key points you should know about Olutasidenib:\n\n1. **Mechanism of Action**: Olutasidenib is an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). Mutations in the IDH1 gene can lead to the production of an oncometabolite called 2-hydroxyglutarate (2-HG), which can contribute to the development and progression of cancer. By inhibiting the mutant IDH1 enzyme, Olutasidenib reduces the levels of 2-HG, potentially slowing or stopping the growth of cancer cells.\n\n2. **Indications**: Olutasidenib is primarily being studied for its use in treating cancers with IDH1 mutations. This includes certain types of acute myeloid leukemia (AML) and other solid tumors. The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_mTQ1tJ1PtYZzFLjJPA4fRgOD", "custom_id": "364_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6df7dada1400cd168334de807123c725", "body": {"id": "chatcmpl-9St3Ww63zndj1QvMvwyAJOKR60OPh", "object": "chat.completion", "created": 1716671846, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pyrotinib is a tyrosine kinase inhibitor (TKI) that targets the human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR). It is primarily used in the treatment of HER2-positive breast cancer. Here are some key points you should know about Pyrotinib:\n\n### Mechanism of Action\n- **HER2 and EGFR Inhibition**: Pyrotinib inhibits the kinase activity of HER2 and EGFR, which are involved in the signaling pathways that promote cell proliferation and survival. By blocking these receptors, Pyrotinib can help to inhibit the growth of cancer cells.\n\n### Indications\n- **HER2-Positive Breast Cancer**: Pyrotinib is indicated for the treatment of patients with HER2-positive metastatic breast cancer, often in combination with other chemotherapeutic agents such as capecitabine.\n\n### Efficacy\n- **Clinical Trials**: Clinical trials have shown that Pyrot"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_JlF9MUFwCuU2zMaRFlOvyvMJ", "custom_id": "365_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "bbf86788dab23bd9692d594f09606e53", "body": {"id": "chatcmpl-9St3X0WRTFll6GvVfVbYrKVcUrkZi", "object": "chat.completion", "created": 1716671847, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Buserelin is a synthetic peptide analog of gonadotropin-releasing hormone (GnRH or LHRH). It is used primarily in the treatment of hormone-sensitive cancers, such as prostate cancer and breast cancer, as well as in assisted reproduction and endometriosis. Here are some key points you should know about Buserelin:\n\n### Mechanism of Action:\n- **GnRH Agonist:** Buserelin initially stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, leading to a temporary increase in sex hormone levels (testosterone in men and estrogen in women).\n- **Downregulation:** With continuous administration, Buserelin desensitizes the GnRH receptors in the pituitary gland, leading to a significant reduction in LH and FSH secretion. This results in decreased production of sex hormones (testosterone and estrogen), which is beneficial in hormone-sensitive conditions.\n\n### Indications:\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_BZ0DL29I70M2Ai6DKTgm51Sn", "custom_id": "366_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b7147b18cea456c5ae9a14d391c18649", "body": {"id": "chatcmpl-9St3XhVRV00ovmJJrPIWmueQPxgTr", "object": "chat.completion", "created": 1716671847, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lifileucel is an investigational cell therapy product being developed for the treatment of certain types of cancer, particularly advanced melanoma. Here are some key points you should know about Lifileucel:\n\n1. **Mechanism of Action**: Lifileucel is a form of adoptive cell therapy that uses tumor-infiltrating lymphocytes (TILs). TILs are immune cells that have naturally infiltrated a patient's tumor. These cells are harvested from the patient's tumor, expanded ex vivo (outside the body), and then re-infused into the patient to help fight the cancer.\n\n2. **Indications**: Lifileucel is primarily being investigated for the treatment of advanced melanoma, particularly in patients who have not responded to other treatments such as immune checkpoint inhibitors and targeted therapies.\n\n3. **Clinical Trials**: Lifileucel has shown promising results in clinical trials, with some patients experiencing significant tumor reduction and prolonged survival. The therapy is currently in various stages"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_La0cXREfXxYbTvE4ANWGBg8G", "custom_id": "367_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6eade058e8d03a31390aea3ac69907f3", "body": {"id": "chatcmpl-9St3YT3lVocmzh08VLRUjXLHm2YRS", "object": "chat.completion", "created": 1716671848, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tabelecleucel (also known as ATA129) is an investigational allogeneic T-cell immunotherapy being developed for the treatment of Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) and other EBV-driven diseases. Here are some key points you should know about Tabelecleucel:\n\n1. **Mechanism of Action**:\n   - Tabelecleucel consists of EBV-specific cytotoxic T lymphocytes (CTLs) derived from healthy donors. These CTLs are designed to target and kill EBV-infected cells, which are often the underlying cause of PTLD and other EBV-associated malignancies.\n\n2. **Indications**:\n   - The primary indication for Tabelecleucel is EBV-associated PTLD, particularly in patients who have failed to respond to rituximab or other standard therapies. It is also being investigated for other EBV-driven diseases, including certain lymphomas and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_yXZu0J11fNrYlBdyhBnYxfd8", "custom_id": "368_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b506245ff296f629626bfaf22ca1e499", "body": {"id": "chatcmpl-9St3YrIjKkXkfx7Fa42WWTj1pYT7r", "object": "chat.completion", "created": 1716671848, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Verzenio (abemaciclib) is a medication used in the treatment of certain types of breast cancer. Here are some key points you should know about Verzenio as a physician:\n\n### Indications:\n1. **Hormone Receptor-Positive, HER2-Negative Breast Cancer**: Verzenio is primarily indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.\n2. **Combination Therapy**: It is often used in combination with endocrine therapy (such as an aromatase inhibitor or fulvestrant) for patients who have progressed following endocrine therapy.\n3. **Monotherapy**: It can also be used as monotherapy in patients with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.\n\n### Mechanism of Action:\n- **CDK4/6 Inhibitor**: Verzenio works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which are involved in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_RAV13oK7k2oghdDesMITNDLN", "custom_id": "369_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b53ab9d1ab54cde1a19b0c8169b4ce6d", "body": {"id": "chatcmpl-9St3YnRQtRtlGlkXvA0qihx75xJyO", "object": "chat.completion", "created": 1716671848, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a typo or misunderstanding in the name \"Abatitor.\" There is no widely recognized medication or medical term by that name. However, if you meant \"Abatacept,\" I can provide information on that.\n\nAbatacept is a biologic medication used primarily in the treatment of autoimmune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. Here are some key points you should know about Abatacept:\n\n### Mechanism of Action:\n- Abatacept is a selective co-stimulation modulator that inhibits T-cell activation.\n- It works by binding to CD80 and CD86 on antigen-presenting cells, preventing their interaction with CD28 on T cells. This inhibition reduces the inflammatory response.\n\n### Indications:\n- Rheumatoid Arthritis (RA): For adults with moderate to severe RA who have had an inadequate response to other disease-modifying antirheumatic drugs (DMARDs).\n- Juvenile Idiopathic Arthritis"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_4B0qcBkzfzm7CScuDivxscmg", "custom_id": "370_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "5be4be849cff6edd5c8d0941d1ea8d21", "body": {"id": "chatcmpl-9St3YMnMJsMGlcwJqyiagxVdwZdi2", "object": "chat.completion", "created": 1716671848, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Calquence (acalabrutinib) is a medication used primarily in the treatment of certain types of blood cancers, specifically mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Here are some key points you should know about Calquence:\n\n### Mechanism of Action\n- **BTK Inhibitor**: Calquence is a Bruton's tyrosine kinase (BTK) inhibitor. BTK is a crucial enzyme in the B-cell receptor signaling pathway, which is important for the growth and survival of malignant B cells. By inhibiting BTK, Calquence disrupts these signaling pathways, leading to reduced proliferation and survival of cancerous B cells.\n\n### Indications\n- **Mantle Cell Lymphoma (MCL)**: Approved for adult patients who have received at least one prior therapy.\n- **Chronic Lymphocytic Leukemia (CLL)**: Approved for the treatment of adult patients with CLL or small lymphocytic lymphoma (S"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_QQs0hZxXBIzCil1ka4hcMz4M", "custom_id": "371_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1154b12f92dbf5ea2e531ca9a032785e", "body": {"id": "chatcmpl-9St3Zx2YWwqZpIGC0StoGwyU2x1Cu", "object": "chat.completion", "created": 1716671849, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aclacin, also known as Aclacinomycin A or Aclarubicin, is an anthracycline antibiotic used primarily in the treatment of certain types of cancer. Here are some key points you should know about Aclacin:\n\n1. **Mechanism of Action**: Aclacin works by intercalating into DNA, thereby inhibiting the synthesis of nucleic acids. It also generates free radicals and inhibits topoisomerase II, leading to DNA strand breaks and apoptosis of cancer cells.\n\n2. **Indications**: Aclacin is used in the treatment of various hematologic malignancies, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It may also be used in other cancers as part of combination chemotherapy regimens.\n\n3. **Administration**: Aclacin is typically administered intravenously. The dosage and schedule depend on the specific protocol being followed, the type of cancer, and the patient's overall health and response to treatment"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_dK8HhpYW1MtL2ZsE4eBZ66II", "custom_id": "372_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a55abee3de32623569d89492a3857dff", "body": {"id": "chatcmpl-9St3Z74Cs3eqOTxRFzUJDvuga6esy", "object": "chat.completion", "created": 1716671849, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kadcyla (ado-trastuzumab emtansine) is a targeted cancer therapy used primarily in the treatment of HER2-positive breast cancer. Here are some key points you should know about Kadcyla:\n\n### Mechanism of Action\n- **Antibody-Drug Conjugate**: Kadcyla is an antibody-drug conjugate (ADC) that combines the HER2-targeted properties of trastuzumab (Herceptin) with the cytotoxic activity of the microtubule inhibitor DM1 (a derivative of maytansine).\n- **Targeting HER2**: The trastuzumab component binds to the HER2 receptor on cancer cells, delivering the cytotoxic agent directly to the cancer cells, which helps to minimize damage to normal cells.\n\n### Indications\n- **Metastatic Breast Cancer**: Kadcyla is indicated for the treatment of patients with HER2-positive metastatic breast cancer who have previously received trastuzumab and a taxane, separately"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Dt2kdU5B7edUnzCsfAO5SVYS", "custom_id": "373_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c3d99ac245fb17cd1fe4950480fef8e4", "body": {"id": "chatcmpl-9St3a6ztcV79WvlfcG0X9ZIhL9CM3", "object": "chat.completion", "created": 1716671850, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or treatment known as \"Afanix.\" It's possible that you might be referring to a new or emerging drug, a brand name that is not widely known, or there might be a typographical error in the name.\n\nIf \"Afanix\" is a new or emerging treatment, here are some general steps you can take to gather more information:\n\n1. **Consult Medical Databases**: Use resources like PubMed, ClinicalTrials.gov, or your institution's medical library to search for any recent studies or clinical trials involving \"Afanix.\"\n\n2. **Pharmaceutical Reps**: Contact representatives from pharmaceutical companies who might have information on new drugs or treatments.\n\n3. **Professional Networks**: Reach out to colleagues or professional networks. Sometimes, new treatments are discussed in professional forums or at medical conferences before they become widely known.\n\n4. **Regulatory Agencies**: Check with regulatory agencies like the FDA"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ouz1JyQa7DwCqc9KubNLjXsL", "custom_id": "374_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "49b9812dcab4f12fe7aaf0a57a2bbdc2", "body": {"id": "chatcmpl-9St3apy94W6HwNzIDJ0E8LzMrS2sM", "object": "chat.completion", "created": 1716671850, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Macrolin\" is not a widely recognized or standard name for a medication, so it is possible that there might be a typo or a misunderstanding. However, if you are referring to macrolides, which are a class of antibiotics, here is some relevant information:\n\n### Macrolides Overview:\nMacrolides are a class of antibiotics that are commonly used to treat a variety of bacterial infections. They work by inhibiting bacterial protein synthesis, which ultimately stops bacterial growth.\n\n### Common Macrolides:\n1. **Erythromycin**\n2. **Clarithromycin**\n3. **Azithromycin**\n\n### Indications:\nMacrolides are often prescribed for:\n- Respiratory tract infections (e.g., pneumonia, bronchitis)\n- Skin infections\n- Sexually transmitted infections (e.g., chlamydia)\n- Helicobacter pylori infection (in combination with other medications)\n- Otitis media\n- Streptococcal pharyngitis (in patients allergic to pen"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_2VkUH8JCRBrzjwM7rUFSjmzw", "custom_id": "375_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "574fe41477bba5ed378606a1d1951930", "body": {"id": "chatcmpl-9St3bpl0g8V2FBXmIRATkJpTSaKtO", "object": "chat.completion", "created": 1716671851, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alecensa (alectinib) is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about Alecensa:\n\n### Indications:\n- **Non-Small Cell Lung Cancer (NSCLC):** Alecensa is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC. It is often used in patients who have progressed on or are intolerant to crizotinib, another ALK inhibitor.\n\n### Mechanism of Action:\n- **ALK Inhibitor:** Alecensa works by inhibiting the activity of the ALK tyrosine kinase receptor, which is involved in the growth and spread of cancer cells. By blocking this receptor, Alecensa can help to slow or stop the progression of the cancer.\n\n### Administration:\n- **Oral Medication:** Alecensa is administered orally, typically at a dose of 600 mg twice daily with food. The capsules should be swallowed whole and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_PUA2hDKYv3MYZ1bCuhvF4iV6", "custom_id": "376_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "70d8c9a5d2d24968b8e2013cadd6a11f", "body": {"id": "chatcmpl-9St3bMBk8YpaNGUwCW80YEqJJIwon", "object": "chat.completion", "created": 1716671851, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Campath, also known by its generic name alemtuzumab, is a monoclonal antibody used primarily in the treatment of certain types of leukemia, particularly B-cell chronic lymphocytic leukemia (B-CLL). Here are some key points you should know about Campath:\n\n### Mechanism of Action\n- **Target**: Campath targets the CD52 antigen, a protein found on the surface of mature lymphocytes.\n- **Action**: By binding to CD52, Campath induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the destruction of these cells.\n\n### Indications\n- **Chronic Lymphocytic Leukemia (CLL)**: Campath is approved for the treatment of B-CLL in patients who have been treated with alkylating agents and have failed fludarabine therapy.\n- **Multiple Sclerosis (MS)**: Alemtuzumab is also approved under the brand name"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ei8NlgcAK9MpJmCT2CLZ2XKh", "custom_id": "377_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "83594c740894fe141726a6629e1c6b8b", "body": {"id": "chatcmpl-9St3cgcm0Q8ZOZntenRNHVE4J46rP", "object": "chat.completion", "created": 1716671852, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about CA ATRA (All-Trans Retinoic Acid), especially if you are involved in the treatment of acute promyelocytic leukemia (APL). Here are some key points you should know:\n\n### Mechanism of Action\n- **Differentiation Agent**: ATRA is a derivative of vitamin A and works by promoting the differentiation of immature leukemic promyelocytes into mature granulocytes.\n- **Target**: It specifically targets the PML-RAR\u03b1 fusion protein, which is a result of the t(15;17) chromosomal translocation commonly found in APL.\n\n### Indications\n- **Acute Promyelocytic Leukemia (APL)**: ATRA is primarily used in the treatment of APL, often in combination with other chemotherapeutic agents like arsenic trioxide or anthracyclines.\n\n### Administration\n- **Oral Formulation**: ATRA is typically administered orally.\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Wn7PaqegQ0IQef4s6gWww8tb", "custom_id": "378_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "32d9dd810159998f33075cb408d36695", "body": {"id": "chatcmpl-9St3cWyNRuCH6qo95YS5SP5BIigOX", "object": "chat.completion", "created": 1716671852, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Hexalen (altretamine) is an antineoplastic agent used primarily in the treatment of ovarian cancer, particularly in patients with persistent or recurrent disease following first-line therapy. Here are some key points you should know about Hexalen:\n\n### Mechanism of Action\n- **Cytotoxic Agent**: Hexalen is believed to work by interfering with the function of DNA and RNA, although its exact mechanism of action is not fully understood. It is thought to cause cross-linking of DNA strands, leading to cell death.\n\n### Indications\n- **Ovarian Cancer**: Hexalen is indicated for the palliative treatment of patients with ovarian cancer that has not responded to other treatments.\n\n### Administration\n- **Oral Medication**: Hexalen is administered orally, typically in capsule form.\n- **Dosage**: The usual dosage is 260 mg/m\u00b2/day, divided into four doses, for 14 or 21 consecutive days in a 28-day cycle. Dosage adjustments"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_CUSeXQ1oapRP8iisjvSYnchb", "custom_id": "379_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "32e00305e07bfdd3bfcdf51a32137d88", "body": {"id": "chatcmpl-9St3cCU9nxXdzj8Ztl04iMF3oqinx", "object": "chat.completion", "created": 1716671852, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aminoblastin is a pharmaceutical product that is typically used in clinical settings for parenteral nutrition. It is an amino acid solution designed to provide essential and non-essential amino acids to patients who are unable to meet their nutritional needs through oral or enteral routes. Here are some key points you should know about Aminoblastin:\n\n1. **Composition**: Aminoblastin contains a mixture of essential and non-essential amino acids. The exact composition can vary depending on the specific formulation, but it generally includes amino acids such as leucine, isoleucine, valine, lysine, methionine, phenylalanine, threonine, tryptophan, and others.\n\n2. **Indications**: It is indicated for patients who require parenteral nutrition due to conditions such as severe gastrointestinal disorders, malabsorption syndromes, severe burns, trauma, or other conditions that impair the ability to ingest or absorb nutrients.\n\n3. **Administration**: Aminoblastin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_RQLsvS8j4vLTutRmC44Mbsmr", "custom_id": "380_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "5f3eca75534d508519d5f7bf621d4fa5", "body": {"id": "chatcmpl-9St3cPuPIQsLQrpiSQguxPzIgq8w7", "object": "chat.completion", "created": 1716671852, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about any medication you might prescribe or encounter in your practice. However, as of my last update in October 2023, there is no widely recognized medication or treatment known as \"Calsed.\" It's possible that it could be a new drug, a brand name not widely recognized, a supplement, or even a typographical error.\n\nHere are some steps you can take to ensure you have accurate information:\n\n1. **Verify the Name**: Double-check the spelling and ensure there are no typographical errors. Sometimes drug names can be easily misspelled or misheard.\n\n2. **Consult Reliable Sources**: Use trusted medical databases and resources such as:\n   - **PubMed**: For research articles and clinical studies.\n   - **UpToDate**: For comprehensive clinical information.\n   - **Micromedex**: For drug information.\n   - **FDA (Food and Drug Administration)**: For approved medications and their uses.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_emldi3qMawEjpRkogSEGz0Vx", "custom_id": "381_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "51432ccf644b81faa0c6b145f4407249", "body": {"id": "chatcmpl-9St3cx5eFrM2OjqS6FrWdtmTC6W2l", "object": "chat.completion", "created": 1716671852, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or substance known as \"Amekrin\" in the medical literature or pharmaceutical databases. It is possible that \"Amekrin\" could be a misspelling, a brand name not widely recognized, a newly developed drug, or a substance specific to a particular region or country.\n\nIf you are referring to a new or emerging medication, here are some general steps you can take to gather more information:\n\n1. **Consult Reliable Sources**: Check reputable medical databases such as PubMed, Medline, or clinical trial registries for any studies or information on \"Amekrin.\"\n\n2. **Pharmaceutical Repositories**: Look into pharmaceutical databases like the FDA (Food and Drug Administration) or EMA (European Medicines Agency) for any approvals or clinical trial data.\n\n3. **Professional Networks**: Reach out to colleagues or professional networks. Sometimes new medications or treatments are discussed in professional forums or at medical conferences before"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_zTD2MxUJzHUDxfcyQI2BvEJa", "custom_id": "382_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d1a7737ac62e86e78294b41ee4cb918a", "body": {"id": "chatcmpl-9St3dabSIxpMTpEr4RvaoDHTKq91X", "object": "chat.completion", "created": 1716671853, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Altraz is a brand name for the drug letrozole, which is a non-steroidal aromatase inhibitor. It is commonly used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Here are some key points you should know about Altraz (letrozole):\n\n### Indications:\n1. **Breast Cancer Treatment**: Primarily used for hormone receptor-positive breast cancer in postmenopausal women.\n2. **Adjuvant Therapy**: Often used as an adjuvant treatment following surgery to reduce the risk of cancer recurrence.\n3. **Metastatic Breast Cancer**: Can be used in cases where the cancer has spread beyond the breast and surrounding tissues.\n4. **Neoadjuvant Therapy**: Sometimes used before surgery to shrink tumors.\n\n### Mechanism of Action:\n- **Aromatase Inhibition**: Letrozole works by inhibiting the enzyme aromatase, which is involved in the synthesis of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_z4cTLP7oxFRJf9gflE3scRO1", "custom_id": "383_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "93ae4336b8bd6470308f64cfca801170", "body": {"id": "chatcmpl-9St3dmBs4mByuc26nEYMvXRPvRjyn", "object": "chat.completion", "created": 1716671853, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erleada (generic name: apalutamide) is a medication used in the treatment of prostate cancer. Here are some key points you should know about Erleada as a physician:\n\n### Indications:\n1. **Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC):** Erleada is indicated for the treatment of patients with nmCRPC.\n2. **Metastatic Castration-Sensitive Prostate Cancer (mCSPC):** It is also approved for use in patients with mCSPC.\n\n### Mechanism of Action:\n- Erleada is an androgen receptor inhibitor. It works by binding to androgen receptors and inhibiting the action of androgens (male hormones), which can promote the growth of prostate cancer cells.\n\n### Dosage and Administration:\n- The recommended dose of Erleada is 240 mg (four 60 mg tablets) taken orally once daily.\n- It can be taken with or without food.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_urMkFvqR4JFgoyuxPxKXKN80", "custom_id": "384_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b30b1cad713512e417a9ef88fc8f74ef", "body": {"id": "chatcmpl-9St3eblqebSVYvaIDSulvnm1S2Rk6", "object": "chat.completion", "created": 1716671854, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like you might be referring to a specific individual named Aitan, but without more context, it's difficult to provide precise information. If Aitan is a patient, you would need to know their medical history, current medications, allergies, and any specific health concerns they have. \n\nHowever, if you are referring to a medical term, medication, or a concept that sounds like \"Aitan,\" please provide more details or clarify the context so I can give you accurate and relevant information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 98, "total_tokens": 138}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_7deve0Y1M2WF91ajeMJsNBow", "custom_id": "385_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "bad8341d52762fbabc0af3079548f817", "body": {"id": "chatcmpl-9St3eaNr9SQpaMDBUCDhqM6NGiFbj", "object": "chat.completion", "created": 1716671854, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be aware of the following key points regarding Arsenol:\n\n1. **Chemical Nature**: Arsenol is a compound that contains arsenic. Arsenic is a well-known toxic element, and its compounds can be highly toxic to humans.\n\n2. **Medical Use**: Historically, arsenic compounds, including those similar to Arsenol, were used in medicine, particularly in the treatment of syphilis before the advent of penicillin. However, due to their toxicity, their use has largely been discontinued in favor of safer alternatives.\n\n3. **Toxicity**: Arsenic compounds can cause acute and chronic poisoning. Symptoms of acute arsenic poisoning include nausea, vomiting, abdominal pain, and severe diarrhea. Chronic exposure can lead to skin changes, peripheral neuropathy, and an increased risk of various cancers, particularly skin, lung, and bladder cancer.\n\n4. **Exposure and Safety**: If you suspect a patient has been exposed to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_q8wYFJUUWPOs5MseYRwFVwcB", "custom_id": "386_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c0a44fcd426da0469153b71bf42f3bc1", "body": {"id": "chatcmpl-9St3ezzaawEGagBvw0nBZG0OnSiym", "object": "chat.completion", "created": 1716671854, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asparaginase is an enzyme used primarily in the treatment of acute lymphoblastic leukemia (ALL). Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Enzyme Function**: Asparaginase catalyzes the hydrolysis of asparagine to aspartic acid and ammonia.\n- **Cancer Cell Targeting**: Leukemic cells, particularly lymphoblasts, are unable to synthesize asparagine due to a lack of asparagine synthetase. Asparaginase depletes extracellular asparagine, starving the leukemic cells and inhibiting their protein synthesis, leading to cell death.\n\n### Indications\n- **Acute Lymphoblastic Leukemia (ALL)**: Asparaginase is a critical component of multi-agent chemotherapy regimens for ALL.\n- **Lymphoblastic Lymphoma**: It is also used in the treatment of lymphoblastic lymphoma.\n\n### Forms and Administration\n- **Types"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_UCCdQQLPm17pilgS2nlNCd0i", "custom_id": "387_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9ba9892afe43e00068e84b312e098bc7", "body": {"id": "chatcmpl-9St3faDiehwhYgtbtZWn5vA5Op4W9", "object": "chat.completion", "created": 1716671855, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erwinase, also known as Erwinia L-asparaginase, is a medication used primarily in the treatment of acute lymphoblastic leukemia (ALL). Here are some key points you should know about Erwinase:\n\n### Indications:\n- **Acute Lymphoblastic Leukemia (ALL):** Erwinase is used as part of a multi-agent chemotherapeutic regimen for patients with ALL, particularly those who have developed hypersensitivity to E. coli-derived asparaginase products.\n\n### Mechanism of Action:\n- **Asparaginase Activity:** Erwinase works by depleting the amino acid asparagine, which is essential for the survival and proliferation of leukemic cells. Normal cells can synthesize asparagine, but leukemic cells cannot, making them more susceptible to asparaginase treatment.\n\n### Administration:\n- **Route:** Erwinase is typically administered via intramuscular injection, although it can also be given intravenously.\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_NdINJg4Q9qCkqiw22Wwe2hGL", "custom_id": "388_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "20c53afd59d42d6c5da26c6c7b2e11f1", "body": {"id": "chatcmpl-9St3fBH8Y1QrY3ZxfuCfKQMVRAwlQ", "object": "chat.completion", "created": 1716671855, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tecentriq (atezolizumab) is a monoclonal antibody used as an immunotherapy for certain types of cancer. Here are some key points you should know about Tecentriq:\n\n### Mechanism of Action\n- **PD-L1 Inhibition**: Tecentriq targets and binds to the programmed death-ligand 1 (PD-L1) protein on the surface of cancer cells and immune cells. By blocking PD-L1, Tecentriq prevents it from binding to the PD-1 receptor on T-cells, thereby enhancing the immune system's ability to attack cancer cells.\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC)**: Tecentriq is approved for use in patients with metastatic NSCLC.\n- **Small Cell Lung Cancer (SCLC)**: It is also indicated for extensive-stage SCLC.\n- **Urothelial Carcinoma**: Tecentriq is used for locally advanced or metastatic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_tNpdTOFFrHBuL79s7GrXGPfS", "custom_id": "389_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "4cd827d6f9533b1a88799c10f2baa1dd", "body": {"id": "chatcmpl-9St3fwjyFXnqxtJf1a9tdq9Wsr5E1", "object": "chat.completion", "created": 1716671855, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bavencio (avelumab) is a medication used in the treatment of certain types of cancer. Here are some key points you should know about Bavencio as a physician:\n\n### Indications:\n1. **Merkel Cell Carcinoma (MCC):**\n   - Bavencio is approved for the treatment of metastatic Merkel cell carcinoma in adults and pediatric patients 12 years and older.\n\n2. **Urothelial Carcinoma:**\n   - It is indicated for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.\n\n3. **Renal Cell Carcinoma (RCC):**\n   - Bavencio, in combination with axitinib, is approved for the first-line treatment of patients with advanced renal cell carcinoma.\n\n### Mechanism of Action:\n- Bavencio is a programmed death-ligand 1 (PD-L1) blocking antibody. It works by binding to PD-L1 and blocking its interaction"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_wrcLy9SzeTtJIRtHyBP8tgaN", "custom_id": "390_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "4c8bbc1f6ce0699270886e097647af7c", "body": {"id": "chatcmpl-9St3gM4R5bT9kWS1C9wgxfZ7GRpTr", "object": "chat.completion", "created": 1716671856, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Yescarta (axicabtagene ciloleucel) is a type of CAR T-cell therapy, which stands for chimeric antigen receptor T-cell therapy. It is used in the treatment of certain types of non-Hodgkin lymphoma, specifically relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Here are some key points you should know about Yescarta:\n\n### Mechanism of Action\n- **CAR T-Cell Therapy**: Yescarta involves modifying a patient's own T cells to express a receptor specific to the CD19 protein found on the surface of B cells, including malignant B cells. These modified T cells are then infused back into the patient to target and kill the cancer cells.\n\n### Indications\n- **FDA Approval**: Yescarta is approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_WUg784vjtNzOioeTLNMU88ii", "custom_id": "391_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7167d6dcdd90fb7aac3d284843b6e733", "body": {"id": "chatcmpl-9St3gYRlhyipoQQJKltce37lZRsm7", "object": "chat.completion", "created": 1716671856, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or treatment known as \"Axishil.\" It is possible that it could be a new or less common drug, a brand name not widely recognized, or a misspelling of another medication. Here are some steps you can take to gather more information:\n\n1. **Check Reliable Sources**: Consult trusted medical databases such as PubMed, Medline, or the FDA's website for any information on \"Axishil.\"\n\n2. **Pharmaceutical Reps**: Contact pharmaceutical representatives or the company that manufactures the drug for detailed information.\n\n3. **Pharmacy Consultation**: Speak with a pharmacist who may have access to more detailed drug databases and can provide information on less common medications.\n\n4. **Medical Literature**: Review recent medical literature or clinical trial databases to see if there are any studies or papers mentioning \"Axishil.\"\n\n5. **Professional Networks**: Utilize professional networks or forums to ask colleagues"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_2Phr0N4spcmEC6mdV3jiJno0", "custom_id": "392_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f60acb5de043dcdc9fb2ec8f164ab0eb", "body": {"id": "chatcmpl-9St3gDKFn4Ql8PYaZchgNB01aLSes", "object": "chat.completion", "created": 1716671856, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azacitidine, marketed under the brand name Vidaza among others, is a chemotherapeutic agent used primarily in the treatment of myelodysplastic syndromes (MDS), a group of bone marrow disorders. Here are some key points you should know about Azacitidine:\n\n### Mechanism of Action:\n- **Hypomethylating Agent**: Azacitidine is a nucleoside analog of cytidine. It incorporates into DNA and RNA, leading to the inhibition of DNA methyltransferase, which results in hypomethylation of DNA. This can reactivate tumor suppressor genes and induce cellular differentiation and apoptosis.\n- **Cytotoxic Effects**: It also has direct cytotoxic effects on abnormal hematopoietic cells in the bone marrow.\n\n### Indications:\n- **Myelodysplastic Syndromes (MDS)**: Azacitidine is primarily used to treat various subtypes of MDS, including refractory anemia, chronic myelomonocytic leukemia, and refractory anemia"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_WUXT0hZwovPKpreRyyjODvuq", "custom_id": "393_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f925aca688753c68cc3bba895200cc01", "body": {"id": "chatcmpl-9St3gibPWgpWL6bjPYLikwOoLNPZ1", "object": "chat.completion", "created": 1716671856, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "TheraCys is a brand name for Bacillus Calmette-Gu\u00e9rin (BCG) live intravesical, which is used primarily in the treatment of bladder cancer. Here are some key points you should know about TheraCys:\n\n### Indications:\n- **Non-Muscle Invasive Bladder Cancer (NMIBC):** TheraCys is used for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR).\n\n### Mechanism of Action:\n- **Immune Response Activation:** TheraCys works by stimulating the immune system. The exact mechanism is not fully understood, but it is believed to involve the activation of immune cells that attack cancer cells in the bladder.\n\n### Administration:\n- **Intravesical Instillation:** TheraCys is administered directly into the bladder via a catheter."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_XrmGnyWxI1E8bHmv6YBVDjrG", "custom_id": "394_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "70bbbada2cdddf4869f49cefc9fd4830", "body": {"id": "chatcmpl-9St3hYJYjBBpKm4xP1ha53y6O2H0V", "object": "chat.completion", "created": 1716671857, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tarvacin, also known as bavituximab, is a chimeric monoclonal antibody that targets phosphatidylserine, a phospholipid component that becomes exposed on the outer leaflet of the cell membrane in tumor blood vessels and virally infected cells. Here are some key points you should know about Tarvacin:\n\n1. **Mechanism of Action**: Bavituximab binds to phosphatidylserine, which is normally located on the inner leaflet of the cell membrane but becomes externalized in certain pathological conditions. By targeting this phospholipid, bavituximab can help to inhibit tumor growth and viral replication by promoting immune-mediated destruction of the affected cells.\n\n2. **Therapeutic Indications**: Bavituximab has been investigated primarily for its potential use in oncology, particularly in the treatment of various cancers such as non-small cell lung cancer (NSCLC), breast cancer, and hepatocellular carcinoma. It has also been"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_mzAesd7ibKZ1T1yoz8HXtQoK", "custom_id": "395_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3da2cdf005512d7b145b3bb7249882f4", "body": {"id": "chatcmpl-9St3ibXyCTRW46NVYaHWkTJQ0C1fz", "object": "chat.completion", "created": 1716671858, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Beleodaq (belinostat) is a histone deacetylase (HDAC) inhibitor used in the treatment of certain types of cancer. Here are some key points you should know about Beleodaq:\n\n### Indications:\n- **Peripheral T-cell Lymphoma (PTCL):** Beleodaq is primarily indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).\n\n### Mechanism of Action:\n- **HDAC Inhibition:** Beleodaq works by inhibiting histone deacetylases, which leads to the accumulation of acetylated histones and other proteins. This can result in cell cycle arrest, differentiation, and apoptosis of cancer cells.\n\n### Administration:\n- **Intravenous Infusion:** Beleodaq is administered as an intravenous infusion. The typical dosing schedule is 1,000 mg/m\u00b2 once daily on days 1-5 of a 21-day cycle.\n\n### Side Effects:\n- **Common Ad"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_vdpPb76Mby0pucgcEmyqnPwm", "custom_id": "396_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "dba1505f3e8381530c9a52cafb40b009", "body": {"id": "chatcmpl-9St3iPT2WOyy074MdAD3u3sFSDfVc", "object": "chat.completion", "created": 1716671858, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about any medication you might prescribe or encounter in your practice. However, \"Camptobell\" does not appear to be a recognized or widely known medication as of my last update in October 2023. It is possible that it could be a new drug, a brand name not widely recognized, a regional name, or a misspelling.\n\nHere are some steps you can take to gather more information:\n\n1. **Check Reliable Sources**: Look up the medication in trusted medical databases such as the Physicians' Desk Reference (PDR), UpToDate, or PubMed. These sources can provide detailed information on indications, dosages, side effects, and contraindications.\n\n2. **Consult Pharmacists**: Pharmacists are a valuable resource for information on medications, including new or less common drugs. They can provide insights into the drug's uses, side effects, and interactions.\n\n3. **Contact the Manufacturer**: If you have access"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_6bmWIqw2oR1qEBZzsm6uotav", "custom_id": "397_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "cf10a89945ca030c004d193f0b671cb3", "body": {"id": "chatcmpl-9St3iQmPHYf46K0rjJMGxuRKMmAdQ", "object": "chat.completion", "created": 1716671858, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belrapzo is a brand name for the drug bendamustine hydrochloride, which is used primarily in the treatment of certain types of cancer. Here are some key points you should know about Belrapzo:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL):** Belrapzo is indicated for the treatment of patients with CLL. It is often used when the disease has not responded to other treatments.\n2. **Non-Hodgkin's Lymphoma (NHL):** It is also used for the treatment of indolent B-cell non-Hodgkin's lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.\n\n### Mechanism of Action:\n- **Alkylating Agent:** Belrapzo works by causing cross-linking of DNA strands, which interferes with DNA replication and transcription, leading to cell death. This makes it effective in targeting rapidly"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_a4unU0c2I8FEj9NG67r4HLAS", "custom_id": "398_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d12bccd2f642df8d5e3edbf7fb0374d2", "body": {"id": "chatcmpl-9St3isLYqLCeN9CvOk21wgZC1644B", "object": "chat.completion", "created": 1716671858, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Altuzan is a brand name for bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A). It is used primarily in the treatment of various types of cancer. Here are some key points you should know about Altuzan:\n\n### Indications:\n1. **Colorectal Cancer**: Used in combination with chemotherapy for metastatic colorectal cancer.\n2. **Non-Small Cell Lung Cancer (NSCLC)**: Used with chemotherapy for non-squamous NSCLC.\n3. **Glioblastoma**: For patients with progressive disease following prior therapy.\n4. **Renal Cell Carcinoma**: Used with interferon alfa for metastatic renal cell carcinoma.\n5. **Cervical Cancer**: In combination with chemotherapy for persistent, recurrent, or metastatic cervical cancer.\n6. **Ovarian Cancer**: For platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.\n\n### Mechanism of Action:\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_KxeJRDwbVirTd0dOMaF2qY3V", "custom_id": "399_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "57321f355e9e8e859cad6f55e13f7102", "body": {"id": "chatcmpl-9St3jK50tTz5Vz4BlNTFR84V7wiqB", "object": "chat.completion", "created": 1716671859, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or treatment known as \"Bexgratin.\" It is possible that you may be referring to a new or experimental drug, a misspelling, or a less common name for an existing medication.\n\nIf \"Bexgratin\" is a new or experimental drug, here are some general steps you should take to stay informed:\n\n1. **Consult Reliable Sources**: Check reputable medical databases, journals, and official health organization websites (such as the FDA, EMA, or WHO) for the latest information on new drugs.\n\n2. **Clinical Trials**: Look for clinical trial data to understand the efficacy, safety, and potential side effects of the drug. Websites like ClinicalTrials.gov can be useful.\n\n3. **Pharmacology**: Understand the pharmacodynamics and pharmacokinetics of the drug. This includes how the drug works in the body, its metabolism, and its excretion.\n\n4. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_39SXxfei6UAISaxK9m910sqy", "custom_id": "400_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "abfe2ecf3ff933dc4a97afa241f4b149", "body": {"id": "chatcmpl-9St3jTmGhcSjjRbFz4BS1qkp882g5", "object": "chat.completion", "created": 1716671859, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Calutide is a brand name for bicalutamide, which is a non-steroidal anti-androgen medication primarily used in the treatment of prostate cancer. Here are some key points you should know about Calutide (bicalutamide):\n\n### Mechanism of Action\n- **Anti-Androgen**: Bicalutamide works by binding to androgen receptors, thereby inhibiting the action of androgens (male hormones) like testosterone. This helps to slow the growth of androgen-dependent prostate cancer cells.\n\n### Indications\n- **Prostate Cancer**: It is commonly used in combination with a luteinizing hormone-releasing hormone (LHRH) analog or surgical castration for the treatment of advanced prostate cancer.\n- **Monotherapy**: In some cases, it may be used as monotherapy for prostate cancer, although this is less common.\n\n### Dosage\n- **Standard Dose**: The typical dose is 50 mg once daily, but the exact dosage may"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_iwVHGadQbwv6AckjzfCqfsPU", "custom_id": "401_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ac400ad85b523ed85bfff5eb438cf82a", "body": {"id": "chatcmpl-9St3kP2hkFHfyThL7sEnPKVd7yro5", "object": "chat.completion", "created": 1716671860, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mektovi (binimetinib) is a medication used in combination with another drug called encorafenib (Braftovi) for the treatment of certain types of melanoma. Here are some key points you should know about Mektovi:\n\n### Indications:\n- **Melanoma**: Mektovi is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. It is used in combination with encorafenib.\n\n### Mechanism of Action:\n- **MEK Inhibitor**: Mektovi is a MEK inhibitor. MEK (mitogen-activated extracellular signal-regulated kinase) is part of the MAPK/ERK pathway, which is often activated in cancers with BRAF mutations. By inhibiting MEK, Mektovi helps to block the growth and spread of cancer cells.\n\n### Dosage and Administration:\n- **Dosage**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_abLi9pkEz8BF26RiJSismR90", "custom_id": "402_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "24f2b6934944c5f9d2e90c492ff168be", "body": {"id": "chatcmpl-9St3kJHx8S4C0oRA1VcxD9DIbK5OR", "object": "chat.completion", "created": 1716671860, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blenoxane is the brand name for bleomycin, a chemotherapeutic agent used primarily in the treatment of various types of cancer. Here are some key points you should know about Blenoxane:\n\n### Indications:\n1. **Hodgkin's Lymphoma**: Often used as part of the ABVD regimen (Adriamycin, Bleomycin, Vinblastine, Dacarbazine).\n2. **Non-Hodgkin's Lymphoma**: Sometimes used in combination with other chemotherapeutic agents.\n3. **Testicular Cancer**: Commonly used in combination regimens such as BEP (Bleomycin, Etoposide, Cisplatin).\n4. **Squamous Cell Carcinomas**: Including those of the head, neck, and skin.\n5. **Malignant Pleural Effusion**: Used as a sclerosing agent.\n\n### Mechanism of Action:\n- Bleomycin works by binding"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_n8QzohPb3YyDc9epNVAXbIgS", "custom_id": "403_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "fa1e319e0163d51854794a7ae2f8a088", "body": {"id": "chatcmpl-9St3l7Ou3TnoqpfC7fitwDudU8RW6", "object": "chat.completion", "created": 1716671861, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blincyto (blinatumomab) is a bispecific T-cell engager (BiTE) immunotherapy used in the treatment of certain types of blood cancers, specifically B-cell precursor acute lymphoblastic leukemia (ALL). Here are some key points you should know about Blincyto:\n\n### Indications:\n1. **Acute Lymphoblastic Leukemia (ALL):**\n   - Blincyto is primarily indicated for the treatment of adults and children with B-cell precursor ALL that is in remission but has minimal residual disease (MRD).\n   - It is also used for the treatment of relapsed or refractory B-cell precursor ALL.\n\n### Mechanism of Action:\n- Blincyto is a bispecific monoclonal antibody that binds to CD19 on B-cells and CD3 on T-cells. This dual binding brings T-cells into close proximity with B-cells, facilitating the T-cells' ability to recognize and destroy the malignant B-cells.\n\n### Administration:\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_aajIZanr3iCZjgTz437V8t3k", "custom_id": "404_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "fc9aa11883ae72c5bfec3cbab5e034c5", "body": {"id": "chatcmpl-9St3lw0KOi73ARIygBaAoUNuyhAio", "object": "chat.completion", "created": 1716671861, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to stay informed about various treatments and therapies, including those offered by companies like Biocure. However, as of my last update in October 2023, there isn't a widely recognized or specific treatment or product universally known as \"Biocure.\" It\u2019s possible that Biocure could refer to a company or a specific line of products or therapies that may not be widely known or could be emerging in the medical field.\n\nHere are some general steps you can take to stay informed about any new treatments or companies:\n\n1. **Research the Company**: Look into Biocure's background, including its history, mission, and the types of products or therapies it offers. Check for any clinical trials, research publications, or case studies associated with the company.\n\n2. **Regulatory Approval**: Verify if the products or treatments offered by Biocure have received approval from relevant regulatory bodies such as the FDA (Food and Drug Administration) in the United States, EMA"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_vHAovGLDkfEdMJ68TCqPVt5Z", "custom_id": "405_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9e8f252f87017d350c1a1d36d8524055", "body": {"id": "chatcmpl-9St3lomE5YCuQTL6jnh2ChoSHwa81", "object": "chat.completion", "created": 1716671861, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bosulif (bosutinib) is a medication used primarily in the treatment of chronic myelogenous leukemia (CML). Here are some key points you should know about Bosulif as a physician:\n\n### Indications:\n- **Chronic Myelogenous Leukemia (CML):** Bosulif is indicated for the treatment of adult patients with newly diagnosed chronic phase Philadelphia chromosome-positive (Ph+) CML.\n- **Resistant or Intolerant CML:** It is also used for patients with chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.\n\n### Mechanism of Action:\n- **Tyrosine Kinase Inhibitor:** Bosulif is a tyrosine kinase inhibitor that targets the BCR-ABL kinase, which is produced by the Philadelphia chromosome abnormality in CML. It also inhibits other kinases such as SRC family kinases, which may contribute to its efficacy.\n\n### Dosage and Administration:\n- **Starting Dose:** The typical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_07ZywfTzTa4NwYQ2son4FcEM", "custom_id": "406_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2565bbd5ec4687f6bb5d097facb482e6", "body": {"id": "chatcmpl-9St3mhtPkEECV5U9b9l2Tb60aWEea", "object": "chat.completion", "created": 1716671862, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adcetris (generic name: brentuximab vedotin) is an antibody-drug conjugate (ADC) used primarily in the treatment of certain types of lymphoma. Here are some key points you should know about Adcetris:\n\n### Indications:\n1. **Hodgkin Lymphoma (HL):**\n   - For patients with classical Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.\n   - As consolidation treatment following ASCT in patients at high risk of relapse or progression.\n\n2. **Systemic Anaplastic Large Cell Lymphoma (sALCL):**\n   - For patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen.\n\n3. **Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-expressing Mycosis Fungoides ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_BBYmddng8JZ0YqemneE7FEiV", "custom_id": "407_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f9bd316479a2e8e1d667eff04ca6c54c", "body": {"id": "chatcmpl-9St3n9KwdtRfdFHRgB7sD8WPXQK6Y", "object": "chat.completion", "created": 1716671863, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alunbrig (brigatinib) is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about Alunbrig as a physician:\n\n### Indications:\n- **Non-Small Cell Lung Cancer (NSCLC):** Alunbrig is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC. It is often used in patients who have progressed on or are intolerant to crizotinib, another ALK inhibitor.\n\n### Mechanism of Action:\n- **ALK Inhibitor:** Alunbrig works by inhibiting the activity of the ALK protein, which can be abnormally expressed in some NSCLC patients. By blocking this protein, Alunbrig helps to slow or stop the growth of cancer cells.\n\n### Dosage and Administration:\n- **Starting Dose:** The recommended starting dose is 90 mg once daily for the first 7 days.\n- **Maintenance Dose:**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_3xDyQRPbTytHreuhQnarYoZh", "custom_id": "408_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c9d4d5218d7e114e7840827db770d946", "body": {"id": "chatcmpl-9St3nzst4Ok9QrlyVuojH8dFoaQ5p", "object": "chat.completion", "created": 1716671863, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Busilvex is a brand name for the drug busulfan, which is a chemotherapy agent used primarily in the conditioning regimen prior to hematopoietic stem cell transplantation (HSCT). Here are some key points you should know about Busilvex:\n\n### Indications:\n- **Conditioning Regimen for HSCT:** Busilvex is used in combination with other chemotherapy agents, such as cyclophosphamide or fludarabine, to prepare patients for bone marrow or stem cell transplantation. It helps to eradicate existing bone marrow cells to make room for the transplanted cells.\n\n### Mechanism of Action:\n- **Alkylating Agent:** Busulfan works by cross-linking DNA strands, which interferes with DNA replication and transcription, leading to cell death. This is particularly effective in rapidly dividing cells, such as cancer cells and bone marrow cells.\n\n### Administration:\n- **Intravenous (IV) Infusion:** Busilvex is administered as an IV"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_I3BfrCRKieX2llq3aAjsNJzI", "custom_id": "409_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a62488dc4be88798bc534a842e0b0aec", "body": {"id": "chatcmpl-9St3o2OKSIZdmjF4i2pZ0pi3Y1OxK", "object": "chat.completion", "created": 1716671864, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a typo or misunderstanding in your question, as \"Cabapan\" does not correspond to any known medication, medical term, or condition in the current medical literature up to my knowledge cutoff in October 2023. If you meant a specific drug, condition, or medical term, please provide more context or check the spelling.\n\nHowever, if you were referring to a specific medication or treatment, here are some general steps you can take to gather the necessary information:\n\n1. **Check Reliable Medical Sources**: Use trusted medical databases such as PubMed, UpToDate, or your institution's library resources to look up the term.\n\n2. **Consult Pharmacology References**: Resources like the Physicians' Desk Reference (PDR), Lexicomp, or Micromedex can provide detailed information on medications, including indications, dosages, side effects, and contraindications.\n\n3. **Ask Colleagues or Specialists**: Sometimes, discussing with colleagues or specialists in pharmac"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_6suzd5pHwKSBzZYPmvCuigih", "custom_id": "410_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "22a954aac6d996d5276cf76524ef6610", "body": {"id": "chatcmpl-9St3oAPXLP77Cnl42y20paeiutsq4", "object": "chat.completion", "created": 1716671864, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cabometyx (cabozantinib) is a medication used primarily in the treatment of certain types of cancer. Here are some key points you should know about Cabometyx:\n\n### Indications:\n1. **Renal Cell Carcinoma (RCC):** Cabometyx is approved for the treatment of advanced renal cell carcinoma.\n2. **Hepatocellular Carcinoma (HCC):** It is also indicated for patients with hepatocellular carcinoma who have been previously treated with sorafenib.\n3. **Medullary Thyroid Cancer (MTC):** Cabozantinib is used in the treatment of progressive, metastatic medullary thyroid cancer.\n\n### Mechanism of Action:\n- Cabozantinib is a tyrosine kinase inhibitor (TKI) that targets multiple tyrosine kinases involved in tumor growth and angiogenesis, including MET, VEGFR, and RET.\n\n### Dosage and Administration:\n- The typical starting dose for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5O5H0K9QODPmWkG5jOTMs2dy", "custom_id": "411_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b8ef22e5f582e5aa58c82428f96f1058", "body": {"id": "chatcmpl-9St3ohb99aBw3B6MF8t9vaiCSVsJG", "object": "chat.completion", "created": 1716671864, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asparlas (calaspargase pegol-mknl) is a medication used in the treatment of acute lymphoblastic leukemia (ALL), a type of cancer of the blood and bone marrow. Here are some key points you should know about Asparlas:\n\n### Mechanism of Action\n- **Enzyme Activity**: Asparlas is a PEGylated (polyethylene glycol-conjugated) form of the enzyme L-asparaginase. It works by breaking down asparagine, an amino acid that leukemia cells need to survive. Normal cells can produce asparagine, but leukemia cells cannot, leading to their death when asparagine is depleted.\n\n### Indications\n- **Acute Lymphoblastic Leukemia (ALL)**: Asparlas is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of ALL in pediatric and young adult patients aged 1 month to 21 years.\n\n### Administration\n- **Dosage**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_TPP9YJd5VyEJvgCIzfrzJfgw", "custom_id": "412_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f49d21cfe1c6cb38386551018f276657", "body": {"id": "chatcmpl-9St3pbd2tnV2xpS2D1e0EKT3iEIkj", "object": "chat.completion", "created": 1716671865, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or treatment known as \"Cabita.\" It's possible that \"Cabita\" could be a new drug, a brand name, a regional name, or a misspelling of another medication. Here are a few steps you can take to gather more information:\n\n1. **Check Medical Databases**: Use resources like PubMed, Medline, or your institution's medical library to search for \"Cabita.\" These databases can provide peer-reviewed articles and clinical trial information.\n\n2. **Consult Pharmacists**: Pharmacists are often up-to-date with new medications and can provide detailed information about drug indications, mechanisms, and side effects.\n\n3. **Contact the Manufacturer**: If \"Cabita\" is a new or regional drug, contacting the pharmaceutical company that produces it can provide you with the most accurate and detailed information.\n\n4. **Professional Networks**: Utilize professional networks or forums to ask colleagues if they have"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_HWtQAwi2TKHRhvPVxu4gUSzh", "custom_id": "413_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "968ffdfa41da1731466b7630db988b12", "body": {"id": "chatcmpl-9St3p2ZouSbUBkeUhPKITwwZJj7WK", "object": "chat.completion", "created": 1716671865, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Biocarb is a brand name for the medication carboplatin, which is a chemotherapy drug used primarily in the treatment of various types of cancer, including ovarian, lung, head and neck, and testicular cancers. Here are some key points you should know about Biocarb (carboplatin):\n\n### Mechanism of Action\n- **Alkylating Agent**: Carboplatin works by binding to DNA and interfering with the cell's repair mechanism, leading to cell death. It forms cross-links within DNA strands, which inhibits DNA synthesis and function.\n\n### Indications\n- **Ovarian Cancer**: Often used as first-line treatment or in recurrent cases.\n- **Lung Cancer**: Used in combination with other chemotherapeutic agents.\n- **Head and Neck Cancer**: Sometimes used in combination with radiation therapy.\n- **Testicular Cancer**: Used in certain regimens for metastatic disease.\n\n### Administration\n- **Intravenous (IV) Infusion**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_PmZFVFKTOdAFZbChvdy3uv5v", "custom_id": "414_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "cd1c967c59e5db463badcfa339924792", "body": {"id": "chatcmpl-9St3pVDGHX4kTGr5rMbmLOTGMVMvq", "object": "chat.completion", "created": 1716671865, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or treatment known as \"Carfilnat.\" It's possible that there may be a typographical error, or it could be a new or less well-known drug that has emerged after my last update. \n\nHowever, if you meant \"Carfilzomib,\" here is some relevant information:\n\n### Carfilzomib Overview:\n- **Class**: Proteasome inhibitor\n- **Indications**: Primarily used in the treatment of multiple myeloma, particularly in patients who have received at least one prior therapy.\n- **Mechanism of Action**: Carfilzomib works by inhibiting the proteasome, a protein complex that degrades unneeded or damaged proteins. By blocking this process, it induces apoptosis (programmed cell death) in cancer cells.\n\n### Key Points for Physicians:\n1. **Administration**:\n   - Carfilzomib is administered intravenously.\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_4NNfx79rpoQcizfbwqIPNskL", "custom_id": "415_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d4c81dd4fd15e9bdc1c0b2afb18d7f69", "body": {"id": "chatcmpl-9St3pvOE7u9o2wdVpT7FFgf2hrqRm", "object": "chat.completion", "created": 1716671865, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Becenun is a brand name for the drug carmustine, which is a type of chemotherapy medication used primarily to treat certain types of cancer. Here are some key points you should know about Becenun (carmustine):\n\n### Indications:\n1. **Brain Tumors**: Including glioblastoma, medulloblastoma, astrocytoma, and ependymoma.\n2. **Multiple Myeloma**: Often used in combination with other drugs.\n3. **Hodgkin's Disease**: Typically used when the disease has not responded to other treatments.\n4. **Non-Hodgkin's Lymphoma**: Similar to Hodgkin's disease, used in refractory cases.\n\n### Mechanism of Action:\n- Carmustine is an alkylating agent that works by cross-linking DNA strands, thereby inhibiting DNA replication and RNA transcription, leading to cell death. It is particularly effective against rapidly dividing cells, such as cancer cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_NhpoCzx4LQz0vRd33eQcwAKt", "custom_id": "416_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "aa977db6f43665b20d9524e66bfe96f3", "body": {"id": "chatcmpl-9St3qDjczLG0Z5hXuREAiKYmlC9yb", "object": "chat.completion", "created": 1716671866, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Biodel was a biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Here are some key points you should know about Biodel:\n\n1. **Specialization**: Biodel specialized in developing novel formulations of insulin and other peptide hormones to improve the treatment of diabetes. Their primary focus was on creating faster-acting insulin formulations to better mimic the body's natural insulin response.\n\n2. **Lead Product**: One of Biodel's lead products was Linjeta\u2122 (formerly known as VIAject\u00ae), a rapid-acting injectable human insulin designed to provide better postprandial glucose control compared to traditional rapid-acting insulins.\n\n3. **Technology**: Biodel utilized proprietary formulation technologies to enhance the pharmacokinetic and pharmacodynamic profiles of insulin. This included the use of excipients that could accelerate the absorption of insulin into the bloodstream.\n\n4. **Clinical Trials**: Biodel conducted several clinical trials to evaluate the safety and efficacy of their insulin formulations. These"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_d3Z59HJ98kTrkHsBg4IH8Vmt", "custom_id": "417_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "184ce46df88f1837a58039389cbf1d66", "body": {"id": "chatcmpl-9St3qj3YHMLsAQJDLsGj0XFzpsKGa", "object": "chat.completion", "created": 1716671866, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Recentin, also known by its generic name cediranib, is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFRs). It is primarily used in oncology for its anti-angiogenic properties, which means it helps to inhibit the growth of new blood vessels that tumors need to grow and spread.\n\nHere are some key points you should know about Recentin:\n\n1. **Mechanism of Action**: Cediranib inhibits VEGFR-1, VEGFR-2, and VEGFR-3, which are involved in angiogenesis and lymphangiogenesis. By blocking these receptors, cediranib can reduce the blood supply to tumors, thereby inhibiting their growth.\n\n2. **Indications**: Cediranib has been investigated for use in various types of cancers, including ovarian cancer, colorectal cancer, and non-small cell lung cancer. However, its approval status may vary by country and specific indications.\n\n3. **Administration**: Cediranib is typically"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_vwMhDWfUyBKLur4Jrv2uahMI", "custom_id": "418_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "18899e66973f409f9cf32ddecc522b8f", "body": {"id": "chatcmpl-9St3rU4BROq5GLO4TFWCLOUj4vUsM", "object": "chat.completion", "created": 1716671867, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Libtayo (cemiplimab-rwlc) is a monoclonal antibody that targets the programmed death receptor-1 (PD-1) pathway, which is involved in the immune system's ability to recognize and attack cancer cells. Here are some key points you should know about Libtayo:\n\n### Indications:\n1. **Cutaneous Squamous Cell Carcinoma (CSCC):**\n   - Libtayo is approved for the treatment of patients with metastatic or locally advanced CSCC who are not candidates for curative surgery or curative radiation.\n\n2. **Basal Cell Carcinoma (BCC):**\n   - It is indicated for patients with locally advanced BCC previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate.\n   - It is also indicated for patients with metastatic BCC previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate.\n\n3. **Non-S"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_oIzDnhLwWwHgbLsmXjAogBz9", "custom_id": "419_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9ab02f2a31fc45e622cba1166ea012a7", "body": {"id": "chatcmpl-9St3sNDf8H5HYBM4sPig1wCEtkbST", "object": "chat.completion", "created": 1716671868, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a typo in your question. If you meant \"Lucifer,\" it is important to clarify that Lucifer is a figure from religious and mythological contexts, often associated with the devil or Satan in Christian theology. This figure is not directly relevant to medical practice or clinical knowledge.\n\nHowever, if you meant something else, such as a specific medical term, condition, or a different context, please provide more details so I can give you the most accurate and helpful information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 98, "total_tokens": 138}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_7iNP6ltRMIdbKuQ448luAO1h", "custom_id": "420_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e69271ea35e8dc98a0201b366c3f78cf", "body": {"id": "chatcmpl-9St3sbMIIIYEEG3Iss4svvJTRcqMG", "object": "chat.completion", "created": 1716671868, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cetuxim is not a recognized medication name, but it is possible that you are referring to Cetuximab, a chimeric monoclonal antibody used in cancer treatment. Here are some key points you should know about Cetuximab:\n\n### Indications:\n1. **Colorectal Cancer**: Cetuximab is used for the treatment of metastatic colorectal cancer, particularly in patients whose tumors express the epidermal growth factor receptor (EGFR) and who do not have mutations in the KRAS gene.\n2. **Head and Neck Cancer**: It is also used in the treatment of squamous cell carcinoma of the head and neck, either in combination with radiation therapy or as a single agent in patients who have failed prior platinum-based therapy.\n\n### Mechanism of Action:\n- Cetuximab targets the EGFR, which is overexpressed in many cancers. By binding to the EGFR, it inhibits the receptor's activation and downstream signaling pathways, leading to reduced"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Sl7dxDklUn7XCCykeaIysLr7", "custom_id": "421_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "4cef6f296946f20a3cc504c19bea385e", "body": {"id": "chatcmpl-9St3tWApDET8uQojVgxPd7DxpGbN3", "object": "chat.completion", "created": 1716671869, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Epidaza, also known by its generic name belinostat, is a histone deacetylase (HDAC) inhibitor used in the treatment of certain types of cancer. Here are some key points you should know about Epidaza:\n\n1. **Indications**: Epidaza is primarily indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). It may be used in patients who have not responded to other treatments.\n\n2. **Mechanism of Action**: Belinostat works by inhibiting histone deacetylases, which leads to an accumulation of acetylated histones and other proteins. This can result in the activation of tumor suppressor genes, cell cycle arrest, and apoptosis (programmed cell death) of cancer cells.\n\n3. **Administration**: Epidaza is administered intravenously. The typical dosage regimen involves a 30-minute infusion once daily on days 1-5 of a 21-day cycle. The exact dosage and schedule"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_yv7vRd3bdQ71pliaoPT9pMDj", "custom_id": "422_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0c2b0bd3169cee7fe07f30883cdcb007", "body": {"id": "chatcmpl-9St3uaWJkQSDg8m1qwVhsd94dBfSE", "object": "chat.completion", "created": 1716671870, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Chlorambucil is an alkylating agent used primarily in the treatment of certain types of cancer. Here are some key points you should know about Chlorambucil:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL)**: Chlorambucil is often used as a first-line treatment.\n2. **Non-Hodgkin's Lymphoma**: It can be used in the treatment of indolent forms of this disease.\n3. **Hodgkin's Disease**: Occasionally used in certain cases.\n4. **Waldenstr\u00f6m's Macroglobulinemia**: It may be used in the management of this condition.\n5. **Other Conditions**: Sometimes used off-label for other conditions like autoimmune diseases, though this is less common.\n\n### Mechanism of Action:\n- Chlorambucil works by cross-linking DNA strands, which inhibits DNA replication and RNA transcription, leading to cell death. It is most"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_3AhutGmon6z0PpkMsdzml7aK", "custom_id": "423_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e2e587ba31aa4b53819b33ce99354567", "body": {"id": "chatcmpl-9St3uEfgGF86eP1i56hGrLoJpG5bi", "object": "chat.completion", "created": 1716671870, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or compound known as \"Abiplatin.\" It's possible that you might be referring to a typographical error or a less common name for a drug. However, if you meant a platinum-based chemotherapy drug, you might be thinking of cisplatin, carboplatin, or oxaliplatin, which are well-known in oncology.\n\nHere are some key points about these platinum-based chemotherapy agents:\n\n### Cisplatin\n- **Mechanism of Action**: Forms DNA crosslinks, inhibiting DNA synthesis and function, leading to cell death.\n- **Indications**: Used in various cancers, including testicular, ovarian, bladder, and lung cancers.\n- **Side Effects**: Nephrotoxicity, ototoxicity, neurotoxicity, nausea, vomiting, and myelosuppression.\n- **Monitoring**: Renal function, electrolytes, and audiometry.\n\n### Carboplatin\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_E9q1qKKcjeAdPm3yqnhkGkyi", "custom_id": "424_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ce0ae9092e6d9a71dfe26bb2530cd3e4", "body": {"id": "chatcmpl-9St3u1GeIXvhBdW85DBsUikjCZiVT", "object": "chat.completion", "created": 1716671870, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Leustatin, also known by its generic name cladribine, is a chemotherapeutic agent used primarily in the treatment of certain types of hematologic cancers. Here are some key points you should know about Leustatin:\n\n### Indications:\n1. **Hairy Cell Leukemia (HCL):** Leustatin is FDA-approved for the treatment of HCL.\n2. **Chronic Lymphocytic Leukemia (CLL):** It is sometimes used off-label for CLL.\n3. **Other Hematologic Malignancies:** It may also be used in other conditions like non-Hodgkin's lymphoma and multiple sclerosis, although these uses are less common and may be off-label.\n\n### Mechanism of Action:\n- Cladribine is a purine nucleoside analog. It gets incorporated into DNA, leading to DNA strand breaks and inhibition of DNA synthesis, which ultimately results in cell death. It is particularly effective against lymphocytes.\n\n### Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_jAgcf9VGNPExOa3e6p40T51I", "custom_id": "425_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d89681acf27e34338070ca1ebc583ad5", "body": {"id": "chatcmpl-9St3u8CWwntDg9xDCXCBofAsnIv5P", "object": "chat.completion", "created": 1716671870, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Biaxin, also known by its generic name clarithromycin, is a macrolide antibiotic used to treat various bacterial infections. Here are some key points you should know about Biaxin:\n\n### Indications:\n1. **Respiratory Tract Infections**: Such as bronchitis, pneumonia, and sinusitis.\n2. **Skin Infections**: Including cellulitis and impetigo.\n3. **Helicobacter pylori Infection**: Often used in combination with other medications for the treatment of H. pylori-associated peptic ulcer disease.\n4. **Mycobacterial Infections**: Including Mycobacterium avium complex (MAC) in patients with HIV.\n\n### Mechanism of Action:\n- Biaxin works by inhibiting bacterial protein synthesis. It binds to the 50S ribosomal subunit, thereby preventing the translocation of peptides.\n\n### Dosage and Administration:\n- The dosage varies depending on the type and severity of the infection,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_XwKcGptWBvUKs7fXpo4e2cFU", "custom_id": "426_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "97da76b983ca6e9a28cab0d1b1b456bb", "body": {"id": "chatcmpl-9St3uVLpCm5fRcpTJYLfc3OjWvMq5", "object": "chat.completion", "created": 1716671870, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Clolar, also known by its generic name clofarabine, is a chemotherapeutic agent used primarily in the treatment of certain types of leukemia. Here are some key points you should know about Clolar:\n\n### Indications:\n- **Acute Lymphoblastic Leukemia (ALL):** Clolar is approved for use in pediatric patients (1 to 21 years old) with relapsed or refractory ALL after at least two prior regimens.\n- **Other Uses:** It may also be used off-label for other hematologic malignancies, but this should be based on clinical judgment and emerging evidence.\n\n### Mechanism of Action:\n- Clolar is a purine nucleoside analog. It inhibits DNA synthesis by incorporating into DNA and inhibiting ribonucleotide reductase, leading to apoptosis of rapidly dividing cells.\n\n### Administration:\n- **Route:** Intravenous infusion.\n- **Dosage:** Typically, the recommended dose is 52 mg/m\u00b2 administered over 2 hours daily"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_7uwBkJnk0zYQT7LVfje8MoCY", "custom_id": "427_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e63b7448f215f56e77a0851a8bb992c3", "body": {"id": "chatcmpl-9St3umeLOGglmlLHGaeZxlnU8GpTD", "object": "chat.completion", "created": 1716671870, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cotellic (generic name: cobimetinib) is a medication used in combination with vemurafenib (Zelboraf) for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Here are some key points you should know about Cotellic:\n\n### Mechanism of Action\n- **Cotellic** is a selective inhibitor of MEK1 and MEK2, which are part of the MAPK/ERK pathway. This pathway is often activated in cancers with BRAF mutations, leading to uncontrolled cell growth.\n\n### Indications\n- **Cotellic** is indicated for use in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.\n\n### Dosage and Administration\n- The recommended dose of Cotellic is 60 mg (three 20 mg tablets"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_igg7XMjHyNtepVEmJmALvfdd", "custom_id": "428_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2fe8612d336bc0a8c60de2c19c05d890", "body": {"id": "chatcmpl-9St3vQbXjj8syrOiH77O4OrOaxykM", "object": "chat.completion", "created": 1716671871, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aliqopa (copanlisib) is a medication used in the treatment of certain types of cancer, specifically relapsed follicular lymphoma in adults who have received at least two prior systemic therapies. Here are some key points you should know about Aliqopa:\n\n### Mechanism of Action\n- **Class**: Aliqopa is a kinase inhibitor.\n- **Target**: It inhibits phosphatidylinositol-3-kinase (PI3K), particularly the PI3K-alpha and PI3K-delta isoforms, which are involved in the growth and survival of malignant B cells.\n\n### Indications\n- **Primary Use**: It is indicated for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies.\n\n### Administration\n- **Form**: Aliqopa is administered as an intravenous infusion.\n- **Dosage**: The recommended dose is 60 mg administered as a 1-hour intravenous infusion on days 1"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_DvK6X9rU8zzObaaYwl19SzUI", "custom_id": "429_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ad68e1c6fd8bcf3a26fc0de2412718e3", "body": {"id": "chatcmpl-9St3vKIwBcBsaeLnIHczgMRT7DamZ", "object": "chat.completion", "created": 1716671871, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Crizalk, also known by its generic name crizotinib, is a medication used primarily in the treatment of certain types of cancer. Here are some key points you should know about Crizalk:\n\n### Indications:\n1. **Non-Small Cell Lung Cancer (NSCLC):** Crizalk is primarily indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive or ROS1-positive, as detected by an FDA-approved test.\n\n### Mechanism of Action:\n- **Tyrosine Kinase Inhibitor:** Crizalk works by inhibiting the activity of ALK, ROS1, and MET tyrosine kinases. These kinases are involved in the proliferation and survival of cancer cells. By inhibiting these kinases, crizotinib can reduce tumor growth and spread.\n\n### Administration:\n- **Oral Medication:** Crizalk is administered orally, typically in capsule form"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_23NfQyYAMmEbd4trXuBEIItb", "custom_id": "430_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b784bc58b2e697d7c7d7e162e863d05b", "body": {"id": "chatcmpl-9St3wQOyefDHSsY7MOJt5ezWP9Mhq", "object": "chat.completion", "created": 1716671872, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alkyloxan is a trade name for cyclophosphamide, a chemotherapeutic and immunosuppressive agent. Here are some key points you should know about it:\n\n### Mechanism of Action:\n- **Alkylating Agent**: Cyclophosphamide works by cross-linking DNA strands, which inhibits DNA replication and RNA transcription, leading to cell death. It is most effective against rapidly dividing cells.\n\n### Indications:\n- **Cancer Treatment**: Used in various cancers, including lymphomas, leukemias, breast cancer, ovarian cancer, and multiple myeloma.\n- **Autoimmune Diseases**: Employed in the treatment of autoimmune conditions like systemic lupus erythematosus, rheumatoid arthritis, and vasculitis.\n\n### Administration:\n- **Routes**: Can be administered orally or intravenously.\n- **Dosing**: Dosage varies based on the condition being treated, patient weight, and response to therapy. It often requires careful calculation and adjustment.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_5rLCRfiR9mlrFpv4R9QWGQL7", "custom_id": "431_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d706439575eb1ea68172615eee5404b6", "body": {"id": "chatcmpl-9St3wGkamfBZmMbaKFxeylaZsEb4V", "object": "chat.completion", "created": 1716671872, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Androcur, also known by its generic name cyproterone acetate, is a medication with anti-androgenic properties. It is primarily used in the treatment of conditions related to androgen excess. Here are some key points you should know about Androcur:\n\n### Indications:\n1. **Prostate Cancer**: Androcur is often used in the treatment of advanced prostate cancer due to its ability to block androgen receptors and reduce the effects of testosterone.\n2. **Hirsutism and Acne in Women**: It can be prescribed for women with severe hirsutism (excessive hair growth) and acne, often in combination with oral contraceptives.\n3. **Transgender Hormone Therapy**: Androcur is sometimes used in transgender women (male-to-female) to reduce masculinizing effects by blocking testosterone.\n4. **Sexual Deviations in Men**: It may be used to reduce sexual drive in men with severe sexual deviations.\n\n### Mechanism"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_juldiHkT1dfGy59ba57JZlJp", "custom_id": "432_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "21697dc5757fb65fc77bf428ebd62cfb", "body": {"id": "chatcmpl-9St3x4Rq7Aqj8M1Pxk3SURD51vYlQ", "object": "chat.completion", "created": 1716671873, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or treatment known as \"Alcysten.\" It is possible that it could be a new or emerging drug, a brand name not widely known, or a misspelling of another medication. Here are a few steps you can take to gather more information:\n\n1. **Check Medical Databases**: Use resources like PubMed, Medline, or other medical literature databases to search for any studies or articles related to \"Alcysten.\"\n\n2. **Consult Pharmacists**: Pharmacists often have access to comprehensive drug databases and might be able to provide more information about the medication.\n\n3. **Contact the Manufacturer**: If you have any packaging or documentation, contact the manufacturer directly for detailed information about the drug.\n\n4. **Professional Networks**: Utilize professional networks or forums to ask colleagues if they have encountered this medication.\n\n5. **Regulatory Agencies**: Check with regulatory agencies like the FDA"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_nUd5x2Z2j99Ac35PFtNmVruA", "custom_id": "433_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "28fb2ca0ac95c6972cf8db69ffeb0cfd", "body": {"id": "chatcmpl-9St3x4VqcgutQsj7hTqdAXV8YejGy", "object": "chat.completion", "created": 1716671873, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vyxeos (daunorubicin and cytarabine) is a liposomal formulation used for the treatment of certain types of acute myeloid leukemia (AML). Here are some key points you should know about Vyxeos:\n\n### Indications:\n- **Vyxeos is indicated for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).**\n\n### Mechanism of Action:\n- **Vyxeos combines two chemotherapeutic agents, daunorubicin and cytarabine, in a fixed 1:5 molar ratio encapsulated in liposomes.**\n- **Daunorubicin intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis.**\n- **Cytarabine is a nucleoside analog that inhibits DNA polymerase, impairing DNA synthesis and repair.**\n\n### Administration:\n- **Vyxeos is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_TbGC44ZCsKEvsuDB9s3aL6mt", "custom_id": "434_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "bb82f061d737f4776d90045ffe5d022b", "body": {"id": "chatcmpl-9St3yGGtcOaWuFGbjDIq1ZoU8Bbd8", "object": "chat.completion", "created": 1716671874, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rafinlar, also known by its generic name dabrafenib, is a medication used primarily in the treatment of certain types of cancer. Here are some key points you should know about Rafinlar:\n\n### Indications:\n1. **Melanoma**: Rafinlar is used to treat patients with unresectable or metastatic melanoma with a BRAF V600E mutation.\n2. **Non-Small Cell Lung Cancer (NSCLC)**: It is also indicated for the treatment of patients with metastatic NSCLC with a BRAF V600E mutation.\n3. **Anaplastic Thyroid Cancer (ATC)**: Rafinlar, in combination with trametinib, is used for the treatment of patients with locally advanced or metastatic ATC with a BRAF V600E mutation.\n\n### Mechanism of Action:\n- Rafinlar is a kinase inhibitor that targets the BRAF V600E mutation, which is a specific genetic alteration found in some cancer cells. By inhib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_KxbfbKLJIbb3ZSxQtEBfj9oU", "custom_id": "435_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "12d57344d16ad4f55eb9df13a87e7edf", "body": {"id": "chatcmpl-9St3ySOhz2wFcU0HK2e13bGagHxTH", "object": "chat.completion", "created": 1716671874, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2021, there is no widely recognized medication or treatment known as \"Bazipar.\" It is possible that you may be referring to a new or emerging drug, a brand name that is not widely known, or there may be a typographical error in the name.\n\nIf \"Bazipar\" is a new or emerging treatment, here are some general steps you can take to stay informed:\n\n1. **Consult Reliable Sources**: Check reputable medical databases such as PubMed, clinical trial registries, or pharmaceutical company announcements for any information on new drugs or treatments.\n\n2. **Medical Journals**: Review recent issues of leading medical journals, as they often publish studies and reviews on new medications and treatments.\n\n3. **Professional Networks**: Engage with professional networks and societies relevant to your specialty. They often provide updates on new treatments and guidelines.\n\n4. **Continuing Medical Education (CME)**: Participate in CME activities, conferences, and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_jDyzlA9gdk7LDxAViN7pha41", "custom_id": "436_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2e2a6e2c87a2a75d1100c740aca902d2", "body": {"id": "chatcmpl-9St3y1xRJAmggP7tOEuFFZPO2LCu2", "object": "chat.completion", "created": 1716671874, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vizimpro (dacomitinib) is a medication used in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about Vizimpro:\n\n### Indications:\n- **Non-Small Cell Lung Cancer (NSCLC):** Vizimpro is indicated for the first-line treatment of patients with metastatic NSCLC with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test.\n\n### Mechanism of Action:\n- **EGFR Inhibition:** Vizimpro is a tyrosine kinase inhibitor that irreversibly binds to and inhibits the activity of EGFR, which is often overexpressed or mutated in NSCLC. By inhibiting EGFR, Vizimpro can help to slow or stop the growth of cancer cells.\n\n### Dosage and Administration:\n- **Recommended Dose:** The recommended dose of Vizimpro is 45 mg taken orally once daily"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_AskZ6lWIrCRTNqKXIgK6pbIi", "custom_id": "437_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "095f37aa08ed5ce09f11bfee8aab3eb8", "body": {"id": "chatcmpl-9St3yGWeaqzMGxbSfwWNybfnyBaI4", "object": "chat.completion", "created": 1716671874, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cosmegen, also known by its generic name dactinomycin, is a chemotherapy medication used primarily in the treatment of various types of cancer. Here are some key points you should know about Cosmegen:\n\n### Indications:\n1. **Wilms' Tumor**: Often used in combination with other chemotherapy agents.\n2. **Rhabdomyosarcoma**: Commonly used in pediatric patients.\n3. **Ewing's Sarcoma**: Part of multi-agent chemotherapy regimens.\n4. **Gestational Trophoblastic Neoplasia**: Used in certain cases.\n5. **Testicular Cancer**: Sometimes used in combination with other drugs.\n\n### Mechanism of Action:\n- **Antineoplastic Antibiotic**: Dactinomycin intercalates into DNA, inhibiting RNA synthesis and thereby preventing protein synthesis and cell replication. This leads to cell death, particularly in rapidly dividing cells.\n\n### Administration:\n- **Intravenous (IV) Injection**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_u9ts74vsETaZb5NP5Mdrp5oK", "custom_id": "438_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a9d6c810594a21a1d0b8216b2e76b1da", "body": {"id": "chatcmpl-9St3zoNpbS7SUGzGV2ZrGXZYKSOmP", "object": "chat.completion", "created": 1716671875, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Danatrol, also known by its generic name danazol, is a synthetic androgen and anabolic steroid that is used primarily in the treatment of endometriosis, fibrocystic breast disease, and hereditary angioedema. Here are some key points you should know about Danatrol:\n\n### Indications:\n1. **Endometriosis**: Danazol helps to reduce the symptoms of endometriosis by suppressing the pituitary-ovarian axis, leading to decreased estrogen production.\n2. **Fibrocystic Breast Disease**: It can alleviate the pain and nodularity associated with this condition.\n3. **Hereditary Angioedema**: Danazol is used to prevent attacks of angioedema by increasing the levels of C1 inhibitor.\n\n### Mechanism of Action:\n- Danazol works by inhibiting the release of gonadotropins (LH and FSH) from the pituitary gland, which in turn reduces the production of sex hormones (estrogen and progester"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_sQn0R8Qqu4w5MtpkPWQU1y3K", "custom_id": "439_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "beace3815d9e8208156200d8d5f56076", "body": {"id": "chatcmpl-9St3zwlubHFN2othMB7TN9ZHYDTg5", "object": "chat.completion", "created": 1716671875, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Darzalex (generic name: daratumumab) is a monoclonal antibody used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Here are some key points you should know about Darzalex:\n\n### Mechanism of Action\n- **Target**: Daratumumab targets CD38, a protein that is highly expressed on the surface of multiple myeloma cells.\n- **Action**: It works by binding to CD38, leading to the destruction of cancer cells through multiple mechanisms, including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and antibody-dependent cellular phagocytosis.\n\n### Indications\n- **Monotherapy**: For patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.\n- **Combination Therapy**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_bR33tqC15kOJktcaLKKJuIn7", "custom_id": "440_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a8373b9ef3695f304efa726d6b25b441", "body": {"id": "chatcmpl-9St3za2LRacxpOKlzWTfCDOFldBLp", "object": "chat.completion", "created": 1716671875, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nubeqa (darolutamide) is a medication used in the treatment of prostate cancer. Here are some key points you should know about it:\n\n1. **Indication**: Nubeqa is primarily indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). It is used in combination with androgen deprivation therapy (ADT).\n\n2. **Mechanism of Action**: Darolutamide is a non-steroidal androgen receptor inhibitor. It works by binding to androgen receptors and inhibiting the action of androgens (male hormones), which can promote the growth of prostate cancer cells.\n\n3. **Dosage and Administration**: The recommended dose of Nubeqa is 600 mg (two 300 mg tablets) taken orally twice daily, with food. It is important to maintain consistent levels of the drug in the body, so adherence to the dosing schedule is crucial.\n\n4. **Side Effects**: Common side effects include fatigue, pain in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ZiiBKlWyxTBNbgMQNl6mn3st", "custom_id": "441_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "bb972c4f95f17313d6812588eed016fb", "body": {"id": "chatcmpl-9St40wxnUf6wRolhjybezYMDon9jY", "object": "chat.completion", "created": 1716671876, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sprycel (dasatinib) is a medication used primarily in the treatment of certain types of leukemia, specifically chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Here are some key points you should know about Sprycel:\n\n### Mechanism of Action\n- **Tyrosine Kinase Inhibitor (TKI):** Sprycel works by inhibiting the activity of BCR-ABL, a tyrosine kinase produced by the Philadelphia chromosome abnormality. This inhibition helps to prevent the proliferation of leukemic cells.\n\n### Indications\n- **Chronic Myeloid Leukemia (CML):** Sprycel is indicated for the treatment of adults with newly diagnosed Philadelphia chromosome-positive (Ph+) CML in chronic phase.\n- **Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL):** It is also used for the treatment of adults with Ph+ ALL who are resistant or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_PP1DeA1aPrEigcT14LcPAXaq", "custom_id": "442_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2a692ebc3e5ddf2843318d75862e24de", "body": {"id": "chatcmpl-9St40wEXQ68MSyQ6Msn8KWwUUrHzT", "object": "chat.completion", "created": 1716671876, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cerubidin, also known by its generic name daunorubicin, is an anthracycline antibiotic commonly used in the treatment of certain types of cancer, particularly acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Here are some key points you should know about Cerubidin:\n\n### Mechanism of Action\n- **DNA Intercalation**: Daunorubicin intercalates into DNA, disrupting the DNA structure and inhibiting the synthesis of nucleic acids.\n- **Topoisomerase II Inhibition**: It inhibits the enzyme topoisomerase II, which is essential for DNA replication and repair, leading to DNA strand breaks.\n- **Free Radical Formation**: The drug generates free radicals that cause additional damage to cellular components, including DNA and cell membranes.\n\n### Indications\n- **Acute Myeloid Leukemia (AML)**: Often used in combination with other chemotherapeutic agents.\n- **Acute Lymphobl"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_dz31iIyddyqF5th0pOOmNfsa", "custom_id": "443_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "4bc1f4e808052ceb97f35273af3f9120", "body": {"id": "chatcmpl-9St41E6yy8LkTXUZ76dcBMFau5MIC", "object": "chat.completion", "created": 1716671877, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "DaunoXome is a liposomal formulation of the chemotherapeutic agent daunorubicin, which is used primarily in the treatment of certain types of cancer. Here are some key points you should know about DaunoXome:\n\n### Indications\n- **Kaposi's Sarcoma**: DaunoXome is primarily indicated for the treatment of advanced HIV-associated Kaposi's sarcoma.\n- **Other Uses**: It may also be used off-label for other types of cancer, but this should be based on clinical judgment and available evidence.\n\n### Mechanism of Action\n- **Daunorubicin**: Daunorubicin is an anthracycline antibiotic that intercalates DNA, inhibiting the synthesis of nucleic acids and leading to cell death.\n- **Liposomal Formulation**: The liposomal encapsulation helps to improve the drug's pharmacokinetics, increasing its half-life and reducing its toxicity by targeting the drug more specifically to cancer cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_HjBc57dSTTEgTwL30Sv7ZVFg", "custom_id": "444_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "509c02c4d0c1e7f14d44cd97fc0a5301", "body": {"id": "chatcmpl-9St41RUvGYXAKZfkFdTUNTEs3EM9C", "object": "chat.completion", "created": 1716671877, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dacogen, also known by its generic name decitabine, is a medication used primarily in the treatment of myelodysplastic syndromes (MDS). Here are some key points you should know about Dacogen:\n\n### Indications:\n- **Myelodysplastic Syndromes (MDS):** Dacogen is approved for the treatment of patients with MDS, including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System (IPSS) groups.\n\n### Mechanism of Action:\n- **Hypomethylating Agent:** Decitabine is a nucleoside analog that incorporates into DNA and inhibits DNA methyltransferase, leading to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_d27dM59XsUHg0hownLGpdi9G", "custom_id": "445_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b6dd74bbe272a4b346f17c69a00e7917", "body": {"id": "chatcmpl-9St41HdNetBi4j0PotSTtQZCf6UWm", "object": "chat.completion", "created": 1716671877, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Firmagon, also known by its generic name degarelix, is a medication used primarily in the treatment of advanced prostate cancer. Here are some key points you should know about Firmagon:\n\n### Mechanism of Action\n- **GnRH Antagonist**: Firmagon is a gonadotropin-releasing hormone (GnRH) antagonist. It works by directly inhibiting the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, which in turn reduces the production of testosterone by the testes. Lowering testosterone levels helps to slow the growth of prostate cancer cells.\n\n### Indications\n- **Advanced Prostate Cancer**: Firmagon is indicated for the treatment of patients with advanced prostate cancer. It is particularly useful in cases where reducing testosterone levels is a key part of the treatment strategy.\n\n### Administration\n- **Subcutaneous Injection**: Firmagon is administered as a subcutaneous injection. The initial dose is typically higher"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_MontViYQL8dsNdsidDMB2VwT", "custom_id": "446_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "94957c78aeec9723644059e1293b5398", "body": {"id": "chatcmpl-9St424cmsyzp6Ls2SxwjsjuyeIaKN", "object": "chat.completion", "created": 1716671878, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ontak (denileukin diftitox) is a fusion protein used in the treatment of certain types of cancer, specifically cutaneous T-cell lymphoma (CTCL) that expresses the CD25 component of the IL-2 receptor. Here are some key points you should know about Ontak:\n\n### Mechanism of Action\n- **Fusion Protein**: Ontak is a recombinant fusion protein combining interleukin-2 (IL-2) with diphtheria toxin. \n- **Target**: It targets cells expressing the IL-2 receptor, which is often overexpressed in certain malignancies like CTCL.\n- **Action**: Once bound to the IL-2 receptor, the diphtheria toxin component inhibits protein synthesis, leading to cell death.\n\n### Indications\n- **Primary Use**: Ontak is primarily indicated for the treatment of persistent or recurrent CTCL.\n- **Other Uses**: It may be used off-label for other malignancies expressing the IL"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_CPfi9OxnzFHAAzc1WzpJqxV9", "custom_id": "447_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2f5e9fec4511235645758483c1c9aa4d", "body": {"id": "chatcmpl-9St429UShGtLEakvaDbPHhmBz3jDp", "object": "chat.completion", "created": 1716671878, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prolia (denosumab) is a medication used primarily to treat osteoporosis in postmenopausal women and men at high risk for fractures. It is also used to treat bone loss in patients undergoing certain types of cancer treatment. Here are some key points you should know about Prolia:\n\n### Mechanism of Action\n- **Denosumab**: Prolia is a monoclonal antibody that works by inhibiting RANKL (Receptor Activator of Nuclear factor Kappa-\u0392 Ligand), a protein involved in the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. By inhibiting RANKL, Prolia decreases bone resorption and increases bone mass and strength.\n\n### Indications\n- **Osteoporosis**: Approved for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture.\n- **Bone Loss**: Used to treat bone loss in patients receiving hormone ablation therapy for prostate or breast"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_QRgt38xy8ehQOYBNkP9SISbP", "custom_id": "448_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "64571cf1725e7b2428e401f2a8273180", "body": {"id": "chatcmpl-9St43jbGPTVQMYa2FtRRYBVZ7tRNl", "object": "chat.completion", "created": 1716671879, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2021, there is no widely recognized medication or substance known as \"Aacidexam.\" It is possible that there may be a typographical error or a misunderstanding in the name provided. \n\nIf you meant a different medication or substance, please provide additional context or check the spelling. If \"Aacidexam\" is a new or emerging medication or treatment that has been introduced after my knowledge cutoff date, I would recommend consulting the latest medical literature, clinical guidelines, or trusted medical databases for the most current and accurate information.\n\nAs a physician, staying updated with the latest medical advancements and drug information is crucial. Utilizing resources such as peer-reviewed journals, professional medical associations, and continuing medical education (CME) programs can help ensure you have the most up-to-date knowledge in your field."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 166, "total_tokens": 207}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_abyYTD4XnmNjgfsBRmUvWLAj", "custom_id": "449_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "13debbafdd6cbaa3a3e9ebab48b7d655", "body": {"id": "chatcmpl-9St43OP7xr6yjl2K7xh1kMVABzlQy", "object": "chat.completion", "created": 1716671879, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cardioxane, also known by its generic name dexrazoxane, is a cardioprotective agent primarily used to reduce the risk of cardiotoxicity associated with certain chemotherapy drugs, particularly anthracyclines like doxorubicin. Here are some key points you should know about Cardioxane:\n\n### Indications:\n1. **Cardioprotection**: It is used to protect the heart from the damaging effects of anthracycline chemotherapy, which can lead to cardiomyopathy and congestive heart failure.\n2. **Extravasation Treatment**: Dexrazoxane is also used to treat extravasation (leakage) of anthracycline chemotherapy drugs into surrounding tissues, which can cause severe local tissue damage.\n\n### Mechanism of Action:\n- **Chelation**: Dexrazoxane works by chelating iron, which is involved in the formation of free radicals that cause oxidative damage to cardiac cells.\n- **Topoisomerase II In"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_yzxvZND7BZdIXVp5bEpdx6Bl", "custom_id": "450_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1654580653076bc7f054c0029ea4cef3", "body": {"id": "chatcmpl-9St446PMdvrrHqhsRJBd0aG4CYzCm", "object": "chat.completion", "created": 1716671880, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or medical product known as \"Desplex.\" It is possible that it could be a new or less common drug, a brand name not widely recognized, or a misspelling of another medication. Here are a few steps you can take to gather more information:\n\n1. **Check Medical Databases:** Use resources like PubMed, UpToDate, or your institution's drug database to search for \"Desplex\" or similar terms.\n\n2. **Consult Colleagues:** Ask other healthcare professionals if they are familiar with the term or if it might be known under a different name.\n\n3. **Pharmaceutical Reps:** Contact pharmaceutical representatives or companies for more information if you suspect it might be a new or region-specific product.\n\n4. **Patient History:** If a patient mentions \"Desplex,\" ask for more details such as the prescribing physician, the condition it is being used to treat, and any packaging or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_lXfVGi7Ijzr0ywEheJXrkpkE", "custom_id": "451_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c7d4acf900568a201d473458d7732ecb", "body": {"id": "chatcmpl-9St44K99R89DpWLiVYWFfvRow1shl", "object": "chat.completion", "created": 1716671880, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Unituxin (dinutuximab) is a monoclonal antibody used primarily in the treatment of high-risk neuroblastoma, a type of cancer that most commonly affects children. Here are some key points you should know about Unituxin:\n\n### Indications:\n- **High-Risk Neuroblastoma**: Unituxin is indicated for use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA) for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.\n\n### Mechanism of Action:\n- **Targeting GD2**: Unituxin targets the disialoganglioside GD2, which is expressed on the surface of neuroblastoma cells and other cells of neuroectodermal origin. By binding to GD2, Unit"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_YbX600NmVXhE2LHIwn11dkf2", "custom_id": "452_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a877ce622e01b5d758e6706cfc97c7eb", "body": {"id": "chatcmpl-9St44OhqfxGUTimKJKCtFPhFgK478", "object": "chat.completion", "created": 1716671880, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2021, there is no widely recognized medication or treatment known as \"Asodocel.\" It is possible that the name could be a typographical error, a brand name not widely recognized, or a very recent development in the medical field that has emerged after my last update.\n\nIf \"Asodocel\" is a new or emerging treatment, I would recommend the following steps to stay informed:\n\n1. **Consult Medical Literature**: Check recent medical journals, clinical trial databases, and other reputable sources for any new publications or studies involving \"Asodocel.\"\n\n2. **Professional Networks**: Engage with professional networks, such as medical associations, conferences, and seminars, to gather information from colleagues and experts who might be familiar with the latest developments.\n\n3. **Pharmaceutical Reps**: Contact pharmaceutical representatives or the company that manufactures \"Asodocel\" for detailed information, including indications, mechanism of action, clinical trial results, side"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Q6HFIqXEDQlqSOCLGVyiS4Zt", "custom_id": "453_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "687a79cf1dee77885353c21b247b684a", "body": {"id": "chatcmpl-9St45Gfq32meWXy7XP9nNPRIWlEff", "object": "chat.completion", "created": 1716671881, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Didox (also known as 3,4-dihydroxybenzohydroxamic acid) is a ribonucleotide reductase inhibitor that has been studied for its potential use in cancer therapy. Here are some key points you should know about Didox:\n\n1. **Mechanism of Action**: Didox inhibits ribonucleotide reductase, an enzyme crucial for DNA synthesis and repair. By inhibiting this enzyme, Didox can potentially slow down or stop the proliferation of cancer cells.\n\n2. **Therapeutic Potential**: Didox has been investigated for its potential use in treating various types of cancer, including leukemia, lymphoma, and solid tumors. It may be used alone or in combination with other chemotherapeutic agents to enhance efficacy.\n\n3. **Clinical Trials**: While preclinical studies have shown promise, the clinical efficacy and safety of Didox are still under investigation. It is important to stay updated on the latest clinical trial results to understand its potential role in cancer therapy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_bGViStdZLwkPVJLWHc47sida", "custom_id": "454_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b1ae5faf11883968130be956010931d7", "body": {"id": "chatcmpl-9St45uIOejpRRrPsqzLp1SEP2qegx", "object": "chat.completion", "created": 1716671881, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adriablastina is a trade name for the chemotherapeutic agent doxorubicin, which is an anthracycline antibiotic commonly used in cancer treatment. Here are some key points you should know about Adriablastina (doxorubicin):\n\n### Mechanism of Action:\n- **DNA Intercalation:** Doxorubicin intercalates between DNA base pairs, disrupting DNA replication and transcription.\n- **Topoisomerase II Inhibition:** It inhibits the enzyme topoisomerase II, preventing the relaxation of supercoiled DNA, which is necessary for replication and transcription.\n- **Free Radical Formation:** Doxorubicin generates free radicals, leading to oxidative damage to cellular components, including DNA, proteins, and lipids.\n\n### Indications:\n- **Breast Cancer**\n- **Lymphomas (Hodgkin's and non-Hodgkin's)**\n- **Leukemias**\n- **Sarcomas (including oste"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_wXLf1oGhRlNmvqhiBbZoRAbk", "custom_id": "455_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6f67122812f16e9e8a4ec1ac6ec75be3", "body": {"id": "chatcmpl-9St45abFHCCdakySqkUe8gs4Z4sXj", "object": "chat.completion", "created": 1716671881, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imfinzi (durvalumab) is a human monoclonal antibody that targets PD-L1 (programmed death-ligand 1). It is used in oncology, particularly for certain types of cancer. Here are some key points you should know about Imfinzi:\n\n### Indications:\n1. **Non-Small Cell Lung Cancer (NSCLC):**\n   - Imfinzi is approved for the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.\n   \n2. **Extensive-Stage Small Cell Lung Cancer (ES-SCLC):**\n   - It is also approved in combination with etoposide and either carboplatin or cisplatin as a first-line treatment for adult patients with ES-SCLC.\n\n### Mechanism of Action:\n- Imfinzi works by binding to PD-L1, a protein that can suppress the immune system. By inhibiting PD-L1, Imfinzi helps to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_BmSHE8wYed8cv4P16vV47bEy", "custom_id": "456_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "5d2a8bcb64438cfd1269ce571468fca2", "body": {"id": "chatcmpl-9St45QeYfjH3XlT586KjxqO5MTSMN", "object": "chat.completion", "created": 1716671881, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Avodart (generic name: dutasteride) is a medication primarily used to treat benign prostatic hyperplasia (BPH), which is an enlargement of the prostate gland. Here are some key points you should know about Avodart:\n\n### Mechanism of Action\n- **5-Alpha-Reductase Inhibitor**: Avodart works by inhibiting the enzyme 5-alpha-reductase, which converts testosterone to dihydrotestosterone (DHT). DHT is a hormone that contributes to prostate growth. By reducing DHT levels, Avodart helps to shrink the prostate and alleviate symptoms of BPH.\n\n### Indications\n- **Benign Prostatic Hyperplasia (BPH)**: Avodart is indicated for the treatment of symptomatic BPH in men with an enlarged prostate. It can improve urinary flow and may reduce the need for prostate surgery later on.\n\n### Dosage and Administration\n- **Standard Dose**: The typical dose is 0"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_lczEN28LxjaLMZvEEQAnYRSR", "custom_id": "457_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "41e94277e5f1aaee4bc718e55957053b", "body": {"id": "chatcmpl-9St46Ql4952Rk7iGbHffYBRNnEpwc", "object": "chat.completion", "created": 1716671882, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Copiktra (duvelisib) is an oral medication used in the treatment of certain types of blood cancers. Here are some key points you should know about Copiktra:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL):**\n   - Copiktra is indicated for the treatment of adult patients with relapsed or refractory CLL/SLL after at least two prior therapies.\n   \n2. **Follicular Lymphoma (FL):**\n   - It is also indicated for the treatment of adult patients with relapsed or refractory FL after at least two prior systemic therapies.\n\n### Mechanism of Action:\n- Copiktra is a dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, enzymes that are involved in the proliferation and survival of malignant B-cells.\n\n### Dosage and Administration:\n- The recommended"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_HeYykDidZBCtUnF8uDXdRnY9", "custom_id": "458_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "978d826460a36f914434abc5e56d9404", "body": {"id": "chatcmpl-9St468QhJucCqB8dOOqa5QOlKkvoD", "object": "chat.completion", "created": 1716671882, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Panorex, also known as a panoramic radiograph or orthopantomogram (OPG). Here are key points you should know:\n\n### 1. **Definition and Purpose:**\n   - **Panorex** is a type of dental X-ray that provides a broad view of the jaws, teeth, sinuses, nasal area, and temporomandibular joints (TMJ).\n   - It is commonly used in dentistry and maxillofacial surgery to diagnose and plan treatment for various conditions.\n\n### 2. **Indications:**\n   - **Dental Assessment:** Evaluating the position of teeth, including impacted teeth, and assessing the need for orthodontic treatment.\n   - **Pathology Detection:** Identifying cysts, tumors, infections, and other abnormalities in the jaw and surrounding structures.\n   - **Trauma:** Assessing fractures or other injuries to the jaw and facial bones.\n   - **TMJ"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ce0vAQW88EWgIaJZVPkUeMUI", "custom_id": "459_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "bada52f3117685fa60977dffc5823dd4", "body": {"id": "chatcmpl-9St46AhQgRXDEKQc9VTyEN6QbUGNg", "object": "chat.completion", "created": 1716671882, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Empliciti (elotuzumab) is a monoclonal antibody used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Here are some key points you should know about Empliciti:\n\n### Mechanism of Action\n- **Target**: Empliciti targets SLAMF7 (Signaling Lymphocytic Activation Molecule Family member 7), a protein found on the surface of myeloma cells and natural killer (NK) cells.\n- **Action**: It works by directly activating NK cells and facilitating the recognition and destruction of myeloma cells by the immune system.\n\n### Indications\n- **Combination Therapy**: Empliciti is typically used in combination with other medications such as lenalidomide and dexamethasone or pomalidomide and dexamethasone.\n- **Relapsed/Refractory Multiple Myeloma**: It is indicated for patients who have received one to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_w7U5azvOJrlgJFB8rRGqyRoG", "custom_id": "460_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "5a98e955b4246ebfa80facf91b1931de", "body": {"id": "chatcmpl-9St47LmKQkXOzYKyZ2oJWBupEVQ5w", "object": "chat.completion", "created": 1716671883, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idhifa (enasidenib) is a medication used in the treatment of certain types of acute myeloid leukemia (AML). Here are some key points you should know about Idhifa as a physician:\n\n### Indications:\n- **Idhifa is indicated for the treatment of adult patients with relapsed or refractory AML with an isocitrate dehydrogenase-2 (IDH2) mutation.** The presence of the IDH2 mutation should be confirmed using an FDA-approved test.\n\n### Mechanism of Action:\n- **Enasidenib is an inhibitor of the IDH2 enzyme.** Mutations in IDH2 can lead to the production of an oncometabolite, 2-hydroxyglutarate (2-HG), which contributes to the development and progression of AML. By inhibiting IDH2, enasidenib reduces 2-HG levels, promoting the differentiation of leukemic cells.\n\n### Administration:\n- **Idh"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_PXo1jJdCZaunWOhJLnGLmCLd", "custom_id": "461_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2078a88762c4f729732eee2b7cb67307", "body": {"id": "chatcmpl-9St47H0iCZPo7tXCVDIF8SZzdHrj1", "object": "chat.completion", "created": 1716671883, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Braftovi (encorafenib) is a medication used primarily in the treatment of certain types of cancer. Here are some key points you should know about Braftovi as a physician:\n\n### Indications\n1. **Melanoma**: Braftovi is approved for use in combination with binimetinib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.\n2. **Colorectal Cancer**: It is also approved in combination with cetuximab for the treatment of patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, after prior therapy.\n\n### Mechanism of Action\n- Braftovi is a kinase inhibitor that targets BRAF V600E and V600K mutations. It inhibits the BRAF kinase, which is part of the MAPK/ERK signaling pathway, thereby reducing tumor cell proliferation.\n\n### Dosage and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_PuWcBwDXzG6qFrINBrQBRsgw", "custom_id": "462_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "05aa8741055118d74f8d8bad08519d2f", "body": {"id": "chatcmpl-9St48gB5j0gqQrUwLFlrZ09zrI61f", "object": "chat.completion", "created": 1716671884, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rozlytrek (entrectinib) is a targeted cancer therapy developed by Roche/Genentech. It is designed to treat specific types of cancer that have a particular genetic mutation. Here are some key points you should know about Rozlytrek:\n\n### Indications:\n1. **NTRK Gene Fusion-Positive Solid Tumors**: Rozlytrek is approved for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.\n2. **ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)**: It is also approved for the treatment of adult patients with ROS1-positive metastatic NSCLC.\n\n### Mechanism of Action:\n- Rozlytrek is a tyros"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_pTe3dHzhHglSfOKUJyDa6MCA", "custom_id": "463_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d955621745ca821584f36b031f086bcd", "body": {"id": "chatcmpl-9St48LhgNd9wb3sLFeYAdy9yl8RF4", "object": "chat.completion", "created": 1716671884, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about any medication you might prescribe or encounter in your practice. Azel could refer to Azelastine, which is a medication commonly used to treat allergic rhinitis and conjunctivitis. Here are some key points you should know:\n\n### Indications:\n- **Allergic Rhinitis:** Azelastine is often prescribed as a nasal spray to relieve symptoms such as sneezing, itching, and runny or stuffy nose.\n- **Allergic Conjunctivitis:** It can also be used as an eye drop to alleviate symptoms like itching and redness in the eyes.\n\n### Mechanism of Action:\n- Azelastine is an antihistamine. It works by blocking histamine receptors (H1 receptors), which helps to reduce the allergic response and alleviate symptoms.\n\n### Dosage and Administration:\n- **Nasal Spray:** Typically, the recommended dose for adults and children over 12 years is one or two sprays in each nostril twice"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_4vkuat2qjoi5tfgT9vIL85Ny", "custom_id": "464_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b95b78bdda369a85569ae368c58bf382", "body": {"id": "chatcmpl-9St49A1DdMQrXnKaYjYBljDi5ZQ8P", "object": "chat.completion", "created": 1716671885, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alrubicin is an investigational drug that has been studied for its potential use in cancer treatment. It is a derivative of doxorubicin, a well-known anthracycline antibiotic used in chemotherapy. Here are some key points you should know about Alrubicin:\n\n1. **Mechanism of Action**: Like doxorubicin, Alrubicin works by intercalating DNA, thereby inhibiting the replication of cancer cells. It also generates free radicals that cause damage to cellular components, leading to cell death.\n\n2. **Development and Research**: Alrubicin has been under investigation in clinical trials to assess its efficacy and safety profile. It is designed to offer similar or improved anti-tumor activity compared to doxorubicin, potentially with a better safety profile.\n\n3. **Potential Benefits**: The modifications in Alrubicin aim to reduce the cardiotoxicity commonly associated with doxorubicin. This could make it a safer option for patients who require anthr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_KIATDmVUvA8XGiLRUhOcGe9P", "custom_id": "465_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "460722b2683947794190e222340003b5", "body": {"id": "chatcmpl-9St49NZmHlqQD8zd4KR0ZiFOzDsis", "object": "chat.completion", "created": 1716671885, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Balversa (erdafitinib) is a medication used primarily for the treatment of certain types of urothelial carcinoma, which is a form of bladder cancer. Here are some key points you should know about Balversa:\n\n### Indications:\n- **FDA Approval**: Balversa is approved by the FDA for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations and has progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.\n\n### Mechanism of Action:\n- **FGFR Inhibitor**: Balversa is a tyrosine kinase inhibitor that targets fibroblast growth factor receptors (FGFRs). It inhibits FGFR1, FGFR2, FGFR3, and FGFR4, which are involved in tumor cell proliferation and survival.\n\n### Dosage and Administration:\n- **Starting Dose**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Oam1fO8TRBn7tWAw30izCdof", "custom_id": "466_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9fdfe390b7b7592957f898df02b66f01", "body": {"id": "chatcmpl-9St4A7kMfhGhjhXqcbyiJKSN89Hey", "object": "chat.completion", "created": 1716671886, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or medical product known as \"Brutravon.\" It is possible that it could be a new or less common drug, a brand name not widely recognized, or a misspelling of another medication.\n\nIf \"Brutravon\" is a new or emerging medication, here are some general steps you can take to gather more information:\n\n1. **Consult Reliable Sources**: Check reputable medical databases such as PubMed, Medline, or the FDA's website for any information on the drug.\n\n2. **Pharmaceutical Reps**: Contact pharmaceutical representatives or the company that manufactures the drug for detailed information, including indications, contraindications, side effects, and clinical trial data.\n\n3. **Medical Literature**: Look for any published studies or clinical trials that mention the drug. Journals and medical conferences are good sources of the latest research.\n\n4. **Professional Networks**: Discuss with colleagues or specialists in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_qUm7H0SQVOEkkizoCX3439kg", "custom_id": "467_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0f74fd36fc0dd7f787ea04bbed05d795", "body": {"id": "chatcmpl-9St4AsYvZxuwh8ufjOMmE3DJIo27C", "object": "chat.completion", "created": 1716671886, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erlocip is a brand name for the drug erlotinib, which is a tyrosine kinase inhibitor used primarily in the treatment of certain types of cancer. Here are some key points you should know about Erlocip:\n\n### Indications:\n1. **Non-Small Cell Lung Cancer (NSCLC):**\n   - Erlocip is often used for the treatment of locally advanced or metastatic NSCLC, particularly in patients with specific mutations in the epidermal growth factor receptor (EGFR) gene.\n2. **Pancreatic Cancer:**\n   - It is also used in combination with gemcitabine for the treatment of locally advanced, unresectable, or metastatic pancreatic cancer.\n\n### Mechanism of Action:\n- Erlotinib works by inhibiting the tyrosine kinase activity of the EGFR, which is involved in the regulation of intracellular signaling pathways implicated in cancer cell proliferation and survival.\n\n### Dosage and Administration:\n- The typical dose for NSCLC is "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Bwr0OIqntt2zUapvpQpuwSdw", "custom_id": "468_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ecf789598694cf2a93afe8279cd721c8", "body": {"id": "chatcmpl-9St4BE1rZhsVlkUcSU8ugpBNr0MHT", "object": "chat.completion", "created": 1716671887, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Emcyt (estramustine phosphate sodium) is a chemotherapy medication primarily used in the treatment of metastatic and/or progressive prostate cancer. Here are some key points you should know about Emcyt:\n\n### Mechanism of Action\n- **Combination of Estradiol and Nitrogen Mustard**: Emcyt combines the properties of estradiol (a form of estrogen) and a nitrogen mustard (a type of alkylating agent). This dual action helps in inhibiting the growth of cancer cells.\n- **Microtubule Inhibition**: It disrupts microtubule function, which is essential for cell division, thereby inhibiting the proliferation of cancer cells.\n\n### Indications\n- **Prostate Cancer**: Emcyt is specifically indicated for the palliative treatment of patients with metastatic and/or progressive prostate cancer.\n\n### Administration\n- **Oral Medication**: Emcyt is administered orally, typically in capsule form.\n- **Dosage**: The dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_680fBknhYsMhpEotTskV372p", "custom_id": "469_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ef282914d218274aa22c92df62cb1797", "body": {"id": "chatcmpl-9St4BZihkMDdfRk0iF28eGwJWonhY", "object": "chat.completion", "created": 1716671887, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a typo or some confusion in your question. \"Aside\" is a term that can have different meanings depending on the context. If you meant \"Aside\" in a medical context, it doesn't directly relate to any specific medical term or concept. However, if you meant something else, such as a specific medication, condition, or medical device, please provide more details so I can give you accurate information.\n\nIf you were referring to a specific medication or medical term that sounds similar to \"Aside,\" please clarify, and I'll be happy to provide the relevant information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 39, "completion_tokens": 117, "total_tokens": 156}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_p9lyktyDhUmaaL14ewNCf7cd", "custom_id": "470_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6bf7d3a65e9158416fcd2a806dc7974f", "body": {"id": "chatcmpl-9St4CO9VGAoH3A97vWhYL6XvMeAdk", "object": "chat.completion", "created": 1716671888, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about Advacan, which is a brand name for the drug sirolimus. Sirolimus is an immunosuppressant medication primarily used to prevent organ rejection in patients who have undergone kidney transplantation. Here are some key points you should know:\n\n### Mechanism of Action\n- **Sirolimus** works by inhibiting the mammalian target of rapamycin (mTOR), which is a key regulatory kinase in cell proliferation. This inhibition leads to a reduction in the activity of T and B cells, thereby suppressing the immune response.\n\n### Indications\n- **Prevention of Organ Rejection**: Primarily used in kidney transplant recipients.\n- **Other Uses**: Sometimes used off-label for other types of organ transplants or certain autoimmune conditions.\n\n### Dosage and Administration\n- **Initial Dose**: Typically, a loading dose is given followed by a maintenance dose.\n- **Monitoring**: Blood levels of sirolimus should"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_AaanPxpPZIQdc9NCt7QNS8JF", "custom_id": "471_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1517d03ac79877ea476769dd0e3570fd", "body": {"id": "chatcmpl-9St4CAXLcXQHDOkIaU8C20bfEMt3N", "object": "chat.completion", "created": 1716671888, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about any medication you might prescribe or encounter in your practice. However, as of my last update in October 2021, there is no widely recognized medication or treatment known as \"Aromadex.\" It's possible that it could be a new drug, a brand name not widely known, or a misspelling of a different medication.\n\nHere are some steps you can take to gather accurate information:\n\n1. **Check Reliable Sources**: Consult trusted medical databases such as PubMed, Medline, or your institution's library for any peer-reviewed articles or clinical trials involving Aromadex.\n\n2. **Pharmaceutical Reps**: Contact pharmaceutical representatives or the company that manufactures the drug for detailed information, including indications, contraindications, side effects, and clinical trial data.\n\n3. **Professional Networks**: Reach out to colleagues or professional networks. Sometimes new medications are discussed in professional forums or at medical conferences before they become widely known.\n\n4."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_WE4SJBBQDB0CPSSGinUwmgbk", "custom_id": "472_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "33dc3a72ccb22252516627e7bdc6ffde", "body": {"id": "chatcmpl-9St4CctAyCTFhy6YzCJFi0QcyebIK", "object": "chat.completion", "created": 1716671888, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Floxuridine, commonly known by its abbreviation FUDR, is a chemotherapeutic agent used primarily in the treatment of cancer. Here are some key points you should know about FUDR as a physician:\n\n### Mechanism of Action\n- **Antimetabolite**: FUDR is a pyrimidine analog, specifically a fluorinated derivative of uracil. It interferes with DNA synthesis by inhibiting thymidylate synthase, an enzyme crucial for DNA replication and repair.\n- **Cell Cycle Specificity**: It is most effective during the S-phase of the cell cycle, where DNA synthesis occurs.\n\n### Indications\n- **Metastatic Colorectal Cancer**: FUDR is often used in the treatment of metastatic colorectal cancer, particularly when delivered via hepatic arterial infusion (HAI) to target liver metastases.\n- **Other Cancers**: It may also be used for other types of cancer, including gastrointestinal cancers, depending on the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ysGZaoPJHFvbyiCjaoRIouxy", "custom_id": "473_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c53be849c4979d5cbc1890fbbd6f4bfe", "body": {"id": "chatcmpl-9St4DYdxuSYhTbc4DdL1Ch6PqaDAz", "object": "chat.completion", "created": 1716671889, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2021, there is no widely recognized medication or treatment known as \"Beneflur.\" It is possible that you may be referring to a new or less common medication, a brand name that is not widely recognized, or a misspelling of another drug.\n\nIf \"Beneflur\" is a new medication or a brand name that has emerged after my last update, I would recommend the following steps to gather accurate and up-to-date information:\n\n1. **Consult Reliable Sources**: Check reputable medical databases such as PubMed, Medline, or the FDA's website for any information on the drug.\n2. **Pharmaceutical Reps**: Contact the pharmaceutical company that manufactures the drug for detailed information, including indications, dosage, side effects, and clinical trial data.\n3. **Medical Literature**: Review recent medical journals or publications that might have studies or reviews on the medication.\n4. **Professional Networks**: Discuss with colleagues or specialists who might have"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_uBpUrIayHkOhG0OYPSykpWLA", "custom_id": "474_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e265ebd8b38550edbb7e0f6736b960a8", "body": {"id": "chatcmpl-9St4Db047bQfrk9QuW6zuo0Ths4ck", "object": "chat.completion", "created": 1716671889, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about any medical product or technology you might encounter or recommend. However, as of my last update in October 2023, there isn't a widely recognized medical product or technology specifically named \"Accusite.\" It's possible that it could be a new or niche product, a brand name, or a term used in a specific medical context that hasn't gained widespread recognition.\n\nHere are some general steps you can take to gather more information about \"Accusite\":\n\n1. **Check Medical Databases and Journals**: Look for any peer-reviewed articles or clinical studies mentioning \"Accusite\" in databases like PubMed, MEDLINE, or other medical journals.\n\n2. **Consult Colleagues and Specialists**: Ask other healthcare professionals if they are familiar with \"Accusite\" and if they have any experience or knowledge about it.\n\n3. **Contact Medical Associations**: Reach out to relevant medical associations or societies that might have more information or resources"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_2UU5hu1SzDpBHOhaPRu11MPh", "custom_id": "475_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6feef9981afb48ab24b29c8ad96a5bb8", "body": {"id": "chatcmpl-9St4DaFA72EVN9t5Paqptl3GdT0Tl", "object": "chat.completion", "created": 1716671889, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Halotestin (generic name: fluoxymesterone) is an anabolic steroid that is used in various medical contexts. Here are some key points you should know about Halotestin as a physician:\n\n### Indications:\n1. **Hypogonadism in Males**: Halotestin is used to treat males with a deficiency or absence of endogenous testosterone.\n2. **Delayed Puberty in Males**: It can be prescribed to stimulate the onset of puberty in males with delayed puberty.\n3. **Breast Cancer in Females**: It is sometimes used in the palliative treatment of androgen-responsive recurrent breast cancer in postmenopausal women.\n\n### Mechanism of Action:\n- Halotestin is a synthetic androgen that mimics the effects of natural testosterone. It binds to androgen receptors, promoting protein synthesis and muscle growth, and has both anabolic and androgenic effects.\n\n### Dosage and Administration:\n- The dosage varies depending on the condition being treated. For hypogonad"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_vTFTgaEx6DTE2WwaqcqBQLSX", "custom_id": "476_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f406d6c282dde1494259fb3229a57079", "body": {"id": "chatcmpl-9St4DsrNK85nJF9j20503lGlqnKsq", "object": "chat.completion", "created": 1716671889, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cytomid, also known by its generic name flutamide, is a nonsteroidal antiandrogen medication primarily used in the treatment of prostate cancer. Here are some key points you should know about Cytomid:\n\n### Mechanism of Action\n- **Antiandrogen**: Flutamide works by inhibiting the action of androgens (male hormones) by binding to androgen receptors in target tissues, such as the prostate. This helps to slow the growth of prostate cancer cells, which often rely on androgens for growth.\n\n### Indications\n- **Prostate Cancer**: It is commonly used in combination with other treatments, such as luteinizing hormone-releasing hormone (LHRH) agonists, to treat metastatic prostate cancer.\n- **Off-label Uses**: Occasionally, it may be used off-label for conditions like hirsutism in women, though this is less common.\n\n### Dosage and Administration\n- **Typical Dosage**: The usual"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_IKv3MRYiMAKirGbSCjAq058x", "custom_id": "477_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "340cd4d9f123dd72a71af1f6486f5b81", "body": {"id": "chatcmpl-9St4EpiRlq35mExVqCzg61IKHV8mQ", "object": "chat.completion", "created": 1716671890, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about any medication you might prescribe or encounter in your practice. \"Antrex\" is not a widely recognized or standard name for a medication, so it\u2019s possible that it could be a brand name, a regional name, or a misspelling. However, there are a few steps you can take to ensure you have the correct information:\n\n1. **Verify the Name**: Double-check the spelling and ensure that \"Antrex\" is the correct name. It could be a typographical error or a misunderstanding.\n\n2. **Consult Reliable Sources**: Use trusted medical resources such as the Physicians' Desk Reference (PDR), UpToDate, or other medical databases to look up the medication. These resources can provide comprehensive information about the drug, including its uses, dosage, side effects, contraindications, and interactions.\n\n3. **Ask Colleagues or Pharmacists**: Sometimes, pharmacists or other healthcare professionals might be familiar with less common"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_aTLdlmjLXvpnFtu91mHqiIvW", "custom_id": "478_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0f61deabaa87ab634820f3470f1b1b13", "body": {"id": "chatcmpl-9St4E4r6azxA0XNAOdkQZ3U0EROTy", "object": "chat.completion", "created": 1716671890, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lentaron, also known by its generic name formestane, is a type of medication known as an aromatase inhibitor. It is primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Here are some key points you should know about Lentaron:\n\n### Mechanism of Action\n- **Aromatase Inhibition**: Lentaron works by inhibiting the enzyme aromatase, which is responsible for converting androgens into estrogens. By reducing estrogen levels, it helps to slow the growth of estrogen receptor-positive breast cancer cells.\n\n### Indications\n- **Breast Cancer**: It is used in the treatment of advanced or metastatic breast cancer in postmenopausal women, particularly those whose cancer has progressed following tamoxifen therapy.\n\n### Administration\n- **Form**: Lentaron is typically administered as an intramuscular injection.\n- **Dosage**: The standard dosage and frequency depend on the specific clinical scenario and patient"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_FRj56hRDnsnWecSCJ8fTAZ0F", "custom_id": "479_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "143c0fd8fe58f70ebc0a87a70d711520", "body": {"id": "chatcmpl-9St4EF41Z1doFmfbB8fFDSMuc6nPX", "object": "chat.completion", "created": 1716671890, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fodosine, also known as forodesine, is a purine nucleoside phosphorylase (PNP) inhibitor that has been investigated for its potential use in treating certain types of hematologic malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL) and cutaneous T-cell lymphoma (CTCL). Here are some key points you should know about Fodosine:\n\n1. **Mechanism of Action**:\n   - Fodosine inhibits the enzyme purine nucleoside phosphorylase (PNP), which is crucial for the salvage pathway of purine metabolism.\n   - By inhibiting PNP, Fodosine leads to the accumulation of deoxyguanosine triphosphate (dGTP) in T-cells, which induces apoptosis in these cells.\n\n2. **Indications**:\n   - Fodosine has been primarily investigated for its use in T-cell malignancies, including T-ALL and CTCL.\n   - It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_jDUJTGq8d7SiCIeSM9UFywfz", "custom_id": "480_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b3b59b1065b7d06e351e5a8128dd6f4e", "body": {"id": "chatcmpl-9St4ErMX3kHFyMoI3sKgANWYebidM", "object": "chat.completion", "created": 1716671890, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tavalisse (fostamatinib disodium hexahydrate) is a medication used to treat adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to previous treatments. Here are some key points you should know about Tavalisse:\n\n### Mechanism of Action\n- **Fostamatinib** is a prodrug that is converted to its active metabolite, R406, which inhibits spleen tyrosine kinase (SYK). SYK is involved in the signaling pathways that lead to platelet destruction in ITP.\n\n### Indications\n- Tavalisse is specifically indicated for the treatment of thrombocytopenia in adult patients with chronic ITP who have not responded adequately to other treatments.\n\n### Dosage and Administration\n- The recommended starting dose is 100 mg orally twice daily.\n- After a month, the dose can be increased to 150 mg twice daily if the platelet count has not increased to a satisfactory level and the patient"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_kcUrwivEI4ZuuvoBASPR7aOq", "custom_id": "481_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2e1d618206764ca43c706d8cdc6db9a0", "body": {"id": "chatcmpl-9St4FSwCRmAP8KWY4TkNEUD2q31UI", "object": "chat.completion", "created": 1716671891, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Muphoran, also known by its generic name fotemustine, is a chemotherapy drug used primarily in the treatment of certain types of cancer, including malignant melanoma and brain metastases. Here are some key points you should know about Muphoran:\n\n1. **Mechanism of Action**: Fotemustine is an alkylating agent that works by adding an alkyl group to the DNA of cancer cells, which interferes with their replication and leads to cell death.\n\n2. **Indications**: It is mainly used for:\n   - Malignant melanoma, particularly when it has metastasized to the brain.\n   - Other types of cancers as determined by clinical trials and oncologist discretion.\n\n3. **Administration**: Fotemustine is typically administered intravenously. The dosing schedule can vary, but it often involves an induction phase followed by a maintenance phase.\n\n4. **Side Effects**: Common side effects include:\n   - Myelosuppression (leading"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_2poJpk0b9vH0GNxi63X9tZta", "custom_id": "482_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "742febd2ac8678db9eadde425e5e98f3", "body": {"id": "chatcmpl-9St4GvnLyylpegVWR0SPOyXKeDnym", "object": "chat.completion", "created": 1716671892, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Faslodex (generic name: fulvestrant) is a medication used primarily in the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women. Here are some key points you should know about Faslodex:\n\n### Mechanism of Action\n- **Estrogen Receptor Antagonist**: Faslodex works by binding to estrogen receptors on cancer cells, blocking the effects of estrogen, and leading to the degradation of the estrogen receptor. This helps to slow the growth of estrogen receptor-positive breast cancer cells.\n\n### Indications\n- **Metastatic Breast Cancer**: It is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women, particularly those who have disease progression following anti-estrogen therapy.\n- **Combination Therapy**: Faslodex can be used in combination with other therapies, such as CDK4/6 inhibitors (e.g., palbociclib) for enhanced efficacy.\n\n### Administration\n- **Intramus"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_x8UXoQ4S0VvdAAvAI82FTcYV", "custom_id": "483_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "4e9ca73c6f926c829ab2172af2cc6912", "body": {"id": "chatcmpl-9St4GbOqOpqVxKtLYCWvriU4a3z6j", "object": "chat.completion", "created": 1716671892, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2023, there is no widely recognized medication or treatment known as \"Cangib.\" It is possible that you may be referring to a new or less common drug, a brand name that is not widely known, or a typographical error.\n\nIf \"Cangib\" is a new medication or treatment, I would recommend the following steps to ensure you have accurate and up-to-date information:\n\n1. **Consult Reliable Sources**: Check reputable medical databases such as PubMed, Medline, or clinical guidelines from recognized health organizations.\n\n2. **Pharmaceutical Information**: Look up the drug in the Physicians' Desk Reference (PDR) or similar pharmaceutical compendiums.\n\n3. **Manufacturer Information**: Contact the manufacturer for detailed information, including indications, contraindications, dosage, side effects, and clinical trial data.\n\n4. **Continuing Medical Education (CME)**: Attend CME courses or seminars that might cover new treatments and medications.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_3xbcymNls9Oh0Itcnf8F3eqc", "custom_id": "484_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b8bbcc6f655539ff3cbb87caa2364cf5", "body": {"id": "chatcmpl-9St4HklKHmpG6kKL8njbk9VkAh5oH", "object": "chat.completion", "created": 1716671893, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about any medication you might prescribe, including Gemcite. However, it seems there might be a typo or confusion in the name \"Gemcite.\" If you meant \"Gemcitabine,\" here is some relevant information:\n\n### Gemcitabine Overview:\n- **Generic Name:** Gemcitabine\n- **Brand Names:** Gemzar, among others\n- **Drug Class:** Antimetabolite, Antineoplastic agent\n\n### Indications:\nGemcitabine is primarily used in the treatment of various cancers, including:\n- Non-small cell lung cancer (NSCLC)\n- Pancreatic cancer\n- Breast cancer\n- Ovarian cancer\n- Bladder cancer\n\n### Mechanism of Action:\nGemcitabine is a nucleoside analog that interferes with DNA synthesis. It is incorporated into DNA during the S-phase of the cell cycle, leading to inhibition of DNA synthesis and function, which ultimately results in cell death"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_oTEKKEge3sbT9QMwxCA6FbqC", "custom_id": "485_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f749d6707c6d5a9b73966bcf33649be7", "body": {"id": "chatcmpl-9St4HjZlXQYwHl9niFo89qBHk39y8", "object": "chat.completion", "created": 1716671893, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mylotarg (generic name: gemtuzumab ozogamicin) is an antibody-drug conjugate used in the treatment of certain types of acute myeloid leukemia (AML). Here are some key points you should know about Mylotarg:\n\n### Indications:\n- **Acute Myeloid Leukemia (AML):** Mylotarg is indicated for the treatment of newly diagnosed CD33-positive AML in adults and for the treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older.\n\n### Mechanism of Action:\n- **Antibody-Drug Conjugate:** Mylotarg consists of a monoclonal antibody (which targets the CD33 antigen on leukemic cells) linked to a cytotoxic agent (calicheamicin). Upon binding to CD33, the conjugate is internalized, and the cytotoxic agent is released inside the cell, leading to cell death.\n\n### Administration:\n- **Intraven"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_MxUSs5ldyM3ZTQjbA0ulm2st", "custom_id": "486_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e51819e37f04f5c031d2b9616147a643", "body": {"id": "chatcmpl-9St4I47EHCVuH3uIxG3QPp6oVsKFz", "object": "chat.completion", "created": 1716671894, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Xospata (generic name: gilteritinib) is a medication used primarily in the treatment of acute myeloid leukemia (AML) that has a specific genetic mutation known as FLT3. Here are some key points you should know about Xospata:\n\n### Indications:\n- **Acute Myeloid Leukemia (AML):** Xospata is indicated for the treatment of adult patients who have relapsed or refractory AML with a FLT3 mutation, as detected by an FDA-approved test.\n\n### Mechanism of Action:\n- **FLT3 Inhibitor:** Gilteritinib is a tyrosine kinase inhibitor that targets FLT3, a receptor tyrosine kinase involved in the proliferation and survival of hematopoietic cells. Mutations in FLT3 are associated with poor prognosis in AML.\n\n### Dosage and Administration:\n- **Recommended Dose:** The typical dose is 120 mg orally once daily, with or without food.\n- **Administration:** Tablets"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_rstCJ3JqaOLcQeqZJlPRwmAY", "custom_id": "487_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c88c7274b30e2cdbaa3dd2e91cff6433", "body": {"id": "chatcmpl-9St4Iw0ktBRU2kdVgciOprqNJRLLV", "object": "chat.completion", "created": 1716671894, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daurismo (glasdegib) is a medication used in the treatment of acute myeloid leukemia (AML). Here are some key points you should know about Daurismo:\n\n1. **Indication**: Daurismo is indicated for the treatment of newly diagnosed AML in adult patients who are 75 years or older or who have comorbidities that preclude the use of intensive induction chemotherapy.\n\n2. **Mechanism of Action**: Daurismo is a hedgehog pathway inhibitor. It works by inhibiting the smoothened (SMO) receptor, which is a key component of the hedgehog signaling pathway. This pathway is often abnormally activated in certain types of cancer, including AML, and its inhibition can help to reduce the proliferation of cancer cells.\n\n3. **Administration**: Daurismo is administered orally. The recommended dose is 100 mg once daily in combination with low-dose cytarabine (LDAC).\n\n4. **Combination Therapy**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_yHidB6l1f0yIaenyWmPYVaMR", "custom_id": "488_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ebb4dcbc514a66aa922e109a861dc220", "body": {"id": "chatcmpl-9St4IaBI5zjfzxDtqx1qrBlkQzqFl", "object": "chat.completion", "created": 1716671894, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or medical term known as \"Novgos.\" It is possible that it could be a new drug, a brand name, a regional product, or a term that has emerged after my last update. Here are a few steps you can take to gather more information:\n\n1. **Consult Medical Databases**: Check reputable medical databases such as PubMed, Medline, or clinical trial registries for any studies or information related to \"Novgos.\"\n\n2. **Pharmaceutical Repositories**: Look into pharmaceutical databases like the FDA's Drug Database, the European Medicines Agency (EMA), or other national drug regulatory authorities.\n\n3. **Professional Networks**: Reach out to colleagues or professional networks. Sometimes new drugs or terms are discussed in professional forums or at medical conferences before they become widely known.\n\n4. **Pharmacy Inquiries**: Contact a pharmacist, as they often have access to the latest information on new medications"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5QECD3ThprUChItoBaCHzbgP", "custom_id": "489_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c676856a91fc3e2eb48f5ea9d502b2fa", "body": {"id": "chatcmpl-9St4JCHxRMwjsVqWrTQYgxhnutjxL", "object": "chat.completion", "created": 1716671895, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Supprelin (histrelin acetate) is a medication used primarily in the treatment of central precocious puberty (CPP) in children. Here are some key points you should know about Supprelin:\n\n### Mechanism of Action\n- **GnRH Agonist**: Supprelin is a gonadotropin-releasing hormone (GnRH) agonist. It works by initially stimulating and then desensitizing the GnRH receptors in the pituitary gland, leading to a decrease in the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This ultimately reduces the levels of sex steroids (estrogen and testosterone), which helps to delay the onset of puberty.\n\n### Indications\n- **Central Precocious Puberty (CPP)**: Supprelin is indicated for the treatment of children with CPP, a condition where puberty starts too early, typically before age 8 in girls and age 9 in boys.\n\n### Administration\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_wxboEeEplm5zL84rr7WCMINc", "custom_id": "490_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6dfa821e01b0977959f1f1fdc5885c1e", "body": {"id": "chatcmpl-9St4JaKO5VG5RiQhYP49fUCOiLrh1", "object": "chat.completion", "created": 1716671895, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cortef is a brand name for hydrocortisone, a corticosteroid medication used to treat a variety of conditions due to its anti-inflammatory and immunosuppressive properties. Here are some key points you should know about Cortef:\n\n### Indications:\n1. **Endocrine Disorders**: Adrenal insufficiency (Addison's disease), congenital adrenal hyperplasia.\n2. **Rheumatic Disorders**: Rheumatoid arthritis, ankylosing spondylitis.\n3. **Collagen Diseases**: Systemic lupus erythematosus, dermatomyositis.\n4. **Dermatologic Diseases**: Severe psoriasis, severe eczema.\n5. **Allergic States**: Severe allergic conditions, asthma.\n6. **Ophthalmic Diseases**: Severe acute and chronic allergic and inflammatory processes.\n7. **Respiratory Diseases**: Sarcoidosis, aspiration pneumonitis.\n8. **Hematologic Disorders**: Idiopathic thrombocytopenic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_N9kCH6NqEgFvwQfQPuS4jhxa", "custom_id": "491_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "366615694c5fb8fbfc9017c74a82897f", "body": {"id": "chatcmpl-9St4JAz5v587seqAX26D5p81fL2Zw", "object": "chat.completion", "created": 1716671895, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2023, there is no widely recognized or established medical substance or treatment known as \"Biosupressin.\" It is possible that it could be a new or emerging treatment, a misspelling, or a term not widely adopted in the medical community.\n\nIf \"Biosupressin\" is a new or experimental treatment, here are some general steps you should take as a physician to stay informed:\n\n1. **Literature Review**: Check the latest medical literature, including peer-reviewed journals, to see if there are any studies or clinical trials involving \"Biosupressin.\"\n\n2. **Clinical Trials**: Look for ongoing or completed clinical trials on clinical trial registries such as ClinicalTrials.gov to gather information about its efficacy, safety, and potential uses.\n\n3. **Professional Networks**: Engage with professional networks and medical societies to see if any colleagues or experts in your field have information or experience with \"Biosupressin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_whafQCxGidQ0W9jGfOxSWSHD", "custom_id": "492_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9d47d06cd902044e51cf642afdfb9c5a", "body": {"id": "chatcmpl-9St4KO9LUlktLPlLyfCAlV44NZcbN", "object": "chat.completion", "created": 1716671896, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zevalin (ibritumomab tiuxetan) is a radioimmunotherapy treatment used primarily for certain types of non-Hodgkin lymphoma (NHL). Here are some key points you should know about Zevalin:\n\n### Indications:\n- **Non-Hodgkin Lymphoma (NHL):** Zevalin is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell NHL, as well as for patients with previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapy.\n\n### Mechanism of Action:\n- **Radioimmunotherapy:** Zevalin combines a monoclonal antibody (ibritumomab) that targets the CD20 antigen on B-cells with a radioactive isotope (yttrium-90 or indium-111). The antibody binds to the CD20 antigen on the surface of B-cells, delivering targeted radiation to destroy both malignant and normal B-cells.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_CsrJmJh5D8igroT4oqWtmAvu", "custom_id": "493_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d4ffce75cad7e45accb04c197904f8ae", "body": {"id": "chatcmpl-9St4KYGUCa66wUVvhptSTJAtqoCtB", "object": "chat.completion", "created": 1716671896, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibrutinib, marketed under the brand name Imbruvica, is an oral Bruton's tyrosine kinase (BTK) inhibitor used primarily in the treatment of certain B-cell malignancies. Here are key points you should know about Ibrutinib:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL)**: Including patients with 17p deletion.\n2. **Mantle Cell Lymphoma (MCL)**: For patients who have received at least one prior therapy.\n3. **Waldenstr\u00f6m's Macroglobulinemia (WM)**.\n4. **Marginal Zone Lymphoma (MZL)**: For patients who require systemic therapy and have received at least one prior anti-CD20-based therapy.\n5. **Chronic Graft-Versus-Host Disease (cGVHD)**: After failure of one or more lines of systemic therapy.\n\n### Mechanism of Action:\n- Ibrutinib works by"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_zBC1jnmXz38hqP1SVYg589uU", "custom_id": "494_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e80e24ff9692c4175819dd54477ddcdc", "body": {"id": "chatcmpl-9St4KEUx7LdNkDLCqBAI67FCaDic9", "object": "chat.completion", "created": 1716671896, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Conmana, also known by its generic name icotinib, is a tyrosine kinase inhibitor (TKI) used primarily in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about Conmana:\n\n1. **Mechanism of Action**: Icotinib targets the epidermal growth factor receptor (EGFR) tyrosine kinase, which is often mutated and overactive in certain types of NSCLC. By inhibiting this receptor, icotinib can help to slow or stop the growth of cancer cells.\n\n2. **Indications**: Conmana is specifically indicated for the treatment of patients with locally advanced or metastatic NSCLC who have EGFR mutations. It is often used as a first-line treatment in these cases.\n\n3. **Administration**: Conmana is administered orally, typically in the form of tablets. The standard dosage is usually 125 mg taken three times daily, but the exact regimen can vary based on the patient's"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_LPZuF3EMVBbS2ujyk00BJtNd", "custom_id": "495_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "005af4ee94b07b01093fd8bada65311f", "body": {"id": "chatcmpl-9St4KgYrfl2cdt6p5V4WzMz4KoX3E", "object": "chat.completion", "created": 1716671896, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idamycin, also known by its generic name idarubicin, is an anthracycline antibiotic used primarily as a chemotherapeutic agent. Here are some key points you should know about Idamycin:\n\n### Indications:\n- **Acute Myeloid Leukemia (AML):** Idarubicin is commonly used in combination with other chemotherapeutic agents for the treatment of AML in adults.\n- **Acute Lymphoblastic Leukemia (ALL):** It may also be used in certain cases of ALL.\n\n### Mechanism of Action:\n- Idarubicin works by intercalating into DNA, thereby inhibiting the enzyme topoisomerase II. This action prevents the replication of DNA and RNA, leading to cell death, particularly in rapidly dividing cancer cells.\n\n### Administration:\n- **Route:** It is typically administered intravenously.\n- **Dosage:** The dosage varies based on the specific protocol, patient\u2019s condition, and whether it is being used in combination"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_BDAlibUHIkB0DdWe3IOLpLnN", "custom_id": "496_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a960ed85edf6dd0c11165d519b22502e", "body": {"id": "chatcmpl-9St4KRJPxLr5TKaEdquPZRX9stDYo", "object": "chat.completion", "created": 1716671896, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zydelig (idelalisib) is a medication used primarily in the treatment of certain types of blood cancers. Here are some key points you should know about Zydelig:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL)**: Often used in combination with rituximab for patients who have received at least one prior therapy.\n2. **Follicular B-cell non-Hodgkin lymphoma (FL)**: For patients who have received at least two prior systemic therapies.\n3. **Small Lymphocytic Lymphoma (SLL)**: For patients who have received at least two prior systemic therapies.\n\n### Mechanism of Action:\n- Zydelig is a selective inhibitor of phosphoinositide 3-kinase delta (PI3K\u03b4), an enzyme involved in the proliferation and survival of B-cells. By inhibiting this enzyme, Zydelig can help to reduce the growth and survival of malignant B-cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_QQ1w4a0SJBWpgyxBuoF1Tbao", "custom_id": "497_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b28e3b3deb68e25abeb5ff84c950064b", "body": {"id": "chatcmpl-9St4LqDOsi25yVig3yJT9OXWDmKhi", "object": "chat.completion", "created": 1716671897, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alquimid is a term that may not be widely recognized in the medical community, and it is possible that it could be a misspelling or a regional name for a substance or product. However, based on the context, it seems like you might be referring to a type of injectable filler used in cosmetic procedures. \n\nIf you are referring to a specific product or substance, here are some general considerations for injectable fillers:\n\n1. **Composition**: Understand the chemical composition of the filler. Common fillers include hyaluronic acid, calcium hydroxylapatite, poly-L-lactic acid, and polymethylmethacrylate (PMMA).\n\n2. **Indications**: Know the approved uses for the filler, such as facial wrinkles, volume loss, or lip enhancement.\n\n3. **Technique**: Be familiar with the injection techniques, including the depth of injection and the anatomical landmarks to avoid complications.\n\n4. **Side Effects**: Be aware of potential side effects, which can range from"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_d2KSQfApvzgk1kW96VGUmyxF", "custom_id": "498_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "403329e2acb1f97069a9f22132215bfd", "body": {"id": "chatcmpl-9St4LZiZXqI9psDUGQhuQUMcu2Pwl", "object": "chat.completion", "created": 1716671897, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Enliven\" could refer to various things depending on the context, such as a medication, a healthcare service, or a wellness program. However, without specific context, it's challenging to provide detailed information. Here are some general steps you can take to understand what \"Enliven\" might refer to in your field:\n\n1. **Check Medical Databases**: Look up \"Enliven\" in medical databases like PubMed, Medline, or your institution's library resources to see if it is a medication or treatment protocol.\n\n2. **Pharmaceutical Repositories**: If \"Enliven\" is a drug, resources like the FDA database, Drugs.com, or the Physicians' Desk Reference (PDR) can provide detailed information on indications, contraindications, side effects, and clinical studies.\n\n3. **Professional Networks**: Consult with colleagues or professional networks. Sometimes new treatments or programs are better understood through peer discussions.\n\n4. **Manufacturer Information**: If \"Enl"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_HYTGUwTpELLUWFJ5VfsDJJ70", "custom_id": "499_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e353ce08dfa86f477c84ab92a6562b04", "body": {"id": "chatcmpl-9St4L01rFQvyLJPchu2sqFjoiW2TB", "object": "chat.completion", "created": 1716671897, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Truseltiq (infigratinib) is a medication used in the treatment of certain types of cancer. Here are some key points you should know about it:\n\n1. **Indication**: Truseltiq is primarily indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. It is used in patients who have already received at least one prior systemic therapy.\n\n2. **Mechanism of Action**: Infigratinib is a tyrosine kinase inhibitor that targets FGFR2. FGFR2 fusions and rearrangements can drive the growth of certain cancers, and by inhibiting this pathway, Truseltiq can help to slow or stop the progression of the disease.\n\n3. **Administration**: Truseltiq is administered orally. The recommended dosage is 125 mg once"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_zEUEhyXgD1bZjb9czcq4Tiwf", "custom_id": "500_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f71d7072558248ccd6ead9e6c637ebe6", "body": {"id": "chatcmpl-9St4LDjgXuzHYe5EwKxdU4yR0M8xs", "object": "chat.completion", "created": 1716671897, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Besponsa (generic name: inotuzumab ozogamicin) is a medication used in the treatment of certain types of cancer, specifically relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Here are some key points you should know about Besponsa:\n\n### Mechanism of Action\n- **Antibody-Drug Conjugate**: Besponsa is an antibody-drug conjugate (ADC) that combines a monoclonal antibody targeting CD22, a cell surface antigen expressed on B-cells, with a cytotoxic agent, calicheamicin. The antibody binds to CD22 on the surface of cancer cells, and the conjugate is internalized, releasing the cytotoxic agent to induce cell death.\n\n### Indications\n- **Relapsed or Refractory B-cell Precursor ALL**: Besponsa is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.\n\n### Administration\n- **Intr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_DgbIuzeuC9OaIQ3Lid3rWByX", "custom_id": "501_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "541a27b4fd2d3515f39fe1d1f4debe0d", "body": {"id": "chatcmpl-9St4M8YNuq4rZxzAGM6oWHyfv0tI8", "object": "chat.completion", "created": 1716671898, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2021, there is no widely recognized medication or treatment known as \"Laroferon.\" It is possible that it could be a new drug, a brand name not widely known, or a misspelling of another medication. Here are a few steps you can take to gather more information:\n\n1. **Check Medical Databases**: Use medical databases such as PubMed, Medline, or your institution's library resources to search for \"Laroferon.\" This can help you find any relevant studies, clinical trials, or reviews.\n\n2. **Consult Pharmacists**: Pharmacists are often well-versed in both generic and brand names of medications. They may be able to provide more information or clarify any confusion.\n\n3. **Contact the Manufacturer**: If you have any packaging or documentation, contact the manufacturer directly for detailed information about the drug, including its indications, contraindications, side effects, and clinical data.\n\n4. **Professional"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_cm8ezZwdhK2rtqpSod44SuPJ", "custom_id": "502_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "09820f91400c4a6b48be705b3e39ba38", "body": {"id": "chatcmpl-9St4Mf7KZ1egUbw9VZaNHMWvqi3kT", "object": "chat.completion", "created": 1716671898, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or treatment called \"Advaferon.\" It's possible that it could be a new or emerging treatment, a brand name not widely known, or a typographical error. Here are some steps you can take to gather more information:\n\n1. **Check Medical Databases**: Look up \"Advaferon\" in medical databases such as PubMed, ClinicalTrials.gov, or other reputable sources to see if there are any studies or clinical trials associated with it.\n\n2. **Consult Pharmaceutical Repositories**: Use resources like the FDA's database, the European Medicines Agency (EMA), or other national drug regulatory authorities to check for any approved medications or treatments under that name.\n\n3. **Contact Colleagues or Specialists**: Reach out to colleagues, particularly those in pharmacology or related specialties, to see if they have any knowledge or insights about \"Advaferon.\"\n\n4. **Pharmaceutical Companies**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_tJcxiPf7KlbSBFBCjQpyYlq3", "custom_id": "503_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "465000a308eab965330c98bc8b19715e", "body": {"id": "chatcmpl-9St4MuUpOqd5uZRrXipLgEIOuH8z7", "object": "chat.completion", "created": 1716671898, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Actimmune (Interferon gamma-1b) is a medication used primarily to reduce the frequency and severity of serious infections associated with Chronic Granulomatous Disease (CGD) and to slow the progression of severe, malignant osteopetrosis. Here are some key points you should know about Actimmune:\n\n### Indications:\n1. **Chronic Granulomatous Disease (CGD):** Actimmune is used to reduce the frequency and severity of serious infections.\n2. **Severe Malignant Osteopetrosis:** It is used to delay the progression of this condition.\n\n### Mechanism of Action:\n- Actimmune is a recombinant form of interferon gamma, a cytokine that plays a crucial role in the immune response. It enhances the oxidative metabolism of macrophages, which helps in killing certain pathogens and modulating the immune response.\n\n### Administration:\n- **Route:** Subcutaneous injection.\n- **Dosage:** The dosage varies based on the condition being treated and the patient's"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_sWTnboi9Sw2p9NVdg6YKalwG", "custom_id": "504_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "cc2dcbf2f224e736ffb52cc47c1cd38a", "body": {"id": "chatcmpl-9St4MabNSHFvsG2zhPREutaM1OX2X", "object": "chat.completion", "created": 1716671898, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Yervoy (ipilimumab) is a monoclonal antibody that is used as an immunotherapy treatment for certain types of cancer. Here are some key points you should know about Yervoy:\n\n### Indications:\n1. **Melanoma**: Yervoy is approved for the treatment of unresectable or metastatic melanoma and as an adjuvant treatment for patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.\n2. **Renal Cell Carcinoma**: It is also used in combination with nivolumab for the treatment of patients with advanced renal cell carcinoma.\n3. **Colorectal Cancer**: Yervoy, in combination with nivolumab, is indicated for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer.\n4. **Other Cancers**: It may be"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_k6RIxHZaaOyZx1pRo8r0l4kv", "custom_id": "505_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "94fe775b70cec2ee203bb8eacfb3bc5e", "body": {"id": "chatcmpl-9St4NJCVIAmLt4snI5DJYC3zwxuDn", "object": "chat.completion", "created": 1716671899, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a typo in your question, as \"Axinotecan\" does not correspond to any known medication. However, if you meant \"Irinotecan,\" I can provide information on that. Irinotecan is a chemotherapy drug used primarily in the treatment of colorectal cancer. Here are some key points you should know about Irinotecan:\n\n### Mechanism of Action\n- **Topoisomerase I Inhibitor**: Irinotecan works by inhibiting the enzyme topoisomerase I, which is essential for DNA replication. This inhibition leads to DNA damage and ultimately cell death, particularly in rapidly dividing cancer cells.\n\n### Indications\n- **Colorectal Cancer**: Often used in combination with other chemotherapy agents such as 5-fluorouracil (5-FU) and leucovorin.\n- **Other Cancers**: Sometimes used off-label for other types of cancer, including small cell lung cancer and pancreatic cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_thr6lejtxgmNLDJvO4q1QX3o", "custom_id": "506_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3a81cb8df83fa631d01c596363d348ee", "body": {"id": "chatcmpl-9St4OB3O1pEm4CK0mUTFkQ5204Q5D", "object": "chat.completion", "created": 1716671900, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Onivyde (irinotecan liposome injection) is a chemotherapeutic agent used primarily in the treatment of metastatic pancreatic cancer. Here are some key points you should know about Onivyde:\n\n### Indications:\n- **Metastatic Pancreatic Cancer**: Onivyde is approved for use in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas whose disease has progressed following gemcitabine-based therapy.\n\n### Mechanism of Action:\n- **Topoisomerase I Inhibitor**: Onivyde is a liposomal formulation of irinotecan, which inhibits topoisomerase I, an enzyme involved in DNA replication. This inhibition leads to DNA damage and cell death, particularly in rapidly dividing cancer cells.\n\n### Administration:\n- **Intravenous Infusion**: Onivyde is administered as an intravenous infusion. The recommended dose is 70 mg/m"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_mMixf1ulxn0zGDfnh0NqakxB", "custom_id": "507_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "bef022003c2c6a5d00a80fa5d0715633", "body": {"id": "chatcmpl-9St4OjjnEcJvJslEZv9XoMllME9kj", "object": "chat.completion", "created": 1716671900, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sarclisa (isatuximab-irfc) is a monoclonal antibody used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Here are some key points you should know about Sarclisa:\n\n### Mechanism of Action\n- **Target**: Sarclisa targets CD38, a glycoprotein expressed on the surface of multiple myeloma cells.\n- **Action**: By binding to CD38, Sarclisa induces cell death through multiple mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC).\n\n### Indications\n- **Combination Therapy**: Sarclisa is typically used in combination with other medications such as pomalidomide and dexamethasone, or carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myel"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_4CuwVSbGqZzQW8OnheObOeQC", "custom_id": "508_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "52bf082c854c64fef9116391754a408a", "body": {"id": "chatcmpl-9St4OMwJzvEuhYPdFMUrrvRazY4Yx", "object": "chat.completion", "created": 1716671900, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Absorica (isotretinoin) is an oral medication primarily used to treat severe recalcitrant nodular acne that has not responded to other treatments, including antibiotics. Here are some key points you should know about Absorica:\n\n### Mechanism of Action\n- **Isotretinoin**: It is a retinoid, which is a derivative of vitamin A. It works by reducing sebaceous gland size and sebum production, inhibiting the growth of acne-causing bacteria, reducing inflammation, and normalizing keratinization.\n\n### Indications\n- **Severe Nodular Acne**: It is indicated for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics.\n\n### Dosage and Administration\n- **Dosing**: The typical starting dose is 0.5 to 1 mg/kg/day, divided into two doses. The total course usually lasts 15-20 weeks.\n- **Absorption**: Absor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ev9CGjID3V5dWImtnvk3JZhY", "custom_id": "509_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "79027749496a1f72d83e5e231ec50142", "body": {"id": "chatcmpl-9St4PijIurNVn1Ab2R6aCH9IuzekL", "object": "chat.completion", "created": 1716671901, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tibsovo (ivosidenib) is a medication used primarily in the treatment of certain types of cancer, specifically acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. Here are some key points you should know about Tibsovo:\n\n### Indications:\n1. **Acute Myeloid Leukemia (AML):**\n   - **Newly Diagnosed AML:** For adult patients who are 75 years or older or who have comorbidities that preclude the use of intensive induction chemotherapy.\n   - **Relapsed or Refractory AML:** For adult patients with relapsed or refractory AML with an IDH1 mutation.\n\n### Mechanism of Action:\n- Tibsovo is an IDH1 inhibitor. It works by inhibiting the mutated IDH1 enzyme, which is involved in the production of an oncometabolite called 2-hydroxyglutarate (2-HG)."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_gHzlouuQjyo99HJWnj32ZNYP", "custom_id": "510_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "bf02fd04f315b165b1da45cc7fe82ea1", "body": {"id": "chatcmpl-9St4PLrjgPVuInN2AH8rtY2O4Bhnw", "object": "chat.completion", "created": 1716671901, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ixempra (ixabepilone) is a chemotherapy medication used primarily in the treatment of metastatic or locally advanced breast cancer, particularly in patients whose cancer is resistant to other treatments. Here are some key points you should know about Ixempra:\n\n### Mechanism of Action\n- **Microtubule Inhibitor**: Ixempra works by stabilizing microtubules, which are essential components of the cell's structure and division machinery. By stabilizing these structures, Ixempra disrupts the normal process of cell division, leading to cell death, particularly in rapidly dividing cancer cells.\n\n### Indications\n- **Breast Cancer**: Ixempra is indicated for the treatment of metastatic or locally advanced breast cancer that is resistant to anthracyclines, taxanes, and capecitabine.\n- **Combination Therapy**: It is often used in combination with capecitabine for patients who have previously been treated with an anthracycline and a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_mz7p2ktdrTSyOTWDhyB9wlvn", "custom_id": "511_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e88b2e79d973821987009148b7454d14", "body": {"id": "chatcmpl-9St4P6IoTAulIB7aaKKkOwhbtwdKr", "object": "chat.completion", "created": 1716671901, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ninlaro (generic name: ixazomib) is an oral proteasome inhibitor used in the treatment of multiple myeloma, a type of blood cancer. Here are some key points you should know about Ninlaro:\n\n### Indications:\n- **Multiple Myeloma**: Ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.\n\n### Mechanism of Action:\n- **Proteasome Inhibition**: Ninlaro works by inhibiting the proteasome, a complex that degrades unneeded or damaged proteins within the cell. This inhibition leads to an accumulation of proteins, inducing apoptosis in cancer cells.\n\n### Administration:\n- **Oral Capsule**: Ninlaro is taken orally, typically once a week on days 1, 8, and 15 of a 28-day cycle.\n- **Combination Therapy**: It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_YrDkybHqFVN6sKS8k5xWZ9xo", "custom_id": "512_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1ed31482385d67cbc51dea29c74681c2", "body": {"id": "chatcmpl-9St4P7zBjK8Iuo5OmHSxA67Xgti00", "object": "chat.completion", "created": 1716671901, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nizoral is a brand name for ketoconazole, an antifungal medication used to treat a variety of fungal infections. Here are some key points you should know about Nizoral:\n\n### Indications:\n1. **Topical Form**: Used to treat fungal infections of the skin such as athlete's foot, jock itch, ringworm, and seborrheic dermatitis (including dandruff).\n2. **Oral Form**: Used for systemic fungal infections, but its use is limited due to potential severe side effects and the availability of safer alternatives.\n\n### Mechanism of Action:\n- Ketoconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting cell membrane integrity and leading to cell death.\n\n### Dosage and Administration:\n- **Topical**: Applied once or twice daily, depending on the specific condition and formulation (cream, shampoo, gel).\n- **Oral**: Typically 200-400 mg daily,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_rUcaltoAUjHQtYEJ2QLgBfXM", "custom_id": "513_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "593b3acdb4f6db537089ec5e033d8763", "body": {"id": "chatcmpl-9St4QYzyr74rawtVCzkGB5cFRpx98", "object": "chat.completion", "created": 1716671902, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about any medication you might prescribe or encounter in your practice. However, as of my last update in October 2021, there is no widely recognized medication or treatment known as \"Ipstyl.\" It's possible that it could be a new drug, a brand name not widely recognized, a misspelling, or a regional name for a medication.\n\nHere are some steps you can take to gather more information:\n\n1. **Check Medical Databases:** Use resources like PubMed, UpToDate, or your institution's medical library to search for \"Ipstyl.\" These databases can provide peer-reviewed articles and clinical studies.\n\n2. **Consult Pharmacists:** Pharmacists are a valuable resource for information on medications, including new drugs or those that are less commonly known.\n\n3. **Contact the Manufacturer:** If you have access to the drug's packaging or any promotional material, contact the manufacturer for detailed information, including indications, contraindications, side effects, and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_pHXUXzw5pqdHM2FZIdZaVHsb", "custom_id": "514_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "79b0445d4d13c99a26b18e3ed85016f8", "body": {"id": "chatcmpl-9St4QGh2GIGa6fQVFP1znyEeiexGV", "object": "chat.completion", "created": 1716671902, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Prevacid (lansoprazole), a proton pump inhibitor (PPI) used primarily to treat conditions related to excess stomach acid. Here are key points you should know:\n\n### Indications:\n1. **Gastroesophageal Reflux Disease (GERD):** Prevacid is commonly prescribed for the treatment of GERD and erosive esophagitis.\n2. **Peptic Ulcer Disease:** It is used for the treatment and prevention of gastric and duodenal ulcers.\n3. **Zollinger-Ellison Syndrome:** Prevacid is indicated for the management of pathological hypersecretory conditions.\n4. **Helicobacter pylori Eradication:** It is often used in combination with antibiotics for the eradication of H. pylori to reduce the risk of duodenal ulcer recurrence.\n\n### Mechanism of Action:\n- Prevacid works by inhibiting the H+/K+ ATPase"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_GYzI7ihMii0Z7c4dvN4x1cha", "custom_id": "515_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9edd89eace887f103ebb0ef3421b74db", "body": {"id": "chatcmpl-9St4QfD9jyYKdpYUENU7HgQZX0qEa", "object": "chat.completion", "created": 1716671902, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medical substance, treatment, or condition known as \"Abnib.\" It is possible that \"Abnib\" could be a typographical error, a brand name not widely known, or a term specific to a particular region or specialty.\n\nIf \"Abnib\" is a new or emerging term, I would recommend the following steps:\n\n1. **Consult Medical Literature**: Check recent medical journals, databases like PubMed, and other reputable sources for any mention of \"Abnib.\"\n\n2. **Professional Networks**: Reach out to colleagues or professional networks to see if anyone has encountered this term.\n\n3. **Pharmaceutical Repositories**: Look into pharmaceutical databases or contact pharmaceutical representatives for any information on new drugs or treatments that might be referred to as \"Abnib.\"\n\n4. **Patient Context**: If a patient mentioned \"Abnib,\" ask for more context. It could be a local"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_TlAQQNwmaxnEMrkWWOXw1VY3", "custom_id": "516_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "afd60595cb30c387d7ce0302bcb7c1e9", "body": {"id": "chatcmpl-9St4ROWNVyQiykPq4zVdy19hEuTtD", "object": "chat.completion", "created": 1716671903, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vitrakvi (larotrectinib) is a targeted cancer therapy that you should be familiar with as a physician, especially if you are involved in oncology or treating patients with solid tumors. Here are some key points you should know:\n\n### Indication\n- **Vitrakvi** is indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation.\n- It is used in cases where the tumor is metastatic or where surgical resection is likely to result in severe morbidity, and there are no satisfactory alternative treatments or the cancer has progressed following treatment.\n\n### Mechanism of Action\n- **Larotrectinib** is a selective TRK inhibitor. It works by inhibiting the TRK fusion proteins, which are the result of NTRK gene fusions. These proteins can drive cancer cell proliferation and survival.\n\n### Efficacy\n- Clinical trials have"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_GR1SVUWrcjWI59Mr6MAFbTEr", "custom_id": "517_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ae62358bd30f21216c5cc39c90e8233f", "body": {"id": "chatcmpl-9St4RYPWstga0pETV4r9OH4PSPDZ2", "object": "chat.completion", "created": 1716671903, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or medical term known as \"Adlinod.\" It is possible that there may be a typographical error, or it could be a new or less common drug, treatment, or medical term that has emerged after my last update.\n\nIf \"Adlinod\" is a new medication or treatment, I would recommend the following steps to stay informed:\n\n1. **Consult Reliable Sources**: Check reputable medical databases such as PubMed, Medline, or clinical guidelines from recognized health organizations.\n2. **Pharmaceutical Reps**: Contact pharmaceutical representatives or the manufacturer for detailed information about the drug, including its indications, contraindications, side effects, and clinical trial data.\n3. **Medical Journals**: Look for recent publications in peer-reviewed medical journals that might provide insights into the drug's efficacy and safety profile.\n4. **Professional Networks**: Engage with professional networks or forums where other physicians might share their"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_6migINcUywHkp8i54bc3SAzG", "custom_id": "518_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7891f4480172e59ce7c2cbee806991f7", "body": {"id": "chatcmpl-9St4R9NixNpm5WRYk7YLNHJJJNBJ4", "object": "chat.completion", "created": 1716671903, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Granocyte is a brand name for lenograstim, which is a recombinant human granulocyte colony-stimulating factor (G-CSF). It is used primarily to stimulate the production of white blood cells, particularly neutrophils, in patients who have neutropenia (low neutrophil count) due to various causes, such as chemotherapy, bone marrow transplantation, or certain types of chronic neutropenia.\n\nHere are some key points you should know about Granocyte:\n\n### Indications:\n1. **Chemotherapy-Induced Neutropenia**: To reduce the duration of neutropenia and the incidence of febrile neutropenia in patients undergoing myelosuppressive chemotherapy.\n2. **Bone Marrow Transplantation**: To accelerate neutrophil recovery and reduce the duration of neutropenia in patients undergoing bone marrow transplantation.\n3. **Peripheral Blood Progenitor Cell (PBPC) Mobilization**: To mobilize hematopoietic progenitor cells into the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_jFmPSauuUmmridg7pJN9TcXC", "custom_id": "519_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2d1d4e24e8d57a2e91b43bc5d1326768", "body": {"id": "chatcmpl-9St4RovPlJIsU50sUYd5yjs2axYA4", "object": "chat.completion", "created": 1716671903, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kisplyx (lenvatinib) is a medication used in the treatment of certain types of cancer. Here are some key points you should know about Kisplyx as a physician:\n\n### Indications:\n- **Renal Cell Carcinoma (RCC):** Kisplyx is often used in combination with everolimus for the treatment of advanced renal cell carcinoma following one prior anti-angiogenic therapy.\n- **Other Indications:** Lenvatinib, the active ingredient in Kisplyx, is also used under the brand name Lenvima for other cancers, such as hepatocellular carcinoma (HCC), differentiated thyroid cancer (DTC), and endometrial carcinoma.\n\n### Mechanism of Action:\n- **Tyrosine Kinase Inhibitor:** Lenvatinib is a multi-targeted tyrosine kinase inhibitor that works by blocking the activity of certain proteins involved in cancer cell growth and angiogenesis (the formation of new blood vessels that supply the tumor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_yaspVNm5TwQ224qF4tdhXxHD", "custom_id": "520_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ae3274aa226f1c8167efe68691cc6f24", "body": {"id": "chatcmpl-9St4RkyCswMGAAxkD5JmkAY08kNNG", "object": "chat.completion", "created": 1716671903, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Femara, also known by its generic name letrozole, is a medication primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Here are some key points you should know about Femara:\n\n### Mechanism of Action\n- **Aromatase Inhibitor**: Femara works by inhibiting the enzyme aromatase, which is involved in the synthesis of estrogen. By reducing estrogen levels, it helps slow the growth of estrogen receptor-positive breast cancer cells.\n\n### Indications\n- **Breast Cancer**: It is commonly prescribed for the adjuvant treatment of hormone receptor-positive early breast cancer, extended adjuvant treatment after 5 years of tamoxifen therapy, and for the treatment of advanced breast cancer.\n- **Off-Label Uses**: Sometimes used off-label for conditions like infertility in women with polycystic ovary syndrome (PCOS) due to its ability to induce ovulation.\n\n### Dosage and Administration\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_XvYuhx4MVcglkRFiy7q1p7O4", "custom_id": "521_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2c6de5ab2e9e0d19b8774f95ac1c754a", "body": {"id": "chatcmpl-9St4Sgze6JGjHqu3nB44ZXXe0mc3d", "object": "chat.completion", "created": 1716671904, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Camcevi (leuprolide mesylate) is a medication used primarily in the treatment of advanced prostate cancer. Here are some key points you should know about Camcevi:\n\n### Mechanism of Action:\n- **GnRH Agonist**: Camcevi is a gonadotropin-releasing hormone (GnRH) agonist. It works by initially stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which leads to a temporary increase in testosterone levels. However, with continuous administration, it downregulates the GnRH receptors in the pituitary gland, leading to decreased production of LH and FSH, and subsequently, a significant reduction in testosterone levels.\n\n### Indications:\n- **Prostate Cancer**: Camcevi is indicated for the palliative treatment of advanced prostate cancer. It helps in reducing the levels of testosterone, which can fuel the growth of prostate cancer cells.\n\n### Administration:\n- **Subcutaneous"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_byfR0ZFotnqbaHh7KIJgUy2U", "custom_id": "522_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b8e9adccb4aa75ce0ba84cc39b8d8113", "body": {"id": "chatcmpl-9St4SygW89hrbATzh5WF3GmLU0zgj", "object": "chat.completion", "created": 1716671904, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ergamisol, also known by its generic name levamisole, is a medication that was originally developed as an anthelmintic (a drug used to treat parasitic worm infections). However, it has also been used for other purposes, including as an immunomodulatory agent. Here are some key points you should know about Ergamisol:\n\n### Medical Uses:\n1. **Anthelmintic**: Levamisole was initially used to treat infections caused by parasitic worms, such as ascariasis and hookworm infections.\n2. **Immunomodulatory Agent**: It has been used in the past as an adjuvant treatment in colorectal cancer to enhance the immune response. However, its use in this context has largely been discontinued due to the availability of more effective treatments and concerns about side effects.\n\n### Mechanism of Action:\n- **Anthelmintic Action**: Levamisole works by causing paralysis of the worms, which are then expelled from the body"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_il9G1gIjh5lFbwhL204j9ehN", "custom_id": "523_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "fa7d0e52a17b7cf06aeb9921a1891f31", "body": {"id": "chatcmpl-9St4SWrjgeLuc3Qybly76IMPchCzU", "object": "chat.completion", "created": 1716671904, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fusilev (levoleucovorin) is a medication used in various clinical settings, primarily in oncology. Here are some key points you should know about Fusilev:\n\n### Indications:\n1. **Methotrexate Rescue**: Fusilev is used to diminish the toxic effects of methotrexate in patients with osteosarcoma. It is administered after high-dose methotrexate therapy to rescue normal cells from the drug's toxic effects.\n2. **Overdose Management**: It is also used to treat accidental overdoses of folic acid antagonists, such as methotrexate.\n3. **Colorectal Cancer**: Fusilev is used in combination with 5-fluorouracil (5-FU) for palliative treatment of patients with advanced metastatic colorectal cancer.\n\n### Mechanism of Action:\n- Fusilev is the pharmacologically active isomer of leucovorin (folinic acid). It works by providing a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_9qWaPvItzR1G9I0nmx4AGMGL", "custom_id": "524_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "03669f05bffd20c19d81e2059378a826", "body": {"id": "chatcmpl-9St4Twd78IkSuqD65EwmE0LjTgJKb", "object": "chat.completion", "created": 1716671905, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "CeeNu, also known by its generic name lomustine, is an alkylating agent used primarily in the treatment of certain types of cancer. Here are some key points you should know about CeeNu:\n\n### Indications:\n1. **Brain Tumors**: CeeNu is often used in the treatment of primary and metastatic brain tumors.\n2. **Hodgkin's Disease**: It is also used as part of combination chemotherapy regimens for Hodgkin's lymphoma.\n3. **Other Cancers**: It may be used off-label for other types of cancers as determined by clinical judgment.\n\n### Mechanism of Action:\n- **Alkylating Agent**: Lomustine works by alkylating DNA and RNA, leading to cross-linking and strand breaks, which ultimately inhibit DNA replication and RNA transcription. This results in cell cycle arrest and apoptosis of cancer cells.\n\n### Administration:\n- **Oral**: CeeNu is administered orally, typically in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_YfaWvA6nNJsSp1EcIV1ZehVZ", "custom_id": "525_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "5ced139af12eba68fd1249e15952bcc5", "body": {"id": "chatcmpl-9St4TDJaNBS2ot8qPKObAyJTbwD1e", "object": "chat.completion", "created": 1716671905, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lorbrena (generic name: lorlatinib) is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC) that is ALK-positive (anaplastic lymphoma kinase-positive). Here are some key points you should know about Lorbrena:\n\n### Indications:\n- **ALK-Positive NSCLC**: Lorbrena is indicated for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to other ALK inhibitors such as crizotinib, alectinib, or ceritinib.\n\n### Mechanism of Action:\n- **Tyrosine Kinase Inhibitor**: Lorbrena is a third-generation ALK tyrosine kinase inhibitor (TKI). It works by inhibiting the activity of the ALK protein, which is involved in the growth and spread of cancer cells.\n\n### Dosage and Administration:\n- **Oral Administration**: Lorbrena is taken orally, typically as a once"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_RanyaQ68vKjDUTA18bTJMBuN", "custom_id": "526_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ba0af3b77afc1f62c090465ca46ead41", "body": {"id": "chatcmpl-9St4Tgg2F6R3b415tOi50M6XcLYGc", "object": "chat.completion", "created": 1716671905, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lutathera (generic name: lutetium Lu 177 dotatate) is a radiopharmaceutical used in the treatment of certain types of neuroendocrine tumors (NETs). Here are some key points you should know about Lutathera:\n\n### Indications:\n- **Neuroendocrine Tumors (NETs):** Lutathera is specifically indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.\n\n### Mechanism of Action:\n- **Targeted Radiotherapy:** Lutathera binds to somatostatin receptors, which are often overexpressed on the surface of neuroendocrine tumor cells. Once bound, the radiolabeled compound delivers targeted radiation to the tumor cells, causing DNA damage and cell death.\n\n### Administration:\n- **Intravenous Infusion:** Lutathera"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_5G3sLkhC3HEObZggWPAiaGCA", "custom_id": "527_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "dd1d8ccbbf7809f7f66f38403ebcd6fa", "body": {"id": "chatcmpl-9St4Tf5EODXXHqzZvs5ouPfsc0u1N", "object": "chat.completion", "created": 1716671905, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Minjuvi (tafasitamab-cxix) is a monoclonal antibody used in the treatment of certain types of lymphoma. Here are some key points you should know about Minjuvi:\n\n1. **Indication**: Minjuvi is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low-grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).\n\n2. **Mechanism of Action**: Minjuvi targets the CD19 antigen, which is expressed on the surface of B-cells. By binding to CD19, tafasitamab-cxix induces cell death through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).\n\n3. **Administration**: Minjuvi is administered intravenously. The dosing schedule typically involves an initial intensive phase followed by"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Q4KevdiXKg4zSafJdV1LRfU4", "custom_id": "528_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "4da59076ac7dee3858cf432b619ff047", "body": {"id": "chatcmpl-9St4Ug6sh3kvdaulOZBA2LwKcpWBW", "object": "chat.completion", "created": 1716671906, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ledaga (chlormethine gel) is a topical chemotherapeutic agent used primarily for the treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL). Here are some key points you should know about Ledaga:\n\n### Indications:\n- **Primary Use**: Ledaga is indicated for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.\n\n### Mechanism of Action:\n- **Alkylating Agent**: Chlormethine, the active ingredient in Ledaga, is an alkylating agent that works by cross-linking DNA strands, thereby inhibiting DNA replication and leading to cell death.\n\n### Administration:\n- **Topical Application**: Ledaga is applied as a gel to the affected skin areas. It is typically applied once daily.\n- **Application Instructions**: Patients should apply a thin film of the gel to the affected areas"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_I6odNPuxypa4c6WkHAH5ZTBa", "custom_id": "529_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f23dbdae232d836311cff1a56c3e3b39", "body": {"id": "chatcmpl-9St4UJMpQ6C5iDxCgCnBhVUF5yHZF", "object": "chat.completion", "created": 1716671906, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Depo-Provera, also known as the Depo shot, is a form of birth control that contains the hormone medroxyprogesterone acetate. It is administered via an intramuscular injection every three months. Here are some key points you should know about Depo-Provera:\n\n### Mechanism of Action\n- **Prevents Ovulation:** Depo-Provera works primarily by inhibiting the release of gonadotropins, which prevents ovulation.\n- **Thickens Cervical Mucus:** It also thickens the cervical mucus, making it more difficult for sperm to enter the uterus.\n- **Alters Endometrial Lining:** The endometrial lining becomes less suitable for implantation.\n\n### Efficacy\n- **High Effectiveness:** When used correctly, Depo-Provera is over 99% effective in preventing pregnancy.\n- **Typical Use:** With typical use, the effectiveness is around 94%.\n\n### Administration\n- **Frequency:** The injection is given"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_7CvPuf6PMlvSXetbEYTTMXm9", "custom_id": "530_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "891497a6cf9b3ca0bf5ce5581c07be04", "body": {"id": "chatcmpl-9St4USFuPopEaAgI9JXhkWLyRYdog", "object": "chat.completion", "created": 1716671906, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or treatment known as \"Maygace.\" It is possible that it could be a new drug, a brand name not widely known, a misspelling, or a term specific to a certain region or context.\n\nIf \"Maygace\" is a new or emerging treatment, here are some general steps you can take to stay informed:\n\n1. **Consult Medical Databases**: Check reputable medical databases such as PubMed, ClinicalTrials.gov, or the FDA's website for any information on new drugs or treatments.\n\n2. **Pharmaceutical Reps**: Contact pharmaceutical representatives who might have the latest information on new drugs.\n\n3. **Medical Journals**: Review recent issues of leading medical journals, as they often publish studies and reviews on new treatments.\n\n4. **Professional Networks**: Engage with professional networks or societies related to your specialty. They often provide updates on new treatments and drugs.\n\n5."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_F1cM9TGGQZLgfpfp639KPkCQ", "custom_id": "531_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3617cb96d3e963bd528ff4842f97a749", "body": {"id": "chatcmpl-9St4U9L8vE16jp9XhajsnpWGzWk2c", "object": "chat.completion", "created": 1716671906, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alkeran, also known by its generic name melphalan, is a chemotherapy medication used primarily in the treatment of multiple myeloma and ovarian cancer. Here are some key points you should know about Alkeran:\n\n### Mechanism of Action\n- **Alkylating Agent**: Alkeran is an alkylating agent that works by binding to DNA and interfering with the replication of cancer cells, leading to cell death.\n\n### Indications\n- **Multiple Myeloma**: Often used in combination with other medications.\n- **Ovarian Cancer**: Typically used when other treatments have not been effective.\n\n### Administration\n- **Oral and Intravenous Forms**: Alkeran is available in both oral tablets and intravenous (IV) formulations.\n- **Dosing**: The dosage varies depending on the type of cancer being treated, the patient's condition, and response to therapy. It is crucial to follow specific protocols and guidelines.\n\n### Side Effects\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Ha0Z7kClb7qDcU9DcOTYjmHQ", "custom_id": "532_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "75d0a528b052227e882d56d8cc011a16", "body": {"id": "chatcmpl-9St4URwjVGK6uBmSBwnbufy5ziQ4k", "object": "chat.completion", "created": 1716671906, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Purinethol, also known by its generic name mercaptopurine, is an important medication used primarily in the treatment of certain types of cancer, particularly acute lymphoblastic leukemia (ALL). Here are some key points you should know about Purinethol:\n\n### Indications:\n- **Acute Lymphoblastic Leukemia (ALL):** Purinethol is commonly used in the maintenance therapy of ALL.\n- **Other Uses:** It may also be used in the treatment of other conditions such as Crohn's disease and ulcerative colitis, although these are off-label uses.\n\n### Mechanism of Action:\n- **Antimetabolite:** Mercaptopurine is a purine analog that interferes with DNA and RNA synthesis. It gets incorporated into the DNA and RNA, leading to faulty replication and transcription, which ultimately inhibits the growth of rapidly dividing cells, such as cancer cells.\n\n### Dosage and Administration:\n- **Oral Administration:** Purinethol is typically administered orally.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_PNyoh9ZV0As5XYwnWYzhkHsE", "custom_id": "533_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "be7b5a40f214a960551bc4f549ce203b", "body": {"id": "chatcmpl-9St4UtcKszEH38YVBLDJuo2fdTh2G", "object": "chat.completion", "created": 1716671906, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a misunderstanding or a typo in your query, as \"Anti Uron\" does not correspond to any known medication, treatment, or medical term in current medical literature or practice. If you meant a specific drug or treatment, please provide more details or check the spelling.\n\nHowever, if you are referring to a specific medication or treatment and there is a typo, here are some general steps you can take to gather accurate information:\n\n1. **Check Reliable Sources**: Refer to trusted medical resources such as the Physicians' Desk Reference (PDR), UpToDate, or peer-reviewed medical journals.\n\n2. **Consult Pharmacists**: Pharmacists can provide detailed information about medications, including their uses, side effects, interactions, and contraindications.\n\n3. **Medical Databases**: Use databases like PubMed, Medline, or Cochrane Library to find research articles and clinical studies related to the medication or treatment in question.\n\n4. **Professional Guidelines**: Look"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_JsH5YPvRZyyyM4d6CL5cblTe", "custom_id": "534_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2467dd800031ed554b43317127869e7e", "body": {"id": "chatcmpl-9St4ViaGfZvNSpt77ZTpbu5qNGonW", "object": "chat.completion", "created": 1716671907, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abitrexate is a brand name for methotrexate, a medication that is commonly used in the treatment of various medical conditions, including certain types of cancer, autoimmune diseases, and ectopic pregnancies. Here are some key points you should know about methotrexate:\n\n### Indications:\n1. **Cancer Treatment**: Methotrexate is used in chemotherapy regimens for cancers such as leukemia, lymphoma, breast cancer, and osteosarcoma.\n2. **Autoimmune Diseases**: It is commonly prescribed for rheumatoid arthritis, psoriasis, and other autoimmune conditions due to its immunosuppressive properties.\n3. **Ectopic Pregnancy**: Methotrexate can be used to treat ectopic pregnancies by inhibiting cell division.\n\n### Mechanism of Action:\n- Methotrexate is a folate antagonist. It inhibits the enzyme dihydrofolate reductase, which is necessary for DNA synthesis and cell replication. This action makes it effective in slowing the growth"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_AWjs5AVoj7QpH2o76ZH7z3BI", "custom_id": "535_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0580c63a8c17b4ae74e4ad52acb7a4cb", "body": {"id": "chatcmpl-9St4UDySoK0vnz8QTFv8PmqzP7En1", "object": "chat.completion", "created": 1716671906, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or substance known as \"Ammoidin.\" It is possible that the name might be misspelled, a brand name not widely known, or a new or experimental drug that has not yet gained widespread recognition.\n\nIf you meant a different medication or if \"Ammoidin\" is a new or less common drug, I would recommend the following steps:\n\n1. **Verify the Name**: Double-check the spelling and ensure that it is correct.\n2. **Consult Reliable Sources**: Look up the medication in trusted medical databases such as PubMed, UpToDate, or the Physicians' Desk Reference (PDR).\n3. **Contact a Pharmacist**: Pharmacists often have access to detailed drug information and can provide insights into less common medications.\n4. **Check Regulatory Agencies**: Look for information from regulatory bodies such as the FDA (Food and Drug Administration) or EMA (European Medicines Agency).\n\nIf"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_CzHNlh2LGxMwC3RZYsUj4Y3v", "custom_id": "536_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b76e4abb81e1ad71ec746ac1548e8e57", "body": {"id": "chatcmpl-9St4VhkucOzIELiXruXRrQ00Zk4vJ", "object": "chat.completion", "created": 1716671907, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or treatment known as \"Adlone.\" It is possible that you might be referring to a specific brand name, a new drug that has been recently introduced, or a typographical error. Here are a few steps you can take to clarify and gather accurate information:\n\n1. **Check Medical Databases**: Use medical databases such as PubMed, UpToDate, or your institution's library resources to search for \"Adlone.\" These databases can provide peer-reviewed articles and clinical studies.\n\n2. **Consult Pharmacists**: Pharmacists are a valuable resource for information on medications, including new drugs or lesser-known treatments. They can provide insights into drug indications, mechanisms of action, side effects, and interactions.\n\n3. **Contact Medical Representatives**: If \"Adlone\" is a new drug, pharmaceutical representatives from the company that manufactures it can provide detailed information, including clinical trial data and approved uses"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_gw9gYzhIcOe73NKgdNCFFEmJ", "custom_id": "537_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9d2f4cffec685fc952ea78239689c5bd", "body": {"id": "chatcmpl-9St4VLywnX55IkWrwj05ZCyQdanfq", "object": "chat.completion", "created": 1716671907, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rydapt (midostaurin) is a multi-targeted kinase inhibitor used primarily in the treatment of certain types of cancer. Here are key points you should know about Rydapt:\n\n### Indications:\n1. **Acute Myeloid Leukemia (AML):**\n   - Rydapt is used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FLT3-mutated AML, as detected by an FDA-approved test.\n\n2. **Systemic Mastocytosis:**\n   - It is also indicated for the treatment of adults with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).\n\n### Mechanism of Action:\n- Midostaurin inhibits multiple receptor tyrosine kinases, including FLT3 and KIT, which are involved in the proliferation and survival of cancer cells.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_cb1547NSlPgHLIiC8wJl4kst", "custom_id": "538_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b56badb67175d6cc7a625d6ec30f8480", "body": {"id": "chatcmpl-9St4VrpaiNe983Sc324pSIP2wSnif", "object": "chat.completion", "created": 1716671907, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or treatment known as \"Lyomit.\" It's possible that it could be a new drug, a brand name not widely known, a misspelling, or a product specific to a certain region or country.\n\nIf \"Lyomit\" is a new or emerging treatment, here are some general steps you can take to gather more information:\n\n1. **Consult Medical Databases**: Use resources like PubMed, Medline, or other medical literature databases to search for any studies or articles related to \"Lyomit.\"\n\n2. **Check with Regulatory Agencies**: Look up information from regulatory bodies such as the FDA (Food and Drug Administration) in the United States, EMA (European Medicines Agency) in Europe, or other relevant national health authorities.\n\n3. **Pharmaceutical Reps and Companies**: Contact pharmaceutical representatives or the company that manufactures or distributes \"Lyomit\" for detailed information, including clinical trial data, indications"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_7h4DroPCwdxFlPE7OAAJCax2", "custom_id": "539_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "aa703320fbaba0d69a973f46f5b6c0ba", "body": {"id": "chatcmpl-9St4VyQwMbPWWneKBhtV8SMqilW3F", "object": "chat.completion", "created": 1716671907, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lysodren (generic name: mitotane) is a medication primarily used in the treatment of adrenocortical carcinoma, a rare cancer of the adrenal cortex. Here are some key points you should know about Lysodren:\n\n### Mechanism of Action\n- **Adrenolytic Activity**: Lysodren works by inhibiting the adrenal cortex's ability to produce steroid hormones. It causes selective destruction of adrenocortical cells, leading to a reduction in hormone production.\n\n### Indications\n- **Adrenocortical Carcinoma**: It is mainly indicated for the treatment of inoperable, metastatic, or recurrent adrenocortical carcinoma.\n- **Cushing's Syndrome**: It may also be used off-label for the management of Cushing's syndrome due to its ability to reduce cortisol production.\n\n### Dosage and Administration\n- **Initial Dose**: The typical starting dose is 2-6 grams per day, divided into three"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_DswzCWScjPv7f45n3DI8htzY", "custom_id": "540_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "96394b994409ef840e6fd6524287b1c1", "body": {"id": "chatcmpl-9St4WoDU5VUkjiuftPZtJYPk6WzPb", "object": "chat.completion", "created": 1716671908, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nitrol, also known as nitroglycerin, is a medication commonly used in the management of angina pectoris (chest pain due to heart disease) and heart failure. Here are some key points you should know about Nitrol:\n\n### Mechanism of Action:\n- **Vasodilation**: Nitroglycerin works by relaxing the smooth muscles in blood vessel walls, leading to vasodilation. This reduces the workload on the heart by decreasing both preload and afterload.\n- **Coronary Artery Dilation**: It also dilates the coronary arteries, improving blood flow to the heart muscle and alleviating ischemia.\n\n### Indications:\n- **Angina Pectoris**: Used for the relief and prevention of angina attacks.\n- **Heart Failure**: Can be used in acute heart failure, particularly when associated with myocardial infarction.\n- **Hypertensive Emergencies**: Sometimes used in the management of hypertensive crises.\n\n### Forms and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_uHtVB5CipNJCYfmQaszYmWYK", "custom_id": "541_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "5d0c0c4439f6a3b915bc31fb6064ea53", "body": {"id": "chatcmpl-9St4W8bww8f8evZivGWkajoAiI5Fk", "object": "chat.completion", "created": 1716671908, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Poteligeo (generic name: mogamulizumab-kpkc) is a monoclonal antibody used in the treatment of certain types of cancer, specifically relapsed or refractory mycosis fungoides (MF) and S\u00e9zary syndrome (SS), which are subtypes of cutaneous T-cell lymphoma (CTCL). Here are some key points you should know about Poteligeo:\n\n### Mechanism of Action\n- **Target**: Poteligeo targets the CC chemokine receptor 4 (CCR4) on the surface of certain cancer cells.\n- **Action**: By binding to CCR4, Poteligeo helps the immune system recognize and destroy these cancer cells.\n\n### Indications\n- **FDA Approval**: Poteligeo is approved for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S\u00e9zary syndrome (SS) after at least one prior systemic therapy.\n\n### Administration\n- **Form**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_vj8uUUbBykay27limAz3EXA1", "custom_id": "542_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "617588f71b2118115a029ccb8bd7cbec", "body": {"id": "chatcmpl-9St4W5KK673PxiaKtn8MejyHa0YO0", "object": "chat.completion", "created": 1716671908, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lumoxiti (moxetumomab pasudotox-tdfk) is a prescription medication used to treat certain types of cancer, specifically relapsed or refractory hairy cell leukemia (HCL) in adult patients who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Here are some key points you should know about Lumoxiti:\n\n### Mechanism of Action\n- **Targeted Therapy**: Lumoxiti is a CD22-directed cytotoxin. It binds to the CD22 antigen on the surface of B-cells, including malignant HCL cells, and delivers a toxin that inhibits protein synthesis, leading to cell death.\n\n### Administration\n- **Intravenous Infusion**: Lumoxiti is administered as an intravenous infusion over 30 minutes on days 1, 3, and 5 of each 28-day cycle. The treatment cycles are repeated every 28 days for up to 6 cycles, depending on"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ja4PjlZXFwJXsEbOq3azfoTS", "custom_id": "543_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "44b23dd4588073accfc4e9feb9ed8c15", "body": {"id": "chatcmpl-9St4WRZnUidsnNXKfm1EkFDDnZnxq", "object": "chat.completion", "created": 1716671908, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fraxiparine, also known by its generic name nadroparin, is a low molecular weight heparin (LMWH) used primarily for its anticoagulant properties. Here are some key points you should know about Fraxiparine:\n\n### Indications:\n1. **Prophylaxis of Venous Thromboembolism (VTE):** Commonly used to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing surgery or those with limited mobility.\n2. **Treatment of VTE:** Used in the treatment of established DVT and PE.\n3. **Acute Coronary Syndromes (ACS):** Sometimes used in the management of unstable angina and non-ST elevation myocardial infarction (NSTEMI).\n4. **Dialysis:** Used to prevent clotting in the extracorporeal circuit during hemodialysis.\n\n### Mechanism of Action:\n- Fraxiparine enhances the activity of antithrom"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_OJTbXBac3ohDak5OQCrCx47L", "custom_id": "544_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1a747f403a70324c28184a3bd2117734", "body": {"id": "chatcmpl-9St4XnhiOQpV6i6vCUATGl8Xuzx7K", "object": "chat.completion", "created": 1716671909, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Portrazza (necitumumab) is a monoclonal antibody used in the treatment of certain types of cancer. Here are some key points you should know about Portrazza as a physician:\n\n### Indications:\n- **Non-Small Cell Lung Cancer (NSCLC):** Portrazza is primarily indicated for the treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin. It is not indicated for non-squamous NSCLC.\n\n### Mechanism of Action:\n- **EGFR Inhibition:** Portrazza targets the epidermal growth factor receptor (EGFR), which is often overexpressed in certain types of cancer cells. By binding to EGFR, it inhibits the receptor's activation and downstream signaling pathways, which can reduce tumor growth and proliferation.\n\n### Administration:\n- **Intravenous Infusion:** Portrazza is administered as an intravenous infusion. The recommended dose is 800 mg on days "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_WBDDp50Nlv9WCaqLMKAJMkg3", "custom_id": "545_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "cdc76c8f4bff02ab03d745fd29477465", "body": {"id": "chatcmpl-9St4XJF4OyRqQFpmhlq4ili02AxoV", "object": "chat.completion", "created": 1716671909, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or treatment known as \"Aqupla.\" It is possible that you might be referring to a new or emerging treatment, a brand name that is not widely known, or a typographical error.\n\nIf \"Aqupla\" is a new or emerging treatment, here are some general steps you can take to stay informed:\n\n1. **Consult Medical Literature**: Check recent medical journals, databases like PubMed, and other reputable sources for any studies or articles mentioning \"Aqupla.\"\n\n2. **Pharmaceutical Repositories**: Look up the drug in pharmaceutical databases such as the FDA's database, the European Medicines Agency (EMA), or other national drug regulatory authorities.\n\n3. **Professional Networks**: Engage with professional networks or forums where physicians discuss new treatments and medications. This can include specialty-specific societies or online platforms like Medscape or Doximity.\n\n4. **Manufacturer Information**: If you have any information about"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_kYUSHxg2DSgd8DhaAfC2HmHu", "custom_id": "546_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "607cf191b99d5ed94a700c71978f34c0", "body": {"id": "chatcmpl-9St4YxEjFKt4gGH7YyuBXzh88CaEK", "object": "chat.completion", "created": 1716671910, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Arranon, also known by its generic name nelarabine, is a chemotherapy medication used primarily in the treatment of certain types of leukemia and lymphoma. Here are some key points you should know about Arranon:\n\n### Indications:\n1. **Acute Lymphoblastic Leukemia (ALL):** Arranon is used for the treatment of T-cell acute lymphoblastic leukemia.\n2. **T-cell Lymphoblastic Lymphoma:** It is also indicated for the treatment of T-cell lymphoblastic lymphoma.\n\n### Mechanism of Action:\n- Nelarabine is a prodrug of ara-G (9-\u03b2-D-arabinofuranosylguanine), which is converted intracellularly to its active form. It incorporates into DNA and inhibits DNA synthesis, leading to cell death, particularly in rapidly dividing cells like cancer cells.\n\n### Administration:\n- Arranon is administered intravenously. The dosing schedule can vary based on the specific treatment protocol, patient age, and other factors.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_5StwY9cTdchzjNh0qRJ4PUPo", "custom_id": "547_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7196b4427601e3245d9c1eaf90466b06", "body": {"id": "chatcmpl-9St4YMkNSY460lXoWEugQoi6B0mNX", "object": "chat.completion", "created": 1716671910, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nerlynx (neratinib) is an oral medication used primarily in the treatment of breast cancer. Here are some key points you should know about it:\n\n### Indications:\n1. **Extended Adjuvant Treatment**: Nerlynx is approved for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, following adjuvant trastuzumab-based therapy.\n2. **Metastatic Breast Cancer**: It is also used in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.\n\n### Mechanism of Action:\n- Neratinib is a tyrosine kinase inhibitor that irreversibly binds to the HER2 receptor, as well as the epidermal growth factor receptor (EGFR), thereby inhibiting downstream signaling pathways that promote cell proliferation.\n\n### Dosage and Administration:\n- The recommended dose for extended"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_9egOQGOG1rEBUDJFKScAWkhC", "custom_id": "548_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f6bfd0da8edc415b89825ac74a2a436f", "body": {"id": "chatcmpl-9St4Y2fi69E6gQChZZ3eUBxATINGv", "object": "chat.completion", "created": 1716671910, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tasigna (generic name: nilotinib) is a tyrosine kinase inhibitor used primarily in the treatment of chronic myeloid leukemia (CML) that is Philadelphia chromosome-positive (Ph+). Here are some key points you should know about Tasigna:\n\n### Indications:\n- **Chronic Myeloid Leukemia (CML):** Tasigna is indicated for the treatment of adult patients with newly diagnosed Ph+ CML in the chronic phase.\n- **Resistant or Intolerant CML:** It is also used for patients with chronic or accelerated phase Ph+ CML who are resistant or intolerant to prior therapy, including imatinib.\n\n### Mechanism of Action:\n- Tasigna works by inhibiting the BCR-ABL tyrosine kinase, which is produced by the Philadelphia chromosome abnormality in CML. This inhibition prevents the proliferation of leukemic cells.\n\n### Dosage and Administration:\n- **Dosage:** The typical starting dose is 300 mg taken"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_y3mvwPq9D1cwcLLQxHgftyw9", "custom_id": "549_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f5acf1284b0cd6708e2c84e58bef516c", "body": {"id": "chatcmpl-9St4YaSvjG92xDHkNYeBdK3upOU7Y", "object": "chat.completion", "created": 1716671910, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Anandron, also known by its generic name nilutamide, is a nonsteroidal antiandrogen medication primarily used in the treatment of prostate cancer. Here are some key points you should know about Anandron:\n\n### Indications:\n- **Prostate Cancer:** Nilutamide is used in combination with surgical castration (orchiectomy) or medical castration (using GnRH agonists) for the treatment of metastatic prostate cancer. It helps to block the action of androgens (male hormones) which can stimulate the growth of prostate cancer cells.\n\n### Mechanism of Action:\n- **Antiandrogen:** Nilutamide works by binding to androgen receptors, thereby inhibiting the action of androgens like testosterone. This helps to slow down or stop the growth of androgen-dependent prostate cancer cells.\n\n### Dosage and Administration:\n- **Initial Dose:** Typically, the initial dose is 300 mg per day for the first 30 days.\n- **Maintenance Dose:** After the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_5DQHkQZ3L6XotKKcGifHoqpv", "custom_id": "550_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "4d783d50ba58b96f8d71817d148163d1", "body": {"id": "chatcmpl-9St4YI70YvRk9iYZmpzoAUbPN9P07", "object": "chat.completion", "created": 1716671910, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Nidran\" is not a widely recognized term in conventional Western medicine, so it might be helpful to clarify the context in which you encountered it. However, it is possible that \"Nidran\" could be a term from traditional or alternative medicine systems, such as Ayurveda, where \"Nidra\" refers to sleep.\n\nIf \"Nidran\" is related to \"Nidra\" in Ayurveda, here are some key points you might find useful:\n\n1. **Importance of Sleep (Nidra)**: In Ayurveda, Nidra (sleep) is considered one of the three pillars of health, along with Ahara (diet) and Brahmacharya (lifestyle). Proper sleep is believed to be essential for maintaining physical and mental health.\n\n2. **Sleep Disorders**: Ayurveda recognizes various sleep disorders and attributes them to imbalances in the body's doshas (Vata, Pitta, and Kapha). For example, insomnia might be linked to an imbalance in Vata dos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_rmVNKNbbhgce84gmUMpB70HR", "custom_id": "551_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e3233adf3459a589ece8ec1b9e0209c4", "body": {"id": "chatcmpl-9St4YQhMGj3jJCPfW0H3g8aLa8XuL", "object": "chat.completion", "created": 1716671910, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyendiv is the brand name for nintedanib, a medication used primarily in the treatment of idiopathic pulmonary fibrosis (IPF) and certain types of non-small cell lung cancer (NSCLC). Here are some key points you should know about Cyendiv:\n\n### Indications:\n1. **Idiopathic Pulmonary Fibrosis (IPF):**\n   - Nintedanib is used to slow the progression of IPF, a chronic and ultimately fatal disease characterized by a progressive decline in lung function.\n\n2. **Non-Small Cell Lung Cancer (NSCLC):**\n   - It is used in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic, or locally recurrent NSCLC of adenocarcinoma tumor histology after first-line chemotherapy.\n\n### Mechanism of Action:\n- Nintedanib is a tyrosine kinase inhibitor that targets multiple pathways involved in fibrosis and cancer progression. It inhibits receptors for vascular endothelial growth factor (VEGF"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_C6uIsFTLHe7HOpxed25GyBrG", "custom_id": "552_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3b734fa8b083bfd0bd351f36410590d5", "body": {"id": "chatcmpl-9St4ZFSFnxHNjjKZnDLss7vALtK4x", "object": "chat.completion", "created": 1716671911, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Niranib is a brand name for a medication that contains the active ingredient niraparib, which is a type of drug known as a PARP (poly ADP-ribose polymerase) inhibitor. PARP inhibitors are a class of targeted cancer therapies that interfere with the DNA repair mechanisms in cancer cells, leading to cell death, particularly in cells that are already compromised in their ability to repair DNA, such as those with BRCA1 or BRCA2 mutations.\n\nHere are some key points you should know about Niranib (niraparib):\n\n1. **Indications**: Niraparib is primarily used for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. It may also be used in other specific cancer types as determined by ongoing research and clinical trials.\n\n2. **Mechanism of Action**: Niraparib inhibits the PARP enzyme, which plays a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_oDJtue027UeXQNh2LYumiXTD", "custom_id": "553_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "cb49aed1f7148659d833fe1b8d85855b", "body": {"id": "chatcmpl-9St4ZYneVUJ5ebXP0EuA0fVj1zMKB", "object": "chat.completion", "created": 1716671911, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Opdivo (nivolumab) is a monoclonal antibody that works as an immune checkpoint inhibitor, specifically targeting the programmed death-1 (PD-1) receptor. It is used in the treatment of various types of cancer. Here are some key points you should know about Opdivo:\n\n### Indications\nOpdivo is approved for the treatment of several types of cancer, including:\n- Melanoma\n- Non-small cell lung cancer (NSCLC)\n- Renal cell carcinoma (RCC)\n- Classical Hodgkin lymphoma (cHL)\n- Squamous cell carcinoma of the head and neck (SCCHN)\n- Urothelial carcinoma\n- Hepatocellular carcinoma (HCC)\n- Colorectal cancer (CRC) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)\n- Esophageal cancer\n- Gastric cancer\n\n### Mechanism of Action\nOpdivo works by blocking the PD-1 receptor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_czutSGWIHq3tTnpOwGKcGXbl", "custom_id": "554_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "cf5c97b13a6ae5098160e74f609181e0", "body": {"id": "chatcmpl-9St4Zsfen1ltbX9ni8U1ywiWeBKwO", "object": "chat.completion", "created": 1716671911, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Myocet is a non-pegylated liposomal formulation of doxorubicin, an anthracycline antibiotic commonly used in cancer chemotherapy. Here are some key points you should know about Myocet:\n\n1. **Indications**: Myocet is primarily indicated for the treatment of metastatic breast cancer in combination with cyclophosphamide. It may also be used in other off-label settings where doxorubicin is indicated, but this should be based on clinical judgment and patient-specific factors.\n\n2. **Mechanism of Action**: Like doxorubicin, Myocet works by intercalating DNA strands, inhibiting topoisomerase II, and generating free radicals, which leads to cytotoxicity and apoptosis in rapidly dividing cancer cells.\n\n3. **Formulation Benefits**: The liposomal encapsulation of doxorubicin in Myocet helps to reduce the cardiotoxicity commonly associated with conventional doxorubicin. This is because the liposomes"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_1MtjZbXjxeZIQJ5LZRd7zhox", "custom_id": "555_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "40e34fae69154838bbd3cce8b0dc2fd6", "body": {"id": "chatcmpl-9St4a7CRKNDsLAheQZBdFMHSEZ0eO", "object": "chat.completion", "created": 1716671912, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nilevar, also known by its generic name norethandrolone, is an anabolic-androgenic steroid (AAS) that was historically used in medicine but is no longer commonly prescribed. Here are some key points you should know about Nilevar:\n\n### Pharmacology\n- **Mechanism of Action**: Nilevar is a synthetic derivative of testosterone. It exhibits both anabolic (muscle-building) and androgenic (development of male characteristics) properties.\n- **Administration**: It was typically administered orally.\n\n### Medical Uses\n- **Historical Uses**: Nilevar was used to treat conditions such as muscle wasting, severe burns, chronic infections, and certain types of anemia. It was also used to promote weight gain in patients who had difficulty maintaining a healthy weight.\n- **Current Status**: Due to the development of newer medications with better safety profiles, Nilevar is rarely used in modern medical practice.\n\n### Side Effects\n- **Androgenic Effects**: These can include acne"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_HBslTA6aRMo91LfoceqYjVXy", "custom_id": "556_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "59e41ac953d1c3c73013eca8d19195c4", "body": {"id": "chatcmpl-9St4anpYfoxsADDK30O69nysOS14c", "object": "chat.completion", "created": 1716671912, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gazyva (obinutuzumab) is a monoclonal antibody used primarily in the treatment of certain types of blood cancers, such as chronic lymphocytic leukemia (CLL) and follicular lymphoma. Here are some key points you should know about Gazyva:\n\n### Mechanism of Action\n- **Target**: Gazyva targets the CD20 protein found on the surface of B-cells.\n- **Action**: It works by binding to CD20, leading to the destruction of these B-cells through multiple mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct cell death.\n\n### Indications\n- **Chronic Lymphocytic Leukemia (CLL)**: Often used in combination with chlorambucil for the treatment of patients with previously untreated CLL.\n- **Follicular Lymphoma**: Used in combination with chemotherapy for the initial treatment of patients with advanced follicular lymphoma,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_fJRFiZ3PgP5tsrjaJvqFj1aH", "custom_id": "557_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6c5f82fbf5c549dc02e7bdbd4ac2bf53", "body": {"id": "chatcmpl-9St4anpPUAeUnDSHWjIiK2JPybmLK", "object": "chat.completion", "created": 1716671912, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It appears there might be a misunderstanding or a typographical error in your query, as \"Longastatina\" does not correspond to any known medical term, medication, or condition in the current medical literature up to my knowledge cutoff in October 2023. \n\nIf you meant a specific medication, condition, or medical term, please provide more context or check the spelling. However, if you were referring to a known term or medication, here are some general guidelines on what a physician should know about any medication or condition:\n\n1. **Indications and Usage**: Understand what the medication or treatment is used for, including the specific conditions it treats.\n\n2. **Mechanism of Action**: Know how the medication works in the body to achieve its therapeutic effects.\n\n3. **Dosage and Administration**: Be familiar with the recommended dosages, routes of administration, and any special instructions for use.\n\n4. **Side Effects and Adverse Reactions**: Be aware of common and serious side"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_uCLmwsSWpabosJEzqYRTVNKO", "custom_id": "558_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "8fbbac300979aa4c8e239bfbdabf6134", "body": {"id": "chatcmpl-9St4aa5EhO0JDxz9nU8TmA96ptaUf", "object": "chat.completion", "created": 1716671912, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Longastatina LAR is not a recognized medication name, so it might be a typographical error or a miscommunication. However, it sounds similar to \"Lanreotide\" (brand name Somatuline Depot) or \"Octreotide LAR\" (brand name Sandostatin LAR), which are long-acting somatostatin analogs used in medical practice. Here is some general information about these medications:\n\n### Lanreotide (Somatuline Depot)\n- **Indications**: Used primarily for the treatment of acromegaly, neuroendocrine tumors, and to manage symptoms associated with carcinoid syndrome.\n- **Mechanism of Action**: Lanreotide mimics natural somatostatin, inhibiting the release of several hormones, including growth hormone and insulin.\n- **Administration**: Given as a deep subcutaneous injection, typically every 4 weeks.\n- **Side Effects**: Common side effects include gastrointestinal issues (diarrhea, abdominal"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_VGW0wanw33hgr5QInJ3iKY1K", "custom_id": "559_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "833798106a154da76bab7b6ab20434a5", "body": {"id": "chatcmpl-9St4ap4nR2ZuPhIvxnTVfWLjurTbM", "object": "chat.completion", "created": 1716671912, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Arzerra (ofatumumab) is a monoclonal antibody used primarily in the treatment of chronic lymphocytic leukemia (CLL). Here are some key points you should know about Arzerra:\n\n### Mechanism of Action\n- **Target**: Ofatumumab targets the CD20 molecule on the surface of B-cells.\n- **Action**: It binds to CD20, leading to B-cell lysis through complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).\n\n### Indications\n- **Chronic Lymphocytic Leukemia (CLL)**: Arzerra is indicated for the treatment of patients with CLL who are refractory to fludarabine and alemtuzumab.\n- **Other Uses**: It may also be used in combination with other therapies for CLL, depending on the specific clinical scenario and guidelines.\n\n### Administration\n- **Route**: Intravenous infusion.\n- **Dosing Schedule"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_oVirc9f9cD8OXPcpLckhBRUS", "custom_id": "560_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "92af66198639912b02d35c663d3c3cfe", "body": {"id": "chatcmpl-9St4bxUe7TIylH2ViEZrU3JmoJbIM", "object": "chat.completion", "created": 1716671913, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lynparza (generic name: olaparib) is a medication used primarily in the treatment of certain types of cancer. Here are some key points you should know about Lynparza as a physician:\n\n### Indications:\n1. **Ovarian Cancer**: Lynparza is approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\n2. **Breast Cancer**: It is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer who have been treated with chemotherapy.\n3. **Pancreatic Cancer**: Lynparza is used as a maintenance treatment for adult patients with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_lNFGiuNcPn69JLtCceeXZ0lQ", "custom_id": "561_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e593414ee4159576fea21d51e8316e45", "body": {"id": "chatcmpl-9St4bUxnmzI2Vzvd52MVVZ1YPKXMv", "object": "chat.completion", "created": 1716671913, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lartruvo (olaratumab) is a medication that was used in the treatment of soft tissue sarcoma, a type of cancer that begins in the tissues that connect, support, or surround other body structures. Here are some key points you should know about Lartruvo:\n\n1. **Mechanism of Action**: Lartruvo is a monoclonal antibody that targets the platelet-derived growth factor receptor alpha (PDGFR-\u03b1). By binding to this receptor, it is thought to inhibit tumor growth.\n\n2. **Indications**: Lartruvo was approved for use in combination with doxorubicin for the treatment of adult patients with soft tissue sarcoma that is not amenable to curative treatment with radiotherapy or surgery and for whom treatment with an anthracycline is appropriate.\n\n3. **Efficacy Concerns**: Lartruvo was granted accelerated approval based on preliminary data suggesting a benefit. However, subsequent confirmatory trials (such as the ANNOUN"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_K7kpIANLe9Y62l915ro9PatJ", "custom_id": "562_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a0655889086e08cdfa8c2c9af44b0b8a", "body": {"id": "chatcmpl-9St4bPYSVdGeFMln9yOLwZPY0FDvt", "object": "chat.completion", "created": 1716671913, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Omapro, also known by its generic name omacetaxine mepesuccinate, is a medication used primarily in the treatment of chronic myeloid leukemia (CML). Here are some key points you should know about Omapro:\n\n### Indications:\n- **Chronic Myeloid Leukemia (CML):** Omapro is indicated for adult patients with chronic or accelerated phase CML who have failed treatment with at least two tyrosine kinase inhibitors (TKIs).\n\n### Mechanism of Action:\n- **Protein Synthesis Inhibition:** Omacetaxine mepesuccinate works by inhibiting protein synthesis, which leads to the reduction of certain proteins that are essential for the survival and proliferation of leukemic cells.\n\n### Administration:\n- **Subcutaneous Injection:** Omapro is administered via subcutaneous injection. The dosing schedule typically involves an induction phase followed by a maintenance phase.\n- **Induction Phase:** Administered twice daily for 14 consecutive days of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_xVpyNH88w0n4ulKAToJkK2MO", "custom_id": "563_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "bb801b82d20c03eb6c625c60c996e570", "body": {"id": "chatcmpl-9St4b3GJxiIlGV2cSOcm8m2qa1fb2", "object": "chat.completion", "created": 1716671913, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prilosec, whose generic name is omeprazole, is a proton pump inhibitor (PPI) commonly used to treat conditions related to excess stomach acid. Here are some key points you should know about Prilosec:\n\n### Indications:\n1. **Gastroesophageal Reflux Disease (GERD):** Prilosec is often prescribed to manage symptoms of GERD, such as heartburn and acid regurgitation.\n2. **Peptic Ulcer Disease:** It is used to treat and prevent ulcers in the stomach and duodenum.\n3. **Erosive Esophagitis:** Prilosec helps heal damage to the esophagus caused by stomach acid.\n4. **Zollinger-Ellison Syndrome:** It is used in the management of this rare condition characterized by excessive gastric acid production.\n5. **H. pylori Infection:** Often used in combination with antibiotics to eradicate Helicobacter pylori.\n\n### Mechanism of Action:\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_IX4j6n0z0VUsNkRohNBiJyYJ", "custom_id": "564_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f104e89c5c656c7edf1520e78fc48344", "body": {"id": "chatcmpl-9St4c2gZhoYQzb4JcrW3znli4e34D", "object": "chat.completion", "created": 1716671914, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Osimert, also known as Osimertinib, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used primarily in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. Here are some key points you should know about Osimertinib:\n\n### Indications:\n1. **First-line Treatment**: Osimertinib is approved for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.\n2. **Second-line Treatment**: It is also indicated for patients with metastatic EGFR T790M mutation-positive NSCLC, who have progressed on or after EGFR TKI therapy.\n\n### Mechanism of Action:\n- Osimertinib selectively inhibits both EGFR-sensitizing mutations and the T790M resistance mutation, which is a common mechanism of resistance to first"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_X1Ve3yPOt72E6I4xp6AeQlXr", "custom_id": "565_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0a2b9c41a298c629c14fbf429045e8e8", "body": {"id": "chatcmpl-9St4cKm4mtJ6PyoouByzWSpqWsrkF", "object": "chat.completion", "created": 1716671914, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or substance known as \"Coxatin.\" It is possible that it could be a new drug, a misspelling, or a less common name for an existing medication. Here are a few steps you can take to gather more information:\n\n1. **Verify the Name**: Double-check the spelling and ensure that it is correct. Sometimes, drug names can be easily misspelled or misheard.\n\n2. **Consult Reliable Sources**: Look up the name in trusted medical databases such as PubMed, Medline, or drug reference guides like the Physicians' Desk Reference (PDR) or the British National Formulary (BNF).\n\n3. **Ask Colleagues**: Consult with other healthcare professionals who might have come across the term.\n\n4. **Contact Pharmaceutical Representatives**: If it is a new drug, pharmaceutical representatives or the company that manufactures it might provide detailed information.\n\n5. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ID2xh7fV86tOcAd5urDVrHIY", "custom_id": "566_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "16f0607c4353a95433b80bc50ed90d61", "body": {"id": "chatcmpl-9St4cFrghR32vzTew4dbsHU0l7W6q", "object": "chat.completion", "created": 1716671914, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abraxane, also known by its generic name paclitaxel albumin-bound, is a chemotherapy medication used primarily in the treatment of various cancers. Here are some key points you should know about Abraxane:\n\n### Indications:\n1. **Breast Cancer**: Abraxane is approved for the treatment of metastatic breast cancer, particularly in patients who have failed combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy.\n2. **Non-Small Cell Lung Cancer (NSCLC)**: It is used in combination with carboplatin for the first-line treatment of locally advanced or metastatic NSCLC in patients who are not candidates for curative surgery or radiation therapy.\n3. **Pancreatic Cancer**: Abraxane is used in combination with gemcitabine for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.\n\n### Mechanism of Action:\n- Abraxane is a formulation of paclitaxel bound to albumin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Pofa3x3hJ0GAmJaHpkqBpHiO", "custom_id": "567_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "cea9a4f029b7e76557fd2c24afbaac4e", "body": {"id": "chatcmpl-9St4cTSrsT9SvXcv8M2BPpqBzx2pI", "object": "chat.completion", "created": 1716671914, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or treatment known as \"Abitaxel.\" It's possible that you might be referring to a typographical error or a lesser-known, experimental, or regional name for a drug. However, if you meant \"Abraxane\" or \"Paclitaxel,\" I can provide information on those.\n\n### Paclitaxel\nPaclitaxel is a chemotherapy drug used to treat various types of cancer, including ovarian, breast, lung, pancreatic, and others. It works by inhibiting cell division, which helps to stop the growth of cancer cells.\n\n#### Key Points:\n- **Mechanism of Action**: Paclitaxel stabilizes microtubules and inhibits their disassembly, which disrupts the mitotic process, leading to cell death.\n- **Administration**: It is usually administered intravenously.\n- **Side Effects**: Common side effects include neutropenia, peripheral neuropathy,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_bKzliya1IAqjzprXtftRRoQO", "custom_id": "568_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "654b389f442540725939deacb39683c9", "body": {"id": "chatcmpl-9St4dFfX3Wo2yyDAFOTIw57Tc5Ebp", "object": "chat.completion", "created": 1716671915, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vonjo (pacritinib) is a medication used in the treatment of myelofibrosis, a type of bone marrow cancer that disrupts the body's normal production of blood cells. Here are some key points you should know about Vonjo:\n\n1. **Mechanism of Action**: Pacritinib is a selective inhibitor of Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). These kinases are involved in the signaling pathways that regulate blood cell production and immune function. By inhibiting these kinases, pacritinib can help reduce the abnormal proliferation of blood cells and alleviate symptoms of myelofibrosis.\n\n2. **Indications**: Vonjo is specifically indicated for the treatment of intermediate or high-risk myelofibrosis, particularly in patients with thrombocytopenia (low platelet counts). It is often considered when other treatments, such as ruxolitinib, are not suitable or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_WyTphjv6R1fia4ccmXjGfKVY", "custom_id": "569_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f4f07b79c04660ca734b0750c4a9215f", "body": {"id": "chatcmpl-9St4dyyurDEGxCCtH6BVVGGHAfpGS", "object": "chat.completion", "created": 1716671915, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibrance (palbociclib) is a medication used primarily in the treatment of certain types of breast cancer. Here are some key points you should know about Ibrance as a physician:\n\n### Indications:\n1. **Breast Cancer**: Ibrance is indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.\n2. **Combination Therapy**: It is typically used in combination with an aromatase inhibitor (e.g., letrozole) as initial endocrine-based therapy in postmenopausal women, or with fulvestrant in patients with disease progression following endocrine therapy.\n\n### Mechanism of Action:\n- **CDK4/6 Inhibitor**: Ibrance works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which are involved in cell cycle progression. By inhibiting these kinases, I"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_UtOIffIDRoQ3MaqFrP59Hehl", "custom_id": "570_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "04268761a067c6473ac3f09dc57f522c", "body": {"id": "chatcmpl-9St4duXoVx9hud8od6Egx98WtNYUG", "object": "chat.completion", "created": 1716671915, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vectibix (generic name: panitumumab) is a monoclonal antibody used in the treatment of metastatic colorectal cancer. Here are some key points you should know about Vectibix as a physician:\n\n### Mechanism of Action\n- **Target**: Vectibix targets the epidermal growth factor receptor (EGFR), which is often overexpressed in colorectal cancer cells.\n- **Action**: By binding to EGFR, Vectibix inhibits the receptor's activation and downstream signaling pathways, which can lead to reduced tumor cell proliferation and survival.\n\n### Indications\n- **Metastatic Colorectal Cancer**: Vectibix is indicated for the treatment of patients with wild-type RAS (KRAS and NRAS) metastatic colorectal cancer. It is not effective in patients with RAS mutations.\n\n### Administration\n- **Route**: Vectibix is administered via intravenous infusion.\n- **Dosage**: The typical dosage is 6 mg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_fmm8Vjq3OTRAmZZIVhkmMF2D", "custom_id": "571_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "aae234ba7da9d27932ea94352bd8bc6b", "body": {"id": "chatcmpl-9St4dRNHN6vlBkdWlvBcSvPk5iT8L", "object": "chat.completion", "created": 1716671915, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a typo or some confusion in your question. If you meant \"Faridat,\" \"Faridac,\" or another specific term, please provide more context or clarify. However, if you are referring to a specific medication, medical condition, or patient name, here are some general guidelines for what you should know as a physician:\n\n1. **Medication (if applicable):**\n   - **Indications:** What conditions or diseases is the medication used to treat?\n   - **Dosage and Administration:** Recommended dosages, routes of administration, and any special instructions.\n   - **Mechanism of Action:** How the medication works in the body.\n   - **Side Effects:** Common and serious side effects to monitor.\n   - **Contraindications:** Situations or conditions where the medication should not be used.\n   - **Interactions:** Potential interactions with other medications, foods, or medical conditions.\n\n2. **Medical Condition (if applicable):**\n   - **Symptoms:**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_udAzucfDFE2eOh7FYfR87thO", "custom_id": "572_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d717f7fd53c00242bc81512b36e56114", "body": {"id": "chatcmpl-9St4eCdDvW0oM8vvrLar9q7ZLj61s", "object": "chat.completion", "created": 1716671916, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a typo in your question. If you meant \"Pazopanib,\" I can provide information on that. Pazopanib is a medication used in the treatment of certain types of cancer, specifically renal cell carcinoma (RCC) and soft tissue sarcoma (STS). Here are some key points you should know about Pazopanib:\n\n### Mechanism of Action\n- **Pazopanib** is a tyrosine kinase inhibitor that targets multiple receptors involved in tumor growth and angiogenesis, including VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-\u03b1/\u03b2, and c-kit.\n\n### Indications\n- **Renal Cell Carcinoma (RCC):** Pazopanib is approved for the treatment of advanced RCC.\n- **Soft Tissue Sarcoma (STS):** It is also approved for the treatment of advanced STS in patients who have received prior chemotherapy.\n\n### Dosage and Administration\n- The usual"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_UJ5FRlHxvaMP2MHMtstaUFBm", "custom_id": "573_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f3b455afb32dbcfea1a4159be9194f73", "body": {"id": "chatcmpl-9St4drJtsqN9qq6qPaspGpo57I3WE", "object": "chat.completion", "created": 1716671915, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Oncaspar (pegaspargase) is a medication used primarily in the treatment of acute lymphoblastic leukemia (ALL). Here are some key points you should know about Oncaspar:\n\n### Mechanism of Action\n- **Enzyme Activity**: Oncaspar is a modified form of the enzyme L-asparaginase. It works by breaking down asparagine, an amino acid that leukemia cells need to survive. Normal cells can produce asparagine, but leukemia cells cannot, making them more susceptible to the effects of Oncaspar.\n\n### Indications\n- **Acute Lymphoblastic Leukemia (ALL)**: Oncaspar is used as part of a multi-agent chemotherapeutic regimen for the treatment of ALL.\n- **Hypersensitivity to Asparaginase**: It is often used in patients who have developed hypersensitivity to native forms of L-asparaginase.\n\n### Administration\n- **Route**: Oncaspar is administered via intr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Lz2QLYFOduxCpvPGlZH5tyct", "custom_id": "574_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1fe814dc65dea0dcf14e463641e5812e", "body": {"id": "chatcmpl-9St4eF31VW3exv27ujc44UK9uVibf", "object": "chat.completion", "created": 1716671916, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pegasys (peginterferon alfa-2a) is a medication used primarily in the treatment of chronic hepatitis B and C. Here are some key points you should know about Pegasys as a physician:\n\n### Mechanism of Action\n- **Pegasys** is a pegylated interferon, which means it is a form of interferon that has been chemically modified by the addition of polyethylene glycol (PEG). This modification increases the half-life of the drug, allowing for less frequent dosing.\n- It works by enhancing the immune system's ability to fight off viral infections.\n\n### Indications\n- **Chronic Hepatitis C**: Often used in combination with other antiviral medications like ribavirin.\n- **Chronic Hepatitis B**: Used as monotherapy or in combination with other antiviral agents.\n\n### Dosage and Administration\n- **Hepatitis C**: Typically administered as a subcutaneous injection once weekly. The dosage may vary depending on the genotype of the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_MCEc9luGXJLmvFFsL7YiqESk", "custom_id": "575_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "730464198193d876e2c38de648abde1b", "body": {"id": "chatcmpl-9St4eiYzOeKa2CtrCIwLvWGzHrtXa", "object": "chat.completion", "created": 1716671916, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "PEG-Intron, also known as peginterferon alfa-2b, is a medication used primarily in the treatment of chronic hepatitis C. Here are some key points you should know about PEG-Intron:\n\n### Mechanism of Action\n- **Interferon Alfa-2b**: PEG-Intron is a pegylated form of interferon alfa-2b. Pegylation involves attaching polyethylene glycol (PEG) to the interferon molecule, which extends its half-life and allows for less frequent dosing.\n- **Antiviral and Immunomodulatory Effects**: It works by enhancing the immune system's response to viral infections and has direct antiviral effects.\n\n### Indications\n- **Chronic Hepatitis C**: It is primarily used in combination with ribavirin for the treatment of chronic hepatitis C in patients with compensated liver disease.\n- **Other Uses**: It may also be used in certain cases of malignant melanoma and other viral infections, although these are less common indications.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_P8Gp5nDJOShDkNblHw2Ca67X", "custom_id": "576_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ba61e65b1ee3e819f06d52dca94057c8", "body": {"id": "chatcmpl-9St4eRb2sAzutPbNADIZACUoTTfjK", "object": "chat.completion", "created": 1716671916, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Caelyx, also known as pegylated liposomal doxorubicin, is a chemotherapeutic agent used in the treatment of various cancers. Here are some key points you should know about Caelyx:\n\n### Indications:\n1. **Ovarian Cancer**: Caelyx is often used for patients with advanced ovarian cancer who have failed first-line platinum-based chemotherapy.\n2. **Breast Cancer**: It is used for metastatic breast cancer, particularly in patients who have increased cardiac risk or have failed other treatments.\n3. **Multiple Myeloma**: In combination with bortezomib, it is used for patients who have received at least one prior therapy.\n4. **AIDS-related Kaposi's Sarcoma**: It is indicated for patients with advanced disease.\n\n### Mechanism of Action:\n- **Doxorubicin**: The active ingredient, doxorubicin, is an anthracycline antibiotic that intercalates DNA, inhib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_vk03zcAgioK4Auwo8wf3o4Tb", "custom_id": "577_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "8056db3b6784e8aa4fcbcd4c013803fc", "body": {"id": "chatcmpl-9St4eIQh60HlxhAeOhaZdHEYB582V", "object": "chat.completion", "created": 1716671916, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Keytruda (pembrolizumab) is a monoclonal antibody used as an immunotherapy treatment for various types of cancer. Here are some key points you should know about Keytruda as a physician:\n\n### Mechanism of Action\n- **PD-1 Inhibition**: Keytruda works by blocking the programmed death-1 (PD-1) receptor on T cells. This inhibition prevents cancer cells from evading the immune system, allowing T cells to recognize and attack the cancer cells.\n\n### Indications\n- **Melanoma**: Both unresectable or metastatic melanoma and adjuvant treatment of melanoma with lymph node involvement.\n- **Non-Small Cell Lung Cancer (NSCLC)**: First-line treatment for metastatic NSCLC with PD-L1 expression and no EGFR or ALK genomic tumor aberrations.\n- **Head and Neck Squamous Cell Carcinoma (HNSCC)**: Recurrent or metastatic HNSCC.\n- **Classical Hodg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_0xDowAx3Atd4AVDvd4mBIGYm", "custom_id": "578_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "4acc2f68548a6202019057b85874399a", "body": {"id": "chatcmpl-9St4fSbLmFUoIkFRUIYPfg8xLGewt", "object": "chat.completion", "created": 1716671917, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alimta, also known by its generic name pemetrexed, is a chemotherapy drug used primarily in the treatment of certain types of cancer, including malignant pleural mesothelioma and non-small cell lung cancer (NSCLC). Here are some key points you should know about Alimta:\n\n### Mechanism of Action\n- **Antifolate Agent**: Alimta works by inhibiting several key enzymes involved in the folate pathway, which is crucial for DNA and RNA synthesis. Specifically, it targets thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase.\n- **Cell Cycle Specificity**: It is most effective during the S-phase of the cell cycle, where DNA synthesis occurs.\n\n### Indications\n- **Malignant Pleural Mesothelioma**: Often used in combination with cisplatin for patients whose disease is unresectable or who are not candidates for curative surgery.\n- **Non"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_MixoWimqbXKutKdymlObxbKz", "custom_id": "579_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "52053aa86e1dd87ab506789d6c1a7bb1", "body": {"id": "chatcmpl-9St4fMcJnzQwo5sNy4FYxCDP3Glp1", "object": "chat.completion", "created": 1716671917, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nipent, also known by its generic name pentostatin, is a chemotherapeutic agent used primarily in the treatment of hairy cell leukemia. Here are some key points you should know about Nipent:\n\n### Mechanism of Action\n- **Pentostatin** is an adenosine deaminase inhibitor. By inhibiting this enzyme, it leads to an accumulation of deoxyadenosine triphosphate, which is toxic to lymphocytes, particularly malignant ones.\n\n### Indications\n- **Hairy Cell Leukemia**: It is primarily indicated for the treatment of this rare type of leukemia.\n- **Other Uses**: It may be used off-label for other hematologic malignancies, but this should be based on clinical judgment and emerging evidence.\n\n### Administration\n- **Dosage**: Typically administered intravenously at a dose of 4 mg/m\u00b2 every other week. The exact dosage and schedule may vary based on patient-specific factors.\n- **Preparation and Handling**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_SxD6ISSxlSzvEzvf6pDlwuKu", "custom_id": "580_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7e2376816756950b6028b370ada6accd", "body": {"id": "chatcmpl-9St4fKHhGyUWLz4WufuBJ9HHcV6fD", "object": "chat.completion", "created": 1716671917, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Omnitarg, also known by its generic name pertuzumab, is a monoclonal antibody used in the treatment of certain types of breast cancer. Here are some key points you should know about Omnitarg:\n\n1. **Mechanism of Action**: Pertuzumab targets the HER2 receptor, a protein that can promote the growth of cancer cells. By binding to the HER2 receptor, pertuzumab inhibits the receptor's ability to pair with other HER family members, thereby blocking the signaling pathways that lead to cell growth and survival.\n\n2. **Indications**: Pertuzumab is primarily used in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic breast cancer. It is also used in the neoadjuvant (pre-surgery) and adjuvant (post-surgery) settings for HER2-positive early breast cancer.\n\n3. **Administration**: Pertuzumab is administered intravenously. The initial dose is typically 840 mg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_COrvwKRwag733T4ax5IY2aNw", "custom_id": "581_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "bb01d147e4ae99f80d61190827f3fa72", "body": {"id": "chatcmpl-9St4foRGHe6NXWYn36oCwHZUAEliV", "object": "chat.completion", "created": 1716671917, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pinorubicin, also known as epirubicin, is an anthracycline antibiotic used primarily as a chemotherapeutic agent. Here are some key points you should know about it:\n\n### Mechanism of Action:\n- **DNA Intercalation**: Epirubicin intercalates into DNA, disrupting the function of topoisomerase II, an enzyme crucial for DNA replication and transcription.\n- **Free Radical Formation**: It generates free radicals that cause damage to cellular components, including DNA, proteins, and cell membranes.\n\n### Indications:\n- **Breast Cancer**: Often used in the treatment of early and advanced breast cancer.\n- **Gastrointestinal Cancers**: Sometimes used for gastric and esophageal cancers.\n- **Lymphomas and Leukemias**: Utilized in certain hematologic malignancies.\n\n### Administration:\n- **Intravenous (IV)**: Typically administered via IV infusion. The dosage and schedule depend on the specific cancer being treated"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_uHWVNYhs4ZbWYhQeYnSYBdYp", "custom_id": "582_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "df2f0fa9557d619af4f1bc58b2178986", "body": {"id": "chatcmpl-9St4fDhvgKMoqecWKMIUAG7ZcaCUg", "object": "chat.completion", "created": 1716671917, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pixuvri (pixantrone) is a medication used primarily in the treatment of certain types of non-Hodgkin lymphoma (NHL), particularly aggressive B-cell NHL. Here are some key points you should know about Pixuvri:\n\n### Mechanism of Action\n- **Pixantrone** is an aza-anthracenedione, which is structurally related to anthracyclines but designed to reduce the cardiotoxicity associated with traditional anthracyclines.\n- It works by intercalating into DNA and inhibiting topoisomerase II, leading to DNA strand breaks and apoptosis of cancer cells.\n\n### Indications\n- Pixuvri is indicated for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.\n\n### Administration\n- **Dosage**: The recommended dose is 50 mg/m\u00b2 administered as an intravenous infusion over 1 hour on days 1, 8, and 15"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_aG8H81swG9l7GNixXqcBUCWv", "custom_id": "583_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "05e6f460a4ba3efaf927a1bbe5ad15ff", "body": {"id": "chatcmpl-9St4gB8iTfwJ03EEjOaR9W4U74Pwm", "object": "chat.completion", "created": 1716671918, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mithracin, also known as plicamycin, is an antineoplastic antibiotic that was historically used in the treatment of certain types of cancer, such as testicular cancer and hypercalcemia associated with malignancy. However, it is important to note that Mithracin is no longer widely used and has been largely replaced by other therapies due to its significant toxicity and the development of more effective and safer alternatives.\n\nHere are some key points you should know about Mithracin:\n\n1. **Mechanism of Action**: Mithracin works by binding to DNA and inhibiting RNA synthesis, which interferes with the growth and proliferation of cancer cells.\n\n2. **Indications**: Historically, it was used for:\n   - Testicular cancer\n   - Hypercalcemia and hypercalciuria associated with malignancy\n\n3. **Administration**: Mithracin was typically administered intravenously.\n\n4. **Side Effects**: The drug is associated with a range of serious side"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_DFvdU79pI8dFZm5go813v9sn", "custom_id": "584_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9457269e7a9344a5d5bacb66797548da", "body": {"id": "chatcmpl-9St4hBXEjdS4x6i9gYO6NcABS4cWZ", "object": "chat.completion", "created": 1716671919, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Actimid is a brand name for the drug pomalidomide, which is an immunomodulatory agent used primarily in the treatment of multiple myeloma, a type of blood cancer. Here are some key points you should know about Actimid (pomalidomide):\n\n### Indications:\n- **Multiple Myeloma:** Actimid is typically used in combination with dexamethasone for patients who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of the last therapy.\n\n### Mechanism of Action:\n- Pomalidomide works by modulating the immune system and has anti-angiogenic properties. It enhances T-cell and natural killer (NK) cell-mediated cytotoxicity and inhibits the proliferation of myeloma cells.\n\n### Dosage and Administration:\n- The typical starting dose is 4 mg orally once daily on days 1-21 of each "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_XSicdtEV5JHb7GTUD38WvQyY", "custom_id": "585_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f61987ad390943d98583f2a0b873ddbd", "body": {"id": "chatcmpl-9St4hOG8UJQ6pMNLBsw3mHrvgrrfl", "object": "chat.completion", "created": 1716671919, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Iclusig (ponatinib) is a tyrosine kinase inhibitor used primarily in the treatment of certain types of leukemia, specifically chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Here are some key points you should know about Iclusig:\n\n### Indications:\n1. **Chronic Myeloid Leukemia (CML):**\n   - For adult patients with chronic, accelerated, or blast phase CML who are resistant or intolerant to prior tyrosine kinase inhibitor therapy.\n2. **Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL):**\n   - For adult patients with Ph+ ALL who are resistant or intolerant to prior tyrosine kinase inhibitor therapy.\n\n### Mechanism of Action:\n- Ponatinib inhibits the BCR-ABL tyrosine kinase, including forms of the enzyme that are resistant to other treatments. It also inhibits other kinases such as VEGFR"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_R9annjEDkLMsW5fqh9gBnEii", "custom_id": "586_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "647375206976478a9a2237b941fdc207", "body": {"id": "chatcmpl-9St4hM84p9qINSZAtxqJ7kZqg7csZ", "object": "chat.completion", "created": 1716671919, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Folotyn (generic name: pralatrexate) is a chemotherapy drug used primarily for the treatment of peripheral T-cell lymphoma (PTCL), a type of non-Hodgkin lymphoma. Here are some key points you should know about Folotyn:\n\n### Mechanism of Action\n- **Antifolate Agent**: Folotyn is a folate analog metabolic inhibitor. It works by inhibiting dihydrofolate reductase (DHFR), an enzyme involved in the synthesis of tetrahydrofolate, which is necessary for DNA synthesis and cell replication. This inhibition leads to the disruption of DNA synthesis and induces cell death, particularly in rapidly dividing cancer cells.\n\n### Indications\n- **Peripheral T-Cell Lymphoma (PTCL)**: Folotyn is specifically approved for the treatment of relapsed or refractory PTCL.\n\n### Administration\n- **Intravenous Infusion**: Folotyn is administered as an intravenous (IV) infusion. The typical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_rEnUGanaxTqokksBgczLRlZp", "custom_id": "587_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2f9752767a985a07a57c1c936a2e3d31", "body": {"id": "chatcmpl-9St4hHuloR4N84E4dQQRw7linD6Lc", "object": "chat.completion", "created": 1716671919, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pravachol, also known by its generic name pravastatin, is a medication that belongs to the class of drugs known as statins. It is commonly prescribed to help lower cholesterol and triglycerides in the blood. Here are some key points you should know about Pravachol:\n\n### Indications:\n1. **Hypercholesterolemia**: Pravachol is used to treat high cholesterol levels, particularly when diet and lifestyle changes have not been sufficient.\n2. **Prevention of Cardiovascular Disease**: It is also used to reduce the risk of heart attack, stroke, and other cardiovascular events in patients with or at high risk for cardiovascular disease.\n\n### Mechanism of Action:\n- Pravastatin works by inhibiting HMG-CoA reductase, an enzyme involved in the synthesis of cholesterol in the liver. This leads to a decrease in the production of cholesterol and an increase in the uptake of LDL cholesterol from the blood.\n\n### Dosage:\n- The typical starting dose for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Dk08wRwN0RUCbUqESApBIpx5", "custom_id": "588_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "15ae0773a84cf7caabfbbca2f8772b69", "body": {"id": "chatcmpl-9St4hM6eIHC1Imur7Nk95bBoGICc2", "object": "chat.completion", "created": 1716671919, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It appears there might be a typo or confusion in the name \"Adnisolone.\" There is no widely recognized medication or substance by that name. However, if you meant \"Prednisolone,\" I can provide information on that. Prednisolone is a corticosteroid used to treat a variety of conditions, including allergies, inflammatory diseases, autoimmune disorders, and certain types of cancer. Here are some key points you should know about Prednisolone:\n\n1. **Mechanism of Action**: Prednisolone works by suppressing the immune system and reducing inflammation. It inhibits the release of substances in the body that cause inflammation.\n\n2. **Indications**: It is commonly prescribed for conditions such as asthma, rheumatoid arthritis, lupus, inflammatory bowel disease, and severe allergic reactions. It is also used in the management of certain types of cancer and to prevent organ transplant rejection.\n\n3. **Dosage and Administration**: The dosage of Prednisolone can vary widely depending on the condition being treated,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_TFa10jZKCArr2nQtQnZP66dC", "custom_id": "589_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ce0917ad2dcbe7194de9f45ec48fc70c", "body": {"id": "chatcmpl-9St4h5wqwvTRinITTkEQWJ6FiXGEY", "object": "chat.completion", "created": 1716671919, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a typo or misunderstanding in your question, as \"Artinizona\" does not correspond to any known medical term, medication, or condition. If you meant something else, please provide more context or clarify the term.\n\nHowever, if you were referring to a specific medication, condition, or medical concept, here are some general guidelines on what a physician should know:\n\n1. **Indications and Usage**: Understand what the medication or treatment is used for, including the specific conditions it treats.\n\n2. **Mechanism of Action**: Know how the medication works in the body to achieve its therapeutic effects.\n\n3. **Dosage and Administration**: Be familiar with the recommended dosages, how to administer the medication, and any special instructions for use.\n\n4. **Side Effects and Adverse Reactions**: Be aware of common and serious side effects, and know how to manage them.\n\n5. **Contraindications and Precautions**: Understand which patients should"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_1BSFDHrfA1L4d1wvUUpupj9D", "custom_id": "590_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9fd95b5578679bce2814e78fe417b474", "body": {"id": "chatcmpl-9St4i6a5wu21E1LIlTMsSwrjVA0xb", "object": "chat.completion", "created": 1716671920, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Indicarb is a brand name for the chemotherapeutic agent carboplatin, which is used primarily in the treatment of various types of cancer, including ovarian, lung, head and neck, and testicular cancers. Here are some key points you should know about Indicarb (carboplatin):\n\n### Mechanism of Action\n- **Platinum-Based Chemotherapy**: Carboplatin is a platinum-containing compound that causes cross-linking of DNA, which interferes with DNA repair and replication, ultimately leading to cell death.\n- **Cell Cycle Non-Specific**: It is effective in various phases of the cell cycle, making it a versatile agent in cancer treatment.\n\n### Indications\n- **Ovarian Cancer**: Often used as first-line treatment in combination with other agents like paclitaxel.\n- **Lung Cancer**: Used in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).\n- **Head and Neck Cancer**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_dRFcZXb5qcx4JffkWD3RUwQK", "custom_id": "591_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6d351273d5629da0b7d1da8e4a7a89cb", "body": {"id": "chatcmpl-9St4iMLjkEza1RxZkiB7NWPBGW9UF", "object": "chat.completion", "created": 1716671920, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Qualaquin (quinine sulfate) is a medication primarily used to treat uncomplicated Plasmodium falciparum malaria. Here are some key points you should know about Qualaquin:\n\n### Indications:\n- **Malaria Treatment**: It is specifically indicated for the treatment of uncomplicated malaria caused by Plasmodium falciparum. It is not recommended for the prevention of malaria or for the treatment of severe or complicated malaria.\n\n### Dosage and Administration:\n- **Adult Dosage**: The typical dosage for adults is 648 mg (two capsules) every 8 hours for 7 days.\n- **Administration**: It should be taken with food to minimize gastrointestinal side effects.\n\n### Mechanism of Action:\n- **Antimalarial Activity**: Quinine works by interfering with the parasite's ability to digest hemoglobin, leading to the accumulation of toxic heme within the parasite, which ultimately kills it.\n\n### Side Effects:\n- **Common Side Effects**: Include nausea,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_X1dwYcoSbj4w2gjoDJ3sTYHI", "custom_id": "592_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "191ba69cfb8dcf249105a089c9191e00", "body": {"id": "chatcmpl-9St4jUzXu02Y9rCX0aFrCuHHZlt5k", "object": "chat.completion", "created": 1716671921, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vanflyta (quizartinib) is a medication used in the treatment of certain types of acute myeloid leukemia (AML). Here are some key points you should know about Vanflyta:\n\n1. **Indication**: Vanflyta is primarily indicated for the treatment of adult patients with relapsed or refractory AML that is FLT3-ITD positive. FLT3-ITD is a mutation in the FLT3 gene that is associated with a poor prognosis in AML.\n\n2. **Mechanism of Action**: Vanflyta is a tyrosine kinase inhibitor that specifically targets the FLT3 receptor. By inhibiting this receptor, it helps to reduce the proliferation of leukemic cells that have the FLT3-ITD mutation.\n\n3. **Administration**: Vanflyta is administered orally. The dosage and treatment regimen can vary based on the specific needs and response of the patient.\n\n4. **Side Effects**: Common side effects include my"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_O6p6uDqOnruUj0PvqbpJySph", "custom_id": "593_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1e29c886ad54a0c84a5e4ba537deaee0", "body": {"id": "chatcmpl-9St4jcip3Xq27Xyjm7eyU8W5V61Fp", "object": "chat.completion", "created": 1716671921, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Supect\" is a brand name for a medication that contains the active ingredient cefpodoxime, which is a third-generation cephalosporin antibiotic. Here are some key points you should know about Supect:\n\n### Indications:\n- **Bacterial Infections:** Supect is used to treat a variety of bacterial infections, including respiratory tract infections, urinary tract infections, skin infections, and sexually transmitted infections like gonorrhea.\n- **Spectrum of Activity:** It is effective against a broad range of Gram-positive and Gram-negative bacteria.\n\n### Mechanism of Action:\n- **Inhibition of Cell Wall Synthesis:** Cefpodoxime works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death.\n\n### Dosage and Administration:\n- **Oral Administration:** Supect is typically administered orally.\n- **Dosage:** The dosage varies depending on the type and severity of the infection, as well as patient factors such as age and renal function. Common adult dosages"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_wFCnZVplg1g6BCrAyxj8KOJ3", "custom_id": "594_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "fcb41cbe9bfc634869267fca460e50d9", "body": {"id": "chatcmpl-9St4kgF7jI2NtkXypNgOMSS5yvNRY", "object": "chat.completion", "created": 1716671922, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tomudex, also known by its generic name raltitrexed, is a chemotherapy medication used primarily in the treatment of colorectal cancer. Here are some key points you should know about Tomudex:\n\n### Mechanism of Action\n- **Antimetabolite**: Raltitrexed is a thymidylate synthase inhibitor. It interferes with DNA synthesis by inhibiting the enzyme thymidylate synthase, which is essential for the synthesis of thymidine, a nucleotide required for DNA replication.\n\n### Indications\n- **Colorectal Cancer**: It is primarily indicated for the treatment of advanced colorectal cancer, either as a monotherapy or in combination with other chemotherapeutic agents.\n\n### Administration\n- **Intravenous Infusion**: Tomudex is administered via intravenous infusion. The dosage and schedule depend on the specific treatment protocol and patient factors such as renal function.\n\n### Dosage\n- **Standard Dose**: The typical dose is 3 mg/m"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_1GNoYrdDKsHdtTJX2hKPuvvU", "custom_id": "595_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e47d3cc421a68e7baa0e46fc87df652e", "body": {"id": "chatcmpl-9St4kvwV5E7yp3QJlBFSAiB9ys05G", "object": "chat.completion", "created": 1716671922, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyramza (ramucirumab) is a monoclonal antibody used as an anti-cancer medication. It works by inhibiting angiogenesis, the process by which new blood vessels form, which tumors need to grow. Here are some key points you should know about Cyramza:\n\n### Indications:\n1. **Gastric Cancer**: Cyramza is approved for use in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, either as a single agent or in combination with paclitaxel.\n2. **Non-Small Cell Lung Cancer (NSCLC)**: It is used in combination with docetaxel for patients with metastatic NSCLC with disease progression on or after platinum-based chemotherapy.\n3. **Colorectal Cancer**: Cyramza is used in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) for metastatic colorectal cancer that has progressed on or after prior therapy with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_x7XtVc2LFAz8dQZhTRvmXPkF", "custom_id": "596_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3293d59b6e4fcd2109a15e7177de8599", "body": {"id": "chatcmpl-9St4kVJp1OLfCagzIpEg1ZPKYp882", "object": "chat.completion", "created": 1716671922, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cymer, Inc. is a company that specializes in the development and production of light sources used in photolithography systems for semiconductor manufacturing. While this might not seem directly relevant to the field of medicine, there are a few points that could be of interest to a physician:\n\n1. **Technological Impact on Medical Devices**: Advances in semiconductor technology, which companies like Cymer contribute to, play a crucial role in the development of medical devices. Improved semiconductor technology can lead to more advanced, reliable, and smaller medical devices, which can enhance patient care.\n\n2. **Medical Imaging and Diagnostics**: Semiconductor technology is integral to the functioning of various medical imaging and diagnostic equipment, such as MRI machines, CT scanners, and ultrasound devices. Innovations in this field can improve the resolution, speed, and accuracy of these diagnostic tools.\n\n3. **Wearable Health Technology**: The miniaturization and enhanced performance of semiconductors have enabled the development of sophisticated wearable health devices. These devices can monitor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_tfMcYCaZaYLoo0F1y5W5somT", "custom_id": "597_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c773c4e530778581a0d74139ce454a03", "body": {"id": "chatcmpl-9St4lYsVInsjCUW2zNCo5pvB8by7s", "object": "chat.completion", "created": 1716671923, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nublexa, also known by its generic name regorafenib, is a multi-kinase inhibitor used primarily in the treatment of certain types of cancer. Here are some key points you should know about Nublexa:\n\n### Indications:\n1. **Colorectal Cancer**: It is used for patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.\n2. **Gastrointestinal Stromal Tumors (GIST)**: It is indicated for patients with locally advanced, unresectable, or metastatic GIST who have been previously treated with imatinib mesylate and sunitinib malate.\n3. **Hepatocellular Carcinoma (HCC)**: It is used for patients with HCC who have been previously treated with sorafenib.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_nkm1Kei1VKcuGsCwDRmUUnhW", "custom_id": "598_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e4c6b4ad31af380882a479fbb91c2515", "body": {"id": "chatcmpl-9St4lebRAIEGQO6eVMI8E8PcZuvQc", "object": "chat.completion", "created": 1716671923, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kisqali (ribociclib) is a medication used in the treatment of certain types of breast cancer. Here are some key points you should know about it:\n\n### Indications:\n- **Breast Cancer**: Kisqali is primarily used for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. It is often prescribed in combination with an aromatase inhibitor or fulvestrant.\n\n### Mechanism of Action:\n- **CDK4/6 Inhibitor**: Kisqali works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which are proteins involved in cell division. By blocking these kinases, Kisqali helps to slow down the growth and spread of cancer cells.\n\n### Administration:\n- **Oral Medication**: Kisqali is taken orally, usually once daily for 21 consecutive days followed by 7 days off treatment, in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_0iVHmzMj1jQ2WX3vKtQY7E8U", "custom_id": "599_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "cd5aae84374ac30173de32672b29302b", "body": {"id": "chatcmpl-9St4ljx51HYcGq9M3qJbzc3De4JKU", "object": "chat.completion", "created": 1716671923, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2023, there is no widely recognized medical term, medication, or condition known as \"Ikgdar.\" It is possible that there may be a typographical error, a very recent development, or a term that is not widely known in the medical community.\n\nIf \"Ikgdar\" is a new or emerging term, I would recommend checking the latest medical literature, databases, or professional guidelines for any updates. Additionally, consulting with colleagues or specialists in the relevant field may provide more information.\n\nIf you have more context or details about \"Ikgdar,\" please provide them, and I will do my best to assist you further."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 136, "total_tokens": 177}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_MUgHRcYgXs8raDax0ujhyGhi", "custom_id": "600_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0eb1c380ca2ee02bfc012a67a3fd6416", "body": {"id": "chatcmpl-9St4m7OVsFS8dsy4LIRtR76Uy4Zdj", "object": "chat.completion", "created": 1716671924, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rituxan Hycela (rituximab and hyaluronidase human) is a combination of rituximab, a monoclonal antibody, and hyaluronidase, an enzyme that helps to increase the absorption of rituximab when administered subcutaneously. Here are some key points you should know about Rituxan Hycela:\n\n### Indications\nRituxan Hycela is indicated for the treatment of:\n1. **Follicular Lymphoma (FL)**: For adult patients with relapsed or refractory, previously untreated, or non-progressing (including stable disease) low-grade FL as a single agent or in combination with chemotherapy.\n2. **Diffuse Large B-Cell Lymphoma (DLBCL)**: For adult patients with previously untreated DLBCL in combination with chemotherapy.\n3. **Chronic Lymphocytic Leukemia (CLL)**: For adult patients in combination with fludarabine and cyclophosph"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ri3YTUreAtCWn67UDfNUrWke", "custom_id": "601_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "71f683895f35dae049cc7607d252dcb6", "body": {"id": "chatcmpl-9St4lB0uQDxjht6jJEJviEmIj47rh", "object": "chat.completion", "created": 1716671923, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Istodax (romidepsin) is a medication used primarily in the treatment of certain types of cancer, specifically cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). Here are some key points you should know about Istodax:\n\n### Mechanism of Action\n- **Histone Deacetylase Inhibitor (HDACi):** Istodax works by inhibiting histone deacetylases, which leads to an accumulation of acetylated histones and proteins. This can result in cell cycle arrest and apoptosis of cancer cells.\n\n### Indications\n- **Cutaneous T-Cell Lymphoma (CTCL):** Istodax is approved for the treatment of CTCL in patients who have received at least one prior systemic therapy.\n- **Peripheral T-Cell Lymphoma (PTCL):** It is also approved for the treatment of PTCL in patients who have received at least one prior therapy.\n\n### Administration\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_S40eAGiTq4rlp9ncSK7bK2aO", "custom_id": "602_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6f891fa041691657a7de3d5bc1b97c55", "body": {"id": "chatcmpl-9St4mlmlBIfdiJLvF5jWhmxBPZggx", "object": "chat.completion", "created": 1716671924, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Besremi (ropeginterferon alfa-2b) is a medication used primarily for the treatment of polycythemia vera, a type of blood cancer characterized by the overproduction of red blood cells. Here are some key points you should know about Besremi:\n\n### Mechanism of Action\n- **Interferon Alfa-2b**: Besremi is a long-acting interferon alfa-2b. It works by modulating the immune system and inhibiting the proliferation of hematopoietic cells, which helps to control the overproduction of red blood cells.\n\n### Indications\n- **Polycythemia Vera**: Besremi is specifically indicated for the treatment of polycythemia vera in adults.\n\n### Administration\n- **Subcutaneous Injection**: Besremi is administered via subcutaneous injection. The dosing schedule typically starts with a lower dose that is gradually increased based on patient response and tolerance.\n\n### Dosage\n- **Individualized"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ZFVLur8v9GbOUiV0c3h14son", "custom_id": "603_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2060ee3d2b0bbcf145886975b74d83ae", "body": {"id": "chatcmpl-9St4m24A78oHis1WnlM1BRS0px8r0", "object": "chat.completion", "created": 1716671924, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rubraca (rucaparib) is a medication used primarily in the treatment of certain types of cancer. Here are some key points you should know about Rubraca as a physician:\n\n### Indications:\n1. **Ovarian Cancer**: Rubraca is approved for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies.\n2. **Maintenance Treatment**: It is also approved as a maintenance treatment for adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\n3. **Prostate Cancer**: Rubraca is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a tax"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_spCbvM63tH0PvZTULnoQse4m", "custom_id": "604_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1d735531b19012684d000f6ff2d7519f", "body": {"id": "chatcmpl-9St4ndixISCula8ZTRquy3Awncrb3", "object": "chat.completion", "created": 1716671925, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Jakafi (ruxolitinib) is a medication that you, as a physician, should be familiar with, especially if you are treating patients with certain hematologic conditions. Here are some key points to know about Jakafi:\n\n### Indications:\n1. **Myelofibrosis (MF):** Jakafi is approved for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.\n2. **Polycythemia Vera (PV):** It is also indicated for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.\n3. **Graft-versus-Host Disease (GVHD):** Jakafi is approved for the treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_458Qvvxi2L38p8fbidOOWSnb", "custom_id": "605_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ea5e9069141c9dabaac65f221d220558", "body": {"id": "chatcmpl-9St4nwKqXaoYcnvShk8iQ35Lqdg4k", "object": "chat.completion", "created": 1716671925, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trodelvy (sacituzumab govitecan-hziy) is a medication used in the treatment of certain types of cancer. Here are some key points you should know about it:\n\n### Indications:\n1. **Metastatic Triple-Negative Breast Cancer (mTNBC):**\n   - Trodelvy is approved for the treatment of adult patients with mTNBC who have received at least two prior therapies for metastatic disease.\n\n2. **Urothelial Cancer:**\n   - It is also approved for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor.\n\n### Mechanism of Action:\n- Trodelvy is an antibody-drug conjugate (ADC). It consists of an anti-Trop-2 antibody linked to SN-38, an active metabolite of the chemotherapy drug irinotecan. Trop-2 is a protein commonly overexpressed in various"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_zOpQLGYqMl8nul2zE8BzXRYf", "custom_id": "606_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d524e5af19a2bca14dd91dbd3156f215", "body": {"id": "chatcmpl-9St4oHJt2c3u2zvq2KRcTmCG8Wugr", "object": "chat.completion", "created": 1716671926, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Leukine (sargramostim) is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) used to stimulate the production of white blood cells, particularly granulocytes and macrophages. Here are some key points you should know about Leukine:\n\n### Indications:\n1. **Hematopoietic Recovery**: Used to accelerate myeloid recovery in patients undergoing autologous or allogeneic bone marrow transplantation.\n2. **Neutropenia**: Used to reduce the incidence of severe and life-threatening infections in patients with severe chronic neutropenia.\n3. **Chemotherapy-Induced Neutropenia**: Used to shorten the duration of neutropenia and reduce the incidence of infection in patients receiving myelosuppressive chemotherapy.\n4. **Radiation Syndrome**: Approved for use in the treatment of acute radiation syndrome to increase survival.\n\n### Mechanism of Action:\n- Leukine acts by binding to specific receptors on the surface"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_MigtI8gASesqJbksLGjgRRnR", "custom_id": "607_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "75bf7926c51016ab301073e4fb45ec5f", "body": {"id": "chatcmpl-9St4oEONIX6xkpwKfH5DURQmrxIb5", "object": "chat.completion", "created": 1716671926, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nexpovio (selinexor) is a medication used primarily in the treatment of certain types of cancer. Here are some key points you should know about Nexpovio:\n\n### Indications:\n1. **Multiple Myeloma**: Nexpovio is often used in combination with other medications for the treatment of relapsed or refractory multiple myeloma in patients who have received at least one prior therapy.\n2. **Diffuse Large B-Cell Lymphoma (DLBCL)**: It is also approved for use in adult patients with relapsed or refractory DLBCL, not otherwise specified, after at least two lines of systemic therapy.\n\n### Mechanism of Action:\n- **Selective Inhibitor of Nuclear Export (SINE)**: Nexpovio works by inhibiting the nuclear export protein XPO1 (exportin 1). This inhibition leads to the accumulation of tumor suppressor proteins in the cell nucleus, which can induce apoptosis (programmed cell death"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_cHmrlyYlife0yyEnHwsP9zYS", "custom_id": "608_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "27b0146c31967e25f3e7e03d30fac225", "body": {"id": "chatcmpl-9St4oj6W3YQj962xSWO5tRJLFMIJk", "object": "chat.completion", "created": 1716671926, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Koselugo (selumetinib) is a medication that you, as a physician, should be familiar with, especially if you are involved in treating pediatric patients with certain genetic conditions. Here are some key points you should know:\n\n### Indications\n- **Koselugo is primarily indicated for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).** NF1 is a genetic disorder that causes tumors to grow along nerves in the skin, brain, and other parts of the body.\n\n### Mechanism of Action\n- **Selumetinib is a kinase inhibitor that targets MEK1 and MEK2, which are part of the RAS/RAF/MEK/ERK pathway.** This pathway is often dysregulated in cancers and certain genetic disorders like NF1. By inhibiting MEK1/2, selumetinib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_fPV6ctTw1l8DxmwTNmviWFwT", "custom_id": "609_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "8e5932cb1f8d85603f0e8935c37c300a", "body": {"id": "chatcmpl-9St4oG7LH01RYsm72Qo6YuXuWfVaA", "object": "chat.completion", "created": 1716671926, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Semustine, also known as methyl-CCNU, is a chemotherapeutic agent that belongs to the nitrosourea class of drugs. It is structurally related to lomustine (CCNU) and carmustine (BCNU). Here are some key points you should know about Semustine:\n\n### Mechanism of Action:\n- **Alkylating Agent**: Semustine works by alkylating DNA, which leads to the formation of cross-links and breaks in the DNA strands. This disrupts DNA replication and transcription, ultimately causing cell death.\n- **Lipid Solubility**: Like other nitrosoureas, Semustine is highly lipid-soluble, allowing it to cross the blood-brain barrier. This makes it useful in treating brain tumors.\n\n### Indications:\n- **Brain Tumors**: Semustine is often used in the treatment of primary and metastatic brain tumors.\n- **Gastrointestinal Cancers**: It has been"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_rGfhN3WbvW9HwDTrpZLb1zu4", "custom_id": "610_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9183c1fcaac116cd98acd2efd282e6b1", "body": {"id": "chatcmpl-9St4pbEuVCRfKue9T3HVmTDGV1KUy", "object": "chat.completion", "created": 1716671927, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Provenge (sipuleucel-T) is an immunotherapy treatment specifically designed for prostate cancer. Here are some key points you should know about it:\n\n### Indications:\n- **Provenge is approved for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).**\n\n### Mechanism of Action:\n- **Provenge is an autologous cellular immunotherapy.** It works by stimulating the patient's immune system to attack prostate cancer cells.\n- The treatment involves collecting a patient's own immune cells (specifically dendritic cells), which are then exposed to a protein that is found on most prostate cancer cells (prostatic acid phosphatase, PAP) combined with an immune-stimulating factor (GM-CSF).\n- These activated cells are then reinfused into the patient, where they help the immune system target and destroy prostate cancer cells.\n\n### Administration:\n- **Provenge is administered in a series of three infusions, typically spaced"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_E3eKT0Jy815DyVimbwB1ctEa", "custom_id": "611_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d9791386194dc233886b29a411c01bfc", "body": {"id": "chatcmpl-9St4pSbk45V2noWk2mbxLMUWe6XRX", "object": "chat.completion", "created": 1716671927, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Odomzo (sonidegib) is a medication used in the treatment of certain types of skin cancer, specifically locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or in patients who are not candidates for surgery or radiation. Here are some key points you should know about Odomzo:\n\n### Mechanism of Action\n- **Hedgehog Pathway Inhibitor**: Odomzo works by inhibiting the Hedgehog signaling pathway, which is involved in the growth and survival of cancer cells. By blocking this pathway, Odomzo can help to slow or stop the growth of cancer cells.\n\n### Indications\n- **Locally Advanced Basal Cell Carcinoma (BCC)**: It is indicated for the treatment of adult patients with locally advanced BCC that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation.\n\n### Dosage and Administration\n- **Dosage**: The recommended dose of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_2clisw91reffOT9mWtEPPfnZ", "custom_id": "612_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f4569dc0fb33b5b2683f4cc1d4ca9c14", "body": {"id": "chatcmpl-9St4pWhV8NXEMxjFqvQvGoFPYhApA", "object": "chat.completion", "created": 1716671927, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nexavar (sorafenib) is an oral multikinase inhibitor used primarily in the treatment of certain types of cancer. Here are some key points you should know about Nexavar as a physician:\n\n### Indications:\n1. **Hepatocellular Carcinoma (HCC):** Nexavar is approved for the treatment of unresectable liver cancer.\n2. **Renal Cell Carcinoma (RCC):** It is used for advanced kidney cancer.\n3. **Differentiated Thyroid Carcinoma (DTC):** Nexavar is indicated for patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.\n\n### Mechanism of Action:\n- Nexavar inhibits multiple intracellular and cell surface kinases, which are involved in tumor cell signaling, angiogenesis, and apoptosis. Key targets include RAF kinase, VEGFR, PDGFR, and others.\n\n### Dosage and Administration:\n- The standard dose is 400 mg ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_pKTwhUmqp2115MEs11TM4sBJ", "custom_id": "613_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "38fba5d3a907a6c3f7d4ee279d7ce52c", "body": {"id": "chatcmpl-9St4uHRIEAzCpWMh16dAHVv0vnf3a", "object": "chat.completion", "created": 1716671932, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zanosar, also known by its generic name streptozocin, is an antineoplastic (anticancer) agent primarily used in the treatment of pancreatic neuroendocrine tumors. Here are some key points you should know about Zanosar:\n\n### Mechanism of Action\n- **Alkylating Agent**: Zanosar is a nitrosourea compound that works by alkylating DNA, leading to the inhibition of DNA synthesis and function, which ultimately induces cell death in rapidly dividing cancer cells.\n\n### Indications\n- **Pancreatic Neuroendocrine Tumors**: Zanosar is specifically indicated for the treatment of metastatic or locally advanced pancreatic neuroendocrine tumors.\n\n### Administration\n- **Intravenous Infusion**: Zanosar is administered via intravenous infusion. The dosing regimen can vary, but it is often given over a period of 5 days every 6 weeks, depending on the patient's response and tolerance.\n\n### Side Effects\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_JyUeDjq5AAHQJAfg6br1UC0k", "custom_id": "614_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e2824b0c331de9374a0facf17bdd801e", "body": {"id": "chatcmpl-9St4pzl8E9H5ddR3658mRgSrxRxMc", "object": "chat.completion", "created": 1716671927, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a typo or misunderstanding in your question, as \"Kitent\" does not correspond to any known medical term, medication, or condition. If you meant something else, could you please provide more context or clarify your question? This will help me provide you with accurate and relevant information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 62, "total_tokens": 102}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_a4X4aMKl1La8XRXEy7XtYCNk", "custom_id": "615_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c1cadcdae1a35b1c0c895cfd76626c91", "body": {"id": "chatcmpl-9St4q914AeyMvX33OVhi3tumMcOdP", "object": "chat.completion", "created": 1716671928, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Elzonris (generic name: tagraxofusp-erzs) is a medication used in the treatment of certain types of cancer, specifically blastic plasmacytoid dendritic cell neoplasm (BPDCN). Here are some key points you should know about Elzonris:\n\n### Mechanism of Action\n- **Tagraxofusp-erzs** is a fusion protein consisting of interleukin-3 (IL-3) and a truncated diphtheria toxin. It targets the IL-3 receptor (CD123) on the surface of BPDCN cells, delivering the diphtheria toxin to the cells and leading to cell death.\n\n### Indications\n- **Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)**: Elzonris is specifically approved for the treatment of BPDCN in adult and pediatric patients aged 2 years and older.\n\n### Administration\n- **Intravenous Infusion**: Elzonris is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_tD23w66vNTiiCpc6j9kE6A5e", "custom_id": "616_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "392bf9ff3055bff73a87aa95597c079b", "body": {"id": "chatcmpl-9St4qfOPohZf9mPO6mNgXgEf0eQV0", "object": "chat.completion", "created": 1716671928, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Talzenna (talazoparib) is an oral poly (ADP-ribose) polymerase (PARP) inhibitor used in the treatment of certain types of breast cancer. Here are some key points you should know about Talzenna:\n\n### Indications:\n- **Breast Cancer**: Talzenna is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer. Patients should be selected for therapy based on an FDA-approved companion diagnostic for Talzenna.\n\n### Mechanism of Action:\n- Talazoparib inhibits PARP enzymes, which play a role in DNA repair. By inhibiting PARP, Talzenna leads to the accumulation of DNA damage in cancer cells, ultimately causing cell death, particularly in cells deficient in BRCA1/2.\n\n### Dosage and Administration:\n- The recommended dose of Talzenna is "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_UYS0Pmqad4MHHwPt2sDuRD2v", "custom_id": "617_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "bf8964c2725e45201ea8ad643f6930be", "body": {"id": "chatcmpl-9St4rfl0LY69INxc09vTvLd47zZ36", "object": "chat.completion", "created": 1716671929, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imlygic (talimogene laherparepvec) is an oncolytic viral therapy used for the treatment of melanoma lesions in the skin and lymph nodes. Here are some key points you should know about Imlygic:\n\n### Mechanism of Action:\n- **Oncolytic Virus**: Imlygic is a genetically modified herpes simplex virus type 1 (HSV-1) designed to selectively replicate within tumors and produce granulocyte-macrophage colony-stimulating factor (GM-CSF).\n- **Tumor Lysis**: The virus causes direct lysis of tumor cells.\n- **Immune Activation**: The release of tumor-derived antigens and GM-CSF helps stimulate a systemic anti-tumor immune response.\n\n### Indications:\n- **Melanoma**: Imlygic is indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.\n\n### Administration:\n- **Intrales"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_OtNsvI9tnNyINX2gY9nba2eB", "custom_id": "618_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "49d43145fa72f080dd12dbdc52a82d8c", "body": {"id": "chatcmpl-9St4rGemc7590f6pt56Qwj8475fRg", "object": "chat.completion", "created": 1716671929, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a typo in your question, as \"Amnoid\" does not correspond to any known medical term, medication, or condition. If you meant \"aminoid,\" \"amino acid,\" or another term, please provide more context or clarify your question so I can give you accurate information.\n\nIf you were referring to something else, please provide additional details or correct the term, and I'll do my best to assist you."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 91, "total_tokens": 132}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Jo46hOKLr6nANhSMaDQacmeG", "custom_id": "619_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "edef4fba0b8b00ae355195a1ba0a4ff5", "body": {"id": "chatcmpl-9St4rAlrvGr6ZrPtrvfH0SM6Fa9l1", "object": "chat.completion", "created": 1716671929, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It appears there might be a misunderstanding or a typo in your question, as \"Istubal\" does not correspond to any known medical term, medication, or condition in the current medical literature up to my knowledge cutoff in 2023. If you meant a specific drug, condition, or medical concept, please provide more context or check the spelling, and I'd be happy to help with accurate information.\n\nIf you have any other questions or need information on a different topic, feel free to ask!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 98, "total_tokens": 138}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_EAMRGFnmzD93jJAjc5hHEJgI", "custom_id": "620_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "fc441e8b88f56f9611bafbfab1055528", "body": {"id": "chatcmpl-9St4riOqhAPX6YBWZL2T1ILJAdy8X", "object": "chat.completion", "created": 1716671929, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Teysuno, also known by its generic name S-1, is an oral anticancer agent used primarily in the treatment of advanced gastric cancer. It is a combination of three pharmacological agents: tegafur, gimeracil, and oteracil. Here are some key points you should know about Teysuno:\n\n### Composition and Mechanism of Action:\n1. **Tegafur**: A prodrug of 5-fluorouracil (5-FU), which is an antimetabolite that interferes with DNA synthesis and inhibits cancer cell growth.\n2. **Gimeracil**: Inhibits dihydropyrimidine dehydrogenase (DPD), an enzyme that breaks down 5-FU, thereby increasing the bioavailability and effectiveness of 5-FU.\n3. **Oteracil**: Reduces the gastrointestinal toxicity of 5-FU by inhibiting its phosphorylation in the gut.\n\n### Ind"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_t6vN277aRccnSMspDhynrHHw", "custom_id": "621_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "64b3446e95d95574db507c3ab6124b86", "body": {"id": "chatcmpl-9St4rR0bqaX3lB2DaL9w6x1zsMrhg", "object": "chat.completion", "created": 1716671929, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ftorafur, also known as tegafur, is an antineoplastic agent used in the treatment of various cancers. It is a prodrug of 5-fluorouracil (5-FU), meaning it is metabolized in the body to produce the active chemotherapeutic agent 5-FU. Here are some key points you should know about Ftorafur:\n\n### Mechanism of Action\n- **Prodrug Conversion**: Ftorafur is converted to 5-FU in the liver. 5-FU then interferes with DNA synthesis by inhibiting the enzyme thymidylate synthase, which is crucial for DNA replication and repair.\n- **Cell Cycle Specificity**: It is most effective during the S-phase of the cell cycle, where DNA synthesis occurs.\n\n### Indications\n- **Colorectal Cancer**: Often used in combination with other agents for the treatment of colorectal cancer.\n- **Gastric Cancer**: Sometimes"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_lkySoWSIiPmpaxksn4ykoaM4", "custom_id": "622_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "51e35f34357e9a2b6034f6ed65cb267c", "body": {"id": "chatcmpl-9St4rKna5njcLRTecGVxgvIQUgyTd", "object": "chat.completion", "created": 1716671929, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gliotem is a brand name for the drug temozolomide, which is an oral alkylating agent used primarily in the treatment of certain types of brain tumors, including glioblastoma multiforme and anaplastic astrocytoma. Here are some key points you should know about Gliotem:\n\n### Indications:\n- **Glioblastoma Multiforme (GBM):** Temozolomide is often used in combination with radiotherapy and as maintenance therapy for newly diagnosed GBM.\n- **Anaplastic Astrocytoma:** It is also used for the treatment of refractory anaplastic astrocytoma, a type of brain tumor that has not responded to other treatments.\n\n### Mechanism of Action:\n- Temozolomide is an alkylating agent that works by methylating DNA at the O6 and N7 positions of guanine, leading to DNA damage and apoptosis of tumor cells.\n\n### Administration:\n- **Oral Administration:**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_NC2Fmq0V190mG6lpmLnsKcKh", "custom_id": "623_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3d308d676f548f1bfe2f40c6180225b6", "body": {"id": "chatcmpl-9St4soSkfwy171ifpSwEKRMWz51uA", "object": "chat.completion", "created": 1716671930, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Torisel (temsirolimus) is a medication used primarily in the treatment of advanced renal cell carcinoma (RCC). Here are some key points you should know about Torisel:\n\n### Mechanism of Action\n- **mTOR Inhibition**: Torisel is an mTOR (mammalian target of rapamycin) inhibitor. mTOR is a kinase involved in cell growth, proliferation, and survival. By inhibiting mTOR, Torisel can reduce tumor cell growth and proliferation.\n\n### Indications\n- **Renal Cell Carcinoma**: Torisel is approved for the treatment of advanced RCC, particularly in patients with poor prognostic features.\n\n### Administration\n- **Intravenous Infusion**: Torisel is administered as an intravenous infusion. The recommended dose is 25 mg infused over a 30-60 minute period once weekly.\n- **Premedication**: Patients should be premedicated with an antihistamine (e.g., diphenhydram"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_gNPVFfIG5ibyipcNChYMSgCl", "custom_id": "624_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c8a1675b1b589a5955ccbaf33779b690", "body": {"id": "chatcmpl-9St4sR1srP7UdpmDnKbhk1gjvzIzc", "object": "chat.completion", "created": 1716671930, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vumon, also known by its generic name teniposide, is a chemotherapeutic agent used primarily in the treatment of certain types of cancer. Here are some key points you should know about Vumon:\n\n### Indications:\n- **Acute Lymphoblastic Leukemia (ALL):** Often used in combination with other chemotherapeutic agents for the treatment of refractory or relapsed ALL in pediatric patients.\n- **Other Cancers:** It may also be used off-label for other types of cancers, including certain lymphomas and brain tumors.\n\n### Mechanism of Action:\n- **Topoisomerase II Inhibitor:** Teniposide works by inhibiting the enzyme topoisomerase II, which is essential for DNA replication and repair. This inhibition leads to DNA strand breaks and ultimately cell death, particularly in rapidly dividing cancer cells.\n\n### Administration:\n- **Intravenous (IV) Infusion:** Vumon is administered via IV infusion. The dosage and schedule depend"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_SwhcdP2OErHrGfZ18lkvGVmV", "custom_id": "625_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "db49d3699f078432f34f12c9672fa36c", "body": {"id": "chatcmpl-9St4sfZxowBppTWWCVgRr9lR1lXwY", "object": "chat.completion", "created": 1716671930, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Contergan, known generically as thalidomide, is a drug that was initially marketed in the late 1950s and early 1960s as a sedative and treatment for morning sickness in pregnant women. However, it became infamous for causing severe birth defects when taken during pregnancy. Here are some key points you should know about thalidomide:\n\n### Historical Context:\n1. **Introduction and Use**: Thalidomide was introduced in 1957 by the German pharmaceutical company Chemie Gr\u00fcnenthal. It was marketed in various countries under different brand names, including Contergan.\n2. **Teratogenic Effects**: It was discovered that thalidomide caused severe congenital malformations, including limb deformities (phocomelia), heart defects, and other organ malformations when taken by pregnant women, particularly during the first trimester.\n3. **Withdrawal and Regulation**: The drug was withdrawn from the market in the early 1960s after the link"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_JA8MTekjl5wEjXlyZhIHs0TV", "custom_id": "626_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7b0cf6e4bc0f5baf3dde0a8e0a643b14", "body": {"id": "chatcmpl-9St4sWkRRsedbZWtwWmw1lI7UypxZ", "object": "chat.completion", "created": 1716671930, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lanvis, also known by its generic name thioguanine, is a medication used primarily in the treatment of certain types of leukemia, such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Here are some key points you should know about Lanvis:\n\n### Mechanism of Action\n- **Antimetabolite**: Lanvis is a purine analog that interferes with DNA and RNA synthesis. It gets incorporated into DNA and RNA, leading to faulty nucleic acid function and cell death.\n- **Cytotoxic**: It is cytotoxic to rapidly dividing cells, which makes it effective against cancer cells.\n\n### Indications\n- **Acute Myeloid Leukemia (AML)**: Often used in combination with other chemotherapeutic agents.\n- **Acute Lymphoblastic Leukemia (ALL)**: Sometimes used in maintenance therapy.\n\n### Administration\n- **Oral**: Lanvis is typically administered orally in tablet form.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_MqNIwznKkrzRT1ZxtfhXJJrK", "custom_id": "627_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "61777888e24edc9c117e02e982ff748c", "body": {"id": "chatcmpl-9St4s1jBEXVZTXl6y3X6E8WeAt78E", "object": "chat.completion", "created": 1716671930, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tepadina, also known by its generic name thiotepa, is an alkylating agent used primarily in the treatment of certain cancers and as a conditioning agent before hematopoietic stem cell transplantation. Here are some key points you should know about Tepadina:\n\n### Indications:\n1. **Cancer Treatment**: Tepadina is used in the treatment of various cancers, including:\n   - Breast cancer\n   - Ovarian cancer\n   - Bladder cancer\n   - Hodgkin's disease\n   - Non-Hodgkin's lymphoma\n\n2. **Stem Cell Transplantation**: It is used as part of the conditioning regimen before hematopoietic stem cell transplantation (HSCT) to help eradicate malignant cells and suppress the immune system to prevent graft rejection.\n\n### Mechanism of Action:\n- Thiotepa is an alkylating agent that works by cross-linking DNA strands, thereby inhibiting DNA synthesis and function, which leads to cell death."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_YgyAnZ1zegVrhkftZJTUnQG7", "custom_id": "628_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "67a60b9a59337e36c97c3151a718505d", "body": {"id": "chatcmpl-9St4tJ7tvxy6DdLhUY6ffXmx0wZOL", "object": "chat.completion", "created": 1716671931, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kymriah (tisagenlecleucel) is a type of CAR-T (chimeric antigen receptor T-cell) therapy, which is a form of immunotherapy used to treat certain types of cancer. Here are some key points you should know about Kymriah:\n\n### Indications\n1. **Acute Lymphoblastic Leukemia (ALL):**\n   - Kymriah is approved for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse.\n\n2. **Diffuse Large B-Cell Lymphoma (DLBCL):**\n   - It is also approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.\n\n### Mechanism of Action\n- Kymriah involves collecting a patient's T cells, genetically modifying"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Xi0p54k8gQLi5OoULiJHnNUR", "custom_id": "629_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c83f1fedd3ef450b4af47307a798a258", "body": {"id": "chatcmpl-9St4tFvpAYawVnUk4h4hfZwQPSxbu", "object": "chat.completion", "created": 1716671931, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fotivda (tivozanib) is a medication used in the treatment of advanced renal cell carcinoma (RCC). Here are some key points you should know about Fotivda:\n\n### Mechanism of Action\n- **Tivozanib** is a tyrosine kinase inhibitor (TKI) that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. This inhibition reduces angiogenesis, which is crucial for tumor growth and metastasis.\n\n### Indications\n- **Advanced Renal Cell Carcinoma (RCC)**: Fotivda is indicated for the treatment of adult patients with relapsed or refractory advanced RCC.\n\n### Dosage and Administration\n- **Recommended Dose**: The typical dose is 1.34 mg taken orally once daily for 21 days, followed by a 7-day rest period, making a 28-day treatment cycle.\n- **Administration**: It should be taken at the same time each day"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_8BgTaPvIuvmkjbxSME2IahCQ", "custom_id": "630_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6918358691befe7bd4e212372726790a", "body": {"id": "chatcmpl-9St4tDHquEgl0wZXFO9uTv76qT9OM", "object": "chat.completion", "created": 1716671931, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or treatment known as \"Evotopin.\" It's possible that it could be a new drug, a brand name not widely known, or a misspelling of another medication. Here are some steps you can take to find accurate information:\n\n1. **Check Medical Databases**: Use resources like PubMed, Medline, or your institution's medical library to search for \"Evotopin.\" These databases can provide peer-reviewed articles and clinical trial information.\n\n2. **Consult Pharmaceutical Repositories**: Look into databases such as the FDA's Drug Database, the European Medicines Agency (EMA), or other national drug regulatory authorities.\n\n3. **Contact Colleagues or Specialists**: Sometimes, new medications or treatments are known within specific medical communities or specialties. Reaching out to colleagues or specialists in pharmacology might provide insights.\n\n4. **Pharmaceutical Representatives**: If \"Evotopin\" is a new drug"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_VP173r78GZbAM5W7RdGVsADN", "custom_id": "631_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "126f3fecbb541f1a775bf12847e34870", "body": {"id": "chatcmpl-9St4tgbE2katXXnV8zmqLG3sWMlYz", "object": "chat.completion", "created": 1716671931, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Acapodene, also known by its generic name toremifene, is a selective estrogen receptor modulator (SERM) primarily used in the treatment of hormone-responsive breast cancer. Here are some key points you should know about Acapodene:\n\n### Indications:\n- **Breast Cancer**: It is mainly indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or unknown tumors.\n\n### Mechanism of Action:\n- **Estrogen Receptor Modulation**: Toremifene binds to estrogen receptors, exerting both estrogenic and anti-estrogenic effects depending on the target tissue. In breast tissue, it acts as an anti-estrogen, inhibiting the proliferation of cancer cells.\n\n### Dosage and Administration:\n- **Typical Dosage**: The usual dose is 60 mg orally once daily.\n- **Administration**: It can be taken with or without food.\n\n### Pharmacokinetics:\n- **Absorption**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Hnw2grMTyxETgBAx87ty39SR", "custom_id": "632_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c80d62b69f9522b92ece9ea15898d1bb", "body": {"id": "chatcmpl-9St4udxr5b5WDJUUXz79qaA6FKZOO", "object": "chat.completion", "created": 1716671932, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bexxar (tositumomab and iodine I-131 tositumomab) is a radioimmunotherapy treatment that was used for certain types of non-Hodgkin lymphoma (NHL), particularly for patients with relapsed or refractory low-grade, follicular, or transformed NHL. Here are some key points you should know about Bexxar:\n\n1. **Mechanism of Action**:\n   - Bexxar combines a monoclonal antibody (tositumomab) with a radioactive isotope (iodine-131). The monoclonal antibody targets the CD20 antigen on the surface of B-cells, including malignant B-cells, and the radioactive component delivers targeted radiation to these cells.\n\n2. **Indications**:\n   - Bexxar was indicated for the treatment of patients with CD20-positive, relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin lymphoma, including patients with rituxim"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_fdz2QkyRfRMXHaVb4nbiml98", "custom_id": "633_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "397d1dbe34f460097965d7ae2d8339ba", "body": {"id": "chatcmpl-9St4uJrXg5cBrfq5RrBDJbx7tY1Ms", "object": "chat.completion", "created": 1716671932, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Yondelis, also known by its generic name trabectedin, is a chemotherapeutic agent used primarily in the treatment of certain types of cancer, including soft tissue sarcoma and relapsed ovarian cancer. Here are some key points you should know about Yondelis:\n\n### Mechanism of Action\n- **DNA Interaction**: Yondelis binds to the minor groove of DNA, causing a bend in the DNA helix. This interferes with the transcription process and disrupts the cell cycle, leading to cell death.\n- **Transcription Inhibition**: It inhibits activated transcription and affects the transcription-coupled nucleotide excision repair pathway, which is particularly effective in cancer cells.\n\n### Indications\n- **Soft Tissue Sarcoma**: Yondelis is approved for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have previously received an anthracycline-containing regimen.\n- **Ovarian Cancer**: It is also"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_cQoQhxOQzVx0iuXSxbr4ATvE", "custom_id": "634_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3c0b1767a778121caebea1ef062a6ce5", "body": {"id": "chatcmpl-9St4uKPYyYY7lWr47m51h8z51XPlX", "object": "chat.completion", "created": 1716671932, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mekinist (generic name: trametinib) is a medication used primarily in the treatment of certain types of cancer. Here are some key points you should know about Mekinist as a physician:\n\n### Indications:\n1. **Melanoma**: Mekinist is used to treat patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.\n2. **Non-Small Cell Lung Cancer (NSCLC)**: It is also indicated for the treatment of patients with metastatic NSCLC with a BRAF V600E mutation.\n3. **Thyroid Cancer**: Mekinist can be used in combination with dabrafenib for the treatment of anaplastic thyroid cancer with a BRAF V600E mutation.\n\n### Mechanism of Action:\n- Mekinist is a MEK inhibitor. It works by inhibiting the MEK1 and MEK2 proteins, which are part of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_02SUsD9jY34Y2Vc1eUyFgwQp", "custom_id": "635_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0ca3ecb8a86c379266dc8d068b010921", "body": {"id": "chatcmpl-9St4vLwvfimsmZlwvEBxVhDdBwlHH", "object": "chat.completion", "created": 1716671933, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2021, there is no widely recognized medication or substance known as \"Amixam.\" It is possible that you may be referring to a new or less common drug, a misspelling, or a brand name that is not widely recognized in the medical community.\n\nIf \"Amixam\" is a new or emerging medication, I would recommend the following steps to gather accurate and up-to-date information:\n\n1. **Consult Reliable Sources**: Check reputable medical databases such as PubMed, Medline, or clinical guidelines from recognized health organizations.\n\n2. **Pharmaceutical Reps**: Contact the pharmaceutical company that manufactures or distributes the drug for detailed information, including indications, contraindications, side effects, and clinical trial data.\n\n3. **Medical Literature**: Review recent medical journals and publications for any studies or articles related to the drug.\n\n4. **Professional Networks**: Discuss with colleagues or specialists who may have experience or knowledge about the medication.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_d2btgKiaO5Wldsv79cQsTVIP", "custom_id": "636_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "463d8c42bb784b7578672f0a79e12f19", "body": {"id": "chatcmpl-9St4vdplXWZURoyEeOIy2b200P6oK", "object": "chat.completion", "created": 1716671933, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or treatment called \"Biceltis.\" It's possible that the name might be misspelled, or it could be a new or less common drug that has emerged after my last update. \n\nIf you meant a specific medication or treatment, please provide more context or check the spelling. However, if \"Biceltis\" is indeed a new or emerging treatment, here are some general steps you can take to stay informed:\n\n1. **Consult Reliable Sources**: Check reputable medical databases such as PubMed, Medline, or clinical guidelines from organizations like the FDA, EMA, or WHO.\n\n2. **Pharmaceutical Reps and Literature**: Contact the pharmaceutical company that manufactures the drug for detailed information, including clinical trial data, indications, contraindications, side effects, and dosing.\n\n3. **Continuing Medical Education (CME)**: Attend CME courses, webinars, or conferences where new treatments and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_P9i5xH7coLVz1JOD0HT9xjVH", "custom_id": "637_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2381dd38dd4ca88522458aede286f433", "body": {"id": "chatcmpl-9St4vusikEFwIFKMn3GsrrpCf2jLM", "object": "chat.completion", "created": 1716671933, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imjudo (tremelimumab) is a monoclonal antibody that targets CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), a protein receptor that downregulates the immune system. By inhibiting CTLA-4, Imjudo can enhance the immune response against cancer cells. Here are some key points you should know about Imjudo:\n\n### Indications\n- **Cancer Treatment**: Imjudo is primarily used in the treatment of certain types of cancer, including melanoma and other solid tumors. It is often used in combination with other immunotherapies, such as PD-1 inhibitors (e.g., nivolumab or pembrolizumab).\n\n### Mechanism of Action\n- **Immune Checkpoint Inhibition**: By blocking CTLA-4, Imjudo prevents the downregulation of T-cells, thereby enhancing the immune system's ability to attack cancer cells.\n\n### Administration\n- **Intravenous Inf"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_3aY67K7eioiSVpQtUORMWNpg", "custom_id": "638_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7919f0033cc8b23f406382ab53fceb30", "body": {"id": "chatcmpl-9St4vO3wPHuL1n051UnCqoybCmnPO", "object": "chat.completion", "created": 1716671933, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about any medication or supplement you might encounter in your practice. However, as of my last update in October 2021, there is no widely recognized medication or supplement by the name \"Ovastat.\" It's possible that it could be a new product, a brand name not widely known, or a regional product.\n\nHere are some general steps you can take to gather more information:\n\n1. **Check Medical Databases**: Use resources like PubMed, Medline, or other medical literature databases to search for any studies or articles related to Ovastat.\n\n2. **Consult Pharmacists**: Pharmacists can be a valuable resource for information on medications, including new or less common ones.\n\n3. **Contact the Manufacturer**: If you have access to the product or its packaging, contact the manufacturer directly for detailed information, including indications, contraindications, side effects, and clinical studies.\n\n4. **Professional Networks**: Utilize professional networks or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_fIUOdSpcBq7zpXWeo8t2KUXG", "custom_id": "639_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e0f17825cb1482e82f3d967900bf5e76", "body": {"id": "chatcmpl-9St4wgYvXOnjrCbIwTmBVENHDekIF", "object": "chat.completion", "created": 1716671934, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lonsurf (trifluridine and tipiracil) is an oral medication used in the treatment of certain types of cancer, specifically metastatic colorectal cancer and metastatic gastric or gastroesophageal junction adenocarcinoma. Here are some key points you should know about Lonsurf:\n\n### Mechanism of Action\n- **Trifluridine**: A nucleoside analog that gets incorporated into DNA, leading to DNA dysfunction and cell death.\n- **Tipiracil**: Inhibits thymidine phosphorylase, which prevents the rapid degradation of trifluridine, thereby increasing its bioavailability.\n\n### Indications\n- **Metastatic Colorectal Cancer**: For patients who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and, if RAS wild-type, an anti-EGFR therapy.\n- **Metastatic Gastric or Gastroesophageal Junction"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_LFaubCMUlB6MFnnfweDZ5ajk", "custom_id": "640_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "3a722e07a442aa1796d48c2c8e3efd58", "body": {"id": "chatcmpl-9St4wpX1iAoVq7Y7Vycanlzf6PNO5", "object": "chat.completion", "created": 1716671934, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Decapeptyl, also known as triptorelin, is a synthetic analogue of gonadotropin-releasing hormone (GnRH). It is used primarily in the treatment of hormone-responsive cancers, such as prostate cancer, and in conditions like endometriosis and uterine fibroids. Here are some key points you should know about Decapeptyl:\n\n### Mechanism of Action:\n- **GnRH Agonist:** Triptorelin initially stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a temporary increase in sex hormones (testosterone in men and estrogen in women).\n- **Downregulation:** Continuous administration leads to downregulation of GnRH receptors in the pituitary gland, resulting in decreased secretion of LH and FSH, and subsequently, a significant reduction in sex hormone levels.\n\n### Indications:\n- **Prostate Cancer:** Used to reduce testosterone levels, which can help in managing advanced prostate cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_UQHfcwoMEN7nxjJtwpV3x5xq", "custom_id": "641_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0a31f72eec7a678bd0e1d0ad6f09bc01", "body": {"id": "chatcmpl-9St4wYVFHomkuHh1tl1ZEizure3BK", "object": "chat.completion", "created": 1716671934, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Depacon is the brand name for the intravenous (IV) formulation of valproate sodium, which is used primarily as an anticonvulsant and mood-stabilizing drug. Here are some key points you should know about Depacon:\n\n### Indications:\n1. **Seizure Disorders**: Depacon is used to treat various types of seizure disorders, including complex partial seizures, simple and complex absence seizures, and multiple seizure types that include absence seizures.\n2. **Status Epilepticus**: It can be used in the management of status epilepticus, particularly when other treatments are ineffective or contraindicated.\n3. **Bipolar Disorder**: It is sometimes used off-label for the acute management of manic episodes associated with bipolar disorder.\n4. **Migraine Prophylaxis**: Depacon can be used for the prevention of migraine headaches.\n\n### Mechanism of Action:\nValproate sodium works by increasing the availability of gamma-aminobutyric acid ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_7KHT6YU7xoSZSUbmoq9lz1VS", "custom_id": "642_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "75f756eb1ca122761262d71da05d5b1f", "body": {"id": "chatcmpl-9St4wY53C2DzlJ97ok0sZpm6om9gY", "object": "chat.completion", "created": 1716671934, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Valstar (valrubicin) is a chemotherapeutic agent used primarily for the treatment of bladder cancer, specifically Bacillus Calmette-Gu\u00e9rin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. Here are some key points you should know about Valstar:\n\n### Mechanism of Action\n- **Valrubicin** is an anthracycline derivative that works by intercalating into DNA and inhibiting topoisomerase II, leading to the disruption of DNA replication and transcription, ultimately causing cell death.\n\n### Indications\n- **Primary Indication**: Treatment of BCG-refractory CIS of the urinary bladder.\n- **Patient Selection**: Typically used in patients who are not candidates for immediate cystectomy.\n\n### Administration\n- **Route**: Intravesical (directly into the bladder).\n- **Dosage**: The standard dose is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_6WUKon3YtiYLoFUwyNhCIurV", "custom_id": "643_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "bff52cf7457f5cba9e5236e8698f533a", "body": {"id": "chatcmpl-9St4xSXFJlE8wwsEAhP4tC7Y2FCOZ", "object": "chat.completion", "created": 1716671935, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Caprelsa (vandetanib) is a medication used primarily for the treatment of medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Here are some key points you should know about Caprelsa:\n\n### Mechanism of Action\n- **Tyrosine Kinase Inhibitor**: Caprelsa works by inhibiting multiple receptor tyrosine kinases, including VEGFR, EGFR, and RET, which are involved in tumor growth and angiogenesis.\n\n### Indications\n- **Medullary Thyroid Cancer**: Specifically indicated for symptomatic or progressive MTC in patients with unresectable locally advanced or metastatic disease.\n\n### Dosage and Administration\n- **Standard Dose**: The typical starting dose is 300 mg once daily, taken with or without food.\n- **Adjustments**: Dose adjustments may be necessary based on patient tolerance and specific side effects.\n\n### Side Effects\n- **Common**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_8duNn548LOAorLjLRFpboFqV", "custom_id": "644_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0ff9bf3f2ce43bfe39a45fb34ea59dab", "body": {"id": "chatcmpl-9St4xkIll1PyZjJQZWGdHN0OS7Oi3", "object": "chat.completion", "created": 1716671935, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zelboraf (vemurafenib) is a medication used primarily in the treatment of certain types of cancer, most notably metastatic melanoma with a specific mutation in the BRAF gene (BRAF V600E mutation). Here are some key points you should know about Zelboraf:\n\n### Mechanism of Action\n- **Targeted Therapy**: Zelboraf is a BRAF inhibitor. It works by targeting and inhibiting the activity of the mutated BRAF protein, which is involved in cell growth and proliferation. By inhibiting this protein, Zelboraf can help slow or stop the growth of cancer cells.\n\n### Indications\n- **Metastatic Melanoma**: Zelboraf is approved for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation.\n- **Erdheim-Chester Disease**: It is also approved for the treatment of patients with Erdheim-Chester Disease (a rare type of non-Langerhans"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_CTlrkQXXxXcJBF0WSW80I1qg", "custom_id": "645_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "64f5fde42189065729bcebff7b666740", "body": {"id": "chatcmpl-9St4x0iSGqse03uefpGFmbP8j7hra", "object": "chat.completion", "created": 1716671935, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Venclexta (venetoclax) is a medication used primarily in the treatment of certain types of blood cancers. Here are some key points you should know about Venclexta as a physician:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL):**\n   - Venclexta is approved for the treatment of adults with CLL or SLL, with or without 17p deletion, who have received at least one prior therapy.\n   - It is also approved for use in combination with obinutuzumab for the first-line treatment of CLL.\n\n2. **Acute Myeloid Leukemia (AML):**\n   - Venclexta is approved for use in combination with azacitidine, decitabine, or low-dose cytarabine for the treatment of newly-diagnosed AML in adults who are 75 years or older, or who have com"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_YsyOUuCOYY4OHtR8VeVcTSlu", "custom_id": "646_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1c13679d2bd2f38f84c1580f168dbd98", "body": {"id": "chatcmpl-9St4xESLfuyh8XbS5wq2qmnmNwD2V", "object": "chat.completion", "created": 1716671935, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alkaban-AQ is a brand name for the drug vincristine sulfate, which is a chemotherapy medication used to treat various types of cancer. Here are some key points you should know about Alkaban-AQ:\n\n### Indications:\n- **Acute Lymphoblastic Leukemia (ALL):** Often used in combination with other chemotherapy agents.\n- **Hodgkin's Disease:** Part of combination chemotherapy regimens.\n- **Non-Hodgkin's Lymphoma:** Used in various chemotherapy protocols.\n- **Rhabdomyosarcoma:** Commonly included in treatment regimens.\n- **Neuroblastoma:** Used in combination with other drugs.\n- **Wilms' Tumor:** Part of multi-agent chemotherapy.\n\n### Mechanism of Action:\n- **Microtubule Inhibition:** Vincristine sulfate works by inhibiting the formation of microtubules, which are essential for cell division. This disruption leads to cell cycle arrest and apoptosis of cancer cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_z64whp5Zv3fp9iT9IEmDX3ST", "custom_id": "647_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ce5da2ca001799f333ea52f8d33366e5", "body": {"id": "chatcmpl-9St4yyBhDHKi3oc6hAO3ERazG4LuD", "object": "chat.completion", "created": 1716671936, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or treatment known as \"Alcrist.\" It is possible that you might be referring to a new or emerging drug, a brand name, or a misspelling of an existing medication. Here are a few steps you can take to gather accurate information:\n\n1. **Check Medical Databases**: Use resources like PubMed, ClinicalTrials.gov, or your institution's medical library to search for \"Alcrist\" and see if there are any relevant studies or clinical trials.\n\n2. **Consult Pharmacists**: Pharmacists often have access to the latest drug information and can provide insights into new medications or formulations.\n\n3. **Professional Networks**: Reach out to colleagues or professional networks. Sometimes new drugs are discussed in medical forums or at conferences before they become widely known.\n\n4. **Manufacturer Information**: If \"Alcrist\" is a new drug, the pharmaceutical company that manufactures it will have detailed"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_pRHAZwqk4lI1tiJCPya5v7mw", "custom_id": "648_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9c8666834766ede883f86f3fce4f515f", "body": {"id": "chatcmpl-9St4yuNvG2R3HeYZBrDS0xC5wibUN", "object": "chat.completion", "created": 1716671936, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Marqibo (vincristine sulfate liposome injection) is a chemotherapeutic agent used primarily in the treatment of certain types of cancer. Here are some key points you should know about Marqibo:\n\n### Indications:\n- **Acute Lymphoblastic Leukemia (ALL):** Marqibo is approved for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) ALL in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.\n\n### Mechanism of Action:\n- **Vincristine Sulfate:** The active ingredient in Marqibo, vincristine, is a vinca alkaloid that inhibits microtubule formation in the mitotic spindle, leading to cell cycle arrest and apoptosis.\n- **Liposomal Formulation:** Marqibo is a liposomal formulation of vincristine, which allows for a different pharmacokinetic profile compared to standard vincristine. The liposomal encapsulation is designed to enhance"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ti7p1onfVBFH6NWEoLMK6pkQ", "custom_id": "649_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b43c21218b453c58df87c5ce130775bc", "body": {"id": "chatcmpl-9St4z4QOd031x7QE9aLJSoKyNmr0G", "object": "chat.completion", "created": 1716671937, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Eldesine, also known by its generic name vindesine, is a chemotherapeutic agent used primarily in the treatment of various types of cancer. Here are some key points you should know about Eldesine:\n\n### Mechanism of Action\n- **Class**: Vindesine is a vinca alkaloid, which means it is derived from the periwinkle plant (Catharanthus roseus).\n- **Action**: It works by inhibiting microtubule formation in the mitotic spindle, thereby preventing cell division and leading to cell death. This makes it effective in targeting rapidly dividing cancer cells.\n\n### Indications\n- **Cancer Types**: Eldesine is used to treat a variety of cancers, including acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma, and certain solid tumors such as breast cancer and lung cancer.\n- **Combination Therapy**: It is often used in combination with other chemotherapeutic agents to enhance efficacy.\n\n### Administration\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_WSXZ1d8LSKExPs5foYvK1I1r", "custom_id": "650_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2bbba710490b976bd9c8cfd4f898fdc1", "body": {"id": "chatcmpl-9St4zhwuIRO6g3mFpAZbEfShRrSOj", "object": "chat.completion", "created": 1716671937, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Javlor, also known by its generic name vinflunine, is a chemotherapeutic agent used primarily in the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, particularly after failure of a prior platinum-containing regimen. Here are some key points you should know about Javlor:\n\n### Mechanism of Action\n- **Vinflunine** is a vinca alkaloid that works by inhibiting microtubule assembly, thereby disrupting mitotic spindle formation and leading to cell cycle arrest and apoptosis in cancer cells.\n\n### Indications\n- Javlor is indicated for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen.\n\n### Administration\n- Javlor is administered intravenously. The dosage and schedule depend on the patient's body surface area and overall health status.\n- It is typically given once every three weeks.\n\n### Side Effects\n- **Common Side Effects**: Neutropenia"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_4qGOT1VGe8CMnzVQVB32N1Hr", "custom_id": "651_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0c73fb8fd9c6e9f74607761275129809", "body": {"id": "chatcmpl-9St4zaScqjaVhPR8CW5XvIkly0ZAU", "object": "chat.completion", "created": 1716671937, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2021, there is no widely recognized medication or medical treatment known as \"Binorel.\" It is possible that you may be referring to a new or less common drug, a brand name, or a typographical error. Here are a few steps you can take to find accurate information:\n\n1. **Check Medical Databases:** Use resources like PubMed, Medline, or other medical literature databases to search for \"Binorel\" or similar terms. These databases can provide peer-reviewed articles and clinical studies.\n\n2. **Consult Pharmacological References:** Use comprehensive pharmacological references such as the Physicians' Desk Reference (PDR), Lexicomp, or Micromedex to look up the drug.\n\n3. **Contact a Pharmacist:** Pharmacists are often well-versed in both brand names and generic names of medications and can provide detailed information.\n\n4. **Reach Out to Colleagues:** Sometimes, discussing with colleagues or specialists in pharmacology or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_uyjxoRLIUOrd0PScpXoAOBUQ", "custom_id": "652_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "cab5707b3d2afc6b17d558f169841aeb", "body": {"id": "chatcmpl-9St4zs1PSOX1m1yGm3T09I8Rc0GXH", "object": "chat.completion", "created": 1716671937, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erivedge (vismodegib) is a medication used primarily for the treatment of advanced basal cell carcinoma (BCC), particularly in cases where the cancer has metastasized, recurred after surgery, or when patients are not candidates for surgery or radiation. Here are some key points you should know about Erivedge:\n\n### Mechanism of Action\n- **Hedgehog Pathway Inhibitor**: Erivedge works by inhibiting the Hedgehog signaling pathway, which is crucial for the growth and survival of cancer cells in basal cell carcinoma. Specifically, it targets the Smoothened (SMO) receptor, a key component in this pathway.\n\n### Indications\n- **Advanced Basal Cell Carcinoma**: It is indicated for adults with metastatic BCC, locally advanced BCC that has recurred following surgery, or those who are not candidates for surgery or radiation.\n\n### Administration\n- **Oral Medication**: Erivedge is administered orally, typically as a "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Yl3dXNtT4nsrC4Kqfq1B8xUo", "custom_id": "653_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ca7f5ec5549f0da0136452ab02502435", "body": {"id": "chatcmpl-9St4zvs5UsXvNsFoI9WOaOCMT1ZpQ", "object": "chat.completion", "created": 1716671937, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zolinza, also known by its generic name vorinostat, is a medication used primarily in the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have progressive, persistent, or recurrent disease after other systemic therapies. Here are some key points you should know about Zolinza:\n\n### Mechanism of Action\n- **Histone Deacetylase Inhibitor (HDACi):** Zolinza works by inhibiting histone deacetylases, which leads to an accumulation of acetylated histones and proteins. This can result in cell cycle arrest, differentiation, and apoptosis of cancer cells.\n\n### Indications\n- **Cutaneous T-cell Lymphoma (CTCL):** Zolinza is specifically approved for the treatment of CTCL in patients with progressive, persistent, or recurrent disease.\n\n### Administration\n- **Oral Administration:** Zolinza is taken orally, usually once daily with food to reduce gastrointestinal side effects.\n- **Dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_RUmgVEvOX5VtpBU70sisE4ke", "custom_id": "654_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "73405a43fee6f42be695387cd2b4a096", "body": {"id": "chatcmpl-9St50QktSkhTv6PY2MZTiogHw3QdV", "object": "chat.completion", "created": 1716671938, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, understanding the Aztec civilization can provide valuable insights into historical medical practices, cultural beliefs, and the evolution of healthcare. Here are some key points you might find interesting:\n\n### 1. **Historical Context:**\n- **Time Period:** The Aztec civilization thrived in central Mexico from the 14th to the 16th century, until the Spanish conquest in 1521.\n- **Capital:** Their capital was Tenochtitl\u00e1n, located on the site of modern-day Mexico City.\n\n### 2. **Medical Practices:**\n- **Herbal Medicine:** The Aztecs had an extensive knowledge of medicinal plants and used them to treat various ailments. They documented their herbal remedies in codices, such as the Badianus Manuscript.\n- **Surgery:** They practiced basic surgical techniques, including wound care and setting broken bones.\n- **Dentistry:** The Aztecs also had rudimentary dental practices, including the use of plant-based treatments for tooth"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_IO7EaKicxeP9CJPzPnrmkYyY", "custom_id": "655_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a81d3de29e6c8d672fec88ab37e3b4ac", "body": {"id": "chatcmpl-9St50mrwtlj8SYwedTAHTdR20VcXz", "object": "chat.completion", "created": 1716671938, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zaltrap (ziv-aflibercept) is a medication used in oncology, specifically for the treatment of metastatic colorectal cancer. Here are some key points you should know about Zaltrap:\n\n### Mechanism of Action\n- **Zaltrap** is a recombinant fusion protein that acts as a decoy receptor for vascular endothelial growth factor (VEGF). It binds to VEGF-A, VEGF-B, and placental growth factor (PIGF), preventing these factors from interacting with their natural receptors on the surface of endothelial cells. This inhibition reduces angiogenesis (the formation of new blood vessels), which is crucial for tumor growth and metastasis.\n\n### Indications\n- **Metastatic Colorectal Cancer**: Zaltrap is approved for use in combination with the FOLFIRI regimen (irinotecan, 5-fluorouracil, and leucovorin) for patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5RGJ3dXSst7wcnGEJ3kTuxSc", "custom_id": "656_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "cd8e25d3f3b0909c172a3c31c66069dd", "body": {"id": "chatcmpl-9St50kzksVYYobd3tpXHYva9oDjzO", "object": "chat.completion", "created": 1716671938, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tabrecta (capmatinib) is a prescription medication used to treat certain types of non-small cell lung cancer (NSCLC). Here are some key points you should know about Tabrecta:\n\n1. **Indication**:\n   - Tabrecta is specifically indicated for the treatment of adult patients with metastatic NSCLC whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.\n\n2. **Mechanism of Action**:\n   - Capmatinib is a kinase inhibitor that targets MET, a receptor tyrosine kinase. By inhibiting MET, Tabrecta can help to slow or stop the growth of cancer cells that have this specific mutation.\n\n3. **Dosage and Administration**:\n   - The recommended dosage of Tabrecta is 400 mg orally twice daily, with or without food. Tablets should be swallowed whole and not crushed, chewed, or split.\n\n4."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_lYgpyfFMNsFVQy8El7YRAg9L", "custom_id": "657_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "124c5aa2b6c1ba8b4cccefb1b73b58ec", "body": {"id": "chatcmpl-9St50hi84kjFIZ42NgvGumMHErHm3", "object": "chat.completion", "created": 1716671938, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Padcev (enfortumab vedotin-ejfv) is a medication used in the treatment of certain types of cancer, specifically urothelial carcinoma, which is the most common type of bladder cancer. Here are some key points you should know about Padcev:\n\n### Indications:\n- **Urothelial Carcinoma**: Padcev is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have previously received a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy, or who are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.\n\n### Mechanism of Action:\n- **Antibody-Drug Conjugate (ADC)**: Padcev is an ADC that targets Nectin-4, a protein highly expressed in urothelial carcinoma cells. It combines an anti-Nectin-4 monoclonal antibody with a cytotoxic agent (monomethyl auristatin E, MMAE)."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_JcMdt8y2dq7LwaeQt5OxOlB0", "custom_id": "658_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "5b7517c3c3ce5af6d031a5ad16c0f36d", "body": {"id": "chatcmpl-9St51g67yYqShNU6xlC6mAshSOoNo", "object": "chat.completion", "created": 1716671939, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enhertu (fam-trastuzumab deruxtecan-nxki) is an antibody-drug conjugate (ADC) used in oncology, specifically for the treatment of certain types of breast cancer and gastric cancer. Here are some key points you should know about Enhertu:\n\n### Indications:\n1. **Breast Cancer**: Enhertu is approved for the treatment of adult patients with HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.\n2. **Gastric Cancer**: It is also approved for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.\n\n### Mechanism of Action:\nEnhertu is an ADC that combines a monoclonal antibody (trastuzumab) targeting HER2 with a topoisomerase I inhibitor (deruxtecan) as the cytotoxic payload. The antibody binds"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ZfLj9nNwlmYmmtotvhDM6Ky5", "custom_id": "659_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "93eb6b1cb92fb7ae7dcd47e742842364", "body": {"id": "chatcmpl-9St51s29UPQNOawYGqBxIx3Fg7vf6", "object": "chat.completion", "created": 1716671939, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Plenaxis (generic name: abarelix) is a medication that was used primarily in the treatment of advanced prostate cancer. It is a gonadotropin-releasing hormone (GnRH) antagonist, which works by directly inhibiting the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. This leads to a rapid decrease in testosterone levels, which is beneficial in managing hormone-sensitive prostate cancer.\n\nHere are some key points you should know about Plenaxis:\n\n1. **Indications**: Plenaxis was indicated for the palliative treatment of men with advanced symptomatic prostate cancer who had refused other hormonal therapies or were not candidates for such treatments.\n\n2. **Mechanism of Action**: As a GnRH antagonist, Plenaxis binds to GnRH receptors in the pituitary gland, preventing the release of LH and FSH. This results in a decrease in testosterone production by the testes, which can help slow"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_uUzFh7YwxumpI0U9FHjBH8R0", "custom_id": "660_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9d98b30abaac1b3840e9d07cb9614fd8", "body": {"id": "chatcmpl-9St51NNU6A3KStmyy3k7doo15SsYB", "object": "chat.completion", "created": 1716671939, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blenrep (belantamab mafodotin-blmf) is a medication used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Here are some key points you should know about Blenrep:\n\n### Mechanism of Action\n- **Antibody-Drug Conjugate (ADC):** Blenrep is an ADC that targets B-cell maturation antigen (BCMA), which is highly expressed on multiple myeloma cells.\n- **Cytotoxic Agent:** It delivers a cytotoxic agent, monomethyl auristatin F (MMAF), directly to the cancer cells, leading to cell cycle arrest and apoptosis.\n\n### Indications\n- **Relapsed/Refractory Multiple Myeloma:** Blenrep is indicated for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immun"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_hUJu4INrZtxptCFqem2aHVzs", "custom_id": "661_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "73709bb523d621bf3364d726c075867c", "body": {"id": "chatcmpl-9St524i21EW57wd89VqXIVs9UqItj", "object": "chat.completion", "created": 1716671940, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tukysa (tucatinib) is an oral tyrosine kinase inhibitor used in the treatment of HER2-positive breast cancer. Here are some key points you should know about Tukysa:\n\n1. **Indications**:\n   - Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.\n\n2. **Mechanism of Action**:\n   - Tucatinib selectively inhibits the HER2 tyrosine kinase, which is part of the epidermal growth factor receptor (EGFR) family. By inhibiting HER2, tucatinib helps to block the growth and spread of cancer cells.\n\n3. **Dosage and Administration**:\n   - The recommended dose of Tukysa is 300 mg taken orally twice daily in combination with trastuzumab"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_yTVVOV64NOCuhyYULn6QoOsB", "custom_id": "662_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b6ac7cfd8cc90c20290c752bb65f8564", "body": {"id": "chatcmpl-9St52vF45ExDHQG5jVMjWYsJf8G3S", "object": "chat.completion", "created": 1716671940, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Darzalex Faspro (daratumumab and hyaluronidase-fihj) is a combination medication used in the treatment of multiple myeloma, a type of blood cancer. Here are some key points you should know about Darzalex Faspro:\n\n### Mechanism of Action\n- **Daratumumab**: A monoclonal antibody that targets CD38, a protein expressed on the surface of multiple myeloma cells. It induces cell death through various mechanisms, including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis.\n- **Hyaluronidase-fihj**: An enzyme that increases the absorption and dispersion of daratumumab when administered subcutaneously.\n\n### Indications\nDarzalex Faspro is approved for use in multiple myeloma in various settings:\n- As monotherapy for patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_m0fSDecMNsvpW6R7yC4a7haC", "custom_id": "663_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e8c4ebcfd6e812d65d483d86159d32f3", "body": {"id": "chatcmpl-9St52ffZepJvZZR1eVjuVQBHuWD1e", "object": "chat.completion", "created": 1716671940, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panretin (generic name: alitretinoin) is a topical medication primarily used in the treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Here are some key points you should know about Panretin:\n\n### Mechanism of Action\n- **Retinoid Activity**: Alitretinoin is a retinoid, which means it is related to vitamin A. It works by binding to retinoid receptors in the skin, which can help to regulate cell growth and differentiation.\n\n### Indications\n- **Kaposi's Sarcoma**: Panretin is specifically indicated for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. It is not indicated for systemic treatment or for visceral Kaposi's sarcoma.\n\n### Administration\n- **Topical Application**: Panretin is applied directly to the skin lesions. It is usually applied two to four times a day, depending on the severity and response to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_IsVk4X64SWwDv59X9z1k454N", "custom_id": "664_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "4d54de6c23a0c6e2ef153289ee8fb04e", "body": {"id": "chatcmpl-9St52N3clYL0h05dLOHZE28KNtR57", "object": "chat.completion", "created": 1716671940, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tecartus (brexucabtagene autoleucel) is a chimeric antigen receptor (CAR) T-cell therapy that has been approved for the treatment of certain types of cancer. Here are some key points you should know about Tecartus:\n\n### Indications\n- **Mantle Cell Lymphoma (MCL):** Tecartus is approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.\n- **Acute Lymphoblastic Leukemia (ALL):** It is also approved for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.\n\n### Mechanism of Action\n- Tecartus involves the genetic modification of a patient's own T cells to express a CAR that targets the CD19 antigen, which is commonly found on the surface of B cells, including malignant B cells.\n- These modified T cells are then expanded and infused back into the patient, where they seek out and destroy CD19-ex"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_sNhIqg2Gol4Uv9OyKs67b7RM", "custom_id": "665_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "287d69c4b721ef27931963e96f02bbc8", "body": {"id": "chatcmpl-9St52984h1zftnr03Hukt9NuE5s0r", "object": "chat.completion", "created": 1716671940, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Piqray (alpelisib) is a medication used in the treatment of certain types of breast cancer. Here are some key points you should know about Piqray as a physician:\n\n### Indications:\n- **Breast Cancer**: Piqray is specifically indicated for the treatment of postmenopausal women, and men, with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced or metastatic breast cancer. It is used in combination with fulvestrant after disease progression following endocrine therapy.\n\n### Mechanism of Action:\n- **PI3K Inhibitor**: Piqray is an alpha-specific phosphatidylinositol-3-kinase (PI3K) inhibitor. It works by inhibiting the PI3K pathway, which is often overactive in cancer cells due to mutations in the PIK3CA gene, leading to cell growth and survival.\n\n### Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_f3lvhjf1zc5IIilGbsDzkP5c", "custom_id": "666_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b2ada3816f45ff72b2b526e793d5a5c5", "body": {"id": "chatcmpl-9St52rAEGlfNiZWdwNOEyjg2suzL2", "object": "chat.completion", "created": 1716671940, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Quinamed, also known by its generic name amonafide, is an investigational anticancer agent. It is a synthetic naphthalimide derivative that has been studied for its potential use in treating various types of cancer, including leukemia and solid tumors. Here are some key points you should know about Quinamed:\n\n1. **Mechanism of Action**: Quinamed works by intercalating into DNA, which disrupts the DNA replication process and inhibits the synthesis of nucleic acids. This leads to the induction of apoptosis (programmed cell death) in cancer cells.\n\n2. **Clinical Trials**: Quinamed has been evaluated in several clinical trials, primarily in the context of hematologic malignancies such as acute myeloid leukemia (AML) and solid tumors. However, its development has faced challenges, and it has not yet received approval from regulatory agencies like the FDA.\n\n3. **Efficacy**: The efficacy of Quinamed has shown mixed results in clinical trials"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Kw32AchFr5Qbl4Bj0dVz80Dz", "custom_id": "667_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "62a5c7340cad8b233e3596d0d0c74cbb", "body": {"id": "chatcmpl-9St53XaVYxLW7KPzHNYbPFMddvYMN", "object": "chat.completion", "created": 1716671941, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Amoxicillin (often referred to as Amoxi), which is a widely used antibiotic. Here are key points you should know:\n\n### Pharmacology\n- **Class**: Amoxicillin is a beta-lactam antibiotic in the penicillin class.\n- **Mechanism of Action**: It works by inhibiting the synthesis of bacterial cell walls, leading to cell lysis and death. It is effective against a broad range of Gram-positive and some Gram-negative bacteria.\n\n### Indications\n- **Common Uses**: Amoxicillin is commonly prescribed for bacterial infections such as:\n  - Upper respiratory tract infections (e.g., sinusitis, pharyngitis)\n  - Lower respiratory tract infections (e.g., bronchitis, pneumonia)\n  - Otitis media\n  - Skin and soft tissue infections\n  - Urinary tract infections\n  - Helicobacter pylori eradication (in combination with other medications)\n\n### Dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_B0anOaepIVpe3CXfjUxm1xSy", "custom_id": "668_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "bd1d8a6bf1f77acb0121ba2213b19f73", "body": {"id": "chatcmpl-9St53LWT3yN8eg07szvSxj67JqBOA", "object": "chat.completion", "created": 1716671941, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like you might be referring to a specific patient named Amelie, but without more context, it's difficult to provide specific information. However, if you are referring to a general medical context or a fictional character named Amelie, here are a few possibilities:\n\n1. **Patient Information**: If Amelie is a patient, you should know her medical history, current medications, allergies, recent lab results, and any other relevant clinical information. This would help you provide the best care tailored to her needs.\n\n2. **Fictional Character**: If you are referring to the character Am\u00e9lie Poulain from the French film \"Am\u00e9lie,\" she is a young woman who decides to change the lives of those around her for the better while struggling with her own isolation. Understanding her psychological profile could be useful if discussing mental health or social behavior.\n\n3. **Medical Conditions**: If \"Amelie\" refers to a medical condition or term that you might have misspelled or mis"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_vgTmOMBmlAt21ljT6Lvm8R9l", "custom_id": "669_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "8110f20d33075d50147dc6321f38effc", "body": {"id": "chatcmpl-9St535ebAcuFWMCRRNbnqAwowMygA", "object": "chat.completion", "created": 1716671941, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pemazyre (pemigatinib) is a medication used primarily for the treatment of certain types of cancer. Here are some key points you should know about Pemazyre:\n\n### Indications:\n- **Cholangiocarcinoma**: Pemazyre is approved for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an FDA-approved test.\n\n### Mechanism of Action:\n- **FGFR Inhibitor**: Pemazyre is a selective inhibitor of FGFR1, FGFR2, and FGFR3. FGFRs are involved in tumor cell proliferation and survival, and their dysregulation is implicated in various cancers.\n\n### Administration:\n- **Oral**: Pemazyre is administered orally, typically once daily for 14 consecutive days followed by 7 days off therapy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_0YYRKO0FmP3cVli44IWBtb5D", "custom_id": "670_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "422e5b6e479df1b7b2921e834119abeb", "body": {"id": "chatcmpl-9St53zZXqsCQvyojfv0HIB0YQg5kn", "object": "chat.completion", "created": 1716671941, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Qinlock (ripretinib) is a medication used in the treatment of advanced gastrointestinal stromal tumors (GIST) that have not responded to prior treatments. Here are some key points you should know about Qinlock:\n\n1. **Indication**: Qinlock is specifically indicated for adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including imatinib.\n\n2. **Mechanism of Action**: Qinlock is a tyrosine kinase inhibitor that targets a broad spectrum of KIT and PDGFRA mutations, which are commonly implicated in GIST. By inhibiting these kinases, Qinlock helps to control tumor growth.\n\n3. **Dosage and Administration**: The recommended dosage of Qinlock is 150 mg taken orally once daily with or without food. Tablets should be swallowed whole and not crushed, chewed, or split.\n\n4. **Side Effects**: Common side effects include alopecia, fatigue, nausea, abdominal pain,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_iMY8Fxeh93nMFVkZOq2OUXR7", "custom_id": "671_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6760eeb387d411e46c1c34aa3c64ca70", "body": {"id": "chatcmpl-9St532zN5SMAiMCL9XIVPBiO89Xji", "object": "chat.completion", "created": 1716671941, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Retevmo (selpercatinib) is a targeted therapy medication used primarily in the treatment of certain types of cancers that have specific genetic mutations. Here are some key points you should know about Retevmo:\n\n### Indications:\n1. **Non-Small Cell Lung Cancer (NSCLC):**\n   - For adult patients with metastatic RET fusion-positive NSCLC.\n   \n2. **Medullary Thyroid Cancer (MTC):**\n   - For adult and pediatric patients (12 years and older) with advanced or metastatic RET-mutant MTC who require systemic therapy.\n   \n3. **Thyroid Cancer:**\n   - For adult and pediatric patients (12 years and older) with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate).\n\n### Mechanism of Action:\n- Retevmo is a kinase inhibitor that targets RET (rearranged during transfection) gene fusions and mutations"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ibEEr5NeUerr8rKOY7Ep41CV", "custom_id": "672_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "96d7598f2827bea6b86ccfcd5252b3b7", "body": {"id": "chatcmpl-9St54wNWzJfkbCxNF5MOkuhaaqYPw", "object": "chat.completion", "created": 1716671942, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Inqovi is a combination medication containing decitabine and cedazuridine, used primarily in the treatment of certain types of myelodysplastic syndromes (MDS). Here are some key points you should know about Inqovi:\n\n### Indications:\n- **Myelodysplastic Syndromes (MDS):** Inqovi is indicated for the treatment of adult patients with MDS, including previously treated and untreated, de novo and secondary MDS with the following French-American-British (FAB) subtypes: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), and chronic myelomonocytic leukemia (CMML).\n- **Intermediate-1, Intermediate-2, and High-Risk MDS:** According to the International Prognostic Scoring System (IPSS).\n\n### Mechanism of Action:\n- **Decitabine:** A hypomethylating agent that incorporates into DNA and inhibits DNA"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_bhFfVv6612wD7JqkVKbyLYIl", "custom_id": "673_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "399dd244e2e44a8319111c26992c70f0", "body": {"id": "chatcmpl-9St5443NIMQ25ldCbo5JgaktzLOOJ", "object": "chat.completion", "created": 1716671942, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about Pepto-Bismol (bismuth subsalicylate) to provide accurate advice and care to your patients. Here are some key points you should know:\n\n### Indications:\n1. **Gastrointestinal Symptoms**: Pepto-Bismol is commonly used to treat symptoms such as nausea, heartburn, indigestion, upset stomach, and diarrhea.\n2. **Helicobacter pylori**: It can be part of a multi-drug regimen for the treatment of H. pylori infections.\n\n### Mechanism of Action:\n- **Antimicrobial**: Bismuth subsalicylate has antimicrobial properties that can help reduce the number of bacteria and viruses in the gastrointestinal tract.\n- **Anti-inflammatory**: The salicylate component has anti-inflammatory effects.\n- **Antacid**: It can neutralize stomach acid to some extent.\n- **Protective Coating**: It forms a protective coating on the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_gnApKrj6SNoVwP17m5FbYVl0", "custom_id": "674_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "bb9ce3180d72556d7742d78e05db498c", "body": {"id": "chatcmpl-9St54vIhjquxx5FK558uharx1lDAw", "object": "chat.completion", "created": 1716671942, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to stay informed about various medical products and technologies, including AiRuiKa. However, as of my last update in October 2023, there isn't specific information available about a product or technology named \"AiRuiKa\" in the medical field. It\u2019s possible that it could be a new drug, medical device, software, or a healthcare-related technology that has emerged recently or is specific to a particular region or specialty.\n\nHere are some general steps you can take to learn more about AiRuiKa:\n\n1. **Literature Review**: Check recent medical journals, databases like PubMed, and other scientific publications for any studies or articles mentioning AiRuiKa.\n\n2. **Professional Networks**: Consult with colleagues, attend medical conferences, or join professional forums and societies where new medical advancements are often discussed.\n\n3. **Regulatory Agencies**: Look up information from regulatory bodies such as the FDA (Food and Drug Administration) in the United States,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_nP5AYuiutTWiFQ6SqXOVj8d1", "custom_id": "675_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "4afbe4ff20d42bb0d891edaef552bd09", "body": {"id": "chatcmpl-9St54pJ9eezv84ktJFTvjCluJRiBp", "object": "chat.completion", "created": 1716671942, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Orgovyx (relugolix) is an oral medication used primarily for the treatment of advanced prostate cancer. Here are some key points you should know about Orgovyx:\n\n### Mechanism of Action\n- **GnRH Receptor Antagonist**: Orgovyx works by directly inhibiting the gonadotropin-releasing hormone (GnRH) receptor, which leads to a rapid decrease in the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This, in turn, reduces the production of testosterone, a hormone that can promote the growth of prostate cancer cells.\n\n### Indications\n- **Advanced Prostate Cancer**: Orgovyx is indicated for the treatment of adult patients with advanced prostate cancer.\n\n### Dosage and Administration\n- **Initial Dose**: The recommended initial dose is 360 mg taken orally on the first day.\n- **Maintenance Dose**: After the initial dose, the recommended dose is 120 mg taken"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_hXXpbICDaoceVfF0Z4Ui2M1F", "custom_id": "676_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "56a0bc2e58590004ce1b8c872ff98877", "body": {"id": "chatcmpl-9St54h0L22QskMLKzfg5fTPW9pBhq", "object": "chat.completion", "created": 1716671942, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Orserdu (elacestrant) is a medication that has been developed for the treatment of certain types of breast cancer. Here are some key points you should know about Orserdu:\n\n1. **Indication**: Orserdu is primarily indicated for the treatment of postmenopausal women and men with estrogen receptor-positive (ER+), HER2-negative advanced or metastatic breast cancer. It is often used in cases where the cancer has progressed following endocrine therapy.\n\n2. **Mechanism of Action**: Orserdu is a selective estrogen receptor degrader (SERD). It works by binding to the estrogen receptor and promoting its degradation, thereby reducing the estrogen-driven growth of cancer cells.\n\n3. **Administration**: Orserdu is typically administered orally. The specific dosage and treatment regimen can vary based on individual patient factors and the specific clinical scenario.\n\n4. **Efficacy**: Clinical trials have shown that Orserdu can be effective in reducing tumor size and delaying disease"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_njDfsie3hzui5fAVpXXNEmN5", "custom_id": "677_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "dd16896a10c908a3ff44f0afc54c359c", "body": {"id": "chatcmpl-9St55HNJfeus1wsdF3GD3fwXrH7l6", "object": "chat.completion", "created": 1716671943, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Neutrexin, also known by its generic name trimetrexate, is an antineoplastic and antiprotozoal agent. Here are some key points you should know about Neutrexin:\n\n### Indications:\n1. **Pneumocystis jirovecii Pneumonia (PCP):** Neutrexin is primarily used in the treatment of moderate to severe PCP in patients who are intolerant to or have failed standard treatments such as trimethoprim-sulfamethoxazole (TMP-SMX).\n2. **Cancer Treatment:** It has also been investigated for use in certain types of cancer, particularly those that are resistant to methotrexate, due to its mechanism of action as a folate antagonist.\n\n### Mechanism of Action:\n- **Folate Antagonist:** Neutrexin inhibits dihydrofolate reductase (DHFR), an enzyme involved in the synthesis of tetrahydrofolate, which is necessary for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_acEie4uQrx90FxNrmxRmiHNu", "custom_id": "678_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "73f7ae2f0364166d4fbe52feb829cc87", "body": {"id": "chatcmpl-9St55y1hJF8pU1sGWoYq4aBplP4Ho", "object": "chat.completion", "created": 1716671943, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tepmetko (tepotinib) is a medication used in the treatment of certain types of cancer. Here are some key points you should know about Tepmetko as a physician:\n\n### Indications:\n- **Non-Small Cell Lung Cancer (NSCLC):** Tepmetko is specifically indicated for the treatment of adult patients with metastatic NSCLC harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.\n\n### Mechanism of Action:\n- **MET Inhibition:** Tepmetko is a tyrosine kinase inhibitor that targets the MET receptor. By inhibiting MET signaling, it can reduce tumor cell proliferation and survival in cancers with MET alterations.\n\n### Dosage and Administration:\n- **Oral Administration:** Tepmetko is administered orally.\n- **Dosage:** The recommended dosage is typically 450 mg once daily, with or without food. Tablets should be swallowed whole and not crushed, chewed, or split.\n\n### Side Effects:\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_GqKGc60AJufYb5sNctg9YK6g", "custom_id": "679_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ab42b491fe3042dd313ce6ffbb2852eb", "body": {"id": "chatcmpl-9St55Jsd7I38cuuSBkMJR7TKXhwLb", "object": "chat.completion", "created": 1716671943, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lytgobi (futibatinib) is a medication that you, as a physician, should be aware of, especially if you are involved in oncology or the treatment of specific cancers. Here are some key points you should know:\n\n### Indications\n- **Lytgobi (futibatinib)** is primarily indicated for the treatment of adults with previously treated, unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma (iCCA) with FGFR2 gene fusions or other rearrangements.\n\n### Mechanism of Action\n- **Futibatinib** is a tyrosine kinase inhibitor that targets fibroblast growth factor receptors (FGFRs). It works by inhibiting the FGFR2 signaling pathway, which is often implicated in the growth and proliferation of certain cancer cells.\n\n### Administration\n- **Dosage and Administration**: Lytgobi is typically administered orally. The specific dosage regimen should be determined based on the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_MHsiXEDAwzl3RC37uHqMxvxC", "custom_id": "680_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7d9e59477b6ed1db2ebb33456d5e8db7", "body": {"id": "chatcmpl-9St56pQwDi1BAvB3TMcwxYOplE2sI", "object": "chat.completion", "created": 1716671944, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Optune is a medical device used in the treatment of glioblastoma multiforme (GBM), an aggressive type of brain cancer. Here are some key points you should know about Optune:\n\n### Mechanism of Action\n- **Tumor Treating Fields (TTFields):** Optune works by delivering low-intensity, alternating electric fields (TTFields) to the tumor site. These fields disrupt the mitotic process of cancer cells, inhibiting their ability to divide and proliferate.\n\n### Indications\n- **Newly Diagnosed GBM:** Optune is used in combination with temozolomide (TMZ) after surgery and radiation therapy.\n- **Recurrent GBM:** It can be used as a monotherapy for patients with recurrent GBM.\n\n### Efficacy\n- **Clinical Trials:** Studies, such as the EF-14 trial, have shown that Optune, when used with TMZ, can improve progression-free survival and overall survival in patients with newly"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Hq2lWHIE992Rn7ORFoXMfqLl", "custom_id": "681_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "8b6ba1124f6a1fd1fec62e51b7bf141b", "body": {"id": "chatcmpl-9St565t3JCYf3psecxEyuR8MSr7yA", "object": "chat.completion", "created": 1716671944, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Breyanzi (lisocabtagene maraleucel) is a chimeric antigen receptor (CAR) T-cell therapy used for the treatment of certain types of relapsed or refractory large B-cell lymphoma. Here are some key points you should know about Breyanzi:\n\n### Indications:\n- **Relapsed or Refractory Large B-Cell Lymphoma**: Breyanzi is indicated for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.\n\n### Mechanism of Action:\n- **CAR T-Cell Therapy**: Breyanzi involves reprogramming a patient's own T cells to express a CAR that targets the CD19 antigen on the surface of B cells. Once these modified T cells are infused back into the patient, they"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_wJvIf7DjbG9oXVuE9vkwIuyX", "custom_id": "682_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ec0a921a3711d15665c3cd7b5182548f", "body": {"id": "chatcmpl-9St56BnSYvyrbf9IVV8mdN8cs0yZj", "object": "chat.completion", "created": 1716671944, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abecma (idecabtagene vicleucel) is a CAR T-cell therapy approved by the FDA for the treatment of multiple myeloma. Here are some key points you should know about Abecma:\n\n### Indication:\n- **Approved Use**: Abecma is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.\n\n### Mechanism of Action:\n- **CAR T-Cell Therapy**: Abecma is a chimeric antigen receptor (CAR) T-cell therapy. It involves collecting a patient's T cells, genetically modifying them to express a CAR that targets the B-cell maturation antigen (BCMA) on multiple myeloma cells, and then infusing these modified cells back into the patient.\n\n### Administration:\n- **Preparation**: The process involves leukapheresis to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_LraD2AAQ6O1DzdkI0Aep8aMq", "custom_id": "683_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "be1b14d25a6c1945560e3b2ddf774e98", "body": {"id": "chatcmpl-9St560pH37HIKMiXUiCc8Yu5s2DXi", "object": "chat.completion", "created": 1716671944, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ayvakit (avapritinib) is a medication used primarily in the treatment of certain types of cancers, specifically gastrointestinal stromal tumors (GIST) and advanced systemic mastocytosis (AdvSM). Here are some key points you should know about Ayvakit:\n\n### Indications:\n1. **Gastrointestinal Stromal Tumors (GIST):**\n   - Ayvakit is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.\n\n2. **Advanced Systemic Mastocytosis (AdvSM):**\n   - It is also approved for the treatment of adults with advanced systemic mastocytosis, including aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).\n\n### Mechanism of Action:\n- Ayvakit is a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_dw8GaQJsAxIzR3ecp93C30Ky", "custom_id": "684_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "89868212206b893825afb19ece34fbf9", "body": {"id": "chatcmpl-9St56arvZmCeHKQzGqz6MXW2UqqoY", "object": "chat.completion", "created": 1716671944, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Turalio (pexidartinib) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. Here are some key points you should know about Turalio:\n\n### Mechanism of Action\n- **Pexidartinib** is a tyrosine kinase inhibitor that targets colony-stimulating factor-1 receptor (CSF1R), KIT, and FLT3-ITD. By inhibiting CSF1R, it reduces the proliferation of cells that drive TGCT.\n\n### Indications\n- **Symptomatic TGCT**: Turalio is specifically indicated for adult patients with symptomatic TGCT that is not amenable to surgery.\n\n### Dosage and Administration\n- **Dosage**: The recommended dosage is 400 mg orally twice daily on an empty"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_yu87vzwmfpyxy1fGbonPaSdT", "custom_id": "685_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "6cf573b9ceb88c5a1be01a04968736c7", "body": {"id": "chatcmpl-9St56ZFSRJBx1MjTOZ5rDkuerTCB4", "object": "chat.completion", "created": 1716671944, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gavreto (pralsetinib) is a targeted therapy used primarily in the treatment of certain types of cancers that exhibit specific genetic mutations. Here are some key points you should know about Gavreto:\n\n### Indications:\n1. **Non-Small Cell Lung Cancer (NSCLC):** Gavreto is approved for the treatment of adult patients with metastatic NSCLC whose tumors have RET (rearranged during transfection) gene fusions.\n2. **Thyroid Cancer:** It is also indicated for the treatment of adult and pediatric patients 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate).\n\n### Mechanism of Action:\n- Gavreto is a selective RET kinase inhibitor. RET gene fusions and mutations can lead to uncontrolled cell growth and cancer. By inhibiting RET, Gavreto helps to block the signaling pathways that"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_PYFzmKDaWFpnkx3pkveNfhLK", "custom_id": "686_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "22541ddf2dd1bf90110889f711b529eb", "body": {"id": "chatcmpl-9St57hOglscoz8cjXEHCkSlcbVbKI", "object": "chat.completion", "created": 1716671945, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zepzelca (lurbinectedin) is a medication used in the treatment of certain types of cancer, specifically small cell lung cancer (SCLC). Here are some key points you should know about Zepzelca:\n\n### Indications:\n- **Small Cell Lung Cancer (SCLC):** Zepzelca is indicated for the treatment of adult patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy.\n\n### Mechanism of Action:\n- **DNA Binding:** Lurbinectedin binds to the minor groove of DNA, leading to the disruption of the DNA-binding proteins, inhibition of transcription, and eventual cell death.\n- **Transcription Inhibition:** It also inhibits the transcription of oncogenes, which can contribute to its antitumor activity.\n\n### Administration:\n- **Dosage:** The recommended dose is 3.2 mg/m\u00b2, administered as an intravenous infusion over 60 minutes every 21 days.\n- **Premedication:** Antiemetic prophyl"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_NfPqzVATNWlSMsQoXDAmXoDl", "custom_id": "687_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c89cd440883f9730fdc78a61c3d21574", "body": {"id": "chatcmpl-9St57qOdDMZ1htWndZqZ0rLg6nkyG", "object": "chat.completion", "created": 1716671945, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Flagyl, also known by its generic name metronidazole, is an antibiotic and antiprotozoal medication. Here are some key points you should know about it:\n\n### Indications:\n1. **Bacterial Infections**: Effective against anaerobic bacteria and certain protozoa. Commonly used for infections such as bacterial vaginosis, pelvic inflammatory disease, and intra-abdominal infections.\n2. **Protozoal Infections**: Used to treat conditions like trichomoniasis, giardiasis, and amebiasis.\n3. **Clostridium difficile**: Sometimes used for mild to moderate cases of C. difficile-associated diarrhea.\n\n### Mechanism of Action:\n- Metronidazole works by entering the bacterial and protozoal cells and interfering with their DNA synthesis, leading to cell death.\n\n### Dosage and Administration:\n- **Oral**: Commonly administered in tablet or capsule form.\n- **Intravenous**: Available for more severe infections"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_mvMSIUpVi4pOwhRg8UdCSYE4", "custom_id": "688_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "85cd70bc78a7d3383e85a2779998683b", "body": {"id": "chatcmpl-9St57Nur6zkvwFy4OtjlxWBDcNDgF", "object": "chat.completion", "created": 1716671945, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Danyelza (naxitamab-gqgk) is a monoclonal antibody used in the treatment of certain types of cancer, specifically high-risk neuroblastoma in pediatric patients. Here are some key points you should know about Danyelza:\n\n1. **Indication**: Danyelza is approved for use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.\n\n2. **Mechanism of Action**: Danyelza is a GD2-binding monoclonal antibody. GD2 is a disialoganglioside expressed on the surface of neuroblastoma cells. By binding to GD2, Danyelza helps the immune system recognize and destroy these cancer cells.\n\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_OG8rhQv8IyHQxWknnKF9yCXR", "custom_id": "689_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d6ec91de45ecbd589fe8442962ae8fda", "body": {"id": "chatcmpl-9St57tTGMieuRgyY7q3fSJVqB6Uys", "object": "chat.completion", "created": 1716671945, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panmycin is a brand name for the antibiotic tetracycline, which is used to treat a variety of bacterial infections. As a physician, here are some key points you should know about Panmycin:\n\n### Mechanism of Action:\n- **Tetracycline** works by inhibiting protein synthesis in bacteria, thereby preventing their growth and multiplication. It binds to the 30S ribosomal subunit of the bacteria.\n\n### Indications:\n- **Respiratory tract infections** (e.g., pneumonia, bronchitis)\n- **Urinary tract infections**\n- **Acne**\n- **Skin infections**\n- **Sexually transmitted infections** (e.g., chlamydia, syphilis)\n- **Rickettsial infections** (e.g., Rocky Mountain spotted fever)\n- **Certain types of gastroenteritis** (e.g., cholera)\n- **Prophylaxis for malaria** (in specific cases)\n\n### Dosage and Administration:\n- **Adults:**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_AgyAKUYvVmV76MWj6Se4zyJy", "custom_id": "690_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "27944867d983082cb3a0c5a2addd71e2", "body": {"id": "chatcmpl-9St57xmN2fLmrQxykLFltRKJxS3KY", "object": "chat.completion", "created": 1716671945, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "De-Noltab, also known as bismuth subcitrate, is a medication primarily used in the treatment of gastrointestinal disorders, particularly peptic ulcers and Helicobacter pylori infections. Here are some key points you should know about De-Noltab:\n\n### Indications:\n1. **Peptic Ulcer Disease**: De-Noltab is used to promote healing of gastric and duodenal ulcers.\n2. **Helicobacter pylori Infection**: It is often part of a combination therapy to eradicate H. pylori, which is a common cause of peptic ulcers.\n\n### Mechanism of Action:\n- **Protective Barrier**: De-Noltab forms a protective coating over the ulcer site, shielding it from stomach acid and pepsin.\n- **Antibacterial Effect**: It has a direct antibacterial effect against H. pylori.\n- **Cytoprotective Properties**: It stimulates the secretion of mucus and bicarbonate, enhancing the mucosal defense"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_N5jnzTON4QUPjZxyU8tmH3ww", "custom_id": "691_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "2f7cfbee73f29fc54609f4bfc5a679cc", "body": {"id": "chatcmpl-9St57Hy5z2wKQ03tHf08EIIgoRCoA", "object": "chat.completion", "created": 1716671945, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Welireg (belzutifan) is a medication that you, as a physician, should be familiar with, especially if you are involved in oncology or the treatment of hereditary cancer syndromes. Here are some key points you should know:\n\n### Indications\n- **Welireg** is primarily indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), and who do not require immediate surgery.\n\n### Mechanism of Action\n- **Belzutifan** is a hypoxia-inducible factor-2 alpha (HIF-2\u03b1) inhibitor. It works by inhibiting the HIF-2\u03b1 protein, which is involved in the regulation of genes that promote tumor growth and survival under low oxygen conditions.\n\n### Dosage and Administration\n- The recommended dosage of Welireg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_CfLvx7TEB9BymPO2JAMXgAAj", "custom_id": "692_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "fccf14840a923314119fd3f63d80411d", "body": {"id": "chatcmpl-9St58QXLJuNLxcm2m7VVfIBMMVm4t", "object": "chat.completion", "created": 1716671946, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rybrevant (amivantamab-vmjw) is a medication used in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about Rybrevant:\n\n### Indications:\n- **NSCLC Treatment**: Rybrevant is specifically indicated for adult patients with locally advanced or metastatic NSCLC with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.\n\n### Mechanism of Action:\n- **Bispecific Antibody**: Rybrevant is a bispecific antibody that targets both EGFR and MET receptors. By binding to these receptors, it inhibits their signaling pathways, which are involved in the growth and survival of cancer cells.\n\n### Administration:\n- **Intravenous Infusion**: Rybrevant is administered as an intravenous infusion. The dosing schedule typically involves a loading dose followed by maintenance doses.\n- **Premedication**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_SZiJtAATX9JQWuzDlkSI0FE7", "custom_id": "693_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ae6d717a162759f70ff1cf2a9e46387d", "body": {"id": "chatcmpl-9St589DHX94tT1Dyfht2IcO7aCSHh", "object": "chat.completion", "created": 1716671946, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Onureg (azacitidine) is an oral medication used primarily in the treatment of certain types of blood cancers, particularly acute myeloid leukemia (AML). Here are some key points you should know about Onureg:\n\n### Indications:\n- **Acute Myeloid Leukemia (AML):** Onureg is indicated for the continued treatment of adult patients with AML who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and who are not able to complete intensive curative therapy.\n\n### Mechanism of Action:\n- **Hypomethylating Agent:** Azacitidine, the active ingredient in Onureg, is a nucleoside metabolic inhibitor that incorporates into DNA and RNA, leading to the inhibition of DNA methyltransferase. This results in hypomethylation of DNA and subsequent reactivation of silenced genes, which can induce cellular differentiation and apoptosis in malignant cells.\n\n### Administration:\n- **Oral Formulation:** Onureg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_gta60Q8UOURIuuucGFMgDH3g", "custom_id": "694_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "81e00ed4247b2d33d02e33a63c6dce83", "body": {"id": "chatcmpl-9St58l32s28yrgdmfQKCM70uhGXL6", "object": "chat.completion", "created": 1716671946, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Colcrys, which is the brand name for colchicine, is a medication primarily used to treat and prevent gout flares and familial Mediterranean fever (FMF). Here are some key points you should know about Colcrys:\n\n### Indications:\n1. **Gout Flares**: Colcrys is used both for the treatment of acute gout flares and for prophylaxis to prevent future flares.\n2. **Familial Mediterranean Fever (FMF)**: It is used to prevent attacks of FMF, a genetic disorder that causes recurrent fevers and inflammation.\n\n### Mechanism of Action:\n- Colchicine works by inhibiting microtubule polymerization, which in turn reduces the activity of neutrophils and decreases inflammation.\n\n### Dosage:\n- **Acute Gout Flares**: The typical dosing for an acute gout flare is 1.2 mg at the first sign of the flare, followed by 0.6 mg one hour later. \n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_NF30ukZRHYZMOHGcJnqYj8lz", "custom_id": "695_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f2ecc436578803b3614aca9e7f0a8eca", "body": {"id": "chatcmpl-9St58HRZqhALOG5B7I1pOfHCQUuLj", "object": "chat.completion", "created": 1716671946, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Jemperli (generic name: dostarlimab) is a monoclonal antibody used in the treatment of certain types of cancer. Here are some key points you should know about Jemperli:\n\n1. **Mechanism of Action**: Jemperli is a programmed death receptor-1 (PD-1) blocking antibody. It works by inhibiting the PD-1 receptor, which can help restore the immune system's ability to recognize and attack cancer cells.\n\n2. **Indications**: Jemperli is primarily indicated for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen. It may also be used for other cancers with similar genetic profiles, but its use should be guided by specific clinical trial data and regulatory approvals.\n\n3. **Administration**: Jemperli is administered via intravenous infusion. The dosing schedule typically involves an initial dose followed by subsequent doses"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_fiLzzJhdRtdaGcTyR0WjG4sA", "custom_id": "696_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c4d554b1ef6ed250247d63d73175a1aa", "body": {"id": "chatcmpl-9St59npD3gGtst89Bo0jFJrReOlM4", "object": "chat.completion", "created": 1716671947, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medical condition, treatment, or pharmaceutical product known as \"Hansizhuang.\" It is possible that it could be a new or emerging term, a regional name, or a misspelling of another medical term. \n\nIf \"Hansizhuang\" is a recent development or a term specific to a particular region or specialty, I would recommend the following steps:\n\n1. **Consult Medical Literature**: Check the latest medical journals, databases, and publications for any recent studies or articles mentioning \"Hansizhuang.\"\n\n2. **Professional Networks**: Reach out to colleagues or professional networks to see if anyone has encountered this term and can provide more context.\n\n3. **Medical Conferences and Seminars**: Attend relevant medical conferences or seminars where new developments and terms are often discussed.\n\n4. **Online Medical Communities**: Participate in online forums and communities for healthcare professionals, such as those on Medscape or Doximity,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_sRrRI0wFyxxMP4pAqpEi33Yf", "custom_id": "697_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7e3f5d2ae6de508cf87b45ebaa505ef2", "body": {"id": "chatcmpl-9St598YkmPEHiKY6aWiWlYfCbeM3J", "object": "chat.completion", "created": 1716671947, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication or treatment known as \"Cejemly.\" It's possible that it could be a new drug, a brand name, or a regional name that has emerged after my last update. Here are some general steps you can take to gather more information:\n\n1. **Consult Reliable Sources**: Check trusted medical databases such as PubMed, Medline, or the FDA's website for any recent approvals or studies related to \"Cejemly.\"\n\n2. **Pharmaceutical Reps**: Contact pharmaceutical representatives or the company that manufactures the drug for detailed information, including indications, contraindications, side effects, and clinical trial data.\n\n3. **Professional Networks**: Engage with professional networks or forums where other physicians might share their experiences or knowledge about new treatments.\n\n4. **Medical Journals**: Look for articles or studies in reputable medical journals that might provide insights into the drug's efficacy, safety, and recommended usage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_uD3ePyObcROceBlhJwYz3Tdi", "custom_id": "698_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "fcbed8a91c89bc98abc800ddfadf6b18", "body": {"id": "chatcmpl-9St59IjhoNqIB6h7fQzilBT8NGb9g", "object": "chat.completion", "created": 1716671947, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fyarro (sirolimus protein-bound particles for injectable suspension) is a medication used in the treatment of certain types of cancer. Here are some key points you should know about Fyarro:\n\n1. **Indications**: Fyarro is primarily indicated for the treatment of patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), a rare type of soft tissue sarcoma.\n\n2. **Mechanism of Action**: Fyarro contains sirolimus, an mTOR (mammalian target of rapamycin) inhibitor. mTOR is a kinase involved in cell growth, proliferation, and survival. By inhibiting mTOR, sirolimus can reduce cancer cell growth and proliferation.\n\n3. **Administration**: Fyarro is administered as an intravenous infusion. The specific dosing regimen should be followed as per the prescribing information, and it typically involves administration on specific days of a 21-day cycle.\n\n4."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_GwSlBMFt5Iv1iMZ2puuUSioI", "custom_id": "699_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "87a3fe10c37f0d2a0719361ba390c598", "body": {"id": "chatcmpl-9St59rTPpcoep11wNi4qmKed90P58", "object": "chat.completion", "created": 1716671947, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Antrypol, also known as suramin, is a medication primarily used to treat African trypanosomiasis (sleeping sickness) and onchocerciasis (river blindness). Here are some key points you should know about Antrypol:\n\n### Indications:\n1. **African Trypanosomiasis**: Effective in the early stages of the disease caused by Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense.\n2. **Onchocerciasis**: Used to treat river blindness caused by the parasitic worm Onchocerca volvulus.\n\n### Mechanism of Action:\n- Suramin inhibits various enzymes and cellular processes in the parasites, leading to their death. It interferes with energy metabolism and other critical functions in the parasites.\n\n### Administration:\n- **Route**: Intravenous (IV) administration.\n- **Dosage**: The dosage and duration of treatment depend on the specific condition being treated"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Jzf6pfrxxhYHO61RRlsEebMH", "custom_id": "700_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "02888540239f561faa8854c715047a6e", "body": {"id": "chatcmpl-9St59DBOoXySKSiVzuve817TnIfvV", "object": "chat.completion", "created": 1716671947, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Krazati (adagrasib) is a medication that has been developed for the treatment of certain types of cancer. Here are some key points you should know about Krazati:\n\n1. **Mechanism of Action**: Krazati is a KRAS G12C inhibitor. KRAS is a gene that encodes a protein involved in cell signaling pathways that control cell growth and division. Mutations in KRAS, particularly the G12C mutation, are common in various cancers and lead to uncontrolled cell growth. Krazati specifically targets and inhibits the KRAS G12C mutant protein, thereby blocking the signaling pathways that promote cancer cell proliferation.\n\n2. **Indications**: Krazati is primarily indicated for the treatment of non-small cell lung cancer (NSCLC) with a KRAS G12C mutation. It may also be investigated for use in other cancers harboring the same mutation, such as colorectal cancer and pancreatic cancer.\n\n3. **Administration**: Krazati"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_jGCU1u803qNwnh8vfOhaocnf", "custom_id": "701_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ee3d685476fdb25f81c903dd6738ef6c", "body": {"id": "chatcmpl-9St59483ASJIymVzlb4Hsfbkc3g3J", "object": "chat.completion", "created": 1716671947, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kimmtrak (tebentafusp-tebn) is a bispecific T-cell engager (BiTE) that has been approved by the FDA for the treatment of unresectable or metastatic uveal melanoma, a rare and aggressive form of eye cancer. Here are some key points you should know about Kimmtrak:\n\n### Mechanism of Action\n- **Bispecific T-cell Engager**: Kimmtrak is designed to bind to both CD3 on T-cells and gp100, a glycoprotein expressed on melanoma cells. This dual binding brings T-cells into close proximity with the melanoma cells, facilitating targeted immune-mediated killing of the cancer cells.\n\n### Indications\n- **Uveal Melanoma**: Specifically approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.\n\n### Administration\n- **Intravenous Infusion**: Kimmtrak is administered via intravenous infusion. The dosing schedule typically involves"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_BIS3WkSAzVM9XrvxElHFzdV6", "custom_id": "702_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "ccad159accc4eeb29192ae58dac4bc3d", "body": {"id": "chatcmpl-9St5AgfmxFMcqFaHS4rvlfBUvSb3T", "object": "chat.completion", "created": 1716671948, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Inrebic (fedratinib) is a medication used primarily for the treatment of intermediate-2 or high-risk primary or secondary myelofibrosis, a type of bone marrow cancer. Here are some key points you should know about Inrebic:\n\n### Mechanism of Action\n- **JAK2 Inhibitor**: Inrebic is a selective inhibitor of Janus kinase 2 (JAK2), which plays a role in the signaling pathways that regulate blood cell production and immune function. By inhibiting JAK2, Inrebic helps to reduce the abnormal proliferation of blood cells and alleviate symptoms associated with myelofibrosis.\n\n### Indications\n- **Myelofibrosis**: Inrebic is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.\n\n### Dosage and Administration\n- **Oral Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_D7wUk6TVq9wCQOMjjKE2YkoD", "custom_id": "703_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f0f3260373c64c49c8ef79e7c835260c", "body": {"id": "chatcmpl-9St5A7lqCMg1zU5KiICUbJIhMpITL", "object": "chat.completion", "created": 1716671948, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) is a combination of trastuzumab, a monoclonal antibody, and hyaluronidase, an enzyme that helps increase the absorption of trastuzumab when administered subcutaneously. It is used primarily in the treatment of HER2-positive breast cancer. Here are some key points you should know about Herceptin Hylecta:\n\n### Indications:\n1. **Adjuvant Treatment**: For HER2-positive early breast cancer, either alone or in combination with chemotherapy.\n2. **Metastatic Breast Cancer**: For HER2-positive metastatic breast cancer, in combination with paclitaxel or as a single agent in patients who have received one or more chemotherapy regimens.\n\n### Mechanism of Action:\n- **Trastuzumab**: Targets the HER2 receptor, inhibiting the proliferation of tumor cells that overexpress this receptor.\n- **Hyaluronidase**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_QGIoMOhXOAppoIRs1zmOpqp0", "custom_id": "704_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "1858912492c2bdf0853324eeb38650af", "body": {"id": "chatcmpl-9St5AxhjCSlsQ7HYBacwGVUHsYrmv", "object": "chat.completion", "created": 1716671948, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brukinsa (zanubrutinib) is a medication used in the treatment of certain types of B-cell malignancies. Here are some key points you should know about Brukinsa as a physician:\n\n### Indications:\n1. **Mantle Cell Lymphoma (MCL):** Brukinsa is indicated for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.\n2. **Waldenstr\u00f6m\u2019s Macroglobulinemia (WM):** It is also approved for the treatment of adult patients with Waldenstr\u00f6m\u2019s macroglobulinemia.\n3. **Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL):** Brukinsa is used in the treatment of CLL/SLL.\n\n### Mechanism of Action:\n- Brukinsa is a Bruton's tyrosine kinase (BTK) inhibitor. BTK is a crucial enzyme in the B-cell receptor signaling pathway"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_WbnaN9StRORke9rJP5Tnlc50", "custom_id": "705_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "07b5388940cd24a4dd7e0de77d070604", "body": {"id": "chatcmpl-9St5AMmTTMh1UBFtNYK86v58w6qZC", "object": "chat.completion", "created": 1716671948, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a typo or some confusion in your question. \"Ivesa\" doesn't appear to correspond to any widely recognized medical term, medication, or condition. If you meant something else, could you please provide more context or clarify your question?\n\nIf \"Ivesa\" is a specific term, product, or concept relevant to your practice, please provide additional details so I can offer more accurate information. If you have any other questions or need information on a different topic, feel free to ask!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 104, "total_tokens": 145}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_tJjmxC3s1D162cq11CC4xBlg", "custom_id": "706_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "cd2557057322750cf64b0f90ddff2814", "body": {"id": "chatcmpl-9St5BbJTPlGm1gYK8vfMAFBuPgnOd", "object": "chat.completion", "created": 1716671949, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carvykti (ciltacabtagene autoleucel) is a chimeric antigen receptor (CAR) T-cell therapy used for the treatment of certain types of cancer, specifically multiple myeloma. Here are some key points you should know about Carvykti:\n\n### Indications:\n- **Multiple Myeloma**: Carvykti is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.\n\n### Mechanism of Action:\n- **CAR T-Cell Therapy**: Carvykti involves modifying a patient's own T cells to express a CAR that targets the B-cell maturation antigen (BCMA) on multiple myeloma cells. These modified T cells are then infused back into the patient to attack and kill the cancer cells.\n\n### Administration:\n- **Personalized Treatment**: The process"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_YhuAfXtll0N1sV7berStobFZ", "custom_id": "707_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "82a3abd18eb18044abdaddb7f34730b2", "body": {"id": "chatcmpl-9St5BOGm6gpqgDPL0GVmZaxLhptjh", "object": "chat.completion", "created": 1716671949, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Scemblix (asciminib) is a medication used in the treatment of chronic myeloid leukemia (CML). Here are some key points you should know about Scemblix:\n\n1. **Mechanism of Action**: Scemblix is a tyrosine kinase inhibitor (TKI) that specifically targets the ABL myristoyl pocket (STAMP). This is different from other TKIs that target the ATP-binding site of the BCR-ABL1 protein. By binding to the myristoyl pocket, asciminib inhibits the BCR-ABL1 kinase activity, which is crucial for the proliferation of CML cells.\n\n2. **Indications**: Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome-positive CML in chronic phase (Ph+ CML-CP) who have been previously treated with two or more TKIs.\n\n3. **Dosage and Administration**: The recommended dose of Scemblix is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_szxXIAvXdwvpGoZvXeLnmTO8", "custom_id": "708_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "24c64d28f408d4ba60db57dbf1e562fa", "body": {"id": "chatcmpl-9St5BnvBw7ciz1YCImV4G9fJVV62R", "object": "chat.completion", "created": 1716671949, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zynlonta (loncastuximab tesirine-lpyl) is a prescription medication used in the treatment of certain types of cancer, specifically relapsed or refractory large B-cell lymphoma. Here are some key points you should know about Zynlonta:\n\n### Mechanism of Action\n- **Antibody-Drug Conjugate (ADC):** Zynlonta is an ADC that combines a monoclonal antibody targeting CD19 with a cytotoxic agent. The antibody binds to CD19-expressing cells, delivering the cytotoxic agent directly to the cancer cells, which helps to minimize damage to normal cells.\n\n### Indications\n- **Relapsed or Refractory Large B-Cell Lymphoma:** Zynlonta is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.\n\n### Administration\n- **Intravenous Infusion:** Zynlonta is administered as an intravenous infusion."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_CdR1cfBv8VBNmVfJnvkXulTS", "custom_id": "709_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "9a07ecbaacfb11d33b3aae160ac032a5", "body": {"id": "chatcmpl-9St5BcI10Ng9RbI6LHCXqlx6YLpVg", "object": "chat.completion", "created": 1716671949, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tazverik (generic name: tazemetostat) is a medication used primarily in the treatment of certain types of cancer. Here are some key points you should know about Tazverik as a physician:\n\n### Indications:\n1. **Epithelioid Sarcoma**: Tazverik is approved for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.\n2. **Follicular Lymphoma**: It is also indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least two prior systemic therapies. Additionally, it can be used for patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.\n\n### Mechanism of Action:\n- Tazverik is an inhibitor of the EZH2"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_fwOHCls3RQirRTH7bY9QSaET", "custom_id": "710_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "b25726fa159d44b8f22e5f22c2a72bd1", "body": {"id": "chatcmpl-9St5BMN0D7m6yIwcjPGjgRWoPUiBQ", "object": "chat.completion", "created": 1716671949, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Opdualag is a combination immunotherapy treatment that includes nivolumab and relatlimab. It is used in the treatment of certain types of cancer, particularly advanced melanoma. Here are some key points you should know about Opdualag:\n\n### Mechanism of Action:\n1. **Nivolumab**: This is a PD-1 (programmed death-1) inhibitor. It works by blocking the PD-1 pathway, which cancer cells often exploit to avoid being attacked by the immune system. By inhibiting this pathway, nivolumab helps to restore the immune system's ability to recognize and destroy cancer cells.\n2. **Relatlimab**: This is a LAG-3 (lymphocyte-activation gene 3) inhibitor. LAG-3 is another checkpoint protein that can downregulate the immune response. By inhibiting LAG-3, relatlimab can further enhance the immune system's ability to fight cancer.\n\n### Indications:\n- Op"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_FxmQxPIXeOmBkyizO5SKbYQR", "custom_id": "711_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "92ef99d484451c193f48524f3a192410", "body": {"id": "chatcmpl-9St5BLAE9HilFClqKk0EUOeAbfzzV", "object": "chat.completion", "created": 1716671949, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about any medication you might prescribe or encounter in your practice. However, as of my last update in October 2023, there is no widely recognized medication or treatment known as \"Berofor.\" It's possible that it could be a brand name, a regional name, or a new medication that has been introduced after my last update.\n\nHere are some general steps you can take to gather more information about Berofor:\n\n1. **Consult Reliable Sources**: Check trusted medical databases such as PubMed, Medline, or your country's drug regulatory authority (e.g., FDA in the United States, EMA in Europe) for any information on Berofor.\n\n2. **Pharmaceutical Reps**: If Berofor is a new medication, pharmaceutical representatives can provide detailed information, including clinical trial data, indications, contraindications, side effects, and dosing guidelines.\n\n3. **Colleagues and Specialists**: Discuss with colleagues or specialists in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_VIm6HfsTX1e9G5u9tnk5Cdch", "custom_id": "712_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c1b0ab7e9df9a68ed2b87a60d095ec3e", "body": {"id": "chatcmpl-9St5CODepGm7sliera04fkIOiFrrw", "object": "chat.completion", "created": 1716671950, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Wellferon, also known by its generic name interferon alfa-n1, is a type of interferon used primarily in the treatment of certain viral infections and cancers. Here are some key points you should know about Wellferon:\n\n### Mechanism of Action\n- **Interferon Activity**: Wellferon is a type of interferon, which are proteins that have antiviral, antiproliferative, and immunomodulatory effects. It works by enhancing the immune system's response to infections and inhibiting the growth of cancer cells.\n\n### Indications\n- **Chronic Hepatitis B and C**: Wellferon has been used in the treatment of chronic hepatitis B and C infections.\n- **Cancer**: It has also been used in the treatment of certain cancers, such as hairy cell leukemia, malignant melanoma, and Kaposi's sarcoma associated with AIDS.\n\n### Administration\n- **Route**: Wellferon is typically administered via subcutaneous or intramuscular injection.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_TNZ0TzRwURXtSaoEajpqpuDL", "custom_id": "713_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "4e22b4253a6b31dc1e1e949979525abf", "body": {"id": "chatcmpl-9St5CPxV2OJcfgpCf0bJaAdjgDoHp", "object": "chat.completion", "created": 1716671950, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Margenza (margetuximab-cmkb) is a monoclonal antibody used in the treatment of certain types of breast cancer. Here are some key points you should know about Margenza as a physician:\n\n1. **Indication**: Margenza is indicated for the treatment of adult patients with metastatic HER2-positive breast cancer. It is typically used in combination with chemotherapy (such as capecitabine) in patients who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.\n\n2. **Mechanism of Action**: Margenza is an anti-HER2 monoclonal antibody that binds to the HER2 receptor, a protein overexpressed in some breast cancers. By binding to HER2, Margenza inhibits the proliferation of tumor cells that overexpress this receptor. It also engages the immune system to help destroy these cancer cells.\n\n3. **Administration**: Margenza is administered intravenously. The recommended dose is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_2njZ0DPECCMy6V5IrtqE3OtM", "custom_id": "714_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "14d62202cbfdb70d88a333e59378a035", "body": {"id": "chatcmpl-9St5CJTkI448zUjPXr0QdBxdue5tZ", "object": "chat.completion", "created": 1716671950, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lumakras (sotorasib) is a medication used in the treatment of certain types of cancer, specifically non-small cell lung cancer (NSCLC) with a specific genetic mutation. Here are some key points you should know about Lumakras:\n\n### Indication\n- **Approved Use**: Lumakras is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy.\n\n### Mechanism of Action\n- **Target**: Lumakras is a KRAS G12C inhibitor. KRAS is a gene that encodes a protein involved in cell signaling pathways that control cell growth and division. Mutations in KRAS can lead to uncontrolled cell growth and cancer.\n- **Action**: By specifically targeting the KRAS G12C mutation, Lumakras inhibits the abnormal signaling pathways, thereby reducing cancer cell proliferation.\n\n### Administration\n- **Form**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_T1xa7IQtrBvFtixkYTokokNq", "custom_id": "715_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "349d74e7c79a37210daf2355a14901e1", "body": {"id": "chatcmpl-9St5CNnUKaGm8UGUgvyPHs2CVvuBY", "object": "chat.completion", "created": 1716671950, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ukoniq (umbralisib) is a medication used in the treatment of certain types of cancer, specifically relapsed or refractory marginal zone lymphoma (MZL) and follicular lymphoma (FL). Here are some key points you should know about Ukoniq:\n\n### Mechanism of Action\n- **Ukoniq** is a dual inhibitor of phosphoinositide 3-kinase (PI3K) delta and casein kinase 1 epsilon (CK1\u03b5). These enzymes are involved in the signaling pathways that promote the growth and survival of cancer cells.\n\n### Indications\n- **Marginal Zone Lymphoma (MZL)**: Ukoniq is indicated for the treatment of adult patients with relapsed or refractory MZL who have received at least one prior anti-CD20-based regimen.\n- **Follicular Lymphoma (FL)**: It is also indicated for the treatment of adult patients with relapsed or refractory FL who have received at least three"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_htkA5EUE81aMh7IlTNK7nHuv", "custom_id": "716_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d4782eeaa69b4eb4ed48d985ac1e4c7b", "body": {"id": "chatcmpl-9St5Cjx2gamuz2tC55x2ZMyCyIcph", "object": "chat.completion", "created": 1716671950, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tyvyt (sintilimab) is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) pathway, which is a key immune checkpoint in the regulation of immune responses. It is used in the treatment of certain types of cancer. Here are some key points you should know about Tyvyt:\n\n1. **Mechanism of Action**: Tyvyt works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances the immune system's ability to recognize and attack cancer cells.\n\n2. **Indications**: Tyvyt is primarily used for the treatment of various cancers, including:\n   - Non-small cell lung cancer (NSCLC)\n   - Hodgkin lymphoma\n   - Other cancers as determined by ongoing clinical trials and regulatory approvals\n\n3. **Administration**: Tyvyt is administered via intravenous infusion. The dosing schedule can vary depending on the specific cancer being treated and the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_LGqL8Ac8UVVMt9QNQ113F11A", "custom_id": "717_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "7f4650f4a1b8b027c5b42b690ce80ea1", "body": {"id": "chatcmpl-9St5DcjvOF1RrNeHO3gSyT60GO6PQ", "object": "chat.completion", "created": 1716671951, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Jaypirca (pirtobrutinib) is a medication that you, as a physician, should be aware of, especially if you are involved in the treatment of hematologic malignancies. Here are some key points you should know:\n\n1. **Mechanism of Action**: Jaypirca is a Bruton's tyrosine kinase (BTK) inhibitor. BTK is an enzyme that plays a crucial role in the signaling pathways that regulate the growth and survival of B-cells. By inhibiting BTK, Jaypirca can help to reduce the proliferation of malignant B-cells.\n\n2. **Indications**: Jaypirca is typically used in the treatment of certain types of B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). It may be used in patients who have not responded to other treatments or who have relapsed.\n\n3. **Administration**: Jaypirca is usually administered orally. The specific dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_kSgeOiLCOgFwTQuq0YfpRHdz", "custom_id": "718_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e0d70440f32fb0a9e25afc0175086b2b", "body": {"id": "chatcmpl-9St5DbjsS9X3hzTK04v9ew5ITh4d4", "object": "chat.completion", "created": 1716671951, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tuoyi (toripalimab) is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) pathway, which is a key immune checkpoint in the regulation of immune responses. Here are some key points you should know about Tuoyi:\n\n1. **Mechanism of Action**:\n   - Tuoyi is an immune checkpoint inhibitor that binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1 and PD-L2. This inhibition enhances the immune system's ability to recognize and attack cancer cells.\n\n2. **Indications**:\n   - Tuoyi is primarily used in the treatment of various cancers, including melanoma, non-small cell lung cancer (NSCLC), nasopharyngeal carcinoma, and urothelial carcinoma. The specific indications can vary based on regulatory approvals in different countries.\n\n3. **Administration**:\n   - Tuoyi is administered via intravenous infusion. The dosing schedule can vary depending on the type of cancer being treated"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_5AAHxto3c2GiIQFGvF2PQRn8", "custom_id": "719_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "41d88fe01970e5cba9c7aae00fc01221", "body": {"id": "chatcmpl-9St5D0iR2KkWLL6m0fILG23yfSFvr", "object": "chat.completion", "created": 1716671951, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tecvayli (generic name: teclistamab) is a medication used in the treatment of certain types of cancer, specifically multiple myeloma. Here are some key points you should know about Tecvayli as a physician:\n\n### Mechanism of Action\n- **Bispecific Antibody**: Tecvayli is a bispecific T-cell engager (BiTE) antibody that targets both B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T-cells. This dual targeting helps direct the body's immune system to attack and kill the myeloma cells.\n\n### Indications\n- **Multiple Myeloma**: Tecvayli is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.\n\n### Administration\n- **Route**: Tecvay"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_xGUCvI40drp4bfbjyxBkCb3O", "custom_id": "720_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "f8281e504305c6478a5961e2035ac758", "body": {"id": "chatcmpl-9St5DuOmI5hOAN8w9px4uURzvBqm4", "object": "chat.completion", "created": 1716671951, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Exkivity (mobocertinib) is a medication used in the treatment of certain types of non-small cell lung cancer (NSCLC). Here are some key points you should know about Exkivity:\n\n### Indication\n- **Exkivity** is specifically indicated for adult patients with locally advanced or metastatic NSCLC with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.\n\n### Mechanism of Action\n- **Mobocertinib** is a tyrosine kinase inhibitor (TKI) that targets EGFR exon 20 insertion mutations. It works by inhibiting the kinase activity of EGFR, which is involved in the proliferation and survival of cancer cells.\n\n### Administration\n- **Dosage**: The recommended dose is 160 mg orally once daily until disease progression or unacceptable toxicity.\n- **Administration**: It should be taken on an empty stomach, at least 1 hour before or "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_8mmZglcJSZUVg87CN3JBJREh", "custom_id": "721_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "64bb60e5a0856a1520e3c497d13e8bde", "body": {"id": "chatcmpl-9St5DgRkQhULVE7qkR2sA0LULVWKj", "object": "chat.completion", "created": 1716671951, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tivdak (tisotumab vedotin-tftv) is a medication used in the treatment of certain types of cancer. Here are some key points you should know about Tivdak:\n\n1. **Indication**: Tivdak is approved for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.\n\n2. **Mechanism of Action**: Tivdak is an antibody-drug conjugate (ADC). It consists of a monoclonal antibody (tisotumab) that targets tissue factor (TF), which is overexpressed in many solid tumors, linked to a cytotoxic agent (vedotin). Upon binding to TF on cancer cells, the ADC is internalized, and the cytotoxic agent is released, leading to cell death.\n\n3. **Administration**: Tivdak is administered via intravenous infusion. The recommended dose is 2 mg/kg (up to a maximum of 200 mg) every three weeks until disease progression or unacceptable toxicity.\n\n4"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_F1uLxiLRB8qc5WBK0AFFhaEU", "custom_id": "722_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d738979520a3b5093814acc8b47d93d7", "body": {"id": "chatcmpl-9St5ERFCP7luwiCqXEi3L5gsHO6J4", "object": "chat.completion", "created": 1716671952, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Somatuline Depot (lanreotide) is a long-acting somatostatin analog used primarily in the treatment of certain medical conditions. Here are key points you should know about it:\n\n### Indications:\n1. **Acromegaly**: Used to reduce growth hormone and IGF-1 levels in patients who have not responded adequately to surgery or radiotherapy.\n2. **Neuroendocrine Tumors (NETs)**: Approved for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.\n3. **Carcinoid Syndrome**: Used to control symptoms such as diarrhea and flushing in patients with carcinoid syndrome.\n\n### Mechanism of Action:\n- Lanreotide mimics natural somatostatin, inhibiting the release of several hormones, including growth hormone, insulin, and glucagon. It also reduces the secretion of serotonin and other substances that can cause symptoms in NETs.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_qKJSLrg0KBHGLxz7QpEWscjK", "custom_id": "723_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "631f7725b43046449b5fc3dfcf3ba44c", "body": {"id": "chatcmpl-9St5EPzt3DsFL7TzzCnILfbrxP83P", "object": "chat.completion", "created": 1716671952, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Jeselhy is a brand name for the medication bempedoic acid, which is used to lower cholesterol levels in the blood. Here are some key points you should know about Jeselhy as a physician:\n\n1. **Indication**: Jeselhy is primarily indicated for the treatment of hypercholesterolemia, particularly in patients who are unable to achieve their LDL cholesterol (LDL-C) goals with diet and other lipid-lowering therapies, such as statins.\n\n2. **Mechanism of Action**: Bempedoic acid works by inhibiting ATP-citrate lyase (ACL), an enzyme involved in the cholesterol biosynthesis pathway. This inhibition leads to reduced cholesterol synthesis in the liver and subsequently lowers LDL-C levels in the blood.\n\n3. **Dosage and Administration**: The typical dosage of Jeselhy is 180 mg once daily, taken orally with or without food. It is important to follow the specific dosing instructions provided by the manufacturer or based on clinical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_BNh2ypfY6nO8RuqILin8MzaW", "custom_id": "724_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "62ac0e97b2faf6e0593dc651a618e057", "body": {"id": "chatcmpl-9St5EC7pwV79DPDXBcqyTXumGaN5g", "object": "chat.completion", "created": 1716671952, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication, treatment, or medical condition known as \"Mostarina.\" It is possible that it could be a misspelling, a brand name not widely recognized, a new or experimental treatment, or a term specific to a particular region or medical community.\n\nIf \"Mostarina\" is a new or emerging term, I would recommend the following steps:\n\n1. **Consult Medical Literature**: Check the latest medical journals, databases like PubMed, and other reputable sources for any recent publications or studies mentioning \"Mostarina.\"\n\n2. **Professional Networks**: Reach out to colleagues or professional networks to see if anyone has encountered this term and can provide more context.\n\n3. **Pharmaceutical Repositories**: Look into pharmaceutical databases or contact pharmaceutical representatives to see if it is a new drug or treatment that has recently been introduced.\n\n4. **Continuing Medical Education (CME)**: Attend relevant CME courses or conferences where new"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_rppPkyqNjOmtdMuOhss3VdAc", "custom_id": "725_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "0a8f4287d834b3cbdfd3415f71927341", "body": {"id": "chatcmpl-9St5EswyYcf0lhciaVz0CT7T4B9ml", "object": "chat.completion", "created": 1716671952, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medical product, drug, or technology known as \"Vercite.\" It is possible that it could be a new or emerging product, a misspelling, or a term used in a specific context that is not broadly known.\n\nIf \"Vercite\" is a new product or term that has emerged after my last update, I would recommend the following steps to stay informed:\n\n1. **Consult Medical Literature**: Check recent medical journals, databases like PubMed, and other reputable sources for any publications or studies mentioning \"Vercite.\"\n\n2. **Professional Networks**: Engage with professional networks, such as medical associations, specialty societies, or online forums where healthcare professionals discuss new developments.\n\n3. **Pharmaceutical Reps and Companies**: If \"Vercite\" is a pharmaceutical product, contacting the company that manufactures it or speaking with a pharmaceutical representative could provide detailed information.\n\n4. **Continuing Medical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Bsa8r4itT9NQbdTU4jSIwDXN", "custom_id": "726_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "a2bd6c8aa7602208cd7e5456177c1a8d", "body": {"id": "chatcmpl-9St5ETmCIZ1WHFEwJuhnx63eFifaj", "object": "chat.completion", "created": 1716671952, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Polivy (polatuzumab vedotin-piiq) is a monoclonal antibody-drug conjugate used in the treatment of certain types of non-Hodgkin lymphoma, specifically relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Here are some key points you should know about Polivy:\n\n### Mechanism of Action\n- **Target**: Polivy targets CD79b, a protein expressed on the surface of B cells.\n- **Conjugate**: It is linked to a cytotoxic agent, monomethyl auristatin E (MMAE), which disrupts microtubule networks within the cell, leading to cell cycle arrest and apoptosis.\n\n### Indications\n- **FDA Approval**: Polivy is approved for use in combination with bendamustine and rituximab (BR) for the treatment of adult patients with relapsed or refractory DLBCL who have received at least two prior therapies.\n\n### Administration\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_tLQijfxzdlpqwBuCO5kvIk6Y", "custom_id": "727_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "d1ad9cecaa356b14d6554de1444b7033", "body": {"id": "chatcmpl-9St5EYra2uTJ3sWi2AelePF0E8313", "object": "chat.completion", "created": 1716671952, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Elahere (mirvetuximab soravtansine-gynx) is a targeted therapy used in the treatment of certain types of cancer. Here are some key points you should know about Elahere:\n\n1. **Indication**: Elahere is primarily indicated for the treatment of adult patients with folate receptor alpha (FR\u03b1)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is typically used in patients who have received prior chemotherapy treatments.\n\n2. **Mechanism of Action**: Elahere is an antibody-drug conjugate (ADC). It consists of a monoclonal antibody that targets FR\u03b1, linked to a cytotoxic agent (DM4, a maytansinoid). The antibody binds to FR\u03b1-expressing cancer cells, delivering the cytotoxic agent directly to the tumor, which helps to minimize damage to normal cells.\n\n3. **Administration**: Elahere is administered via intravenous"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_LQZVhEuIQe01qzbUiKVkFGF2", "custom_id": "728_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "8cc0f3bda88e53c4895bcd320508f621", "body": {"id": "chatcmpl-9St5FCeEk0OiYaRxBSnTjXKsUa2X2", "object": "chat.completion", "created": 1716671953, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lunsumio (generic name: mosunetuzumab) is a bispecific antibody used in the treatment of certain types of B-cell non-Hodgkin lymphoma (NHL). Here are some key points you should know about Lunsumio:\n\n1. **Mechanism of Action**: Lunsumio is a bispecific T-cell engager (BiTE) that targets both CD20 on B-cells and CD3 on T-cells. By binding to these two proteins, it brings T-cells into close proximity with B-cells, facilitating the T-cells' ability to kill the malignant B-cells.\n\n2. **Indications**: Lunsumio is typically indicated for the treatment of adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma who have received at least two prior systemic therapies.\n\n3. **Administration**: Lunsumio is administered via intravenous infusion. The dosing schedule can be complex, often involving a step-up"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ki5IpCVdFOrIcblYqyqnLXFt", "custom_id": "729_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "01dc324de9588907abd5afa85ea02226", "body": {"id": "chatcmpl-9St5FYCbeNoUz4CMvCTyNODJJd576", "object": "chat.completion", "created": 1716671953, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy product used for the treatment of certain types of bladder cancer, specifically high-grade, Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC). Here are some key points you should know about Adstiladrin:\n\n1. **Mechanism of Action**: Adstiladrin is a non-replicating adenoviral vector-based gene therapy. It delivers the gene for interferon alfa-2b directly into the bladder wall cells. The cells then produce interferon alfa-2b, which has anti-tumor properties.\n\n2. **Indications**: It is indicated for patients with high-grade, BCG-unresponsive NMIBC, including carcinoma in situ (CIS) with or without papillary tumors.\n\n3. **Administration**: Adstiladrin is administered via intravesical instillation, meaning it"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_gIQqCODd9RJ42nu4sQReR9Ki", "custom_id": "730_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "59e5d7431b50dfeafbf9642ce724ca0e", "body": {"id": "chatcmpl-9St5FnAnUZEE0Evlf75Db6bDmH9D2", "object": "chat.completion", "created": 1716671953, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rezlidhia (olutasidenib) is a medication used in the treatment of certain types of cancer, specifically acute myeloid leukemia (AML). Here are some key points you should know about Rezlidhia:\n\n1. **Indication**: Rezlidhia is indicated for the treatment of adult patients with relapsed or refractory AML who have a susceptible IDH1 mutation, as detected by an FDA-approved test.\n\n2. **Mechanism of Action**: Olutasidenib is an inhibitor of the isocitrate dehydrogenase 1 (IDH1) enzyme. Mutations in the IDH1 gene can lead to the production of an oncometabolite, 2-hydroxyglutarate (2-HG), which contributes to the development and progression of AML. By inhibiting the mutant IDH1 enzyme, olutasidenib reduces 2-HG levels, thereby potentially restoring normal cellular differentiation and reducing leukemic cell proliferation.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_HEf2UpqUiRz3v0bfGV38oIfB", "custom_id": "731_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "61f1524615aac1cbbf2ad95d45260cb0", "body": {"id": "chatcmpl-9St5Fw9nxbjDKuyPlXuf4xX5fbGNH", "object": "chat.completion", "created": 1716671953, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like you might be referring to a specific patient named Irene, but without more context, it's difficult to provide specific information. However, as a physician, here are some general guidelines you should follow when getting to know any patient:\n\n1. **Medical History**: Gather a comprehensive medical history, including past illnesses, surgeries, allergies, medications, and family medical history.\n\n2. **Current Symptoms**: Understand the current symptoms or concerns that brought the patient to seek medical attention.\n\n3. **Lifestyle Factors**: Inquire about lifestyle factors such as diet, exercise, smoking, alcohol consumption, and stress levels.\n\n4. **Social History**: Learn about the patient's social history, including occupation, living situation, and support systems.\n\n5. **Mental Health**: Assess the patient's mental health, including any history of mental health conditions, current mood, and stressors.\n\n6. **Physical Examination**: Conduct a thorough physical examination to identify any signs of illness or abnormalities.\n\n7. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 39, "completion_tokens": 200, "total_tokens": 239}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_FB7cSOlsXg8aMVPFwRYTu6xO", "custom_id": "732_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "e9b9752667cb0683a8233a89f3533457", "body": {"id": "chatcmpl-9St5FiKCvEvzMHlvJcjk8QB6SaQg1", "object": "chat.completion", "created": 1716671953, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be aware that \"Bigonist\" is not a standard medical term or a recognized medication. It might be a typographical error or a misunderstanding of a term. Here are a few steps you can take to clarify and address the situation:\n\n1. **Verify the Term**: Double-check the spelling and context in which you encountered \"Bigonist.\" It could be a misspelling of a known drug or medical term.\n\n2. **Consult Reliable Sources**: Use trusted medical databases, textbooks, or online resources like PubMed, UpToDate, or professional medical associations to search for the term.\n\n3. **Ask for More Information**: If a patient or colleague mentioned \"Bigonist,\" ask them for more details. They might provide additional context that can help you identify the correct term or medication.\n\n4. **Consider Similar Terms**: Think about similar-sounding medications or terms. For example, \"agonist\" is a common suffix in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_eP31WnppNfYF79U1h346x2Sy", "custom_id": "733_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "c6d1761648ca3731962f0ddb6f04c528", "body": {"id": "chatcmpl-9St5FkHjDpPIYDfh8u9QBSKddnBjG", "object": "chat.completion", "created": 1716671953, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Contego is a term that can refer to different things depending on the context, so it's important to clarify which specific context you are referring to. Here are a few possibilities:\n\n1. **Contego Medical**: If you are referring to Contego Medical, it is a company that develops medical devices, particularly focused on vascular and endovascular procedures. They are known for their innovative embolic protection devices, which are designed to improve patient outcomes during procedures such as carotid artery stenting. As a physician, you should be aware of their products, how they work, and the clinical evidence supporting their use.\n\n2. **Contego Solutions**: If you are referring to Contego Solutions, it is a company that provides compliance and risk management solutions, often for financial institutions. This might be less relevant to your practice as a physician unless you are involved in the administrative or financial aspects of healthcare management.\n\n3. **General Term**: \"Contego\" is a Latin word meaning \"to protect"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_KZoNtox00m91TYDvGrYAc6Hp", "custom_id": "734_sentiment_question_physician_0.0_gpt-4o", "response": {"status_code": 200, "request_id": "46f33e450a1aef2fd97d9fd6867b659f", "body": {"id": "chatcmpl-9St5Fmw7XiuzzE4qj2dlktRX1f16A", "object": "chat.completion", "created": 1716671953, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ebvallo (tabelecleucel) is a medication that has been developed for the treatment of Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD). Here are some key points you should know about Ebvallo:\n\n1. **Indication**: Ebvallo is indicated for the treatment of patients with EBV-associated PTLD who have either failed to respond to or are not eligible for rituximab-based therapy. PTLD is a potentially life-threatening condition that can occur after solid organ or hematopoietic stem cell transplantation due to immunosuppression.\n\n2. **Mechanism of Action**: Ebvallo is an allogeneic T-cell immunotherapy. It consists of EBV-specific cytotoxic T lymphocytes (CTLs) that target and kill EBV-infected cells. These CTLs are derived from healthy donors and are selected for their ability to recognize and attack EBV-infected cells.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_k4EeY6C14VQXHUvwfwBY8QlF", "custom_id": "1_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "86510ef436a38d1bfac7d607d984d604", "body": {"id": "chatcmpl-9St5GuReXksEQw2ylmN6GYS247mwJ", "object": "chat.completion", "created": 1716671954, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abemaciclib is an oral selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which are key regulators of the cell cycle. It is primarily used in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. Here are some key points you should know about Abemaciclib:\n\n1. **Indications**:\n   - Abemaciclib is approved for use in combination with endocrine therapy (e.g., aromatase inhibitors or fulvestrant) for the treatment of HR+/HER2- advanced or metastatic breast cancer.\n   - It can also be used as monotherapy for patients with HR+/HER2- breast cancer who have shown disease progression following endocrine therapy and prior chemotherapy.\n\n2. **Mechanism of Action**:\n   - Abemaciclib inhibits CDK4 and CDK6, leading to reduced phosphorylation of the retinoblastoma"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_zkLzvJ453EhEURyVmMI6z9Dx", "custom_id": "2_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "332c74c33b66235b5ae0f97dc89baafa", "body": {"id": "chatcmpl-9St5GvrIoGKADYy3VexxBPz3NiICa", "object": "chat.completion", "created": 1716671954, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abiraterone acetate is a medication used primarily in the treatment of prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC). As a physician, it's important to be well-informed about its indications, mechanism of action, administration guidelines, potential side effects, and monitoring requirements. Here are key points you should know:\n\n### Indications:\n- Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC) in combination with prednisone.\n\n### Mechanism of Action:\n- Abiraterone works by inhibiting CYP17A1, an enzyme involved in androgen biosynthesis. This inhibition leads to decreased production of testosterone and other androgens, which can fuel the growth of prostate cancer cells.\n\n### Administration:\n- Abiraterone is usually taken orally, often in combination with prednisone.\n- The standard dose is typically 1,000 mg (four 250 mg tablets"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_9Vrl4ltzQOpZGHzRbYBqlem8", "custom_id": "3_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2d7fc62b87b0aee6172a7c1598c9886a", "body": {"id": "chatcmpl-9St5GS8W7hlH0Hq4Hv4gGLRwQ5WSq", "object": "chat.completion", "created": 1716671954, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Acalabrutinib is a medication primarily used in the treatment of certain types of blood cancers. Here are key points you should know about it:\n\n### Indications:\n- **Chronic Lymphocytic Leukemia (CLL)**: It's approved for the treatment of adults with CLL.\n- **Mantle Cell Lymphoma (MCL)**: It's indicated for the treatment of adults with MCL who have received at least one prior therapy.\n\n### Mechanism of Action:\n- Acalabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor. By inhibiting BTK, it disrupts B-cell receptor signaling, which is essential for the survival and proliferation of malignant B cells.\n\n### Administration:\n- **Dosage**: Typically, 100 mg taken orally twice daily.\n- **Administration**: Can be taken with or without food. Capsules should be swallowed whole with water, not chewed, broken, or opened.\n\n### Side Effects:\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ZiS08TWCYpwphmpQkY5cr45T", "custom_id": "4_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e00c37351123ba5e10ae92abf604b00e", "body": {"id": "chatcmpl-9St5GbznvOowZCNR9kDqNfXw8hmG5", "object": "chat.completion", "created": 1716671954, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aclarubicin, also known as aclacinomycin A, is an anthracycline antibiotic used primarily in cancer chemotherapy. Here are some key points you should know:\n\n### Mechanism of Action:\n1. **DNA Intercalation**: Aclarubicin intercalates into DNA and inhibits nucleic acid synthesis, disrupting DNA replication and transcription.\n2. **Topoisomerase II Inhibition**: It inhibits topoisomerase II, an enzyme involved in DNA replication, thus preventing the re-ligating of DNA strands.\n3. **Free Radical Formation**: It can generate free radicals, leading to oxidative damage to cellular components, including DNA, proteins, and lipids.\n\n### Indications:\n- Aclarubicin is primarily used in the treatment of hematological malignancies such as acute myeloid leukemia (AML) and other types of leukemia.\n\n### Administration:\n- It is usually administered intravenously.\n\n### Side Effects:\n1. **Cardiotoxicity"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_w6n00SjhGNIDyaNX86ZhfW5B", "custom_id": "5_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "296dcf0fabcfdbebf14853d6e844d849", "body": {"id": "chatcmpl-9St5GgctwNztUUqyiOuQP59hyp7Mb", "object": "chat.completion", "created": 1716671954, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab emtansine, also known as T-DM1 (brand name Kadcyla), is an antibody-drug conjugate used primarily in the treatment of HER2-positive breast cancer. Here are some key points you should know about it:\n\n1. **Mechanism of Action**:\n   - **Antibody Component**: Trastuzumab is a monoclonal antibody that targets the HER2 receptor, which is overexpressed in some breast cancers. It inhibits HER2-mediated signaling pathways, leading to cell growth inhibition and apoptosis.\n   - **Drug Component**: Emtansine (DM1) is a cytotoxic agent that interferes with microtubule function, leading to cell cycle arrest and apoptosis. DM1 is linked to trastuzumab and is delivered directly to HER2-positive cancer cells.\n\n2. **Indications**:\n   - Trastuzumab emtansine is primarily indicated for patients with HER2-positive metastatic breast cancer who"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_5kwVfTfsHOrO27M1tkPhCKg5", "custom_id": "6_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d534bd5708de49141bcdd53f41983b86", "body": {"id": "chatcmpl-9St5HgshRaMIXOJP3tm4b5pi9P97N", "object": "chat.completion", "created": 1716671955, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Afatinib is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC). Here are several key points you should know about Afatinib:\n\n### Mechanism of Action:\n- **Tyrosine Kinase Inhibitor (TKI):** Afatinib is an irreversible inhibitor of the ErbB family of receptors, which includes EGFR (epidermal growth factor receptor), HER2, and HER4. It blocks downstream signaling pathways, inhibiting tumor cell proliferation and survival.\n\n### Indications:\n- **NSCLC with EGFR Mutations:** Afatinib is approved for the first-line treatment of patients with metastatic NSCLC whose tumors have specific types of EGFR mutations (e.g., exon 19 deletions or exon 21 (L858R) substitution mutations).\n\n### Administration:\n- **Dosage:** Typically, Afatinib is administered orally at a dose of 40 mg once daily. Adjustments may be necessary based on patient tolerance"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_kjpAyeiuYX9p3no0rV1oGMjR", "custom_id": "7_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "1fc7dc4dc992fdc4a9c11f50d542a568", "body": {"id": "chatcmpl-9St5HjXL9mJht6TM4UcyG9S0vQwKm", "object": "chat.completion", "created": 1716671955, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aldesleukin, also known by its brand name Proleukin, is a recombinant human interleukin-2 (IL-2) used primarily in the treatment of metastatic renal cell carcinoma and metastatic melanoma. Here are key points you should know about Aldesleukin:\n\n### Mechanism of Action:\n- **Immune Modulation**: Aldesleukin stimulates the growth and activity of T-cells and natural killer (NK) cells, enhancing the body's immune response to target and destroy cancer cells.\n\n### Indications:\n- **Metastatic Renal Cell Carcinoma**: Approved for patients with metastatic renal cell carcinoma.\n- **Metastatic Melanoma**: Approved for patients with metastatic melanoma.\n\n### Administration:\n- **Route**: Given by intravenous (IV) infusion.\n- **Dosing Regimen**: Typically administered in cycles, often involving multiple infusions over several days followed by a rest period.\n\n### Side Effects:\n- **Common**: Flu"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Z0fRsQ7wLwi544EB9hkUrm52", "custom_id": "8_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c6a20c15edfdfd56b3cf62c6953267f9", "body": {"id": "chatcmpl-9St5HubuBLxIw5eXf2AcetbnRTNfU", "object": "chat.completion", "created": 1716671955, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alectinib is a targeted cancer therapy used primarily in the treatment of non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK) mutations. Here are some essential points you should know about Alectinib as a physician:\n\n### Mechanism of Action\n- **ALK Inhibitor:** Alectinib specifically targets and inhibits ALK, a receptor tyrosine kinase that is involved in the growth and survival of cancer cells. This inhibition can lead to reduced tumor cell proliferation and increased apoptosis.\n\n### Indications\n- **NSCLC:** Alectinib is approved for the treatment of patients with ALK-positive metastatic NSCLC. It is often used in cases where the cancer has progressed despite previous treatments.\n\n### Efficacy\n- **Progression-Free Survival:** Clinical trials have shown that Alectinib significantly improves progression-free survival compared to crizotinib, another ALK inhibitor. \n- **Central Nervous System (C"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_2RKNuXlRMPC2iv41io5wQhYu", "custom_id": "9_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ab9f5af1ea09f4fb2f1fa2ac5df8f913", "body": {"id": "chatcmpl-9St5HZFEGIyMvcrDVh5bO7LMz26oB", "object": "chat.completion", "created": 1716671955, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alemtuzumab is a monoclonal antibody that targets CD52, a protein found on the surface of mature lymphocytes. It is used primarily for the treatment of certain types of blood cancers and multiple sclerosis. Here are some key points you should know:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL):**\n   - Alemtuzumab is approved for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been treated with alkylating agents and have failed fludarabine therapy.\n   \n2. **Multiple Sclerosis (MS):**\n   - It is used for relapsing forms of multiple sclerosis, generally in patients who have had an inadequate response to two or more other medications for MS.\n\n### Mechanism of Action:\n- Alemtuzumab binds to CD52, a cell surface antigen present on the majority of B and T lymphocytes. This binding results in the destruction of these cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_mQnChmAuMMyZDKke7jpsqSE2", "custom_id": "10_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f29d19ef23554164fc23f9366bf86283", "body": {"id": "chatcmpl-9St5Hd8Xr4XlTpAwDaD7bSfNABHNi", "object": "chat.completion", "created": 1716671955, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "All-trans retinoic acid (ATRA), also known as tretinoin, is a derivative of vitamin A and plays a crucial role in the regulation of cell growth and differentiation. It is used in both dermatology and oncology. Below are some key points you should be aware of:\n\n### Dermatological Use\n1. **Acne Treatment**: ATRA is widely used topically to treat acne vulgaris. It helps by promoting cell turnover and preventing the formation of new comedones.\n2. **Photoaging**: It can improve the appearance of fine wrinkles, pigmentation, and skin texture by promoting collagen production and cell turnover.\n3. **Application**: Typically applied once daily, preferably at night. Patients should be advised to use sunscreen as ATRA can increase photosensitivity.\n\n### Oncological Use\n1. **Acute Promyelocytic Leukemia (APL)**: ATRA is a cornerstone in the treatment of APL, a subtype of acute myeloid leukemia"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_JgOmK0o4LeLxWS2yF1HsbBZZ", "custom_id": "11_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d4a3f4d2ebf406d39a59b6b2a248caa3", "body": {"id": "chatcmpl-9St5IavHifjYxJgeVpMS7tsOva0IM", "object": "chat.completion", "created": 1716671956, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Altretamine, also known by the brand name Hexalen, is an antineoplastic (anti-cancer) agent primarily used in the treatment of ovarian cancer, particularly in cases where the cancer has not responded to other treatments. Below are key points you should know about Altretamine:\n\n### Mechanism of Action:\n- Altretamine is classified as an alkylating agent. Its exact mechanism is not fully understood, but it is believed to damage the DNA of cancer cells, thereby inhibiting their ability to replicate and ultimately leading to cell death.\n\n### Indications:\n- Altretamine is mainly indicated for the treatment of persistent or recurrent ovarian cancer following first-line therapy.\n\n### Administration:\n- Altretamine is administered orally, typically in capsule form.\n- The usual recommended dose is 260 mg/m\u00b2/day, divided into four doses, for 14 or 21 consecutive days in a 28-day cycle. Adjustments may be required based on patient tolerance and response.\n\n### Side Effects"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_POOsAsSuASX2AsaowhguAK7t", "custom_id": "12_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "3f4af8d39a07f1d6c35ab09db4546638", "body": {"id": "chatcmpl-9St5IRpcDNgyf5ExxZVJ5UwjifiOh", "object": "chat.completion", "created": 1716671956, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aminoglutethimide is a medication that has been used primarily as an adrenocortical steroid synthesis inhibitor. Here are some key points you should know about it:\n\n### Mechanism of Action\nAminoglutethimide inhibits the enzyme aromatase, which is responsible for the conversion of androgens to estrogens. It also inhibits the enzyme P450scc (cholesterol side-chain cleavage enzyme), which is involved in the conversion of cholesterol to pregnenolone, a precursor in the synthesis of all steroid hormones.\n\n### Indications\n- **Cushing's Syndrome:** Aminoglutethimide has been used to treat Cushing's syndrome by reducing the production of cortisol.\n- **Breast Cancer:** It can be used in postmenopausal women with estrogen receptor-positive breast cancer to reduce estrogen levels and slow tumor growth.\n- **Prostate Cancer:** Sometimes used off-label in advanced prostate cancer for its anti-androgen effects.\n\n### Dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_4WS5MyBEMMVRaa4CnCtO3aEs", "custom_id": "13_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9b8da52f8fe6ee60c7ea1e47048227c5", "body": {"id": "chatcmpl-9St5IdN82G2ATE9bJHgUHYTOez3DK", "object": "chat.completion", "created": 1716671956, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amrubicin is a synthetic anthracycline and a third-generation chemotherapy drug used primarily in the treatment of small cell lung cancer (SCLC). Here are some key points you should know about Amrubicin:\n\n### Mechanism of Action:\n- **Topoisomerase II Inhibitor:** Amrubicin works by inhibiting the enzyme topoisomerase II, which is essential for DNA replication and cell division. This inhibition leads to DNA damage and apoptosis (cell death) in rapidly dividing cancer cells.\n\n### Indications:\n- **Small Cell Lung Cancer (SCLC):** Amrubicin is often used for the treatment of SCLC, particularly in cases where the disease has relapsed or is refractory to first-line treatment.\n- **Other Cancers:** There is ongoing research into its effectiveness in other types of cancer, but its primary indication remains SCLC.\n\n### Administration:\n- **Intravenous (IV) Infusion:** Amrubicin is administered intravenously, typically over a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Yjdzsdz8aro6we2qnlE3qepo", "custom_id": "14_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "3e9f70f9d08d873ec0b94e70aa6d2daa", "body": {"id": "chatcmpl-9St5IOLTlxUihtgL1m1jFAnEFK9Ow", "object": "chat.completion", "created": 1716671956, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amsacrine is an antineoplastic agent used primarily in the treatment of certain types of cancer, particularly acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). As a physician, here are several key aspects you should know about Amsacrine:\n\n### Mechanism of Action:\n- **Topoisomerase II Inhibition:** Amsacrine works by inhibiting the enzyme topoisomerase II, which is crucial for DNA replication. This inhibition leads to DNA strand breaks, thereby preventing the proliferation of cancer cells.\n  \n### Pharmacokinetics:\n- **Administration:** Amsacrine is typically administered intravenously.\n- **Metabolism and Excretion:** It is metabolized in the liver and excreted primarily through the kidneys.\n\n### Clinical Use:\n- **Indications:** Mainly used for treating acute lymphoblastic and myeloid leukemias, particularly in patients who are refractory to other treatments or have relapsed.\n- **Combination Therapy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_y9aWWXJKaCLz92zgPs8hWUJ8", "custom_id": "15_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "304eb2cb9f2c238a30cb87b2a2f967a7", "body": {"id": "chatcmpl-9St5IK5F9Bq3WKZ6p0295l46onaR7", "object": "chat.completion", "created": 1716671956, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Anastrozole is a medication primarily used in the treatment of breast cancer, specifically hormone receptor-positive breast cancer. Here are key points you should know about Anastrozole as a physician:\n\n### Mechanism of Action\n- **Aromatase Inhibitor:** Anastrozole works by inhibiting the enzyme aromatase, which is involved in the conversion of androgens to estrogens. By lowering estrogen levels, it helps slow the growth of estrogen-dependent breast cancer cells.\n\n### Indications\n- **Breast Cancer in Postmenopausal Women:** Anastrozole is commonly used in the adjuvant treatment of hormone receptor-positive early breast cancer and in the treatment of advanced or metastatic breast cancer in postmenopausal women.\n- **Prevention:** It may also be used in the prevention of breast cancer in high-risk postmenopausal women.\n\n### Administration\n- **Dosage:** The typical dose is 1 mg taken orally once daily.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_rV8LaNLCJnC4kgRD5UTNCCSy", "custom_id": "16_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8222889e0bbb6e8d209ed76926d30509", "body": {"id": "chatcmpl-9St5IJVxH55ZdjWGy2hPv5vG7d6U9", "object": "chat.completion", "created": 1716671956, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Apalutamide is an androgen receptor inhibitor used primarily in the treatment of prostate cancer. Here are some key points you should know about Apalutamide:\n\n### Indications:\n1. **Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC):**\n   - Apalutamide is approved for patients with nmCRPC, a condition where prostate cancer continues to progress despite low levels of testosterone, but has not yet spread to other parts of the body.\n\n2. **Metastatic Castration-Sensitive Prostate Cancer (mCSPC):**\n   - It is also approved for use in patients with mCSPC, where prostate cancer has spread to other parts of the body but still responds to treatments that lower testosterone levels.\n\n### Mechanism of Action:\n- Apalutamide works by inhibiting the androgen receptor, which plays a critical role in the growth of prostate cancer cells. By blocking these receptors, Apalutamide prevents androg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Kb50nqxuOpgyhUC1g5iG5iDk", "custom_id": "17_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d915570a1d6aa7cbf685e77fbbc5e203", "body": {"id": "chatcmpl-9St5IXOdTT4UtMfHzl7Scl1PXWCfp", "object": "chat.completion", "created": 1716671956, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Apatinib is a small-molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor-2 (VEGFR-2). It is primarily used in the treatment of advanced or metastatic gastric cancer, particularly in patients who have not responded to prior chemotherapy regimens. Below are some key points you should know about Apatinib:\n\n### Mechanism of Action\n- **VEGFR-2 Inhibition:** Apatinib inhibits VEGFR-2, which plays a crucial role in tumor angiogenesis. By blocking this receptor, Apatinib reduces the blood supply to the tumor, thereby inhibiting its growth.\n\n### Indications\n- **Advanced Gastric Cancer:** Apatinib is approved for the treatment of advanced or metastatic gastric cancer in patients who have failed at least two prior chemotherapy regimens.\n- **Other Cancers:** Research is ongoing to evaluate its efficacy in other types of cancer, including non-small cell lung cancer, hepatocellular carcinoma, and colorectal cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_6EIheH3mxOHI4V38Yx5cs3fE", "custom_id": "18_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "fd19135ef1fb4f5ec969346fcf81e4e5", "body": {"id": "chatcmpl-9St5ILoYtW3VjFxwC2LcZNp6I10Wr", "object": "chat.completion", "created": 1716671956, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of arsenic trioxide, especially if you are involved in oncology or toxicology. Here are key points you should be aware of:\n\n### Medical Uses:\n1. **Cancer Treatment**: Arsenic trioxide is FDA-approved for the treatment of acute promyelocytic leukemia (APL), particularly in patients who have relapsed or are resistant to other treatments. It works by causing the cancerous cells to undergo apoptosis (programmed cell death).\n\n### Mechanism of Action:\n2. **Apoptosis Induction**: Arsenic trioxide induces apoptosis and promotes the differentiation of leukemic cells into more mature forms that eventually die naturally.\n3. **Gene Expression Modulation**: It affects the transcription of genes involved in cell cycle regulation and apoptosis.\n\n### Administration:\n4. **Intravenous Infusion**: The drug is typically administered intravenously. The dosing regimen can vary, but it often involves daily infusions over a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_LyHFjhvCBcVdLglDpfKzbR2c", "custom_id": "19_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2f2eb6f81ba99b8a37dca99833aaec04", "body": {"id": "chatcmpl-9St5JdXG95Llz25weSCwrqUdFAaf8", "object": "chat.completion", "created": 1716671957, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Asparaginase, particularly if you are involved in the treatment of hematologic malignancies like acute lymphoblastic leukemia (ALL). Here are key points to consider:\n\n### Mechanism of Action:\n- **Asparaginase** is an enzyme that catalyzes the hydrolysis of the amino acid asparagine to aspartic acid and ammonia.\n- Many leukemic cells are unable to synthesize asparagine due to a deficiency in asparagine synthetase, making them dependent on extracellular asparagine. By depleting this amino acid, Asparaginase effectively starves the leukemic cells, inhibiting protein synthesis and leading to apoptosis.\n\n### Indications:\n- Primarily used in the treatment of acute lymphoblastic leukemia (ALL).\n- It may also be used in other hematologic malignancies or off-label for specific conditions as determined by clinical guidelines and emerging studies.\n\n### Types of Asparagin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_pKnFhKyWIUEUDuXZCC3lN1ly", "custom_id": "20_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a52d896d24cdd3bd52f206282bd91bcb", "body": {"id": "chatcmpl-9St5JNnkPr2qV7HGYHAPS5h0o0M2V", "object": "chat.completion", "created": 1716671957, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asparaginase Erwinia chrysanthemi is an enzyme used in the treatment of acute lymphoblastic leukemia (ALL), particularly in patients who have developed hypersensitivity or allergic reactions to E. coli-derived asparaginase products. Here are key points you should know about it:\n\n1. **Mechanism of Action**: Asparaginase Erwinia chrysanthemi works by depleting the amino acid asparagine, which is essential for the growth of leukemic cells. Normal cells can synthesize asparagine, but leukemic cells cannot, leading to their death when asparagine levels fall.\n\n2. **Indications**: It is primarily used in patients with ALL who are allergic to other forms of asparaginase, such as those derived from Escherichia coli.\n\n3. **Administration**: It is usually administered via intramuscular injection. The dosage and frequency depend on the specific treatment protocol and patient response.\n\n4. **Side"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_JEteOy2Vd1BULxkk0uGUOPHF", "custom_id": "21_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "3cd95246533478459d08ff85c949ec3e", "body": {"id": "chatcmpl-9St5Jgkto0JMgyU81hgWYt5FwrZve", "object": "chat.completion", "created": 1716671957, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Atezolizumab (brand name Tecentriq) is a monoclonal antibody used as an immune checkpoint inhibitor. It specifically targets and inhibits the programmed death-ligand 1 (PD-L1) protein. Here's a detailed overview of what you should know about atezolizumab:\n\n### Indications:\n1. **Non-Small Cell Lung Cancer (NSCLC)**: Used for patients with metastatic NSCLC whose tumors have high PD-L1 expression.\n2. **Small Cell Lung Cancer (SCLC)**: Approved for extensive-stage SCLC in combination with chemotherapy.\n3. **Urothelial Carcinoma**: Used for locally advanced or metastatic urothelial carcinoma.\n4. **Triple-Negative Breast Cancer (TNBC)**: Approved for PD-L1 positive, unresectable, locally advanced or metastatic TNBC in combination with nab-paclitaxel.\n5. **Hepatocellular Carcinoma (HCC)**: In combination"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_3EA0jnW6CTn0f0CERXtZTDse", "custom_id": "22_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2636a79fb379bc44cad9218f79c80617", "body": {"id": "chatcmpl-9St5JoKJLbTDHK2g30PK2ctCj8Pdc", "object": "chat.completion", "created": 1716671957, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Avelumab is a human monoclonal antibody used as an immunotherapy treatment for certain types of cancer. Here are several key points you should know about Avelumab:\n\n1. **Mechanism of Action**:\n   - Avelumab targets and inhibits the Programmed Death-Ligand 1 (PD-L1). By binding to PD-L1, Avelumab prevents it from interacting with its receptors, PD-1 and B7.1, on T cells and antigen-presenting cells. This blockade can restore and enhance T-cell responses against cancer cells.\n\n2. **Indications**:\n   - Avelumab is approved for the treatment of metastatic Merkel cell carcinoma (MCC).\n   - It is also approved for use in combination with axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC).\n   - It may be used for other indications based on evolving clinical evidence and regulatory approvals.\n\n3. **Administration**:\n   - Avelumab"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Nj6iNa8eavfvBV3xbst9hNvD", "custom_id": "23_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e06b06de25c223dd7276f51f861de660", "body": {"id": "chatcmpl-9St5J2AvL2ySMvnXBvbswXFIfzp9i", "object": "chat.completion", "created": 1716671957, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Axicabtagene ciloleucel (Yescarta) is a type of chimeric antigen receptor (CAR) T-cell therapy used in the treatment of certain types of blood cancers. Here are some key points that you, as a physician, should be aware of:\n\n1. **Indications**:\n   - Initially approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, and high-grade B-cell lymphoma.\n   - It is also approved for relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.\n\n2. **Mechanism of Action**:\n   - Axicabtagene ciloleucel is an autologous T-cell immunotherapy. Patient's T-cells are collected, genetically modified to express a chimeric antigen receptor (CAR) that targets the CD19 antigen on B-c"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_srDvHEoCWHOvquH70Hpbuy9n", "custom_id": "24_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "bd1efb6da1d4584b3bb032a1b62b002e", "body": {"id": "chatcmpl-9St5JIZLWfJ623LFSpGggIVZNDarq", "object": "chat.completion", "created": 1716671957, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Axitinib, especially if you are treating patients with certain types of cancer. Here are key points you should be aware of:\n\n### Indications:\n- **Renal Cell Carcinoma (RCC)**: Axitinib is primarily used for the treatment of advanced renal cell carcinoma after the failure of one prior systemic therapy.\n\n### Mechanism of Action:\n- **Tyrosine Kinase Inhibitor**: Axitinib is a potent, selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. By inhibiting these receptors, Axitinib blocks the pathways that promote tumor angiogenesis and growth.\n\n### Dosage and Administration:\n- **Starting Dose**: The usual starting dose is 5 mg taken orally twice daily, approximately 12 hours apart, with or without food.\n- **Dose Adjustments**: Dose can be adjusted based on individual patient tolerability,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_8iBAK4oMjNjWS4aGJedHIxJc", "custom_id": "25_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0f666529ca2ba022be9748b07855a985", "body": {"id": "chatcmpl-9St5JwqF1KG3kV7D0uKeg0GFmpNSG", "object": "chat.completion", "created": 1716671957, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azacitidine is a chemotherapeutic agent primarily used in the treatment of certain types of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Here are some key points you should know about Azacitidine:\n\n### Mechanism of Action\n- Azacitidine is a nucleoside metabolic inhibitor. It incorporates into RNA to a lesser extent and DNA to a greater extent, where it inhibits DNA methyltransferase, leading to hypomethylation of DNA. This hypomethylation can restore normal function to genes that control cell differentiation and proliferation, thereby exerting anti-cancer effects.\n\n### Indications\n- **Myelodysplastic Syndromes (MDS):** Azacitidine is FDA-approved for the treatment of various subtypes of MDS, including refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_tXcRAT7W1rFN190yVpNmlugo", "custom_id": "26_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d00a28c0dc1813a13972ea77af915662", "body": {"id": "chatcmpl-9St5KbaZiy8ZWzLRY98n4FQaGYTLe", "object": "chat.completion", "created": 1716671958, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bacillus Calmette-Gu\u00e9rin (BCG) is a vaccine primarily used against tuberculosis (TB). As a physician, it's important to be familiar with its applications, administration, and potential side effects. Here are key points to know about BCG:\n\n1. **Origin and Composition**:\n   - BCG is a live attenuated strain of Mycobacterium bovis, developed by Albert Calmette and Camille Gu\u00e9rin in the early 20th century.\n\n2. **Indications**:\n   - **Tuberculosis Prevention**: Primarily used in countries with a high prevalence of TB to prevent severe forms of tuberculosis, such as TB meningitis and miliary TB in children.\n   - **Bladder Cancer Treatment**: Intravesical BCG is used as an immunotherapy treatment for superficial bladder cancer, particularly carcinoma in situ and for reducing the recurrence of non-muscle invasive bladder cancer.\n\n3. **Administration**:\n   - **Vaccination**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_k4Dj8yzThlL1j7jrgyvZk4LC", "custom_id": "27_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ba01b7451dc68f885f1436b257ec897c", "body": {"id": "chatcmpl-9St5Kb1hySMfc1lJ4VaIDr2e9ghzg", "object": "chat.completion", "created": 1716671958, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bavituximab is a monoclonal antibody developed by Peregrine Pharmaceuticals (now Avid Bioservices) that targets phosphatidylserine (PS), a molecule that becomes exposed on the outer membrane of cells in the tumor vasculature but is typically found on the inner leaflet of the plasma membrane in normal cells. Here are some key points you should be aware of:\n\n### Mechanism of Action:\n- **Targeting PS**: Bavituximab binds to PS, which is externalized on the surface of tumor blood vessels and apoptotic cells.\n- **Immune Modulation**: By binding to PS, bavituximab is thought to enhance the immune system's ability to recognize and attack tumor cells. It can stimulate antibody-dependent cellular cytotoxicity (ADCC) and potentially inhibit the immunosuppressive environment created by tumors.\n\n### Clinical Development:\n- **Cancer Indications**: Bavituximab has been studied in various types of cancers"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_VctCt4oCWBuiDZ0E8dygZv5p", "custom_id": "28_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9c83986f78c518c1c5cf0ac49508947c", "body": {"id": "chatcmpl-9St5Kid7j7vaaHRTfnW2iSe7P20Dx", "object": "chat.completion", "created": 1716671958, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belinostat is a histone deacetylase (HDAC) inhibitor used in the treatment of certain types of cancer. Here are some key points you should know about Belinostat:\n\n**1. Indications:**\n   - Belinostat is primarily indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). This is a rare and aggressive type of non-Hodgkin lymphoma.\n\n**2. Mechanism of Action:**\n   - It works by inhibiting histone deacetylases, enzymes involved in the removal of acetyl groups from histone proteins. This inhibition leads to an accumulation of acetylated histones and other proteins, resulting in changes in gene expression, cell cycle arrest, and apoptosis (programmed cell death) of cancer cells.\n\n**3. Administration:**\n   - Belinostat is administered intravenously. The typical dosing regimen involves a 30-minute infusion once daily on days 1-5 of a 21-day"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_5kiojtH1lXLeI0p1QpExJFGR", "custom_id": "29_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "29d25e00e357463727ebf5cf421747cd", "body": {"id": "chatcmpl-9St5KH7nl476tZHA63VKXezEsFdgf", "object": "chat.completion", "created": 1716671958, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belotecan is a chemotherapeutic agent used primarily in the treatment of cancer. Here are some key aspects you should be aware of as a physician:\n\n### Mechanism of Action\nBelotecan is a topoisomerase I inhibitor. It works by interfering with the action of topoisomerase I, an enzyme that helps relax DNA supercoiling during replication. By inhibiting this enzyme, Belotecan induces DNA damage, leading to apoptosis (programmed cell death) in rapidly dividing cancer cells.\n\n### Indications\nBelotecan is primarily indicated for:\n- Small cell lung cancer (SCLC): It may be used in cases where first-line treatments have failed.\n- Ovarian cancer: It may also be used in cases that are resistant to platinum-based therapies.\n\n### Administration\nBelotecan is typically administered intravenously. The dosage and schedule depend on several factors, including the type of cancer being treated, the patient's overall health, and their response to the treatment. Adjust"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_MH8smGwdQsNeRCD36DUORn19", "custom_id": "30_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f9611cc097e0d4672789ba57fa105fa1", "body": {"id": "chatcmpl-9St5K0wDXUg4lqADiex0lwWjDhaaL", "object": "chat.completion", "created": 1716671958, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bendamustine is a chemotherapy medication primarily used to treat certain types of cancer, such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Here are some key points you should know about Bendamustine:\n\n### Mechanism of Action\nBendamustine is an alkylating agent that works by causing cross-linking of DNA strands, leading to cell death. It has unique properties as it combines the mechanisms of alkylating agents and purine analogs, making it effective against cancer cells that may be resistant to other types of chemotherapy.\n\n### Indications\nBendamustine is approved for:\n- Chronic lymphocytic leukemia (CLL)\n- Indolent B-cell non-Hodgkin lymphoma (iNHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen\n\n### Administration\n- **Dosage Forms**: It is typically administered intravenously"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_j8OoONeYawj7bluPfCZthc7x", "custom_id": "31_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "7c920e33c131d5e7d98ac5cadbf63c5d", "body": {"id": "chatcmpl-9St5KBFqV4uk6safVaMSiEvOEe1cS", "object": "chat.completion", "created": 1716671958, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bevacizumab, sold under the brand name Avastin, is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A). As a physician, here's what you should know about Bevacizumab:\n\n1. **Mechanism of Action**:\n   - Bevacizumab works by binding to VEGF-A, preventing it from interacting with its receptors on the surface of endothelial cells. This inhibits the formation of new blood vessels (angiogenesis), which is a process critical for tumor growth and metastasis.\n\n2. **Indications**:\n   - Bevacizumab is used in the treatment of various cancers, including metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, and cervical cancer. It is often used in combination with other chemotherapy agents.\n   - It is also used off-label for the treatment of age-related macular degeneration and diabetic retinopathy, though this use is less common compared to its oncological applications.\n\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_W88VKmy5n6t50sAMfegzeq1d", "custom_id": "32_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "74c188975490f901c5f5e48b21b49bee", "body": {"id": "chatcmpl-9St5Kgpm2ZkMzG6nAiqLNTJbhCJM3", "object": "chat.completion", "created": 1716671958, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bexarotene is a retinoid medication primarily used in the treatment of cutaneous T-cell lymphoma (CTCL). Here are some key points a physician should know about Bexarotene:\n\n### Mechanism of Action:\n- **Retinoid Receptor Activation**: Bexarotene selectively activates retinoid X receptors (RXRs), which regulate gene expression involved in cell differentiation and proliferation.\n\n### Indications:\n- **Cutaneous T-cell Lymphoma (CTCL)**: Specifically for patients with refractory or persistent CTCL after other systemic therapies have been tried.\n\n### Dosage Forms:\n- **Oral Capsules**: Available in various dosages, typically taken once daily.\n- **Topical Gel**: Applied directly to the skin lesions.\n\n### Dosage:\n- **Oral**: Typically starts at 300 mg/m\u00b2/day, with adjustments based on patient response and tolerability.\n- **Topical**: Applied as a thin layer to the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_HPSHMn43NGGGlhWgLftVjdj4", "custom_id": "33_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5b9dba19ba2a80a2d2b55830d7a8e487", "body": {"id": "chatcmpl-9St5LFTbN0qzcLn9k9GXANLPJ51LE", "object": "chat.completion", "created": 1716671959, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bicalutamide is a non-steroidal anti-androgen medication primarily used in the treatment of prostate cancer. Here are some key points you should know about Bicalutamide:\n\n1. **Mechanism of Action**:\n   - Bicalutamide works by binding to androgen receptors in prostate cancer cells, preventing androgens (such as testosterone) from stimulating cancer cell growth.\n\n2. **Indications**:\n   - It is commonly prescribed as part of combination therapy with a gonadotropin-releasing hormone (GnRH) analog (like leuprolide or goserelin) for the treatment of advanced prostate cancer.\n   - It can also be used in monotherapy for patients with less advanced disease.\n\n3. **Dosage**:\n   - The typical dose is 50 mg once daily when used in combination with a GnRH analog.\n   - For monotherapy, higher doses (150 mg daily) may be used, though this practice varies and isn't universally accepted.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_G7GMjImHDDx8882iIXzMJoWQ", "custom_id": "34_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "1732ed59fd821641c05501a68c8e8811", "body": {"id": "chatcmpl-9St5LqTePSvjBDu9H7ztRiVJG9kcq", "object": "chat.completion", "created": 1716671959, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Binimetinib is a medication used in the treatment of certain types of cancers. Here are some key points you should be aware of as a physician:\n\n### Mechanism of Action\n- **Class**: Binimetinib is a MEK inhibitor. MEK (mitogen-activated protein kinase kinase) is part of the MAPK/ERK pathway which is involved in cell division and proliferation.\n- **Target**: It specifically inhibits MEK1 and MEK2, enzymes that play a role in the signaling pathway that helps regulate cell growth and survival.\n\n### Indications\n- **Melanoma**: Binimetinib is primarily used for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. It is often used in combination with another drug, encorafenib, which targets a different part of the same pathway (BRAF).\n\n### Dosage and Administration\n- **Typical Dosage**: The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_rNQEw4hIoYBiTMjPB1HVDFeK", "custom_id": "35_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5e0deec560dd753b7a4f99ad9ee5eb70", "body": {"id": "chatcmpl-9St5LCYkO0Z41rrxjfavmpQF2mArQ", "object": "chat.completion", "created": 1716671959, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bleomycin is an antineoplastic antibiotic used primarily in the treatment of certain types of cancer. As a physician, it's important to be familiar with the following key points about Bleomycin:\n\n### Indications:\n- **Hodgkin's lymphoma**\n- **Non-Hodgkin's lymphoma**\n- **Testicular cancer**\n- **Squamous cell carcinomas** (head, neck, and cervix)\n- **Malignant pleural effusion** (as a sclerosing agent)\n\n### Mechanism of Action:\n- Bleomycin binds to DNA, causing breaks in the DNA strands through free radical formation, ultimately inhibiting DNA synthesis. It is cell cycle-specific, predominantly affecting the G2 and M phases.\n\n### Administration:\n- Bleomycin can be administered intravenously, intramuscularly, subcutaneously, or intrapleurally (for pleural effusions).\n- Dosage and frequency depend on the specific cancer being treated, patient\u2019s age, body"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_zQLT6TxJq5aJGorIo9aLDAGF", "custom_id": "36_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "883255493b3146f880cd059a1a0785a0", "body": {"id": "chatcmpl-9St5Le0uyISKeEduOQjilv3LQ4hnJ", "object": "chat.completion", "created": 1716671959, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blinatumomab is a bispecific T-cell engager (BiTE) used in the treatment of certain types of blood cancers, specifically B-cell precursor acute lymphoblastic leukemia (ALL). Here's a detailed overview of what you should know about Blinatumomab:\n\n### Mechanism of Action:\n- **Bispecific Monoclonal Antibody:** Blinatumomab is designed to engage both CD19 on B-cells and CD3 on T-cells. By bringing T-cells in close proximity to cancerous B-cells, it facilitates the T-cells' ability to recognize and destroy the malignant cells.\n\n### Indications:\n- **Relapsed or Refractory B-cell Precursor ALL:** Blinatumomab is FDA-approved for the treatment of adult and pediatric patients with relapsed or refractory B-cell precursor ALL.\n- **Minimal Residual Disease (MRD):** It is also approved for the treatment of patients with B-cell precursor ALL in first or second"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_O4xIxcF6eCtTYbLF9YiYUPvH", "custom_id": "37_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "876d1840a0be79ccbec26d4a3849d1b5", "body": {"id": "chatcmpl-9St5LSdtnAEaJfvqZ4gsDh14pjMGF", "object": "chat.completion", "created": 1716671959, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bortezomib is a proteasome inhibitor used primarily in the treatment of multiple myeloma and mantle cell lymphoma. Here are some key points you should know about Bortezomib:\n\n### Mechanism of Action\n- **Proteasome Inhibition:** Bortezomib inhibits the 26S proteasome, which is essential for degrading ubiquitinated proteins. This inhibition disrupts various cellular processes, leading to apoptosis in cancer cells.\n\n### Indications\n- **Multiple Myeloma:** Bortezomib is approved for use as both a first-line treatment and for patients who have relapsed or are refractory to other treatments.\n- **Mantle Cell Lymphoma:** It is also approved for the treatment of mantle cell lymphoma in patients who have received at least one prior therapy.\n\n### Administration\n- **Routes:** Bortezomib can be administered intravenously (IV) or subcutaneously (SC). The SC route is often preferred due to a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_HacsRGkc0OV45AIxVmX5kAzJ", "custom_id": "38_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "76aceace1ac63fdca2accf80d91a5c77", "body": {"id": "chatcmpl-9St5LoHLBu5SiRYfXl43MoYcRIJem", "object": "chat.completion", "created": 1716671959, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bosutinib is a tyrosine kinase inhibitor primarily used in the treatment of chronic myelogenous leukemia (CML). Here are some key points you should know about it:\n\n### Mechanism of Action:\n- **Target**: Bosutinib inhibits the BCR-ABL kinase, which is produced by the Philadelphia chromosome abnormality in CML cells. It also inhibits Src-family kinases.\n- **Effect**: By blocking these kinases, Bosutinib prevents the phosphorylation of proteins involved in the signaling pathways that promote the proliferation of leukemic cells.\n\n### Indications:\n- **Chronic Myelogenous Leukemia (CML)**: Specifically for adult patients with Philadelphia chromosome-positive (Ph+) CML who are either newly diagnosed or who have resistance or intolerance to prior therapy.\n\n### Dosing:\n- **Typical Dose**: For newly diagnosed patients, the recommended dose is 400 mg orally once daily with food. For patients with resistance or intolerance to prior therapy, the dose is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_3CS63790BEt7jhSi1pYXsGOm", "custom_id": "39_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "47266ed75daafca689f6c5a20f37938c", "body": {"id": "chatcmpl-9St5LNAlSHKloxRu6IHAVYtzELXlx", "object": "chat.completion", "created": 1716671959, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brentuximab vedotin is an important medication used in the treatment of certain types of cancer, specifically Hodgkin lymphoma and systemic anaplastic large cell lymphoma (sALCL). Here are key points you should know about Brentuximab vedotin:\n\n1. **Mechanism of Action**:\n   - Brentuximab vedotin is an antibody-drug conjugate (ADC). It consists of an anti-CD30 monoclonal antibody linked to the cytotoxic agent monomethyl auristatin E (MMAE).\n   - CD30 is a cell membrane protein expressed in certain malignancies, including Hodgkin lymphoma and sALCL.\n   - The drug binds to CD30-expressing cells, is internalized, and then releases MMAE, which disrupts the microtubule network, leading to cell cycle arrest and apoptosis.\n\n2. **Indications**:\n   - Classical Hodgkin lymphoma (cHL) after failure of autologous stem cell transplant"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_sRG6Ai6cpbGRl2ISOOBNrCTV", "custom_id": "40_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ba82497941058b163789ce8593d04d69", "body": {"id": "chatcmpl-9St5MBmTxjpqil7R1SO0QuXJHbhMr", "object": "chat.completion", "created": 1716671960, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brigatinib is a targeted cancer therapy used primarily for the treatment of non-small cell lung cancer (NSCLC) that has specific genetic mutations. Here are key points you should know as a physician:\n\n### Indications:\n- **Approved Use**: Brigatinib is approved for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC. It is often used when the cancer has progressed on or is intolerant to crizotinib, another ALK inhibitor.\n\n### Mechanism of Action:\n- **Targeted Therapy**: Brigatinib is a tyrosine kinase inhibitor (TKI) that targets ALK and other kinases such as ROS1 and insulin-like growth factor-1 receptor (IGF-1R). It works by inhibiting the growth and spread of cancer cells with these mutations.\n\n### Dosage and Administration:\n- **Initial Dose**: Typically, the recommended starting dose is 90 mg once daily for the first 7 days"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_j1zieBxVjfRLk4yX08iZhoSt", "custom_id": "41_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5291f730ce8b39ba9fdebc43a20f5f4b", "body": {"id": "chatcmpl-9St5MQLcdI6QX96TkelmFPYN06UPM", "object": "chat.completion", "created": 1716671960, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Busulfan is an alkylating agent used predominantly in the treatment of chronic myelogenous leukemia (CML) and as part of conditioning regimens before bone marrow or stem cell transplantation. Here are key points a physician should know about Busulfan:\n\n1. **Mechanism of Action:**\n   - Busulfan alkylates DNA, leading to DNA strand breaks and cross-linking, which ultimately impairs cell replication and leads to cell death.\n\n2. **Indications:**\n   - Chronic Myelogenous Leukemia (CML)\n   - Conditioning regimen for hematopoietic stem cell transplantation (HSCT), often combined with other agents like cyclophosphamide or fludarabine.\n\n3. **Administration:**\n   - Available in oral and intravenous forms.\n   - Intravenous busulfan requires precise dosing and monitoring due to its narrow therapeutic window and variable pharmacokinetics.\n\n4. **Dosing and Monitoring:**\n   - Dosing varies based"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_EvbL12Z0jC5pUFvD0iqtjAPS", "custom_id": "42_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "eae40ff88a8143bdc758f1ff6c5ee100", "body": {"id": "chatcmpl-9St5MCL5pAUDAYnRDZJ6QVjVFkFHR", "object": "chat.completion", "created": 1716671960, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cabazitaxel is a chemotherapeutic agent primarily used in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Here are some key points that you, as a physician, should know about Cabazitaxel:\n\n### Mechanism of Action:\n- Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III.\n- It works by inhibiting microtubule depolymerization, thereby stabilizing microtubules and inhibiting cell division, which ultimately leads to cell death.\n\n### Indications:\n- Cabazitaxel is indicated for patients with mCRPC who have previously been treated with a docetaxel-containing treatment regimen.\n\n### Administration:\n- Cabazitaxel is administered intravenously.\n- The standard dose is often 25 mg/m\u00b2 every three weeks, but some studies suggest that a lower dose of 20 mg/m\u00b2 may be used to reduce toxicity while maintaining efficacy.\n- It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_NgeiDWJyxR2MKb8d7c9qNrwk", "custom_id": "43_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8e5ba87c4c9cf3acb74cbe9d9ef71454", "body": {"id": "chatcmpl-9St5M9gFCnlLFVYR6jv2IZC13XZ5b", "object": "chat.completion", "created": 1716671960, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cabozantinib is a tyrosine kinase inhibitor (TKI) used primarily in the treatment of certain types of cancers. Here are several key points you should know about this medication:\n\n### Indications:\n1. **Renal Cell Carcinoma (RCC)**: Cabozantinib is approved for the treatment of advanced renal cell carcinoma.\n2. **Hepatocellular Carcinoma (HCC)**: It is also used for patients with hepatocellular carcinoma who have been previously treated with sorafenib.\n3. **Medullary Thyroid Cancer (MTC)**: Cabozantinib is indicated for progressive, metastatic medullary thyroid cancer.\n\n### Mechanism of Action:\nCabozantinib targets multiple tyrosine kinases, including MET, VEGFR, and AXL, which are involved in tumor growth, angiogenesis, and metastasis.\n\n### Dosage:\n- The dosage varies based on the specific cancer being treated. For instance, the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_MwzfonXAJGH5GEHWmwGIWV36", "custom_id": "44_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "52540a04acac80c5a828cf2cf9d6cc19", "body": {"id": "chatcmpl-9St5NuN6g4Noyc7NypblefDejqzRy", "object": "chat.completion", "created": 1716671961, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Calaspargase pegol-mknl (brand name: Asparlas) is an important medication used in the treatment of acute lymphoblastic leukemia (ALL), particularly in pediatric and young adult patients. Here's a detailed overview of what you should know about Calaspargase as a physician:\n\n### Mechanism of Action\n- **Enzymatic Activity**: Calaspargase is an asparagine-specific enzyme. It hydrolyzes L-asparagine into L-aspartic acid and ammonia. Leukemic cells are unable to synthesize L-asparagine, an amino acid essential for their growth and survival. By depleting L-asparagine in the bloodstream, Calaspargase effectively starves the leukemic cells, leading to their death.\n\n### Indications\n- **Acute Lymphoblastic Leukemia (ALL)**: It is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of ALL.\n\n### Administration and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_DF0yPH9SZMl9wWWJPLCcaIc1", "custom_id": "45_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0a1d1122776686cc904b723d1d164c47", "body": {"id": "chatcmpl-9St5NGzBrKLyQ92hh7iDFqXrnJkjB", "object": "chat.completion", "created": 1716671961, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Capecitabine is an oral chemotherapeutic agent used primarily in the treatment of various cancers, including breast and colorectal cancer. Here are key points you should know about Capecitabine:\n\n### Mechanism of Action:\n- **Prodrug**: Capecitabine is a prodrug that is metabolized to 5-fluorouracil (5-FU) in the body. It mimics the effects of continuous infusion of 5-FU but in an oral form.\n- **Enzyme Activation**: The conversion to 5-FU is catalyzed by thymidine phosphorylase, which is found in higher concentrations in tumor tissues, providing a degree of tumor selectivity.\n\n### Indications:\n- **Breast Cancer**: Used in metastatic breast cancer, often in combination with other agents like docetaxel, especially in patients who have not responded to other treatments.\n- **Colorectal Cancer**: Used in metastatic colorectal cancer and as adju"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_TiKUbn9xGyuX6a7CSjGfFz0a", "custom_id": "46_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a824f19b6d68034f79b75f17ac10a9a0", "body": {"id": "chatcmpl-9St5N3d4U5PbURwdMlGtnNoRRMEKt", "object": "chat.completion", "created": 1716671961, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carboplatin is a chemotherapy medication used primarily in the treatment of various types of cancer, including ovarian, lung, head and neck, and certain types of brain cancer. Here are some key points you should know about Carboplatin as a physician:\n\n### Mechanism of Action\n- **Platinum-based Agent**: Carboplatin is a platinum-containing compound that works by cross-linking with DNA, thereby interfering with DNA replication and transcription, which ultimately leads to cell death. It is less reactive than its predecessor, cisplatin, but still effective.\n  \n### Indications\n- **Ovarian Cancer**: Often used as first-line treatment in combination with other agents like paclitaxel.\n- **Lung Cancer**: Commonly used for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).\n- **Head and Neck Cancer**: Sometimes used in combination with other chemotherapeutic agents.\n- **Brain Tumors**: Utilized"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_NAtKut9oPRSsp1jBiPPZeHWS", "custom_id": "47_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2cf3bde62c36291bd64004e5e843d843", "body": {"id": "chatcmpl-9St5NyTHcs4rp2DNI92mY0bxLexqb", "object": "chat.completion", "created": 1716671961, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carfilzomib is a proteasome inhibitor used primarily in the treatment of multiple myeloma, particularly for patients who have received at least one prior therapy. Here are some key points you should know about Carfilzomib:\n\n### Mechanism of Action:\n- **Proteasome Inhibition**: Carfilzomib selectively and irreversibly inhibits the chymotrypsin-like activity of the 20S proteasome, leading to an accumulation of polyubiquitinated proteins and subsequent apoptosis of cancer cells.\n\n### Indications:\n- **Multiple Myeloma**: It is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.\n- **Combination Therapy**: Often used in combination with other agents such as lenalidomide and dexamethasone, or with dexamethasone alone.\n\n### Dosage and Administration:\n- **Intravenous Administration**: Admin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ZaEvnuOiKMUWdTyEVjV4OaMn", "custom_id": "48_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ed4e1d2ea6076ce83310af9854fa23d5", "body": {"id": "chatcmpl-9St5NKgycx5Gi4uk0tLrt4ZRtbfs9", "object": "chat.completion", "created": 1716671961, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carmustine, also known by its brand name BiCNU, is a chemotherapy agent commonly used in the treatment of various types of cancer. As a physician, it's important to be aware of several key aspects regarding Carmustine:\n\n1. **Mechanism of Action**: Carmustine is an alkylating agent that works by interfering with the DNA replication process in cancer cells, leading to cell death. It is particularly effective in crossing the blood-brain barrier, making it useful in treating brain tumors.\n\n2. **Indications**: Carmustine is used to treat multiple types of cancer, including:\n   - Brain tumors (glioblastoma, medulloblastoma, astrocytoma)\n   - Multiple myeloma\n   - Hodgkin's lymphoma\n   - Non-Hodgkin's lymphoma\n\n3. **Administration**: Carmustine can be administered intravenously or as a wafer implant (Gliadel wafer) directly into the brain during surgery. The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_VMogQLGO8qqNdWjMYuIATuu8", "custom_id": "49_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "04e7ed8dd9e20cceaef46d364ef438f9", "body": {"id": "chatcmpl-9St5NUcL7ir0PwlkxfdZFjCyx4xia", "object": "chat.completion", "created": 1716671961, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carmustine wafer (also known by its brand name, Gliadel\u00ae) is a form of chemotherapy treatment specifically designed for the treatment of high-grade malignant gliomas, such as glioblastoma multiforme. It is an implantable wafer that is placed directly into the brain during surgery. Here are several key points you should know about Carmustine wafer polifeprosan 20:\n\n### Mechanism of Action\n- **Active Ingredient**: Carmustine (BCNU) is an alkylating agent that works by cross-linking DNA and RNA, thus inhibiting tumor cell replication and growth.\n- **Localized Treatment**: The wafer allows for direct delivery of chemotherapy to the tumor site, achieving high concentrations of the drug locally while minimizing systemic exposure and associated side effects.\n\n### Indications\n- **Primary Indication**: It is used for the treatment of newly diagnosed high-grade malignant glioma as an adjunct to surgery and radiation.\n- **Recurrent Glioblastoma**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_lhZgSgSIqKFaBR3WvcVPfd01", "custom_id": "50_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "7ebe821a433170ea2d0ac13b546229a9", "body": {"id": "chatcmpl-9St5NoFfXgEoPutHuE2VAYaqxWeSs", "object": "chat.completion", "created": 1716671961, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cediranib is a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFRs), primarily VEGFR-2, but also VEGFR-1 and VEGFR-3 to a lesser extent. It is used in oncology to inhibit angiogenesis, the process by which new blood vessels form from pre-existing vessels, which is crucial for tumor growth and metastasis.\n\nHere are some key points you should know about Cediranib:\n\n### Mechanism of Action\n- **Targeting VEGFRs**: Cediranib inhibits the activity of VEGFRs, thereby blocking the VEGF signaling pathway. This inhibition reduces the proliferation and migration of endothelial cells and decreases tumor vascularization.\n\n### Indications\n- **Cancer Treatment**: Cediranib is primarily investigated for its efficacy in treating various types of cancers, including ovarian cancer, glioblastoma, colorectal cancer, and non-small cell lung cancer, often in combination with other chemotherapeutic agents.\n\n### Pharmacokinetics"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5Up8ayHm3apcXp6kKykGpGpR", "custom_id": "51_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "29d864587b1c6e825522d0556e4884ac", "body": {"id": "chatcmpl-9St5OtPSxyd85WITqHKd2DE1GcPtm", "object": "chat.completion", "created": 1716671962, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cemiplimab is a monoclonal antibody used in immunotherapy, specifically targeting programmed death-1 (PD-1) receptors on T-cells. By inhibiting these receptors, cemiplimab enhances the body's immune response against cancer cells. Here are key aspects you should know about cemiplimab:\n\n### Indications:\n1. **Cutaneous Squamous Cell Carcinoma (CSCC):**\n   - Approved for the treatment of metastatic or locally advanced CSCC in patients who are not candidates for curative surgery or radiation.\n\n2. **Basal Cell Carcinoma (BCC):**\n   - Approved for patients with locally advanced BCC previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate.\n   - Also used for metastatic BCC under similar conditions.\n\n### Mechanism of Action:\n- Cemiplimab binds to PD-1 receptors on T-cells, preventing their interaction with PD-L1 and PD-L"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_N8eR4VmM5xv1ZSkVuKGyHJ23", "custom_id": "52_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ce0754df14222a2defd77d4489bf7715", "body": {"id": "chatcmpl-9St5OktCQNq8wER1ydUbRXyJxK0hC", "object": "chat.completion", "created": 1716671962, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ceritinib is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. As a physician, here are some key points you should know about Ceritinib:\n\n### Indications:\n- **Primary Use**: Ceritinib is indicated for the treatment of patients with ALK-positive metastatic NSCLC.\n- **Patient Population**: Typically used in patients who have progressed on or are intolerant to crizotinib, another ALK inhibitor.\n\n### Mechanism of Action:\n- **ALK Inhibition**: Ceritinib is a tyrosine kinase inhibitor that targets ALK, leading to inhibition of ALK phosphorylation and subsequently blocking downstream signaling pathways involved in tumor growth and survival.\n\n### Pharmacokinetics:\n- **Absorption**: Ceritinib is administered orally and is best taken with food to enhance its bioavailability.\n- **Metabolism**: Primarily metabolized by the liver via CYP"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_trui9hZVphFbvfRnkXNTGpKo", "custom_id": "53_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "01096076923b99d2d85e9156738cf546", "body": {"id": "chatcmpl-9St5OaOzZpmP3KYESEizJQj0qGzOR", "object": "chat.completion", "created": 1716671962, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cetuximab is a chimeric monoclonal antibody used primarily in the treatment of certain types of cancer. Here are some key points you should know about Cetuximab:\n\n1. **Mechanism of Action**:\n   - Cetuximab targets the epidermal growth factor receptor (EGFR) on the surface of cancer cells. It inhibits the binding of natural ligands like EGF and TGF-\u03b1, which in turn blocks the EGFR signaling pathways involved in cell proliferation, survival, angiogenesis, and metastasis.\n\n2. **Indications**:\n   - Cetuximab is approved for use in:\n     - Metastatic colorectal cancer (mCRC) that is EGFR-expressing and RAS wild-type.\n     - Head and neck squamous cell carcinoma (HNSCC), either in combination with radiation therapy for locally or regionally advanced disease or as a single agent for recurrent or metastatic disease.\n\n3. **Administration**:\n   -"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_14PqjYKvMZA9BswOZgrlNFF5", "custom_id": "54_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c1756cd299147a00d560e714bb907b7e", "body": {"id": "chatcmpl-9St5OxOxcczQuKWQt7dsI4FYNfSZI", "object": "chat.completion", "created": 1716671962, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Chidamide is an oral histone deacetylase (HDAC) inhibitor used in the treatment of certain types of cancer. Here are some key points that you, as a physician, should know about Chidamide:\n\n1. **Mechanism of Action**:\n   - Chidamide inhibits HDAC enzymes, which play a role in modifying chromatin structure and regulating gene expression. This inhibition can lead to the reactivation of suppressed genes that control cell growth and apoptosis, thereby exerting anti-tumor effects.\n\n2. **Indications**:\n   - Chidamide is primarily used in the treatment of peripheral T-cell lymphoma (PTCL) and relapsed or refractory PTCL.\n   - It has also been investigated in other hematologic malignancies and solid tumors, but its use outside of PTCL is generally within the context of clinical trials.\n\n3. **Dosage and Administration**:\n   - The typical dosage for Chidamide in adults is 30 mg orally twice"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_FFLiWe26O8vub9QfZx5fNncL", "custom_id": "55_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5130ff4d9448bd9d060d6f6a6f28abea", "body": {"id": "chatcmpl-9St5OTUktUiHFRaweBB9NVTUAf6Q9", "object": "chat.completion", "created": 1716671962, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Chlorambucil is an alkylating agent used primarily in the treatment of certain types of cancer. Here are key points you should know as a physician:\n\n1. **Mechanism of Action**: Chlorambucil works by cross-linking DNA strands, leading to the inhibition of DNA replication and RNA transcription, ultimately causing cell death. It's most effective in the resting phase of the cell cycle (G0).\n\n2. **Indications**:\n   - Chronic Lymphocytic Leukemia (CLL)\n   - Hodgkin's Lymphoma\n   - Non-Hodgkin's Lymphoma\n   - Waldenstr\u00f6m's Macroglobulinemia\n   - Sometimes used off-label for other conditions like certain autoimmune diseases\n\n3. **Administration**:\n   - Oral administration is the most common route.\n   - Dosage and regimen depend on the specific condition being treated and patient factors.\n\n4. **Side Effects**:\n   - Bone marrow suppression (leading to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_yVYXHdMiSQPL2P3o16CL8UME", "custom_id": "56_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2a8f13555e4961fa951b6cfd82fe0a9d", "body": {"id": "chatcmpl-9St5OXWINlbb5mMxx5ZFXi5K2Jiya", "object": "chat.completion", "created": 1716671962, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cisplatin is a chemotherapy medication widely used to treat various types of cancers, including testicular, ovarian, bladder, lung, and head and neck cancers. As a physician, it is important to be familiar with several key aspects of Cisplatin to ensure its safe and effective use:\n\n1. **Mechanism of Action**:\n   - Cisplatin is a platinum-based drug that works by causing DNA crosslinking and subsequent apoptosis (cell death). This inhibits DNA replication and transcription, leading to cell death, particularly in rapidly dividing cancer cells.\n\n2. **Administration**:\n   - Cisplatin is typically administered intravenously. The dosage and schedule depend on the type of cancer being treated, the patient's overall health, and other individual factors.\n   - It is often given in cycles, with rest periods in between to allow the body to recover.\n\n3. **Common Side Effects**:\n   - Nephrotoxicity (kidney damage): This is a major concern. Ade"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_4ERtRIWepjfotvaE1SmpVBOd", "custom_id": "57_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "585a7062d36f589b1c4e116f06c3dd1c", "body": {"id": "chatcmpl-9St5OLMTGuWVX13hJqcNTtdWCTpzf", "object": "chat.completion", "created": 1716671962, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cladribine is a chemotherapeutic agent and immunosuppressive medication primarily used in the treatment of certain types of cancers and multiple sclerosis (MS). Here are some key points you should consider as a physician:\n\n1. **Mechanism of Action**:\n   - Cladribine is a purine nucleoside analog that mimics adenosine. It interferes with DNA synthesis and repair, leading to the death of rapidly dividing cells.\n   - It is particularly effective against lymphocytes, making it useful in conditions where the immune system is overactive or malignant.\n\n2. **Indications**:\n   - **Hematologic Malignancies**: Cladribine is used to treat hairy cell leukemia, chronic lymphocytic leukemia (CLL), and other lymphoproliferative disorders.\n   - **Multiple Sclerosis**: Specifically, it is approved for use in relapsing forms of MS. It helps reduce the frequency of relapses and slows the progression"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_OTSr0ywPUEnVhYt0DWeJzOYE", "custom_id": "58_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "07762070ebbec2a95216b47a03e3505c", "body": {"id": "chatcmpl-9St5Oh0dB1gSmIBhi4BRHGCI3IW7Z", "object": "chat.completion", "created": 1716671962, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, there are several important aspects you should know about Clarithromycin, an antibiotic belonging to the macrolide class. Here are some key points:\n\n### Mechanism of Action:\n- **Bacterial Protein Synthesis Inhibition:** Clarithromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and thereby preventing bacterial growth.\n\n### Indications:\n- **Respiratory Infections:** Such as pharyngitis, tonsillitis, sinusitis, bronchitis, and pneumonia.\n- **Skin Infections:** Including cellulitis and folliculitis.\n- **Helicobacter pylori Eradication:** Often used in combination therapy for peptic ulcer disease.\n- **Mycobacterial Infections:** Like Mycobacterium avium complex (MAC) in immunocompromised patients.\n\n### Dosage and Administration:\n- **Adult Dosage:** Typically 250-500 mg twice daily, depending on the severity of the infection.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Zvn2OlpGS8kkGgH5aASlfKQi", "custom_id": "59_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b631c98fad0ad1d4dc0f3bbf2ffc302a", "body": {"id": "chatcmpl-9St5PxSa4No2MDwGnPL75kg283e2Z", "object": "chat.completion", "created": 1716671963, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Clofarabine is a chemotherapeutic agent used primarily in the treatment of certain types of leukemia, specifically acute lymphoblastic leukemia (ALL) in pediatric patients. Here are some key points to know about Clofarabine as a physician:\n\n### Mechanism of Action\n- **Antimetabolite:** Clofarabine is a purine nucleoside analog that interferes with DNA synthesis. It is incorporated into DNA and inhibits ribonucleotide reductase and DNA polymerase, leading to apoptosis (programmed cell death) of rapidly dividing cells.\n\n### Indications\n- **Acute Lymphoblastic Leukemia (ALL):** Clofarabine is approved for use in pediatric patients (ages 1-21) with relapsed or refractory ALL after at least two prior regimens.\n- **Other Uses:** It is sometimes used off-label for other hematologic malignancies, such as acute myeloid leukemia (AML).\n\n### Administration\n- **Intravenous"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_pAEWEZcd2xpLueKD3NsESjXJ", "custom_id": "60_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a5d41d52b0894a58a4aada6f41cd8f43", "body": {"id": "chatcmpl-9St5PAamkbfYHXmiwek8K525vgBEF", "object": "chat.completion", "created": 1716671963, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cobimetinib is a targeted cancer therapy used in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Here are key points you should know about cobimetinib:\n\n### Mechanism of Action\n- **Cobimetinib** is a selective inhibitor of MEK1 and MEK2, which are part of the MAPK/ERK signaling pathway. This pathway is often activated in cancers with BRAF mutations.\n- By inhibiting MEK1/2, cobimetinib helps to block cell proliferation and induce apoptosis in melanoma cells.\n\n### Indications\n- Cobimetinib is specifically indicated for use in combination with vemurafenib, another targeted therapy that inhibits the mutated BRAF protein.\n- It is approved for patients with unresectable or metastatic melanoma harboring the BRAF V600E or V600K mutation.\n\n### Dosage and Administration\n- The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_wBHYqddAMkUXEnMuDcT6tZPa", "custom_id": "61_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "57bd40a36f8f41eb7080a56d7cf4ebfa", "body": {"id": "chatcmpl-9St5PnYaeqzkedJDUF56Hliy3imOu", "object": "chat.completion", "created": 1716671963, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Copanlisib is a medication used primarily in the treatment of certain types of cancer, specifically relapsed follicular lymphoma, which is a type of non-Hodgkin lymphoma. Here are some key points you should know about it as a physician:\n\n### Mechanism of Action:\n- **Class**: Copanlisib is a phosphatidylinositol-3-kinase (PI3K) inhibitor.\n- **Target**: It inhibits PI3K, specifically the alpha and delta isoforms, leading to apoptosis and inhibition of proliferation in malignant B cells.\n\n### Indications:\n- **Approved Use**: It is approved for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies.\n\n### Administration:\n- **Form**: It is administered intravenously.\n- **Dosing Schedule**: Typically given on a 28-day cycle, with an infusion on days 1, 8, and 15 of each cycle.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_fkzraIMVXkPueKKcnwgidkEl", "custom_id": "62_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "28753bcb2027f8361926cc94d119ece6", "body": {"id": "chatcmpl-9St5PrcLbUOHf3WnCg7DWzwrJkUuS", "object": "chat.completion", "created": 1716671963, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Crizotinib is a targeted cancer therapy used primarily to treat non-small cell lung cancer (NSCLC) that is positive for specific genetic mutations. Here are key points a physician should know about Crizotinib:\n\n### Mechanism of Action\n- **Targeted Therapy:** Crizotinib is a tyrosine kinase inhibitor (TKI) that targets and inhibits the activity of the ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) proteins, which can drive the growth of cancer cells in some NSCLC cases.\n- **Genetic Testing:** Before initiating treatment, it is essential to test the tumor for ALK or ROS1 rearrangements to determine if Crizotinib is appropriate.\n\n### Indications\n- **NSCLC:** Approved for the treatment of patients with ALK-positive or ROS1-positive metastatic non-small cell lung cancer.\n- **Other Cancers:** It is sometimes used off-label for other cancers with ALK or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_o3aKrlJgRYiOtHMGHPyRFEzs", "custom_id": "63_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "bf962176168eba16bf25de37bc41e151", "body": {"id": "chatcmpl-9St5PVc9MDXZdxNeqTvDOXCeZwl3G", "object": "chat.completion", "created": 1716671963, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyclophosphamide is an important drug with a wide range of uses, primarily in oncology and immunology. Here are key points you should know about it:\n\n### Mechanism of Action\n- **Alkylating Agent**: Cyclophosphamide is a prodrug that gets metabolized in the liver to form active metabolites, which alkylate DNA, leading to cross-linking and inhibition of DNA replication and transcription. This results in cell death, particularly in rapidly dividing cells.\n\n### Indications\n- **Cancer Treatment**: It's used to treat various cancers, including lymphomas, leukemias, breast cancer, ovarian cancer, and multiple myeloma.\n- **Autoimmune Disorders**: It is also used in autoimmune diseases like severe rheumatoid arthritis, systemic lupus erythematosus (SLE), and vasculitis.\n\n### Administration\n- **Routes**: It can be administered orally or intravenously.\n- **Dosing**: The dosing varies depending on the condition"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_X24Vdhg3qpmjKB2k3IgEsQCd", "custom_id": "64_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "aa650b81c27b876a453a3327f2541378", "body": {"id": "chatcmpl-9St5QhOudlDeQYAxM2yqG79koeVsD", "object": "chat.completion", "created": 1716671964, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyproterone acetate (CPA) is a synthetic steroidal antiandrogen and progestogen with various clinical applications. Below are key points that you, as a physician, should know about this medication:\n\n### Mechanism of Action\n1. **Antiandrogenic Effects**: CPA competes with androgens (like testosterone and dihydrotestosterone) for binding to androgen receptors, thereby inhibiting their effects.\n2. **Progestogenic Effects**: It also has strong progestogenic properties, influencing the hypothalamic-pituitary-gonadal axis to reduce luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, leading to decreased testosterone production.\n\n### Indications\n1. **Prostate Cancer**: Used in the treatment of advanced prostate cancer due to its ability to block androgen receptors.\n2. **Hirsutism and Acne**: Prescribed for women with conditions like hirsutism, severe acne,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Ubre5UF6yXuHezRUEBATTv0v", "custom_id": "65_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6a3b3fd3c56c1fc3d476d0b9785f04f2", "body": {"id": "chatcmpl-9St5Qm10yvuvonYJnY222HCuO5ksX", "object": "chat.completion", "created": 1716671964, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cytarabine, also known as Ara-C, is a chemotherapy agent primarily used in the treatment of hematologic malignancies such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and non-Hodgkin's lymphoma. Here are some key points you should know about Cytarabine:\n\n### Mechanism of Action:\n- **Antimetabolite:** Cytarabine is a pyrimidine nucleoside analog. It interferes with DNA synthesis by inhibiting DNA polymerase, which is crucial for DNA replication.\n- **Cell Cycle Specificity:** It is most effective during the S-phase of the cell cycle, where DNA synthesis occurs.\n\n### Indications:\n- **Acute Myeloid Leukemia (AML):** Often used in combination regimens for induction and consolidation therapy.\n- **Acute Lymphoblastic Leukemia (ALL):** Used in various phases of treatment.\n- **Non-Hodgkin's Lymphoma:** Sometimes used"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_iduv5ZoRl2s1ixbWpgMDmOPG", "custom_id": "66_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0cee41f7e9d85df2749a2010764e5e98", "body": {"id": "chatcmpl-9St5Q0ZgOIBZuRhK1o0PmZHf2QlRZ", "object": "chat.completion", "created": 1716671964, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of cytarabine and daunorubicin liposomal, especially if you are treating patients with acute myeloid leukemia (AML) or related conditions. Here are key points to consider:\n\n### Overview\n- **Cytarabine and daunorubicin liposomal** (brand name: Vyxeos) is a combination chemotherapy drug used primarily to treat certain types of AML.\n- This formulation encapsulates cytarabine and daunorubicin in liposomes, which helps in delivering the drugs more effectively to cancer cells and may reduce some side effects compared to non-liposomal forms.\n\n### Indications\n- **Approved for use in adults with newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).**\n\n### Mechanism of Action\n- **Cytarabine** is a nucleoside analog that interferes with DNA synthesis.\n- **Daunorubicin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_jvQKfHy1HT3Q8sODf1l1gFUI", "custom_id": "67_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "4615a66b5b58ea129579e4e34d79d61e", "body": {"id": "chatcmpl-9St5QPag77ui9of5gACEwPH1yMeeR", "object": "chat.completion", "created": 1716671964, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dabrafenib is a medication used primarily in the treatment of certain types of cancer, particularly those involving mutations in the BRAF gene. Below are some key points you should know about Dabrafenib:\n\n### Indications:\n1. **Melanoma**: Dabrafenib is often used to treat unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.\n2. **Non-Small Cell Lung Cancer (NSCLC)**: It is also approved for use in patients with metastatic NSCLC harboring a BRAF V600E mutation.\n3. **Thyroid Cancer**: Dabrafenib can be used in patients with anaplastic thyroid cancer that is BRAF V600E mutation-positive and has no satisfactory locoregional treatment options.\n\n### Mechanism of Action:\n- Dabrafenib is a kinase inhibitor that targets the BRAF V600E mutation. BRAF is a protein kinase involved in sending signals inside cells,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_5awsMzh1NMuoPCdGOZ660guH", "custom_id": "68_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "7ff0c02fcb80f20a86398a1ba3ce7080", "body": {"id": "chatcmpl-9St5Qy6HY73bOCeXwmGgDIg4ODOkT", "object": "chat.completion", "created": 1716671964, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dacarbazine, also known as DTIC, is an alkylating agent used primarily in the treatment of various cancers, including malignant melanoma and Hodgkin's lymphoma. Here's a detailed overview of what you should know about this medication:\n\n### Mechanism of Action:\n- **Alkylating Agent**: Dacarbazine works by adding an alkyl group to the DNA of cancer cells, leading to DNA cross-linking and strand breaks. This ultimately inhibits DNA synthesis and function, causing cell death.\n- **Prodrug**: It requires metabolic activation in the liver by cytochrome P450 enzymes to form its active metabolite, which exerts the cytotoxic effects.\n\n### Indications:\n- **Malignant Melanoma**: Often used for metastatic melanoma.\n- **Hodgkin's Lymphoma**: Commonly part of the ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) chemotherapy regimen.\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_CUAYz8dXwap8fFQvG6BCR9vQ", "custom_id": "69_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "df41b5ecf4f1611f3d96d8db340f5a80", "body": {"id": "chatcmpl-9St5QKGszhRkqX5cZEe5Yffnya0AE", "object": "chat.completion", "created": 1716671964, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dacomitinib is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should be aware of as a physician:\n\n1. **Mechanism of Action**:\n   - Dacomitinib is a tyrosine kinase inhibitor (TKI) that specifically targets the epidermal growth factor receptor (EGFR) family. It irreversibly inhibits EGFR, HER2, and HER4, which are involved in the proliferation and survival of cancer cells.\n\n2. **Indications**:\n   - It is indicated for the first-line treatment of patients with metastatic NSCLC with EGFR-activating mutations (e.g., exon 19 deletions or exon 21 L858R substitution mutations). \n\n3. **Administration**:\n   - Dacomitinib is administered orally, typically at a dose of 45 mg once daily, with or without food.\n\n4. **Efficacy**:\n   - Clinical trials, such"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_MK53GZPNbugPFmfAlOdVyg1s", "custom_id": "70_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "3cc66fdacf7ab47bd071d395b26c599a", "body": {"id": "chatcmpl-9St5RfdIJUEVQJoRJupEmX7fPVXiF", "object": "chat.completion", "created": 1716671965, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dactinomycin, also known as actinomycin D, is a chemotherapeutic agent used primarily in the treatment of various types of cancer. Here are some key points you should know about dactinomycin:\n\n### Mechanism of Action\n- **Intercalation**: Dactinomycin works by intercalating into DNA, which inhibits RNA synthesis and, to a lesser extent, DNA synthesis.\n- **Inhibition of Transcription**: By binding to the DNA template, it prevents RNA polymerase from moving along the DNA, thereby inhibiting transcription.\n- **Apoptosis Induction**: This disruption leads to apoptosis (programmed cell death) in rapidly dividing cancer cells.\n\n### Indications\nDactinomycin is typically used to treat:\n- **Wilms' Tumor**: A type of kidney cancer that primarily affects children.\n- **Rhabdomyosarcoma**: A cancerous tumor of the muscles attached to the bones"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ndQnRpzkwW25RqnlFmikCWPE", "custom_id": "71_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b412ca546b0a7828ea8e96c9f5b584a1", "body": {"id": "chatcmpl-9St5RvKCx3LUZaL3i3Z111oUPsnwT", "object": "chat.completion", "created": 1716671965, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Danazol is a synthetic steroid with antigonadotropic and anti-estrogenic activity. It is primarily used in the treatment of endometriosis and fibrocystic breast disease. Here are some key points you should be aware of as a physician:\n\n1. **Mechanism of Action**: Danazol suppresses the pituitary-ovarian axis, leading to decreased estrogen production. It also has weak androgenic and anabolic activity.\n\n2. **Indications**:\n   - **Endometriosis**: Danazol helps to alleviate pain and reduce lesions associated with endometriosis.\n   - **Fibrocystic Breast Disease**: It can reduce breast pain, tenderness, and nodularity.\n   - **Hereditary Angioedema**: Danazol can be used to prevent episodes of swelling in patients with this condition.\n\n3. **Dosage**:\n   - For endometriosis: Typically, 200-800 mg daily in divided doses.\n   - For fibroc"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_KIxxSS3jisFzrAcYY37mH3tc", "custom_id": "72_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6c0d54cb1a5d1f3a94f2872487bd0594", "body": {"id": "chatcmpl-9St5RdBucvxtQHOxLrlSiOZonQsdY", "object": "chat.completion", "created": 1716671965, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daratumumab is a monoclonal antibody that is used primarily in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Here are some key points you should know about Daratumumab:\n\n### Mechanism of Action\n- **Target**: Daratumumab targets CD38, a protein that is highly expressed on the surface of myeloma cells.\n- **Action**: It works through multiple mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and induction of apoptosis (programmed cell death).\n\n### Indications\n- **Multiple Myeloma**: It is indicated for the treatment of multiple myeloma, both as a monotherapy and in combination with other treatments such as lenalidomide, bortezomib, and dexamethasone.\n- **Newly Diagnosed and Relapsed/Refractory**: It can be used in newly diagnosed patients who"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_uGfA7hbjTzuGTi0bySqTjxGl", "custom_id": "73_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "cd335867d138c34003a518e2e67187e4", "body": {"id": "chatcmpl-9St5RrAWZDzVE7FwtOCN457EU4Bow", "object": "chat.completion", "created": 1716671965, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Darolutamide is a medication used primarily in the treatment of prostate cancer, specifically non-metastatic castration-resistant prostate cancer (nmCRPC). Here are several key points you should know about Darolutamide:\n\n### Mechanism of Action\n- **Androgen Receptor Antagonist**: Darolutamide works by inhibiting the action of androgens (male hormones) which can promote the growth of prostate cancer cells. It binds to androgen receptors and prevents them from interacting with hormones like testosterone.\n\n### Indications\n- **Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC)**: Approved for use in patients whose prostate cancer has not spread to other parts of the body but continues to progress despite low levels of testosterone (castration-resistant).\n\n### Dosage and Administration\n- **Standard Dosage**: Typically administered as 600 mg taken orally twice daily, with or without food.\n- **Combination with Androgen Deprivation Therapy (ADT"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_XfDKzM3debprdvV5i0b6NKUC", "custom_id": "74_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9bb07edd7ffb6b6929e8197c6820cfda", "body": {"id": "chatcmpl-9St5R9zJkq7rfkgfJYISFJrBKlpFK", "object": "chat.completion", "created": 1716671965, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dasatinib is a tyrosine kinase inhibitor (TKI) that is primarily used in the treatment of certain types of leukemia. Here are several key points you should know about Dasatinib:\n\n### Indications\n1. **Chronic Myeloid Leukemia (CML)**: Dasatinib is approved for the treatment of adults with chronic, accelerated, or blast phase CML who are resistant or intolerant to prior therapy, including imatinib.\n2. **Acute Lymphoblastic Leukemia (ALL)**: It is also indicated for the treatment of adults with Philadelphia chromosome-positive (Ph+) ALL.\n\n### Mechanism of Action\n- Dasatinib inhibits the BCR-ABL kinase, which is produced by the Philadelphia chromosome abnormality in CML and Ph+ ALL. It also inhibits other kinases such as SRC family kinases, c-KIT, EPHA2, and PDGFR\u03b2.\n\n### Dosage and Administration\n- **CML**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_EHgUONIu73GgWLdPET1094Qz", "custom_id": "75_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a14a76a35327e21f13b277a5cccbc63b", "body": {"id": "chatcmpl-9St5R4cMx1O391qgmWTf6E0BpZGqD", "object": "chat.completion", "created": 1716671965, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daunorubicin is an anthracycline antibiotic commonly used in chemotherapy for treating various types of cancer, most notably acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Here are several key points you should know about Daunorubicin:\n\n### Mechanism of Action\n- **DNA Intercalation**: Daunorubicin intercalates between DNA base pairs, disrupting DNA replication and transcription.\n- **Topoisomerase II Inhibition**: It inhibits the enzyme topoisomerase II, leading to DNA strand breaks.\n- **Free Radical Formation**: Daunorubicin generates free radicals that can damage cellular components, including DNA, proteins, and lipids.\n\n### Indications\n- **Acute Myeloid Leukemia (AML)**: Often used in combination with other chemotherapeutic agents.\n- **Acute Lymphoblastic Leukemia (ALL)**: Used as part of combination therapy.\n\n### Administration\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_J3T7lJqC3wqXLcPtilWkV41M", "custom_id": "76_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e2247997070fa66011434e4d540b78b9", "body": {"id": "chatcmpl-9St5SQPyBOtBB02wVPmUE2KVZCHp8", "object": "chat.completion", "created": 1716671966, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daunorubicin liposomal is a chemotherapeutic agent used primarily in the treatment of certain types of cancer, such as acute myeloid leukemia (AML). Here are several key points you should be aware of as a physician:\n\n### Mechanism of Action:\n- **Daunorubicin**: An anthracycline antibiotic that intercalates DNA, thereby inhibiting the synthesis of nucleic acids and exerting cytotoxic effects.\n- **Liposomal Formulation**: Encapsulation in liposomes alters the pharmacokinetics and biodistribution, potentially reducing cardiotoxicity and enhancing delivery to tumor cells.\n\n### Indications:\n- Daunorubicin liposomal is approved for use in adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).\n\n### Administration:\n- Given intravenously.\n- Dosage and schedule depend on multiple factors including patient age, weight, overall health"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_r0Ihrb9QELrUeR4xBa9PdD17", "custom_id": "77_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ce8521fd64327d41da3288fd6b1bcce7", "body": {"id": "chatcmpl-9St5SR3MBjfYbqxE07HWjxaf93RYQ", "object": "chat.completion", "created": 1716671966, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Decitabine (trade name Dacogen) is a hypomethylating agent used primarily in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Here are some key points you should know about Decitabine:\n\n### Mechanism of Action:\n1. **Hypomethylation**: Decitabine incorporates into DNA and inhibits DNA methyltransferase, leading to hypomethylation of DNA. This can reactivate tumor suppressor genes that are silenced in cancer cells.\n2. **Cytotoxic Effects**: At higher doses, Decitabine has direct cytotoxic effects on rapidly dividing cells.\n\n### Indications:\n1. **Myelodysplastic Syndromes (MDS)**: It is indicated for the treatment of all subtypes of MDS, including refractory anemia, chronic myelomonocytic leukemia (CMMoL), and refractory anemia with excess blasts (RAEB).\n2. **Acute Myelo"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_sRxtllXZJbq0XyFfyTonRF4G", "custom_id": "78_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "465ff15f75b247aa33931a8deecc37d2", "body": {"id": "chatcmpl-9St5Szc7oxNpPQR25qKvl89bLJwrW", "object": "chat.completion", "created": 1716671966, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Degarelix is a medication used primarily in the management of advanced prostate cancer. As a physician, it's important to understand several key aspects of this drug:\n\n1. **Mechanism of Action**:\n   - Degarelix is a gonadotropin-releasing hormone (GnRH) antagonist. It works by directly binding to and blocking GnRH receptors in the pituitary gland, leading to a rapid decrease in the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).\n   - This results in a reduction of testosterone production by the testes, which is beneficial in slowing the growth of testosterone-sensitive prostate cancer cells.\n\n2. **Indications**:\n   - Degarelix is indicated for the treatment of advanced prostate cancer. It is often used when immediate testosterone suppression is needed.\n\n3. **Administration**:\n   - It is administered as a subcutaneous injection.\n   - The typical initial dose is 240 mg, given as two 120 mg injections"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_vI7prT0AGOrQ8xfN3PbK1oPM", "custom_id": "79_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9bd1602ef980f78977b039006efe9da1", "body": {"id": "chatcmpl-9St5TkhFpQ8If8MLBf7esDwyfBjfE", "object": "chat.completion", "created": 1716671967, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Denileukin diftitox is a fusion protein used as an antineoplastic agent, particularly for the treatment of certain types of lymphomas. Here are the key points you should know about it:\n\n### Mechanism of Action:\n- **Fusion Protein**: Denileukin diftitox is a recombinant fusion protein composed of interleukin-2 (IL-2) and diphtheria toxin fragments.\n- **Targeted Therapy**: It binds specifically to cells expressing the IL-2 receptor (CD25), which is often upregulated in malignant cells of certain lymphomas.\n- **Cytotoxic Effect**: Once bound to the IL-2 receptor, the diphtheria toxin component inhibits protein synthesis, leading to cell death.\n\n### Indications:\n- **Approved Uses**: It is primarily approved for the treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL) that expresses the CD25 component of the IL-2 receptor.\n- **Off-Label Uses"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_zfGzjxYLWmn8ZbaJ0d5vF0Jp", "custom_id": "80_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "79082488ee402176e3111285d1528eda", "body": {"id": "chatcmpl-9St5TPXOJlaGd8lVjeQO8MDq2z6OV", "object": "chat.completion", "created": 1716671967, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Denosumab is a fully human monoclonal antibody used primarily in the treatment of conditions characterized by bone loss. Here are several key points you should know about Denosumab:\n\n### Mechanism of Action\n- **RANKL Inhibition**: Denosumab works by binding to the receptor activator of nuclear factor kappa-\u0392 ligand (RANKL), a protein essential for the formation, function, and survival of osteoclasts. By inhibiting RANKL, Denosumab decreases osteoclast activity, leading to reduced bone resorption and increased bone mass and strength.\n\n### Indications\n- **Osteoporosis**: Denosumab is approved for the treatment of osteoporosis in postmenopausal women and in men at high risk for fracture.\n- **Bone Loss**: It is also used for bone loss associated with hormone ablation in men with prostate cancer and women receiving adjuvant aromatase inhibitor therapy for breast cancer.\n- **Giant Cell"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_bZ9v81n4uzRUmr2dFcSNp0AQ", "custom_id": "81_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e5db2ed14b9b5a2df8d7bc089bf0d8e7", "body": {"id": "chatcmpl-9St5TAbQBdeywfQpughM6oBC2WDCf", "object": "chat.completion", "created": 1716671967, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dexamethasone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. Here are some key points you should know about Dexamethasone:\n\n### Pharmacology:\n1. **Mechanism of Action**: Dexamethasone works by inhibiting multiple inflammatory cytokines, leading to reduced inflammation and immune response.\n2. **Potency**: It is much more potent than cortisol and other corticosteroids like prednisone.\n3. **Half-Life**: It has a long half-life, allowing for once-daily dosing in many cases.\n\n### Indications:\n1. **Inflammatory and Autoimmune Conditions**: Used to treat conditions such as rheumatoid arthritis, lupus, and inflammatory bowel disease.\n2. **Allergic Reactions**: Effective in managing severe allergic reactions and asthma exacerbations.\n3. **Cerebral Edema**: Often used to reduce swelling in cases of brain tumors or injuries.\n4. **Cancer**: Used as part"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Uwk8Hdee6lH2FAjBbKkGVDJA", "custom_id": "82_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b4f7d50864da6f1bff3ca16e3054b4aa", "body": {"id": "chatcmpl-9St5TyViWGIj7i02rE1MYX4qsTN6Y", "object": "chat.completion", "created": 1716671967, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dexrazoxane is a cardioprotective agent primarily used to mitigate the cardiotoxic effects of certain chemotherapeutic agents, particularly anthracyclines like doxorubicin and daunorubicin. Here are key points about dexrazoxane that you should know as a physician:\n\n### Mechanism of Action\n- **Cardioprotection**: Dexrazoxane works by chelating iron, thereby reducing the formation of free radicals which are responsible for the cardiotoxicity associated with anthracyclines.\n- **Topoisomerase II Inhibition**: It also inhibits topoisomerase II, which is implicated in the DNA damage caused by anthracyclines.\n\n### Indications\n- **Cardioprotection**: Approved for use in adults and children to reduce the risk of cardiomyopathy associated with doxorubicin administration in patients with metastatic breast cancer who have received a cumulative dose of 300 mg/m\u00b2 of doxorubicin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_omo64R5L4JB3E1XPGLAnAXxl", "custom_id": "83_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0e2df148d9f5f491e3c8c1d0751e6f39", "body": {"id": "chatcmpl-9St5TDC4K7XG8QABHWxUUs8Soso95", "object": "chat.completion", "created": 1716671967, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Diethylstilbestrol (DES) is a synthetic form of estrogen that was prescribed to pregnant women between the 1940s and 1970s to prevent miscarriages, premature labor, and related pregnancy complications. However, it was later discovered that DES had serious long-term health effects for both the women who took it and their offspring. Here are some key points you should be aware of:\n\n### Historical Context:\n- **Usage**: DES was widely prescribed because it was believed to help prevent pregnancy complications.\n- **Discontinuation**: In 1971, the U.S. Food and Drug Administration (FDA) advised against the use of DES in pregnant women after studies revealed a link between DES exposure and cancer.\n\n### Health Effects:\n- **Mothers (First Generation)**: Women who took DES have a modestly increased risk of breast cancer.\n- **DES Daughters (Second Generation)**: \n  - Increased risk of a rare vaginal and cervical cancer called clear cell adenoc"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_U2l36HjP5T0DPOeXMVIYRfLT", "custom_id": "84_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "38e9bd94fc998504dc63f33400a45776", "body": {"id": "chatcmpl-9St5Tnd1IO7FfPq9gqBFH63XGaG8F", "object": "chat.completion", "created": 1716671967, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dinutuximab is a monoclonal antibody primarily used in the treatment of high-risk neuroblastoma, a type of cancer that most commonly affects children. Here are some key points you should know about Dinutuximab:\n\n### Mechanism of Action\n- **Target**: Dinutuximab targets the GD2 glycoprotein, which is highly expressed on neuroblastoma cells and other cancers of neuroectodermal origin.\n- **Immune Activation**: By binding to GD2, Dinutuximab enables the immune system to recognize and destroy cancer cells through mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).\n\n### Indications\n- **Neuroblastoma**: Approved for use in pediatric patients with high-risk neuroblastoma who have achieved at least a partial response to prior first-line multiagent, multimodality therapy.\n- **Combination Therapy**: Often used in combination with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_B3eLLYzjtOo3NCFbOudvFPpX", "custom_id": "85_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "96f223ef5e5cdf812a9fcb382d075181", "body": {"id": "chatcmpl-9St5U58Ce24GiuxImlWyFPkHTQvRd", "object": "chat.completion", "created": 1716671968, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Docetaxel is a chemotherapy medication used primarily to treat various types of cancer, including breast cancer, non-small cell lung cancer, prostate cancer, stomach cancer, and head and neck cancer. Here are some key points you should know about Docetaxel:\n\n### Mechanism of Action:\n- **Microtubule Stabilization:** Docetaxel works by inhibiting cell division. It stabilizes microtubules and prevents their depolymerization, which disrupts the mitotic and interphase cellular functions.\n\n### Indications:\n- **Breast Cancer:** Both early-stage and metastatic.\n- **Non-Small Cell Lung Cancer (NSCLC):** As a first-line treatment in combination with other medications or as a single agent for patients who have previously received platinum-based chemotherapy.\n- **Prostate Cancer:** For metastatic castration-resistant prostate cancer in combination with prednisone.\n- **Gastric Cancer:** For advanced cases, typically in combination with cisplatin and 5-fl"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_AZZmMECZEE3WIb448HeG2dzu", "custom_id": "86_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ac385d177e9d3bccbce8beea81fee4b5", "body": {"id": "chatcmpl-9St5UZLft1TfgVANp49pPUekMikE0", "object": "chat.completion", "created": 1716671968, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Doxifluridine is an oral fluoropyrimidine derivative, which is a prodrug of 5-fluorouracil (5-FU), a widely used chemotherapeutic agent. Here are some key points you should know about Doxifluridine:\n\n1. **Mechanism of Action**: Doxifluridine is converted into 5-FU in the body, primarily by the enzyme thymidine phosphorylase. 5-FU then interferes with DNA and RNA synthesis, leading to cell death, particularly in rapidly proliferating cells such as cancer cells.\n\n2. **Clinical Use**: Doxifluridine is used mainly in the treatment of various cancers, including colorectal, gastric, and breast cancers. It is often administered as part of combination chemotherapy regimens.\n\n3. **Administration**: It is typically given orally, which can be more convenient for patients compared to intravenous administration of 5-FU. This can also potentially improve patient compliance and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_4lMpfKvVHhO6MICvkY7QlnRH", "custom_id": "87_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "74d5616b8416837c89256487298a3cc3", "body": {"id": "chatcmpl-9St5U2XQCt0SjF8IXxhXQS0GFyasa", "object": "chat.completion", "created": 1716671968, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Doxorubicin is an anthracycline antibiotic commonly used as a chemotherapeutic agent. Here are several key points you should know about Doxorubicin:\n\n### Mechanism of Action:\n1. **Intercalation into DNA**: Doxorubicin intercalates into DNA, which inhibits the replication and transcription processes.\n2. **Topoisomerase II Inhibition**: It inhibits topoisomerase II, an enzyme crucial for DNA replication, causing double-strand breaks.\n3. **Free Radical Formation**: Generates free radicals that induce cell damage and apoptosis.\n\n### Indications:\nDoxorubicin is used to treat a variety of cancers, including:\n- Breast cancer\n- Leukemias\n- Lymphomas\n- Sarcomas\n- Bladder cancer\n- Ovarian cancer\n\n### Administration:\n- **Routes**: Primarily administered intravenously.\n- **Dosing**: Dosage depends on the type of cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_9F2THpOG67DGxwXrrzZYPwRG", "custom_id": "88_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0824f157edb0ea84ec38bc00df9361ca", "body": {"id": "chatcmpl-9St5U4yvoYip19FCrY6tpztTLzQ0s", "object": "chat.completion", "created": 1716671968, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Durvalumab is a human monoclonal antibody that targets programmed death-ligand 1 (PD-L1), a protein involved in suppressing the immune system. Here are some key points you should know about Durvalumab:\n\n### Mechanism of Action\n- **PD-L1 Inhibition**: Durvalumab binds to PD-L1, blocking its interaction with PD-1 and CD80. This helps restore immune responses, allowing the body to better recognize and attack cancer cells.\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC)**: Approved for the treatment of locally advanced, unresectable NSCLC in patients whose disease has not progressed following platinum-based chemoradiation therapy.\n- **Urothelial Carcinoma**: Approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_QLKwQmoQiXxEeAfI6h42x5rD", "custom_id": "89_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "bec28f1ad0af87b5adec44632d3c4c62", "body": {"id": "chatcmpl-9St5Uswyokuz1OlmyVTjXv39z0uzB", "object": "chat.completion", "created": 1716671968, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dutasteride is a medication that you, as a physician, might prescribe primarily for the treatment of benign prostatic hyperplasia (BPH), a condition in which the prostate gland is enlarged. Here are some key points about Dutasteride that you should be aware of:\n\n### Mechanism of Action\n- **5-alpha-reductase Inhibitor**: Dutasteride inhibits both type 1 and type 2 isoforms of 5-alpha-reductase, the enzyme responsible for converting testosterone to dihydrotestosterone (DHT). Reduced levels of DHT lead to shrinkage of the enlarged prostate over time.\n\n### Indications\n- **Benign Prostatic Hyperplasia (BPH)**: It is primarily used to improve urinary flow and reduce the risk of urinary retention and surgery related to BPH.\n- **Androgenetic Alopecia**: It is sometimes used off-label for the treatment of male pattern hair loss, though this is more commonly treated with finaster"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_LSqg7dlScJJkiIJnhtuQxXlY", "custom_id": "90_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5f8ad811c1e1b6027fdf2e4901582c74", "body": {"id": "chatcmpl-9St5V0CySR4I4xRa6yniZB35lbOga", "object": "chat.completion", "created": 1716671969, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Duvelisib, marketed under the brand name Copiktra, is an oral phosphoinositide 3-kinase (PI3K) inhibitor used for the treatment of certain types of blood cancers. Here are some key points that you, as a physician, should know about Duvelisib:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL):**\n   - Duvelisib is indicated for the treatment of adult patients with relapsed or refractory CLL or SLL after at least two prior therapies.\n\n2. **Follicular Lymphoma (FL):**\n   - It is also indicated for the treatment of adult patients with relapsed or refractory FL after at least two prior systemic therapies.\n\n### Mechanism of Action:\n- Duvelisib inhibits PI3K-\u03b4 and PI3K-\u03b3, enzymes that are involved in the survival, proliferation,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_xoASDBdhDEyCfqdulVnuA5Sm", "custom_id": "91_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "eca6fbbc172cf1f3b308c77f356a7b91", "body": {"id": "chatcmpl-9St5Vr7NLjytkKsnK6Ra85uzoiu2P", "object": "chat.completion", "created": 1716671969, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Edrecolomab is a monoclonal antibody that was developed for the treatment of certain types of cancer, particularly colorectal cancer. Here are some key points to consider:\n\n### Mechanism of Action:\n- **Target**: Edrecolomab targets the EpCAM (epithelial cell adhesion molecule) antigen, which is overexpressed in many epithelial cancers.\n- **Function**: By binding to EpCAM, Edrecolomab is believed to help the immune system recognize and destroy cancer cells.\n\n### Clinical Use and Efficacy:\n- **Indications**: Initially investigated for adjuvant therapy in colorectal cancer.\n- **Efficacy**: Clinical trials showed mixed results. Some studies suggested a benefit in terms of survival, while others did not demonstrate significant advantages over standard therapies.\n- **Current Status**: It has largely fallen out of favor and is not commonly used in current clinical practice. Newer, more effective therapies have surpassed it.\n\n### Safety and Side"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_TJMVphkGIMmKKn5qgSYEl0FP", "custom_id": "92_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "fdeb9c91b112d0cc0f0dda9f425c8fa7", "body": {"id": "chatcmpl-9St5VAGM5tktv7iv9mCLV2L4gkikH", "object": "chat.completion", "created": 1716671969, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Elotuzumab is a humanized monoclonal antibody used in the treatment of multiple myeloma. Here are key points you should know about Elotuzumab:\n\n### Mechanism of Action\n- **Target**: Elotuzumab targets SLAMF7 (Signaling Lymphocytic Activation Molecule Family member 7), a protein highly expressed on myeloma cells and natural killer (NK) cells.\n- **Dual Action**: By binding to SLAMF7, elotuzumab directly activates NK cells and also tags myeloma cells for destruction by the immune system.\n\n### Indications\n- **Multiple Myeloma**: It is used in combination with other agents for the treatment of patients with multiple myeloma who have received one to three prior therapies.\n\n### Combination Therapy\n- **With Lenalidomide and Dexamethasone**: One common regimen involves elotuzumab in combination with lenalidomide and dexameth"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_x9OMC93CHX30ygMKt8bc305R", "custom_id": "93_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "fb65f8e4e627d2c9301e08d44ae9e3c3", "body": {"id": "chatcmpl-9St5Voc2eeOly1Mt4YrhvXCL5OOwU", "object": "chat.completion", "created": 1716671969, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enasidenib (brand name Idhifa) is an oral medication used primarily for the treatment of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. Here are some important aspects you should know as a physician:\n\n### Mechanism of Action:\n- Enasidenib is an inhibitor of the mutant IDH2 enzyme. In AML, mutations in IDH2 can lead to the production of an oncometabolite, 2-hydroxyglutarate (2-HG), which impairs cellular differentiation. By inhibiting this enzyme, enasidenib reduces 2-HG levels, promoting the differentiation of leukemic cells into more mature blood cells.\n\n### Indications:\n- Enasidenib is indicated for the treatment of adult patients with relapsed or refractory AML who have an IDH2 mutation as detected by an FDA-approved test.\n\n### Administration:\n- The recommended dose"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_VZ6QmOfiFHk6WNMdTXzkGoxC", "custom_id": "94_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d0092472411099f8ca41351886041410", "body": {"id": "chatcmpl-9St5VRakEb0d6JfmgfT4Ia7EdZBri", "object": "chat.completion", "created": 1716671969, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Encorafenib is a medication primarily used in the treatment of specific types of cancer, notably melanoma with a BRAF V600E or V600K mutation and metastatic colorectal cancer with a BRAF V600E mutation. As a physician, you should be aware of the following key points about Encorafenib:\n\n### Mechanism of Action\n- **Encorafenib** is a BRAF inhibitor, which works by targeting and inhibiting the activity of the BRAF V600E and V600K mutant kinases. This inhibition helps to block the MAPK/ERK signaling pathway, which is often overactive in certain cancers due to these mutations.\n\n### Indications\n- **Melanoma:** Encorafenib is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.\n- **Colorectal Cancer:** When used in combination with cetuximab, Encorafenib is indicated for the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_HsmbkuqC4Yo7ElV9nN5zeaPU", "custom_id": "95_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d699a2202c286137590f2bcef23371ac", "body": {"id": "chatcmpl-9St5VWIZEmVYwMbyqmeerJC8JUQi3", "object": "chat.completion", "created": 1716671969, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Entrectinib, marketed under the brand name Rozlytrek, is a medication used to treat specific types of cancer by targeting certain genetic mutations. Here are several key points you should be aware of as a physician:\n\n### Indications:\n1. **NTRK Gene Fusion-Positive Solid Tumors:** \n   - Indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment.\n\n2. **ROS1-Positive Non-Small Cell Lung Cancer (NSCLC):**\n   - Indicated for the treatment of adult patients with ROS1-positive metastatic NSCLC.\n\n### Mechanism of Action:\n- Entrectinib is a tyrosine kinase inhibitor that targets TRKA/B/C and ROS"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Y3FTt50r1cArtSQOT3MgquQu", "custom_id": "96_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d43f1e38c32e115fdccf4a5b6056443d", "body": {"id": "chatcmpl-9St5WnXFMTmuBmfG5QHKpjKyiSafA", "object": "chat.completion", "created": 1716671970, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enzalutamide is an androgen receptor inhibitor commonly used in the treatment of prostate cancer. Here are some key points a physician should know about Enzalutamide:\n\n### Indications\n- **Prostate Cancer**: It is primarily indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC).\n\n### Mechanism of Action\n- **Androgen Receptor Inhibition**: Enzalutamide works by inhibiting the androgen receptor (AR) signaling pathway. It blocks the binding of androgens to the AR, impedes AR nuclear translocation, and inhibits AR-mediated DNA binding and transcription.\n\n### Administration\n- **Dosage**: The typical dose for Enzalutamide is 160 mg orally once daily. This can be adjusted based on patient tolerance and specific clinical settings.\n- **Administration Considerations**: It can be taken with or without food.\n\n### Adverse Effects\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_9EufvOGrERqiVzck6DXY7O0p", "custom_id": "97_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5d4be2cfb30772abfd18a5bbdbb5f174", "body": {"id": "chatcmpl-9St5WQrCZc7aedbkpPESpNAzc1fkF", "object": "chat.completion", "created": 1716671970, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Epirubicin is an anthracycline antibiotic and a chemotherapy drug used primarily in the treatment of various cancers, including breast cancer, gastric cancer, and others. As a physician, it's important to be familiar with its pharmacology, indications, administration, side effects, and monitoring requirements. Here's a detailed overview:\n\n### Pharmacology\n- **Mechanism of Action**: Epirubicin intercalates into DNA, disrupting the replication and transcription processes, and inhibits topoisomerase II, preventing the ligation of the double-stranded DNA breaks, leading to apoptosis (cell death).\n- **Metabolism**: It is metabolized primarily in the liver to active and inactive metabolites.\n- **Elimination**: The drug and its metabolites are excreted primarily via the biliary system and, to a lesser extent, the kidneys.\n\n### Indications\n- **Breast Cancer**: Commonly used as part of adjuvant therapy in early breast cancer, and in metastatic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_jxM9YUjDW78y9VYiKLAW58qY", "custom_id": "98_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d73ad5235dd2b555dd5cceef2e478f0e", "body": {"id": "chatcmpl-9St5WaUVpqB5Fujpby6AkaCbCz9oV", "object": "chat.completion", "created": 1716671970, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erdafitinib is a targeted therapy drug that belongs to a class of medications known as fibroblast growth factor receptor (FGFR) inhibitors. It is primarily used in the treatment of certain types of cancer, specifically urothelial carcinoma (a type of bladder cancer), that have specific genetic alterations in the FGFR genes.\n\nHere are some key points you should know about Erdafitinib:\n\n### Indications:\n- **Urothelial Carcinoma**: Erdafitinib is approved for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations. It is typically used in patients who have progressed during or following at least one line of prior platinum-containing chemotherapy.\n\n### Mechanism of Action:\n- **FGFR Inhibition**: Erdafitinib works by inhibiting the FGFR tyrosine kinase, which is involved in tumor cell proliferation and survival. By blocking this pathway, the drug can help"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_e6OlwKasT1qCV3aReW3nZbD3", "custom_id": "99_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c57b97a74b47aeb584be8f067dd6ef4b", "body": {"id": "chatcmpl-9St5WL6cE6EaM0wRvFTrIxZYH8OyE", "object": "chat.completion", "created": 1716671970, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Eribulin is a synthetic analog of halichondrin B, a naturally occurring compound derived from marine sponges. It is primarily used in oncology for the treatment of certain types of cancer. Here are the key points you should know about Eribulin:\n\n### Indications\n- **Metastatic Breast Cancer**: Eribulin is approved for patients who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease, including an anthracycline and a taxane.\n- **Liposarcoma**: It is also approved for patients with unresectable or metastatic liposarcoma who have received prior chemotherapy that included an anthracycline.\n\n### Mechanism of Action\n- Eribulin works by inhibiting the growth phase of microtubules, leading to the suppression of microtubule dynamics and eventually causing cell cycle arrest and apoptosis. It is a microtubule dynamics inhibitor.\n\n### Administration\n- **Dosage**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_edFgSmZY056pewKHTJEKaNex", "custom_id": "100_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "3d3d51f276b25092cdaed13cf883b608", "body": {"id": "chatcmpl-9St5WdPzOl37Jfce8ocHt0XPN4XIK", "object": "chat.completion", "created": 1716671970, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erlotinib is an important medication used primarily in the treatment of certain types of cancer. Here are key points you should know as a physician:\n\n### Indications:\n1. **Non-Small Cell Lung Cancer (NSCLC):** Erlotinib is commonly used for the treatment of locally advanced or metastatic NSCLC with specific epidermal growth factor receptor (EGFR) mutations.\n2. **Pancreatic Cancer:** It is also approved for use in combination with gemcitabine for the treatment of locally advanced, unresectable, or metastatic pancreatic cancer.\n\n### Mechanism of Action:\n- **EGFR Inhibition:** Erlotinib is a tyrosine kinase inhibitor that specifically targets the EGFR, which is involved in the signaling pathways that regulate cell division and survival. By inhibiting EGFR, erlotinib can reduce tumor growth and proliferation.\n\n### Dosage and Administration:\n- **NSCLC:** The typical dose is 150 mg orally once daily.\n- **Pan"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_M4FD21ODCLuJM8TTXoCD8DxS", "custom_id": "101_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e2481ae9f925865a11a61187e7a3fd88", "body": {"id": "chatcmpl-9St5WRfpWnBYX6heYpl4GEnklRCow", "object": "chat.completion", "created": 1716671970, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Estramustine is a chemotherapy medication used primarily in the treatment of prostate cancer. Here are some key points you should know about Estramustine:\n\n### Mechanism of Action\n1. **Combination Drug**: Estramustine combines estradiol, an estrogen hormone, with a nitrogen mustard, an alkylating agent. This dual action helps in disrupting microtubule function, which is essential for cell division, thereby inhibiting the growth of cancer cells.\n2. **Anti-Mitotic**: The drug interferes with microtubule dynamics, crucial for mitosis, leading to cell cycle arrest and apoptosis in cancer cells.\n\n### Indications\n1. **Prostate Cancer**: It's primarily used for hormone-refractory metastatic prostate cancer, particularly in patients who no longer respond to conventional hormone therapy.\n\n### Administration\n1. **Oral Form**: Estramustine is typically administered orally in capsule form.\n2. **Dosage**: Dosage varies"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Hkywl3eq1oCLRG2KVulBNXJF", "custom_id": "102_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "25f256ec172b589ee7f640b6167fee66", "body": {"id": "chatcmpl-9St5WP8iaZqnM5ZBs4PprQC8cVhVW", "object": "chat.completion", "created": 1716671970, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Etoposide is a chemotherapeutic agent commonly used in the treatment of various malignancies, including small cell lung cancer, testicular cancer, lymphomas, and certain types of leukemia. Here are some key points that you should know about Etoposide:\n\n### Mechanism of Action\n- **Topoisomerase II Inhibition**: Etoposide works by inhibiting the enzyme topoisomerase II, which leads to DNA strand breaks and prevents the cell from replicating its DNA and dividing.\n  \n### Pharmacokinetics\n- **Administration**: Etoposide can be administered orally or intravenously.\n- **Metabolism**: It is metabolized primarily in the liver.\n- **Excretion**: Both renal and biliary excretion are involved, so dose adjustments may be necessary in patients with renal or hepatic impairment.\n\n### Indications\n- **Small Cell Lung Cancer (SCLC)**: Often used in combination with other chemotherapeutic agents.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_mW3I2AbT6wYzN1G8yQZ08Fql", "custom_id": "103_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "4b2806fb1b062317ad9a2bb5bc4473ac", "body": {"id": "chatcmpl-9St5WA9OuiuMBnAKdrCetPHCpuE1j", "object": "chat.completion", "created": 1716671970, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Everolimus is a medication used for various indications, primarily in oncology and transplant medicine. Here are some key points you should know as a physician:\n\n### Indications:\n1. **Oncology**:\n   - **Advanced Kidney Cancer**: After failure of treatment with sunitinib or sorafenib.\n   - **Hormone Receptor-Positive, HER2-Negative Breast Cancer**: In combination with exemestane in postmenopausal women after failure of treatment with letrozole or anastrozole.\n   - **Neuroendocrine Tumors**: Of pancreatic origin, and other types of progressive neuroendocrine tumors.\n   - **Tuberous Sclerosis Complex (TSC)**: Associated with renal angiomyolipoma and subependymal giant cell astrocytoma (SEGA).\n\n2. **Transplant Medicine**:\n   - **Prevention of Organ Rejection**: Used in kidney and liver transplant recipients as part of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Ql54kbn8pmI1ezcoF6CbY9w3", "custom_id": "104_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a7b253b77b6460f0f754a7f96a23d23e", "body": {"id": "chatcmpl-9St5XLKN9Msl6ue6NnxQluwV9wMgE", "object": "chat.completion", "created": 1716671971, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Exemestane is an aromatase inhibitor primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Here are some key points you should know about Exemestane as a physician:\n\n### Mechanism of Action\n- **Aromatase Inhibition:** Exemestane works by irreversibly inhibiting the enzyme aromatase, which converts androgens to estrogens. This reduction in estrogen levels helps slow the growth of estrogen receptor-positive breast cancer cells.\n\n### Indications\n- **Breast Cancer:** It is commonly prescribed for postmenopausal women with estrogen receptor-positive breast cancer, either as adjuvant therapy or after initial treatment with tamoxifen.\n- **Advanced Breast Cancer:** It may also be used in cases of advanced breast cancer that have progressed following tamoxifen therapy.\n\n### Dosage\n- **Standard Dosage:** The typical dose is 25 mg taken orally once daily after a meal. \n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Kr3L5S8eBimLg2qy3VwisMNc", "custom_id": "105_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d3fa0179454a74b6a6585a3909bcc6da", "body": {"id": "chatcmpl-9St5Xxy47BiONV7kJTZdoGH4FtCpy", "object": "chat.completion", "created": 1716671971, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Floxuridine is a chemotherapy medication primarily used in the treatment of various cancers, particularly those affecting the gastrointestinal tract, liver, and certain types of metastatic cancers. Here are some key points you should know about Floxuridine:\n\n### Mechanism of Action\n- **Antimetabolite:** Floxuridine is a pyrimidine analog and works by inhibiting DNA synthesis. It gets metabolized to fluorouracil (5-FU), which interferes with the synthesis of DNA and RNA by inhibiting the enzyme thymidylate synthase.\n- **Cell Cycle Specific:** It is most effective during the S-phase of the cell cycle, where DNA replication occurs.\n\n### Indications\n- **Hepatic Metastases:** Often used in the treatment of liver metastases, particularly from colorectal cancer.\n- **Gastrointestinal Cancers:** Can be used for cancers of the stomach, pancreas, and other parts of the GI tract.\n\n### Administration\n- **Intra"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_rlPiO7abDDQGBzE14O81dedS", "custom_id": "106_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "29aae705d93fa28a0b04a41b4b98e8fb", "body": {"id": "chatcmpl-9St5X45zngWmxF5J99ci0CteabxKk", "object": "chat.completion", "created": 1716671971, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fludarabine is a chemotherapy medication primarily used to treat hematologic malignancies, particularly chronic lymphocytic leukemia (CLL). Here are some key points you should know about Fludarabine:\n\n### Pharmacology\n- **Mechanism of Action**: It is a purine analog that interferes with DNA synthesis. It gets phosphorylated intracellularly to its active form, which inhibits DNA polymerase, ribonucleotide reductase, and DNA primase, leading to inhibition of DNA synthesis and cell death.\n- **Administration**: It can be administered intravenously or orally. The IV form is more commonly used in clinical settings.\n\n### Indications\n- **Chronic Lymphocytic Leukemia (CLL)**: Fludarabine is often used as a first-line treatment or in combination with other agents.\n- **Other Hematologic Malignancies**: It may also be used in the treatment of non-Hodgkin lymphoma and other lymphoproliferative"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_o6dXofxgsnrSNCloNiK7WbUo", "custom_id": "107_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2c2a81f244e54bca5eae30a39983f0bf", "body": {"id": "chatcmpl-9St5XNW83j4qg5PkOUjehGWhKkz3P", "object": "chat.completion", "created": 1716671971, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fluorouracil, also known as 5-FU, is a chemotherapy medication used to treat various types of cancer. Here are some key points you should know about it:\n\n### Mechanism of Action:\n- **Antimetabolite**: Fluorouracil is a pyrimidine analog that interferes with DNA and RNA synthesis. It inhibits thymidylate synthase, leading to a depletion of thymidine triphosphate, which is essential for DNA replication and repair.\n- **Cell Cycle Specificity**: It is most effective in the S-phase of the cell cycle, when DNA synthesis occurs.\n\n### Indications:\n- **Cancer Types**: Commonly used for colorectal cancer, breast cancer, gastric cancer, pancreatic cancer, and certain head and neck cancers.\n- **Topical Use**: It can also be used topically for actinic keratosis, basal cell carcinoma, and other skin conditions.\n\n### Administration:\n- **Routes**: Can"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Zy75J9fwEa3WD3sqKHCSNZN2", "custom_id": "108_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6c71b77b2feaefa988cc13431e238247", "body": {"id": "chatcmpl-9St5X51llk26zUKSwd1iZYfDkH6sA", "object": "chat.completion", "created": 1716671971, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fluoxymesterone is an anabolic-androgenic steroid (AAS) that is used in the medical field for various therapeutic purposes. Here are some key points you should know about this medication:\n\n### Indications\n1. **Hypogonadism in Males:** Used to treat males with testosterone deficiency.\n2. **Delayed Puberty in Males:** Can be prescribed to stimulate the onset of puberty in carefully selected males with delayed puberty.\n3. **Breast Cancer in Females:** Sometimes used as part of palliative treatment for breast cancer in postmenopausal women.\n\n### Mechanism of Action\n- Fluoxymesterone is a synthetic derivative of testosterone. It works by binding to androgen receptors, which then interact with DNA in cells to stimulate protein synthesis and promote growth of specific tissues, including muscle and bone.\n\n### Dosage and Administration\n- The dosage varies depending on the indication and the patient's condition. For hypogonadism, doses typically range from 5"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_6NBHsA9ZeQeIcr5578w40QVx", "custom_id": "109_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "bce190bff943c809b9c46aadca18eacf", "body": {"id": "chatcmpl-9St5Xm1XlM1jCBh5dfD3xLdbeC08b", "object": "chat.completion", "created": 1716671971, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Flutamide is a nonsteroidal antiandrogen medication primarily used in the treatment of prostate cancer. Here are key points you should know about Flutamide:\n\n### Mechanism of Action\n- **Antiandrogenic Effects**: Flutamide works by inhibiting the action of androgens (male hormones), such as testosterone, by binding to androgen receptors in the target tissues. This prevents the androgens from stimulating the growth of prostate cancer cells.\n\n### Indications\n- **Prostate Cancer**: It is commonly used in combination with other treatments, such as luteinizing hormone-releasing hormone (LHRH) agonists, to treat advanced prostate cancer.\n- **Off-Label Uses**: Occasionally, it may be used off-label for conditions like hirsutism or to manage androgen-related disorders in women, although this is less common.\n\n### Dosage and Administration\n- **Typical Dosage**: The typical adult dose for prostate cancer is 250"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_yyb9pf37eYY5yi7Kefv86Osa", "custom_id": "110_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e1f0023c1ee05fc4f97dff43da13d90a", "body": {"id": "chatcmpl-9St5YrMx00RIrxMADlkbwG3IiDXZH", "object": "chat.completion", "created": 1716671972, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Folinic acid, also known as leucovorin, is a medication that is used for various medical purposes. Here are some key points you should know about it:\n\n### Mechanism of Action:\n- Folinic acid is the active form of folic acid and works by bypassing the normal metabolic pathway that converts folic acid to its active form, tetrahydrofolate.\n- It acts as a cofactor in the synthesis of purines and pyrimidines, which are essential for DNA and RNA synthesis.\n\n### Indications:\n1. **Chemotherapy Adjunct:**\n   - Used to \"rescue\" cells from the toxic effects of methotrexate by providing a source of reduced folate.\n   - Enhances the efficacy and tolerability of 5-fluorouracil (5-FU) in the treatment of colorectal cancer.\n\n2. **Megaloblastic Anemia:**\n   - Indicated for the treatment of megaloblastic anemia due to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_10rlT8o5kxa9ig2hYp0PDo6S", "custom_id": "111_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "87b9dea041bfb16e22e9e6f741a34ac5", "body": {"id": "chatcmpl-9St5Y0zxfoBBQQXRnGh1ePurC8TKW", "object": "chat.completion", "created": 1716671972, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Formestane is a synthetic steroidal substance that functions primarily as an aromatase inhibitor. Below are key points you should know about Formestane:\n\n### Mechanism of Action\n- **Aromatase Inhibition**: Formestane works by inhibiting the enzyme aromatase, which is responsible for converting androgens into estrogens. This reduces estrogen levels in the body.\n- **Steroidal Structure**: It is classified as a steroidal aromatase inhibitor, meaning it resembles the structure of steroids and binds irreversibly to the aromatase enzyme.\n\n### Clinical Use\n- **Breast Cancer Treatment**: Formestane has been used primarily in the treatment of estrogen receptor-positive breast cancer in postmenopausal women. By lowering estrogen levels, it helps to slow down or stop the growth of hormone-sensitive tumors.\n- **Administration**: It was commonly administered via intramuscular injection, usually in a hospital or clinical setting, although it has largely"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_RUxoJqage5hilJnr2tnedBnE", "custom_id": "112_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "be45a0f40419e673fe18f74a7668c4ee", "body": {"id": "chatcmpl-9St5Y7ZKv3POzjUY2WfvwirX4IQm9", "object": "chat.completion", "created": 1716671972, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Forodesine is a purine nucleoside phosphorylase (PNP) inhibitor with potential applications in treating certain hematologic malignancies. Here are some key points you should know:\n\n1. **Mechanism of Action**: Forodesine inhibits PNP, an enzyme involved in the purine salvage pathway. By inhibiting PNP, forodesine leads to the accumulation of deoxyguanosine triphosphate (dGTP) in lymphocytes, which induces apoptosis, particularly in T-cells.\n\n2. **Indications**: Forodesine has been primarily investigated for the treatment of T-cell malignancies, including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell non-Hodgkin's lymphoma (T-NHL). It may also have potential in other hematologic conditions characterized by aberrant T-cell activity.\n\n3. **Administration**: Forodesine is typically administered orally. The dosage and treatment regimen may vary based on specific clinical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_yp4a7xOSQiV7aibCO96NZ5xh", "custom_id": "113_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "033f9b093d63dd75cfaa51d7f237e4f9", "body": {"id": "chatcmpl-9St5YzRBY25Amnn61jZHf37NkIxzn", "object": "chat.completion", "created": 1716671972, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fostamatinib is an oral spleen tyrosine kinase (SYK) inhibitor that is used primarily for the treatment of chronic immune thrombocytopenia (ITP) in adults who have had an insufficient response to previous treatments. Here are some key points you should know about Fostamatinib:\n\n### Indications:\n- **Chronic Immune Thrombocytopenia (ITP)**: For patients who have not responded adequately to other treatments.\n\n### Mechanism of Action:\n- **SYK Inhibition**: Fostamatinib inhibits spleen tyrosine kinase, which plays a critical role in the immune system's signaling pathways. This inhibition helps to reduce the destruction of platelets.\n\n### Dosage and Administration:\n- **Starting Dose**: The typical starting dose is 100 mg twice daily.\n- **Adjustment**: The dosage may be increased to 150 mg twice daily based on the patient\u2019s platelet count and tolerability.\n- **Administration**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_X745ZlNrQazYRSy9u5RZVbKP", "custom_id": "114_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "43d431083fba4f4800383e2b7c9dcb61", "body": {"id": "chatcmpl-9St5Y5JMF6LTnnJDCYiJymMd2Ase9", "object": "chat.completion", "created": 1716671972, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fotemustine is a nitrosourea alkylating agent used primarily in the treatment of malignant melanoma, particularly when the disease has metastasized to the brain. Here are some important points you should know about it:\n\n1. **Mechanism of Action**:\n   - Fotemustine works by alkylating DNA and RNA, which leads to the disruption of DNA replication and transcription, ultimately causing cell death. Its ability to cross the blood-brain barrier makes it particularly useful in treating brain metastases.\n\n2. **Indications**:\n   - It is primarily indicated for the treatment of metastatic melanoma, including cases with brain metastases. It may also be considered for other cancers in some off-label uses, but this is less common.\n\n3. **Administration**:\n   - Fotemustine is administered intravenously. The dosing regimen often involves an induction phase, where the drug is given weekly for a few weeks, followed by a maintenance phase with less frequent dosing.\n\n4"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_vhi5ceb0TLSNBwrP4UadVyXc", "custom_id": "115_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "66422839e20e5cce6f311261d809954a", "body": {"id": "chatcmpl-9St5Y8lNw1LNw7hNPDnu8v6i0tBOg", "object": "chat.completion", "created": 1716671972, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fulvestrant is a medication primarily used in the treatment of hormone receptor-positive metastatic breast cancer. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Selective Estrogen Receptor Downregulator (SERD):** Fulvestrant works by binding to estrogen receptors and promoting their degradation. This action effectively inhibits the estrogen receptor signaling pathways that promote the growth of breast cancer cells.\n\n### Indications\n- **Hormone Receptor-Positive Breast Cancer:** It is commonly used in postmenopausal women with hormone receptor-positive metastatic breast cancer, especially in cases where the disease has progressed following anti-estrogen therapy, such as with tamoxifen or aromatase inhibitors.\n\n### Administration\n- **Intramuscular Injection:** Fulvestrant is administered via intramuscular injection, typically given as a 500 mg dose (administered as two 250 mg injections) into the buttocks on days 1, 15, 29,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_dUO53z60WdXq2rlaueIHfcLI", "custom_id": "116_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0daf5fd556e0773e04153b02f32355a7", "body": {"id": "chatcmpl-9St5Z6eUcww4KdXfnvXVX9lemKQLQ", "object": "chat.completion", "created": 1716671973, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gefitinib is a tyrosine kinase inhibitor that is primarily used in the treatment of certain types of non-small cell lung cancer (NSCLC). Here are some key points you should know about Gefitinib:\n\n### Mechanism of Action\n- **Target:** Gefitinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. By inhibiting this enzyme, it prevents the activation of the EGFR pathway, which is involved in the proliferation and survival of cancer cells.\n- **Mutation Specificity:** Gefitinib is particularly effective in patients whose tumors have specific activating mutations in the EGFR gene (e.g., exon 19 deletions or exon 21 L858R substitution mutations).\n\n### Indications\n- **Approved Use:** Gefitinib is approved for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.\n- **Testing Requirement:** Patients should be"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_cVvM5i5LotTJadm4Cy36ytRt", "custom_id": "117_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a137a4563de40ae2558b81ea76d374f2", "body": {"id": "chatcmpl-9St5ZIPACzMezUHFu2GKFYadDRmZZ", "object": "chat.completion", "created": 1716671973, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Gemcitabine, its uses, mechanisms of action, side effects, and considerations for patient management. Here's an overview:\n\n### General Information\n**Gemcitabine** is a nucleoside analog used as chemotherapy. Its chemical name is 2',2'-difluorodeoxycytidine, and it's commonly known under the brand name Gemzar.\n\n### Mechanism of Action\nGemcitabine is a prodrug that is metabolized inside the cell to its active triphosphate form (dFdCTP). It incorporates into DNA during the S-phase of the cell cycle, leading to inhibition of DNA synthesis and induction of apoptosis. It also inhibits ribonucleotide reductase, reducing the pool of deoxynucleotide triphosphates necessary for DNA synthesis.\n\n### Indications\nGemcitabine is used to treat various types of cancers, including:\n- Pancreatic cancer (first-line treatment)\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_pWiWFe6uXHxYpQNNiPgCS9Ey", "custom_id": "118_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f6f043d0fe2ad305dc983cdfdfdac3e0", "body": {"id": "chatcmpl-9St5ZarneWAuNK0jY30SklYbPtyCU", "object": "chat.completion", "created": 1716671973, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gemtuzumab ozogamicin is an important agent in the treatment of acute myeloid leukemia (AML). Here are the key points you should know about it as a physician:\n\n### Mechanism of Action:\n- **Antibody-Drug Conjugate**: Gemtuzumab ozogamicin is a monoclonal antibody (gemtuzumab) linked to a cytotoxic agent (ozogamicin).\n- **Target**: The antibody component targets CD33, a cell surface antigen expressed on myeloid leukemia cells.\n- **Cytotoxic Effect**: Once bound to CD33-expressing cells, the conjugate is internalized, and the cytotoxic agent (calicheamicin) is released to induce DNA strand breaks and apoptosis.\n\n### Indications:\n- **Acute Myeloid Leukemia (AML)**: It is approved for use in adults with newly diagnosed CD33-positive AML and in patients aged 2 years and older with relapsed"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_s4Qy0svcRec644QRXiIkLgxB", "custom_id": "119_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "62dda6c678cda2d6341ba59a871efc4c", "body": {"id": "chatcmpl-9St5ZuXTYJEjLKbbDT5HxRe9grqNX", "object": "chat.completion", "created": 1716671973, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gilteritinib is a medication used primarily in the treatment of acute myeloid leukemia (AML), specifically in patients who have a particular genetic mutation known as FLT3. As a physician, here are some important points you should know about Gilteritinib:\n\n### Mechanism of Action\n- **FLT3 Inhibition**: Gilteritinib is a tyrosine kinase inhibitor that specifically targets the FLT3 receptor. Mutations in the FLT3 gene are associated with poor prognosis in AML, and inhibiting this receptor can help control the proliferation of leukemic cells.\n  \n### Indications\n- **Acute Myeloid Leukemia (AML)**: Gilteritinib is indicated for the treatment of adult patients with relapsed or refractory AML who have an FLT3 mutation (either FLT3-ITD or FLT3-TKD).\n\n### Dosage and Administration\n- **Standard Dose**: The typical starting dose is 120 mg orally once daily"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ZTCsQA7bHbeYUzrLpWPvOxwu", "custom_id": "120_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2bbe590f91d6411ffd4b168a0bfeed13", "body": {"id": "chatcmpl-9St5ZgIUWFNnMpsgERX95nECqAKuq", "object": "chat.completion", "created": 1716671973, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it\u2019s important to have a comprehensive understanding of Glasdegib, especially if you are treating patients with specific types of cancer. Here are key points you should know:\n\n### General Information:\n- **Brand Name:** Daurismo\n- **Class:** Hedgehog pathway inhibitor\n- **Indication:** Glasdegib is typically used in combination with low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years or older or who have comorbidities that preclude the use of intensive induction chemotherapy.\n\n### Mechanism of Action:\n- Glasdegib targets the Hedgehog signaling pathway, which is involved in the regulation of cell growth and differentiation. By inhibiting this pathway, Glasdegib can reduce the proliferation of cancer cells.\n\n### Pharmacokinetics:\n- **Absorption:** Oral administration with peak concentrations achieved within 2-4 hours.\n- **Metabolism:** Primarily metabolized by the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_25IoajGrxPTtt8T3pJpChPik", "custom_id": "121_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f12368b5a4ca5678339a818f4a8434f3", "body": {"id": "chatcmpl-9St5Z3pPf0sJVRgQ3rzpBxVIb7QJN", "object": "chat.completion", "created": 1716671973, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Goserelin is a synthetic analog of gonadotropin-releasing hormone (GnRH) used primarily in the treatment of hormone-sensitive cancers and some other hormonal disorders. Here are key points you should know about Goserelin:\n\n### Mechanism of Action:\n- **GnRH Agonist**: Goserelin acts as an agonist at GnRH receptors. Initially, it stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a temporary surge in sex hormones (testosterone in men and estradiol in women).\n- **Downregulation**: With continued administration, it causes downregulation of GnRH receptors in the pituitary gland, leading to decreased secretion of LH and FSH. This results in reduced production of sex hormones (testosterone and estrogen), which is beneficial in hormone-sensitive conditions.\n\n### Indications:\n- **Prostate Cancer**: Used in the management of advanced prostate cancer by reducing testosterone levels"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_KkMftaDppQdyo6XJVL3dpgAv", "custom_id": "122_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5425b3d03f4ed934616b42ba7d6fcf80", "body": {"id": "chatcmpl-9St5aSCmLMghJsTygKvDdtUCkERCo", "object": "chat.completion", "created": 1716671974, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Histrelin is a synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH) used primarily in the treatment of hormone-sensitive conditions. Here are the key aspects you should know about Histrelin:\n\n### Indications\n1. **Central Precocious Puberty (CPP)**: Histrelin is used to treat children with CPP, a condition where puberty starts too early (before age 8 in girls and age 9 in boys).\n2. **Prostate Cancer**: It is used to treat advanced prostate cancer by reducing testosterone levels, which can slow the growth of cancer cells.\n\n### Mechanism of Action\n- Histrelin works by initially stimulating and then downregulating the GnRH receptors in the pituitary gland. This leads to a decrease in the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), ultimately reducing the levels of sex hormones (testosterone in males and estrogen in females).\n\n### Administration\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_e6ZgT8rGJUW0elQ08kEUWl5F", "custom_id": "123_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "3badda5c592ac7962570b66757f4dbe5", "body": {"id": "chatcmpl-9St5a8BxM0jRjEQbjkyqaw2Jw99YL", "object": "chat.completion", "created": 1716671974, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Hydrocortisone is a corticosteroid medication commonly used for its anti-inflammatory and immunosuppressive properties. Here are some key points you should know about hydrocortisone:\n\n### Pharmacology\n- **Mechanism of Action**: Hydrocortisone mimics the effects of cortisol, a naturally occurring hormone produced by the adrenal glands. It works by reducing inflammation and modulating the immune response.\n- **Forms**: Hydrocortisone is available in several forms, including oral tablets, topical creams and ointments, injectables, and rectal suppositories.\n\n### Indications\n- **Inflammatory Conditions**: It is used to treat various inflammatory and autoimmune conditions such as rheumatoid arthritis, lupus, and inflammatory bowel disease.\n- **Allergic Reactions**: Hydrocortisone can be used to manage severe allergic reactions, including anaphylaxis.\n- **Adrenal Insufficiency**: It is the drug of choice for replacing cortisol in patients with adrenal insufficiency ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_968S4iE65LtFUtquSUdzPfZb", "custom_id": "124_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a4d4f9533cae49343cbb92125b10bb72", "body": {"id": "chatcmpl-9St5ataJl9cwQG6d8J14pCBU2WriD", "object": "chat.completion", "created": 1716671974, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Hydroxyurea to effectively manage and treat patients who require this medication. Here are the key points you should know:\n\n### Indications:\n1. **Sickle Cell Disease**: Hydroxyurea is commonly used to reduce the frequency of painful crises and the need for blood transfusions.\n2. **Chronic Myelogenous Leukemia (CML)**: It's used to reduce white blood cell counts.\n3. **Polycythemia Vera**: Hydroxyurea helps decrease red blood cell mass.\n4. **Essential Thrombocythemia**: It helps to lower platelet counts and reduce the risk of clotting complications.\n\n### Mechanism of Action:\n- Hydroxyurea works by inhibiting ribonucleotide reductase, leading to decreased DNA synthesis. This affects rapidly dividing cells, such as those in the bone marrow, and helps to manage excessive cell production.\n\n### Dosage and Administration:\n- **S"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_6fNrdwgExDgNDljha9ykAEFn", "custom_id": "125_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "926eb190af3131a484ce4f83ec1da449", "body": {"id": "chatcmpl-9St5aMFhHOKVqBXMytH4zBJ95qrlT", "object": "chat.completion", "created": 1716671974, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibritumomab tiuxetan is a radioimmunotherapy agent used primarily in the treatment of certain types of non-Hodgkin lymphoma (NHL). Here are some key points you should know about this medication:\n\n### Mechanism of Action\n- **Monoclonal Antibody**: Ibritumomab tiuxetan is a monoclonal antibody that targets the CD20 antigen found on the surface of B-cells.\n- **Radioimmunotherapy**: It is conjugated with a radioactive isotope (either Yttrium-90 or Indium-111), which delivers targeted radiation to the cancer cells, thereby killing them.\n\n### Indications\n- **Relapsed or Refractory NHL**: It is typically used for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin lymphoma.\n- **First-line Consolidation**: Sometimes used as a first-line consolidation therapy for patients who achieve a partial or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_6PFNJZmNUVMseMst5Tr5SfFS", "custom_id": "126_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "fbc2759ea4bbbdda2665cbffb53a5aac", "body": {"id": "chatcmpl-9St5aaCnuhCO7OCZ724DCupuUtx02", "object": "chat.completion", "created": 1716671974, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibrutinib is a significant medication used primarily in oncology and hematology. Here are key points a physician should be aware of:\n\n### Mechanism of Action:\n- **Ibrutinib** is a Bruton's tyrosine kinase (BTK) inhibitor. BTK is crucial for B-cell receptor signaling, which is essential for the growth and survival of malignant B cells.\n\n### Indications:\n- **Chronic Lymphocytic Leukemia (CLL)**\n- **Mantle Cell Lymphoma (MCL)**\n- **Waldenstr\u00f6m\u2019s Macroglobulinemia (WM)**\n- **Marginal Zone Lymphoma (MZL)**\n- **Chronic Graft versus Host Disease (cGVHD)**, among others.\n\n### Dosage and Administration:\n- Dosages can vary depending on the condition being treated, but it is typically taken orally once daily.\n- It's important to encourage patients to take it at the same time each day and not"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ylEdH5sXAMZ0ZengQu1tfyGa", "custom_id": "127_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "12e4e77a6c728902fef852871c098b4c", "body": {"id": "chatcmpl-9St5aCEwKRCB6NIMi6o5UxYi0jGE0", "object": "chat.completion", "created": 1716671974, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Icotinib is an oral tyrosine kinase inhibitor (TKI) specifically targeting the epidermal growth factor receptor (EGFR). It is primarily used in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. Here are several key points you should know about Icotinib:\n\n### Mechanism of Action:\n- **EGFR Inhibition**: Icotinib selectively inhibits EGFR, which is often overexpressed or mutated in various cancers, including NSCLC. By binding to the adenosine triphosphate (ATP) binding site of the EGFR tyrosine kinase domain, it prevents phosphorylation and subsequent activation of downstream signaling pathways that promote cancer cell proliferation and survival.\n\n### Clinical Use:\n- **Indication**: Icotinib is indicated for the treatment of patients with locally advanced or metastatic NSCLC who have specific EGFR mutations (e.g., exon 19 deletions or exon 21 L858R substitution mutations"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_11Vti0hKLkW3SzGMnFBT54Jo", "custom_id": "128_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9b04d3050323a23559cfacc4b1ad9f32", "body": {"id": "chatcmpl-9St5bGGt09IslZ3jkYF2NH1j9yM97", "object": "chat.completion", "created": 1716671975, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idarubicin is an important chemotherapeutic agent used primarily in the treatment of various types of leukemia. Here are key points you should know about Idarubicin as a physician:\n\n### 1. **Mechanism of Action:**\n   - Idarubicin is an anthracycline antibiotic.\n   - It intercalates into DNA, disrupting topoisomerase II activity, which inhibits DNA replication and RNA synthesis, leading to cell death.\n\n### 2. **Indications:**\n   - Primarily used for acute myeloid leukemia (AML).\n   - Also used in acute lymphoblastic leukemia (ALL) and other hematologic malignancies.\n\n### 3. **Administration:**\n   - Administered intravenously.\n   - Dosage varies depending on specific protocols and patient factors (e.g., age, renal function).\n\n### 4. **Side Effects:**\n   - **Cardiotoxicity:** Risk of cumulative dose-dependent cardiotoxicity. Monitor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_YnEMJWmgdmuy8WfwJUzE4OzQ", "custom_id": "129_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "575e23f23895f704bf9ffa36016cc873", "body": {"id": "chatcmpl-9St5bpQcPLZKR5Suek2U3JtrvVpMM", "object": "chat.completion", "created": 1716671975, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idelalisib is an oral medication that is primarily used in the treatment of certain types of blood cancers. Here are key points you should know about Idelalisib:\n\n### Mechanism of Action:\n- Idelalisib is a selective inhibitor of the delta isoform of phosphoinositide 3-kinase (PI3K\u03b4), an enzyme that plays a critical role in the survival, proliferation, and migration of B-cells.\n- By inhibiting PI3K\u03b4, Idelalisib disrupts signaling pathways that are essential for the growth and survival of malignant B-cells.\n\n### Indications:\n- **Chronic Lymphocytic Leukemia (CLL):** Often used in combination with rituximab for patients who have received at least one prior therapy.\n- **Follicular B-cell Non-Hodgkin Lymphoma (FL):** For patients who have received at least two prior systemic therapies.\n- **Small Lymphocytic L"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_1szmwWfvN8Onz6IQK1Uea064", "custom_id": "130_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "3c7c77ea9a694c9eff8d3dff280af11f", "body": {"id": "chatcmpl-9St5b34zmTo7X4PqCr2svtGi5a8SV", "object": "chat.completion", "created": 1716671975, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ifosfamide is an alkylating agent used primarily in the treatment of various cancers. Here are some key points you should be aware of as a physician:\n\n### Indications:\n- **Cancer Types**: Ifosfamide is commonly used to treat testicular cancer, sarcomas, lymphomas, and certain types of lung cancer, among others.\n- **Combination Therapy**: It is often used in combination with other chemotherapy agents to enhance efficacy.\n\n### Mechanism of Action:\n- **DNA Alkylation**: Ifosfamide works by cross-linking DNA strands, which interferes with DNA replication and transcription, ultimately leading to cell death.\n\n### Administration:\n- **Routes**: It is administered intravenously.\n- **Hydration and Mesna**: Adequate hydration and the use of Mesna (a uroprotective agent) are critical to prevent hemorrhagic cystitis, a common side effect.\n\n### Side Effects:\n- **Bone Marrow Suppression"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_FlOyI9oVffS49cU1MRYNAEBh", "custom_id": "131_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d8e843e1b649a6ab0df007851d122623", "body": {"id": "chatcmpl-9St5bjcQQSIHnry4iPSSlHJbrJo3M", "object": "chat.completion", "created": 1716671975, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imatinib, commonly known by its brand name Gleevec, is a tyrosine kinase inhibitor used primarily in the treatment of certain types of cancers. Here are key points that a physician should know about Imatinib:\n\n### Indications\n1. **Chronic Myeloid Leukemia (CML):** Imatinib is most commonly used for the treatment of Philadelphia chromosome-positive CML in chronic phase, accelerated phase, or blast crisis.\n2. **Acute Lymphoblastic Leukemia (ALL):** It is also used for Philadelphia chromosome-positive ALL.\n3. **Gastrointestinal Stromal Tumors (GIST):** Imatinib is used in the treatment of KIT (CD117)-positive unresectable and/or metastatic malignant GIST.\n4. **Other Indications:** It has applications in treating other malignancies, including certain types of myelodysplastic/myeloproliferative diseases, hypereosinophilic syndrome, and dermatofib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_9l0oKlGAjmePwfGX9ThglA0v", "custom_id": "132_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f987c7a7e62403c461b16877b40c7da1", "body": {"id": "chatcmpl-9St5baUa77rOM9ceSOzMgZ6FZ9WhI", "object": "chat.completion", "created": 1716671975, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Infigratinib (brand name Truseltiq) is a tyrosine kinase inhibitor that targets fibroblast growth factor receptor (FGFR) pathways. Here are some key points you should know as a physician:\n\n### Indications\n- Infigratinib is primarily used for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) that has an FGFR2 fusion or rearrangement.\n- Patients must be selected for therapy based on an FDA-approved test.\n\n### Mechanism of Action\n- Infigratinib inhibits FGFR1, FGFR2, and FGFR3, which are involved in cell proliferation, survival, migration, and angiogenesis. By blocking these receptors, infigratinib can help to slow or stop the growth of cancer cells.\n\n### Administration\n- It is administered orally.\n- The recommended dosage is 125 mg once daily for 21 consecutive days followed by "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_9O1hgE8xxTfSir1gqspsS1Uk", "custom_id": "133_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "71e7f006adcf5724f291b814b806daf8", "body": {"id": "chatcmpl-9St5bItUZNRO327ybIxyArdxjVZZV", "object": "chat.completion", "created": 1716671975, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Inotuzumab ozogamicin is an important medication in the field of oncology, specifically for the treatment of certain types of blood cancers. Here are key points you should know about it:\n\n### Mechanism of Action\n- **Antibody-Drug Conjugate (ADC):** Inotuzumab ozogamicin is an ADC, consisting of a monoclonal antibody directed against CD22, a cell surface antigen present on B cells, linked to a cytotoxic agent called calicheamicin.\n- **Targeted Therapy:** The monoclonal antibody binds selectively to CD22-expressing cells, facilitating the internalization of the conjugate. Once inside the cell, the cytotoxic agent is released, inducing DNA breaks and leading to cell death.\n\n### Indications\n- **Acute Lymphoblastic Leukemia (ALL):** It is primarily indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).\n\n### Administration\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_RYdDCcB46AOta4eaZoF1w7Ah", "custom_id": "134_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "be104fe788b36a3849a9f1b43cf0e51d", "body": {"id": "chatcmpl-9St5cKUFjbCtK83bgrZh8bU58oIzi", "object": "chat.completion", "created": 1716671976, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon alfa-2a is a recombinant form of a naturally occurring protein that is part of the immune system. As a physician, there are several important aspects you should know about this medication:\n\n1. **Mechanism of Action**: Interferon alfa-2a exerts its effects by binding to specific receptors on the surface of cells, initiating a complex cascade of intracellular events. This leads to the expression of several genes that inhibit viral replication, enhance immune response, and possess antiproliferative effects.\n\n2. **Indications**:\n   - Chronic Hepatitis B and C: It is used to treat chronic viral hepatitis infections.\n   - Certain Cancers: It can be used in the treatment of certain types of cancers, such as hairy cell leukemia, malignant melanoma, and Kaposi's sarcoma.\n   - Other Conditions: It may also be used for other conditions as determined by a specialist, such as certain hematologic malignancies and condylomata acuminata ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_rOvY6zTmXzuubzR76e0WjCWv", "custom_id": "135_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c5aa0bc881878cca2a8bf90e0c456129", "body": {"id": "chatcmpl-9St5cf3cpnCu37Cs2F5GPGlh65Ya2", "object": "chat.completion", "created": 1716671976, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon alfa-2b is a type of cytokine in the interferon family, primarily used for its antiviral, antiproliferative, and immunomodulatory properties. Here's a detailed overview of what you should know about it as a physician:\n\n### Mechanism of Action\nInterferon alfa-2b binds to specific receptors on the cell surface, initiating a complex signaling cascade that leads to:\n- Inhibition of viral replication within host cells.\n- Activation of natural killer (NK) cells and macrophages.\n- Increased antigen presentation to T lymphocytes.\n- Inhibition of cell proliferation.\n\n### Indications\nInterferon alfa-2b is used in the treatment of various conditions, including:\n- Chronic Hepatitis B and C.\n- Certain types of cancers, such as hairy cell leukemia, malignant melanoma, and follicular lymphoma.\n- Condylomata acuminata (genital warts).\n- Kaposi's sarcoma in patients with HIV/AIDS.\n\n### Administration\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_HrXqGOlvracrJc5bA3qa1xYV", "custom_id": "136_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "fe5967710e4716cc68bf0cd1482d2e0c", "body": {"id": "chatcmpl-9St5cuiPb9wbvsS0MorUej9WB52cw", "object": "chat.completion", "created": 1716671976, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon gamma-1b is a medication and an important immunomodulatory cytokine. Here\u2019s a summary of key points you should know about it:\n\n### Mechanism of Action:\n- **Immune Modulation:** Interferon gamma-1b enhances the immune system\u2019s ability to fight infections and certain diseases. It activates macrophages, increases antigen presentation, and promotes Th1 immune responses.\n- **Antiviral and Antitumor Effects:** It has antiviral properties and can inhibit tumor growth by enhancing the cytotoxic activity of natural killer cells and macrophages.\n\n### Indications:\n- **Chronic Granulomatous Disease (CGD):** It is used to reduce the frequency and severity of serious infections in patients with CGD.\n- **Severe, Malignant Osteopetrosis:** It is indicated to delay disease progression in patients with this condition.\n\n### Administration:\n- **Route:** Interferon gamma-1b is administered via subcutaneous injection.\n- **Dos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_MM3ZUI0jdO75CwaOhIQfiOPM", "custom_id": "137_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6d8556b14d0a3fd1f39e211a69358958", "body": {"id": "chatcmpl-9St5cBxpeLCCnAUw6XLh5Pjt6Yc6d", "object": "chat.completion", "created": 1716671976, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ipilimumab is a monoclonal antibody used in the treatment of certain types of cancer. Here are key points you should know about it:\n\n### Mechanism of Action\n- **Immune Checkpoint Inhibitor**: Ipilimumab targets CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4), a protein receptor that downregulates the immune system.\n- **Immune Activation**: By inhibiting CTLA-4, ipilimumab enhances the immune response against cancer cells.\n\n### Indications\n- **Melanoma**: Approved for the treatment of unresectable or metastatic melanoma.\n- **Renal Cell Carcinoma**: Used in combination with nivolumab for certain cases.\n- **Colorectal Cancer**: In combination with nivolumab for microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) cancers.\n- **Other Cancers**: Investigational use in various"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_s9x13Yh5VsjKENcYTF7PnvgS", "custom_id": "138_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f5f7d1315ab747f2d42756d6dd3c88cb", "body": {"id": "chatcmpl-9St5cpIfCiypAYCLstTRxTEal3lN5", "object": "chat.completion", "created": 1716671976, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Irinotecan is a chemotherapeutic agent commonly used in the treatment of various cancers, most notably colorectal cancer. Here are key points you should know about Irinotecan:\n\n### Mechanism of Action\n- **Topoisomerase I Inhibition**: Irinotecan works by inhibiting the enzyme topoisomerase I, which is essential for DNA replication. By interfering with this enzyme, Irinotecan causes DNA damage and prevents cancer cells from proliferating.\n\n### Indications\n- **Colorectal Cancer**: Often used in combination with other chemotherapeutic agents such as 5-fluorouracil and leucovorin (FOLFIRI regimen).\n- **Other Cancers**: May also be used for small cell lung cancer, gastric cancer, and others, depending on the context and specific clinical guidelines.\n\n### Administration\n- **Intravenous Infusion**: Usually administered as an IV infusion, either as a single agent or in combination with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Jv9fdslN9gw0GiDb1CNel2O5", "custom_id": "139_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "383282f46b73ae6fa62b86811abd8aa9", "body": {"id": "chatcmpl-9St5dcoqJuB57kpARqk6hX0zA6FD4", "object": "chat.completion", "created": 1716671977, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Irinotecan liposome, also known as liposomal irinotecan or by its brand name, Onivyde, is a formulation of the chemotherapy drug irinotecan encapsulated in a liposome. This formulation is specifically designed to enhance the delivery of irinotecan to tumor cells, improve its pharmacokinetic profile, and reduce its systemic toxicity.\n\nHere are some key points a physician should know about irinotecan liposome:\n\n### Indications:\n1. **Pancreatic Cancer**: Irinotecan liposome is approved for use in combination with fluorouracil (5-FU) and leucovorin for the treatment of metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.\n\n### Mechanism of Action:\n- **Topoisomerase I Inhibition**: Irinotecan is a prodrug that is metabolized to its active form, SN-38. SN-38 inhibits topoisomerase I, an enzyme"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_3s84e15dBNZTVstuMLaWqTPw", "custom_id": "140_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f8995aa3ef6dd3380122ee351882cf73", "body": {"id": "chatcmpl-9St5dPw6yUCTfhpWubPnWB9gsqAqt", "object": "chat.completion", "created": 1716671977, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Isatuximab is a monoclonal antibody used in the treatment of multiple myeloma, a type of cancer that forms in plasma cells. Here are some key points you should know about Isatuximab:\n\n### Mechanism of Action\n- **Target:** Isatuximab targets CD38, a protein widely expressed on the surface of multiple myeloma cells.\n- **Action:** It works through multiple mechanisms, including direct anti-tumor activity, immune-mediated cell killing, and modulation of the tumor microenvironment.\n\n### Indications\n- **Combination Therapy:** Isatuximab is often used in combination with other drugs such as pomalidomide and dexamethasone, particularly for patients who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.\n\n### Administration\n- **Intravenous Infusion:** Isatuximab is administered via intravenous infusion, typically in a healthcare setting.\n- **D"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_h2Jd1F5572SMCp9TBEjcoEce", "custom_id": "141_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "387be6b119befc2a343e9584f4865431", "body": {"id": "chatcmpl-9St5d032CAqoJwuvJWQ50xNQ9MhSv", "object": "chat.completion", "created": 1716671977, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's essential to have a comprehensive understanding of isotretinoin, commonly known by its former brand name Accutane, which is a powerful medication primarily used to treat severe acne that has not responded to other treatments. Here are some key points to consider:\n\n### Mechanism of Action\n- **Retinoid Derivative**: Isotretinoin is a retinoid, derived from vitamin A, and works primarily by reducing sebaceous gland size and sebum production, leading to decreased bacterial growth and inflammation.\n- **Keratinization**: It also normalizes the differentiation of follicular epithelial cells, preventing comedone formation.\n\n### Indications\n- **Severe Nodular Acne**: Most commonly prescribed for severe, recalcitrant nodular acne.\n- **Other Uses**: Sometimes used off-label for conditions like rosacea, hidradenitis suppurativa, and certain skin cancers.\n\n### Dosage and Administration\n- **Individualized Dosing**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_0oww1V5L882kr4Le83M6dokG", "custom_id": "142_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "bba516be32f24a9148048cfcdf07dea3", "body": {"id": "chatcmpl-9St5dD3IHW6ShkAZzH7Kd19cGeP1p", "object": "chat.completion", "created": 1716671977, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ivosidenib is an important medication that you should be familiar with, especially if you are involved in the treatment of certain types of cancer. Here are key points to understand about Ivosidenib:\n\n### Indications:\n- **Acute Myeloid Leukemia (AML):** Ivosidenib is primarily used for the treatment of adult patients with relapsed or refractory AML who have a susceptible isocitrate dehydrogenase-1 (IDH1) mutation, as detected by an FDA-approved test.\n- **Newly Diagnosed AML:** It is also indicated for adults with newly diagnosed AML who are \u226575 years old or who have comorbidities that preclude the use of intensive induction chemotherapy.\n\n### Mechanism of Action:\n- **IDH1 Inhibition:** Ivosidenib is a targeted therapy that inhibits the IDH1 enzyme. Mutations in IDH1 result in the production of an oncometabolite called 2-hydroxygl"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_dqhnMGTGEwg5hYKVgKY7sEYv", "custom_id": "143_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e999cd6df19fc9029a03e39da52990c7", "body": {"id": "chatcmpl-9St5d1Q7ZvrwppOHOsJGLym3XlwIM", "object": "chat.completion", "created": 1716671977, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ixabepilone is an antineoplastic agent used primarily in the treatment of metastatic or locally advanced breast cancer. It belongs to a class of drugs known as epothilone analogs and works by stabilizing microtubules, which disrupts mitotic spindle formation and ultimately inhibits cancer cell division.\n\nHere are some key points you should know about Ixabepilone:\n\n1. **Indications**: \n   - Ixabepilone is approved for use in combination with capecitabine for patients with metastatic or locally advanced breast cancer who are resistant to or have failed previous anthracycline and taxane therapy.\n   - It can also be used as monotherapy for patients whose tumors are resistant to anthracyclines, taxanes, and capecitabine.\n\n2. **Mechanism of Action**:\n   - Ixabepilone binds to \u03b2-tubulin subunits on microtubules, stabilizing them and preventing their disassembly"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_nCjABUdYd4f6y94guSQOqqiD", "custom_id": "144_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "854f0d600790c429e94819491a822084", "body": {"id": "chatcmpl-9St5dg1eCSKQMAezrIJ0rfub0vYdb", "object": "chat.completion", "created": 1716671977, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ixazomib is a medication primarily used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Here are some key points you should know about Ixazomib:\n\n### Mechanism of Action\n- **Proteasome Inhibitor:** Ixazomib is a proteasome inhibitor, which means it works by blocking the proteasome, a complex that degrades unneeded or damaged proteins within the cell. By inhibiting this process, Ixazomib causes an accumulation of proteins within cells, leading to cell death, particularly in rapidly dividing cancer cells.\n\n### Indications\n- **Multiple Myeloma:** Ixazomib is indicated for the treatment of multiple myeloma in combination with lenalidomide and dexamethasone, particularly in patients who have received at least one prior therapy.\n\n### Administration\n- **Oral Formulation:** Ixazomib is taken orally, typically once a week on"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_QHrYY2936TZPfmwDydKoKDLu", "custom_id": "145_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "936e54f1ecdcc71ff412a43a2a402921", "body": {"id": "chatcmpl-9St5d9ZMfmxBLBSkvDdpIxoTBOiCW", "object": "chat.completion", "created": 1716671977, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ketoconazole is an antifungal medication that is used to treat a variety of fungal infections. Here are some important aspects you should know about Ketoconazole as a physician:\n\n### Mechanism of Action\n- **Inhibition of Ergosterol Synthesis:** Ketoconazole works by inhibiting the synthesis of ergosterol, a crucial component of fungal cell membranes. This leads to increased membrane permeability and ultimately the death of the fungal cell.\n\n### Indications\n- **Topical Forms:** Used for treating fungal infections of the skin such as tinea corporis (ringworm), tinea cruris (jock itch), tinea pedis (athlete's foot), and seborrheic dermatitis.\n- **Oral Forms:** Indicated for systemic fungal infections such as blastomycosis, histoplasmosis, and coccidioidomycosis. However, its use has declined due to the availability of newer antifungals with better safety profiles.\n\n### Pharmacokinetics\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_17fZXK0hjcnLq0h02QAJkOPC", "custom_id": "146_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "07034162d8d2e5ac377b26658410bcab", "body": {"id": "chatcmpl-9St5dCWqhit0ks4CuHihkvD6wWNhG", "object": "chat.completion", "created": 1716671977, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lanreotide is a medication primarily used in the treatment of acromegaly and symptoms associated with neuroendocrine tumors, particularly those of the gastrointestinal tract and pancreas. Here are some key points you should know about Lanreotide:\n\n### Mechanism of Action\n- **Somatostatin Analog**: Lanreotide is a long-acting somatostatin analog. It works by mimicking the action of somatostatin, a hormone that inhibits the release of several other hormones, including growth hormone (GH) and insulin-like growth factor 1 (IGF-1).\n- **Hormone Secretion Inhibition**: By inhibiting GH and IGF-1, Lanreotide helps control symptoms and progression in conditions like acromegaly. It also reduces the secretion of various peptides and bioamines that can contribute to the symptoms of neuroendocrine tumors.\n\n### Indications\n- **Acromegaly**: Used in patients who have had an inadequate"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_TLFMGQhn26S56moi6kBjCGDI", "custom_id": "147_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d7b064c954d89e7898b906ab677de50b", "body": {"id": "chatcmpl-9St5diKC2m774cFAfAQEOTDIde82b", "object": "chat.completion", "created": 1716671977, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lansoprazole is a proton pump inhibitor (PPI) that is commonly prescribed to treat conditions involving excessive stomach acid. As a physician, it's important to be familiar with the following aspects of Lansoprazole:\n\n### Indications:\n1. **Gastroesophageal Reflux Disease (GERD)**: Reduces heartburn and other symptoms.\n2. **Peptic Ulcer Disease**: Promotes healing of ulcers in the stomach and duodenum.\n3. **Erosive Esophagitis**: Helps heal damage to the esophagus from stomach acid.\n4. **Zollinger-Ellison Syndrome**: Manages excessive acid production conditions.\n5. **Helicobacter pylori Infection**: Often used in combination with antibiotics for eradication.\n\n### Mechanism of Action:\n- Lansoprazole inhibits the H+/K+ ATPase enzyme (the proton pump) in the parietal cells of the stomach, effectively reducing gastric acid secretion.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_BIPw4YMFL7kIZZ6H63cIvrHk", "custom_id": "148_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e2e1698a73f34af849050f94303dc708", "body": {"id": "chatcmpl-9St5egWxVnv6vjfwrcUh4idFmtCeM", "object": "chat.completion", "created": 1716671978, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lapatinib is a tyrosine kinase inhibitor used primarily in the treatment of certain types of breast cancer. Here are some key points you should know about Lapatinib:\n\n### Indications\n- **Breast Cancer**: Lapatinib is often used in combination with other medications, such as capecitabine or letrozole, for the treatment of HER2-positive metastatic breast cancer. It is particularly useful in patients who have received prior therapy, including an anthracycline, a taxane, and trastuzumab.\n\n### Mechanism of Action\n- **Dual Inhibition**: Lapatinib inhibits both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases. This dual inhibition can help reduce tumor cell proliferation in cancers overexpressing these receptors.\n\n### Administration\n- **Oral**: Lapatinib is administered orally and should be taken on an empty stomach,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ehexgs1Uj22qFSobvl019Xzm", "custom_id": "149_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9cdd98e30f278c17e0ca212fc74f79e8", "body": {"id": "chatcmpl-9St5e7NNXE8W3JZ0OfIGYu1OPOEfC", "object": "chat.completion", "created": 1716671978, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Larotrectinib is a targeted cancer therapy that is primarily indicated for the treatment of solid tumors harboring a neurotrophic receptor tyrosine kinase (NTRK) gene fusion. Here are some key points you should know about Larotrectinib:\n\n### Mechanism of Action\n- **Targeted Therapy:** Larotrectinib is a selective TRK inhibitor. It works by inhibiting the TRK fusion proteins that drive tumor growth in cancers with NTRK gene fusions.\n\n### Indications\n- **Tumor-Agnostic Therapy:** Larotrectinib is approved for use in adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. It is meant for cases where:\n  - The cancer is metastatic or where surgical resection is likely to result in severe morbidity.\n  - There are no satisfactory alternative treatments or the cancer has progressed following treatment.\n\n### Efficacy\n- **Clinical Trials:** Clinical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_z73BUwqhypxofNfmTvu6x6qG", "custom_id": "150_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d2b4e01a80fb87864157f70e8e44428c", "body": {"id": "chatcmpl-9St5eGYJRCdPeOsIEOMCBBLJAcrK3", "object": "chat.completion", "created": 1716671978, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lenalidomide is a medication primarily used to treat certain hematological malignancies and conditions such as multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma. As a physician, you should be aware of several key aspects of lenalidomide:\n\n### Mechanism of Action\nLenalidomide has multiple mechanisms of action, including:\n- Immunomodulatory effects: Enhances T cell and NK cell activation, and increases cytokine production.\n- Anti-angiogenic properties: Inhibits the growth of new blood vessels that tumors need to grow.\n- Direct anti-tumor effects: Induces apoptosis and inhibits proliferation of malignant cells.\n\n### Indications\nLenalidomide is FDA-approved for:\n- Multiple myeloma (often in combination with dexamethasone or other agents)\n- Myelodysplastic syndromes, specifically those with deletion 5q cytogenetic abnormality\n- Mantle cell lymphoma after at least one prior"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_JbtOfEBFKGs5EHjp3XQOCsio", "custom_id": "151_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c67e058f91f2100f1701050bd4dc38a7", "body": {"id": "chatcmpl-9St5e9VSF19q7ZGT6z124V3CM9fYm", "object": "chat.completion", "created": 1716671978, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lenograstim is a recombinant human granulocyte colony-stimulating factor (rhG-CSF) used primarily to stimulate the production of white blood cells, particularly neutrophils, in patients who have neutropenia. Here are some key points you should know about Lenograstim:\n\n### Indications:\n1. **Chemotherapy-Induced Neutropenia**: To reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving cytotoxic chemotherapy.\n2. **Bone Marrow Transplantation**: To reduce the duration of neutropenia and its complications in patients undergoing bone marrow transplantation.\n3. **Peripheral Blood Progenitor Cell Mobilization**: To mobilize peripheral blood progenitor cells for collection and subsequent autologous or allogeneic transplantation.\n4. **Severe Chronic Neutropenia**: For the treatment of severe congenital, cyclic, or idiopathic neutropenia.\n\n### Mechanism of Action:\nLenogr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Vkpa64crEvDtxfegUS9j8H8v", "custom_id": "152_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "aaff0c7a091e1f9f86034b23920f7e28", "body": {"id": "chatcmpl-9St5eWEpFZSkmbZ1Pq0P29EHUUI4Q", "object": "chat.completion", "created": 1716671978, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lenvatinib is a multi-targeted tyrosine kinase inhibitor used in the treatment of certain types of cancer. Here are key points that a physician should know about Lenvatinib:\n\n### Indications:\n1. **Differentiated Thyroid Cancer (DTC)**: For patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC.\n2. **Renal Cell Carcinoma (RCC)**: In combination with everolimus for patients with advanced RCC who have received prior anti-angiogenic therapy.\n3. **Hepatocellular Carcinoma (HCC)**: For first-line treatment of patients with unresectable HCC.\n4. **Endometrial Carcinoma**: In combination with pembrolizumab for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for cur"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_cBhqTsXMLB2VhXuSh4jllgyT", "custom_id": "153_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2d3ab6bb2b548b5b555c964ba574368d", "body": {"id": "chatcmpl-9St5eLaGPg3QGGkZFbPKq9J5Mb3UQ", "object": "chat.completion", "created": 1716671978, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Letrozole is a medication that belongs to the class of drugs known as aromatase inhibitors. It is commonly used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Here are some key aspects of Letrozole that you should be aware of as a physician:\n\n### Mechanism of Action\n- **Aromatase Inhibition**: Letrozole works by inhibiting the enzyme aromatase, which is responsible for the conversion of androgens to estrogens. This reduction in estrogen levels can help slow or reverse the growth of estrogen receptor-positive breast cancers.\n\n### Indications\n- **Breast Cancer**: Letrozole is primarily indicated for the adjuvant treatment of hormone receptor-positive early breast cancer, extended adjuvant treatment after 5 years of tamoxifen therapy, and for the first-line treatment of hormone receptor-positive or unknown metastatic breast cancer.\n- **Fertility Treatment** (Off-label): Letrozole is sometimes"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_r69h1kJyjMcXjchpiUYPqasT", "custom_id": "154_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "22b2e3c7d10be1cb284c6f1454873fc9", "body": {"id": "chatcmpl-9St5f0n92XNLASHvZXIxy3680kBSR", "object": "chat.completion", "created": 1716671979, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Leuprolide is a synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH or LHRH) that is used primarily in the treatment of hormone-responsive cancers such as prostate cancer, breast cancer, and certain conditions like endometriosis and uterine fibroids. Here are several key points you should know about Leuprolide:\n\n### Mechanism of Action\n- **Initial Stimulation**: Initially, Leuprolide stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland.\n- **Subsequent Suppression**: With continuous administration, it downregulates the GnRH receptors in the pituitary, leading to a significant decrease in LH and FSH secretion. This results in reduced production of sex steroids (testosterone in men and estrogen in women).\n\n### Indications\n- **Prostate Cancer**: Used in advanced prostate cancer to reduce testosterone levels.\n- **Bre"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_OsoDNpKjKZColdL1tN1EAl0H", "custom_id": "155_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "01e2f3b74bfe71de1eff5279b3a2151d", "body": {"id": "chatcmpl-9St5fKvgeGLfIyzEKTG9F0ggiHLqN", "object": "chat.completion", "created": 1716671979, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Levamisole is an anthelmintic and immunomodulatory agent that has been used in both humans and animals. Here are several key points you should know about Levamisole:\n\n### Medical Uses:\n1. **Anthelmintic Agent**: Levamisole was originally used to treat parasitic worm infections, especially those caused by nematodes.\n2. **Immunomodulator**: In the past, Levamisole has been used as an immunomodulatory agent in various autoimmune diseases and certain cancers, such as colorectal cancer, in combination with other chemotherapeutic agents. However, its use has diminished over time due to safety concerns.\n\n### Mechanism of Action:\n1. **Anthelmintic Action**: Levamisole works by stimulating the nicotinic acetylcholine receptors at the neuromuscular junction of the parasites, causing paralysis and subsequent expulsion of the worms.\n2. **Immunomodulatory Action**: The exact mechanism is not fully"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_PY2GCsav2QqzDLcad8FRyPp1", "custom_id": "156_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5deb5424f08c6ad9145af9be3935155b", "body": {"id": "chatcmpl-9St5fHX1oqGhchY8sTXt3Aou8AT4f", "object": "chat.completion", "created": 1716671979, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Levoleucovorin, also known as levofolinic acid or by its brand name Fusilev, is the active enantiomer of leucovorin, which is a derivative of folic acid. It is commonly used in oncology and in other medical contexts. Here are some key points that you should know about levoleucovorin:\n\n### Indications\n1. **Methotrexate Rescue**: Levoleucovorin is often used to reduce the toxic effects of high-dose methotrexate therapy in cancer treatment. It \"rescues\" normal cells by supplying a source of folate, counteracting the folate-antagonist effects of methotrexate.\n2. **Colorectal Cancer**: It is used in combination with 5-fluorouracil (5-FU) in the treatment of advanced colorectal cancer. Levoleucovorin enhances the efficacy of 5-FU by stabilizing the bond between 5-FU and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_zviMeBtgDI8FeBI67PDLarZJ", "custom_id": "157_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "4a6e97ef98ed5cbe9a87280a8c5ad0c7", "body": {"id": "chatcmpl-9St5fIRyxq4VIXpROrYX6TxC9fCHe", "object": "chat.completion", "created": 1716671979, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lomustine, also known by its brand name CeeNU and chemical name CCNU, is an alkylating agent used in chemotherapy. As a physician, there are several key aspects you should be aware of regarding Lomustine:\n\n### Indications\n- **Primary Use**: Lomustine is primarily used to treat brain tumors, including glioblastoma multiforme and other malignant gliomas.\n- **Other Uses**: It is also used for Hodgkin's lymphoma that has relapsed or is refractory to other treatments. Occasionally, it may be used off-label for other types of cancer.\n\n### Mechanism of Action\n- **Alkylating Agent**: Lomustine interferes with DNA replication and RNA transcription by alkylating DNA, which ultimately leads to cell death. It is cell-cycle nonspecific.\n- **Lipid Solubility**: Lomustine is highly lipid-soluble, which allows it to cross the blood-brain barrier effectively, making"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_sNVFnY5HAnDzGsY4uqhbZtZY", "custom_id": "158_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "78e13fa10e7aa8c202058c3ae2b6ec66", "body": {"id": "chatcmpl-9St5fmHqVqmDVV0AdPrlZT8F8Nwrw", "object": "chat.completion", "created": 1716671979, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lorlatinib is a targeted therapy drug used primarily for the treatment of non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK) or ROS1 gene rearrangements. Here are some key points you should know about Lorlatinib:\n\n### Mechanism of Action:\n- **Inhibitor:** Lorlatinib is a potent inhibitor of ALK and ROS1 tyrosine kinases.\n- **Target:** It specifically targets and inhibits the activity of ALK and ROS1 fusion proteins, which are involved in the growth and survival of cancer cells.\n\n### Indications:\n- **ALK-positive NSCLC:** Lorlatinib is indicated for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to prior ALK tyrosine kinase inhibitor (TKI) therapy.\n- **ROS1-positive NSCLC:** It is also indicated for patients with ROS1-positive NSCLC.\n\n### Administration:\n- **Oral Drug:** Lor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_9TrmPMxHNfe0RdWlXdA5AgJk", "custom_id": "159_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c5959a340424780a060b8096c38f9001", "body": {"id": "chatcmpl-9St5fP20xhRoxdYhBwOf2vBQzCDFX", "object": "chat.completion", "created": 1716671979, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lutetium Lu 177 dotatate (also known by its brand name Lutathera) is a radiolabeled somatostatin analog used in the treatment of specific types of neuroendocrine tumors (NETs). Here are some key points you should know about it:\n\n### Indications:\n- Lutetium Lu 177 dotatate is primarily indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including tumors originating in the foregut, midgut, and hindgut.\n\n### Mechanism of Action:\n- Lutetium Lu 177 dotatate works by binding to somatostatin receptors, which are commonly overexpressed in certain types of neuroendocrine tumors.\n- Once bound, the radiolabeled compound delivers targeted radiation to the tumor cells, thereby killing them or inhibiting their growth.\n\n### Administration:\n- It is administered via intravenous infusion.\n- The standard dosing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_dXAiedxLTy1lOWSXKZbrfyv2", "custom_id": "160_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2ff9707f45a2263f270b1b1b0375d647", "body": {"id": "chatcmpl-9St5g2uJtmNDrxhpin3GdEQokZVce", "object": "chat.completion", "created": 1716671980, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tafasitamab (brand name Monjuvi) is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. It is used primarily in the treatment of certain types of B-cell malignancies, particularly relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with lenalidomide, and is followed by monotherapy in patients who are not eligible for autologous stem cell transplantation (ASCT).\n\nHere are some key points you should know about Tafasitamab:\n\n1. **Mechanism of Action**: Tafasitamab targets the CD19 antigen, which is expressed on the surface of B-cells. It induces cell death through several mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and direct induction of apoptosis.\n\n2. **Indications**: Tafasitamab is indicated for adult patients with relapsed or refractory DLBCL not otherwise specified,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_IGkLzKLN5IO9Q78W9xUXcBNR", "custom_id": "161_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9f14332c7b63a11ecba9b67e45fdfb85", "body": {"id": "chatcmpl-9St5grgC0O34OLn0Eha0xvXcgsmSD", "object": "chat.completion", "created": 1716671980, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mechlorethamine, also known as nitrogen mustard, is a chemotherapeutic agent primarily used in the treatment of certain types of cancer, such as Hodgkin's lymphoma, non-Hodgkin's lymphoma, and mycosis fungoides (a type of cutaneous T-cell lymphoma). Here are key points a physician should know about Mechlorethamine:\n\n### Mechanism of Action\n- **Alkylating Agent**: Mechlorethamine is an alkylating agent that works by cross-linking DNA strands, which inhibits DNA replication and transcription, leading to cell death. This is particularly effective against rapidly dividing cancer cells.\n\n### Administration\n- **Routes**: It can be administered intravenously (IV) or topically (for cutaneous T-cell lymphoma).\n- **Preparation and Handling**: Due to its vesicant properties, it must be handled with care to avoid skin contact and inhalation. Proper protective equipment should be used during preparation and administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_JkKYquDNlET1IoXzguwnbaCe", "custom_id": "162_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "abb9d9b3c3c672ca822a047264c91184", "body": {"id": "chatcmpl-9St5gron7Hdj58vvuddqVRrJteiou", "object": "chat.completion", "created": 1716671980, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Medroxyprogesterone is a synthetic progestin, a type of hormone. It is used in various medical contexts, including hormone replacement therapy, contraception, and the treatment of certain menstrual disorders. Here are some key points you should know as a physician:\n\n1. **Mechanism of Action**: Medroxyprogesterone works by mimicking the effects of natural progesterone. It regulates ovulation and menstrual cycles, suppresses gonadotropin secretion, and alters the endometrium to prevent implantation.\n\n2. **Indications**:\n   - **Contraception**: Medroxyprogesterone acetate (MPA) is used as an injectable contraceptive (Depo-Provera) for long-term prevention of pregnancy.\n   - **Menstrual Disorders**: It is prescribed for abnormal uterine bleeding, amenorrhea, and endometriosis.\n   - **Hormone Replacement Therapy (HRT)**: It is used alongside estrogen in women who have not undergone"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_dQQhvV4qYJZ03UniejBn1KWU", "custom_id": "163_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "568e74accb499d43d4fe512a7da9091f", "body": {"id": "chatcmpl-9St5gUHeh1mH5pCjLa9KRLedpIFQY", "object": "chat.completion", "created": 1716671980, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Megestrol acetate is a synthetic progestin with diverse clinical applications. Here are some key points you should know about Megestrol:\n\n1. **Indications**:\n   - **Cancer**: Primarily used in the palliative treatment of advanced breast cancer and endometrial cancer. It can help in managing hormone-responsive tumors by competing for hormone receptor sites.\n   - **Appetite Stimulant**: Commonly used to stimulate appetite and promote weight gain in patients with significant weight loss, such as those with AIDS or cancer.\n\n2. **Mechanism of Action**:\n   - Megestrol works by mimicking the hormone progesterone, exerting progestational and antigonadotropic effects, which can influence hormone-dependent tumors.\n   - It may also have glucocorticoid-like effects, which contribute to its appetite-stimulating properties.\n\n3. **Dosage**:\n   - **For cancer**: The typical dosage ranges from 40 mg to 320"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_KZ6LmcLIM8faBbTHRRISt6Nq", "custom_id": "164_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c7c38321b4f91fcb162fb06815cb0587", "body": {"id": "chatcmpl-9St5gCVofUecl4pnNJQHngIU3bHhZ", "object": "chat.completion", "created": 1716671980, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Melphalan is an alkylating chemotherapeutic agent primarily used in the treatment of multiple myeloma and ovarian cancer. Here are several key points you should know about Melphalan:\n\n### Mechanism of Action:\n- **Alkylating Agent**: Melphalan works by cross-linking DNA strands, which inhibits DNA replication and RNA transcription, ultimately leading to cell death. This mechanism is particularly effective against rapidly dividing cancer cells.\n\n### Indications:\n- **Multiple Myeloma**: Melphalan is often used in combination with other drugs for the treatment of multiple myeloma.\n- **Ovarian Cancer**: It is also used in the treatment of advanced ovarian carcinoma.\n- **Other Uses**: Occasionally, it may be used for other malignancies such as melanoma and amyloidosis, though these are off-label uses.\n\n### Administration:\n- **Forms**: It can be administered orally or intravenously. The choice of administration route depends on the specific clinical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_s8Osw6fdYuFSYoL4JaLCPA4V", "custom_id": "165_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d57b916a722e33c990ee7f725c5df2b6", "body": {"id": "chatcmpl-9St5gJPQdGArfhu7tNub3YqcV5J1v", "object": "chat.completion", "created": 1716671980, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mercaptopurine, also known as 6-mercaptopurine or 6-MP, is an important medication used primarily in the treatment of certain types of cancer and autoimmune diseases. Here are key points you should know as a physician:\n\n### Indications\n1. **Acute Lymphoblastic Leukemia (ALL)**: It's a standard component of maintenance therapy.\n2. **Chronic Myeloid Leukemia (CML)**: Used less commonly now due to the advent of tyrosine kinase inhibitors.\n3. **Inflammatory Bowel Disease (IBD)**: Including Crohn's disease and ulcerative colitis, often as a steroid-sparing agent.\n\n### Mechanism of Action\n- Mercaptopurine is a purine analog that interferes with DNA and RNA synthesis. It is converted intracellularly to thioinosine monophosphate (TIMP), which inhibits several enzymes involved in purine metabolism, ultimately leading to cytotoxicity in rapidly"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Tycrh71yBiwF6bYdLQGvnvTx", "custom_id": "166_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f3c17345394fb741810f380314f2082b", "body": {"id": "chatcmpl-9St5gFHzjRZ0quDzmqpqoqSaYRlwL", "object": "chat.completion", "created": 1716671980, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mesna (2-mercaptoethane sulfonate sodium) is a medication commonly used in oncology to protect the bladder lining from the harmful effects of certain chemotherapy drugs, particularly ifosfamide and cyclophosphamide. Here are some key points you should know about Mesna:\n\n### Mechanism of Action:\n- **Chemoprotective Agent:** Mesna works by binding to and neutralizing acrolein, a toxic metabolite of ifosfamide and cyclophosphamide, which can cause hemorrhagic cystitis (bleeding and inflammation of the bladder).\n\n### Indications:\n- **Hemorrhagic Cystitis Prevention:** It is primarily used prophylactically to prevent hemorrhagic cystitis in patients receiving high-dose ifosfamide or cyclophosphamide.\n  \n### Administration:\n- **Intravenous or Oral:** Mesna can be administered intravenously or orally. The dosing regimen usually involves multiple doses to ensure continuous protection, as Mesna has"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_S7IYA9jfIzECsNeoXrcRcAPI", "custom_id": "167_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "50d89de313965d635e14656a97d8e8dc", "body": {"id": "chatcmpl-9St5hzWs8mYWgxqXH6X0ojDWA0poN", "object": "chat.completion", "created": 1716671981, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Methotrexate is a medication with a wide range of uses but also significant potential for adverse effects. Below are key points a physician should know about methotrexate:\n\n### Indications:\n1. **Rheumatology:**\n   - Rheumatoid arthritis (RA)\n   - Juvenile idiopathic arthritis\n   - Psoriatic arthritis\n\n2. **Dermatology:**\n   - Severe psoriasis\n\n3. **Oncology:**\n   - Various cancers, including leukemia, lymphoma, and breast cancer\n\n4. **Gastroenterology:**\n   - Crohn's disease (off-label)\n\n### Mechanism of Action:\n- Methotrexate is a folate antagonist. It inhibits dihydrofolate reductase, interfering with DNA synthesis, repair, and cellular replication. This mechanism is beneficial in conditions with rapid cell turnover or immune activation.\n\n### Dosing Considerations:\n- **RA and psoriasis:** Typically given once a week, either orally or via subcutaneous"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_tCOx607CtEbC4tJXdCek1NF7", "custom_id": "168_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f301392ef0698b2802ebbee6874c4b79", "body": {"id": "chatcmpl-9St5hL9SUt4iFVOURdRk1iNQOlTM0", "object": "chat.completion", "created": 1716671981, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Methoxsalen, also known as 8-methoxypsoralen, is a medication primarily used in conjunction with UVA light therapy (PUVA therapy) to treat skin conditions such as psoriasis, vitiligo, and some types of cutaneous T-cell lymphoma. Here are several key points you should know about Methoxsalen:\n\n### Mechanism of Action\n- **Photosensitizer**: Methoxsalen sensitizes the skin to ultraviolet A (UVA) light. Upon exposure to UVA, Methoxsalen intercalates into DNA, forming cross-links and inhibiting DNA synthesis and cell proliferation, which is beneficial in hyperproliferative skin conditions.\n\n### Indications\n- **Psoriasis**: Effective in reducing lesions and symptoms.\n- **Vitiligo**: Can help repigment the skin by stimulating melanocytes.\n- **Cutaneous T-cell lymphoma**: Used as part of a treatment regimen.\n\n### Administration\n- **Oral Form"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Z3vRp5H4izT8bSn3zvkvqKTy", "custom_id": "169_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "92d3275f397e42b4092d29f74cdedfd2", "body": {"id": "chatcmpl-9St5hjBj04SdjgOiCnfIMxmuxsfDt", "object": "chat.completion", "created": 1716671981, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Methylprednisolone is a synthetic corticosteroid used to reduce inflammation and suppress the immune system. Here are some key points you should know about it:\n\n### Indications:\n1. **Anti-inflammatory:** Used for conditions like arthritis, lupus, psoriasis, and allergic reactions.\n2. **Immunosuppressive:** Used in autoimmune diseases and to prevent organ transplant rejection.\n3. **Endocrine Disorders:** Management of certain conditions like adrenal insufficiency.\n4. **Respiratory Conditions:** Asthma, COPD exacerbations.\n5. **Dermatologic Diseases:** Severe skin conditions.\n6. **Other:** Acute spinal cord injuries, certain types of cancer.\n\n### Mechanism of Action:\n- Methylprednisolone works by mimicking the effects of cortisol, a naturally occurring hormone produced by the adrenal glands. It reduces inflammation by inhibiting multiple inflammatory cytokines and suppresses the immune system by decreasing the activity of the immune cells.\n\n### Forms and Dosage:\n- Available in oral"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_oUnpoD4kZYIVxonbHecBY6zp", "custom_id": "170_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "21de833c00acbf57ee83cd6ba4d660f9", "body": {"id": "chatcmpl-9St5hLefay4Kpt7WnJHGjDRdWXOps", "object": "chat.completion", "created": 1716671981, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Midostaurin is a multi-targeted kinase inhibitor used in the treatment of certain types of cancer, specifically acute myeloid leukemia (AML) and advanced systemic mastocytosis. Here are key points you should be aware of:\n\n### Indications and Usage\n1. **Acute Myeloid Leukemia (AML)**: Midostaurin is approved for use in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for adult patients with newly diagnosed FLT3-mutated AML, as detected by an FDA-approved test.\n2. **Advanced Systemic Mastocytosis**: This includes aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), and mast cell leukemia.\n\n### Mechanism of Action\n- **Kinase Inhibition**: Midostaurin inhibits multiple receptor tyrosine kinases, including FLT3, KIT, PDGFR, VEGFR, and others."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_P8qbvYe7PJsFNXwrBqp31qQY", "custom_id": "171_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a3ed4635319ad99e9ab0a4e307bc5914", "body": {"id": "chatcmpl-9St5hRlH5K70v6wJ624ey4kswp4pK", "object": "chat.completion", "created": 1716671981, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mitomycin is an antineoplastic antibiotic that is primarily used as a chemotherapeutic agent. Here\u2019s a detailed overview of what you should know about Mitomycin:\n\n### Mechanism of Action\n- **DNA Cross-Linking**: Mitomycin is an alkylating agent that cross-links DNA, inhibiting DNA synthesis and function. This leads to cell death, particularly in rapidly dividing cells, which makes it effective against certain types of cancer.\n\n### Indications\n- **Cancer Treatment**: Mitomycin is used to treat various types of cancers, including:\n  - Gastric cancer\n  - Pancreatic cancer\n  - Colorectal cancer\n  - Breast cancer\n  - Bladder cancer (often used intravesically for superficial bladder cancer)\n  - Anal cancer (in combination with other agents like 5-fluorouracil and radiation)\n\n### Administration\n- **Intravenous (IV)**: Systemic administration for various solid tumors.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_eNPOuio3L4WCvVwZbWmYoWdV", "custom_id": "172_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "250ab4ebc849f401b9de4da6f450d0e2", "body": {"id": "chatcmpl-9St5hDJLx2UjSqUbQB852510cXMpC", "object": "chat.completion", "created": 1716671981, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mitotane is an important medication primarily used in the treatment of adrenocortical carcinoma, a rare and aggressive form of cancer originating in the adrenal cortex. Here are several key points you should be aware of regarding Mitotane:\n\n### Mechanism of Action\n- **Adrenal Cytotoxicity**: Mitotane selectively targets and destroys adrenal cortex cells. It is believed to inhibit steroidogenesis by modifying the peripheral metabolism of steroids and directly suppressing the adrenal cortex.\n  \n### Indications\n- **Adrenocortical Carcinoma**: Mitotane is primarily used for inoperable adrenocortical carcinoma or as adjuvant therapy post-surgery to reduce the risk of recurrence.\n- **Cushing's Syndrome**: It can also be used off-label to manage Cushing's syndrome due to its adrenal-suppressing properties.\n\n### Pharmacokinetics\n- **Absorption and Distribution**: Mitotane is lipid-soluble and tends to accumulate"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_TcQUJYj4ED5ExrPorTldfpBV", "custom_id": "173_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "08363b71978fb3353c8f61dba84b98b4", "body": {"id": "chatcmpl-9St5hQFCjCBXuW1UZmgCSFd20GSR9", "object": "chat.completion", "created": 1716671981, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mitoxantrone is a synthetic antineoplastic (anti-cancer) drug that is primarily used in the treatment of certain types of cancer and multiple sclerosis (MS). Here are some key points you should be aware of as a physician:\n\n### Indications\n1. **Cancer**: Mitoxantrone is used in the treatment of certain types of cancer, including:\n   - Acute myeloid leukemia (AML)\n   - Advanced hormone-refractory prostate cancer\n   - Non-Hodgkin\u2019s lymphoma\n   - Breast cancer (advanced stage)\n\n2. **Multiple Sclerosis**: It is also approved for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive-relapsing, or worsening relapsing-remitting MS.\n\n### Mechanism of Action\nMitoxantrone works by intercalating into DNA, causing crosslinks and strand breaks. It also inhibits topoisomerase II, an"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_LTTDtZx5KXYFlTbAtIjYoeiG", "custom_id": "174_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "29a7150f6502f5109e5560fce30b8721", "body": {"id": "chatcmpl-9St5hKUo40nHuhuSnf4G4qIVU8lJ3", "object": "chat.completion", "created": 1716671981, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mogamulizumab is a humanized monoclonal antibody used primarily in the treatment of certain types of cancer, specifically cutaneous T-cell lymphoma (CTCL) and adult T-cell leukemia/lymphoma (ATL). Here are key points you should know as a physician:\n\n### Mechanism of Action\n- **Target**: Mogamulizumab targets CCR4 (C-C chemokine receptor type 4), which is often expressed on the surface of malignant T cells in CTCL and ATL.\n- **Function**: By binding to CCR4, mogamulizumab facilitates the destruction of these malignant cells through antibody-dependent cell-mediated cytotoxicity (ADCC).\n\n### Indications\n- **Cutaneous T-cell Lymphoma (CTCL)**: Approved for patients with relapsed or refractory mycosis fungoides (MF) and S\u00e9zary syndrome (SS).\n- **Adult T-cell Leukemia/Lymphoma (ATL)**: Used in cases where the disease"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_clflSDp7Q6bbvyWDRIT0vGvH", "custom_id": "175_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "da559d2dc7b5162abc233d900e81ac9b", "body": {"id": "chatcmpl-9St5hj2uvPUtetyBtNO1FoRulhkNE", "object": "chat.completion", "created": 1716671981, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Moxetumomab pasudotox is an important therapeutic agent for certain hematologic malignancies. Here are some key points you should know about it:\n\n### Indications\n- **Moxetumomab pasudotox-tdfk** (trade name: Lumoxiti) is primarily indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.\n\n### Mechanism of Action\n- It is a **CD22-directed cytotoxin**. Moxetumomab pasudotox is a recombinant immunotoxin that combines an anti-CD22 antibody fragment with a truncated form of Pseudomonas exotoxin A.\n- The drug binds to CD22, a cell surface antigen expressed on the majority of B cells, including HCL cells. After binding, it gets internalized and releases the exotoxin inside the cell,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_kCno6bb9LZpFur7NNmmJUPPb", "custom_id": "176_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "06459a53e950c51d23b53e4dae8aa1f1", "body": {"id": "chatcmpl-9St5hoK6g9BOfkkAoMbxdDQncC7xj", "object": "chat.completion", "created": 1716671981, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nadroparin is a low molecular weight heparin (LMWH) used primarily as an anticoagulant. It is important for physicians to understand the following key points about Nadroparin:\n\n1. **Mechanism of Action**:\n   - Nadroparin enhances the activity of antithrombin III, which inhibits factor Xa and thrombin (factor IIa), leading to anticoagulant effects.\n\n2. **Indications**:\n   - **Prevention of Venous Thromboembolism (VTE)**: Used in patients undergoing surgery or those who are at high risk of developing VTE.\n   - **Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)**.\n   - **Prevention of clotting in extracorporeal circulation during hemodialysis**.\n   - **Acute Coronary Syndrome (ACS)**: Including unstable angina and non-ST-elevation myocardial infarction (NSTEM"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_29dN86iBevZZ0QGQ1sSUfVtu", "custom_id": "177_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "783096b2e352e5e1709cf90071cf3639", "body": {"id": "chatcmpl-9St5i39QUxgVmnYkSldoGLqFHQmUL", "object": "chat.completion", "created": 1716671982, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Necitumumab is a fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFR). It is used primarily in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC). Here are some key points you should know about Necitumumab:\n\n### Indications:\n- **Non-Small Cell Lung Cancer (NSCLC):** Necitumumab is approved for use in combination with gemcitabine and cisplatin for the first-line treatment of patients with metastatic squamous NSCLC.\n\n### Mechanism of Action:\n- **EGFR Inhibition:** Necitumumab binds to the extracellular domain of the EGFR, preventing the receptor from binding to its natural ligands. This inhibits the EGFR signaling pathway, which is often involved in the proliferation and survival of cancer cells.\n\n### Administration:\n- **Intravenous Infusion:** Necitumumab is administered by intravenous infusion. The typical dosing schedule is 800 mg on days 1 and "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_bKkc4ToSZJ0tVYyuCZBkIs3H", "custom_id": "178_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "05b89013291f0e25c1169467cab002f2", "body": {"id": "chatcmpl-9St5iQypbLcduvVc3wU9lX1vqLZaj", "object": "chat.completion", "created": 1716671982, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nedaplatin is an antineoplastic agent used in chemotherapy, primarily for the treatment of various cancers. Here are key points you should know about Nedaplatin:\n\n### Mechanism of Action\n- **Platinum-based Drug**: Nedaplatin, like other platinum compounds (e.g., cisplatin, carboplatin), forms DNA adducts, leading to DNA cross-linking and ultimately inducing apoptosis in cancer cells.\n- **Cell Cycle Non-specific**: It affects both dividing and non-dividing cells.\n\n### Indications\n- **Cancers**: Commonly used for head and neck cancer, esophageal cancer, bladder cancer, non-small cell lung cancer, ovarian cancer, and cervical cancer.\n- **Combination Therapy**: Often used in combination with other chemotherapeutic agents for synergistic effects.\n\n### Administration and Dosage\n- **Intravenous Infusion**: Typically administered intravenously.\n- **Dosing**: Dosage depends on factors such as the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_f7v0dm59h4OB6R5pTXzU8oCW", "custom_id": "179_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5911f772e0a3e0cd8547fb795eba1d56", "body": {"id": "chatcmpl-9St5iCHI63jG2aaLQW1uMZEPyg1vA", "object": "chat.completion", "created": 1716671982, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about Nelarabine, particularly if you are treating patients with certain types of leukemia and lymphoma. Here is a detailed overview of the drug:\n\n### Indications:\n- **Nelarabine** is primarily used to treat T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) that have not responded to or have relapsed following at least two chemotherapy regimens.\n\n### Mechanism of Action:\n- **Nelarabine** is a prodrug of Ara-G (9-\u03b2-D-arabinofuranosylguanine), which is converted into its active form by cellular kinases. Ara-G is incorporated into DNA, leading to the inhibition of DNA synthesis and apoptosis of T-lymphoblasts.\n\n### Dosage and Administration:\n- **Adult Dosing**: Typically, 1,500 mg/m\u00b2 administered intravenously over 2 hours on days 1, "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_rIeUE7JIDzRDblYcZBgEJabT", "custom_id": "180_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "33307b59f3627029da400d99697615a5", "body": {"id": "chatcmpl-9St5i3U5UcWpyf9zTzIYGbLSMvbdC", "object": "chat.completion", "created": 1716671982, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Neratinib is a medication used in the treatment of breast cancer, specifically HER2-positive breast cancer. Here are some important aspects that you, as a physician, should know about Neratinib:\n\n### Mechanism of Action\n- **HER2 Inhibition**: Neratinib is an irreversible tyrosine kinase inhibitor that targets the HER2 (human epidermal growth factor receptor 2) and EGFR (epidermal growth factor receptor) pathways, which are involved in the growth and proliferation of cancer cells.\n\n### Indications\n- **Extended Adjuvant Therapy**: Neratinib is primarily used as an extended adjuvant therapy in patients with early-stage HER2-positive breast cancer who have completed adjuvant trastuzumab-based therapy.\n- **Metastatic Breast Cancer**: It may also be used in combination with other drugs for the treatment of metastatic HER2-positive breast cancer.\n\n### Dosage and Administration\n- **Oral Administration**: Neratin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_AEu1OaoUaaLuRT3qj55sVZgR", "custom_id": "181_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e013c35c144d4b2c3cd3a935e8db7910", "body": {"id": "chatcmpl-9St5iBvUn5gV85XCAcsYCrwr9FBul", "object": "chat.completion", "created": 1716671982, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nilotinib is an important medication in the treatment of certain types of cancer, specifically chronic myeloid leukemia (CML). Here are some key points you should know about Nilotinib:\n\n1. **Mechanism of Action**:\n   - Nilotinib is a tyrosine kinase inhibitor (TKI) that specifically targets the BCR-ABL protein, which is produced by the Philadelphia chromosome abnormality in CML. By inhibiting this protein, Nilotinib helps to control the proliferation of leukemic cells.\n\n2. **Indications**:\n   - Nilotinib is primarily indicated for the treatment of Philadelphia chromosome-positive CML in chronic and accelerated phases in adult patients.\n\n3. **Dosage and Administration**:\n   - Nilotinib is typically administered orally. The standard dosage can vary based on the phase of CML and the patient's response to treatment. It is important to follow specific guidelines regarding dosing intervals and to take the drug on an empty"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_oj2tON16cOhagXe5lOdGO8bA", "custom_id": "182_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c9f94c29c2b46b32f5e753c9855c4025", "body": {"id": "chatcmpl-9St5i3ZA3q0n2qUcZg7VjxSIYWJC7", "object": "chat.completion", "created": 1716671982, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nilutamide is a nonsteroidal antiandrogen medication primarily used in the treatment of prostate cancer. Here are some key points you should be aware of as a physician:\n\n### Mechanism of Action\n- Nilutamide works by inhibiting the action of androgens (male hormones) by binding to androgen receptors in prostate cancer cells, thereby blocking the stimulatory effect of these hormones on the cancer cells.\n\n### Indications\n- It is mainly used in combination with surgical castration (orchiectomy) or medical castration (using GnRH analogs) in the treatment of metastatic prostate cancer.\n- It may also be used in other androgen-dependent conditions, though this is less common.\n\n### Dosage and Administration\n- The typical starting dose is 300 mg per day for the first month, followed by a maintenance dose of 150 mg per day.\n- It is administered orally and can be taken with or without food.\n\n### Side Effects\n- Common side effects include hot flashes"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_MWMY5UocvTxD32rCXmp9BY83", "custom_id": "183_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "cedaeffb24a04f2a6aa432b362710a22", "body": {"id": "chatcmpl-9St5iIf9uTVX4Zvccg3hsyVSJ6mTy", "object": "chat.completion", "created": 1716671982, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nimustine, also known by its chemical name 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU), is a chemotherapeutic agent used primarily in the treatment of certain types of brain tumors, including gliomas, and other cancers. Here are some key points you should know about Nimustine:\n\n### Mechanism of Action\n- **Alkylating Agent**: Nimustine belongs to the nitrosourea class of alkylating agents. It works by cross-linking DNA strands, thereby inhibiting DNA replication and transcription, leading to cell cycle arrest and apoptosis in cancer cells.\n\n### Indications\n- **Brain Tumors**: It is often used in the treatment of malignant gliomas, including astrocytomas and medulloblastomas.\n- **Other Cancers**: It may also be used in combination with other chemotherapeut"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_V0T0JjGkOyrwWFuO4Xn579Xp", "custom_id": "184_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "7ff7a06601ceb7db1a4a0f36e1c629f3", "body": {"id": "chatcmpl-9St5jv7f50OwZwT31Z9abb4tswEjm", "object": "chat.completion", "created": 1716671983, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nintedanib is a tyrosine kinase inhibitor used primarily in the treatment of idiopathic pulmonary fibrosis (IPF) and certain types of non-small cell lung cancer (NSCLC). Here are key points a physician should know about Nintedanib:\n\n### Mechanism of Action:\n- **Tyrosine Kinase Inhibition**: Nintedanib inhibits multiple tyrosine kinases, including those involved in angiogenesis (VEGFR, PDGFR, FGFR) and fibrosis pathways.\n- **Anti-fibrotic and Anti-inflammatory**: By blocking these pathways, Nintedanib reduces fibrotic activity and inflammation in lung tissues.\n\n### Indications:\n- **Idiopathic Pulmonary Fibrosis (IPF)**: It is approved to slow the progression of IPF.\n- **Non-Small Cell Lung Cancer (NSCLC)**: Specifically for patients with adenocarcinoma histology after first-line chemotherapy.\n\n### Administration:\n- **Dosage**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_zg1XNu8tUNZBwOpP0hd1kkuY", "custom_id": "185_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "83a270516a8e2579fa308e0f8b268818", "body": {"id": "chatcmpl-9St5jCnKkrljomoapa4Mr1nczhZsG", "object": "chat.completion", "created": 1716671983, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Niraparib is an oral poly (ADP-ribose) polymerase (PARP) inhibitor used primarily in the treatment of certain types of cancers. Here are several key points you should know about Niraparib:\n\n### Indications:\n1. **Ovarian Cancer**: Niraparib is approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\n2. **Other Cancers**: It is also being investigated and used in other cancer types, including breast and prostate cancers, particularly those with BRCA mutations or other homologous recombination deficiencies (HRD).\n\n### Mechanism of Action:\n- Niraparib inhibits PARP enzymes, which play a role in DNA repair. By inhibiting these enzymes, Niraparib causes DNA damage to accumulate in cancer cells, particularly those deficient in homologous recombination repair (such as BRCA-mutated cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_8d2pzy0IwiAIaRGSgCwZvgFn", "custom_id": "186_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "05a53c29489e49d7db45ddcd7f8cf78b", "body": {"id": "chatcmpl-9St5jxMHFDKNdmOWLKQtwBcwwueNb", "object": "chat.completion", "created": 1716671983, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nivolumab is an important medication in the field of oncology, and as a physician, there are several critical aspects you should be aware of:\n\n### Mechanism of Action:\n- **Nivolumab** is a monoclonal antibody that targets the programmed death-1 (PD-1) receptor on T-cells. By inhibiting PD-1, nivolumab enhances the immune system's ability to recognize and destroy cancer cells.\n\n### Indications:\n- **Approved Uses:** Nivolumab is used to treat various cancers, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, colorectal cancer with microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR), and hepatocellular carcinoma.\n- **Investigational Uses:** It is also being studied for other types of cancer and in combination with other therapeutic agents.\n\n### Administration:\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_xlTpzVkA7Yp71Yyuge4KDXgq", "custom_id": "187_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ca6bec81644c1b810aaa4c70dc506e7e", "body": {"id": "chatcmpl-9St5jhDdisqTUX2lOoQYvTmBjcfei", "object": "chat.completion", "created": 1716671983, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Non-pegylated liposomal doxorubicin is a formulation of the chemotherapeutic agent doxorubicin, encapsulated in liposomes to alter its pharmacokinetics and reduce some of its toxicities. Here are key points you should be aware of:\n\n### Mechanism of Action:\n- **Doxorubicin**: An anthracycline antibiotic that intercalates DNA, inhibits topoisomerase II, and generates free radicals leading to cytotoxicity.\n- **Liposomal Encapsulation**: Enhances delivery to tumor cells while reducing exposure to healthy tissues.\n\n### Indications:\n- **Breast Cancer**: Used in metastatic settings.\n- **Ovarian Cancer**: Typically in recurrent or refractory cases.\n- **Kaposi\u2019s Sarcoma**: Particularly in patients with AIDS.\n- **Multiple Myeloma**: In combination with other agents like bortezomib.\n\n### Pharmacokinetics:\n- **Distribution**: Liposomal"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_jdxoy2bYofZwY5YhLgD49adt", "custom_id": "188_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6aeb1550ea5a466bfa0abf2819b232cd", "body": {"id": "chatcmpl-9St5j1FZU6Gmw7PRHrX1UISvYbOi4", "object": "chat.completion", "created": 1716671983, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Norethandrolone, also known as norethandrolone or nortestosterone, is a synthetic anabolic-androgenic steroid (AAS) that was developed in the mid-20th century. Here are some key points you should know about it as a physician:\n\n1. **Chemical Structure and Properties**:\n   - Norethandrolone is a derivative of 19-nortestosterone (nandrolone).\n   - It has both anabolic (muscle-building) and androgenic (masculinizing) properties, but its anabolic effects are more pronounced.\n\n2. **Medical Uses**:\n   - Historically, it has been used to treat a variety of conditions such as chronic wasting diseases, severe burns, and osteoporosis.\n   - It has also been used in some cases for the treatment of anemia due to its ability to stimulate erythropoiesis (red blood cell production).\n\n3. **Mechanism of Action**:\n   - Norethandrol"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_wH5IY6JmQzDQH6oFd4YInddL", "custom_id": "189_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "1a5162b51736203b42ae436d50483b84", "body": {"id": "chatcmpl-9St5jaa0J5j3D6NnBkdgNFJ43BQcp", "object": "chat.completion", "created": 1716671983, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Obinutuzumab is a monoclonal antibody used primarily in the treatment of certain types of blood cancers, such as chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). Here are some key points you should know as a physician:\n\n### Mechanism of Action:\n- Obinutuzumab is a humanized anti-CD20 monoclonal antibody.\n- It targets the CD20 protein found on the surface of B-cells, leading to B-cell lysis via several mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct cell death.\n\n### Indications:\n- Approved for use in combination with other chemotherapeutic agents, such as chlorambucil, for the treatment of previously untreated CLL.\n- Used in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma in patients who have relapsed or are refractory to a rituximab-containing regimen.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_iFiVZce4ZuwefVYCt4RDnU5Q", "custom_id": "190_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6073e69318ad688920b95e8d959a083d", "body": {"id": "chatcmpl-9St5kaxvuxgoTUIYQFiyHI03kg2uD", "object": "chat.completion", "created": 1716671984, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Octreotide is a synthetic octapeptide that mimics natural somatostatin pharmacologically, though it is more potent and has a longer half-life. It is used in various clinical settings due to its inhibitory effects on the secretion of several hormones and other substances.\n\nHere are key points you should know about Octreotide:\n\n### Indications\n1. **Acromegaly**: It is used to reduce growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels in patients for whom surgery or radiotherapy is not an option, or when these treatments fail to control the disease.\n2. **Neuroendocrine Tumors (NETs)**: It helps control symptoms like flushing and diarrhea in patients with carcinoid tumors and vasoactive intestinal peptide-secreting tumors (VIPomas).\n3. **Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)**: It is used to control the growth of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_LJFgLBm16L7WLbNfuVGizaIc", "custom_id": "191_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ecb34d69ae91b2df852c6ee62ab3fbe0", "body": {"id": "chatcmpl-9St5k83chPSmzW910kxFO0VUh0Q2j", "object": "chat.completion", "created": 1716671984, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Octreotide LAR (Long-Acting Release) is a long-acting formulation of octreotide, a somatostatin analog, which is used in various clinical settings. Here are some key points you should know about Octreotide LAR:\n\n### Indications:\n1. **Acromegaly**: Used to reduce growth hormone and IGF-1 levels in patients who have had an inadequate response to surgery or radiotherapy.\n2. **Neuroendocrine Tumors (NETs)**: Helps control symptoms of carcinoid syndrome (e.g., flushing, diarrhea) and inhibits tumor growth.\n3. **Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)**: Used for symptom control and to slow tumor progression.\n4. **Thyrotropin-Secreting Pituitary Adenomas**: Helps in managing hormone levels.\n\n### Mechanism of Action:\n- Octreotide LAR mimics natural somat"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_bdlWMWPRN1ipRMxqO1k9ypjw", "custom_id": "192_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b85a8e7fc4bf62a04b52b32eda860d23", "body": {"id": "chatcmpl-9St5k0RdZ0Joi1F9wgC07h2LuEmOu", "object": "chat.completion", "created": 1716671984, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ofatumumab is a medication used in the treatment of certain types of cancers and autoimmune conditions. Here are some key points you should know about Ofatumumab:\n\n1. **Mechanism of Action**: Ofatumumab is a fully human monoclonal antibody that targets CD20, a protein found on the surface of B lymphocytes (B cells). By binding to CD20, Ofatumumab induces cell lysis through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity.\n\n2. **Indications**:\n   - **Chronic Lymphocytic Leukemia (CLL)**: Ofatumumab is approved for the treatment of CLL, particularly in patients who have not responded to other treatments.\n   - **Multiple Sclerosis (MS)**: It is also approved for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.\n\n3. **Administration**:\n   - **CLL**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_vHJ4k4ClUnuOjq2bEyZTmhYm", "custom_id": "193_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "aafe0304b58e0206f81da9ac70cb262b", "body": {"id": "chatcmpl-9St5kacPMumNxziL9fZ1wH8hsC2Tb", "object": "chat.completion", "created": 1716671984, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Olaparib is a medication used in the treatment of certain types of cancer. Here are some key points you should know:\n\n### Mechanism of Action:\n- **PARP Inhibitor:** Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor. PARP enzymes are involved in DNA repair, and inhibiting them can lead to the accumulation of DNA damage, particularly in cancer cells with existing deficiencies in DNA repair mechanisms, such as those with BRCA1 or BRCA2 mutations.\n\n### Indications:\n- **BRCA-mutated Ovarian Cancer:** It is commonly used for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\n- **Breast Cancer:** It is also approved for the treatment of HER2-negative metastatic breast cancer with germline BRCA mutations.\n- **Prostate Cancer:** Olaparib is used"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_k8UODLHOiTbaUVL5oT59pF4X", "custom_id": "194_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b7d9f66d823e63eb6e407bc6389caccc", "body": {"id": "chatcmpl-9St5k6jWhcpEOG9VSD2AG4W4WctdO", "object": "chat.completion", "created": 1716671984, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Olaratumab is a monoclonal antibody that was developed for the treatment of soft tissue sarcoma. It specifically targets the platelet-derived growth factor receptor alpha (PDGFR\u03b1), which is often implicated in tumor growth and the proliferation of cancer cells. Here's a detailed overview that you might find useful as a physician:\n\n### Indications and Usage\n- **Primary Indication**: Olaratumab was primarily indicated for use in combination with doxorubicin for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and who are not amenable to curative treatment with radiotherapy or surgery.\n\n### Mechanism of Action\n- **Monoclonal Antibody**: Olaratumab binds to PDGFR\u03b1, thereby inhibiting its interaction with its ligands (PDGF-AA, PDGF-BB, and PDGF-CC). This inhibition interferes with the receptor's"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_A2kATYY2hhrPROo4twlJ2qE6", "custom_id": "195_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "062fa2ce7b0bf38d29bca0a840cb1b98", "body": {"id": "chatcmpl-9St5kYtXC3QweCpSJuVRDHufLEujW", "object": "chat.completion", "created": 1716671984, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Omacetaxine mepesuccinate, commonly known as omacetaxine, is a chemotherapeutic agent used primarily in the treatment of chronic myeloid leukemia (CML) that is resistant to tyrosine kinase inhibitors (TKIs). Here are some key points you should know about omacetaxine:\n\n### Mechanism of Action:\n- **Protein Synthesis Inhibition**: Omacetaxine works by inhibiting protein synthesis. It binds to the A-site cleft of the ribosome and interferes with the elongation step of protein synthesis, leading to the inhibition of the growth of leukemic cells.\n\n### Indications:\n- **Chronic Myeloid Leukemia (CML)**: Particularly indicated for adult patients with chronic or accelerated phase CML who have shown resistance or intolerance to at least two TKIs.\n\n### Administration:\n- **Subcutaneous Injection**: Omacetaxine is administered subcutaneously.\n- **Induction Phase**: The typical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_U3jgxqI9bjJsBeni8lPHbTcO", "custom_id": "196_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c1010b1356f307cd26e8fe9042a7875f", "body": {"id": "chatcmpl-9St5k33wfHe1cL0qttD4GaU0shfXA", "object": "chat.completion", "created": 1716671984, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Omeprazole is a proton pump inhibitor (PPI) commonly prescribed for the treatment of various gastrointestinal conditions. Here are the key points you should know about Omeprazole as a physician:\n\n1. **Mechanism of Action**: Omeprazole works by irreversibly inhibiting the H+/K+ ATPase enzyme (proton pump) in the gastric parietal cells, leading to a marked reduction in gastric acid secretion.\n\n2. **Indications**:\n   - Gastroesophageal reflux disease (GERD)\n   - Peptic ulcer disease (PUD)\n   - Zollinger-Ellison syndrome\n   - H. pylori eradication (in combination with antibiotics)\n   - Erosive esophagitis\n   - Prophylaxis of stress ulcers\n\n3. **Dosage Forms**: Omeprazole is available in various forms including delayed-release capsules, tablets, and oral suspension. The typical adult dose ranges from 20 mg to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_OoJVsrjFPTdPzzKHhCZHBCSR", "custom_id": "197_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "02c755821d98fed8ad8221f0354260a0", "body": {"id": "chatcmpl-9St5kyFgMstzeuGYtRi4RTUqNX9zU", "object": "chat.completion", "created": 1716671984, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Osimertinib (brand name Tagrisso) is a medication used to treat certain types of non-small cell lung cancer (NSCLC). Here are some key points you should be aware of as a physician:\n\n### Indications:\n1. **EGFR Mutation-Positive NSCLC**: Osimertinib is specifically indicated for patients with metastatic NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.\n2. **Resistance to Other EGFR Inhibitors**: It is also indicated for NSCLC patients who have developed resistance to first- or second-generation EGFR inhibitors due to the T790M mutation.\n\n### Mechanism of Action:\n- Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that selectively inhibits both EGFR sensitizing mutations and T790M resistance mutations while sparing wild-type EGFR.\n\n### Dosing:\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_GVavM2lrCvlbFLVyznUPgfOO", "custom_id": "198_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0afe6654b0cfce3e954ee8e5318e320d", "body": {"id": "chatcmpl-9St5l6mApSp9CNE2DnhbcIWs8QSVw", "object": "chat.completion", "created": 1716671985, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Oxaliplatin is a platinum-based chemotherapeutic agent used primarily in the treatment of colorectal cancer. Here are key points you should know about Oxaliplatin:\n\n### Mechanism of Action:\n- **DNA Cross-Linking:** Oxaliplatin forms cross-links with DNA, which inhibits DNA replication and transcription, leading to cell death. It primarily forms intra-strand cross-links between guanine and adenine or guanine and guanine bases.\n- **Cytotoxic Effects:** The resultant DNA damage triggers apoptosis in rapidly dividing cancer cells.\n\n### Indications:\n- **Colorectal Cancer:** Oxaliplatin is commonly used in combination with other chemotherapeutic agents such as 5-fluorouracil (5-FU) and leucovorin (LV) in regimens such as FOLFOX (5-FU, LV, and Oxaliplatin).\n- **Other Cancers:** It may also be used off-label for other malignancies, including pancreatic and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Cu68eVxH3bSygYd18SLn2s2A", "custom_id": "199_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "136b03c5580aa590cad5cf89f181c52a", "body": {"id": "chatcmpl-9St5l5aD3LqJFcwwEqvAr4HfZCD5J", "object": "chat.completion", "created": 1716671985, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Paclitaxel nanoparticle albumin-bound, often referred to as nab-paclitaxel or by its brand name Abraxane, is a formulation of the chemotherapy drug paclitaxel that is bound to albumin nanoparticles. This formulation is designed to improve the delivery and efficacy of paclitaxel while reducing some of the associated side effects typically seen with solvent-based paclitaxel formulations.\n\nHere's what you should know as a physician:\n\n### Indications\n- **Breast Cancer**: Nab-paclitaxel is approved for the treatment of metastatic breast cancer, particularly in patients who have failed combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy.\n- **Non-Small Cell Lung Cancer (NSCLC)**: It is used in combination with carboplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC who are not candidates for curative surgery or radiation therapy.\n- **Pancreatic Cancer**: Nab-paclit"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_uEq201r4Hbwz7YYun3GuWYmE", "custom_id": "200_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6c00bf4eb371f65ab7e85cee444a0b8f", "body": {"id": "chatcmpl-9St5l9XPT14LqA0HPeff4576AH6Mf", "object": "chat.completion", "created": 1716671985, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Paclitaxel is a widely used chemotherapeutic agent, primarily utilized in the treatment of various cancers. Here are several key points you should know about Paclitaxel:\n\n### Mechanism of Action\n- **Microtubule Stabilization**: Paclitaxel works by stabilizing microtubules, thus inhibiting their disassembly. This action disrupts the normal process of cell division (mitosis), leading to cell death, particularly in rapidly dividing cancer cells.\n\n### Indications\n- **Cancer Types**: Paclitaxel is commonly used to treat a variety of cancers, including ovarian cancer, breast cancer, lung cancer (non-small cell), and Kaposi's sarcoma. It may also be used off-label for other malignancies.\n\n### Administration\n- **Intravenous Infusion**: Typically administered intravenously as an infusion. The dosage and schedule can vary depending on the type of cancer being treated, the specific regimen, and patient factors.\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_MQcHZlZfN988jo7yyPkQhNUY", "custom_id": "201_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "1f762a9bd5f021bc7a9ced2d51d11fcf", "body": {"id": "chatcmpl-9St5laMvalNbACd5JTx4iFZLRcB05", "object": "chat.completion", "created": 1716671985, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pacritinib is a medication primarily used in the treatment of myelofibrosis, a type of bone marrow disorder. Here are some key points you should know about Pacritinib as a physician:\n\n1. **Mechanism of Action**: Pacritinib is a selective inhibitor of Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). These kinases are often dysregulated in myeloproliferative disorders, and their inhibition helps to manage disease symptoms and progression.\n\n2. **Indications**: Pacritinib is used for the treatment of myelofibrosis, particularly in patients with low platelet counts (<50,000/\u00b5L). It is an option for patients who may not tolerate or benefit from other JAK2 inhibitors like ruxolitinib.\n\n3. **Dosage and Administration**: The typical dosage of Pacritinib is 200 mg orally twice daily."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_AN73zPRIR0O4vXsJVGPfxhUk", "custom_id": "202_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "51aefd8699a5018183614d5669f017be", "body": {"id": "chatcmpl-9St5tAwEW0quD1RQEoO5H7R1JGH1J", "object": "chat.completion", "created": 1716671993, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Palbociclib is an important drug in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. Here are key points you should know about it:\n\n### Mechanism of Action\n- **CDK 4/6 Inhibition**: Palbociclib is a selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6. These kinases play a crucial role in cell cycle progression from the G1 phase to the S phase. By inhibiting CDK 4/6, Palbociclib induces cell cycle arrest in the G1 phase, thereby inhibiting cancer cell proliferation.\n\n### Indications\n- **Combination Therapy**: Palbociclib is typically used in combination with endocrine therapy (e.g., letrozole or fulvestrant) for the treatment of HR+/HER2- advanced or metastatic breast cancer.\n- **First-Line Treatment"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_GUBRQRcica9tmKiTrYxkYYC4", "custom_id": "203_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "4858b1dcc5ee35c4174473de10f96a38", "body": {"id": "chatcmpl-9St5mww8WPSyEKAbKTohevgZlNz12", "object": "chat.completion", "created": 1716671986, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panitumumab is a fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Here are some key points you should know about Panitumumab:\n\n### Indications\n- **Colorectal Cancer**: Panitumumab is primarily used for the treatment of metastatic colorectal cancer, particularly in patients who have wild-type RAS (KRAS and NRAS) tumors. It is not recommended for patients with RAS-mutant tumors as they do not respond to EGFR inhibitors.\n\n### Mechanism of Action\n- **EGFR Inhibition**: Panitumumab binds specifically to the extracellular domain of EGFR, preventing the natural ligands from activating the receptor. This inhibition leads to the downregulation of key signaling pathways (e.g., RAS-RAF-MEK-ERK, PI3K-AKT) involved in cell proliferation, survival, and metastasis.\n\n### Administration\n- **Intravenous Infusion**: Panitumumab is administered as"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_BZ5jUzC2uMnptt5vEofHv9MV", "custom_id": "204_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "061251ce0c111e1900cfd5aad102f1d9", "body": {"id": "chatcmpl-9St5mC5f3zgHhKra1N2MV9XloqzHk", "object": "chat.completion", "created": 1716671986, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panobinostat is a potent pan-deacetylase inhibitor that is used primarily in the treatment of multiple myeloma, a type of blood cancer. Here are some key points you should be aware of as a physician:\n\n### Mechanism of Action\n- **Deacetylase Inhibition**: Panobinostat inhibits histone deacetylases (HDACs), leading to increased acetylation of histone proteins. This results in a more open chromatin structure and altered gene expression, which can induce cell cycle arrest, apoptosis, and inhibit angiogenesis.\n\n### Indications\n- **Multiple Myeloma**: Panobinostat is indicated for the treatment of multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least two prior regimens, including bortezomib and an immunomodulatory agent.\n\n### Administration\n- **Oral Route**: Panobinostat is administered orally. The typical dosing schedule"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Ww4yaQunYC83weq9QoR219H6", "custom_id": "205_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "83b1a1f9311e8f265f7f0529a21a2d9e", "body": {"id": "chatcmpl-9St5mL99dDLLNkA5HtWCYApFtzfoC", "object": "chat.completion", "created": 1716671986, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pazopanib, marketed under the brand name Votrient, is an oral medication used in the treatment of certain types of cancers. As a physician, it's crucial to understand the following aspects of Pazopanib:\n\n### Indications:\n1. **Renal Cell Carcinoma (RCC):** Pazopanib is approved for the treatment of advanced renal cell carcinoma.\n2. **Soft Tissue Sarcoma (STS):** It is also indicated for the treatment of advanced soft tissue sarcoma in patients who have received prior chemotherapy.\n\n### Mechanism of Action:\n- Pazopanib is a tyrosine kinase inhibitor that targets multiple receptors, including vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-\u03b1, PDGFR-\u03b2), and c-kit, which are involved in tumor growth and angiogenesis.\n\n### Administration:\n- **Dosage:** The recommended dose is typically 800"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_BJUH4Wgz6HBOOLFAwnSshM8C", "custom_id": "206_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "baf15a8fb08b0c16d866c1b416f03d81", "body": {"id": "chatcmpl-9St5mGKGU3l1FhGwuFE9Af9uFJ8IT", "object": "chat.completion", "created": 1716671986, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pegaspargase (brand name: Oncaspar) is an important medication used in the treatment of acute lymphoblastic leukemia (ALL). As a physician, here are key points to know about Pegaspargase:\n\n### Mechanism of Action:\n- **Enzyme Function**: Pegaspargase is a pegylated form of L-asparaginase. It works by breaking down the amino acid asparagine into aspartic acid and ammonia.\n- **Cancer Cell Targeting**: Leukemic cells are unable to synthesize asparagine, which is necessary for protein synthesis and cell survival. Pegaspargase reduces circulating asparagine levels, thereby starving the leukemic cells and inhibiting their growth.\n\n### Indications:\n- Primarily indicated for the treatment of acute lymphoblastic leukemia (ALL) and sometimes non-Hodgkin\u2019s lymphoma.\n- Often used in combination with other chemotherapeutic agents as part of a multi-agent chemotherapy regimen"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_srfZAiosXN9hxCX8Z0jL2e0h", "custom_id": "207_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a72fa660bc8350fd3c668e8d47702d60", "body": {"id": "chatcmpl-9St5nGqmUWJeUThuWAexzxZRyKPvO", "object": "chat.completion", "created": 1716671987, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Peginterferon alfa-2a is a medication used primarily in the treatment of chronic hepatitis C and, in some cases, chronic hepatitis B. Here are key points you should know about it:\n\n### Mechanism of Action\n- **Interferon-Based Therapy:** Peginterferon alfa-2a is a pegylated form of interferon alfa-2a. Pegylation involves attaching polyethylene glycol (PEG) to the interferon molecule, which increases its half-life and allows for less frequent dosing.\n- **Antiviral and Immunomodulatory Effects:** The drug works by enhancing the immune response against viral infections, inhibiting viral replication, and modulating the immune system.\n\n### Indications\n- **Chronic Hepatitis C:** Often used in combination with other antiviral medications like ribavirin or direct-acting antivirals (DAAs).\n- **Chronic Hepatitis B:** Can be used as monotherapy or in combination with other antiviral agents.\n\n### Administration\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_yKoOIzNEFQVeuzmFTmm7TOmY", "custom_id": "208_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c7d2e350d90918fde5d4523dcd03b999", "body": {"id": "chatcmpl-9St5nXKJt9KrQlIHg4gNPTEjMeXKc", "object": "chat.completion", "created": 1716671987, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Peginterferon alfa-2b is a medication primarily used in the treatment of chronic hepatitis C, and sometimes for other viral infections and certain types of cancer. Here are some important points a physician should know about this drug:\n\n### Mechanism of Action\n- **Immunomodulatory and Antiviral Effects**: Peginterferon alfa-2b is a pegylated form of interferon alfa-2b, which enhances its half-life and therapeutic efficacy. It works by modulating the immune response and exerting direct antiviral effects, thereby inhibiting viral replication.\n\n### Indications\n- **Chronic Hepatitis C**: Often used in combination with other antiviral agents like ribavirin.\n- **Chronic Hepatitis B**: In some cases, although other treatments are often preferred.\n- **Malignant Melanoma**: As adjuvant therapy.\n- **Other Viral Infections and Cancers**: Occasionally used off-label or in clinical trials for other conditions"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_n7JZcj18YVn16WFupYcIoCD7", "custom_id": "209_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d5d1dc836d6d3684ee3e8dd8665ff49c", "body": {"id": "chatcmpl-9St5nG6jwQlmz97LB1M0zGSiIuQjM", "object": "chat.completion", "created": 1716671987, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pegylated liposomal doxorubicin is a formulation of the chemotherapy drug doxorubicin that is encapsulated in liposomes with polyethylene glycol (PEG) on their surface. This formulation has distinct pharmacokinetic and pharmacodynamic properties compared to conventional doxorubicin. Here are several key points you should know:\n\n### Mechanism of Action\n1. **Doxorubicin**: It works by intercalating DNA and inhibiting topoisomerase II, which prevents DNA replication and transcription. It also generates free radicals that cause damage to cellular components.\n\n### Formulation Benefits\n2. **Liposomal Encapsulation**: Encapsulation in liposomes helps to protect the drug from rapid degradation and clearance, thereby increasing its half-life.\n3. **Pegylation**: The addition of PEG helps to evade the immune system, reducing uptake by the reticuloendothelial system and increasing circulation time.\n\n### Pharmacokinetics\n4. **Extended Circulation**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_mU8MlX1QAHj97Y1FOW8KGQvQ", "custom_id": "210_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "88d5b296853c4f544ceb77be882b8780", "body": {"id": "chatcmpl-9St5nHWfCUsOQSOFY5vpEKmzbXPIs", "object": "chat.completion", "created": 1716671987, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pembrolizumab, marketed under the brand name Keytruda, is a monoclonal antibody used in cancer immunotherapy. Here are key points you should know about Pembrolizumab:\n\n### Mechanism of Action\n- **Immune Checkpoint Inhibitor:** Pembrolizumab targets the programmed cell death protein 1 (PD-1) receptor on T cells. By blocking this receptor, it prevents cancer cells from evading the immune response, thus enhancing the body's ability to fight cancer.\n\n### Indications\nPembrolizumab is approved for a variety of cancers, including:\n- **Melanoma**\n- **Non-Small Cell Lung Cancer (NSCLC)**\n- **Head and Neck Squamous Cell Carcinoma (HNSCC)**\n- **Hodgkin Lymphoma**\n- **Urothelial Carcinoma**\n- **Gastric Cancer**\n- **Esophageal Cancer**\n- **Cervical Cancer**\n- **Hep"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_3p8XpDHPA4c4khceRWjsyscB", "custom_id": "211_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "56ab94eb5b1e67ce8c1ec9e3832857af", "body": {"id": "chatcmpl-9St5nXdxEWyyxGoM4BjA7RN3jIdSx", "object": "chat.completion", "created": 1716671987, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pemetrexed is a chemotherapy drug primarily used to treat certain types of cancer, including malignant pleural mesothelioma and non-small cell lung cancer (NSCLC). Here are some key points you should know about Pemetrexed:\n\n### Mechanism of Action\n- **Antimetabolite**: Pemetrexed is a folate analog metabolic inhibitor. It disrupts folate-dependent metabolic processes essential for cell replication.\n- **Targets Multiple Enzymes**: It inhibits several key folate-dependent enzymes involved in the synthesis of purine and pyrimidine nucleotides, including thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).\n\n### Indications\n- **Malignant Pleural Mesothelioma**: Often used in combination with cisplatin for patients whose disease is unresectable or for those who are not candidates for surgery.\n- **Non-S"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_mjD8tgUnSYHn16G5SjT3bPYb", "custom_id": "212_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "10940591b97528c3a83f5b4cefc22218", "body": {"id": "chatcmpl-9St5oT9O9KntdHufM2vpV1e9R6YBk", "object": "chat.completion", "created": 1716671988, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pentostatin, also known by the brand name Nipent, is a purine analog and a type of antineoplastic agent primarily used in the treatment of certain types of hematologic malignancies. Here are some key points you should know about Pentostatin:\n\n### Indications\n- **Hairy Cell Leukemia:** Pentostatin is FDA-approved for the treatment of hairy cell leukemia. It has shown significant efficacy in achieving complete and partial remission in patients.\n- **Other Uses:** It may also be used off-label for other hematologic conditions such as chronic lymphocytic leukemia (CLL) and T-cell prolymphocytic leukemia (T-PLL), although these uses are less common and should be guided by clinical judgment and evidence.\n\n### Mechanism of Action\n- Pentostatin inhibits adenosine deaminase (ADA), an enzyme involved in purine metabolism. By inhibiting ADA, pentostatin leads to an accumulation of adenosine and deoxyadenos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_fgUvtKJfDs3CGgIk80iH1Cnc", "custom_id": "213_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "22beb13f86415d54c8823c1c4af8cec6", "body": {"id": "chatcmpl-9St5ovNburWS7kcCwko5laq2aStnC", "object": "chat.completion", "created": 1716671988, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pertuzumab is a monoclonal antibody that is used as a targeted therapy for certain types of breast cancer. Here are some key points you should know about pertuzumab:\n\n### Mechanism of Action\n- **HER2 Targeting**: Pertuzumab specifically targets the human epidermal growth factor receptor 2 (HER2) protein. HER2 is overexpressed in some breast cancers and promotes the growth of cancer cells.\n- **Mechanism**: Pertuzumab binds to the HER2 receptor and inhibits its dimerization with other HER receptors, which is crucial for signal transduction pathways that promote cell proliferation and survival. This inhibition helps to prevent cancer cell growth and induces cell death.\n\n### Indications\n- **HER2-Positive Breast Cancer**: Pertuzumab is primarily used to treat HER2-positive breast cancer. It is often used in combination with trastuzumab (another HER2-targeting antibody) and chemotherapy.\n- **Early and Metastatic Breast Cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_7XitcoWAoAAdPZXTWeFLqY7t", "custom_id": "214_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0a9953362e4e04844ca00ff5893db182", "body": {"id": "chatcmpl-9St5oeWylQcIH8oOWGavUaZIojEHG", "object": "chat.completion", "created": 1716671988, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pirarubicin is an anthracycline antibiotic used primarily as a chemotherapeutic agent in the treatment of various cancers. It is important to understand both its therapeutic benefits and potential risks to provide effective care for your patients. Here are key points you should know:\n\n### Mechanism of Action:\n- **DNA Intercalation**: Pirarubicin works by intercalating into DNA, which inhibits the synthesis of DNA and RNA, thereby preventing cell division.\n- **Topoisomerase II Inhibition**: It inhibits the enzyme topoisomerase II, leading to breaks in DNA strands, which contributes to its cytotoxic effects on cancer cells.\n\n### Indications:\n- Pirarubicin is used in the treatment of multiple types of cancers, including but not limited to:\n  - Breast cancer\n  - Bladder cancer\n  - Non-Hodgkin's lymphoma\n  - Acute leukemia\n\n### Administration:\n- It is typically administered intravenously. Dosage and frequency"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_bzrN2Ge6PPUp0JfECCsKlTGc", "custom_id": "215_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "54c6ce02f9a97b0983acc48c5b88fd9a", "body": {"id": "chatcmpl-9St5o8owmPr3PZamuXvDCdWMw5Cry", "object": "chat.completion", "created": 1716671988, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pixantrone is a chemotherapeutic agent used primarily for the treatment of relapsed or refractory aggressive non-Hodgkin lymphoma (NHL). It is a member of the anthracenedione class of drugs and is structurally related to anthracyclines like doxorubicin, but it has been designed to reduce the cardiotoxicity commonly associated with anthracyclines.\n\nHere are key points you should know about Pixantrone:\n\n### Mechanism of Action:\n- Pixantrone intercalates into DNA and inhibits topoisomerase II, leading to DNA strand breaks and apoptosis in rapidly dividing cancer cells.\n\n### Indications:\n- It is specifically approved for use in adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas who have received at least two prior lines of therapy.\n\n### Administration:\n- Pixantrone is administered as an intravenous infusion. The typical dosing regimen involves a 28-day cycle, with the drug"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_NyANPzkN8uN5Nwhfxa5rCcVu", "custom_id": "216_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2960c48e58cb0466a5f200ce33d04efd", "body": {"id": "chatcmpl-9St5oTGqj2pY35xfd7G7dARbI88C7", "object": "chat.completion", "created": 1716671988, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Plicamycin, also known as Mithramycin, is an antibiotic antineoplastic agent. It has been historically used for both its anticancer properties and its ability to manage hypercalcemia and hypercalciuria associated with certain malignancies. Here are some key points you should know about Plicamycin:\n\n### Mechanism of Action\n- **DNA Interaction**: Plicamycin binds to the minor groove of DNA at GC-rich regions, thereby inhibiting RNA synthesis. This disrupts the synthesis of mRNA and subsequently protein synthesis, which is vital for cell proliferation.\n- **Calcium Metabolism**: It inhibits osteoclast-mediated bone resorption, thus reducing serum calcium levels.\n\n### Indications\n- **Testicular Cancer**: It has been used in the treatment of certain types of testicular cancer (e.g., nonseminomatous testicular cancer).\n- **Hypercalcemia**: It is used to manage hypercalcemia and hypercalciuria"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_XJNw0UXugezQBqGdYFpet2Tk", "custom_id": "217_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8966ac497eb5f4998ea139c30591a906", "body": {"id": "chatcmpl-9St5oziKuFIxVTcnyC9W6JT9RCwVE", "object": "chat.completion", "created": 1716671988, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pomalidomide is an important medication primarily used in the treatment of multiple myeloma, a type of cancer that affects plasma cells. Here is a detailed overview that can help you as a physician:\n\n### Mechanism of Action:\n- Pomalidomide is an immunomodulatory agent that has multiple mechanisms of action. It exhibits anti-angiogenic properties, inhibits the proliferation of myeloma cells, and modulates the immune system by enhancing the function of T cells and NK (natural killer) cells. It also induces apoptosis of myeloma cells.\n\n### Indications:\n- **Multiple Myeloma:** Pomalidomide is used in combination with dexamethasone for the treatment of adults with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of the last therapy.\n\n### Dosage and Administration:\n- The typical starting"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_wrzMfMoKPoxvm3IMUvlwulci", "custom_id": "218_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a4e70bc6fcf7957e36e8ad9ff801b8e4", "body": {"id": "chatcmpl-9St5p8pD8iviiA69NXjktjFkDZrzm", "object": "chat.completion", "created": 1716671989, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ponatinib is a tyrosine kinase inhibitor (TKI) used primarily in the treatment of certain types of leukemia, particularly chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+). Here are some key points you should consider as a physician:\n\n### **Indications:**\n1. **Chronic Myeloid Leukemia (CML):**\n   - Used in adults with chronic, accelerated, or blast phase CML who are resistant or intolerant to other TKIs.\n   - Particularly effective against CML with the T315I mutation, which confers resistance to many other TKIs.\n   \n2. **Acute Lymphoblastic Leukemia (ALL):**\n   - Indicated for Ph+ ALL in adults who are resistant or intolerant to prior TKI therapy.\n\n### **Mechanism of Action:**\n- Ponatinib inhibits the BCR-ABL tyrosine kinase, including the forms"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_XP6WCtvWzJygqPYXoqiMMP5X", "custom_id": "219_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8e2dd35c97fc259837182af7adb9a296", "body": {"id": "chatcmpl-9St5p9w04FdrXIJS0sFinRtngHzzD", "object": "chat.completion", "created": 1716671989, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's essential to have a comprehensive understanding of pralatrexate, especially if you will be prescribing or managing patients on this medication. Here are key points to consider:\n\n### 1. **Indication**\nPralatrexate is primarily indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).\n\n### 2. **Mechanism of Action**\nPralatrexate is a folate analog metabolic inhibitor. It works by inhibiting dihydrofolate reductase (DHFR), leading to a reduction in tetrahydrofolate, thus disrupting DNA synthesis and cell replication.\n\n### 3. **Administration**\n- **Route:** Intravenous (IV) infusion.\n- **Dosing:** Typically administered at a dose of 30 mg/m\u00b2 once weekly for 6 weeks in 7-week cycles. Adjustments may be necessary based on patient tolerance and adverse effects.\n\n### 4. **Side Effects**\nCommon side effects include:\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_TxIEXPhTGo62kd9NewoNnAsn", "custom_id": "220_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2c44c528455976d4918aeb733327051e", "body": {"id": "chatcmpl-9St5pTn9pxXRRJ0VRgT6MTudRlzZO", "object": "chat.completion", "created": 1716671989, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pravastatin is a medication commonly used to manage and prevent cardiovascular disease by lowering cholesterol levels. Here are some key points you should be aware of:\n\n### Mechanism of Action\n- **Statin Class:** Pravastatin is a statin, which works by inhibiting HMG-CoA reductase, an enzyme involved in the synthesis of cholesterol in the liver.\n- **Cholesterol Reduction:** It effectively reduces low-density lipoprotein (LDL) cholesterol and triglycerides while modestly increasing high-density lipoprotein (HDL) cholesterol.\n\n### Indications\n- **Hypercholesterolemia:** Used for primary hypercholesterolemia (high cholesterol) and mixed dyslipidemia.\n- **Cardiovascular Disease Prevention:** Indicated for reducing the risk of myocardial infarction, stroke, and the need for revascularization procedures in patients with or at high risk for coronary artery disease.\n- **Post-MI Prophylaxis:** It can be used post"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_sAentcOVYHCham66EQk7OVSL", "custom_id": "221_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a2482e983257bdc479a4b3d7137cfaa8", "body": {"id": "chatcmpl-9St5pfKlscru8voHsJqnwuqVvmWcJ", "object": "chat.completion", "created": 1716671989, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, having a comprehensive understanding of Prednisolone is crucial to ensure its safe and effective use in your patients. Here's a detailed overview:\n\n### Mechanism of Action:\n- **Prednisolone** is a glucocorticoid, a type of corticosteroid, which mimics the effects of cortisol, a steroid hormone produced by the adrenal glands.\n- It works by suppressing the immune response and inflammation, reducing the activity of the immune system.\n\n### Indications:\n- **Inflammatory conditions**: Rheumatoid arthritis, lupus, and other autoimmune diseases.\n- **Allergic reactions**: Severe allergic reactions, asthma, and allergic rhinitis.\n- **Dermatologic conditions**: Psoriasis, eczema, and other inflammatory skin conditions.\n- **Gastrointestinal diseases**: Crohn\u2019s disease and ulcerative colitis.\n- **Respiratory diseases**: Chronic obstructive pulmonary disease (COPD), severe asthma.\n- **Hematologic disorders**: Auto"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_0xnbhGlv5V3UY3IwnjlqVeMv", "custom_id": "222_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9f5f7b8c1ef7c5e579dcedd4cacccf67", "body": {"id": "chatcmpl-9St5pnDtQw0jKXpQkL3xxDt6ql02i", "object": "chat.completion", "created": 1716671989, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prednisone is a synthetic glucocorticoid used for its anti-inflammatory and immunosuppressive properties. Here are several key points that physicians should know about Prednisone:\n\n### Indications\n- **Autoimmune Diseases**: Conditions such as rheumatoid arthritis, lupus, and inflammatory bowel disease.\n- **Allergic Reactions**: Severe allergic reactions and asthma exacerbations.\n- **Respiratory Conditions**: Chronic obstructive pulmonary disease (COPD) exacerbations.\n- **Dermatologic Conditions**: Severe skin diseases like psoriasis and eczema.\n- **Cancer**: As part of chemotherapy regimens for certain cancers.\n- **Endocrine Disorders**: Adrenal insufficiency and congenital adrenal hyperplasia.\n\n### Mechanism of Action\n- Prednisone works by mimicking cortisol, a natural hormone produced by the adrenal glands. It binds to glucocorticoid receptors, leading to reduced production of inflammatory mediators and suppression of the immune system.\n\n### Administration and Dosage\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_MtENbDP3sEzufRSkzhhQX4Kh", "custom_id": "223_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0cdb4165f74e437569d0cc2d2fbb1ed7", "body": {"id": "chatcmpl-9St5pmEmeyYL7SHifGd5oF3oC5llp", "object": "chat.completion", "created": 1716671989, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Procarbazine is an antineoplastic (anti-cancer) agent primarily used in the treatment of Hodgkin's lymphoma and certain brain tumors. As a physician, it's crucial to understand several key aspects of this medication:\n\n1. **Mechanism of Action**:\n   - Procarbazine is an alkylating agent that works by inhibiting DNA, RNA, and protein synthesis, leading to cell death. It is a part of the methylhydrazine derivative class and is often used in combination chemotherapy regimens.\n\n2. **Indications**:\n   - Primarily used for Hodgkin's lymphoma, often in combination regimens such as MOPP (mechlorethamine, vincristine, procarbazine, prednisone).\n   - Also indicated for certain brain tumors, including gliomas.\n\n3. **Dosage and Administration**:\n   - The dosage varies depending on the specific regimen and the patient's condition. It is typically administered orally.\n   - Doses are"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_UXkQvvkir0CDFEgw1AwaGqAr", "custom_id": "224_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "38457567298dad5df4e754a09e187e7a", "body": {"id": "chatcmpl-9St5qSe4RY2XroirjqZBD1So7dNx8", "object": "chat.completion", "created": 1716671990, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to understand both the medical uses and potential side effects of quinine to ensure its safe and effective use. Here are several key points:\n\n### Medical Uses:\n1. **Treatment of Malaria:**\n   - Quinine is primarily used to treat uncomplicated malaria caused by Plasmodium falciparum, especially in cases where the parasite is resistant to other antimalarial drugs.\n   - It's typically used in combination with other antimalarial medications to enhance efficacy and reduce resistance.\n\n2. **Nocturnal Leg Cramps:**\n   - Quinine was previously used to treat nocturnal leg cramps but its use for this indication has significantly declined due to safety concerns. In many countries, this use is now off-label and not recommended.\n\n### Mechanism of Action:\n- Quinine works by interfering with the parasite's ability to digest hemoglobin, thus killing the parasite in the blood.\n\n### Dosage and Administration:\n- Quinine is usually administered orally in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_jqCwke3lQ2Mi7TN300wcB2Uy", "custom_id": "225_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "4f9a4e80b47c832a51ac71319516eda6", "body": {"id": "chatcmpl-9St5qDYug0It8f6X625MreY1JBN8a", "object": "chat.completion", "created": 1716671990, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Quizartinib, also known by its chemical name AC220, is a targeted therapy drug primarily used in the treatment of acute myeloid leukemia (AML). Here are some key points you should know:\n\n1. **Mechanism of Action**: Quizartinib is a tyrosine kinase inhibitor (TKI) that specifically targets FLT3 (FMS-like tyrosine kinase 3), a receptor tyrosine kinase that is commonly mutated in AML. Mutations in FLT3, especially internal tandem duplications (FLT3-ITD), are associated with poor prognosis in AML.\n\n2. **Indications**: Quizartinib is indicated for the treatment of adult patients with relapsed or refractory AML who have FLT3-ITD mutations. It is important to test for FLT3 mutations to determine the appropriateness of this therapy.\n\n3. **Administration**: Quizartinib is administered orally. The dosing regimen can vary, so refer to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_f4xlh6tAzKZtyi73zdxFJOD2", "custom_id": "226_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a2c77a992a789e6f42892dc1ebcd1bd1", "body": {"id": "chatcmpl-9St5qA07r2kV2pBqtJ4yLjH8RyzdH", "object": "chat.completion", "created": 1716671990, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Radotinib is a second-generation tyrosine kinase inhibitor (TKI) primarily used in the treatment of chronic myeloid leukemia (CML). Here are some key points you should know about it as a physician:\n\n### Mechanism of Action:\n- **Target**: Radotinib specifically inhibits the BCR-ABL1 tyrosine kinase, which is produced by the Philadelphia chromosome abnormality in CML.\n- **Activity**: It is designed to bind to the ATP-binding site of the BCR-ABL1 protein, thereby blocking its kinase activity and subsequently inhibiting the proliferation of leukemic cells.\n\n### Indications:\n- **Chronic Myeloid Leukemia (CML)**: Radotinib is indicated for the treatment of adult patients with chronic phase (CP) or accelerated phase (AP) Philadelphia chromosome-positive CML who have resistance or intolerance to prior therapy, including imatinib.\n\n### Dosage and Administration:\n- **Dosage**: The recommended dose"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_QtZJ1TmtWoYYv98b9wOK9nPC", "custom_id": "227_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e778a4dc5649341dce50abdf520bcbc7", "body": {"id": "chatcmpl-9St5qD8WVFIwlBwfexwsaN65EQTtU", "object": "chat.completion", "created": 1716671990, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Raltitrexed is a chemotherapy medication primarily used to treat colorectal cancer. Here are some key points that you, as a physician, should know about Raltitrexed:\n\n1. **Mechanism of Action:**\n   - Raltitrexed is a thymidylate synthase inhibitor. It works by inhibiting thymidylate synthase, an enzyme essential for DNA synthesis. This inhibition leads to a reduction in DNA replication and cell division, particularly affecting rapidly dividing cancer cells.\n\n2. **Indications:**\n   - Raltitrexed is mainly indicated for the treatment of advanced colorectal cancer. It can be used as a monotherapy or in combination with other chemotherapeutic agents.\n\n3. **Dosage and Administration:**\n   - The typical dose of Raltitrexed is 3 mg/m\u00b2 administered as an intravenous infusion over 15 minutes every three weeks. Dosage may need adjustment based on patient-specific factors such as renal function.\n\n4. **Side Effects:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_8c8bmtvVfd4TdHiSWJdT2CLM", "custom_id": "228_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "59e85a37d83ddc55253602a191c0e5ee", "body": {"id": "chatcmpl-9St5quKlgfXiyn9A8LJxB43qj5pdm", "object": "chat.completion", "created": 1716671990, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ramucirumab is a monoclonal antibody used in cancer treatment that targets vascular endothelial growth factor receptor 2 (VEGFR-2). As a physician, it is important to be well-informed about its indications, mechanism of action, administration, and potential side effects.\n\n### Indications:\nRamucirumab is approved for use in several types of cancer, including:\n- **Gastric or Gastroesophageal Junction Adenocarcinoma**: Used as a single agent or in combination with paclitaxel after prior chemotherapy.\n- **Colorectal Cancer**: In combination with FOLFIRI (folinic acid, fluorouracil, and irinotecan) for metastatic colorectal cancer after disease progression with a bevacizumab-containing regimen.\n- **Non-Small Cell Lung Cancer (NSCLC)**: In combination with docetaxel after prior platinum-based chemotherapy.\n- **Hepatocellular Carcinoma**: For patients with alpha-fetoprotein"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_5YLabx7hJJMrwoa1gJQTXpde", "custom_id": "229_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "92440600bb6fb9240bc51b72808dcb70", "body": {"id": "chatcmpl-9St5qqgyygNXhjbpRMnZzychXFCgx", "object": "chat.completion", "created": 1716671990, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ranimustine, also known by its trade name Cymerin, is an alkylating agent used primarily in the treatment of various cancers. Here are some key points you should know about Ranimustine:\n\n1. **Mechanism of Action**: Ranimustine works by interfering with DNA replication and RNA transcription in cancer cells, leading to cell death. It forms cross-links in DNA strands, thereby preventing the cancer cells from proliferating.\n\n2. **Indications**: Ranimustine is often used in the treatment of hematologic malignancies such as non-Hodgkin's lymphoma, multiple myeloma, and certain types of leukemia. It may also be used in combination with other chemotherapy agents for solid tumors, although this is less common.\n\n3. **Administration**: Ranimustine is typically administered intravenously. The dosage and schedule depend on the specific type of cancer being treated, the patient's overall health, and their response to therapy.\n\n4. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_WvWqWausb33bVNj0uPfZDD58", "custom_id": "230_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "44f016816d9450764af309770a30f6da", "body": {"id": "chatcmpl-9St5rtEQxov1GHQ1HStdPtJTe1dWk", "object": "chat.completion", "created": 1716671991, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Regorafenib is an oral multi-kinase inhibitor used primarily in the treatment of certain types of cancers. Here are key points a physician should know about Regorafenib:\n\n### Indications:\n1. **Colorectal Cancer**: It is used for the treatment of metastatic colorectal cancer in patients who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.\n2. **Gastrointestinal Stromal Tumors (GIST)**: For patients with locally advanced, unresectable, or metastatic GIST who have been previously treated with imatinib and sunitinib.\n3. **Hepatocellular Carcinoma (HCC)**: For patients who have been previously treated with sorafenib.\n\n### Mechanism of Action:\n- Regorafenib works by inhibiting multiple protein kinases involved in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_E9S7oWBEThcInMTpSqiOeyuA", "custom_id": "231_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "877dade3ed5a87fcbe626eccc4f8091e", "body": {"id": "chatcmpl-9St5rhEDqd7WILq5wYi7Sqw6qvxmh", "object": "chat.completion", "created": 1716671991, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ribociclib, marketed under the brand name Kisqali, is an important medication used in the treatment of certain types of breast cancer. Here are key points you should be familiar with as a physician:\n\n### Mechanism of Action\n- **CDK4/6 Inhibitor**: Ribociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). By inhibiting these kinases, it helps to prevent the proliferation of cancer cells by inducing cell cycle arrest in the G1 phase.\n\n### Indications\n- **Hormone Receptor-Positive, HER2-Negative Breast Cancer**: Ribociclib is used in combination with an aromatase inhibitor (e.g., letrozole) or fulvestrant for the treatment of pre/perimenopausal and postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.\n\n### Administration\n- **Dosage**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_oOBbf7Hvz6MAvyftkRzRFYHU", "custom_id": "232_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e16fc23c5b5ce8ddb0b0abca12a6d072", "body": {"id": "chatcmpl-9St5rkncwfNsToTc14b2nEY5QYVDu", "object": "chat.completion", "created": 1716671991, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rituximab is a monoclonal antibody used in the treatment of various conditions, particularly certain types of cancer and autoimmune diseases. Here are some key points you should know about Rituximab as a physician:\n\n### Indications:\n1. **Hematological Cancers:**\n   - Non-Hodgkin's Lymphoma (NHL)\n   - Chronic Lymphocytic Leukemia (CLL)\n\n2. **Autoimmune Diseases:**\n   - Rheumatoid Arthritis (RA)\n   - Granulomatosis with Polyangiitis (GPA, formerly Wegener's Granulomatosis)\n   - Microscopic Polyangiitis (MPA)\n\n### Mechanism of Action:\n- Rituximab targets the CD20 antigen on the surface of B-cells, leading to their destruction. This helps in reducing the number of B-cells, which are involved in the pathogenesis of both certain cancers and autoimmune diseases.\n\n### Administration:\n- **Route"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_nYrgru3lU1C1OjAOpxuaP34a", "custom_id": "233_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8ca20697474f7d582d7a5dc9609f45c5", "body": {"id": "chatcmpl-9St5rUZNBMfVAeiWy68aOHBQpdIFq", "object": "chat.completion", "created": 1716671991, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rituximab and hyaluronidase human is a combination medication used primarily in the treatment of certain types of cancer, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, as well as some autoimmune diseases like rheumatoid arthritis. Here are some key points you should be aware of as a physician:\n\n### Mechanism of Action:\n- **Rituximab**: This is a monoclonal antibody that targets CD20, a protein found on the surface of B-cells. By binding to CD20, rituximab induces B-cell lysis through various mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and induction of apoptosis.\n- **Hyaluronidase Human**: This is an enzyme that breaks down hyaluronic acid, a substance in the extracellular matrix. The addition of hyaluronidase increases the permeability of tissues, facilitating the dispersion and absorption of rituximab when"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_c1VBwGweeCQGX6jwpdibELjh", "custom_id": "234_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6124a5cdbeea587c4a05a1cc83184cfa", "body": {"id": "chatcmpl-9St5rqcCmq6uXMxkUZQYfljyIOoV5", "object": "chat.completion", "created": 1716671991, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Romidepsin, also known by its brand name Istodax, is an anticancer agent used primarily in the treatment of certain types of T-cell lymphomas. Here are some critical points you should know about Romidepsin:\n\n### Indications:\n1. **Peripheral T-cell Lymphoma (PTCL):** Romidepsin is approved for the treatment of PTCL in patients who have received at least one prior therapy.\n2. **Cutaneous T-cell Lymphoma (CTCL):** It is also indicated for the treatment of CTCL in patients who have received at least one prior systemic therapy.\n\n### Mechanism of Action:\nRomidepsin is a histone deacetylase (HDAC) inhibitor. By inhibiting HDAC enzymes, it causes an accumulation of acetylated histones and other proteins, leading to cell cycle arrest and apoptosis of cancer cells.\n\n### Administration:\n- **Route:** Romidepsin is administered intravenously.\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_xA9cqwFNVJmNY1KGinaptFKw", "custom_id": "235_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "4f179c7d60ad739edb1a8ebe40dcd9f6", "body": {"id": "chatcmpl-9St5rwZXVOk207fsONW0YYWegvk9o", "object": "chat.completion", "created": 1716671991, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ropeginterferon alfa-2b, also known by its brand name Besremi, is a long-acting pegylated interferon used primarily in the treatment of polycythemia vera (PV), a type of myeloproliferative disorder. Here are several key points you should know about Ropeginterferon alfa-2b:\n\n### Mechanism of Action\n- Ropeginterferon alfa-2b is an interferon alfa-2b conjugated to a polyethylene glycol molecule. This pegylation increases the half-life of the drug, allowing for less frequent dosing compared to non-pegylated interferons.\n- It works by modulating the immune system and has antiviral, antiproliferative, and immunomodulatory effects. Specifically, in PV, it helps to reduce the overproduction of red blood cells by the bone marrow.\n\n### Indications\n- Approved for the treatment of polycythemia vera in adults.\n- It may also"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_VisHxxga9LhJMXk9SY06HGRJ", "custom_id": "236_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "fcfe4694e6ca41167ed61e1e1afa6238", "body": {"id": "chatcmpl-9St5sPi3h8A9cd6Mg0U0kru5QqwEj", "object": "chat.completion", "created": 1716671992, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rucaparib is an oral small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, particularly PARP-1, PARP-2, and PARP-3. It is primarily used in oncology for the treatment of certain types of cancers, especially ovarian cancers and prostate cancers that have specific genetic mutations. Here are the key points you should know about Rucaparib:\n\n### Indications:\n1. **Ovarian Cancer:**\n   - Rucaparib is indicated for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies.\n   - It's also used as maintenance therapy for recurrent ovarian cancer in patients who are in complete or partial response to platinum-based chemotherapy.\n\n2. **Prostate Cancer:**\n   - Rucaparib is indicated for the treatment of patients with BRCA-mutated metastatic castration-resistant prostate"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_P2Q8ZLrLv9wwXgyfZtw25f5a", "custom_id": "237_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d34f3ad6e80b35953528c37ef9990182", "body": {"id": "chatcmpl-9St5sDf2slLl6ZtxBX8cz9fhpixnQ", "object": "chat.completion", "created": 1716671992, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ruxolitinib is a medication that is primarily used in the treatment of certain types of myeloproliferative disorders. Here are several key points that you, as a physician, should know about Ruxolitinib:\n\n### Indications\n1. **Myelofibrosis:** Ruxolitinib is FDA-approved for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.\n2. **Polycythemia Vera:** It is also approved for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.\n3. **Graft-Versus-Host Disease (GVHD):** It has been approved for steroid-refractory acute and chronic GVHD.\n\n### Mechanism of Action\nRuxolitinib is a Janus"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Xbnp60yyfYuTOxmYYC31pz14", "custom_id": "238_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "cb7fdaa48aa96ce2ac1337e1d2a10148", "body": {"id": "chatcmpl-9St5sdhJaEk6cYLw7X7y2IFsufEPE", "object": "chat.completion", "created": 1716671992, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sacituzumab govitecan, sold under the brand name Trodelvy, is a targeted cancer therapy used primarily for the treatment of certain types of advanced or metastatic cancers, specifically triple-negative breast cancer (TNBC) and urothelial cancer. Here are some key points that you, as a physician, should know about this medication:\n\n### Mechanism of Action:\n1. **Antibody-Drug Conjugate (ADC):** Sacituzumab govitecan is an ADC that combines an anti-Trop-2 monoclonal antibody with a topoisomerase inhibitor (SN-38, the active metabolite of irinotecan).\n2. **Targeting Trop-2:** Trop-2 is a protein commonly overexpressed on the surface of many epithelial cancers, including TNBC and urothelial cancer. The antibody component specifically binds to Trop-2.\n3. **Cytotoxic Payload:** Once bound to Trop-2 on the cancer cell surface, the ADC"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_lwHdZPyizVBGOzOdX8fcHeHi", "custom_id": "239_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "547e4dcc05a2a5c7facc7ecca39b17c7", "body": {"id": "chatcmpl-9St5sIaLoqdn1KxJohQUSaSDIyNgL", "object": "chat.completion", "created": 1716671992, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sargramostim is a recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) used to stimulate the production of white blood cells, particularly granulocytes and macrophages. It's primarily used in clinical settings to enhance bone marrow recovery and function. Here are some key points you should know about Sargramostim:\n\n### Indications\n1. **Bone Marrow Transplantation**: Used to accelerate myeloid recovery in patients undergoing autologous or allogeneic bone marrow transplantation.\n2. **Peripheral Blood Progenitor Cell Transplantation**: Aids in mobilizing hematopoietic progenitor cells for collection and later infusion.\n3. **Chemotherapy-Induced Neutropenia**: Helps reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy.\n4. **Myeloid Reconstitution**: Used in patients with acute myeloid leukemia (AML) to accelerate"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_HWR6GYj2bPSIe0X4YrGRKEmQ", "custom_id": "240_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ca1c2829b449e9d9c5456159b39b8463", "body": {"id": "chatcmpl-9St5suKi6PRU8bv2CyLAnaKaoUpez", "object": "chat.completion", "created": 1716671992, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Selinexor is an oral selective inhibitor of nuclear export (SINE) compound, primarily used in the treatment of certain cancers. Here are some key points you should know about Selinexor:\n\n### Mechanism of Action\n- **Nuclear Export Inhibition**: Selinexor works by inhibiting the nuclear export protein exportin-1 (XPO1). By blocking XPO1, Selinexor prevents the export of tumor suppressor proteins (TSPs) from the nucleus to the cytoplasm, leading to the accumulation of TSPs in the nucleus and promoting cancer cell apoptosis.\n\n### Indications\n- **Multiple Myeloma**: Selinexor is approved for use in combination with dexamethasone for patients with relapsed or refractory multiple myeloma who have received at least four prior therapies.\n- **Diffuse Large B-Cell Lymphoma (DLBCL)**: It is also approved for the treatment of relapsed or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_jBaoJ8gR7sqYV0qRuSRcncNi", "custom_id": "241_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "49bdaa054a27e1b6aed2a9abf49b5398", "body": {"id": "chatcmpl-9St5suIhSLyuDVltqFO1Tgc5Pi3uZ", "object": "chat.completion", "created": 1716671992, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Selumetinib is a medication that has gained attention for its use in certain types of cancer treatment. Here are the key points you should know about Selumetinib:\n\n### Mechanism of Action\n- **Target:** Selumetinib is a selective inhibitor of MEK1 and MEK2, which are part of the MAPK/ERK signaling pathway.\n- **Pathway Role:** This pathway is often upregulated in various cancers, and its inhibition can reduce cell proliferation and induce apoptosis in tumor cells.\n\n### Indications\n- **Neurofibromatosis Type 1 (NF1):** Selumetinib is FDA-approved for the treatment of pediatric patients (aged 2 years and older) with symptomatic, inoperable plexiform neurofibromas, which are associated with NF1.\n- **Other Cancers:** Research and clinical trials are ongoing to explore its efficacy in other cancers, including certain types of melanoma, thyroid cancer, and lung cancer.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_1MbSUjQ0dB5mLw4EH0N9vWuN", "custom_id": "242_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "af61261cdbc22442c7485da9b7df33dc", "body": {"id": "chatcmpl-9St5s0PHQhaE9vUDJU5fxsA6LFKRD", "object": "chat.completion", "created": 1716671992, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Semustine, also known as methyl-CCNU, is an alkylating agent used in chemotherapy. Here are some key points you should know about Semustine:\n\n1. **Mechanism of Action**: Semustine works by alkylating DNA, which leads to the formation of cross-links and abnormal base pairing. This disrupts DNA replication and transcription, ultimately causing cell death. It is particularly effective against rapidly dividing cells, which include many types of cancer cells.\n\n2. **Indications**: Semustine has been used in the treatment of various cancers, including brain tumors, Hodgkin's disease, and gastrointestinal cancers. However, its use has declined due to the development of more effective and better-tolerated alternatives.\n\n3. **Administration**: Semustine is typically administered orally. The dosing regimen can vary based on the type of cancer being treated, the patient's overall health, and other factors. It is usually given in cycles, with periods of treatment followed by"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_pSqEZjnE2vm2HzXqIbjDdSfP", "custom_id": "243_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "62c95195d3c3bc6191e6aeb961c79f71", "body": {"id": "chatcmpl-9St5tLulLO6Xbo1EsJJz8YUJERvD7", "object": "chat.completion", "created": 1716671993, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sipuleucel-T, marketed under the brand name Provenge, is an autologous cellular immunotherapy used to treat certain types of advanced prostate cancer. Here are key points you should know about Sipuleucel-T:\n\n### Indications\n- **Prostate Cancer**: Specifically indicated for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).\n\n### Mechanism of Action\n- **Immunotherapy**: Sipuleucel-T is designed to stimulate the patient's immune system to attack prostate cancer cells. It involves collecting the patient\u2019s own immune cells (antigen-presenting cells or APCs), exposing them to a protein (PAP-GM-CSF) that targets prostate cancer, and then reinfusing them back into the patient.\n\n### Administration Process\n1. **Leukapheresis**: The patient undergoes leukapheresis to collect APCs.\n2. **Cell Processing**: The collected cells are sent to a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Hdl1imJ2Icufiiy4sFcie9qc", "custom_id": "244_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "13310a22d52f6a089c1974ab5433ac3d", "body": {"id": "chatcmpl-9St5toyJuVHEVBgJcJOGkIKTTkgTr", "object": "chat.completion", "created": 1716671993, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sonidegib is a medication used primarily in the treatment of advanced basal cell carcinoma (BCC), specifically in cases where the cancer is locally advanced and cannot be treated with surgery or radiation, or in cases where the cancer has metastasized. Here are some key points you should know about Sonidegib:\n\n### Mechanism of Action\n- Sonidegib is a Hedgehog pathway inhibitor. The Hedgehog signaling pathway plays a crucial role in cell growth and differentiation, and its dysregulation is implicated in the development of BCC.\n- Sonidegib specifically targets and inhibits the Smoothened (SMO) receptor, a critical component of the Hedgehog pathway, thus preventing the pathway's activation and subsequent tumor growth.\n\n### Indications\n- Sonidegib (Odomzo) is approved for the treatment of adults with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or for patients who are not candidates for surgery or radiation"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_uVMY2dwNlieoo8yDJTZEdWrh", "custom_id": "245_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8cc7bc759c650a54c7ea4dbcf2d2fae6", "body": {"id": "chatcmpl-9St5tO94WuvEnpphOBcEyYrln3luX", "object": "chat.completion", "created": 1716671993, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sorafenib is an oral multikinase inhibitor used primarily in the treatment of certain types of cancer. Here are some key points you should know about Sorafenib:\n\n### Indications\n1. **Hepatocellular Carcinoma (HCC)**: It is approved for the treatment of advanced liver cancer.\n2. **Renal Cell Carcinoma (RCC)**: Used for advanced kidney cancer.\n3. **Thyroid Cancer**: Specifically for differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.\n\n### Mechanism of Action\nSorafenib inhibits multiple intracellular and cell surface kinases, which play a role in tumor cell proliferation and angiogenesis. Key targets include:\n- **Raf kinase** (part of the MAPK/ERK pathway)\n- **VEGFR-2 and VEGFR-3** (vascular endothelial growth factor receptors)\n- **PDGFR-\u03b2** (platelet-derived growth factor receptor)\n- **C-KIT**,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_8rj3EX7uIbWFio0bWA2mcsuH", "custom_id": "246_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "51afd18722758457d5615ad013315fd2", "body": {"id": "chatcmpl-9St5ur7ryBMyhqwnXJBLzTfsD79ok", "object": "chat.completion", "created": 1716671994, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Streptozocin (also spelled streptozotocin) is a chemotherapy agent used primarily in the treatment of pancreatic neuroendocrine tumors. Here are several key points you should know about this medication:\n\n### Mechanism of Action\n- **Alkylating Agent:** Streptozocin is an alkylating agent that causes DNA damage, leading to cell death. It specifically targets pancreatic beta cells, which is why it is also used experimentally to induce diabetes in animal models.\n\n### Indications\n- **Cancer Treatment:** It is primarily used for treating metastatic pancreatic islet cell carcinoma.\n- **Experimental Use:** In research, streptozocin is used to induce diabetes in animal models due to its selective toxicity to insulin-producing beta cells in the pancreas.\n\n### Administration\n- **Routes:** It can be administered intravenously.\n- **Dosage:** The dosage and schedule depend on the specific clinical scenario and patient condition. It's crucial to follow oncology protocols for administration.\n\n### Side Effects"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_BDvAiWAwJYLjgQpDGgnljaVn", "custom_id": "247_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "20f86af6eb5f9adad7941b24ffe0e8bd", "body": {"id": "chatcmpl-9St5u3DONy9uJcTgr0BXETYQPVBpW", "object": "chat.completion", "created": 1716671994, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sunitinib, sold under the brand name Sutent among others, is a multi-kinase inhibitor used primarily in the treatment of certain types of cancer. Here are some key points that you, as a physician, should know about Sunitinib:\n\n### Indications:\n1. **Renal Cell Carcinoma (RCC):** Sunitinib is often used as a first-line treatment for advanced or metastatic RCC.\n2. **Gastrointestinal Stromal Tumor (GIST):** It is indicated for the treatment of GIST after disease progression on or intolerance to imatinib mesylate.\n3. **Pancreatic Neuroendocrine Tumors (pNET):** Sunitinib is also approved for the treatment of unresectable, well-differentiated pNET in patients with disease progression.\n\n### Mechanism of Action:\n- **Multi-Kinase Inhibitor:** Sunitinib inhibits multiple receptor tyrosine kinases"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_GZOYpg5KxoJJNJxoWiLpO39k", "custom_id": "248_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8955284059343eaed79e28751514765e", "body": {"id": "chatcmpl-9St5uXXKb0SOFW7ozLPOMgCyHbE8w", "object": "chat.completion", "created": 1716671994, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tagraxofusp, also known as SL-401, is a targeted therapy drug that has been approved for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Here's a detailed overview of what you should know about this medication as a physician:\n\n### Mechanism of Action:\nTagraxofusp is a fusion protein consisting of two main components:\n1. **Interleukin-3 (IL-3)**: This component targets the IL-3 receptor, which is overexpressed on the surface of BPDCN cells.\n2. **Diphtheria Toxin**: Once the fusion protein binds to the IL-3 receptor on the cancer cells, the diphtheria toxin is internalized, inhibiting protein synthesis and leading to cell death.\n\n### Indications:\n- **BPDCN**: It is primarily used for the treatment of blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive hematologic malignancy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_GacXtyHYLJJVNlWEWD2Jl6I9", "custom_id": "249_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0453cc88d160527896e1330d3961321b", "body": {"id": "chatcmpl-9St5uu0Ryk6dOoGKEPoYLfEYosfza", "object": "chat.completion", "created": 1716671994, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Talazoparib is a potent PARP (poly ADP-ribose polymerase) inhibitor used primarily in the treatment of certain types of cancer. Here are key points you should know about Talazoparib:\n\n### Indications\n1. **Breast Cancer**: Talazoparib is approved for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer.\n\n### Mechanism of Action\n1. **PARP Inhibition**: Talazoparib inhibits the PARP enzyme, which plays a critical role in DNA repair. By inhibiting PARP, Talazoparib leads to the accumulation of DNA damage in cancer cells, particularly those deficient in homologous recombination repair (such as BRCA1/2 mutations), ultimately causing cell death.\n\n### Pharmacokinetics\n1. **Absorption**: Talazoparib is absorbed orally,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_hm9tbP60sI0C3IFdWqzTZ3SQ", "custom_id": "250_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b8164b7c8b333375b247d397e95c2ca7", "body": {"id": "chatcmpl-9St5ugLXgShkZHzIyULwA96Psk4Qs", "object": "chat.completion", "created": 1716671994, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Talimogene laherparepvec, commonly referred to as T-VEC, is an oncolytic virus therapy used in the treatment of melanoma. Here are some key points you should be aware of:\n\n### Mechanism of Action:\n1. **Oncolytic Virus:** T-VEC is a genetically modified herpes simplex virus type 1 (HSV-1) designed to selectively infect and lyse cancer cells.\n2. **GM-CSF Expression:** The virus is engineered to express granulocyte-macrophage colony-stimulating factor (GM-CSF), which enhances the anti-tumor immune response by attracting dendritic cells to the tumor site, promoting an adaptive immune response against the tumor.\n\n### Indications:\n- T-VEC is primarily indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.\n\n### Administration:\n- **Intralesional Injection:** T-VEC is administered directly into the tumor lesions"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_fuVQTDbVVyRja2hYC7YriX6n", "custom_id": "251_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "3b15a0ee9af9a7a1a8389f71451debf6", "body": {"id": "chatcmpl-9St5ufMUeq4SodSCdPa5dr9eftc9R", "object": "chat.completion", "created": 1716671994, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tamibarotene is a synthetic retinoid that is primarily used in the treatment of acute promyelocytic leukemia (APL), particularly in patients who have relapsed or are refractory to first-line treatment with all-trans retinoic acid (ATRA). Here are some key points you should know about Tamibarotene:\n\n### Mechanism of Action\n- **Retinoic Acid Receptor (RAR) Agonist**: Tamibarotene selectively binds to the retinoic acid receptor alpha (RAR\u03b1), promoting differentiation and apoptosis of malignant promyelocytes in APL.\n- **Overcomes Resistance**: It has been designed to overcome resistance to ATRA by having a higher affinity for RAR\u03b1 and a lower affinity for cellular retinoic acid-binding proteins.\n\n### Indications\n- **Acute Promyelocytic Leukemia (APL)**: Specifically used in patients with relapsed or refractory APL.\n- **Potential Uses**: Research is ongoing into its efficacy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_nVoephcEusFPdKva6NHipfk8", "custom_id": "252_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "1c1722c3110ac420a197199c4ad9b57d", "body": {"id": "chatcmpl-9St5uAEZzYj8Px0fxdDGoZgZ8hZYk", "object": "chat.completion", "created": 1716671994, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tamoxifen is a selective estrogen receptor modulator (SERM) commonly used in the treatment and prevention of breast cancer. As a physician, here are some key points you should be aware of regarding Tamoxifen:\n\n### Indications\n1. **Breast Cancer Treatment**: Primarily used for estrogen receptor-positive (ER+) breast cancer in both premenopausal and postmenopausal women.\n2. **Breast Cancer Prevention**: Used in women at high risk for developing breast cancer to reduce the incidence of the disease.\n3. **Other Uses**: Occasionally used in other estrogen-related conditions such as gynecomastia and infertility due to anovulation.\n\n### Mechanism of Action\n- Tamoxifen binds to estrogen receptors on breast cancer cells, thereby blocking estrogen's proliferative effects. This reduces tumor growth and the risk of recurrence.\n\n### Dosage and Administration\n- The typical dose for breast cancer treatment is 20 mg orally once daily. It can be taken"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_mRkGLc5Yhd1LjPdrEjUNUncp", "custom_id": "253_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0ab38441ba00c0bc5406bfe1add019f6", "body": {"id": "chatcmpl-9St5ui2ZevHlTFQJ8echVP805TO90", "object": "chat.completion", "created": 1716671994, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tegafur/gimeracil/oteracil, often referred to by its brand name S-1, is an oral chemotherapeutic agent used primarily in the treatment of various cancers, including gastric cancer, colorectal cancer, and pancreatic cancer. Here are some key points you should know about this medication:\n\n### Composition and Mechanism of Action:\n1. **Tegafur**: A prodrug of 5-fluorouracil (5-FU). It is metabolized in the body to 5-FU, which inhibits thymidylate synthase, leading to disruption of DNA synthesis and cell death in rapidly dividing cancer cells.\n\n2. **Gimeracil**: An inhibitor of dihydropyrimidine dehydrogenase (DPD), the enzyme responsible for the breakdown of 5-FU. By inhibiting DPD, gimeracil increases the bioavailability and efficacy of 5-FU.\n\n3. **Oterac"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_xYIJ8wGifGKxG6l3A27aR15T", "custom_id": "254_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6eec4238b0aedf9366955f2d0a353b1c", "body": {"id": "chatcmpl-9St5va1QLdHJRNmqMz1vO5DKiXjUL", "object": "chat.completion", "created": 1716671995, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tegafur and uracil are components of a combination chemotherapy medication used primarily in the treatment of certain types of cancers, including colorectal cancer. Here\u2019s a detailed overview of what you should know about this combination:\n\n### Mechanism of Action\n- **Tegafur**: Tegafur is a prodrug of 5-fluorouracil (5-FU). Once metabolized in the body, it is converted into 5-FU, which interferes with the synthesis of DNA and RNA. This ultimately inhibits the growth and proliferation of cancer cells.\n- **Uracil**: Uracil is included to enhance the efficacy of tegafur. It acts by inhibiting dihydropyrimidine dehydrogenase (DPD), the enzyme responsible for the breakdown of 5-FU. This inhibition increases and prolongs the availability of 5-FU in the body.\n\n### Indications\n- Primarily used for colorectal cancer, but it"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_QNgSq51Ir6wmnlfhx9DR72wG", "custom_id": "255_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "816f88dc4e03ce810538b15c0fb59911", "body": {"id": "chatcmpl-9St5vrJgh2Hd2bErGpU4z6RNkMA8u", "object": "chat.completion", "created": 1716671995, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Temozolomide is an oral chemotherapy medication primarily used in the treatment of certain types of brain tumors, such as glioblastoma multiforme and anaplastic astrocytoma. Here are some key points you should know about Temozolomide:\n\n### Mechanism of Action\n- **Alkylating Agent:** Temozolomide is an alkylating agent that works by methylating DNA, which leads to DNA damage and apoptosis (programmed cell death) in rapidly dividing cancer cells.\n\n### Indications\n- **Glioblastoma Multiforme:** Often used in newly diagnosed cases in combination with radiotherapy, followed by maintenance therapy.\n- **Anaplastic Astrocytoma:** Used in cases where the tumor has recurred or progressed.\n\n### Administration\n- **Oral Route:** Temozolomide is administered orally in capsule form.\n- **Dosing Schedule:** Typically given once daily, often in cycles (e.g., 5 days on"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_2DBpFK1DgbRPyAXjbJ7ZlXjj", "custom_id": "256_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2b4a9513fb65083950b8711df0a5fc32", "body": {"id": "chatcmpl-9St5vQbH725F6BYzkpkdccAJW2XsE", "object": "chat.completion", "created": 1716671995, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Temsirolimus is an mTOR (mammalian target of rapamycin) inhibitor used primarily in the treatment of advanced renal cell carcinoma (RCC) and has also been explored for other malignancies. Here are some key points you should know about Temsirolimus:\n\n### Mechanism of Action:\n- **mTOR Inhibition**: Temsirolimus inhibits the mTOR pathway, which is crucial for cell growth, proliferation, and survival. It specifically binds to the FKBP-12 protein to form a complex that inhibits mTORC1 (mTOR Complex 1).\n- **Antineoplastic Effects**: By inhibiting mTOR, Temsirolimus reduces protein synthesis and cell proliferation, and it can induce apoptosis in certain cancer cells.\n\n### Indications:\n- **Advanced Renal Cell Carcinoma (RCC)**: Temsirolimus is primarily used for treating advanced RCC, particularly in patients with poor prognostic features.\n- **Other Cancers**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_V5TTXA3I1nLohrR2SUGWxoTU", "custom_id": "257_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a19d092daaab99f215ac5e8a3b5d16fd", "body": {"id": "chatcmpl-9St5v93DvA65gfb6FnycXp1y1I6Nb", "object": "chat.completion", "created": 1716671995, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Teniposide, also known by its brand name Vumon, is a chemotherapeutic agent used primarily in the treatment of certain types of cancer. Here are some key points you should know about Teniposide as a physician:\n\n### Mechanism of Action:\n- **Class:** Teniposide is a topoisomerase II inhibitor. It works by interfering with the enzyme topoisomerase II, which is involved in DNA replication and repair. By inhibiting this enzyme, Teniposide causes breaks in DNA strands, leading to cell death, particularly in rapidly dividing cancer cells.\n\n### Indications:\n- **Acute Lymphoblastic Leukemia (ALL):** Teniposide is often used in combination with other chemotherapeutic agents for the treatment of refractory or relapsed ALL in pediatric and adult patients.\n- **Other Cancers:** Though primarily used for ALL, it may also be used off-label for other types of cancer, including certain lymphomas and brain tumors, depending on"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_XgUTuQuVOb85vZ4oudRBOsJr", "custom_id": "258_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "fd27cc5fe82af85ebaba09331eea6f14", "body": {"id": "chatcmpl-9St5vnBpf0J7QpmTer1MyIAXCrekY", "object": "chat.completion", "created": 1716671995, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Thalidomide is a medication with a complex and historically significant profile. Here are key points you should know about it:\n\n### Historical Context\n1. **Initial Use and Tragedy**:\n   - Thalidomide was originally marketed in the late 1950s and early 1960s as a sedative and anti-nausea drug, particularly for pregnant women.\n   - It led to a major medical disaster when it was found to cause severe birth defects (phocomelia) in thousands of babies worldwide.\n\n### Mechanism of Action\n2. **Immunomodulatory Effects**:\n   - Thalidomide has multiple mechanisms of action. It is known for its immunomodulatory, anti-inflammatory, and anti-angiogenic properties.\n   - It inhibits tumor necrosis factor-alpha (TNF-\u03b1) and modulates other cytokines, impacting various pathways in the immune system.\n\n### Current Medical Uses\n3. **Indications**:\n   - Despite its"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_WlunLwct5xd9GRq8WoORBn1p", "custom_id": "259_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c22d6ad55d5b95f81860b4b453a38a5d", "body": {"id": "chatcmpl-9St5w1x6TDNHpblJeGe9tdUjWXiC8", "object": "chat.completion", "created": 1716671996, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Thioguanine, also known as 6-thioguanine (6-TG), is a purine analogue and antimetabolite used primarily in the treatment of certain types of leukemia. Here are some key points you should know about thioguanine:\n\n### Indications:\n- **Acute Myeloid Leukemia (AML):** Thioguanine is often used in combination with other chemotherapeutic agents.\n- **Acute Lymphoblastic Leukemia (ALL):** It can be part of maintenance therapy.\n\n### Mechanism of Action:\n- **Antimetabolite:** Thioguanine is incorporated into DNA and RNA, leading to the inhibition of DNA synthesis and function, which induces cell cycle arrest and apoptosis in rapidly dividing cells.\n- **Thiopurine Metabolism:** It is metabolized by the enzyme thiopurine methyltransferase (TPMT) and other pathways, producing active metabolites that exert cytotoxic effects.\n\n### Pharmacokinetics"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_uTuWrYIJud5MNwzyguFcCyvX", "custom_id": "260_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e8dac2751e6bcc12e180238af93d17ff", "body": {"id": "chatcmpl-9St5w27QgwDoAeM0waDMxjNZTiaWq", "object": "chat.completion", "created": 1716671996, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Thiotepa is an alkylating agent used primarily in the treatment of certain types of cancers. Here are some key points you should know about Thiotepa:\n\n### Mechanism of Action\n- **Alkylating Agent**: Thiotepa works by cross-linking DNA strands, which inhibits DNA replication and transcription, leading to cell death. It is particularly effective against rapidly dividing cancer cells.\n\n### Indications\n- **Hematologic Malignancies**: It is often used in conditioning regimens prior to hematopoietic stem cell transplantation.\n- **Solid Tumors**: Used in the treatment of breast cancer, ovarian cancer, and bladder cancer, among others.\n- **Central Nervous System (CNS) Cancers**: Sometimes used intrathecally for CNS malignancies.\n\n### Administration\n- **Routes**: Can be administered intravenously, intravesically (directly into the bladder), or intrathecally (into the cerebrospinal fluid).\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Co3jOIYSjcHTpAQVeD97a1nY", "custom_id": "261_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "af308167e9c9976a2f554f1de6585619", "body": {"id": "chatcmpl-9St5wmYUUC2lBsatzRqqhTqkfub3i", "object": "chat.completion", "created": 1716671996, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tisagenlecleucel (brand name Kymriah) is a type of CAR-T (Chimeric Antigen Receptor T-cell) therapy. It was one of the first gene therapies approved by the FDA. Here are some key points you should know about Tisagenlecleucel:\n\n### Indications:\n1. **Pediatric and Young Adult Acute Lymphoblastic Leukemia (ALL)**: It is approved for the treatment of patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse.\n2. **Adult Relapsed/Refractory (r/r) Large B-cell Lymphoma**: It is also approved for adult patients with r/r large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.\n\n### Mechanism of Action:\n- Tisagenlecle"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_OyBBK7dTzGP7v8Reit91BQmI", "custom_id": "262_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8f7aba6f942326fa69820b5a0edcc94c", "body": {"id": "chatcmpl-9St5wjJIWSDMKP0afvFra1Sn2jQCE", "object": "chat.completion", "created": 1716671996, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tivozanib is an oral tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. It is primarily used in the treatment of advanced renal cell carcinoma (RCC). Here are some key points you should be aware of as a physician:\n\n### Indications:\n- **Advanced Renal Cell Carcinoma (RCC):** Tivozanib is indicated for the treatment of adult patients with advanced RCC who have received at least two prior systemic therapies.\n\n### Mechanism of Action:\n- **VEGFR Inhibition:** Tivozanib inhibits VEGF-induced endothelial cell proliferation and survival, which reduces angiogenesis (the formation of new blood vessels) and tumor growth.\n\n### Administration:\n- **Dosing Schedule:** Typically, tivozanib is administered orally at a dose of 1.34 mg once daily for 21 consecutive days followed by 7 days off treatment, in a 28-day cycle"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_UndkROUdhS1IYcyVkhPkBsdt", "custom_id": "263_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6458a44ae3d49261a91a3a852803affa", "body": {"id": "chatcmpl-9St5w69cGxk9QgzxPq9G7fbuenhMf", "object": "chat.completion", "created": 1716671996, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Topotecan is a chemotherapeutic agent used primarily in the treatment of certain types of cancer. Here are some key points you should know about Topotecan as a physician:\n\n### Mechanism of Action\n- **Topoisomerase I Inhibition**: Topotecan works by inhibiting topoisomerase I, an enzyme crucial for DNA replication. By stabilizing the complex between topoisomerase I and DNA, it prevents the religation of the DNA strand, leading to DNA damage and cell death.\n\n### Indications\n- **Small Cell Lung Cancer (SCLC)**: Topotecan is approved for the treatment of relapsed small cell lung cancer.\n- **Ovarian Cancer**: It is used for metastatic ovarian cancer that has not responded to initial chemotherapy.\n- **Cervical Cancer**: In combination with cisplatin, Topotecan is used for the treatment of recurrent or persistent cervical cancer.\n\n### Administration\n- **Intravenous (IV)**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_XtnBYohosxkDbmkbrrSDWmQs", "custom_id": "264_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "88a6dfecdf113b695bd8f537c6920fde", "body": {"id": "chatcmpl-9St5wRL8kNof57rgDJLtWiC4loPeA", "object": "chat.completion", "created": 1716671996, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Toremifene is a selective estrogen receptor modulator (SERM) used primarily in the treatment of estrogen receptor-positive metastatic breast cancer in postmenopausal women. Here are key points you should know about Toremifene:\n\n### Mechanism of Action\n- **Estrogen Receptor Modulation**: Toremifene binds to estrogen receptors, exerting either estrogenic or antiestrogenic effects depending on the target tissue.\n- **Antiestrogenic Effects in Breast Tissue**: It prevents estrogen from binding to its receptor, thereby inhibiting the growth of estrogen-dependent breast cancer cells.\n\n### Indications\n- **Breast Cancer**: Specifically indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or unknown tumors.\n\n### Administration and Dosage\n- **Oral Administration**: Typically administered orally.\n- **Dosage**: The usual dose is 60 mg once daily, but always follow the specific prescribing information for the patient.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_a8Njsj8QjpW7p72YFwIgaQKt", "custom_id": "265_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "51e51e42a7e4b42067f18d00abf8350d", "body": {"id": "chatcmpl-9St5xiKU9oJea3e9QmBAzx0AFPW8I", "object": "chat.completion", "created": 1716671997, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tositumomab and I-131 (iodine I-131) are components of a radioimmunotherapy treatment used primarily for certain types of non-Hodgkin\u2019s lymphoma, specifically low-grade or transformed low-grade non-Hodgkin\u2019s lymphoma that has not responded adequately to conventional therapies. Here are some key points you should know:\n\n### Mechanism of Action\n- **Tositumomab**: This is a monoclonal antibody that targets the CD20 antigen found on the surface of B-cells, including malignant B-cells. By binding to CD20, it directs the immune system to attack the cancerous cells.\n- **I-131**: This is a radioactive isotope of iodine. When attached to tositumomab (forming the radioimmunoconjugate), it delivers targeted radiation to the CD20-positive B-cells, helping to destroy them.\n\n### Indications\n- Primarily used for patients with CD20-positive relapsed or refractory"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Fn3GQoWkLTnnTISTA8O4KnWo", "custom_id": "266_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ec9fb7b853bb143e37b993c1eeb9d57c", "body": {"id": "chatcmpl-9St5xPT1B4MALVrJDTmUegiinuxAW", "object": "chat.completion", "created": 1716671997, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trabectedin is a chemotherapeutic agent used mainly in the treatment of certain types of soft tissue sarcomas and ovarian cancer. Here are some key points you should know about it:\n\n### Mechanism of Action\n- **DNA Interaction:** Trabectedin binds to the minor groove of DNA, causing bending and disrupting the cell cycle. It interferes with transcription and DNA repair mechanisms.\n- **Impact on Tumor Microenvironment:** It affects the tumor microenvironment by modulating the production of cytokines and inhibiting tumor-associated macrophages, which can contribute to its antitumor activity.\n\n### Indications\n- **Soft Tissue Sarcoma:** Approved for patients with advanced soft tissue sarcoma, particularly liposarcoma and leiomyosarcoma, after the failure of anthracycline-based therapy.\n- **Ovarian Cancer:** Often used in combination with pegylated liposomal doxorubicin (PLD) for patients with recurrent ovarian cancer who have received prior platinum-based"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_SaD1ZBa47u4iWyq5hgr6P921", "custom_id": "267_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "eaa43143e2ae66d761f001db81823ed2", "body": {"id": "chatcmpl-9St5xRqielPvF0EXFrGpOhWGkudqn", "object": "chat.completion", "created": 1716671997, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is essential to have a thorough understanding of Trametinib, a medication used primarily in the treatment of certain types of cancer. Here are key points you should know:\n\n### Indications:\n- **Trametinib** is primarily used to treat melanoma with BRAF V600E or V600K mutations, either as a monotherapy or in combination with other drugs like dabrafenib.\n- It is also used for non-small cell lung cancer (NSCLC) and other cancers with similar mutations.\n\n### Mechanism of Action:\n- Trametinib is a **MEK inhibitor**. MEK1 and MEK2 are kinases in the MAPK/ERK pathway, which is often upregulated in cancers with BRAF mutations.\n- By inhibiting these kinases, trametinib reduces cell proliferation and induces apoptosis in tumor cells.\n\n### Dosage and Administration:\n- The standard dose for adults is 2 mg taken orally once daily.\n- It should"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_GWdmV7hjXiZLIvIeiFJGRJCC", "custom_id": "268_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5e4eeb9cb480976804f934c875f38d1a", "body": {"id": "chatcmpl-9St5xU5CqdVw3ZQ10scsZx3WwexwF", "object": "chat.completion", "created": 1716671997, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tranexamic acid (TXA) is a synthetic derivative of the amino acid lysine and is used primarily as an antifibrinolytic agent. As a physician, here are some key points you should know:\n\n1. **Mechanism of Action**: Tranexamic acid works by inhibiting the activation of plasminogen to plasmin, an enzyme involved in the breakdown of fibrin clots. This helps to reduce bleeding by stabilizing the formation of blood clots.\n\n2. **Indications**:\n   - **Trauma**: TXA is used to reduce mortality in trauma patients with significant bleeding.\n   - **Surgery**: It is often administered prophylactically in surgeries with a high risk of bleeding, such as cardiac, orthopedic, and dental procedures.\n   - **Menorrhagia**: Used to reduce heavy menstrual bleeding.\n   - **Postpartum Hemorrhage**: To manage severe bleeding after childbirth.\n   - **Hereditary Angioed"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_bv5y1gPg5v1O35Fx1cx0ePoT", "custom_id": "269_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "1f8bcb6505705e7ee808d0027c484d00", "body": {"id": "chatcmpl-9St5xkUm0IygleVx6jg49Wm9vtTeM", "object": "chat.completion", "created": 1716671997, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Trastuzumab, a monoclonal antibody primarily used in the treatment of HER2-positive breast cancer. Here are the key points you should know:\n\n### Mechanism of Action\n- **HER2 Receptor Targeting**: Trastuzumab binds to the human epidermal growth factor receptor 2 (HER2), which is overexpressed in some breast cancers and other types of cancers. This binding inhibits the proliferation of tumor cells that overexpress HER2.\n\n### Indications\n- **Breast Cancer**: It is used in both early-stage and metastatic HER2-positive breast cancer, often in combination with other chemotherapeutic agents.\n- **Gastric Cancer**: Trastuzumab is also approved for the treatment of HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.\n\n### Administration\n- **Routes**: Trastuzumab is typically administered intravenously, but there is also a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_E1kDHDlFMsELofRXMLZrcWQj", "custom_id": "270_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "efcd82d3a7c4c6483b1fc1d8e57bfdfa", "body": {"id": "chatcmpl-9St5xpixxJBXqhN0Niob1YOktGWxU", "object": "chat.completion", "created": 1716671997, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tremelimumab is a monoclonal antibody that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which is an immune checkpoint inhibitor. Here are several key points you should know about Tremelimumab:\n\n### Mechanism of Action:\n- **Immune Modulation:** Tremelimumab binds to CTLA-4, a protein receptor that downregulates immune responses. By inhibiting CTLA-4, Tremelimumab enhances the body's immune response against cancer cells.\n- **T-Cell Activation:** The inhibition of CTLA-4 leads to increased T-cell activation and proliferation, which can result in a more robust anti-tumor immune response.\n\n### Indications:\n- **Cancer Treatment:** Tremelimumab is primarily used in the treatment of certain types of cancer, including melanoma and other solid tumors. It may be used alone or in combination with other immune checkpoint inhibitors like PD-1/PD-L1 inhibitors.\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_6VzZvrYY73umI4mZEQUtcIii", "custom_id": "271_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c6e9c9587c1ad7b929ce212144313e40", "body": {"id": "chatcmpl-9St5xjsmwXDzRrOL86kHzaBQC7MGy", "object": "chat.completion", "created": 1716671997, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Treosulfan is a chemotherapy agent that has been used primarily in the treatment of ovarian cancer and as part of conditioning regimens for hematopoietic stem cell transplantation (HSCT). Here are some key points that you should know about Treosulfan:\n\n### Mechanism of Action\n- **Alkylating Agent**: Treosulfan is a bifunctional alkylating agent. It works by forming cross-links in DNA, leading to disruption of DNA synthesis and function, which ultimately induces cell death.\n- **Prodrug**: Treosulfan is converted in the body to a biologically active form, which is responsible for its cytotoxic effects.\n\n### Indications\n- **Ovarian Cancer**: Historically, Treosulfan has been used in the treatment of advanced ovarian cancer.\n- **Conditioning Regimen for HSCT**: More recently, it has been employed as part of conditioning regimens in patients undergoing hematopoietic stem cell transplantation"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_RzWjT1JvQeZTj5t8Jf7DPTtC", "custom_id": "272_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "cb713af2e650abd0e41e4f76f9d7484b", "body": {"id": "chatcmpl-9St5y8gRpSaEc06yKB45MW7TzXYr9", "object": "chat.completion", "created": 1716671998, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trifluridine and tipiracil, marketed under the brand name Lonsurf, are combined as an oral anticancer medication used primarily in the treatment of metastatic colorectal cancer and metastatic gastric or gastroesophageal junction adenocarcinoma. Here are key points you should know about this drug combination:\n\n### Mechanism of Action:\n- **Trifluridine**: A nucleoside analog that gets incorporated into DNA, leading to DNA dysfunction and inhibition of cell proliferation.\n- **Tipiracil**: A thymidine phosphorylase inhibitor that prevents the rapid degradation of trifluridine, thereby increasing its bioavailability and effectiveness.\n\n### Indications:\n- **Metastatic Colorectal Cancer**: Indicated for adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and, if RAS wild-type, an anti-EGFR therapy.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_e5x4yMINciVPFo5aC8gzy6Dl", "custom_id": "273_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c71c105df403c54912d0a83aee7529ec", "body": {"id": "chatcmpl-9St5yZHCtoeE4swkpVRxjH188UJnQ", "object": "chat.completion", "created": 1716671998, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Triptorelin is a synthetic decapeptide and a gonadotropin-releasing hormone (GnRH) agonist used primarily in the treatment of hormone-responsive cancers such as prostate cancer, central precocious puberty, and sometimes in other conditions like endometriosis and uterine fibroids. Here are key points you should know about Triptorelin:\n\n### Mechanism of Action\n- **GnRH Agonist**: Triptorelin acts by initially stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a temporary increase in sex hormones (testosterone in men and estrogen in women).\n- **Downregulation**: With continuous administration, it desensitizes the GnRH receptors, leading to decreased secretion of LH and FSH, which results in a significant reduction in sex hormone levels.\n\n### Indications\n- **Prostate Cancer**: Used for palliative treatment to reduce testosterone levels.\n- **Central"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Y3B4cB8AJPF5gjFOKZbq5Wec", "custom_id": "274_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d74353dc5a7f08728bfcc4e7888358c7", "body": {"id": "chatcmpl-9St5yw3HExABKNbbmCmx3C0oGcBpY", "object": "chat.completion", "created": 1716671998, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Valproate, also known as valproic acid, divalproex sodium, or sodium valproate, is a medication primarily used to treat epilepsy and bipolar disorder and to prevent migraine headaches. Here are key points you should know about Valproate:\n\n### Indications:\n1. **Epilepsy**: It's used to treat various types of seizures, including absence seizures, tonic-clonic seizures, and complex partial seizures.\n2. **Bipolar Disorder**: Used as a mood stabilizer, particularly for treating manic episodes.\n3. **Migraine**: It's effective in the prevention of migraines but is not used for acute treatment.\n\n### Mechanism of Action:\nValproate increases the levels of gamma-aminobutyric acid (GABA) in the brain, which helps to calm nerve activity. It also affects sodium channels and has some impact on the function of glutamate.\n\n### Dosage and Administration:\n- **Oral Tablets/Capsules**: Can"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_tlhCxuYdPLch8GQoMUgmniLg", "custom_id": "275_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "4f8ac44003b6145a54f33a419624561d", "body": {"id": "chatcmpl-9St5ybMvL9iD3vnhUHw0XkAuTNMwg", "object": "chat.completion", "created": 1716671998, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Valrubicin is an anthracycline chemotherapy drug primarily used for the treatment of bladder cancer, specifically for intravesical therapy in patients with Bacillus Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the bladder who are not candidates for immediate cystectomy. Here are some important points you should know about Valrubicin:\n\n### Indications\n- **Primary Indication**: Intravesical therapy for BCG-refractory carcinoma in situ (CIS) of the bladder.\n- **Off-label Use**: Sometimes considered in other types of bladder cancer, but this is less common and should be approached with caution.\n\n### Mechanism of Action\n- Valrubicin works by interfering with the DNA replication and repair processes in cancer cells, ultimately leading to cell death. As an anthracycline, it intercalates into DNA and inhibits topoisomerase II, an enzyme crucial for DNA replication.\n\n### Administration\n- **Route"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_aBNLBkq8FcuXBPqKTbIToMJr", "custom_id": "276_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c72cfce13b1850935b0fe65ff0bcda93", "body": {"id": "chatcmpl-9St5yx0McZJ3FM3btuyBEdhCKwvpF", "object": "chat.completion", "created": 1716671998, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vandetanib is a targeted therapy drug used primarily in the treatment of medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread (metastasized) to other parts of the body. Here are some key points you should know about Vandetanib:\n\n### Mechanism of Action:\n1. **Tyrosine Kinase Inhibitor (TKI)**: Vandetanib inhibits multiple receptor tyrosine kinases including VEGFR (vascular endothelial growth factor receptor), EGFR (epidermal growth factor receptor), and RET (rearranged during transfection) kinase.\n2. **Angiogenesis Inhibition**: By inhibiting VEGFR, Vandetanib reduces blood supply to tumors, thereby inhibiting their growth.\n3. **Direct Antitumor Activity**: Inhibition of EGFR and RET kinases can directly affect tumor cells by blocking their growth signals.\n\n### Indications:\n- Primarily approved for the treatment of symptomatic or progressive"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_rXVwrBDeX6oE2VBa6nZm3dWn", "custom_id": "277_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e10a2294fad30b049025566d33ddd075", "body": {"id": "chatcmpl-9St5yxW2D741wXWfiglaN5Vn9SJSY", "object": "chat.completion", "created": 1716671998, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vemurafenib is a targeted therapy drug primarily used to treat certain types of cancer, specifically those that have a mutation in the BRAF gene. Here are some key points you should know about Vemurafenib:\n\n### Indications:\n- **Metastatic Melanoma:** Vemurafenib is approved for the treatment of unresectable or metastatic melanoma with the BRAF V600E mutation.\n- **Other Cancers:** It may also be used off-label for other cancers harboring the BRAF V600 mutation, such as some thyroid and colorectal cancers.\n\n### Mechanism of Action:\n- Vemurafenib is a BRAF kinase inhibitor. It works by selectively inhibiting the mutated form of the BRAF protein (BRAF V600E), which is involved in the MAPK/ERK signaling pathway that promotes cancer cell growth.\n\n### Administration:\n- **Dosage:** The usual dosage is 960 mg orally twice daily.\n- **Form:** It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_R7uub9TXtcxsyo3iox3wEslZ", "custom_id": "278_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b41db21a2d05a70ca2b905b7e0a79a7c", "body": {"id": "chatcmpl-9St5zwcIHJ0IC1IJh5MJyJeeYXRdX", "object": "chat.completion", "created": 1716671999, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Venetoclax is an oral B-cell lymphoma-2 (BCL-2) inhibitor used primarily in the treatment of certain hematologic malignancies. As a physician, it is important to be well-informed about its uses, mechanisms, administration, and potential side effects. Here are key points you should know:\n\n### Indications\n- **Chronic Lymphocytic Leukemia (CLL)**: Venetoclax is indicated for the treatment of patients with CLL or small lymphocytic lymphoma (SLL) with or without 17p deletion, who have received at least one prior therapy.\n- **Acute Myeloid Leukemia (AML)**: It is also used in combination with azacitidine, decitabine, or low-dose cytarabine for the treatment of newly-diagnosed AML in adults who are 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.\n\n### Mechanism of Action\nVenet"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_CZ8Hp92tw6WWsGxaX8doNIHN", "custom_id": "279_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5ea39484f859c5214ed0e144c9597870", "body": {"id": "chatcmpl-9St5zQTYpbHZCRfb4kURWwz9vEjoG", "object": "chat.completion", "created": 1716671999, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vinblastine is a chemotherapy medication used to treat various types of cancer. As a physician, you should be aware of the following key points about Vinblastine:\n\n### Mechanism of Action\n- **Antimicrotubule Agent**: Vinblastine is a vinca alkaloid that inhibits the assembly of microtubules, thereby preventing cell division during the metaphase of mitosis.\n\n### Indications\n- **Cancer Types**: Useful in treating Hodgkin's lymphoma, non-Hodgkin's lymphoma, breast cancer, testicular cancer, Kaposi's sarcoma, choriocarcinoma, and others.\n\n### Administration\n- **Route**: Typically administered intravenously.\n- **Dosage**: Dosage varies based on the specific cancer being treated, the patient's body surface area, and their overall health. It is often given in combination with other chemotherapy agents.\n\n### Side Effects\n- **Common**: Nausea, vomiting, constipation, hair"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_tg1LWozaRcGnap3YDxh0zLFP", "custom_id": "280_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8d72ffffc40b8cc630d44f358518ed09", "body": {"id": "chatcmpl-9St5z3KpqMjEzCYxlduxrMdZT116k", "object": "chat.completion", "created": 1716671999, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vincristine is an important chemotherapeutic agent used primarily in the treatment of various types of cancer. Here are some key points you should know about Vincristine:\n\n### Mechanism of Action\n- **Microtubule Inhibition:** Vincristine works by binding to tubulin, a protein essential for microtubule formation. This inhibits microtubule assembly and disrupts mitotic spindle formation, ultimately leading to cell cycle arrest at the metaphase stage and apoptosis of cancer cells.\n\n### Indications\n- **Hematologic Malignancies:** Commonly used in the treatment of leukemias (e.g., acute lymphoblastic leukemia), lymphomas (e.g., Hodgkin's and non-Hodgkin's lymphoma).\n- **Solid Tumors:** Can be used for certain solid tumors such as rhabdomyosarcoma, neuroblastoma, and Wilms' tumor.\n\n### Administration\n- **Intravenous Use Only:** Vincristine is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_nn7d98GMqBqETlMvPjNEHn8C", "custom_id": "281_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5c0b31480f3044f6492993763ce5cce7", "body": {"id": "chatcmpl-9St5z3jC5lS1nPpM9yRsqoACnlj9D", "object": "chat.completion", "created": 1716671999, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vincristine liposomal, also known as liposomal vincristine sulfate, is a chemotherapy agent used primarily for the treatment of certain types of cancer. Here's what you should know about it as a physician:\n\n### Mechanism of Action:\nVincristine is a vinca alkaloid that works by inhibiting microtubule formation in the mitotic spindle, thereby blocking cell division and leading to cell death. The liposomal formulation encapsulates the drug in liposomes, which can alter its distribution, increase its half-life, and potentially reduce toxicity.\n\n### Indications:\nVincristine liposomal is approved for the treatment of various hematologic malignancies, including:\n- Acute lymphoblastic leukemia (ALL)\n- Non-Hodgkin lymphoma (NHL)\n\n### Dosage and Administration:\n- The dosing regimen can vary based on the specific condition being treated, patient factors, and the treatment protocol in use.\n- It is administered intravenously.\n- Always follow the specific guidelines and protocols"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_HCxne2UQ30PjRtTJ9OVUHYZy", "custom_id": "282_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "cd05c92542964fba8e2239f035968ff6", "body": {"id": "chatcmpl-9St5zxK2d4810nt6DC9hzkKQSwUsJ", "object": "chat.completion", "created": 1716671999, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vindesine is a synthetic derivative of vinblastine, an alkaloid extracted from the Madagascar periwinkle plant (Catharanthus roseus). It belongs to the class of drugs known as vinca alkaloids and is used primarily as an antineoplastic (anticancer) agent. Here are some key points you should know about Vindesine:\n\n### Mechanism of Action\n- **Microtubule Inhibition**: Vindesine works by binding to tubulin, a protein that is essential for the formation of microtubules. By inhibiting microtubule assembly, it disrupts mitotic spindle formation, leading to cell cycle arrest in the metaphase and subsequent apoptosis (programmed cell death).\n\n### Indications\n- **Cancer**: Vindesine is used in the treatment of various types of cancers, including:\n  - Acute lymphoblastic leukemia (ALL)\n  - Non-Hodgkin's lymphoma (NHL)\n  - Hodgkin's disease\n "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_3tBJqWmnFAGwZiHBFgRPgLxA", "custom_id": "283_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a21a62fdb7e078ecc92f10593e3df690", "body": {"id": "chatcmpl-9St5zXOj0rjOIGbtY8SqN5mym2GyA", "object": "chat.completion", "created": 1716671999, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vinflunine is a chemotherapeutic agent used primarily in the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, particularly when other treatments have failed. Here are some key points you should be aware of:\n\n### Mechanism of Action:\n- **Microtubule Inhibition:** Vinflunine is a novel vinca alkaloid that inhibits microtubule assembly, leading to cell cycle arrest at the G2-M phase and subsequent apoptosis of cancer cells.\n\n### Indications:\n- **Urothelial Carcinoma:** It is mainly indicated for patients with advanced or metastatic transitional cell carcinoma of the urothelium who have previously been treated with a platinum-containing regimen.\n\n### Administration:\n- **Intravenous Infusion:** Vinflunine is administered as an intravenous infusion. The dosing regimen typically depends on the patient's body surface area (BSA) and is adjusted based on tolerability and the presence of side effects.\n\n### Side Effects:\nCommon"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_VFmtqsN8s8RLeEwhekZf06CR", "custom_id": "284_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0c593e971616512271bc9740789b33cb", "body": {"id": "chatcmpl-9St60nlBm6zDQl2cqw8AskJhPMCiD", "object": "chat.completion", "created": 1716672000, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vinorelbine is a chemotherapeutic agent used primarily in the treatment of non-small cell lung cancer (NSCLC) and metastatic breast cancer. Here are some critical points you should know about Vinorelbine as a physician:\n\n### Mechanism of Action\n- **Vinorelbine** is a vinca alkaloid and works by inhibiting mitosis. It binds to tubulin, disrupting the formation of the mitotic spindle, which is essential for cell division. This action leads to cell cycle arrest in the metaphase and eventually results in cell death.\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC):** Vinorelbine is commonly used as part of combination chemotherapy regimens or as a single agent in the treatment of NSCLC.\n- **Breast Cancer:** It is also used for metastatic breast cancer, especially in patients who have failed other chemotherapy treatments.\n\n### Administration\n- **Routes:** Vinorelbine can be administered intravenously (IV) or orally."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_x2ngdzmsETYKMdpDQv4hLYRc", "custom_id": "285_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "29705f7d1bc677b91807006d62e56247", "body": {"id": "chatcmpl-9St60ks4L4gZuBIMZ8Kc0PUwCYWE1", "object": "chat.completion", "created": 1716672000, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vismodegib is a medication used primarily for the treatment of basal cell carcinoma (BCC), particularly in cases where the cancer is locally advanced or metastatic and cannot be treated with surgery or radiation. Here are key points you should know about Vismodegib:\n\n### Mechanism of Action\n- **Hedgehog Pathway Inhibitor:** Vismodegib works by inhibiting the Hedgehog signaling pathway, which is involved in the development and growth of basal cell carcinoma. It specifically targets the Smoothened (SMO) receptor, thereby blocking downstream signaling that leads to cancer cell growth.\n\n### Indications\n- **Advanced Basal Cell Carcinoma:** It is indicated for adults with metastatic BCC, or with locally advanced BCC that has recurred following surgery, or for those who are not candidates for surgery or radiation.\n\n### Administration\n- **Oral Medication:** Vismodegib is administered orally, typically as a 150 mg capsule once daily, with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_t6TAz8ZnHRCMjYCCsZLiW2uU", "custom_id": "286_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "83f3ecb3b94dc6462b5914002de65175", "body": {"id": "chatcmpl-9St60lMcXucNYsIKEbmI1SDD7nT9e", "object": "chat.completion", "created": 1716672000, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vorinostat, also known by its brand name Zolinza, is a histone deacetylase (HDAC) inhibitor used primarily in the treatment of cutaneous T-cell lymphoma (CTCL) that is persistent, progressive, or recurrent despite other therapies. Here are several key points you should know about Vorinostat:\n\n### Mechanism of Action\n- **HDAC Inhibition:** Vorinostat inhibits histone deacetylases, which leads to an accumulation of acetylated histones and proteins. This alteration in chromatin structure can result in the activation or repression of gene expression, affecting cell cycle progression, differentiation, and apoptosis.\n\n### Indications\n- **FDA Approval:** Vorinostat is approved by the FDA for the treatment of CTCL in patients who have progressive, persistent, or recurrent disease on or following two systemic therapies.\n\n### Administration\n- **Dosage:** The typical starting dose for Vorinostat is 400 mg orally once daily with food.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5H8JYtT08eNn7aoliXMZHWWs", "custom_id": "287_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a2cdcc1bbd901ef4d707e381584707f5", "body": {"id": "chatcmpl-9St60c9gjLeJfbjeZ2gB9H1d9M0gd", "object": "chat.completion", "created": 1716672000, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Zidovudine (also known as AZT or Retrovir), which is an antiretroviral medication used primarily for the treatment of HIV/AIDS. Here are key points you should be aware of:\n\n### Mechanism of Action\n- **Zidovudine** is a nucleoside reverse transcriptase inhibitor (NRTI). It works by inhibiting the action of reverse transcriptase, an enzyme crucial for the replication of HIV. This helps reduce the viral load in the patient's body.\n\n### Indications\n- **HIV Treatment**: Zidovudine is used in combination with other antiretroviral medications to treat HIV-1 infection in adults and children.\n- **Prevention of Mother-to-Child Transmission**: It is used during pregnancy to reduce the risk of perinatal transmission of HIV from a mother to her baby.\n- **Post-Exposure Prophylaxis (PEP)**: Zid"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_MrvsJWmYHxld3KAI5hU84s2f", "custom_id": "288_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "95991e6a33c60dc22ab7e38ef925fc6f", "body": {"id": "chatcmpl-9St60wdp4BvRrxsAyAhgHC2RWxjeS", "object": "chat.completion", "created": 1716672000, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ziv-aflibercept, also known simply as aflibercept or by its brand name Zaltrap, is a recombinant fusion protein used primarily in oncology. Here\u2019s a comprehensive overview of what you should know about this medication:\n\n### Mechanism of Action\nZiv-aflibercept is designed to inhibit angiogenesis, the process by which new blood vessels form. It works by binding to vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PIGF), thereby preventing these ligands from interacting with their receptors on the surface of endothelial cells. This inhibition can reduce blood supply to tumors, thereby inhibiting their growth.\n\n### Indications\nZiv-aflibercept is primarily approved for use in combination with the FOLFIRI regimen (5-fluorouracil, leucovorin, and irinotecan) for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_0Tz8ByYm3D0BZs5W3bIW040E", "custom_id": "289_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d51d97e9ff35e8b6489abb1994ab868a", "body": {"id": "chatcmpl-9St604wAZGKyrqN7of0JxIbBEaS2X", "object": "chat.completion", "created": 1716672000, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Capmatinib, marketed under the brand name Tabrecta, is an oral medication used to treat non-small cell lung cancer (NSCLC) that has a specific mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping. Below are key points you should know about Capmatinib:\n\n### Mechanism of Action\n- **MET Inhibitor:** Capmatinib inhibits the MET tyrosine kinase, which is involved in pathways leading to cell growth, survival, and metastasis. By targeting MET, Capmatinib can reduce tumor cell proliferation and induce apoptosis in cancer cells with MET exon 14 skipping mutations.\n\n### Indications\n- **NSCLC:** Specifically indicated for adults with metastatic NSCLC with a mutation leading to MET exon 14 skipping. It is often used after other treatments have failed or when no other treatment options are viable.\n\n### Dosage and Administration\n- **Oral Tablet:** The recommended dose is typically 400 mg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_gXV5T8Q7Z6JNbaHJ1cqNIjbu", "custom_id": "290_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "055abf13690c1b5add3caead4c095548", "body": {"id": "chatcmpl-9St61KuFwnMvDXhZOiXEAXd95UyZL", "object": "chat.completion", "created": 1716672001, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enfortumab vedotin (brand name Padcev) is an antibody-drug conjugate (ADC) used in the treatment of certain types of advanced urothelial carcinoma, which is a type of bladder cancer. Here are some key points you should know about this medication:\n\n### Mechanism of Action\n1. **Antibody-Drug Conjugate**: Enfortumab vedotin combines a monoclonal antibody that targets Nectin-4, a protein highly expressed in urothelial cancer cells, with a cytotoxic agent called monomethyl auristatin E (MMAE).\n2. **Targeted Therapy**: The antibody binds to Nectin-4 on cancer cells, delivering the cytotoxic agent directly to the cancer cells and sparing normal cells to some extent.\n\n### Indications\n1. **Advanced Urothelial Carcinoma**: It is indicated for adult patients with locally advanced or metastatic urothelial carcinoma who have previously received a programmed death receptor-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_pSgXcKFQHhArM22OpYl6qzWE", "custom_id": "291_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9e0eecea44e946f91e8131685600c53a", "body": {"id": "chatcmpl-9St61pXLkY0dnVjfyqinHFKtqboyi", "object": "chat.completion", "created": 1716672001, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab deruxtecan, also known by its brand name Enhertu, is a targeted cancer therapy used primarily in the treatment of certain types of breast cancer. Here are some key points that you should know as a physician:\n\n### Mechanism of Action:\n1. **Antibody-Drug Conjugate (ADC):** Trastuzumab deruxtecan is an ADC combining a monoclonal antibody (trastuzumab) targeting HER2 (human epidermal growth factor receptor 2) with a cytotoxic chemotherapy agent (deruxtecan).\n2. **Targeting HER2:** The trastuzumab component binds to the HER2 receptor on cancer cells, which is overexpressed in certain types of breast cancer. This binding facilitates the internalization of the conjugate into the cancer cell.\n3. **Release of Deruxtecan:** Once inside the cell, the linker connecting trastuzumab and deruxtecan is cleaved, releasing the cytotoxic agent"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_jECqsfnN7pQ1G7I2puFGdieJ", "custom_id": "292_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "1587f6b603d5b837daec3656dd0cd607", "body": {"id": "chatcmpl-9St61GSxl98gUJbACSMcooA51IwZn", "object": "chat.completion", "created": 1716672001, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abarelix is a synthetic decapeptide and a gonadotropin-releasing hormone (GnRH) antagonist used in the treatment of advanced prostate cancer. As a physician, here are some key points you should know about Abarelix:\n\n1. **Mechanism of Action**: Abarelix works by directly inhibiting the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, leading to a rapid decrease in testosterone production by the testes. This is beneficial in prostate cancer treatment because testosterone can stimulate the growth of prostate cancer cells.\n\n2. **Indications**: Abarelix is primarily indicated for the palliative treatment of patients with advanced symptomatic prostate cancer who are candidates for androgen deprivation therapy but are not appropriate candidates for other hormonal treatments.\n\n3. **Administration**: Abarelix is administered as an intramuscular injection. The dosing regimen typically involves an initial loading dose followed by maintenance doses at specific intervals.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_D0BJ41KzsRCTwdwA3zApcDUF", "custom_id": "293_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "be08fed6bef71ca8a118599c8e081fd0", "body": {"id": "chatcmpl-9St61OMdz9Td21e8CLPdEuHccKkbM", "object": "chat.completion", "created": 1716672001, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belantamab mafodotin is an important therapeutic agent in the field of oncology, specifically for the treatment of multiple myeloma. Here are some key points you should know as a physician:\n\n### Mechanism of Action:\n- **Target:** Belantamab mafodotin is an antibody-drug conjugate (ADC) that targets B-cell maturation antigen (BCMA), which is highly expressed on multiple myeloma cells.\n- **Conjugate:** It is conjugated with a cytotoxic agent, monomethyl auristatin F (MMAF), which disrupts the microtubule network within the cancer cells, leading to apoptosis.\n\n### Indications:\n- **Multiple Myeloma:** It is approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.\n\n### Administration:\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ZMIDdaMUGgYMMTv6jJAX9Qpp", "custom_id": "294_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a29a547e9dcd975f4308dd1b04b055d9", "body": {"id": "chatcmpl-9St61UNeIBsKoRqyrQ0zvW8JghwAy", "object": "chat.completion", "created": 1716672001, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tucatinib is an important medication in the treatment of certain types of breast cancer. Here are the key points you should be aware of as a physician:\n\n### Mechanism of Action\n- **Tucatinib** is a tyrosine kinase inhibitor that specifically targets the HER2 receptor, a protein overexpressed in some breast cancer cells. By inhibiting the HER2 receptor, tucatinib can help to slow down or stop the growth of these cancer cells.\n\n### Indications\n- **HER2-positive Breast Cancer:** Tucatinib is indicated for the treatment of HER2-positive breast cancer, particularly in metastatic settings. It is often used in combination with other therapies such as trastuzumab and capecitabine.\n\n### Administration\n- **Oral Medication:** Tucatinib is administered orally, typically in tablet form. The usual dosage is 300 mg taken twice daily, in combination with trastuzumab and capecitabine.\n\n### Clinical Efficacy\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_xNYmq2yPXyRRHs4agTUiQAD5", "custom_id": "295_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "bd4461351314dc7ec5f4ed378af3e7af", "body": {"id": "chatcmpl-9St62Qnrqu5qfmOAqLhbzOxwFSJc1", "object": "chat.completion", "created": 1716672002, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daratumumab and hyaluronidase-fihj is a combination medication used in the treatment of multiple myeloma, a type of blood cancer. Here\u2019s what you should know about it as a physician:\n\n### Daratumumab\n1. **Mechanism of Action**: Daratumumab is a monoclonal antibody that targets CD38, a surface protein that is overexpressed on multiple myeloma cells. By binding to CD38, daratumumab induces cell death through multiple mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP).\n\n2. **Indications**: Daratumumab is indicated for the treatment of multiple myeloma in various settings:\n   - As monotherapy for patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_fPfvvtnDinxpRBvfzMWnSRLP", "custom_id": "296_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "23c02b76b7445734b9c65f2897e9ba7a", "body": {"id": "chatcmpl-9St62u7hEwdv2v6XFqyncpbRQGFGo", "object": "chat.completion", "created": 1716672002, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alitretinoin is a retinoid, a class of medications derived from vitamin A, primarily used for its anti-inflammatory and anti-proliferative properties. Here are several key points that a physician should know about Alitretinoin:\n\n### Indications:\n1. **Chronic Hand Eczema**: Alitretinoin is commonly prescribed for patients with severe chronic hand eczema that is unresponsive to potent topical corticosteroids.\n2. **Kaposi's Sarcoma**: It is also used topically for cutaneous lesions in patients with Kaposi's sarcoma, particularly in those with AIDS.\n\n### Mechanism of Action:\n- Alitretinoin binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene expression that regulates cell differentiation, proliferation, and apoptosis. This contributes to its effectiveness in inflammatory and hyperproliferative skin conditions.\n\n### Administration:\n- **Oral Form**: For chronic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_7h7xoapaMIntOJo7vcvdHm6x", "custom_id": "297_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ee29e362f72fe9cf72af0c0d33a37918", "body": {"id": "chatcmpl-9St62MFdowdcT1N5qwMnI8w88XBu1", "object": "chat.completion", "created": 1716672002, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brexucabtagene autoleucel, marketed under the name Tecartus, is a type of CAR T-cell therapy used in the treatment of certain types of cancer, particularly relapsed or refractory mantle cell lymphoma (MCL). Here are key points you should know about this therapy:\n\n### Mechanism of Action:\n- **CAR T-Cell Therapy:** Brexucabtagene autoleucel involves genetically modifying a patient\u2019s own T-cells to express a chimeric antigen receptor (CAR) that targets the CD19 antigen found on the surface of B-cells, including malignant B-cells.\n- **Targeted Action:** Once these engineered T-cells are reintroduced into the patient\u2019s body, they seek out and destroy CD19-expressing cells.\n\n### Indications:\n- **Mantle Cell Lymphoma (MCL):** Approved for use in adults with relapsed or refractory MCL who have not responded to other forms of treatment.\n\n### Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_oC6r9Xrp5qZCitSgGQUvbW9x", "custom_id": "298_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b29c0cff5cbe54fbcb277f84e7bb201e", "body": {"id": "chatcmpl-9St62NY07spcmyhqrsXBWYV7uxY1q", "object": "chat.completion", "created": 1716672002, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it\u2019s important to be well-informed about Alpelisib, particularly if you are treating patients with certain types of breast cancer or other conditions where this medication may be indicated. Here are some key points you should know:\n\n### Indications:\n- **Breast Cancer**: Alpelisib is primarily indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced or metastatic breast cancer. It is used in combination with fulvestrant following disease progression on or after an endocrine-based regimen.\n\n### Mechanism of Action:\n- **PI3K Inhibitor**: Alpelisib is a selective inhibitor of the phosphatidylinositol-3-kinase (PI3K) catalytic subunit alpha, which is encoded by the PIK3CA gene. Mutations in PIK3CA are common in breast cancer and lead to activation of the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_rocScxdCYtMp14cOkJuCSwoD", "custom_id": "299_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "482dc13ba6ba36a0c07a50efaf83122f", "body": {"id": "chatcmpl-9St62IKT571bnw3rWuwXMqllySN0g", "object": "chat.completion", "created": 1716672002, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amonafide is an investigational anti-cancer drug that belongs to the class of topoisomerase II inhibitors. It has been studied primarily for its potential use in treating various types of cancer, including acute myeloid leukemia (AML) and solid tumors. Here are some key points you should know about Amonafide as a physician:\n\n1. **Mechanism of Action**:\n   - Amonafide intercalates into DNA and inhibits the enzyme topoisomerase II. This leads to the stabilization of the DNA-topoisomerase II complex, preventing the re-ligation of the DNA strands and ultimately causing DNA damage and cell death.\n\n2. **Clinical Trials and Studies**:\n   - Amonafide has been evaluated in clinical trials for various cancers, including AML, breast cancer, and other solid tumors. While it has shown promise in preclinical studies and early-phase clinical trials, results have been mixed, and it has not yet been approved by regulatory agencies"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_jsFxLXXIOdwiIEuT8ObqNy9O", "custom_id": "300_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9f3fe88a503efc76bde6baf6532df976", "body": {"id": "chatcmpl-9St62rgxPReHycF4JDEZyp94otH7M", "object": "chat.completion", "created": 1716672002, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amoxicillin is a widely used antibiotic that belongs to the penicillin class of medications. Here are some key points that physicians should know about Amoxicillin:\n\n1. **Mechanism of Action**:\n   - Amoxicillin works by inhibiting the synthesis of bacterial cell walls, leading to the death of the bacteria. It is a beta-lactam antibiotic.\n\n2. **Spectrum of Activity**:\n   - It is effective against a broad range of gram-positive and some gram-negative bacteria. It is commonly used to treat infections caused by Streptococcus species, Haemophilus influenzae, Escherichia coli, and other susceptible organisms.\n\n3. **Indications**:\n   - Amoxicillin is used to treat various infections, including:\n     - Otitis media\n     - Sinusitis\n     - Pharyngitis\n     - Pneumonia\n     - Urinary tract infections\n     - Skin and soft tissue infections\n     - Helicobacter pylori infection ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_PxF2A9Nc7IhuTTrVUao4lVzT", "custom_id": "301_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "147a46c56911800d87cc8ea39b39bc13", "body": {"id": "chatcmpl-9St63t3e8ApaVArcN9HgYmFszrDa7", "object": "chat.completion", "created": 1716672003, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aumolertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used in the treatment of non-small cell lung cancer (NSCLC). Here are some key points that you, as a physician, should know about this medication:\n\n### Indications:\n- **NSCLC**: Aumolertinib is specifically indicated for the treatment of patients with locally advanced or metastatic NSCLC with an EGFR exon 19 deletion or exon 21 (L858R) substitution mutation, as detected by an FDA-approved test.\n\n### Mechanism of Action:\n- Aumolertinib selectively inhibits both EGFR-sensitizing mutations and the T790M resistance mutation while sparing wild-type EGFR, which helps to reduce off-target effects.\n\n### Administration:\n- **Oral**: Aumolertinib is administered orally, typically once daily.\n- **Dosage**: The standard recommended dosage is "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_BlWBFbuyB3QmJ3SbMpNwXApQ", "custom_id": "302_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "97a7b30576d018639d0ce7a51761e099", "body": {"id": "chatcmpl-9St63i4pYvKl6LBihHnaks2ZMsxCR", "object": "chat.completion", "created": 1716672003, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pemigatinib is a targeted therapy drug used primarily for the treatment of certain types of cholangiocarcinoma, which is a cancer of the bile ducts. Here are some key points you should know about Pemigatinib:\n\n### Indications:\n- **Cholangiocarcinoma:** Pemigatinib is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.\n\n### Mechanism of Action:\n- **FGFR Inhibitor:** Pemigatinib works by inhibiting the FGFR2 pathway. FGFR2 fusions and rearrangements can drive the growth of cancer cells, and by blocking this pathway, Pemigatinib can help control tumor growth.\n\n### Administration:\n- **Oral Medication:** Pemigatinib is administered orally, usually in a 21-day cycle (13.5 mg once daily for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_cmdUIXEYvcYhxSZSEhbfUMZP", "custom_id": "303_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0b15a2e510aadbccab752d9f41085347", "body": {"id": "chatcmpl-9St63DQxolgzlac5YOo4JZdoxZFmo", "object": "chat.completion", "created": 1716672003, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ripretinib (brand name: Qinlock) is a tyrosine kinase inhibitor used primarily for the treatment of adult patients with advanced gastrointestinal stromal tumors (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. Here are some key points you should know about Ripretinib:\n\n### Mechanism of Action:\nRipretinib is designed to inhibit a broad spectrum of KIT and PDGFRA mutations, which are commonly implicated in GIST. By targeting these mutations, it helps to block the signaling pathways that promote tumor cell growth and survival.\n\n### Indications:\n- Approved for the treatment of advanced GIST in patients who have previously been treated with three or more kinase inhibitors, including imatinib.\n\n### Dosage and Administration:\n- The recommended dosage of Ripretinib is 150 mg orally once daily.\n- It can be taken with or without food.\n- Tablets should be swallowed whole and not crushed, split, or chewed"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_fyhauLBkWjTVR0wtUaVwJa1T", "custom_id": "304_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ddc2d889e75286447231676ce6f68b39", "body": {"id": "chatcmpl-9St63NukYYOedwdzQCHr86RaWzbI3", "object": "chat.completion", "created": 1716672003, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Selpercatinib, marketed under the brand name Retevmo, is an oral tyrosine kinase inhibitor specifically targeting rearranged during transfection (RET) kinase. Here are some key points a physician should know about Selpercatinib:\n\n### Indications\n1. **Non-Small Cell Lung Cancer (NSCLC)**: Approved for adult patients with metastatic RET fusion-positive NSCLC.\n2. **Thyroid Cancer**: Approved for adult and pediatric patients 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.\n3. **Papillary Thyroid Cancer**: Approved for adult and pediatric patients 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).\n\n### Mechanism of Action\n- Selpercatinib inhibits RET kinase, which is involved in cell proliferation and survival. By blocking RET"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_hQoMJ3L2NUD35qnSpSI58Yuj", "custom_id": "305_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9c5a652bacb82077f0a0aec8b83e245a", "body": {"id": "chatcmpl-9St64RA7iucnoyDDUNRSFlb0h4ADC", "object": "chat.completion", "created": 1716672004, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Decitabine and cedazuridine is a combination medication used primarily in the treatment of certain types of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Here are key points you should know about this combination therapy:\n\n### Mechanism of Action\n- **Decitabine**: It is a cytidine analog that incorporates into DNA and inhibits DNA methyltransferase, leading to hypomethylation of DNA. This can reactivate silenced genes that are crucial for normal cell differentiation and proliferation.\n- **Cedazuridine**: It is a cytidine deaminase inhibitor, which helps to increase the bioavailability of decitabine when taken orally. It inhibits the enzyme cytidine deaminase, which would otherwise degrade decitabine in the gastrointestinal tract and liver.\n\n### Indications\n- Approved for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Udl4Qx2rWwLxmjTIYiM2bugK", "custom_id": "306_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "86c6539599752f1efc65b36271171539", "body": {"id": "chatcmpl-9St64Xq9kID8jw6q7PVIGWSDTkhaL", "object": "chat.completion", "created": 1716672004, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bismuth subsalicylate is a medication commonly used to treat temporary discomforts of the stomach and gastrointestinal tract, including nausea, heartburn, indigestion, upset stomach, and diarrhea. Here are some key points you should know about it as a physician:\n\n1. **Mechanism of Action**:\n   - Bismuth subsalicylate has multiple actions: it has antisecretory effects (reducing fluid secretion in the intestines), antimicrobial activity against certain pathogens (e.g., Helicobacter pylori), and anti-inflammatory properties due to its salicylate component.\n\n2. **Indications**:\n   - It is used for the relief of diarrhea, nausea, heartburn, indigestion, and upset stomach.\n   - It is part of some regimens for treating Helicobacter pylori infection in combination with other medications.\n\n3. **Dosage and Administration**:\n   - Available in various forms including chewable tablets, caplets, and liquid.\n   - Typical dosing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_RRBLhhATkvcN3zF4UA5xsaTM", "custom_id": "307_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "4eba014bb80c6867878aa55afa77b7a8", "body": {"id": "chatcmpl-9St64ulyOzP2rPIXshoP3A2KQ1yhf", "object": "chat.completion", "created": 1716672004, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Camrelizumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor, which is a checkpoint inhibitor involved in the immune system's response to cancer cells. Here are key points you should know about Camrelizumab as a physician:\n\n### Mechanism of Action\n- **PD-1 Inhibition**: Camrelizumab binds to the PD-1 receptor on T cells, preventing its interaction with PD-L1 and PD-L2 ligands. This blockade reactivates T cells, enhancing the immune system's ability to attack and destroy cancer cells.\n\n### Indications\n- **Cancer Types**: Camrelizumab is primarily used in the treatment of various types of cancer, including Hodgkin lymphoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and esophageal squamous cell carcinoma (ESCC), among others.\n- **Combination Therapy**: It is often used in combination with other therapies"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_IrCiK01TW85xJPttFAvXuBbK", "custom_id": "308_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "424e41a145b00fb076f18a2358d01953", "body": {"id": "chatcmpl-9St64E8ivl4VhVnTXeNV4oxZGPVid", "object": "chat.completion", "created": 1716672004, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about Relugolix, a medication that has gained attention for its applications in treating certain hormone-dependent conditions. Here are key points you should know:\n\n### Mechanism of Action:\n- **Relugolix** is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist.\n- It works by binding to and inhibiting the GnRH receptors in the pituitary gland, leading to a rapid decrease in the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).\n- This suppression results in decreased production of sex hormones, such as testosterone in men and estrogen and progesterone in women.\n\n### Indications:\n- **Prostate Cancer:** Relugolix is approved for the treatment of advanced prostate cancer. By lowering testosterone levels, it helps to manage the progression of prostate cancer.\n- **Uterine Fibroids:** It is also approved for the management of heavy menstrual bleeding associated with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_d1Q9yPiyEBM10F9EAjHlXeZD", "custom_id": "309_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "3353d5c42aaf219fc714df05dbb1690a", "body": {"id": "chatcmpl-9St656WPxXh3eoMkWxsSqQ5S4BeRV", "object": "chat.completion", "created": 1716672005, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Elacestrant, also known by its development code name RAD1901, is an investigational selective estrogen receptor degrader (SERD). It has been studied primarily for the treatment of estrogen receptor-positive (ER+), HER2-negative advanced or metastatic breast cancer. Here are some key points you should know about Elacestrant:\n\n1. **Mechanism of Action**:\n   - Elacestrant works by binding to estrogen receptors (ER) on breast cancer cells and promoting their degradation. This reduces the number of functional estrogen receptors, thereby inhibiting the growth of ER+ breast cancer cells that rely on estrogen signaling.\n\n2. **Indications**:\n   - It is currently being investigated for use in postmenopausal women with ER+, HER2- advanced or metastatic breast cancer, particularly in patients who have progressed on prior endocrine therapy (e.g., aromatase inhibitors, tamoxifen, or other SERDs).\n\n3. **Clinical Trials**:\n   - The efficacy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_JD5lLTR8ey06ADdkcuZO3jXy", "custom_id": "310_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "1e4923679a82ec6b20e7d4003215a2db", "body": {"id": "chatcmpl-9St641UrsXPX5Z2gyKq9CmpFRMsJb", "object": "chat.completion", "created": 1716672004, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trimetrexate is a chemotherapeutic agent that belongs to the class of drugs known as folate analogs. It is primarily used in the treatment of certain types of cancers and opportunistic infections. Here are some key points you should know about Trimetrexate:\n\n### Mechanism of Action:\n- **Folate Antagonist**: Trimetrexate inhibits dihydrofolate reductase (DHFR), an enzyme involved in the synthesis of tetrahydrofolate, which is necessary for the synthesis of purines and thymidylate. This inhibition disrupts DNA synthesis and cell division, particularly affecting rapidly dividing cells.\n\n### Indications:\n- **Pneumocystis jirovecii Pneumonia (PCP)**: Trimetrexate is often used in combination with leucovorin for the treatment of moderate to severe PCP in patients who are intolerant to or have failed conventional therapies such as trimethoprim-sulfamethoxazole.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_r4vhrYrc4Mcgt2SUZYrB7qBp", "custom_id": "311_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "cfff99efaed17fc1f7003496d172a309", "body": {"id": "chatcmpl-9St65qcP9HjEcjzhbmQxPhBKJMt3v", "object": "chat.completion", "created": 1716672005, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tepotinib is an oral, selective inhibitor of the c-Met receptor tyrosine kinase, which is encoded by the MET gene. It is used primarily in oncology, particularly for treating non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. Here are key points you should know:\n\n1. **Indications**: Tepotinib is indicated for the treatment of adult patients with metastatic NSCLC harboring MET exon 14 skipping alterations.\n\n2. **Mechanism of Action**: Tepotinib inhibits the c-Met receptor, which plays a role in cellular processes such as proliferation, survival, and metastasis. By blocking this pathway, Tepotinib can reduce tumor growth and spread in cancers driven by MET alterations.\n\n3. **Administration**: Tepotinib is administered orally, with or without food. The typical dosing regimen is 450 mg once daily.\n\n4. **Efficacy**: Clinical trials have shown that Tepotinib can lead to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_nYpvttUHpslkB02K4blACFNE", "custom_id": "312_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "398adc2400b7af5629d96404ef1a0cb7", "body": {"id": "chatcmpl-9St658TmnoLSlZtr58925cfPr5GuV", "object": "chat.completion", "created": 1716672005, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Futibatinib (also known by its developmental code TAS-120) is a targeted cancer therapy that inhibits fibroblast growth factor receptor (FGFR) tyrosine kinases. Here are some key points you should know about Futibatinib:\n\n### Mechanism of Action:\n- **FGFR Inhibition:** Futibatinib is designed to bind irreversibly to FGFR1-4, inhibiting their kinase activity. FGFRs are involved in various cellular processes, including cell growth, survival, migration, and differentiation. Dysregulation of FGFR signaling is implicated in several cancers.\n\n### Indications:\n- **Cholangiocarcinoma:** Futibatinib has shown promising results in treating patients with cholangiocarcinoma (bile duct cancer) that harbor FGFR2 gene fusions or rearrangements.\n- **Other Cancers:** Research is ongoing to evaluate the efficacy of Futibatinib in other malignancies with aberrant FGFR signaling,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_HQMZ2xO5uN94vHt67J97wNOX", "custom_id": "313_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "dba6e11b7a17c7bb8d39c478ab94bfbf", "body": {"id": "chatcmpl-9St65hLDeZyG59vwHPUDCNzcdNUCi", "object": "chat.completion", "created": 1716672005, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "The NovoTTF-100A system, commercially known as Optune, is a medical device approved for treating certain types of brain tumors, specifically glioblastoma multiforme (GBM). Here are key points you should know about Optune:\n\n### Indications:\n1. **Newly Diagnosed GBM**:\n   - Optune is used in combination with temozolomide (TMZ) after surgery and radiation therapy.\n   \n2. **Recurrent GBM**:\n   - Optune can be used as a monotherapy following recurrence after initial treatment.\n\n### Mechanism of Action:\n- **Tumor Treating Fields (TTFields)**: Optune delivers low-intensity, alternating electric fields (TTFields) to the tumor site. These fields disrupt mitotic spindle formation and other cellular structures essential for cell division, inhibiting tumor growth and potentially causing tumor cell death.\n\n### Application:\n- **Electrode Arrays**: The device involves adhesive transducer arrays placed on the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_0ko04SC4tUVFwWArhcjdORAB", "custom_id": "314_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f0c80002d822319a676be0699de0e2f1", "body": {"id": "chatcmpl-9St65Regq50bviu4jLstszSQNZMvr", "object": "chat.completion", "created": 1716672005, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lisocabtagene maraleucel (commonly known as liso-cel and branded as Breyanzi) is a type of CAR T-cell therapy used in the treatment of certain types of cancer, specifically B-cell lymphomas. Here are some key points you should know about this therapy as a physician:\n\n### Indications:\n1. **Approved Uses**: It is approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.\n\n### Mechanism of Action:\n2. **CAR T-Cell Therapy**: Liso-cel is a chimeric antigen receptor (CAR) T-cell therapy where a patient's T cells are genetically modified to express a CAR that targets CD19, a protein found on the surface of B cells."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_CaTn1HUX2oWwEanHpeCk76P8", "custom_id": "315_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b04e3973e5a7df353e8995fe45974abb", "body": {"id": "chatcmpl-9St65HpkcueTAMzfSfIPslkWd9jd0", "object": "chat.completion", "created": 1716672005, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idecabtagene vicleucel, also known by its brand name Abecma, is a type of CAR T-cell therapy used in the treatment of multiple myeloma. As a physician, here are several key points you should know about this therapy:\n\n### Mechanism of Action\n- **CAR T-Cell Therapy**: Idecabtagene vicleucel is a chimeric antigen receptor (CAR) T-cell therapy. It involves modifying a patient's own T cells to express a CAR that targets the B-cell maturation antigen (BCMA) on multiple myeloma cells.\n- **Target**: BCMA is a protein expressed on the surface of multiple myeloma cells, making it a suitable target for CAR T-cell therapies.\n\n### Indications\n- **Relapsed/Refractory Multiple Myeloma**: Abecma is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_LIQ70JYTFtnAnlEX73riWJw2", "custom_id": "316_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "7570662f1536297583ef64603b359308", "body": {"id": "chatcmpl-9St66as1r2yWMWc046MTdLaRUOS8b", "object": "chat.completion", "created": 1716672006, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Avapritinib is a targeted therapy drug primarily used in the treatment of certain types of cancers, particularly gastrointestinal stromal tumors (GISTs) and advanced systemic mastocytosis (SM). Here are some key points you should know as a physician:\n\n### Mechanism of Action:\n- **Type:** Tyrosine kinase inhibitor.\n- **Targets:** It inhibits the activity of specific tyrosine kinases, including KIT and PDGFRA, which are often mutated and overactive in GIST and SM.\n\n### Indications:\n- **Gastrointestinal Stromal Tumors (GIST):** Specifically, it is approved for adult patients with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.\n- **Advanced Systemic Mastocytosis (SM):** Approved for adult patients with advanced forms, including aggressive SM, SM with associated hematological neoplasm, and mast cell leukemia.\n\n### Dosage:\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_0776NNjj8yhtpB7SWqogyEKI", "custom_id": "317_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e2e7efa611891ace1a12c71f7e63e743", "body": {"id": "chatcmpl-9St66Zg9Tu8T2T3R41OyW04DIgh9x", "object": "chat.completion", "created": 1716672006, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pexidartinib is an oral tyrosine kinase inhibitor that is primarily used to treat adults with symptomatic tenosynovial giant cell tumor (TGCT), also known as pigmented villonodular synovitis (PVNS), or diffuse-type giant cell tumor (GCT), which is not amenable to improvement with surgery. Here are several key points you should know about Pexidartinib:\n\n### Mechanism of Action\n- **Targeting CSF1R:** Pexidartinib works by inhibiting colony-stimulating factor 1 receptor (CSF1R), a key driver in the pathogenesis of TGCT. It also inhibits other kinases such as KIT and FLT3-ITD.\n  \n### Indications\n- **TGCT Treatment:** It is approved for the treatment of adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery.\n\n### Dosage and Administration\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_3aOfnMWi4t7Bm1hLoE9qe24u", "custom_id": "318_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5807a8245ad55d4feaaa925b5e728558", "body": {"id": "chatcmpl-9St66j4bG9ATzzb7rqHAcKIyzQR6n", "object": "chat.completion", "created": 1716672006, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pralsetinib, marketed under the brand name Gavreto, is a targeted cancer therapy that is classified as a RET (rearranged during transfection) kinase inhibitor. It is specifically designed to treat cancers that harbor RET gene alterations, including mutations and fusions. Here are some key points you should know about Pralsetinib:\n\n### Indications:\n1. **Non-Small Cell Lung Cancer (NSCLC):**\n   - For adult patients with metastatic NSCLC with RET fusions, as detected by an FDA-approved test.\n\n2. **Thyroid Cancer:**\n   - For adult and pediatric patients (12 years and older) with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.\n   - For adult and pediatric patients (12 years and older) with RET fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate).\n\n### Mechanism of Action:\n- Pralset"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_nfnJEMconndpSHPU7xebVtCx", "custom_id": "319_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "3ae1a477d71031be72e7893c8ecd846f", "body": {"id": "chatcmpl-9St66bPnfGYLHVKzUsukgZyZxP69a", "object": "chat.completion", "created": 1716672006, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lurbinectedin, marketed under the brand name Zepzelca, is a synthetic analog of trabectedin, a marine-derived antineoplastic agent. It is primarily used for the treatment of adults with metastatic small cell lung cancer (SCLC) who have experienced disease progression on or after platinum-based chemotherapy. Here are some key points you should know about Lurbinectedin:\n\n### Mechanism of Action\n- **DNA Binding**: Lurbinectedin binds to the minor groove of DNA, leading to DNA damage.\n- **Transcription Inhibition**: It inhibits RNA polymerase II, which is essential for mRNA synthesis, thereby disrupting transcription and leading to cell cycle arrest and apoptosis.\n- **Tumor Microenvironment**: It also exerts effects on the tumor microenvironment by reducing the production of inflammatory cytokines and inhibiting the infiltration of tumor-associated macrophages.\n\n### Indications\n- **Metastatic Small Cell Lung Cancer (SCLC)**: Approved for patients with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Wrerbh5NJVQA2ix4MG9yxeYf", "custom_id": "320_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "91a6a2b3f2e2cdec7c488890c9070e54", "body": {"id": "chatcmpl-9St66dE8X6HP4juO0I3iKvZ3d6Cpl", "object": "chat.completion", "created": 1716672006, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Metronidazole is an antibiotic and antiprotozoal medication commonly used to treat a variety of infections. Here are some key points you should know about Metronidazole as a physician:\n\n### Indications:\n1. **Bacterial Infections:**\n   - Anaerobic bacterial infections\n   - Bacterial vaginosis\n   - Pelvic inflammatory disease\n   - Intra-abdominal infections\n   - Skin and soft tissue infections\n\n2. **Protozoal Infections:**\n   - Trichomoniasis\n   - Giardiasis\n   - Amebiasis\n\n3. **Other Uses:**\n   - Helicobacter pylori eradication (in combination with other antibiotics)\n   - Clostridioides difficile-associated diarrhea\n\n### Mechanism of Action:\nMetronidazole works by entering bacterial and protozoal cells and interfering with their DNA, leading to cell death. It is particularly effective against anaerobic organisms.\n\n### Dosage and Administration:\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_yzdxdVdl06bCSr5YrvNW5zE7", "custom_id": "321_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "49c6c9fbd762c5f481270a6afa7674f0", "body": {"id": "chatcmpl-9St66cMtr5ftwXUy8L7MFoum9s6t2", "object": "chat.completion", "created": 1716672006, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Naxitamab is a monoclonal antibody used in oncology, specifically for the treatment of certain types of neuroblastoma, a cancer that most commonly affects children. Here are some key points you should consider as a physician:\n\n### Indications:\n- **Neuroblastoma**: Naxitamab is indicated for use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of pediatric patients aged 1 year and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.\n\n### Mechanism of Action:\n- Naxitamab targets GD2, a disialoganglioside expressed on neuroblastoma cells and other cells of neuroectodermal origin. By binding to GD2, it induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_8c9VT43YQc8qzrC348xRvw8T", "custom_id": "322_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "59398c204dcb393c359ad78f9ef458aa", "body": {"id": "chatcmpl-9St67UUUZ5GK4biERPkUzT3kErORU", "object": "chat.completion", "created": 1716672007, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tetracycline is a broad-spectrum antibiotic that physicians often use to treat a variety of bacterial infections. Here are some key points you should know about Tetracycline:\n\n### Mechanism of Action:\n- **Inhibition of Protein Synthesis:** Tetracycline works by binding to the 30S ribosomal subunit of bacteria, thereby inhibiting protein synthesis. This action is typically bacteriostatic, meaning it inhibits bacterial growth rather than killing bacteria outright.\n\n### Indications:\n- **Infections:** Tetracycline is used to treat infections caused by susceptible organisms, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and certain gastrointestinal infections.\n- **Acne:** It is commonly prescribed for acne due to its anti-inflammatory properties and effectiveness against Propionibacterium acnes.\n- **Malaria:** It is sometimes used in combination with other drugs to treat malaria.\n- **Other Indications:** Rickettsial infections, Lyme disease, ch"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Rw5Wulxtgr8T7LZv5QVmZJyM", "custom_id": "323_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5e95db49b9144481970db14f4147fbd8", "body": {"id": "chatcmpl-9St67qiR9PbAqVuohGlxlOg1IfDUd", "object": "chat.completion", "created": 1716672007, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tripotassium dicitratobismuthate, commonly known as bismuth subcitrate potassium or colloidal bismuth subcitrate (CBS), is a medication primarily used for the treatment of gastrointestinal disorders, particularly peptic ulcers and Helicobacter pylori infections. Here are some key points you should know as a physician:\n\n### Mechanism of Action\n- **Protective Barrier:** It forms a protective layer over the ulcer site, shielding it from stomach acid and pepsin, which can contribute to ulcer healing.\n- **Antibacterial:** It exhibits antibacterial activity against Helicobacter pylori, a bacterium implicated in the development of peptic ulcers and chronic gastritis.\n- **Mucosal Defense:** It may enhance mucosal defense mechanisms by stimulating the secretion of mucus and bicarbonate and promoting epithelial growth.\n\n### Indications\n- **Peptic Ulcer Disease:** Particularly for patients with a history of ulcers or current ulceration.\n- **Helicobacter pylori Er"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5iCpyRMfr9K5RzQo7Z9VhbVS", "custom_id": "324_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "7012e051be1ab11d6924ce64309ea932", "body": {"id": "chatcmpl-9St67qbAYJaZvEycgCiAETulGWDO6", "object": "chat.completion", "created": 1716672007, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belzutifan (Welireg) is a relatively new medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of specific types of cancer. As a physician, it is important to have a comprehensive understanding of Belzutifan, including its indications, mechanism of action, dosing, side effects, and monitoring requirements. Here are key points you should know:\n\n### Indications\nBelzutifan is primarily indicated for the treatment of patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors (pNETs), and who do not require immediate surgery.\n\n### Mechanism of Action\nBelzutifan is a hypoxia-inducible factor (HIF)-2\u03b1 inhibitor. HIF-2\u03b1 is a transcription factor that plays a crucial role in the cellular response to hypoxia and is implicated in the pathogenesis of VHL"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_rgBNhwgRIBqSJDXl52UNG0rP", "custom_id": "325_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "27e35f0d529e9134f174d97dbde8e41d", "body": {"id": "chatcmpl-9St6773pedwJNNNl9KSj3960VEOgl", "object": "chat.completion", "created": 1716672007, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amivantamab is a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) receptors. It is primarily used in the treatment of non-small cell lung cancer (NSCLC) with specific EGFR exon 20 insertion mutations. Here are some key points you should know about Amivantamab:\n\n### Indications:\n- **Non-Small Cell Lung Cancer (NSCLC)**: Amivantamab is indicated for patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, who have progressed on or after platinum-based chemotherapy.\n\n### Mechanism of Action:\n- **Dual Targeting**: Amivantamab binds to both EGFR and MET receptors, thereby inhibiting their signaling pathways, which are crucial for tumor cell proliferation and survival.\n- **Immune-Mediated Effects**: It also induces antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Vg2wqfCY1PZpEhqaBXUEOZfh", "custom_id": "326_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "55bc0614d4fc664c00181e242f3353ef", "body": {"id": "chatcmpl-9St67bsMZAhFWelrDbxmnBfdJPdOk", "object": "chat.completion", "created": 1716672007, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azacitidine is a chemotherapeutic agent used primarily in the treatment of certain types of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The oral formulation of azacitidine offers an alternative to the injectable form, which can be more convenient for some patients. Here are some key points you should know about oral azacitidine:\n\n### Mechanism of Action\n- **Hypomethylating Agent:** Azacitidine incorporates into RNA and DNA, inhibiting DNA methyltransferase. This leads to DNA hypomethylation and reactivation of genes that can suppress cancer growth.\n\n### Indications\n- **Myelodysplastic Syndromes (MDS):** Used for various subtypes including refractory anemia, with or without ringed sideroblasts, and with excess blasts.\n- **Acute Myeloid Leukemia (AML):** Particularly in patients not eligible for intensive chemotherapy.\n\n### Dosage and Administration\n- **Dosing:** The specific dose"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_hCa9xoOXkdMbDOL2N0KhCNOL", "custom_id": "327_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "caa45cadd9a9d524ec01142649e236ea", "body": {"id": "chatcmpl-9St67YDlmZMKhI18wwdW3BVeiuU0l", "object": "chat.completion", "created": 1716672007, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Colchicine is a medication primarily used to treat gout and familial Mediterranean fever. As a physician, here are some key points you should know about Colchicine:\n\n1. **Mechanism of Action**:\n   - Colchicine works by inhibiting microtubule polymerization, which affects leukocyte function and reduces inflammation. It disrupts the migration of neutrophils to inflamed areas, thereby reducing the inflammatory response.\n\n2. **Indications**:\n   - Acute gout flares: Colchicine is commonly used to alleviate the pain and inflammation associated with acute gout attacks.\n   - Prophylaxis of gout flares: It can be used in low doses to prevent recurrent gout attacks.\n   - Familial Mediterranean fever (FMF): Colchicine helps prevent flares and amyloidosis in FMF patients.\n\n3. **Dosage and Administration**:\n   - For acute gout: Initial dose typically is 1.2 mg followed by 0.6 mg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_EaLSAIbP2hgjYge9FjS4yV4k", "custom_id": "328_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2bb8ce1865364b9c575c7592ff07f983", "body": {"id": "chatcmpl-9St68rlXPwMJiAEjavlGy2RL02Zy9", "object": "chat.completion", "created": 1716672008, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dostarlimab is a type of immunotherapy known as a programmed death receptor-1 (PD-1) blocking antibody. Here are some key points you should know about it as a physician:\n\n1. **Mechanism of Action**: Dostarlimab is a monoclonal antibody that targets PD-1, a protein on the surface of T cells. By blocking PD-1, dostarlimab helps to restore the immune system's ability to recognize and destroy cancer cells.\n\n2. **Indications**: As of my knowledge cutoff in 2023, dostarlimab has been approved for the treatment of certain types of cancer. It's particularly used for patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) endometrial cancer and has shown promise in other cancers as well.\n\n3. **Administration**: Dostarlimab is administered intravenously. The dosing schedule can vary, but it typically involves an initial loading"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_gypVareEcqSOt3pFkiyQ7aZx", "custom_id": "329_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "07f3dda323c9949a85359110dd668812", "body": {"id": "chatcmpl-9St68g0ICuuF1kLTC9XeFDutlBJGR", "object": "chat.completion", "created": 1716672008, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Serplulimab is a humanized anti-PD-1 (programmed cell death protein 1) monoclonal antibody used in immuno-oncology. It is designed to block the PD-1/PD-L1 pathway, which tumors exploit to evade the immune system. By inhibiting this pathway, Serplulimab aims to enhance the body's immune response against cancer cells.\n\nHere are some key points you should know as a physician:\n\n1. **Mechanism of Action**:\n    - Serplulimab binds to PD-1 receptors on T-cells, preventing the interaction with its ligands, PD-L1 and PD-L2.\n    - This blockade reactivates T-cells, enabling them to recognize and attack cancer cells.\n\n2. **Indications**:\n    - The specific indications for Serplulimab may vary based on clinical trials and regulatory approvals. It's typically considered for use in various types of cancer, including but not limited to non-small cell lung cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_iIHuMl4jWb1vNlyqC5tfqPa9", "custom_id": "330_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "7e188d218a01a1efa447949aaffcc29b", "body": {"id": "chatcmpl-9St68oypQH0i5uQI4m8Q1jtoOk9tb", "object": "chat.completion", "created": 1716672008, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sugemalimab is a monoclonal antibody targeting PD-L1 (programmed death-ligand 1), which is used in the treatment of various cancers, particularly non-small cell lung cancer (NSCLC). Here are some key points you should know about this drug:\n\n1. **Mechanism of Action**: Sugemalimab works by binding to PD-L1, a protein expressed on the surface of cancer cells and immune cells, which normally interacts with the PD-1 receptor on T-cells to inhibit immune response. By blocking this interaction, Sugemalimab enhances the immune system\u2019s ability to recognize and attack cancer cells.\n\n2. **Indications**: Sugemalimab is primarily used for the treatment of NSCLC, including both squamous and non-squamous types. It is often used in combination with chemotherapy as a first-line treatment for advanced or metastatic NSCLC.\n\n3. **Clinical Trials and Efficacy**: Clinical trials, such as the GEM"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_B8OPtAazZnEZw4M0XJ3uSv0M", "custom_id": "331_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5db258077ee95186c2e2205b76be232a", "body": {"id": "chatcmpl-9St68GdYifQf7amY2QwKMxIs4wVGA", "object": "chat.completion", "created": 1716672008, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sirolimus protein-bound particles, also known as nanoparticulate sirolimus or nanoparticle albumin-bound (nab) sirolimus, are a formulation of the drug sirolimus designed to enhance its delivery and efficacy. Here are key points you should know about this formulation:\n\n1. **Mechanism of Action**:\n   - Sirolimus is an mTOR (mechanistic target of rapamycin) inhibitor that has immunosuppressive and antiproliferative properties.\n   - It binds to the FK506-binding protein (FKBP-12), forming a complex that inhibits mTOR, which subsequently leads to cell cycle arrest in the G1 phase and inhibition of protein synthesis.\n\n2. **Indications**:\n   - Sirolimus is used primarily for its immunosuppressive properties in preventing organ transplant rejection.\n   - The protein-bound particle formulation may be used in oncology for certain cancer types due to its antiproliferative effects.\n\n3. **Pharmacok"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_I0NAz5v8Z70hWMAmqmvjVuOZ", "custom_id": "332_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5e55b1f51c95a3a175e7d639c96e0d4c", "body": {"id": "chatcmpl-9St69sqEezZ65ylHxqzdM3yJxjUdh", "object": "chat.completion", "created": 1716672009, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Suramin is a medication that has been historically used to treat African trypanosomiasis (sleeping sickness) and onchocerciasis (river blindness). Here are some key points that a physician should know about Suramin:\n\n1. **Mechanism of Action**: Suramin is an antiparasitic drug that inhibits enzymes involved in energy metabolism, which is essential for the survival of parasites. Its exact mechanism of action is not fully understood but it is known to interfere with cellular processes of the parasites.\n\n2. **Indications**:\n   - **African Trypanosomiasis**: It is used primarily in the hemolymphatic stage of the disease caused by Trypanosoma brucei rhodesiense.\n   - **Onchocerciasis**: Historically used for river blindness, although it has largely been replaced by ivermectin.\n\n3. **Administration**: Suramin is administered intravenously. The dosing regimen can vary based on the specific condition being treated,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_3JvRTFwH3hcbOBENzCs6Dtlf", "custom_id": "333_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "61419515729da4bbe2cac79036ee4535", "body": {"id": "chatcmpl-9St69Fzlz34nYT9KEhyWtEyp2EaUR", "object": "chat.completion", "created": 1716672009, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adagrasib is a small molecule inhibitor that targets the KRAS G12C mutation, which is a common driver mutation in various cancers, particularly non-small cell lung cancer (NSCLC) and colorectal cancer, among others. This mutation is notoriously difficult to target, and Adagrasib represents a significant advancement in precision oncology.\n\nHere's what you should know about Adagrasib:\n\n1. **Mechanism of Action**: Adagrasib specifically binds to the KRAS G12C mutant protein and locks it in an inactive state, thereby inhibiting downstream signaling pathways that promote cancer cell growth and survival.\n\n2. **Indications**: It has shown promise particularly in patients with KRAS G12C-mutated NSCLC and is being investigated for other cancers harboring the same mutation. It is often considered for patients who have progressed on or are intolerant to standard therapies.\n\n3. **Efficacy**: Clinical trials have demonstrated that Adagrasib can achieve meaningful responses"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_FLGCrmChaeJudWbG9S2pVvpL", "custom_id": "334_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "03962514c4dc80450d43fae7d5204205", "body": {"id": "chatcmpl-9St69uJcwB8EJOU3ga1ekbYlpXTb3", "object": "chat.completion", "created": 1716672009, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tebentafusp is an innovative therapeutic agent designed for the treatment of certain types of cancer, particularly uveal melanoma, a rare and aggressive form of melanoma that originates in the eye. Here are some key points that you, as a physician, should be aware of regarding tebentafusp:\n\n1. **Mechanism of Action**:\n   - Tebentafusp is a bispecific fusion protein that targets glycoprotein 100 (gp100), an antigen present on melanoma cells. It is engineered to direct T-cells to recognize and kill tumor cells expressing gp100.\n   - It binds to gp100 on melanoma cells and to CD3 on T-cells, facilitating the T-cell-mediated lysis of melanoma cells.\n\n2. **Indications**:\n   - Tebentafusp is primarily indicated for the treatment of HLA-A*02:01-positive adult patients with metastatic or unresectable uveal melanoma.\n\n3. **Administration**:\n   - Tebentafusp"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_gtnCDPN7CUEXqJoGFXr3UC29", "custom_id": "335_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "42f82fd5f56ab504ddaaf0cbc72eaced", "body": {"id": "chatcmpl-9St69JsDYAYqfWmXXaxBeGD4VKG7T", "object": "chat.completion", "created": 1716672009, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fedratinib is a medication used primarily for the treatment of certain types of myelofibrosis, which is a type of bone marrow cancer. Here are some key points you should know about Fedratinib as a physician:\n\n### Indications:\n- **Primary Myelofibrosis**\n- **Post-Polycythemia Vera Myelofibrosis**\n- **Post-Essential Thrombocythemia Myelofibrosis**\n\n### Mechanism of Action:\n- Fedratinib is a selective inhibitor of the Janus kinase 2 (JAK2) enzyme, which plays a critical role in the signaling pathways that control the production of blood cells. By inhibiting JAK2, Fedratinib helps reduce the abnormal proliferation of blood cells.\n\n### Dosage:\n- The typical starting dose is 400 mg taken orally once daily with or without food. Dose adjustments may be necessary based on individual patient response and tolerance.\n\n### Common Side Effects:\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_RfJT70XtQa2cEx5SSbkiCsfI", "custom_id": "336_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "44870887eb86667eca7e93563a78d537", "body": {"id": "chatcmpl-9St693F5jQCIPI9HEPEzat5s9unxA", "object": "chat.completion", "created": 1716672009, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab and hyaluronidase-oysk is a combination drug used in the treatment of HER2-positive breast cancer. Here are some key points you should be aware of:\n\n### Trastuzumab:\n1. **Mechanism of Action**:\n   - Trastuzumab is a monoclonal antibody that targets the HER2 (human epidermal growth factor receptor 2) protein, which is overexpressed in some breast cancers.\n   - It works by binding to the HER2 receptor, inhibiting cell growth, and mediating antibody-dependent cellular cytotoxicity (ADCC).\n\n2. **Indications**:\n   - HER2-positive breast cancer (both early-stage and metastatic).\n   - HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.\n\n3. **Administration**:\n   - Trastuzumab can be administered intravenously or subcutaneously.\n   - The subcutaneous form is often combined with hyaluronidase to facilitate"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_nilTooeTY0iAGyeRfGwY7qeB", "custom_id": "337_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "97fe8e3d644bd072ecc9a93ff88a4081", "body": {"id": "chatcmpl-9St69udwb4PNG3Kn3w21R5bnKHlNP", "object": "chat.completion", "created": 1716672009, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zanubrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that is used primarily in the treatment of certain types of B-cell malignancies. Here are some key points you should know about Zanubrutinib as a physician:\n\n### Indications\nZanubrutinib is used for the treatment of:\n1. **Mantle Cell Lymphoma (MCL)**: Specifically for adult patients who have received at least one prior therapy.\n2. **Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)**.\n3. **Waldenstr\u00f6m's Macroglobulinemia (WM)**.\n\n### Mechanism of Action\n- Zanubrutinib inhibits BTK, an enzyme that plays a crucial role in the B-cell receptor (BCR) signaling pathway.\n- By inhibiting BTK, Zanubrutinib interferes with the survival and proliferation of malignant B cells.\n\n### Administration\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_MFzcTptV7hrT8QoOaf7sKb0L", "custom_id": "338_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a6c98368f9e1086d951e393eb8f15d19", "body": {"id": "chatcmpl-9St691VqKCnK76DPbwCOlvzQCXsej", "object": "chat.completion", "created": 1716672009, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Furmonertinib is a relatively novel agent used in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about Furmonertinib as a physician:\n\n### Mechanism of Action:\n- **Tyrosine Kinase Inhibitor (TKI):** Furmonertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It targets specific mutations in the EGFR gene, which are often implicated in the pathogenesis of NSCLC.\n- **Mutations Targeted:** It is particularly effective against the T790M mutation in the EGFR gene, which is a common resistance mutation that develops in patients who have been treated with first- and second-generation EGFR TKIs.\n\n### Indications:\n- **NSCLC:** Furmonertinib is indicated for the treatment of patients with EGFR mutation-positive NSCLC, especially those who have developed resistance to earlier-generation EGFR inhibitors.\n\n### E"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_A15IVUPyy6dLLicChQ5ROH5G", "custom_id": "339_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d50a8223b933fe2b6b9e7a3e218c02c0", "body": {"id": "chatcmpl-9St69Ir5BQKWYWhxmApidV5eQmOVL", "object": "chat.completion", "created": 1716672009, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ciltacabtagene autoleucel, also known as cilta-cel, is a type of chimeric antigen receptor (CAR) T-cell therapy. It has been designed to target B-cell maturation antigen (BCMA) on the surface of multiple myeloma cells. Here are some key points you should be aware of:\n\n1. **Indication**: Cilta-cel is primarily indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.\n\n2. **Mechanism of Action**: Cilta-cel involves engineering a patient's own T-cells to express a CAR that specifically targets BCMA. Once these modified T-cells are infused back into the patient, they recognize and kill BCMA-expressing multiple myeloma cells.\n\n3. **Efficacy**: Clinical trials"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_TtpuFdOXBNtQ99vgrgZrUR2j", "custom_id": "340_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "31fa4f4ea261b331d16727823163b925", "body": {"id": "chatcmpl-9St6AHS557vyBF7G2MRktcx3CmFjX", "object": "chat.completion", "created": 1716672010, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asciminib is a medication used in the treatment of chronic myeloid leukemia (CML) that specifically targets the BCR-ABL1 fusion protein, which is a hallmark of the disease. Here are some important points you should know as a physician:\n\n### Mechanism of Action:\n- **STI (Specifically Targeted Inhibitor)**: Asciminib is known as a \"STAMP\" (Specifically Targeting the ABL Myristoyl Pocket) inhibitor. It binds to the myristoyl pocket of the ABL1 kinase domain, which is distinct from where other tyrosine kinase inhibitors (TKIs) like imatinib bind.\n- **Dual Inhibition**: This unique binding site allows asciminib to inhibit both the native and mutated forms of BCR-ABL1, including some forms that are resistant to other TKIs.\n\n### Indications:\n- **Chronic Myeloid Leukemia (CML)**: Asciminib is indicated"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_D7Lf4WNygeYgMwR8rZWMEm80", "custom_id": "341_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "676a4a588b3ecd3eb6eb01b0c2db6989", "body": {"id": "chatcmpl-9St6AzLJ7OPlzbasKcN8Ea5X2dEXZ", "object": "chat.completion", "created": 1716672010, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Loncastuximab tesirine (brand name Zynlonta) is an antibody-drug conjugate (ADC) used for the treatment of certain types of cancer, specifically relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Here\u2019s what you need to know about it:\n\n### Mechanism of Action\n- **Antibody-Drug Conjugate:** Loncastuximab tesirine combines a monoclonal antibody targeting CD19, a protein expressed on the surface of B-cells, with a cytotoxic agent (a pyrrolobenzodiazepine [PBD] dimer). \n- **Targeting and Killing Cancer Cells:** The monoclonal antibody binds to CD19 on the surface of B-cells, including malignant B-cells. Upon binding, the ADC is internalized, and the cytotoxic agent is released inside the cell, causing DNA cross-linking and cell"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_FCS4AhHvd6Yl5M1FQjZHO2ZH", "custom_id": "342_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a76407e52dedda1ae6919e25eb1dfe6c", "body": {"id": "chatcmpl-9St6ANVekFUz5YKE5GCX5sXVe5g33", "object": "chat.completion", "created": 1716672010, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tazemetostat is an important medication in the field of oncology, particularly for its role in the treatment of certain cancers. Here are some key points you should know about Tazemetostat:\n\n### Mechanism of Action\n- **EZH2 Inhibitor**: Tazemetostat is an inhibitor of the enzyme enhancer of zeste homolog 2 (EZH2), which is part of the polycomb repressive complex 2 (PRC2). EZH2 is involved in the methylation of histone H3 on lysine 27 (H3K27me3), leading to gene silencing. Mutations or overexpression of EZH2 can contribute to oncogenesis.\n\n### Indications\n- **Epithelioid Sarcoma**: Tazemetostat is FDA-approved for the treatment of metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.\n- **Follicular Lymphoma**: It is also approved for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_y3tKQ0WA6dkzPgVfqPrg5zOs", "custom_id": "343_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a13284a779b7aa69213b466a058f774b", "body": {"id": "chatcmpl-9St6A9dbKkO94zOAx7pSOKOCHsSGC", "object": "chat.completion", "created": 1716672010, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nivolumab and relatlimab are both immunotherapy drugs used in the treatment of certain types of cancer. Here\u2019s a detailed overview for you as a physician:\n\n### Nivolumab\n\n**Class:**\n- Nivolumab is a monoclonal antibody that inhibits the programmed death-1 (PD-1) receptor.\n\n**Mechanism of Action:**\n- By blocking the PD-1 receptor, nivolumab prevents cancer cells from evading immune detection. This enhances the body\u2019s immune response against tumors.\n\n**Indications:**\n- Nivolumab is used to treat various cancers, including:\n  - Melanoma\n  - Non-small cell lung cancer (NSCLC)\n  - Renal cell carcinoma (RCC)\n  - Hodgkin lymphoma\n  - Squamous cell carcinoma of the head and neck\n  - Urothelial carcinoma\n  - Hepatocellular carcinoma\n  - Esophageal squamous cell carcinoma\n  - Colore"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_VnPMbpZKr1BVOfvtNRsvSNMa", "custom_id": "344_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "945dcceba75fcd126d3dc29073bda8bc", "body": {"id": "chatcmpl-9St6ASo01enW4NF05YtEw2zqXxYVN", "object": "chat.completion", "created": 1716672010, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon alfa-2c is a type of recombinant interferon used in the treatment of various viral infections and certain types of cancers. Here are some key points you should know about it:\n\n### Mechanism of Action\nInterferon alfa-2c is part of the interferon family, which are proteins that play a role in the immune response. It works by:\n\n1. **Antiviral Activity**: Inhibiting viral replication within host cells.\n2. **Antiproliferative Effects**: Inhibiting the growth of tumor cells.\n3. **Immunomodulatory Effects**: Enhancing the immune system's ability to fight off infections and tumors.\n\n### Indications\nInterferon alfa-2c is used to treat a variety of conditions, including:\n\n1. **Chronic Hepatitis B and C**: To reduce viral load and liver inflammation.\n2. **Certain Cancers**: Such as hairy cell leukemia, malignant melanoma, follicular lymphoma"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ywTQ9b3aNtDYckhBVfmL7Edf", "custom_id": "345_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "7058ce101466a39b81380caab4a99fa5", "body": {"id": "chatcmpl-9St6BuVE9FIFEbKP9KMTisbMBlpoG", "object": "chat.completion", "created": 1716672011, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon alfa-n1 (also known as IFN-\u03b1n1) is a type of recombinant interferon used in the treatment of various medical conditions, particularly those involving viral infections and certain types of cancer. Here are some key points you should know about Interferon alfa-n1:\n\n### Mechanism of Action:\n- **Antiviral Activity**: Interferon alfa-n1 enhances the immune response against viral infections by inducing the production of antiviral proteins that inhibit viral replication.\n- **Antiproliferative Effects**: It can inhibit the growth of cancer cells by modulating the expression of genes involved in cell proliferation and apoptosis.\n- **Immunomodulatory Effects**: It enhances the activity of immune cells such as natural killer cells and macrophages.\n\n### Indications:\n- **Chronic Hepatitis B and C**: Used to treat chronic hepatitis B and C infections.\n- **Certain Cancers**: Such as hairy cell leukemia, malignant melanoma, follicular lymphoma"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_wP57AObXcXoVO1jveg4jaXml", "custom_id": "346_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "db5350379829b5a1ed83adf3f681c74b", "body": {"id": "chatcmpl-9St6B5lmLw0bwY8WSdhF82zk5QS2g", "object": "chat.completion", "created": 1716672011, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Margetuximab is a monoclonal antibody that targets the HER2 (human epidermal growth factor receptor 2) protein, which is overexpressed in some types of breast cancer and other cancers. Here's a detailed overview of what you should know as a physician:\n\n### Mechanism of Action\n- **HER2 Targeting**: Margetuximab binds to the HER2 protein on the surface of cancer cells, inhibiting their growth and survival.\n- **Enhanced Immune Activation**: It is engineered to have increased affinity for activating Fc gamma receptors on immune cells, which enhances antibody-dependent cellular cytotoxicity (ADCC).\n\n### Indications\n- **HER2-Positive Breast Cancer**: Margetuximab is indicated for the treatment of patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.\n\n### Administration\n- **Dosage and Schedule**: Typically"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_2dx9AqQYenFlJGiZe9Zz1Xv1", "custom_id": "347_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "afdf30a9a56e9c6ed8810d68dd364548", "body": {"id": "chatcmpl-9St6B7xHhYXsmyHvkQIGfe7XxBMQV", "object": "chat.completion", "created": 1716672011, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sotorasib is a targeted cancer therapy drug, specifically an inhibitor of the KRAS G12C mutation, which is often found in various types of cancers, including non-small cell lung cancer (NSCLC). Here are some key points you should know about Sotorasib:\n\n### Mechanism of Action:\n- **KRAS G12C Inhibitor:** Sotorasib selectively and irreversibly binds to the KRAS G12C mutant protein, locking it in an inactive GDP-bound state, thereby inhibiting downstream signaling pathways that promote cancer cell proliferation and survival.\n\n### Indications:\n- **Non-Small Cell Lung Cancer (NSCLC):** Sotorasib is approved for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic therapy.\n\n### Dosage and Administration:\n- **Oral Administration:** Sotorasib is taken orally, typically once daily.\n- **Dosage:** The standard dose is 960"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_EeDI69jmEU49TeGgklnRWoWN", "custom_id": "348_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "84aa7398f1996c57f8e2c4d8406479c6", "body": {"id": "chatcmpl-9St6Bb9Peq0D57ZkVoVJN1sKuOUZx", "object": "chat.completion", "created": 1716672011, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Umbralisib is a medication that was used for the treatment of certain types of blood cancers, specifically relapsed or refractory marginal zone lymphoma (MZL) and follicular lymphoma (FL). It is an oral inhibitor of phosphoinositide 3-kinase delta (PI3K\u03b4) and casein kinase 1 epsilon (CK1\u03b5), which are enzymes involved in the growth and survival of malignant B cells. \n\nHowever, as a physician, it is crucial to be aware of the following key points related to Umbralisib:\n\n1. **Indications:** Umbralisib was indicated for patients with relapsed or refractory MZL who have received at least one prior anti-CD20-based regimen, and for those with relapsed or refractory FL who have received at least three prior lines of systemic therapy.\n\n2. **Mechanism of Action:** By inhibiting PI3K\u03b4 and CK1\u03b5, umbralisib disrupts signaling pathways that contribute to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_QKJ5XVeSj48JhTpvnRc4erW7", "custom_id": "349_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2835c6d3ab192cae260c43198c0eeb14", "body": {"id": "chatcmpl-9St6BbU1uCKNSatHrSNwopInnC9XQ", "object": "chat.completion", "created": 1716672011, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sintilimab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. It is used in immunotherapy for treating certain types of cancer. Here are key points you should know about Sintilimab:\n\n1. **Mechanism of Action**:\n   - Sintilimab binds to the PD-1 receptor on T-cells, blocking its interaction with PD-L1 and PD-L2 ligands found on tumor cells. This inhibition reactivates the immune system to recognize and attack cancer cells.\n\n2. **Indications**:\n   - Sintilimab is primarily used for the treatment of various cancers, including non-small cell lung cancer (NSCLC), Hodgkin lymphoma, and other solid tumors. Specific indications may vary by regulatory approvals in different countries.\n\n3. **Administration**:\n   - It is typically administered intravenously. The dosage and schedule can vary based on the type of cancer being treated and the specific treatment protocol.\n\n4. **E"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_eZiRQhOaBkNibbbg538L29ns", "custom_id": "350_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "da414e8c1d9fec87fb15736699e5ac83", "body": {"id": "chatcmpl-9St6BBec5yYDT8NcNVImPwq7ewPP7", "object": "chat.completion", "created": 1716672011, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pirtobrutinib (also known as LOXO-305) is a novel, non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor that has been developed for the treatment of certain hematologic malignancies, particularly B-cell lymphomas and chronic lymphocytic leukemia (CLL). Here are some key points you should know as a physician:\n\n### Mechanism of Action:\n- **BTK Inhibition**: Pirtobrutinib targets and inhibits BTK, a critical enzyme in the B-cell receptor signaling pathway which plays a role in the survival and proliferation of malignant B-cells.\n- **Reversible Binding**: Unlike first-generation BTK inhibitors (such as ibrutinib) that form a covalent bond with BTK, pirtobrutinib binds non-covalently, which allows it to be effective even in the presence of BTK mutations that confer resistance to covalent inhibitors.\n\n### Indications:\n- **B-cell"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_EssW7Bv8Juq820H79WaEoEMB", "custom_id": "351_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5644b9ef20f42ab59f26301100716e28", "body": {"id": "chatcmpl-9St6Bn0wLV1vOtBNDscJ7WIqiRANH", "object": "chat.completion", "created": 1716672011, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Toripalimab is a monoclonal antibody that targets the programmed cell death protein-1 (PD-1) receptor, which is used in cancer immunotherapy. Here are key points you should know about Toripalimab:\n\n### Mechanism of Action\n- **PD-1 Inhibition**: Toripalimab blocks the PD-1 receptor on T cells, preventing its interaction with PD-L1 and PD-L2 ligands. This inhibition can enhance T-cell responses against tumor cells, thereby facilitating an immune-mediated attack on the cancer.\n\n### Indications\n- **Approved Uses**: Toripalimab is primarily used for treating various types of cancers, including melanoma, nasopharyngeal carcinoma, and urothelial carcinoma. It is often prescribed when other treatments have failed or are not suitable.\n- **Research and Trials**: Ongoing clinical trials are exploring its efficacy in treating other cancers, such as non-small cell lung cancer (NSCLC), hepatocellular carcinoma"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_hp3B69wmDi2qA2ZtySUkwI3k", "custom_id": "352_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "730786f6986470fdb9011a286eb2efeb", "body": {"id": "chatcmpl-9St6CYYuAEyJhEjFmaw85xsei2Ymz", "object": "chat.completion", "created": 1716672012, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Teclistamab is a bispecific antibody that targets both CD3 on T cells and BCMA (B-cell maturation antigen) on multiple myeloma cells. Here are some key points you should know about Teclistamab as a physician:\n\n1. **Mechanism of Action**: Teclistamab redirects T cells to recognize and kill multiple myeloma cells by simultaneously binding to CD3 on T cells and BCMA on myeloma cells.\n\n2. **Indications**: It's primarily used for the treatment of relapsed or refractory multiple myeloma. Relapsed or refractory multiple myeloma refers to cases where the cancer has returned after treatment or is resistant to existing therapies.\n\n3. **Administration**: Teclistamab is typically administered via subcutaneous injection, but the exact regimen may vary based on the clinical protocol or specific patient needs.\n\n4. **Efficacy**: Clinical trials have shown promising results in terms of response rates in patients"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_506Rqg0e9LGj9Cqx2urRrYoU", "custom_id": "353_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "25a48f38aa60e22f655a10133bef4ca1", "body": {"id": "chatcmpl-9St6COAvwlwZ6Gw3OueLpxeqnKofB", "object": "chat.completion", "created": 1716672012, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mobocertinib (brand name Exkivity) is an oral tyrosine kinase inhibitor (TKI) specifically designed to target epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Here\u2019s what you should know as a physician:\n\n### Indications:\n- **Non-Small Cell Lung Cancer (NSCLC):** Mobocertinib is primarily indicated for adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 20 insertion mutations and who have progressed on or after platinum-based chemotherapy.\n\n### Mechanism of Action:\n- **EGFR Inhibition:** Mobocertinib selectively inhibits EGFR exon 20 insertion mutations, which are less responsive to other EGFR inhibitors. It works by binding to the tyrosine kinase domain of the mutated EGFR, thereby inhibiting downstream signaling pathways that promote tumor cell proliferation and survival.\n\n### Dosage and Administration:\n- **Oral Administration:** The recommended dose for Mobocertinib is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_enVozMZtga7E8hOCJSKD4Pqf", "custom_id": "354_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c2e47ba46990e2751bd5727f09f3745b", "body": {"id": "chatcmpl-9St6CSe4NObWhsod9DRMesRlbXCXA", "object": "chat.completion", "created": 1716672012, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tisotumab vedotin (brand name Tivdak) is an antibody-drug conjugate (ADC) used in oncology, specifically for the treatment of certain types of cancer. Here are some key points you should know as a physician:\n\n### Indications\n- **FDA Approval:** Tisotumab vedotin is approved for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.\n- **Off-label use:** Though primary use is for cervical cancer, ongoing studies may explore its efficacy in other cancers.\n\n### Mechanism of Action\n- **Antibody-Drug Conjugate:** It is composed of a human monoclonal antibody targeting tissue factor (TF), linked to the cytotoxic agent monomethyl auristatin E (MMAE).\n- **Target:** Tissue factor is overexpressed in many solid tumors.\n- **Cytotoxicity:** Upon binding to TF-expressing cells, the ADC is internalized, and MMAE is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_dMP1dckf3k6KqSf2CgOkqy2b", "custom_id": "355_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "fed095741e4cc06c1a3382103277f6ac", "body": {"id": "chatcmpl-9St6ChAxQtA4XfcpaNxS4lMAcFOA6", "object": "chat.completion", "created": 1716672012, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lanreotide (brand name Somatuline Depot) is a long-acting somatostatin analog used primarily in the management of certain medical conditions. Here are key points you should know about Lanreotide LAR (Long-Acting Release):\n\n### Indications:\n1. **Acromegaly**: Lanreotide is used to reduce growth hormone and insulin-like growth factor-1 (IGF-1) levels in patients with acromegaly, particularly when surgery or radiotherapy is not effective or feasible.\n2. **Neuroendocrine Tumors (NETs)**: It is used to treat patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to help control symptoms caused by hormone secretion and to slow tumor growth.\n3. **Thyroid Tumors**: It can also be used for certain types of thyroid tumors.\n\n### Mechanism of Action:\n- Lanreotide mimics natural somatostatin,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_LkFyia7AAj6jTBLGsKx0UnWb", "custom_id": "356_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "fd453152a262564070aa90d078a114e1", "body": {"id": "chatcmpl-9St6CcP1q800tS9GM7VQIoBVP1Y9X", "object": "chat.completion", "created": 1716672012, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pimitespib is a relatively new drug in the field of oncology, classified as a heat shock protein 90 (Hsp90) inhibitor. Here are some key points you should know about it:\n\n### Mechanism of Action:\n- **Hsp90 Inhibition:** Pimitespib works by inhibiting Hsp90, a molecular chaperone involved in the proper folding, stability, and function of many proteins that are crucial for tumor growth and survival. By inhibiting Hsp90, pimitespib disrupts these processes, leading to the degradation of client proteins and ultimately inducing apoptosis in cancer cells.\n\n### Indications:\n- **Cancer Treatment:** Primarily, pimitespib is being investigated and used for the treatment of various types of cancers, including gastrointestinal stromal tumors (GIST) and other malignancies that are resistant to standard therapies.\n\n### Dosage and Administration:\n- **Oral Administration:** Pimitespib is typically administered orally. The exact dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_FAtNkPeYSLNIC04i1TKJ1pT4", "custom_id": "357_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8974766dc299e6fa91c97093da05bcde", "body": {"id": "chatcmpl-9St6CP48ERRG8lgGIG36RnAr8tKtz", "object": "chat.completion", "created": 1716672012, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prednimustine is a chemotherapeutic agent that combines prednisolone and chlorambucil. It is primarily used in the treatment of certain types of cancers, including lymphomas and leukemias. Here are some important aspects you should be aware of:\n\n1. **Mechanism of Action**:\n   - **Prednisolone**: A corticosteroid with anti-inflammatory and immunosuppressive properties.\n   - **Chlorambucil**: An alkylating agent that interferes with DNA replication and cell division.\n\n2. **Indications**:\n   - Mainly used in hematologic malignancies such as Hodgkin's and non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions where immunosuppression is beneficial.\n\n3. **Dosage and Administration**:\n   - The dosage and administration schedule can vary based on the specific condition being treated, the patient's response, and their overall health status. It usually requires careful adjustment and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_LsrzIr1tFS2WpgLbpPFX1nIz", "custom_id": "358_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c049f1410ed06cda55b016eaba337390", "body": {"id": "chatcmpl-9St6CupXkwXXWB0NHATSTSi7qLoJ4", "object": "chat.completion", "created": 1716672012, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pipobroman is a chemotherapeutic agent primarily used in the treatment of certain types of chronic myeloproliferative disorders, such as polycythemia vera and essential thrombocythemia. Here are some key points you should know about Pipobroman:\n\n### Mechanism of Action\n- **Alkylating Agent:** Pipobroman is an alkylating agent, meaning it works by adding alkyl groups to DNA, which leads to cross-linking of DNA strands, ultimately inhibiting DNA replication and RNA transcription. This results in cell cycle arrest and apoptosis, particularly in rapidly dividing cells.\n\n### Indications\n- **Polycythemia Vera:** A condition characterized by an increased number of red blood cells.\n- **Essential Thrombocythemia:** A disorder in which the bone marrow produces too many platelets.\n\n### Dosage and Administration\n- **Individualized Dosing:** The dosage of Pipobroman is individualized based on patient response and blood counts. Regular"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_XwM5eqM5uNCwMOuGejgkj0Xm", "custom_id": "359_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b3fa5093aa79ba7d81351ffc6902ea31", "body": {"id": "chatcmpl-9St6Do9BbRo3OEuvRo71KdJYw70sn", "object": "chat.completion", "created": 1716672013, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Polatuzumab vedotin (Polivy) is a monoclonal antibody conjugated to a cytotoxic agent used in the treatment of certain types of non-Hodgkin lymphoma (NHL). Here are some key points you should know as a physician:\n\n### Mechanism of Action\n- **Target**: Polatuzumab vedotin targets CD79b, a protein expressed on the surface of B cells.\n- **Conjugate**: It is conjugated to monomethyl auristatin E (MMAE), a potent microtubule-disrupting agent.\n- **Action**: Upon binding to CD79b, the conjugate is internalized by the B cell, and MMAE is released, leading to cell cycle arrest and apoptosis of the malignant B cells.\n\n### Indications\n- **Diffuse Large B-Cell Lymphoma (DLBCL)**: Polatuzumab vedotin is indicated in combination with bendamustine and ritux"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_VhlicfDBSJQUSvwqikdA9rsL", "custom_id": "360_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a143b4f4f174acfa1af2ad1cf559ab62", "body": {"id": "chatcmpl-9St6D80vN5XWOSXXyOI4zFISPDVi8", "object": "chat.completion", "created": 1716672013, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mirvetuximab soravtansine (also known as IMGN853) is an antibody-drug conjugate (ADC) designed for the treatment of certain types of cancer. Here are key points you should know about this medication:\n\n### Mechanism of Action\n- **Target**: Mirvetuximab soravtansine targets the folate receptor alpha (FR\u03b1), which is overexpressed in various types of cancer, including ovarian cancer.\n- **Components**: It consists of a monoclonal antibody (mirvetuximab) that binds to FR\u03b1, linked to a cytotoxic agent (soravtansine, a maytansinoid DM4).\n- **Action**: Upon binding to FR\u03b1 on cancer cells, the ADC is internalized, and the cytotoxic agent is released, leading to cell death.\n\n### Indications\n- **Ovarian Cancer**: It is primarily investigated for the treatment of patients with FR"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Pd5ypVx4Xvn8GRzkiUn5sJbN", "custom_id": "361_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8f5437ae873d045fbb006e3a1f42f9c6", "body": {"id": "chatcmpl-9St6DMASrIW5qM7FaqyCyqJ2quxE1", "object": "chat.completion", "created": 1716672013, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mosunetuzumab is a bispecific antibody that is designed to engage T cells and direct them to kill B cells. It targets both CD3, which is present on T cells, and CD20, which is present on B cells. This dual-targeting mechanism allows the patient's own immune system to recognize and eliminate B cells, including malignant B cells found in certain types of B-cell lymphomas. Here are some key points you should know about Mosunetuzumab:\n\n### Indications\n- **Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (NHL):** Mosunetuzumab has shown promise in treating patients with relapsed or refractory NHL, particularly those who have not responded adequately to other therapies.\n\n### Mechanism of Action\n- **Bispecific Antibody:** By binding to CD3 on T cells and CD20 on B cells, Mosunetuzumab brings these cells into close proximity, facilitating the T-cell-mediated killing of the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_pYn3FBQgQgfGcbD77YVJQbV8", "custom_id": "362_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c9d541d64bac53136d3706ca246a662b", "body": {"id": "chatcmpl-9St6DCifMciedkTBqJEJbIpftRlOi", "object": "chat.completion", "created": 1716672013, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nadofaragene firadenovec (brand name Adstiladrin) is a gene therapy medication used for the treatment of high-risk, non-muscle invasive bladder cancer (NMIBC). Here are some key points you should know about it:\n\n### Mechanism of Action\n- **Gene Therapy Vector**: Nadofaragene firadenovec is an adenoviral vector-based gene therapy.\n- **Transgene**: It delivers the human interferon alfa-2b gene to bladder cells.\n- **Interferon Alfa-2b**: The transduced cells produce interferon alfa-2b, a cytokine with anti-tumor activity, which helps in modulating the immune response against cancer cells.\n\n### Indications\n- **High-Risk NMIBC**: It is specifically indicated for patients with high-risk NMIBC who are unresponsive to Bacillus Calmette-Gu\u00e9rin (BCG) therapy, a common first-line treatment.\n\n### Administration\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_65FA2eKKb4rXhd2aV0OZewAu", "custom_id": "363_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "524c5dc351d982038bdff45312ada69e", "body": {"id": "chatcmpl-9St6DGXSx6qYE2wgA9OWnAHWYOWId", "object": "chat.completion", "created": 1716672013, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Olutasidenib is a relatively new and emerging therapeutic agent, particularly in the field of oncology. Here's a detailed overview of what you should know about this drug:\n\n### General Information\n- **Drug Class**: Olutasidenib is an IDH1 (isocitrate dehydrogenase 1) inhibitor.\n- **Indication**: It is primarily being investigated for the treatment of cancers that harbor IDH1 mutations, including acute myeloid leukemia (AML) and potentially other solid tumors.\n\n### Mechanism of Action\n- **IDH1 Mutation**: IDH1 mutations are found in a subset of cancers and lead to the production of an oncometabolite called 2-hydroxyglutarate (2-HG).\n- **Inhibition**: Olutasidenib specifically inhibits the mutant IDH1 enzyme, reducing levels of 2-HG and thereby promoting cellular differentiation and reducing proliferation of cancerous cells.\n\n### Clinical Efficacy\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_KSpjTVfCzId8Kf5lqh91PEzD", "custom_id": "364_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "de2926e2b07afe2aaf2eae294b282f6a", "body": {"id": "chatcmpl-9St6ERrQoWmY86Nyg3K69UW01Ecik", "object": "chat.completion", "created": 1716672014, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pyrotinib is an oral, small-molecule tyrosine kinase inhibitor (TKI) that targets the epidermal growth factor receptor (EGFR/HER1), human epidermal growth factor receptor 2 (HER2), and human epidermal growth factor receptor 4 (HER4). It is primarily used in the treatment of HER2-positive breast cancer. Here are some key points you should know as a physician:\n\n### Indications and Usage\n- **HER2-Positive Breast Cancer**: Pyrotinib is typically used in combination with other therapies, such as capecitabine, for patients with HER2-positive metastatic breast cancer, especially those who have previously received trastuzumab-based treatments.\n\n### Mechanism of Action\n- **Inhibition of TKIs**: By inhibiting HER1, HER2, and HER4, pyrotinib disrupts the signaling pathways that promote cell growth and survival, leading to decreased proliferation and increased apoptosis of cancer cells.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5P6F1N92IXcXVFsRFxIOuoUV", "custom_id": "365_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "da364c34b8748973cbd4e3a6c7e520ed", "body": {"id": "chatcmpl-9St6ESOyJAaO29Fjs57Up54KB95Zn", "object": "chat.completion", "created": 1716672014, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Buserelin is a synthetic peptide analog of gonadotropin-releasing hormone (GnRH). It is used primarily for its role in regulating the release of gonadotropins (luteinizing hormone [LH] and follicle-stimulating hormone [FSH]) from the anterior pituitary gland. Here are some key points a physician should know about Buserelin:\n\n### Indications\n1. **Prostate Cancer**: Buserelin is commonly used in the treatment of advanced prostate cancer as it helps reduce testosterone levels, which can slow the growth of cancer cells.\n2. **Endometriosis**: It can be used to manage endometriosis by reducing estrogen levels.\n3. **Infertility Treatment**: Buserelin is sometimes used in assisted reproductive technologies (ART) to control ovarian stimulation.\n\n### Mechanism of Action\n- **Initial Stimulation**: Buserelin initially stimulates the release of LH and FSH by binding to GnRH receptors.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Mv70qg5Yszqo2oHKY503RZbb", "custom_id": "366_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "3b7429ec1d42013ce8618b8ea3980064", "body": {"id": "chatcmpl-9St6ESsXsbrejcexVuvgYl86nuass", "object": "chat.completion", "created": 1716672014, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lifileucel is an investigational cell therapy product that is being developed for the treatment of advanced melanoma. Here are some key points you should know:\n\n1. **Nature of the Therapy**: Lifileucel is a type of adoptive cell therapy using tumor-infiltrating lymphocytes (TILs). This involves extracting TILs from a patient's tumor, expanding them in the laboratory, and then infusing them back into the patient to help fight the cancer.\n\n2. **Mechanism of Action**: The therapy leverages the body\u2019s own immune system. TILs are a type of white blood cell that has already recognized the tumor cells as abnormal. By expanding these cells outside of the body and reintroducing them in large numbers, the therapy aims to boost the immune response against the tumor.\n\n3. **Indications**: Lifileucel is primarily being studied for use in patients with advanced melanoma, particularly those who have not responded to other treatments,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_xXY0vpmqAHOyObTRFDj0sn0t", "custom_id": "367_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "763e6955d3d2540e50d8af87451b4969", "body": {"id": "chatcmpl-9St6EIJu6jhzZdKFEduXzYjEQ9iKr", "object": "chat.completion", "created": 1716672014, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tabelecleucel (also known as ATA129) is an investigational T-cell immunotherapy product being developed by Atara Biotherapeutics. It is designed for the treatment of Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorders (PTLD) and other EBV-associated hematologic malignancies and solid tumors. Here are some key points you, as a physician, should be aware of:\n\n### Mechanism of Action\n- **Tabelecleucel** is composed of allogeneic EBV-specific cytotoxic T lymphocytes (CTLs).\n- These cells are derived from healthy donors and are selected for their ability to target and kill EBV-infected cells.\n- The therapy works by restoring the patient\u2019s ability to fight EBV-associated malignancies through targeted cytotoxic activity.\n\n### Indications\n- **PTLD after hematopoietic cell transplantation (HCT)**: Particularly in patients who are refractory to rituximab.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_b3BIzeYje1VWrX7LdQHe4saI", "custom_id": "368_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5a89e515b0f17a12e4f74d111d78cc85", "body": {"id": "chatcmpl-9St6EdOIpDReprtaSZeTuqzOePtTi", "object": "chat.completion", "created": 1716672014, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Verzenio (generic name: abemaciclib) is a medication used in the treatment of certain types of breast cancer. Here are key points you should know about Verzenio as a physician:\n\n### Indications\nVerzenio is indicated for:\n1. **Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer:**\n   - In combination with an aromatase inhibitor as initial endocrine-based therapy.\n   - In combination with fulvestrant in patients with disease progression following endocrine therapy.\n   - As monotherapy in adult patients with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.\n\n### Mechanism of Action\n- Verzenio is a selective inhibitor of cyclin-dependent kinases (CDK) 4 and 6. CDK4/6 are involved in regulating the cell cycle; their inhibition helps to prevent the proliferation of cancer cells.\n\n### Dosage and Administration\n- The typical starting dose is 150"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_4RR78cYxgrUhGhqV5TuhP9Xa", "custom_id": "369_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5970502bc972fc317a443af824a282aa", "body": {"id": "chatcmpl-9St6FtUNf39VSFxFwh3RBOj41tD0M", "object": "chat.completion", "created": 1716672015, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a typo or misunderstanding regarding the name \"Abatitor,\" as it doesn't correspond to any known medication or medical term. If you meant \"Abatacept,\" I can provide information about that. Abatacept is a biologic medication used primarily to treat autoimmune diseases such as rheumatoid arthritis and juvenile idiopathic arthritis. \n\nHere's a brief overview of Abatacept:\n\n### Mechanism of Action:\n- Abatacept is a selective co-stimulation modulator that inhibits T-cell activation. It works by binding to CD80 and CD86 on antigen-presenting cells, thereby preventing these molecules from interacting with CD28 on T cells. This inhibition reduces the inflammatory activity that contributes to autoimmune diseases.\n\n### Indications:\n- **Rheumatoid Arthritis (RA):** Used in adults with moderate to severe RA who have had an inadequate response to other disease-modifying antirheumatic drugs (DMARDs).\n- **Juvenile Idiopathic Arthritis ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_h6px8ZYhQITWK3XhgR7pEw2Q", "custom_id": "370_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9d397ec5cc39a9b64c6f0c452acad0d2", "body": {"id": "chatcmpl-9St6FL2npFINrB44YKY5iq5emijRx", "object": "chat.completion", "created": 1716672015, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Calquence (acalabrutinib) is a medication used primarily to treat certain types of blood cancers, specifically mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Here are some key points you should know about Calquence:\n\n### Mechanism of Action\n- **BTK Inhibitor**: Calquence is a Bruton's tyrosine kinase (BTK) inhibitor. BTK is an enzyme that plays a crucial role in the signaling pathways that drive the proliferation and survival of B-cells, which are often cancerous in conditions like MCL and CLL.\n- **Blocking BTK Activity**: By inhibiting BTK, Calquence disrupts these signaling pathways, leading to reduced growth and survival of malignant B-cells.\n\n### Indications\n- **Mantle Cell Lymphoma (MCL)**: Calquence is approved for adult patients with MCL who have received at least one prior therapy.\n- **Chronic Lymphocytic Leuk"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_IvghQfEUOu3kp4fhPQ76NJDo", "custom_id": "371_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8ddd829494173090dfd9fb6efcd5a54c", "body": {"id": "chatcmpl-9St6FNpudnRglZBmCHy8dENCBNlrJ", "object": "chat.completion", "created": 1716672015, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aclacin, also known as Aclarubicin, is an anthracycline antibiotic used primarily as a chemotherapeutic agent. Here are some key points you should be aware of:\n\n### Mechanism of Action\n- **DNA Intercalation**: Aclarubicin intercalates into DNA, disrupting the synthesis of nucleic acids and proteins. This leads to inhibition of topoisomerase II activity, causing breaks in the DNA strands and ultimately inducing apoptosis in rapidly dividing cells.\n- **Free Radical Formation**: It can generate free radicals, which cause oxidative damage to cellular components, including DNA, proteins, and lipids.\n\n### Indications\n- **Hematologic Malignancies**: Aclarubicin is primarily used in the treatment of various types of leukemia, particularly acute myeloid leukemia (AML). It may also be used in other hematologic malignancies as part of combination chemotherapy regimens.\n  \n### Administration\n- **Intravenous**: Aclar"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_xLad4pOfFh8efL0AIeIxD9t7", "custom_id": "372_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9dcdce7ea9371dd56d4eb046940fd18a", "body": {"id": "chatcmpl-9St6FwqhAKX9nmpTMpugvF2vkHfIz", "object": "chat.completion", "created": 1716672015, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kadcyla (ado-trastuzumab emtansine) is a targeted cancer therapy used primarily for treating HER2-positive breast cancer. Here are key points to consider:\n\n1. **Mechanism of Action:**\n   - Kadcyla combines the HER2-targeted action of trastuzumab (Herceptin) with the cytotoxic activity of the chemotherapy agent DM1 (a derivative of maytansine), delivered specifically to HER2-positive cancer cells.\n\n2. **Indications:**\n   - It is approved for the treatment of patients with HER2-positive metastatic breast cancer who have previously received trastuzumab and a taxane, either separately or in combination.\n   - It can also be used for adjuvant treatment in patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.\n\n3. **Administration:**\n   - Kadcyla is administered intravenously, typically every three weeks, with dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ip78GqpviNrWF3lyUxff23z6", "custom_id": "373_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a69c9b2720a83fcc7244a250f3b3448d", "body": {"id": "chatcmpl-9St6Fpr9DtQS0yxHyWR29V7rodGUF", "object": "chat.completion", "created": 1716672015, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff in October 2023, there is no widely known or documented medication, treatment, or medical device named \"Afanix.\" It is possible that it is a new drug, a brand name, or a term that has surfaced after my last update.\n\nHowever, if \"Afanix\" refers to a specific drug or treatment, here are general steps you should take to understand it thoroughly:\n\n1. **Clinical Trials and Studies**: Review any published clinical trials or studies associated with Afanix to understand its efficacy, safety profile, and potential side effects.\n\n2. **Mechanism of Action**: Understand the pharmacodynamics and pharmacokinetics of Afanix. Knowing how it works in the body and how it is metabolized can be crucial for patient care.\n\n3. **Indications and Usage**: Familiarize yourself with the specific conditions or diseases for which Afanix is indicated. Off-label uses might also be documented in case studies or medical literature"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ny8wBSrOPe3Rcfqx91kk3x8N", "custom_id": "374_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ac65be6d4f31c0ef922e181d205bef47", "body": {"id": "chatcmpl-9St6FmJh4wVrg17NFOpO0qotbQJvo", "object": "chat.completion", "created": 1716672015, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Macrolin appears to be a brand name or a trade name, but without more specific information, it's not entirely clear which exact medication or product it refers to. However, in general, here\u2019s how you might approach understanding any medication you come across in your practice:\n\n1. **Generic Name and Drug Class**:\n   - Determine the generic name of the medication. This will help you understand the drug class it belongs to and its primary mechanism of action.\n\n2. **Indications**:\n   - Identify the primary indications for which the medication is prescribed. This includes understanding what conditions it treats and any off-label uses.\n\n3. **Dosage and Administration**:\n   - Understand the standard dosages, how the medication should be administered (e.g., orally, intravenously), and any special considerations for different patient populations (e.g., pediatric, geriatric, patients with renal impairment).\n\n4. **Contraindications and Precautions**:\n   - Be aware of any contraindications,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_NYg9XykPoR7nDRqj3xIh5yud", "custom_id": "375_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c174c33321710129c31dd5fb7eeda87d", "body": {"id": "chatcmpl-9St6GiWuBdLQbfoQNPUzhuGIcvJOm", "object": "chat.completion", "created": 1716672016, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alecensa (generic name: alectinib) is a medication used in the treatment of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. Here are some key points you should know about Alecensa:\n\n### Indications\n- **Primary Use**: Alecensa is primarily indicated for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer.\n- **Target Population**: It is specifically used in patients whose tumors are ALK-positive, which is a genetic alteration found in some NSCLC patients.\n\n### Mechanism of Action\n- Alecensa is a tyrosine kinase inhibitor (TKI) that targets and inhibits the activity of the ALK receptor tyrosine kinase. By blocking ALK, alectinib helps to prevent cancer cells from growing and dividing.\n\n### Administration\n- **Dosage**: The recommended dosage is 600 mg (four 150 mg capsules) taken orally twice daily with food"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_nDPehzQmdNPyhxqokmURB0Vm", "custom_id": "376_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "aa5c1f1553f364bb19ea9c07383a3ee1", "body": {"id": "chatcmpl-9St6G6es3ZPf0OEGMLL3NML3xPyqy", "object": "chat.completion", "created": 1716672016, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sure, as a physician, it's important to have a comprehensive understanding of Campath (alemtuzumab) to effectively utilize it in clinical practice. Here are key points to consider:\n\n### Mechanism of Action:\n- **Campath (alemtuzumab)** is a monoclonal antibody directed against CD52, a protein present on the surface of mature lymphocytes, including T and B cells. \n- By binding to CD52, alemtuzumab leads to the destruction of these lymphocytes through antibody-dependent lysis and complement-mediated cytolysis.\n\n### Indications:\n- Campath is primarily used in the treatment of B-cell chronic lymphocytic leukemia (CLL).\n- It's also approved for use in relapsing forms of multiple sclerosis (MS), although under the brand name Lemtrada.\n\n### Administration:\n- Campath is typically administered via intravenous infusion.\n- Dosing schedules can vary, but for CLL, it often involves a gradual dose escalation to mitigate infusion-related"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_UAiPBO35181oVrHUoGOVTXvr", "custom_id": "377_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "57c9633365422b0450b7bd4282773649", "body": {"id": "chatcmpl-9St6GSuGYwNDsoSGD8IQuFSpNiFta", "object": "chat.completion", "created": 1716672016, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "All-Trans Retinoic Acid (ATRA), also known as tretinoin, is a derivative of Vitamin A and is primarily used in the treatment of acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia. Here are some key points that you, as a physician, should be aware of regarding ATRA:\n\n1. **Mechanism of Action**:\n   - ATRA works by promoting the differentiation of immature leukemic promyelocytes into mature granulocytes, thereby reducing the accumulation of these immature cells in the bone marrow and blood.\n\n2. **Indications**:\n   - ATRA is principally indicated for the induction of remission in patients with newly diagnosed APL (characterized by the presence of the t(15;17) translocation and/or PML-RARA gene expression).\n   - It is often used in combination with other chemotherapeutic agents, such as arsenic trioxide or anthracyclines, for improved efficacy.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_JxKCXLhL9uxRFJzpDmnmxGkp", "custom_id": "378_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "98a483b20bf43673bb75983598f1f50a", "body": {"id": "chatcmpl-9St6GUToby7BNH736cvj1dVbreKGA", "object": "chat.completion", "created": 1716672016, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Hexalen, the brand name for altretamine, is an antineoplastic agent primarily used in the treatment of ovarian cancer. Here are several key points you should know about Hexalen:\n\n### Indications:\n- **Primary Indication:** Hexalen is indicated for the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with other regimens.\n\n### Mechanism of Action:\n- **Mechanism:** The exact mechanism of action of Hexalen is not fully understood. It is believed to interfere with the function of DNA, leading to cell death, which helps to inhibit the growth of cancer cells.\n\n### Administration:\n- **Dosage Form:** Hexalen is available in oral capsule form.\n- **Typical Dosage:** The typical dosage is 260 mg/m\u00b2/day, divided into four doses, taken for 14 or 21 consecutive days, followed by a rest period, usually as part of a 28-day cycle. The exact regimen may vary based on the patient's condition"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_aC8pH7sFZKeJF2f7GRF0CYpU", "custom_id": "379_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "54aa31ba1ce70b6fca007e371e755caf", "body": {"id": "chatcmpl-9St6GmZ0yS02H6krhXvWCGv2oiVcQ", "object": "chat.completion", "created": 1716672016, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my latest update in October 2023, there is no widely recognized medical or pharmaceutical product specifically named \"Aminoblastin.\" It might be a brand name, a regional product, or a new or experimental compound not yet widely known in the medical community. However, here are some general steps you can take to gather information:\n\n1. **Check Medical Databases**: Utilize medical databases like PubMed, Medline, or clinical trial registries to search for any research articles, clinical trials, or studies related to Aminoblastin.\n\n2. **Consult Pharmacological Resources**: Check comprehensive pharmacological resources such as the Physician's Desk Reference (PDR), Lexicomp, or Micromedex for any mention of Aminoblastin.\n\n3. **Contact Manufacturer**: If Aminoblastin is a new or regional product, contacting the manufacturer directly can provide the most accurate and detailed information.\n\n4. **Verify with Regulatory Authorities**: Check with regulatory bodies like the FDA ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ooWrvuHuvpT5SfvrMjwuC2jt", "custom_id": "380_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "43f04377288eebd412b520fcac1f5928", "body": {"id": "chatcmpl-9St6HtrbZZK05QkIUUlbdlgvWaubM", "object": "chat.completion", "created": 1716672017, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It appears there might be a typo or misunderstanding regarding the term \"Calsed.\" If you meant \"Calsed,\" it doesn't correspond to any widely recognized medical term, medication, or condition in current medical literature.\n\nHowever, if you're referring to something specific and the term might be misspelled or miscommunicated, here are a few possibilities you might be thinking of:\n\n1. **Calcitriol**: This is the active form of Vitamin D3, often used to treat conditions like hypocalcemia and metabolic bone disease in patients with chronic renal failure.\n\n2. **Calcium Supplements**: Often used to treat or prevent low blood calcium levels in people who do not get enough calcium from their diets. They are also used in various conditions such as osteoporosis, osteomalacia, and certain muscular diseases.\n\n3. **Cialis (Tadalafil)**: A medication used to treat erectile dysfunction and symptoms of benign prostatic hypertrophy (enlarged prostate).\n\nIf you have a specific"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_remIhTD7Z7tiGH6n8cFAFCIO", "custom_id": "381_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "074abe71499106255d975fe5c29d038f", "body": {"id": "chatcmpl-9St6HzVlaxAJDUW7QWlNOKPkskpiz", "object": "chat.completion", "created": 1716672017, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to have accurate and up-to-date information regarding any medication or compound you may encounter. However, as of my last update in October 2021, there is no widely recognized medication or compound known as \"Amekrin\" in the medical literature or pharmacological databases.\n\nIf \"Amekrin\" is a newly developed drug, experimental compound, or a name used in a specific context or region which I am not aware of, here are some general steps you can take to gather more information:\n\n1. **Consult Reliable Databases:** Use trusted medical databases such as PubMed, Medline, or the FDA database to search for any clinical trials, studies, or approval information regarding \"Amekrin.\"\n\n2. **Check Professional Resources:** Refer to resources like the Physicians' Desk Reference (PDR), the British National Formulary (BNF), or other professional drug compendiums.\n\n3. **Contact Professional Organizations:** Reach out to relevant medical or pharmaceutical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_CQCMIX5cve3ndAKX9ygrGzWs", "custom_id": "382_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e27c05a27eadfca0362156514c23ca23", "body": {"id": "chatcmpl-9St6H8SGcbNr9HeJE8x1Q27em7Hg6", "object": "chat.completion", "created": 1716672017, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Altraz, which contains the active ingredient anastrozole, is a medication primarily used in the treatment of breast cancer. Here are some key points you should know about Altraz as a physician:\n\n### Indications:\n1. **Breast Cancer Treatment:**\n   - Altraz is mainly used for postmenopausal women with hormone receptor-positive early breast cancer or advanced breast cancer.\n   - It is particularly useful for patients who have progressed on tamoxifen therapy.\n\n### Mechanism of Action:\n- **Aromatase Inhibitor:** Anastrozole works by inhibiting the enzyme aromatase, which is involved in the synthesis of estrogen. By lowering estrogen levels, it helps to slow the growth of estrogen-dependent breast cancer cells.\n\n### Dosage and Administration:\n- **Standard Dose:** The typical dosage is 1 mg orally once daily.\n- **Administration:** It can be taken with or without food.\n\n### Side Effects:\nCommon side effects include:\n1"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_SafZX0VBCFYja0wWjeltmiuI", "custom_id": "383_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9101179559c47b118c032d47a3611e9c", "body": {"id": "chatcmpl-9St6Hl8gILiytJgIv4prMqdEh5axH", "object": "chat.completion", "created": 1716672017, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erleada (generic name: apalutamide) is a medication used in the treatment of prostate cancer. Here are some key points you should be aware of as a physician:\n\n### Indications:\n1. **Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC):**\n   - Erleada is used for patients whose prostate cancer has not spread to other parts of the body but continues to grow despite low levels of testosterone.\n\n2. **Metastatic Castration-Sensitive Prostate Cancer (mCSPC):**\n   - It is also indicated for patients whose prostate cancer has spread to other parts of the body and who are still responsive to treatments that lower testosterone levels.\n\n### Mechanism of Action:\n- **Androgen Receptor Inhibitor:**\n  - Erleada works by inhibiting the action of androgens (male hormones) by binding directly to the androgen receptor. This prevents androgens from stimulating the growth of prostate"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_7JCwuXgCyVHLoTNwRi3GLgow", "custom_id": "384_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "48a6f5982225c3d1cd956ccfb0a388e9", "body": {"id": "chatcmpl-9St6HohH4Wqr32FmeYyVA3S4rqT4H", "object": "chat.completion", "created": 1716672017, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2021, there is no widely recognized medical condition, medication, or notable medical figure by the name \"Aitan.\" It\u2019s possible that \"Aitan\" could refer to a person's name, a less common medical term, or something that has emerged more recently beyond my latest knowledge update.\n\nIf \"Aitan\" is a patient's name, you should approach their care with the same comprehensive and patient-centered principles you apply to all patients. This includes:\n\n1. **Medical History**: Gather a thorough medical history, including any known conditions, medications, allergies, surgeries, and family medical history.\n2. **Cultural Sensitivity**: If there are cultural or religious considerations associated with the name \"Aitan,\" be respectful and mindful of these in your interactions and care plans.\n3. **Individualized Care**: Focus on personalized care tailored to the specific needs, symptoms, and health goals of the individual.\n\nIf \"Aitan\" refers to a specific"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_rXFRY2hnjrA55Ij0ou5OKXsc", "custom_id": "385_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d00c061659aa60ede244e90121c470f2", "body": {"id": "chatcmpl-9St6HvwBzu0qsvrt3TITCMos3nbZ2", "object": "chat.completion", "created": 1716672017, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be aware that \"Arsenol\" can refer to a few different things depending on the context, but it is not a commonly recognized term in modern medical practice. You might be referring to historical arsenic-based medications or a specific drug or compound that is less commonly known. Here's some general information that could be relevant:\n\n1. **Historical Context**:\n   - **Arsenic Compounds**: Historically, arsenic compounds such as Fowler's solution or Salvarsan (arsphenamine) were used to treat various diseases, including syphilis and certain types of leukemia. These treatments have largely been replaced by safer and more effective medications.\n\n2. **Toxicity and Safety**:\n   - **Arsenic Toxicity**: Arsenic is a well-known toxic element. Chronic exposure or ingestion can lead to arsenic poisoning, which can cause symptoms like abdominal pain, vomiting, diarrhea, and even more severe outcomes like multi-organ failure and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_CMbxdQzFzYn4vjCLxuQUwnAj", "custom_id": "386_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d48d32e57343f67840be3b8d4dbe3f0f", "body": {"id": "chatcmpl-9St6IZ2XDpTmFadZW0gF43alyTFct", "object": "chat.completion", "created": 1716672018, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asparaginase is an important chemotherapeutic agent used primarily in the treatment of acute lymphoblastic leukemia (ALL). As a physician, here are key points you should know about Asparaginase:\n\n### Mechanism of Action:\n- **Enzyme Activity**: Asparaginase catalyzes the hydrolysis of asparagine to aspartic acid and ammonia. Leukemic cells, which are unable to synthesize asparagine independently, rely on circulating asparagine. Depletion of asparagine leads to inhibition of protein synthesis and apoptosis in these cells.\n\n### Indications:\n- **Acute Lymphoblastic Leukemia (ALL)**: Asparaginase is a critical component of multi-agent chemotherapy regimens for ALL in both pediatric and adult patients.\n- **Other Uses**: It may also be used in some cases of non-Hodgkin lymphoma, though this is less common.\n\n### Types of Asparaginase:\n- **Native Asparagin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Yf8tFyfO7X0txckLjPqKl694", "custom_id": "387_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "7d35a21d2628caaca0b3549745e7091c", "body": {"id": "chatcmpl-9St6I46rKBAD6AW7p0JLYfiPVCToc", "object": "chat.completion", "created": 1716672018, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erwinase, also known as asparaginase Erwinia chrysanthemi, is an enzyme used in the treatment of acute lymphoblastic leukemia (ALL), particularly in patients who have developed hypersensitivity to E. coli-derived asparaginase products. Here are some key points you should know about Erwinase:\n\n### **Mechanism of Action**\n- Erwinase works by depleting the amino acid asparagine, which is essential for the survival and proliferation of leukemic cells. Normal cells can synthesize asparagine, but leukemic cells generally cannot, making them more susceptible to asparagine depletion.\n\n### **Indications**\n- Primarily used in patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity or allergy to E. coli-derived asparaginase products such as Elspar (L-asparaginase) or Oncaspar (pegaspargase).\n\n### **Administration**\n- It is usually administered via intramus"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_3t1oQu9DLFxsPmdG1RaugQdQ", "custom_id": "388_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "756fb6413abc3e1a0922cf4e6b605472", "body": {"id": "chatcmpl-9St6IvgtlSIb8jcyxaoJxyNyevjya", "object": "chat.completion", "created": 1716672018, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tecentriq (atezolizumab) is a monoclonal antibody that functions as an immune checkpoint inhibitor targeting the protein programmed death-ligand 1 (PD-L1). It is used in cancer immunotherapy to treat various types of cancer. Here are key points you should be aware of as a physician:\n\n1. **Mechanism of Action**:\n   - Tecentriq binds to PD-L1, blocking its interaction with PD-1 and B7.1 receptors on T cells. This inhibition prevents the \"off\" signal that tumors use to evade immune detection, thereby enabling T cells to attack cancer cells.\n\n2. **Indications**:\n   - Tecentriq is approved for use in several cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), urothelial carcinoma, triple-negative breast cancer (TNBC), and hepatocellular carcinoma (HCC), among others.\n   - It is often used in combination"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_2SXKXXqZIDt5Q22t0LVBUt0j", "custom_id": "389_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0c63927df9a967c25e108eb78a532e0d", "body": {"id": "chatcmpl-9St6Ix5C15uKHXU1aSXODhxaS3DVA", "object": "chat.completion", "created": 1716672018, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bavencio (avelumab) is a prescription medication used in the treatment of certain types of cancers. As a physician, it's important to be informed about its indications, mechanism of action, administration, potential side effects, and monitoring requirements. Here's a detailed overview:\n\n### Indications\nBavencio is approved for the treatment of:\n1. **Metastatic Merkel Cell Carcinoma (MCC)**: In adults and pediatric patients 12 years and older.\n2. **Locally Advanced or Metastatic Urothelial Carcinoma (UC)**: In patients who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.\n3. **Advanced Renal Cell Carcinoma (RCC)**: In combination with axitinib for first-line treatment.\n\n### Mechanism of Action\n- Bavencio is a human monoclonal antibody that targets PD-L1 (Programmed Death-Ligand "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_wYPVUNMjG9ongM80Ydhb99ld", "custom_id": "390_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2db74ae4fbe9ea7c6374004557102cea", "body": {"id": "chatcmpl-9St6ItspLuAn4FVDgT1Md1Bs8EV0M", "object": "chat.completion", "created": 1716672018, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Yescarta (axicabtagene ciloleucel) is a type of CAR T-cell therapy approved for certain types of non-Hodgkin lymphoma, including relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. As a physician, here are some key points you should know:\n\n### Mechanism of Action:\n- **CAR T-cell Therapy**: Yescarta involves modifying a patient's T cells to express a chimeric antigen receptor (CAR) that targets the CD19 antigen on the surface of B cells. This allows the modified T cells to identify and kill cancer cells.\n\n### Indications:\n- **Approved Use**: Yescarta is indicated for adult patients with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.\n\n### Administration:\n- **Process**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_2us8Q4xttTaqAMGSs7gjhcfV", "custom_id": "391_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "cc369fd2a8c675fa481e461448ffe093", "body": {"id": "chatcmpl-9St6IeXeZGSH0UGLy5swZy0WlRmgj", "object": "chat.completion", "created": 1716672018, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there isn't a widely recognized drug, treatment, or medical device specifically called \"Axishil.\" It's possible that it could be a new or region-specific product, a brand name, or even a typographical error. \n\nHere are steps you can take to get accurate information:\n\n1. **Check Reliable Medical Sources:** Look up Axishil in medical databases such as PubMed, UpToDate, or other reputable medical journals and resources.\n\n2. **Consult Colleagues or Specialists:** Sometimes, peers or specialists in a particular field may have more information about newer or less common treatments.\n\n3. **Pharmaceutical Reps:** If Axishil is a pharmaceutical product, representatives from the company might provide detailed information about its indications, mechanisms, side effects, and clinical trial data.\n\n4. **Regulatory Agencies:** Check with regulatory agencies like the FDA (Food and Drug Administration) or EMA (European Medicines Agency) for approved uses and warnings"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_98qCdInMXrvwKWLlZY6gGs1W", "custom_id": "392_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8c8d3c8a38cbc191e863aa0cfcd83ded", "body": {"id": "chatcmpl-9St6JlRsPm21L70MUl1ABP55VLb30", "object": "chat.completion", "created": 1716672019, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azacitidine, marketed under the name Vidaza among others, is an antineoplastic (anticancer) agent used primarily in the treatment of myelodysplastic syndromes (MDS). It's part of a class of drugs known as hypomethylating agents. Here are some key points you should know about azacitidine:\n\n### Mechanism of Action\nAzacitidine works by incorporating into DNA and RNA, inhibiting DNA methyltransferase, which leads to hypomethylation of DNA. This hypomethylation can restore normal function to genes that control cell growth and differentiation, potentially leading to the death of cancerous cells.\n\n### Indications\nAzacitidine is primarily used for:\n- Myelodysplastic syndromes (MDS): including refractory anemia, chronic myelomonocytic leukemia, and other related conditions.\n- Acute myeloid leukemia (AML): in certain contexts, particularly for patients who are not candidates for intensive chemotherapy.\n\n### Administration\n- **Form**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_QITkXogOfgjzmkKn2BgROD7A", "custom_id": "393_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9ad6f07f1b3d8f41108d11668482f597", "body": {"id": "chatcmpl-9St6JRaPV2BBoMjJMLADrprhXZ3wJ", "object": "chat.completion", "created": 1716672019, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it\u2019s important to have a comprehensive understanding of TheraCys, especially if you are treating patients with bladder cancer. Here\u2019s an overview of TheraCys and what you should know:\n\n### What is TheraCys?\nTheraCys is a brand of Bacillus Calmette-Gu\u00e9rin (BCG) live intravesical, which is an immunotherapy used primarily to treat bladder cancer. It contains live, attenuated strains of Mycobacterium bovis.\n\n### Indications\nTheraCys is primarily indicated for:\n- Treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder.\n- Prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR).\n\n### Mechanism of Action\nBCG therapy works by stimulating the immune system to attack cancer cells. When administered intravesically, BCG induces a local immune response in the bladder"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_jcnUtnjg3Cviez67lBO64iDs", "custom_id": "394_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "1327f4bf8b2e3b26d6544a9042ce2500", "body": {"id": "chatcmpl-9St6JwtNvDzb4zbB2imxNOkYppet8", "object": "chat.completion", "created": 1716672019, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tarvacin, also known as Bavituximab, is a chimeric monoclonal antibody that targets phosphatidylserine, a molecule that is typically located on the inner leaflet of the cell membrane but becomes exposed on the outer leaflet in tumor blood vessels and virally infected cells. Here are some key points to know about Tarvacin:\n\n1. **Mechanism of Action**:\n   - Tarvacin binds specifically to phosphatidylserine exposed on the surface of tumor blood vessels and virally infected cells.\n   - This binding can help the immune system recognize and attack these cells.\n\n2. **Indications**:\n   - Tarvacin has been investigated primarily for its potential use in oncology, targeting various types of cancer.\n   - Research has also explored its use in treating viral infections due to its mechanism of targeting infected cells.\n\n3. **Clinical Trials and Development**:\n   - Tarvacin has undergone various phases of clinical trials to assess its safety and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_TB6XjyD00q4zBfg644qdWGwo", "custom_id": "395_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "25beac8cc9eebf1a98b47d261016d4fd", "body": {"id": "chatcmpl-9St6JtdrQqMAtXnSsNCLLZ4ctUlSW", "object": "chat.completion", "created": 1716672019, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Beleodaq (belinostat) is a histone deacetylase (HDAC) inhibitor used in oncology. Here are key points you should know about it as a physician:\n\n### Indications:\n- **Peripheral T-Cell Lymphoma (PTCL)**: Beleodaq is primarily indicated for the treatment of patients with relapsed or refractory PTCL.\n\n### Mechanism of Action:\n- **Histone Deacetylase Inhibition**: Beleodaq inhibits HDAC enzymes, leading to the accumulation of acetylated histones and other proteins, which can result in cell cycle arrest, differentiation, and apoptosis of cancer cells.\n\n### Administration:\n- **Intravenous (IV)**: Beleodaq is administered via IV infusion. The usual dosage is 1000 mg/m\u00b2 once daily on days 1-5 of a 21-day cycle.\n\n### Side Effects:\n- **Common Adverse Reactions**: These include nausea, fatigue, fever, anemia"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_68qCeSiaazg1PT1MCbFYgGE6", "custom_id": "396_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6d51eca9eedb98a55e20deba19399532", "body": {"id": "chatcmpl-9St6JdhXhB5VbywZd0teEzU7AJ592", "object": "chat.completion", "created": 1716672019, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medication, treatment, or medical device called \"Camptobell.\" It is possible that the name might be a misspelling, a brand name not widely known, a recently released product, or a regional name for something more familiar.\n\nHowever, if you provide additional context or specify if it's a drug, medical device, or treatment, I can try to give more relevant information or help you identify it. Always refer to the latest medical literature, pharmaceutical references, or consult with a pharmacist for the most accurate and current information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 122, "total_tokens": 164}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_LCu0hUFCv44zGl1P16maaDtU", "custom_id": "397_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "4f98a8bed9b52b9c39678d76bb31d1e4", "body": {"id": "chatcmpl-9St6KP1PSiaQZphOE2mQuR90MpQFU", "object": "chat.completion", "created": 1716672020, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belrapzo is a brand name for the drug bendamustine hydrochloride, which is a chemotherapy medication used to treat certain types of cancer. Here is some important information you should know about Belrapzo:\n\n### Indications\nBelrapzo is primarily used to treat:\n1. **Chronic Lymphocytic Leukemia (CLL):** It can be used as a first-line treatment.\n2. **Non-Hodgkin's Lymphoma (NHL):** Specifically for patients with indolent B-cell types of NHL that have progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.\n\n### Mechanism of Action\nBelrapzo is an alkylating agent that works by causing cross-linking of DNA strands, which in turn inhibits DNA synthesis and function. This disruption leads to cell death, particularly in rapidly dividing cancer cells.\n\n### Dosage and Administration\n- **Administration:** Belrapzo is administered intraven"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_J4Z23QDP7ezMVIxVisIb1tPv", "custom_id": "398_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "14fc8f01c0144f4ba4c10745af961f7c", "body": {"id": "chatcmpl-9St6Kocas6agTEEV053RfDXbQ4zn1", "object": "chat.completion", "created": 1716672020, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Altuzan is a brand name for bevacizumab, a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A). It is primarily used in the treatment of various types of cancers. Here are key points you should know about Altuzan:\n\n1. **Mechanism of Action**:\n    - Bevacizumab binds to VEGF-A, preventing it from interacting with its receptors on the surface of endothelial cells. This inhibits the formation of new blood vessels (angiogenesis), which is crucial for tumor growth and metastasis.\n\n2. **Indications**:\n    - Altuzan is used in the treatment of several cancers, including:\n        - Metastatic colorectal cancer\n        - Non-squamous non-small cell lung cancer\n        - Glioblastoma\n        - Metastatic renal cell carcinoma\n        - Cervical cancer\n        - Ovarian cancer\n        - Fallopian tube cancer\n        - Primary peritoneal cancer\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_oni9acpJfP7r593mthE72Gzq", "custom_id": "399_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "59a4a1aaca4ba295bb3457e7b41249bd", "body": {"id": "chatcmpl-9St6KTgPGPWFuB3wCaBSng7a7I6V4", "object": "chat.completion", "created": 1716672020, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2021, I couldn't find any information on a medication or treatment called \"Bexgratin.\" It is possible that it is a new drug, a typographical error, or a very specialized treatment that has not yet entered common medical literature.\n\nIf \"Bexgratin\" is a new drug or treatment that has been developed or approved after my last update, I would recommend the following steps to get the most reliable and current information:\n\n1. **Check Reputable Medical Databases**: Use resources like PubMed, ClinicalTrials.gov, or your institution's access to medical journals to search for \"Bexgratin.\" These databases will provide peer-reviewed articles and clinical trial information.\n\n2. **Consult Drug Information Resources**: Use trusted drug information resources such as the Physician's Desk Reference (PDR), Lexicomp, or Micromedex.\n\n3. **Reach out to Colleagues**: Network with other healthcare professionals who may"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_7li6JrfoAAgOFLoS04vqY2NI", "custom_id": "400_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0c0632de43db1cfb2e9538ecc6dc7163", "body": {"id": "chatcmpl-9St6KCQXmCr6yYF8pCXguV7m1xRqG", "object": "chat.completion", "created": 1716672020, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Calutide is a medication that is commonly used in the treatment of prostate cancer. Its active ingredient is bicalutamide, which is classified as a non-steroidal anti-androgen. Here are some key points you should know about Calutide:\n\n### Mechanism of Action\n- **Anti-androgen:** Bicalutamide works by binding to androgen receptors and inhibiting the action of androgens (male hormones) like testosterone. This helps to slow the growth of prostate cancer cells that rely on these hormones to proliferate.\n\n### Indications\n- **Prostate Cancer:** Bicalutamide is primarily used in combination with other treatments such as luteinizing hormone-releasing hormone (LHRH) analogs or surgical castration to treat advanced prostate cancer.\n\n### Dosage and Administration\n- **Typical Dosage:** The usual dose is 50 mg once daily, but the specific dosage may vary depending on the patient's condition and treatment plan.\n- **Administration:** It can"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_X1FJD4496ZZVzSDoDDzVPV1I", "custom_id": "401_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ff2126a83e4b1e092c33e685acbc44a1", "body": {"id": "chatcmpl-9St6KczqyAaNdyDTwS1p9sBi6FMDX", "object": "chat.completion", "created": 1716672020, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mektovi (binimetinib) is a medication used in combination with another drug called encorafenib (Braftovi) for the treatment of certain types of melanoma. Here are some key points you should know as a physician:\n\n### Indications:\n- **Melanoma Treatment**: Mektovi is indicated for use in combination with encorafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.\n\n### Mechanism of Action:\n- **MEK Inhibitor**: Binimetinib is a MEK inhibitor. MEK is a part of the MAPK/ERK pathway, which is often activated in cancers with BRAF mutations. By inhibiting this pathway, binimetinib helps reduce tumor cell proliferation.\n\n### Dosage and Administration:\n- **Standard Dose**: The recommended dose of Mektovi is 45 mg taken orally twice"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_gKRr6vMYNn9mDRllVN14Tq45", "custom_id": "402_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ff9faee73195c9b75fa0774e22dffe57", "body": {"id": "chatcmpl-9St6K0alwANvYg9qwqAbv6a98lxdG", "object": "chat.completion", "created": 1716672020, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blenoxane, known generically as bleomycin, is an antineoplastic (anticancer) antibiotic used in the treatment of various malignancies. Here are some key points you should know as a physician:\n\n### Indications\n- **Cancers Treated**: Blenoxane is commonly used to treat Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer, and certain types of head and neck cancers. It may also be used for other malignancies as part of combination chemotherapy regimens.\n- **Other Uses**: It can be used intrapleurally for pleurodesis in patients with malignant pleural effusion.\n\n### Mechanism of Action\n- **Cytotoxicity**: Bleomycin induces DNA strand breaks by intercalating into DNA and generating free radicals, leading to cell death.\n- **Cell Cycle Specificity**: It is most active in the G2 and M phases of the cell cycle.\n\n### Administration and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_7nNTPIfofjh0fD4mzcCYAH8H", "custom_id": "403_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "760d6b12d70ecc2f49bbe3c1aa07bb9c", "body": {"id": "chatcmpl-9St6LppAHvGUY6uN62ne20JLvDMNL", "object": "chat.completion", "created": 1716672021, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blincyto (blinatumomab) is an important medication used in the treatment of certain types of blood cancers. Here\u2019s a comprehensive overview of what you should know about Blincyto as a physician:\n\n### Indications:\n- **Acute Lymphoblastic Leukemia (ALL)**: Blincyto is primarily used to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD). It is also approved for patients with relapsed or refractory B-cell precursor ALL.\n\n### Mechanism of Action:\n- **Bispecific T-cell Engager (BiTE)**: Blincyto is a bispecific antibody that engages T-cells (CD3) and targets CD19 on B-cells. This dual binding allows T-cells to recognize and destroy CD19-expressing leukemia cells.\n\n### Administration:\n- **Intravenous Infusion**: Blincyto is administered as a continuous intravenous infusion"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5dRrqm9MinNKABG1ePR2SVN8", "custom_id": "404_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "473c3864d01a5242df5587cfe20ec79e", "body": {"id": "chatcmpl-9St6L5gA6Hz1vpgvc1HvmGswJrtsZ", "object": "chat.completion", "created": 1716672021, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff in October 2021, \"Biocure\" could refer to a few different things, depending on the context. For clarity, here are a few possibilities:\n\n1. **Biocure Pharmaceuticals**: This is a biopharmaceutical company that is often involved in developing and manufacturing biotechnology-based treatments. Biocure Pharmaceuticals, or similar companies, might focus on areas such as cancer therapy, regenerative medicine, or immunotherapy. As a physician, staying informed about new treatments and clinical trials from such companies can be beneficial for providing advanced care to patients.\n\n2. **Biocure Treatments**: This could refer more broadly to any biological or biotechnology-based treatments. These might include gene therapies, monoclonal antibodies, personalized medicine approaches, or regenerative therapies. Understanding the mechanisms, indications, potential side effects, and latest research in these areas is crucial for informed clinical decision-making.\n\n3. **Biocure as a General Term**: Sometimes \"biocure\" is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_c9NFBrSEJ9uupD8KXzFLOXiM", "custom_id": "405_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b34977a87b2fae6c2427dd1fcfd7f926", "body": {"id": "chatcmpl-9St6Lcy4AyTRnimepX6ktjvM47JP9", "object": "chat.completion", "created": 1716672021, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to be well-informed about Bosulif (bosutinib), which is a kinase inhibitor used primarily in the treatment of chronic myelogenous leukemia (CML). Here are key points you should know:\n\n### Indications and Usage:\n- **Bosulif** is indicated for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) with resistance or intolerance to prior therapy.\n\n### Mechanism of Action:\n- **Bosutinib** inhibits BCR-ABL kinase, the abnormal kinase produced by the Philadelphia chromosome, which is responsible for the uncontrolled proliferation of leukemic cells in CML.\n\n### Dosage and Administration:\n- The recommended dose of Bosulif is **400 mg orally once daily** with food for patients with newly diagnosed chronic phase Ph+ CML.\n- For patients with chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy, the recommended dose"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_d1ZlGTUXMfkFTUWKHxVSJsPh", "custom_id": "406_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b13853ee067a6068b5c190dabe15164c", "body": {"id": "chatcmpl-9St6LcnH6upNUMw9yiMuEpKGt3HJb", "object": "chat.completion", "created": 1716672021, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adcetris (brentuximab vedotin) is an antibody-drug conjugate used in the treatment of certain types of cancer, primarily Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Here are key points you should know about Adcetris:\n\n### Mechanism of Action\n- **Monoclonal Antibody:** Adcetris consists of an anti-CD30 monoclonal antibody linked to an antimitotic agent (monomethyl auristatin E, MMAE).\n- **Target:** It specifically targets the CD30 antigen, which is expressed on the surface of malignant cells in Hodgkin lymphoma and some non-Hodgkin lymphomas.\n- **Action:** Upon binding to CD30, the conjugate is internalized by the cell, and MMAE is released to disrupt the microtubule network, leading to cell cycle arrest and apoptosis.\n\n### Indications\n- **Classical Hodgkin Lymphoma (cHL):** Adcetris is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_jYViJjrSEuAt5Jq1nb6bncEK", "custom_id": "407_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "dec2abe7d0329f580006d7dabd2edd97", "body": {"id": "chatcmpl-9St6LkGZ42JhEHsIFFQruflORVZUu", "object": "chat.completion", "created": 1716672021, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alunbrig (brigatinib) is a prescription medication used primarily to treat certain types of non-small cell lung cancer (NSCLC) that have a specific genetic mutation known as anaplastic lymphoma kinase (ALK)-positive. Here are some key points you should know about Alunbrig:\n\n### Mechanism of Action\n- **Tyrosine Kinase Inhibitor (TKI)**: Alunbrig works by inhibiting the activity of the ALK protein, which can promote the growth of cancer cells. By blocking this protein, Alunbrig can help to slow or stop the growth of these cancer cells.\n\n### Indications\n- **ALK-Positive NSCLC**: It is approved for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib, another ALK inhibitor.\n- **First-Line Treatment**: Alunbrig is also approved for the first-line treatment of ALK-positive metastatic NSCLC.\n\n### Dos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_2KEHUSEKUd78Ws953rWE0OOJ", "custom_id": "408_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "facc6a7f98ce7fecc59f0a7e2ef4a244", "body": {"id": "chatcmpl-9St6MgwWrOK6ekUS9exabKhIz3AIR", "object": "chat.completion", "created": 1716672022, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Busilvex (busulfan) is an antineoplastic agent primarily used in the preparation of patients for hematopoietic progenitor cell transplantation (HPCT). Here are some key points you should know about Busilvex:\n\n1. **Indications**:\n   - Busilvex is mainly indicated for use in combination with cyclophosphamide or other chemotherapy agents as part of a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation (HPCT) for chronic myelogenous leukemia (CML).\n   - It may also be used for other hematologic conditions requiring HPCT, such as myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML).\n\n2. **Mechanism of Action**:\n   - Busulfan is an alkylating agent that causes DNA cross-linking, leading to apoptosis of rapidly dividing cells, including malignant and hematopoietic cells.\n\n3. **Dosage and Administration**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_viTJ259HOGJU953BJo3HJthq", "custom_id": "409_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "412c8e68e60c922ecdd4a629a37b809b", "body": {"id": "chatcmpl-9St6MdeOzVCrpk0vw6sK5R26MAxZj", "object": "chat.completion", "created": 1716672022, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2023, there isn't a well-known or widely recognized drug or medical treatment called \"Cabapan.\" It's possible that there might be a typographical error, or it could be a very new or highly specialized treatment that hasn't gained widespread recognition yet.\n\nHowever, if you're referring to a specific medication or treatment that might be known by a different name, it's important to consider the following general guidelines when familiarizing yourself with any new drug or treatment:\n\n1. **Mechanism of Action**: Understand how the medication works in the body. This includes knowing its pharmacodynamics and pharmacokinetics.\n\n2. **Indications and Usage**: Know the specific conditions or diseases for which the drug is approved. Also, be aware of any off-label uses that are supported by clinical evidence.\n\n3. **Dosage and Administration**: Familiarize yourself with the recommended dosage, routes of administration, and any special instructions for use.\n\n4. **Contraindications**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_a7wQwTQ0ccbMvMxpoFNQPuUd", "custom_id": "410_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "52c5dafceb8fe84c2b767c3f266eafae", "body": {"id": "chatcmpl-9St6MKe5EepKGlszKBfxH9tU0tgAq", "object": "chat.completion", "created": 1716672022, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cabometyx (cabozantinib) is an oral tyrosine kinase inhibitor used primarily in oncology. Here are key points that you, as a physician, should know:\n\n### Indications:\n1. **Renal Cell Carcinoma (RCC):** Cabometyx is used for the treatment of advanced renal cell carcinoma.\n2. **Hepatocellular Carcinoma (HCC):** It is indicated for patients who have been previously treated with sorafenib.\n3. **Differentiated Thyroid Cancer (DTC):** For patients with locally advanced or metastatic disease that has progressed following prior VEGFR-targeted therapy and who are ineligible for or refractory to radioactive iodine.\n\n### Mechanism of Action:\n- Cabometyx inhibits multiple receptor tyrosine kinases (RTKs) including MET, VEGFR, AXL, and RET. These RTKs are involved in tumor growth, angiogenesis, metastasis, and drug resistance.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_zpMNfQhtX5l0SGHUQJkQMRSl", "custom_id": "411_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d584731b0cffe90575fda868c8b41232", "body": {"id": "chatcmpl-9St6M1yK9z5IVW4b51wFNPVvNUAJU", "object": "chat.completion", "created": 1716672022, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asparlas (calaspargase pegol-mknl) is a medication used in the treatment of acute lymphoblastic leukemia (ALL), particularly in pediatric and young adult patients. Here are some key points you should know about Asparlas:\n\n1. **Mechanism of Action:** Asparlas is an asparagine-specific enzyme that works by depleting asparagine, an amino acid essential for the survival and proliferation of leukemic cells. By breaking down asparagine, Asparlas starves the leukemia cells, inhibiting their growth and leading to cell death.\n\n2. **Indications:** Asparlas is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) in pediatric and young adult patients aged 1 month to 21 years.\n\n3. **Dosage and Administration:** The recommended dosage of Asparlas is 2,500 units/m\u00b2 administered intravenously no more frequently than every"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_K2Ttv3iM5u6s5mVO9OfezBGf", "custom_id": "412_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "60e2be522d13d5cb8f09ce834552506d", "body": {"id": "chatcmpl-9St6MaJnNhmWJxKy9b7lly1vhhmp1", "object": "chat.completion", "created": 1716672022, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medical substance, drug, or condition known as \"Cabita.\" It\u2019s possible that \"Cabita\" could be a brand name, a regional term, or a misspelling. Here are some steps you can take to find the relevant information:\n\n1. **Clarify the Term**: Double-check the spelling and context in which you encountered \"Cabita.\" It might be a misspelling or shorthand for something else.\n  \n2. **Consult Reliable Sources**: Use medical databases like PubMed, UpToDate, or WebMD to search for information. Pharmacological databases and drug reference guides like the Physicians' Desk Reference (PDR) might also be useful.\n\n3. **Ask Colleagues**: Sometimes, other healthcare professionals might have encountered the term and can provide insight.\n\n4. **Patient History**: If \"Cabita\" came up in patient history or documentation, ask the patient or the referring healthcare provider for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ZVhYKlK7YQh2Sj4Kn2p5cDDS", "custom_id": "413_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "072e217f8146553ba31126be5f77692e", "body": {"id": "chatcmpl-9St6MTYyrRNy2COTExCpy4LdcXItk", "object": "chat.completion", "created": 1716672022, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, you should be aware of several key aspects regarding Biocarb, which is a brand name for the medication carboplatin. Carboplatin is a chemotherapy drug used primarily in the treatment of various types of cancer, including ovarian, lung, head and neck, and testicular cancers. Here are some important points:\n\n### Mechanism of Action:\n- **Alkylating Agent**: Carboplatin works by binding to DNA in cancer cells, causing cross-linking and interfering with the cell's ability to divide and grow. This ultimately leads to cell death.\n\n### Indications:\n- **Approved Uses**: Carboplatin is FDA-approved for the treatment of ovarian cancer. It is often used off-label for other cancers, including lung cancer, head and neck cancers, and testicular cancer.\n- **Combination Therapy**: Often used in combination with other chemotherapy agents like paclitaxel to enhance therapeutic effects.\n\n### Dosage and Administration:\n- **Dosing**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_2fxdGtQbpBnUPlmIQ664fwHS", "custom_id": "414_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "15dc2b499a3a3d262a27e7380f56d5db", "body": {"id": "chatcmpl-9St6Nj6Sy2cHckHPXB1Dp6wmhF0KR", "object": "chat.completion", "created": 1716672023, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2021, there is no widely known or recognized drug or medical treatment named \"Carfilnat.\" It's possible that \"Carfilnat\" could be a typographical error, a new or experimental drug, or a local or brand name not recognized globally. However, it sounds similar to \"Carfilzomib,\" which is a drug used in oncology.\n\n### Carfilzomib: Key Information\n\n**1. Classification:**\n   - Carfilzomib is a proteasome inhibitor.\n\n**2. Indications:**\n   - It is primarily used to treat multiple myeloma, a type of blood cancer. Carfilzomib is typically used in patients who have received at least one prior therapy.\n\n**3. Mechanism of Action:**\n   - Carfilzomib works by inhibiting the proteasome, a protein complex that degrades unneeded or damaged proteins. By blocking this process, carfilz"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_lULqJ8ARkSVmhR776VxWypNk", "custom_id": "415_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "db1aad819d4d1107c8cfc7b50dea5331", "body": {"id": "chatcmpl-9St6Ngf0Gq426q7iFmZpatLm2kb8Q", "object": "chat.completion", "created": 1716672023, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Becenun, also known as Carmustine, is a chemotherapy drug that belongs to the class of alkylating agents. As a physician, there are several important aspects you should be familiar with regarding Becenun:\n\n### Indications:\n- **Primary Use:** Becenun is primarily used in the treatment of various types of cancers, including brain tumors (gliomas, glioblastoma multiforme, medulloblastoma, astrocytoma), multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas.\n- **Combination Therapy:** It is often used in combination with other chemotherapy drugs and treatment modalities.\n\n### Mechanism of Action:\n- Becenun works by alkylating DNA and RNA, which interferes with the replication of cancer cells, ultimately leading to cell death. This non-specific action means it affects both dividing cancer cells and normal cells.\n\n### Administration:\n- **Routes:** Becenun is administered either intravenously or as"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ha3UkwbuEJDkzVnvXGa4W08w", "custom_id": "416_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e3cbbc95fd20e9a69a381c36bc45681c", "body": {"id": "chatcmpl-9St6N9Jb57KVZtZUNCrBb6PVPzquX", "object": "chat.completion", "created": 1716672023, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Biodel, Inc. was a biopharmaceutical company focused on the development and commercialization of treatments for diabetes and other endocrine disorders. Here are several key points you might want to know about Biodel:\n\n1. **Product Focus**: Biodel primarily focused on developing new formulations of insulin and other injectable therapies for diabetes management. Their main product was Linjeta (formerly known as VIAject), a rapid-acting insulin designed to improve postprandial glucose control.\n\n2. **Technology**: Biodel used proprietary formulation technologies to enhance the delivery and performance of insulin. They aimed to create insulin analogs that had faster onset and shorter duration of action compared to existing rapid-acting insulin products.\n\n3. **Clinical Trials**: Biodel conducted multiple clinical trials to test the efficacy and safety of their insulin formulations. They aimed to demonstrate that their products could provide better glycemic control with fewer side effects such as hypoglycemia.\n\n4. **Regulatory Status**: Biodel faced challenges in getting"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Op9q1KaxQw5Yt8I1e4JeiboJ", "custom_id": "417_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e083f2447eb5bd9762bde06a229be4c3", "body": {"id": "chatcmpl-9St6NKzceiEQE6rijAj0BT0NRz0rL", "object": "chat.completion", "created": 1716672023, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Recentin is the trade name for cediranib, an oral tyrosine kinase inhibitor that targets vascular endothelial growth factor (VEGF) receptors. It has been investigated primarily for its potential to treat various types of cancer by inhibiting angiogenesis, the process by which new blood vessels form, which tumors need to grow and metastasize.\n\nHere are several key points that a physician should know about Recentin (cediranib):\n\n1. **Mechanism of Action**:\n   - Cediranib inhibits VEGF receptors, primarily VEGFR-2, which play a crucial role in angiogenesis. By blocking these receptors, cediranib can reduce the blood supply to tumors, potentially inhibiting their growth.\n\n2. **Indications**:\n   - Cediranib has been investigated in clinical trials for several types of cancer, including colorectal cancer, non-small cell lung cancer, glioblastoma, and ovarian cancer. However, its approval status can vary by country and specific indication, so it's"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_YRsStdprR9PmC7YxO3TDce2N", "custom_id": "418_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6156bc7f0738d6b671c587a7b258757f", "body": {"id": "chatcmpl-9St6NHQuQ58gYtcBfs5qq57vLt7Yx", "object": "chat.completion", "created": 1716672023, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Libtayo (cemiplimab-rwlc) is a monoclonal antibody used as an immune checkpoint inhibitor, specifically targeting the PD-1 (programmed cell death protein 1) pathway. It enhances the body's immune response against cancer cells. Here are several key points you should know about Libtayo:\n\n### Indications:\nLibtayo is approved for the treatment of:\n- **Cutaneous Squamous Cell Carcinoma (CSCC):** For patients with metastatic or locally advanced CSCC who are not candidates for curative surgery or radiation.\n- **Basal Cell Carcinoma (BCC):** For patients with locally advanced BCC previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate.\n- **Non-Small Cell Lung Cancer (NSCLC):** For patients whose tumors express PD-L1 (\u226550% tumor proportion score) as determined by an FDA-approved test, and who do not have EGFR,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Xyb1NxgfBJVMMUpphsNdB4t8", "custom_id": "419_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "70d8616366dd74ec48072313e5ea5bd1", "body": {"id": "chatcmpl-9St6O8dhMFax6D9zI4u0O6M3U37wO", "object": "chat.completion", "created": 1716672024, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a typo in your question. If you meant \"Lucifer,\" it's important to clarify whether you are referring to the historical and religious figure or something else. Lucifer is traditionally known as a figure in various religious texts, most notably in Christianity, where he is often equated with Satan or the Devil. This figure is not directly relevant to medical practice or patient care.\n\nHowever, if you are referring to a medication, treatment, or medical condition, please provide more context or correct the spelling, and I'd be happy to provide relevant information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 113, "total_tokens": 153}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_RIIQ5DzXJKm4E9W8NIwwlLFn", "custom_id": "420_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "94736edd648570b30e76aaef2e43637a", "body": {"id": "chatcmpl-9St6OtHjI1sRkKgnEax4kypXQH5xK", "object": "chat.completion", "created": 1716672024, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cetuxim is not a widely recognized or standard medication name as of my last update in October 2021. It is possible that there may be a typo, a less common regional name, or a recent development in pharmaceutical naming. However, \"Cetuxim\" might be a misspelling or confusion with \"cetuximab,\" which is a well-known monoclonal antibody used in the treatment of certain cancers.\n\nIf you meant cetuximab, here are key points you should know about it:\n\n### Mechanism of Action\n- **Cetuximab** is a chimeric (mouse/human) monoclonal antibody that targets the epidermal growth factor receptor (EGFR).\n- It inhibits the binding of EGF and other ligands to EGFR, thereby blocking receptor dimerization and subsequent signal transduction pathways involved in cell proliferation, survival, and angiogenesis.\n\n### Indications\n- Cetuximab is approved for use in combination with chemotherapy for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ufGYhiH1d8KCAKGLrdfAYG3t", "custom_id": "421_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "aebe909bde1dc2fa59add531e739dc20", "body": {"id": "chatcmpl-9St6ObCSqMLGqtPxrz6tTVlWd0Kie", "object": "chat.completion", "created": 1716672024, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Epidaza, known generically as belinostat, is a histone deacetylase (HDAC) inhibitor used primarily in the treatment of certain types of cancer. Here are some key points you should know about Epidaza:\n\n1. **Indications**: \n   - Belinostat is approved for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). It is often considered when other treatments have not been effective.\n\n2. **Mechanism of Action**:\n   - As an HDAC inhibitor, belinostat works by interfering with the function of histone deacetylases. This leads to an accumulation of acetylated histone proteins, which can result in cell cycle arrest and apoptosis of cancer cells.\n\n3. **Administration**:\n   - Epidaza is administered intravenously. The typical dosing schedule involves a daily infusion over 30 minutes for five consecutive days in a 21-day cycle.\n\n4. **Side Effects**:\n   - Common side"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_RhwrrISKjyzrEkuRxnumaqiJ", "custom_id": "422_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "501d3a5bf763508db8918c78ff60bead", "body": {"id": "chatcmpl-9St6OnW2AtWQ62rlXxzkf6UJnIUgP", "object": "chat.completion", "created": 1716672024, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Chlorambucil is an alkylating agent used primarily in the treatment of certain types of cancer. Here are the key points that you should know about Chlorambucil:\n\n### Indications:\n- **Chronic Lymphocytic Leukemia (CLL):** Chlorambucil is often used as a first-line treatment.\n- **Non-Hodgkin's Lymphoma (NHL):** It is sometimes used in the treatment of various forms of NHL.\n- **Hodgkin's Lymphoma:** Less commonly used but can be part of the treatment regimen.\n- **Waldenstr\u00f6m's Macroglobulinemia:** An indication due to its effectiveness in this rare type of cancer.\n- **Autoimmune diseases:** Occasionally used off-label for severe autoimmune conditions like nephrotic syndrome.\n\n### Mechanism of Action:\n- Chlorambucil is a bifunctional alkylating agent that interferes with DNA replication and RNA transcription by forming cross-links between"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_eikKUR5MSZzQPq58ygyd97Cl", "custom_id": "423_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8896d8769f26db3cf958d951a48ff3b8", "body": {"id": "chatcmpl-9St6OsnIQUI9cA6bJnsBI58wIoYRR", "object": "chat.completion", "created": 1716672024, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff in October 2021, there is no widely recognized medication or compound known as \"Abiplatin.\" It's possible that the name you are referring to is either a misspelling, a brand name for a medication not widely known, or a new drug or experimental compound that has been introduced after my last update.\n\nHowever, if \"Abiplatin\" is intended to refer to a chemotherapy drug similar to others in the \"-platin\" family, such as cisplatin, carboplatin, or oxaliplatin, here are some general points about platinum-based chemotherapy agents:\n\n1. **Mechanism of Action**: Platinum-based drugs work by forming cross-links with DNA in cancer cells, which inhibits DNA synthesis and function, leading to cell death.\n\n2. **Indications**: These drugs are commonly used to treat various types of cancer, including testicular, ovarian, bladder, lung, and colorectal cancers.\n\n3. **Administration**: These medications are typically"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_nCG2cwN3qDYrZhEiea8y3elg", "custom_id": "424_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d24c66e195e7d13b9b77548ac663feca", "body": {"id": "chatcmpl-9St6OzLmxiiLB0NTHC4gWLz274rrw", "object": "chat.completion", "created": 1716672024, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Leustatin, also known by its generic name cladribine, is an important medication in the realm of oncology and hematology. Here are key points you should know about Leustatin:\n\n### Indications:\n1. **Hairy Cell Leukemia (HCL)**: Leustatin is primarily used for the treatment of hairy cell leukemia, a rare type of chronic leukemia.\n2. **Other Hematologic Malignancies**: It may also be used off-label for other hematologic malignancies such as chronic lymphocytic leukemia (CLL) and certain types of non-Hodgkin's lymphomas.\n\n### Mechanism of Action:\n- **Purine Analog**: Leustatin is a purine nucleoside analog. It gets incorporated into DNA during the S-phase of the cell cycle, leading to DNA strand breakage and disruption of DNA synthesis and repair, ultimately causing cell death.\n- **Selective Cytotoxicity**: It has selective cytotoxicity towards"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_WzoeCdaeU25GHObTFQLWPIFu", "custom_id": "425_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "812c237bf92ce94baff0acfd4885777e", "body": {"id": "chatcmpl-9St6OsXYwNSmHBZz2EPUxkDJGxmZZ", "object": "chat.completion", "created": 1716672024, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Biaxin (generic name: clarithromycin), which is a macrolide antibiotic used to treat various bacterial infections. Here are key points you should know:\n\n### Indications:\n- **Respiratory Infections:** Such as acute exacerbations of chronic bronchitis, sinusitis, and community-acquired pneumonia.\n- **Skin Infections:** Including uncomplicated skin and skin structure infections.\n- **Helicobacter pylori Infection:** Used in combination with other medications to treat H. pylori-associated duodenal ulcer disease.\n- **Mycobacterial Infections:** Including Mycobacterium avium complex (MAC) in patients with HIV.\n\n### Mechanism of Action:\n- Biaxin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, which effectively stops bacterial growth.\n\n### Dosage and Administration:\n- Available in several forms: immediate-release tablets, extended-release tablets, and oral suspension.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_xvEmIFQhxo6lm4QdcEqfqZnU", "custom_id": "426_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "4f4cf66adff4a38cb0895292fdf57b04", "body": {"id": "chatcmpl-9St6P1FJDhbL0cm9EFie1vkQz5s8G", "object": "chat.completion", "created": 1716672025, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Clolar, also known by its generic name clofarabine, is a medication used primarily in oncology. Here are some key points that a physician should know about Clolar:\n\n### Indications:\n- **Acute Lymphoblastic Leukemia (ALL):** Clolar is approved for the treatment of pediatric patients (ages 1 to 21) with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.\n- **Off-label Uses:** Though not officially approved, clofarabine may sometimes be used off-label for other types of leukemia or hematologic malignancies, such as acute myeloid leukemia (AML).\n\n### Mechanism of Action:\n- **Antimetabolite:** Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by incorporating into DNA and RNA, leading to chain termination. It also inhibits ribonucleotide reductase, reducing the pool of deoxynucleotide triphosphates necessary for DNA"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_mVe7dWeE9OCRd5oGZ4dCwJeK", "custom_id": "427_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e4a58ab0ab37e184c4a0add37bb6edfe", "body": {"id": "chatcmpl-9St6PZk43WwQiWOLykLxVUoT1Ykf0", "object": "chat.completion", "created": 1716672025, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cotellic (generic name: cobimetinib) is a prescription medication used in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Here\u2019s a comprehensive overview of what you should know as a physician:\n\n### Indications:\n- **Melanoma Treatment**: Cotellic is indicated for use in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.\n\n### Mechanism of Action:\n- **MEK Inhibitor**: Cotellic is a selective inhibitor of MEK1 and MEK2, which are part of the MAPK/ERK pathway. This pathway is involved in cellular proliferation and survival. By inhibiting MEK, Cotellic helps to slow down or stop the growth of cancer cells that have the BRAF"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_k1TNVq5G0JsNUUNARCJNKGth", "custom_id": "428_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9184bbf3a7c1bf402d82a2d783fcb396", "body": {"id": "chatcmpl-9St6PuYFxihvvMZuJ27IyUqQwUFi1", "object": "chat.completion", "created": 1716672025, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about Aliqopa (copanlisib), which is a medication used primarily for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies. Here are some key points you should know:\n\n### Mechanism of Action\nAliqopa is a phosphatidylinositol-3-kinase (PI3K) inhibitor, specifically targeting the PI3K-alpha and PI3K-delta isoforms. By inhibiting these enzymes, Aliqopa interferes with cell growth and survival pathways, which can help to control the proliferation of cancer cells.\n\n### Indications\n- **Relapsed Follicular Lymphoma**: Aliqopa is indicated for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies.\n\n### Administration\n- **Route**: Aliqopa is administered intravenously.\n- **Dosage**: The recommended dose is 60"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Ie5aRj7bRv0ur5p36sLW6h9f", "custom_id": "429_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b753351a2870d13b3e0fbf5c897a78ec", "body": {"id": "chatcmpl-9St6PxAMkaSIw5CWP49ZkT3fjtiSZ", "object": "chat.completion", "created": 1716672025, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Crizalk (crizotinib) is a targeted therapy medication used primarily in the treatment of certain types of cancer. Here are key points you should know as a physician:\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC):** Crizalk is approved for the treatment of patients with metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK)-positive or ROS1-positive. \n\n### Mechanism of Action\n- **ALK Inhibitor:** Crizotinib inhibits the ALK tyrosine kinase receptor, which can be abnormally expressed and drive the growth of cancer cells.\n- **ROS1 Inhibitor:** It also targets ROS1, another receptor tyrosine kinase involved in some lung cancers.\n\n### Administration\n- **Dosage:** The standard dose is 250 mg taken orally twice daily. It can be taken with or without food.\n- **Form:** Crizalk comes in capsule form.\n\n### Side Effects\nCommon side effects"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_J0kaXJoSQnI0psTS8oNe6xpm", "custom_id": "430_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9c5f2c74bfbb106df895b5059aeb882a", "body": {"id": "chatcmpl-9St6PF91PPtwPadZ3x5OXquPIEmUJ", "object": "chat.completion", "created": 1716672025, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to have a thorough understanding of Alkyloxan, also known as Cyclophosphamide. Here are some key points you should be aware of:\n\n### Pharmacology:\n- **Class**: Alkylating agent.\n- **Mechanism of Action**: Cyclophosphamide adds alkyl groups to DNA, leading to DNA cross-linking and strand breakage, which ultimately inhibits DNA replication and transcription, causing cell death. It is a prodrug, meaning it requires metabolic activation in the liver.\n\n### Indications:\n- **Cancer**: Used in the treatment of various malignancies, including lymphomas, leukemias, multiple myeloma, ovarian cancer, breast cancer, and small cell lung cancer.\n- **Autoimmune Diseases**: Employed for immunosuppression in conditions such as severe rheumatoid arthritis, systemic lupus erythematosus, and vasculitides.\n\n### Dosage:\n- **Formulations**: Available in oral"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ONrVAwuktBz9rBTD9SQClLP5", "custom_id": "431_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "19fd257b6e42074cceedbccafac577a7", "body": {"id": "chatcmpl-9St6QuXEyiHYAjjFnPHzhV2gSRI6y", "object": "chat.completion", "created": 1716672026, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Androcur (cyproterone acetate) is a synthetic steroidal anti-androgen and progestin that is used primarily in the treatment of several medical conditions related to androgen excess. Here are key points you should know about Androcur:\n\n### Indications:\n1. **Prostate Cancer**: Androcur is often used in the treatment of advanced prostate cancer as it can help reduce the effects of testosterone, which can fuel the growth of prostate cancer cells.\n2. **Hirsutism and Severe Acne**: In female patients, Androcur can be used to treat conditions like severe acne, hirsutism (excessive hair growth), and other androgen-related disorders.\n3. **Transgender Hormone Therapy**: It is sometimes used in transgender women as part of hormone therapy to reduce masculinizing features.\n4. **Sexual Deviations in Males**: It can be used to reduce sexual drive in men with paraphilias or hypersexuality"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_nTmuXvqb7wcr48KAWsGMre7M", "custom_id": "432_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9c6537203e390e3a364d8dced69f4b45", "body": {"id": "chatcmpl-9St6QUpGhgd1mdvDvUEFddno5XLQG", "object": "chat.completion", "created": 1716672026, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff in October 2023, there is no widely known or established medication or treatment by the name of \"Alcysten.\" It is possible that the name could be a typographical error, a brand name not widely recognized, or a new or experimental treatment not yet broadly known or approved.\n\nHowever, if you are referring to a specific medication or treatment, here are some general steps you can take to find accurate and current information:\n\n1. **Check Medical Databases:** Use trusted medical databases like PubMed, ClinicalTrials.gov, or your institution's medical library to search for any studies or clinical trials involving the name.\n\n2. **Consult Pharmaceutical References:** Refer to resources like the Physician's Desk Reference (PDR), British National Formulary (BNF), or similar pharmaceutical reference guides that might have information on new or lesser-known drugs.\n\n3. **Contact Professional Associations:** Reach out to professional medical associations or societies relevant to your specialty, as they may have more"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_nxIak4Nb5bp8GX47JmLBj0P8", "custom_id": "433_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "967e7aa5ad33cad9ea950bcc254e5250", "body": {"id": "chatcmpl-9St6QDyNmC4hpCBnxXG32IOMuNUaP", "object": "chat.completion", "created": 1716672026, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vyxeos (daunorubicin and cytarabine) is a combination chemotherapy medication used primarily for the treatment of certain types of acute myeloid leukemia (AML). Here are some key points you should know about Vyxeos:\n\n1. **Indications**: Vyxeos is approved for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults. These are specific high-risk forms of AML.\n\n2. **Mechanism of Action**:\n   - **Daunorubicin**: An anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis.\n   - **Cytarabine**: A nucleoside metabolic inhibitor that interferes with DNA synthesis during the S-phase of the cell cycle.\n\n3. **Formulation**: Vyxeos is a liposomal formulation that encapsulates"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_sXVXhGiuCq5fsBNsjaVLSwwt", "custom_id": "434_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ca4a53157c213a0ae266b2f51001307b", "body": {"id": "chatcmpl-9St6Q7sTUq9PVMaz8V1iA5OUNFsFZ", "object": "chat.completion", "created": 1716672026, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rafinlar is the brand name for dabrafenib, a medication used primarily in the treatment of certain types of cancer. Here are some key points you should know about Rafinlar:\n\n### Indications\n1. **Melanoma**: It is used to treat patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.\n2. **Non-Small Cell Lung Cancer (NSCLC)**: It is indicated for the treatment of patients with metastatic NSCLC with a BRAF V600E mutation.\n3. **Thyroid Cancer**: It can be used in combination with trametinib for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation and with no satisfactory locoregional treatment options.\n\n### Mechanism of Action\nRafinlar is a kinase inhibitor that specifically targets the BRAF V600E mutation. BRAF is a part of the MAPK/ERK signaling"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_fNT0zf1IGFnH312htrxkFDtl", "custom_id": "435_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d0db412d333d9cfb9306fd51b9f81650", "body": {"id": "chatcmpl-9St6Q1B1iSnqQxAYFw2xTe8QC3PVv", "object": "chat.completion", "created": 1716672026, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bazipar is a hypothetical drug that does not have established information or recognition in medical literature as of my last update in October 2023. If Bazipar is a newly developed or investigational drug, here are some general steps you should take as a physician to stay informed:\n\n1. **Mechanism of Action:** Understand how Bazipar works in the body. This includes its biochemical interactions and the physiological effects it aims to achieve.\n\n2. **Indications and Usage:** Know what conditions Bazipar is approved to treat or is being investigated for. This might include specific diseases, symptoms, or patient populations.\n\n3. **Clinical Trials and Research:** Stay updated on the latest clinical trials and studies involving Bazipar. This includes understanding the phases of the trials, the outcomes, and any ongoing research.\n\n4. **Dosage and Administration:** Be aware of the recommended dosages, routes of administration, and any important considerations for using Bazipar safely and effectively.\n\n5. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_aPGd9uvA5q12TueSmx6ZbYio", "custom_id": "436_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9d58cf464919ccb1c0eee74adfe2b1aa", "body": {"id": "chatcmpl-9St6RRCVvk4A6lUEmrBvbsfxpI1Rh", "object": "chat.completion", "created": 1716672027, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vizimpro (dacomitinib) is a medication used in the treatment of non-small cell lung cancer (NSCLC). Here are key points that you should know about Vizimpro:\n\n### Indications:\n- **Vizimpro** is specifically indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations, as detected by an FDA-approved test.\n\n### Mechanism of Action:\n- **Dacomitinib**, the active ingredient in Vizimpro, is an irreversible tyrosine kinase inhibitor that blocks the activity of EGFR by binding to the ATP-binding site of the receptor. This inhibition prevents downstream signaling pathways involved in cancer cell proliferation and survival.\n\n### Dosage and Administration:\n- The recommended dosage of Vizimpro is **45 mg orally once daily** until disease progression or unacceptable toxicity.\n- Tablets should be swallowed whole, and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Sz3eZ2qRn7G9c6r4jnIpxpT6", "custom_id": "437_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "437046dda2b2b9e938e43fb4e6bc7df2", "body": {"id": "chatcmpl-9St6RQ0hHNkhQx2Tl4RfkXCRKA6UP", "object": "chat.completion", "created": 1716672027, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cosmegen is a brand name for dactinomycin, a chemotherapeutic agent used in the treatment of various cancers. Here are some key points you should know about Cosmegen:\n\n### Indications:\n- **Wilms' Tumor**: Often used in combination with other drugs.\n- **Rhabdomyosarcoma**: Used as part of a multi-drug regimen.\n- **Ewing's Sarcoma**: Sometimes included in treatment protocols.\n- **Gestational Trophoblastic Neoplasia**: Used in certain cases.\n- **Testicular Cancer**: For specific types and cases.\n\n### Mechanism of Action:\n- Dactinomycin intercalates into DNA, inhibiting RNA synthesis, which prevents protein synthesis and ultimately leads to cell death. It is particularly effective in rapidly dividing cells, which is why it is used in cancer therapy.\n\n### Administration:\n- Typically given intravenously.\n- Dosage and treatment schedules vary depending on the type of cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_c2mrs49ylqm9nRkH17Ye616q", "custom_id": "438_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "120b0afb345721fb05d452fd50d1d93b", "body": {"id": "chatcmpl-9St6RAlHfWvS45eH0YG6R67cOSn7a", "object": "chat.completion", "created": 1716672027, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Danatrol, the brand name for danazol, is a synthetic androgen and anabolic steroid. It is primarily used in the treatment of endometriosis, fibrocystic breast disease, and hereditary angioedema. Here are key points you should know about Danatrol:\n\n### Indications\n1. **Endometriosis**: Danazol helps alleviate pain and reduce the size of endometrial lesions.\n2. **Fibrocystic Breast Disease**: It is used to relieve severe pain and tenderness in the breasts.\n3. **Hereditary Angioedema**: Danazol can prevent and reduce the frequency and severity of attacks.\n\n### Mechanism of Action\nDanazol works by suppressing the pituitary-ovarian axis, leading to a decrease in estrogen production. It also has weak androgenic properties, which contribute to its efficacy in treating the aforementioned conditions.\n\n### Dosage and Administration\n- **Endometriosis**: Typically, 200-800 mg daily in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_gdA6La7nOYE7CqBNEq28Hccw", "custom_id": "439_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f5b58c05b0b7f8b72907b5520e18ce42", "body": {"id": "chatcmpl-9St6RR24M31EYWfz4vcR7oawH9P6d", "object": "chat.completion", "created": 1716672027, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Darzalex (generic name: daratumumab) is a monoclonal antibody used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells. Here are key points you should know about Darzalex:\n\n1. **Mechanism of Action:**\n   - Darzalex targets CD38, a protein highly expressed on the surface of multiple myeloma cells. By binding to CD38, Darzalex induces cell death through multiple mechanisms, including complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and antibody-dependent cellular cytotoxicity.\n\n2. **Indications:**\n   - Darzalex is approved for use in adult patients with multiple myeloma. It is often used in combination with other medications, such as lenalidomide, bortezomib, and dexamethasone, depending on the treatment regimen and patient condition.\n   - It can be used in patients who have received at least one prior therapy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_KySGNHK48U79lBw0mf7NVvPC", "custom_id": "440_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "387cbd2ca80bb424a3f986f6898a622f", "body": {"id": "chatcmpl-9St6RpHmGUmoE55EZB2Se8kv1ht0b", "object": "chat.completion", "created": 1716672027, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nubeqa (darolutamide) is an oral medication used in the treatment of prostate cancer. Here are key points you should be aware of as a physician:\n\n1. **Indication**:\n   - Nubeqa is indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).\n\n2. **Mechanism of Action**:\n   - Darolutamide works as an androgen receptor inhibitor. It prevents androgens (male hormones) from binding to androgen receptors, thereby inhibiting the growth of prostate cancer cells.\n\n3. **Dosage and Administration**:\n   - The recommended dose is 600 mg (two 300 mg tablets) taken twice daily with food.\n   - It should be taken in conjunction with a gonadotropin-releasing hormone (GnRH) analog or following surgical castration.\n\n4. **Efficacy**:\n   - Clinical trials have shown that Nubeqa significantly extends metastasis-free survival (M"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_92AOvTE3H3TWkt2f5qtB1Fk4", "custom_id": "441_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "683a7c2b9fa86ae1efd1a56c0a0010d5", "body": {"id": "chatcmpl-9St6R2HEWsQItxZUHFQhQC0FGqVeO", "object": "chat.completion", "created": 1716672027, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sprycel (dasatinib) is a medication used primarily in the treatment of certain types of leukemia, specifically chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). As a physician, here are the key points you should know about Sprycel:\n\n### Indications:\n1. **Chronic Myeloid Leukemia (CML):**\n   - First-line treatment for newly diagnosed adult patients with chronic-phase CML.\n   - Treatment for adults with chronic, accelerated, or myeloid or lymphoid blast phase CML with resistance or intolerance to prior therapy, including imatinib.\n2. **Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL):**\n   - Treatment for adults with Ph+ ALL with resistance or intolerance to prior therapy.\n\n### Mechanism of Action:\n- **Tyrosine Kinase Inhibitor (TKI):** Dasatinib inhibits the BCR-ABL"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_qTloHcF5w8nsVMjO9ijOEySf", "custom_id": "442_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "3e5e2e0ded6ac39c4d3e3737bc888898", "body": {"id": "chatcmpl-9St6SXsOfyMd4aJtsmWtqYvWxtwum", "object": "chat.completion", "created": 1716672028, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cerubidin, also known by its generic name daunorubicin, is an anthracycline antibiotic commonly used in chemotherapy for various types of cancer. Here are the key points you should know about Cerubidin as a physician:\n\n### Indications:\n1. **Acute Myeloid Leukemia (AML):** It's often used in combination with other chemotherapy agents for the treatment of AML in adults and children.\n2. **Acute Lymphoblastic Leukemia (ALL):** It's also used in the treatment of ALL.\n\n### Mechanism of Action:\n- **DNA Intercalation:** Daunorubicin intercalates between DNA base pairs, disrupting DNA replication and transcription.\n- **Topoisomerase II Inhibition:** It inhibits the enzyme topoisomerase II, preventing the relaxation of supercoiled DNA, which is necessary for replication.\n- **Free Radical Formation:** It generates free radicals that cause DNA and cell membrane damage.\n\n### Administration:\n- **Form"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_jsVrghQSmzQ5eKHgxFbtyYqX", "custom_id": "443_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "12048901967c9720eecff8ce556f8338", "body": {"id": "chatcmpl-9St6S2I0JACmNaLNu7V9FgVBlUxPF", "object": "chat.completion", "created": 1716672028, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "DaunoXome is a chemotherapeutic agent specifically formulated as a liposomal encapsulation of daunorubicin. It is primarily used in the treatment of Kaposi's sarcoma, particularly in patients with HIV. Here are several key points you should know about DaunoXome:\n\n### Mechanism of Action\n- **Daunorubicin**: The active ingredient in DaunoXome, daunorubicin, is an anthracycline antibiotic. It works by intercalating DNA, thereby inhibiting the synthesis of nucleic acids and inducing cell death.\n- **Liposomal Formulation**: The liposomal encapsulation helps to improve the drug's therapeutic index by enhancing its delivery to the tumor site while reducing systemic toxicity.\n\n### Indications\n- **Kaposi's Sarcoma**: DaunoXome is primarily indicated for the treatment of advanced HIV-associated Kaposi's sarcoma.\n- **Other Uses**: While its main indication is for Kaposi's"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_BFh6M3rAO9tj2BdyjkbLv1EW", "custom_id": "444_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "7282e859782b3f99f75cbecf7459d8da", "body": {"id": "chatcmpl-9St6SKJSlMLiHLbIccnHb8XaiyA3K", "object": "chat.completion", "created": 1716672028, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dacogen, known generically as decitabine, is a medication used primarily in the treatment of myelodysplastic syndromes (MDS). Here are some key points you should know about Dacogen:\n\n### Indications\n- **Myelodysplastic Syndromes (MDS)**: Dacogen is indicated for the treatment of patients with MDS, including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System (IPSS) groups.\n\n### Mechanism of Action\n- **Hypomethylating Agent**: Dacogen is a nucleoside analog that incorporates into DNA and inhibits DNA methyltransferase, leading to hypomethylation"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_sPCvuau3WHWjY8szZ7KxNOU0", "custom_id": "445_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c2a309854277aeeb3307ca8e8a241e92", "body": {"id": "chatcmpl-9St6SfjqV1JwbeOpzfXEJ0pYNHTt9", "object": "chat.completion", "created": 1716672028, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Firmagon (generic name: degarelix) is a medication used in the treatment of advanced prostate cancer. It is a gonadotropin-releasing hormone (GnRH) receptor antagonist that works by rapidly reducing the production of testosterone, a hormone that can promote the growth of prostate cancer cells. Here are some key points you should be aware of as a physician:\n\n### Mechanism of Action\n- **GnRH Antagonist**: Firmagon directly inhibits the GnRH receptors in the pituitary gland, leading to a rapid decrease in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, which in turn reduces testosterone production.\n\n### Indications\n- **Advanced Prostate Cancer**: It is primarily indicated for the treatment of patients with advanced prostate cancer.\n\n### Administration\n- **Injection**: Firmagon is administered as a subcutaneous injection. The initial dose is typically 240 mg, divided into two 120 mg injections, followed by maintenance"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_4Q3BslJtzeWX2KtV9H9WAMiv", "custom_id": "446_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8175ccdf53e7816cf2b183e45a097312", "body": {"id": "chatcmpl-9St6SejSRJkm6UdmP6CF9OT7BLXpR", "object": "chat.completion", "created": 1716672028, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ontak (denileukin diftitox) is a fusion protein composed of interleukin-2 (IL-2) and a fragment of diphtheria toxin. It is used primarily in the treatment of certain types of cutaneous T-cell lymphoma (CTCL), particularly in patients whose disease has not responded adequately to other therapies. Here are some key points you should know about Ontak:\n\n### Mechanism of Action\n- **Targeting IL-2 Receptors:** Ontak binds to the IL-2 receptors (CD25 component) on the surface of malignant T-cells.\n- **Toxin Delivery:** Once bound, the diphtheria toxin fragment is internalized by the cell, leading to cell death through inhibition of protein synthesis.\n\n### Indications\n- **Cutaneous T-Cell Lymphoma (CTCL):** Ontak is indicated for the treatment of persistent or recurrent CTCL expressing the CD25 component of the IL-2 receptor.\n\n### Administration\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_QWZ4OIkR5RCMmqQzb5yO4DHP", "custom_id": "447_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0150eb42bb2cc8686a47ffe56145bc1c", "body": {"id": "chatcmpl-9St6Ttff1hm7teW3Xy0wyZzJaykWM", "object": "chat.completion", "created": 1716672029, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prolia (denosumab) is a medication used primarily for the treatment of osteoporosis in postmenopausal women and in men who are at high risk for fractures. It is also used in certain patients with bone loss due to hormone ablation therapy for cancer. Here are some key points you should know:\n\n### Mechanism of Action\n- **Denosumab** is a monoclonal antibody that works by inhibiting RANK ligand (RANKL), a protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption.\n\n### Indications\n- **Osteoporosis**: In postmenopausal women and men at high risk for fractures.\n- **Bone loss due to hormone ablation therapy**: In men with prostate cancer and women with breast cancer undergoing hormone ablation therapy.\n- **Glucocorticoid-induced osteoporosis**: In patients receiving long-term systemic glucocorticoid therapy.\n\n### Administration\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_IwWImQZ62BVZEHNeUeMIvmbS", "custom_id": "448_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "46ec565ea7123af03ee24d5c55e4c0d9", "body": {"id": "chatcmpl-9St6TEzZkUxsFEFLL4qnSu91hoONP", "object": "chat.completion", "created": 1716672029, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aacidexam is a pharmaceutical product containing dexamethasone, which is a potent synthetic corticosteroid with anti-inflammatory and immunosuppressant properties. Here are several key points you should know about Aacidexam as a physician:\n\n### Indications:\n- **Anti-inflammatory:** Used to reduce inflammation in various conditions such as rheumatoid arthritis, asthma, and inflammatory bowel disease.\n- **Immunosuppressant:** Helps in managing autoimmune diseases and preventing organ transplant rejection.\n- **Allergic Reactions:** Treats severe allergic reactions and anaphylaxis.\n- **Endocrine Disorders:** Manages adrenal insufficiency and congenital adrenal hyperplasia.\n- **Neoplastic Diseases:** Used in combination with other medications to treat certain types of cancer, such as leukemia and lymphoma.\n- **Cerebral Edema:** Reduces swelling associated with brain tumors or brain surgeries.\n\n### Dosage and Administration:\n- **Formulations:** Available in oral tablets, injectable forms, and topical preparations.\n- **Individualization"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_LLgc4xDEjaaUCSWmRmzQPiLo", "custom_id": "449_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e25a057dbbf46b523576988920d7065d", "body": {"id": "chatcmpl-9St6TOLZMI6xZQcZcDnApfrdhLlLl", "object": "chat.completion", "created": 1716672029, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cardioxane, also known by its generic name dexrazoxane, is a cardioprotective agent primarily used to reduce the risk of cardiotoxicity associated with certain chemotherapy treatments, particularly anthracyclines like doxorubicin and epirubicin. Here are some key points you should know about Cardioxane:\n\n### Mechanism of Action:\n1. **Chelating Agent:** Dexrazoxane is a chelating agent that binds to iron and prevents the formation of iron-anthracycline complexes which are responsible for generating free radicals that cause cardiac damage.\n2. **Topoisomerase II Inhibition:** It also inhibits topoisomerase II, which mitigates the DNA damage induced by anthracyclines.\n\n### Indications:\n1. **Cardioprotection:** Primarily used to protect the heart from the toxic effects of anthracycline chemotherapy in patients who are at high risk for cardiotoxicity.\n2. **Extravasation Treatment"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_NxAzQSwzykqAxpeHXviksdzy", "custom_id": "450_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ce23597c380f4a3cc410086d9393b396", "body": {"id": "chatcmpl-9St6T5NhrCCGBSdnpXkW6npRqkP76", "object": "chat.completion", "created": 1716672029, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2021, there is no widely known or recognized medication or substance called \"Desplex.\" It is possible that you may be referring to a brand name, a misspelling, or a lesser-known product that has emerged after my last update. \n\nIf \"Desplex\" is a new or uncommon medication, here are some general steps you can take to gather the necessary information:\n\n1. **Verify the Name**: Double-check the spelling and ensure the name is accurate. Sometimes, drug names can be easily confused or misspelled.\n\n2. **Consult Reliable Sources**: Look up the drug in reputable medical databases such as PubMed, UpToDate, or the Physicians' Desk Reference (PDR). These resources often provide comprehensive information on drugs, including indications, contraindications, dosages, and side effects.\n\n3. **Contact a Pharmacist**: Pharmacists are often well-versed in both common and obscure medications. They can provide"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_UFbiSZjvGHV5necXqw9WBgr8", "custom_id": "451_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "85060ca4ef2bc50296703dedcb9a33fd", "body": {"id": "chatcmpl-9St6UMCLgkpc6URqVaYuZ8OX73zUq", "object": "chat.completion", "created": 1716672030, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Unituxin (dinutuximab) is a chimeric monoclonal antibody that targets the disialoganglioside GD2, which is highly expressed in neuroblastoma cells. It is primarily used in the treatment of high-risk pediatric neuroblastoma. Here are some key points you should be aware of:\n\n### Indications:\n- **High-Risk Neuroblastoma:** Unituxin, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid, is indicated for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.\n\n### Mechanism of Action:\n- **Targeting GD2:** Unituxin binds to GD2 on neuroblastoma cells, leading to lysis of these cells through antibody-dependent cell-mediated cytotoxicity (ADCC)"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_t1sFM34dzUUaQavsWlXbZr9C", "custom_id": "452_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "7635de5c322ef846ce0beabe9b295f2d", "body": {"id": "chatcmpl-9St6UETpB2Hm7o8Q5awf3Sw0pp5MI", "object": "chat.completion", "created": 1716672030, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asodocel, also known as BCMA CAR-T, is an investigational chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA). It is primarily being explored as a treatment for multiple myeloma, a type of blood cancer that affects plasma cells. Here are some key points you should be aware of:\n\n1. **Mechanism of Action**: Asodocel involves the genetic modification of a patient's T cells to express a CAR that specifically targets BCMA, a protein highly expressed on multiple myeloma cells. This allows the engineered T cells to recognize and kill the cancer cells.\n\n2. **Clinical Trials**: Asodocel is currently in various stages of clinical trials. These studies are designed to evaluate its safety, efficacy, and optimal dosing. Preliminary results have shown promising efficacy in patients with relapsed or refractory multiple myeloma, but ongoing studies are necessary to confirm these findings and establish long-term outcomes.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_bHXFSsbzEiNkwbpsRwL0mjis", "custom_id": "453_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6b30f028d0361a945271fd5e55c83cd6", "body": {"id": "chatcmpl-9St6UWCVJ4pX3tfnwvo7TTFH5yngl", "object": "chat.completion", "created": 1716672030, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Didox (also known by its chemical name, 3,4-dihydroxybenzohydroxamic acid) is an investigational drug with potential applications in oncology and other medical fields. Here are some key points you should know about Didox:\n\n### Mechanism of Action\n- **Ribonucleotide Reductase Inhibition**: Didox primarily acts by inhibiting ribonucleotide reductase, an enzyme crucial for DNA synthesis and repair. By hindering this enzyme, Didox can disrupt the proliferation of rapidly dividing cells, such as cancer cells.\n\n### Therapeutic Applications\n- **Cancer Treatment**: Didox has been studied in various cancer types, including leukemia, lymphoma, and solid tumors. Its ability to interfere with DNA synthesis makes it a candidate for combination therapy with other chemotherapeutic agents.\n- **Radioprotection**: Some research suggests that Didox may offer protective effects against radiation-induced damage, which could have implications for both cancer therapy and protection in radiation exposure"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ZRJkC8tOCh1jEZfwRON2gYFr", "custom_id": "454_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "657b3a5d19ef374c383e9ac92dd623d3", "body": {"id": "chatcmpl-9St6UT154QBW36vCj27grMBiOkmkG", "object": "chat.completion", "created": 1716672030, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adriablastina is a brand name for the chemotherapeutic agent doxorubicin, which is an anthracycline antibiotic. Doxorubicin is widely used in oncology for the treatment of various cancers, including but not limited to, breast cancer, lymphomas, leukemias, and sarcomas. Here are several key points you should be aware of as a physician:\n\n### Mechanism of Action\n- **DNA Intercalation**: Doxorubicin intercalates into DNA, disrupting the enzyme topoisomerase II, which is essential for DNA replication and transcription.\n- **Free Radical Formation**: It generates free radicals that cause damage to cellular membranes, DNA, and proteins.\n- **Apoptosis Induction**: It induces apoptosis in cancer cells through various pathways, including the generation of reactive oxygen species (ROS) and activation of caspases.\n\n### Indications\n- **Solid Tumors**: Breast cancer, ovarian cancer,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_lBvQN4pJDNmWX0E9TNBCOhBA", "custom_id": "455_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c0c5110b9412a61fcde638f32f9b8c56", "body": {"id": "chatcmpl-9St6U3NzQBWfgj70N4grWNV8IYsIg", "object": "chat.completion", "created": 1716672030, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imfinzi (durvalumab) is a human monoclonal antibody that targets the programmed death-ligand 1 (PD-L1). It is an immune checkpoint inhibitor used primarily in the treatment of certain types of cancer. Here are key points you should know about Imfinzi:\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC):** Imfinzi is approved for the treatment of patients with Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.\n- **Extensive-Stage Small Cell Lung Cancer (ES-SCLC):** It is also approved for use in combination with chemotherapy for the first-line treatment of patients with extensive-stage small cell lung cancer.\n- **Other cancers:** Research and clinical trials are ongoing to evaluate its effectiveness in other types of cancer.\n\n### Mechanism of Action\n- Imfinzi works by binding to PD-L1 and blocking its interaction with the PD-1 and CD80 molecules. This releases"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_qQBiQPJaN0IjzogYnYz7MnS8", "custom_id": "456_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "39bc4b5d65869ba6abd0d2a567758f47", "body": {"id": "chatcmpl-9St6VCrNVrbvIVpCCnaZ93lksgKSC", "object": "chat.completion", "created": 1716672031, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it\u2019s important to have a comprehensive understanding of Avodart (dutasteride) to effectively prescribe and manage its use in patients. Here are key points to consider:\n\n### Indications:\n- **Primary Use**: Avodart is primarily used to treat benign prostatic hyperplasia (BPH) in men with an enlarged prostate. It helps improve urinary flow and may reduce the need for prostate surgery later on.\n\n### Mechanism of Action:\n- **5-Alpha-Reductase Inhibitor**: Avodart works by inhibiting the enzyme 5-alpha-reductase, which converts testosterone to dihydrotestosterone (DHT). DHT is a hormone that contributes to prostate growth, so reducing its levels helps to shrink the prostate.\n\n### Dosage and Administration:\n- **Typical Dosage**: The usual dose is 0.5 mg taken once daily, with or without food.\n- **Capsules**: Should be swallowed whole and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_iwGbFjNySqFTya7vUrhx3ypU", "custom_id": "457_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "cbf64ad8c26540890b1b6e7505e3ce2b", "body": {"id": "chatcmpl-9St6Vma9UCggqetG2dciW59cEl8Nb", "object": "chat.completion", "created": 1716672031, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Copiktra (duvelisib) is an oral medication used for the treatment of certain types of blood cancers. As a physician, it's important to be well-informed about its indications, mechanism of action, dosing, side effects, and necessary monitoring. Here's a comprehensive overview:\n\n### Indications:\n- **Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL):** For patients who have received at least two prior therapies.\n- **Relapsed or Refractory Follicular Lymphoma (FL):** For patients who have received at least two prior systemic therapies.\n\n### Mechanism of Action:\n- Copiktra is a dual inhibitor of PI3K-\u03b4 and PI3K-\u03b3, which are enzymes involved in the proliferation and survival of B-cells, contributing to the growth of certain types of cancer.\n\n### Dosing:\n- The recommended dose is 25 mg taken orally twice daily, with or without food"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_weLTf83J5j2ujjR3ybucPVyi", "custom_id": "458_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0f0f459fc46c8c8890a669d1d7dfb0a9", "body": {"id": "chatcmpl-9St6VTOzkAkN8eI2Dg9TzMc5jpx3z", "object": "chat.completion", "created": 1716672031, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a thorough understanding of Panorex, also known as a panoramic radiograph, particularly if you are involved in dental or maxillofacial care. Here are some key points:\n\n1. **Definition and Purpose**:\n   - **Panorex** is a type of extraoral X-ray that captures a panoramic view of the entire mouth in a single image, including the teeth, upper and lower jaws, and surrounding structures and tissues.\n   - It is commonly used in dentistry and oral surgery to diagnose and plan treatment for various conditions.\n\n2. **Indications**:\n   - **Assessment of Dental Health**: It helps in diagnosing dental caries, periodontal disease, and other dental conditions.\n   - **Orthodontic Planning**: Assists in evaluating the position and growth of teeth and jaws.\n   - **Impacted Teeth**: Useful for identifying impacted teeth, such as wisdom teeth.\n   - **Jaw Disorders**: Helps in diagnosing tempor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Xw4SMK7CK1QUyfeOGfYjIC0s", "custom_id": "459_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b7a95bee2afc212f4adfbb70d0327a9a", "body": {"id": "chatcmpl-9St6V2xVOUJ4yt5dHbUvXpyxBAN0U", "object": "chat.completion", "created": 1716672031, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Empliciti (elotuzumab) is a monoclonal antibody used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Here are some key points you should know as a physician:\n\n### Mechanism of Action\n- **Target**: Empliciti targets SLAMF7 (Signaling Lymphocytic Activation Molecule Family member 7), a protein highly expressed on myeloma cells and natural killer (NK) cells.\n- **Action**: It works by directly activating NK cells and tagging myeloma cells for destruction by the immune system.\n\n### Indications\n- Empliciti is used in combination with other therapies for patients with multiple myeloma, particularly those who have received one to three prior therapies.\n- Common combinations include Empliciti with lenalidomide and dexamethasone or with pomalidomide and dexamethasone.\n\n### Administration\n- **Route**: Intr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ugJbFzTmZQeFlYkcD9DMlDj6", "custom_id": "460_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9c364122954b9e10e53531994ce5d89e", "body": {"id": "chatcmpl-9St6VACbDVRY3MIDcUlky6FUcSCxq", "object": "chat.completion", "created": 1716672031, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idhifa (enasidenib) is a medication used in the treatment of certain types of cancer, specifically acute myeloid leukemia (AML). Here are some key points you should know about Idhifa:\n\n### Indications:\n- **Acute Myeloid Leukemia (AML):** Idhifa is indicated for the treatment of relapsed or refractory AML in adults with an isocitrate dehydrogenase-2 (IDH2) mutation. The presence of this mutation should be confirmed using an FDA-approved test.\n\n### Mechanism of Action:\n- **IDH2 Inhibitor:** Idhifa targets and inhibits the mutant IDH2 enzyme, which is involved in the production of an oncometabolite called 2-hydroxyglutarate (2-HG). Elevated levels of 2-HG interfere with cellular differentiation and contribute to the malignant transformation of cells. By inhibiting IDH2, Idhifa reduces 2-HG levels,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_sKMFQe6we0TGXVDtoPBFZ2aA", "custom_id": "461_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "738459330212d5df43e158038ad6a492", "body": {"id": "chatcmpl-9St6VU3Cjb3IKUJLsv60DN7hHU7iV", "object": "chat.completion", "created": 1716672031, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Braftovi (encorafenib) is a medication used in cancer treatment, specifically for certain types of advanced or metastatic cancers. Here are some key points you should know about Braftovi as a physician:\n\n### Indications\n1. **Melanoma**: Braftovi is used in combination with binimetinib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.\n2. **Colorectal Cancer**: It is also used in combination with cetuximab for the treatment of adults with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, after prior therapy.\n\n### Mechanism of Action\n- Braftovi is a BRAF kinase inhibitor. It targets and inhibits the activity of the mutated BRAF protein kinase, which is involved in the growth and spread of cancer cells.\n\n### Dosage and Administration\n- The recommended dosage for melanoma is 450 mg orally once daily"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_UDde5e0nvIWNzvRoMO3YNnef", "custom_id": "462_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ffddaf8abea5425194ff7f6ea9828ed6", "body": {"id": "chatcmpl-9St6VFWXpkJBXjMXv9AZYZ2fici63", "object": "chat.completion", "created": 1716672031, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rozlytrek (entrectinib) is a medication used in the treatment of certain types of cancer. Here are some key points you should know about it:\n\n### Indications\n- **ROS1-Positive Non-Small Cell Lung Cancer (NSCLC):** Rozlytrek is approved for the treatment of adult patients with ROS1-positive NSCLC.\n- **NTRK Gene Fusion-Positive Solid Tumors:** It is also indicated for the treatment of adult and pediatric patients 12 years of age and older with NTRK gene fusion-positive solid tumors that are metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or have progressed following treatment.\n\n### Mechanism of Action\n- Rozlytrek is a tyrosine kinase inhibitor that targets ROS1 and NTRK (neurotrophic tyrosine receptor kinase) gene fusions. By inhibiting these kinases, it interferes with the growth and survival"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_SRD271NZIZT4Cdl29PK6UGQP", "custom_id": "463_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "7f1fadfc1ddf9d6b0c3dcaa36d3981bb", "body": {"id": "chatcmpl-9St6W8BTViO50ekbhG9n8SI6Ysh2S", "object": "chat.completion", "created": 1716672032, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azelastine (commonly referred to as Azel) is a second-generation antihistamine, often used in its hydrochloride form. It's primarily used to treat symptoms of allergic rhinitis (such as nasal congestion, sneezing, and runny nose) and allergic conjunctivitis (such as itchy, red, and watery eyes). Here are some key points you should know as a physician:\n\n### Pharmacology:\n1. **Mechanism of Action**: Azelastine works by blocking histamine H1 receptors, thereby preventing the effects of histamine in the body, which is a key mediator in allergic reactions. It also has anti-inflammatory properties.\n\n2. **Formulations**:\n   - **Nasal Spray**: Used for treating symptoms of allergic rhinitis.\n   - **Ophthalmic Solution**: Used for treating symptoms of allergic conjunctivitis.\n\n### Indications:\n- **Allergic Rhinitis**: Both seasonal and perennial.\n- **Allergic Conjunct"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_1tMg7t1u7z2eITQj9TRxeuqh", "custom_id": "464_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6ba32b99478de76e421cadf1bca254e8", "body": {"id": "chatcmpl-9St6WH5aRvZo5oMU858Hgkdyt4z6h", "object": "chat.completion", "created": 1716672032, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alrubicin, also known as doxorubicin hydrochloride liposome, is a chemotherapeutic agent used primarily in the treatment of various types of cancer. Here are some key points you should know about Alrubicin:\n\n### Mechanism of Action:\n- **Anthracycline Antibiotic**: Alrubicin is an anthracycline antibiotic that intercalates DNA, inhibiting the enzyme topoisomerase II, which is essential for DNA replication and repair. This leads to the disruption of DNA function and, ultimately, cell death.\n- **Liposomal Formulation**: The liposomal encapsulation allows for a more targeted delivery to cancer cells, potentially reducing systemic toxicity and enhancing the drug's efficacy.\n\n### Indications:\n- **Various Cancers**: Alrubicin is indicated for the treatment of various malignancies, including breast cancer, ovarian cancer, multiple myeloma, Kaposi's sarcoma, and certain types of leukemia and lymphomas.\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_jG1knhld2h7yZPwrQZrD146E", "custom_id": "465_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a1cce936e5523e5427b71265d1ace744", "body": {"id": "chatcmpl-9St6WBY3Emjz6RDG4z3mCrq3V7FFd", "object": "chat.completion", "created": 1716672032, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Balversa (erdafitinib) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of bladder cancer. Here are some key points you should know about Balversa:\n\n1. **Indication**:\n   - Balversa is indicated for the treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations.\n   - It is typically used in patients who have progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.\n\n2. **Mechanism of Action**:\n   - Balversa is a tyrosine kinase inhibitor that targets fibroblast growth factor receptors (FGFRs), which play a role in cell growth and survival. By inhibiting these receptors, Balversa can help slow down or stop the growth of cancer cells.\n\n3. **Dosage and Administration**:\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_pR5a33aO5xgt4659kvclG3An", "custom_id": "466_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a7710b6ae20c7c09da1d0fbacbe2e693", "body": {"id": "chatcmpl-9St6WvVjan0d1GHJfvc21hkYxHrpl", "object": "chat.completion", "created": 1716672032, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff in October 2023, there is no known medication or medical treatment by the name \"Brutravon.\" It is possible that it could be a brand name or a new drug that has been introduced after my last update. Here are some steps you can take to find accurate and up-to-date information:\n\n1. **Consult Medical Databases**: Use medical databases like PubMed, ClinicalTrials.gov, or your institution\u2019s library resources to search for peer-reviewed articles or clinical trials related to \"Brutravon.\"\n\n2. **Check with Professional Organizations**: Reach out to professional organizations relevant to your field. They often have the latest information on new drugs and treatments.\n\n3. **Pharmaceutical Reps and Companies**: Contact the pharmaceutical company that manufactures Brutravon if known, or speak to a pharmaceutical representative for detailed information.\n\n4. **FDA or EMA Websites**: Check the U.S. Food and Drug Administration (FDA) or European Medicines Agency ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_OstEYP71QTn8033B7NPH9P2L", "custom_id": "467_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "1940d826862a959073dfe06c7ec81b06", "body": {"id": "chatcmpl-9St6WkXrXifgQOnFfJUU1Nozf9HD0", "object": "chat.completion", "created": 1716672032, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erlocip is a brand name for the drug erlotinib, which is a tyrosine kinase inhibitor (TKI) used primarily in the treatment of certain types of cancer. Here are some important aspects you should know about Erlocip as a physician:\n\n### Indications:\n1. **Non-Small Cell Lung Cancer (NSCLC):** Erlocip is commonly used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations.\n2. **Pancreatic Cancer:** It is also used in combination with gemcitabine for the treatment of locally advanced, unresectable, or metastatic pancreatic cancer.\n\n### Mechanism of Action:\n- Erlotinib inhibits the tyrosine kinase domain of the EGFR, which is involved in the proliferation and survival of cancer cells. By blocking this pathway, it helps to inhibit tumor growth and progression.\n\n### Dosage and Administration:\n- **NS"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_QrdsubNclv9AcsPvb6dUcLOH", "custom_id": "468_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "92a98a05e4af877aa02b8cc99297b881", "body": {"id": "chatcmpl-9St6WT9zOCtuWgRkYlrG6R2VZXZnN", "object": "chat.completion", "created": 1716672032, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Emcyt, known generically as estramustine phosphate, is a chemotherapy medication primarily used in the treatment of prostate cancer. As a physician, there are several important aspects you should be aware of when prescribing and managing treatment with Emcyt:\n\n1. **Mechanism of Action**:\n   - Emcyt combines estradiol (a form of estrogen) with a nitrogen mustard ester (a type of alkylating agent). It works by disrupting microtubule function and thereby inhibiting cell division, which is particularly effective against prostate cancer cells.\n\n2. **Indications**:\n   - It is typically used for palliative treatment of metastatic or progressive prostate cancer, especially when the cancer is resistant to other forms of hormone therapy.\n\n3. **Administration**:\n   - Emcyt is administered orally in capsule form. The typical dosage varies based on the individual patient\u2019s medical condition, response to treatment, and specific protocol being followed.\n\n4. **Side Effects**:\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_2XjZBGTk3NugJWtuvkESmJ4E", "custom_id": "469_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "13414a3a958ae5a94abd41f6fc7aca9f", "body": {"id": "chatcmpl-9St6XHB5195QCZSsjxxDWUDgZtNmk", "object": "chat.completion", "created": 1716672033, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like you might be referring to a specific medical term, medication, or concept, but \"Aside\" doesn't appear to correspond to any well-known medical terminology, drug, or procedure. If \"Aside\" is a new drug, medical device, or specific term within a specialized context, it might be helpful to provide more detail or verify the name.\n\nHowever, here are a few general tips for physicians when encountering new or unfamiliar terms or treatments:\n\n1. **Consult Reliable Sources:**\n   - Use trusted medical databases like PubMed, UpToDate, or professional guidelines from organizations such as the American Medical Association (AMA) or the World Health Organization (WHO).\n\n2. **Peer Consultation:**\n   - Discuss the term or treatment with colleagues or specialists who might have more experience or knowledge in that area.\n\n3. **Continuing Medical Education (CME):**\n   - Engage in CME courses and seminars, which often cover the latest advancements and terminologies in medicine.\n\n4. **Patient"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 39, "completion_tokens": 200, "total_tokens": 239}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_BWhUi0H2MsYKIdoC27FDxpkB", "custom_id": "470_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "373bcca37802c6728d9286ca0fd68126", "body": {"id": "chatcmpl-9St6X2dU2rqitC65l0NEnsXUjhRhv", "object": "chat.completion", "created": 1716672033, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Advacan\" does not appear to be a widely recognized or standard medication, at least as of my last update in 2023. It's possible that you might be referring to a brand name or a new drug that has been introduced after my last update, or there might be a typo or regional difference in the name.\n\nHowever, if you meant \"Advagraf\" or \"Prograf,\" which are brand names for tacrolimus, I can provide some information on that. Tacrolimus is an immunosuppressive drug primarily used to lower the risk of organ rejection in patients who have undergone organ transplants, such as liver, kidney, or heart transplants. It works by inhibiting the activity of T-cells, which are crucial for the immune response.\n\nHere are some key points to know about tacrolimus:\n\n1. **Mechanism of Action**: Tacrolimus binds to the FK506-binding protein (FKBP) within T-cells, inhibiting calcine"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_VovCqsXNkGoKtKlAboVlthir", "custom_id": "471_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "7e209801a2c0cc49855d52300ae9faa7", "body": {"id": "chatcmpl-9St6XsZqLaYdjyzgcIkDYeEDvYyof", "object": "chat.completion", "created": 1716672033, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2023, there is no widely known or recognized medication or medical treatment called \"Aromadex.\" It is possible that you might be referring to a specific brand name, a lesser-known compound, or a new product that was introduced after my last update.\n\nIf \"Aromadex\" is a new or specialized product, here are some general steps you can take as a physician to obtain reliable information:\n\n1. **Consult Medical Literature and Databases**: Check reputable medical databases such as PubMed, Medline, and others for any published studies or articles on \"Aromadex.\"\n\n2. **Drug Information Resources**: Utilize drug information resources like the Physicians' Desk Reference (PDR), Epocrates, or online platforms like Drugs.com or UpToDate to find detailed information on the product.\n\n3. **Manufacturer Information**: If \"Aromadex\" is a specific brand or proprietary product, consult the manufacturer's website or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_dZ4780FRReVjeshBAmFeVPg4", "custom_id": "472_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "994c8a5052a565dad173a6cde3e54409", "body": {"id": "chatcmpl-9St6XD69etEfm26KMOQVqGsSjQlHD", "object": "chat.completion", "created": 1716672033, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to be well-informed about FUDR (Floxuridine), a chemotherapeutic agent, to effectively utilize it in clinical practice. Here are some key points you should be aware of:\n\n1. **Mechanism of Action**:\n   - Floxuridine is a pyrimidine analog that inhibits DNA synthesis. It gets converted to 5-fluorouracil (5-FU) in the body, which interferes with the synthesis of thymidine, a nucleotide necessary for DNA replication.\n\n2. **Indications**:\n   - FUDR is primarily used for the treatment of metastatic colorectal cancer that has spread to the liver. It is also used for hepatic artery infusion therapy to deliver the drug directly to liver tumors, thereby achieving higher local concentrations and minimizing systemic side effects.\n\n3. **Administration**:\n   - It is commonly administered via continuous arterial infusion using an implanted pump, particularly for liver metastases. This localized delivery can enhance"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_1vxslUGe4nsBC7Xp07ACBnpW", "custom_id": "473_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0ed3410e8cb2877e41b08582456898b6", "body": {"id": "chatcmpl-9St6X9KWPrA9jHTWsvebJig55mbiE", "object": "chat.completion", "created": 1716672033, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of any medication you prescribe or discuss with your patients. However, as of my knowledge cutoff date in October 2021, there is no widely recognized medication or treatment called \"Beneflur.\" It's possible that it could be a new drug, a brand name not widely recognized, or a typographical error. Here are some general steps you can take to ensure you have accurate information:\n\n1. **Verify the Name and Spelling**: Double-check the spelling of the medication to ensure that it is correct.\n\n2. **Consult Reputable Sources**: Use trusted medical resources such as drug databases (e.g., Lexicomp, Micromedex), official guidelines, or peer-reviewed journals to find information on the drug.\n\n3. **Contact a Pharmacist**: Pharmacists are often very knowledgeable about medications and can provide detailed information about new or less common drugs.\n\n4. **Check Regulatory Agencies**: Look up the medication on regulatory agency"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_NPTyB0KLLfjaipdvSSJifCRe", "custom_id": "474_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "907888d773d1e074432be5efc96493c8", "body": {"id": "chatcmpl-9St6XONZvjxdIpGbKOOm8tbbxrqKo", "object": "chat.completion", "created": 1716672033, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, there are a few key points you should know about Accusite:\n\n1. **Accusite Overview**: Accusite is often associated with a specific type of medical device or technology used for precision targeting in medical treatments, particularly in dermatology and aesthetic procedures. It might also refer to a specific brand or product designed for these purposes.\n\n2. **Uses**: Accusite technology is commonly used for accurately targeting and treating skin conditions such as lesions, warts, and other dermatological issues. It is designed to improve the precision of treatments, thereby reducing collateral damage to surrounding healthy tissues.\n\n3. **Mechanism**: The technology typically involves some form of visual or laser-guided system that allows for precise targeting. This precision is crucial for minimizing side effects and improving patient outcomes.\n\n4. **Training and Proficiency**: Proper training is essential for the effective use of Accusite technology. Physicians need to be familiar with the device's operation, including calibration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_DKV7diTcYd7ShDHia36eDWqr", "custom_id": "475_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "bcdedd7e74a83c79c24b5c3a7503455f", "body": {"id": "chatcmpl-9St6Y4n1fNTkYFF4gQrhghOjJ0qJq", "object": "chat.completion", "created": 1716672034, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Halotestin (fluoxymesterone) is an anabolic steroid. Here are some key points you should be aware of as a physician:\n\n### Indications:\n1. **Hypogonadism in Males:** Halotestin is used to treat male hypogonadism, which can be primary (congenital or acquired) or secondary (due to the failure of the hypothalamus or pituitary gland).\n2. **Delayed Puberty in Males:** It can be prescribed for boys with delayed puberty to induce the development of secondary sexual characteristics.\n3. **Palliation of Breast Cancer:** It is used in women to treat advanced breast cancer, particularly in postmenopausal women or those who have hormone-responsive tumors.\n\n### Mechanism of Action:\nHalotestin works by binding to androgen receptors, which leads to increased protein synthesis and decreased protein breakdown, promoting muscle growth and the development of male characteristics.\n\n### Dosage and Administration:\n- The dosage of Halotestin varies"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_r3ogPU7rzFd6tInuXZiPQ5E7", "custom_id": "476_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "75bd4d97a4ab27e20b2ca81e6d218181", "body": {"id": "chatcmpl-9St6YiAwzuFJCdoEdjXnuMT81npeQ", "object": "chat.completion", "created": 1716672034, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cytomid is the brand name for flutamide, a non-steroidal anti-androgen medication primarily used to treat prostate cancer. Here are some key points you should know about Cytomid (flutamide):\n\n### Mechanism of Action:\n- **Anti-androgen Activity:** Flutamide works by blocking androgen receptors, which prevents androgens (male hormones) like testosterone from stimulating the growth of prostate cancer cells.\n\n### Indications:\n- **Prostate Cancer:** It is mainly used in the treatment of metastatic prostate cancer.\n- **Combination Therapy:** Often used in combination with a gonadotropin-releasing hormone (GnRH) agonist or antagonist to achieve maximal androgen blockade.\n\n### Dosage and Administration:\n- **Standard Dosage:** Typically, 250 mg orally three times a day. \n- **Combination Protocols:** Dosage may vary when combined with other treatments, and adjustments might be necessary based on patient response and side effects.\n\n### Side Effects:\n- **Common"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_BByxKDyoIsutKo3t50Tl4OiU", "custom_id": "477_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e3608800be63908809370ce8a919e921", "body": {"id": "chatcmpl-9St6Y5PXndrNsUzIBRLJGn2zOafT5", "object": "chat.completion", "created": 1716672034, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to be well-informed about the medications and supplements your patients may be using. \"Antrex\" can refer to different products depending on the context and region. However, one common reference is to an herbal supplement containing a blend of ingredients purported to support general health. Here's what you should consider:\n\n1. **Ingredients and Composition**: Understand the specific formulation of Antrex, including its active ingredients. Common herbal ingredients in similar supplements may include ginseng, ginkgo biloba, or other botanicals. Verify the exact composition as it can vary by manufacturer.\n\n2. **Mechanism of Action**: Research how the ingredients in Antrex are believed to work. For example, ginseng is often used for its supposed adaptogenic properties, while ginkgo biloba is thought to support cognitive function.\n\n3. **Indications and Uses**: Determine the conditions or symptoms for which Antrex is commonly recommended. Patients may use it for general wellness, energy enhancement, or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_AUscoamLVvGsJdrhwbGE08Ae", "custom_id": "478_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c8d0a724133d11af903f7917808ca0c1", "body": {"id": "chatcmpl-9St6YsKOmuuOCbB2T6WcruvvxGeXF", "object": "chat.completion", "created": 1716672034, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lentaron (formestane) is a medication that has been used primarily in the treatment of hormone-sensitive breast cancer in postmenopausal women. As a physician, here are some key points you should be knowledgeable about regarding Lentaron:\n\n1. **Mechanism of Action**: Lentaron is an aromatase inhibitor. It works by blocking the enzyme aromatase, which is responsible for converting androgens into estrogens. By reducing estrogen levels, it helps to slow or stop the growth of estrogen-dependent breast cancer cells.\n\n2. **Indications**: It is mainly indicated for the treatment of estrogen receptor-positive breast cancer in postmenopausal women. It can be used in cases where tumors have recurred or progressed following anti-estrogen therapy.\n\n3. **Administration**: Lentaron is typically administered as an intramuscular injection. The dosing schedule can vary, but it is often given every two weeks.\n\n4. **Side Effects**: Common side effects include"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_cH12xFCL6Afoun0flybO8HIa", "custom_id": "479_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "87578e0cd6fba7e08513dfe705847308", "body": {"id": "chatcmpl-9St6Yj8AqzidgMobaJAbBkLweqzmz", "object": "chat.completion", "created": 1716672034, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fodosine, also known as forodesine, is an investigational drug that targets the enzyme purine nucleoside phosphorylase (PNP). Here are several key points you should know about Fodosine:\n\n1. **Mechanism of Action**:\n   - Fodosine inhibits PNP, an enzyme crucial for the salvage pathway of purine metabolism. \n   - By inhibiting PNP, Fodosine disrupts the proliferation of certain types of lymphocytes, particularly T-cells, making it useful in conditions where these cells are overactive or malignant.\n\n2. **Indications**:\n   - Fodosine has been primarily investigated for the treatment of hematologic malignancies, including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).\n   - There may be potential uses in other lymphoproliferative disorders and autoimmune diseases, although these applications are still under investigation.\n\n3. **Clinical Trials and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_hf56LT7ZQ4NvtjEJjO88pGZ0", "custom_id": "480_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "1499f1931f51c7bda37664402d110885", "body": {"id": "chatcmpl-9St6YwOoRGrqoY0vtEebYPo1m2WiQ", "object": "chat.completion", "created": 1716672034, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tavalisse (fostamatinib disodium hexahydrate) is an oral spleen tyrosine kinase (SYK) inhibitor used primarily for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to previous treatment. Here are some key points you should know about Tavalisse:\n\n1. **Mechanism of Action**: Tavalisse works by inhibiting SYK, a key signaling molecule in the immune process that leads to platelet destruction. By inhibiting SYK, Tavalisse helps to reduce the immune-mediated destruction of platelets.\n\n2. **Indication**: It is specifically approved for adult patients with chronic ITP who have not responded adequately to other treatments such as corticosteroids, immunoglobulins, or splenectomy.\n\n3. **Dosage**: The typical starting dose is 100 mg taken orally twice daily. Based on the patient's platelet count and tolerability, the dose may be"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Y6HRY72gBgj3f6QjLfR8GTwr", "custom_id": "481_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "cdf24e907384bcb12548af6b23e87809", "body": {"id": "chatcmpl-9St6ehwbyxrK7sCzWopJFqssq8GGF", "object": "chat.completion", "created": 1716672040, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my most recent update, there's no widely recognized medication known as \"Muphoran.\" It's possible that you might be referring to a drug that is either very new, highly specialized, or not widely known under this name. Alternatively, there could be a misspelling or misunderstanding of the drug name.\n\nIf you have more context or additional details, I might be able to assist you better. However, as a physician, here are some general steps you can take when encountering unfamiliar medications:\n\n1. **Consult Reliable Sources**: Use trusted medical resources such as the Physician's Desk Reference (PDR), UpToDate, or peer-reviewed journals to look up the medication.\n\n2. **Pharmacist Consultation**: Consult with a pharmacist who might have additional insights or access to different drug databases.\n\n3. **Professional Networks**: Engage with professional networks or colleagues who might have experience or knowledge about the medication.\n\n4. **Clinical Trials and Research**: Look for clinical trials or research"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_sTOVhBeeAbdJ88SbhcHHmxw9", "custom_id": "482_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "382a5673913ac4ca5e081161bac0b8e5", "body": {"id": "chatcmpl-9St6ZRY2h9oDJUO5T4d8XD6U0lEor", "object": "chat.completion", "created": 1716672035, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Faslodex (generic name: fulvestrant) is a medication used in the treatment of certain types of hormone receptor-positive metastatic breast cancer. Here are key points you should know about Faslodex:\n\n### Indications:\n1. **Hormone Receptor-Positive Metastatic Breast Cancer:**\n   - Used in postmenopausal women with hormone receptor-positive metastatic breast cancer.\n   - Often used in patients who have disease progression following endocrine therapy.\n\n### Mechanism of Action:\n- Faslodex is a selective estrogen receptor degrader (SERD). It binds to estrogen receptors and accelerates their degradation, reducing the number of receptors available to support cancer cell growth.\n\n### Administration:\n- **Dosage:**\n  - The typical dose is 500 mg administered intramuscularly (IM) into the buttocks.\n  - Given on days 1, 15, and 29, and once monthly thereafter.\n- **Mode of Administration:**\n  - Administer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_MTcBuaJtLXD6GhCpXLLRge5p", "custom_id": "483_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9d95907b35ad951dda7941ddd3924a17", "body": {"id": "chatcmpl-9St6ZNdWcrbORFQhBq70eFaMeq3P3", "object": "chat.completion", "created": 1716672035, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2023, there is no widely recognized drug, treatment, or medical term known as \"Cangib.\" It is possible that you may have misspelled the name, it could be a new or lesser-known drug, or it might be a term used regionally or within a specific medical community.\n\nIf \"Cangib\" is a new or emerging treatment:\n\n1. **Stay Updated**: Keep up-to-date with the latest medical literature, guidelines, and pharmacology resources. New drugs and treatments are continually being developed and approved.\n\n2. **Consult Reliable Sources**: Refer to trusted medical databases such as PubMed, ClinicalTrials.gov, or the FDA website for the most current information about new drugs and treatments.\n\n3. **Drug Information**: Obtain comprehensive information on the drug's mechanism of action, indications, contraindications, dosage, side effects, and interactions.\n\n4. **Clinical Guidelines**: Follow the latest clinical guidelines and recommendations"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_QBTWSs6hgkwZaW9gfUjwZZoM", "custom_id": "484_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "3cc4ee4c761d65f628219598a767e9ee", "body": {"id": "chatcmpl-9St6ZbA47mcckMLylbTRKLGQ0CLMT", "object": "chat.completion", "created": 1716672035, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, it appears that \"Gemcite\" isn't a recognized or established medication. It's possible that it could be a typographical error, a new medication that has been developed after my last update, or a specific product name that isn't widely recognized in the medical community.\n\nHowever, if you were referring to \"Gemcitabine\" (a common chemotherapy drug), here are some key points you should know:\n\n### Overview of Gemcitabine\n\n**1. **Mechanism of Action:**\n   - Gemcitabine is a nucleoside analog, which means it interferes with DNA synthesis. It gets incorporated into the DNA during the S-phase of the cell cycle, leading to inhibition of DNA replication and subsequently causing cell death.\n\n**2. Indications:**\n   - Gemcitabine is primarily used to treat various cancers, including:\n     - Pancreatic cancer\n     - Non-small cell lung cancer (NSCLC)\n     -"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_0HznYogMt2f98Q9Na7TPq0B6", "custom_id": "485_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "3de37db087ab272d5521018e0013e83f", "body": {"id": "chatcmpl-9St6ZZfdKXa5ZtkXMv4ih8WNBjPFX", "object": "chat.completion", "created": 1716672035, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mylotarg (generic name: gemtuzumab ozogamicin) is a medication used in the treatment of acute myeloid leukemia (AML). It is specifically indicated for patients with newly diagnosed CD33-positive AML and for patients with relapsed or refractory CD33-positive AML. Here are some key points you should know about Mylotarg:\n\n### Mechanism of Action:\n- **Gemtuzumab Ozogamicin** is an antibody-drug conjugate. It consists of a humanized anti-CD33 antibody linked to a cytotoxic agent called calicheamicin.\n- The drug binds to the CD33 antigen, which is expressed on the surface of leukemic blast cells in most patients with AML.\n- After binding to CD33, the conjugate is internalized, and the calicheamicin is released inside the cell, leading to DNA damage and cell death.\n\n### Indications:\n- **Newly Diagnosed AML:** For the treatment of newly diagnosed CD"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Ey9JgPB3fzYiAdO3BCXgABUF", "custom_id": "486_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "4afd641068e0472b2773835318e6da9a", "body": {"id": "chatcmpl-9St6ZrYOCwBxIgxHLS0KiMtpjCoX1", "object": "chat.completion", "created": 1716672035, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Xospata (generic name: gilteritinib) is a medication used in the treatment of acute myeloid leukemia (AML), specifically for patients who have relapsed or refractory AML with a FLT3 mutation. Here\u2019s a comprehensive overview of what you, as a physician, should know about Xospata:\n\n### Indications:\n- **Primary Use:** Xospata is indicated for the treatment of adult patients who have relapsed or refractory AML with a FLT3 mutation, as detected by an FDA-approved test.\n\n### Mechanism of Action:\n- **FLT3 Inhibitor:** Gilteritinib is a tyrosine kinase inhibitor that targets FLT3, including both FLT3-ITD (internal tandem duplication) and FLT3-TKD (tyrosine kinase domain) mutations, which are known to drive the proliferation of leukemic cells.\n\n### Dosage and Administration:\n- **Recommended Dose:** The typical starting dose is 120 mg orally once daily"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_JqQmPs6xaMZQjAkffutmrjaz", "custom_id": "487_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "030395980bcbfc4a2715363fd8f2d018", "body": {"id": "chatcmpl-9St6ZytlIj8U5ug9NFiWnICZU5QpI", "object": "chat.completion", "created": 1716672035, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daurismo, also known by its generic name glasdegib, is a medication used in the treatment of acute myeloid leukemia (AML). Here are some key points that you should know about Daurismo as a physician:\n\n### Indications\n- **Acute Myeloid Leukemia (AML):** Daurismo is indicated for use in combination with low-dose cytarabine for the treatment of newly-diagnosed AML in adult patients who are 75 years or older or who have comorbidities that preclude the use of intensive induction chemotherapy.\n\n### Mechanism of Action\n- **Hedgehog Pathway Inhibitor:** Daurismo works by inhibiting the Hedgehog signaling pathway, which is involved in the development and growth of cancer cells. Specifically, it targets the Smoothened (SMO) receptor, a key component in this pathway.\n\n### Dosage and Administration\n- **Oral Administration:** Daurismo is administered orally. The recommended dosage is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_B4Fvgc01PoHK3QqYzPTY6O52", "custom_id": "488_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0c1ece8a4578ba9a338faea59f3fb35f", "body": {"id": "chatcmpl-9St6aai1zXClFPybyOVKHufDXhn4o", "object": "chat.completion", "created": 1716672036, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2021, there is no widely recognized medical product or term called \"Novgos.\" It is possible that you might be referring to a specific drug, medical device, or term that has emerged after my last update, or it might be a typo or miscommunication.\n\nHere are a few steps you can take to get accurate information:\n\n1. **Verify the Name**: Double-check the spelling and context. Sometimes, drug names or medical terms can be easily misspelled or misheard.\n\n2. **Consult Medical Databases**: Use reputable medical databases like PubMed, Medline, or professional medical organizations to search for the term.\n\n3. **Ask Colleagues**: Discuss with your peers or specialists in relevant fields to see if they are familiar with \"Novgos.\"\n\n4. **Check Regulatory Websites**: Look up the term on regulatory websites like the FDA (Food and Drug Administration) or EMA (European Medicines Agency) if it's a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_d65YD2tn4ZmgbHXOQoMujBYu", "custom_id": "489_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "4cd0937c64bf482b1254419ccf988a0b", "body": {"id": "chatcmpl-9St6a4HesOAUsyJXq3PiNAJ0MNDpa", "object": "chat.completion", "created": 1716672036, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Supprelin LA (histrelin acetate) is a long-acting implant used primarily for the treatment of central precocious puberty (CPP) in children. Here are some key points you should know about Supprelin:\n\n### Indications\n- **Central Precocious Puberty (CPP)**: Supprelin is indicated for the treatment of children with CPP, a condition where puberty starts too early, typically before age 8 in girls and age 9 in boys.\n\n### Mechanism of Action\n- **GnRH Agonist**: Supprelin is a gonadotropin-releasing hormone (GnRH) agonist. It works by initially stimulating and then desensitizing the pituitary gland, which leads to a decrease in the production of sex hormones (estrogen and testosterone).\n\n### Administration\n- **Implant**: Supprelin is administered as a subcutaneous implant. The implant is typically placed in the upper arm and releases histrelin acetate continuously over "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_CvGyOrlBHqD2OKh5F1xjh44Y", "custom_id": "490_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0b5dac79bf8ad555d9c919ea87f81620", "body": {"id": "chatcmpl-9St6a3tiJVs4VevNyJ0P5dOnIGtA2", "object": "chat.completion", "created": 1716672036, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cortef, also known by its generic name hydrocortisone, is a corticosteroid medication used primarily for its anti-inflammatory and immunosuppressive properties. Here are some important points you should know as a physician:\n\n### Indications:\n1. **Endocrine Disorders:** Used as replacement therapy in adrenocortical insufficiency (e.g., Addison's disease).\n2. **Inflammatory and Autoimmune Conditions:** Such as rheumatoid arthritis, lupus, and inflammatory bowel disease.\n3. **Allergic Reactions:** Severe allergic states, including asthma exacerbations and anaphylaxis.\n4. **Dermatologic Conditions:** Various skin conditions like eczema and psoriasis.\n5. **Respiratory Diseases:** Chronic obstructive pulmonary disease (COPD) exacerbations.\n6. **Other Conditions:** It can be used for a variety of other inflammatory and autoimmune conditions, and occasionally for certain cancers as part of chemotherapy protocols.\n\n### Mechanism of Action:\n- Hydrocortisone mim"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_j5GpldEPMFk5M1KlgEDtNRsG", "custom_id": "491_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e781a9b3566688fab0d326ab5bbe856b", "body": {"id": "chatcmpl-9St6arRE5STtxjJf3dASz3DGxUcOn", "object": "chat.completion", "created": 1716672036, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2021, there is no widely recognized medical or scientific information about a substance or drug called \"Biosupressin.\" It is possible that it could be a new or emerging treatment, a misspelling or variation of an existing drug name, or a concept that has not yet been widely documented in the medical literature.\n\nIf you have encountered this term in a recent context, I would recommend the following steps:\n\n1. **Consult Reliable Sources:** Check recent medical journals, pharmaceutical databases, and trusted online medical resources like PubMed, Medline, or the websites of professional medical organizations for any new information.\n\n2. **Contact Colleagues:** Discuss with colleagues or specialists who might have more information or insight into this term.\n\n3. **Manufacturer Information:** If it is a new drug or product, information from the manufacturer or the regulatory body (like FDA or EMA) might be available.\n\n4. **Medical Conferences and Seminars:** Attend professional conferences"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_6a5135bv8vsoFPER4PeYcscu", "custom_id": "492_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "302eabee43aaad0554b13ef5aa73adb6", "body": {"id": "chatcmpl-9St6aV5PS53Cm3V1Nfum3u8405Doo", "object": "chat.completion", "created": 1716672036, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zevalin (ibritumomab tiuxetan) is a radioimmunotherapy treatment used primarily for certain types of B-cell non-Hodgkin lymphoma (NHL). As a physician, here are key points you should know about Zevalin:\n\n### Mechanism of Action:\n- **Monoclonal Antibody**: Zevalin consists of ibritumomab, a monoclonal antibody that targets the CD20 antigen present on the surface of B-cells, including malignant B-cells.\n- **Radioactive Component**: Tiuxetan acts as a chelator that binds to radioactive isotopes, typically Yttrium-90 (90Y), delivering targeted radiation to the cancer cells.\n\n### Indications:\n- **Relapsed or Refractory NHL**: Zevalin is approved for use in patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin lymphoma.\n- **Consolidation Therapy**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_6XANTh2pQxvfXkTdGNeoKFax", "custom_id": "493_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2bc14165cd219eaf7304c4aad9a4acf4", "body": {"id": "chatcmpl-9St6aZ6PjhaxgnOVre6k9UgpuLc8o", "object": "chat.completion", "created": 1716672036, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibrutinib, marketed under the brand name Imbruvica, is a small molecule drug that acts as a Bruton's tyrosine kinase (BTK) inhibitor. It is primarily used in the treatment of various B-cell malignancies. Here are key points to consider:\n\n### Indications\nIbrutinib is approved for the treatment of several conditions, including:\n- Chronic Lymphocytic Leukemia (CLL)\n- Mantle Cell Lymphoma (MCL) after at least one prior therapy\n- Waldenstr\u00f6m's Macroglobulinemia (WM)\n- Marginal Zone Lymphoma (MZL) after at least one prior anti-CD20-based therapy\n- Chronic Graft-Versus-Host Disease (cGVHD) after failure of one or more lines of systemic therapy\n\n### Mechanism of Action\nIbrutinib binds covalently to BTK, an enzyme crucial for the survival and proliferation of B-cells. By"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_IwcXQxMl1xWLfkfri4ItFDmN", "custom_id": "494_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8a4fbb1817d9127ee88883bd414c316e", "body": {"id": "chatcmpl-9St6aZ9VjZZDCabUyID52pxdWgyFS", "object": "chat.completion", "created": 1716672036, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Conmana, also known by its generic name icotinib, is a tyrosine kinase inhibitor (TKI) used primarily for the treatment of non-small cell lung cancer (NSCLC) that has specific mutations in the epidermal growth factor receptor (EGFR). Here are some key points you should consider:\n\n### Mechanism of Action:\n- **EGFR Inhibition**: Icotinib targets and inhibits the tyrosine kinase activity of the EGFR, which is involved in the signaling pathways that regulate cell division and survival. By inhibiting EGFR, icotinib can help reduce tumor growth and proliferation.\n\n### Indications:\n- **NSCLC**: It is specifically indicated for the treatment of patients with locally advanced or metastatic NSCLC who have EGFR mutations.\n\n### Dosage and Administration:\n- **Oral Administration**: Typically administered orally, often in the form of tablets.\n- **Dosing Schedule**: The recommended dosage is generally 125 mg taken three times"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_V1qNElvQUrTyWY5bR336OPTL", "custom_id": "495_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "251b7e758110dae49a4b827f76d70e2b", "body": {"id": "chatcmpl-9St6buuusI2TloSimBdWSF6NadJmd", "object": "chat.completion", "created": 1716672037, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idamycin, known generically as idarubicin, is an anthracycline antibiotic commonly used in the treatment of various types of cancer, including acute myeloid leukemia (AML). Here are some key points you should know about Idamycin:\n\n### Indications:\n- Primarily used for the induction and consolidation treatment of acute myeloid leukemia (AML) in adults.\n- Sometimes used in combination with other chemotherapeutic agents.\n\n### Mechanism of Action:\n- Idarubicin intercalates into DNA, disrupting the function of the enzyme topoisomerase II. This inhibits DNA replication and RNA synthesis, leading to cell death.\n- It also generates free radicals that cause damage to cellular components, contributing to its cytotoxic effects.\n\n### Administration:\n- Administered intravenously (IV), typically in a hospital setting due to its potent nature and need for close monitoring.\n- Dosage and schedule vary depending on the specific protocol and patient condition, but it's often given in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_moHZbYfyuVGxMV9JReAzH6Wk", "custom_id": "496_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6338b6f8284ac06897c56a63716490d2", "body": {"id": "chatcmpl-9St6bhIXYKSIoNDJmaLgMEsP2PytJ", "object": "chat.completion", "created": 1716672037, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zydelig (idelalisib) is a medication used primarily to treat certain types of blood cancers, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL), and small lymphocytic lymphoma (SLL). As a physician, you should be aware of the following key points about Zydelig:\n\n### Indications and Usage\n- **Chronic Lymphocytic Leukemia (CLL):** Zydelig is often used in combination with rituximab for patients whose cancer has relapsed.\n- **Follicular Lymphoma (FL):** It is used in patients who have received at least two prior systemic therapies.\n- **Small Lymphocytic Lymphoma (SLL):** Similar to FL, it's used for patients who have undergone multiple treatments.\n\n### Mechanism of Action\n- Zydelig is a selective inhibitor of phosphoinositide 3-kinase delta (PI3K\u03b4"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_nfuzE2IxujZCcGe0IVIRXkYD", "custom_id": "497_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "724b550e7224d3affa0de95a7c14c08b", "body": {"id": "chatcmpl-9St6bB02a9yiEF13EhDEcIxqjEyw7", "object": "chat.completion", "created": 1716672037, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Alquimid\" does not appear to be a recognized term in medical literature or practice. It might be a misspelling or a misinterpretation of a drug name, medical term, or a product. To provide accurate information, it would be helpful to clarify the context or check the spelling.\n\nIf you meant a specific medication, medical device, or treatment, please provide more details or verify the name so I can offer precise information. If \"Alquimid\" refers to a lesser-known treatment or a regional product, consulting local medical guidelines or a pharmaceutical database might be helpful.\n\nFor any medication or treatment, as a physician, it is crucial to know the following:\n1. **Indications and Usage**: Understand what conditions it treats and in which patient populations it is approved for use.\n2. **Mechanism of Action**: Know how the medication works at a biochemical or physiological level.\n3. **Dosage and Administration**: Be aware of the correct dosages, routes"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_zoD2B8eyavH8g9DTdkLM3659", "custom_id": "498_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "dee60858109da8866a41e7042892bf97", "body": {"id": "chatcmpl-9St6bO0yJPvwvTkwV1280BGWTyIl8", "object": "chat.completion", "created": 1716672037, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enliven is a brand name for the medication nintedanib, which is primarily used to treat idiopathic pulmonary fibrosis (IPF) and certain types of non-small cell lung cancer (NSCLC) in combination with other treatments. Here are some key points you should know about Enliven (nintedanib):\n\n### Mechanism of Action\n- **Nintedanib** is a tyrosine kinase inhibitor that targets multiple growth factor receptors, including those for vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF). By inhibiting these pathways, nintedanib reduces fibroblast activity, which is believed to play a critical role in the pathology of idiopathic pulmonary fibrosis.\n\n### Indications\n- **Idiopathic Pulmonary Fibrosis (IPF):** Nintedanib is approved for slowing the rate of decline in pulmonary function in patients with IPF.\n- **Non-Small Cell Lung Cancer ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_qU8GaSQmVffb5EemaRl2Ltbg", "custom_id": "499_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c82c5925632218267de3db71c2ce461b", "body": {"id": "chatcmpl-9St6bkrQls7FgichU3IWEUXUr9Usu", "object": "chat.completion", "created": 1716672037, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Truseltiq (infigratinib) is a medication that you, as a physician, may prescribe for specific cases of cancer. Here are key points you should be aware of:\n\n### Indications and Usage\n- **Truseltiq** is primarily indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) that has a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, as detected by an FDA-approved test.\n\n### Mechanism of Action\n- Truseltiq is a kinase inhibitor that targets FGFR2, a protein that can play a role in the proliferation and survival of cancer cells. By inhibiting this receptor, Truseltiq may help slow or stop the growth of cancer cells that have this genetic alteration.\n\n### Administration and Dosage\n- The typical regimen involves oral administration of Truseltiq. The dosage can vary, but it"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_pMoxZEvK2MAz8iJspbPisGnF", "custom_id": "500_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c89da6373ee0af06a18725a001e98a2e", "body": {"id": "chatcmpl-9St6brJm1lnp5PInzAd3M1R6Oijrp", "object": "chat.completion", "created": 1716672037, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Besponsa (generic name: inotuzumab ozogamicin) is a medication used primarily in the treatment of certain types of blood cancers, specifically relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). As a physician, there are several important aspects you should know about Besponsa:\n\n### Mechanism of Action\n- **Antibody-Drug Conjugate**: Besponsa is an antibody-drug conjugate (ADC) that targets CD22, a cell surface antigen expressed on B-cells. The drug comprises a monoclonal antibody linked to a cytotoxic agent, calicheamicin.\n- **Targeting and Killing Cancer Cells**: Upon binding to CD22, Besponsa is internalized by the cancer cell, where the cytotoxic agent is released to induce DNA breaks and trigger cell death.\n\n### Indications\n- **Relapsed or Refractory B-cell Precursor ALL**: Besponsa is specifically indicated for the treatment"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_0y1oRy2CrZyThStATigkJS2F", "custom_id": "501_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d9768366f3e393952b98d6d2a3fea897", "body": {"id": "chatcmpl-9St6bMwolk7gZwutlfVlaOrnXLS48", "object": "chat.completion", "created": 1716672037, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Laroferon\" does not appear to correspond to any known medical treatment, drug, or term in the current medical literature up to my knowledge cutoff in October 2023. It\u2019s possible that it could be a typographical error, a proprietary name for a product not widely recognized, or a very new drug or treatment that has not yet gained widespread recognition.\n\nIf you meant a specific medication or treatment with a similar name, I would recommend checking the most recent and reputable medical databases or resources such as PubMed, FDA, or professional medical organizations for the latest information.\n\nIf \"Laroferon\" is indeed a new or experimental treatment, staying updated through continuous medical education, attending relevant medical conferences, and consulting peer-reviewed journals would be crucial for acquiring accurate and current information. Additionally, consulting with a pharmacist or a specialist in the relevant field could provide further insights."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 42, "completion_tokens": 175, "total_tokens": 217}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_v18dlgHn1kdkHxlhAwXBhNEo", "custom_id": "502_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "56f9cda9798d21a956d8aa063d01df64", "body": {"id": "chatcmpl-9St6bjskpzApICfjIXvkPtJUZ3biI", "object": "chat.completion", "created": 1716672037, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely known or established medical product or drug called \"Advaferon.\" It is possible that it could be a newly developed drug, a regional brand name, or a typographical error. If it's a new therapeutic agent or a drug in development, here are some general steps you should take as a physician to stay informed:\n\n1. **Literature Review:** Search for clinical studies, journal articles, and reviews about \"Advaferon\" in medical databases such as PubMed, ClinicalTrials.gov, or other reputable scientific resources.\n\n2. **Drug Information Resources:** Check recognized drug information resources like the FDA (Food and Drug Administration), EMA (European Medicines Agency), or other national regulatory bodies, as well as medical compendiums like the Physician's Desk Reference (PDR), Lexicomp, or Micromedex.\n\n3. **Consult Peers and Experts:** Discuss with colleagues or specialists in the relevant field."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_bwLwYIkHZr5CMAnZbtFlEsH3", "custom_id": "503_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2f65ba3082e9af019844cbf4c1521b2b", "body": {"id": "chatcmpl-9St6cfSzZY4GEbsWyXpryZ4kZoM4K", "object": "chat.completion", "created": 1716672038, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Actimmune (Interferon gamma-1b) is a medication used primarily in the treatment of chronic granulomatous disease (CGD) and severe, malignant osteopetrosis (SMO). As a physician, it is important to understand several key aspects of Actimmune:\n\n### Indications:\n1. **Chronic Granulomatous Disease (CGD):** Actimmune helps reduce the frequency and severity of serious infections associated with CGD.\n2. **Severe Malignant Osteopetrosis (SMO):** It is used to delay disease progression in patients with SMO.\n\n### Mechanism of Action:\n- Actimmune is a recombinant form of interferon gamma, a cytokine that plays a role in immune response regulation. It enhances the oxidative metabolism of phagocytes, which helps in killing certain bacteria and fungi.\n\n### Administration:\n- Actimmune is administered via subcutaneous injection.\n- The typical dosage for CGD and SMO is 50 mcg/m\u00b2"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_p5UQDrZDpRmdFpysIROerPL8", "custom_id": "504_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "4705f9801a5b59e0b3d5605253611e53", "body": {"id": "chatcmpl-9St6cRrFkmierr4UoB0ZCKCFlWPsG", "object": "chat.completion", "created": 1716672038, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Yervoy (ipilimumab) is an immune checkpoint inhibitor used primarily in the treatment of certain types of cancer, including melanoma, renal cell carcinoma, and colorectal cancer, among others. Here are some key points you should know about Yervoy:\n\n### Mechanism of Action:\n- **Ipilimumab** is a monoclonal antibody that targets CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), a protein receptor that downregulates the immune system.\n- By inhibiting CTLA-4, Yervoy enhances T-cell activation and proliferation, thereby boosting the body's immune response against cancer cells.\n\n### Indications:\n- **Unresectable or Metastatic Melanoma**: Often used as monotherapy or in combination with nivolumab (another immune checkpoint inhibitor).\n- **Renal Cell Carcinoma**: Used in combination with nivolumab for first-line treatment of advanced cases.\n- **Colorectal Cancer**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_WONmX7mnPeRR1GbxRYtNqOqo", "custom_id": "505_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "4c72d2bc01904bf73dbaad1a8d5138e4", "body": {"id": "chatcmpl-9St6ckKrLLHkJjvENrg1c0fb52CNP", "object": "chat.completion", "created": 1716672038, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a slight misspelling, as there is no widely recognized drug named \"Axinotecan.\" You might be referring to \"Irinotecan,\" a chemotherapy medication used primarily to treat cancers such as colorectal cancer. Here are some key points about Irinotecan that you, as a physician, should know:\n\n### Mechanism of Action:\n- **Topoisomerase I Inhibitor**: Irinotecan inhibits the enzyme topoisomerase I, which is essential for DNA replication. By doing so, it prevents proper DNA unwinding, leading to breaks in the DNA strands and ultimately causing cell death, particularly in rapidly dividing cancer cells.\n\n### Indications:\n- **Colorectal Cancer**: Often used in combination with other chemotherapy agents (e.g., fluorouracil and leucovorin) for the treatment of metastatic colorectal cancer.\n- **Other Cancers**: May be used off-label for other types of cancers, such as gastric"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_aqHMNNDTxELo90GP1k6j60Vu", "custom_id": "506_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0445dca1cd2226d2696622e87be825ab", "body": {"id": "chatcmpl-9St6cJZnPV1WYtY7svODdqrJxEUO3", "object": "chat.completion", "created": 1716672038, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Onivyde (irinotecan liposome injection) is a chemotherapy medication used specifically for the treatment of metastatic pancreatic cancer. Here are key points you should know about Onivyde:\n\n1. **Indication**:\n   - Onivyde is indicated in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.\n\n2. **Mechanism of Action**:\n   - Onivyde is a liposomal formulation of irinotecan. Irinotecan is a topoisomerase I inhibitor, which works by interfering with the DNA replication process in cancer cells, leading to cell death.\n\n3. **Dosage and Administration**:\n   - The recommended dose of Onivyde is 70 mg/m\u00b2, administered as an intravenous infusion over 90 minutes every two weeks. This is given in combination with leucovorin "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_WSLsr2f9izJGU4RyAH4U4KvE", "custom_id": "507_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "756c229173a958f0e064157827c5c0b6", "body": {"id": "chatcmpl-9St6cIbg21Tzuft0uFVAzIbGcC0MI", "object": "chat.completion", "created": 1716672038, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sarclisa (generic name: isatuximab-irfc) is a monoclonal antibody medication used in the treatment of multiple myeloma, a type of blood cancer. Here are some key points you should know as a physician:\n\n### Indications\n- **Multiple Myeloma:** Sarclisa is indicated for use in combination with other therapies for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.\n\n### Mechanism of Action\n- **CD38 Targeting:** Sarclisa targets a specific protein called CD38 found on the surface of multiple myeloma cells. By binding to CD38, Sarclisa helps the immune system kill these cancer cells.\n\n### Administration\n- **Intravenous Infusion:** Sarclisa is administered as an intravenous (IV) infusion. The infusion schedule typically starts with weekly doses followed by biweekly doses.\n- **Premedication:** Patients often require premedication with corticosteroids, ant"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_CG4yzXJyBca2QnykeeQamwrm", "custom_id": "508_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "aba5a4cd7fd93c2ff37ba006948ce423", "body": {"id": "chatcmpl-9St6c7CoVr28KPzskO3BKEIsY9PUj", "object": "chat.completion", "created": 1716672038, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Absorica (isotretinoin) is an oral medication primarily used to treat severe recalcitrant nodular acne that hasn't responded to other treatments, such as antibiotics. Here are the key points you should know about Absorica:\n\n### Mechanism of Action\n- **Isotretinoin**: It's a retinoid, meaning it is related to vitamin A. It works by reducing sebaceous gland size and sebum production, inhibiting the growth of acne-causing bacteria, and reducing inflammation.\n\n### Indications\n- **Severe Acne**: Indicated for severe nodular acne that is resistant to other forms of treatment.\n- **Off-Label Uses**: Sometimes used off-label for other dermatologic conditions, such as rosacea, but these uses are less common.\n\n### Dosage and Administration\n- **Dosing**: Typically, the dose ranges from 0.5 to 1 mg/kg/day, divided into two doses with food. The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_j3dgYPfrB13vxJDFRf5Al6eV", "custom_id": "509_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "804ef48dca2a71337b9e1b34538ea8b4", "body": {"id": "chatcmpl-9St6c4Rx6EmOyfc8Bgw7zVMzKBRLU", "object": "chat.completion", "created": 1716672038, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's crucial to be well-informed about Tibsovo (ivosidenib), especially if you are considering it for treating patients with specific types of cancer. Here are key points you should know:\n\n### Indications and Usage\n- **Tibsovo (ivosidenib)** is an oral medication primarily used to treat adults with acute myeloid leukemia (AML) that have a susceptible isocitrate dehydrogenase-1 (IDH1) mutation.\n- It is indicated for patients with relapsed or refractory AML, and for patients with newly diagnosed AML who are 75 years or older or have comorbidities precluding the use of intensive induction chemotherapy.\n\n### Mechanism of Action\n- Ivosidenib is an inhibitor of the IDH1 enzyme, which is involved in cellular metabolism. Mutations in the IDH1 gene can lead to the production of an oncometabolite, 2-hydroxyglutarate (2-HG),"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_yNBViLIzzBDMf3r2GvyrXRSb", "custom_id": "510_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "46ca82d76a733458dc6defeeb4281186", "body": {"id": "chatcmpl-9St6dRrxenPTAQvhOCHrsEO2qlhSy", "object": "chat.completion", "created": 1716672039, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ixempra (ixabepilone) is a chemotherapy medication used primarily for the treatment of metastatic or locally advanced breast cancer, particularly in patients who have not responded to other treatments. Here's what you should know about Ixempra:\n\n### Mechanism of Action\nIxempra is a microtubule inhibitor. It works by stabilizing microtubules and thereby inhibiting cell division, which leads to cell death. It is similar to taxanes but is effective even against tumors that are resistant to taxanes.\n\n### Indications\n- **Metastatic or Locally Advanced Breast Cancer:** Ixempra is approved for use in patients with metastatic or locally advanced breast cancer that is resistant to anthracyclines, taxanes, and capecitabine.\n- **Combination Therapy:** It is often used in combination with capecitabine for patients who have not responded to other treatments.\n\n### Administration\n- **Form:** Ixempra is administered intravenously.\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_VCSoeWXpel6gcBDkqSeQx8AJ", "custom_id": "511_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "4980dc34e006c89262e0e501cfe52cfb", "body": {"id": "chatcmpl-9St6dImz7NgccvHR9Dfa8Qm0Zj3Of", "object": "chat.completion", "created": 1716672039, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ninlaro (generic name: ixazomib) is an oral proteasome inhibitor used in the treatment of multiple myeloma, a type of cancer that affects plasma cells. It's important for physicians to understand the following key points about Ninlaro:\n\n1. **Indication**: Ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.\n\n2. **Mechanism of Action**: Ixazomib inhibits the 20S proteasome, a component of the proteasome complex responsible for degrading ubiquitinated proteins, leading to cell cycle arrest and apoptosis in myeloma cells.\n\n3. **Dosage and Administration**:\n    - **Dosage**: The recommended dose is 4 mg taken orally once a week on Days 1, 8, and 15 of a 28-day treatment cycle.\n    - **Administration**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_nlEpTuiGDLLyeySwtxNtUn6F", "custom_id": "512_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "7f80e60eff1a1543c918db15d0aec0d4", "body": {"id": "chatcmpl-9St6d66MG21YcYzd76hIitrOTAykP", "object": "chat.completion", "created": 1716672039, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nizoral is a brand name for the antifungal medication ketoconazole. It's important for a physician to understand several key aspects about this drug:\n\n### Indications:\n- **Topical Nizoral**: It's commonly used to treat fungal infections of the skin, such as seborrheic dermatitis, tinea corporis (ringworm), tinea cruris (jock itch), tinea pedis (athlete's foot), and tinea versicolor.\n- **Oral Nizoral**: This form can be used for systemic fungal infections, but its use is limited due to potential severe side effects and the availability of safer alternatives.\n\n### Mechanism of Action:\n- Ketoconazole works by inhibiting the synthesis of ergosterol, a critical component of fungal cell membranes, thereby disrupting cell membrane integrity and leading to cell death.\n\n### Dosage and Administration:\n- **Topical**: Typically applied once or twice daily to the affected area. Duration of treatment can vary depending"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_yi303BN61GEC2Bv8CNfgUHLX", "custom_id": "513_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "221d9d17b52b452364993971b7de997b", "body": {"id": "chatcmpl-9St6dU9T9G0tUCBpyOsgmmjV66GCW", "object": "chat.completion", "created": 1716672039, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have comprehensive knowledge about Ipstyl (Octreotide), a medication primarily used to treat symptoms associated with certain types of tumors and hormonal disorders. Here are some key points you should know:\n\n### Mechanism of Action\n- **Octreotide** is a synthetic analog of somatostatin, a hormone that inhibits the release of several other hormones and substances.\n- **Primary Actions**: Reduces the secretion of growth hormone, insulin, glucagon, and certain gastrointestinal peptides like gastrin, vasoactive intestinal peptide (VIP), and serotonin.\n\n### Indications\n- **Acromegaly**: Used to reduce growth hormone levels and alleviate symptoms in patients who have not responded to surgery or radiation.\n- **Carcinoid Tumors**: Helps manage symptoms like flushing and diarrhea caused by hormone-secreting tumors.\n- **VIPomas**: Treats severe watery diarrhea associated with Vasoactive Intestinal Peptide-secreting tumors.\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_SFHPDH6j8vXWrhB430VNcmBL", "custom_id": "514_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "25adc217768ff474ae8052f3150988ac", "body": {"id": "chatcmpl-9St6dI2V913fQm3usCRIVLKjlUt7H", "object": "chat.completion", "created": 1716672039, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prevacid is a brand name for the drug lansoprazole, which is a proton pump inhibitor (PPI). Here are some key points you should know about Prevacid as a physician:\n\n### Indications:\n1. **Gastroesophageal Reflux Disease (GERD):** Prevacid is commonly used to treat and manage GERD, reducing symptoms and healing esophagitis.\n2. **Peptic Ulcer Disease (PUD):** It helps in the treatment of gastric and duodenal ulcers.\n3. **Erosive Esophagitis:** Used to promote healing of erosive esophagitis.\n4. **Zollinger-Ellison Syndrome:** Used in the management of pathological hypersecretory conditions.\n5. **Helicobacter pylori Eradication:** Often used in combination with antibiotics for the eradication of H. pylori.\n\n### Mechanism of Action:\n- Lansoprazole works by inhibiting the hydrogen-potassium ATP"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_0BWaFBYDMcqn0w6IIZy6xuBY", "custom_id": "515_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "12f972c15dc82eebe0dfe8e9969cdd01", "body": {"id": "chatcmpl-9St6eWGVRnUQwIO0GoU5f6tdsYrNh", "object": "chat.completion", "created": 1716672040, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It appears there might be some confusion with the term \"Abnib,\" as it does not correspond to any well-known medical term, medication, or condition in standard medical literature as of my last update in October 2023. It is possible that \"Abnib\" could be a typographical error or a colloquial term not widely recognized in the medical community.\n\nTo provide accurate advice, I would need more context or clarification. Here are a few steps you could take:\n\n1. **Verify the Term**: Double-check the spelling and context in which you encountered \"Abnib.\" It might be a misspelling of a medical term or drug name.\n\n2. **Contextual Information**: Provide additional details about where you encountered the term. For instance, was it in a patient's medical history, a research paper, or a conversation with a colleague?\n\n3. **Consult Reliable Sources**: If you have access to medical databases, clinical guidelines, or a network of colleagues, you"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_1JtXpvML5VJONsoB3sX3C6bF", "custom_id": "516_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "63bdce549655ec6c441014a67df8b003", "body": {"id": "chatcmpl-9St6euaxm8T5IWNZ6IDfjvo3dO3jA", "object": "chat.completion", "created": 1716672040, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vitrakvi, known generically as larotrectinib, is a targeted cancer therapy that you should be familiar with for the treatment of certain types of cancers. Here are some key points you should know:\n\n### 1. Mechanism of Action:\n- **Targeted Therapy:** Vitrakvi is a TRK (tropomyosin receptor kinase) inhibitor. It specifically targets and inhibits TRK fusion proteins, which are the result of genetic alterations where the NTRK genes (NTRK1, NTRK2, NTRK3) fuse with other unrelated genes.\n- **Oncogenic Driver:** These TRK fusions act as oncogenic drivers in various types of tumors, leading to uncontrolled cell growth.\n\n### 2. Indications:\n- **Tumor-Agnostic Approval:** Vitrakvi is one of the first drugs approved by the FDA based on a common biomarker rather than the location of the tumor. It is approved for the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_VTa1IcIZvCmiyibvPAk59aWW", "custom_id": "517_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f41de36b5996f29634d56f67c7436b80", "body": {"id": "chatcmpl-9St6eecLIEa3zAULcSGYQ6VhJ47bl", "object": "chat.completion", "created": 1716672040, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there isn't any widely known medical substance, condition, or pharmaceutical called \"Adlinod.\" It's possible that \"Adlinod\" could be a typographical error or a placeholder name for a drug or condition that isn't well-documented in medical literature up to that point.\n\nIf \"Adlinod\" is a new or emerging term, I recommend checking the latest medical journals, clinical trial databases, or professional medical resources for any recent updates or publications. Additionally, consulting with colleagues or professional networks might provide insights if it's something new or under investigation.\n\nIf you meant a different term or need information on a specific condition, medication, or medical topic, please provide more details so I can assist you more effectively."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 152, "total_tokens": 193}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_WcFxCEJJoT7KuPeMuY7e39l7", "custom_id": "518_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e4f410f445c63278e24ffe9e090a0aaf", "body": {"id": "chatcmpl-9St6eTAWEgchN8ZetTCUo1azu62fy", "object": "chat.completion", "created": 1716672040, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Granocyte is a brand name for lenograstim, a granulocyte colony-stimulating factor (G-CSF) used to stimulate the production of white blood cells, particularly neutrophils. It is commonly used in clinical settings to manage neutropenia, which can occur as a result of chemotherapy, bone marrow transplantation, or other medical conditions. Here are some key points you should know about Granocyte as a physician:\n\n### Indications:\n1. **Chemotherapy-induced Neutropenia**: To reduce the duration of severe neutropenia and the incidence of febrile neutropenia in patients undergoing myelosuppressive chemotherapy.\n2. **Bone Marrow Transplantation**: To promote engraftment and recovery of neutrophil counts.\n3. **Peripheral Blood Progenitor Cell (PBPC) Mobilization**: To mobilize hematopoietic progenitor cells into the peripheral blood for collection and subsequent autologous or allogeneic transplantation.\n4."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_NiDKaTWLdr1wBtoDMb6VQyOo", "custom_id": "519_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8febb323128ff1a81b8573a885fcddf6", "body": {"id": "chatcmpl-9St6euJz5TLWPUnvvKZIkCDW0Rv3S", "object": "chat.completion", "created": 1716672040, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kisplyx (generic name: lenvatinib) is a tyrosine kinase inhibitor that is used in combination with everolimus for the treatment of advanced renal cell carcinoma (RCC) in patients who have received prior anti-angiogenic therapy. Here are some key points you should know about Kisplyx:\n\n### Mechanism of Action\n- Lenvatinib inhibits multiple receptor tyrosine kinases (RTKs), including vascular endothelial growth factor (VEGF) receptors, which play a critical role in tumor angiogenesis, and other RTKs involved in tumor proliferation.\n\n### Indications\n- Approved in combination with everolimus for the treatment of patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy.\n\n### Dosage and Administration\n- The recommended dose of Kisplyx is 18 mg (one 10 mg capsule and two 4 mg capsules) taken orally once daily in combination with 5 mg of everolimus taken orally once daily"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_I5nO1Wfo8zAj3IlpdDffNL9D", "custom_id": "520_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5a921b1e00348c1ce6a1ae1706f5067c", "body": {"id": "chatcmpl-9St6e9hamzwe0qMV1FVDT8z6tZKTz", "object": "chat.completion", "created": 1716672040, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Femara, also known by its generic name letrozole, is a medication primarily used in the treatment of hormone receptor-positive breast cancer. Here are some important points you should know about Femara:\n\n### Indications:\n1. **Breast Cancer**: Femara is mainly prescribed for postmenopausal women with hormone receptor-positive early breast cancer, advanced breast cancer, or metastatic breast cancer.\n2. **Fertility Treatment**: Off-label, letrozole is sometimes used to stimulate ovulation in women with polycystic ovary syndrome (PCOS) or unexplained infertility.\n\n### Mechanism of Action:\n- Femara is an aromatase inhibitor. It works by decreasing the amount of estrogen produced in the body. Since some breast cancers grow in response to estrogen, lowering estrogen levels can slow the growth of these cancers.\n\n### Dosage and Administration:\n- The typical dose for breast cancer treatment is 2.5 mg taken once daily, with or without food.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_cFHEPhpI9p8iNMOeLcvxLZKo", "custom_id": "521_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b204795d4f67518ce29ecbc6ec82f151", "body": {"id": "chatcmpl-9St6eHeWKub1qlu1eC6i4ohBFflG7", "object": "chat.completion", "created": 1716672040, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Camcevi (leuprolide mesylate) is a medication used primarily in the treatment of advanced prostate cancer. It is a gonadotropin-releasing hormone (GnRH) agonist, which means it works by initially stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a temporary increase in testosterone levels. However, with continued use, it ultimately suppresses the production of these hormones, resulting in decreased testosterone levels, which helps slow the growth of prostate cancer.\n\nHere are some key points you should know about Camcevi:\n\n1. **Indications**: Camcevi is indicated for the palliative treatment of advanced prostate cancer. It is not a curative treatment but helps manage symptoms and progression.\n\n2. **Mechanism of Action**: As a GnRH agonist, Camcevi causes an initial surge in LH and FSH levels, leading to a temporary increase in testosterone. Continued administration leads"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Svww1SHx4q874TCOrB0k9OrI", "custom_id": "522_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2b0804774c9b4bb59e24752a1d609e87", "body": {"id": "chatcmpl-9St6fjg6ds6W1ZLWqzBf4gLajev6u", "object": "chat.completion", "created": 1716672041, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ergamisol, also known as levamisole, is a medication that has various uses but also significant concerns, particularly regarding its safety profile. Here are some key points you should know about it:\n\n### Uses\n1. **Anthelmintic Agent**: Originally, levamisole was used as an anthelmintic to treat parasitic worm infections in animals and humans.\n2. **Immunomodulatory Drug**: It has been used as an immunomodulatory agent, particularly in the past for conditions like rheumatoid arthritis and as an adjuvant therapy in colorectal cancer to enhance immune response.\n\n### Mechanism of Action\nLevamisole works by stimulating the immune system, although the exact mechanism is not completely understood. It also interferes with the energy metabolism of parasites, contributing to its anthelmintic properties.\n\n### Adverse Effects\n1. **Hematologic Toxicity**: Levamisole has been associated with agranulocytosis and neutrop"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_aW55F6bRij0hJUmnsgBDXFAB", "custom_id": "523_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "dc241002c8bd6632edc821acbd2c290f", "body": {"id": "chatcmpl-9St6fO8vCYyhSNAQFQTYD3ppgIHmG", "object": "chat.completion", "created": 1716672041, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fusilev, known generically as levoleucovorin, is a chemotherapeutic agent that is used primarily in the context of cancer treatment. Here are some key points a physician should know about Fusilev:\n\n1. **Indications**:\n   - **Methotrexate Rescue**: Fusilev is used to diminish the toxic effects of methotrexate in patients who have received high doses of methotrexate or in those who have impaired methotrexate elimination.\n   - **Combination Therapy**: It is also used in combination with 5-fluorouracil (5-FU) for the palliative treatment of patients with advanced metastatic colorectal cancer.\n\n2. **Mechanism of Action**:\n   - Fusilev is the active enantiomer of leucovorin (folinic acid) and works by rescuing normal cells from the toxic effects of methotrexate by replenishing reduced folate pools. When used with 5"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_vM7JDY6FnaJfZ3WqvYovRR8l", "custom_id": "524_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "762b556a1828a217e21065b1fd75ab73", "body": {"id": "chatcmpl-9St6fe9hDyrS2eSODDOKCNxSO065Y", "object": "chat.completion", "created": 1716672041, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "CeeNu, also known by its generic name lomustine, is an alkylating agent used primarily in chemotherapy. As a physician, here are key points you should know about CeeNu:\n\n### Indications:\n- **Primary Use:** CeeNu is primarily used to treat certain types of cancer, including brain tumors (primary and metastatic), Hodgkin's lymphoma, and other malignancies.\n- **Off-label Uses:** Occasionally used for other cancers as part of combination chemotherapy protocols.\n\n### Mechanism of Action:\n- **Alkylating Agent:** Lomustine works by alkylating DNA and RNA, leading to cross-linking and strand breaks, which ultimately inhibits DNA replication and transcription. This results in cell cycle arrest and apoptosis (cell death).\n\n### Administration:\n- **Oral Drug:** CeeNu is administered orally, typically in capsule form.\n- **Dosing Interval:** It is usually given once every 6 weeks to allow for bone marrow recovery due to its my"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Ns5OKA7dkgwwTj7ECg3b103n", "custom_id": "525_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e851e8cb4a895db9a6cc5bea0215eff7", "body": {"id": "chatcmpl-9St6fQx0FVJBZmCm1O0KwjTeJHhQb", "object": "chat.completion", "created": 1716672041, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lorbrena (generic name: lorlatinib) is a medication used in the treatment of non-small cell lung cancer (NSCLC). It is specifically designed for patients whose tumors are anaplastic lymphoma kinase (ALK)-positive, which means that their cancer cells have a specific genetic mutation involving the ALK gene.\n\nHere are some key points you should know about Lorbrena as a physician:\n\n### Indications:\n- **Lorbrena** is indicated for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to prior ALK inhibitor therapy.\n\n### Mechanism of Action:\n- **Lorlatinib** is a tyrosine kinase inhibitor that targets ALK and ROS1, blocking the activity of these proteins which are involved in the growth and spread of cancer cells.\n\n### Dosage and Administration:\n- The typical starting dose is **100 mg orally once daily**.\n- It can be taken with or without food.\n- Tablets should be swallowed whole"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_K76lVIUcCOt2vERj6tzW224W", "custom_id": "526_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f171dfdfc97e0fc8944f22c6022f8056", "body": {"id": "chatcmpl-9St6flthMpH9crydEkmfVia8XwgUA", "object": "chat.completion", "created": 1716672041, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lutathera, or ^177Lutetium-DOTATATE, is a radiopharmaceutical used for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Here\u2019s a summary of key information that you should know as a physician:\n\n### Indications:\n- **Lutathera** is indicated for the treatment of adults with somatostatin receptor-positive GEP-NETs, including foregut, midgut, and hindgut neuroendocrine tumors.\n\n### Mechanism of Action:\n- **Lutathera** is a peptide receptor radionuclide therapy (PRRT) that binds to somatostatin receptors, which are often overexpressed on neuroendocrine tumor cells. Once bound, the radiolabeled peptide is internalized, delivering beta radiation directly to the tumor cells, causing cellular damage and death.\n\n### Administration:\n- **Dosage**: The typical dose is "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_de3Z15LKhsf1Dw4mSnF0wncN", "custom_id": "527_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d07a47401b6c5a1efd8774d15ebae2ab", "body": {"id": "chatcmpl-9St6fRd8FqHBpVV2SN7gqiyd2NmYv", "object": "chat.completion", "created": 1716672041, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Minjuvi (tafasitamab-cxix) is a prescription medication used in the treatment of certain types of cancer. Specifically, it is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. Here are some key points you should know about Minjuvi:\n\n### Indications:\nMinjuvi is primarily indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low-grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).\n\n### Mechanism of Action:\nMinjuvi works by targeting the CD19 antigen, a protein expressed on the surface of B-cells. By binding to CD19, Minjuvi promotes the destruction of these B-cells through antibody-dependent cell-mediated cytotoxicity (ADCC) and other immune-mediated mechanisms.\n\n### Administration:\n- **Formulation:** Minjuvi is available as an intravenous"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_CBGaoWMqUBxrGmK4hKXfnwEK", "custom_id": "528_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a4227067365d1484e80935ed19893708", "body": {"id": "chatcmpl-9St6gwGillorI9KbZtJWSER1eiEg8", "object": "chat.completion", "created": 1716672042, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Ledaga (chlormethine gel) to ensure its safe and effective use in your patients. Here are key points you should be aware of:\n\n### Indications:\n- **Ledaga** is primarily indicated for the treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in patients who have received prior skin-directed therapy.\n\n### Mechanism of Action:\n- **Chlormethine (mechlorethamine)** is an alkylating agent that works by cross-linking DNA strands, thereby inhibiting DNA replication and transcription, leading to cell death. It is used topically in gel form to target cutaneous lesions.\n\n### Dosage and Administration:\n- **Application**: A thin layer of gel should be applied once daily to the affected areas of the skin.\n- **Instructions**: Patients should apply the gel to clean, dry skin, and should wash their hands thoroughly after"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_c5YQSTa2FBGNtAyF4wY4m4EN", "custom_id": "529_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d419b12893ad4121418de3200f099df2", "body": {"id": "chatcmpl-9St6grGYT24NldN4TwgYYhQTS69kP", "object": "chat.completion", "created": 1716672042, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Depo-Provera, also known as medroxyprogesterone acetate, is a long-acting injectable contraceptive that is commonly used for birth control. Here are some key points you should know about Depo-Provera:\n\n### Mechanism of Action:\n- Depo-Provera works primarily by inhibiting ovulation. It also thickens cervical mucus, which impedes sperm penetration, and alters the endometrial lining, making it less suitable for implantation.\n\n### Administration:\n- It is administered as an intramuscular injection, typically in the buttocks or upper arm, once every 12 weeks (3 months).\n\n### Efficacy:\n- It is highly effective, with a failure rate of less than 1% with perfect use. However, typical use may have a slightly higher failure rate.\n\n### Benefits:\n- Convenience of not needing daily administration.\n- Reduced menstrual bleeding and, in some cases, amenorrhea.\n- Decreased risk of endometrial cancer.\n- Can be"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_DdqWFLQYaFDRCMrNYKnydsHZ", "custom_id": "530_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "1e6cba48cedebd81c834a8324d5440a6", "body": {"id": "chatcmpl-9St6gCqOezk9VoHxFG7Kaah8sDiOi", "object": "chat.completion", "created": 1716672042, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized drug or medical treatment known as \"Maygace.\" It is possible that this could be a typographical error, a newly developed medication, a brand name not widely known, or a specific treatment used in a particular region or country.\n\nIf \"Maygace\" is a new or emerging treatment, here are general steps you can take to gather more information:\n\n1. **Consult Medical Databases**: Check reputable medical databases like PubMed, Medline, or clinical trial registries for any mentions of \"Maygace.\"\n\n2. **Manufacturer Information**: If it's a newly developed drug, information from the pharmaceutical company that manufactures it will be valuable.\n\n3. **Medical Conferences and Journals**: Keep an eye on recent publications and presentations at medical conferences.\n\n4. **Professional Networks**: Engage with professional networks or medical associations that might have the latest information on new treatments.\n\n5. **Pharmacy Resources"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_HDHYlb3DEtjMXkQ2JziIxclO", "custom_id": "531_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8c34fef8c168bdfbea6b4d2de9af4fc6", "body": {"id": "chatcmpl-9St6ggUElUjFsLqSY80lznw03wA0H", "object": "chat.completion", "created": 1716672042, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alkeran, also known by its generic name melphalan, is an alkylating agent used primarily in the treatment of multiple myeloma and ovarian cancer. Here are some key points you should be aware of:\n\n### Indications:\n1. **Multiple Myeloma**: It is often used in combination with other medications, such as prednisone, for treating multiple myeloma.\n2. **Ovarian Cancer**: It is used as a palliative treatment for epithelial ovarian cancer.\n\n### Mechanism of Action:\nAlkeran works by cross-linking DNA strands, which inhibits DNA synthesis and RNA transcription. This leads to cell death, particularly in rapidly dividing cells such as cancer cells.\n\n### Administration:\n- **Oral Form**: Usually taken on an empty stomach, at least one hour before or two hours after eating.\n- **Intravenous Form**: Administered by healthcare professionals, dosage and schedule depend on the specific condition being treated and patient response.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_7fMDrNMZpncJ9zW7VcXCLuuz", "custom_id": "532_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0e6936bcea9c73b46a5ca1f2dd5b0235", "body": {"id": "chatcmpl-9St6gBg75wd2JKJuQXinvHm9PsEUg", "object": "chat.completion", "created": 1716672042, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Purinethol, also known by its generic name mercaptopurine, is an important medication primarily used in the treatment of certain types of cancer, particularly acute lymphoblastic leukemia (ALL). Here are some critical points you should know about Purinethol:\n\n### Mechanism of Action:\n- **Antimetabolite:** Mercaptopurine is a purine analog that interferes with DNA and RNA synthesis.\n- **Cytotoxic:** It inhibits the proliferation of cancer cells by incorporating into their nucleic acids, disrupting their function and leading to cell death.\n\n### Indications:\n- **Acute Lymphoblastic Leukemia (ALL):** Used as part of combination chemotherapy regimens.\n- **Chronic Myeloid Leukemia (CML):** Sometimes used, though less commonly.\n- **Crohn's Disease and Ulcerative Colitis:** Occasionally used off-label for its immunosuppressive effects.\n\n### Dosage:\n- **Individualized:** Dosage often depends on"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_x3XPZrI12U1Jfj1sJpWHfPdj", "custom_id": "533_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f43eb129924623cd204755f8e9c9b2a6", "body": {"id": "chatcmpl-9St6gmZE1WSTVR02yhwco0ZaGicZ9", "object": "chat.completion", "created": 1716672042, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a typo or some confusion regarding \"Anti Uron.\" As of my knowledge cutoff in October 2023, there is no widely recognized medication or medical treatment by that name. It's possible that the term could be misspelled, misremembered, or a brand name not widely known or used.\n\nTo provide accurate information, it would be helpful to double-check the name or provide a bit more context about what \"Anti Uron\" is supposed to be or treat. If it\u2019s a new medication, you might want to consult recent medical literature, pharmaceutical databases, or contact a pharmacist for up-to-date information.\n\nIf you have more details or another name for the drug or treatment in question, feel free to share!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 150, "total_tokens": 191}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_WJQguIqQ2sPteNXKF82n5DQm", "custom_id": "534_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "4ef99ddca9fc0cc6c2810c5a7071006f", "body": {"id": "chatcmpl-9St6gcM5izMVpOc0tFut9cjN6HCdk", "object": "chat.completion", "created": 1716672042, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abitrexate is a brand name for methotrexate, a medication with a wide range of uses. Here are key points you should know about it:\n\n### Indications:\n1. **Cancer Treatment**: Methotrexate is used in higher doses to treat certain cancers, including leukemia, lymphoma, breast cancer, lung cancer, and osteosarcoma.\n2. **Autoimmune Diseases**: In lower doses, it is commonly used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn's disease.\n3. **Ectopic Pregnancy**: It can be used to manage ectopic pregnancies in certain cases.\n\n### Mechanism of Action:\nMethotrexate is an antimetabolite and antifolate drug. It inhibits the enzyme dihydrofolate reductase (DHFR), which is crucial for DNA synthesis, repair, and cellular replication. This inhibition affects rapidly dividing cells, such as cancer cells and cells involved in inflammatory processes.\n\n### Administration:\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ctd5JprEe4QGWqLeT3Fz5sUS", "custom_id": "535_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e3308240f637deadcc7b60fafb6d0d81", "body": {"id": "chatcmpl-9St6hE7gez9vhUNqmvYHTOsaGsxkk", "object": "chat.completion", "created": 1716672043, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, here are some key points you should know about Ammoidin:\n\n1. **Active Ingredient**: Ammoidin is a medication that contains the active ingredient psoralen, which is a naturally occurring substance found in various plants.\n\n2. **Mechanism of Action**: Psoralen works by making the skin more sensitive to ultraviolet (UV) light. When combined with UV light therapy (UVA), it can help to treat certain skin conditions by slowing down the growth of skin cells and reducing inflammation.\n\n3. **Indications**: Ammoidin is primarily used in the treatment of skin conditions such as psoriasis, vitiligo, and eczema. It is often used in conjunction with UVA light therapy (PUVA therapy).\n\n4. **Administration**: Ammoidin can be administered orally in tablet form or topically as a lotion or cream, depending on the specific condition being treated and the preferred method of administration.\n\n5. **Dosage and Treatment Protocol**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ACLOyKsqf5YNR6B3GPp07ALJ", "custom_id": "536_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0cf818e708156beda8d421ea8e86fc73", "body": {"id": "chatcmpl-9St6hRLCGyCwQfnDeC1G1S3FKONav", "object": "chat.completion", "created": 1716672043, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adlone is a brand name for corticotropin, a medication used primarily for its anti-inflammatory and immunosuppressant properties. Here are some key points you should know about Adlone:\n\n### Indications and Uses\n1. **Adrenocorticotropic Hormone (ACTH) Deficiency**: Adlone stimulates the adrenal cortex to secrete cortisol, corticosterone, and other steroids.\n2. **Diagnostic Testing**: Used in the diagnostic testing of adrenocortical function.\n3. **Inflammatory and Autoimmune Conditions**: It can be used in the treatment of a variety of conditions such as rheumatoid arthritis, multiple sclerosis, and certain types of nephrotic syndrome.\n\n### Mechanism of Action\n- **Stimulates the Adrenal Cortex**: Adlone acts on the adrenal cortex to stimulate the production and release of cortisol, aldosterone, and other corticosteroids.\n- **Anti-inflammatory and Immunosuppressive Effects**: By increasing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_lpq7MXaC5QVuwzATvf3ce5Ct", "custom_id": "537_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "491c4f193eb521e91d90784959a43ee8", "body": {"id": "chatcmpl-9St6hT60KO9Xj9jyTR5Ytji6FXlde", "object": "chat.completion", "created": 1716672043, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rydapt (midostaurin) is an oral multi-kinase inhibitor used in the treatment of certain types of cancer. Here are some key points that you, as a physician, should be aware of:\n\n### Indications:\n1. **Acute Myeloid Leukemia (AML)**:\n   - Rydapt is used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy for adults with newly diagnosed FLT3-mutated AML.\n   - It's essential to confirm the presence of FLT3 mutation through appropriate testing before initiating treatment.\n\n2. **Systemic Mastocytosis**:\n   - It is indicated for adults with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).\n\n### Mechanism of Action:\n- Midostaurin inhibits multiple receptor tyrosine kinases, including FLT3 and KIT, which are involved in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_b8jO30lbfMGaSc0SDB44mJhk", "custom_id": "538_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "457436ca875e0250c8e88f857b8162c3", "body": {"id": "chatcmpl-9St6hV4M64thc77mBeGWlIqZPvldN", "object": "chat.completion", "created": 1716672043, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Lyomit\" doesn't correspond to any widely recognized medication or medical term as of my latest update in October 2023. It's possible that it could be a brand name, a new drug, or a term specific to a certain region or specialty that hasn't become widely known yet.\n\nHowever, if you meant a specific medication or medical term that sounds similar to \"Lyomit,\" here are a few steps you can take to find accurate information:\n\n1. **Check Drug Databases:** Utilize professional resources such as UpToDate, Micromedex, or the FDA database to search for the term.\n2. **Consult Pharmacists:** Pharmacists often have extensive knowledge about medications, including brand names and newly released drugs.\n3. **Medical Literature:** Search PubMed or other medical journals for any studies or articles mentioning \"Lyomit.\"\n4. **Professional Networks:** Reach out to colleagues or professional networks for any insights or information they might have.\n\nIf you have more specific details or context about \"Ly"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_UsUeVoVeKuj1DaVndWzjzLhC", "custom_id": "539_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b3f0c334f6829742ff971f08e800ffcd", "body": {"id": "chatcmpl-9St6hUhtNaHIFZVRsqUwJolecWLwc", "object": "chat.completion", "created": 1716672043, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lysodren (generic name: mitotane) is a medication primarily used in the treatment of adrenocortical carcinoma, a rare cancer of the adrenal glands. Here are some key points you should know about Lysodren:\n\n### Indications:\n- **Adrenocortical Carcinoma:** Lysodren is indicated for the treatment of inoperable, functional, or nonfunctional adrenocortical carcinoma.\n- **Cushing's Syndrome:** It can also be used off-label for managing Cushing\u2019s syndrome due to adrenal carcinoma or other causes.\n\n### Mechanism of Action:\n- **Adrenolytic Activity:** Lysodren has cytotoxic effects on the adrenal cortex, leading to adrenal atrophy. It inhibits the production of adrenal steroids, reducing hormone levels.\n\n### Dosage and Administration:\n- **Individualized Dosing:** The dosage must be individualized based on the patient's response and tolerance. Initial doses typically start at 2-6 grams per day,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_n0gODNYT9lgJLYClTmE87odb", "custom_id": "540_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "1c1250e3229f34deacef19c945dcabc2", "body": {"id": "chatcmpl-9St6hs8PlB0k6zKHHsiNTiAnpmWoO", "object": "chat.completion", "created": 1716672043, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, understanding the pharmacological profile, indications, contraindications, side effects, and administration guidelines of Nitrol (generic name: nitroglycerin) is crucial. Here's a detailed overview:\n\n### **Pharmacological Profile:**\n- **Class:** Nitrate\n- **Mechanism of Action:** Nitroglycerin works by releasing nitric oxide (NO), which causes vasodilation. This results in decreased myocardial oxygen demand by reducing both preload and afterload, and it can also improve oxygen delivery to the heart by dilating coronary arteries.\n\n### **Indications:**\n- **Angina Pectoris:** Nitrol is primarily used for the treatment and prevention of angina pectoris.\n- **Heart Failure:** It can be used in acute heart failure with myocardial ischemia to reduce the workload on the heart.\n- **Hypertensive Emergencies:** Sometimes used in hypertensive emergencies, especially when there is accompanying myocardial ischemia.\n\n### **Contraindications:**\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_WJU8cT3FyrGAfSbdubw7jR8U", "custom_id": "541_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b149d0fa15cd505306203dbb1503a4f3", "body": {"id": "chatcmpl-9St6hdG8rzjFa6MaNASYhkGafgENs", "object": "chat.completion", "created": 1716672043, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Poteligeo (generic name: mogamulizumab-kpkc) is a monoclonal antibody used primarily in the treatment of certain types of lymphoma, specifically relapsed or refractory mycosis fungoides (MF) and S\u00e9zary syndrome (SS), which are subtypes of cutaneous T-cell lymphoma (CTCL). Here are some key points you should know about Poteligeo:\n\n### Mechanism of Action:\n- **CC Chemokine Receptor 4 (CCR4) Targeting:** Poteligeo works by targeting CCR4, a protein found on the surface of some cancer cells. By binding to CCR4, Poteligeo facilitates the immune system\u2019s ability to recognize and destroy these cancer cells.\n\n### Indications:\n- **Mycosis Fungoides (MF):** Poteligeo is indicated for adult patients with relapsed or refractory MF after at least one prior systemic therapy.\n- **S\u00e9zary Syndrome (SS):** It is also indicated"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_HyvWkrjTAXP1bCSYl7NtJPx2", "custom_id": "542_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "97c71267d650fa98dc7ad02267f10b7b", "body": {"id": "chatcmpl-9St6iKzPJ5LYIFKwzvZjf3l0Hkpzz", "object": "chat.completion", "created": 1716672044, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lumoxiti (moxetumomab pasudotox-tdfk) is a CD22-directed cytotoxin used for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA). Here are some key points you should know about Lumoxiti:\n\n### Mechanism of Action:\n- **Target:** Lumoxiti targets the CD22 antigen on the surface of B-cells.\n- **Cytotoxic Component:** It consists of an antibody that binds to CD22 linked to a truncated form of Pseudomonas exotoxin A, which inhibits protein synthesis leading to cell death.\n\n### Indications:\n- **Primary Use:** It is indicated for adult patients with relapsed or refractory hairy cell leukemia after at least two prior systemic therapies, including a PNA.\n\n### Administration:\n- **Route:** Lumoxiti is administered intravenously.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_hqpGT9l6UUtbJB0JJhsjg2HH", "custom_id": "543_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a359ce31b0b000d6681534cce5c337bf", "body": {"id": "chatcmpl-9St6iUe1a9IXLT5kt6bKfseYOemtb", "object": "chat.completion", "created": 1716672044, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fraxiparine, also known by its generic name nadroparin, is a low molecular weight heparin (LMWH) used primarily for its anticoagulant properties. Here are key points you should know about Fraxiparine as a physician:\n\n### Indications:\n1. **Prophylaxis of Venous Thromboembolism (VTE)**: Often used in patients undergoing surgery, especially orthopedic procedures, and in those with an increased risk of thromboembolism.\n2. **Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)**: Helps to prevent the extension of existing clots and the formation of new ones.\n3. **Acute Coronary Syndromes (ACS)**: Sometimes used in the management of unstable angina and non-Q-wave myocardial infarction.\n4. **Heparin-Induced Thrombocytopenia (HIT)**: Can be used in certain cases where patients develop HIT"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_DMoBa1TUVDpgzxwyNFjgpSFx", "custom_id": "544_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e7492c96ab326bb2ff1f62f79a0ea7ca", "body": {"id": "chatcmpl-9St6iUPEohf86yyRe8BVrHZcfefJ2", "object": "chat.completion", "created": 1716672044, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Portrazza (necitumumab) is a monoclonal antibody used in the treatment of certain types of cancer. Here are key points you should be aware of as a physician:\n\n### Indications:\n- **Non-Small Cell Lung Cancer (NSCLC):** Portrazza is primarily indicated for use in combination with gemcitabine and cisplatin for the first-line treatment of patients with metastatic squamous NSCLC.\n\n### Mechanism of Action:\n- **EGFR Inhibitor:** Portrazza targets the epidermal growth factor receptor (EGFR), which is often overexpressed in certain cancers, including squamous NSCLC. By binding to EGFR, necitumumab inhibits its activation and subsequent signaling pathways involved in cell proliferation and survival.\n\n### Administration:\n- **Intravenous Infusion:** The drug is administered via IV infusion, typically given on days 1 and 8 of each 3-week cycle, in combination with gemcitabine and cispl"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5KBZejTMB7PLbeof4YWecAEh", "custom_id": "545_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5b3bda0263fafc52ee777636c4eeebf1", "body": {"id": "chatcmpl-9St6ioeubypiHZFrgr9a7VkJzVEEN", "object": "chat.completion", "created": 1716672044, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2021, there isn't a widely recognized medication or treatment named \"Aqupla.\" It is possible that you may be referring to a brand name, a product that has been introduced after my last update, or a misspelling of another drug or treatment.\n\nHowever, if \"Aqupla\" is a new medication or treatment that has emerged after my knowledge update, I would recommend the following general steps to get up-to-date information:\n\n1. **Consult Medical Databases**: Use reputable medical databases such as PubMed, Medline, or clinical guidelines from organizations like the FDA, EMA, or your country's health authority to look up the latest information.\n\n2. **Pharmaceutical Reps**: If the drug is new, pharmaceutical representatives can provide you with the latest data, including clinical trial results, safety profiles, and usage guidelines.\n\n3. **Continuing Medical Education (CME)**: Participate in CME courses or seminars that may cover new treatments and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_UPtFN2PJMJLfaEjJq1z2lzAb", "custom_id": "546_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b2ecec1c85db1e94ea44c42f35a858cf", "body": {"id": "chatcmpl-9St6iubwovNlRIxYybcEbNIO9WWJa", "object": "chat.completion", "created": 1716672044, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Arranon, also known by its generic name nelarabine, is a chemotherapy drug used in the treatment of certain types of leukemia and lymphoma, specifically T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). Below are some important points you should be aware of as a physician:\n\n### Mechanism of Action:\n- **Nelarabine** is a prodrug that is converted into its active form, ara-GTP, within the body.\n- Ara-GTP incorporates into DNA during replication, leading to the inhibition of DNA synthesis and ultimately causing cell death, particularly in rapidly dividing cells like cancer cells.\n\n### Indications:\n- **T-cell acute lymphoblastic leukemia (T-ALL)**\n- **T-cell lymphoblastic lymphoma (T-LBL)**\n- Typically used in patients who have not responded to or have relapsed after at least two chemotherapy regimens.\n\n### Administration:\n- Administered intravenously (IV).\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_OAA7ee8ArmQFtPKOIaJSf6Wu", "custom_id": "547_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "da54b02e5cf662b16175a6d0432cd2c4", "body": {"id": "chatcmpl-9St6i7YRujvQOLlnbaUUxe0Suc2X8", "object": "chat.completion", "created": 1716672044, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nerlynx (neratinib) is an oral medication used primarily in the treatment of breast cancer. Here are some key points you should know about Nerlynx:\n\n### Indications:\n1. **Extended Adjuvant Treatment**: Nerlynx is approved for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer who have completed adjuvant trastuzumab-based therapy.\n2. **Metastatic Breast Cancer**: It can also be used in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.\n\n### Mechanism of Action:\n- Nerlynx is a tyrosine kinase inhibitor that irreversibly binds to and inhibits the HER2 receptor, as well as other members of the HER family (HER1, HER3, and HER4), which are involved in the growth and proliferation of cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_zbVxoGg5MJpeOizr3sUf8YYA", "custom_id": "548_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5916bbcec4110dda61882a45e998d45d", "body": {"id": "chatcmpl-9St6ifObP32vSAygNm0SbBhbAqr6V", "object": "chat.completion", "created": 1716672044, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tasigna (generic name: nilotinib) is a medication used primarily in the treatment of chronic myeloid leukemia (CML). Here are some key points that a physician should know about Tasigna:\n\n### Indications and Usage:\n- **Chronic Myeloid Leukemia (CML):** Tasigna is approved for use in adults with Philadelphia chromosome-positive CML in the chronic phase (newly diagnosed) and in the chronic or accelerated phase after resistance or intolerance to prior therapy, including imatinib.\n\n### Mechanism of Action:\n- **Tyrosine Kinase Inhibitor:** Tasigna works by inhibiting the BCR-ABL kinase, which is produced by the Philadelphia chromosome abnormality. This inhibition helps to prevent the proliferation of leukemic cells.\n\n### Dosage and Administration:\n- **Dosage:** The typical dosing for newly diagnosed chronic phase CML is 300 mg twice daily, and for resistant or intolerant CML in chronic or accelerated phase, it"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_8to5rXIfsbmc86xLDDJrFeFF", "custom_id": "549_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "3825f8af8696525777d6557fcdaeefdd", "body": {"id": "chatcmpl-9St6iVfSIhq4WlPGrASlh7JWAozTG", "object": "chat.completion", "created": 1716672044, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Anandron is the trade name for nilutamide, which is a nonsteroidal antiandrogen medication primarily used in the treatment of prostate cancer. Here are some key points you should know about Anandron (nilutamide):\n\n### Mechanism of Action\n- **Antiandrogen Properties**: Nilutamide works by inhibiting the action of androgens (male hormones) at the androgen receptor level, which can help slow the growth of androgen-dependent prostate cancer cells.\n\n### Indications\n- **Prostate Cancer**: It is typically used in combination with surgical castration (orchiectomy) for the treatment of metastatic prostate cancer.\n\n### Dosage and Administration\n- **Initial Dose**: The standard initial dose is usually 300 mg daily for the first 4 weeks.\n- **Maintenance Dose**: After the initial period, the dose is often reduced to 150 mg daily.\n\n### Pharmacokinetics\n- **Absorption**: Nilutamide is well"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5SjfgtJFxQBOcbQNRaXBR3bm", "custom_id": "550_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "62da14ac193fc94fabd4edb5c7392d47", "body": {"id": "chatcmpl-9St6jmoUYvquFkCYaJ34g2kxCq8rH", "object": "chat.completion", "created": 1716672045, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Nidran, though there seems to be some ambiguity around the term as it might not be widely recognized in conventional medical literature. Here are a couple of possibilities based on different contexts:\n\n1. **Nidra in Ayurveda**:\n   - **Ayurvedic Context**: \"Nidra\" is an Ayurvedic term that refers to sleep. According to Ayurveda, Nidra is one of the three pillars of health, alongside Ahara (diet) and Brahmacharya (regulated lifestyle). Proper sleep is considered essential for maintaining health and well-being.\n   - **Importance**: Adequate sleep is believed to restore energy, rejuvenate the body, and support mental and physical functions. Lack of proper sleep (insomnia or disturbed sleep) can lead to various health issues, including weakened immunity, mental health disorders, and metabolic disturbances.\n   - **Treatment**: Ayurvedic treatments for sleep disturbances may include lifestyle modifications, dietary recommendations"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Ks8m0CqSLrffKYsGkIISV3y1", "custom_id": "551_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b626ba0c46c26635f5731aed151eb30e", "body": {"id": "chatcmpl-9St6jYOEKpCeuDAISkRXevTsz5fCn", "object": "chat.completion", "created": 1716672045, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyendiv is a brand name for the drug nintedanib, which is primarily used to treat idiopathic pulmonary fibrosis (IPF) and certain types of non-small cell lung cancer (NSCLC). Here are some key points you should know about Cyendiv:\n\n### Mechanism of Action\n- **Nintedanib** is a kinase inhibitor that targets multiple tyrosine kinases involved in the regulation of angiogenesis, fibroblast proliferation, and other pathways critical to the pathogenesis of IPF and NSCLC.\n\n### Indications\n- **Idiopathic Pulmonary Fibrosis (IPF):** Nintedanib slows the progression of IPF by inhibiting pathways that lead to lung tissue scarring.\n- **Non-Small Cell Lung Cancer (NSCLC):** Specifically, nintedanib is used in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic, or locally recurrent NSCLC of adenocarcinoma histology after first"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_IzY6xT7SGUCZ3q6s2oh0bENl", "custom_id": "552_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d7a18e4861579ac51e7a8837bfefe7b8", "body": {"id": "chatcmpl-9St6jDksZW1aYOhGY7qru2MNXj2We", "object": "chat.completion", "created": 1716672045, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Niranib is a medication that may not be widely recognized under that specific name, as it does not correspond to a well-known drug in common medical practice up to my knowledge cutoff in October 2021. However, the name is somewhat similar to a class of drugs known as \"nibs,\" which are tyrosine kinase inhibitors (TKIs). These drugs are often used in the treatment of various cancers by inhibiting specific enzymes involved in the growth and proliferation of cancer cells.\n\nHere are some general points that might be relevant if Niranib is indeed a tyrosine kinase inhibitor or a similar type of drug:\n\n### Mechanism of Action:\n- **Targeted Therapy**: TKIs like those ending in \"-nib\" (e.g., imatinib, erlotinib) typically target specific enzymes or growth factor receptors involved in cancer cell signaling pathways.\n- **Inhibition**: By inhibiting these targets, the drugs can slow down or stop the growth of cancer cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_2xLRoUutOI8X92vihgzOEPHR", "custom_id": "553_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6622a52081a940d45062f8bb46680e0f", "body": {"id": "chatcmpl-9St6jjITF2pYCM6SNLCW6MWnaIvyO", "object": "chat.completion", "created": 1716672045, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Opdivo (nivolumab) is an immune checkpoint inhibitor used in oncology. Here are key points you should know about Opdivo:\n\n**Mechanism of Action:**\n- Opdivo is a monoclonal antibody that targets the programmed death-1 (PD-1) receptor on T cells. By blocking this receptor, it prevents cancer cells from evading the immune response, thereby allowing the immune system to target and destroy them.\n\n**Indications:**\n- Opdivo is approved for a variety of cancers, including:\n  - Metastatic melanoma\n  - Non-small cell lung cancer (NSCLC)\n  - Renal cell carcinoma (RCC)\n  - Classical Hodgkin lymphoma\n  - Squamous cell carcinoma of the head and neck (SCCHN)\n  - Urothelial carcinoma\n  - Hepatocellular carcinoma (HCC)\n  - Colorectal cancer (CRC) with microsatellite instability-high (MSI-H) or mismatch"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_7IlvVJRVzeYWG4hXweaPO020", "custom_id": "554_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b44733c8229aa933c91f50a173b094b8", "body": {"id": "chatcmpl-9St6jDec5AnUTw2us32nucrORq7PU", "object": "chat.completion", "created": 1716672045, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's crucial to be well-informed about Myocet (liposomal doxorubicin), especially if you're considering its use for your patients. Here are some key points:\n\n### Indications:\n- **Myocet** is primarily indicated for use in combination with cyclophosphamide for the treatment of metastatic breast cancer.\n\n### Mechanism of Action:\n- **Myocet** is a liposome-encapsulated form of doxorubicin, an anthracycline antibiotic. It works by intercalating DNA strands, thereby inhibiting DNA replication and RNA synthesis, which leads to cell death. The liposomal encapsulation is designed to reduce the cardiotoxicity associated with conventional doxorubicin.\n\n### Dosage and Administration:\n- The dosage of Myocet typically differs from that of conventional doxorubicin and must be adjusted accordingly.\n- It is administered intravenously, and the exact dosage and regimen depend on the specific protocol being followed and the patient's condition"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_13RshSF2bCQ3XlwdEQ3MnDG8", "custom_id": "555_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "864b0c4d1daa69f2a8654bcac0c567e6", "body": {"id": "chatcmpl-9St6jGMCARByD5TlGBr4c9AHAAlTD", "object": "chat.completion", "created": 1716672045, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nilevar, known generically as norethandrolone, is an anabolic-androgenic steroid (AAS). Here are some key points you should know about Nilevar:\n\n### Pharmacology:\n- **Mechanism of Action**: Nilevar, like other AAS, mimics the effects of testosterone, promoting protein synthesis and muscle growth. It has both anabolic (muscle-building) and androgenic (characteristic-inducing) properties.\n- **Administration**: It is typically administered orally.\n\n### Clinical Uses:\n- Historically, Nilevar was used for conditions where muscle growth was desired, such as severe weight loss due to surgery, chronic infections, or trauma.\n- It was also used to treat certain types of anemia due to its ability to stimulate erythropoiesis (production of red blood cells).\n\n### Side Effects:\n- **Androgenic Effects**: Include acne, increased body hair, and deepening of the voice. In women, it can cause virilization"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5bfio22JwzdDkQ8s2Nhfw1hf", "custom_id": "556_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b3c40673a31e841b03fe1327b4f2ee9e", "body": {"id": "chatcmpl-9St6jHu8LTiXm7quxK4n4Al2uWwQs", "object": "chat.completion", "created": 1716672045, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gazyva (obinutuzumab) is a monoclonal antibody used primarily in the treatment of certain types of blood cancers, specifically chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL). As a physician, here are several key points you should be aware of regarding Gazyva:\n\n### Mechanism of Action\n- **Gazyva** targets the CD20 protein found on the surface of B-lymphocytes, leading to the lysis of these cells. This is achieved through several mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and direct cell death.\n\n### Indications\n- **Chronic Lymphocytic Leukemia (CLL)**: Gazyva is often used in combination with chlorambucil for the treatment of previously untreated CLL.\n- **Follicular Lymphoma (FL)**: It is used in combination with bendamustine followed by Gazyva mon"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_evD4x0noH3DB1PqS8qxnlIRb", "custom_id": "557_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8c65f2447aea0eb9c41a292acbba9d60", "body": {"id": "chatcmpl-9St6kQ9hvO8j2j8lccZVUTgfgU8cI", "object": "chat.completion", "created": 1716672046, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Longastatina appears to be a non-standard or possibly fictional term, as it does not correspond to any known medical condition, medication, or widely recognized concept in the field of medicine up to my knowledge cutoff in 2023. \n\nIf Longastatina is a term encountered in a specific context, such as a brand name, a colloquial term, or a term used in a particular region or by a specific group, it would be crucial to obtain more details about its use and context. Here are a few steps you can take:\n\n1. **Clarify the Term**: Verify the spelling and context in which the term was encountered. This could involve consulting with colleagues, checking medical literature, or inquiring with the source of the term.\n\n2. **Contextual Understanding**: Determine if the term is used in a particular speciality, region, or within certain patient populations. Sometimes medical terms can be colloquial or brand-specific.\n\n3. **Consult Reliable Sources**: Use reputable medical databases"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_3v6kpqWVuG9TVdb0J0fmsgJl", "custom_id": "558_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e0120a4d6a3647f1f4c5a33f201746e0", "body": {"id": "chatcmpl-9St6kahQMGz017ZkHUWh6Fb4XZ9wq", "object": "chat.completion", "created": 1716672046, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Longastatina LAR is not a recognized or approved pharmaceutical drug name as of my last update in 2023. It is possible that you might be referring to a drug with a different name, or it might be a non-standard or regional name for a medication. \n\nIf you were referring to a medication similar in name, you might be thinking of \"Lanreotide\" (brand name Somatuline Depot) or \"Octreotide\" (brand name Sandostatin LAR), which are long-acting somatostatin analogs used in the treatment of conditions such as acromegaly, neuroendocrine tumors, and certain other hormone-secreting tumors.\n\n### Key Points on Lanreotide and Octreotide:\n\n1. **Mechanism of Action**:\n   - Both drugs are somatostatin analogs that inhibit the release of several hormones, including growth hormone, insulin, and glucagon.\n   \n2. **Indications**:\n   - **Ac"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_shwF1NXnoonB37Hy0a6Cxtdt", "custom_id": "559_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "56a0e58094ba6020889d1071fd3c436b", "body": {"id": "chatcmpl-9St6kp9Yzb7pIcbyYT2FTeWvAH0yO", "object": "chat.completion", "created": 1716672046, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Arzerra (ofatumumab) is a monoclonal antibody used in the treatment of certain types of chronic lymphocytic leukemia (CLL). Here are some key points you should know about Arzerra:\n\n1. **Mechanism of Action**:\n   - Arzerra targets the CD20 molecule on the surface of B-cells, leading to cell lysis through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity.\n\n2. **Indications**:\n   - It is indicated for the treatment of patients with CLL who have not responded to fludarabine and alemtuzumab.\n   - It may also be used in combination with other therapies for certain CLL patients.\n\n3. **Administration**:\n   - Arzerra is administered as an intravenous infusion.\n   - The initial dose is typically lower and is gradually increased in subsequent infusions to monitor for potential infusion reactions.\n\n4. **Premedication**:\n   - Premedication with corticosteroids"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_c0tVde4DOuycfw4l0ix2wcpp", "custom_id": "560_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "1ab92db1fb41ea7e29789a541c790af6", "body": {"id": "chatcmpl-9St6kILbpOIZPDmgrSr9IxkceUdsF", "object": "chat.completion", "created": 1716672046, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lynparza, also known by its generic name olaparib, is a PARP (poly ADP-ribose polymerase) inhibitor used primarily for the treatment of certain types of cancers. Here are some key points you should know:\n\n### Indications:\n1. **Ovarian Cancer:** Lynparza is often used for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\n2. **Breast Cancer:** It's indicated for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer.\n3. **Pancreatic Cancer:** Lynparza is approved for the maintenance treatment of patients with gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.\n4. **Prostate"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_6aCBVZHRnJGUOyBqkMX9DOuR", "custom_id": "561_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b5b32296e3e5918b47bd46b91319203d", "body": {"id": "chatcmpl-9St6khs5psDtIZH2qoEQPFfYDI5lx", "object": "chat.completion", "created": 1716672046, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lartruvo (olaratumab) is a medication that was used in the treatment of soft tissue sarcoma, a type of cancer that forms in the soft tissues of the body. Here are some key points you should know about Lartruvo:\n\n1. **Mechanism of Action**: Lartruvo is a monoclonal antibody that works by binding to the platelet-derived growth factor receptor alpha (PDGFR-\u03b1) on the surface of cells. This action is intended to inhibit the activity of PDGFR-\u03b1, which can promote the growth and survival of cancer cells.\n\n2. **Indications**: Lartruvo was approved for use in combination with doxorubicin for the treatment of adult patients with soft tissue sarcoma that is not amenable to curative treatment with radiotherapy or surgery and who have not been previously treated with doxorubicin.\n\n3. **Administration**: Lartruvo was administered as an intravenous infusion. The dosing schedule typically involved an"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_LC9qVys7e3YbmYwvoL03utAT", "custom_id": "562_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "cbfe64c362446ff6caa7377ace4233bb", "body": {"id": "chatcmpl-9St6kpLne0elGumXygEiPQeunQOHp", "object": "chat.completion", "created": 1716672046, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Omapro, also known as omacetaxine mepesuccinate or homoharringtonine, is an antineoplastic agent used primarily in the treatment of certain types of leukemia. Here are some key points that you, as a physician, should know about Omapro:\n\n### Indications:\n- **Chronic Myeloid Leukemia (CML):** Omapro is primarily used for adult patients with chronic or accelerated phase CML who are resistant to, or intolerant of, at least two tyrosine kinase inhibitors (TKIs).\n\n### Mechanism of Action:\n- **Protein Synthesis Inhibition:** Omapro works by inhibiting protein synthesis, which ultimately leads to the death of rapidly proliferating leukemic cells.\n\n### Administration:\n- **Subcutaneous Injection:** Omapro is administered via subcutaneous injection. The dosing regimen typically starts with induction therapy, followed by maintenance therapy.\n- **Induction Phase:** Often given twice daily for 14 consecutive days"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_jeI2hMHGXAB3ENLuX3dlj3fB", "custom_id": "563_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "fa2236f77ff0c18a79af555620b26923", "body": {"id": "chatcmpl-9St6lrjnMD3EOcqLEnjvQUrcDPr0P", "object": "chat.completion", "created": 1716672047, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to have a comprehensive understanding of Prilosec (generic name: omeprazole) to effectively manage and advise your patients. Here are key points to consider:\n\n### Indications\n- **Gastroesophageal Reflux Disease (GERD)**: Prilosec is commonly prescribed for the treatment of GERD to reduce symptoms and promote healing of erosive esophagitis.\n- **Peptic Ulcer Disease (PUD)**: It is used for the treatment and prevention of gastric and duodenal ulcers, including those associated with Helicobacter pylori infection when combined with antibiotics.\n- **Zollinger-Ellison Syndrome**: Prilosec is used to manage hypersecretory conditions.\n- **Maintenance Therapy**: It can be prescribed for long-term management of conditions requiring sustained acid suppression.\n\n### Mechanism of Action\n- **Proton Pump Inhibitor (PPI)**: Omeprazole works by irrevers"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_dNKHj0MkpA2cn7b3pRg9dfTv", "custom_id": "564_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "4096e69b0407d1d606e86633bf8e29d7", "body": {"id": "chatcmpl-9St6lYk8CLd3D5m5YGD1SqZKlrl0c", "object": "chat.completion", "created": 1716672047, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Osimert, known by its brand name Tagrisso, is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used in the treatment of non-small cell lung cancer (NSCLC). Here are some key points you should know about Osimert as a physician:\n\n### Indications\n1. **First-line Treatment**: Osimert is approved for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.\n2. **Secondary Treatment**: It is also indicated for patients with metastatic EGFR T790M mutation-positive NSCLC, who have progressed on or after EGFR TKI therapy.\n\n### Mechanism of Action\n- Osimert irreversibly binds to and inhibits both the EGFR activating mutations (exon 19 deletions and exon 21 L858R mutations) and the T790M resistance mutation.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_1qJxakdzgOWKUGFG9eFCeqFd", "custom_id": "565_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "cb5cce7ddbf2f5d96bfdda4b7a55a445", "body": {"id": "chatcmpl-9St6lyDdmXKLozxtqOiahjn8jWADg", "object": "chat.completion", "created": 1716672047, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2021, there is no widely recognized medication or substance known as \"Coxatin.\" It is possible that \"Coxatin\" might be a typo, a fictional name, or a very new or uncommon drug that has emerged after my last update.\n\nIf \"Coxatin\" is a new or investigational drug, it is important for you as a physician to:\n\n1. **Verify the Name and Indications**: Ensure that the name is correct and determine the therapeutic indications for which it is prescribed or studied.\n   \n2. **Mechanism of Action**: Understand the pharmacological mechanism of action. This knowledge helps in predicting the drug's potential benefits and side effects.\n\n3. **Clinical Trials**: Look for any clinical trial data available, including efficacy, safety, and any known adverse reactions. This information is often found in medical journals, clinical trial registries, or pharmaceutical company releases.\n\n4. **Dosage and Administration**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_1SoO9ngGr2kwKJGvFtC3WIxm", "custom_id": "566_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ad5fa9f874e269698bb035b758b78810", "body": {"id": "chatcmpl-9St6lFCLLWoxcnzY4hRyXXT3tl3Pj", "object": "chat.completion", "created": 1716672047, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abraxane, also known by its generic name nanoparticle albumin-bound paclitaxel, is a chemotherapy drug used primarily for the treatment of various cancers. Here are some key points you should know about Abraxane as a physician:\n\n### Indications\n1. **Breast Cancer**: Abraxane is indicated for the treatment of metastatic breast cancer, particularly in patients who have failed combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy.\n2. **Non-Small Cell Lung Cancer (NSCLC)**: It is used in combination with carboplatin for the first-line treatment of locally advanced or metastatic NSCLC in patients who are not candidates for curative surgery or radiation therapy.\n3. **Pancreatic Cancer**: It is used in combination with gemcitabine as a first-line treatment for patients with metastatic adenocarcinoma of the pancreas.\n\n### Mechanism of Action\nAbraxane is a formulation of paclitaxel, a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_NOo58BOmRk8AGAgENhnZ8Ylb", "custom_id": "567_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "10eda240e0af5ac31580239dfdaea2d4", "body": {"id": "chatcmpl-9St6lBk8S4OR8GOpVXyk68ko5WY4D", "object": "chat.completion", "created": 1716672047, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff in October 2021, there is no medication or treatment known as \"Abitaxel.\" It's possible that there might be a spelling error or confusion with another drug name. You might be referring to \"Abraxane\" or \"Paclitaxel\" (Taxol), which are well-known chemotherapy agents used primarily in the treatment of various cancers.\n\n### Paclitaxel (Taxol)\nPaclitaxel is a mitotic inhibitor used in the treatment of various types of cancer, including ovarian, breast, lung, pancreatic, and others. It's derived from the bark of the Pacific yew tree.\n\n#### Mechanism of Action:\n- Paclitaxel works by stabilizing the microtubule polymer and protecting it from disassembly, which inhibits cell division and leads to cell death.\n\n#### Indications:\n- Breast cancer\n- Ovarian cancer\n- Non-small cell lung cancer\n- Kaposi's sarcoma\n- Other off-label uses"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_kcgaPwJqGsWzunzXUw9TrwXl", "custom_id": "568_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9b287e9bbb2673e41f7d763231acfd09", "body": {"id": "chatcmpl-9St6lWmz4HqNsfnBX8FiBBiFMhyNW", "object": "chat.completion", "created": 1716672047, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vonjo (pacritinib) is a medication that you may find relevant in the context of treating certain hematologic conditions. Here are some key points you should know about it:\n\n1. **Indication**: Vonjo is primarily indicated for the treatment of intermediate or high-risk primary or secondary myelofibrosis, particularly in patients with low platelet counts (thrombocytopenia). Myelofibrosis is a type of bone marrow cancer that disrupts the body's normal production of blood cells.\n\n2. **Mechanism of Action**: Pacritinib is a selective inhibitor of Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). By inhibiting these kinases, pacritinib can help reduce the abnormal blood cell production and fibrosis associated with myelofibrosis.\n\n3. **Dosing**: The typical dosage of Vonjo is 200 mg taken orally twice daily. However, dosing may"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_OGz5mFPiJ9VPtSlaPWKMFqTc", "custom_id": "569_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c7b211780183976506c2536262d46902", "body": {"id": "chatcmpl-9St6mBek6mDK0rkVtz9M7GRiuMrC3", "object": "chat.completion", "created": 1716672048, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibrance (palbociclib) is a medication used in the treatment of certain types of breast cancer. Here are some key points you should know about Ibrance as a physician:\n\n### Indications:\n1. **Breast Cancer**: Ibrance is primarily indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.\n2. **Combination Therapy**: It is often used in combination with endocrine therapy, such as letrozole or fulvestrant, depending on whether the patient is postmenopausal or has disease progression following endocrine therapy.\n\n### Mechanism of Action:\n- Ibrance is a cyclin-dependent kinase (CDK) 4 and 6 inhibitor. It works by inhibiting these kinases, which are involved in cell cycle progression, thereby preventing cancer cell proliferation.\n\n### Administration:\n- **Dosage**: The typical starting dose is 125 mg taken orally once daily for 21 consecutive days, followed by "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_AYIQ8lLfa8iw2uJy5CQHzVEN", "custom_id": "570_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "3fba8cf8ce17fcb1f0366ee6851029fc", "body": {"id": "chatcmpl-9St6mA7gyUsbqheFLOnO99UUyjNBE", "object": "chat.completion", "created": 1716672048, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vectibix (panitumumab) is a monoclonal antibody used in the treatment of metastatic colorectal cancer. Here are some key points you should know:\n\n1. **Mechanism of Action**: Vectibix targets the epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting their growth and survival.\n\n2. **Indications**: It is primarily used for the treatment of patients with wild-type RAS metastatic colorectal cancer. It should not be used in patients with RAS-mutant tumors, as they do not respond to EGFR inhibition.\n\n3. **Administration**: Vectibix is administered via intravenous infusion. The typical dosing schedule is 6 mg/kg every 14 days.\n\n4. **Side Effects**:\n   - **Dermatologic Toxicity**: The most common side effect is a rash, which can range from mild to severe. It often presents as acneiform and can affect the face, chest, and back.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_TuMdyDf6UKTzKUt23Yg6ikYs", "custom_id": "571_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "eeeb893feed2755cbca8df6c13a6b3f7", "body": {"id": "chatcmpl-9St6mSHToi6355v0cnYQMYXBm4yaQ", "object": "chat.completion", "created": 1716672048, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a typo or a misunderstanding in your question. \"Faridak\" does not correspond to any known medical condition, medication, or widely recognized term in the healthcare field. \n\nIf you meant something else, could you please provide more context or clarify your question? If \"Faridak\" is indeed the term you intended to use, additional details would be helpful to provide an accurate and useful response."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 84, "total_tokens": 124}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_yVxOehLeNbrqmyoTXNy5lph4", "custom_id": "572_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ce36e1abfbca7084e9f36a5187de4a51", "body": {"id": "chatcmpl-9St6mbZ8bZqBd8IQeOFhELBxakner", "object": "chat.completion", "created": 1716672048, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a typo in your question, as \"Pazopater\" does not correspond to any known medication or medical term. If you're referring to \"Pazopanib,\" I can provide information on that.\n\nPazopanib is a medication used in the treatment of certain types of cancer. Here are key points you should know:\n\n### Indications\n- **Renal Cell Carcinoma (RCC):** Pazopanib is approved for the treatment of advanced renal cell carcinoma.\n- **Soft Tissue Sarcoma (STS):** It's also used to treat advanced soft tissue sarcoma in patients who have received prior chemotherapy.\n\n### Mechanism of Action\n- **Tyrosine Kinase Inhibitor:** Pazopanib works by inhibiting multiple tyrosine kinases, including VEGFR, PDGFR, and KIT. These receptors play a role in tumor growth, angiogenesis, and metastatic progression.\n\n### Administration\n- **Oral Administration:** Pazopan"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_qt4VwYkwfk0dS6ZvYa4kRjpn", "custom_id": "573_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9b3289b92f3c470632a547fc08ac6916", "body": {"id": "chatcmpl-9St6m9MkVrluJcOxOc2ZJG5ryD66o", "object": "chat.completion", "created": 1716672048, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Oncaspar (pegaspargase) is a medication used in the treatment of acute lymphoblastic leukemia (ALL). Here are key points you, as a physician, should know about Oncaspar:\n\n### Mechanism of Action:\n- **Enzyme**: Oncaspar is a modified enzyme called pegaspargase, which is a pegylated form of L-asparaginase.\n- **Function**: It depletes the amino acid asparagine, which leukemic cells rely on for survival and proliferation. Normal cells can synthesize asparagine, but leukemic cells cannot, leading to their death when asparagine is depleted.\n\n### Indications:\n- **ALL**: Oncaspar is primarily used in treating acute lymphoblastic leukemia, especially in patients who have developed hypersensitivity to native forms of L-asparaginase.\n- **First-line and second-line therapy**: It can be used as part of combination chemotherapy regimens both in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_RsbMbOHCqfP6RZGG7byywMbk", "custom_id": "574_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0900fcab7b415bb47aa1a413aaa80676", "body": {"id": "chatcmpl-9St6mRi6F8VhDX9SHn7e8rtrzCeyz", "object": "chat.completion", "created": 1716672048, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pegasys (peginterferon alfa-2a) is a prescription medication used primarily in the treatment of chronic hepatitis C and, in some cases, hepatitis B. Here are key points you should be aware of as a physician:\n\n### Mechanism of Action\n- **Interferon**: Pegasys is a type of interferon, which works by modulating the immune response to fight the viral infections.\n- **Pegylation**: The pegylation process extends the half-life of the interferon, allowing for less frequent dosing (usually once weekly).\n\n### Indications\n- **Chronic Hepatitis C**: Often used in combination with other antiviral medications (e.g., ribavirin) for the treatment of chronic hepatitis C.\n- **Chronic Hepatitis B**: Can be used as monotherapy or in combination with other antiviral agents.\n\n### Dosage and Administration\n- **Dosage**: Typically administered as a subcutaneous injection once weekly. Dosing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_YW1lC6ZIk7HoEPbfwA7zKLuz", "custom_id": "575_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "7876edcffdad8cdb918c4e5632534b39", "body": {"id": "chatcmpl-9St6mF0wpFe3Ctdbhyr6nJe3iIaQV", "object": "chat.completion", "created": 1716672048, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "PEG-Intron (peginterferon alfa-2b) is a medication used primarily in the treatment of chronic hepatitis C. Here are some key points you should be aware of as a physician:\n\n### Mechanism of Action:\n- **Interferon:** PEG-Intron is a pegylated form of interferon alfa-2b. The pegylation process involves attaching polyethylene glycol (PEG) to the interferon molecule, which increases its half-life and allows for less frequent dosing.\n- **Immunomodulation:** It works by enhancing the immune response to target and eliminate the hepatitis C virus (HCV).\n\n### Indications:\n- **Chronic Hepatitis C:** Primarily indicated for the treatment of chronic hepatitis C, often in combination with ribavirin.\n- **Other Uses:** It may also be used in other off-label contexts, including certain types of cancer, although this is less common.\n\n### Administration:\n- **Route:** Administered subcutaneously.\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_5Tb4asvY1iXY7UhBpdPYqmIA", "custom_id": "576_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b8bf587d0873d6860d38901ce3918c2c", "body": {"id": "chatcmpl-9St6mjannmHZHC5Y8zfQzjAgahLc7", "object": "chat.completion", "created": 1716672048, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Caelyx is a brand name for pegylated liposomal doxorubicin, which is a chemotherapeutic agent used primarily in the treatment of various cancers, including ovarian cancer, multiple myeloma, and AIDS-related Kaposi's sarcoma. Here are some key points you should know about Caelyx:\n\n### Mechanism of Action:\n- **Doxorubicin**: The active ingredient is doxorubicin, an anthracycline antibiotic that works by intercalating DNA, inhibiting topoisomerase II, and generating free radicals, which results in the disruption of DNA replication and transcription.\n- **Pegylated Liposomal Formulation**: The pegylation and liposomal encapsulation help in extending the drug's circulation time, enhancing its delivery to tumor tissues, and reducing its uptake by normal tissues, thereby potentially reducing the toxicity.\n\n### Indications:\n- **Ovarian Cancer**: For patients with ovarian cancer who have relapsed after platinum"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_uIVPneUPcXYgGEQqWS7ufkIO", "custom_id": "577_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "48f40ac3251141cdbf6dac43e7122592", "body": {"id": "chatcmpl-9St6nL5tdfcgRNdefIgHvWMpznhJi", "object": "chat.completion", "created": 1716672049, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Keytruda (pembrolizumab) is a monoclonal antibody used as an immunotherapy treatment for various types of cancer. Here are some essential points you should know:\n\n1. **Mechanism of Action:**\n   - Keytruda works by inhibiting the programmed death receptor-1 (PD-1) pathway. By blocking PD-1, Keytruda helps to restore the immune system's ability to recognize and destroy cancer cells.\n\n2. **Indications:**\n   - Keytruda is approved for the treatment of several cancers, including but not limited to:\n     - Melanoma\n     - Non-small cell lung cancer (NSCLC)\n     - Head and neck squamous cell carcinoma (HNSCC)\n     - Classical Hodgkin lymphoma\n     - Urothelial carcinoma\n     - Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors\n     - Primary mediastinal large B-cell lymphoma (PM"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_x4JEjs1YWenuwSaXSgkCOCdF", "custom_id": "578_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "633620fdb46a3725b5a67f13515cf689", "body": {"id": "chatcmpl-9St6ndR39edqFpms2rBBvFamzY0cl", "object": "chat.completion", "created": 1716672049, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alimta, also known by its generic name pemetrexed, is a chemotherapy drug used primarily in the treatment of certain types of cancer, including malignant pleural mesothelioma and non-small cell lung cancer (NSCLC). Here's a comprehensive overview of what you should know about Alimta:\n\n### Mechanism of Action:\n- **Antifolate Chemotherapy**: Alimta works by inhibiting several key enzymes involved in folate metabolism and DNA synthesis, including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. This disruption in folate-dependent processes impedes cancer cell replication and induces cell death.\n\n### Indications:\n- **Malignant Pleural Mesothelioma**: Alimta is often used in combination with cisplatin for the initial treatment of patients who are not candidates for surgery.\n- **Non-Small Cell Lung Cancer (NSCLC)**: It is used as monotherapy for maintenance"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_9YKZWSdMhK76ZI9jdR4HoCUd", "custom_id": "579_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "1956763753acf03c8496074d8f137a98", "body": {"id": "chatcmpl-9St6nDss7tdDqtM4s9kV1dU5Fis3O", "object": "chat.completion", "created": 1716672049, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nipent, also known by its generic name pentostatin, is a chemotherapy medication used primarily for the treatment of hairy cell leukemia. Here are some key points you should know about Nipent as a physician:\n\n### Mechanism of Action:\n- **Pentostatin** is a purine analog that inhibits the enzyme adenosine deaminase.\n- This inhibition leads to the accumulation of intracellular adenosine and deoxyadenosine triphosphate, which inhibits ribonucleotide reductase and DNA synthesis, primarily affecting lymphocytes.\n\n### Indications:\n- **Hairy Cell Leukemia (HCL)**: It is FDA-approved for the treatment of this type of leukemia.\n- It may be used off-label for other conditions, such as T-cell prolymphocytic leukemia and chronic lymphocytic leukemia, although these uses are less common and should be evaluated on a case-by-case basis.\n\n### Administration and Dosage:\n- Typically administered as an intravenous infusion.\n- The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_EHD32hgSb5yPGvuAphdEv7Zy", "custom_id": "580_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "24d55c750c22c9943b7298e7869b654c", "body": {"id": "chatcmpl-9St6n8AJvBpbKELQpcGctB2TmvxZD", "object": "chat.completion", "created": 1716672049, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Omnitarg, also known by its generic name pertuzumab, is a monoclonal antibody used primarily in the treatment of certain types of breast cancer. As a physician, it is important to be aware of the following key points about Omnitarg:\n\n1. **Mechanism of Action**: Pertuzumab targets the human epidermal growth factor receptor 2 (HER2). It binds to a different epitope on HER2 compared to trastuzumab (another HER2-targeting antibody), and it inhibits dimerization (pairing) of HER2 with other HER receptors, which is essential for cell growth and proliferation. This inhibition can help to slow or stop the growth of HER2-positive cancer cells.\n\n2. **Indications**: Omnitarg is primarily used in combination with trastuzumab and chemotherapy for the treatment of HER2-positive breast cancer. It is approved for use in:\n    - Neoadjuvant treatment (before surgery) for locally advanced, inflammatory"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_WLJ4SG6bw1IuSvS9DtHo4MSE", "custom_id": "581_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c4b715cc591e9cb9ad72e0798c9be1da", "body": {"id": "chatcmpl-9St6nMgO6FPjGSQ6f0vlr7Gp1xcyT", "object": "chat.completion", "created": 1716672049, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pinorubicin, also known as pirarubicin, is an anthracycline antibiotic and a chemotherapy agent used primarily in the treatment of various cancers. Here are some key points you should know about Pinorubicin:\n\n### Mechanism of Action\n- **DNA Intercalation**: Pinorubicin works by intercalating into DNA, which disrupts the function of the enzyme topoisomerase II. This inhibits DNA replication and transcription, ultimately leading to cell death.\n- **Free Radical Formation**: It generates free radicals that can damage cellular components, contributing to its cytotoxic effects.\n\n### Indications\n- Pinorubicin is used in the treatment of several types of cancer, including:\n  - Breast cancer\n  - Bladder cancer\n  - Lymphomas\n  - Leukemias\n  - Ovarian cancer\n\n### Administration\n- The drug is typically administered intravenously.\n- Dosing regimens can vary based on the type of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_DUeKMnuLwSHwp5XHCBAUul1J", "custom_id": "582_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6570a1bb8ef3eddb4778e677e2990972", "body": {"id": "chatcmpl-9St6ob8Vrdv0635aLq18xGFDsMWSH", "object": "chat.completion", "created": 1716672050, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pixuvri (pixantrone) is a medication used in the treatment of certain types of cancer, specifically aggressive non-Hodgkin B-cell lymphomas. Here are several key points you should know about Pixuvri:\n\n1. **Mechanism of Action**: Pixuvri is an aza-anthracenedione, which is structurally related to anthracyclines but has been modified to reduce the risk of cardiotoxicity. It works by intercalating into DNA and disrupting the replication of cancer cells, ultimately leading to cell death.\n\n2. **Indications**: Pixuvri is primarily indicated for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.\n\n3. **Administration**: Pixuvri is administered intravenously. The typical dosing schedule involves administration on days 1, 8, and 15 of a 28-day cycle. The exact dosing and number of cycles can vary based on the patient's"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_4vqxXRDpkJIlrQMouhQCaIPX", "custom_id": "583_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "41b16dce8e4ffd6d4d7ba2c07391ffad", "body": {"id": "chatcmpl-9St6oPE70LTAuPKW9rnik2xVb9tPm", "object": "chat.completion", "created": 1716672050, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mithracin (plicamycin) is an antineoplastic antibiotic, primarily used in the treatment of certain types of cancer such as testicular cancer and for the management of hypercalcemia and hypercalciuria associated with malignancy. Here are key points you should know about Mithracin:\n\n### Mechanism of Action\n- Mithracin inhibits DNA-dependent RNA synthesis by binding to the DNA template, interfering with the transcription process and thereby inhibiting the growth of rapidly proliferating cells.\n\n### Indications\n1. **Testicular Cancer**: Traditionally used for testicular tumors, particularly advanced cases.\n2. **Hypercalcemia of Malignancy**: Employed to manage elevated calcium levels in the blood which may be associated with certain cancers.\n\n### Administration\n- Mithracin is administered intravenously, typically in a hospital setting due to the need for close monitoring.\n- Dosage and administration schedules may vary based on the specific condition being treated and the patient's overall health status.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_dxGTZ2mCkzXiBiBJc3hPV88h", "custom_id": "584_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6f92cbc567def434567c2feb7784c040", "body": {"id": "chatcmpl-9St6oy40JiWbJzEpVTcmQSShwhM6o", "object": "chat.completion", "created": 1716672050, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Actimid is a medication that you might recognize by its generic name, pomalidomide. It is a thalidomide analog and belongs to a class of drugs known as immunomodulatory agents. Here are some key points you should know about Actimid:\n\n### Indications\n- **Multiple Myeloma:** Actimid is primarily used to treat multiple myeloma, particularly in patients who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on or within 60 days of completion of the last therapy.\n\n### Mechanism of Action\n- **Immunomodulatory Effects:** Pomalidomide modulates the immune system and has anti-angiogenic properties. It enhances T-cell and natural killer (NK) cell-mediated cytotoxicity and inhibits the proliferation of myeloma cells.\n- **Anti-inflammatory:** It also decreases the production of pro-inflammatory cytokines.\n\n### Dosage and Administration\n- **Or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_gg8QEwMoFNVULoMJmUKZ3TB1", "custom_id": "585_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "84fa7a804d39177b23d14d930f127233", "body": {"id": "chatcmpl-9St6oITIHlWDUQO0VKyyW0CCT0AbO", "object": "chat.completion", "created": 1716672050, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Iclusig (ponatinib) is a medication used primarily to treat certain types of leukemia, particularly chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Here are key points you should know about Iclusig as a physician:\n\n### Indications:\n1. **Chronic Myeloid Leukemia (CML):**\n   - Approved for use in adult patients with chronic phase, accelerated phase, or blast phase CML who are resistant or intolerant to other tyrosine kinase inhibitors (TKIs).\n   - Also used in patients with T315I-positive CML, a mutation that confers resistance to many other TKIs.\n\n2. **Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL):**\n   - Approved for use in adult patients with Ph+ ALL who are resistant or intolerant to other TKIs.\n   - Also used in patients with T315I-positive Ph+ ALL.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_estVS78Rso7T8DNpGmTwWnVe", "custom_id": "586_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "16f022fa686c82034712edff2e7c84db", "body": {"id": "chatcmpl-9St6obIRIqa2bfR3xrSo02D2Gz6QT", "object": "chat.completion", "created": 1716672050, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Folotyn (pralatrexate) is a chemotherapeutic agent used primarily for the treatment of peripheral T-cell lymphoma (PTCL), including relapsed or refractory PTCL. Here\u2019s a detailed overview of what you should know about Folotyn:\n\n### Indications:\n- **Primary Indication**: Folotyn is indicated for the treatment of patients with relapsed or refractory PTCL.\n  \n### Mechanism of Action:\n- **Antifolate Agent**: Pralatrexate is an antifolate that inhibits dihydrofolate reductase (DHFR), an enzyme involved in the folate pathway, which is crucial for DNA synthesis and replication. This inhibition leads to decreased DNA synthesis and induces cell death, particularly in rapidly dividing cancer cells.\n\n### Administration:\n- **Route**: Intravenous (IV) infusion.\n- **Dosage**: The typical starting dose is 30 mg/m\u00b2 given as an IV push over 3-5 minutes once"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_OST0C33m3FwD6NvxCaFlYQzz", "custom_id": "587_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "27959e26770dbba9db5fa799835c27d9", "body": {"id": "chatcmpl-9St6oh6JoDWj3NFweNiPRCG2Fzj7s", "object": "chat.completion", "created": 1716672050, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pravachol, also known by its generic name pravastatin, belongs to a class of medications called statins. Statins are commonly prescribed to lower cholesterol levels and reduce the risk of cardiovascular disease. Here are some key points you should know about Pravachol:\n\n### Indications\n- **Hyperlipidemia**: Pravachol is used to lower elevated total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides, and to increase high-density lipoprotein cholesterol (HDL-C).\n- **Cardiovascular Risk Reduction**: It's prescribed to reduce the risk of myocardial infarction, stroke, and revascularization procedures in patients with or without established cardiovascular disease.\n- **Primary Prevention**: In patients with hypercholesterolemia and no clinically evident coronary heart disease, it can reduce the risk of myocardial infarction and cardiovascular mortality.\n\n### Mechanism of Action\n- Pravastatin works by inhibiting HMG-CoA reductase, an"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_hNQVqmyS7FgazSGuKkC349BH", "custom_id": "588_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "81646b101b04066394adaf8965166d4b", "body": {"id": "chatcmpl-9St6oCPoHARWvLTlQeqGKyRZ98MDR", "object": "chat.completion", "created": 1716672050, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff in October 2023, there is no widely recognized medication called \"Adnisolone\" in the medical literature or pharmacopeia. It's possible that the name could be a typographical error, a brand name not widely known, or a new medication that has emerged after my last update.\n\nHowever, if you meant to refer to a different medication, such as prednisone or prednisolone, which are corticosteroids commonly used to treat a variety of inflammatory and autoimmune conditions, here are some key points you should know:\n\n### Prednisone/Prednisolone Overview:\n1. **Mechanism of Action:**\n   - They are glucocorticoids that suppress the immune system and reduce inflammation by inhibiting multiple inflammatory cytokines.\n\n2. **Indications:**\n   - Used for conditions such as asthma, COPD exacerbations, rheumatoid arthritis, lupus, allergic reactions, inflammatory bowel disease, and certain types of cancer.\n\n3. **Dosage:**\n   - The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_4IYEoZY6YmRml3yP6cIurJw2", "custom_id": "589_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "568f08d10e691413ab123870f358d918", "body": {"id": "chatcmpl-9St6pa6DLjwHFi1voC8tbFeNvqNMV", "object": "chat.completion", "created": 1716672051, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no known drug or medical condition called \"Artinizona.\" It's possible that you might be referring to something else, or it could be a typo or a new term that has emerged after my last update. \n\nIf you meant a different term or have more context, please provide additional details so I can assist you better. If \"Artinizona\" is indeed a new medical term or drug, I recommend consulting the latest medical literature or databases for the most current information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 107, "total_tokens": 148}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_WeD6iCkyPpaNh7mcgqZxL0lN", "custom_id": "590_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ace24eb97775f346e27016eeb602c054", "body": {"id": "chatcmpl-9St6pwXLxPmzo4lp5jWQxJxF7LJH4", "object": "chat.completion", "created": 1716672051, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Indicarb is a trade name for carboplatin, a chemotherapy medication used primarily to treat various types of cancer, including ovarian cancer, lung cancer, head and neck cancers, and others. As a physician, here are several key points you should know about Indicarb (carboplatin):\n\n### Mechanism of Action\n- **Alkylating Agent:** Carboplatin belongs to a class of drugs known as alkylating agents. It works by causing crosslinking of DNA strands, which interferes with DNA replication and transcription, leading to cell death, particularly in rapidly dividing cells such as cancer cells.\n\n### Indications\n- **Ovarian Cancer:** Most commonly used for ovarian carcinoma, especially in cases where the cancer is advanced or recurrent.\n- **Other Cancers:** Also used in the treatment of lung cancer, head and neck cancers, brain tumors, and as part of preparative regimens for bone marrow transplantation.\n\n### Administration\n- **Dosage:** The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_BW3YleLAt22VJIk7xHH7CEKV", "custom_id": "591_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "1081d90f7c8aefcffa77ee9678abf866", "body": {"id": "chatcmpl-9St6pO6GteTv9YVezpcvBZ1V7J8m9", "object": "chat.completion", "created": 1716672051, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Qualaquin is a brand name for quinine sulfate, which is a medication primarily used to treat uncomplicated Plasmodium falciparum malaria. Here are some key points you should be aware of as a physician:\n\n### Indications & Usage\n- **Malaria Treatment**: Qualaquin is FDA-approved for the treatment of uncomplicated malaria caused by Plasmodium falciparum.\n- **Off-Label Uses**: Though not FDA-approved for such purposes, quinine has been used off-label for nocturnal leg cramps and other conditions, but this is generally not recommended due to safety concerns.\n\n### Dosage & Administration\n- **Adult Dosage**: The typical dosage for adults is 648 mg (two 324 mg capsules) every 8 hours for 7 days.\n- **Pediatric Dosage**: Dosing for children is based on body weight and should be carefully calculated.\n- **Administration**: It should be taken with food to minimize gastrointestinal upset.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_wybYopX5mwmNKHFKUTaMvM6r", "custom_id": "592_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f491d916f16c25466b92b87938e611fd", "body": {"id": "chatcmpl-9St6p67RngAZA9aTAD6Koz9vvoYnU", "object": "chat.completion", "created": 1716672051, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's essential to be well-informed about any medication you prescribe. Vanflyta (quizartinib) is a medication used primarily in the treatment of acute myeloid leukemia (AML) with a specific genetic mutation (FLT3-ITD). Here are some key points you should know about Vanflyta:\n\n1. **Mechanism of Action**:\n   - Vanflyta is a tyrosine kinase inhibitor (TKI) that specifically targets and inhibits the FLT3 receptor tyrosine kinase, which is often mutated in AML. The FLT3-ITD mutation leads to uncontrolled cell proliferation, and by inhibiting this pathway, quizartinib can help control the growth of leukemia cells.\n\n2. **Indications**:\n   - Vanflyta is indicated for the treatment of adult patients with relapsed or refractory AML with the FLT3-ITD mutation. It is often used in combination with other chemotherapy agents.\n\n3. **Dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_TEzXmlwMb1tLuFMQ4DJ6Khs6", "custom_id": "593_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "16840190fdd495cccd7f3ab311310158", "body": {"id": "chatcmpl-9St6phA05UWo0u92OBmOG02B1DeO1", "object": "chat.completion", "created": 1716672051, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Supect\" is not a specific or widely recognized medical term or brand name for a medication or treatment in common medical practice as of my knowledge cutoff in October 2023. However, it is possible that it could be a misspelling, a regional brand name, or a new product that has emerged since my last update.\n\nIf \"Supect\" is a brand name for a pharmaceutical product or a specific medical device, the following general guidelines can help you understand what you need to know about any new medication or treatment:\n\n1. **Active Ingredients**: Understand the active ingredients in the product, their mechanisms of action, and their pharmacokinetics and pharmacodynamics.\n   \n2. **Indications and Usage**: Know the clinical indications for which the product is approved and any off-label uses that might be supported by evidence.\n\n3. **Dosage and Administration**: Be familiar with the recommended dosages, routes of administration, and any special instructions for use.\n\n4. **Contra"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_EZQO3JQJ3WTrrkMbmzdkrKxw", "custom_id": "594_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "bf9495bfe63f772918a5c6a7cd812278", "body": {"id": "chatcmpl-9St6p58MZ0XKfHm7oWKEuirqFMbQu", "object": "chat.completion", "created": 1716672051, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tomudex, also known by its generic name raltitrexed, is a chemotherapy medication used primarily for the treatment of advanced colorectal cancer. Here are several key points you should know about Tomudex:\n\n1. **Mechanism of Action**:\n   - Raltitrexed is a thymidylate synthase inhibitor. It disrupts DNA synthesis by inhibiting the enzyme thymidylate synthase, which is crucial for the production of thymidine, a nucleotide required for DNA replication and repair.\n\n2. **Indications**:\n   - It is mainly indicated for the treatment of advanced colorectal cancer, particularly in cases where fluorouracil-based therapy is not suitable.\n\n3. **Administration**:\n   - Tomudex is typically administered intravenously. The dosing schedule is usually once every three weeks, but this can vary based on individual patient factors and response to the treatment.\n\n4. **Side Effects**:\n   - Common side effects include gastrointestinal disturbances (nausea,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_amWzrqywT548tIt76hNVqW9j", "custom_id": "595_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "bbd3c849e66e31a32a2e5b12114b5828", "body": {"id": "chatcmpl-9St6q9TpDwJ6A8zorqcWEFDoSiLxN", "object": "chat.completion", "created": 1716672052, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyramza (ramucirumab) is a monoclonal antibody used in oncology, specifically for the treatment of certain types of cancer. Here are key points you should know as a physician:\n\n### Indications\nCyramza is approved for use in multiple cancer types, often in combination with other chemotherapy agents, including:\n1. **Gastric Cancer**: For patients with advanced gastric or gastro-esophageal junction adenocarcinoma after prior chemotherapy.\n2. **Colorectal Cancer**: In combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) for metastatic colorectal cancer after disease progression following prior therapy.\n3. **Non-Small Cell Lung Cancer (NSCLC)**: In combination with docetaxel for metastatic NSCLC with disease progression on or after platinum-based chemotherapy.\n4. **Hepatocellular Carcinoma (HCC)**: For patients with alpha-fetoprotein (AFP)"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_bLXcR00HIWt3QaaHdwJdKUE4", "custom_id": "596_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "588edff3a8f7955e81f6b48bbfbb6bad", "body": {"id": "chatcmpl-9St6qIrk11CK8IbBVAeIze1rSP1ZC", "object": "chat.completion", "created": 1716672052, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cymer, Inc. is a company that plays a significant role in the semiconductor industry, particularly in the production of light sources for photolithography, a critical process in the manufacturing of integrated circuits. Here are some key points you might find relevant as a physician, especially if your practice or research intersects with technology or medical devices:\n\n1. **Semiconductor Technology**: Cymer is known for its light source technology used in extreme ultraviolet (EUV) and deep ultraviolet (DUV) lithography. These technologies are essential for creating the microchips that power modern electronic devices, including medical equipment.\n\n2. **Medical Device Manufacturing**: Many advanced medical devices, such as imaging systems, diagnostic tools, and wearable technology, rely on semiconductor components. Understanding the role of companies like Cymer can provide insights into the technological advancements that impact medical device development.\n\n3. **Innovation in Healthcare**: The evolution of semiconductor technology, driven by companies like Cymer, contributes to the miniaturization and increased"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_v7KX4QCnR5rrkUGPA6UX4iQp", "custom_id": "597_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "80216e2b5d49ad2d3b323540c33e3543", "body": {"id": "chatcmpl-9St6qX8dTO0kNumMNK9Ycjb8RSjkt", "object": "chat.completion", "created": 1716672052, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nublexa, also known by its generic name regorafenib, is a medication used in the treatment of certain types of cancer. As a physician, here are key points you should know about Nublexa (regorafenib):\n\n1. **Mechanism of Action**:\n   - Regorafenib is a multi-kinase inhibitor that targets various kinases involved in tumor growth, angiogenesis, and the tumor microenvironment. It inhibits kinases such as VEGFR, PDGFR, FGFR, KIT, RET, and RAF, among others.\n\n2. **Indications**:\n   - It is approved for use in metastatic colorectal cancer (CRC) in patients who have previously been treated with fluoropyrimidine-,"}, "logprobs": null, "finish_reason": "content_filter"}], "usage": {"prompt_tokens": 41, "completion_tokens": 151, "total_tokens": 192}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ZHGDY082Zoapdy6UvVmbkndR", "custom_id": "598_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d1752c883d5c4b1a8bbbc3ef6cef7000", "body": {"id": "chatcmpl-9St6qKFtwOA2oK8ufH0heQqUBgOXE", "object": "chat.completion", "created": 1716672052, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kisqali (ribociclib) is a medication used in the treatment of certain types of breast cancer. Here are some key points you should know as a physician:\n\n### Indications:\n- **Breast Cancer**: Kisqali is indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, usually in combination with an aromatase inhibitor as initial endocrine-based therapy or with fulvestrant in patients who have received prior endocrine therapy.\n\n### Mechanism of Action:\n- **CDK4/6 Inhibitor**: Kisqali inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), which are crucial for cell cycle progression. By blocking these kinases, Kisqali helps to prevent cancer cell proliferation.\n\n### Dosage and Administration:\n- **Oral Administration**: Kisqali is administered orally, typically in a dosage of 600 mg (three 200 mg tablets) once daily for 21 consecutive days followed by "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_1nDy0z5uh9YNVJZUC6LTOMTJ", "custom_id": "599_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b237fdc73d2da9087dac75e4b626c8bc", "body": {"id": "chatcmpl-9St6qr2yP4l0TvsrBmBORlce6As0A", "object": "chat.completion", "created": 1716672052, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2021, there are no widely recognized medical treatments, medications, or conditions known as \"Ikgdar.\" It's possible that you might be referring to a term that is either highly specialized, a brand name, or a term that has emerged after my knowledge cutoff date.\n\nIf \"Ikgdar\" is a new medication, treatment, or medical condition that has been introduced after my last update, I would recommend checking recent medical literature, clinical guidelines, or reputable medical databases such as PubMed, UpToDate, or contacting a professional medical organization for the most current and accurate information.\n\nPlease provide more context or verify the term to help me give a more precise response."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 143, "total_tokens": 184}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_hgut4EayEB2RYIe6YEsoOzuS", "custom_id": "600_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6dca66a4128c7a4c4f66be2544bee5b4", "body": {"id": "chatcmpl-9St6qik5JlG5qc6pKKleNvBLyW20W", "object": "chat.completion", "created": 1716672052, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rituxan Hycela (rituximab and hyaluronidase human) is a combination of rituximab, a monoclonal antibody, and hyaluronidase, an enzyme that helps increase the absorption of rituximab when administered subcutaneously. It is used in the treatment of certain types of blood cancers, including non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Here are some key points you should know about Rituxan Hycela:\n\n### Indications:\n1. **Follicular Lymphoma (FL):**\n   - As a single agent for previously untreated, relapsed, or refractory FL.\n   - In combination with chemotherapy for the first-line treatment of FL.\n   - As maintenance therapy for patients responding to induction therapy.\n\n2. **Diffuse Large B-Cell Lymphoma (DLBCL):**\n   - In combination with CHOP (cyclophosphamide, do"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_x2wKdt8C6IPhZqQWMtbn7xiw", "custom_id": "601_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9b40cbf233098a2c56a758c5770c979b", "body": {"id": "chatcmpl-9St6q8P2OmND75fVEWdaTQyPRzGDP", "object": "chat.completion", "created": 1716672052, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Istodax, also known by its generic name romidepsin, is a prescription medication used primarily in the treatment of certain types of cancer. Here are some key points you should know about Istodax:\n\n1. **Indications**:\n   - Istodax is used for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.\n   - It is also approved for the treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy.\n\n2. **Mechanism of Action**:\n   - Istodax is a histone deacetylase (HDAC) inhibitor. It works by inhibiting the activity of HDAC enzymes, which leads to the accumulation of acetylated histone proteins and other proteins. This accumulation can result in cell cycle arrest and apoptosis (programmed cell death) of cancer cells.\n\n3. **Administration**:\n   - Istodax is administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_9iyDOMiWlfrnaV3nkUdlSNAK", "custom_id": "602_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "7e752e88fb5b4f3d7ba9275c74459910", "body": {"id": "chatcmpl-9St6qQJt18qoaz16Lwq3Q9WtV3WUU", "object": "chat.completion", "created": 1716672052, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Besremi (ropeginterferon alfa-2b) is a medication used primarily in the treatment of polycythemia vera, a type of blood cancer characterized by the overproduction of red blood cells. Here are some critical points you should know about Besremi:\n\n### Mechanism of Action\n- Besremi is a long-acting pegylated interferon. It works by modulating the immune system to help control blood cell production and reduce the proliferation of abnormal blood cells.\n\n### Indications\n- It is specifically indicated for the treatment of polycythemia vera in adults. \n\n### Administration\n- Besremi is administered via subcutaneous injection. The dosing schedule can vary, but it is typically given every two weeks initially, and then potentially less frequently based on patient response and tolerance.\n\n### Efficacy\n- Clinical trials have demonstrated that Besremi can effectively reduce hematocrit levels, decrease the need for phlebotomy, and normalize blood counts"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_CsdZKhzlsd0ERMdZG6cj5Jre", "custom_id": "603_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6393dda72f1bf491d28a6a4d14984b1f", "body": {"id": "chatcmpl-9St6rW9Wwqy2tGwObUGrPdN8GrzIi", "object": "chat.completion", "created": 1716672053, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rubraca (rucaparib) is a medication used primarily in the treatment of certain types of cancer. Here are key points you should be aware of as a physician:\n\n### Indications:\n1. **Ovarian Cancer**: Rubraca is approved for the treatment of adult patients with deleterious BRCA mutation (germline and/or somatic) associated with advanced ovarian cancer who have been treated with two or more chemotherapies.\n2. **Maintenance Therapy**: For adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\n3. **Prostate Cancer**: It is also approved for the treatment of patients with BRCA-mutant (germline and/or somatic) metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.\n\n### Mechanism of Action:\n- Rubraca is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_drw99ujAU0Wvn7lb8rwvf5sZ", "custom_id": "604_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e08c8e78ecd6118255ef62f1a14b1166", "body": {"id": "chatcmpl-9St6r5mgSMYabI0tez8xh2waIRz1Y", "object": "chat.completion", "created": 1716672053, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Jakafi (ruxolitinib) is a medication that you should be familiar with if you're treating conditions like myelofibrosis or polycythemia vera. Here are some key points to know:\n\n1. **Indications**: Jakafi is primarily used to treat intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. It\u2019s also approved for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.\n\n2. **Mechanism of Action**: Jakafi is a Janus kinase (JAK) inhibitor, specifically inhibiting JAK1 and JAK2. These kinases are involved in the signaling of several cytokines and growth factors that are important for hematopoiesis and immune function.\n\n3. **Dosage and Administration**: The dosing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_RDOqGmQCG4mv3J5e6fTzVRqT", "custom_id": "605_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f3116e7a24c358588ebe5b8055d0ddd3", "body": {"id": "chatcmpl-9St6rn4H0AohiFkeaniln4UTYoT86", "object": "chat.completion", "created": 1716672053, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trodelvy (generic name: sacituzumab govitecan) is a medication used primarily in the treatment of certain types of cancer. Here are some key points you should know about Trodelvy:\n\n1. **Indications:**\n   - **Metastatic Triple-Negative Breast Cancer (mTNBC):** Trodelvy is approved for the treatment of adults with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease.\n   - **Urothelial Cancer:** It is also approved for the treatment of patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor.\n\n2. **Mechanism of Action:**\n   - Trodelvy is an antibody-drug conjugate (ADC). It consists of an antibody (sacituzumab) that targets the Trop-2 receptor, which is often overexpressed in various cancers, linked to a chemotherapy agent"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_kibsLOn3Ck3QHQiEgSWsxY1d", "custom_id": "606_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "304a2d6b9cd1040bd4cdd25c3a829cad", "body": {"id": "chatcmpl-9St6rdrwDSLumF6a5oG6EAfkeyXdh", "object": "chat.completion", "created": 1716672053, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Certainly! Leukine (sargramostim) is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). Here\u2019s what you should know as a physician:\n\n### Indications:\n1. **Bone Marrow Transplantation (BMT):**\n   - Leukine is used to accelerate myeloid recovery in patients undergoing autologous or allogeneic BMT.\n2. **Peripheral Blood Progenitor Cell (PBPC) Mobilization:**\n   - It helps in mobilizing progenitor cells into the peripheral blood for collection and subsequent autologous transplantation.\n3. **Myeloid Reconstitution:**\n   - It is indicated for myeloid reconstitution following autologous or allogeneic BMT.\n4. **Neutropenia:**\n   - Leukine can be used to reduce the incidence of severe and life-threatening infections in patients with severe chronic neutropenia.\n5. **Chemotherapy-Induced Neutrop"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_GsWudfGDPxpKDumLxMhcrGH0", "custom_id": "607_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "107df13b0fce696f86dd9898aabdd206", "body": {"id": "chatcmpl-9St6ri55tp3E9OwJERGtxXaPLWO9i", "object": "chat.completion", "created": 1716672053, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nexpovio (generic name: selinexor) is an important drug in the treatment of multiple myeloma and certain other hematologic malignancies. Here are some key points you should know about it as a physician:\n\n### Mechanism of Action:\n- **Selinexor** is a selective inhibitor of nuclear export (SINE). It works by binding to and inhibiting exportin 1 (XPO1), a protein that mediates the nuclear export of various proteins involved in cancer cell growth and survival.\n- By inhibiting XPO1, selinexor leads to the accumulation of tumor suppressor proteins in the nucleus, thereby promoting cancer cell death.\n\n### Indications:\n- Nexpovio is approved for use in combination with other therapies for the treatment of relapsed or refractory multiple myeloma.\n- It is also used in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL).\n\n### Dosage and Administration:\n- The dosage and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_6SaeUkn5eLxeNZlpxkYexXgj", "custom_id": "608_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c734d86f33e095abee97e200945334d6", "body": {"id": "chatcmpl-9St6rkFu9HPvgGMDPY6GRDWWgcHHf", "object": "chat.completion", "created": 1716672053, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Koselugo (selumetinib) is a medication that is used primarily for the treatment of neurofibromatosis type 1 (NF1) in pediatric patients. Here are some key points you should be aware of as a physician:\n\n### Indications\n- **Neurofibromatosis Type 1 (NF1)**: Specifically indicated for the treatment of pediatric patients (aged 2 years and older) with symptomatic, inoperable plexiform neurofibromas (PN).\n\n### Mechanism of Action\n- **MEK Inhibitor**: Koselugo is an inhibitor of the mitogen-activated protein kinases 1 and 2 (MEK1/2), which play a role in the signal transduction pathway downstream of the RAS protein, often mutated in NF1. By inhibiting MEK1/2, Koselugo can help reduce the growth of plexiform neurofibromas.\n\n### Dosage and Administration\n- **Dos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_RjXX5Tb6e2QmFt3QRnZIRqYL", "custom_id": "609_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "84b4877c3fc0947951842a149c93d196", "body": {"id": "chatcmpl-9St6rKV5brMljD9ZW0cbzCCr7n8YU", "object": "chat.completion", "created": 1716672053, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Semustine, also known as MeCCNU (methyl-CCNU), is a chemotherapeutic agent that belongs to the nitrosourea class of alkylating agents. It's chemically related to lomustine (CCNU) and carmustine (BCNU). Here are several key points to consider:\n\n### Indications\n- **Cancer Treatment**: Semustine is primarily used in the treatment of certain types of cancers, including brain tumors, colorectal cancer, and Hodgkin's lymphoma. It is often used when other treatments have failed or as part of combination chemotherapy regimens.\n\n### Mechanism of Action\n- **Alkylating Agent**: Semustine works by cross-linking DNA strands, which leads to the inhibition of DNA replication and RNA transcription. This ultimately results in cell death, particularly in rapidly dividing cells such as cancer cells.\n\n### Administration\n- **Oral Medication**: Unlike some other chemotherapeutic agents, Semustine is administered orally"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_rVbtteIN98xvoNFYLsoQaTi0", "custom_id": "610_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "52bdf487d77f11661196019cf8b5d602", "body": {"id": "chatcmpl-9St6seFMTwUlS0goaA9C303JRl3i0", "object": "chat.completion", "created": 1716672054, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Provenge (sipuleucel-T) is an immunotherapy treatment specifically approved for prostate cancer. Here are several key points you should know about Provenge:\n\n### Indications:\n- **Prostate Cancer:** Provenge is indicated for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). It is typically used in patients for whom androgen deprivation therapy has not been effective.\n\n### Mechanism of Action:\n- **Immunotherapy:** Provenge is an autologous cellular immunotherapy designed to stimulate an immune response against prostate cancer cells.\n- **Personalized Treatment:** The treatment involves collecting a patient's own immune cells (dendritic cells), which are then exposed to a protein that is found on prostate cancer cells (prostatic acid phosphatase) linked to an immune-stimulating agent (GM-CSF). These activated cells are then infused back into the patient to help the immune system target and attack prostate cancer cells.\n\n### Administration:\n- **Course"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_k8ogEcFNmhBbgOXPlfWsWzwj", "custom_id": "611_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "abb9d6c1a3a3b641d30a97d87cfb5b89", "body": {"id": "chatcmpl-9St6sJGKGS2Z9cbWp0PeTSn55U8zx", "object": "chat.completion", "created": 1716672054, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Odomzo (sonidegib) is a medication used in the treatment of certain types of skin cancer, specifically locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy or for patients who are not candidates for these treatments. Here are some key points that you should know about Odomzo:\n\n### Mechanism of Action:\n- **Hedgehog Pathway Inhibitor**: Odomzo works by inhibiting the Hedgehog (Hh) signaling pathway, which is implicated in the pathogenesis of basal cell carcinoma. It specifically targets the Smoothened (SMO) receptor, a key component of this pathway.\n\n### Indications:\n- **Locally Advanced Basal Cell Carcinoma**: For adult patients with locally advanced BCC that has recurred post-surgery or radiation, or for those who are not suitable candidates for surgery or radiation.\n\n### Administration:\n- **Oral Medication**: Odomzo is administered orally, typically in a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_2bXQ0WYqJvNNlERpGdiGXlqs", "custom_id": "612_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ec7443462e703d252e125e052a80000a", "body": {"id": "chatcmpl-9St6scLGf0y2p7HrJygM4yrW23oID", "object": "chat.completion", "created": 1716672054, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nexavar (sorafenib) is an oral multi-kinase inhibitor used in the treatment of certain types of cancer. Here are key points that you, as a physician, should know about Nexavar:\n\n1. **Indications**:\n   - **Hepatocellular carcinoma (HCC)**: It is approved for the treatment of advanced HCC.\n   - **Renal cell carcinoma (RCC)**: It is used to treat advanced RCC.\n   - **Differentiated Thyroid Carcinoma (DTC)**: It is indicated for patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.\n\n2. **Mechanism of Action**:\n   - Nexavar inhibits multiple intracellular and cell surface kinases, which are involved in tumor cell proliferation and angiogenesis. These include RAF kinases, VEGFR-1, -2, -3, PDGFR-beta, KIT, FLT-3, RET, and others"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_DzDWcZ4eyz5dDtAKZ6aMSUbz", "custom_id": "613_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "65f3a4ffea780b72de03a988c195bcb3", "body": {"id": "chatcmpl-9St6sqxLgICIgC3nwYdQlZp7ZWOrq", "object": "chat.completion", "created": 1716672054, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Streptozocin, marketed under the brand name Zanosar, is an antineoplastic agent primarily used in the treatment of pancreatic islet cell carcinoma. Here are some key points you should be aware of as a physician:\n\n### Mechanism of Action\n- Streptozocin is a nitrosourea compound that has both alkylating and antimetabolite properties.\n- It specifically targets pancreatic beta cells due to its glucose moiety, which facilitates its uptake into these cells.\n\n### Indications\n- The primary indication for Zanosar is metastatic or locally advanced pancreatic islet cell carcinoma.\n- It may also be used off-label for other types of cancer, but this should be based on thorough clinical judgment and evidence.\n\n### Administration\n- Zanosar is administered intravenously.\n- The dosing regimen can vary, but common schedules include daily administration for 5 consecutive days every 6 weeks or weekly administration.\n- Dose adjustments may be necessary based on patient response and tolerability"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_OPj5KK4MVrJSog89DKOXx2Ij", "custom_id": "614_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9efbeeb90c9484f8642a98182f1ecf1f", "body": {"id": "chatcmpl-9St6sxwF5sLKctC3IeZDYBPHHyfMu", "object": "chat.completion", "created": 1716672054, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It appears there might be a misunderstanding in your question. As of my knowledge cutoff date in October 2023, there is no widely recognized medical product, condition, drug, or term known as \"Kitent.\" If you meant something else, please provide more context or check the spelling, and I would be happy to help with the information you need.\n\nIf \"Kitent\" is a new or emerging term, product, or concept that has appeared after my last update, I would recommend consulting the latest medical literature, trusted medical websites, or professional guidelines for the most up-to-date information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 119, "total_tokens": 159}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Ep83mAGuXwcOa4EVHflYifdK", "custom_id": "615_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "3ac97fa98cf07c1f54ec6cc1d195db96", "body": {"id": "chatcmpl-9St6su6z2gfY3feKLUwFwcZm8xPzA", "object": "chat.completion", "created": 1716672054, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Elzonris (generic name: tagraxofusp-erzs) is a prescription medication used in the treatment of certain hematologic malignancies. It is particularly indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive form of blood cancer. Here are key aspects you should know about Elzonris:\n\n### Mechanism of Action\nElzonris is a targeted therapy composed of a recombinant fusion protein that combines interleukin-3 (IL-3) with a truncated diphtheria toxin. The IL-3 component targets cells expressing the IL-3 receptor (CD123), which is commonly overexpressed in BPDCN cells. The diphtheria toxin component then exerts cytotoxic effects, leading to cell death.\n\n### Indications\n- **Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN):** Elzonris is FDA-approved for the treatment of BPDCN"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_CNFFGjbz6vZ8JW9haxwArQdE", "custom_id": "616_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "efdc41d2045cc73ef7074061be41ea15", "body": {"id": "chatcmpl-9St6tkvh4woWy39PuF09Kbotx6rtE", "object": "chat.completion", "created": 1716672055, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Talzenna (generic name: talazoparib) is an oral medication used primarily for the treatment of certain types of breast cancer. Here are some key points you should be aware of about Talzenna as a physician:\n\n### Indications\n- **Breast Cancer**: Talzenna is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. This should be confirmed by an FDA-approved test.\n\n### Mechanism of Action\n- **PARP Inhibitor**: Talazoparib is a poly (ADP-ribose) polymerase (PARP) inhibitor. It works by inhibiting the PARP enzyme, which helps repair DNA damage in cells. Cancer cells with BRCA mutations rely more heavily on PARP due to their compromised ability to repair DNA, so inhibiting PARP leads to the accumulation of DNA damage and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_TxAOAZ9FxbXBRnJavJcDkWS4", "custom_id": "617_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "07c3f64221d74a9c18faa01a625363ea", "body": {"id": "chatcmpl-9St6tDQmYEGeekF5YLWFbq4Ix5XmA", "object": "chat.completion", "created": 1716672055, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imlygic (talimogene laherparepvec) is an oncolytic viral therapy used primarily for the treatment of melanoma lesions in patients with recurrent melanoma that cannot be surgically removed. Here are some key points you should know about Imlygic:\n\n### Mechanism of Action\n- **Oncolytic Virus**: Imlygic is based on a genetically modified herpes simplex virus type 1 (HSV-1). It selectively infects and kills cancer cells.\n- **Replication**: Once injected into the tumor, the virus replicates inside cancer cells, leading to cell lysis and the release of tumor-derived antigens.\n- **GM-CSF**: The virus is engineered to express granulocyte-macrophage colony-stimulating factor (GM-CSF), which helps stimulate an anti-tumor immune response.\n\n### Indications\n- **Melanoma**: Imlygic is indicated for the local treatment of unresectable cutaneous, subcutaneous, and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_cOhd7MZGGYtQqC93tSt5jeIb", "custom_id": "618_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "fb72cc54f2f04eb2013ff3f039061565", "body": {"id": "chatcmpl-9St6tuxHNUL7RrQ77I2dDMTnbQdhe", "object": "chat.completion", "created": 1716672055, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a typo or misunderstanding in your question, as \"Amnoid\" does not correspond to any known medical term, medication, or condition. If you meant \"Amniotic,\" it pertains to the amniotic fluid, sac, or membrane associated with pregnancy. Amniotic fluid is critical for fetal development, providing a protective cushion, allowing for movement, and aiding in the development of the lungs and digestive system.\n\nAs a physician, here are some key points you should know about amniotic fluid and related conditions:\n\n1. **Amniotic Fluid Functions:**\n   - Protects the fetus by cushioning against physical trauma.\n   - Allows for fetal movement, which is essential for musculoskeletal development.\n   - Maintains a constant temperature.\n   - Facilitates lung and digestive system development by enabling the fetus to \"breathe\" and swallow the fluid.\n\n2. **Amniotic Fluid Abnormalities:**\n   - **Polyhydramnios:** Excess"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Led2rSPfZrf6NddReExjpQnb", "custom_id": "619_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "3ee81515c2fbc49d119a58d8868a72ef", "body": {"id": "chatcmpl-9St6tRNobtUAy1XAnkw4nW0M405mY", "object": "chat.completion", "created": 1716672055, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely known drug, medical device, or treatment called \"Istubal.\" It's possible that it could be a misspelling or a less commonly known name for something else. Here are a few steps you can take to find more information:\n\n1. **Check Medical Databases:** Use reputable medical databases such as PubMed, Medline, or your institution's library resources to search for \"Istubal.\"\n\n2. **Consult Colleagues:** Ask colleagues or specialists if they have heard of \"Istubal.\" Sometimes, local or regional names for medications or treatments might not be widely recognized.\n\n3. **Verify with Patients:** If a patient mentioned this name, verify the spelling and context. Patients sometimes misremember or mispronounce drug names.\n\n4. **Pharmaceutical References:** Use pharmaceutical references like the Physician's Desk Reference (PDR) or an equivalent to check if \"Istubal\" is listed.\n\n5. **Contact Medical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ERbAfUEmHQyF5Vfd3oaX5RUQ", "custom_id": "620_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "204a19b674c862c103ddb1eb9666c5fd", "body": {"id": "chatcmpl-9St6tyqyv2POaqiNwyJZH9mtjKIHf", "object": "chat.completion", "created": 1716672055, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Teysuno is an oral anti-cancer medication that you should be familiar with, especially if you are treating patients with advanced gastric cancer. Here are some key points about Teysuno:\n\n### Composition and Mechanism of Action\n- **Active Ingredients**: Teysuno is a combination of three active substances: tegafur, gimeracil, and oteracil. \n  - **Tegafur**: A prodrug of 5-fluorouracil (5-FU), an anti-cancer agent.\n  - **Gimeracil**: A dihydropyrimidine dehydrogenase (DPD) inhibitor that prevents the degradation of 5-FU, thereby increasing its effectiveness.\n  - **Oteracil**: Inhibits the phosphorylation of 5-FU in the gastrointestinal tract, reducing gastrointestinal toxicity.\n\n### Indications\n- **Primary Use**: Teysuno is primarily indicated for the treatment of advanced"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_5eminMQjkfOJNqzBv8YMKZ4Y", "custom_id": "621_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5ed3d05873a09e6ec75d55f74019e565", "body": {"id": "chatcmpl-9St6t1xWVWYalV8XvwqBjj2NatYOE", "object": "chat.completion", "created": 1716672055, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ftorafur, also known as tegafur, is a chemotherapeutic agent used primarily in the treatment of various cancers, including colorectal and breast cancer. It is a prodrug of 5-fluorouracil (5-FU), meaning it is metabolized in the body to produce the active drug. Here are some key points you should know about Ftorafur:\n\n### Mechanism of Action:\n- **Prodrug:** Ftorafur is converted to 5-FU in the body.\n- **Active Metabolite:** 5-FU interferes with DNA synthesis by inhibiting thymidylate synthase, an enzyme essential for DNA replication and repair.\n- **Cell Cycle Specificity:** 5-FU is most effective during the S-phase of the cell cycle when DNA synthesis occurs.\n\n### Indications:\n- **Colorectal Cancer:** Often used in combination with other agents.\n- **Breast Cancer:** Can be used in certain chemotherapy protocols"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_aNBF8Pl1z4ECicUa6ImGYZuo", "custom_id": "622_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a27f169bd72da948402f6784477b1985", "body": {"id": "chatcmpl-9St6tzTTsyuXBhW84GZIIVsyPiLRc", "object": "chat.completion", "created": 1716672055, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gliotem is a brand name for the chemotherapy drug temozolomide, which is commonly used in the treatment of certain types of brain tumors, such as glioblastoma multiforme (GBM) and anaplastic astrocytoma. Here are some key points that you, as a physician, should be aware of:\n\n### Mechanism of Action:\n- **Alkylating Agent:** Temozolomide is an oral alkylating agent that works by methylating the DNA at the O6 and N7 positions of guanine, leading to DNA damage, which triggers apoptosis in rapidly dividing tumor cells.\n\n### Indications:\n- **Glioblastoma Multiforme (GBM):** Often used as the first-line treatment in combination with radiotherapy.\n- **Anaplastic Astrocytoma:** Can be used for newly diagnosed cases or as a second-line treatment after the recurrence of the tumor.\n\n### Administration:\n- **Oral Administration:** Temozol"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_IVEfofLptusfAuiRtpRcYmxN", "custom_id": "623_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b5248249f9bd41236a405ff8f22deac7", "body": {"id": "chatcmpl-9St6t0ZqGT6u5r7l4tKCBo3vPbs4h", "object": "chat.completion", "created": 1716672055, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Torisel (temsirolimus), which is an intravenous mTOR (mammalian target of rapamycin) inhibitor used primarily in the treatment of certain cancers. Here are key points you should know:\n\n### Indications:\n1. **Renal Cell Carcinoma (RCC)**: Torisel is primarily indicated for the treatment of advanced renal cell carcinoma, particularly in patients with poor prognostic features.\n2. **Mantle Cell Lymphoma (MCL)**: It may also be used off-label for the treatment of relapsed or refractory mantle cell lymphoma.\n\n### Mechanism of Action:\n- **mTOR Inhibition**: Torisel works by inhibiting the mTOR kinase, which plays a role in cell growth, proliferation, and survival. By blocking mTOR, Torisel can reduce tumor cell proliferation and induce apoptosis.\n\n### Administration:\n- **Dosing**: Typically, Torisel is administered as a once"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_P1uDy0rQd8ePcTLXp9jRAPB0", "custom_id": "624_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "03e0d2788cec19aba6f7ca2d61794e11", "body": {"id": "chatcmpl-9St6upUH1M8SUOr4khHQuh6614Its", "object": "chat.completion", "created": 1716672056, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vumon, also known by its generic name teniposide, is an antineoplastic (cancer-fighting) agent used primarily in the treatment of various types of cancer. Here are some key points you should know about Vumon as a physician:\n\n### Indications:\n- **Acute Lymphoblastic Leukemia (ALL):** Often used in combination with other chemotherapeutic agents.\n- **Hodgkin's Disease and Non-Hodgkin's Lymphoma:** Used in specific chemotherapy regimens.\n- **Other Cancers:** Has been used in the treatment of certain types of solid tumors and other hematologic malignancies.\n\n### Mechanism of Action:\n- Teniposide is a topoisomerase II inhibitor. It works by interfering with the DNA replication process, which inhibits the proliferation of cancer cells.\n\n### Administration:\n- **Formulation:** Typically administered as an intravenous infusion.\n- **Dosage:** The dosage can vary based on the specific cancer being"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ppeZNBe1NqS59r5ACKGQLwPM", "custom_id": "625_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "95dfbbc7412d94b99ae8b85242912358", "body": {"id": "chatcmpl-9St6u7yiPm2J3eHnRTdb1iLKhtwC5", "object": "chat.completion", "created": 1716672056, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Contergan, known generically as thalidomide, is a medication with a controversial history, primarily due to its teratogenic effects when it was first marketed. Here are the key points you should know about it:\n\n### Historical Context\n1. **Introduction and Early Use:**\n   - Thalidomide was first introduced in the late 1950s by the German pharmaceutical company Gr\u00fcnenthal.\n   - It was initially marketed as a sedative and later as a remedy for morning sickness in pregnant women.\n\n2. **Teratogenic Effects:**\n   - Thalidomide caused severe birth defects, including phocomelia (malformation of the limbs), when taken by pregnant women.\n   - The drug was withdrawn from the market in the early 1960s after the link to birth defects was established.\n\n### Current Uses\nDespite its past, thalidomide has found a place in modern medicine due to its immunomodulatory, anti-inflammatory, and anti-angi"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_e8i301IZ7tx2J0TPnYu8OTgc", "custom_id": "626_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2eabee9df063beee37fb6642b8e59ef6", "body": {"id": "chatcmpl-9St6uK7pWUA5vEbC4c1pxDHtgnvOd", "object": "chat.completion", "created": 1716672056, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lanvis, also known by its generic name tioguanine (or thioguanine), is a medication primarily used in the treatment of certain types of cancers, particularly acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Here are some key points you should know about Lanvis:\n\n### Mechanism of Action\n- **Antimetabolite**: Lanvis is a purine analog and acts as an antimetabolite. It interferes with DNA and RNA synthesis by incorporating into DNA and RNA strands, ultimately leading to cell death.\n- **Cell Cycle Specificity**: It is most active in the S-phase of the cell cycle where DNA synthesis occurs.\n\n### Indications\n- **Acute Myeloid Leukemia (AML)**: Often used in combination with other chemotherapeutic agents.\n- **Acute Lymphoblastic Leukemia (ALL)**: Also used, typically during remission induction or maintenance phases.\n\n### Administration\n- **Or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_JzkJyhoXnsVnTT1YFAv6aYjm", "custom_id": "627_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d86aaab7b807eb01f914affac40ddecb", "body": {"id": "chatcmpl-9St6ulLR4cFceFsZQR0soqoj5fIaU", "object": "chat.completion", "created": 1716672056, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tepadina (thiotepa) is an alkylating agent used primarily in the treatment of certain cancers and as part of conditioning regimens prior to hematopoietic stem cell transplantation. Here are some key points you should know about Tepadina:\n\n1. **Mechanism of Action**: Thiotepa works by alkylating DNA, which leads to cross-linking of DNA strands. This inhibits DNA replication and RNA transcription, ultimately causing cell death. It is most effective against rapidly dividing cells, which include cancer cells.\n\n2. **Indications**: Tepadina is indicated for:\n   - Malignant effusions (e.g., pleural effusions, malignant ascites).\n   - Various cancers including breast cancer, ovarian cancer, and bladder cancer.\n   - Conditioning regimens before bone marrow or hematopoietic stem cell transplantation.\n\n3. **Administration**:\n   - Tepadina can be administered intravenously, intraperitoneally, or intravesically,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ZTl7iWEfVFGhCNMNaqdPAqXq", "custom_id": "628_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d0e973f2087ce514cbf43ae2de2e081a", "body": {"id": "chatcmpl-9St6uoQ5T0Z6XCucE1MODz95HdJlN", "object": "chat.completion", "created": 1716672056, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kymriah (tisagenlecleucel) is a type of CAR T-cell therapy, which stands for chimeric antigen receptor T-cell therapy. It is used in oncology for the treatment of certain types of cancers. Here are some key points you should know about Kymriah:\n\n1. **Indications**:\n   - Kymriah is approved for the treatment of patients up to 25 years old with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.\n   - It is also approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.\n\n2. **Mechanism of Action**:\n   - Kymriah involves reprogramming a patient\u2019s own T cells to target and kill cancer cells. T cells are collected from the patient, genetically modified to express a CAR that targets the CD19 antigen found on B cells, and then infused back into the patient"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_3GCN8KUg90gZYX9W3D6cDwNi", "custom_id": "629_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5e467821cf4e60b1b7c684798d38d90f", "body": {"id": "chatcmpl-9St6uUPhtrim9MTv4RRcBEIc9Zw8w", "object": "chat.completion", "created": 1716672056, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fotivda (generic name: tivozanib) is an oral tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. It is primarily used for the treatment of renal cell carcinoma (RCC). Here are some key points you should be aware of:\n\n1. **Indications**: Fotivda is approved for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.\n\n2. **Mechanism of Action**: Tivozanib inhibits VEGF receptors, which play a crucial role in angiogenesis, the process by which new blood vessels form from pre-existing vessels. By inhibiting these receptors, tivozanib can reduce the blood supply to tumors, thereby inhibiting their growth and proliferation.\n\n3. **Administration**: The recommended dose of Fotivda is 1.34 mg once daily for 21 days, followed"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_awdGMzSNf6nUxnWVmNuKFQWA", "custom_id": "630_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0aedf868d485695d62cf0dd16311e27d", "body": {"id": "chatcmpl-9St6ur34lTYrZgUnxkpQX51DpWeE3", "object": "chat.completion", "created": 1716672056, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my latest update in October 2023, there appears to be no widely recognized medication or treatment called \"Evotopin.\" It's possible that the name might be misspelled, be a less common or newly released drug, or it might be a name used in a specific region or context that isn't widely known.\n\nIf \"Evotopin\" is a new or experimental drug, here are some general steps you should take as a physician to stay informed:\n\n1. **Verify the Name and Spelling**: Double-check the name to ensure it is correct. Sometimes drug names can be easily confused or misspelled.\n\n2. **Consult Reliable Sources**: Use trusted medical databases and resources such as PubMed, the National Institutes of Health (NIH), or professional medical societies to search for information about the drug.\n\n3. **Pharmaceutical Reps and Companies**: Contact the pharmaceutical company that manufactures the drug for the most accurate and comprehensive information, including clinical trial data, indications,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_804fCQgI83xTPxW8ANTgIhBp", "custom_id": "631_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "06dadcd1c644fcd29378866e544644bf", "body": {"id": "chatcmpl-9St6vaJiTQqksoFzfdmDqapbEqkAn", "object": "chat.completion", "created": 1716672057, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Acapodene is a brand name for toremifene, a nonsteroidal selective estrogen receptor modulator (SERM) commonly used in the treatment of certain types of breast cancer. Here are some key points you should know about Acapodene (toremifene):\n\n1. **Indications**: Toremifene is primarily used in the treatment of estrogen receptor-positive metastatic breast cancer in postmenopausal women. It is also sometimes used off-label for other conditions as determined by a physician.\n\n2. **Mechanism of Action**: Toremifene works by binding to estrogen receptors and blocking the effects of estrogen on breast tissue, which can inhibit the growth of estrogen-dependent cancer cells.\n\n3. **Dosage and Administration**: The usual dose for breast cancer treatment is typically 60 mg orally once daily. It is important to follow the prescribed dosage and administration guidelines.\n\n4. **Side Effects**: Common side effects include hot flashes, sweating, nausea"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_fVyrtKR5kmD44pldpwBEXs7J", "custom_id": "632_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "21ff2f5c024fd6a04ab3a6140be95350", "body": {"id": "chatcmpl-9St6vimlr5GH4bXomptPrgQtmfhz1", "object": "chat.completion", "created": 1716672057, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bexxar (tositumomab and iodine I-131 tositumomab) is a radioimmunotherapy treatment that was used for certain types of non-Hodgkin lymphoma (NHL), particularly for patients with relapsed or refractory low-grade, follicular, or transformed NHL. Here are some key points you should know as a physician:\n\n1. **Mechanism of Action**: Bexxar combines a monoclonal antibody (tositumomab) that targets the CD20 antigen on B-cells with a radioactive iodine isotope (I-131). This dual mechanism allows it to kill cancer cells both through immune system-mediated processes and localized radiation.\n\n2. **Indications**: Bexxar was primarily used for patients with CD20-positive, relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin lymphoma, including patients who had not responded to rituximab.\n\n3. **Administration**: The treatment"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_eqAgUI7tdesFLYknM7MDIKv4", "custom_id": "633_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6e71eaa7da246741a3160743ce60f050", "body": {"id": "chatcmpl-9St6vhIeQQCHGcSkXagq9EJbXJFET", "object": "chat.completion", "created": 1716672057, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Yondelis, also known by its generic name trabectedin, is a chemotherapeutic agent used primarily in the treatment of certain types of cancer, such as soft tissue sarcoma and ovarian cancer. Here are some key points you should know about Yondelis as a physician:\n\n### Pharmacology and Mechanism of Action\n- **Source**: Originally derived from the sea squirt *Ecteinascidia turbinata*, trabectedin is now produced synthetically.\n- **Mechanism of Action**: It binds to the minor groove of DNA, interfering with cell division and the transcription process. This results in disruption of the cell cycle and eventually leads to cancer cell death.\n\n### Indications\n- **Soft Tissue Sarcoma**: Approved for use in patients with advanced soft tissue sarcoma, particularly liposarcoma and leiomyosarcoma, who have previously received chemotherapy.\n- **Ovarian Cancer**: Often used in combination with doxorubicin for the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Zt5tuzNyED7VoQkCxu4Vot0a", "custom_id": "634_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "1b43c41704966d4ed1c8a4e731a21900", "body": {"id": "chatcmpl-9St6vQCLU1smRWJGgs45ovizMQJlK", "object": "chat.completion", "created": 1716672057, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mekinist, known generically as trametinib, is a targeted cancer therapy that you might prescribe primarily for the treatment of certain types of melanoma, particularly those that have a specific mutation in the BRAF gene (BRAF V600E or V600K mutations). Here are some key points you should be aware of:\n\n### Mechanism of Action:\n- **MEK Inhibition:** Mekinist is a MEK inhibitor, which means it targets the MEK1 and MEK2 enzymes. These enzymes are part of the MAPK/ERK pathway, which is involved in cellular proliferation. By inhibiting MEK, trametinib can help slow down or stop the growth of cancer cells that rely on this pathway for growth and survival.\n\n### Indications:\n- **Melanoma:** It's indicated for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.\n- **Combination Therapy:** Often used in combination with dabrafenib ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_A5rRnEqkh4VFYWQTCvZUMhlv", "custom_id": "635_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5dc09b06db1bd7a3e1c65453ec9d2aa2", "body": {"id": "chatcmpl-9St6wz9iMI4KvoZarsRYFPB2noxLi", "object": "chat.completion", "created": 1716672058, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there isn't a medication or compound widely recognized or documented under the name \"Amixam\" in the medical literature or pharmacopoeias. It is possible that \"Amixam\" could be a new or experimental drug, a regional brand name, or a typographical error. Here are a few steps you might consider to gather more information:\n\n1. **Consult Medical Databases**: Check reliable medical databases such as PubMed, Medline, or drug-specific databases like the FDA's or EMA's website to see if there are any recent studies or drug approvals under this name.\n\n2. **Pharmaceutical Repositories**: Look into pharmaceutical repositories or databases like the British National Formulary (BNF), Physicians' Desk Reference (PDR), or similar entities in your country.\n\n3. **Ask Colleagues**: Sometimes, colleagues might have come across newer drugs or brand names that are less documented.\n\n4. **Pharmacy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_nakIIsvVNghA7OSN4dMZN0yc", "custom_id": "636_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "fd3279d86e6458ca4db22b39edecb201", "body": {"id": "chatcmpl-9St6v7RXWC5OhdrbxB1q6aXw4UusD", "object": "chat.completion", "created": 1716672057, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized drug or treatment specifically named \"Biceltis.\" It's possible that you may be referring to a drug that is either very new, region-specific, or perhaps a typographical error. Here are a few steps you can take to ensure you have the correct information:\n\n1. **Verify Spelling and Name**: Double-check the spelling of the drug or treatment name. Drug names can be complex and sometimes similar-sounding names can cause confusion.\n\n2. **Consult Medical References**: Use reliable medical references such as the Physician's Desk Reference (PDR), UpToDate, or other clinical decision support tools available to you.\n\n3. **Ask Colleagues or Pharmacists**: Sometimes, discussing with fellow healthcare professionals or pharmacists can provide clarity if a new or less common drug is mentioned.\n\n4. **Search Medical Journals**: If the drug is very new, it might be covered in recent medical literature"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_m6R8vlMGZM5NqmHfSnPhth0Q", "custom_id": "637_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "612c81627fb2087a64aacb763d3b30cc", "body": {"id": "chatcmpl-9St6vLYZYsPRgFL83IuT75FP6Okyi", "object": "chat.completion", "created": 1716672057, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imjudo is the brand name for tremelimumab, a monoclonal antibody that targets CTLA-4 (cytotoxic T-lymphocyte-associated protein 4). As a physician, it is important to understand several key aspects of this medication:\n\n### Mechanism of Action:\n- **CTLA-4 Inhibition**: Tremelimumab works by blocking CTLA-4, a molecule on T-cells that downregulates immune responses. By inhibiting CTLA-4, tremelimumab enhances the immune system's ability to attack cancer cells.\n\n### Indications:\n- **Cancer Treatment**: Imjudo is primarily used in the treatment of various types of cancer, including melanoma, non-small cell lung cancer, and others, often in combination with other immunotherapies like PD-1/PD-L1 inhibitors.\n\n### Administration:\n- **Intravenous Infusion**: Imjudo is typically administered via intravenous infusion. The dosage and schedule depend"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_wT1gUpZDJOR9PRwAweievLmX", "custom_id": "638_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "568dbee10f97761dc647f378e7b7dbea", "body": {"id": "chatcmpl-9St6w5a6B22nrMhbYqWhPRSSqapUH", "object": "chat.completion", "created": 1716672058, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my latest update in 2021, there doesn't appear to be a widely recognized medication or treatment called \"Ovastat.\" It's possible that it could be a new or less common drug, a brand name not widely known, or a typographical error. However, here are some steps you can take to ensure you have accurate information:\n\n1. **Check Reliable Medical Databases**: Look up \"Ovastat\" in trusted medical databases such as PubMed, Medline, or the FDA database to find any clinical trials, research papers, or official drug listings.\n\n2. **Consult Pharmacological Resources**: Use resources like the Physician's Desk Reference (PDR), UpToDate, or Lexicomp to find detailed drug information.\n\n3. **Contact Professional Organizations**: Reach out to professional bodies such as the American Medical Association (AMA) or your specialty's professional organization for any updates or information on new drugs.\n\n4. **Network with Colleagues**: Discuss with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_UlO9TaNltkhe8FaXf3KwCL7p", "custom_id": "639_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "24a6a21eb3a52e3f8df05e0af457062a", "body": {"id": "chatcmpl-9St6w3lKvFt8OD7Wz8PAtFjVlXxHP", "object": "chat.completion", "created": 1716672058, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lonsurf (trifluridine and tipiracil) is an oral medication used primarily in the treatment of metastatic colorectal cancer and metastatic gastric or gastroesophageal junction adenocarcinoma. Here are some key points you should know as a physician:\n\n### Indications:\n1. **Metastatic Colorectal Cancer**:\n   - Indicated for patients who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.\n2. **Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma**:\n   - Indicated in patients previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.\n\n### Mechanism of Action:\n- **Trifluridine**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_MtSOLYYOGgLxscjU46PXd2ga", "custom_id": "640_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "dbf097349d477148b4553eda5197c30c", "body": {"id": "chatcmpl-9St6wrM8v51fepDunuGMYxVkOdKow", "object": "chat.completion", "created": 1716672058, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Decapeptyl, also known as triptorelin, is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH). It is used primarily in the treatment of hormone-responsive cancers such as prostate cancer, as well as in conditions like endometriosis, uterine fibroids, and central precocious puberty. Here are some key points you should consider as a physician:\n\n1. **Mechanism of Action**:\n   - Triptorelin initially stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. However, with continuous administration, it eventually leads to downregulation of GnRH receptors and suppression of LH and FSH secretion, resulting in decreased production of sex hormones (testosterone in men and estrogen in women).\n\n2. **Indications**:\n   - **Prostate Cancer**: Used for palliative treatment.\n   - **Endometriosis**: Helps reduce estrogen"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_x6dyB1lmJw16KftQR7tCa3Wk", "custom_id": "641_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9ab7fc338e3503cd5226a945d0b51476", "body": {"id": "chatcmpl-9St6wK2WwcC25vu6IOQ0HlBdbMTn0", "object": "chat.completion", "created": 1716672058, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Depacon is the brand name for valproate sodium, a medication primarily used to treat epilepsy and other seizure disorders. Here are some key points you should know about Depacon as a physician:\n\n### Indications\n- **Epilepsy:** Depacon is used to treat various types of seizures, including complex partial seizures, simple and complex absence seizures, and multiple seizure types that include absence seizures.\n- **Migraine Prophylaxis:** It is sometimes used off-label for the prevention of migraine headaches.\n- **Bipolar Disorder:** Valproate sodium can be used to treat manic episodes associated with bipolar disorder.\n\n### Mechanism of Action\n- Depacon works by increasing the levels of gamma-aminobutyric acid (GABA) in the brain, which helps to calm nerve activity and reduce seizures.\n\n### Administration\n- Depacon is available as an injectable form, which can be particularly useful for patients who cannot take oral medications.\n- It is usually administered intravenously.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_5bEv8Rdy9ijT7FFFLsqcswmo", "custom_id": "642_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5754f57e964e6f10e56bc1e6f9b9efcb", "body": {"id": "chatcmpl-9St6wHqLlpDIV6t5sN5DHVdNhkhE9", "object": "chat.completion", "created": 1716672058, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Valstar (valrubicin) is an important medication for you to be familiar with as a physician, particularly if you are working in the field of oncology or urology. Here are some key points you should know about Valstar:\n\n### Indications:\n- **Bladder Cancer:** Valstar is primarily used for the treatment of Bacillus Calmette-Gu\u00e9rin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.\n\n### Mechanism of Action:\n- Valrubicin is an anthracycline chemotherapeutic agent. It works by interfering with DNA replication and transcription. It is believed to intercalate DNA and inhibit topoisomerase II, which leads to the inhibition of cancer cell growth and promotes apoptosis.\n\n### Administration:\n- **Intravesical Administration:** Valrubicin is administered directly into the bladder (intravesical). This localized delivery helps concentrate the drug"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_7FhgMCL4sQy8pjNyTQLdPY2n", "custom_id": "643_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "964fc438e257ce4c4c922e1ef305ad59", "body": {"id": "chatcmpl-9St6wGflCQGfHj0Hk4bvsJ8zK7ZH7", "object": "chat.completion", "created": 1716672058, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Caprelsa (vandetanib) is a medication that is used primarily in the treatment of medullary thyroid cancer. Here are some key points that you, as a physician, should be aware of regarding Caprelsa:\n\n1. **Mechanism of Action**:\n   - Vandetanib is a tyrosine kinase inhibitor that targets multiple pathways, including the RET (rearranged during transfection) proto-oncogene, vascular endothelial growth factor receptor (VEGFR), and epidermal growth factor receptor (EGFR).\n\n2. **Indications**:\n   - It is used for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable, locally advanced, or metastatic disease.\n\n3. **Dosage and Administration**:\n   - The recommended dose of Caprelsa is 300 mg once daily, taken with or without food.\n   - Tablets should be swallowed whole with water and should not be crushed or chewed.\n   - Dose adjustments may"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_cqDjA976JWkqJLXxk7dAeHjY", "custom_id": "644_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0242619e0fba8e8cc1a1a4b0563fe29b", "body": {"id": "chatcmpl-9St6wfJqZLiCoRElWYd3Nt57sVRdY", "object": "chat.completion", "created": 1716672058, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zelboraf (vemurafenib) is a medication used primarily to treat melanoma, a type of skin cancer, that has spread to other parts of the body or cannot be removed by surgery. It is especially effective in patients whose cancer cells harbor a specific mutation in the BRAF gene, known as BRAF V600E.\n\nHere are key points you should know about Zelboraf as a physician:\n\n1. **Mechanism of Action**: Zelboraf is a BRAF inhibitor. It works by targeting and inhibiting the activity of the BRAF V600E-mutated protein, which is involved in promoting cancer cell growth.\n\n2. **Indications**: It is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E mutation. It is not recommended for patients who do not have this mutation.\n\n3. **Genetic Testing**: Before prescribing Zelboraf, it is essential to confirm the presence of the BRAF V"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_enkAd2evtZVh8rKaPQqgwHXl", "custom_id": "645_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "4141cfc5addf1ea65df7fe4c210d60b3", "body": {"id": "chatcmpl-9St6wq7BVqN72OioR0leFJ0vKjnwp", "object": "chat.completion", "created": 1716672058, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Venclexta (venetoclax) is a medication used primarily in the treatment of certain types of cancers, particularly chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Here are key points you should know about Venclexta:\n\n### Mechanism of Action\n- **Target:** Venclexta is a selective B-cell lymphoma-2 (BCL-2) inhibitor. BCL-2 is a protein that helps cancer cells survive by preventing apoptosis (programmed cell death).\n- **Function:** By inhibiting BCL-2, Venclexta promotes apoptosis in cancer cells, thereby reducing the number of malignant cells in the body.\n\n### Indications\n- **Chronic Lymphocytic Leukemia (CLL):** Often used in combination with other agents like rituximab or obinutuzumab, or as monotherapy.\n- **Acute Myeloid Leukemia (AML):** Typically used in combination with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_MY3xhCzJyUz7Le77l4ucn8cB", "custom_id": "646_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ffff1b6a6999bbe2e684fa9f5eef681c", "body": {"id": "chatcmpl-9St6wrUWbmZupUkQNrsuRl1Z47pcq", "object": "chat.completion", "created": 1716672058, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alkaban-AQ is a brand name for the drug daunorubicin, which is an anthracycline antibiotic used primarily as a chemotherapy agent. Here are key points you should know about it as a physician:\n\n### Indications:\n- **Acute Myeloid Leukemia (AML):** It's commonly used in the treatment of AML in adults.\n- **Acute Lymphoblastic Leukemia (ALL):** It's also utilized in the treatment of ALL in both adults and children.\n\n### Mechanism of Action:\n- **DNA Intercalation:** Daunorubicin intercalates between DNA base pairs, inhibiting the synthesis of DNA and RNA.\n- **Topoisomerase II Inhibition:** It inhibits topoisomerase II, preventing the relaxation of supercoiled DNA, which is necessary for replication and transcription.\n- **Free Radical Formation:** It generates free radicals that cause damage to cellular components, including DNA and cell membranes.\n\n### Administration:\n- **Intr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_BAPRW7yUiki0FEuUpXES5nfg", "custom_id": "647_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0e1f57fd05a0bdf0714ff2fed3b6a5a0", "body": {"id": "chatcmpl-9St6wKbK8yicZ1EyN2hfAHYjtISuy", "object": "chat.completion", "created": 1716672058, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff in October 2021, there is no widely recognized medication or treatment called \"Alcrist.\" It's possible that it could be a misspelling, a new drug that has been introduced after my last update, or a term used in a specific context not widely known in the medical community.\n\nIf \"Alcrist\" refers to a new or emerging treatment:\n\n1. **Indications and Usage**: Understand the specific conditions or diseases it is designed to treat.\n2. **Mechanism of Action**: Know how it works at a biochemical or molecular level.\n3. **Dosage and Administration**: Be familiar with the recommended dosage, form of administration (oral, IV, etc.), and the schedule.\n4. **Contraindications and Precautions**: Be aware of any conditions or factors that would make the use of Alcrist inappropriate.\n5. **Side Effects and Adverse Reactions**: Know the common and serious side effects associated with the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_TAzoW7BkZNTOYAvEJA7O9pxy", "custom_id": "648_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "836d47238c3766d3ebd38d0c06862b09", "body": {"id": "chatcmpl-9St6xvR7rPiVo0D7t9QAtbkO44xAO", "object": "chat.completion", "created": 1716672059, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Marqibo (vincristine sulfate liposome injection) is a chemotherapeutic agent used primarily in the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). Here are some key points you should know about Marqibo:\n\n### Indications and Usage\n- **Marqibo** is indicated for the treatment of adult patients with Ph- ALL in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.\n- It is a liposomal formulation of vincristine, designed to enhance delivery to cancer cells and potentially reduce toxicity compared to conventional vincristine.\n\n### Mechanism of Action\n- **Vincristine** works by inhibiting microtubule formation in the mitotic spindle, which is essential for cell division. This leads to apoptosis (programmed cell death) in rapidly dividing cancer cells.\n- The liposomal formulation encapsulates the vincristine in a lipid bilayer, which can help to improve"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_eIuxPSvndnS1DtR1FDFnKKdn", "custom_id": "649_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d4c0f3541e979873f5163d4601599b29", "body": {"id": "chatcmpl-9St6xkU1KW5Or0VucDRXE6DzQJspD", "object": "chat.completion", "created": 1716672059, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Eldesine, also known by its generic name vindesine, is a chemotherapeutic agent used primarily in the treatment of various types of cancer. Here are some key points about Eldesine that you should know as a physician:\n\n### Pharmacology:\n1. **Class:** Vindesine is a synthetic vinca alkaloid, chemically related to vincristine and vinblastine.\n2. **Mechanism of Action:** It works by inhibiting microtubule formation in the mitotic spindle, thereby stopping cell division and leading to cell death. This makes it particularly effective against rapidly dividing cells, including cancer cells.\n\n### Indications:\n1. **Types of Cancer:** Eldesine is used in the treatment of certain leukemias, lymphomas, and solid tumors such as lung cancer and breast cancer. It is often used when other treatments have not been effective.\n2. **Combination Therapy:** It is frequently used in combination with other chemotherapeutic agents to enhance efficacy.\n\n### Administration:\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_G9JyghKkozqKSo3fOxAP69KD", "custom_id": "650_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "425d44bf4011b98405280d6638a97ff2", "body": {"id": "chatcmpl-9St6xXA2I28Wuylg995i51Ib9h5p1", "object": "chat.completion", "created": 1716672059, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Javlor is the brand name for vinflunine, a chemotherapy medication used primarily in the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, particularly after failure of a prior platinum-containing regimen. Here are some key points you should know about Javlor:\n\n### Mechanism of Action\n- **Vinflunine** is a vinca alkaloid that inhibits microtubule assembly, thereby disrupting mitotic spindle formation and cell division, leading to cell death.\n\n### Indications\n- Javlor is indicated for patients with advanced or metastatic transitional cell carcinoma of the urothelial tract who have previously undergone a platinum-containing regimen.\n\n### Administration\n- **Dosage**: The usual starting dose is 320 mg/m\u00b2 administered as an intravenous infusion over 20 minutes every three weeks. Dosage adjustments may be necessary based on patient tolerance and side effects.\n- **Premedication**: Anti-emetic medication is often recommended to prevent nausea and vomiting.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_mKFeZoVWPAefKjixfXs6ddwN", "custom_id": "651_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "38c5f701dc71cc5385fd1e0f1d4b1fb4", "body": {"id": "chatcmpl-9St6xmJdfz68Kfpvw2Ba8W95QMZRv", "object": "chat.completion", "created": 1716672059, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, you should know the following about Binorel:\n\n1. **Drug Classification**: Binorel is a medication that may fall into specific categories such as antihypertensives, antidiabetics, or another class depending on its chemical composition and primary use.\n\n2. **Mechanism of Action**: Understanding how Binorel works at the molecular level is crucial. This includes knowing its pharmacodynamics (what the drug does to the body) and pharmacokinetics (what the body does to the drug).\n\n3. **Indications**: Familiarize yourself with the conditions for which Binorel is prescribed. For example, it could be used for managing hypertension, diabetes, or another medical condition.\n\n4. **Dosage and Administration**: Know the recommended dosage ranges, how it should be administered (orally, intravenously, etc.), and any special instructions for its use.\n\n5. **Contraindications**: Be aware of any conditions or factors that would contraindicate"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_W57AFfHrySnmBOWQo0NrKpFm", "custom_id": "652_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "ddf090604a7f9318b5ccaa7b0ce559fd", "body": {"id": "chatcmpl-9St6x4z1FDXhYwRG8fBc7vELbbGqx", "object": "chat.completion", "created": 1716672059, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erivedge (vismodegib) is an oral medication primarily used in the treatment of advanced basal cell carcinoma (BCC), particularly in cases where the cancer is either locally advanced for which surgery or radiation therapy is not appropriate, or metastatic. Here are some key points you should know about Erivedge:\n\n### Mechanism of Action\n- **Hedgehog Pathway Inhibitor**: Erivedge works by inhibiting the Hedgehog signaling pathway, which is crucial for cell differentiation and proliferation. Mutations in this pathway are often implicated in the development and progression of BCC.\n\n### Indications\n- **Advanced Basal Cell Carcinoma**: Indicated for patients with locally advanced BCC that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation. It is also used for metastatic BCC.\n\n### Dosage and Administration\n- **Dosage**: The recommended dose is 150 mg taken orally once daily.\n- **Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_MZNkGV1TbWRDiyKsngzQOR9C", "custom_id": "653_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "dff617ae16dc2cf1ce9817e71a7e09d3", "body": {"id": "chatcmpl-9St6xsw0PykNn9lGOs6xlRnsnPX0Z", "object": "chat.completion", "created": 1716672059, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zolinza, also known generically as vorinostat, is a medication used primarily in the treatment of cutaneous T-cell lymphoma (CTCL), a type of cancer that manifests in the skin. Here are several important aspects you should know about Zolinza:\n\n### Mechanism of Action\n- **Histone Deacetylase Inhibitor (HDAC):** Zolinza works by inhibiting the enzyme histone deacetylase (HDAC). This inhibition leads to an accumulation of acetylated histones and proteins, which can result in the activation of tumor suppressor genes, cell cycle arrest, and apoptosis (programmed cell death) of cancer cells.\n\n### Indications\n- **Primary Use:** It is primarily indicated for the treatment of CTCL in patients who have progressive, persistent, or recurrent disease after prior systemic therapies.\n\n### Dosage and Administration\n- **Recommended Dose:** The typical dose is 400 mg taken orally once daily with food. The capsules"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_JqvYuUd9FNchpeNLRyvT5ZAc", "custom_id": "654_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f1a6fcfa1305c45fa04b38d9cd79334b", "body": {"id": "chatcmpl-9St6xAJdEvrNlslWvux2mUGt0Px4w", "object": "chat.completion", "created": 1716672059, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, understanding the Aztec civilization can provide valuable context for the history of medicine, cultural practices, and the evolution of healthcare. Here are several key points:\n\n1. **Herbal Medicine**: The Aztecs had an extensive knowledge of herbal medicine. They used a wide variety of plants for their medicinal properties. Some of these, such as the use of aloe vera for skin conditions, are still relevant today.\n\n2. **Surgical Practices**: The Aztecs practiced trepanation, a form of surgery that involves drilling or scraping a hole into the skull. This procedure was used to treat head injuries and other conditions.\n\n3. **Public Health**: The Aztecs had a strong understanding of public health concepts. They emphasized cleanliness and had systems for waste removal and the provision of clean water, which helped prevent the spread of disease.\n\n4. **Temazcal**: The Aztecs used sweat baths, known as temazcal, for both therapeutic and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_19qRAc5SqGZm5wE0aBfVrJBD", "custom_id": "655_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9cbb86c426108f77eee2a37ab7215185", "body": {"id": "chatcmpl-9St6y8LRHU6EkvOeBGf51koFYolnB", "object": "chat.completion", "created": 1716672060, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zaltrap, also known by its generic name ziv-aflibercept, is a medication used in the treatment of metastatic colorectal cancer. Here are some key points you should know about Zaltrap:\n\n1. **Mechanism of Action:**\n   - Zaltrap is a recombinant fusion protein that acts as a vascular endothelial growth factor (VEGF) inhibitor. It binds to VEGF-A, VEGF-B, and placental growth factor (PlGF), thereby preventing these factors from activating their receptors on the surface of endothelial cells. This inhibition reduces angiogenesis, which is the formation of new blood vessels that tumors need to grow and metastasize.\n\n2. **Indications:**\n   - Zaltrap is approved for use in combination with the FOLFIRI (folinic acid, fluorouracil, and irinotecan) chemotherapy regimen for patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen.\n\n3. **Administration:**\n   -"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_zrcZ6uabnwoPYJQM31qh4lmr", "custom_id": "656_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0cd1c9132c6b66703ec79391508a3d01", "body": {"id": "chatcmpl-9St6yYLDw5uOWSnW8uG46mkj7c6yM", "object": "chat.completion", "created": 1716672060, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tabrecta (capmatinib) is a targeted therapy approved by the FDA for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping. Here are some key points you should know about Tabrecta:\n\n### Indications:\n- **Approved Use**: Specifically indicated for patients with metastatic NSCLC with MET exon 14 skipping mutations.\n  \n### Mechanism of Action:\n- **Targeted Therapy**: Tabrecta is a tyrosine kinase inhibitor that targets MET, a receptor tyrosine kinase involved in various cellular processes including proliferation, survival, and migration. By inhibiting MET, Tabrecta can help to slow or stop the growth of cancer cells that have this specific mutation.\n\n### Administration:\n- **Dosage**: The recommended dosage is 400 mg orally twice daily, with or without food.\n- **Administration Considerations**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_sxnrLOB8x9xZMO17LPdJAJ24", "custom_id": "657_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "1ff538b18136aa8d5520e8883eb2fab7", "body": {"id": "chatcmpl-9St6yPRMf7FwSWwTPIbyEEuGkWWH7", "object": "chat.completion", "created": 1716672060, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Padcev (enfortumab vedotin-ejfv) is a medication used in the treatment of adults with locally advanced or metastatic urothelial cancer. Here are key points you should be aware of:\n\n1. **Indications**:\n   - **Locally Advanced or Metastatic Urothelial Cancer**: Padcev is indicated for patients who have previously received a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy, or who are ineligible for cisplatin-containing chemotherapy and have received one or more prior lines of therapy.\n\n2. **Mechanism of Action**:\n   - Padcev is an antibody-drug conjugate composed of a monoclonal antibody specific to Nectin-4, a protein highly expressed in urothelial cancer cells, linked to a microtubule-disrupting agent called monomethyl auristatin E (MMAE). Upon binding to Nectin-4, the conjugate is internalized into the cancer cell where"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_pIh32uuB25HxU4tUiPyXuHec", "custom_id": "658_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "4e5b2841123ba06b7023e11d644a5c1f", "body": {"id": "chatcmpl-9St6yBaopqwh50c5mUkwkIcSmbAbN", "object": "chat.completion", "created": 1716672060, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enhertu, also known by its generic name fam-trastuzumab deruxtecan-nxki, is an antibody-drug conjugate (ADC) designed for the treatment of specific types of cancer. Here is some key information you should know about Enhertu:\n\n### Mechanism of Action:\n- **Antibody-Drug Conjugate**: Enhertu consists of an anti-HER2 antibody linked to a topoisomerase I inhibitor (deruxtecan). The antibody targets HER2-positive cancer cells and delivers the cytotoxic drug directly to them, which helps in killing the cancer cells while minimizing damage to normal cells.\n\n### Indications:\n- **HER2-Positive Breast Cancer**: Enhertu is approved for the treatment of adult patients with HER2-positive metastatic breast cancer who have received two or more prior anti-HER2-based regimens.\n- **HER2-Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC)**: It is also indicated for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ls8LSjNwrOfXgJ3fmsdrtFPC", "custom_id": "659_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "52d766f6fe0b50eddac4f5eba6d8e6ef", "body": {"id": "chatcmpl-9St6ypQTYLNUkSDCPoqCGoAQsHESd", "object": "chat.completion", "created": 1716672060, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Plenaxis, also known by its generic name abarelix, is a medication that was used primarily to treat advanced prostate cancer. Here are key points you should know about it:\n\n### Mechanism of Action\n- **GnRH Antagonist**: Plenaxis is a gonadotropin-releasing hormone (GnRH) antagonist. It works by directly inhibiting the receptors for GnRH in the pituitary gland, leading to a rapid decrease in the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This results in a significant reduction in testosterone levels, which can help control the growth of testosterone-dependent prostate cancer cells.\n\n### Indications\n- **Advanced Prostate Cancer**: It was indicated for the palliative treatment of men with advanced symptomatic prostate cancer who had refused surgical castration or were not candidates for other forms of androgen deprivation therapy (ADT).\n\n### Administration\n- **Route of Administration**: Plenaxis was administered via"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_n8dkwOa9vGbdjYHBONqPpbAK", "custom_id": "660_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2179b92c163a387893cfe1694e6c513a", "body": {"id": "chatcmpl-9St6y5gdYoJ8ye1k1cEBOiOrIrE7k", "object": "chat.completion", "created": 1716672060, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blenrep (belantamab mafodotin) is a monoclonal antibody-drug conjugate used to treat multiple myeloma, a type of blood cancer. Here are some key points you should know about Blenrep:\n\n### Indications:\n- **FDA Approval**: Blenrep was approved by the U.S. FDA in August 2020 for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.\n- **Mechanism of Action**: Blenrep targets B-cell maturation antigen (BCMA) on the surface of myeloma cells and delivers a cytotoxic agent, monomethyl auristatin F (MMAF), directly to the cancer cells, leading to cell death.\n\n### Administration:\n- **Dosage**: The recommended dose is 2.5 mg/kg administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_gK1cmyLBgY2gaAqtWZvLjT8s", "custom_id": "661_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "28af34fa0e34c97bf22ade0423a3d1fa", "body": {"id": "chatcmpl-9St6yzFNhAHtBFKHIQtzvKpBTRsg8", "object": "chat.completion", "created": 1716672060, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tukysa (tucatinib) is a medication used in the treatment of certain types of breast cancer. Specifically, it is indicated for use in combination with trastuzumab and capecitabine in adults with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. Here are some key points you should know as a physician:\n\n### Mechanism of Action\n- **Tucatinib** is a tyrosine kinase inhibitor that selectively inhibits the HER2 protein. HER2 is overexpressed in some breast cancer cells and promotes their growth.\n\n### Dosage and Administration\n- **Recommended Dose**: The typical dose is 300 mg (two 150 mg tablets) taken orally twice daily.\n- **Combination**: Tukysa is taken in combination with trastuzumab and capecitabine. Ensure patients are also on the correct dosages of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_3QDQcLYMN3rUESnQLq19NRVb", "custom_id": "662_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "21f0c7ffc63b9b3c347e480b7c5e3960", "body": {"id": "chatcmpl-9St6ystZpw14BBB62DtlJ7KNtmWdq", "object": "chat.completion", "created": 1716672060, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Darzalex Faspro (daratumumab and hyaluronidase-fihj) is a combination medication used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Here are some key points you should know about Darzalex Faspro:\n\n### Mechanism of Action\n- **Daratumumab**: A monoclonal antibody that targets CD38, a protein expressed on the surface of multiple myeloma cells, leading to cell death through various mechanisms, including complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and apoptosis.\n- **Hyaluronidase-fihj**: An enzyme that helps to increase the absorption and dispersion of daratumumab when administered subcutaneously.\n\n### Indications\nDarzalex Faspro is indicated for:\n- Newly diagnosed multiple myeloma in combination with other therapies.\n- Relapsed or refractory multiple myeloma.\n\n### Administration\n- **Subcutaneous"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_UWIbHXIy4SLYQRkAIIAAa88r", "custom_id": "663_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e95bf7474274a2a40401bfc245e80e22", "body": {"id": "chatcmpl-9St6zOpqXj9on9s7mfwaQ6dxRIvmf", "object": "chat.completion", "created": 1716672061, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panretin (generic name: alitretinoin) is a topical retinoid medication primarily used in the treatment of cutaneous lesions in patients with AIDS-related Kaposi\u2019s sarcoma. Here are some key points a physician should know about Panretin:\n\n### Indications and Usage\n- **Primary Use**: Panretin is indicated for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.\n- **Patient Selection**: It is typically prescribed for patients who do not require systemic anti-Kaposi\u2019s sarcoma therapy.\n\n### Mechanism of Action\n- **Retinoid Activity**: Alitretinoin is a retinoid, which means it is related to vitamin A. It works by modulating the growth and differentiation of cells, which can help reduce the proliferation of Kaposi's sarcoma lesions.\n\n### Administration\n- **Formulation**: Panretin is available as a gel.\n- **Application**: The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_anwcbUHT8Au74ve913As3UX7", "custom_id": "664_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "45199cce71b425c671e02598a871f577", "body": {"id": "chatcmpl-9St6zYSjvpmxnOq7MnUn9LdvxfjMB", "object": "chat.completion", "created": 1716672061, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tecartus (brexucabtagene autoleucel) is an important therapy in the field of oncology, specifically for hematologic malignancies. Here are key points you should be aware of as a physician:\n\n1. **Indications**: Tecartus is a chimeric antigen receptor (CAR) T-cell therapy approved for treating adult patients with relapsed or refractory mantle cell lymphoma (MCL) and relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).\n\n2. **Mechanism of Action**: Tecartus involves modifying a patient\u2019s own T cells to express a CAR that targets the CD19 antigen on the surface of B cells, including malignant B cells in MCL and ALL. Once these engineered T cells are infused back into the patient, they seek out and destroy CD19-expressing cells.\n\n3. **Administration**: The therapy is personalized and involves several steps:\n   - **Leukapheresis**: Collecting the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_iYeRdX0R7VVAQiSyQB8EMGhW", "custom_id": "665_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d19620f1ddc4f1159965005998299c4f", "body": {"id": "chatcmpl-9St6zLqBU0mljIR5U8YJ7pjVKFarg", "object": "chat.completion", "created": 1716672061, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Piqray (alpelisib) is a targeted therapy used in the treatment of certain types of breast cancer. As a physician, you should be aware of the following key points about Piqray:\n\n1. **Indication**: Piqray is primarily indicated for the treatment of postmenopausal women, and men, with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced or metastatic breast cancer. It is used in combination with fulvestrant after disease progression following an endocrine-based regimen.\n\n2. **Mechanism of Action**: Piqray is a PI3K inhibitor that specifically targets the alpha isoform of the phosphatidylinositol-3-kinase (PI3K) enzyme. By inhibiting this enzyme, Piqray helps to reduce cancer cell growth and survival, especially in tumors with PIK3CA mutations.\n\n3. **Dosage and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_J96FG3xaIcv9owetmVrFQka7", "custom_id": "666_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "214b21536cef848b0ecac9d6713ecfe2", "body": {"id": "chatcmpl-9St6zryEHUkO3d0ASjXqyCTmRcGjd", "object": "chat.completion", "created": 1716672061, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Quinamed (generic name: aminocamptothecin) is a chemotherapeutic agent. As a physician, it's critical to have a comprehensive understanding of its properties, indications, administration, side effects, and precautions. Here's an overview:\n\n### Basic Information:\n- **Class**: Quinamed is a topoisomerase I inhibitor, which interferes with the DNA replication process in cancer cells, leading to cell death.\n- **Indications**: Quinamed is generally used in the treatment of certain cancers, although its specific indications can vary. It may be used in clinical trials or specialized treatment protocols.\n\n### Mechanism of Action:\n- Quinamed works by inhibiting the enzyme topoisomerase I. This enzyme is crucial for DNA replication and transcription. By inhibiting it, Quinamed causes DNA breaks that ultimately lead to apoptosis (cell death) of cancerous cells.\n\n### Administration:\n- **Formulation**: It is often administered intravenously.\n- **Dosage**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_wmO6R7SlrhWe4z2UVpzEfFqs", "custom_id": "667_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6e56cebb557de6e58e313dc47f4396ca", "body": {"id": "chatcmpl-9St6z3kr6aeyDfehMNnEmwPzZTcZ6", "object": "chat.completion", "created": 1716672061, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amoxi, or amoxicillin, is a commonly used antibiotic in the penicillin group. As a physician, you should be aware of several important aspects regarding its use:\n\n1. **Mechanism of Action**: Amoxicillin works by inhibiting the synthesis of bacterial cell walls, leading to bacterial lysis and death. It is effective against a range of Gram-positive and some Gram-negative bacteria.\n\n2. **Indications**: Amoxicillin is used to treat various bacterial infections, including:\n   - Upper respiratory tract infections (e.g., pharyngitis, sinusitis)\n   - Lower respiratory tract infections (e.g., bronchitis, pneumonia)\n   - Ear infections (otitis media)\n   - Skin and soft tissue infections\n   - Urinary tract infections\n   - Helicobacter pylori eradication (in combination with other medications)\n\n3. **Dosage**: The dosage varies based on the age of the patient, the type and severity of the infection, and renal"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ueg6yYP71J1E4QIERfOtfO4U", "custom_id": "668_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "edf54cf18b0a1f193f11cf5f8a50f9af", "body": {"id": "chatcmpl-9St6zC5oWSYS8fco6veqd3F3fOuUR", "object": "chat.completion", "created": 1716672061, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Amelie\" could refer to several different things, so it's important to clarify the context. Here are some common references:\n\n1. **Amelie (film)**: A 2001 French romantic comedy directed by Jean-Pierre Jeunet. The film follows the story of a shy waitress, Am\u00e9lie Poulain, who decides to change the lives of those around her for the better while grappling with her own isolation. As a physician, knowledge about this film might be relevant in understanding cultural references or when discussing mental health themes such as loneliness, social anxiety, and the pursuit of happiness.\n\n2. **Am\u00e9lie (musical)**: A stage adaptation of the 2001 film. It shares similar themes and could be relevant for discussions around cultural and emotional well-being.\n\n3. **Amelie as a name**: If you have a patient named Amelie, what you need to know would depend on her medical history, current health concerns, and personal context. As with any"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_DOEPixDG4wfg9pOc9uMA9YP6", "custom_id": "669_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0d44c64c2253a75e88a4d3e207859f00", "body": {"id": "chatcmpl-9St6zm2rC0VRbzbAeU57YuBL0levd", "object": "chat.completion", "created": 1716672061, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pemazyre (pemigatinib) is a targeted therapy drug that is used primarily to treat certain types of cancers. Here are some key points that you should know about Pemazyre as a physician:\n\n### Indications:\n- **Cholangiocarcinoma:** Pemazyre is approved for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) that have an FGFR2 (fibroblast growth factor receptor 2) fusion or rearrangement.\n\n### Mechanism of Action:\n- Pemazyre is a tyrosine kinase inhibitor that targets FGFR1, FGFR2, and FGFR3. By inhibiting these receptors, Pemazyre can interfere with the growth and survival of cancer cells that rely on these pathways.\n\n### Administration:\n- **Dosage:** The typical dosage is 13.5 mg once daily for 14 consecutive days followed by 7 days off therapy, in 21"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_akbnAK2Jq00pOz7bM9K7aveH", "custom_id": "670_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "bae57cb9af8009f9cea086071d30dbbd", "body": {"id": "chatcmpl-9St6zJ0sRr2E4963gJzWvVKBYLPxS", "object": "chat.completion", "created": 1716672061, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Qinlock (ripretinib) is an oral kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumors (GIST). As a physician, here are several key points you should know about Qinlock:\n\n1. **Indication**:\n   - Qinlock is specifically indicated for the treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including imatinib.\n\n2. **Mechanism of Action**:\n   - Qinlock works by inhibiting multiple kinases, including KIT and PDGFRA, which are commonly mutated in GIST. It targets both primary and secondary mutations, thereby helping to overcome resistance to previous treatments.\n\n3. **Dosage and Administration**:\n   - The recommended dose of Qinlock is 150 mg orally once daily, with or without food. Tablets should be swallowed whole.\n\n4. **Efficacy**:\n   - Clinical trials have shown that Qinlock significantly improves progression-free survival in patients with advanced"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_YsSD0LsCiRPLbv6eN43ZOl4Y", "custom_id": "671_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "67cd621fc195b94bfeac434e94bf79e4", "body": {"id": "chatcmpl-9St6zsCKItWWcct8jkkYXyXWTLRdx", "object": "chat.completion", "created": 1716672061, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Retevmo (selpercatinib) is a targeted therapy medication that is used to treat certain types of cancers. As a physician, it's important to be familiar with the following key points about Retevmo:\n\n1. **Indications**:\n   - Retevmo is approved for use in adults with non-small cell lung cancer (NSCLC) that has a rearranged during transfection (RET) gene fusion.\n   - It's also approved for adults and children aged 12 years and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation.\n   - Additionally, it is indicated for adults and children aged 12 years and older with advanced or metastatic thyroid cancer with a RET gene fusion who require systemic therapy and for whom no other satisfactory treatment options are available.\n\n2. **Mechanism of Action**:\n   - Selpercatinib is a selective RET kinase inhibitor. RET gene fusions and mutations can drive the development of certain"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_juMPsSbvtq1w9YEutT9eGh4X", "custom_id": "672_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "4d3b665a2507dff383aee7526183d7aa", "body": {"id": "chatcmpl-9St70vSOFI1JxYJLQghv6qnmRTyCc", "object": "chat.completion", "created": 1716672062, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Inqovi is a prescription medication used for the treatment of certain types of myelodysplastic syndromes (MDS), including chronic myelomonocytic leukemia (CMML). It is a combination of decitabine and cedazuridine. Here are some key points you should know about Inqovi:\n\n1. **Mechanism of Action:**\n   - **Decitabine:** It is a hypomethylating agent that integrates into DNA and inhibits DNA methyltransferase, leading to hypomethylation of DNA and reactivation of silenced genes that regulate differentiation and proliferation.\n   - **Cedazuridine:** It is a cytidine deaminase inhibitor. By inhibiting cytidine deaminase, it increases the bioavailability of decitabine when administered orally, allowing for oral dosing instead of intravenous administration.\n\n2. **Indications:**\n   - Inqovi is indicated for the treatment of adult patients with myelodysplastic syndromes (MDS)"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_17chpSJq9hxJgbKPqIv7AWFt", "custom_id": "673_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "b6d8372cdd0ed9391deefce02c6888d2", "body": {"id": "chatcmpl-9St70kEATvAjOcWHSvCMY7gKfFQX3", "object": "chat.completion", "created": 1716672062, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, there are several key points you should know about Pepto-Bismol (bismuth subsalicylate):\n\n### Indications:\n1. **Gastrointestinal Distress:** Pepto-Bismol is commonly used to treat symptoms such as nausea, heartburn, indigestion, upset stomach, and diarrhea. It can also be used for travelers' diarrhea.\n2. **Helicobacter pylori:** It is sometimes used as part of a combination therapy for the eradication of H. pylori in peptic ulcer disease.\n\n### Mechanism of Action:\n- **Bismuth Subsalicylate:** It has antimicrobial, anti-inflammatory, and antacid properties. It works by coating the stomach lining and intestines, providing a protective barrier against stomach acid and irritating substances.\n\n### Dosage:\n- **Adults and Children Over 12:** The typical dosage is 524 mg (30 mL or two 262 mg tablets) every 30 minutes to an hour"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_z2Fd22v5yx5rSu0XEnOikId5", "custom_id": "674_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "fa908578bbcec82d71ec24f067880094", "body": {"id": "chatcmpl-9St70HVYkmHtGJjBYAog2W7JEjhDO", "object": "chat.completion", "created": 1716672062, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, you should be aware that AiRuiKa is a brand name for a medication that may be used in different contexts depending on the country and specific formulation. Here are a few key points you might find relevant:\n\n1. **Active Ingredient**: The active ingredient in AiRuiKa can vary, so it's important to check the specific formulation. In some contexts, it may refer to an antibiotic or another type of medication.\n\n2. **Indications**: Depending on its active ingredient, AiRuiKa could be used for treating bacterial infections, managing chronic conditions, or other therapeutic purposes. Verify the specific indications based on the formulation you are dealing with.\n\n3. **Dosage and Administration**: Proper dosing is crucial for effectiveness and safety. Ensure you refer to the latest clinical guidelines or the product's prescribing information for accurate dosing instructions.\n\n4. **Side Effects**: Be aware of the potential side effects associated with the active ingredient in AiRuiKa. Common side"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_zMv0B92Zs4qV2KtXaNqzWDhi", "custom_id": "675_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "355f610add0df463987cfe6512cc0ffc", "body": {"id": "chatcmpl-9St70u3lGXMKqM2lAuWOYypfqZdFd", "object": "chat.completion", "created": 1716672062, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Orgovyx (relugolix) is an oral medication used in the treatment of advanced prostate cancer. Here are some key points you should know about Orgovyx:\n\n1. **Mechanism of Action**: Orgovyx is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It works by directly inhibiting the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a decrease in testosterone levels. This is important in prostate cancer treatment because testosterone can promote the growth of prostate cancer cells.\n\n2. **Administration**: Orgovyx is taken orally, which can be more convenient for patients compared to injectable treatments. The recommended dosage is 120 mg once daily after an initial loading dose of 360 mg on the first day.\n\n3. **Efficacy**: Clinical trials have shown that Orgovyx effectively lowers testosterone levels to castrate levels within days. The HERO study demonstrated that Orgovyx achieved"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ICHt7Q47eojYtMqKPzR7pp7k", "custom_id": "676_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "633343d61477d9c815f9a138baf38844", "body": {"id": "chatcmpl-9St70MeVpB7EXEjUmxiRdlkh6dSDB", "object": "chat.completion", "created": 1716672062, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Orserdu (elacestrant) is a medication that you might find relevant in the context of treating certain types of breast cancer. Here are some key points you should know about it:\n\n1. **Mechanism of Action**: Orserdu is a selective estrogen receptor degrader (SERD). It works by binding to estrogen receptors on breast cancer cells, leading to the degradation of these receptors and ultimately reducing the growth of estrogen receptor-positive (ER+) breast cancer cells.\n\n2. **Indications**: Orserdu is primarily indicated for the treatment of postmenopausal women with ER+ and HER2- advanced or metastatic breast cancer, particularly in cases where the cancer has progressed following endocrine therapy.\n\n3. **Administration**: Orserdu is generally administered orally. The dosage and treatment regimen can vary based on the specific patient profile and the progression of the disease.\n\n4. **Side Effects**: Common side effects of Orserdu include nausea, fatigue, decreased appetite,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_z8ZBHYUXo4RK1fFmVN0pToVz", "custom_id": "677_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e9ba83f9aff91912ddecdc41a7b67694", "body": {"id": "chatcmpl-9St71WSc14NHVXdYOU7wN3OZsplLx", "object": "chat.completion", "created": 1716672063, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Neutrexin, also known as trimetrexate glucuronate, is a chemotherapeutic agent primarily used in the treatment of Pneumocystis jirovecii pneumonia (PCP) in patients with compromised immune systems, such as those with AIDS, who are intolerant to or do not respond to standard treatments like trimethoprim-sulfamethoxazole (TMP-SMX) and pentamidine. Here are several key points you should be aware of regarding Neutrexin:\n\n### Mechanism of Action\n- **Folate Antagonist:** Neutrexin inhibits dihydrofolate reductase (DHFR), an enzyme critical for DNA synthesis and cell division. This action leads to inhibition of thymidine and purine synthesis, which are essential for the growth of both normal and pathogenic cells.\n\n### Indications\n- **Pneumocystis jirovecii Pneumonia (PCP):** Primarily used for PCP in patients who"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_wYjMCWUyszSIUOlAlkFzdFIj", "custom_id": "678_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "58034fdad3e79a0d4ab2ac6ac60e20e1", "body": {"id": "chatcmpl-9St715cJ5wCdBJTu9Zcw1JkO02fJo", "object": "chat.completion", "created": 1716672063, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tepmetko (generic name: tepotinib) is a medication used in the treatment of certain types of non-small cell lung cancer (NSCLC). As a physician, it's important to be well-versed in various aspects of this drug, including its indications, mechanism of action, dosing, side effects, and patient monitoring. Here's a comprehensive overview:\n\n### Indications:\n- **Tepmetko** is indicated for the treatment of adult patients with metastatic NSCLC harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. These genetic alterations can drive cancer growth, and Tepmetko specifically targets these mutations.\n\n### Mechanism of Action:\n- Tepotinib is a selective MET inhibitor. It works by inhibiting the activity of the MET receptor tyrosine kinase, which is involved in various cellular processes including proliferation, survival, and metastasis. By blocking MET signaling, Tepmetko can help to slow down or stop the growth of cancer cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_azjtAulnCDutFmgOw2JuqIL2", "custom_id": "679_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "7a0fa893efdd5863341718116624eb5f", "body": {"id": "chatcmpl-9St712TI41CL93IFx2BzFC9kx6HhK", "object": "chat.completion", "created": 1716672063, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lytgobi (futibatinib) is a medication that's relatively new and has specific indications, mechanism of action, and safety considerations that you should be aware of as a physician. Here's a detailed overview:\n\n### Indication:\nLytgobi (futibatinib) is indicated for the treatment of patients with previously treated, unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene rearrangements, including gene fusions. This is a specific form of biliary tract cancer.\n\n### Mechanism of Action:\nFutibatinib is a potent and selective inhibitor of fibroblast growth factor receptors (FGFRs). FGFRs are a family of receptor tyrosine kinases involved in various processes including cell proliferation, differentiation, and angiogenesis. By inhibiting FGFR2, which can be aberrantly activated in certain cancers due to mutations or gene fusions, futibatinib can"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_SHbGfcTam9Z5zO87UzIskOy9", "custom_id": "680_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "09c91719f99a50ae330c7a8e2ddadfab", "body": {"id": "chatcmpl-9St71LKwSMGXCCXBkHlM42RIJXqEX", "object": "chat.completion", "created": 1716672063, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Optune is a medical device used in the treatment of glioblastoma multiforme (GBM), a type of aggressive brain tumor. It's important for physicians to be familiar with several key aspects of Optune:\n\n1. **Mechanism of Action**:\n   - Optune works by delivering Tumor Treating Fields (TTFields), which are low-intensity, alternating electric fields. These fields disrupt mitosis (cell division) in cancer cells, thereby inhibiting tumor growth and potentially causing cancer cell death.\n\n2. **Indications**:\n   - Optune is indicated for the treatment of adult patients with newly diagnosed and recurrent GBM. For newly diagnosed patients, it is used in combination with temozolomide, after surgery and radiation therapy with concomitant chemotherapy have been completed.\n\n3. **Usage and Administration**:\n   - The device consists of an electric field generator and transducer arrays that are placed directly on the scalp. The arrays must be worn continuously (at least "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_9l2E1BqaAe8oGdYbaSbHL0up", "custom_id": "681_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9f1fbef576198c42c0f08d0ab4b7f86f", "body": {"id": "chatcmpl-9St71QjAIngXbQUAeHz1jCGsTkUl8", "object": "chat.completion", "created": 1716672063, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Breyanzi (lisocabtagene maraleucel) is a chimeric antigen receptor (CAR) T-cell therapy used for the treatment of certain types of large B-cell lymphoma. Here are some key points you should know about Breyanzi:\n\n1. **Indications:**\n   - Breyanzi is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.\n\n2. **Mechanism of Action:**\n   - Breyanzi is an autologous CAR T-cell therapy. It involves collecting a patient\u2019s own T-cells, engineering them to express a CAR that targets the CD19 antigen on B-cells, and then infusing the modified T-cells back into the patient. These engineered T-c"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_H8rQekDlAak9y0NtD3xQbG5m", "custom_id": "682_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5f28e6807287c4712de84b896a87f5ad", "body": {"id": "chatcmpl-9St71Ec2YCOzdxPX8VXfxxHERYZKv", "object": "chat.completion", "created": 1716672063, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abecma (idecabtagene vicleucel) is a type of CAR T-cell therapy used for the treatment of multiple myeloma. Here are key points a physician should know about Abecma:\n\n### Indications:\n- **FDA Approval**: Abecma is approved for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.\n\n### Mechanism of Action:\n- **CAR T-Cell Therapy**: Abecma involves genetically modifying a patient's T cells to express a chimeric antigen receptor (CAR) that targets B-cell maturation antigen (BCMA) on multiple myeloma cells.\n- **Target**: BCMA is highly expressed on multiple myeloma cells and some normal B-lineage cells.\n\n### Administration:\n- **Preparation**: The process begins with leukapheresis to collect"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Bfj1Lbcd93xdSlYeHrsQTk64", "custom_id": "683_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e54833de46fd521f718838f7c899efc2", "body": {"id": "chatcmpl-9St71N4A5h32fSwkpF10X22BSwP90", "object": "chat.completion", "created": 1716672063, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ayvakit (avapritinib) is a medication used primarily for the treatment of certain types of cancer. As a physician, it's important to be well-informed about its indications, mechanisms, dosing, side effects, and monitoring requirements. Here are key points to consider:\n\n### Indications:\n1. **Gastrointestinal Stromal Tumors (GIST):** Ayvakit is approved for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.\n2. **Systemic Mastocytosis:** Ayvakit is also approved for the treatment of adults with advanced systemic mastocytosis (AdvSM), including aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).\n\n### Mechanism of Action:\n- Ayvakit is a tyrosine kinase inhibitor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_IlX41UcFHqdoPfVF8gLcOTnj", "custom_id": "684_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "466c321a2adc3683a9b8e5236445a9c4", "body": {"id": "chatcmpl-9St72DwflxrF7GMO05IYUd7UGUkyi", "object": "chat.completion", "created": 1716672064, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Turalio (pexidartinib), which is a medication used primarily to treat a rare type of tumor known as tenosynovial giant cell tumor (TGCT) that is symptomatic and not amenable to improvement with surgery. Here are key points you should know:\n\n### Mechanism of Action\n- **Pexidartinib** is a tyrosine kinase inhibitor that targets colony-stimulating factor 1 receptor (CSF1R), KIT, and FLT3-ITD.\n- By inhibiting CSF1R, it is effective in reducing the proliferation of cells that overexpress this receptor, which is common in TGCT.\n\n### Indications\n- **Turalio** is indicated for the treatment of adult patients with symptomatic TGCT associated with severe morbidity or functional limitations, and not amenable to improvement with surgery.\n\n### Administration\n- **Dosage**: The recommended dose is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_MTVfiekZZ6Tzj0xssL273AFt", "custom_id": "685_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "3171f42afcf17fbb28b87a3411364e1b", "body": {"id": "chatcmpl-9St72yztviZmBjtQoczVynlW3VeKR", "object": "chat.completion", "created": 1716672064, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gavreto (pralsetinib) is a prescription medication that is used to treat certain types of cancer. Here are some key points you should know as a physician:\n\n### Indications:\n1. **Non-Small Cell Lung Cancer (NSCLC):**\n   - Gavreto is indicated for the treatment of adult patients with metastatic RET fusion-positive NSCLC.\n   \n2. **Thyroid Cancer:**\n   - It is used in the treatment of adult and pediatric patients 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.\n   - It is also indicated for adult and pediatric patients 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate).\n\n### Mechanism of Action:\n- Gavreto is a selective RET kinase inhibitor. RET fusions and mutations are genetic alterations that can drive the development of certain types of cancers"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_jcbhlQfIeBVYfFPKhsH3FMfb", "custom_id": "686_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9b2d68517b562fbab2df619729f45fd5", "body": {"id": "chatcmpl-9St72xz2F1MzL3o4OhbPI6GDb6MPK", "object": "chat.completion", "created": 1716672064, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zepzelca (generic name: lurbinectedin) is a medication used in the treatment of small cell lung cancer (SCLC). Here are some key points you should know about Zepzelca:\n\n1. **Indication**: Zepzelca is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.\n\n2. **Mechanism of Action**: Zepzelca is an alkylating drug that binds to the DNA minor groove, inhibiting the transcription process and leading to tumor cell death. It also affects the tumor microenvironment by inhibiting the transcription of certain oncogenes and cytokines, thereby reducing the proliferation of cancer cells.\n\n3. **Administration**: Zepzelca is administered via intravenous infusion. The recommended dosage is 3.2 mg/m\u00b2 over 60 minutes, repeated every 21 days until disease progression or unacceptable toxicity.\n\n4. **Side Effects**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_pirpaPRjQgSkdTz2rnPg4c63", "custom_id": "687_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "9a3e1c0a682e2f0cb6200b2d43b9261f", "body": {"id": "chatcmpl-9St72xXeQ1dh8T9kwhdUezdEXCcI3", "object": "chat.completion", "created": 1716672064, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Certainly! Flagyl is the brand name for metronidazole, which is an antibiotic and antiprotozoal medication. Here are several key points you should know about it:\n\n### Indications\n1. **Bacterial Infections**: It's commonly used to treat anaerobic bacterial infections, including those of the abdomen, pelvis, skin, and central nervous system.\n2. **Protozoal Infections**: Effective against certain protozoal infections, such as giardiasis, trichomoniasis, and amebiasis.\n3. **Clostridium difficile**: Often used in the treatment of mild to moderate C. difficile-associated diarrhea.\n\n### Mechanism of Action\n- Metronidazole works by entering the cells of anaerobic microorganisms and interacting with their DNA. This interaction leads to inhibition of nucleic acid synthesis and eventually results in the death of the microorganism.\n\n### Dosage Forms\n- Available in various forms including tablets, extended-release tablets, topical gels and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_yuQl05keX3ZJ9CAynETcJSMA", "custom_id": "688_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "47cf551bc54adc683ac7ccfd3efd3b9b", "body": {"id": "chatcmpl-9St72zPF3nqR8EMvxH6QHIwnJrUbt", "object": "chat.completion", "created": 1716672064, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Danyelza (naxitamab-gqgk) is a medication used in the treatment of certain pediatric cancers, specifically neuroblastoma. Here are the key points you should know as a physician:\n\n### Indications:\n- **Danyelza** is approved for use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of pediatric patients aged one year and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.\n\n### Mechanism of Action:\n- **Naxitamab** is a monoclonal antibody that targets GD2, a disialoganglioside highly expressed on neuroblastoma cells and other tumors of neuroectodermal origin. By binding to GD2, naxitamab helps the immune system recognize and destroy cancer cells.\n\n### Administration:\n- **Administration** is intravenous (IV). The dosing regimen typically involves multiple cycles, and each cycle consists"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ch9mDGWgd8eEqktRFhDzOprh", "custom_id": "689_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f50889b9d3b5fe31d92071f1172fb83c", "body": {"id": "chatcmpl-9St72FModiBoC2RHxvAalncs1g25s", "object": "chat.completion", "created": 1716672064, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panmycin is a brand name for the antibiotic tetracycline, which is part of the tetracycline class of medications. As a physician, here are key points you should know about Panmycin:\n\n### Pharmacology:\n- **Mechanism of Action**: Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the ribosomal acceptor (A) site. This action is bacteriostatic rather than bactericidal.\n- **Spectrum of Activity**: Effective against a wide range of gram-positive and gram-negative bacteria, including some anaerobes, rickettsiae, chlamydiae, and mycoplasmas. However, resistance is common due to widespread use.\n\n### Indications:\n- **Infections**: Used to treat various infections such as respiratory tract infections, urinary tract infections, skin infections, and sexually transmitted infections (e.g., chlamydia).\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_FgweWRFIOB9CwSls9eNrALfr", "custom_id": "690_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "22b3f34668ba4ac86c099d4da6bc6290", "body": {"id": "chatcmpl-9St72V8OERSu20TzvOaIpcYNjmFWO", "object": "chat.completion", "created": 1716672064, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "De-Noltab, known generically as bismuth subcitrate, is a medication primarily used in the treatment of gastrointestinal disorders, particularly peptic ulcers and Helicobacter pylori infections. Here are some key points you should know about De-Noltab:\n\n### Indications:\n1. **Peptic Ulcer Disease (PUD):** De-Noltab is used in the treatment of gastric and duodenal ulcers.\n2. **Helicobacter pylori Infection:** It is often used as part of combination therapy to eradicate H. pylori, which is a common cause of peptic ulcers.\n\n### Mechanism of Action:\n- **Cytoprotective Effect:** De-Noltab forms a protective barrier over the ulcer site against stomach acid and pepsin.\n- **Antibacterial Effect:** It has a direct antibacterial effect on H. pylori, thereby helping in its eradication.\n\n### Dosage and Administration:\n- The typical dosage for adults is usually **120"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_jNCClvpuWx4S0LzfD7t09THt", "custom_id": "691_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "5d93df8535c82bd651b60c0b30eff961", "body": {"id": "chatcmpl-9St73kgoiej3WPSKbwqk1G9Vilc2M", "object": "chat.completion", "created": 1716672065, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Welireg (belzutifan) is a medication used in the treatment of certain types of cancers, particularly those related to von Hippel-Lindau (VHL) disease. Here's some important information you should know about Welireg:\n\n### Indications:\n- **Von Hippel-Lindau (VHL) Disease:** Welireg is indicated for adult patients with VHL disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), and who do not require immediate surgery.\n\n### Mechanism of Action:\n- **HIF-2\u03b1 Inhibitor:** Welireg works by inhibiting hypoxia-inducible factor 2 alpha (HIF-2\u03b1), a transcription factor that promotes the expression of genes involved in tumor growth, angiogenesis, and metastasis. By inhibiting HIF-2\u03b1, Welireg can reduce tumor growth and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_qLl5FFAFvlNE5ju2pJpcM7ue", "custom_id": "692_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "6a48ef4bcc77904d57395d0da3521e3e", "body": {"id": "chatcmpl-9St73saR2rCQE5MwA2al3OB0rR8Lz", "object": "chat.completion", "created": 1716672065, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rybrevant (amivantamab-vmjw) is a medication that you, as a physician, may find relevant in the treatment of certain types of non-small cell lung cancer (NSCLC). Here are some key points you should know about Rybrevant:\n\n1. **Indication**:\n   - Rybrevant is approved for the treatment of adult patients with locally advanced or metastatic NSCLC with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.\n\n2. **Mechanism of Action**:\n   - Amivantamab-vmjw is a bispecific antibody that targets EGFR and MET, two proteins involved in the growth and survival of cancer cells. By binding to these proteins, Rybrevant can inhibit tumor growth.\n\n3. **Administration**:\n   - Rybrevant is administered via intravenous infusion. The initial dose is typically given over a longer period, with subsequent doses administered at regular intervals.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ZJydMosS0g6SxfSiWpGNWt3W", "custom_id": "693_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "33c918c7b2b2fcbf0aa1186e0982b780", "body": {"id": "chatcmpl-9St73nUALlW5SLDscSbyjciJpBh6I", "object": "chat.completion", "created": 1716672065, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Onureg (azacitidine) is an oral formulation of azacitidine, which is a nucleoside metabolic inhibitor used in the treatment of certain hematologic malignancies. Here are some key points you should know as a physician:\n\n### Indications:\n- Onureg is primarily indicated for the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and who are not able to complete intensive curative therapy.\n\n### Mechanism of Action:\n- Azacitidine works by incorporating into DNA and RNA, causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. This leads to cell death and can restore normal function in the bone marrow.\n\n### Administration:\n- Onureg is an oral tablet taken once daily.\n- It is typically administered for 14 days of a 28-day cycle.\n- It is crucial"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_RcudDV33xZZQngmohjgMmNjl", "custom_id": "694_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d250a384e3d60a941fdc27b2353b2d9d", "body": {"id": "chatcmpl-9St73SSPJzkqQjk4NprGeS1NkQWTZ", "object": "chat.completion", "created": 1716672065, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Colcrys, which is the brand name for colchicine, is a medication commonly used to treat gout and familial Mediterranean fever (FMF). As a physician, here are several important points you should know about Colcrys:\n\n### Indications\n1. **Gout**: Colcrys is used to treat acute gout flares and for prophylaxis of gout flares.\n2. **Familial Mediterranean Fever (FMF)**: Used to prevent attacks of FMF in both adults and children aged 4 years and older.\n\n### Mechanism of Action\n- Colchicine works by decreasing inflammation. It inhibits the assembly of microtubules, which in turn disrupts various cellular processes, including the movement of neutrophils to sites of inflammation.\n\n### Dosage\n- **Acute Gout Flare**: Initial dose is typically 1.2 mg (two tablets of 0.6 mg) at the first sign of a flare, followed by 0."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Bf2isfn7c6KwxNEVBEp7iIPT", "custom_id": "695_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "bc1beae256f15861bc18716361c6c2ab", "body": {"id": "chatcmpl-9St73lvOiE6g5Y42OLbvU11GrK4A5", "object": "chat.completion", "created": 1716672065, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Jemperli, also known by its generic name dostarlimab, is a monoclonal antibody that functions as an immune checkpoint inhibitor. Specifically, it targets the programmed death receptor-1 (PD-1) pathway, which is involved in the body's immune response to cancer cells. By inhibiting PD-1, Jemperli helps to enhance the body's immune response against cancer cells.\n\nHere are some key points you should know about Jemperli:\n\n1. **Indications:**\n   - Jemperli is approved by the FDA for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen.\n   - It may also be used in other cancers with similar dMMR characteristics, but specific indications can vary, so it's crucial to refer to current guidelines and approval status in your region.\n\n2. **Mechanism of Action:**\n   - As an immune checkpoint inhibitor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_vlgqzbZr9LsWAJDNedGraIYv", "custom_id": "696_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e217b03eab4d9a775d449a56e6112a48", "body": {"id": "chatcmpl-9St73aWzcJFNRa3834W2vmBT5Vq7P", "object": "chat.completion", "created": 1716672065, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, \"Hansizhuang\" does not correspond to any widely recognized medical term, condition, medication, or treatment in established medical literature or practice. It's possible that it could be a term relevant to a very specific or niche area, a non-English term, or even a typographical error. Here are a few steps you can take to get more information:\n\n1. **Verify the Term**: Double-check the spelling and context in which you encountered \"Hansizhuang.\" Sometimes, slight variations in spelling can lead to different meanings or terms.\n\n2. **Contextual Inquiry**: Determine the context in which \"Hansizhuang\" was mentioned. Is it related to a particular medical specialty, region, or patient population? This can provide clues about its relevance and meaning.\n\n3. **Consult Colleagues and Resources**: Reach out to colleagues or consult medical databases, journals, or professional networks. Sometimes peer discussions can shed light on obscure or emerging"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_9zLjpiSywgMs1te6nCCJZrsI", "custom_id": "697_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "1c3750b59d6d2479e76eec9d2ff384ae", "body": {"id": "chatcmpl-9St73rAL77EpKbR8Kh14QNQNDv0xz", "object": "chat.completion", "created": 1716672065, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2021, there is no information about a drug or treatment called \"Cejemly.\" It's possible that the name you provided is misspelled, a brand name not widely recognized, or a new drug that was introduced after my last update. \n\nIf \"Cejemly\" is a recent development or a new drug, I would recommend taking the following steps to gather accurate and up-to-date information:\n\n1. **Consult Medical Databases:** Use reputable medical databases such as PubMed, Medline, or clinical practice guidelines to find scientific literature or clinical trial results related to the drug.\n  \n2. **Check Regulatory Agencies:** Look up information from regulatory agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), or other national health authorities. These agencies often provide detailed information on newly approved drugs, including indications, dosing, side effects, and clinical trial data.\n\n3. **Pharmaceutical Company Resources:**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_31ck2mesELA08WxBKaYLIVjy", "custom_id": "698_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "196787eb6545bf1579d5647a7da1ddaf", "body": {"id": "chatcmpl-9St74QsatiPB05dYLB9JNFEYcgK0E", "object": "chat.completion", "created": 1716672066, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fyarro (sirolimus albumin-bound nanoparticles) is a medication used in the treatment of certain types of cancer. Here are some key points a physician should know about Fyarro:\n\n1. **Indications**:\n   - Fyarro is primarily indicated for the treatment of malignant perivascular epithelioid cell tumors (PEComa), a rare type of soft tissue sarcoma. \n\n2. **Mechanism of Action**:\n   - Sirolimus, the active ingredient in Fyarro, is an mTOR (mammalian target of rapamycin) inhibitor. It works by inhibiting the mTOR pathway, which is involved in cell growth, proliferation, and survival. This inhibition can help slow down or stop the growth of cancer cells.\n\n3. **Formulation**:\n   - Fyarro is formulated as sirolimus albumin-bound nanoparticles, which can enhance the delivery and distribution of the drug in the body, potentially improving its efficacy and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_91VEDLwNVBylyLRyz39ssI30", "custom_id": "699_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c73c5ef13562fdd83c2b724dab5e7ea9", "body": {"id": "chatcmpl-9St74UPk0dlvcJaKRNh24xxoFinny", "object": "chat.completion", "created": 1716672066, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Antrypol is a drug that was historically used to treat trypanosomiasis, also known as sleeping sickness, which is caused by the Trypanosoma parasite. However, it\u2019s important to mention that Antrypol is not commonly used in modern medicine due to the development of more effective and less toxic treatments.\n\nHere are some key points to consider:\n\n1. **Mechanism of Action**: Antrypol interferes with the parasitic cell's metabolism, ultimately leading to the death of the parasite.\n\n2. **Indications**: It was used primarily for African trypanosomiasis. There are two forms of this disease: \n    - **Gambian (West African) sleeping sickness**, caused by Trypanosoma brucei gambiense.\n    - **Rhodesian (East African) sleeping sickness**, caused by Trypanosoma brucei rhodesiense.\n\n3. **Administration**: Antrypol was typically administered via"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_JS36nOIENMvz3bQFSYBjZ71n", "custom_id": "700_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "845270c1362365c7113753c31dc47d64", "body": {"id": "chatcmpl-9St74bbUwGaRgVEHiVL6tMtBaJCC6", "object": "chat.completion", "created": 1716672066, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Krazati is the brand name for adagrasib, which is a medication used in the treatment of certain cancers. Specifically, it targets cancers with a specific genetic mutation known as KRAS G12C. Here are some key points you should know about Krazati:\n\n### Indications:\n- **KRAS G12C Mutation:** Krazati is indicated for the treatment of adult patients with non-small cell lung cancer (NSCLC) that has the KRAS G12C mutation and has progressed following prior systemic therapy.\n\n### Mechanism of Action:\n- **KRAS Inhibitor:** Krazati works by selectively and irreversibly binding to the KRAS G12C protein, thereby inhibiting its oncogenic activity. This can lead to tumor cell death in cancers driven by this mutation.\n\n### Administration:\n- **Oral Medication:** Krazati is administered orally, typically in the form of tablets. The dosage and schedule depend on the specific needs of the patient and the prescribing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_qPLvBr2Km2SpRjlVMpJkkJcn", "custom_id": "701_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e638cbf33f4fe44008ce3014581ae500", "body": {"id": "chatcmpl-9St746Xyjp2HdQBngDDWkZDO8PRUf", "object": "chat.completion", "created": 1716672066, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kimmtrak (generic name: tebentafusp-tebn) is a relatively new medication approved for the treatment of certain types of cancer. Here's a comprehensive overview tailored for a physician:\n\n### Indication\nKimmtrak is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma, a rare but aggressive form of melanoma that occurs in the eye.\n\n### Mechanism of Action\nKimmtrak is a bispecific gp100 peptide-HLA-directed CD3 T cell engager. It works by binding to gp100, a melanoma-associated antigen presented on the surface of uveal melanoma cells by HLA-A*02:01, and simultaneously binding to CD3 on T cells. This dual binding redirects T cells to the melanoma cells, promoting T cell activation and subsequent tumor cell lysis.\n\n### Administration\nKimmtrak is administered via intravenous (IV) infusion. The dosing regimen typically involves an initial phase with weekly infusions. The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_RnlXImlgUsokax5VB8vkEUAJ", "custom_id": "702_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8feec78e9bd3dbf61c7210ee41ad8aef", "body": {"id": "chatcmpl-9St74HiXgrYikNkB1vzcO9ey9QiFs", "object": "chat.completion", "created": 1716672066, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Inrebic (generic name: fedratinib) is a medication used in the treatment of adult patients with certain types of myelofibrosis, which is a type of bone marrow cancer. Understanding the following key points about Inrebic will be helpful for you as a physician:\n\n1. **Mechanism of Action**: Inrebic is a kinase inhibitor that targets the Janus-associated kinase 2 (JAK2) pathway. This pathway is often dysregulated in myeloproliferative disorders like myelofibrosis.\n\n2. **Indications**: Inrebic is approved for the treatment of intermediate-2 or high-risk primary or secondary myelofibrosis (post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis).\n\n3. **Dosage and Administration**: The recommended dose of Inrebic is usually 400 mg orally once daily. It should be taken with a high-fat"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_L3jyAa4NVsatw7U0ne6PRRhJ", "custom_id": "703_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "7a4869d0916ec2b378942bb499d1abe8", "body": {"id": "chatcmpl-9St74HOYraYvZpUEdcTNa0yttx0ou", "object": "chat.completion", "created": 1716672066, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) is a combination medication used to treat certain types of breast cancer. Here are some key points you should know about it:\n\n### Indications:\n1. **HER2-Positive Breast Cancer**: It is used in the treatment of HER2-positive breast cancer, which overexpresses the HER2 protein. It can be used in both early-stage and metastatic settings.\n2. **Adjuvant Therapy**: For early breast cancer, it can be used as part of adjuvant therapy, either following surgery or chemotherapy.\n3. **Metastatic Breast Cancer**: For metastatic disease, it can be used in combination with other chemotherapeutic agents.\n\n### Mechanism of Action:\n- **Trastuzumab**: This is a monoclonal antibody that specifically targets the HER2 receptor on the surface of cancer cells, inhibiting their growth and survival.\n- **Hyaluronid"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_0Dc5TeVU8reyvCCeH0EylDgA", "custom_id": "704_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d8f10d984ec954f639dc416ba166762d", "body": {"id": "chatcmpl-9St74yI42sADTdd6SfUrdoxGZkr0g", "object": "chat.completion", "created": 1716672066, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brukinsa (generic name: zanubrutinib) is a medication that you should be familiar with if you are treating patients with certain types of hematologic malignancies. Here are some key points to consider:\n\n### Indications\n- **Brukinsa** is primarily indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.\n- It is also approved for the treatment of adults with Waldenstr\u00f6m's macroglobulinemia (WM) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).\n\n### Mechanism of Action\n- **Zanubrutinib** is a Bruton's tyrosine kinase (BTK) inhibitor. It works by binding to BTK, thereby inhibiting the BTK-mediated signaling pathways which are essential for the proliferation and survival of malignant B-cells.\n\n### Dosage and Administration\n- The recommended dose of Brukinsa is 160 mg taken orally"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_2Q8yiJCCpAPuTRyC7GiGtddW", "custom_id": "705_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8518ecd95bbb187f0367e2d1712fc94c", "body": {"id": "chatcmpl-9St74YmDKM42pAcT4EiodjT1vRtLg", "object": "chat.completion", "created": 1716672066, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ivesa is not a widely recognized term in the medical community, so it is possible that there may be some confusion or a typographical error. However, here are a few steps you can take to clarify and gather the necessary information:\n\n1. **Verify the Term**: Double-check the spelling and context in which you encountered \"Ivesa.\" It could be a specific medical term, a medication, a technology, or an organization.\n\n2. **Consult Medical Databases**: Use medical databases such as PubMed, UpToDate, or your institution's library resources to search for \"Ivesa\" and see if any relevant information is available.\n\n3. **Ask Colleagues**: Sometimes colleagues may have encountered specific terms or products and can provide insights or direct you to the appropriate sources.\n\n4. **Check Regulatory and Professional Organizations**: Organizations such as the FDA (Food and Drug Administration), AMA (American Medical Association), or specialty-specific organizations may have information on new medications"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_7PoueLLPyRbAUaJsjl08EWa1", "custom_id": "706_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "86625dc50dd95ec447142df440553724", "body": {"id": "chatcmpl-9St74Kpy4hxryQEpnEFkgyrTLh7Sd", "object": "chat.completion", "created": 1716672066, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carvykti (ciltacabtagene autoleucel) is a chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for the treatment of adult patients with relapsed or refractory multiple myeloma. Here are some key points you should know about Carvykti as a physician:\n\n### Indication:\n- Carvykti is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma, specifically those who have received at least four prior lines of therapy, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.\n\n### Mechanism of Action:\n- Carvykti is an autologous, genetically modified T-cell immunotherapy. The patient's T cells are collected and genetically engineered to express a CAR that targets the B-cell maturation antigen (BCMA) on the surface of multiple myeloma cells. Once infused back into the patient, these CAR T cells can recognize and kill BCMA-ex"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_u6GTuEjVG0KydpsGoBsZMiA6", "custom_id": "707_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "848bd6a9023c9acae5603587fdb171ae", "body": {"id": "chatcmpl-9St74KVEwbRTuQ0TyZmab9WxEBygb", "object": "chat.completion", "created": 1716672066, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Scemblix (asciminib) is a relatively new medication approved for the treatment of chronic myeloid leukemia (CML). Here are some key points you should know as a physician:\n\n### Mechanism of Action:\n- **Targeted Therapy**: Scemblix is a tyrosine kinase inhibitor (TKI) specifically targeting the ABL myristoyl pocket (STAMP inhibitor). This is a novel mechanism compared to other TKIs which target the ATP-binding site of the BCR-ABL1 protein.\n\n### Indications:\n- **Chronic Myeloid Leukemia (CML)**: It is indicated for the treatment of adult patients with Philadelphia chromosome-positive CML in chronic phase who have been previously treated with two or more TKIs.\n\n### Administration:\n- **Oral Medication**: Scemblix is administered orally with or without food. The dosing regimen is typically 40 mg twice daily or 80 mg once daily, but this can vary based on"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_llGxU0a187YgFqY1e2NBbiLg", "custom_id": "708_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0bd128614123db1d594e1e20f1473c49", "body": {"id": "chatcmpl-9St75igb6GlldFWwTFhjhf3s4Cufc", "object": "chat.completion", "created": 1716672067, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's crucial to stay informed about emerging treatments and medications. Zynlonta (loncastuximab tesirine-lpyl) is a relatively new therapeutic option that you might find relevant, depending on your medical specialty. Here are some key points you should know:\n\n### Indications and Usage\n- **Zynlonta** is approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma.\n\n### Mechanism of Action\n- **Loncastuximab tesirine-lpyl** is an antibody-drug conjugate (ADC) that targets CD19, a protein expressed on the surface of B-cells.\n- The drug consists of a humanized monoclonal antibody linked to a cytotoxic agent (pyrrolobenz"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_usyRT39SqFLoaSB5EOR5V1gS", "custom_id": "709_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f11767f953fb5aa8380916cf0251c4a6", "body": {"id": "chatcmpl-9St75BJAjheqBiH8mlvGBO7iTjoB5", "object": "chat.completion", "created": 1716672067, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tazverik (generic name: tazemetostat) is a medication used primarily in the treatment of certain types of cancer. As a physician, here are key points you should be aware of regarding Tazverik:\n\n### Indications:\n1. **Epithelioid Sarcoma**: Tazverik is approved for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.\n2. **Follicular Lymphoma**: It is also indicated for adults with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, and who have received at least two prior systemic therapies. Additionally, it is indicated for follicular lymphoma patients without the EZH2 mutation who have no satisfactory alternative treatment options.\n\n### Mechanism of Action:\n- **EZH2 Inhibition**: Tazverik works by"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_wXniIRv92GsuO0yddb0WbURA", "custom_id": "710_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "379f6657e8e40f81718e249c365c15d7", "body": {"id": "chatcmpl-9St75WdWZGp52gSddiupgERYF5EJr", "object": "chat.completion", "created": 1716672067, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Opdualag is a combination immunotherapy treatment that includes nivolumab (a PD-1 inhibitor) and relatlimab (a LAG-3 inhibitor). It is used in the treatment of certain types of cancer, particularly melanoma. Here's a detailed overview of what you should know about Opdualag:\n\n1. **Mechanism of Action**:\n   - **Nivolumab**: This is a monoclonal antibody that targets the programmed death-1 (PD-1) receptor on T cells, blocking its interaction with PD-L1 and PD-L2 on tumor cells. This inhibition allows T cells to effectively attack tumor cells.\n   - **Relatlimab**: This monoclonal antibody targets the LAG-3 (lymphocyte activation gene-3) protein, which is another checkpoint that suppresses T cell activity. By inhibiting LAG-3, relatlimab enhances T cell activation and immune response against cancer cells.\n\n2. **Indications**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_K9zKpez7IXUPww74BFJ29gh0", "custom_id": "711_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "81f2ec2502b92dbae3c309783f2f8f76", "body": {"id": "chatcmpl-9St75mn70u8HgLolFif1orwWwTWcz", "object": "chat.completion", "created": 1716672067, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to have a comprehensive understanding of any medication you may prescribe, including Berofor. However, as of my knowledge cutoff date in October 2023, there is no widely recognized medication or treatment known as \"Berofor.\" It is possible that this could be a typographical error, a brand name not widely recognized, or a more recent development in pharmaceuticals that I am not aware of.\n\nTo ensure patient safety and effective treatment, consider the following steps:\n\n1. **Verify the Name**: Double-check the spelling and ensure that \"Berofor\" is the correct name of the medication. Sometimes names can be confused or misspelled.\n\n2. **Consult Reliable Sources**: Refer to trusted medical resources such as the Physicians' Desk Reference (PDR), FDA database, or peer-reviewed medical journals for information on the medication.\n\n3. **Drug Information**: Gather comprehensive data on the drug, including:\n   - **Indications**: Conditions or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_DYJETwuZK9AjTPsoJgLovsOf", "custom_id": "712_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "16d5981baa95602d68a9f361f5c9cc07", "body": {"id": "chatcmpl-9St75MPdrLttpxYLWQ8w65qZWJEMq", "object": "chat.completion", "created": 1716672067, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Wellferon, also known by its generic name interferon alfa-n1, is a type of medication that was used as an immunotherapy for certain types of cancer and viral infections. It belongs to the class of drugs known as interferons, which are proteins that play a role in the immune response.\n\nHere are some important points to consider:\n\n1. **Mechanism of Action**:\n   - Interferon alfa-n1 works by stimulating the immune system to attack abnormal cells and viruses. It has antiviral, antiproliferative, and immune-modulating effects.\n\n2. **Indications**:\n   - Wellferon was used primarily for the treatment of certain cancers, including hairy cell leukemia and chronic myelogenous leukemia (CML), as well as for chronic hepatitis B and C.\n\n3. **Administration**:\n   - It was typically administered via subcutaneous or intramuscular injection. The dosage and schedule depended on the specific condition being treated and the patient\u2019s response to the medication"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_7qRnvJThdgMixnmwyCgvbCxG", "custom_id": "713_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "fdd8c514372da60c3f91252d08f7b156", "body": {"id": "chatcmpl-9St75SYA6IpkBfzv7qtl5poayQNU3", "object": "chat.completion", "created": 1716672067, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Margenza (margetuximab-cmkb) is a monoclonal antibody used in the treatment of certain types of breast cancer. Here are some key points you should know about Margenza:\n\n### Indication:\n- **Margenza** is used in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.\n\n### Mechanism of Action:\n- Margenza is a chimeric IgG1 monoclonal antibody that binds to the extracellular domain of the HER2 receptor, a protein overexpressed in some breast cancers. It works by blocking HER2 receptor signaling and mediating antibody-dependent cellular cytotoxicity (ADCC).\n\n### Administration:\n- **Dosage**: Margenza is usually administered as an intravenous infusion. The recommended dosage is 15 mg/kg every three weeks (21-day cycle) in combination with chemotherapy.\n- **Inf"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_csbceYtyPAZo2lQv0oCN3HJ9", "custom_id": "714_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f0f3cc4f133294bc87c8ab7c2714ec15", "body": {"id": "chatcmpl-9St75OiAFKMJNDAtQJWQCikV2gEeu", "object": "chat.completion", "created": 1716672067, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lumakras (sotorasib) is a medication used in the treatment of non-small cell lung cancer (NSCLC) with a specific genetic mutation. Here are some key points you should know:\n\n1. **Indication**: Lumakras is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, following at least one prior systemic therapy. KRAS mutations are among the most common mutations in NSCLC.\n\n2. **Mechanism of Action**: Lumakras is a KRAS G12C inhibitor. KRAS is a protein involved in cell signaling pathways that control cell growth and division. The G12C mutation is a specific change in the KRAS gene, and Lumakras works by irreversibly binding to this mutant KRAS protein, inhibiting its activity and thereby inhibiting tumor growth.\n\n3. **Dosage and Administration**: The recommended dosage of Lumakras is 960 mg (eight 120 mg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_HsifMChlOhyAAc4mJLnKT4gE", "custom_id": "715_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "45b9acb2bb7a5738a6b9afbb1536f0fc", "body": {"id": "chatcmpl-9St75urJyBv5SKT9T7VS3mS4Oljvf", "object": "chat.completion", "created": 1716672067, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ukoniq (umbralisib) is a medication that was used to treat certain types of lymphoma, specifically marginal zone lymphoma (MZL) and follicular lymphoma (FL). Here are some important points you should know about Ukoniq:\n\n1. **Mechanism of Action**: Ukoniq is an oral kinase inhibitor targeting phosphoinositide 3-kinase (PI3K)-delta and casein kinase 1 epsilon (CK1\u03b5). These proteins are involved in the growth and survival of malignant B-cells.\n\n2. **Indications**: Ukoniq was indicated for the treatment of adult patients with relapsed or refractory MZL who have received at least one prior anti-CD20-based regimen and for adult patients with relapsed or refractory FL who have received at least three prior lines of systemic therapy.\n\n3. **Dosage and Administration**: The recommended dosage was 800 mg taken orally once daily with food.\n\n4. **Side Effects**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_sHokX7gYXiks6evriP1FxtDS", "custom_id": "716_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "aa0f38e3e58aa3a5365a75247a5e2bbc", "body": {"id": "chatcmpl-9St75t1ifDPUKfqg6iP9LrgUH4mAV", "object": "chat.completion", "created": 1716672067, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tyvyt (sintilimab injection) is an immune checkpoint inhibitor that targets the programmed cell death protein-1 (PD-1) pathway. It's used primarily in oncology for the treatment of certain types of cancer. Here are some key points you should know about Tyvyt:\n\n### Mechanism of Action\n- **PD-1 Inhibition:** Tyvyt works by blocking the PD-1 receptor on T-cells, preventing its interaction with PD-L1 and PD-L2. This inhibition enhances the immune system's ability to detect and destroy cancer cells.\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC):** Often indicated for use in combination with other chemotherapeutic agents for the treatment of non-small cell lung cancer.\n- **Hodgkin Lymphoma:** Approved for use in patients with relapsed or refractory classic Hodgkin lymphoma.\n- **Other Cancers:** Research and clinical trials are ongoing to expand its use to other types of cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_GBy1hmxdNsopAUKQMpLxWV5A", "custom_id": "717_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "badc3b873af76a823081ef35e6e383f2", "body": {"id": "chatcmpl-9St753F8JxbqCH0nsemdHsh4m9964", "object": "chat.completion", "created": 1716672067, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be up-to-date on new medications and treatments. Jaypirca (generic name: pirtobrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor. Here are several key points about Jaypirca that you should be aware of:\n\n1. **Mechanism of Action**:\n   - Jaypirca is designed to inhibit BTK, a key enzyme in the B-cell receptor signaling pathway. This inhibition can lead to decreased proliferation and survival of malignant B cells.\n\n2. **Indications**:\n   - Jaypirca is primarily used in the treatment of B-cell malignancies, such as certain types of lymphomas and chronic lymphocytic leukemia (CLL).\n\n3. **Dosage and Administration**:\n   - The dosage and administration of Jaypirca can vary depending on the specific condition being treated and the patient's overall health. It's typically administered orally.\n   - It's important to follow the specific prescribing information for the appropriate dosing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_k8JHhEz53uTj5Ei4qjeD2I45", "custom_id": "718_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f3fc10fd068fb6f248844f23a8faae99", "body": {"id": "chatcmpl-9St75TbFC7qbgQziYwaNcX5jNLcdx", "object": "chat.completion", "created": 1716672067, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's crucial to be well-informed about Tuoyi (Toripalimab), a monoclonal antibody used in cancer immunotherapy. Here are some key points to consider:\n\n1. **Mechanism of Action**: \n   - Tuoyi (Toripalimab) is a PD-1 (Programmed Death-1) inhibitor. It works by blocking the interaction between PD-1 on T-cells and its ligands (PD-L1 and PD-L2) on tumor cells, thereby enhancing the immune response against cancer cells.\n\n2. **Indications**:\n   - Toripalimab is used for treating various cancers, including melanoma, nasopharyngeal carcinoma, and urothelial carcinoma. Its specific indications can vary based on regulatory approvals in different regions.\n\n3. **Administration**:\n   - Toripalimab is administered via intravenous infusion. The dosing schedule and duration of treatment can vary depending on the type and stage of cancer being treated.\n\n4"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_xc8AKRD4pWLOUAax4IAzlxT5", "custom_id": "719_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "a5bd3cdb9e67280a6a4d3f9a119cf4c2", "body": {"id": "chatcmpl-9St75ML5Eh6mmXRHrSfhbZCUnEYfM", "object": "chat.completion", "created": 1716672067, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tecvayli (teclistamab) is a relatively new medication that has been approved for the treatment of certain types of cancer, specifically for relapsed or refractory multiple myeloma. Here are some key points you should know about Tecvayli:\n\n### Mechanism of Action\n- **Bispecific Antibody**: Tecvayli is a bispecific T-cell engager (BiTE) antibody that targets both CD3 on T-cells and B-cell maturation antigen (BCMA) on myeloma cells. By binding to both, it brings T-cells into close proximity with myeloma cells, promoting T-cell-mediated destruction of the cancer cells.\n\n### Indications\n- **Multiple Myeloma**: Tecvayli is specifically indicated for patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_sgL1qb4gsi0PjDi4o8wvCDvd", "custom_id": "720_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0c0bc95d0ef4af9cdb26e4ccbe1f37c7", "body": {"id": "chatcmpl-9St76TTycPRFJiFplgd1yZpWBMM1t", "object": "chat.completion", "created": 1716672068, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Exkivity (mobocertinib) is a medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain types of non-small cell lung cancer (NSCLC). Here are some essential points you should know as a physician:\n\n### 1. **Indication**\n- **Approved Use**: Exkivity is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as confirmed by an FDA-approved test, and whose disease has progressed on or after platinum-based chemotherapy.\n\n### 2. **Mechanism of Action**\n- **Target**: Exkivity is a tyrosine kinase inhibitor (TKI) that specifically targets EGFR exon 20 insertion mutations, which are less common but more resistant to other EGFR inhibitors.\n\n### 3. **Dosage and Administration**\n- **Recommended Dose**: The recommended dose is 160 mg orally once"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_A2KU8h5EEeRWxaiUSdq4bSOQ", "custom_id": "721_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "4acac5ed0e3580cf52a2a744daa5fb92", "body": {"id": "chatcmpl-9St76PjchXHmL43Oh4JP5y0mRp3D2", "object": "chat.completion", "created": 1716672068, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tivdak (tisotumab vedotin-tftv) is a medication used in oncology, specifically indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tivdak is a first-in-class antibody-drug conjugate composed of a tissue factor-directed antibody and the microtubule-disrupting agent monomethyl auristatin E (MMAE).\n\nHere are key points you should know about Tivdak:\n\n1. **Mechanism of Action**: Tivdak targets tissue factor (TF), a cell-surface protein involved in tumor growth, angiogenesis, and metastasis. Upon binding to TF on cancer cells, the conjugate is internalized, and MMAE is released, leading to cell cycle arrest and apoptosis by disrupting the microtubule network within the cell.\n\n2. **Indications**: Tivdak is used for patients with recurrent or metastatic cervical cancer who have previously been treated with chemotherapy and whose disease has progressed.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Fjmx4dg8eQV7LC87WkaZ28pd", "custom_id": "722_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f5ed47d24c2d4ea42e224e7e7a8a7c18", "body": {"id": "chatcmpl-9St760ywyNzhzuKnj0yBJuMPMNieN", "object": "chat.completion", "created": 1716672068, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Somatuline Depot (lanreotide) is a long-acting somatostatin analog used primarily in the treatment of certain medical conditions. As a physician, it is essential to have a comprehensive understanding of its indications, administration, mechanism of action, side effects, and monitoring requirements. Here is an overview:\n\n### Indications:\n1. **Acromegaly**: Somatuline Depot is used to reduce growth hormone and insulin-like growth factor 1 (IGF-1) levels in patients with acromegaly, particularly when surgery or radiotherapy are not suitable or have not been fully effective.\n2. **Neuroendocrine Tumors (NETs)**: It is used for the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to control symptoms and tumor growth.\n3. **Carcinoid Syndrome**: Somatuline Depot can be used to manage symptoms associated with carcinoid syndrome, such"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_oko1SUuOd1iB4eEX4LQNd9cL", "custom_id": "723_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "28474830323e887676afc44a98eb6759", "body": {"id": "chatcmpl-9St76k4qPyMCU4VooPiVADcAFnGES", "object": "chat.completion", "created": 1716672068, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Jeselhy, also known as lecanemab, is a medication used to treat Alzheimer's disease. It is a monoclonal antibody designed to target and clear amyloid-beta plaques, which are associated with the progression of Alzheimer's. Here are some key points you should know about Jeselhy as a physician:\n\n1. **Mechanism of Action**: Jeselhy works by binding to amyloid-beta plaques in the brain, facilitating their clearance and potentially slowing the progression of Alzheimer's disease.\n\n2. **Indications**: It is indicated for patients with early-stage Alzheimer's disease or mild cognitive impairment due to Alzheimer's, as these are the stages where amyloid-beta plaques are thought to play a significant role.\n\n3. **Administration**: Jeselhy is typically administered via intravenous infusion. The dosage and frequency of administration are determined based on the specific needs of the patient and clinical guidelines.\n\n4. **Efficacy**: Clinical trials have shown that Jeselhy can reduce amyloid-beta plaques"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_SjEMMv8z1cp0soztneGmlvKL", "custom_id": "724_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "c6f2f80eb28231535afceff3fd2875c6", "body": {"id": "chatcmpl-9St76ESMEQeh0cvj6OkaLqUE2ly4Z", "object": "chat.completion", "created": 1716672068, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, \"Mostarina\" does not appear to be a recognized medical term, condition, medication, or treatment in conventional medical literature or practice. It's possible that the term could be a misspelling, a very recent development in medicine, a regional or non-standard term, or related to a specific niche or emerging area that hasn't yet gained widespread recognition.\n\nIf you encountered the term \"Mostarina\" in a specific context (e.g., patient history, medical literature, regional practice), I recommend checking the following:\n\n1. **Contextual Clarity**: Review the context in which \"Mostarina\" was mentioned. Sometimes context can provide clues about its meaning or relevance.\n\n2. **Consult Colleagues**: Ask colleagues or specialists in the relevant field if they are familiar with the term.\n\n3. **Literature Search**: Conduct a thorough literature search in medical databases like PubMed, Google Scholar, or specific medical journals to see if there"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_cGMTaLzRBBP8wfqPdTCNGrqN", "custom_id": "725_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "08314ef1c3c5c3a11797c6427884e25a", "body": {"id": "chatcmpl-9St76HVOQZae97A50KD1r4kOODZ8a", "object": "chat.completion", "created": 1716672068, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized medical treatment, drug, or condition known as \"Vercite.\" It's possible that you might be referring to something that is either very new, highly specialized, or perhaps a misspelling or variation of a known term. Here are a few steps you can take to find accurate information:\n\n1. **Check Medical Databases:** Utilize databases like PubMed, Medline, or professional medical journals to search for \"Vercite\" or similar terms to see if there are any relevant studies or articles.\n\n2. **Consult Professional Networks:** Reach out to colleagues or professional networks such as the American Medical Association (AMA) or specialty-specific organizations to see if anyone has knowledge on \"Vercite.\"\n\n3. **Pharmaceutical Repositories:** If you suspect it's a medication, check resources like the FDA database or pharmaceutical compendiums such as the Physicians' Desk Reference (PDR).\n\n4. **Clarify the Term"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_xGfDi2DttG2LmWBxw7SPOEtf", "custom_id": "726_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "246143cc971cd8232fc7b7896b8c3045", "body": {"id": "chatcmpl-9St76xrgDIyHQVKcaZ5NkPpN5A9Ek", "object": "chat.completion", "created": 1716672068, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Polivy (polatuzumab vedotin-piiq) is a medication used in the treatment of certain types of non-Hodgkin lymphoma (NHL), specifically relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Here are some key points you should know about Polivy:\n\n1. **Mechanism of Action**:\n   - Polivy is an antibody-drug conjugate (ADC). It combines a monoclonal antibody targeting CD79b, a protein expressed on B cells, with a cytotoxic agent called monomethyl auristatin E (MMAE). This allows the drug to deliver the cytotoxic agent directly to cancer cells, minimizing damage to normal cells.\n\n2. **Indications**:\n   - Polivy is indicated for use in combination with bendamustine and rituximab (BR) for the treatment of adult patients with relapsed or refractory DLBCL, not otherwise specified, after at least two prior therapies.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_3QXm2wooPn8hQIuNGiKGSf48", "custom_id": "727_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "f509393c988b220b6cced8181272b4b0", "body": {"id": "chatcmpl-9St76bSm5mJgU3ylXSDH5y6plY7ce", "object": "chat.completion", "created": 1716672068, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Elahere, also known by its generic name mirvetuximab soravtansine, is a targeted cancer therapy used in the treatment of certain types of ovarian cancer. Here are some key points you should know about Elahere:\n\n1. **Mechanism of Action**: \n   - Elahere is an antibody-drug conjugate (ADC). It consists of a monoclonal antibody (mirvetuximab) that targets the folate receptor alpha (FR\u03b1), which is often overexpressed in ovarian cancer cells. The antibody is linked to a cytotoxic agent (soravtansine), which is released into the cancer cells upon binding, leading to cell death.\n\n2. **Indications**:\n   - Elahere is indicated for the treatment of patients with FR\u03b1-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.\n\n3. **Administration**:\n   - Elahere is administered intravenously."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_R4FB6BTv6PRvgvRkXVJm8KU0", "custom_id": "728_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "e7fb7a4732c9500e829d5f84b6a50f24", "body": {"id": "chatcmpl-9St77i78pgeHhgxmXgULd6U38DpD4", "object": "chat.completion", "created": 1716672069, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to be well-informed about Lunsumio (generic name: mosunetuzumab), which is a prescription medication used in the treatment of certain types of cancer. Here are several key points you should know:\n\n### Indications\n- **Lunsumio is used primarily for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies.**\n\n### Mechanism of Action\n- **Lunsumio is a bispecific CD20-directed CD3 T-cell engager. It works by binding to the CD20 antigen on B-cells and the CD3 receptor on T-cells, thereby recruiting and activating T-cells to attack and kill the B-cells.**\n\n### Administration\n- **Lunsumio is administered via intravenous infusion.**\n- **The dosing schedule includes a step-up dosing regimen in the first cycle to mitigate the risk of cytokine release syndrome (CRS)."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_hpWRNhhOgcWOYMdGTNX2NNNC", "custom_id": "729_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "0e9cfccf2e7404c2410b22a4dcd483a2", "body": {"id": "chatcmpl-9St77QRVR2XUl5KHJWV1zeiimf7gg", "object": "chat.completion", "created": 1716672069, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adstiladrin (nadofaragene firadenovec-vncg) is a gene therapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Here are the key points you should know:\n\n1. **Indication**: Adstiladrin is used specifically for patients with high-grade NMIBC who are unresponsive to Bacillus Calmette-Gu\u00e9rin (BCG) therapy. This includes patients with carcinoma in situ (CIS) with or without papillary tumors.\n\n2. **Mechanism of Action**: Adstiladrin is a non-replicating adenoviral vector-based gene therapy. It delivers the human interferon alfa-2b gene directly into the bladder cells. The expressed interferon alfa-2b has immunomodulatory effects, which help in combating cancer cells.\n\n3. **Administration**: The therapy is administered intravesically, meaning it is directly instilled into the bladder via a catheter. This is typically done in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_NbPIKBeaLCnNDS93U8kx6abV", "custom_id": "730_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "8ca08834ffced002857d005aba93e83e", "body": {"id": "chatcmpl-9St77m8CbZ3bG62MwVzi2ikb8W7YV", "object": "chat.completion", "created": 1716672069, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rezlidhia, also known by its generic name olutasidenib, is a medication that you might encounter in the treatment of certain types of cancer, specifically acute myeloid leukemia (AML). Here are some key points you should know about Rezlidhia:\n\n1. **Indication**: Rezlidhia is typically indicated for the treatment of adult patients with relapsed or refractory AML who have an isocitrate dehydrogenase-1 (IDH1) mutation. It is important to confirm the presence of this mutation through appropriate diagnostic testing before initiating treatment.\n\n2. **Mechanism of Action**: Olutasidenib is an inhibitor of the IDH1 enzyme. Mutations in the IDH1 gene can lead to the production of an abnormal enzyme that contributes to the proliferation of malignant cells. By inhibiting this enzyme, Rezlidhia helps to reduce the growth and survival of cancer cells.\n\n3. **Administration**: Rezlidhia is typically"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_XPuYD10Y0zFEB8d2xPTiHWRm", "custom_id": "731_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "3eaa05370e232de8de08e93b9a42caf9", "body": {"id": "chatcmpl-9St77qmB7mhNX0IapLI4F37Ie9ZVM", "object": "chat.completion", "created": 1716672069, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "To provide a relevant answer, I need more context about who Irene is. In general, when considering a patient named Irene, a physician should know the following:\n\n1. **Medical History**: Detailed information about her past illnesses, surgeries, allergies, ongoing treatments, and family medical history.\n\n2. **Current Health Status**: Information about her current symptoms, recent changes in health, and any concerns she may have.\n\n3. **Medications**: A comprehensive list of all medications she is currently taking, including over-the-counter drugs, supplements, and herbal remedies.\n\n4. **Lifestyle Factors**: Information about her diet, exercise habits, smoking status, alcohol consumption, and other lifestyle choices that might affect her health.\n\n5. **Mental Health**: Any history of mental health issues, current mental health status, and any treatments or therapies she is undergoing for mental health.\n\n6. **Social and Environmental Factors**: Her living situation, occupation, stress levels, and support system, as these"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 39, "completion_tokens": 200, "total_tokens": 239}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_MapgblKWB8PRVbhrvQDrxsTG", "custom_id": "732_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "2efd6e44ffc7b90823204c5918d4d6c6", "body": {"id": "chatcmpl-9St775Fu2C50TeRCufbzWG8mXuv4I", "object": "chat.completion", "created": 1716672069, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It appears there might be some confusion or a typographical error regarding \"Bigonist.\" As of my latest update, there is no widely recognized medical term, condition, medication, or concept specifically known as \"Bigonist.\"\n\nIf you meant something else or if this is a typo, could you please provide more context or clarify your question? This would help ensure that I can provide you with accurate and relevant information.\n\nIn the meantime, if you are looking for information on a specific medical topic, medication, or condition, please feel free to share more details, and I would be happy to assist you!"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 122, "total_tokens": 163}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_JnFIBhLvYqM6c3vTHH9YUiCN", "custom_id": "733_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d0a00f7fc2cad5159e4468afe703fd85", "body": {"id": "chatcmpl-9St77aGVvGZNsvCUumXPrjftgxq4F", "object": "chat.completion", "created": 1716672069, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Contego could refer to several different things, but in a medical context, it is most likely referring to Contego Medical, a company that specializes in developing innovative medical devices aimed at improving patient outcomes, particularly in vascular and cardiovascular procedures. Here are some key points you should know:\n\n1. **Integrated Embolic Protection:** Contego Medical is known for its products that integrate embolic protection directly into the delivery system of vascular devices. This is designed to simplify procedures and provide more effective protection against embolic events, such as stroke, during interventions.\n\n2. **Key Products:**\n   - **Vanguard IEP Peripheral Balloon Angioplasty System:** This device combines a peripheral angioplasty balloon with distal embolic protection in a single catheter, aimed at reducing the risk of embolization during peripheral vascular interventions.\n   - **Paladin Carotid PTA Balloon System:** This system is used for carotid artery interventions and also integrates embolic protection to minimize the risk of stroke during the procedure.\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_sKbaHuhsEGEjbGAjK4pRks7n", "custom_id": "734_sentiment_question_physician_0.7_gpt-4o", "response": {"status_code": 200, "request_id": "d88c508e160f41293ef19b2bf6d55c03", "body": {"id": "chatcmpl-9St77YIImbLOEX6t3JiZ4oMQ0ph6x", "object": "chat.completion", "created": 1716672069, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ebvallo (tabelecleucel) is a therapeutic option that you might encounter in your practice, particularly if you are dealing with conditions that involve Epstein-Barr Virus (EBV). Here are key points you should know about Ebvallo:\n\n1. **Mechanism of Action**: Ebvallo is an allogeneic T-cell immunotherapy specifically designed to target and eliminate EBV-infected cells. It harnesses the power of T-cells to recognize and attack EBV-related malignancies.\n\n2. **Indications**: It is primarily indicated for patients with EBV-associated post-transplant lymphoproliferative disease (EBV+ PTLD) who have either failed standard treatments or are not suitable candidates for such treatments. This can include patients post solid organ transplant or hematopoietic stem cell transplant.\n\n3. **Administration**: Ebvallo is administered intravenously. The specific dosing regimen and frequency will depend on the patient's condition and response to therapy. It's"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_sCRSln8coFO92x20epJ7oNYU", "custom_id": "1_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "80e5ea0322b62fa3b4e4dc0aa16c7f56", "body": {"id": "chatcmpl-9St77GLKPUWpcQiaH8Y2rm4SYCrSw", "object": "chat.completion", "created": 1716672069, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abemaciclib is an important medication primarily used in the treatment of specific types of breast cancer. Here are some key points a physician should know about Abemaciclib:\n\n### Mechanism of Action:\n\n- **CDK4/6 Inhibitor**: Abemaciclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which are crucial for cell cycle progression and proliferation in cancer cells.\n\n### Indications:\n\n- **Breast Cancer**: It's primarily indicated for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer, usually in combination with endocrine therapy (e.g., aromatase inhibitors or fulvestrant).\n\n### Dosing:\n\n- **Adults**: The recommended starting dose is usually 150 mg taken orally twice daily.\n- **Combinations**: When used with endocrine therapies, the dosing might vary based on the combination and the patient's tolerance"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_UsQ1ST2sLoVvOOkKlZjNOVue", "custom_id": "2_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0d4524cc3fd8427e066704b552c11021", "body": {"id": "chatcmpl-9St777SqUUqRHx0AhKBRwXWzU4U7v", "object": "chat.completion", "created": 1716672069, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abiraterone acetate, commonly known just as Abiraterone, is a medication primarily used in the treatment of prostate cancer. Here's an overview of its key aspects:\n\n### Indications and Usage\n- **Prostate Cancer Treatment**: Abiraterone is particularly used for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mHSPC).\n- **Combination**: It is typically used in combination with prednisone or prednisolone to help manage side effects and improve effectiveness.\n\n### Mechanism of Action\n- **CYP17 Inhibition**: Abiraterone inhibits CYP17A1, an enzyme critical for androgen biosynthesis. This leads to a significant reduction in circulating levels of androgens, which are known to drive the growth of prostate cancer cells.\n\n### Dosage and Administration\n- **Dosage**: The standard dose is 1,000 mg orally once daily. It is combined with prednisone 5"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_kmry6oDxrChurgid9z8Q7ek2", "custom_id": "3_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b7e0f29a78241fa0ce4ea259f58c84cb", "body": {"id": "chatcmpl-9St77UzTIzdUPYXQcgu1l2E0hALfo", "object": "chat.completion", "created": 1716672069, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Acalabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor used primarily in the treatment of certain hematologic malignancies. Here are key points you, as a physician, should know about Acalabrutinib:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)**\n2. **Mantle Cell Lymphoma (MCL):** Specifically for patients who have received at least one prior therapy.\n\n### Mechanism of Action:\n- Acalabrutinib selectively inhibits BTK, a key enzyme in the B-cell receptor signaling pathway. By inhibiting BTK, Acalabrutinib disrupts malignant B-cell proliferation and survival.\n\n### Dosage and Administration:\n- **Standard Dose:** Typically, 100 mg taken orally twice daily.\n- It can be taken with or without food.\n- Capsules should be swallowed whole and not opened, broken, or che"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_xXmeZgiyl31poEw1mSt9euB3", "custom_id": "4_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b8eedb1a8cca5664887a500d010471f6", "body": {"id": "chatcmpl-9St77wCuH9ronweZMVSybLurK72oo", "object": "chat.completion", "created": 1716672069, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aclarubicin, also known as aclacinomycin A, is an anthracycline antibiotic primarily used in oncology for its anti-cancer properties. Here are some key points you should know about Aclarubicin:\n\n1. **Mechanism of Action:**\n   - Aclarubicin works by intercalating into DNA and inhibiting the enzyme topoisomerase II, which is crucial for DNA replication and transcription. This prevents cancer cells from proliferating and can lead to cell death.\n\n2. **Indications:**\n   - It is used mainly in the treatment of various types of leukemia, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It may also be used for other hematological malignancies.\n\n3. **Administration:**\n   - Aclarubicin is typically administered intravenously. The dosage and schedule depend on the specific protocol in use, as well as the patient\u2019s overall health, kidney and liver function, and response"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_K8gmreyUCX7sxLtBg0mIDq1r", "custom_id": "5_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "00bc7251a0cdb42ba65932ed629fd32f", "body": {"id": "chatcmpl-9St77nMJQq9W4JFRwEIzI9Wh9Hm6S", "object": "chat.completion", "created": 1716672069, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab emtansine, also known as T-DM1 and marketed under the brand name Kadcyla, is an important medication used in the treatment of breast cancer. Here are key points you should know:\n\n### Mechanism of Action\nTrastuzumab emtansine is an antibody-drug conjugate (ADC) that combines two components:\n1. **Trastuzumab**: A monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2), a protein overexpressed in some breast cancers. Trastuzumab binds to HER2, inhibiting signaling pathways that promote tumor cell growth and survival. It also mediates immune effector functions, such as antibody-dependent cellular cytotoxicity (ADCC).\n2. **DM1 (emtansine)**: A cytotoxic agent linked to trastuzumab. DM1 is a derivative of maytansine, a potent microtubule inhibitor. Once the conjugate"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ACNwKOEl1bmG7pyHttOW6w67", "custom_id": "6_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "640056eb4c44bef9d0a95b5dcf308ca3", "body": {"id": "chatcmpl-9St771hgfUGkOn6TuqkxHg775J5WU", "object": "chat.completion", "created": 1716672069, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Afatinib is a targeted cancer therapy that acts as a tyrosine kinase inhibitor (TKI). It is primarily used in the treatment of certain types of non-small cell lung cancer (NSCLC). Here is important information you should know about Afatinib as a physician:\n\n### Mechanism of Action:\n- Afatinib irreversibly inhibits the activity of the ErbB family of receptor tyrosine kinases, including EGFR (epidermal growth factor receptor) and HER2 (human epidermal growth factor receptor 2).\n- By blocking these receptors, Afatinib hinders the signaling pathways that promote cell proliferation and survival in cancer cells.\n\n### Indications:\n- **NSCLC with EGFR Mutations:** Afatinib is approved for first-line treatment of NSCLC with specific types of EGFR mutations (such as exon 19 deletions or exon 21 L858R substitutions).\n- **Squamous Cell Carcinoma:** It is also used for the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_oNiJWlRuu8PoKJxkOKYjVsht", "custom_id": "7_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e84029509ac01f395df79afbf0fdeb10", "body": {"id": "chatcmpl-9St77nF7gQqClr2cFGJ0goKfiltqc", "object": "chat.completion", "created": 1716672069, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aldesleukin, also known as interleukin-2 (IL-2), is an immunotherapy drug used primarily for the treatment of metastatic renal cell carcinoma and metastatic melanoma. Here are several key points that you should know as a physician:\n\n### Mechanism of Action\n- **Immunomodulation**: Aldesleukin stimulates the proliferation of T cells and enhances the activity of natural killer (NK) cells, leading to an enhanced immune response against tumor cells.\n- **Cytokine Release**: It promotes the release of other cytokines, which can help in the immune system's capacity to target and destroy cancer cells.\n\n### Indications\n- **Metastatic Renal Cell Carcinoma**: Aldesleukin has been approved for the treatment of metastatic renal cell carcinoma.\n- **Metastatic Melanoma**: It is also used in cases of metastatic melanoma.\n\n### Administration\n- **Routes**: It is typically administered via intravenous infusion.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_xWsOdgN49mOg6rjNzIqEIizp", "custom_id": "8_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "62bbcc413d6c5a491ee7cab8dc07c68a", "body": {"id": "chatcmpl-9St78W3A8UkH6I8EnGgzoz6pxDSKW", "object": "chat.completion", "created": 1716672070, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alectinib is a medication primarily used in the treatment of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. Here are key points you should know about Alectinib as a physician:\n\n### Usage:\n1. **Indication**: Alectinib is indicated for the treatment of patients with ALK-positive metastatic NSCLC. It is often used when patients have either not responded to or cannot tolerate other ALK inhibitors like crizotinib.\n2. **Mechanism of Action**: Alectinib is a tyrosine kinase inhibitor that targets ALK and RET kinase. It works by blocking the kinase activity of the ALK receptor, thereby inhibiting tumor cell proliferation and inducing cell death.\n\n### Administration:\n1. **Dosage**: The standard recommended dose is 600 mg taken orally twice daily with food. Dosage adjustments may be necessary based on individual patient factors and tolerance.\n2. **Form**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Hq4FJhmxIYP9LM15WNdJaYFW", "custom_id": "9_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5b59bb5fadddbd362d0e6d98154c421d", "body": {"id": "chatcmpl-9St78rrvWCL0JzCqVf3U9hcf19pW3", "object": "chat.completion", "created": 1716672070, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alemtuzumab is a monoclonal antibody used primarily in the treatment of certain types of cancer and autoimmune diseases. Here are several key points you should know about Alemtuzumab:\n\n### Indications\n1. **Chronic Lymphocytic Leukemia (CLL)**: It's approved for patients with CLL who have been treated with other chemotherapy.\n2. **Multiple Sclerosis (MS)**: Particularly for relapsing forms of multiple sclerosis, where it\u2019s used after other therapies have failed.\n\n### Mechanism of Action\nAlemtuzumab targets CD52, a protein present on the surface of mature lymphocytes. By binding to CD52, Alemtuzumab directs the immune system to destroy these cells. This reduces the number of lymphocytes and causes immunosuppression.\n\n### Administration\n- Given by intravenous infusion.\n- For MS, treatment typically involves courses given over several days followed by months or years of no treatment.\n\n### Dosing\n- For CLL:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_eEip8CyNb3lUoJ1KrGYso4mY", "custom_id": "10_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4a77f068e1ab27fe523b30eecd471cf0", "body": {"id": "chatcmpl-9St78dxzzm2nmyKmz6ENVG5jWziDu", "object": "chat.completion", "created": 1716672070, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "All-trans retinoic acid (ATRA) is a derivative of vitamin A (retinoid) that plays a critical role in cellular differentiation and proliferation. Here are key points you should know about it as a physician:\n\n### 1. **Clinical Uses:**\n- **Acute Promyelocytic Leukemia (APL):**\n  - ATRA is primarily used in the treatment of APL, a subtype of acute myeloid leukemia. It induces differentiation of the promyelocytes, leading to clinical remission in most patients.\n  - Often used in combination with arsenic trioxide or chemotherapy for better outcomes.\n\n- **Dermatology:**\n  - Used topically for the treatment of acne, photoaged skin, and other dermatological conditions due to its ability to modulate skin cell growth and differentiation.\n  \n### 2. **Mechanism of Action:**\n- ATRA binds to nuclear receptors (retinoic acid receptors - RARs) that regulate gene expression.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_J1StRr714xHsduyJmxTZxUJP", "custom_id": "11_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ddf68c193609040d97910cead610c21d", "body": {"id": "chatcmpl-9St78zQPVKtoI8rlbck0FxW1VK0l8", "object": "chat.completion", "created": 1716672070, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Altretamine is a medication primarily used in the treatment of ovarian cancer. Here are several key points you should know as a physician:\n\n1. **Mechanism of Action**:\n    - Although the exact mechanism is not fully understood, Altretamine is thought to work by interfering with the growth of cancer cells and their replication.\n\n2. **Indications**:\n    - Altretamine is used mainly for palliative treatment in patients with persistent or recurrent ovarian cancer following treatment with cisplatin and/or alkylating agent-based chemotherapy.\n\n3. **Administration**:\n    - It is an oral chemotherapeutic agent, typically administered in capsule form.\n    - Dosing regimens can vary, but a common approach includes administering the drug in multiple doses throughout the day, such as four times daily for 14 or 21 consecutive days in a 28-day cycle.\n\n4. **Side Effects**:\n    - Common side effects include nausea, vomiting, and peripheral neuropathy.\n    - Hem"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_XbP67Q743dQmcTahtchirLJk", "custom_id": "12_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d6094693eade76354af65efb221c4ccd", "body": {"id": "chatcmpl-9St786pnVsv0kvoK22ya8XbGoEWTm", "object": "chat.completion", "created": 1716672070, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aminoglutethimide is a medication with a primary role in endocrinology and oncology due to its effects on steroid synthesis. Below are some key points a physician should know about this drug:\n\n### Mechanism of Action\n- **Inhibition of Steroidogenesis**: Aminoglutethimide inhibits the enzyme aromatase (CYP19) and the enzyme cholesterol side-chain cleavage enzyme (CYP11A1), which are crucial in the biosynthesis of steroids, including glucocorticoids, mineralocorticoids, estrogens, and androgens.\n\n### Indications\n- **Cushing's Syndrome**: It is used to treat Cushing's syndrome by reducing the synthesis of cortisol.\n- **Breast Cancer**: It is sometimes used as part of the treatment regimen for estrogen receptor-positive breast cancer in postmenopausal women, particularly when other treatments are not suitable or effective.\n- **Prostate Cancer**: It can be used"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_zEJFL2Tu1jDnTDSwBNGXIj2F", "custom_id": "13_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2bcc9734324812b3267ae886f9d89f31", "body": {"id": "chatcmpl-9St78S9bEMhKPz7REZ3TrkHJNa3Gu", "object": "chat.completion", "created": 1716672070, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it\u2019s important to have a comprehensive understanding of Amrubicin, particularly if you are treating patients with certain types of cancer. Here are the key points:\n\n### General Information:\n- **Class:** Amrubicin is an anthracycline derivative and functions as a potent anticancer agent.\n- **Indications:** It is primarily used in the treatment of small cell lung cancer (SCLC), both first-line and recurrent settings. It has also been investigated for efficacy in other types of cancers such as non-small cell lung cancer (NSCLC) and certain forms of leukemia.\n\n### Mechanism of Action:\n- **Topoisomerase II Inhibition:** Amrubicin inhibits topoisomerase II, an enzyme critical for DNA replication and cell division. This leads to DNA strand breaks and subsequent cell death, particularly in rapidly dividing cancer cells.\n- **Activation:** It is administered as a prodrug and converted to its active form, amrubicinol, which has a higher"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_eZZA48c5PdrHLeWykXBxET4g", "custom_id": "14_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5dd2c0fc14799ebb279cd19534edcbd4", "body": {"id": "chatcmpl-9St78ognBecVulsauwtgMMgJ2TtR7", "object": "chat.completion", "created": 1716672070, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amsacrine is an antineoplastic agent used primarily in the treatment of certain types of acute leukemia, particularly acute myeloid leukemia (AML). Here are several key points you should know about Amsacrine:\n\n### Mechanism of Action\n- **Topoisomerase II Inhibitor**: Amsacrine works by inhibiting the enzyme topoisomerase II, which is crucial for DNA replication and repair. This inhibition leads to breaks in the DNA strands, thus interfering with the proliferation of rapidly dividing cancer cells.\n\n### Indications\n- **Acute Myeloid Leukemia (AML)**: It is often used in induction therapy for AML.\n- **Acute Lymphoblastic Leukemia (ALL)**: Occasionally used for relapsed or refractory cases.\n\n### Administration\n- **Intravenous Infusion (IV)**: Amsacrine is typically administered via IV infusion. The dosing schedule and regimen depend on the specific protocol being followed and the patient's overall"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_tvj3xxaTZNXuTEV7szZdd55t", "custom_id": "15_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ca3d5035c13303b6a5343e1709ed0f75", "body": {"id": "chatcmpl-9St78S4TLjbtxpi48HdEaeFRoTnPQ", "object": "chat.completion", "created": 1716672070, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Anastrozole is a medication primarily used in the treatment of breast cancer. As a physician, here are key points you should know about this drug:\n\n### Mechanism of Action\n- **Class**: Anastrozole is a non-steroidal aromatase inhibitor.\n- **Function**: It works by inhibiting the enzyme aromatase, which is involved in the conversion of androgens to estrogens. This reduction in estrogen levels helps to halt the growth of estrogen receptor-positive breast cancer cells.\n\n### Indications\n- **Breast Cancer**: It\u2019s used mainly in postmenopausal women for the treatment of hormone receptor-positive early breast cancer, metastatic breast cancer, or as adjuvant therapy.\n\n### Dosage and Administration\n- **Typical Dosage**: The standard dose is 1 mg once daily, taken orally.\n- **Administration Advice**: It can be taken with or without food.\n\n### Side Effects\n- **Common Side Effects**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_zxRhFbqTDbxCpg3r9wVgId6e", "custom_id": "16_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4345a2db778b6909da38faa10f61d907", "body": {"id": "chatcmpl-9St78LaxF11T8gMbbYth2dmAJ7lrn", "object": "chat.completion", "created": 1716672070, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to have a comprehensive understanding of Apalutamide, a medication used primarily in the treatment of prostate cancer. Here are key points you should be aware of:\n\n### Indications:\n1. **Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)**: Apalutamide is approved for patients whose prostate cancer has not yet spread to other parts of the body and who are no longer responding to hormone therapy.\n2. **Metastatic Castration-Sensitive Prostate Cancer (mCSPC)**: Apalutamide is also indicated for use in patients whose prostate cancer has metastasized but is still sensitive to hormone therapy.\n\n### Mechanism of Action:\n- Apalutamide is an androgen receptor inhibitor. It works by binding directly to the ligand-binding domain of the androgen receptor, preventing androgen receptor nuclear translocation and DNA binding. This inhibits androgen receptor-mediated transcription, leading to decreased prostate cancer cell proliferation.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_HR3OxWdUbIackQ8Fgu8kzD4F", "custom_id": "17_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4ff5e78cb085e79e665fe4f8610fc7dd", "body": {"id": "chatcmpl-9St78r5RfGaH4ad7Ghvf7CQjqeSia", "object": "chat.completion", "created": 1716672070, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Apatinib is a small-molecule tyrosine kinase inhibitor primarily targeting the vascular endothelial growth factor receptor-2 (VEGFR-2), which is a crucial component in the pathway of angiogenesis. Here are key points you should know about Apatinib:\n\n### Indications\n- **Gastric Cancer:** Apatinib is primarily used in the treatment of advanced or metastatic gastric cancer and gastroesophageal junction adenocarcinoma, especially for patients who have failed to respond to two or more lines of prior chemotherapy.\n- **Other Cancers:** Research is ongoing, but there is interest in its potential use for other solid tumors such as liver, colorectal, and lung cancer.\n\n### Mechanism of Action\n- **Anti-Angiogenic:** By inhibiting VEGFR-2, Apatinib effectively reduces tumor blood supply, impeding tumor growth and metastasis.\n  \n### Administration\n- **Oral Intake:** Apatinib is administered orally, usually in tablet form.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_8bu93UEZACcRyWOZuSi6WKFS", "custom_id": "18_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1b591bfc531023416c4a449f5dca9b5b", "body": {"id": "chatcmpl-9St78LloO6ComyfaI2wPEUo3F31kn", "object": "chat.completion", "created": 1716672070, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Arsenic trioxide is a valuable medication with specific clinical uses, but it also carries significant risks due to its toxicity. Here are key points a physician should know:\n\n### Clinical Uses\n1. **Acute Promyelocytic Leukemia (APL)**: Arsenic trioxide is primarily used in the treatment of acute promyelocytic leukemia. It is particularly effective in patients who have relapsed or are refractory to all-trans retinoic acid (ATRA) and chemotherapy.\n\n### Mechanism of Action\n- Arsenic trioxide induces cancer cell apoptosis and promotes differentiation of the leukemic cells. The exact mechanisms are complex and involve multiple pathways, including oxidative stress, inhibition of angiogenesis, and modulation of oncogenic signaling pathways.\n\n### Administration\n- **Dosage**: Typically administered intravenously. The dosing schedule often involves an induction phase followed by a consolidation phase.\n- **Monitoring**: Requires careful monitoring of the patient\u2019s electrolytes and cardiac function due to potential adverse"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_NRoJlAM3gxkYxEXlhn3ApS6y", "custom_id": "19_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5e84825c7ca2d40712d68bf1df794775", "body": {"id": "chatcmpl-9St79pylPXszrupy4U91EGrrmAQKA", "object": "chat.completion", "created": 1716672071, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to have a thorough understanding of Asparaginase, especially if you are involved in the treatment of acute lymphoblastic leukemia (ALL) or other cancers. Here are the key points you should know:\n\n### Mechanism of Action\n- **Asparaginase** is an enzyme that catalyzes the hydrolysis of asparagine into aspartic acid and ammonia.\n- **Cancer Cells**: Some cancer cells, particularly lymphoblasts in ALL, are unable to synthesize asparagine sufficiently. Asparaginase depletes asparagine in the bloodstream, starving the cancer cells and leading to their apoptosis while sparing normal cells that can produce their own asparagine.\n\n### Indications\n- **Primary Use**: Treatment of acute lymphoblastic leukemia (ALL).\n- **Other Uses**: It may be used in some non-Hodgkin lymphomas and other cancers as part of a multi-agent chemotherapy regimen.\n\n### Types"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_eD23V9SQU7sUDr7ExzqgD2Z9", "custom_id": "20_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a85f4e2ed0260b32fcb2dd0f468156f5", "body": {"id": "chatcmpl-9St79n2Mwlazkfu7XTHWo469gS0J4", "object": "chat.completion", "created": 1716672071, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asparaginase Erwinia chrysanthemi (often abbreviated as Erwinia asparaginase) is a medication used primarily in the treatment of acute lymphoblastic leukemia (ALL) as part of multi-agent chemotherapy regimens. It's particularly important when the patient has developed hypersensitivity or allergy to E. coli-derived asparaginase products (such as pegylated asparaginase or native E. coli asparaginase). Below are some key points you should know about Asparaginase Erwinia chrysanthemi:\n\n1. **Mechanism of Action**:\n   - It works by depleting the amino acid asparagine, which is essential for the survival and proliferation of leukemic cells. Normal cells can synthesize asparagine, but leukemic cells cannot, making them more susceptible to this treatment.\n\n2. **Indications**:\n   - Used in pediatric and adult patients with ALL.\n   - Specifically indicated for patients who have developed hypers"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_NMfurIohOJtzZrf9yXa4WS7Y", "custom_id": "21_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a2bec4192354543af68de737f98dadbd", "body": {"id": "chatcmpl-9St79cxDVlFqkQC5xwMYpYy9zf7YC", "object": "chat.completion", "created": 1716672071, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Atezolizumab is an immune checkpoint inhibitor, specifically a monoclonal antibody, used primarily in the treatment of certain types of cancer. Here are key points a physician should know about Atezolizumab:\n\n### Mechanism of Action\n- **Immune Checkpoint Inhibition**: Atezolizumab targets and binds to PD-L1 (Programmed Death-Ligand 1) on tumor cells and immune cells, blocking its interaction with the PD-1 receptor. This action prevents the \"immune evasion\" strategy of the tumor, allowing the immune system to recognize and destroy cancer cells.\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC)**: As a first-line treatment in combination with chemotherapy or as monotherapy in previously treated cases.\n- **Small Cell Lung Cancer (SCLC)**: In combination with chemotherapy for extensive-stage SCLC.\n- **Urothelial Carcinoma**: For patients with advanced or metastatic urothelial"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_TajolfnTFW7nrdVLEy8oIENX", "custom_id": "22_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "711eb07e22bfe2197989f32257cd962d", "body": {"id": "chatcmpl-9St79jh9MenQl08zo9EYqiDaX8nOz", "object": "chat.completion", "created": 1716672071, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Avelumab, marketed under the trade name Bavencio, is a human monoclonal antibody used in oncology, primarily known for its role as an immune checkpoint inhibitor. Here are key points that you, as a physician, should be aware of:\n\n### Mechanism of Action\n- **Checkpoint Inhibition**: Avelumab targets and inhibits PD-L1 (programmed death-ligand 1), a protein that tumors use to evade the immune system by engaging the PD-1 receptor on T-cells. By blocking this interaction, avelumab helps to restore the immune response against cancer cells.\n\n### Indications\n- **Metastatic Merkel Cell Carcinoma (mMCC)**: Approved for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma.\n- **Urothelial Carcinoma**: Indicated for maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ZDSjpoekQtNAsYyqsd4dtQxG", "custom_id": "23_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "74567b011ff35a7f56f03abef3860898", "body": {"id": "chatcmpl-9St79yLYGKNoa347inPwtkaIfQ1e8", "object": "chat.completion", "created": 1716672071, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Axicabtagene ciloleucel (axi-cel) is an important treatment option in the field of hematology and oncology, particularly for certain types of refractory and relapsed lymphomas. It is a type of chimeric antigen receptor (CAR) T-cell therapy, which is an innovative form of immunotherapy. Here are some key points you should know about axi-cel:\n\n1. **Indications**:\n   - Axi-cel is approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This includes diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.\n\n2. **Mechanism of Action**:\n   - CAR T-cell therapy involves modifying a patient's own T-cells to express a chimeric antigen receptor that specifically targets CD19, a protein expressed on"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_qTTeJkC1IQMoGWnww6AbxkAT", "custom_id": "24_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "cb2610e9d11dde271f6123161ac148b0", "body": {"id": "chatcmpl-9St79Cb0bJ7IcP7MCfOHG3K93UgVw", "object": "chat.completion", "created": 1716672071, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Axitinib is a tyrosine kinase inhibitor that is primarily used to treat renal cell carcinoma (RCC), particularly in patients who have been previously treated with other cancer medicines. Here are several key points you should know about Axitinib as a physician:\n\n### Mechanism of Action:\n- **Target:** Axitinib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3. By doing so, it interferes with tumor angiogenesis, which is essential for tumor growth and metastasis.\n  \n### Indications:\n- **Approved Use:** It is primarily indicated for the treatment of advanced renal cell carcinoma after the failure of one prior systemic therapy.\n\n### Dosing:\n- **Standard Dose:** The typical starting dose is 5 mg taken orally twice daily. Doses may be adjusted based on individual tolerance and side effects, with 7 mg and 10 mg also being used in some cases.\n  \n### Pharmacokinetics:\n- **Met"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_LCayPwABFvPQlX8u5EFwh5y8", "custom_id": "25_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "fd5a71f6a6d42c3b32632a5c41ae3c41", "body": {"id": "chatcmpl-9St79i9AoQaiU43WO2mSXtO6vWdG4", "object": "chat.completion", "created": 1716672071, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azacitidine is a chemotherapeutic agent used primarily in the treatment of specific types of myelodysplastic syndromes (MDS) and certain subtypes of acute myeloid leukemia (AML). Here are some important details about Azacitidine that you should be aware of as a physician:\n\n### Mechanism of Action:\n- **Hypomethylating Agent:** Azacitidine inhibits DNA methyltransferase, leading to hypomethylation of DNA and reactivation of genes that control tumor suppression and cell differentiation.\n- **Cytotoxic Effects:** Incorporates into RNA and DNA, disrupting nucleic acid metabolism and exerting direct cytotoxic effects on abnormal hematopoietic cells in the bone marrow.\n\n### Indications:\n- **Myelodysplastic Syndromes (MDS):** For treatment of all International Prognostic Scoring System (IPSS) risk categories.\n- **Acute Myeloid Leukemia (AML):** Particularly in older patients or those who are not candidates for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_xV50dHbQCZ3zEUPpdsll7UNW", "custom_id": "26_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "3622021ea8a12e988113baaa131dd00b", "body": {"id": "chatcmpl-9St79hfPo2I9w8Xr1lrpxvLvdNlas", "object": "chat.completion", "created": 1716672071, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bacillus Calmette-Gu\u00e9rin (BCG) is an attenuated live vaccine derived from Mycobacterium bovis, which is primarily used for tuberculosis (TB) prevention. As a physician, several key points are important to know about BCG:\n\n1. **Indications and Usage**:\n   - **Tuberculosis (TB) Prophylaxis**: BCG is primarily administered to infants and young children in countries with a high prevalence of TB to provide some level of immunity against TB.\n   - **Bladder Cancer Treatment**: BCG is also used as an intravesical therapy for superficial bladder cancer (non-muscle invasive bladder cancer). It helps to stimulate the immune system to attack cancer cells in the bladder.\n\n2. **Administration**:\n   - **For TB Prevention**: Typically given as a single intradermal injection, usually in the upper arm.\n   - **For Bladder Cancer**: Administered directly into the bladder through"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_kbVjNF6khxn3Fdm55AP9TIe8", "custom_id": "27_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "06623cec8c39117017c07b2dfa0241f5", "body": {"id": "chatcmpl-9St79zFKdigaXUOzcLQmCSouQ0Fgo", "object": "chat.completion", "created": 1716672071, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bavituximab is a monoclonal antibody that has been investigated for its potential use in treating various types of cancers and viral infections. Here are some key points you may find relevant as a physician:\n\n1. **Mechanism of Action**:\n   - Bavituximab targets phosphatidylserine, a molecule that is normally found on the inner leaflet of the cell membrane but becomes exposed on the surface of tumor blood vessels in response to oxidative stress.\n   - By binding to phosphatidylserine, bavituximab can disrupt the tumor microenvironment, enhance immune response against the tumor, and inhibit tumor growth.\n\n2. **Clinical Development**:\n   - Bavituximab has been studied in several Phase I, II, and III clinical trials for various malignancies, including non-small cell lung cancer (NSCLC) and hepatocellular carcinoma.\n   - Most notably, it was tested in combination with chemotherapy agents like paclitaxel and carbop"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_8TyYJ4aaw6UCXluTcMN7n0Rd", "custom_id": "28_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "679525a4b846e38fe8ffad6bcb06f27e", "body": {"id": "chatcmpl-9St79TIicyPWxRBMqisXpG47DrtIo", "object": "chat.completion", "created": 1716672071, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belinostat (brand name: Beleodaq) is an anticancer agent specifically classified as a histone deacetylase (HDAC) inhibitor. It is primarily used in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Below are key points you should consider when working with Belinostat:\n\n### Mechanism of Action:\nBelinostat inhibits HDAC enzymes, leading to an accumulation of acetylated histones and proteins. This disruption affects chromatin structure and opens the DNA to transcription factors that can induce apoptosis (programmed cell death) of cancer cells, as well as cell cycle arrest.\n\n### Indications:\n- **Peripheral T-cell lymphoma (PTCL):** FDA-approved for treating relapsed or refractory PTCL.\n\n### Dosage and Administration:\n- The standard dose is typically 1000 mg/m\u00b2 administered as an intravenous (IV) infusion over 30 minutes once daily on days 1\u20135 of a 21-day cycle."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_yCcftTSIsc9hRi50BglyjIfN", "custom_id": "29_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9bc40e2874c01bde703341125bc47f5e", "body": {"id": "chatcmpl-9St7A4Fm2AtasFr9GaKrGReteDvhJ", "object": "chat.completion", "created": 1716672072, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belotecan is an anti-cancer drug that belongs to the class of topoisomerase I inhibitors, which are used in chemotherapy to treat various types of cancer. Here's an overview of what you should know as a physician:\n\n1. **Mechanism of Action**:\n   - Belotecan inhibits topoisomerase I, an enzyme that plays a critical role in DNA replication by alleviating torsional strain on the DNA helix. By inhibiting this enzyme, belotecan induces DNA damage and apoptosis in rapidly dividing cancer cells.\n\n2. **Indications**:\n   - Clinical use of belotecan includes treatment for small cell lung cancer and ovarian cancer. It has been explored in other types of cancers as well in clinical trials, but these are the primary approved indications.\n\n3. **Administration**:\n   - Belotecan is typically administered intravenously. The dosage and treatment regimen may vary depending on the type of cancer, patient\u2019s condition, and concurrent treatments.\n\n4. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_UdZa7Oo9Z0ihD2BiJjjoTNTv", "custom_id": "30_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "dece6a7ddbac3b95bf160c67027e80b9", "body": {"id": "chatcmpl-9St79Rtep762BKLilQarYNvpaHg1Z", "object": "chat.completion", "created": 1716672071, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bendamustine is a chemotherapy medication used primarily in the treatment of certain types of cancers. Here\u2019s an overview of what you should know about it:\n\n### 1. **Mechanism of Action**\n- **Alkylating Agent:** Bendamustine is an alkylating agent that works by causing DNA damage, which disrupts the replication of cancer cells and leads to cell death. Unlike some other alkylating agents, Bendamustine also has properties of a purine analog, making it somewhat unique.\n\n### 2. **Indications**\n- **Chronic Lymphocytic Leukemia (CLL):** Approved for the treatment of CLL.\n- **Non-Hodgkin's Lymphoma (NHL):** Specifically, for indolent B-cell types that have progressed despite treatment with a rituximab regimen.\n- **Multiple Myeloma:** Often used off-label for this condition as well.\n\n### 3. **Administration**\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_01a6eD46PUInRjZBHFZjdxWb", "custom_id": "31_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a68a5c64bd4d7792518d592a7004a5ee", "body": {"id": "chatcmpl-9St7A7vfG4UQRnXlSuEMvbeDnExW1", "object": "chat.completion", "created": 1716672072, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bevacizumab, marketed under the brand name Avastin, is a monoclonal antibody used primarily in the treatment of various cancers. Here are some essential details that physicians should know:\n\n### Mechanism of Action\n- **VEGF Inhibition:** Bevacizumab targets and inhibits vascular endothelial growth factor A (VEGF-A), a protein that promotes angiogenesis (the formation of new blood vessels). By inhibiting VEGF-A, Bevacizumab reduces blood supply to tumors, inhibiting their growth.\n\n### Indications\nBevacizumab is FDA-approved for various cancers, including but not limited to:\n- Metastatic colorectal cancer\n- Non-small cell lung cancer (NSCLC)\n- Glioblastoma\n- Renal cell carcinoma\n- Cervical cancer\n- Ovarian cancer (recurrent, platinum-resistant)\n\n### Administration\n- **Intravenous Infusion:** Bevacizumab is administered via intravenous infusion, often in combination with chemotherapy regimens.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_GymDghMYtp68BxVOqWGXjHaK", "custom_id": "32_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f0bda794d2a25541d73ac7cf99792373", "body": {"id": "chatcmpl-9St7AOsMMARSFUAhYV577YNbUbcau", "object": "chat.completion", "created": 1716672072, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bexarotene is an important drug to be familiar with, especially in the context of oncology and dermatology. Here are some key points that you, as a physician, should know about this medication:\n\n### Indications:\n- **Cutaneous T-cell Lymphoma (CTCL):** Bexarotene is primarily used for the treatment of cutaneous T-cell lymphoma, particularly in patients who have refractory or persistent disease after other treatments.\n\n### Mechanism of Action:\n- **Retinoid X Receptor (RXR) Agonist:** Bexarotene is a synthetic retinoid that selectively activates RXRs. Activation of these receptors influences the expression of genes that regulate cell differentiation and proliferation, which can inhibit the growth of cancer cells.\n\n### Forms and Dosage:\n- **Oral Capsules:** Typically used for systemic treatment of CTCL.\n- **Topical Gel:** Used for localized skin lesions.\n- **Dose Adjustment:** May be necessary based on response and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_oXIpYT8W5lY5TgIkKFseprVx", "custom_id": "33_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "3d790f0b36c87f6df1f810f773907586", "body": {"id": "chatcmpl-9St7A9KLqGITZJ0XN1Ua7gHzGs2n2", "object": "chat.completion", "created": 1716672072, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bicalutamide is a non-steroidal anti-androgen medication primarily used in the treatment of prostate cancer. Here\u2019s a detailed overview of what you should know:\n\n### Indications:\n- **Prostate Cancer:** Bicalutamide is often used in combination with luteinizing hormone-releasing hormone (LHRH) analogs to treat metastatic prostate cancer. It can also be used as monotherapy in some cases.\n\n### Mechanism of Action:\n- **Anti-Androgen:** Bicalutamide works by binding to androgen receptors on prostate cancer cells, inhibiting the action of male hormones (androgens) which can promote tumor growth.\n\n### Pharmacokinetics:\n- **Absorption:** Bicalutamide is well-absorbed orally.\n- **Metabolism:** It is extensively metabolized in the liver.\n- **Elimination:** Primarily eliminated through feces and to a lesser extent through urine.\n\n### Dosage:\n- **Standard Dose:** Typically, 50 mg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_m6mMcDr24RxWQWkwg1CajPio", "custom_id": "34_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "15ac4688ae7b9e8ec079e0993ae15b9a", "body": {"id": "chatcmpl-9St7AN96IYuLC8hlcdf8QeJuWbJp8", "object": "chat.completion", "created": 1716672072, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Certainly! As a physician, it's important to be well-informed about Binimetinib. Here are key points you should know:\n\n### Mechanism of Action\n- **Binimetinib** is a selective inhibitor of MEK1 and MEK2, both of which are part of the MAPK/ERK pathway. This pathway is often activated in various cancers, particularly those involving mutations in the BRAF gene.\n\n### Indications\n- Binimetinib is primarily indicated for the treatment of **unresectable or metastatic melanoma** with BRAF V600E or V600K mutations, in combination with the BRAF inhibitor encorafenib.\n- It's also being investigated in clinical trials for other types of cancers that involve the MAPK/ERK pathway.\n\n### Dosage and Administration\n- The usual recommended dose is **45 mg orally twice daily**.\n- It should be taken at the same time each day, with or without food.\n\n### Side Effects\nCommon side"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_wMOsX5E74WVMDctQuIsJyDr1", "custom_id": "35_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6862f2bebeab6094788f6d54f7362f24", "body": {"id": "chatcmpl-9St7AXo1JcOFwP6GaXivsU92hvP5S", "object": "chat.completion", "created": 1716672072, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bleomycin is an antineoplastic (anticancer) agent commonly used in the treatment of various malignancies, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer, ovarian cancer, and certain types of squamous cell carcinomas. As a physician, it's important to be aware of the following key aspects of Bleomycin:\n\n### Mechanism of Action\n- **DNA Interaction**: Bleomycin works by binding to DNA and causing strand breaks through the generation of free radicals. This results in the inhibition of DNA synthesis and subsequent cell death.\n\n### Indications\n- **Cancers Treated**: Hodgkin's lymphoma, non-Hodgkin's lymphoma, germ cell tumors of the testes and ovaries, and squamous cell carcinomas of the head, neck, and cervix.\n- **ABVD Regimen**: Frequently used as part of the ABVD (doxorubicin, bleomycin, vinblastine, dac"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_8AnFtnsZ7iSHh27YJ1AHZOgK", "custom_id": "36_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "467cf56c65db9a1d5c647317e6344bae", "body": {"id": "chatcmpl-9St7AbZlW84OTX6omxCrmqozFVbKc", "object": "chat.completion", "created": 1716672072, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blinatumomab is a bi-specific T-cell engager (BiTE) antibody construct that has shown significant effectiveness in the treatment of certain types of blood cancers. Here are key things you should know as a physician:\n\n1. **Mechanism of Action**: Blinatumomab is designed to engage T-cells and direct them to attack malignant B-cells. It does this by binding to CD19 on B-cells and CD3 on T-cells, thus forming a link that activates T-cell-mediated cytotoxic activity against the CD19-expressing B-cells.\n\n2. **Indications**: Blinatumomab is primarily used for the treatment of:\n   - Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children.\n   - Minimal residual disease (MRD)-positive B-cell precursor ALL.\n\n3. **Administration**: Blinatumomab is administered as a continuous intravenous infusion. The regimen typically involves a "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Gz2gove4aRRYtph1sTilqzmS", "custom_id": "37_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "060aab22506e19843f693c49a21f00d1", "body": {"id": "chatcmpl-9St7AJlNKTpkl24XpYjZXXKin3VMQ", "object": "chat.completion", "created": 1716672072, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bortezomib is a highly important drug in the treatment of certain hematologic malignancies. Here are some key points you should know as a physician:\n\n### Mechanism of Action:\n- **Proteasome Inhibitor**: Bortezomib inhibits the 26S proteasome, which plays a crucial role in degrading ubiquitinated proteins. This inhibition leads to the accumulation of misfolded and damaged proteins within the cell, ultimately causing cell cycle arrest and apoptosis, particularly in cancer cells.\n\n### Indications:\n- **Multiple Myeloma**: Bortezomib is commonly used to treat multiple myeloma, either alone or in combination with other medications such as lenalidomide, dexamethasone, or melphalan.\n- **Mantle Cell Lymphoma**: Approved for the treatment of mantle cell lymphoma, particularly in patients who have received at least one prior therapy.\n\n### Administration:\n- **Routes**: It can be administered intraven"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_fRjvpfSBjy0qKJxYEtW19OiR", "custom_id": "38_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5ab3a7e1a0cb63ee96ac3daef814f0b5", "body": {"id": "chatcmpl-9St7AfMVNprzNi9SwsoRgeqF6ywvJ", "object": "chat.completion", "created": 1716672072, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bosutinib (brand name Bosulif) is an oral tyrosine kinase inhibitor (TKI) used primarily in the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). As a physician, it's important to be aware of its indications, mechanism of action, administration guidelines, and potential side effects. Here are some key points:\n\n### Indications:\nBosutinib is indicated for the treatment of adult patients with:\n- Newly diagnosed chronic phase Ph+ CML.\n- Chronic, accelerated, or blast phase Ph+ CML who have been previously treated with at least one prior TKI.\n\n### Mechanism of Action:\n- Bosutinib inhibits the BCR-ABL kinase, which is produced by a fusion gene found in most patients with CML. This kinase is a constitutively active tyrosine kinase that promotes the proliferation and survival of leukemic cells.\n- Besides BCR-ABL, bosutinib also inhibits other kinases such as SRC-family kin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_uegaOpf25pRFbKxoSeOSEkwT", "custom_id": "39_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "dde268445c4fa64fc489915d3d2a6b88", "body": {"id": "chatcmpl-9St7AGHg2Jz64Vh8tTw0RptcmxAG3", "object": "chat.completion", "created": 1716672072, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brentuximab vedotin (brand name: Adcetris) is an antibody-drug conjugate (ADC) that combines an anti-CD30 monoclonal antibody with the cytotoxic agent monomethyl auristatin E (MMAE). This targeted therapy is primarily used in the management of certain types of lymphomas. Here are the key points you should be aware of:\n\n### Indications:\n1. **Hodgkin Lymphoma (HL)**:\n   - In patients who have failed autologous stem cell transplantation (ASCT) or at least two prior multi-agent chemotherapy regimens.\n   - In patients with high risk of relapse or progression as post-ASCT consolidation.\n\n2. **Systemic Anaplastic Large Cell Lymphoma (sALCL)**:\n   - In patients who have failed at least one prior multi-agent chemotherapy regimen.\n\n3. **Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL)** and other CD30"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_KlUTSbWMcH3x6geQpZBS4ZsE", "custom_id": "40_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "06141b6a8f2cd2c6168fba0ed6a3dba8", "body": {"id": "chatcmpl-9St7B2GZUmKsiQpWmdjVpNOBIFlDO", "object": "chat.completion", "created": 1716672073, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brigatinib is a targeted cancer medication primarily used for the treatment of non-small cell lung cancer (NSCLC) that is ALK-positive (anaplastic lymphoma kinase-positive). Here's a detailed overview of what you should be aware of as a physician:\n\n### Mechanism of Action\n\nBrigatinib is a tyrosine kinase inhibitor (TKI) that targets ALK, among other kinases. It works by interfering with the growth and proliferation of cancer cells that express the ALK fusion oncogene. Due to its activity against various ALK mutants, it is particularly useful in cases where resistance to other ALK inhibitors, such as crizotinib, has developed.\n\n### Indications\n\n- **Non-Small Cell Lung Cancer (NSCLC):** Brigatinib is approved for the treatment of ALK-positive metastatic NSCLC, especially in patients who have progressed on or are intolerant to crizotinib.\n  \n### Dosage and Administration\n\n- **Initial Dosing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_HDzeTd4snl0wQkZ8jmDwJnNP", "custom_id": "41_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "53989ef2a068ecf120c47acb7167420f", "body": {"id": "chatcmpl-9St7B353HGFk36Tbm81Kjp6VM9Bha", "object": "chat.completion", "created": 1716672073, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Busulfan is a chemotherapy drug that belongs to the class of alkylating agents. It is commonly used in the treatment of chronic myeloid leukemia (CML) and as a preparative regimen for hematopoietic stem cell transplantation (HSCT). Here are some important points you should know about Busulfan as a physician:\n\n### Pharmacology\n- **Mechanism of Action**: Busulfan works by forming cross-links in DNA, which prevents cell replication and leads to cell death. This is particularly effective in rapidly dividing cells, such as cancerous cells.\n- **Formulations**: It is available in both oral and intravenous (IV) formulations. The dosing regimen may vary based on the indication and the formulation used.\n\n### Indications\n- **Chronic Myeloid Leukemia (CML)**: Busulfan is one of the drugs used for the treatment of CML, especially in patients who are not candidates for other treatments like tyrosine kinase inhibitors"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_oiqgXVaf9EHPmeEOVwL36sEz", "custom_id": "42_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "858e6d923dcb4fcc63a14bb2a05855b8", "body": {"id": "chatcmpl-9St7Bznb2DGhEeNMNHYyetWlOz7uK", "object": "chat.completion", "created": 1716672073, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cabazitaxel is a chemotherapy drug, specifically a taxane, that is used primarily in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Here are key points every physician should know about this agent:\n\n1. **Mechanism of Action**: Cabazitaxel works by inhibiting the depolymerization of microtubules, which is crucial for cell division. This disruption leads to the apoptosis (cell death) of rapidly dividing cancer cells.\n\n2. **Indications**: Cabazitaxel is typically indicated for patients with mCRPC who have previously been treated with a docetaxel-containing treatment regimen.\n\n3. **Administration**: \n   - It is administered intravenously.\n   - The standard dose is 25 mg/m\u00b2, given every three weeks in combination with a daily regimen of 10 mg oral prednisone.\n\n4. **Premedication and Prophylaxis**:\n   - Premedication with antihistamines, corticosteroids"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_kyt68RIjFQwWDQvk2EI99GoB", "custom_id": "43_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0bd9ac809814cd6918e23221eb0bc1ce", "body": {"id": "chatcmpl-9St7BE9N1nRDs2IxfR8Q2pMipyzUR", "object": "chat.completion", "created": 1716672073, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cabozantinib is an oral tyrosine kinase inhibitor that is used to treat certain types of cancer. Here are key points that you, as a physician, should know about Cabozantinib:\n\n### Indications\n- **Renal Cell Carcinoma (RCC):** Cabozantinib is indicated for the treatment of advanced RCC.\n- **Hepatocellular Carcinoma (HCC):** Approved for patients who have previously been treated with sorafenib.\n- **Medullary Thyroid Cancer (MTC):** Used in cases of progressive, metastatic MTC.\n\n### Mechanism of Action\nCabozantinib inhibits multiple tyrosine kinases, including MET, VEGFR, and RET. This inhibition interferes with tumor growth, angiogenesis, and metastatic progression.\n\n### Dosage\n- For RCC and HCC, the usual dose is **60 mg** once daily.\n- For MTC, the dose is typically **140 mg** once"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_LgTTEuFAH5iDcdGUqFxJK2n7", "custom_id": "44_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "edf914675c073cf30b6135688a2f4618", "body": {"id": "chatcmpl-9St7BuOBL6yQxc3NmB4uxLrtaSnmH", "object": "chat.completion", "created": 1716672073, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Calaspargase pegol (trade name Asparlas) is a medication used to treat acute lymphoblastic leukemia (ALL). Here are important aspects you should be aware of as a physician:\n\n### Mechanism of Action:\n- **Enzyme Action**: Calaspargase is a PEGylated enzyme that works by breaking down the amino acid asparagine into aspartic acid and ammonia. Leukemic cells are unable to synthesize asparagine and rely on external sources. Depleting asparagine starves the leukemia cells, inhibiting their growth and leading to cell death.\n\n### Indications:\n- **FDA Approval**: It is primarily indicated for the treatment of ALL, typically in combination with other chemotherapeutic agents.\n- **Patient Population**: Approved for both pediatric and young adult patients.\n\n### Administration:\n- **Dosage**: Administered intravenously. Dosage and scheduling are determined based on factors like patient age, overall health, and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_8wTHC649aZLlY55TL8NVRDk1", "custom_id": "45_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4e1fbe9dbb80509a19ec2926f1fefd9c", "body": {"id": "chatcmpl-9St7B3MRY2eFCtKTCMTUwOYqQ1Nlr", "object": "chat.completion", "created": 1716672073, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Capecitabine is an oral chemotherapeutic agent used primarily in the treatment of various cancers, including colorectal cancer, breast cancer, and other types of solid tumors. Below are some key points that you should know as a physician:\n\n### Mechanism of Action\n- **Prodrug:** Capecitabine is a prodrug that is metabolized in the body to fluorouracil (5-FU), a pyrimidine analog that inhibits the enzyme thymidylate synthase, leading to impaired DNA synthesis and cell death.\n\n### Indications\n- **Metastatic Colorectal Cancer:** Used as first-line treatment either alone or in combination with other agents.\n- **Metastatic Breast Cancer:** Often used in patients who have not responded to other chemotherapy regimens.\n- **Other Uses:** Capecitabine is sometimes used off-label for other types of cancer based on clinical judgment.\n\n### Dosage and Administration\n- **Oral Administration:** Typically taken twice daily within "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_lMFBfSn6QDT5Cbsk2E5uhNnk", "custom_id": "46_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "c0624ccfa1836d95ca9504aaf5a41174", "body": {"id": "chatcmpl-9St7BDNen1OFF16IcoINYJ49nLc1w", "object": "chat.completion", "created": 1716672073, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carboplatin is a chemotherapy medication used to treat various types of cancer, and as a physician, here are the key points you should consider about this drug:\n\n### Indications:\n1. **Types of Cancer**: Carboplatin is used in the treatment of ovarian, lung, head and neck, brain, and other types of cancer.\n\n### Pharmacology:\n2. **Mechanism of Action**: Carboplatin is a platinum-based compound that causes DNA cross-linking, leading to apoptosis (cell death) in rapidly dividing cells, including cancer cells.\n3. **Administration**: It is usually administered via intravenous infusion.\n\n### Dosing and Adjustment:\n4. **Dosing**: Dosing is typically based on body surface area (BSA) or the Calvert formula (which considers the patient's glomerular filtration rate (GFR) to individualize the dose).\n5. **Renal Function**: Dose adjustments are necessary in patients with renal impairment since Carboplatin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_gYayvgam9mZLoTUIef9f5SXt", "custom_id": "47_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b2f1ee3912174fa1bac2733c68778b2e", "body": {"id": "chatcmpl-9St7BT8w8OrarC4J3GM8sMQtgyQH6", "object": "chat.completion", "created": 1716672073, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carfilzomib is a proteasome inhibitor primarily used in the treatment of multiple myeloma, a type of blood cancer. Here are important points you, as a physician, should be aware of regarding Carfilzomib:\n\n### Mechanism of Action\n- Carfilzomib selectively inhibits the chymotrypsin-like activity of the 20S proteasome, which is part of the ubiquitin-proteasome pathway. This inhibition leads to an accumulation of polyubiquitinated proteins, inducing apoptosis in cancer cells.\n\n### Indications\n- Carfilzomib is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.\n- It is often used in combination with other therapies, such as dexamethasone, lenalidomide, or daratumumab.\n\n### Administration\n- Carfilzomib is administered intravenously.\n- It is typically given over a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_cRthjETF0PvTeJm3sqOqr5ok", "custom_id": "48_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ffb402f545a0f7c9c7ff4be6efe25b7d", "body": {"id": "chatcmpl-9St7BqlB1cEVq2Mt6XtTPWrrEjre4", "object": "chat.completion", "created": 1716672073, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carmustine, also known by the brand name BiCNU, is a chemotherapeutic agent used primarily for the treatment of several types of cancer. Here are some key points you should know about Carmustine:\n\n### Indications\n- **Primary Brain Tumors:** Including glioblastoma multiforme, brain stem gliomas, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors.\n- **Multiple Myeloma:** Often used in combination with other drugs like prednisone.\n- **Hodgkin\u2019s Lymphoma and Non-Hodgkin\u2019s Lymphoma:** Used in patients whose disease has progressed or relapsed after other treatments.\n- **Other Indications:** Sometimes used off-label for other malignancies.\n\n### Mechanism of Action\n- Carmustine belongs to the class of alkylating agents known as nitrosoureas.\n- It works by cross-linking DNA and RNA, thereby inhibiting the replication of cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Uen0HhQDRn64y4Tw8Ph37SUa", "custom_id": "49_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1daf49af7e6b52232e21836807ea7930", "body": {"id": "chatcmpl-9St7B0ixK8O0KMx42VUDho9uqpkOj", "object": "chat.completion", "created": 1716672073, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carmustine wafer polifeprosan 20 is a specialized formulation used in the treatment of certain types of brain tumors. Here are key points you should know about it as a physician:\n\n### General Information:\n1. **Trade Name**: Gliadel\u00ae Wafer.\n2. **Composition**: Each wafer contains carmustine (a chemotherapeutic agent) embedded in a biodegradable polymer matrix (polifeprosan 20).\n\n### Indications:\n- **Primary malignant glioma**: For patients undergoing primary surgical resection.\n- **Recurrent glioblastoma multiforme**: For patients undergoing surgical resection, particularly when other treatments have failed.\n\n### Mechanism of Action:\n- **Localized Delivery**: The wafer is placed directly in the resection cavity during surgery. This allows high concentrations of carmustine to be delivered directly to the tumor site while minimizing systemic exposure and side effects.\n- **Chemotherapeutic Action**: Carmustine (BCNU) is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_wpzHMxuM5eumVLME0z8eJqM3", "custom_id": "50_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8ea7b6d778345858685fd005618887a5", "body": {"id": "chatcmpl-9St7CLyd0QKtb36ln1x7gcgJeXBwU", "object": "chat.completion", "created": 1716672074, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cediranib is a small molecule tyrosine kinase inhibitor primarily targeting the vascular endothelial growth factor (VEGF) receptors. Here are some key points a physician should know about Cediranib:\n\n### Mechanism of Action:\n- **VEGF Inhibition:** Cediranib inhibits the VEGF receptors (VEGFR-1, VEGFR-2, and VEGFR-3), blocking VEGF-mediated signaling pathways which are crucial for angiogenesis (formation of new blood vessels). This inhibition can reduce tumor blood supply, potentially inhibiting tumor growth.\n- **Multi-targeted:** Besides VEGFR, Cediranib also targets other receptors such as platelet-derived growth factor receptors (PDGFR) and c-Kit, contributing to its anti-angiogenic and anti-tumor effects.\n\n### Indications:\n- **Oncological Use:** Cediranib has been investigated in various types of cancers including ovarian cancer, colorectal cancer, and glioblastoma, often in combination with other therapies such"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_aoQ2ujQlpMhGGqzuU4Q19uYN", "custom_id": "51_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "66a7917dd2d214e23554613acf704a36", "body": {"id": "chatcmpl-9St7Cf6cnO3DREFlGQTVmuI2qtJJN", "object": "chat.completion", "created": 1716672074, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cemiplimab is a human monoclonal antibody that targets the programmed cell death-1 (PD-1) receptor, an immune checkpoint inhibitor commonly used in the treatment of certain cancers. Here are some key points you should know as a physician:\n\n1. **Mechanism of Action:**\n   - Cemiplimab binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1 and PD-L2. This inhibition prevents the \"off\" signal from being sent, thereby enhancing the immune system's ability to attack cancer cells.\n\n2. **Indications:**\n   - Cemiplimab is approved for the treatment of advanced cutaneous squamous cell carcinoma (CSCC) that is metastatic or locally advanced and not curable by surgery or radiation.\n   - It is also approved for patients with non-small cell lung cancer (NSCLC) with high PD-L1 expression (\u226550%) as first-line treatment and for advanced basal cell carcinoma (BCC)"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_fABkgFMK7IuGG7vndzrqsQ9R", "custom_id": "52_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4a3d7962e9a079ed9595c87880ab2939", "body": {"id": "chatcmpl-9St7C27Ls2z8YGVuKMaRk1KFhs9xu", "object": "chat.completion", "created": 1716672074, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ceritinib (marketed under the brand name Zykadia) is a targeted cancer therapy primarily used to treat patients with non-small cell lung cancer (NSCLC) that show specific genetic mutations. Here are some key points you should be aware of as a physician:\n\n### Indications:\n- **NSCLC with ALK Mutation:** Ceritinib is indicated for the treatment of patients with metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK)-positive. ALK mutations are relatively rare and the identification of such a genotype necessitates genomic testing.\n\n### Mechanism of Action:\n- **Kinase Inhibitor:** Ceritinib is an ALK kinase inhibitor, meaning it binds to and inhibits the enzyme tyrosine kinase produced by the ALK-mutated gene, thereby preventing the proliferation of cancer cells.\n\n### Administration:\n- **Dosage:** Ceritinib is typically administered orally, and the initial recommended dose is 450 mg once daily with food. Adjustments may be necessary"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ZXsyuTeQXyKIQ7MDMNXIRzcV", "custom_id": "53_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "40c9f3811a3825987f6e136cb50d4644", "body": {"id": "chatcmpl-9St7CydGHxoqJWAUzD9Wd9z3rHzZH", "object": "chat.completion", "created": 1716672074, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), which is involved in the growth and spread of cancer cells. Here are several important aspects for you to know about Cetuximab:\n\n### Mechanism of Action\n- **Inhibition of EGFR**: Cetuximab binds to the extracellular domain of the EGFR, preventing the receptor's activation by endogenous ligands such as EGF and TGF-\u03b1. This inhibition results in the suppression of downstream signaling pathways, which can lead to decreased cell proliferation and increased apoptosis in certain cancers.\n\n### Indications\n- **Colorectal Cancer**: Cetuximab is commonly used in combination with chemotherapy for the treatment of advanced or metastatic colorectal cancer, particularly for patients with wild-type KRAS and NRAS genes, as mutations in these genes can predict resistance to EGFR inhibitors.\n- **Head and Neck Cancer**: It is also indicated for the treatment of squamous cell"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_7CoEtE6qCvLPKceM8wn2a1G6", "custom_id": "54_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "53911184123778c4703a1562c9b1bf84", "body": {"id": "chatcmpl-9St7CXnhwdJmKrrTy83KIK8nbKfjg", "object": "chat.completion", "created": 1716672074, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Chidamide is an orally bioavailable, benzamide-type histone deacetylase (HDAC) inhibitor primarily used in the treatment of certain types of cancer, particularly T-cell lymphomas. As a physician, it is important to be well-informed about the following aspects of Chidamide:\n\n1. **Mechanism of Action**:\n   - Chidamide works by inhibiting the activity of specific histone deacetylases (mainly Class I HDACs, such as HDAC1, HDAC2, HDAC3, and HDAC10, and Class IIb HDACs).\n   - By inhibiting HDACs, Chidamide induces hyperacetylation of histone proteins, leading to the reactivation of tumor suppressor genes and apoptosis of cancer cells.\n\n2. **Indications**:\n   - It is primarily indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) in certain countries.\n   - It might be"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_3wZnmLRpjLwpIqqENH5tPymX", "custom_id": "55_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9adc338ee8048df18e24e82829f9836d", "body": {"id": "chatcmpl-9St7CHbMgP30TfpPcxjd1gJQuvI0L", "object": "chat.completion", "created": 1716672074, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Chlorambucil is an alkylating agent used mainly in the treatment of certain cancers, particularly hematologic malignancies. Here are key points a physician should know about Chlorambucil:\n\n### Mechanism of Action\n- **Alkylating Agent**: Chlorambucil works by cross-linking DNA strands, which inhibits DNA replication and RNA transcription, ultimately leading to cell death.\n- **Cell Cycle Phase**: It is cell cycle-nonspecific but most effective in the late G1 and S phases.\n\n### Indications\n- **Chronic Lymphocytic Leukemia (CLL)**: Often used as first-line therapy or in combination regimens.\n- **Non-Hodgkin\u2019s Lymphoma**: Used in certain types, including low-grade lymphomas.\n- **Waldenstr\u00f6m's Macroglobulinemia**: Sometimes included in treatment regimens.\n- **Hodgkin's Disease**: Occasionally used as part of combination chemotherapy protocols"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_IPbySxdPqxWLJWLvbiAW77rb", "custom_id": "56_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "35f2f5d4279ff1c1607084fd9611711d", "body": {"id": "chatcmpl-9St7CbLeRtbgbwDe5S8zvRLrNuEVC", "object": "chat.completion", "created": 1716672074, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cisplatin is a chemotherapy drug that is widely used to treat a variety of cancers, including testicular, ovarian, bladder, lung, and head and neck cancers. Here are some key points about Cisplatin that you should be aware of as a physician:\n\n### Mechanism of Action:\n- **Cisplatin** interferes with DNA replication by forming cross-links between and within DNA strands, leading to apoptosis (programmed cell death).\n\n### Administration and Dosage:\n- **Route of Administration:** Intravenous (IV).\n- **Dosage:** Varies depending on the type of cancer, stage, and patient\u2019s overall condition. Usually given in combination with other chemotherapy agents and with hydration protocols to reduce nephrotoxicity.\n\n### Side Effects:\n1. **Nephrotoxicity:** Kidney damage is a major concern. Adequate hydration and diuretics like mannitol may be used to minimize risk.\n2. **Ototoxicity:** Hearing loss,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_MTj3uJdnx8vVGkGPkOPe6vz0", "custom_id": "57_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f39aff394eafec752bd8c05d0c73a734", "body": {"id": "chatcmpl-9St7CLkuM5xix15IL8wuSjU9AihSf", "object": "chat.completion", "created": 1716672074, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cladribine, also known by the brand name Mavenclad, is a medication used primarily in the treatment of certain types of hematologic malignancies and more recently in relapsing forms of multiple sclerosis (MS). Here are some key points you should know about Cladribine:\n\n### Mechanism of Action:\n- Cladribine is a purine nucleoside analog that interferes with DNA synthesis and repair, leading to cell death. It is selectively toxic to lymphocytes, which makes it useful in conditions where these cells proliferate abnormally.\n\n### Indications:\n1. **Hematologic Malignancies**: \n   - Hairy cell leukemia\n   - Chronic lymphocytic leukemia (CLL)\n   - Other lymphoproliferative disorders on a case-by-case basis\n\n2. **Multiple Sclerosis (MS)**:\n   - Specifically approved for adults with highly active relapsing forms of MS.\n\n### Administration:\n- For hematologic malignancies:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_FYhtxJ6mNtssyEVLJcbgiPGU", "custom_id": "58_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "15241e390ed7d46c27f1bcac9ab0fabd", "body": {"id": "chatcmpl-9St7C18aeJIDwoFR1oME9hlazH35G", "object": "chat.completion", "created": 1716672074, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Clarithromycin is a macrolide antibiotic that is commonly used to treat various bacterial infections. As a physician, there are several key points you should be aware of when prescribing and managing treatment with clarithromycin:\n\n1. **Spectrum of Activity:**\n   - Clarithromycin is effective against a variety of gram-positive bacteria, some gram-negative bacteria, and atypical pathogens. It is particularly useful for respiratory infections, skin infections, and Helicobacter pylori eradication in combination with other medications.\n\n2. **Pharmacokinetics:**\n   - It is well-absorbed orally and can be taken with or without food. Clarithromycin undergoes hepatic metabolism and has an active metabolite, 14-hydroxyclarithromycin, which also has antimicrobial activity.\n   - Its half-life is approximately 3 to 4 hours for immediate-release formulations and extended for sustained-release formulations.\n\n3. **Dosing:**\n   - The usual adult dose for most infections is 250"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Q6oPpmMcYgN0mmRmAGEODoUF", "custom_id": "59_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0843c3a11857dfdb4ca1d14e7497979d", "body": {"id": "chatcmpl-9St7CIvyM0AZl7bdqwPxNn7Cv8WiL", "object": "chat.completion", "created": 1716672074, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Clofarabine is a chemotherapeutic agent primarily used in the treatment of certain types of pediatric acute lymphoblastic leukemia (ALL). Here are important aspects a physician should know about Clofarabine:\n\n### Mechanism of Action\n- **Antimetabolite Activity**: Clofarabine is a purine nucleoside analog that inhibits DNA synthesis. It gets incorporated into DNA and RNA, disrupting the function and leading to cell death.\n- **Inhibition of Enzymes**: It inhibits ribonucleotide reductase and DNA polymerase, which are essential for DNA replication and repair.\n\n### Indications\n- Clofarabine is mainly indicated for pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL).\n- It is occasionally used off-label for other hematologic malignancies, such as acute myeloid leukemia (AML), especially in clinical trials or experimental settings.\n\n### Administration\n- **Route**: Administered intravenously.\n- **Dos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_GPjK8ehDB3DYCe0sStHwgGeA", "custom_id": "60_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9479a1aaa3f461180002d2165a324375", "body": {"id": "chatcmpl-9St7CKmqfEyUtU4ZZCMNZAKzL98s7", "object": "chat.completion", "created": 1716672074, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cobimetinib is a medication that falls under the category of targeted cancer therapies. It is a selective inhibitor of the MEK1 and MEK2 proteins, which are part of the MAPK/ERK signaling pathway\u2014 a pathway often implicated in cancer cell proliferation and survival. Cobimetinib is commonly used in combination with vemurafenib, another targeted therapy, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.\n\nHere are key points you should be aware of as a physician:\n\n1. **Indications**: Cobimetinib is approved for use in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma. Testing for the BRAF mutation is required before initiating therapy.\n\n2. **Mechanism of Action**: Cobimetinib inhibits the MEK1 and MEK2 enzymes, which decreases the phosphorylation"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_KuxyHmJAiQdip0vlspXC3rKK", "custom_id": "61_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "32ac5aa76e9c0b7dcbfc5e32d37976c5", "body": {"id": "chatcmpl-9St7CTTrdYOxGhvnxhEIBDPVWP6f4", "object": "chat.completion", "created": 1716672074, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Copanlisib (brand name Aliqopa) is a medication used primarily to treat certain types of non-Hodgkin lymphoma, particularly follicular lymphoma in adults who have relapsed after at least two prior treatments. It is a selective inhibitor of phosphatidylinositol-3-kinase (PI3K), a class of enzymes involved in cell growth, proliferation, and survival.\n\nHere are some key points you should know about Copanlisib:\n\n### Mechanism of Action:\n- **PI3K Inhibition:** Copanlisib selectively inhibits the PI3K-alpha and PI3K-delta isoforms. This inhibition blocks signaling pathways that promote cell division and survival, which are often dysregulated in cancer cells.\n\n### Indications:\n- **Relapsed Follicular Lymphoma:** It is indicated for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies.\n\n### Administration:\n- **Intravenous Infusion:**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_9sP6RMCDoUOkZOo7AptIbXUT", "custom_id": "62_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7b5053256faded17e6cae35965a8fda9", "body": {"id": "chatcmpl-9St7DgPonM6S6hNQOt36fxJvSPcMw", "object": "chat.completion", "created": 1716672075, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Crizotinib, sold under the brand name Xalkori among others, is an oral medication primarily used for the treatment of certain types of cancer. Here are key points you should know about Crizotinib as a physician:\n\n1. **Indications**: Crizotinib is mainly indicated for the treatment of non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK) or ROS1 mutations. It may also be used for the treatment of ALK-positive anaplastic large cell lymphoma (ALCL).\n\n2. **Mechanism of Action**: Crizotinib is a tyrosine kinase inhibitor that specifically targets ALK, ROS1, and MET receptor tyrosine kinases. By inhibiting these kinases, Crizotinib disrupts tumor growth and proliferation.\n\n3. **Administration**: Crizotinib is taken orally in capsule form. The recommended dosage is determined based on the specific patient and condition, but"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_mlV6ueStlfLPooYvDjTL5deH", "custom_id": "63_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "fe8324f477c6b0b3c5eeb8980e8cc314", "body": {"id": "chatcmpl-9St7D35Hhex7RDgvzFSrN89Nh5OJD", "object": "chat.completion", "created": 1716672075, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyclophosphamide is a widely used chemotherapeutic and immunosuppressive agent. Here are key points you should be aware of as a physician:\n\n### Pharmacology\n- **Classification**: Alkylating agent\n- **Mechanism of Action**: It cross-links DNA, leading to cell death. It\u2019s particularly effective against rapidly dividing cells.\n- **Administration**: Oral and intravenous forms are available.\n\n### Indications\n- **Cancer**: Frequently used in the treatment of various cancers, including lymphomas, leukemias, breast cancer, and ovarian cancer.\n- **Autoimmune Diseases**: Effective in managing diseases like systemic lupus erythematosus (SLE), rheumatoid arthritis, and vasculitis.\n\n### Dosing\n- **Cancer Treatment**: Typically dosed based on body surface area (BSA). Regimens vary significantly depending on the specific cancer and treatment protocol.\n- **Autoimmune Diseases**: Lower doses compared to cancer treatment, often tailored to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_hrJvhZQhKWwQAphN9ThtM4UO", "custom_id": "64_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "213ec377014962b10a8e7219a6a74766", "body": {"id": "chatcmpl-9St7DnK8APv1gTiMwLF07J6QvSC41", "object": "chat.completion", "created": 1716672075, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyproterone acetate (CPA) is an anti-androgen and progestogen medication that is used for a variety of clinical indications due to its ability to block the effects of androgens (male sex hormones) and exert a progestogenic effect. Here are some important aspects that you, as a physician, should be aware of:\n\n### Indications\n1. **Prostatic Cancer**: CPA is used in the palliative treatment of advanced prostate cancer.\n2. **Hypersexuality in Men**: It can be used to manage severe hypersexuality and sexual deviations in men.\n3. **Androgenic Disorders in Women**: It is used in combination with estrogen in the treatment of hirsutism, severe acne, and other androgen-related disorders in women.\n4. **Endometriosis**: CPA can be used off-label in the management of endometriosis due to its progestogenic effects.\n\n### Mechanism of Action\n- **Anti-androgenic Effects"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_9CErPuGSdqXJoet8r8lsmdRY", "custom_id": "65_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "810bd20c3cd14edc948750984f38cfb0", "body": {"id": "chatcmpl-9St7DLeJdHG0aJtFqK89nBnmYxwAL", "object": "chat.completion", "created": 1716672075, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cytarabine, also known as Ara-C, is a chemotherapy agent used primarily in the treatment of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and certain types of non-Hodgkin lymphoma. Here are some key points that a physician should know about Cytarabine:\n\n### Mechanism of Action\n- **Nucleoside Analog**: Cytarabine is a pyrimidine nucleoside analog that inhibits DNA synthesis. It gets incorporated into DNA during the S-phase of the cell cycle, leading to chain termination.\n- **Cell Cycle Specificity**: It is most effective during the S-phase (DNA synthesis phase) of the cell cycle.\n\n### Indications\n- **Acute Myeloid Leukemia (AML)**: Frequently used in induction and consolidation therapy.\n- **Acute Lymphoblastic Leukemia (ALL)**: Often part of combination chemotherapy regimens.\n- **Non-Hodgkin Lymphoma**: Used"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_D58PjbprevUSmwyB8qdOfGlZ", "custom_id": "66_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a25b7ae58e5cbae076e27dd2c13f0661", "body": {"id": "chatcmpl-9St7DzKmSLca9YQrLH0NiHBCUfJRp", "object": "chat.completion", "created": 1716672075, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cytarabine and daunorubicin liposomal, often known by the brand name Vyxeos, is a liposomal formulation that combines the two chemotherapeutic agents cytarabine and daunorubicin. Here are key points you should know as a physician:\n\n### Indications:\n1. **Acute Myeloid Leukemia (AML)**: This combination is particularly used for the treatment of newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).\n\n### Mechanism of Action:\n1. **Cytarabine**: It's a nucleoside analog that interrupts DNA synthesis, primarily affecting rapidly dividing cells.\n2. **Daunorubicin**: An anthracycline antibiotic that intercalates into DNA, disrupting DNA and RNA synthesis, and inhibits topoisomerase II.\n\n### Liposomal Formulation:\n1. **Enhanced Delivery**: Liposomes help deliver the drugs more directly"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_XJwKgZxK8o8krTIXL9u8VBNp", "custom_id": "67_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "690d6540bbf8ba04b3eed50a06d936ec", "body": {"id": "chatcmpl-9St7DztY4OCFxD29Sag6VWcIXxIy3", "object": "chat.completion", "created": 1716672075, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dabrafenib is a medication that you, as a physician, should be familiar with, especially if you treat patients with melanoma or certain other cancers. Here's an overview of critical points:\n\n### Indications\n- **Melanoma:** Dabrafenib is primarily indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.\n- **Non-Small Cell Lung Cancer (NSCLC):** It's also indicated for patients with metastatic NSCLC with BRAF V600E mutation.\n- **Thyroid Cancer:** Used for certain patients with anaplastic thyroid cancer with BRAF V600E mutation.\n- **Adjuvant Treatment:** In combination with trametinib, dabrafenib is approved for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, and involvement of lymph nodes, following complete resection.\n\n### Mechanism"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_wNqmto3P6ugNWXwbTQYMwMRv", "custom_id": "68_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1aeaaeebb46564687242a115282c21c3", "body": {"id": "chatcmpl-9St7Dz3OKzDL7STNBzTwAXMAzUKUN", "object": "chat.completion", "created": 1716672075, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dacarbazine, also known by its trade name DTIC, is an antineoplastic agent used primarily in the treatment of certain cancers, including malignant melanoma and Hodgkin's lymphoma. Here are key points you should know about this drug:\n\n### Mechanism of Action\n- **Alkylating Agent:** Dacarbazine functions as an alkylating agent. It undergoes metabolic activation in the liver, forming active metabolites that alkylate and crosslink DNA, leading to the disruption of DNA synthesis and function, ultimately causing cell death.\n\n### Indications\n- **Malignant Melanoma:** Often used in metastatic malignant melanoma where it has shown effectiveness.\n- **Hodgkin\u2019s Lymphoma:** Part of the ABVD regimen (Adriamycin, Bleomycin, Vinblastine, Dacarbazine), it is used in the treatment of Hodgkin\u2019s lymphoma.\n- **Other Cancers:** Occasionally, it may be used off-label for other soft"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_BNDC9gx4sqRdT4ptgeTN2470", "custom_id": "69_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4e0d95a3f247d3577b33b842daacedbf", "body": {"id": "chatcmpl-9St7DGbRl8zCRE5pG2a4dhBdWNW28", "object": "chat.completion", "created": 1716672075, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dacomitinib is a targeted cancer therapy, specifically a tyrosine kinase inhibitor (TKI), used in the treatment of certain forms of non-small cell lung cancer (NSCLC). Here are some key points you should know:\n\n### Mechanism of Action\n- **Dacomitinib** inhibits the activity of the epidermal growth factor receptor (EGFR) by binding to its tyrosine kinase domain. It targets both wild-type and certain mutant forms of EGFR, which are often involved in the proliferation and survival of cancer cells.\n\n### Indications\n- It is primarily indicated for the first-line treatment of patients with metastatic NSCLC that has EGFR-activating mutations, which are detected through appropriate diagnostic tests.\n\n### Administration\n- **Route**: Oral.\n- **Dosage**: Commonly, the recommended dose is 45 mg once daily, taken with or without food. However, dosage adjustments may be necessary based on individual patient tolerability and specific side effects.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_6tZZbffy5QFoZuviecdf5CzJ", "custom_id": "70_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4fcc5b311c562ef9b13d68359c92d747", "body": {"id": "chatcmpl-9St7DdQ8tMUshOUieF36ZGSYnK8LK", "object": "chat.completion", "created": 1716672075, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dactinomycin, also known as actinomycin D, is a chemotherapy medication used primarily in the treatment of various types of cancer. Below are key points you should consider as a physician regarding Dactinomycin:\n\n### Mechanism of Action:\n- **Mode of Action**: Dactinomycin is an antineoplastic antibiotic that binds to DNA and inhibits RNA synthesis. It intercalates between guanine-cytosine base pairs, preventing the elongation of RNA chains by RNA polymerase. This leads to a suppression of protein synthesis\u2014an essential process for tumor cell proliferation.\n\n### Indications:\n- **Cancer Types**: It is commonly used for treating certain cancers, including:\n  - Wilms' tumor\n  - Rhabdomyosarcoma\n  - Ewing's sarcoma\n  - Gestational trophoblastic neoplasia (choriocarcinoma)\n  - Certain adult malignancies like testicular cancer and melanoma (less commonly"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_PZdPl4pyjf0n3rcNGyR3eECL", "custom_id": "71_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0ab924abd437b84e59e0712cff704ab2", "body": {"id": "chatcmpl-9St7ECFMhfPwheHqHd2MIcoa2oB9y", "object": "chat.completion", "created": 1716672076, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Danazol is a synthetic steroid that has a variety of clinical uses, primarily due to its ability to suppress the pituitary-ovarian axis. Here are some key aspects a physician should know about Danazol:\n\n### Indications:\n1. **Endometriosis:** Danazol is commonly used to treat endometriosis by inducing a hypoestrogenic state, which helps in alleviating the symptoms.\n2. **Fibrocystic Breast Disease:** It can also be prescribed for benign fibrocystic breast disease to reduce breast pain and nodularity.\n3. **Hereditary Angioedema:** Danazol helps in preventing episodes of hereditary angioedema by increasing the synthesis of C1 inhibitor protein.\n\n### Mechanism of Action:\nDanazol works by inhibiting the release of gonadotropins from the pituitary gland, leading to a decrease in estrogen and progesterone production in women. It also has weak androgenic and anabolic properties.\n\n### Dosage and Administration:\n- Dos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Fobp3cWrEiBMurfiMC1sfsNB", "custom_id": "72_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7766ec8b73e4bc7d500cc3af1297da47", "body": {"id": "chatcmpl-9St7Ea8CvUvBPuarFykk2WcuIBMG8", "object": "chat.completion", "created": 1716672076, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is crucial to have a thorough understanding of daratumumab, a monoclonal antibody used in the treatment of multiple myeloma. Here are the key points you should know:\n\n### Mechanism of Action\n- **Target:** Daratumumab targets CD38, a cell surface glycoprotein highly expressed on myeloma cells.\n- **Action:** It kills myeloma cells through multiple mechanisms:\n  - Complement-dependent cytotoxicity (CDC)\n  - Antibody-dependent cell-mediated cytotoxicity (ADCC)\n  - Antibody-dependent cellular phagocytosis (ADCP)\n  - Direct apoptosis induction\n\n### Indications\n- **Monotherapy and Combination Use:** Daratumumab is indicated for use in patients with multiple myeloma, both as a monotherapy and in combination with other therapies, typically after one or more lines of prior therapy.\n- **Front-line Treatment:** It is also approved for newly diagnosed patients, especially in combination with standard"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_IZx1Ak1xStRVeSmEvb5iCGm8", "custom_id": "73_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "cd0555e1e797300a5a6ed713ce5c4149", "body": {"id": "chatcmpl-9St7Ef5Jj86AWjtsGXY54VsjRsxet", "object": "chat.completion", "created": 1716672076, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Darolutamide is a medication used in the management of prostate cancer, particularly non-metastatic castration-resistant prostate cancer (nmCRPC). Here are some key points you should know:\n\n1. **Mechanism of Action**: Darolutamide is an androgen receptor inhibitor that works by binding to androgen receptors and inhibiting the androgen receptor signaling pathway, which is crucial in the growth of prostate cancer cells.\n\n2. **Indications**: It's primarily indicated for the treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC). \n\n3. **Dosage and Administration**: The recommended dose is generally 600 mg (two 300 mg tablets) taken orally twice daily, with food. Patients should be on concurrent GnRH analogue therapy or have had bilateral orchiectomy.\n\n4. **Pharmacokinetics**:\n   - **Absorption**: Darolutamide is rapidly absorbed, with peak plasma concentrations reached about 1-4"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_P9UWUkVjWSjngOYzUxDy7VAP", "custom_id": "74_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "89477aadf0413f0f2675e59fcdcb59b4", "body": {"id": "chatcmpl-9St7E6Rp6KnwoeAN7PZx8G4aW91fX", "object": "chat.completion", "created": 1716672076, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's essential to have a thorough understanding of Dasatinib, including its uses, pharmacology, administration, side effects, and monitoring requirements. Here are the key points:\n\n1. **Indications:**\n   - Dasatinib is primarily used for the treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with Philadelphia chromosome-positive (Ph+).\n\n2. **Mechanism of Action:**\n   - Dasatinib is a tyrosine kinase inhibitor. It works by blocking BCR-ABL, a fusion protein with increased tyrosine kinase activity responsible for CML and Ph+ ALL proliferation. Dasatinib inhibits multiple tyrosine kinases, including BCR-ABL, SRC family kinases, c-Kit, and PDGFR.\n\n3. **Pharmacokinetics:**\n   - It is usually administered orally.\n   - Absorption: Dasatinib is rapidly absorbed, with peak plasma concentrations occurring"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_EH7HGr1XBtty9QrEoRZhj0hM", "custom_id": "75_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "70644fd3509c71437e2857622987b441", "body": {"id": "chatcmpl-9St7EVQzRlCUK0csizWM97XDpXaK5", "object": "chat.completion", "created": 1716672076, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daunorubicin is an anthracycline antibiotic commonly used as a chemotherapeutic agent. It is primarily utilized in the treatment of certain types of leukemia, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Here are several key points you should be aware of regarding Daunorubicin:\n\n### Mechanism of Action:\n1. **Intercalation into DNA**: Daunorubicin intercalates between base pairs in the DNA helix, inhibiting the replication and transcription processes.\n2. **Topoisomerase II Inhibition**: It inhibits the enzyme topoisomerase II, which is vital for DNA unwinding and replication, leading to DNA strand breaks.\n3. **Generation of Free Radicals**: It generates free radicals, causing oxidative damage to cellular components, including membranes, proteins, and DNA.\n\n### Indications:\n- **Acute Myeloid Leukemia (AML)**\n- **Acute L"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_OSYN9alPOex7OB8f2YEl7ivF", "custom_id": "76_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e4894475c09c62f89aeff3ad2b4cfc4e", "body": {"id": "chatcmpl-9St7EmSGIwK8TRuCtZRC8QRpvN3Xk", "object": "chat.completion", "created": 1716672076, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daunorubicin liposomal is a form of chemotherapy used to treat certain types of cancer, particularly acute myeloid leukemia (AML). It is daunorubicin encased in liposomes, which are tiny spherical vesicles composed of a lipid bilayer. This encapsulation is designed to improve the drug\u2019s delivery to cancer cells while reducing the impact on normal, healthy tissues. Here are several key points to keep in mind:\n\n### Indications\n- Primarily used for the treatment of acute myeloid leukemia (AML) and sometimes other hematologic malignancies.\n- May be utilized in specific cases or as part of combination therapy, depending on individual patient factors and disease characteristics.\n\n### Pharmacokinetics and Dynamics\n- The liposomal formulation alters the distribution, metabolism, and clearance of daunorubicin.\n- Allows for prolonged circulation time in the bloodstream.\n- Enhances drug accumulation in tumor tissues due to the enhanced permeability and retention (EPR) effect.\n\n### Administration\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_nOCleZh7hSCmX27Y5x0VTODd", "custom_id": "77_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d36790d30cf1cda97c221e902fd2ffae", "body": {"id": "chatcmpl-9St7EJagY6bYH7uWNRDtYscJACJhC", "object": "chat.completion", "created": 1716672076, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Decitabine is a nucleoside metabolic inhibitor used primarily in the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Here are essential key points to consider about Decitabine:\n\n1. **Mechanism of Action:**\n   - Decitabine is a cytosine analog that incorporates into DNA during replication. It inhibits DNA methyltransferase, leading to hypomethylation of DNA, which can reactivate suppressed genes that regulate cell differentiation and proliferation.\n\n2. **Indications:**\n   - It is primarily indicated for the treatment of patients with myelodysplastic syndromes (MDS), which are a group of bone marrow disorders, and for certain cases of acute myeloid leukemia (AML), particularly in older adults who are not candidates for standard induction chemotherapy.\n\n3. **Administration:**\n   - Decitabine is administered intravenously. The specific dosage and schedule can vary, but a common regimen for MDS involves administering"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_s0Et7MBofwf7t01Yun7kqBeK", "custom_id": "78_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "064846d82eec4cd320268b973780bff6", "body": {"id": "chatcmpl-9St7EU671TCQmESPaGFob21lBsnMG", "object": "chat.completion", "created": 1716672076, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Degarelix is a GnRH (gonadotropin-releasing hormone) antagonist used primarily in the management of advanced prostate cancer. Unlike GnRH agonists, which initially cause a surge in testosterone release before eventually leading to lower levels, GnRH antagonists like Degarelix immediately reduce testosterone levels without the initial surge. Here are some essential points you should know about Degarelix:\n\n### Mechanism of Action:\n- **GnRH Antagonist**: Degarelix competitively binds to GnRH receptors in the pituitary gland, effectively inhibiting the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).\n- **Reduction of Testosterone**: This inhibition leads to a rapid decline in testosterone production by the testes, reducing testosterone levels to castrate levels within a few days.\n\n### Indications:\n- Primarily used in the treatment of advanced or metastatic hormone-sensitive prostate cancer.\n\n### Administration:\n- **Loading Dose**: The initial dose is usually"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_XKvfnzCTwcGRfOA5ut4tZeEc", "custom_id": "79_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f53d63d64950ddb84ee737c621346184", "body": {"id": "chatcmpl-9St7FGDK4vc2iE6VwYka3va5IDHSf", "object": "chat.completion", "created": 1716672077, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to have a comprehensive understanding of Denileukin diftitox, which is a type of targeted therapy used in the treatment of certain cancers. Here are some key points:\n\n### Mechanism of Action\n- **Denileukin diftitox (Ontak)** is a recombinant fusion protein that combines interleukin-2 (IL-2) with diphtheria toxin.\n- The IL-2 component targets the drug to cells that express the high-affinity IL-2 receptor, which is commonly found on the surface of malignant cells in certain types of T-cell lymphomas.\n- Once bound, the diphtheria toxin component inhibits protein synthesis, leading to cell death.\n\n### Indications\n- Primarily used for the treatment of **cutaneous T-cell lymphoma (CTCL)** and must be used in patients whose neoplastic cells express the CD25 component of the IL-2 receptor.\n\n### Administration \n- Typically administered via **intravenous infusion**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_63KXacnRMlguixDHlLJQF8GZ", "custom_id": "80_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "cc0730ad2281b90e02080f3a7dc78d11", "body": {"id": "chatcmpl-9St7FtaZix1R1TTjLMSrbd3qUkzvN", "object": "chat.completion", "created": 1716672077, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Denosumab is a human monoclonal antibody used primarily to treat osteoporosis, bone loss, and certain cancers that spread to the bones. It works by inhibiting a protein called RANKL, which is involved in the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. Here are some key points to consider as a physician:\n\n1. **Indications**:\n   - **Osteoporosis**: For postmenopausal women and men at high risk of fracture.\n   - **Bone Loss**: Associated with hormone ablation therapy in prostate and breast cancer patients.\n   - **Bone Metastases**: Helps to reduce skeletal-related events in patients with bone metastases from solid tumors.\n   - **Giant Cell Tumor of Bone (GCTB)**: In adults and skeletally mature adolescents.\n\n2. **Administration**:\n   - **Dosage**: Typically administered subcutaneously.\n   - **Frequency**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_izbJkryAFOFlTB8ksjyHume8", "custom_id": "81_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9a721723b9c486c2ffc1836b1315adcc", "body": {"id": "chatcmpl-9St7Fyev8TtqyL9kHNxPVf45jniWZ", "object": "chat.completion", "created": 1716672077, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dexamethasone is a corticosteroid used to reduce inflammation and suppress the immune system in various conditions. As a physician, you should be aware of several key aspects about this medication:\n\n### Indications\n1. **Inflammatory Conditions:** Commonly used to treat conditions like allergies, asthma, rheumatoid arthritis, and inflammatory bowel disease.\n2. **Autoimmune Disorders:** Used in diseases such as lupus and multiple sclerosis.\n3. **Cancer:** Helps reduce inflammation and manage symptoms in certain types of cancer, often used in combination with other medications.\n4. **Cerebral Edema:** Used to reduce swelling in the brain, either due to tumors, brain surgery, or head injury.\n5. **COVID-19:** Found to reduce mortality in severe cases requiring respiratory support.\n6. **Adrenal Insufficiency:** Utilized in managing conditions like Addison\u2019s disease.\n7. **Other Uses:** Can be used in the management of acute mountain sickness, and in certain diagnostic procedures.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_G8w7R3TcgD09zPy3zphwX2mI", "custom_id": "82_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6a311745e7794d24969a588892866dfd", "body": {"id": "chatcmpl-9St7FNMTTGy8LsPNqUsVas9sWIVh6", "object": "chat.completion", "created": 1716672077, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dexrazoxane is a pharmaceutical agent with multiple clinical applications, primarily used to mitigate the cardiotoxic effects of certain chemotherapy drugs, such as anthracyclines, and to treat extravasation injuries caused by anthracycline leakage into surrounding tissues. Here are some key points you should know about Dexrazoxane:\n\n### Mechanism of Action\n1. **Cardioprotection:** Dexrazoxane functions as a cardioprotective agent by chelating iron and consequently reducing the formation of anthracycline-iron complexes that generate free radicals, which can lead to cardiac muscle damage.\n2. **Extravasation Management:** It helps neutralize the effects of anthracyclines that have leaked out of blood vessels, thereby minimizing tissue damage.\n\n### Indications\n1. **Secondary Prevention of Cardiotoxicity:** It is mainly used in cancer patients undergoing repeated treatments with anthracyclines (e.g., doxorubicin, daunorubicin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_vh531WT7Ok2RNjg8PVm05bZH", "custom_id": "83_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6173bd21db680f8e6a858a6aa3bd9642", "body": {"id": "chatcmpl-9St7Fal4mHjpoteHk8ChutH3tdJAm", "object": "chat.completion", "created": 1716672077, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Diethylstilbestrol (DES) is a synthetic nonsteroidal estrogen that was commonly prescribed between the 1940s and the 1970s to pregnant women to prevent miscarriages, preterm labor, and other pregnancy complications. As a physician, there are several critical aspects you should be aware of regarding DES:\n\n### Historical Context\n1. **Prescription History:** DES was widely prescribed to millions of pregnant women before its risks were fully understood.\n2. **FDA Action:** The FDA banned the use of DES in pregnant women in 1971 after studies demonstrated its serious adverse effects.\n\n### Adverse Effects\n1. **Maternal Risks:** DES has been linked to an increased risk of breast cancer in women who took the drug during pregnancy.\n2. **DES Daughters:** Female offspring of women who took DES are at significantly increased risk for:\n   - Clear cell adenocarcinoma (a rare type of vaginal and cervical cancer)\n   - Reproductive tract anomalies (e.g"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_X0OUuMpGa5pWKDGtmWmFt9LO", "custom_id": "84_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "726af62b386e0f07f3bd472282d12958", "body": {"id": "chatcmpl-9St7FxdqxztVtouvahJPkdfjhvTwy", "object": "chat.completion", "created": 1716672077, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dinutuximab is a monoclonal antibody used primarily in the treatment of high-risk neuroblastoma, a type of cancer that arises from immature nerve cells and primarily affects children. Here are several key points you should know about Dinutuximab:\n\n### Mechanism of Action\n- **Target**: Dinutuximab targets the GD2 ganglioside, an antigen highly expressed on the surface of neuroblastoma cells and other tumors of neuroectodermal origin.\n- **Action**: By binding to GD2, Dinutuximab facilitates the destruction of cancer cells through immune-mediated mechanisms, including antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).\n\n### Clinical Use\n- **Indications**: It is indicated for patients with high-risk neuroblastoma who have achieved at least a partial response to prior first-line multi-agent chemotherapy. It is often part of a multimodal therapy regimen including surgery, radiation therapy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_TzidtuytHcmPmEoIYqmT2814", "custom_id": "85_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "329fde5b8d5e4a6fb6f35c9deb6c035e", "body": {"id": "chatcmpl-9St7Fy8sZlw1duBYSprnaPbHvrHWj", "object": "chat.completion", "created": 1716672077, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Docetaxel is a chemotherapeutic agent used primarily in the treatment of various cancers. Here are several key points you should be aware of as a physician:\n\n### Mechanism of Action\n- **Docetaxel** is a semisynthetic taxane that works by disrupting the microtubular network in cells, which is essential for mitotic and interphase cellular functions. It promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly, thereby resulting in decreased cell proliferation.\n\n### Indications\n- **Breast Cancer:** Often used in adjuvant therapy and for metastatic breast cancer.\n- **Non-Small Cell Lung Cancer (NSCLC):** Used alone or in combination with other chemotherapy agents.\n- **Prostate Cancer:** Administered for advanced hormone-refractory prostate cancer.\n- **Gastric Cancer:** Often used in combination chemotherapy for advanced cases.\n- **Head and Neck Cancer:** For both recurrent and advanced cases.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_FzrvEkkT6yLKWa0HopLwFRYi", "custom_id": "86_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b3c547b1677007cff90e114f4c27c6fa", "body": {"id": "chatcmpl-9St7Gv9VKDFWQpqXWvLgbkrCmHibo", "object": "chat.completion", "created": 1716672078, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Doxifluridine, also known as 5'-deoxy-5-fluorouridine (5'-DFUR), is an oral prodrug of the chemotherapeutic agent 5-fluorouracil (5-FU). Here are some key points you should know about Doxifluridine as a physician:\n\n### Mechanism of Action\n- **Prodrug of 5-FU**: Doxifluridine is metabolized in the body to 5-fluorouracil (5-FU). This conversion primarily occurs in the liver and tumor tissues.\n- **Antimetabolite**: Once converted to 5-FU, it interferes with DNA synthesis by inhibiting the enzyme thymidylate synthase, which leads to the disruption of DNA replication in rapidly dividing cancer cells.\n\n### Indications\n- **Cancer Treatment**: It is used in the treatment of various cancers, including gastrointestinal cancers (e.g., colorectal, gastric"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_riw8EicnBqamYS7pvse267hl", "custom_id": "87_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d73a850328ccee898dea8a7a2bb5487e", "body": {"id": "chatcmpl-9St7GOUZiD3ev4CKEAu0x9CgCFtuX", "object": "chat.completion", "created": 1716672078, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Doxorubicin is a powerful chemotherapeutic agent classified in the anthracycline class of drugs. It is widely used in the treatment of various cancers, including leukemias, lymphomas, and solid tumors such as breast cancer, ovarian cancer, and sarcomas. Here are some key points you should know about Doxorubicin:\n\n### Mechanism of Action\n1. **Intercalation into DNA:** Doxorubicin intercalates between DNA base pairs, disrupting the DNA structure and inhibiting the synthesis of DNA and RNA.\n2. **Inhibition of Topoisomerase II:** The drug inhibits the enzyme topoisomerase II, which is necessary for DNA replication and transcription. This leads to DNA strand breaks.\n3. **Generation of Free Radicals:** Doxorubicin generates free radicals, which cause oxidative damage to cellular components, including DNA, proteins, and cell membranes.\n\n### Pharmacokinetics\n1. **Administration:**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_pw8JutxVUpsNt0NjpGti7VFS", "custom_id": "88_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0732d2bb0fdac33ca37e04eb74dc1ef9", "body": {"id": "chatcmpl-9St7G9aMbwHA86ngJ5XKCER4cSktg", "object": "chat.completion", "created": 1716672078, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Durvalumab is an immunotherapy drug used in oncology. It is a human monoclonal antibody that targets PD-L1 (programmed death-ligand 1). Here are some key points you should know about Durvalumab as a physician:\n\n### Indications:\n- **Non-Small Cell Lung Cancer (NSCLC)**: Durvalumab is often used in the treatment of stage III NSCLC that is unresectable and has not progressed following chemoradiation therapy.\n- **Urothelial Carcinoma**: It is also approved for use in patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.\n\n### Mechanism of Action:\nDurvalumab blocks PD-L1, a protein that tumors use to evade the immune system, thereby allowing the immune system to identify and attack cancer cells.\n\n### Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_WNMmDj7t3UjoZQ0AqN1m71Ys", "custom_id": "89_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "320908d952a03ddbf03e9824ceb058b3", "body": {"id": "chatcmpl-9St7G3OveBSM4ntLRJsVyziDwA0ID", "object": "chat.completion", "created": 1716672078, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dutasteride is a medication commonly used to treat conditions related to the prostate gland, particularly benign prostatic hyperplasia (BPH). Here are some key points you should know about dutasteride:\n\n### Mechanism of Action:\n- **5-alpha-Reductase Inhibitor**: Dutasteride inhibits both type 1 and type 2 isoforms of the enzyme 5-alpha-reductase, which is involved in the conversion of testosterone to dihydrotestosterone (DHT). DHT is a hormone that contributes to prostate growth. By reducing DHT levels, dutasteride helps shrink the prostate and improve symptoms of BPH.\n\n### Indications:\n- **Benign Prostatic Hyperplasia (BPH)**: Used to improve urinary flow and reduce the risk of acute urinary retention and the need for BPH-related surgery.\n- **Potential Off-Label Use**: Sometimes used off-label for conditions like androgenetic alopecia (male pattern hair loss).\n\n### Dos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_qYFMpbMWQ0zQiYBFqVsr33G3", "custom_id": "90_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "bf24d57739369ff2ad79f1bb835a8bc0", "body": {"id": "chatcmpl-9St7G2VinmvCTD9w6Bz97OxcZozG7", "object": "chat.completion", "created": 1716672078, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Duvelisib (brand name Copiktra) is an oral medication used in the treatment of hematologic malignancies, specifically certain types of blood cancers. Here are some key points you should know about Duvelisib as a physician:\n\n### Mechanism of Action\n- **Duvelisib** is a dual inhibitor of phosphoinositide 3-kinase (PI3K) delta and gamma isoforms. These enzymes are involved in the growth and survival of malignant B-cells, which are implicated in the proliferation of certain blood cancers.\n\n### Indications\n- **Chronic Lymphocytic Leukemia (CLL)**: Approved for use in relapsed or refractory CLL.\n- **Small Lymphocytic Lymphoma (SLL)**: Also indicated for relapsed or refractory SLL.\n- **Follicular Lymphoma (FL)**: Approved for patients with relapsed or refractory FL after at least two prior systemic therapies.\n\n### Administration\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_TTWGgjfgAu2TSzY1YTbs43q6", "custom_id": "91_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "886f30102b86cd4357f2eb91ac8e2dd0", "body": {"id": "chatcmpl-9St7GYdwzJ60ricu6Lf0nxRGDuXrR", "object": "chat.completion", "created": 1716672078, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Edrecolomab is a monoclonal antibody that targets the 17-1A antigen (also known as EpCAM or epithelial cell adhesion molecule) found on the surface of colorectal carcinoma cells and some normal epithelial tissues. Here are some key points you should know about Edrecolomab:\n\n1. **Mechanism of Action**: Edrecolomab works by binding to the 17-1A antigen, leading to the destruction of cancer cells through immune-mediated mechanisms, including complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).\n\n2. **Indication and Use**: Historically, Edrecolomab was investigated primarily for the adjuvant treatment of stage III colorectal cancer following surgery. It aimed to reduce the risk of recurrence by targeting residual cancer cells.\n\n3. **Efficacy**: Early clinical trials showed that Edrecolomab could provide a survival benefit in stage III colorectal cancer patients. However, subsequent"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Jm2d1x3r0NvfRGzxHs6IvBOG", "custom_id": "92_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "c845c347edc780897e119b5c856ab18c", "body": {"id": "chatcmpl-9St7G9cAjTlAF1iuTURSNuUShnQfV", "object": "chat.completion", "created": 1716672078, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Elotuzumab is a monoclonal antibody used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells. Here are some key points you should know as a physician:\n\n### Mechanism of Action\n- **Target:** Elotuzumab specifically targets SLAMF7 (Signaling Lymphocytic Activation Molecule Family member 7), a protein expressed on myeloma cells and some immune cells.\n- **Function:** By binding to SLAMF7, elotuzumab enhances natural killer (NK) cell function and promotes antibody-dependent cellular cytotoxicity (ADCC), thereby helping to attack and kill myeloma cells.\n\n### Indications\n- Elotuzumab is approved for use in combination with other medications, such as lenalidomide and dexamethasone, for the treatment of adults with relapsed or refractory multiple myeloma who have received one to three prior therapies.\n\n### Administration\n- **Form:** It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_8ypavkCQAzmRRQA9VyhvGivs", "custom_id": "93_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a2a0c70713fea441744224186e64ae89", "body": {"id": "chatcmpl-9St7GSZ71fRWosWj5hYmSeDpvolig", "object": "chat.completion", "created": 1716672078, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enasidenib (sold under the brand name Idhifa) is an oral medication primarily used to treat patients with relapsed or refractory acute myeloid leukemia (AML) that have a specific mutation in the isocitrate dehydrogenase-2 (IDH2) gene. Here are some key points you should know about Enasidenib:\n\n1. **Mechanism of Action**:\n   - Enasidenib is an IDH2 inhibitor. Mutations in IDH2 lead to the production of an oncometabolite called 2-hydroxyglutarate (2-HG), which contributes to the block in cellular differentiation seen in AML. Enasidenib inhibits the mutated IDH2 enzyme, thereby reducing 2-HG levels and promoting the differentiation of leukemic cells into mature blood cells.\n\n2. **Indications**:\n   - It is indicated for the treatment of adult patients with relapsed or refractory AML with an IDH2 mutation"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5dHQqkIkFzfTkcBzQdJXAZfj", "custom_id": "94_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d7ee6b0ccb061e245773c019bfae8557", "body": {"id": "chatcmpl-9St7HBiwpHvqNj0LnzHIeMdaeoiH8", "object": "chat.completion", "created": 1716672079, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to have a comprehensive understanding of Encorafenib, a medication used primarily in the treatment of certain kinds of cancer. Below are key points you should know:\n\n### Basic Information\n- **Class**: Encorafenib is a kinase inhibitor specifically targeting the BRAF V600E mutation.\n- **Indication**: It is often used in combination with binimetinib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. It is also approved in combination with cetuximab for the treatment of metastatic colorectal cancer with a BRAF V600E mutation after prior therapy.\n\n### Mechanism of Action\n- **BRAF Inhibition**: Encorafenib selectively inhibits mutated BRAF (a protein kinase involved in cell growth) variants, which are often present in certain cancers. This inhibition helps to reduce abnormal cell growth and proliferation.\n  \n### Administration and Dosing\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_eKMq04a2Rme2tUx81fBWqgKg", "custom_id": "95_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9370b23cb4c2cd4aaef8713f17b33b83", "body": {"id": "chatcmpl-9St7H7uDbp3Pxdpvd27ndN2OCsFyn", "object": "chat.completion", "created": 1716672079, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Entrectinib, marketed under the name Rozlytrek, is an oral tyrosine kinase inhibitor used in oncology. Here are the key points you should know about it:\n\n### Indications:\n1. **NTRK Gene Fusion-Positive Solid Tumors:**\n   - Entrectinib is indicated for the treatment of adult and pediatric patients (12 years of age and older) with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment.\n\n2. **ROS1-Positive Non-Small Cell Lung Cancer (NSCLC):**\n   - It is also approved for the treatment of adults with ROS1-positive metastatic NSCLC.\n\n### Mechanism of Action:\n- Entrectinib targets and inhibits the tyrosine kinases TRKA/B/C and ROS1,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_TpiTBYTRF14t6sBLtzc32SPw", "custom_id": "96_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1cf37b80f14cac686582c36637b4e049", "body": {"id": "chatcmpl-9St7HhJEakI3OfO48gIfxGpHbxSfD", "object": "chat.completion", "created": 1716672079, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enzalutamide is an androgen receptor inhibitor used primarily to treat metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). Here are some key points you should know about Enzalutamide as a physician:\n\n### Mechanism of Action\n- **Androgen Receptor Inhibition:** Enzalutamide works by inhibiting the androgen receptor signaling pathway, which is crucial for the growth and survival of prostate cancer cells. It prevents androgens (male hormones) from binding to their receptors, entering the cell nucleus, and activating gene expression needed for cancer growth.\n\n### Indications\n- **Metastatic Castration-Resistant Prostate Cancer (mCRPC):** Used in patients whose prostate cancer has spread to other parts of the body and is resistant to medical or surgical treatments that lower testosterone.\n- **Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC):** Used in patients"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_QWFFDlOO5uUh0FPnv2jWXkXG", "custom_id": "97_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ea7afe90b438358b30100c01764d3672", "body": {"id": "chatcmpl-9St7H3zfwYhEcT9nsYrMxqFo1yZTp", "object": "chat.completion", "created": 1716672079, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Epirubicin is an anthracycline antibiotic primarily used as a chemotherapeutic agent in oncology. Here are several key points a physician should know about Epirubicin:\n\n### Mechanism of Action:\n- **DNA Intercalation**: Epirubicin works by intercalating between DNA base pairs, disrupting enzyme functions involved in DNA replication and transcription.\n- **Topoisomerase II Inhibition**: The drug inhibits topoisomerase II, an enzyme crucial for DNA unwinding, leading to breaks in the DNA strands.\n- **Free Radical Production**: It generates free radicals that damage cellular components, contributing to its cytotoxic effects.\n\n### Indications:\n- **Breast Cancer**: Frequently used in adjuvant and metastatic breast cancer treatment.\n- **Other Cancers**: It can also be used for other malignancies, such as gastric cancer and lymphomas, though it\u2019s not the first-line treatment for these conditions.\n\n### Administration:\n- Typically,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_LijBevInjVaJxK3ZjlDjFYIu", "custom_id": "98_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "fe46b8e26e7fff0cb4571154ba097223", "body": {"id": "chatcmpl-9St7HsSeYjLtqs5dbofwiaTMfOpgR", "object": "chat.completion", "created": 1716672079, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erdafitinib is a medication that falls under the category of kinase inhibitors and is primarily used in the treatment of certain types of cancer. Here are some key points you, as a physician, should know about Erdafitinib:\n\n1. **Indications**: Erdafitinib is approved for the treatment of adults with locally advanced or metastatic urothelial carcinoma (a type of bladder cancer) that has susceptible FGFR3 or FGFR2 genetic alterations. Patients should have disease progression during or after at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.\n\n2. **Mechanism of Action**: Erdafitinib works as a potent oral inhibitor of fibroblast growth factor receptors (FGFRs). By inhibiting FGFR, Erdafitinib can block the signaling pathways involved in tumor growth and survival, especially in cancers where FGFR mutations or abnormalities are driving disease progression.\n\n3. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_jZb4P9NyRMP8CekWOByE7DBq", "custom_id": "99_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "15788dcd30737f4530cd5411bd081d67", "body": {"id": "chatcmpl-9St7HzSaE1onbeBdFYt9j0QOu8cz1", "object": "chat.completion", "created": 1716672079, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Eribulin is an anticancer agent primarily used in the treatment of certain types of breast cancer and liposarcoma. Here's a detailed overview that should be helpful for a physician:\n\n### Mechanism of Action\n- **Microtubule Dynamics:** Eribulin is a synthetic analog of halichondrin B, a natural product with anticancer properties. It works by inhibiting microtubule dynamics, thereby hindering cell division and causing apoptosis (cell death).\n\n### Indications\n- **Metastatic Breast Cancer:** Eribulin is indicated for patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens, including an anthracycline and a taxane.\n- **Unresectable or Metastatic Liposarcoma:** It is also approved for patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.\n\n### Administration\n- **Dosage:** The typical dosage is 1"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_a6QjxeAwNjDPUrdFLSfqFoBD", "custom_id": "100_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f5437fec60ddbdab631b6713d4072d74", "body": {"id": "chatcmpl-9St7HaAhryk1xrD4R79PJNrYBqSDi", "object": "chat.completion", "created": 1716672079, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erlotinib is a tyrosine kinase inhibitor specifically targeting the epidermal growth factor receptor (EGFR). It's widely used in the treatment of certain types of non-small cell lung cancer (NSCLC) and pancreatic cancer. Here are some key points you should know about Erlotinib:\n\n### Mechanism of Action\n- **EGFR Inhibition:** Erlotinib inhibits the intracellular phosphorylation of tyrosine kinases associated with the EGFR. This inhibition leads to decreased tumor cell proliferation and increased tumor cell apoptosis.\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC):** Used in patients with NSCLC, particularly those with specific EGFR mutations.\n- **Pancreatic Cancer:** Commonly given in combination with gemcitabine for treating locally advanced, unresectable, or metastatic pancreatic cancer.\n\n### Dosage and Administration\n- **Standard Dosage:** Typically, 150 mg orally once daily for NSCLC and 100 mg orally once daily for pancreatic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_poE6lLqt5HZCGMokDwPlC4MX", "custom_id": "101_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "22041be982e1456cddcaf4e61a70f7b8", "body": {"id": "chatcmpl-9St7H3qfZ2ilkeHpTuX8ZHgwY3IE4", "object": "chat.completion", "created": 1716672079, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Certainly! As a physician, it is important to understand the following key points about Estramustine:\n\n### 1. **Mechanism of Action:**\n   - **Estramustine** is a type of chemotherapy drug used primarily to treat prostate cancer. It combines estradiol (a form of estrogen) with nitrogen mustard (a chemotherapy agent).\n   - It works by disrupting microtubule functions, which are crucial for cell division, thus inhibiting the growth of cancer cells.\n\n### 2. **Indications:**\n   - **Primary Use:** It is most commonly indicated for metastatic or progressive prostate cancer.\n   - **Secondary Uses:** It might be considered in certain cases where hormonal therapy has failed.\n\n### 3. **Dosage and Administration:**\n   - **Formulation:** Estramustine is typically administered orally in the form of capsules.\n   - **Dosage:** The specific dosage can vary but is generally around 14 mg/kg per day, divided"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_F4VT7MZHVBcUwL2Be51Ph28z", "custom_id": "102_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d203349b12851fb3d43c835b242f356c", "body": {"id": "chatcmpl-9St7HCJ78bOyxNBfbrI06AsQB2Khs", "object": "chat.completion", "created": 1716672079, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Etoposide is an important chemotherapeutic agent, and as a physician, there are several key aspects you should be familiar with:\n\n### Mechanism of Action\n- **Etoposide** is a topoisomerase II inhibitor. It works by causing DNA breaks during the G2 and S phases of the cell cycle, which leads to apoptosis of cancer cells.\n\n### Indications\n- Etoposide is commonly used to treat various malignancies, such as **small cell lung cancer**, germ cell tumors, Hodgkin's disease, non-Hodgkin's lymphoma, and some solid tumors like ovarian cancer and gastric cancer.\n\n### Administration\n- **Routes of administration**: Etoposide can be given intravenously (IV) or orally (PO). \n- **Dosing considerations**: The dosage may vary depending on the type of cancer, the regimen used, patient factors (e.g., renal function, hepatic function), and whether the drug is being used in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_s9dG71PK7k8ivOL8CBrwVHOy", "custom_id": "103_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7074d4258eb83420648ab00175cd19e6", "body": {"id": "chatcmpl-9St7HsmodnaHAKHxnYmSYKrkno2rV", "object": "chat.completion", "created": 1716672079, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Everolimus is an important medication used in various medical fields, including oncology, transplantation, and cardiology. Here's a comprehensive overview of what you, as a physician, should know about Everolimus:\n\n### Pharmacology and Mechanism of Action:\n- **Class:** It is a derivative of sirolimus (rapamycin) and belongs to the class of mTOR (mechanistic Target of Rapamycin) inhibitors.\n- **Mechanism:** Everolimus inhibits the mTORC1 pathway, which plays a crucial role in cell growth, proliferation, metabolism, and angiogenesis. By inhibiting this pathway, Everolimus can reduce cell proliferation and slow tumor growth.\n\n### Indications:\nEverolimus has multiple indications across different medical specialities:\n- **Oncology:**\n  - Advanced renal cell carcinoma (RCC)\n  - Hormone receptor-positive, HER2-negative breast cancer in postmenopausal women\n  - Neuroendocrine tumors of pancreatic, gastrointestinal,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_wh7novzmprQZVRHEj23ueFl1", "custom_id": "104_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6d7e588edf173712234b54b51babf342", "body": {"id": "chatcmpl-9St7I5qt2wwJVns4uEiIoZLZTMkWa", "object": "chat.completion", "created": 1716672080, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Exemestane is an important medication used primarily in the treatment of certain types of breast cancer. Here are key points that a physician should know about this drug:\n\n1. **Mechanism of Action**:\n   - Exemestane is an aromatase inhibitor. It works by blocking the aromatase enzyme, which converts androgens into estrogens. By reducing estrogen levels, it helps to slow or reverse the growth of estrogen receptor-positive (ER+) breast cancer cells.\n\n2. **Indications**:\n   - Exemestane is typically prescribed for postmenopausal women with ER+ breast cancer.\n   - It is used as an adjuvant treatment after surgery to prevent cancer recurrence.\n   - It can also be used in cases of advanced breast cancer that have progressed after other hormonal therapies such as tamoxifen.\n\n3. **Dosage and Administration**:\n   - The standard dosage is 25 mg orally once daily after a meal.\n   - Consistent"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_dsKOA58lJx5PKscXBdxKgQGS", "custom_id": "105_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "657a81354a6ca3d2db7ba885fed72a52", "body": {"id": "chatcmpl-9St7IjEeb1IqmndnypCzcZt8F3RSq", "object": "chat.completion", "created": 1716672080, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Floxuridine is a chemotherapeutic agent used primarily in the treatment of certain types of cancers. Here are essential points that you, as a physician, should know about Floxuridine:\n\n### Pharmacology:\n1. **Mechanism of Action**: Floxuridine is a pyrimidine analog. It works primarily by inhibiting thymidylate synthase, leading to the disruption of DNA synthesis and cell division.\n\n2. **Formulation and Administration**: Floxuridine is typically administered via intra-arterial infusion, particularly in the context of hepatic artery infusion for liver metastases, especially from colorectal cancer.\n\n### Indications:\n1. **Primary Uses**: It is most commonly used for palliative treatment of metastatic colorectal cancer in the liver, but may also be used in other cancers based on clinical judgment.\n\n### Pharmacokinetics:\n1. **Absorption and Distribution**: Given intra-arterially, Floxuridine targets the liver tumors directly"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_LnfJcfCQ8GRBHXTbeVbozgJY", "custom_id": "106_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0b43983c0beb294b56a45865f7b6b60f", "body": {"id": "chatcmpl-9St7IbWVIVBVaCzvLlmMJz4AozCat", "object": "chat.completion", "created": 1716672080, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is crucial to have a comprehensive understanding of Fludarabine, particularly if you administer or manage treatment regimens that include this drug. Here is a detailed overview of the key aspects:\n\n### General Overview:\nFludarabine is a chemotherapy medication primarily used to treat hematological malignancies, particularly chronic lymphocytic leukemia (CLL) and low-grade non-Hodgkin's lymphoma. It is a purine analog and works by interfering with DNA synthesis.\n\n### Mechanism of Action:\n- Fludarabine is an antimetabolite. Once inside the cell, it is phosphorylated to its active triphosphate form.\n- It inhibits ribonucleotide reductase and DNA polymerase, thereby disrupting DNA synthesis and repair.\n- It induces apoptosis (programmed cell death) in certain types of malignant cells.\n\n### Indications:\n- Chronic lymphocytic leukemia (CLL)\n- Low-grade non-Hodgkin's lymphoma\n- Off-label uses"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_amKuzUBV8Qvrjc8eR29fwVGh", "custom_id": "107_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "44118888dca033e1ea1d50c9c4908060", "body": {"id": "chatcmpl-9St7Iofswv3dXMFIxPJCZUf3YvfYi", "object": "chat.completion", "created": 1716672080, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fluorouracil, also known as 5-Fluorouracil (5-FU), is an important medication in the treatment of various cancers. Here are key points you should know as a physician:\n\n### Mechanism of Action\n- **Antimetabolite:** Fluorouracil is a pyrimidine analog which works by inhibiting the enzyme thymidylate synthase. This results in the disruption of DNA synthesis and RNA function, causing cell death, particularly in rapidly dividing cancer cells.\n\n### Indications\n- **Cancer Treatment:** It is used primarily in the management of colorectal cancer, breast cancer, gastric cancer, pancreatic cancer, and head and neck cancers.\n- **Topical Use:** It's used in a topical form to treat actinic keratoses, basal cell carcinoma, and in some cases, squamous cell carcinoma.\n\n### Administration\n- **Intravenous (IV):** Often administered via IV as part of various chemotherapy regimens.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_HvKOgD48Dk031Ul3SLVNBP4Y", "custom_id": "108_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "bb1a08187531c0ef1aeb79b91f230e00", "body": {"id": "chatcmpl-9St7InnKrG1pWL10V1J399JILQm8l", "object": "chat.completion", "created": 1716672080, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fluoxymesterone, known by the brand names Halotestin and Androxy, is an anabolic steroid with potent androgenic properties. As a physician, there are several important aspects to be aware of:\n\n1. **Indications**:\n   - **Men**: Fluoxymesterone is used to treat hypogonadism, delayed puberty, and impotence due to androgen deficiency.\n   - **Women**: It may be used in the palliative treatment of androgen-responsive recurrent breast cancer in postmenopausal women.\n\n2. **Mechanism of Action**:\n   - It mimics the actions of testosterone by binding to androgen receptors and influencing gene expression and protein synthesis, which leads to increased nitrogen retention and protein anabolism. \n\n3. **Administration and Dosage**:\n   - Doses vary depending on the condition being treated. For hypogonadism, doses typically range from 5-20 mg per day.\n   - For breast cancer treatment, doses can"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_8vAHqqWvTjVbBkxU9F7eq4At", "custom_id": "109_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e1eb67d3ab5cb017321a36fdbac1a3a0", "body": {"id": "chatcmpl-9St7IcZCA2i22XUp9oWQVp2gyhwsl", "object": "chat.completion", "created": 1716672080, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Flutamide is a non-steroidal anti-androgen medication primarily used in the treatment of prostate cancer. Here's a detailed overview of what you should know about Flutamide as a physician:\n\n### Mechanism of Action\n- **Anti-Androgen Effect**: Flutamide works by blocking androgen receptors, thus inhibiting the action of testosterone and dihydrotestosterone (DHT), which are key hormones that promote the growth of prostate cancer cells.\n\n### Indications\n- **Prostate Cancer**: Typically used in the management of advanced prostate cancer, often in combination with a luteinizing hormone-releasing hormone (LHRH) agonist to achieve maximum androgen blockade (MAB).\n- **Off-Label Uses**: Occasionally used for conditions like hirsutism in women, though this is less common and should be approached with caution.\n\n### Dosage and Administration\n- **Standard Dosage**: 250 mg taken orally three times a day (every 8 hours"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_y4E7YxoZqa4xDXKzOtAvKqD8", "custom_id": "110_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5bcd018dd6758bf82fe4251d300ed72b", "body": {"id": "chatcmpl-9St7J8mpsfeBQQ9vquSGLHQt5HbAT", "object": "chat.completion", "created": 1716672081, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Folinic acid, also known as leucovorin, is a form of folate (vitamin B9) that is used in various medical treatments. Here are some key points you should know about it as a physician:\n\n### 1. **Chemistry and Function:**\n- **Biologically Active Form:** Unlike folic acid, which needs to be converted into its active form within the body (tetrahydrofolate), folinic acid is already a form of reduced folate and can be readily used by the body.\n\n### 2. **Clinical Uses:**\n\n- **Chemotherapy Adjunct:** One of the primary uses of folinic acid is as an adjuvant in cancer treatment. It is commonly used alongside the chemotherapeutic agent methotrexate to \"rescue\" normal cells from its toxic effects. This use is often referred to as \"leucovorin rescue.\"\n  \n- **Potentiation of Fluorouracil (5-FU"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_lDK5Hr5pYE5c1TfEaRsfAWYI", "custom_id": "111_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "cd589443ee4104538a263e1f4a7b0cb2", "body": {"id": "chatcmpl-9St7Jlrkj9BBY052oqLA6VgDuSi90", "object": "chat.completion", "created": 1716672081, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Formestane, also known by the brand name Lentaron, is a steroidal aromatase inhibitor (AI) used primarily in the treatment of hormone-responsive breast cancer in postmenopausal women. Here\u2019s what you need to know about it as a physician:\n\n### Mechanism of Action\n- **Aromatase Inhibition**: Formestane works by inhibiting the enzyme aromatase, which is responsible for the conversion of androgens to estrogens. By reducing estrogen levels, formestane helps to slow the growth of estrogen receptor-positive breast cancers.\n\n### Pharmacokinetics\n- **Administration**: It is usually administered intramuscularly (IM).\n- **Absorption and Metabolism**: Following IM injection, formestane is slowly absorbed into the bloodstream, providing a long duration of action. It is metabolized in the liver and excreted via the kidneys.\n\n### Indications\n- **Breast Cancer**: Indicated for post"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_cyNB5A15ISTN4GSmuk29ydUz", "custom_id": "112_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "42ed4ed5910aa70030d32624d8d10aaf", "body": {"id": "chatcmpl-9St7JlV6KlGFBkjlAeeRB81sJiMje", "object": "chat.completion", "created": 1716672081, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Forodesine, also known as immucillin H, is a purine nucleoside phosphorylase (PNP) inhibitor primarily investigated for its potential in treating hematologic malignancies. Here's what you should know about it:\n\n### Mechanism of Action:\n- **Inhibition of PNP:** Forodesine inhibits the enzyme purine nucleoside phosphorylase (PNP), which plays a crucial role in the purine salvage pathway.\n- **Accumulation of Deoxyguanosine Triphosphate:** By inhibiting PNP, forodesine causes an accumulation of deoxyguanosine triphosphate (dGTP) in lymphocytes, which leads to apoptosis, particularly in malignant cells such as T-cells.\n\n### Indications:\n- **Hematologic Malignancies:** Forodesine is primarily researched for its application in certain blood cancers, including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell non-Hodgkin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_LqRji9rGv0N9TvNVFHZwwBb7", "custom_id": "113_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b3bb4d99fc178ca9d209f8cc6f49c805", "body": {"id": "chatcmpl-9St7J4GiiG0b4HgI3N1L1sLQ2v63A", "object": "chat.completion", "created": 1716672081, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fostamatinib is an oral medication primarily used to treat chronic immune thrombocytopenia (ITP) in adults who have had an insufficient response to previous treatment. Here are several key aspects you should know about Fostamatinib:\n\n1. **Mechanism of Action:**\n   - Fostamatinib is a spleen tyrosine kinase (SYK) inhibitor. SYK inhibition reduces the destruction of platelets by the immune system, thereby increasing platelet counts in patients with ITP.\n\n2. **Indications:**\n   - It is FDA-approved for the treatment of adult patients with chronic ITP.\n\n3. **Dosage:**\n   - The standard starting dose is usually 100 mg orally twice daily. Based on patient response and tolerability, the dose may be increased to 150 mg twice daily after a period of 4 weeks.\n\n4. **Safety and Side Effects:**\n   - Common side effects include hypertension, liver enzyme elevation, diarrhea,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_LTVLcZ2kjudujKYbbHONapGO", "custom_id": "114_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8be3e5829178aed39399bbec30b23859", "body": {"id": "chatcmpl-9St7JJ2e8tV89mCCJYuwtcrotG6Ln", "object": "chat.completion", "created": 1716672081, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fotemustine is an alkylating agent used in chemotherapy, primarily for the treatment of malignant melanoma, especially when it involves brain metastases, and certain types of brain tumors such as gliomas. Here are some key points you should know as a physician:\n\n1. **Mechanism of Action**:\n   - Fotemustine works by binding to DNA and interfering with its replication process, which leads to cell death. It specifically adds an alkyl group to the DNA, resulting in intra- and inter-strand cross-linking.\n\n2. **Indications**:\n   - Malignant melanoma with or without brain metastases.\n   - Primary brain tumors, particularly high-grade gliomas.\n\n3. **Administration**:\n   - Fotemustine is usually administered as an intravenous infusion. The dosing regimen can vary, but a common one involves an induction phase followed by a maintenance phase.\n   - It's essential to follow specific protocols regarding dosing schedules to maximize efficacy and minimize toxicity.\n\n4."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_QZhZGOTlrllhBSIa7mNc79AH", "custom_id": "115_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7c168e3c797b10ae35cc3b50db433643", "body": {"id": "chatcmpl-9St7JI4qOo2hheQrkdiiwoFPzTtE3", "object": "chat.completion", "created": 1716672081, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fulvestrant is an estrogen receptor antagonist used primarily in the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women. Here are some key points you should know about Fulvestrant as a physician:\n\n1. **Mechanism of Action:**\n   - Fulvestrant works by binding to and degrading the estrogen receptor (ER), leading to a complete inhibition of estrogen signaling. This impairs the growth of ER-positive breast cancer cells.\n\n2. **Indications:**\n   - Fulvestrant is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women:\n      - As monotherapy.\n      - In combination with other agents such as CDK4/6 inhibitors (e.g., palbociclib, abemaciclib) for patients who have progressed on prior endocrine therapy.\n\n3. **Dosage and Administration:**\n   - Fulvestrant is administered as an intramuscular injection.\n   - The recommended dose"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_KlHrbD03UJCBFnwg9zHmdFCX", "custom_id": "116_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5efa50a067329c0953ceac0effcc11ef", "body": {"id": "chatcmpl-9St7JrYl6J0rncP9t0dJKxSISjq74", "object": "chat.completion", "created": 1716672081, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gefitinib is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC). Here's a comprehensive overview of what you should know about Gefitinib:\n\n### 1. **Mechanism of Action**:\n- Gefitinib is a tyrosine kinase inhibitor (TKI) that targets the epidermal growth factor receptor (EGFR). It works by inhibiting the EGFR tyrosine kinase, which is involved in the signaling pathways that lead to cell division and survival. This inhibition can lead to reduced tumor cell proliferation and increased apoptosis.\n\n### 2. **Indications**:\n- Gefitinib is primarily prescribed for patients with metastatic NSCLC who have specific mutations in the EGFR (e.g., exon 19 deletions or exon 21 L858R substitution mutations). It is particularly effective in tumors that have these activating mutations.\n\n### 3. **Administration**:\n- Gefitinib is available in tablet form and is usually taken orally once daily,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Erpw9qSppEAkLkgz4jkpDPqp", "custom_id": "117_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "89178c62e88d4c107a4ee88ba4a1d8a5", "body": {"id": "chatcmpl-9St7Ju3TjUh9FatUOj1ryCpcTaXjq", "object": "chat.completion", "created": 1716672081, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gemcitabine is a nucleoside analog used as chemotherapy. Here are some key points you should know as a physician:\n\n### Mechanism of Action\n- **Antimetabolite**: Gemcitabine gets incorporated into DNA during replication, causing chain termination.\n- **Inhibits Ribonucleotide Reductase**: Reduces deoxyribonucleotide levels, essential for DNA synthesis and repair.\n\n### Indications\n- **Cancers Treated**: Effective against a variety of cancers, including pancreatic, non-small cell lung, ovarian, and breast cancers.\n- **Combination Therapy**: Often used in combination with other chemotherapeutic agents.\n\n### Dosage and Administration\n- **Administration**: Given intravenously.\n- **Dosing Schedule**: Typically administered once a week for three weeks, followed by a week off; the exact schedule may vary based on cancer type and patient response.\n\n### Pharmacokinetics\n- **Half-Life**: Short, necessitating"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_3LuanRq3rHixqn0DMwzXWef6", "custom_id": "118_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "49dfa32d6129554644e34d378386c850", "body": {"id": "chatcmpl-9St7J2tjqYQGSC79HnwfWrJ6Lljls", "object": "chat.completion", "created": 1716672081, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gemtuzumab ozogamicin is an important drug to understand in the treatment of certain types of leukemia. Here are some key considerations and information you should know as a physician:\n\n### 1. **Indications:**\n   - **Acute Myeloid Leukemia (AML):** Gemtuzumab ozogamicin is primarily used for the treatment of adults with newly diagnosed AML whose CD33-positive status has been confirmed. It is sometimes used in relapsed or refractory cases, as well.\n\n### 2. **Mechanism of Action:**\n   - Gemtuzumab ozogamicin is a conjugated monoclonal antibody. It targets the CD33 antigen, commonly expressed on the surface of leukemic blast cells in AML. The drug is a combination of a recombinant humanized anti-CD33 monoclonal antibody linked to calicheamicin, a cytotoxic agent. Upon binding to CD33, it gets internalized into the cell, where the caliche"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_E2zGHHm5jhzE6KTVXJhv9NJn", "custom_id": "119_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "662deffe6290eda42ed424b968a95c39", "body": {"id": "chatcmpl-9St7J1MThLXThEAHIo29MVxCWt6aq", "object": "chat.completion", "created": 1716672081, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gilteritinib (brand name Xospata) is a targeted therapy used primarily in the treatment of acute myeloid leukemia (AML) that is positive for the FLT3 mutation. Here are key points you should know about Gilteritinib:\n\n### Mechanism of Action\n- **Targeted Therapy**: Gilteritinib is a tyrosine kinase inhibitor that specifically targets FLT3 (FMS-like tyrosine kinase 3), including both ITD (internal tandem duplications) and TKD (tyrosine kinase domain) mutations. It also inhibits AXL and ALK, which may contribute to its activity.\n\n### Indications\n- **Relapsed or Refractory AML**: It is indicated for the treatment of adult patients with relapsed or refractory AML who have a FLT3 mutation as detected by an FDA-approved test.\n\n### Administration\n- **Dosing**: The standard dose is 120 mg taken orally once a day. The tablets"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ISgzOnrs6iIwjn8snEODBw5s", "custom_id": "120_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d0f667060545b525248e97acce6f80ef", "body": {"id": "chatcmpl-9St7Klhim7NFRlIlwcK1r3BChksjv", "object": "chat.completion", "created": 1716672082, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Glasdegib is a medication used primarily in the treatment of certain types of cancer, particularly acute myeloid leukemia (AML). As a physician, it is important to be versed in its indications, mechanism of action, dosage, side effects, interactions, and monitoring requirements.\n\n### Indications\n- **Acute Myeloid Leukemia (AML)**: Glasdegib is approved for use in combination with low-dose cytarabine for the treatment of newly-diagnosed AML in adult patients who are 75 years or older or who have comorbidities that preclude the use of intensive chemotherapy.\n\n### Mechanism of Action\n- **Hedgehog Pathway Inhibitor**: Glasdegib is an oral inhibitor of the Hedgehog signaling pathway, specifically the Smoothened (SMO) receptor. The Hedgehog pathway is implicated in the maintenance and proliferation of cancer stem cells, and its inhibition can disrupt the growth and survival of these cells.\n\n### Dosage\n- The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_I6IKrw3dlQTvEyAu4FONMiKC", "custom_id": "121_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "cb2f5365a87cb7231cf34f19d03e1265", "body": {"id": "chatcmpl-9St7KQgmNUiuFRIQCefIBL8eoS53z", "object": "chat.completion", "created": 1716672082, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, there are several important aspects you should know about Goserelin, a synthetic analogue of the naturally occurring luteinizing hormone-releasing hormone (LHRH or GnRH). Below are some key points:\n\n### Indications\nGoserelin is mainly used for its ability to suppress the production of certain hormones, and it is indicated for:\n1. **Prostate Cancer**: For palliative treatment in advanced prostate cancer.\n2. **Breast Cancer**: Used in the management of advanced breast cancer in pre- and perimenopausal women.\n3. **Endometriosis**: To manage the symptoms and reduce the size of endometriotic lesions.\n4. **Endometrial Thinning**: Prior to endometrial ablation procedures.\n5. **Assisted Reproductive Technology (ART)**: Used in some protocols to control ovarian stimulation.\n\n### Mechanism of Action\nGoserelin acts as an agonist at pituitary GnRH receptors. Initially,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_6PUquDwa33M7SYWzSxbMZb5k", "custom_id": "122_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "753c605491d7bebe8136215bdcdb1f33", "body": {"id": "chatcmpl-9St7K7UbPsI9AzCSYHKDSJ1h1WDoc", "object": "chat.completion", "created": 1716672082, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, there are several important aspects you should know about Histrelin, which is a potent gonadotropin-releasing hormone (GnRH) agonist used primarily for the treatment of hormone-sensitive conditions. Here are the key points you should consider:\n\n### Mechanism of Action:\n- **GnRH Agonist:** Histrelin works by initially stimulating the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). However, with continuous administration, it leads to downregulation of GnRH receptors and subsequent suppression of LH and FSH secretion, resulting in decreased production of sex hormones (testosterone in males and estrogen in females).\n\n### Indications:\n- **Prostate Cancer:** Used in advanced prostate cancer to suppress testosterone levels, which can help slow cancer growth.\n- **Central Precocious Puberty (CPP):** Used in children with CPP to delay the onset of puberty by reducing the secretion of sex hormones.\n\n### Form"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_BExHUNZV4t1PCblpCm3XDKIF", "custom_id": "123_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "fd60391ba3c109933733eee536573fb6", "body": {"id": "chatcmpl-9St7KMw4RNbowYWYjPKKTesXY6VPT", "object": "chat.completion", "created": 1716672082, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a thorough understanding of hydrocortisone, including its mechanisms, indications, formulations, potential side effects, and contraindications. Here's an overview:\n\n### Mechanism of Action\nHydrocortisone is a corticosteroid that mimics the effects of cortisol. It has potent anti-inflammatory, immunosuppressive, and vasoconstrictive properties. By suppressing the immune response, hydrocortisone reduces inflammation and mitigates allergic reactions.\n\n### Indications\nHydrocortisone is used in a variety of medical conditions:\n- **Inflammatory Disorders**: Including arthritis, colitis, and conditions like lupus.\n- **Allergic Reactions**: Severe allergic responses such as anaphylaxis.\n- **Endocrine Disorders**: Used in adrenal insufficiency (Addison's disease) and congenital adrenal hyperplasia.\n- **Dermatologic Issues**: Used topically for skin conditions like eczema, psoriasis, and dermatitis.\n- **Autoimmune"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_hrEcIfI2kBN3ieZZDmgpwUi5", "custom_id": "124_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "78a13c98b5378389719685cc44507533", "body": {"id": "chatcmpl-9St7KhQyvby2GSFj7wYyIs8wRFlDK", "object": "chat.completion", "created": 1716672082, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Hydroxyurea is a medication used to treat a variety of conditions. As a physician, it's important to understand the pharmacology, indications, monitoring requirements, potential side effects, and patient education points associated with this drug.\n\n### Pharmacology:\n- **Mechanism of Action**: Hydroxyurea inhibits ribonucleotide reductase, leading to a decreased production of deoxyribonucleotides, which results in inhibition of DNA synthesis. It also has effects on the cell cycle, particularly arresting cells at the G1/S phase.\n\n### Indications:\n- **Hematologic Disorders**: \n  - Chronic myeloid leukemia (CML)\n  - Polycythemia vera\n  - Essential thrombocythemia\n- **Sickle Cell Disease**: \n  - Increases fetal hemoglobin (Hb F) levels, which reduces the frequency of sickle cell crises and other complications\n- **Solid Tumors**: \n  - Occasionally used in combination"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_mjjDNRqKRMRpz9pEYQRdEzzd", "custom_id": "125_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f0118dcb2bfe2ef87633dd811c66aa9c", "body": {"id": "chatcmpl-9St7KS4cksrcfy4MudYyKYTmVagp8", "object": "chat.completion", "created": 1716672082, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibritumomab tiuxetan, marketed under the name Zevalin, is a radioimmunotherapy agent used primarily for the treatment of certain types of non-Hodgkin lymphoma (NHL). As a physician, here are several key points you should be aware of regarding this drug:\n\n### Mechanism of Action:\n- **Monoclonal Antibody:** Ibritumomab is a monoclonal antibody that specifically targets the CD20 antigen, which is commonly found on the surface of B-cells, including malignant B-cells.\n- **Radiolabeled:** Tiuxetan is a chelator that links the monoclonal antibody to a radioactive isotope, typically yttrium-90 (Y-90) or indium-111 (In-111).\n- **Dual Action:** The drug combines the specificity of the monoclonal antibody with the cytotoxic effects of radiation, targeting and destroying both the targeted B-cells and nearby cells.\n\n### Indications:\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_IyU2EavuChrurjwFIoBrrzt0", "custom_id": "126_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "11e12022a55b41c082016e2d572def8d", "body": {"id": "chatcmpl-9St7KUoBxudzwGUcUgg949aZgWbgv", "object": "chat.completion", "created": 1716672082, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibrutinib, marketed under the brand name Imbruvica among others, is an oral medication used in the treatment of certain B-cell malignancies. Here\u2019s a detailed overview of what you should know as a physician:\n\n### Indications:\nIbrutinib is primarily indicated for the treatment of:\n1. Mantle cell lymphoma (MCL)\n2. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)\n3. Waldenstr\u00f6m's macroglobulinemia (WM)\n4. Marginal zone lymphoma (MZL) in patients who have received at least one prior therapy\n5. Chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy\n\n### Mechanism of Action:\nIbrutinib is a Bruton's tyrosine kinase (BTK) inhibitor. BTK is a crucial enzyme in the B-cell receptor signaling pathway, which plays a significant role in the proliferation, survival"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_yESYTpsdFaCmKKIfrXlqGq99", "custom_id": "127_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "35952a365f6a7a195933ad42c5021ad0", "body": {"id": "chatcmpl-9St7KkjWfTM3rKfglcA5JGDxbF2gO", "object": "chat.completion", "created": 1716672082, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Icotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR). It is primarily used in the treatment of non-small cell lung cancer (NSCLC), especially in patients who have specific EGFR mutations. Here are some key points a physician should know about Icotinib:\n\n1. **Mechanism of Action**: \n   - Icotinib selectively inhibits the tyrosine kinase activity of EGFR, which is involved in the proliferation and survival of cancer cells. By blocking this pathway, it can help reduce tumor growth and progression.\n\n2. **Indications**: \n   - Icotinib is commonly indicated for patients with advanced or metastatic NSCLC who have EGFR mutations. It is often considered for first-line treatment in these patients.\n\n3. **Administration**:\n   - Icotinib is orally administered. The recommended dose is typically taken three times a day, but it's essential to follow specific dosing guidelines and adjustments based"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ftw9CpXmR2i0jLfcXXpQYHGD", "custom_id": "128_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a95a6e7701ac06eb3050a310f93f4cea", "body": {"id": "chatcmpl-9St7LukiIM9RyjaiZsy6pQsPjVpDr", "object": "chat.completion", "created": 1716672083, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idarubicin is an anthracycline antibiotic used primarily in the treatment of various forms of cancer, particularly hematologic malignancies. Here are key points you should know about Idarubicin:\n\n### Indications:\n1. **Acute Myeloid Leukemia (AML)**: Primarily used in combination with other agents (e.g., cytarabine) for the induction therapy of AML in adults.\n2. **Acute Lymphoblastic Leukemia (ALL)**: Sometimes part of combination chemotherapy regimens for ALL.\n\n### Mechanism of Action:\n- Idarubicin intercalates with DNA, disrupting essential functions such as DNA replication and transcription. It inhibits topoisomerase II, which leads to breaks in double-stranded DNA and ultimately induces apoptosis in rapidly dividing cancer cells.\n\n### Administration:\n- **Form**: Available as an intravenous preparation.\n- **Dosage**: Commonly calculated based on body surface area (mg/m\u00b2). Dosage adjustments may"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_R1eurOa44xUqOBJGc0zxw4zo", "custom_id": "129_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "eb0901d9b87b82d199ddd13f77c66cd8", "body": {"id": "chatcmpl-9St7Ln8xSrqTWOeEnzOBRu3ZIQoLt", "object": "chat.completion", "created": 1716672083, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idelalisib is an oral medication used primarily in the treatment of certain hematologic malignancies, especially in patients with relapsed or refractory forms of these cancers. Here are some key points that you should know about Idelalisib:\n\n### Indications\nIdelalisib is approved for the treatment of:\n- Relapsed Chronic Lymphocytic Leukemia (CLL), often used in combination with rituximab.\n- Relapsed Follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.\n- Relapsed Small Lymphocytic Lymphoma (SLL).\n\n### Mechanism of Action\nIdelalisib inhibits phosphoinositide 3-kinase delta (PI3K-\u03b4), an enzyme that is important in the activation, proliferation, and survival of B-lymphocytes. By inhibiting this pathway, Idelalisib disrupts signaling that is crucial for the growth and survival"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_SP1WCdPncc3F7IRNNl0eQuO5", "custom_id": "130_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "305468bb34d1bead27ce9b5bcb5d5338", "body": {"id": "chatcmpl-9St8DFusJJ2CHlFWgJp2Lk8LCi6Ij", "object": "chat.completion", "created": 1716672137, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to have a comprehensive understanding of Ifosfamide, an alkylating agent often used in chemotherapy protocols. Here are some key points you should be aware of:\n\n### Indications:\n1. **Cancer Treatment**: Ifosfamide is commonly used to treat various types of cancers, including testicular cancer, sarcomas, lymphomas, and some types of solid tumors.\n\n### Mechanism of Action:\n2. **Alkylating Agent**: It works by cross-linking DNA strands, inhibiting DNA synthesis, and function, leading to cell death. It is particularly effective against rapidly dividing cells.\n\n### Administration:\n3. **Intravenous Infusion**: Ifosfamide is typically administered intravenously. Dosing regimens can vary based on the type of cancer and treatment protocol.\n\n### Adverse Effects:\n4. **Bone Marrow Suppression**: This can lead to anemia, leukopenia, and thrombocytopenia"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_FbCFnYtOVEGLNjxwVhaMPLOq", "custom_id": "131_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b2fbe3ce8e363ec1fd9f6f9dbb9e6095", "body": {"id": "chatcmpl-9St7L6QJtX0QLAU6rvVLxIQAwyHZO", "object": "chat.completion", "created": 1716672083, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imatinib is a tyrosine kinase inhibitor that is primarily used in the treatment of various types of cancers, most notably chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). Here is a summary of essential information about Imatinib that you should be aware of as a physician:\n\n### Indications:\n1. **Chronic Myeloid Leukemia (CML)**: Imatinib is effective in all phases of CML (chronic, accelerated, and blast crisis).\n2. **Gastrointestinal Stromal Tumors (GISTs)**: Approved for the treatment of unresectable and/or metastatic GISTs.\n3. **Other Indications**: Sometimes used for other malignancies with specific genetic aberrations such as Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).\n\n### Mechanism of Action:\nImatinib specifically inhibits the BCR-ABL tyrosine kinase, the abnormal protein produced by the Philadelphia chromosome trans"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_xH1lvwGSX1k3oKM56LOqn0fs", "custom_id": "132_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8b2acd6c47e3ce2d5c028ee4e0c401d0", "body": {"id": "chatcmpl-9St7LyHnek0F47QDt26faFUOCCniq", "object": "chat.completion", "created": 1716672083, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Infigratinib is a medication that you might encounter in the treatment of certain cancers, particularly cholangiocarcinoma, which is a type of bile duct cancer. Here are some key points you should know about infigratinib:\n\n### Mechanism of Action\n- **Targeted Therapy**: Infigratinib is a tyrosine kinase inhibitor that specifically targets mutant forms of the fibroblast growth factor receptor (FGFR) 2, which are implicated in the growth of some cancers.\n- **Precision Medicine**: It is most effective in patients whose tumors harbor specific FGFR2 gene fusions or other rearrangements.\n\n### Indications\n- **FDA Approval**: Infigratinib was approved by the FDA in May 2021 for the treatment of previously treated, unresectable locally advanced, or metastatic cholangiocarcinoma with FGFR2 fusions or other rearrangements.\n\n### Administration and Dosage\n- **Oral Administration**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_YCm1wNWW5Q6lmtjnDIgC6Cie", "custom_id": "133_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e33aed4c2d82cefcdeb0f86c63620595", "body": {"id": "chatcmpl-9St7LKXC6vlDqwlgCx0xycBgzrZtI", "object": "chat.completion", "created": 1716672083, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Inotuzumab ozogamicin is a targeted therapy medication used for treating certain types of cancer, specifically relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Here are key points you should know about the drug:\n\n### Mechanism of Action:\n1. **Antibody-Drug Conjugate (ADC)**: Inotuzumab ozogamicin comprises a monoclonal antibody attached to a cytotoxic agent. The antibody targets CD22, a surface antigen expressed on B-cells.\n2. **Selective Binding**: The drug binds to CD22 on cancer cells, facilitating internalization and release of the cytotoxic agent (calicheamicin), which induces DNA strand breaks and apoptosis in the targeted cancer cells.\n\n### Indications:\n- **Approved Use**: Specifically indicated for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).\n- **Target Population**: Typically considered after patients have not responded to other treatments or have relapsed"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_8dDAATpa7yQsDykfMssHjV1H", "custom_id": "134_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "25c19ea0333be742de35a51abf88209d", "body": {"id": "chatcmpl-9St7L81RYqjODobil6eIZEndvNg11", "object": "chat.completion", "created": 1716672083, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon alfa-2a is a type of cytokine used primarily in the treatment of various viral infections and certain types of cancer. Here are some key points you should know about it as a physician:\n\n1. **Mechanism of Action**:\n   - Interferon alfa-2a works by binding to specific receptors on cell surfaces, leading to immunomodulatory effects. It helps in inhibiting viral replication within host cells and enhancing the immune response against malignancies.\n\n2. **Indications**:\n   - Chronic Hepatitis B and C: It is used to help reduce the viral load and improve liver function.\n   - Certain cancers: It is approved for treating hairy cell leukemia, chronic myeloid leukemia, follicular lymphoma, and Kaposi's sarcoma, among others.\n   - Additionally, it can be used in other malignancies or viral infections off-label.\n\n3. **Administration**:\n   - It is administered via subcutaneous or intramuscular injection. The dosing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_4oo1gWoWTL5W7iIKY7zbpdnt", "custom_id": "135_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ac96967bc1873f5f9e484688ce406332", "body": {"id": "chatcmpl-9St7LsQkMLPXqkyhzEtT61CtknUAO", "object": "chat.completion", "created": 1716672083, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon alfa-2b is a type of recombinant protein used for its antiviral and antineoplastic properties. Here are several key points you should know about it:\n\n1. **Mechanism of Action**:\n   - Interferon alfa-2b binds to specific receptors on the cell surface, initiating a series of intracellular events. These lead to inhibition of viral replication, modulation of the immune response, and suppression of cell proliferation.\n\n2. **Indications**:\n   - It's approved for a variety of conditions including chronic hepatitis B and C, certain types of cancer (like hairy cell leukemia, malignant melanoma, and follicular lymphoma), and other viral infections or malignancies.\n\n3. **Administration**:\n   - It can be administered via subcutaneous, intramuscular, or intravenous routes, depending on the condition being treated.\n\n4. **Adverse Effects**:\n   - Common side effects include flu-like symptoms (fever, chills, fatigue, muscle aches), gastrointestinal disturbances, and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_WZAYTEUYGPBUNUiqoKBYZ3WY", "custom_id": "136_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "efc7165ce36f52b94202e2ff67ad18a8", "body": {"id": "chatcmpl-9St7L6Ya5PiKWMqhwIn5WzFIiCZoP", "object": "chat.completion", "created": 1716672083, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon gamma-1b is a synthetic version of the naturally occurring protein, interferon gamma, which plays a critical role in the immune response. Here are some key points that a physician should know about Interferon gamma-1b:\n\n### Indications\n- **Chronic Granulomatous Disease (CGD):** Interferon gamma-1b is approved for reducing the frequency and severity of serious infections associated with this genetic disorder.\n- **Severe, Malignant Osteopetrosis:** It\u2019s used to delay the progression of this rare bone disease by improving immune system function.\n\n### Mechanism of Action\n- **Immune Modulation:** Interferon gamma-1b enhances the oxidative metabolism of macrophages, which helps in killing certain intracellular pathogens and also enhances antigen processing and presentation to T-lymphocytes.\n- **Activation of Immune Cells:** It activates various immune cells, including macrophages, natural killer cells, and neutrophils, assisting in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_8ZyZdGRN6Fa6C9euow0xRmH2", "custom_id": "137_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "714dd2daa6bafe00f1c635e5c80e3c69", "body": {"id": "chatcmpl-9St7MIeTqBsTEQ0SbIyTfCEZIjlrj", "object": "chat.completion", "created": 1716672084, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ipilimumab is an immune checkpoint inhibitor that can have significant implications for various types of cancer treatment. Here are some key points you should know about it:\n\n1. **Mechanism of Action**:\n   - Ipilimumab is a monoclonal antibody that targets CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4), a checkpoint protein on T cells that downregulates the immune response.\n   - By inhibiting CTLA-4, ipilimumab enhances T-cell activation and proliferation, thereby boosting the immune system's ability to attack cancer cells.\n\n2. **Indications**:\n   - It is primarily used for the treatment of metastatic melanoma.\n   - It has also been approved for use in combination with nivolumab for certain types of advanced renal cell carcinoma, colorectal cancer, and non-small cell lung cancer, among others.\n\n3. **Administration**:\n   - Ipilimumab is given as an intravenous infusion.\n   - The dosing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_g3Kz5fMh7QHTyttBJJ3w0bBV", "custom_id": "138_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "3cbc91b8df4b47dc2c778f5698dd93e2", "body": {"id": "chatcmpl-9St7Mg42rALALc3OBWcOHEdIyJa6O", "object": "chat.completion", "created": 1716672084, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Irinotecan is a chemotherapy drug that is primarily used to treat certain cancers, such as colorectal cancer. Here are some key points that you, as a physician, should be aware of regarding Irinotecan:\n\n### Mechanism of Action:\n- **Irinotecan** is a prodrug that is converted in the body to its active form, SN-38.\n- **SN-38** inhibits topoisomerase I, an enzyme vital for DNA replication. This leads to DNA damage and ultimately the death of rapidly dividing cancer cells.\n\n### Indications:\n- **Colorectal Cancer**: Often used for metastatic colorectal cancer, either alone or in combination with other drugs like 5-fluorouracil (5-FU) and leucovorin.\n- **Other Cancers**: Sometimes used off-label for other cancers such as small-cell lung cancer, pancreatic cancer, and others.\n\n### Administration:\n- **Dosage**: The dosage varies depending on the regimen"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_FClTq1PhufRBdMCCldEdYW8N", "custom_id": "139_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "00dbe5f646bb2aca7acb625ee20a2248", "body": {"id": "chatcmpl-9St7MCfpoXwUUTXG9lfeOtFNP6o8t", "object": "chat.completion", "created": 1716672084, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Irinotecan liposome (marketed under the brand name ONIVYDE, among others) is a liposomal formulation of the chemotherapy agent irinotecan, used primarily in the treatment of certain cancers. Here are some key points a physician should know:\n\n### Indications:\n1. **Pancreatic Cancer:** Irinotecan liposome is specifically approved for use in combination with fluorouracil and leucovorin for the treatment of metastatic pancreatic cancer after disease progression following gemcitabine-based therapy.\n2. **Other Potential Uses:** Research is ongoing for its efficacy in other types of cancer, but the primary indication remains metastatic pancreatic cancer.\n\n### Mechanism of Action:\n1. **Topoisomerase I Inhibitor:** Irinotecan and its active metabolite SN-38 inhibit topoisomerase I, an enzyme involved in DNA replication and transcription. This inhibition leads to DNA damage and cell death.\n2. **Liposomal Formulation:** The lip"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_rhXVvGRmOvT0QRcocKYIzKrc", "custom_id": "140_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "dfef676471738465a765f60d4cceadb0", "body": {"id": "chatcmpl-9St7MTEkbdwSlrtexV7JtTuGd2Zxe", "object": "chat.completion", "created": 1716672084, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Isatuximab, marketed under the brand name Sarclisa, is a monoclonal antibody used primarily in the treatment of multiple myeloma, a type of blood cancer. Here\u2019s what you should know as a physician:\n\n### Mechanism of Action\n- Isatuximab targets the CD38 antigen, which is highly expressed on the surface of multiple myeloma cells.\n- It induces cell death through a variety of mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis via cross-linking.\n\n### Indications\n- Typically indicated for patients with relapsed or refractory multiple myeloma.\n- Often used in combination with other treatments, such as pomalidomide and dexamethasone, or carfilzomib and dexamethasone.\n\n### Administration\n- Administered intravenously.\n- The dosing regimen generally includes an initial weekly phase followed by every two-week maintenance schedules.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_U7MdP340tJw6d77hubkmnwae", "custom_id": "141_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "57e3d20fed9db3f4c1bd807afb254cfc", "body": {"id": "chatcmpl-9St7MJE8pMcuIVT6TcT8Rt1aphowy", "object": "chat.completion", "created": 1716672084, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Isotretinoin is a potent medication primarily used to treat severe acne that has not responded to other treatments. Here are some key points you should know about isotretinoin:\n\n### Indications:\n- **Severe nodular acne**: It\u2019s prescribed for patients with severe nodular acne that hasn't responded adequately to other acne therapies, including antibiotics.\n- **Moderate acne**: In some cases, it is also used for moderate acne that has proven resistant to treatment and is causing physical and psychological distress.\n\n### Mechanism of Action:\n- **Decreases Sebum Production**: Isotretinoin significantly reduces the size and activity of sebaceous glands.\n- **Antibacterial Effect**: While it doesn\u2019t directly kill bacteria, the reduction in sebum creates an environment less conducive to the growth of *Cutibacterium acnes* (formerly *Propionibacterium acnes*).\n- **Anti-inflammatory**: It has anti-inflammatory properties that help reduce acne"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_w6BcGOp9vyH75MmAmlVvl2tl", "custom_id": "142_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b15e7b6c4e9b98bd437f791f6b1e7628", "body": {"id": "chatcmpl-9St7MAGVVvD7kyJErLe5bIhSv9tCT", "object": "chat.completion", "created": 1716672084, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ivosidenib (brand name Tibsovo) is a targeted cancer therapy specifically designed to inhibit isocitrate dehydrogenase 1 (IDH1) mutations. Here are several key points you should know about Ivosidenib:\n\n### Indications:\n1. **Acute Myeloid Leukemia (AML)**: It is primarily indicated for the treatment of adult patients with relapsed or refractory AML and for newly diagnosed AML patients who are over 75 years old or those who have comorbidities precluding the use of intensive chemotherapy.\n2. **Cholangiocarcinoma**: More recently, Ivosidenib has been approved for patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation.\n\n### Mechanism of Action:\n- Ivosidenib specifically inhibits the IDH1 enzyme which is mutated in some cancers. The mutation leads to the production of an oncometabolite known as 2-hydro"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_MNiminLYZcV6K09G56RGFWnk", "custom_id": "143_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0fa19320e81a620f9bb447cf6ab3b730", "body": {"id": "chatcmpl-9St7MzXHOPyz7su50cKanwHodVjiZ", "object": "chat.completion", "created": 1716672084, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sure, as a physician, it is important to have a thorough understanding of Ixabepilone, especially if you are considering it as a treatment option for your patients. Here is an overview:\n\n### Overview:\nIxabepilone is a microtubule inhibitor belonging to the epothilone class of anticancer agents. It is specifically classified as an epothilone B analog.\n\n### Indications:\n- **Breast Cancer**: Ixabepilone is indicated for the treatment of metastatic or locally advanced breast cancer. It is often used in combination with capecitabine for patients resistant to treatment with anthracyclines and taxanes.\n- It is also used as monotherapy in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.\n\n### Mechanism of Action:\n- Ixabepilone binds to and stabilizes microtubules, promoting cell cycle arrest and apoptosis in cancer cells.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_vqjwbr4nZC3maVpN8jZdpTMS", "custom_id": "144_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7d0dbaff916d19d512b0a09f5ceb8c09", "body": {"id": "chatcmpl-9St7NjGFjJAvBeg54XkpyL0Nq6A3k", "object": "chat.completion", "created": 1716672085, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ixazomib (trade name Ninlaro) is an oral proteasome inhibitor used in the treatment of multiple myeloma, particularly in patients who have received at least one prior therapy. Here are key points a physician should be aware of regarding Ixazomib:\n\n### Mechanism of Action\n- **Proteasome Inhibition**: Ixazomib selectively inhibits the 20S proteasome, which is part of the larger 26S proteasome complex responsible for degrading ubiquitinated proteins. By inhibiting this proteasome, Ixazomib disrupts protein homeostasis, leading to an accumulation of misfolded proteins and ultimately causing cell death, particularly in cancer cells that produce large quantities of proteins.\n\n### Indications\n- **Multiple Myeloma**: Ixazomib is approved in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Pq6YsE1lKquj3vGshWJe1HZH", "custom_id": "145_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "80fae948ae23f59d8c7eb089f6bc2076", "body": {"id": "chatcmpl-9St7NFfyN4kYncjzHxcMk0wJlyAyH", "object": "chat.completion", "created": 1716672085, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, there are several critical aspects of Ketoconazole that you should be familiar with:\n\n1. **Indications and Usage**:\n   - Ketoconazole is an antifungal medication used to treat a variety of fungal infections.\n   - It is available in several forms, including oral tablets, topical creams, shampoos, and over-the-counter formulations.\n   - Common uses include treating seborrheic dermatitis, tinea versicolor, cutaneous candidiasis, and systemic fungal infections.\n\n2. **Mechanism of Action**:\n   - Ketoconazole works by inhibiting the cytochrome P450 enzyme 14\u03b1-demethylase, which is necessary for converting lanosterol to ergosterol, an essential component of fungal cell membranes. This leads to increased membrane permeability and ultimately the death of the fungal cell.\n\n3. **Safety and Efficacy**:\n   - **Oral Ketoconazole**: Due to the risk of serious adverse effects, the use of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_AgJ20de1M3k1XG2xJqL2exVH", "custom_id": "146_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e71988834c6d3344069e623f6eeaa2ae", "body": {"id": "chatcmpl-9St7N4UTvGzH6AqgYnsQLYWOPOWrk", "object": "chat.completion", "created": 1716672085, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Certainly! Lanreotide is a synthetic analogue of the naturally occurring hormone somatostatin. It\u2019s primarily used in medical practice for its inhibitory effects on the secretion of various endocrine, neuroendocrine, exocrine, and paracrine functions. Here are some key points a physician should know about Lanreotide:\n\n### Indications:\n1. **Acromegaly**:\n   - Lanreotide is used for long-term treatment in patients with acromegaly, particularly when surgery and/or radiotherapy are not suitable or have not been fully effective.\n   \n2. **Neuroendocrine Tumors**:\n   - It's indicated for the management of symptoms associated with neuroendocrine tumors, including carcinoid syndrome. It can help control hormone-related symptoms and slow tumor growth.\n   \n3. **Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)**:\n   - Lanreotide can be used to treat patients with G"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_T7WlL6EGQ5dgnY27grPi7vqq", "custom_id": "147_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1b303cfbc1cc037d47d39743ad93f079", "body": {"id": "chatcmpl-9St7NPKLeY8szsKSZ1KeUPxVZ4zcb", "object": "chat.completion", "created": 1716672085, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, understanding Lansoprazole is crucial for managing various gastrointestinal conditions effectively. Here are key points to consider:\n\n### Pharmacological Profile:\n- **Class:** Proton Pump Inhibitor (PPI)\n- **Mechanism of Action:** Lansoprazole inhibits the hydrogen-potassium ATPase enzyme system (\"proton pump\") in the gastric parietal cells, resulting in reduced gastric acid secretion.\n\n### Indications:\n- **Gastroesophageal Reflux Disease (GERD)**\n- **Peptic Ulcer Disease** (PUD)\n- **Erosive Esophagitis**\n- **Zollinger-Ellison Syndrome**\n- **Helicobacter pylori Eradication** (in combination with antibiotics)\n- **Pathological Hypersecretory Conditions**\n\n### Dosage and Administration:\n- **Formulations:** Available in delayed-release capsules and orally disintegrating tablets.\n- **Dosage:** Typically 15 mg or 30 mg, usually taken once daily"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_a2d9MbC6CqnO2Wwa3nEsQ6XR", "custom_id": "148_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "fd0729c3dcafe5d9f96390ba6084cf1e", "body": {"id": "chatcmpl-9St7N2Dfmom5UdRiOwv5tQghCCQSn", "object": "chat.completion", "created": 1716672085, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lapatinib is a targeted therapy medication used primarily in the treatment of certain types of breast cancer. Here are key points you should know about Lapatinib:\n\n1. **Mechanism of Action**:\n   - Lapatinib is an oral tyrosine kinase inhibitor (TKI) that targets the intracellular domain of both HER2 (Human Epidermal growth factor Receptor 2) and EGFR (Epidermal Growth Factor Receptor).\n   - It works by inhibiting the tyrosine kinase activity associated with these receptors, thereby interfering with the downstream signaling pathways that promote cancer cell growth and proliferation.\n\n2. **Indications**:\n   - Approved for use in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cancer who have received prior therapy including an anthracycline, a taxane, and trastuzumab.\n   - Also used in combination with letrozole for postmenopausal women with hormone receptor-positive"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_9IQKVnyalIK8hidsPPNaHfR2", "custom_id": "149_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ee18c1aecea37110f7e8f49682585be9", "body": {"id": "chatcmpl-9St7NpPYpfXTLUPm4NSVFbJisB3he", "object": "chat.completion", "created": 1716672085, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Larotrectinib is a targeted cancer therapy and an important agent in the treatment of certain cancers. Here is a comprehensive overview that might be relevant to you as a physician:\n\n### Mechanism of Action\n- **Target**: Larotrectinib is a selective inhibitor of the tropomyosin receptor kinase (TRK) family: TRKA, TRKB, and TRKC.\n- **Action**: It works by blocking the activity of TRK fusion proteins, which can drive cancer growth. TRK gene fusions result from the abnormal joining of a TRK gene with another unrelated gene, leading to uncontrolled cell proliferation.\n\n### Indications\n- **Primary Use**: It's indicated for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation.\n- **Specific Cases**: The tumors should be metastatic or where surgical resection is likely to result in severe morbidity, and there are no satisfactory alternative treatments or the cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_7hJIGwult9X0z67wfUOY3Lbg", "custom_id": "150_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "790432c9f26963bab1573085f66d4078", "body": {"id": "chatcmpl-9St7NBzylGB1vWAyOiQFwkMFVaJsR", "object": "chat.completion", "created": 1716672085, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lenalidomide, marketed under the brand name Revlimid among others, is an oral immunomodulatory drug (IMiD) with antiangiogenic and antineoplastic properties. Given its diverse mechanisms of action and applications, here are some key points you should know about Lenalidomide as a physician:\n\n### Indications:\n1. **Multiple Myeloma**: Often used in combination with dexamethasone or other agents.\n2. **Myelodysplastic Syndromes (MDS)**: Specifically for patients with 5q deletion (del(5q)), with or without additional cytogenetic abnormalities.\n3. **Mantle Cell Lymphoma**: For patients whose disease has relapsed or progressed after two prior therapies.\n\n### Mechanisms of Action:\n1. **Immunomodulatory Effects**: Enhances T-cell and NK cell-mediated cytotoxicity and elevates the production of cytokines like IL-2 and interferons.\n2. **Anti"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_GVbpiIfp5MWaIIyCl8zEhKX7", "custom_id": "151_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a2a038835b11a553c941af192d85d037", "body": {"id": "chatcmpl-9St7OG5wXwtYqRA3XpMAjJungdWzP", "object": "chat.completion", "created": 1716672086, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lenograstim, also known by its recombinant form as granulocyte colony-stimulating factor (G-CSF), is a medication primarily used to stimulate the production of white blood cells, especially neutrophils, in certain clinical situations. Here are key points you should know as a physician:\n\n### Indications:\n1. **Chemotherapy-induced Neutropenia:** Lenograstim is often used to reduce the incidence, duration, and severity of neutropenia in patients undergoing chemotherapy, thereby reducing the risk of infection.\n2. **Bone Marrow Transplantation:** It is used to support patients after bone marrow transplantation by promoting quicker neutrophil recovery.\n3. **Severe Chronic Neutropenia:** It may be prescribed for patients with congenital, cyclic, or idiopathic neutropenia to increase neutrophil counts and reduce the risk of infections.\n\n### Mechanism of Action:\nLenograstim binds to and activates the G-CSF receptor on hematopoietic cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_48JiL0raETUTzC5mXeppMHYc", "custom_id": "152_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ad74fc3e6435f7c2a6e3ddb906d7a5f1", "body": {"id": "chatcmpl-9St7Oa6NU6BrrhFKscMsIqiyVG5sV", "object": "chat.completion", "created": 1716672086, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lenvatinib is a tyrosine kinase inhibitor (TKI) used primarily in oncology. It's essential to understand its indications, mechanism of action, administration, potential side effects, drug interactions, and monitoring requirements. Here are the key points a physician should be aware of:\n\n### Indications\nLenvatinib is approved for treating:\n1. Differentiated thyroid cancer that is refractory to radioactive iodine therapy.\n2. Advanced renal cell carcinoma, especially in combination with everolimus after one prior anti-angiogenic therapy.\n3. Hepatocellular carcinoma for patients who have had no prior systemic therapy.\n4. Advanced endometrial carcinoma (in combination with pembrolizumab) that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), and in cases where disease progressed after prior systemic therapy and patients are not candidates for curative surgery or radiation.\n\n### Mechanism of Action\nLenvatinib works by inhibiting multiple receptor ty"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_JMGxscCPXyEhicKjUVEJ40yX", "custom_id": "153_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b76be52e110356814128f675385bcfa7", "body": {"id": "chatcmpl-9St7OBM5uqNhc6u2jAJ9alM5r9YgC", "object": "chat.completion", "created": 1716672086, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Letrozole is a medication widely used in the field of oncology and reproductive medicine. Here are some crucial points you should be aware of regarding Letrozole:\n\n### Mechanism of Action:\n- **Aromatase Inhibitor**: Letrozole works by inhibiting the enzyme aromatase, which converts androgens into estrogens. By reducing estrogen levels, it helps slow or halt the growth of estrogen receptor-positive (ER+) breast cancer cells.\n\n### Indications:\n- **Breast Cancer**: Primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It is effective in both adjuvant settings (following surgery) and metastatic settings.\n- **Ovulation Induction**: Off-label use for inducing ovulation in women with polycystic ovary syndrome (PCOS) or other ovulatory disorders.\n\n### Administration:\n- **Dosage**: Typically prescribed as a tablet taken once daily. The dosage for breast cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_63LeYx5iKlDjrnyxCQdU7Efl", "custom_id": "154_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a66a1df00e4b58306fe96f7c2b3d7cbf", "body": {"id": "chatcmpl-9St7O8YuVHSsWz6eh2DrLFz74rdzx", "object": "chat.completion", "created": 1716672086, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Leuprolide is a synthetic gonadotropin-releasing hormone (GnRH) analog commonly used in medicine. As a physician, here is what you should know about it:\n\n### Mechanism of Action:\nLeuprolide acts as a GnRH agonist. Initially, it causes a surge in the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a temporary increase in sex hormones (testosterone in men and estrogen in women). However, with continuous administration, it eventually suppresses the release of these hormones by downregulating GnRH receptors in the pituitary gland. This results in reduced production of sex hormones.\n\n### Indications:\nLeuprolide has multiple clinical applications, including:\n- **Prostate cancer:** It is used to lower testosterone levels in advanced prostate cancer.\n- **Endometriosis:** Helps reduce estrogen levels to alleviate symptoms.\n- **Precocious puberty:** Administered to delay puberty in children with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_NItEflsPdWGpzxi0OKP4YdGS", "custom_id": "155_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "61fb203ba85915c42c873d188e7db6ea", "body": {"id": "chatcmpl-9St7OZLiWz43VKEZoAQw7hlI5d5YT", "object": "chat.completion", "created": 1716672086, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Levamisole is a medication primarily known for its use in veterinary medicine as an anthelmintic, which means it expels parasitic worms and other internal parasites. However, it has had some historical use in human medicine, particularly in immunomodulatory contexts and adjuvant chemotherapy.\n\nHere are key points you should know about Levamisole:\n\n1. **Mechanism of Action**: Levamisole works as an antiparasitic through its action on the nervous system of the parasites, causing paralysis and subsequent expulsion from the host body. Its immunomodulatory effects are believed to be due to the stimulation of T-lymphocyte activity and the enhancement of monocytes and macrophages.\n\n2. **Human Medicine Use**:\n   - **Past Use in Autoimmune and Inflammatory Conditions**: In the past, Levamisole was sometimes used as an immunomodulatory agent for conditions like rheumatoid arthritis and systemic lupus erythematosus.\n   - **Adjuvant Therapy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_NrNgg6eySNb5SmwLQ67r8N9U", "custom_id": "156_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "71ddc04248bd189f92002f76707e6bf7", "body": {"id": "chatcmpl-9St7OLLm7KV4LNwso8cGldx0TYhvI", "object": "chat.completion", "created": 1716672086, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Levoleucovorin is a medication that you may encounter in various clinical contexts, often in oncology and hematology. Here are some key points about Levoleucovorin that you should know:\n\n### General Information\n- **Description**: Levoleucovorin is the active enantiomer of racemic leucovorin (folinic acid). It is used to diminish the toxic effects of folic acid antagonists such as methotrexate, and to enhance the efficacy of fluoropyrimidines such as fluorouracil.\n- **Brand Names**: Common brand names include Fusilev.\n\n### Indications\n- **Methotrexate Toxicity**: Levoleucovorin is used as a rescue agent after high-dose methotrexate therapy to prevent or treat methotrexate-induced toxicity.\n- **5-Fluorouracil (5-FU) Potentiation**: It is used in combination with 5-FU to enhance the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_v0YKBx42vqOUSXpQiwnpcnOO", "custom_id": "157_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "26d235cc4745b410118bc991fe972425", "body": {"id": "chatcmpl-9St7O5Es0Hzz30QCupIrKC56Q50QV", "object": "chat.completion", "created": 1716672086, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lomustine (also known as CCNU) is an oral anticancer drug that belongs to the class of alkylating agents. Its main mechanism of action involves the alkylation of DNA and RNA, leading to cross-linking and strand breakage, which ultimately disrupts the growth of cancer cells. Here are several key points a physician should know about Lomustine:\n\n### Indications:\n1. **Primary Use:** Lomustine is primarily used to treat brain tumors, including glioblastoma multiforme.\n2. **Other Uses:** It may also be used in the treatment of Hodgkin's lymphoma, particularly in cases where the disease is refractory or relapsed after initial treatment.\n\n### Administration:\n1. **Oral Medication:** Lomustine is available in capsule form and is typically taken once every 6 weeks to allow the bone marrow time to recover.\n2. **Dosing:** The exact dosage is usually based on the patient's body surface area (BSA) and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_y5ZcC9BOuMU3lUmP3K2h8k95", "custom_id": "158_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "37da3e9fc14c5dd2dc21f6c08668ac5a", "body": {"id": "chatcmpl-9St7PLj9plKkPfw88Zpsei9iSnkVw", "object": "chat.completion", "created": 1716672087, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lorlatinib is a third-generation small molecule tyrosine kinase inhibitor (TKI) specifically designed to target certain types of anaplastic lymphoma kinase (ALK)-positive and ROS1-positive non-small cell lung cancer (NSCLC). Here are key points that physicians should consider:\n\n### Indications\n- **ALK-Positive NSCLC**: It is indicated for the treatment of adult patients with ALK-positive metastatic NSCLC who have progressed on (or are intolerant to) prior ALK TKIs.\n- **ROS1-Positive NSCLC**: It is also indicated for patients with ROS1-positive metastatic NSCLC.\n\n### Mechanism of Action\n- Lorlatinib selectively inhibits ALK and ROS1 tyrosine kinases, blocking the proliferation of cancer cells that harbor mutations or rearrangements in these genes.\n\n### Administration\n- **Dosage**: The typical dose is 100 mg taken orally once daily. It can be taken with or without food.\n- **Adjustments**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_uDyJSRmJagHRCCgK7Bx8oEPs", "custom_id": "159_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "57bfe0d9f530d84e3424f56bd3a2c599", "body": {"id": "chatcmpl-9St7P8B5QbgpgN73Cl6WIvjzk8DIx", "object": "chat.completion", "created": 1716672087, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lutetium Lu 177 dotatate, marketed under the brand name Lutathera, is a radiopharmaceutical used in the treatment of certain types of neuroendocrine tumors (NETs). Here is a comprehensive overview of what you should know about Lutetium Lu 177 dotatate:\n\n### Indications\n- Primarily indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.\n  \n### Mechanism of Action\n- Lutetium Lu 177 dotatate is a form of peptide receptor radionuclide therapy (PRRT). It works by binding to somatostatin receptors, which are highly expressed in certain neuroendocrine tumor cells. After binding, it delivers targeted radiation to the tumor cells, causing cellular damage and death.\n\n### Administration\n- Lutetium Lu 177 dotat"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_lHZBxSrzsDSggTu5W0xjjX01", "custom_id": "160_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "263463ecd802074b984d3418d1de4316", "body": {"id": "chatcmpl-9St7PngaqIPOJd7OS3urv8ZzaEGQO", "object": "chat.completion", "created": 1716672087, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tafasitamab (also known by its brand name Monjuvi) is a targeted immunotherapy drug used primarily in the treatment of certain types of B-cell non-Hodgkin lymphomas, specifically relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Here are some key points you should know about Tafasitamab:\n\n### Mechanism of Action\n- **Target**: Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody.\n- **Function**: By binding to the CD19 antigen on the surface of B-cells, Tafasitamab induces cell death through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and direct apoptosis induction.\n\n### Indications\n- Tafasitamab is indicated for the treatment of adult patients with relapse or refractory DLBCL, including those who are not eligible for autologous stem cell transplantation (AS"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_7MLp3162hoZrxNogCYQBdvkE", "custom_id": "161_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "c1072113a7fe2638e386b491c7787b1d", "body": {"id": "chatcmpl-9St7PF3H521lMojbto6L9ClbIgOjN", "object": "chat.completion", "created": 1716672087, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mechlorethamine, also known as nitrogen mustard, is a chemotherapy agent that falls under the class of alkylating agents. Here are key points that a physician should know about Mechlorethamine:\n\n### Indications\n- **Hodgkin's Disease**: Part of the MOPP regimen (Mechlorethamine, Vincristine, Procarbazine, Prednisone).\n- **Non-Hodgkin's Lymphoma**: Used in specific combinations.\n- **Cutaneous T-cell Lymphoma**: Often as a topical formulation.\n\n### Mechanism of Action\n- **Alkylating Agent**: Cross-links DNA strands, thereby inhibiting DNA replication and RNA transcription, leading to cell death. Targets rapidly dividing cells.\n\n### Administration\n- **Intravenous (IV)**: The most traditional method for systemic cancers.\n- **Topical**: For skin involvement, as in cutaneous lymphomas.\n\n### Dosage and Schedule\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_mpGXXIhm2BOhCVNMsxZFKBdr", "custom_id": "162_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "c104dbb5fe79274afd4dac0aa7c8f8ea", "body": {"id": "chatcmpl-9St7PrS5xO3zXWLSb83Hh0NOvUbZm", "object": "chat.completion", "created": 1716672087, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Medroxyprogesterone is a synthetic derivative of the naturally occurring hormone progesterone. It's commonly used in various medical settings, and as a physician, you should be familiar with its indications, mechanisms of action, dosing, contraindications, side effects, and important patient counseling points. Here are some key aspects:\n\n### Indications:\n1. **Contraception**: Depo-Provera (medroxyprogesterone acetate) is an injectable form used as a long-term contraceptive.\n2. **Hormone Replacement Therapy (HRT)**: Used in combination with estrogen to prevent endometrial hyperplasia in postmenopausal women undergoing estrogen replacement therapy.\n3. **Menstrual Disorders**: Used to treat secondary amenorrhea, abnormal uterine bleeding due to hormonal imbalance, and for the management of endometriosis.\n4. **Cancer Treatment**: Used in certain cases of endometrial and renal carcinoma.\n\n### Mechanism of Action:\nMedroxyprogesterone"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_oUD0Yr58ckI2bN7tYGnzC3IU", "custom_id": "163_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f7d4392ecc9ec366a7837c9b7e7f82a3", "body": {"id": "chatcmpl-9St7PLj0tprxdzEzWS33wMCDqptUs", "object": "chat.completion", "created": 1716672087, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Megestrol is a synthetic progestin, a derivative of the hormone progesterone, and it is commonly used in various clinical settings. Here are some essential points you should be aware of regarding Megestrol:\n\n### Indications:\n1. **Appetite Stimulation and Weight Gain**:\n   - Primarily used to treat significant weight loss or anorexia in patients with cancer or AIDS.\n   - Helps improve appetite and promote weight gain in these conditions.\n\n2. **Palliative Treatment in Cancer**:\n   - Used for palliative management of advanced, recurrent, or metastatic endometrial and breast cancer.\n\n3. **Off-Label Uses**:\n   - Sometimes used off-label to manage hot flashes in men undergoing androgen-deprivation therapy for prostate cancer or women experiencing menopausal symptoms.\n\n### Mechanism of Action:\n- Megestrol exerts its effects by binding to progesterone receptors, leading to changes in the endometrial lining and potential anti-estrogen effects at higher doses.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_4iGGglF1Ifc5KCJEzffkQnA7", "custom_id": "164_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0999c45e11fbbe260b4d10f4596ab5e0", "body": {"id": "chatcmpl-9St7PDshcuj418E3RF19tvTlvAWnC", "object": "chat.completion", "created": 1716672087, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Melphalan is a chemotherapy medication used to treat multiple myeloma, ovarian cancer, and certain types of leukemia, among other conditions. As a physician, here are several key points you should know:\n\n### Mechanism of Action:\n- **Alkylating Agent**: Melphalan belongs to the class of alkylating agents. It works by cross-linking DNA strands, thereby inhibiting DNA replication and transcription which leads to cell cycle arrest and apoptosis.\n\n### Indications:\n- **Multiple Myeloma**: Melphalan is commonly used in combination with other drugs such as prednisone for treating multiple myeloma.\n- **Ovarian Cancer**: It is also indicated for use in palliative treatment of ovarian carcinoma.\n- **Bone Marrow Transplantation**: It can be used as a part of conditioning regimes before a bone marrow transplant.\n\n### Administration:\n- **Oral**: Available in tablet form.\n- **Intravenous (IV)**: Also available"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Cv5gj4WLF8syiu84DkgRkGQb", "custom_id": "165_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "aa68e502303117877e7f7c2580cd4905", "body": {"id": "chatcmpl-9St7P7XsmDxEIxdG2WXu2i3ZG7IpF", "object": "chat.completion", "created": 1716672087, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it\u2019s important to be well-versed with the pharmacological, therapeutic, and safety aspects of mercaptopurine (6-MP). Here are some key points:\n\n### Pharmacology\n1. **Mechanism of Action:**\n   - Mercaptopurine is a purine analog that interferes with nucleic acid synthesis. It is incorporated into DNA and RNA, leading to cytotoxic effects, especially in rapidly dividing cells.\n   - It inhibits purine nucleotide synthesis and metabolism, which is crucial for DNA replication and cell division.\n\n### Indications\n1. **Acute Lymphoblastic Leukemia (ALL):**\n   - Often used as part of the maintenance therapy for Acute Lymphoblastic Leukemia.\n2. **Chronic Myeloid Leukemia (CML):**\n   - Occasionally used in certain regimens.\n3. **Inflammatory Bowel Disease (IBD):**\n   - Used off-label for Crohn\u2019s disease and ulcer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_saIxmjNjS8sdUIc1BNip3GsA", "custom_id": "166_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b5435fe61fc322e32cb0eb791369241c", "body": {"id": "chatcmpl-9St7PKI0SOMtp0PyapEn1efM2Qw4t", "object": "chat.completion", "created": 1716672087, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mesna (sodium 2-mercaptoethane sulfonate) is a medication commonly used in oncology practice to reduce the risk of hemorrhagic cystitis, a potential adverse effect of certain chemotherapeutic agents, notably ifosfamide and cyclophosphamide. As a physician, here are several key points you should be aware of regarding Mesna:\n\n1. **Mechanism of Action**:\n   - Mesna acts as a uroprotective agent. It works by binding to acrolein, a toxic metabolite of cyclophosphamide and ifosfamide, forming a non-toxic compound that can then be excreted in the urine, preventing damage to the bladder lining.\n\n2. **Indications**:\n   - Mesna is primarily indicated for the prevention of ifosfamide-induced hemorrhagic cystitis.\n   - It may also be used in patients receiving high doses of cyclophosphamide.\n\n3. **Dosage and Administration**:\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5WpPdg8AlSHsLX7By2nc5avD", "custom_id": "167_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7ce69c518fff61cdf5ab2fcb887a82cc", "body": {"id": "chatcmpl-9St7PdND6m7NL0PynCtCeCyt0aRUF", "object": "chat.completion", "created": 1716672087, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Methotrexate is a potent medication used in various medical fields, including oncology, rheumatology, and dermatology. Below are key points a physician should be aware of regarding Methotrexate:\n\n### Indications:\n\n- **Oncology**: Used for certain cancers, such as acute lymphoblastic leukemia (ALL), non-Hodgkin\u2019s lymphoma, and osteosarcoma.\n- **Rheumatology**: Commonly used for autoimmune diseases like rheumatoid arthritis (RA) and psoriatic arthritis.\n- **Dermatology**: Employed in the treatment of severe psoriasis.\n- **Other**: Also used in ectopic pregnancy management and inflammatory bowel disease (IBD).\n\n### Mechanism of Action:\n\n- **Anti-metabolite**: Methotrexate inhibits dihydrofolate reductase (DHFR), reducing tetrahydrofolate availability. This inhibits DNA synthesis, replication, and repair in rapidly dividing cells.\n\n### Dosing:\n\n- D"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_L2VZR4raZlS12kfnnKpVLCc7", "custom_id": "168_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "45fac53f0622fecc9c1ba27576e8d920", "body": {"id": "chatcmpl-9St7Pobyjj27xwERVfaxQgPr6mEgF", "object": "chat.completion", "created": 1716672087, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Methoxsalen, also known as 8-methoxypsoralen or by the brand name Oxsoralen, is a drug used primarily in combination with UVA light therapy (PUVA) for the treatment of psoriasis, vitiligo, and certain types of cutaneous T-cell lymphoma. Here are key points you should be aware of:\n\n### Mechanism of Action\n- **Photosensitizer**: Methoxsalen is a psoralen derivative that, when activated by UVA light, forms interstrand crosslinks in DNA, thereby inhibiting DNA synthesis and cell proliferation.\n  \n### Indications\n- **Psoriasis**: Especially useful for widespread or refractory cases.\n- **Vitiligo**: Can help repigment the skin in some cases.\n- **Cutaneous T-cell Lymphoma**: Used as part of PUVA therapy.\n\n### Administration\n- **Oral**: Typically, methoxsalen is taken 1.5-2 hours"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_FoFbIhLhKf4YU6Pb1dIKmfEy", "custom_id": "169_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8a293ce60267ad34dc57b8a70371f3b7", "body": {"id": "chatcmpl-9St7PfGAuZxs2l5GGkzpDrh8U5HKj", "object": "chat.completion", "created": 1716672087, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Methylprednisolone is a corticosteroid drug often prescribed to reduce inflammation and suppress the immune system. Here are key points you should know:\n\n1. **Mechanism of Action**: Methylprednisolone works by mimicking the effects of hormones your body produces naturally in the adrenal glands. It suppresses inflammation and modulates the immune response.\n\n2. **Indications**: It is used to treat a variety of conditions including allergies, asthma, autoimmune diseases (e.g., lupus, rheumatoid arthritis), skin conditions, and certain types of cancers. It's also used for acute exacerbations of chronic conditions like multiple sclerosis.\n\n3. **Forms & Administration**: Methylprednisolone is available in various forms including tablets, injectable solutions, and topical creams. The mode of administration depends on the condition being treated\u2014oral for systemic issues, injections for localized or severe systemic issues, and topical for skin conditions.\n\n4. **Dosing**: Dosing varies widely depending on the condition treated"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Iq1CEhCuZNxuNcd8fBvq3t6L", "custom_id": "170_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7eabe987cea3c566f4b0f80b2f02281f", "body": {"id": "chatcmpl-9St7Ppt3Bwum8ExNC2SJNg9dWlGmC", "object": "chat.completion", "created": 1716672087, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Midostaurin is an orally bioavailable multi-targeted kinase inhibitor primarily used in the treatment of acute myeloid leukemia (AML) and advanced systemic mastocytosis. Here are key points you should know as a physician:\n\n### Indications\n1. **Acute Myeloid Leukemia (AML)**\n   - Midostaurin is indicated for the treatment of adult patients with newly diagnosed AML that is FLT3-mutated, as detected by an FDA-approved test.\n2. **Systemic Mastocytosis**\n   - It is also approved for the treatment of aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), and mast cell leukemia.\n\n### Mechanism of Action\n- Midostaurin inhibits multiple kinases, including FLT3, KIT, PDGFR (platelet-derived growth factor receptors), and others, leading to the inhibition of cellular proliferation, induction of apoptosis, and decreased tumor growth.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_inC08PZP7TQ0gPGzkDPDKRAQ", "custom_id": "171_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b3f92f6fa73c05cf47679d16ae54064f", "body": {"id": "chatcmpl-9St7PJs3HmYOjLaWNlNFoc6zZF8oN", "object": "chat.completion", "created": 1716672087, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mitomycin is an important chemotherapeutic agent primarily used in oncology for its anti-tumor properties. As a physician, here are key points you should be aware of regarding Mitomycin:\n\n### Mechanism of Action\n- **DNA Crosslinking:** Mitomycin exerts its effects by alkylating and cross-linking DNA, which inhibits DNA synthesis and transcription, ultimately leading to cell death.\n\n### Indications\n- **Cancer Treatments:** Mitomycin is used to treat various cancers, including stomach, pancreatic, anal, bladder, and breast cancers. It's often part of combination chemotherapy regimens.\n- **Topical Application:** In ophthalmology, a topical form is used to prevent scarring in certain eye surgeries.\n\n### Administration\n- **Routes:** Mitomycin can be administered intravenously, and in some cases, as an intravesical therapy (directly into the bladder) for bladder cancer.\n- **Dosage:** Dosage varies depending on the type and stage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_tRirYFf3SrFQ4HxyzAbp5OZ0", "custom_id": "172_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a3874e5e8bf57f8bc46ac228af090951", "body": {"id": "chatcmpl-9St7PAc66CvqGxh6QHHegHelTJpXt", "object": "chat.completion", "created": 1716672087, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mitotane is an antineoplastic medication mainly used in the treatment of adrenocortical carcinoma, a rare and aggressive cancer of the adrenal cortex. It acts by inhibiting steroidogenesis and has cytotoxic effects on the adrenal cortex cells. Here are some key points you should know about Mitotane:\n\n1. **Mechanism of Action**: Mitotane modifies peripheral metabolism of steroids and directly suppresses the adrenal cortex, leading to atrophy of the adrenal gland. It reduces the production of cortisol and other adrenal steroids.\n\n2. **Indications**: \n   - Primary indication is adrenocortical carcinoma, especially in cases where surgery is not feasible or as an adjuvant therapy to surgical intervention.\n   - Sometimes used off-label for Cushing's syndrome due to ectopic ACTH production.\n\n3. **Administration and Dosage**:\n   - Typically administered orally.\n   - Dosage varies based on the individual patient condition, tolerance, and treatment response. Initial"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_wQOB75ghNX4PljjJYK74y9m6", "custom_id": "173_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "dff1a95e0b0a8fe55cd7612ae9d5ed50", "body": {"id": "chatcmpl-9St7QwOan3OEzy6gcFUwjnwuvl9AS", "object": "chat.completion", "created": 1716672088, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mitoxantrone is an antineoplastic (anti-cancer) drug that belongs to the class of medications known as anthracenediones. As a physician, it\u2019s important to understand the following key points about Mitoxantrone:\n\n### Indications:\n1. **Cancer Treatments**:\n   - Approved for use in treating certain types of cancer, including:\n     - Acute myeloid leukemia (AML) in adults.\n     - Advanced prostate cancer that is resistant to hormone therapy (hormone-refractory prostate cancer).\n     - Relapsing forms of multiple sclerosis to reduce neurological disability and the frequency of clinical relapses.\n\n### Mechanism of Action:\n- Mitoxantrone works by intercalating into DNA, inhibiting both DNA and RNA synthesis. It also interferes with topoisomerase II, an enzyme critical for DNA repair, leading to cell death. Its primary action is cytotoxic to both proliferating and non-proliferating cells.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Ke8tg00NP8Jvc2JIleeH8IJJ", "custom_id": "174_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0f9e4e3d6ef52e5aa83c89bfde133834", "body": {"id": "chatcmpl-9St7QIKdjRMOxMn7RU14GCn3Le6Pj", "object": "chat.completion", "created": 1716672088, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mogamulizumab is a humanized monoclonal antibody used in the treatment of certain types of cancers, specifically cutaneous T-cell lymphoma (CTCL) and adult T-cell leukemia/lymphoma (ATLL). Here are some key points you should know about Mogamulizumab:\n\n### Mechanism of Action\n- **Target:** Mogamulizumab targets CC chemokine receptor 4 (CCR4), which is frequently overexpressed on the surface of certain cancer cells, particularly in CTCL and ATLL.\n- **Function:** By binding to CCR4, Mogamulizumab induces antibody-dependent cellular cytotoxicity (ADCC) and can directly kill these cancer cells.\n\n### Indications\n- **FDA Approved Uses:** Mogamulizumab is approved for use in patients with relapsed or refractory Mycosis Fungoides (MF) or S\u00e9zary Syndrome (SS), which are subtypes of CTCL.\n- **Other Uses:** It's also used in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_CiVd8pGJUA66Dy5kPm1lhrTJ", "custom_id": "175_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f82d0406caee45f7c38e039144f213b2", "body": {"id": "chatcmpl-9St7Q3Wri0K6DJYv88cDJYTgQCXwY", "object": "chat.completion", "created": 1716672088, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Moxetumomab pasudotox is a targeted therapy used primarily for the treatment of relapsed or refractory hairy cell leukemia (HCL). It's a recombinant immunotoxin specifically designed to target CD22, a cell surface antigen commonly expressed in B-cell malignancies including HCL. Here are key points you should know:\n\n### Mechanism of Action\n- **Targeting CD22:** Moxetumomab pasudotox binds to the CD22 antigen on B-cells.\n- **Internalization and Cytotoxicity:** Upon binding, the drug is internalized by the cell, where it releases a bacterial toxin (PE38, a truncated form of Pseudomonas exotoxin) that inhibits protein synthesis, leading to cell death.\n\n### Indications\n- **Hairy Cell Leukemia (HCL):** It's approved for use in adult patients who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.\n\n### Administration\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_g7k9QHKGnhG9SQwbl30kVdxk", "custom_id": "176_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d30fa86205013425acdd70b4e042c57f", "body": {"id": "chatcmpl-9St7Qw8KcqmntzyWxc3Qve8GjmLPF", "object": "chat.completion", "created": 1716672088, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nadroparin is a low molecular weight heparin (LMWH) that is primarily used for its anticoagulant properties. As a physician, you should be aware of several key aspects of nadroparin:\n\n### Indications:\n1. **Prophylaxis of Venous Thromboembolism (VTE):** Frequently used in patients undergoing surgery and those who are immobilized.\n2. **Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE):** Used both in acute settings and for secondary prevention.\n3. **Anticoagulation in Unstable Angina and Non-Q-Wave Myocardial Infarction (MI):** Nadroparin can help prevent clot progression and recurrence.\n4. **Prophylactic use in extracorporeal circulation in hemodialysis.**\n\n### Mechanism of Action:\n- Nadroparin potentiates the activity of antithrombin III, inhib"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_nmNxJsjZDO8NYvA5WJzznqUC", "custom_id": "177_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f14dd591dea0f8f39ccb2e4c67b972b5", "body": {"id": "chatcmpl-9St7QEBf8lNMAGvhyHC0Xukq7qS4r", "object": "chat.completion", "created": 1716672088, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Necitumumab is a monoclonal antibody used in oncology, specifically for the treatment of certain types of lung cancer. Here's what you should know about it:\n\n1. **Mechanism of Action:**\n   - Necitumumab targets the epidermal growth factor receptor (EGFR), a protein found on the surface of some cells and involved in cell growth and survival. By binding to EGFR, necitumumab inhibits its activation, thereby slowing tumor growth and proliferation.\n\n2. **Indications:**\n   - Necitumumab is primarily indicated for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC). It is typically used in combination with chemotherapy agents such as gemcitabine and cisplatin.\n\n3. **Administration:**\n   - Necitumumab is administered intravenously. The recommended dose is 800 mg given on Days 1 and 8 of each 3-week cycle.\n\n4. **Efficacy:**\n   - Clinical trials have shown that"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_P9qf7gW79AHnznQSZRgSGUKw", "custom_id": "178_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "3f8d02e72c0a398ad8c7f39d05a606d9", "body": {"id": "chatcmpl-9St7RilEu3gTAW0UBgicSgxm5Nahg", "object": "chat.completion", "created": 1716672089, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nedaplatin is a platinum-based chemotherapy drug, similar to cisplatin and carboplatin, used primarily in the treatment of various cancers. Here are some key points you should know as a physician:\n\n1. **Mechanism of Action**:\n   - Nedaplatin, like other platinum compounds, forms DNA adducts and intrastrand cross-links, which inhibit DNA synthesis and repair, leading to cell death. This makes it effective in treating rapidly dividing cancer cells.\n\n2. **Indications**:\n   - Nedaplatin is used to treat several types of cancers, including those of the lungs, esophagus, head and neck, and bladder. Its use can be specific to certain cancer protocols and may differ depending on regional medical guidelines.\n\n3. **Administration**:\n   - Nedaplatin is typically administered via intravenous infusion. The dosage and schedule depend on the type of cancer being treated, the patient's overall health, and response to therapy.\n\n4. **Side Effects**:\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_rCgM7QMjydKs1vxgioI2wqHa", "custom_id": "179_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "23f95a262ac4a8f5469cf26767f3dd08", "body": {"id": "chatcmpl-9St7QRK0e41qjz2PwNLIaJPgrPbAD", "object": "chat.completion", "created": 1716672088, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nelarabine is an anticancer chemotherapy drug classified as a purine nucleoside analog. It is primarily used in the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). Here are some key points you should know about Nelarabine:\n\n1. **Mechanism of Action:**\n   - Nelarabine is a prodrug of 9-\u03b2-D-arabinofuranosylguanine (ara-G). After administration, it is converted into ara-GTP, which incorporates into DNA and RNA, ultimately leading to cell death, particularly in T-lymphoblasts.\n\n2. **Indications:**\n   - It is indicated for patients with T-ALL and T-LBL who have not responded to or have relapsed following at least two chemotherapy regimens.\n   - Its use is often considered in cases where other treatments have failed.\n\n3. **Administration:**\n   - Nelarabine is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_6nDAGayMxE0BVexubt3qiieZ", "custom_id": "180_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "811a3010d1bb5bef7af88e0bba7b70b0", "body": {"id": "chatcmpl-9St7QCTdqoGqR8j1hlnpgDpeu5RYl", "object": "chat.completion", "created": 1716672088, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Neratinib is an oral tyrosine kinase inhibitor that targets the HER2 receptor, which is overexpressed in some types of cancer, notably certain breast cancers. Here are some key points you should be aware of as a physician:\n\n### Indications\n- **Breast Cancer**: Neratinib is primarily used for the extended adjuvant treatment of HER2-positive early-stage breast cancer to reduce the risk of recurrence. \n- **Metastatic Breast Cancer**: It can also be used in combination with other chemotherapies for the treatment of HER2-positive metastatic breast cancer.\n\n### Mechanism of Action\n- Neratinib irreversibly binds to the tyrosine kinase domains of HER1, HER2, and HER4, inhibiting cell proliferation and promoting apoptosis in HER2-overexpressing tumor cells.\n\n### Administration and Dosage\n- **Dosing**: Typically, the recommended dose is 240 mg (six 40 mg tablets) taken orally once"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_M5hTkqVOV1x96NMYNOW0u6Qb", "custom_id": "181_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1664b3522058a27bbe115b664dcfb7ba", "body": {"id": "chatcmpl-9St7QXFo23QiW4iwC63xONCVzSiNR", "object": "chat.completion", "created": 1716672088, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be aware of several key aspects of Nilotinib, a tyrosine kinase inhibitor primarily used to treat certain types of leukemia. Here's a comprehensive overview:\n\n### Indications:\n1. **Chronic Myeloid Leukemia (CML):**\n   - Nilotinib is approved for the treatment of adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic or accelerated phase after resistance or intolerance to prior therapy including imatinib.\n   - It is also used as a first-line treatment for newly diagnosed Ph+ CML in the chronic phase.\n\n### Mechanism of Action:\n- Nilotinib works by inhibiting the BCR-ABL kinase, which is produced by the Philadelphia chromosome abnormality in CML. This kinase is responsible for the uncontrolled proliferation of leukemic cells.\n\n### Administration:\n- **Dosage:** \n  - The usual dose is 300 mg twice daily for newly diagnosed CML and 400 mg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_nouzM6XBhPbXCD8iiwbkxevl", "custom_id": "182_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "dda1cc3277ac2391f8c5f0b890794624", "body": {"id": "chatcmpl-9St7Q8ZhyGubdUztvcmuUOLeioXnD", "object": "chat.completion", "created": 1716672088, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nilutamide is a nonsteroidal antiandrogen (NSAA) primarily used in the treatment of prostate cancer. It works by inhibiting the action of androgens (male hormones) at the androgen receptor, which can slow or stop the growth of androgen-dependent cancer cells. Here are some important points you should know about Nilutamide:\n\n### Indications:\n1. **Prostate Cancer:** Nilutamide is typically used in combination with surgical castration (orchiectomy) for the treatment of metastatic prostate cancer. It is an alternative to other antiandrogens and is often used in patients who do not tolerate or respond to other therapies.\n\n### Mechanism of Action:\n- **Androgen Receptor Antagonism:** Nilutamide binds to androgen receptors, preventing androgens like testosterone and dihydrotestosterone from binding. This inhibits the growth of cancer cells that are dependent on these hormones.\n  \n### Dosing:\n- The usual starting dose is 300 mg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_YQs50XtZcASTbTGYebA4BNYr", "custom_id": "183_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "90320d095f2243f56caf6515ebb3dd90", "body": {"id": "chatcmpl-9St7RkSorcQMB8dAIeUGVL4iljUtf", "object": "chat.completion", "created": 1716672089, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nimustine, also known by its trade name ACNU, is a chemotherapeutic agent that belongs to the nitrosourea class. As a physician, there are several important considerations and facts you should be aware of regarding Nimustine:\n\n### Mechanism of Action:\n- **Alkylating Agent:** Nimustine works by alkylating DNA and RNA, leading to the disruption of DNA synthesis and function, which eventually causes cell death. \n- **Crosses Blood-Brain Barrier:** Due to its lipophilic nature, it effectively crosses the blood-brain barrier, making it particularly useful for treating primary and metastatic brain tumors.\n\n### Indications:\n- **Primary Use:** It is primarily used for the treatment of brain tumors, including gliomas and astrocytomas.\n- **Other Cancers:** While its main use is in brain tumors, Nimustine might also be used in other malignancies as part of combination therapies.\n\n### Dosage and Administration:\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_7dgIjJq5XHttieUFZGRDxuzN", "custom_id": "184_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "3123ecb35c6091d960e99922ce9a19d8", "body": {"id": "chatcmpl-9St7RI8W0wNOqPBTPavV1VJrpoUJZ", "object": "chat.completion", "created": 1716672089, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nintedanib, marketed under brand names such as Ofev, is a medication used to treat certain types of lung diseases, including idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases, as well as non-small cell lung cancer (NSCLC). Here are several important aspects a physician should be aware of regarding Nintedanib:\n\n### Mechanism of Action:\n- **Nintedanib** is a tyrosine kinase inhibitor that targets multiple pathways involved in fibrosis and angiogenesis. It inhibits receptors such as platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and vascular endothelial growth factor receptor (VEGFR).\n\n### Indications:\n1. **Idiopathic Pulmonary Fibrosis (IPF):**\n   - Used to slow the rate of decline in lung function in patients with IPF.\n2. **Other Progressive Fibrosing Interstitial Lung Diseases:** \n   - To slow the rate of decline"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_uT59E6nBLcJSxzo5RuXszZCj", "custom_id": "185_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8ecec33e55bad8337a61fcc3b96cc5c1", "body": {"id": "chatcmpl-9St7RlAQhMGN7lbRHq2xuGctrgZTS", "object": "chat.completion", "created": 1716672089, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Niraparib (brand name: Zejula) is an oral pharmaceutical drug that belongs to a class of medications called poly (ADP-ribose) polymerase (PARP) inhibitors. It is primarily used in the treatment of certain types of ovarian cancer. Here are some essential points you should know as a physician:\n\n### Indications and Usage:\n1. **Ovarian Cancer**: Niraparib is approved for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\n2. **First-line Maintenance**: It is also approved for use as a maintenance treatment in patients with advanced ovarian cancer who have responded to first-line platinum-based chemotherapy, regardless of BRCA mutation status.\n\n### Mechanism of Action:\n- Niraparib inhibits PARP enzymes, which are involved in DNA repair. By blocking these enzymes, it leads to increased DNA damage in cancer cells, particularly"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_yE1Ltm4PtqCQSGCgEmUKNyej", "custom_id": "186_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "c1dbd46f01601d42bed1893d283951d1", "body": {"id": "chatcmpl-9St7RAKK1Z3xGh5qso9GEXjfDcARF", "object": "chat.completion", "created": 1716672089, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nivolumab is an immunotherapy drug that is classified as a PD-1 (programmed death-1) checkpoint inhibitor. Here are some key points you should know about Nivolumab:\n\n1. **Mechanism of Action**:\n   - Nivolumab works by blocking the PD-1 receptor on T-cells. This receptor normally interacts with PD-L1 and PD-L2 on tumor cells and other cells in the body to downregulate immune responses. By inhibiting this interaction, Nivolumab boosts the immune system's ability to fight cancer cells.\n\n2. **Indications**:\n   - Nivolumab is approved for use in several types of cancer, either as monotherapy or in combination with other therapies. These include:\n     - Melanoma\n     - Non-Small Cell Lung Cancer (NSCLC)\n     - Renal Cell Carcinoma (RCC)\n     - Hodgkin Lymphoma\n     - Squamous Cell Carcin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_OuEx9kHVpFlsO5rtKoovDqyN", "custom_id": "187_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "86042efdd1b9ea0f0fc51a70abc291cb", "body": {"id": "chatcmpl-9St7RfZ3LEawXAED1OzJVa5BdVYxQ", "object": "chat.completion", "created": 1716672089, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, there are several key points you should know about non-pegylated liposomal doxorubicin:\n\n1. **Mechanism of Action**:\n   - Non-pegylated liposomal doxorubicin works similarly to conventional doxorubicin by intercalating DNA strands, inhibiting topoisomerase II enzyme, and generating free radicals, ultimately blocking cancer cell replication and leading to cell death.\n   - The liposomal formulation helps improve drug delivery to the tumor site while potentially reducing systemic toxicity compared to free doxorubicin.\n\n2. **Indications**:\n   - It is typically indicated for use in various solid tumors and hematologic malignancies, including metastatic breast cancer, ovarian cancer, and multiple myeloma (often in combination with other drugs) as well as Kaposi's sarcoma.\n\n3. **Pharmacokinetics**:\n   - The liposomal encapsulation alters the distribution, metabolism, and elimination of doxorubicin,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_QSSXixAgG8Z0KRjgBLlQcvVH", "custom_id": "188_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5588bf08fb1936f563c467ca9e05e1e6", "body": {"id": "chatcmpl-9St7Rsh7GK7iPrSKDWOMUSBTyqk2Y", "object": "chat.completion", "created": 1716672089, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Norethandrolone, also known as Norethandrolone or Noretandrolone, is an anabolic-androgenic steroid (AAS). Although it's not commonly used today, understanding its pharmacology, potential uses, and effects is important for a physician.\n\n### Pharmacology\n- **Structure**: Norethandrolone is a synthetic derivative of testosterone with modifications that enhance its anabolic properties while reducing androgenic effects.\n- **Mechanism of Action**: It works by binding to androgen receptors, promoting protein synthesis, and increasing nitrogen retention in muscles, which enhances muscle mass and strength.\n  \n### Potential Uses\nHistorically, Norethandrolone has been used in various medical scenarios, such as:\n- **Aplastic Anemia**: To stimulate erythropoiesis or red blood cell production.\n- **Chronic Wasting Conditions**: In conditions such as severe burns, chronic infections, or after severe trauma to promote muscle growth and counter"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_myk7s0Ja9GU6S1DWFqJR3y6c", "custom_id": "189_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b2b7e44077b2369d7ff151f4b1935f03", "body": {"id": "chatcmpl-9St7SoVAsbfOMlh4uja673ql5ldIU", "object": "chat.completion", "created": 1716672090, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Obinutuzumab, as it is a medication that you may prescribe for your patients. Here is some essential information about the drug:\n\n### What is Obinutuzumab?\n- **Obinutuzumab** is a monoclonal antibody that targets the CD20 protein found on the surface of B-cells.\n- It is used primarily in the treatment of certain types of B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL).\n\n### Indications\n- **Chronic Lymphocytic Leukemia (CLL):** Typically used in combination with chemotherapy, such as chlorambucil, for patients who are previously untreated.\n- **Follicular Lymphoma (FL):** Used in combination with bendamustine for patients who did not respond to or have relapsed after a rituximab-containing regimen, and as maintenance therapy for responders.\n\n### Mechanism"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_bHw8T7OY4tCgaQeWp3u82Uvq", "custom_id": "190_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a3f1ab10ac8abe5d76534c689cf776c3", "body": {"id": "chatcmpl-9St7SkrjVFmfgLUNpZa2z3UQLXQqo", "object": "chat.completion", "created": 1716672090, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Octreotide is a synthetic octapeptide that mimics natural somatostatin pharmacologically, though it is more potent and longer-acting. Physicians should be well-versed in its indications, administration, side effects, and monitoring requirements. Here's a comprehensive overview:\n\n### Uses and Indications\n1. **Acromegaly**: Octreotide reduces growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels.\n2. **Carcinoid Syndrome**: Helps manage symptoms like flushing and diarrhea by inhibiting the release of serotonin and other vasoactive substances.\n3. **VIPomas**: Reduces severe diarrhea associated with vasoactive intestinal peptide-secreting tumors.\n4. **Other Neuroendocrine Tumors**: Can be used for symptom control in various neuroendocrine tumors.\n5. **Bleeding Esophageal Varices**: Helps control acute bleeding by reducing portal blood flow and pressure.\n6. **Other Off-label"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_VtakZds7DCqFaFqQi3TnTclH", "custom_id": "191_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "307066ad86983506bf8599e40194e31a", "body": {"id": "chatcmpl-9St7SpLFLGOXsEueugY5lNYDubuIT", "object": "chat.completion", "created": 1716672090, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Octreotide LAR (Long-Acting Release) is a formulation of octreotide, a synthetic analogue of the natural hormone somatostatin. It is used in various clinical settings, primarily for its inhibitory effects on hormone secretion. Here are key points you should know as a physician:\n\n### Indications:\n1. **Acromegaly**: Octreotide LAR is used to reduce growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels in patients who have not responded to surgery or radiotherapy.\n2. **Neuroendocrine Tumors (NETs)**: It is indicated for symptomatic control of carcinoid syndrome and for hormone-secreting tumors, such as VIPomas.\n3. **Other Hormonal Disorders**: It may be employed off-label in conditions characterized by excess hormone production.\n\n### Mechanism of Action:\nOctreotide mimics natural somatostatin but is more potent in inhibiting the secretion"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_q87KyGafcjYgCngIFFpgYuds", "custom_id": "192_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4459ebe31554660a119b5976a2450107", "body": {"id": "chatcmpl-9St7SGPRU5y67KDWaDCqjzkareZkC", "object": "chat.completion", "created": 1716672090, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ofatumumab is a fully human monoclonal antibody used in the treatment of certain medical conditions. Here\u2019s a detailed overview of what you should know about Ofatumumab as a physician:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL):**\n   - Ofatumumab is approved for the treatment of patients with CLL, particularly those who have not responded to other treatments, including fludarabine and alemtuzumab.\n\n2. **Relapsing Multiple Sclerosis (RMS):**\n   - Ofatumumab is also used for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome (CIS), relapsing-remitting disease, and active secondary progressive disease in adults.\n\n### Mechanism of Action:\n- Ofatumumab targets the CD20 protein found on the surface of B lymphocytes. By binding to this protein, the drug induces cell lysis through multiple mechanisms, including complement-dependent cytotoxicity (CDC"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_vpCKGl6E5AegcdxWQ61lHGv7", "custom_id": "193_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2bad7b7ec926992d4157b4b6d06ae862", "body": {"id": "chatcmpl-9St7SBEthYqcO6fzNFhs3pnj9WMhy", "object": "chat.completion", "created": 1716672090, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Olaparib is a pharmacological drug utilized primarily in the treatment of certain types of cancers. Here are key points you should be aware of:\n\n### Mechanism of Action\n- **PARP Inhibitor**: Olaparib inhibits the enzyme poly (ADP-ribose) polymerase (PARP) which is involved in DNA repair. By inhibiting PARP, the drug induces synthetic lethality in cancer cells with compromised homologous recombination repair, such as those with BRCA1 or BRCA2 mutations.\n\n### Indications\n- **Ovarian Cancer**: It is used as maintenance treatment for adult patients with recurrent ovarian cancer who are in a complete or partial response to platinum-based chemotherapy.\n- **Breast Cancer**: It is approved for the treatment of HER2-negative, BRCA-mutated metastatic breast cancer.\n- **Pancreatic Cancer**: It is also indicated for the treatment of BRCA-mutated metastatic pancreatic adenocarcinoma.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_FXdIMUimkYqf90bJ0XL1gAqa", "custom_id": "194_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "057090e5223a7c215e24bc9d4acf14aa", "body": {"id": "chatcmpl-9St7SXKP57UOOYH0lbhlgiMfuJ0wi", "object": "chat.completion", "created": 1716672090, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Olaratumab is a monoclonal antibody that was developed to target and inhibit platelet-derived growth factor receptor alpha (PDGFR\u03b1), which is involved in the growth of certain types of cancer cells. Here are some key points a physician should know about Olaratumab:\n\n1. **Indications**: Olaratumab was initially approved in combination with doxorubicin for the treatment of adults with soft tissue sarcoma (STS) that cannot be cured with radiation or surgery, specifically targeting those in whom other treatments are not appropriate.\n\n2. **Mechanism of Action**: Olaratumab binds to PDGFR\u03b1 and inhibits its activity. PDGFR\u03b1 is involved in cell growth, and by inhibiting this receptor, olaratumab aims to slow or stop the growth of cancer cells.\n\n3. **Administration**: Olaratumab is administered via intravenous infusion. The recommended dosage regimen involves an initial dose, followed by subsequent doses administered on specific days in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_O2tRMTcOSJ1SHTdFmLrODcCP", "custom_id": "195_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "deaf0ba35bc88ad723a47f1cf86df1fb", "body": {"id": "chatcmpl-9St7SPpahsIr3G3zQKZBLf1aq6Py4", "object": "chat.completion", "created": 1716672090, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Omacetaxine mepesuccinate, often referred to simply as omacetaxine or by the brand name Synribo, is a chemotherapeutic agent used primarily in the treatment of chronic myeloid leukemia (CML). Here is some key information you should consider as a physician:\n\n### Mechanism of Action\n- **Protein Synthesis Inhibition**: Omacetaxine works by inhibiting protein synthesis. It\u2019s a cephalotaxine ester, which, unlike tyrosine kinase inhibitors (TKIs), targets cellular protein translation rather than specific genetic mutations such as BCR-ABL.\n\n### Indications\n- **Chronic Myeloid Leukemia (CML)**: It's specifically indicated for adult patients with chronic or accelerated phase CML who are resistant to, or intolerant of, two or more TKIs.\n\n### Administration\n- **Subcutaneous Injection**: Omacetaxine is administered subcutaneously. Induction dosing is typically 1."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_lni0uvMjwvYayoPdHwoUbjVa", "custom_id": "196_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "41997475ecf737f29c3803999e9f8a9f", "body": {"id": "chatcmpl-9St7SR8fRxfESne9tV81WK6gDjkow", "object": "chat.completion", "created": 1716672090, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Certainly! Omeprazole is a commonly prescribed medication that belongs to a class of drugs known as proton pump inhibitors (PPIs). Here are key points you should be aware of when prescribing or advising about Omeprazole:\n\n### Indications:\n1. **Gastroesophageal Reflux Disease (GERD):** It is often used to treat symptoms of GERD, where stomach acid frequently flows back into the esophagus.\n2. **Peptic Ulcer Disease:** It helps heal gastric and duodenal ulcers by reducing stomach acid.\n3. **Zollinger-Ellison Syndrome:** This is a rare condition characterized by tumors that cause the stomach to produce too much acid.\n4. **Erosive Esophagitis:** It's used for the healing and maintenance of erosive esophagitis.\n\n### Mechanism of Action:\nOmeprazole works by irreversibly inhibiting the hydrogen-potassium adenosine triphosphatase enzyme system (H+/K"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_OufzZGS9I4OtDfVDbDfEjD2S", "custom_id": "197_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b019d26a9bd5a4353d4c695dc2d5ca63", "body": {"id": "chatcmpl-9St7SmUPwMV4ecy93kQC3SBDcciIq", "object": "chat.completion", "created": 1716672090, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Osimertinib is an important medication in the treatment of certain types of non-small cell lung cancer (NSCLC). Here's a comprehensive outline of what you should know:\n\n### Mechanism of Action:\n- **EGFR Inhibitor:** Osimertinib is a tyrosine kinase inhibitor that specifically targets the epidermal growth factor receptor (EGFR) with sensitizing mutations and T790M resistance mutations.\n\n### Indications:\n- **First-line Treatment:** For patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.\n- **Second-line Treatment:** For patients with metastatic EGFR T790M mutation-positive NSCLC, whose disease has progressed on or after EGFR tyrosine kinase inhibitor therapy.\n\n### Administration:\n- **Oral:** Typically taken as a tablet once daily.\n- Recommended to be taken with or without food.\n\n### Dosage:\n- The usual dose is 80 mg once daily."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_5jnTzx8ECIToA93XVlfwhJrI", "custom_id": "198_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "cca4a5ad989678cd81a06be2fddcb11c", "body": {"id": "chatcmpl-9St7SPAelJEp3EJXCpUp2khVF5vUc", "object": "chat.completion", "created": 1716672090, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Oxaliplatin is a platinum-based chemotherapy drug widely used in the treatment of colorectal cancer. As a physician, you should be aware of various aspects concerning its clinical use, mechanism of action, side effects, and administration. Here\u2019s a detailed overview:\n\n### Mechanism of Action:\n- **DNA Crosslinking:** Oxaliplatin forms crosslinks with DNA, interfering with DNA replication and transcription, leading to cell death. This cytotoxic effect is more pronounced in rapidly dividing cancer cells.\n\n### Indications:\n- **Colorectal Cancer:** Primarily indicated for the treatment of metastatic colorectal cancer, often in combination with other drugs like fluorouracil and leucovorin (FOLFOX regimen).\n- **Adjuvant Therapy:** Used as adjuvant therapy in Stage III colon cancer following tumor resection.\n\n### Administration:\n- **Intravenous (IV) Infusion:** Administered intravenously, typically over a 2-hour period.\n- **Dosage:** Dosing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_fpnjeFcIIaqL4idVTeT4OfVK", "custom_id": "199_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7757bd8200288593e2dd6275ae31dc81", "body": {"id": "chatcmpl-9St7SdOKMWH0IbzycKLcELbLt8XvP", "object": "chat.completion", "created": 1716672090, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Paclitaxel nanoparticle albumin-bound (nab-paclitaxel), often known by its brand name Abraxane, is a chemotherapeutic agent used primarily in the treatment of various cancers. Here are key points you should know about it:\n\n### Mechanism of Action:\n- **Paclitaxel**: A taxane derivative that promotes microtubule assembly and inhibits their disassembly, effectively disrupting cell division and inducing apoptosis in cancer cells.\n- **Nanoparticle Albumin-Bound (nab)**: Delivers paclitaxel in an albumin-bound form, allowing for better solubility and tissue distribution compared to solvent-based formulations.\n\n### Indications:\nNab-paclitaxel is indicated for:\n- Metastatic breast cancer\n- Non-small cell lung cancer (NSCLC)\n- Advanced pancreatic cancer\n\n### Administration:\n- **Formulation**: Injectable suspension\n- **Route**: Intravenous infusion\n- **Dosage**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_4yHpZY6FPOTpZHPsDmJeLVs1", "custom_id": "200_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9a2926754d367cfb4aac4080adfd504c", "body": {"id": "chatcmpl-9St7SYtlkXunvePxTBkpVruVXotp8", "object": "chat.completion", "created": 1716672090, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Paclitaxel is a chemotherapy medication widely used for the treatment of various types of cancers, including ovarian, breast, lung, and others. Here are key points a physician should know about Paclitaxel:\n\n### Mechanism of Action\n- **Microtubule Stabilization**: Paclitaxel works by stabilizing microtubules and inhibiting their depolymerization, which disrupts the normal mitotic process and leads to cell death.\n\n### Indications\n- **Ovarian Cancer**: Often used with cisplatin or carboplatin.\n- **Breast Cancer**: Used as adjuvant treatment and in metastatic settings.\n- **Non-Small Cell Lung Cancer (NSCLC)**: Commonly used in combination with other chemotherapeutic agents.\n- **Kaposi\u2019s Sarcoma**: Particularly in patients with AIDS.\n\n### Administration\n- **Intravenous Infusion**: Paclitaxel is typically administered via intravenous infusion.\n  -"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_y3AXlAJHxdDxPKMU4p2iQuNT", "custom_id": "201_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "fcce26ee7a8a30bcf6d51f090be753de", "body": {"id": "chatcmpl-9St7T6ZV3ARSm9G6E4XdZD4t06YUs", "object": "chat.completion", "created": 1716672091, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pacritinib is an important medication in the realm of hematology and oncology, particularly for its use in the treatment of myelofibrosis. Here are several key points that a physician should know:\n\n### Indication and Approval:\n1. **Primary Use**: Pacritinib is primarily used for the treatment of patients with myelofibrosis, especially those with severe thrombocytopenia (platelet counts below 50,000/\u00b5L).\n2. **FDA Approval**: Check the latest guidelines and updates on FDA approval status for specific indications, as regulatory statuses can change.\n\n### Mechanism of Action:\n1. **JAK Inhibition**: Pacritinib is a selective oral kinase inhibitor with activity against Janus Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).\n2. **Pathophysiology Target**: By inhibiting JAK2, Pacritinib targets a key pathway"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_t4fobQONQFeLLtsiCII1xgeJ", "custom_id": "202_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9926dfedfb62a16f2634239576bbdc81", "body": {"id": "chatcmpl-9St7TFOSpPcRAWnjr1k94jnAxnVSV", "object": "chat.completion", "created": 1716672091, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Palbociclib is a targeted cancer therapy primarily used in the treatment of certain types of breast cancer. Here are some key points you should be aware of as a physician:\n\n1. **Mechanism of Action:**\n   - Palbociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor. It works by inhibiting these kinases, which play a crucial role in cell division. By blocking their activity, palbociclib helps to halt the proliferation of cancer cells.\n\n2. **Indications:**\n   - It is commonly used in combination with hormonal therapies such as an aromatase inhibitor (e.g., letrozole) or fulvestrant. This combination is typically for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.\n   - It is usually prescribed for postmenopausal women, as well as men and premenopausal"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_E41bzNgu1YrACskb6lrQON2b", "custom_id": "203_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "37f53b3b98f373cd0565fef1a4578d96", "body": {"id": "chatcmpl-9St7T9d7ncVVi3FBhY9qlcz4kLT7x", "object": "chat.completion", "created": 1716672091, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panitumumab is a fully human monoclonal antibody targeted against the epidermal growth factor receptor (EGFR), which is used to treat certain types of cancer, primarily metastatic colorectal cancer. Here are key points you should be aware of:\n\n### Mechanism of Action:\n- **EGFR Inhibition:** Panitumumab binds specifically to the extracellular domain of the EGFR, preventing natural ligands like epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-\u03b1) from binding. This inhibition disrupts signal transduction pathways that promote cell division and survival.\n\n### Indications:\n- **Metastatic Colorectal Cancer:** It is used in patients with wild-type KRAS (exon 2) metastatic colorectal cancer. It's less effective in patients with KRAS mutations because these mutations can activate downstream signaling regardless of EGFR inhibition.\n\n### Administration:\n- **Intravenous Infusion:** Panitumumab is administered via IV infusion, typically at a dose of 6"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_mQjkMlDO3bNRRuGmjDyNmgMt", "custom_id": "204_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "104b21da00afba9b6ffc83a09a6c38aa", "body": {"id": "chatcmpl-9St7TIHILCv6eVzetlg7w0eZiL20Q", "object": "chat.completion", "created": 1716672091, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panobinostat is a histone deacetylase (HDAC) inhibitor used primarily in the treatment of multiple myeloma, a type of cancer that affects plasma cells. It was approved by the FDA under the brand name Farydak. Here are some key points that you, as a physician, should be aware of:\n\n1. **Mechanism of Action:**\n   - Panobinostat works by inhibiting histone deacetylases, which leads to an accumulation of acetylated histones and other proteins, causing cell cycle arrest and apoptosis of cancer cells. This inhibition disrupts the function of DNA repair, gene expression, and protein degradation pathways in cancer cells.\n\n2. **Indications:**\n   - It are indicated in combination with bortezomib and dexamethasone for patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent.\n\n3. **Administration:**\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_bDxDMpZxMQH1ViplGbFzwkmd", "custom_id": "205_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "83b5c7cd20c5c6a07bae74891779f630", "body": {"id": "chatcmpl-9St7TrTb9HSFlUl29xzZ07lBomkkN", "object": "chat.completion", "created": 1716672091, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pazopanib is a medication used primarily in oncology. Here\u2019s a comprehensive overview of what you should know about it as a physician:\n\n### Indications\n- **Renal Cell Carcinoma (RCC)**: First-line treatment for advanced RCC.\n- **Soft Tissue Sarcoma (STS)**: Specifically for patients who have received prior chemotherapy.\n\n### Mechanism of Action\n- Pazopanib is a tyrosine kinase inhibitor (TKI) that targets multiple receptor tyrosine kinases:\n  - Vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3)\n  - Platelet-derived growth factor receptors (PDGFR-\u03b1 and PDGFR-\u03b2)\n  - Fibroblast growth factor receptors (FGFR-1 and FGFR-3)\n  - KIT\n  - Interleukin-2 receptor inducible T-cell kinase (ITK)\n  - Leukocyte-specific protein tyrosine kinase ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_WeQjnIZjJVKouOYxBoL8mvlg", "custom_id": "206_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1248f5b1af4bff4ef7e705da52b95fae", "body": {"id": "chatcmpl-9St7TWtiVs6MoxW4u3Oh7Pl3rgzSZ", "object": "chat.completion", "created": 1716672091, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pegaspargase is a medication used primarily in the treatment of acute lymphoblastic leukemia (ALL). Here are key points you should be aware of as a physician:\n\n### Mechanism of Action\n- **Pegaspargase** is a form of the enzyme L-asparaginase that has been modified by the addition of polyethylene glycol (PEG). \n- It works by breaking down the amino acid asparagine, which leukemia cells need to survive and proliferate. Normal cells can synthesize asparagine, but leukemia cells often cannot, making them particularly sensitive to this treatment.\n\n### Indications\n- Pegaspargase is specifically indicated for the treatment of patients with ALL.\n- It can also be used for some patients with other types of leukemia or lymphomas where the depletion of asparagine is beneficial.\n\n### Administration\n- **Route**: It is given as an intramuscular (IM) or intravenous (IV) injection.\n- **Frequency**: Typically"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_upQQhV8k12M64av4JVrnQUgL", "custom_id": "207_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6b19d5c42d5c3ca759b46265a2ec08b6", "body": {"id": "chatcmpl-9St7TABK9rvSgbunyFhRR7RpRLmGh", "object": "chat.completion", "created": 1716672091, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, being well-informed about Peginterferon alfa-2a is crucial for effective patient management. Peginterferon alfa-2a is a pegylated form of interferon used primarily in the treatment of chronic hepatitis C and sometimes chronic hepatitis B. Here are key points you should be aware of:\n\n### Mechanism of Action:\n1. **Anti-Viral Activity:** Peginterferon alfa-2a has antiviral properties that help to reduce the replication of hepatitis viruses.\n2. **Immune Modulation:** It modulates the immune system to enhance the body's immune response against the virus.\n\n### Pharmacokinetics:\n1. **Pegylation:** The pegylation process extends the half-life of interferon, allowing for less frequent dosing (typically once a week) compared to non-pegylated forms.\n2. **Administration:** It is administered via subcutaneous injection.\n\n### Indications:\n1. **Chronic Hepatitis C:** Often used in combination"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_kLwSYuo6qZEKOCIc6e7ABHp5", "custom_id": "208_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "dde947b287709d5eafef9f66a73cf286", "body": {"id": "chatcmpl-9St7TfKx9XVEViTUXlMzO2xhEFT4A", "object": "chat.completion", "created": 1716672091, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Peginterferon alfa-2b is a type of medication known as a pegylated interferon, which is used in the treatment of certain viral infections and some cancers. Here are key points you should be aware of as a physician:\n\n### Mechanism of Action\n- **Interferon Activity**: Peginterferon alfa-2b is a synthetic form of the naturally occurring protein interferon. It works by activating the immune system, enhancing immune response to fight viruses and tumors.\n- **Pegylation**: The pegylation process (attachment of polyethylene glycol) increases the half-life of the interferon in the body, allowing for less frequent dosing compared to non-pegylated forms.\n\n### Indications\n- **Chronic Hepatitis C**: Peginterferon alfa-2b is often used, sometimes in combination with ribavirin and other antiviral medications, to treat chronic Hepatitis C infections.\n- **Chronic Hepatitis B**: It may"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_LkxkGmLZNuWTIB7wTRhmp5zh", "custom_id": "209_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "92505c14a84277563f5f7848e125b302", "body": {"id": "chatcmpl-9St7TZsW648RUKG5XYwrpWTrWxcRD", "object": "chat.completion", "created": 1716672091, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pegylated liposomal doxorubicin, commonly known by the brand name Doxil (among others), is a chemotherapeutic agent used primarily in the treatment of various cancers. Here are several key points you should know about this medication:\n\n### Mechanism of Action\n- **Doxorubicin**: An anthracycline antibiotic that intercalates DNA strands, thereby inhibiting the enzyme topoisomerase II and preventing DNA replication and RNA synthesis.\n- **Pegylation and Liposomal Encapsulation**: Enhances the pharmacokinetics and reduces the toxicity of doxorubicin by integrating it into liposomes and covering them with polyethylene glycol (PEG). This allows the drug to stay in the bloodstream longer, preferentially accumulate in tumor tissues, and induce less harm to healthy tissues.\n\n### Indications\n- **Ovarian Cancer**: Usually in patients with disease that has progressed after platinum-based chemotherapy.\n- **AIDS-Related Kaposi's Sar"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_DVJyEtHysKMKKO24sOwPhQNf", "custom_id": "210_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "732d86ced3763be0da142c95764febbd", "body": {"id": "chatcmpl-9St7UsQ6wwBa5QVATo76FaE1AOoHQ", "object": "chat.completion", "created": 1716672092, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pembrolizumab, sold under the brand name Keytruda, is a monoclonal antibody that functions as an immune checkpoint inhibitor. It is primarily used in oncology for the treatment of various types of cancer. Here are some key points you should know about Pembrolizumab:\n\n### Mechanism of Action\n- **PD-1 Inhibition**: Pembrolizumab targets the programmed cell death protein 1 (PD-1) pathway. PD-1 is a checkpoint protein on T cells that, when activated, downregulates the immune response. Tumor cells often exploit this pathway to avoid immune detection. Pembrolizumab blocks PD-1, thereby enhancing the immune system's ability to fight cancer cells.\n\n### Indications\nPembrolizumab is approved for a range of cancers, including:\n- **Melanoma**\n- **Non-Small Cell Lung Cancer (NSCLC)**\n- **Head and Neck Squamous Cell Carcinoma (HNSCC)**\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_IKUOR6dmm5gBosiBDw4SViLN", "custom_id": "211_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6675d236b91d6422544d6f2b17d97a66", "body": {"id": "chatcmpl-9St7Tx0J09R2nwDYEyImcF5GCcoBn", "object": "chat.completion", "created": 1716672091, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pemetrexed is a chemotherapy drug used primarily in the treatment of certain types of cancer, including malignant pleural mesothelioma and non-small cell lung cancer (NSCLC). Here are several key points you should know about Pemetrexed as a physician:\n\n### Mechanism of Action:\n- **Antifolate Agent:** Pemetrexed inhibits three key enzymes in the folate pathway: thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). This inhibition disrupts the synthesis of purine and pyrimidine nucleotides, thereby hindering DNA and RNA synthesis, leading to cell death.\n\n### Indications:\n- **Malignant Pleural Mesothelioma:** Used in combination with cisplatin for patients whose disease is unresectable or who are not candidates for surgery.\n- **Non-Small Cell Lung Cancer (NSCLC):** Used as a monotherapy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_QEnkMFLSA5kBnzDBr7dF3pyT", "custom_id": "212_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "dd8a38f3e9303414a1fda3a953c2df19", "body": {"id": "chatcmpl-9St7To0K8wvlj2ycVpMhKT4pR0TrR", "object": "chat.completion", "created": 1716672091, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pentostatin, also known by its brand name Nipent, is an important chemotherapeutic agent primarily used in the treatment of specific types of cancer, particularly hairy cell leukemia. Here are key points you should be aware of:\n\n1. **Mechanism of Action**:\n   - Pentostatin is a purine analog that functions as an adenosine deaminase inhibitor. By inhibiting this enzyme, it disrupts DNA synthesis, leading to apoptosis (programmed cell death) in proliferating lymphocytes.\n\n2. **Indications**:\n   - Primarily used for hairy cell leukemia.\n   - It may also be used off-label for other conditions, such as chronic lymphocytic leukemia (CLL) and T-cell prolymphocytic leukemia (T-PLL).\n\n3. **Administration**:\n   - It is usually administered intravenously.\n   - The dosage and frequency depend on the specific protocol, but it\u2019s often given every other week.\n\n4. **Side Effects"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_GzniQDTCNU09KOdT0HajjXzD", "custom_id": "213_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5083f2617393675ef56e39bc4cb344b6", "body": {"id": "chatcmpl-9St7ULHy1fsshzBhRFzO036C5Ht34", "object": "chat.completion", "created": 1716672092, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it\u2019s critical to have a thorough understanding of Pertuzumab, particularly if you are involved in oncology. Pertuzumab is a monoclonal antibody used in the treatment of HER2-positive breast cancer. Here are several key aspects you should consider:\n\n### Mechanism of Action:\n- **HER2 Inhibition**: Pertuzumab is designed to target the HER2 (human epidermal growth factor receptor 2) protein. It binds to the dimerization domain of HER2, preventing it from pairing with other HER family members, such as HER3. This inhibition disrupts cell signaling that can lead to tumor growth.\n  \n### Indications:\n- **HER2-Positive Breast Cancer**: Pertuzumab is primarily used in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic breast cancer or as neoadjuvant (pre-surgical) therapy.\n- **Combination Therapy**: It\u2019s often given with other chemotherapy agents,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_pvp5dp7mTRTU2RXAmZPYRcKX", "custom_id": "214_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1a02252cff982e9b13e92bc71b38e4e0", "body": {"id": "chatcmpl-9St7UWtLj5i7q32drWyazNkOjrq42", "object": "chat.completion", "created": 1716672092, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pirarubicin is an anthracycline antineoplastic agent, which means it's used in the treatment of various cancers. Here are some important points you should know about Pirarubicin:\n\n### Pharmacology\n- **Mechanism of Action**: Pirarubicin works by intercalating into DNA, interfering with the enzyme topoisomerase II. This action inhibits DNA replication and RNA synthesis, leading to cell death.\n- **Metabolism**: It is mainly metabolized in the liver and excreted in the bile and urine.\n\n### Indications\n- Pirarubicin is commonly used to treat breast cancer, bladder cancer, and certain types of leukemia and lymphomas. Its use may vary based on regional medical guidelines and approval status.\n\n### Administration\n- It is typically administered intravenously. Dosing will depend on the type of cancer being treated, the patient's overall health and response to therapy, and specific protocols followed by the treatment center.\n- Bladder cancer treatment"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_u3V65iM7GQSVeCC0z80EdqXJ", "custom_id": "215_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "12dab0f275e45bd49356833c1e0ef3d1", "body": {"id": "chatcmpl-9St7U6oMrjKkHZ2pyo7CMNhXHjXuI", "object": "chat.completion", "created": 1716672092, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pixantrone is a chemotherapeutic agent used primarily in the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL). Here is a comprehensive overview of what you should know about Pixantrone:\n\n### Mechanism of Action:\n- **DNA Intercalation:** Pixantrone is an anthracenedione, similar to anthracyclines but less cardiotoxic. It intercalates into DNA, disrupting DNA replication and transcription, leading to cell death.\n- **Topoisomerase II Inhibition:** It also inhibits topoisomerase II, preventing the relaxation of supercoiled DNA, which is necessary for replication and transcription.\n\n### Indications:\n- **Relapsed or Refractory NHL:** Indicated for adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas, particularly when other treatment options have been exhausted.\n\n### Dosage and Administration:\n- **Administration Route:** Intravenous infusion.\n- **Typical Dos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_CJ7t0QFmI8ICg3lNxm8jPsUE", "custom_id": "216_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "54ca25f587e4f3655640b0590fb063b2", "body": {"id": "chatcmpl-9St7UEH5UEmQUITrm2dDdxS8YhSrn", "object": "chat.completion", "created": 1716672092, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Plicamycin, also known as mithramycin, is an antineoplastic antibiotic primarily derived from the bacterium Streptomyces plicatus. Here are some key points that you, as a physician, should know about Plicamycin:\n\n### Indications:\n1. **Cancer Treatment**: Primarily used in the treatment of testicular cancer and certain other solid tumors.\n2. **Hypercalcemia and Hypercalciuria**: It can be used as an off-label treatment for hypercalcemia and hypercalciuria, particularly in patients with malignancies that are associated with these conditions.\n\n### Mechanism of Action:\n- Plicamycin works by binding to DNA and inhibiting RNA synthesis. This inhibition disrupts protein synthesis and leads to decreased cell proliferation, particularly in rapidly dividing cells such as cancer cells.\n\n### Administration:\n- Plicamycin is administered intravenously. Dosage and administration schedules can vary based on the specific condition being treated and the patient"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_pfYunLqp21Nubf6fT5DBBFtX", "custom_id": "217_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2935761aee2272550ae0f44a0d7ed99f", "body": {"id": "chatcmpl-9St7UIds86SjKVk3vbvPp14U9HOGt", "object": "chat.completion", "created": 1716672092, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pomalidomide is a thalidomide analogue and immunomodulatory agent (IMiD) commonly used in the treatment of multiple myeloma. Here are some critical points you should know:\n\n### Indications and Usage\n- **Multiple Myeloma:** It is typically used in combination with dexamethasone or other agents for patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or within 60 days of completion of their last therapy.\n\n### Mechanism of Action\n- **Immunomodulation:** Pomalidomide modulates the immune response by inhibiting the proliferation of myeloma cells and enhancing T cell and natural killer (NK) cell-mediated cytotoxicity.\n- **Anti-angiogenic:** It inhibits angiogenesis, which can reduce the blood supply to myeloma tumors.\n- **Direct tumor cell targeting:** It induces apoptosis ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_9PAaDBFcGk6Kty43eCJFYG02", "custom_id": "218_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "743848d6b50d3d87961c5142d721403e", "body": {"id": "chatcmpl-9St7Ue59YRW7wHKWYivPhYYya2FkC", "object": "chat.completion", "created": 1716672092, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ponatinib is a potent tyrosine kinase inhibitor (TKI) designed to target the BCR-ABL protein, which is typically found in patients with chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) who have the Philadelphia chromosome (Ph+). Here is a comprehensive overview of what you should know about Ponatinib:\n\n### Indications:\n1. **Chronic Myeloid Leukemia (CML)**: Ponatinib is used particularly in patients who have T315I mutation-positive CML or those for whom other treatments have failed.\n2. **Acute Lymphoblastic Leukemia (ALL)**: Specifically for patients with Ph+ ALL who are resistant or intolerant to prior TKI therapy.\n\n### Mechanism of Action:\nPonatinib works by binding to the ATP-binding site of the BCR-ABL tyrosine kinase, inhibiting its activity. It is effective against BCR-ABL including mutations that confer resistance to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_JHTSBuU3WdxEO7uypHSAC7u9", "custom_id": "219_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1ec15c36bb2876889790891320b5c0ee", "body": {"id": "chatcmpl-9St7UqHSZA6AxkFnlml9dytd3iWSb", "object": "chat.completion", "created": 1716672092, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pralatrexate is a chemotherapeutic agent primarily used for the treatment of peripheral T-cell lymphoma (PTCL), including relapsed or refractory cases. Here are some key points you should know about pralatrexate:\n\n### Mechanism of Action:\n- **Antifolate Agent:** Pralatrexate inhibits dihydrofolate reductase and thymidylate synthase, enzymes critical for DNA synthesis and repair. By interfering with folate metabolism, it impedes tumor cell growth.\n\n### Indications:\n- **Peripheral T-cell Lymphoma (PTCL):** It is specifically approved for the treatment of relapsed or refractory PTCL.\n\n### Administration:\n- **Intravenous Injection:** It is administered as an intravenous (IV) injection, often weekly, but the dosing schedule can vary.\n- **Dosing:** The typical dose is 30 mg/m\u00b2 administered over 3-5 minutes every week for six weeks, followed by a one-week rest period.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_927397958d"}}, "error": null}
{"id": "batch_req_ZTXSCoCU8zRXLSOpbhPZgyOT", "custom_id": "220_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9cca48e02187b6345f6edea11f5b8624", "body": {"id": "chatcmpl-9St7ULu5a4sh2QHpsc3OfcebXzuo2", "object": "chat.completion", "created": 1716672092, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pravastatin is a commonly prescribed medication that belongs to a class of drugs known as statins (or HMG-CoA reductase inhibitors). Here are some key points you should know about pravastatin:\n\n1. **Indications**: \n   - Primarily used to lower cholesterol and triglycerides in the blood.\n   - Helps in reducing the risk of cardiovascular events such as myocardial infarction, stroke, and the need for revascularization procedures in patients with or at risk of atherosclerotic cardiovascular disease.\n\n2. **Mechanism of Action**: \n   - Pravastatin works by inhibiting HMG-CoA reductase, an enzyme involved in the synthesis of cholesterol in the liver. This leads to an increase in the uptake of LDL cholesterol by the liver and subsequently lowers its level in the blood.\n\n3. **Dosage**: \n   - The dosage can range from 10 mg to 80 mg once daily, often administered in the evening or at bedtime"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_CiBGPJRFM48yNRLy8WLHAarg", "custom_id": "221_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7cb5dd90fc4a2952be98e32afb711a60", "body": {"id": "chatcmpl-9St7VVgCo1Ew5UMrFirLd1UVNUK2B", "object": "chat.completion", "created": 1716672093, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it\u2019s important to have a comprehensive understanding of Prednisolone, a glucocorticoid medication commonly used to treat a variety of inflammatory and autoimmune conditions. Here are some key points to consider:\n\n### Mechanism of Action:\n- **Anti-inflammatory and Immunosuppressive Effects**: Prednisolone exerts powerful anti-inflammatory and immunosuppressive effects by inhibiting the release of inflammatory mediators and suppressing the immune response.\n\n### Indications:\n- **Rheumatologic Disorders**: Rheumatoid arthritis, systemic lupus erythematosus.\n- **Respiratory Conditions**: Asthma, COPD exacerbations, and other inflammatory lung diseases.\n- **Allergic Reactions**: Severe allergic reactions, anaphylaxis.\n- **Dermatologic Conditions**: Eczema, psoriasis, and other severe skin conditions.\n- **Gastrointestinal Diseases**: Crohn\u2019s disease, ulcerative colitis.\n- **Endocrine Disorders**: Ad"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_SXpQI1kH3I42jxQFT1IF9yp2", "custom_id": "222_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7f97a6cf60eb7f2bc0f297c8d47bdb63", "body": {"id": "chatcmpl-9St7VHLEnH9BbDiVMnBFDrsmkKCLM", "object": "chat.completion", "created": 1716672093, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Certainly! As a physician, understanding Prednisone is crucial due to its widespread use and significant impact on various conditions. Here are key points you should consider:\n\n### Pharmacology and Mechanism of Action:\n- **Classification**: Prednisone is a synthetic corticosteroid.\n- **Mechanism**: It acts as an immunosuppressant and anti-inflammatory by mimicking the effects of cortisol, a naturally occurring hormone produced by the adrenal glands. Prednisone is converted in the liver to its active form, prednisolone.\n- **Administration**: Oral is the most common form, but it can also be given via injection or as a topical preparation.\n\n### Indications:\n- **Autoimmune Diseases**: Used for conditions like rheumatoid arthritis, lupus, and multiple sclerosis.\n- **Allergic Reactions**: Used to treat severe allergies and asthma.\n- **Inflammatory Conditions**: Benefits patients with inflammatory bowel diseases like Crohn's disease and ulcerative colitis.\n- **Respiratory"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_BQS23X3O1x0TTgWtGOzmPceV", "custom_id": "223_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5bb40245da9039880e3a48bad665a35e", "body": {"id": "chatcmpl-9St7Vmbn5B5RpLinCKWGqqdOEjJ9J", "object": "chat.completion", "created": 1716672093, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Procarbazine is a chemotherapeutic agent primarily used in the treatment of Hodgkin's lymphoma and certain types of brain tumors. Here are several key points you should know about its use, mechanism, administration, and side effects:\n\n### Mechanism of Action\n- Procarbazine is an alkylating agent that works by inhibiting DNA, RNA, and protein synthesis. It induces strand breaks in DNA and incorporates itself into the nucleic acid, which causes faulty cell division and ultimately cell death.\n\n### Indications\n- Primarily used in combination therapy for Hodgkin's lymphoma (e.g., in the MOPP regimen: mechlorethamine, vincristine (Oncovin), procarbazine, and prednisone).\n- Also used for the treatment of certain brain tumors, such as gliomas.\n\n### Administration\n- Procarbazine is administered orally in capsule form.\n- Dosing schedules vary depending on the type and stage of the malignancy, and it"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_7Hp4CdP75yAGLbTuqJzhUlS6", "custom_id": "224_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "fdc353271937b4f563549a86b16b4d00", "body": {"id": "chatcmpl-9St7VWMLXIKImwsIZkld8Pz6KIZYV", "object": "chat.completion", "created": 1716672093, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Quinine is a medication that has been used for many years, primarily for the treatment and prevention of malaria. Here are some key points you should know about quinine:\n\n### Pharmacology\n- **Mechanism of Action**: Quinine works by interfering with the parasite's ability to digest hemoglobin, which is crucial for its survival and replication within red blood cells.\n- **Administration**: Quinine is usually administered orally, but it can also be given intravenously in severe cases of malaria.\n\n### Medical Uses\n- **Malaria**: Quinine is particularly effective against Plasmodium falciparum, the most dangerous form of malaria. It is usually used in combination with other antimalarial drugs to prevent resistance.\n- **Leg Cramps**: Though not FDA-approved for this purpose, quinine has been used off-label to treat nocturnal leg cramps. However, due to potential side effects, this use is generally discouraged.\n\n### Side Effects\nQuinine has a range"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_FAqWM0QivcoL4VHyn25hVXFU", "custom_id": "225_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4f304cc4a262c6f122103e0c0809abbf", "body": {"id": "chatcmpl-9St7VumYqibiYgyfiD8F9kSDBe6cU", "object": "chat.completion", "created": 1716672093, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Quizartinib is a targeted therapy that acts as a tyrosine kinase inhibitor (TKI), with a particular focus on the FLT3 (FMS-like tyrosine kinase 3) receptor. This medication is primarily relevant in the context of hematological malignancies, specifically acute myeloid leukemia (AML). Here are the key points you should be aware of:\n\n### Mechanism of Action:\n- **FLT3-ITD Mutation**: Quizartinib targets the internal tandem duplication (ITD) mutations in the FLT3 gene. These mutations are one of the most common genetic alterations in AML and are associated with a poor prognosis.\n- **Kinase Inhibition**: By inhibiting the FLT3 receptor, Quizartinib can trigger apoptosis in leukemic cells, hence impeding disease progression.\n\n### Indications:\n- **AML**: Quizartinib is most commonly used in patients with relapsed or refractory AML that have the FLT3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_UPXIvmylT6QSSxqJVPRgX3H5", "custom_id": "226_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8b2ac5b2a32afd1e6a3d8feee4eddf92", "body": {"id": "chatcmpl-9St7VN7T70WM4zR3ndvuwQ4YbSeBm", "object": "chat.completion", "created": 1716672093, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Radotinib, marketed under the brand name Supect, is a second-generation tyrosine kinase inhibitor (TKI) specifically targeting the BCR-ABL fusion protein. It is primarily used in the treatment of chronic myeloid leukemia (CML), particularly in patients who are Philadelphia chromosome-positive (Ph+). Here's what you should know about Radotinib:\n\n1. **Mechanism of Action**: Radotinib inhibits the BCR-ABL tyrosine kinase, which is produced by the Philadelphia chromosome and is responsible for the uncontrolled proliferation of leukemic cells in CML.\n\n2. **Indications**: Radotinib is indicated for the treatment of adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML who are resistant or intolerant to prior therapy, including imatinib.\n\n3. **Dosage and Administration**: The recommended dose is typically 400 mg twice daily. The tablets should be taken on an empty stomach, either two"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_y4xFIQl8QVlpmOe4QqB3aMTi", "custom_id": "227_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d0da961886dadbe052cb69670328ab98", "body": {"id": "chatcmpl-9St7VkJYuP7goAQNbxDEFAAQLanv1", "object": "chat.completion", "created": 1716672093, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Raltitrexed is an antineoplastic agent used mainly in the treatment of colorectal cancer. It is a quinazoline folate analog that inhibits thymidylate synthase (TS), an enzyme essential for DNA synthesis and cell division. Here are some key points you should be aware of as a physician:\n\n### Indications:\n1. **Colorectal Cancer**: Primarily used for the treatment of advanced colorectal cancer, especially in patients who cannot tolerate 5-fluorouracil (5-FU) therapy.\n\n### Mechanism of Action:\n1. **Thymidylate Synthase Inhibition**: Raltitrexed specifically inhibits TS by mimicking the natural substrate of the enzyme, leading to a depletion of thymidylate triphosphate, which is essential for DNA replication and repair.\n\n### Pharmacokinetics:\n1. **Administration**: Administered intravenously.\n2. **Distribution**: Widely distributed in body tissues.\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_pzpbohl4MPhW8VRwbjtX9yK3", "custom_id": "228_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "59f33b4b08c9750512ef510289621477", "body": {"id": "chatcmpl-9St7VXVJJGx7yS9NWlFnvXY3s3djk", "object": "chat.completion", "created": 1716672093, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ramucirumab is a monoclonal antibody used in oncology for its anti-angiogenic properties, meaning it inhibits the formation of new blood vessels that tumors need to grow. Here are some key points you should know about Ramucirumab:\n\n### Mechanism of Action\n- **Target**: Ramucirumab specifically targets and binds to the extracellular domain of the vascular endothelial growth factor receptor 2 (VEGFR-2).\n- **Function**: By binding to VEGFR-2, it inhibits the interaction of VEGF ligands with the receptor, thereby blocking the downstream signaling pathways that promote angiogenesis and tumor growth.\n\n### Indications\nRamucirumab is approved for use in various types of cancers, often in combination with other chemotherapeutic agents:\n- **Gastric Cancer**: For advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.\n- **Colorectal Cancer**: In combination with FOLFIRI (irinotecan, fol"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_OnwHnMSwZRY5cYbDGTF3cbca", "custom_id": "229_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "3c1e637e3591150ec289f20bb79aaaaf", "body": {"id": "chatcmpl-9St7Vn4EJilQN1fslg8SHr0URNZIG", "object": "chat.completion", "created": 1716672093, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ranimustine, also known as MCNU, is an alkylating agent used primarily in the treatment of various types of cancer, particularly hematological malignancies and certain solid tumors. Here are some key points you should know about Ranimustine:\n\n1. **Mechanism of Action:**\n   - Ranimustine belongs to the nitrosourea class of chemotherapy drugs. It works by alkylating DNA, leading to cross-linking and strand breaks, which ultimately inhibit DNA replication and transcription. This results in the death of rapidly dividing cancer cells.\n\n2. **Indications:**\n   - Ranimustine is used in the treatment of malignant lymphomas, multiple myeloma, and certain solid tumors such as lung cancer and brain tumors.\n\n3. **Administration:**\n   - It is typically administered intravenously. The dosage and schedule depend on various factors, including the type of cancer, patient's condition, and concomitant therapies.\n\n4. **Side Effects:**\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_7uxD8A5V3XyaQs73Dm61Nh6E", "custom_id": "230_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d8327e5e87eee0523c544021ea83d710", "body": {"id": "chatcmpl-9St7WZKlYUgRbv6ZXDPMwnm2xXdEC", "object": "chat.completion", "created": 1716672094, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Regorafenib is an oral multi-kinase inhibitor that is used in the treatment of certain cancers. Here are key points you should know about Regorafenib:\n\n1. **Mechanism of Action:**\n   - Regorafenib inhibits multiple protein kinases, including VEGFR1-3, TIE2, PDGFR-\u03b2, FGFR1 and 2, among others. This inhibition affects tumor angiogenesis, oncogenesis, and the tumor microenvironment.\n\n2. **Indications:**\n   - Regorafenib is approved for the treatment of metastatic colorectal cancer (CRC), gastrointestinal stromal tumors (GIST) after disease progression on or intolerance to imatinib and sunitinib, and advanced hepatocellular carcinoma (HCC) in patients who have previously been treated with sorafenib.\n\n3. **Administration:**\n   - Regorafenib is administered orally, typically at a starting dose of 160 mg once daily for the first"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_1XYYAdYKJYpkXFwqQpwUAYEU", "custom_id": "231_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "08fdb8aea5b6a9954aab9a34f2b2d1e1", "body": {"id": "chatcmpl-9St7WWWbMR4xkxrnU2gmTLdS8T1Q9", "object": "chat.completion", "created": 1716672094, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ribociclib, marketed as Kisqali, is a medication used primarily for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. It is a cyclin-dependent kinase (CDK) 4/6 inhibitor, which works by interfering with the cell cycle, thereby inhibiting cancer cell proliferation.\n\nAs a physician, you should be aware of the following key points about Ribociclib:\n\n### Indications and Usage:\n- Ribociclib is typically used in combination with an aromatase inhibitor (such as letrozole) or fulvestrant for postmenopausal women, or in pre/perimenopausal women with ovarian suppression.\n- It is used for patients with HR-positive, HER2-negative advanced or metastatic breast cancer.\n\n### Mechanism of Action:\n- Ribociclib selectively inhibits CDK4 and CDK6, which are proteins involved in cell cycle regulation."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_UO9HQRaPKZTofGrdgqvUt8FZ", "custom_id": "232_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "25981f3ad99e7b60f5e7f0abce7f480f", "body": {"id": "chatcmpl-9St7WwDunshOcmLC10el0j6f4xXBD", "object": "chat.completion", "created": 1716672094, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rituximab is a chimeric monoclonal antibody used to treat various conditions, most notably certain types of cancers and autoimmune diseases. Here are key points you should be aware of:\n\n### Mechanism of Action\n- **Target**: Rituximab targets the CD20 protein found on the surface of B-lymphocytes.\n- **Effect**: It leads to B-cell depletion through mechanisms like complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and apoptosis.\n\n### Indications\n- **Oncology**: Used in treating non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and other types of B-cell lymphomas.\n- **Autoimmune Diseases**: Used for rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA). Also, it might be used off-label for other autoimmune conditions.\n\n### Administration\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Lg5HC3S7vjrv7iv3uulWkF2g", "custom_id": "233_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9503a4a1a7fe2824d8a6e08cdfff36b0", "body": {"id": "chatcmpl-9St7WgbD3aneAEzTv2Djlv8foyIhn", "object": "chat.completion", "created": 1716672094, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rituximab and hyaluronidase human is a combination medication primarily used in the treatment of certain types of cancers, such as non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), as well as conditions like rheumatoid arthritis (RA). Here are some key points you should be aware of:\n\n### Rituximab:\n\n1. **Mechanism of Action**:\n   - Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of B-lymphocytes. It works by binding to CD20 and inducing B-cell lysis through various mechanisms including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and apoptosis.\n\n2. **Indications**:\n   - Rituximab is approved for use in conditions like:\n     - Non-Hodgkin's lymphoma (NHL)\n     - Chronic lymphocytic leukemia (CLL)\n     -"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_cmv6evYYlFss2l3rh322YqsO", "custom_id": "234_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0ab8af2d42c1d234bed21d00f77a1c1e", "body": {"id": "chatcmpl-9St7W0pJFiwuLtURDWasTbpC5oHNe", "object": "chat.completion", "created": 1716672094, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Romidepsin, marketed under the trade name Istodax, is a histone deacetylase (HDAC) inhibitor used primarily in the treatment of certain types of T-cell lymphoma. Here's a detailed overview of what you should know:\n\n### Mechanism of Action\n- **Histone Deacetylase Inhibition:** Romidepsin inhibits HDAC enzymes, which leads to an accumulation of acetylated histones and other proteins. This alteration can induce cell cycle arrest, differentiation, and apoptosis of malignant cells.\n\n### Indications\n- **Cutaneous T-cell Lymphoma (CTCL):** Approved for patients who have received at least one prior systemic therapy.\n- **Peripheral T-cell Lymphoma (PTCL):** Approved for patients who have received at least one prior therapy.\n\n### Administration\n- **Dosage:** Typically administered as an intravenous infusion at a dose of 14 mg/m\u00b2 over a 4-hour period on days 1, 8,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_D208q2L6qrudXsbcm6s2u9R9", "custom_id": "235_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "3b91b2c8f167b956c997ca4cd9050ee9", "body": {"id": "chatcmpl-9St7WyCNu5Vb653HEcOVEwfjWFMNg", "object": "chat.completion", "created": 1716672094, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ropeginterferon alfa-2b (sold under the brand name Besremi, among others) is a medication primarily used for the treatment of certain hematologic conditions, specifically polycythemia vera (PV), a type of blood cancer. Here\u2019s a detailed overview of what you should know about Ropeginterferon alfa-2b:\n\n### Mechanism of Action:\n1. **Interferon:** Ropeginterferon alfa-2b is a long-acting, mono-pegylated interferon.\n2. **Anti-proliferative and Immunomodulatory Effects:** It works by exerting anti-proliferative, anti-viral, and immunomodulatory effects, leading to a reduction in the proliferation of abnormal blood cells and improving immune response.\n\n### Indications:\n1. **Polycythemia Vera (PV):** Used for the treatment of PV without symptomatic splenomegaly.\n\n### Administration:\n1. **Subcutaneous Injection:** Typically"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_j5ZxpQghmlTu5mGoADph3ouW", "custom_id": "236_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "3240c80be1efc145d7b169f2a9031962", "body": {"id": "chatcmpl-9St7WZIuIs4s7u5xpCpGj5rSGcZ6M", "object": "chat.completion", "created": 1716672094, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be familiar with various aspects of Rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor. Here's what you should know:\n\n### Indications:\n1. **Ovarian Cancer**: Rucaparib is approved for the treatment of patients with BRCA-mutated (germline and/or somatic) ovarian cancer who have been treated with two or more chemotherapies.\n2. **Maintenance Treatment**: It's also indicated as a maintenance treatment for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.\n\n### Mechanism of Action:\nRucaparib works by inhibiting PARP enzymes, which play a key role in DNA repair. By blocking these enzymes, Rucaparib induces cell death in cancer cells, particularly those with BRCA1/2 mutations, since these cells already have compromised DNA repair mechanisms.\n\n### Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_gT1P2UCqTCmrZF5HyGY5ks58", "custom_id": "237_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ce77978825698aa5b518ec1d642ae056", "body": {"id": "chatcmpl-9St7WMF2qshyZN2WssMozPsUW5pKH", "object": "chat.completion", "created": 1716672094, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ruxolitinib is a medication that you should be familiar with if you're involved in the treatment of certain hematologic conditions. Here are important details:\n\n1. **Mechanism of Action**: Ruxolitinib is a Janus kinase (JAK) inhibitor, specifically inhibiting JAK1 and JAK2 enzymes. These kinases are involved in the signaling pathways of various cytokines and growth factors, which are crucial for hematopoiesis and immune function.\n\n2. **Indications**: \n   - Primarily, it is used to treat myelofibrosis, which is a type of bone marrow cancer that disrupts the body's production of blood cells.\n   - It's also approved for treating polycythemia vera, particularly in patients who have an inadequate response to or are intolerant of hydroxyurea.\n   - More recently, it has been used in the treatment of steroid-refractory acute graft-versus-host disease (GVHD).\n\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_nvcTPQeRmPXd7Go8MgYauKoY", "custom_id": "238_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "eab20f7944dcc5b843d6d1c736654e54", "body": {"id": "chatcmpl-9St7WArAUTxY72ALNebU4VFY6H7MN", "object": "chat.completion", "created": 1716672094, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of sacituzumab govitecan, especially if you are treating patients with certain types of cancer. Here are key points you should know:\n\n### Overview\n- **Sacituzumab govitecan (Trodelvy)**: It is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody that targets Trop-2, a protein overexpressed in various epithelial cancers, linked to SN-38, an active metabolite of the chemotherapeutic agent irinotecan.\n\n### Indications\n- **Metastatic Triple-Negative Breast Cancer (mTNBC)**: For adult patients who have received at least two prior therapies for metastatic disease.\n- **Metastatic Urothelial Cancer (mUC)**: In adult patients who have previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor.\n\n### Mechanism of Action\n- **Targeting**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ttCOGC7arEHKGDJWVyWnlrct", "custom_id": "239_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "807881456f935e0b7ce61465cf55a488", "body": {"id": "chatcmpl-9St7WzigjpFjZMTq8ckXbqlBUPF1i", "object": "chat.completion", "created": 1716672094, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sargramostim is a recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) that stimulates the proliferation, differentiation, and activation of myeloid cells. Here are key points you should know as a physician:\n\n### Indications:\n1. **Hematopoietic Support**:\n   - **Chemotherapy-induced Neutropenia**: To reduce the incidence of febrile neutropenia and to facilitate dose-intense chemotherapy protocols.\n   - **Bone Marrow Transplantation**: To accelerate myeloid recovery post-autologous or allogeneic marrow transplantation.\n   - **Peripheral Blood Progenitor Cell (PBPC) Mobilization and Transplantation**: To enhance the mobilization of progenitor cells into peripheral blood for collection and after transplantation to hasten myeloid recovery.\n   - **Engraftment**: Used post-engraftment after a bone marrow transplant to support the recovery of white blood cells.\n\n2. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_jb1qmBysjBhOkcFBnc7BC1np", "custom_id": "240_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "25e87900cfb2c77b12e4c11e4232b3b0", "body": {"id": "chatcmpl-9St7XYy21BVJbwznuicdqYWEUOa2H", "object": "chat.completion", "created": 1716672095, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Selinexor, marketed under the brand name Xpovio, is an oral selective inhibitor of nuclear export (SINE) compound that is used primarily in the treatment of multiple myeloma and diffuse large B-cell lymphoma (DLBCL). Below are several key points a physician should know about Selinexor:\n\n1. **Mechanism of Action**:\n   Selinexor inhibits exportin 1 (XPO1), a key nuclear export protein. By blocking XPO1, Selinexor prevents the transport of tumor suppressor proteins and growth regulatory proteins from the nucleus to the cytoplasm, leading to their accumulation in the nucleus and an increase in their anti-cancer activity.\n\n2. **Indications**:\n   - **Multiple Myeloma**: Selinexor is approved for use in combination with other medications (such as dexamethasone) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_IrNdWFdkw9Wrc43BXrC4qSsf", "custom_id": "241_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "bb581cc82910dd799e319579eb804040", "body": {"id": "chatcmpl-9St7XuFyuPcoGXAl972uraEL0lR1W", "object": "chat.completion", "created": 1716672095, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be informed about Selumetinib, especially as it pertains to its indications, mechanisms of action, dosing guidelines, possible side effects, and considerations in patient management. Here are some key points you should be aware of:\n\n### General Overview\n- **Generic Name**: Selumetinib\n- **Brand Name**: Koselugo\n- **Drug Class**: Mitogen-Activated Protein Kinase (MEK) Inhibitor\n- **Indication**: Primarily indicated for the treatment of neurofibromatosis type 1 (NF1) in pediatric patients aged 2 years or older with symptomatic, inoperable plexiform neurofibromas (PN).\n\n### Mechanism of Action\nSelumetinib is an orally bioavailable inhibitor of MEK1 and MEK2, which are part of the MAPK/ERK signaling pathway. This pathway is often dysregulated in various cancers and disorders, including NF1."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_sYih6ebeEQtvXh7tOQAip0n5", "custom_id": "242_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b92ec3465193c2d344eda9f7db1dfb28", "body": {"id": "chatcmpl-9St7XkcfHrsixEkdMqV4Cv32vo8X8", "object": "chat.completion", "created": 1716672095, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Semustine, also known by its chemical name methyl-CCNU (methyl-1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea), is a nitrosourea compound that was once used as an antineoplastic agent. It has a similar mechanism of action to other nitrosourea compounds like lomustine (CCNU) and carmustine (BCNU). Here are some key points you should know as a physician:\n\n### Mechanism of Action:\n1. **Alkylation**: Semustine works by alkylating DNA and RNA, leading to the cross-linking of DNA strands, which ultimately inhibits DNA synthesis and function.\n2. **Cell Cycle Effects**: It is cell-cycle nonspecific, meaning it can affect cells at any stage of the cell cycle, making it potent against rapidly dividing cancer cells.\n\n### Therapeutic Uses:\n- Primarily used in the past to treat various types of cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_fS6QcrexHwhtw5iiXb5EUoxc", "custom_id": "243_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "52161aa8d25a4a17ec5cd842635fa994", "body": {"id": "chatcmpl-9St7XlroG1D8FjXGUuFGxl167mOFN", "object": "chat.completion", "created": 1716672095, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sipuleucel-T (brand name Provenge) is an autologous cellular immunotherapy used for the treatment of prostate cancer. It was one of the first cancer immunotherapies to be approved by the FDA and is specifically indicated for use in patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).\n\nHere are some key points to note:\n\n1. **Mechanism of Action**:\n   - Sipuleucel-T is designed to stimulate the patient's immune system to attack prostate cancer cells. It is an autologous cellular immunotherapy, meaning it uses the patient's own immune cells.\n   - The therapy involves collecting peripheral blood mononuclear cells (including antigen-presenting cells, or APCs) from the patient through leukapheresis.\n   - These cells are then exposed to a recombinant fusion protein (PA2024) consisting of prostatic acid phosphatase (PAP) linked to granulocyte-macrophage colony-stimulating factor ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_tziSUDL3j2W0aCt4i2mkO81L", "custom_id": "244_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "11a2f7a4e5bbb4b831fddc3cb41ab720", "body": {"id": "chatcmpl-9St7X8gB6Qn3Fa34x3hqimW0sNOsU", "object": "chat.completion", "created": 1716672095, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sonidegib, marketed under the trade name Odomzo, is an oral hedgehog pathway inhibitor used primarily in the treatment of advanced basal cell carcinoma (BCC). Here are some key points that you, as a physician, should know:\n\n### Indications\n- **Advanced Basal Cell Carcinoma:** Sonidegib is indicated for the treatment of locally advanced BCC that has recurred following surgery or radiation therapy, or for patients who are not candidates for surgery or radiation therapy.\n\n### Mechanism of Action\n- **Hedgehog Pathway Inhibitor:** Sonidegib works by inhibiting the Hedgehog signaling pathway, which is often aberrantly activated in BCC. Specifically, it binds to and inhibits the Smoothened (SMO) receptor, a crucial component of this pathway.\n\n### Administration\n- **Dosage:** The recommended dose of Sonidegib is 200 mg taken orally once daily, at least 1 hour before or 2 hours"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_GzBErWAKlCA9TsVcT7vmOzvN", "custom_id": "245_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8a35d045757d0f40ee0d0c7a69ffd21e", "body": {"id": "chatcmpl-9St7XZ891MifiUDDZWIuZuvE4uCfC", "object": "chat.completion", "created": 1716672095, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sorafenib is an oral multikinase inhibitor used in the treatment of certain types of cancer. As a physician, it is vital to understand its indications, mechanism of action, dosing, and management of potential side effects. Here are some key points:\n\n### Indications\nSorafenib is primarily indicated for:\n1. **Hepatocellular carcinoma (HCC):** It is often used as a first-line treatment.\n2. **Renal cell carcinoma (RCC):** Specifically for advanced renal cell carcinoma.\n3. **Differentiated thyroid carcinoma (DTC):** Used for treatment in patients with locally recurrent or metastatic progressive DTC refractory to radioactive iodine treatment.\n\n### Mechanism of Action\nSorafenib inhibits multiple intracellular and cell surface kinases, which play a role in tumor cell signaling, angiogenesis, and apoptosis. The primary targets include:\n- RAF kinases (CRAF, BRAF) including mutant BRAF\n- VEGFR-1, VEGFR"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_5zWAaX4msD1by4YZ3dECcpgc", "custom_id": "246_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b7f34cec3fcb8cea96713998074a8c67", "body": {"id": "chatcmpl-9St7XWgPopNzqUG9LfCt2XRS4OG15", "object": "chat.completion", "created": 1716672095, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Streptozocin (also spelled streptozotocin) is an antineoplastic agent commonly used in the treatment of certain types of pancreatic cancer, specifically pancreatic neuroendocrine tumors (PNETs). It is also used in research settings to induce diabetes in experimental animal models due to its selective toxicity to insulin-producing beta cells of the pancreas. Here are some important aspects you should be aware of:\n\n### Mechanism of Action\n- **Chemical Nature:** Streptozocin is a naturally occurring nitrosourea compound that has alkylating properties.\n- **Mechanism:** It primarily acts by alkylating DNA, leading to the impairment of DNA synthesis and function, which induces cell death. It shows selective uptake by pancreatic beta cells due to its glucose moiety.\n\n### Clinical Uses\n- **Cancer Treatment:** It's mainly used to treat metastatic pancreatic islet cell tumors and has shown some efficacy against other neuroendocrine tumors.\n- **Research Tool:** Utilized extensively in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_JtLQWpOAaRE6H8Mw49gCxtvH", "custom_id": "247_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ebae13dce18b7c6ef101dcb00e1a9cc6", "body": {"id": "chatcmpl-9St7X7gwiYYnK7fcU0RazdE2Nej1b", "object": "chat.completion", "created": 1716672095, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sunitinib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that is used in the treatment of various cancers. Here are some key points you should know about Sunitinib:\n\n### Indications:\n1. **Renal Cell Carcinoma (RCC)**: It's commonly used as first-line treatment for metastatic RCC.\n2. **Gastrointestinal Stromal Tumor (GIST)**: Approved for patients with unresectable or metastatic GIST who have progressed on or are intolerant to imatinib.\n3. **Pancreatic Neuroendocrine Tumors (pNETs)**: Used for treating advanced or metastatic pNETs.\n\n### Mechanism of Action:\n- Sunitinib inhibits multiple RTKs that are involved in tumor growth, neoangiogenesis, and metastatic progression. These include:\n  - Vascular endothelial growth factor receptors (VEGFR)\n  - Platelet-derived growth factor receptors (PDGFR)\n  -"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_AULQhWWExZlcDbu6pA2Wx0DZ", "custom_id": "248_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d4b68e25de30a1ea86d11b9a4db31b46", "body": {"id": "chatcmpl-9St7XG1vGRmQCxiDdhrGFbT4OjN4k", "object": "chat.completion", "created": 1716672095, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tagraxofusp, marketed under the brand name Elzonris, is a fusion protein therapy used primarily in the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). It combines interleukin-3 (IL-3) with a truncated diphtheria toxin, targeting the CD123 receptor which is overexpressed in BPDCN and certain other hematologic malignancies. Here are key points that physicians should know about Tagraxofusp:\n\n1. **Indications:**\n   - FDA-approved for the treatment of BPDCN in adult and pediatric patients two years and older.\n   \n2. **Mechanism of Action:**\n   - Tagraxofusp binds to the CD123 receptor on cells, facilitating the entry of the diphtheria toxin into the cells. The toxin inhibits protein synthesis, leading to cell death of CD123-expressing malignant cells.\n\n3. **Administration:**\n   - Given via intravenous infusion, typically once daily"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_pJMqP7S0D4WjNIBZaKJCwrhX", "custom_id": "249_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "703386bde7ee0d93d970457310f133e4", "body": {"id": "chatcmpl-9St7Yh3o1mbazWhTNidwcvFdfSEbL", "object": "chat.completion", "created": 1716672096, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Talazoparib is a potent oral poly (ADP-ribose) polymerase (PARP) inhibitor used primarily in the treatment of specific types of breast cancer. As a physician, here are key points you should be aware of regarding Talazoparib:\n\n1. **Mechanism of Action**:\n   - Talazoparib inhibits the PARP enzyme, which plays a crucial role in DNA repair. By inhibiting this enzyme, Talazoparib causes cancer cells to accumulate DNA damage, leading to cell death, particularly in cells with BRCA1 or BRCA2 mutations that already have impaired DNA repair mechanisms.\n\n2. **Indications**:\n   - Talazoparib is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. Patients should be selected for therapy based on an FDA-approved companion diagnostic for Talazoparib.\n\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_toi2qkKnlonkvTs7oJ2ubsnm", "custom_id": "250_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "211bf7c2f2df7bad55d72749d7f1e4fa", "body": {"id": "chatcmpl-9St7Y5giQ0fH8BIz0OZrFrMNaJHH4", "object": "chat.completion", "created": 1716672096, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Talimogene laherparepvec (often abbreviated as T-VEC) is an oncolytic viral therapy used in the treatment of certain types of cancer, particularly advanced melanoma. Here\u2019s a detailed overview of what you should know as a physician:\n\n### Mechanism of Action\n- **Oncolytic Virus**: T-VEC is a genetically modified herpes simplex virus type 1 (HSV-1). It selectively infects and destroys cancer cells while sparing normal cells.\n- **GM-CSF Expression**: The virus has been engineered to express granulocyte-macrophage colony-stimulating factor (GM-CSF), which boosts an anti-tumor immune response.\n- **Dual Action**: It works by directly lysing (destroying) cancer cells and stimulating a systemic immune response against the tumor.\n\n### Indications\n- T-VEC is approved for the treatment of unresectable, regionally or distantly metastatic melanoma. It is particularly useful for patients with injectable"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_yiE4wq6ysECBYQSnaJ5QwEyn", "custom_id": "251_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8fd4ead510aeeffcb5fdce36c81bedbb", "body": {"id": "chatcmpl-9St7YxywtyX2q94WwU0bZnobtt51K", "object": "chat.completion", "created": 1716672096, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tamibarotene is a synthetic retinoid compound that has shown promise in the treatment of certain types of cancer, particularly acute promyelocytic leukemia (APL). Here are some key points you should know about Tamibarotene:\n\n1. **Mechanism of Action**: Tamibarotene works by binding to retinoic acid receptors (RARs) in cells. This binding promotes differentiation and inhibits the proliferation of malignant cells. It is more selective for the RAR-\u03b1 and RAR-\u03b2 subtypes, which are often implicated in leukemia.\n\n2. **Indications**: Tamibarotene is primarily used in the treatment of APL, especially in cases where patients are resistant to or have relapsed after treatment with all-trans retinoic acid (ATRA). It has also been explored in other types of cancer and skin conditions, though its primary use remains in APL.\n\n3. **Administration**: Tamibarotene is usually administered orally. The dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_e5BZaPsig0GdO6fHbCU2uoiD", "custom_id": "252_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "04a33d52a4f5cc1d3413744a529f16d8", "body": {"id": "chatcmpl-9St7Yq5BDHw2dzLP8e42vCDFYaS8x", "object": "chat.completion", "created": 1716672096, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tamoxifen is a selective estrogen receptor modulator (SERM) primarily used in the treatment and prevention of breast cancer. Here are some key points you should know about Tamoxifen:\n\n### Mechanism of Action:\n- **Estrogen Receptor Modulation**: Tamoxifen binds to estrogen receptors, blocking estrogen from exerting its effects on certain tissues such as breast tissue. In breast tissue, it acts as an estrogen antagonist, inhibiting cell proliferation.\n- **Tissue-Specific Effects**: While it acts as an antagonist in breast tissue, Tamoxifen can act as an agonist in other tissues such as bones and the endometrium, providing beneficial effects like bone density maintenance.\n\n### Indications:\n- **Breast Cancer Treatment**: It is used for estrogen receptor-positive (ER+) breast cancer in both premenopausal and postmenopausal women.\n- **Breast Cancer Prevention**: It's also prescribed for women at high risk of developing breast cancer.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_EuJwuHXDp0wIgkF0BxGz354G", "custom_id": "253_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2db948e215371167f2d99d3fc5bde03c", "body": {"id": "chatcmpl-9St7Y7HR4xqh3Xj5GIv68n0lSwVjI", "object": "chat.completion", "created": 1716672096, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tegafur, gimeracil, and oteracil are components of an oral anticancer medication often known under the brand name S-1, which is used primarily in the treatment of gastric cancer and other solid tumors. Here's a comprehensive overview of each component and the combination:\n\n### Tegafur\n- **Mechanism of Action**: Tegafur is a prodrug of 5-fluorouracil (5-FU). It is converted into 5-FU in the body, which then interferes with DNA synthesis by inhibiting the enzyme thymidylate synthase, and incorporates into RNA to interfere with RNA processing and function.\n- **Pharmacokinetics**: Tegafur is slowly converted to 5-FU in the liver, allowing for a more prolonged exposure to 5-FU compared to direct administration.\n\n### Gimeracil\n- **Mechanism of Action**: Gimeracil inhibits dihydropyrimid"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 49, "completion_tokens": 200, "total_tokens": 249}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_X5DMLRsk13lEJBdzDF8QNy7h", "custom_id": "254_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9edf740bb62af8edca9160f8739e83ab", "body": {"id": "chatcmpl-9St7YuKh8xJbaROKUHpTVxTszFrBs", "object": "chat.completion", "created": 1716672096, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tegafur and uracil are commonly used in combination in certain cancer treatments, particularly for colorectal cancer. Here's a detailed understanding of both:\n\n### Tegafur\n1. **Classification**: Tegafur is an oral prodrug of 5-fluorouracil (5-FU), a well-known chemotherapeutic agent.\n   \n2. **Mechanism of Action**: Tegafur is metabolized in the liver to 5-FU, which then interferes with DNA synthesis by inhibiting the enzyme thymidylate synthase. This action disrupts the synthesis of thymidine, a nucleoside necessary for DNA replication and repair, ultimately leading to cell death.\n   \n3. **Pharmacokinetics**: Tegafur has a longer half-life compared to 5-FU, allowing for oral administration and more stable plasma levels of 5-FU.\n   \n4. **Indications**: It is mainly used in the treatment of colorectal"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_EN7x4zD52mEJyw9WWJPGk5nW", "custom_id": "255_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "671e8051014cfc891c101560acfae2c2", "body": {"id": "chatcmpl-9St7YdwINofyCTNJcAYHzix2QWPni", "object": "chat.completion", "created": 1716672096, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it\u2019s important to have a comprehensive understanding of Temozolomide, a chemotherapeutic agent commonly used in the treatment of certain brain tumors. Here are key points to know:\n\n### General Information:\n1. **Indications:**\n   - **Malignant Gliomas:** Temozolomide is primarily used to treat adults with newly diagnosed glioblastoma multiforme in combination with radiotherapy (RT) and as a maintenance treatment thereafter.\n   - **Anaplastic Astrocytoma:** It is also indicated for patients with refractory anaplastic astrocytoma, defined as those who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine.\n\n2. **Mechanism of Action:**\n   - Temozolomide is an alkylating agent of the imidazotetrazine derivative class. It temozolomide is nonclassical alkylating agent which causes DNA alkylation,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_tynaJsV0TnVZMjWN7UJislAZ", "custom_id": "256_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "c1037a63e9764d786708472f5075aeca", "body": {"id": "chatcmpl-9St7YHKUvynFYBH8YZUZd2FGbAPrL", "object": "chat.completion", "created": 1716672096, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Temsirolimus, particularly if you are managing patients with certain types of cancer. Here are key points you should consider:\n\n### 1. Mechanism of Action:\n- **Temsirolimus** is an mTOR (mammalian target of rapamycin) inhibitor. It interferes with the mTOR pathway, which is crucial for cell growth, proliferation, and survival. By inhibiting this pathway, Temsirolimus can help to halt the growth of cancer cells.\n\n### 2. Indications:\n- **Renal Cell Carcinoma:** It is primarily approved for the treatment of advanced renal cell carcinoma (RCC).\n- Other off-label uses might include certain types of lymphomas and other solid tumors, though these applications would be determined based on evolving clinical evidence and guidelines.\n\n### 3. Administration:\n- **Intravenous Infusion:** Temsirolimus is administered via intravenous infusion. The usual dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_zeTwGuN6WAjPQnF9p9TkGity", "custom_id": "257_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "c9396d6ac0da19a4e4e6b71320ce1818", "body": {"id": "chatcmpl-9St7Zs3CO05U5BnS0OSU4Y8cBG6eI", "object": "chat.completion", "created": 1716672097, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, understanding Teniposide is essential, especially if you are involved in oncology or treating hematologic conditions. Here's a comprehensive overview:\n\n### General Information\n- **Generic Name:** Teniposide\n- **Brand Name:** Vumon\n- **Drug Class:** Plant alkaloids and podophyllotoxin derivatives\n- **Mechanism of Action:** Teniposide inhibits the enzyme topoisomerase II, which is necessary for DNA unwinding, making it crucial for DNA replication and transcription. It induces breaks in the DNA strands, leading to apoptosis of the cancer cells.\n\n### Indications\n- **Primary Use:** Teniposide is primarily used in the treatment of childhood acute lymphoblastic leukemia (ALL), particularly in patients who have relapsed or are refractory to first-line treatment.\n- **Other Uses:** It can be used in combination with other chemotherapeutic agents for various malignancies, including small cell lung cancer, non-Hodgkin lymphoma, and neuroblast"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_OA4KnjwCEvN5R3UmEqtcHaBa", "custom_id": "258_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e271f1ffd3f1ecca1e8b0efd744446b9", "body": {"id": "chatcmpl-9St7ZZINqewlxACgqgU44T04Q7hqT", "object": "chat.completion", "created": 1716672097, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Thalidomide is a medication with a complex history and a range of contemporary uses. Here's what you should know about it:\n\n### History:\n1. **Initial Use and Tragedy**: Thalidomide was first marketed in the late 1950s as a sedative and later as a treatment for morning sickness in pregnant women. However, it caused severe birth defects (phocomelia) when taken by pregnant women, affecting thousands of children worldwide.\n\n2. **Withdrawal and Regulations**: Due to its teratogenic effects, Thalidomide was withdrawn from the market in the early 1960s. This tragedy led to stricter drug regulations and monitoring processes globally.\n\n### Mechanism of Action:\n- **Multi-faceted**: Thalidomide works via multiple pathways. It possesses immunomodulatory, anti-inflammatory, and anti-angiogenic properties. The exact mechanisms are still being researched, but it affects the production of TNF-alpha and other cytokines,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Ea6PsmFgw5cICgM4jZKkATEH", "custom_id": "259_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "410cb74ea4c0ccca20db67c4f0bc4535", "body": {"id": "chatcmpl-9St7ZstRU20dzguZmjKxuIuJ3OTKi", "object": "chat.completion", "created": 1716672097, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Thioguanine, also known as 6-thioguanine (6-TG), is a purine analog and a type of chemotherapy drug used primarily in the treatment of certain types of leukemia, such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Here are some key points you should know about Thioguanine:\n\n### Mechanism of Action:\n- **Inhibition of DNA Synthesis**: Thioguanine is incorporated into DNA and RNA, leading to the inhibition of DNA replication and RNA transcription. This inhibits the proliferative capacity of rapidly dividing cancer cells.\n- **Enzyme Inhibition**: It also inhibits enzymes involved in purine metabolism, contributing to its cytotoxic effects.\n\n### Indications:\n- **Acute Myeloid Leukemia (AML)**: Often used in combination with other chemotherapeutic agents.\n- **Acute Lymphoblastic Leukemia (ALL)**: Sometimes used as part of maintenance therapy.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_BqerxBlbf8wmViNNXOLRLfon", "custom_id": "260_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f7dd3c82c645178fda87fcf18aa4a491", "body": {"id": "chatcmpl-9St7Zrfp6JeC5uiWv4aPQzbW20QCs", "object": "chat.completion", "created": 1716672097, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is essential to have a comprehensive understanding of Thiotepa, particularly if you are involved in oncology or hematology. Here are some key points:\n\n**1. Mechanism of Action:**\nThiotepa is an alkylating agent that cross-links DNA, leading to the disruption of DNA synthesis and function, ultimately causing cell death. It is particularly toxic to rapidly dividing cells, which makes it effective against certain types of cancer.\n\n**2. Indications:**\nThiotepa is used to treat various types of cancer, including:\n   - Breast cancer\n   - Ovarian cancer\n   - Bladder cancer\n   - Lymphomas (Hodgkin's and non-Hodgkin's)\n   - It is also used in high-dose chemotherapy regimens before hematopoietic stem cell transplantation.\n\n**3. Dosage and Administration:**\n- Thiotepa can be administered intravenously, intracavitarily (e.g., intraperitone"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_wlwbc6OZEDl3NLt6JIBHp3G0", "custom_id": "261_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "21bc570a2e9ffe6b4d789e21347139f7", "body": {"id": "chatcmpl-9St7ZtTmF8KueJ5FNJ5f7VSxGEkw0", "object": "chat.completion", "created": 1716672097, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tisagenlecleucel, sold under the brand name Kymriah, is a type of chimeric antigen receptor T-cell (CAR-T) therapy. It's designed to treat certain types of blood cancers. Here's what you should know:\n\n### Indications:\n- **Pediatric and Young Adult Acute Lymphoblastic Leukemia (ALL):** Indicated for patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse.\n- **Adult Relapsed or Refractory (r/r) Large B-cell Lymphoma:** Includes diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.\n\n### Mechanism of Action:\n- **CAR-T Cells:** Tisagenlecleucel genetically modifies a patient's T-cells to express a chimeric antigen receptor that specifically targets CD19, a protein found on the surface of B cells,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_cqSZtM4f9FlI6RhvYRkm20JZ", "custom_id": "262_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8459f10c78f5cb67dc76331e0f307dcb", "body": {"id": "chatcmpl-9St7ZbolJxWIReihPD4hb47v5CsR9", "object": "chat.completion", "created": 1716672097, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tivozanib is a targeted cancer therapy, specifically a tyrosine kinase inhibitor, that selectively inhibits vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3. Here are some key points you, as a physician, should know about Tivozanib:\n\n1. **Indications**: Tivozanib is primarily indicated for the treatment of advanced renal cell carcinoma (RCC). It may be used in patients who have received prior therapy or as a first-line treatment.\n\n2. **Mechanism of Action**: By inhibiting the VEGF receptors, Tivozanib interferes with the blood supply that tumors need to grow and metastasize, thereby inhibiting tumor growth.\n\n3. **Efficacy**: Clinical trials have shown that Tivozanib can significantly extend progression-free survival in patients with advanced RCC compared to some other treatments.\n\n4. **Administration**: Tivozanib is administered orally, typically as a once-d"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_PC9igrNiDwUgehGub35KUu78", "custom_id": "263_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "aade393eb6cec67c62f066f8b08893d1", "body": {"id": "chatcmpl-9St7ZaXZI1QojPF9ROb9dcEThgghJ", "object": "chat.completion", "created": 1716672097, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Topotecan is a chemotherapeutic agent primarily used to treat certain types of cancer. Here are key points you should know about it:\n\n1. **Mechanism of Action**: Topotecan is a topoisomerase I inhibitor. It interferes with the enzyme topoisomerase I, which is essential for DNA replication. By inhibiting this enzyme, topotecan causes DNA damage, leading to cell death, especially in rapidly dividing cancer cells.\n\n2. **Indications**: \n   - **Ovarian Cancer**: For patients with metastatic ovarian cancer after failure of initial or subsequent chemotherapy.\n   - **Small Cell Lung Cancer (SCLC)**: For chemotherapy-sensitive SCLC patients with relapse within 6 months of completing first-line therapy.\n   - **Cervical Cancer**: In combination with cisplatin, for the treatment of stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment.\n\n3. **Administration**:\n   -"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_uqmhulWYZegACrjMtmjPzwpb", "custom_id": "264_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1b667e7736ce2f0fd1e482ad876e3fac", "body": {"id": "chatcmpl-9St7ZQG54T7WrskOaqh18nSBgQHPP", "object": "chat.completion", "created": 1716672097, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Toremifene is a selective estrogen receptor modulator (SERM) primarily used in the treatment of estrogen receptor-positive metastatic breast cancer in postmenopausal women. Here are several key points you should know about toremifene:\n\n### Pharmacology and Mechanism of Action:\n- **Mechanism of Action**: Toremifene binds to estrogen receptors on tumors and other tissue targets, producing an anti-estrogenic effect, which helps inhibit the proliferation of estrogen-dependent cancer cells.\n- **Pharmacokinetics**: It is well absorbed orally and has a long half-life, ranging from 5 to 7 days. It is metabolized in the liver, primarily via the CYP3A4 pathway.\n\n### Indications:\n- **Primary Indication**: It is mainly indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women.\n\n### Dosage:\n- **Standard Dosage**: The typical dosage is 60 mg once daily, taken"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_I7taTHER2as7MaKiXXZI5I5F", "custom_id": "265_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "951ec3e90874729d9ae3c72a6f62b272", "body": {"id": "chatcmpl-9St7ZsAKWmH2TARwuyBBM0BgQ0cWG", "object": "chat.completion", "created": 1716672097, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tositumomab and I-131 Tositumomab (Bexxar) is a radioimmunotherapy treatment that was used for certain types of non-Hodgkin lymphoma (NHL), particularly when the disease was refractory to other treatments or had relapsed. Here's a comprehensive overview:\n\n### Tositumomab Component:\n1. **Mechanism of Action**:\n   - Tositumomab is a monoclonal antibody that targets the CD20 antigen on B-cells.\n   - By binding to CD20, it induces cell death through various mechanisms, including apoptosis and immune system-mediated killing.\n\n2. **Administration**:\n   - Administered intravenously in two steps: an initial dosimetric dose and a subsequent therapeutic dose.\n   - The dosimetric dose helps calculate the appropriate therapeutic dose based on the patient's individual biodistribution of the radioisotope.\n\n### I-131 Component:\n1. **Iodine-131 (I"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_zgnyfCbbKTRwgXlbVSRa3i10", "custom_id": "266_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6a1d96675a61f3c5093e4969361123e4", "body": {"id": "chatcmpl-9St7aLFBzbMi1ZGaEH1Q1JFFBhz7P", "object": "chat.completion", "created": 1716672098, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trabectedin (brand name Yondelis) is a chemotherapeutic agent derived from the sea squirt, Ecteinascidia turbinata. Here are some key points to know about Trabectedin:\n\n### Indications:\n- **Soft Tissue Sarcoma:** Trabectedin is primarily used for the treatment of advanced soft tissue sarcoma, particularly liposarcoma and leiomyosarcoma, that has progressed despite prior anthracycline-based chemotherapy.\n- **Relapsed Ovarian Cancer:** It is also used in combination with pegylated liposomal doxorubicin (PLD) for relapsed ovarian cancer after failure of platinum-based chemotherapy.\n\n### Mechanism of Action:\n- **DNA Interaction:** Trabectedin binds to the minor groove of DNA, causing a bend in the DNA helix that interferes with the transcriptional machinery and leads to DNA strand breaks.\n- **Induction of Apoptosis:** It causes cell cycle arrest and induces apoptosis in cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_yznVy7EybokJGyU66TDb7T3l", "custom_id": "267_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1620ee017036b38749b8e104786d0e05", "body": {"id": "chatcmpl-9St7a7jx95BNfuxGIZnjtWHYJaJwR", "object": "chat.completion", "created": 1716672098, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trametinib is a targeted cancer therapy known as a MEK inhibitor. Here are key points a physician should be aware of regarding this medication:\n\n### Indications\n- **Approved Uses**: Trametinib is primarily used to treat certain types of cancer, specifically:\n  - Metastatic melanoma with a BRAF V600E or V600K mutation.\n  - Non-small cell lung cancer (NSCLC) with the same mutations.\n  - It may also be used in combination with other medications like dabrafenib (a BRAF inhibitor) to enhance efficacy.\n\n### Mechanism of Action\n- **MEK Inhibitor**: Trametinib inhibits MEK1 and MEK2, enzymes in the MAPK/ERK pathway, which is often overactive in cancers with BRAF mutations. By inhibiting these enzymes, trametinib can reduce cancer cell proliferation and survival.\n\n### Administration\n- **Form**: It is taken orally in tablet form.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_wLITppeWkvQhPQ4SnHwvWPpt", "custom_id": "268_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b1a1164b5f929a93d160a24cd53bda0c", "body": {"id": "chatcmpl-9St7abTWktbSOH92tPVInQ2ISqWLY", "object": "chat.completion", "created": 1716672098, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, you should know that Tranexamic acid (TXA) is an antifibrinolytic medication that inhibits the breakdown of fibrin clots, stabilizing them and reducing bleeding. Here are some key points:\n\n1. **Mechanism of Action**: Tranexamic acid works by competitively inhibiting the activation of plasminogen to plasmin, an enzyme that breaks down fibrin clots. This action helps to maintain clot stability and reduces bleeding.\n\n2. **Indications**:\n   - **Trauma**: TXA is used in the management of traumatic hemorrhage. Early administration (within three hours of injury) is associated with reduced mortality.\n   - **Surgical Bleeding**: Prophylactic use in various surgical procedures (e.g., cardiac, orthopedic, and liver surgery) to reduce intraoperative and postoperative bleeding.\n   - **Heavy Menstrual Bleeding**: TXA is often prescribed to women experiencing menorrhagia.\n   -"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_N9WDcQzylVFMTPTwgRMAEW8t", "custom_id": "269_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "c45254efef887966650516d374bf8376", "body": {"id": "chatcmpl-9St7aihseZ7jtZvtqSao3oH3k5MBL", "object": "chat.completion", "created": 1716672098, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab, commonly known by its brand name Herceptin, is a monoclonal antibody used in the treatment of certain types of breast cancer and gastric cancer. Here are key points you should be aware of as a physician:\n\n### Mechanism of Action:\n- **HER2 Targeting:** Trastuzumab specifically targets the HER2 receptor, a protein overexpressed in some breast and gastric cancers. HER2-positive cancers tend to be more aggressive.\n- **Antibody-Dependent Cytotoxicity:** It binds to the HER2 receptor on cancer cells, inhibiting their proliferation and may engage immune cells to destroy the targeted cancer cells.\n\n### Indications:\n- **Breast Cancer:** It's commonly used to treat HER2-positive breast cancer, both in the early-stage setting (adjuvant therapy) and in the metastatic setting.\n- **Gastric Cancer:** Indicated for HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.\n\n### Administration:\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_IjmALJMTazJtvrUTL5pJ6zNU", "custom_id": "270_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "030aaadd091e636858bf4e80a84f3d20", "body": {"id": "chatcmpl-9St7aVTHwj5DnrFFaoCKdWus7G3B7", "object": "chat.completion", "created": 1716672098, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tremelimumab is a fully human monoclonal antibody that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), an immune checkpoint receptor on T cells. By inhibiting CTLA-4, tremelimumab enhances T-cell activity and amplifies the body's immune response against tumor cells.\n\nHere are several key points you should know about tremelimumab:\n\n### Indications and Uses:\n1. **Cancer Treatment**: Tremelimumab is primarily being investigated and used in the treatment of various cancers, including melanoma, mesothelioma, and certain types of advanced liver cancer (hepatocellular carcinoma).\n\n2. **Combination Therapy**: Often, tremelimumab is used in combination with other immune checkpoint inhibitors, such as PD-1 or PD-L1 inhibitors (e.g., durvalumab), to enhance anti-tumor efficacy.\n\n### Mechanism of Action:\n1. **CTLA-4 Inhibition**: Tremel"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_yjp2JrQC9whgoRApAQK1yi4Y", "custom_id": "271_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "036c356221d6b5fb39c1f1da42495bdb", "body": {"id": "chatcmpl-9St7aJb3yKOLD5rRbbTWg1wwGB4yg", "object": "chat.completion", "created": 1716672098, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Treosulfan is a chemotherapy agent used primarily in the treatment of certain types of cancers, especially ovarian cancer. It can also be used as a part of conditioning regimens before hematopoietic stem cell transplantation (HSCT). Here are some important points to consider:\n\n### Pharmacology\n- **Mechanism of Action:** Treosulfan is a prodrug that is converted in the body to a bifunctional alkylating agent. It works by cross-linking DNA, leading to DNA strand breaks and ultimately apoptosis (cell death).\n  \n### Indications\n- **Ovarian Cancer:** Treosulfan has been used for the treatment of advanced ovarian cancer, particularly in patients who have already undergone prior chemotherapy.\n- **Conditioning for HSCT:** Treosulfan is used before HSCT to help eliminate malignant cells and create space in the bone marrow for new, healthy cells to grow.\n\n### Administration\n- **Dosage and Routes:** Administration protocols can vary but it"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_vB9mpqPoFl5IIwXb8ewih7ct", "custom_id": "272_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "018ffdba08f64953a06160d2dfa3f478", "body": {"id": "chatcmpl-9St7aVUIpilxdQqx6XgSmLCJR1DoI", "object": "chat.completion", "created": 1716672098, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trifluridine and tipiracil combination, marketed under the name Lonsurf, is an oral anti-cancer medication used primarily in the treatment of metastatic colorectal cancer and metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. As a physician, here are some key points you should know:\n\n### Mechanism of Action\n- **Trifluridine**: This is a nucleoside analog that gets incorporated into DNA during replication, leading to DNA dysfunction and ultimately cell death.\n- **Tipiracil**: This component inhibits thymidine phosphorylase, an enzyme involved in the degradation of trifluridine, thus maintaining higher systemic levels of trifluridine.\n\n### Indications\n- **Metastatic Colorectal Cancer**: Typically used in patients who have been previously treated with other chemotherapy regimens or who have progressed beyond first-line treatment.\n- **Metastatic Gastric or GEJ Adenocarcinoma**: Used for patients"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_bbjwlTcOTJzt18LAMudhkCHf", "custom_id": "273_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "dab32c88fca1dcd36089f79d7c7f614e", "body": {"id": "chatcmpl-9St7aVGDaX3os0vdrIHSgWirXMRbq", "object": "chat.completion", "created": 1716672098, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Triptorelin is a synthetic decapeptide agonist analog of gonadotropin-releasing hormone (GnRH) used primarily in the treatment of hormone-dependent conditions. Here are some key points you should know about Triptorelin:\n\n1. **Mechanism of Action**:\n   - Triptorelin initially stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland.\n   - With continuous administration, it downregulates GnRH receptors, leading to decreased secretion of LH and FSH, and ultimately reduced production of sex steroids (testosterone and estrogen).\n\n2. **Indications**:\n   - **Prostate Cancer**: Used in the palliative treatment of advanced prostate cancer due to its ability to lower testosterone levels.\n   - **Endometriosis**: Helps reduce estrogen production, which can alleviate symptoms.\n   - **Precocious Puberty**: Used to delay the onset of puberty in children"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_TXluMJnxqd0Kl23UXbc3skID", "custom_id": "274_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8e9459cac83a5db2cd3f9d715956ddbd", "body": {"id": "chatcmpl-9St7aOnXx2StcNGVz5N0c3aTi9t1x", "object": "chat.completion", "created": 1716672098, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Valproate (also known as valproic acid, divalproex sodium, and other formulations) is an anticonvulsant and mood-stabilizing drug that is used to treat a variety of conditions, most notably epilepsy, bipolar disorder, and, in some instances, migraine headaches. Here is a summary of key points you should be aware of:\n\n1. **Mechanism of Action:**\n   - Valproate affects the central nervous system by increasing the levels of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter. This helps to stabilize neuronal activity and prevent seizures.\n\n2. **Indications:**\n   - **Epilepsy:** Used for various types of seizures including absence, partial, and generalized seizures.\n   - **Bipolar Disorder:** Effective in the management of manic episodes and maintenance therapy to prevent recurrence.\n   - **Migraine Prophylaxis:** Sometimes used to prevent migraine headaches.\n\n3. **Dosage and Administration:**\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_MLONQa5XDWYPzM6xlklhV3gM", "custom_id": "275_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a34864c62c4f7cec7f5f55a82962ab99", "body": {"id": "chatcmpl-9St7aByIvPF9MQ69rBOtDTGERBxqr", "object": "chat.completion", "created": 1716672098, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Valrubicin is a chemotherapeutic agent used primarily for the treatment of bladder cancer. Below are some key points you should be aware of as a physician:\n\n### Mechanism of Action\n- Valrubicin is an anthracycline derivative. It works by intercalating DNA and inhibiting the enzyme topoisomerase II, leading to disruption of DNA function and cell death.\n\n### Indications\n- Valrubicin is indicated for the treatment of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.\n\n### Administration\n- It is administered intravesically, meaning it is instilled directly into the bladder through a catheter.\n- The recommended dose is typically 800 mg administered once a week for six weeks.\n\n### Efficacy\n- Valrubicin has shown efficacy in inducing complete responses in a subset of patients with BCG-refractory CIS, though the complete response rate and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_YRSFOyh9fsRpT9eQnO6dZrz1", "custom_id": "276_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8c5f3bce4fcf532309c7a7aa8ba1334a", "body": {"id": "chatcmpl-9St7bT7fPuQrRjO3zO8M8MJka3bEH", "object": "chat.completion", "created": 1716672099, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vandetanib is a medication specifically used for the treatment of certain types of thyroid cancer. Here are some key points you should know about Vandetanib as a physician:\n\n1. **Indications**: Vandetanib is primarily used in the treatment of symptomatic or progressive medullary thyroid cancer (MTC) in patients with unresectable, locally advanced, or metastatic disease.\n\n2. **Mechanism of Action**: Vandetanib is a kinase inhibitor that targets multiple receptors involved in tumor growth and angiogenesis, including the vascular endothelial growth factor receptor (VEGFR), the epidermal growth factor receptor (EGFR), and the rearranged during transfection (RET) tyrosine kinases.\n\n3. **Dosage and Administration**: The usual dosage for adults is 300 mg once daily, taken orally with or without food. It's important to monitor the patient\u2019s response and adjust the dosage accordingly.\n\n4. **Adverse Effects**: Common adverse effects include diarrhea,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_KqZ3W1dm5ptwr0pGp4uoYGyY", "custom_id": "277_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "31869febd6f1a2380472446d01cd4ea5", "body": {"id": "chatcmpl-9St7b1QAcFwMNv778VPpUwFBssRMR", "object": "chat.completion", "created": 1716672099, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vemurafenib is a targeted therapy that is primarily used to treat certain types of cancer, specifically unresectable or metastatic melanoma with a mutation in the BRAF gene (specifically, the BRAF V600E mutation). As a physician, here are some important points to know about Vemurafenib:\n\n1. **Mechanism of Action**: Vemurafenib is a BRAF inhibitor. It works by selectively inhibiting the mutated BRAF V600E kinase, which is part of the MAPK/ERK signaling pathway involved in cell growth and proliferation.\n\n2. **Indications**: The primary indication for Vemurafenib is the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation. It may also be used in other BRAF V600 mutation-positive cancers, but this is less common and typically off-label.\n\n3. **Administration**: Vemurafenib is an oral medication, usually administered twice"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_lUkYPA5Lq1LVoUvUzwYVDOnX", "custom_id": "278_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "34b2f94b0c6876406934d8255244b2c0", "body": {"id": "chatcmpl-9St7bADpIo4cnDmWtOjkUrREZE2Xy", "object": "chat.completion", "created": 1716672099, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Venetoclax is an oral medication that is used primarily to treat certain types of blood cancers, including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It is also used in combination with other therapies for acute myeloid leukemia (AML). As a physician, it's important to understand the mechanism of action, indications, dosing considerations, potential side effects, and monitoring requirements for Venetoclax.\n\n### Mechanism of Action\nVenetoclax is a BCL-2 inhibitor. BCL-2 is a protein that prevents apoptosis in cancer cells. By inhibiting BCL-2, Venetoclax promotes the apoptotic death of cancer cells, thereby reducing tumor burden.\n\n### Indications\n- **Chronic Lymphocytic Leukemia (CLL)**\n- **Small Lymphocytic Lymphoma (SLL)**\n- **Acute Myeloid Leukemia (AML)**: Typically in combination with other agents, such"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_2bUPTUhQiq93eJ6PAl3BZ10c", "custom_id": "279_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9ad742c504579a77402d4d34696b7990", "body": {"id": "chatcmpl-9St7bPUwjGH8hufhiZMgFlvkpSydw", "object": "chat.completion", "created": 1716672099, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vinblastine is a chemotherapy medication primarily used for the treatment of certain types of cancer, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer, breast cancer, and Kaposi's sarcoma. Here are some important aspects a physician should know about Vinblastine:\n\n### Mechanism of Action:\n- **Microtubule Inhibitor**: Vinblastine interferes with the microtubule formation during cell division. It binds to tubulin, inhibiting the polymerization of tubulin into microtubules, thus preventing the mitotic spindle formation and causing cell cycle arrest in metaphase.\n\n### Administration:\n- **Route**: Vinblastine is typically administered intravenously.\n- **Dosage**: The dose varies based on the type of cancer, patient\u2019s weight/height (body surface area), and clinical protocol. It's important to follow specific guidelines for dosing.\n\n### Pharmacokinetics:\n- **Distribution**: It distributes widely in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Bg58QDvWwMZnkPHgBAjV2YhZ", "custom_id": "280_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b3aa9b597c9b73c37eecf5b49428a600", "body": {"id": "chatcmpl-9St7buh74kP5ZzXrmc00RIxU0ewNy", "object": "chat.completion", "created": 1716672099, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vincristine is a chemotherapeutic agent used primarily in the treatment of various malignancies. Here are some key points you should be aware of as a physician:\n\n### Mechanism of Action:\n- **Vincristine** is a vinca alkaloid that works by inhibiting microtubule formation in the mitotic spindle, thereby arresting cell division at the metaphase stage of mitosis. This is crucial in the treatment of rapidly dividing cancer cells.\n\n### Clinical Uses:\n- It is used in the treatment of several types of cancer, including:\n  - Acute lymphoblastic leukemia (ALL)\n  - Hodgkin lymphoma\n  - Non-Hodgkin lymphoma\n  - Wilms' tumor\n  - Neuroblastoma\n  - Rhabdomyosarcoma\n  - Other pediatric solid tumors\n\n### Administration:\n- Vincristine is administered intravenously. Care should be taken to avoid extravasation, as vincristine is a vesicant and can"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_5WzvuXJFSMpkUsZbNm4sttSF", "custom_id": "281_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "46c5c84bc4188ce9fa837f9e044641f6", "body": {"id": "chatcmpl-9St7b8m2bCjn7UHRuWFgfsHy96Hq4", "object": "chat.completion", "created": 1716672099, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vincristine liposomal is a formulation of vincristine sulfate encapsulated in liposomes designed to enhance the delivery of the drug to malignant cells while potentially reducing toxicity. It's primarily used in certain types of cancer treatment, most notably in some hematologic malignancies. Here's a comprehensive overview of what you should know about this medication:\n\n### Indications:\n- **Acute Lymphoblastic Leukemia (ALL):** Vincristine liposomal has been approved for use in adults with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia.\n\n### Mechanism of Action:\n- **Vincristine:** It binds to tubulin and inhibits microtubule formation, which disrupts mitotic spindle formation, leading to cell-cycle arrest in metaphase and subsequent apoptosis.\n\n### Pharmacokinetics:\n- **Liposomal Formulation:** The liposomal encapsulation alters the pharmacokinetics by increasing the half-life of vincristine and altering its distribution in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_VnckTb2N6yy6HhhzpBqoFsk4", "custom_id": "282_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "be384e57cf6ca581325fd0f4edcd19cd", "body": {"id": "chatcmpl-9St7bjo7uBJAazzc6PC2llU1n6Nec", "object": "chat.completion", "created": 1716672099, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vindesine is an antineoplastic agent used primarily in the treatment of various types of cancer. As a physician, you should be aware of the following key points about vindesine:\n\n### Mechanism of Action\n- **Classification**: Vindesine is a vinca alkaloid.\n- **Action**: It works by inhibiting microtubule formation during cell division, which ultimately results in the inhibition of mitosis and induces apoptosis in cancer cells.\n\n### Indications\n- **Use**: Vindesine is often used in combination chemotherapy protocols and is indicated for the treatment of various malignancies, including:\n  - Acute lymphoblastic leukemia (particularly in children)\n  - Non-Hodgkin lymphoma\n  - Certain types of lung cancer\n  - Melanoma\n- **Off-label Use**: It may also be used off-label for other types of cancer as determined by clinical guidelines and the patient's oncologist.\n\n### Administration\n- **Formulation**: Vindesine is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_fDHQXbcilVQjQx8apnTmX5LL", "custom_id": "283_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5294a6b47d9ecf989e38b86474e3c8d9", "body": {"id": "chatcmpl-9St7b95NXUZFTvtvKjH2ozny3hd9C", "object": "chat.completion", "created": 1716672099, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vinflunine is a novel semi-synthetic vinca alkaloid that is used primarily in the treatment of cancer. As a physician, here are some key points you should know about vinflunine:\n\n### Indications\n- **Bladder Cancer:** Vinflunine is approved for use in patients with advanced or metastatic transitional cell carcinoma of the urothelial tract, particularly in those who have failed prior platinum-based therapies.\n\n### Mechanism of Action\n- **Antimitotic Agent:** Vinflunine works by inhibiting the polymerization of tubulin, thereby disrupting microtubule dynamics, which are crucial for mitotic spindle formation during cell division. This interruption leads to cell cycle arrest at the metaphase and subsequently induces apoptosis.\n\n### Administration and Dosage\n- **Intravenous Infusion:** Vinflunine is administered via intravenous infusion. The dosage typically depends on the patient\u2019s body surface area, renal function, and other individual factors. The recommended dose for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_FdB5c68ps7UvGA9Et5kv75Uj", "custom_id": "284_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "81137375051662dc0de574f67db5baa5", "body": {"id": "chatcmpl-9St7bbfivqMHptrw2KddLgGdu3Ehl", "object": "chat.completion", "created": 1716672099, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vinorelbine is a semi-synthetic vinca alkaloid used as chemotherapy to treat various cancers, most commonly non-small cell lung cancer (NSCLC) and breast cancer. Here are key points you should know about Vinorelbine:\n\n### Mechanism of Action\n- **Microtubule Inhibition**: Vinorelbine interferes with the polymerization of tubulin into microtubules, thus inhibiting mitosis and causing cell cycle arrest at the metaphase.\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC)**: Often used alone or in combination with other agents (e.g., cisplatin).\n- **Breast Cancer**: Particularly in metastatic settings, either as a single agent or as part of a combination therapy.\n\n### Administration\n- **Route**: Intravenous (IV) infusion or oral capsules.\n- **Dosage**: Dose varies based on the indication, patient\u2019s body surface area, and combination therapy protocols. For"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Mey8UrBUwCxnengBY07A4g02", "custom_id": "285_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "73d222516f7bf6ccba08bba402821083", "body": {"id": "chatcmpl-9St7bSJ6bLPM2M9rCwqiyWyuhUV68", "object": "chat.completion", "created": 1716672099, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vismodegib is a medication commonly used in the treatment of advanced basal cell carcinoma (BCC), a type of skin cancer. It's important for a physician to be familiar with the following key aspects of Vismodegib:\n\n1. **Mechanism of Action**:\n   - Vismodegib is a hedgehog pathway inhibitor. It specifically targets and inhibits the activity of the smoothened (SMO) receptor, a critical component of the hedgehog signaling pathway, which plays a significant role in the development and growth of certain types of cancer, including basal cell carcinoma.\n\n2. **Indications**:\n   - Vismodegib is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced BCC that has recurred following surgery or who are not candidates for surgery or radiation.\n\n3. **Administration**:\n   - It is administered orally, typically as a 150 mg capsule taken once daily, with or without food.\n\n4."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_zkFcJufCvaMKKVqqz9m3VNe8", "custom_id": "286_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "cdd8bd0ab097007b0eb63514b371cef1", "body": {"id": "chatcmpl-9St7bPloLAstDrZGgzpuyYOEEdTBK", "object": "chat.completion", "created": 1716672099, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vorinostat, also known by its trade name Zolinza, is a histone deacetylase (HDAC) inhibitor primarily used in the treatment of cancer. Here are key points you should know about Vorinostat:\n\n### Mechanism of Action\n- **HDAC Inhibition:** Vorinostat inhibits HDAC enzymes, which play a crucial role in modifying the chromatin structure. Inhibition leads to an increased acetylation of histone proteins, thus affecting gene expression by promoting the transcription of tumor suppressor genes and inhibiting oncogenes.\n  \n### Indications\n- **Cutaneous T-cell Lymphoma (CTCL):** Vorinostat is FDA-approved for the treatment of CTCL in patients with progressive, persistent, or recurrent disease after prior systemic therapies.\n\n### Administration\n- **Oral Administration:** Vorinostat is available in capsule form and is usually taken once daily with food to enhance absorption and reduce gastrointestinal side effects.\n\n### Dosage\n- The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_qwghIgDp2flB60olvkM60IM2", "custom_id": "287_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "490b90e2b7bb491527fed0771f7c54af", "body": {"id": "chatcmpl-9St7cEkJTUWW5oh0IvmIUAJTcMd40", "object": "chat.completion", "created": 1716672100, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zidovudine, also known as AZT (Azidothymidine), is an antiretroviral medication used primarily in the treatment of HIV (Human Immunodeficiency Virus) infection. Here are some crucial points for a physician to know about Zidovudine:\n\n### Mechanism of Action:\n- **Zidovudine** is a nucleoside reverse transcriptase inhibitor (NRTI). It works by inhibiting the enzyme reverse transcriptase, which is crucial for the replication of HIV within the host's cells.\n\n### Indications:\n- **HIV Treatment:** It is used as part of combination antiretroviral therapy (ART) for HIV infection.\n- **Prevention of Perinatal Transmission:** Zidovudine is administered to HIV-infected pregnant women and their newborns to reduce the risk of mother-to-child transmission of HIV.\n- **Post-exposure Prophylaxis (PEP):** It can be part of PEP regimens"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_95imSMUQUW0JnWPlhAmsut2K", "custom_id": "288_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f44701fe7cb70bb6b359b23ff31dd878", "body": {"id": "chatcmpl-9St7cYYepkhsndvZvVQr88LObApBK", "object": "chat.completion", "created": 1716672100, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ziv-aflibercept, also known simply as aflibercept and marketed under the name Zaltrap, is a recombinant fusion protein used primarily in the treatment of metastatic colorectal cancer. Here are key points you should know about Ziv-aflibercept:\n\n### Mechanism of Action\n- **VEGF-Trap**: Ziv-aflibercept acts as a VEGF (vascular endothelial growth factor) trap. It binds to VEGF-A, VEGF-B, and placental growth factor (PLGF), inhibiting their interaction with their respective receptors on the surface of endothelial cells.\n- **Anti-angiogenic**: By inhibiting VEGF pathways, Ziv-aflibercept exerts anti-angiogenic effects, reducing the growth of new blood vessels that tumors need for growth and metastasis.\n\n### Indications\n- **Metastatic Colorectal Cancer (mCRC)**: Commonly used in combination with fluorouracil, leucovorin, and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ltAtJ8hUht3TUmWqML6M9NE5", "custom_id": "289_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a034da09a20a4bed0d2141f7f487e1ba", "body": {"id": "chatcmpl-9St7cLyLhEyJ4OPzVuxnZ4hLDEsU2", "object": "chat.completion", "created": 1716672100, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Capmatinib (marketed under the trade name Tabrecta) is a tyrosine kinase inhibitor that specifically targets the MET (mesenchymal-epithelial transition factor) receptor. Here are some key points you should know about Capmatinib:\n\n1. **Indication:**\n   - Capmatinib is approved for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor a MET exon 14 skipping mutation. This mutation can lead to oncogenic activation of the MET receptor, which promotes tumor growth and survival.\n\n2. **Mechanism of Action:**\n   - Capmatinib inhibits the MET receptor tyrosine kinase, which can interfere with the signaling pathways involved in cell growth, motility, and survival. By inhibiting MET, capmatinib can help to reduce tumor proliferation and induce apoptosis in cancer cells expressing aberrant MET activation.\n\n3. **Dosage:**\n   - The recommended dosage of Capmat"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Cxw7BrTNEXD7ssq6V1jmJscz", "custom_id": "290_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "c792c95be4ec2dad477b25180255e7b9", "body": {"id": "chatcmpl-9St7cZBBOsPKpEkIa9NDAWS87w4iJ", "object": "chat.completion", "created": 1716672100, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enfortumab vedotin (EV), marketed under the brand name Padcev, is a targeted therapy drug used primarily in oncology, particularly in the treatment of advanced or metastatic urothelial carcinoma. Here are some key points you should be aware of:\n\n### 1. Mechanism of Action:\nEnfortumab vedotin is an antibody-drug conjugate (ADC). It consists of an antibody specifically targeting Nectin-4, a protein expressed on the surface of urothelial carcinoma cells, linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE). Once bound to Nectin-4 on cancer cells, EV is internalized, and MMAE is released to inhibit cell division, leading to cell death.\n\n### 2. Indications:\nEV is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have previously received a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy or are ineligible"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Q9kzM8rPKPbr2Ok3TJQrlh9J", "custom_id": "291_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "56c8327cd6ec601b27a5b6c61d0e6c75", "body": {"id": "chatcmpl-9St7c9earKinc2Ycw2IZWEmVFGIuM", "object": "chat.completion", "created": 1716672100, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trastuzumab deruxtecan is a sophisticated antibody-drug conjugate (ADC) designed for specific oncology indications. If you're a physician, here are several important aspects you should know about it:\n\n### Mechanism of Action\n- **Antibody Component (Trastuzumab)**: The antibody part targets the human epidermal growth factor receptor 2 (HER2), which is overexpressed in certain cancers, including some breast, gastric, and other solid tumors.\n- **Cytotoxic Payload (Deruxtecan)**: Once the ADC binds to HER2-expressing cells, it is internalized, and a potent topoisomerase I inhibitor (deruxtecan) is released intracellularly. This inhibits DNA replication and leads to cancer cell death.\n\n### Indications\n- Primarily used for HER2-positive breast cancer.\n- It may also be indicated for HER2-positive gastric cancer and certain other HER2-expressing tumors.\n- The specific indications can evolve"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_nKOrxYJehWj1Et4i4LZ77RlD", "custom_id": "292_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a727b871949ebf7eae22c408b86b8e35", "body": {"id": "chatcmpl-9St7cTDo0l1hxXGj4xBn3LS5XSG8P", "object": "chat.completion", "created": 1716672100, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abarelix is a synthetic decapeptide and a type of gonadotropin-releasing hormone (GnRH) antagonist. It is used primarily in the palliative treatment of advanced prostate cancer to help manage symptoms and reduce the production of testosterone, which can stimulate the growth of prostate cancer cells. Here's what you should know about Abarelix as a physician:\n\n### Mechanism of Action\n- **GnRH Antagonist**: Unlike GnRH agonists, which initially cause a surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) before downregulating them, Abarelix directly blocks the GnRH receptors in the pituitary gland. This leads to a rapid decrease in the secretion of LH and FSH, subsequently reducing testosterone levels without the initial surge.\n \n### Indications\n- **Advanced Prostate Cancer**: Abarelix is primarily indicated for the palliative treatment of patients with advanced symptomatic prostate cancer who cannot receive other hormonal therapies"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_JJrEw1uo1E6rShxbxMjz8jAl", "custom_id": "293_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "41e63624c7e5a528f46a57b046593601", "body": {"id": "chatcmpl-9St7cfxRzlWEdiTgVCpGkKdZAUrsC", "object": "chat.completion", "created": 1716672100, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belantamab mafodotin is a medication used in the treatment of certain types of multiple myeloma, particularly in patients who have not responded to other treatments. Here are some key points about belantamab mafodotin that you should know as a physician:\n\n### Mechanism of Action\n- **Antibody-Drug Conjugate (ADC)**: Belantamab mafodotin is an antibody-drug conjugate that targets CD38, a protein commonly expressed on the surface of multiple myeloma cells.\n- **Delivery of Cytotoxic Agent**: The drug comprises an anti-CD38 monoclonal antibody linked to a cytotoxic agent, monomethyl auristatin F (MMAF). This allows for targeted delivery of the cytotoxic agent to the cancer cells, minimizing off-target effects.\n\n### Indications\n- **Relapsed or Refractory Multiple Myeloma**: It is typically prescribed for patients who have received at least four prior therapies including an"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_VDhWWlsMsfyoFE9Wvi6BJyTU", "custom_id": "294_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "56b736525d111b3c56e3b5a633d3f4f4", "body": {"id": "chatcmpl-9St7cMpoh7qf706xHfqn69gKARAQv", "object": "chat.completion", "created": 1716672100, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tucatinib is an important medication in the oncology field, specifically for the treatment of breast cancer. Here are key points you should know as a physician:\n\n### 1. **Mechanism of Action:**\n   - **Tucatinib** is a small molecule tyrosine kinase inhibitor. It selectively inhibits the HER2 (human epidermal growth factor receptor 2) tyrosine kinase, which can be overexpressed in some breast cancers and leads to uncontrolled cell growth.\n\n### 2. **Indications:**\n   - Tucatinib is used in combination with other drugs like trastuzumab (another HER2 inhibitor) and capecitabine.\n   - It is primarily indicated for patients with **HER2-positive metastatic breast cancer** who have received one or more prior anti-HER2-based regimens in the metastatic setting.\n\n### 3. **Administration:**\n   - **Dosage**: Typically, Tucatinib is administered orally at a dose of "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_UAdC0xeI8biPPJPdLrcEMrm2", "custom_id": "295_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f826829172438901355eb4ba98feff94", "body": {"id": "chatcmpl-9St7dKpfuvj696ymlIqemDhsf3OBA", "object": "chat.completion", "created": 1716672101, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daratumumab and hyaluronidase are often co-administered in the context of treating multiple myeloma, a type of blood cancer. Here's what you should know about them:\n\n### Daratumumab\n\n1. **Mechanism of Action**: Daratumumab is a monoclonal antibody that targets CD38, a protein highly expressed on the surface of multiple myeloma cells. By binding to CD38, it induces cell death through several mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP).\n\n2. **Indications**: Daratumumab is used for the treatment of multiple myeloma in various settings:\n   - As monotherapy in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double refractory to a PI and an immunomodulatory agent.\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_he1pxTMltFcyOYexDlTPbTsZ", "custom_id": "296_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "47cd27fb1cfd3652416a12873732c74c", "body": {"id": "chatcmpl-9St7ddUH94Scv3ttXgZRgHbVVAedX", "object": "chat.completion", "created": 1716672101, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alitretinoin (also known as 9-cis-retinoic acid) is a medication primarily used for the treatment of severe chronic hand eczema that has not responded to other treatments such as topical corticosteroids. It is an oral retinoid, which means it is a derivative of vitamin A, and it belongs to the same family of medications as isotretinoin.\n\nHere are key points you should be aware of:\n\n### Indications\n- **Chronic Hand Eczema:** Approved for the treatment of severe chronic hand eczema unresponsive to potent topical corticosteroids.\n- **Kaposi's Sarcoma:** Alitretinoin has also been used topically for cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.\n\n### Mechanism of Action\nAlitretinoin works by modulating cell proliferation, differentiation, and apoptosis. It exerts its effects by binding to retinoic acid receptors (RARs) and retinoid X receptors (RXRs),"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_VKp3fl4Wn8UaHl8bTwkRwPZ3", "custom_id": "297_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "47785f461398d12b52073b6928ecde3e", "body": {"id": "chatcmpl-9St7dVRYmy9VxUIzZDGsKIpif8LyP", "object": "chat.completion", "created": 1716672101, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Brexucabtagene autoleucel, also known by its trade name Tecartus, is a form of CAR T-cell therapy used in the treatment of certain types of cancer. Here are the important pieces of information you should know about it as a physician:\n\n1. **Indications**:\n   - **Mantle Cell Lymphoma (MCL)**: It is FDA-approved for adult patients with relapsed or refractory MCL.\n   - **Acute Lymphoblastic Leukemia (ALL)**: It has also been used for the treatment of relapsed or refractory B-cell precursor ALL in adults.\n\n2. **Mechanism of Action**:\n   - CAR T-cell therapy involves modifying a patient\u2019s T cells to express a chimeric antigen receptor (CAR) that targets the CD19 antigen present on the surface of B cells, including malignant B cells.\n   - Once these engineered CAR T cells are reintroduced into the patient, they seek out and destroy CD19"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_63d82I5Pwm9lXdWB2BnAKj6A", "custom_id": "298_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "fbbd31ea589b85ae893e9825ff7cd5d9", "body": {"id": "chatcmpl-9St7dUrBp4XC1XAAqSAAcDXGSsldu", "object": "chat.completion", "created": 1716672101, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alpelisib, marketed under the brand name Piqray, is an oral PI3K inhibitor that specifically targets the alpha isoform of phosphoinositide 3-kinase (PI3K\u03b1). It is primarily used in the treatment of certain types of breast cancer. Here are some key points you should know about Alpelisib:\n\n### Indications\n- **Breast Cancer:** Alpelisib is FDA-approved for use in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced, or metastatic breast cancer following progression on or after an endocrine-based regimen.\n\n### Mechanism of Action\n- **PI3K Inhibition:** Alpelisib inhibits the PI3K pathway, which is often activated in cancer through mutations. By blocking this pathway, Alpelisib aims to inhibit cancer cell growth and survival.\n\n### Administration\n- **Dos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_PiekaXS8UCLkXPEdh5p3lD5K", "custom_id": "299_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4694da5d37987298e26497c11e15994b", "body": {"id": "chatcmpl-9St7dOBNsVizrg9thOHdlGYzLAmxg", "object": "chat.completion", "created": 1716672101, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amonafide is an investigational anti-cancer agent and an imidazoacridinone derivative. Here are some key points you should know as a physician:\n\n1. **Mechanism of Action**:\n   - Amonafide primarily works by interfering with DNA synthesis and function. It intercalates into DNA and inhibits topoisomerase II, an enzyme crucial for DNA replication, transcription, and recombination.\n\n2. **Indications**:\n   - Amonafide has been studied primarily for its potential use in treating various types of cancer, including leukemias and solid tumors. It has shown some promise in clinical trials but has not been widely approved for clinical use.\n\n3. **Clinical Trials**:\n   - It has undergone several phases of clinical trials. While some trials have shown potential efficacy, others have identified limitations due to toxicity and side effects.\n\n4. **Side Effects**:\n   - Common side effects include gastrointestinal disturbances (nausea, vomiting,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_rmdwsBk1i5HPRcMnCqp7gmuq", "custom_id": "300_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9e4bddf1fa64e85d34a55ca2baf7f724", "body": {"id": "chatcmpl-9St7dZpGCrumQr8blGQnRYtgMfzAj", "object": "chat.completion", "created": 1716672101, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it\u2019s important to have a comprehensive understanding of Amoxicillin, its uses, side effects, contraindications, and other pertinent details. Here are key points to consider:\n\n### 1. **Basic Information**\n- **Class**: Beta-lactam antibiotic within the penicillin group.\n- **Mechanism of Action**: Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death.\n\n### 2. **Indications**\n- **Bacterial Infections**: Effective against a range of Gram-positive and some Gram-negative bacteria.\n- **Common Uses**: \n  - Respiratory tract infections (e.g., pharyngitis, sinusitis, bronchitis, pneumonia)\n  - Otitis media\n  - Skin and soft tissue infections\n  - Urinary tract infections (UTIs)\n  - Helicobacter pylori eradication (used in combination therapy)\n\n### 3. **Dosage and Administration**\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_R7NGYlvRbHGChgfobImWVipM", "custom_id": "301_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "dd6a681f77b0214b6f69329be4bd9209", "body": {"id": "chatcmpl-9St7dprfQFea4KGjgvymvCgHc5sKY", "object": "chat.completion", "created": 1716672101, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aumolertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) used in the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. Here is some key information you should be aware of:\n\n1. **Mechanism of Action**:\n   - Aumolertinib selectively inhibits both the activating EGFR mutations (like exon 19 deletions and L858R mutations) and the T790M resistance mutation, a common cause of resistance in first- and second-generation EGFR inhibitors.\n\n2. **Indications**:\n   - It is primarily indicated for NSCLC patients who have progressed on or after treatment with first- or second-generation EGFR TKIs and who have developed the T790M resistance mutation.\n   - It can also be considered for treatment-na\u00efve patients with EGFR-mutant NSCLC.\n\n3. **Efficacy**:\n   - Clinical trials have demonstrated significant"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_00Sz1yEYkUUhKAORAodR0ssR", "custom_id": "302_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b8a7d51f97677ed9d35590668463cb44", "body": {"id": "chatcmpl-9St7dkp9A8lWIOsAoznWRwY94RKWm", "object": "chat.completion", "created": 1716672101, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pemigatinib is a targeted therapy medication, specifically a tyrosine kinase inhibitor, that is used in the treatment of certain types of cancer. Here\u2019s what you should know about it:\n\n### Indications:\n- **Cholangiocarcinoma:** Pemigatinib is primarily approved for the treatment of adults with previously treated, unresectable, locally advanced, or metastatic cholangiocarcinoma (bile duct cancer) that carries a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement. Patients are typically required to undergo biomarker testing to confirm the presence of these genetic alterations.\n\n### Mechanism of Action:\n- **Inhibition of FGFRs:** Pemigatinib inhibits FGFR1, FGFR2, and FGFR3, which are proteins that play a critical role in cell division, growth, and repair. By inhibiting these proteins, pemigatinib can impede the growth of cancer cells that express FGFR alterations.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ZYibhF8Erz2qR1b3rHgYaOKS", "custom_id": "303_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9fed1ddeae2cb5b5a6eb158045ac03fc", "body": {"id": "chatcmpl-9St7dIY1HZOjvRNaX1evSnzILpfwQ", "object": "chat.completion", "created": 1716672101, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ripretinib, marketed under the brand name Qinlock, is a tyrosine kinase inhibitor that is primarily used for the treatment of gastrointestinal stromal tumors (GIST) that are not amenable to surgery and have progressed following prior therapies. Here's an essential overview of what you should know about Ripretinib:\n\n### Indications and Usage\n- **Indication**: Approved for the treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including imatinib.\n- **Role in Therapy**: It is often considered after other treatments such as imatinib, sunitinib, and regorafenib have been tried and have failed.\n\n### Mechanism of Action\n- Ripretinib works by inhibiting a broad spectrum of kinases including KIT proto-oncogene receptor tyrosine kinase and platelet-derived growth factor receptor A (PDGFRA), which are often mutated in GISTs. This inhibition effectively reduces tumor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_q7dDKLJKPskP5Eke40WA1Tr9", "custom_id": "304_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7db6547ca1888f79ff734a16e496b005", "body": {"id": "chatcmpl-9St7dBZBcvNpC12Ux2iy2H8rL9WFl", "object": "chat.completion", "created": 1716672101, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Selpercatinib, marketed under the brand name Retevmo, is a targeted therapy used primarily to treat cancers that have specific genetic alterations involving the RET gene. As a physician, it is important to be aware of the following aspects about Selpercatinib:\n\n1. **Mechanism of Action**:\n   - Selpercatinib is a selective RET kinase inhibitor. It works by inhibiting the activity of abnormal RET proteins that drive cancer cell proliferation and survival.\n\n2. **Indications**:\n   - Advanced or metastatic non-small cell lung cancer (NSCLC) with RET gene fusions.\n   - Advanced or metastatic medullary thyroid cancer (MTC) with RET mutations.\n   - Advanced or metastatic thyroid cancers with RET gene fusions, who require systemic therapy and are refractory to other treatments.\n\n3. **Administration**:\n   - Selpercatinib is administered orally. The recommended dosage can vary based on the specific condition being treated and patient factors such"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_lU697LoNplUUREeGY22SoTHz", "custom_id": "305_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "31b65daf42a5a893c2cb4d9d6700024c", "body": {"id": "chatcmpl-9St7dcqjvQT3GZiVx6fxof6rw3n1j", "object": "chat.completion", "created": 1716672101, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Decitabine and cedazuridine is a combination medication used in the treatment of certain hematologic conditions such as myelodysplastic syndromes (MDS). Here are key points you should be aware of regarding this combination:\n\n1. **Mechanisms of Action**:\n   - **Decitabine**: A cytidine analog, decitabine gets incorporated into DNA and inhibits DNA methyltransferase, leading to hypomethylation of DNA and reactivation of silenced tumor suppressor genes, inducing cellular differentiation or apoptosis.\n   - **Cedazuridine**: An inhibitor of cytidine deaminase, an enzyme that degrades decitabine. By inhibiting this enzyme, cedazuridine increases the oral bioavailability of decitabine.\n\n2. **Indications**:\n   - This combination is primarily used to treat adults with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the International Prognostic Sc"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_gnoXfFxw7EZ7nd7z86vUahSO", "custom_id": "306_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4870e6e52895db9ec4613837b0c049d7", "body": {"id": "chatcmpl-9St7e9qo0pfBQq8WxGYQiB8p4fKlP", "object": "chat.completion", "created": 1716672102, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bismuth subsalicylate is a medication commonly used to treat temporary discomforts related to the gastrointestinal (GI) tract, such as diarrhea, nausea, heartburn, indigestion, and upset stomach. Here are key points about Bismuth subsalicylate that a physician should be aware of:\n\n### Mechanism of Action:\n1. **Antimicrobial Activity:** Bismuth subsalicylate exerts a mild antimicrobial effect, which can help combat infections in the GI tract.\n2. **Anti-inflammatory Properties:** The salicylate moiety provides anti-inflammatory effects, similar to aspirin.\n3. **Protective Coating:** It can coat ulcers and erosions in the stomach and intestines, protecting them from stomach acid.\n4. **Binding Toxins:** It binds to toxins produced by bacteria, reducing their effects.\n\n### Indications:\n- Acute diarrhea, including traveler's diarrhea.\n- Gastroesophageal reflux disease (GERD) symptoms such as heartburn.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_jT4vSVLTpMIjtLI9SHj1aZP3", "custom_id": "307_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7aedcfa964b66eb017152a3f5795b7fa", "body": {"id": "chatcmpl-9St7eDxHwmNUh6VKJdKXUoaKtqgpo", "object": "chat.completion", "created": 1716672102, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Camrelizumab is an anti-PD-1 (Programmed Death-1) monoclonal antibody used as an immunotherapy treatment primarily in oncology. Here are several essential aspects to be aware of:\n\n1. **Mechanism of Action**: Camrelizumab works by inhibiting the PD-1 receptor on T-cells. This blockade prevents the binding of PD-1 with its ligands (PD-L1 and PD-L2), which are often overexpressed on tumor cells. By blocking this interaction, Camrelizumab helps to reactivate T-cell-mediated immune responses against cancer cells.\n\n2. **Indications**: It has shown efficacy in treating various types of cancers, including Hodgkin lymphoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma, and esophageal squamous cell carcinoma, among others. The specific indications can vary based on clinical trial outcomes and regulatory approvals in different regions.\n\n3. **Administration**: Camrelizumab is usually"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Nqnd0bvE4hB3E4r8ZKF7FSOH", "custom_id": "308_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6b5798ad51bb5e7226a724000a8db13f", "body": {"id": "chatcmpl-9St7egPZGjt7Gd03qKkxLn2L6YsRB", "object": "chat.completion", "created": 1716672102, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Relugolix is a medication that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist. Here are some key points for you as a physician:\n\n### Indications:\n1. **Prostate Cancer:** Relugolix is primarily indicated for the treatment of advanced prostate cancer. It helps in reducing testosterone levels, which can slow the growth of prostate cancer.\n2. **Gynecological Conditions:** It might also be prescribed for conditions such as uterine fibroids and endometriosis, where it helps by reducing estrogen levels, thereby alleviating symptoms like pain and heavy menstrual bleeding.\n\n### Mechanism of Action:\n- **GnRH Antagonist:** Relugolix works by directly inhibiting the GnRH receptors in the pituitary gland, which leads to a rapid decrease in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels.\n- **Hormonal Suppression:** This suppression reduces testosterone production in men and estrogen production"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ZMsWGD5NV8FCwtEKARfobHgZ", "custom_id": "309_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4f05c37212ebbfad05a1e5f2a13489f4", "body": {"id": "chatcmpl-9St7eNp5IsRzNLCPLA7fHWqnudL3Z", "object": "chat.completion", "created": 1716672102, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Elacestrant is a relatively new drug in the realm of oncology, particularly for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Here are some key points that a physician should know about Elacestrant:\n\n1. **Mechanism of Action**:\n   - Elacestrant is an oral selective estrogen receptor degrader (SERD). It works by binding to estrogen receptors on cancer cells, leading to the degradation of these receptors, thereby inhibiting estrogen-driven cell proliferation.\n\n2. **Indication**:\n   - It is specifically indicated for postmenopausal women and men with advanced or metastatic breast cancer that is HR-positive and HER2-negative. It can be particularly useful in patients who have previously been treated with endocrine therapy or those who have developed resistance to such therapies.\n\n3. **Clinical Trial Evidence**:\n   - The approval and use of Elacestrant are backed by clinical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_DXfSdqRWJZeClwaCQUjVRawR", "custom_id": "310_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "440a34852a57f950550aa687a5a4c139", "body": {"id": "chatcmpl-9St7eEGv6dKRmwMlspZ6bc7Bu9rFY", "object": "chat.completion", "created": 1716672102, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trimetrexate is an antimetabolite and antifolate chemotherapy agent that can also serve as an antipneumocystis and antiprotozoal drug. Here's a detailed overview of what you should know about this medication:\n\n### Mechanism of Action:\n- **Antifolate Activity**: Trimetrexate inhibits dihydrofolate reductase (DHFR), an enzyme critical for the tetrahydrofolate synthesis needed for the formation of thymidine, purine nucleotides, and subsequently DNA and RNA synthesis. This disruption affects rapidly dividing cells, leading to their death.\n\n### Indications:\n- **Pneumocystis Pneumonia (PCP)**: Trimetrexate is often used in patients with Pneumocystis jirovecii pneumonia, particularly when they cannot tolerate the standard first-line treatment (trimethoprim/sulfamethoxazole) due to allergy or adverse effects.\n- **Cancer Treatment**: Occasionally, it"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_qxUFbMAFMI3JgjbpxdDrgBib", "custom_id": "311_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "46104527b337b9ed3b3a0f910e32678f", "body": {"id": "chatcmpl-9St7ehTfmiMd0UjqSoFrXeltbsCVJ", "object": "chat.completion", "created": 1716672102, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tepotinib is an oral, small-molecule inhibitor of the MET (mesenchymal-epithelial transition) receptor tyrosine kinase. It has been developed for the treatment of cancers that exhibit MET gene alterations such as MET exon 14 (METex14) skipping mutations or MET amplifications. Here are some key points you should know:\n\n### Mechanism of Action\n- **Inhibition of MET Receptor:** Tepotinib specifically targets the MET receptor, which plays a critical role in various cellular processes, including proliferation, survival, and metastasis. By inhibiting this receptor, tepotinib can disrupt these processes, thereby inhibiting tumor growth and progression.\n\n### Indications\n- **Non-Small Cell Lung Cancer (NSCLC):** Tepotinib has been approved for the treatment of adult patients with metastatic NSCLC harboring METex14 skipping alterations. This specific genetic alteration can be identified through molecular testing.\n\n### Efficacy\n- **Clinical Trials:**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_jYYQlMVrxY9RaGxSNSoNIe5J", "custom_id": "312_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f53c7838448719e9b010a883bc12a75b", "body": {"id": "chatcmpl-9St7eZB1GH5VcrxB0qsxQVdOgr2j0", "object": "chat.completion", "created": 1716672102, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Futibatinib (TAS-120) is an emerging tyrosine kinase inhibitor that has shown promise in the treatment of certain cancers, particularly those involving FGFR (fibroblast growth factor receptor) gene abnormalities. Here are some key aspects you should know about Futibatinib:\n\n1. **Mechanism of Action:** Futibatinib targets FGFR1-4, blocking the signaling pathways that are often involved in the proliferation and survival of cancer cells. Its covalent binding properties confer sustained inhibition of FGFR signaling, which can lead to antiproliferative effects in tumors with FGFR alterations.\n\n2. **Indications:** The primary focus of research has been on cholangiocarcinoma, a type of cancer that occurs in the bile ducts, especially in patients with FGFR2 gene fusions or other alterations. It has also been studied in various other cancers such as urothelial carcinoma and hepatocellular carcinoma.\n\n3. **Clinical Efficacy:** Clinical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_5MeaE7yE64Yb0onnncxP7vv4", "custom_id": "313_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2e5d1287f1d60182af4e3fb75ac62e2a", "body": {"id": "chatcmpl-9St7e3VXCnjbQ3KAxt7qShLryjkAs", "object": "chat.completion", "created": 1716672102, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "The NovoTTF-100A system, commonly known as Optune, is a medical device used in the treatment of glioblastoma multiforme (GBM), which is an aggressive type of brain tumor. Here are the key points you should know as a physician:\n\n### Mechanism of Action\n\n1. **Tumor Treating Fields (TTFields)**: Optune delivers low-intensity, alternating electric fields directly to the tumor site. These fields, known as TTFields, disrupt cell division in cancer cells, inhibiting tumor growth and potentially leading to cancer cell death.\n\n2. **Selective Action**: TTFields generally affect dividing cells more than non-dividing cells, which helps to reduce potential harm to healthy brain tissue.\n\n### Indications\n\n1. **Recurrent GBM**: Optune is FDA approved for use in adult patients with recurrent GBM following surgery, radiation therapy, and chemotherapy.\n\n2. **Newly Diagnosed GBM**: It is also approved for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_C0qycVNkhpUxR36JutWRpycQ", "custom_id": "314_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "89f24038808f7b32dc674e28fd3183d6", "body": {"id": "chatcmpl-9St7eEddol6eBJpqsED2nPFjCd8eg", "object": "chat.completion", "created": 1716672102, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lisocabtagene maraleucel, often abbreviated as liso-cel and marketed under the brand name Breyanzi, is a chimeric antigen receptor (CAR) T-cell therapy used for the treatment of certain types of blood cancers, primarily B-cell lymphomas. Here are key points you should know about liso-cel:\n\n1. **Indications**:\n   - Approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.\n   - Types of lymphoma it treats include diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.\n\n2. **Mechanism of Action**:\n   - Liso-cel involves modifying a patient's T-cells to express a chimeric antigen receptor (CAR) that targets the CD19 protein found on the surface of B-cells (both cancerous and normal"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_slDlHT9gj8kEjqFARxxJ3ac1", "custom_id": "315_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "3de4102e81f45642509e8f5341bfb667", "body": {"id": "chatcmpl-9St7f6JzSIowjEHwGzzyGbQW6VdMG", "object": "chat.completion", "created": 1716672103, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idecabtagene vicleucel, also known by its brand name Abecma, is a chimeric antigen receptor (CAR) T-cell therapy. Here are several key points that you, as a physician, should know about this treatment:\n\n### Indication:\n- **Multiple Myeloma**: Idecabtagene vicleucel is specifically approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.\n\n### Mechanism of Action:\n- **CAR T-cell Therapy**: This therapy involves modifying a patient's own T-cells to express a CAR that targets the B-cell maturation antigen (BCMA), which is commonly found on the surface of multiple myeloma cells.\n- **Immune Activation**: The modified T-cells are then re-infused into the patient, where they"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_IDm8D4HpD6nhwFYm3KxSK33j", "custom_id": "316_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8cc3750d2b2f3eea7291185f93276bfc", "body": {"id": "chatcmpl-9St7fP3g5C42843TeDHhgOUubhH2i", "object": "chat.completion", "created": 1716672103, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Avapritinib is a tyrosine kinase inhibitor used primarily in oncology and hematology for the treatment of certain types of cancers. Here are some key points you should know about Avapritinib:\n\n### Indications:\n1. **Gastrointestinal Stromal Tumors (GIST):** Avapritinib is specifically indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.\n2. **Systemic Mastocytosis (SM):** It is also used in various forms of SM, including aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).\n\n### Mechanism of Action:\n- Avapritinib selectively inhibits KIT and PDGFRA kinases that are often mutated and overactive in GISTs and certain forms"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_3dtBzgmEXDLTXVV9R9rNKve7", "custom_id": "317_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "abb3cd5e136360fe64dd803a844a4cdb", "body": {"id": "chatcmpl-9St7fKqJQ0aEN0QotOHvi7pAsLlwO", "object": "chat.completion", "created": 1716672103, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pexidartinib is a medication that you may encounter in the context of treating certain rare types of tumors. Here\u2019s a concise overview that covers key aspects relevant to your practice:\n\n### Indications\n- **Tenosynovial Giant Cell Tumor (TGCT):** Pexidartinib is primarily indicated for the treatment of adult patients with symptomatic TGCT, also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS), when the tumor is not amenable to improvement with surgery.\n\n### Mechanism of Action\n- **CSF1R Inhibition:** Pexidartinib works by inhibiting the colony stimulating factor 1 receptor (CSF1R), which plays a critical role in the pathogenesis of TGCTs. It also has inhibitory activity against KIT and FLT3-ITD.\n\n### Administration and Dosage\n- **Oral Administration:** P"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_kyvoFTNHxIkiBxzCjuYxKyPV", "custom_id": "318_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0507ddcda8b3acb7bd955b9cafa25ace", "body": {"id": "chatcmpl-9St7fqEuOy00ejOwSBnjNUE9OX9cO", "object": "chat.completion", "created": 1716672103, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pralsetinib is a tyrosine kinase inhibitor that targets rearranged during transfection (RET) receptor abnormalities. Here are some key points you should know about Pralsetinib:\n\n### Indications:\n1. **Non-Small Cell Lung Cancer (NSCLC)**: It is used in adult patients with metastatic RET fusion-positive NSCLC.\n2. **Thyroid Cancer**: It can be prescribed for patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. It is also used for RET fusion-positive thyroid cancer in patients who require systemic therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate).\n\n### Mechanism of Action:\nPralsetinib works by inhibiting the RET kinase that is abnormally activated due to mutations or fusions in the RET gene. This inhibition helps prevent the proliferation and survival of cancer cells driven by these alterations.\n\n### Dosing:\n- **For adults**: The typical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_HMUnZQUrlIMFjh4nSkL4SNV5", "custom_id": "319_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a32ce27b9147290116b68c434651c7e1", "body": {"id": "chatcmpl-9St7ffpWbZOhEdkj8bmCYCJiukDc8", "object": "chat.completion", "created": 1716672103, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lurbinectedin is an anticancer medication that is used primarily in the treatment of small cell lung cancer (SCLC). It is a synthetic compound derived from a marine organism, and it functions as a selective inhibitor of oncogenic transcription.\n\n### Key Points:\n\n1. **Mechanism of Action**:\n   - Lurbinectedin binds to the minor groove of DNA, leading to strand breaks and stalling the transcription process.\n   - It inhibits the transcription of protein-coding genes, particularly those involved in tumor cell survival, proliferation, and drug resistance.\n   \n2. **Indications**:\n   - Lurbinectedin is approved for the treatment of adult patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy.\n\n3. **Administration**:\n   - It is administered as an intravenous infusion. The typical dose is 3.2 mg/m\u00b2, given over 60 minutes every 21 days.\n\n4. **Side Effects**:\n   - Common side effects include my"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_a7ruU92jfBDbT32r071u5UKW", "custom_id": "320_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ad8a9e39161de0297b6e7ec4faf5631f", "body": {"id": "chatcmpl-9St7fq5aJ7cbCfMI6GheoDCl0HmWU", "object": "chat.completion", "created": 1716672103, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Metronidazole is an antimicrobial medication that you would commonly use to treat various infections caused by susceptible anaerobic bacteria and certain protozoa. Here are key points you should know about Metronidazole:\n\n1. **Mechanism of Action**: Metronidazole disrupts DNA synthesis in susceptible organisms by forming toxic free radicals, which ultimately leads to cell death.\n\n2. **Indications**:\n   - Anaerobic Bacterial Infections: Such as Bacteroides fragilis, Clostridium difficile (for C. difficile-associated diarrhea), and other anaerobes.\n   - Protozoal Infections: Such as Trichomoniasis, Giardiasis, and Amebiasis.\n   - Other Infections: Including bacterial vaginosis, pelvic inflammatory disease, intra-abdominal infections, and certain skin and soft tissue infections.\n\n3. **Administration**:\n   - Available in oral, intravenous, and topical forms.\n   - Oral doses typically range from 250 mg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_WecBaMffejmq7dsuz7JEA0r7", "custom_id": "321_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7b30024479bd562d5506a528e2889999", "body": {"id": "chatcmpl-9St7frRdOz8G3XDPRruMK7t4WZFQO", "object": "chat.completion", "created": 1716672103, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Naxitamab is a monoclonal antibody used in the treatment of high-risk neuroblastoma, particularly in patients whose disease has recurred or is resistant to initial treatments. Here are key points to consider:\n\n### Mechanism of Action:\n- **Target**: Naxitamab targets GD2, a disialoganglioside highly expressed on neuroblastoma cells.\n- **Action**: By binding to GD2, naxitamab promotes antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, aiding in the destruction of cancer cells.\n\n### Indications:\n- **FDA Approval**: Naxitamab is approved for use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of pediatric patients one year or older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.\n- **Clinical Use**: Typically used after patients have shown some response to prior therapies such as"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_wf7SBRrwEEGJO7zF5GHrSD9D", "custom_id": "322_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4246bae2e6348aed5e750ba8a9dcb70d", "body": {"id": "chatcmpl-9St7fzLCjT4xlc3ToOwhaOc8PJZJO", "object": "chat.completion", "created": 1716672103, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tetracycline is a broad-spectrum antibiotic that is widely used to treat a variety of bacterial infections. Here are some key points you should know as a physician:\n\n### Pharmacological Properties:\n1. **Mechanism of Action:** Tetracycline inhibits protein synthesis by binding to the 30S ribosomal subunit of bacteria, preventing the attachment of aminoacyl-tRNA to the bacterial ribosome.\n2. **Spectrum of Activity:** It is effective against a wide range of gram-positive and gram-negative bacteria, as well as certain intracellular pathogens like Chlamydia, Mycoplasma, and Rickettsia.\n\n### Indications:\n1. **Respiratory Tract Infections:** Useful in treating atypical pneumonia caused by Mycoplasma pneumoniae and Chlamydia pneumoniae.\n2. **Acne:** Often prescribed for severe acne due to its anti-inflammatory properties.\n3. **Sexually Transmitted Infections:** Effective against Chlamydia trachomatis.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5fvDEJ86qGmwmKS2IDZG1YSm", "custom_id": "323_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "768b2ede903d3538466cbfc5505ab027", "body": {"id": "chatcmpl-9St7f2awAJKjzctqZ1a3Gqjuv46JG", "object": "chat.completion", "created": 1716672103, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tripotassium dicitratobismuthate, also known under trade names like De-Nol, is a medication primarily used for its gastroprotective properties, particularly in the treatment of peptic ulcer disease and Helicobacter pylori infections. Here are key points you should be aware of as a physician:\n\n### Pharmacological Properties:\n- **Mode of Action**: It forms a protective barrier over ulcers and erosions in the gastrointestinal tract, which helps shield the mucosa from stomach acid and digestive enzymes. Additionally, it has mild antimicrobial activity against Helicobacter pylori, a bacterium often implicated in peptic ulcers.\n- **Chemical Composition**: It contains bismuth, which contributes to its therapeutic effects. \n\n### Indications:\n- **Peptic Ulcer Disease**: Helps heal and protect ulcers in the stomach and duodenum.\n- **Helicobacter pylori Eradication**: Often used as part of combination therapy (with antibiotics and proton pump inhibitors) to eradicate"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Fbitm6ZZ4Br2nh4L6X5XaXW2", "custom_id": "324_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5a8b4336153981b29311bb0cd424dc9c", "body": {"id": "chatcmpl-9St7fgHeTmDIzBrQqe4yH85hhyF77", "object": "chat.completion", "created": 1716672103, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belzutifan, also known by its brand name Welireg, is a relatively new medication approved by the FDA in August 2021. It is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNETs), and who do not require immediate surgery.\n\nHere are some key points you should know about Belzutifan:\n\n1. **Mechanism of Action:**\n   - Belzutifan is a hypoxia-inducible factor-2 alpha (HIF-2\u03b1) inhibitor. In VHL disease, mutations in the VHL gene lead to the stabilization and accumulation of HIF-2\u03b1, which promotes the formation of tumors. Belzutifan inhibits HIF-2\u03b1, thus helping to reduce tumor growth.\n\n2. **Administration:**\n   - Belzutifan"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_8FPDe5Jj20bww1ZpOEcAGUig", "custom_id": "325_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "3040385dd058cd7f1351021e646294bd", "body": {"id": "chatcmpl-9St7fTveVUQI5fxVd4QDwY2TmDSwL", "object": "chat.completion", "created": 1716672103, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amivantamab, marketed under the brand name Rybrevant, is a medication used in oncology, specifically in the treatment of non-small cell lung cancer (NSCLC). It is important to know the following details about Amivantamab if you are a physician:\n\n### Indications and Usage:\nAmivantamab is approved for use in adult patients with locally advanced or metastatic NSCLC with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.\n\n### Mechanism of Action:\nAmivantamab is a bispecific antibody targeting both EGFR and MET receptors, which are often involved in the proliferation and survival of cancer cells. By binding to these receptors, it helps inhibit tumor cell growth and promotes immune-mediated destruction of the cancer cells.\n\n### Dosage and Administration:\n- **Initial Doses**: The recommended initial dose is based on body weight:\n  - Less than 80 kg: 1050 mg (weekly"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_EpAl90YgpUxQS0lKzKuygpx8", "custom_id": "326_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "98ec9851805e3150c89257e671ca0b74", "body": {"id": "chatcmpl-9St7gP40SiZ0b07tfoOre7F3Ja1uM", "object": "chat.completion", "created": 1716672104, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azacitidine is a chemotherapeutic drug primarily used to treat certain types of blood cancers, such as Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Azacitidine is traditionally administered by injection, but an oral formulation is available. Here are key points you should know about Azacitidine oral:\n\n### Indications and Uses\n- **Myelodysplastic Syndromes (MDS):** Used to treat patients with MDS to reduce the risk of progression to acute myeloid leukemia and to improve hematologic function.\n- **Acute Myeloid Leukemia (AML):** Used to treat newly diagnosed AML in adults who are 75 years or older, or who have comorbid conditions that preclude the use of intensive induction chemotherapy.\n\n### Mechanism of Action\n- Azacitidine is a nucleoside analog of cytidine. It incorporates into RNA and DNA, leading to inhibition of protein synthesis and DNA methylation, and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_QSNWFm5nrWCGckdU56dmdHLV", "custom_id": "327_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2d9c251e3a8392856b22ce8b8582b202", "body": {"id": "chatcmpl-9St7gjnCo2cu49tpuwceBZiF0wQpq", "object": "chat.completion", "created": 1716672104, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, there are several important aspects you should know about colchicine, especially given its use in treating conditions like gout and familial Mediterranean fever (FMF). Here are some key points:\n\n### Indications:\n1. **Gout**:\n   - Colchicine is primarily used for the treatment and prevention of gout flares. It is particularly effective when administered early in the course of an attack.\n2. **Familial Mediterranean Fever (FMF)**:\n   - It helps in preventing attacks of this hereditary inflammatory disorder.\n\n### Mechanism of Action:\n- Colchicine works by decreasing inflammation and is believed to inhibit the migration of neutrophils to the site of inflammation. It binds to tubulin, disrupting microtubule function, which is essential for various cellular processes.\n\n### Dosage and Administration:\n1. **Gout**:\n   - Acute attack: Typically, 1.2 mg initially followed by 0.6 mg after 1 hour (maximum 1"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_jOwFonDl6uB4XsfhrHIgx6uk", "custom_id": "328_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "617d298e13407a5c8e0758288d6a6f91", "body": {"id": "chatcmpl-9St7gFIX2U8JhItTJvzaunBmRPdh6", "object": "chat.completion", "created": 1716672104, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dostarlimab is a monoclonal antibody that functions as a programmed death receptor-1 (PD-1) inhibitor. It is primarily used in the treatment of certain types of cancer. Here are several key points you should know about Dostarlimab:\n\n### Indications:\n- **Recurrent or advanced endometrial cancer:** Dostarlimab is approved for the treatment of patients with recurrent or advanced endometrial cancer that has progressed on or after a platinum-based regimen and whose tumors are either mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H).\n\n### Mechanism of Action:\n- **PD-1 Inhibition:** Dostarlimab blocks the interaction between PD-1, a checkpoint protein on T cells, and its ligands, PD-L1 and PD-L2, found on cancer cells. This essentially lifts the \"brakes\" off the immune system, allowing T cells to attack the cancer cells more effectively.\n\n### Administration:\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_53zV5ysfhG0nPYLLSEskNmJd", "custom_id": "329_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e6f856f7f2709000b6b81f351f435928", "body": {"id": "chatcmpl-9St7gzFN5PDcJu30IKPd7oTcwwF6O", "object": "chat.completion", "created": 1716672104, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to stay updated on novel therapies and treatments, including emerging drugs like Serplulimab. Here is some relevant information regarding Serplulimab that you might find useful:\n\n### General Information\n- **Drug Class**: Serplulimab is a monoclonal antibody targeting PD-1 (Programmed Death-1), which is involved in immune checkpoint inhibition.\n- **Indication**: Designed primarily for oncology applications, particularly in treating certain types of cancer by modulating the immune response.\n\n### Mechanism of Action\n- **PD-1 Inhibition**: Serplulimab works by inhibiting the PD-1 receptor on T cells. This blockade prevents the interaction between PD-1 and its ligands (PD-L1 and PD-L2), leading to the activation of T cells and an enhanced immune response against cancer cells.\n\n### Clinical Applications\n- **Cancer Types**: It is being investigated and used for various types of cancers, most notably in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Fu69E63JnW48dyXTINJBwNnK", "custom_id": "330_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b23907757c291d1cb90373f52f53b707", "body": {"id": "chatcmpl-9St7gwOYSKXuK62HLpsHq1P2AaDAy", "object": "chat.completion", "created": 1716672104, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sugemalimab is a monoclonal antibody that targets PD-L1 (programmed death-ligand 1), playing a role in cancer immunotherapy. Here's what you should know about it as a physician:\n\n### Mechanism of Action:\n- **PD-L1 Inhibition**: Sugemalimab binds to PD-L1, blocking its interaction with PD-1 receptors on T cells. This inhibition lifts the \"brakes\" on the immune system, allowing T cells to better recognize and attack tumor cells.\n\n### Indications:\n- **Non-Small Cell Lung Cancer (NSCLC)**: Sugemalimab has shown efficacy in treating patients with NSCLC, both as a monotherapy and in combination with chemotherapy.\n- **Other Cancers**: There is ongoing research and clinical trials examining its potential efficacy in treating other types of malignancies, including lymphomas and other solid tumors.\n\n### Administration:\n- **Intravenous Infusion**: Sugemalimab is typically administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_oXI8REt5fBtPDLBj03N3sJJW", "custom_id": "331_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4f4bf618eedf81200423613c8e5917f3", "body": {"id": "chatcmpl-9St7goLFaFs6OiTiPAmiTRylLJdg5", "object": "chat.completion", "created": 1716672104, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sirolimus protein-bound particles (brand name Fyarro) are a novel formulation of sirolimus, which is an mTOR (mammalian target of rapamycin) inhibitor used primarily in the treatment of certain cancers and autoimmune conditions. Here are some critical points you should know about this formulation:\n\n### General Information:\n1. **Mechanism of Action**:\n   - Sirolimus inhibits the mTOR pathway, which is crucial for cell growth, proliferation, and survival. This inhibition can suppress tumor growth and reduce the activity of the immune system.\n\n2. **Indications**:\n   - Sirolimus protein-bound particles are approved for the treatment of specific cancer types, especially certain types of soft tissue sarcomas. It may also be used off-label for other conditions as determined by clinical considerations.\n\n### Pharmacokinetics:\n1. **Bioavailability**:\n   - The protein-bound formulation is designed to enhance the delivery and bioavailability of sirolimus. It helps achieve"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_kDPcIUkFxoIBdGfxDbIdbU7u", "custom_id": "332_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ac9648ec1a91c7d6271647fbf662449c", "body": {"id": "chatcmpl-9St7g4wSNlv1SR8lG0qWgNlyijGVy", "object": "chat.completion", "created": 1716672104, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Suramin is a medication that has been used historically for the treatment of African trypanosomiasis (sleeping sickness) and onchocerciasis (river blindness). Here are several key points every physician should know about Suramin:\n\n### Mechanism of Action:\n- **Antiprotozoal and Anthelmintic:** It inhibits multiple enzymes involved in cellular metabolism by interfering with energy metabolism pathways in protozoa and parasites.\n\n### Therapeutic Uses:\n- **African Trypanosomiasis:** Effective in the early hemolymphatic stage of the disease caused by Trypanosoma brucei rhodesiense and, to some extent, Trypanosoma brucei gambiense.\n- **Onchocerciasis:** Used as an alternative treatment, though less preferred due to the advent of ivermectin.\n\n### Dosing and Administration:\n- **Form:** Available as an intravenous solution.\n- **Dosage:** Requires careful dosing based on the indication and patient\u2019s condition."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_7XWUcnT8wr9UugcaIIAL1wFn", "custom_id": "333_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0685cafefd4358f7d2b27601af92d6e7", "body": {"id": "chatcmpl-9St7h1O04Kgcu7cpwXauVrhdROAZs", "object": "chat.completion", "created": 1716672105, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adagrasib is a relatively new and targeted cancer therapy that has garnered attention in oncology, particularly for its role in treating certain types of lung cancer. Here are key points you should be aware of as a physician:\n\n### Mechanism of Action\nAdagrasib is a small molecule inhibitor of KRAS G12C, a specific mutation in the KRAS gene. KRAS is a well-known oncogene, and mutations in this gene, especially G12C, are frequently associated with various cancers. By specifically targeting and inhibiting KRAS G12C, Adagrasib aims to block the growth and proliferation of cancer cells driven by this mutation.\n\n### Indications\nAs of the latest information, Adagrasib is primarily being investigated and used for the treatment of:\n- Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C mutation.\n\nClinical trials are ongoing to explore its effectiveness in other KRAS G12C-mutated cancers such as colorectal cancer and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_DL095fnUZdHmN4kkrkwnYvbP", "custom_id": "334_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "17a1b8863cea1cb2d2b36e4dda5f1e36", "body": {"id": "chatcmpl-9St7h1LgwEfkMZ2gPCuBCcu5OGhXj", "object": "chat.completion", "created": 1716672105, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tebentafusp is an innovative biologic therapy specifically designed for the treatment of uveal melanoma, a rare and aggressive form of eye cancer. Approved by the FDA in January 2022, this treatment has garnered considerable interest due to its novel mechanism of action and significant clinical trial results.\n\nHere are several key details you should know:\n\n### Mechanism of Action:\n- **Bispecific Molecule**: Tebentafusp is a bispecific T cell engager (BiTE) molecule. It comprises two components: one that targets a protein called gp100 presented on the surface of melanoma cells, and another component that binds to CD3 on T cells.\n- **Immune Activation**: By simultaneously binding to gp100 on the tumor cells and CD3 on T cells, tebentafusp brings these cells into close proximity, effectively \"arming\" T cells to recognize and kill the melanoma cells.\n\n### Indications:\n- **Uveal Melanoma**: Tebentafusp is primarily"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_fm2E1POuV4YrJs1ievo0cU8P", "custom_id": "335_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5c90442cb1306520614a7131172abdd6", "body": {"id": "chatcmpl-9St7hzifzLFi7gLhGsCfeugcojgwz", "object": "chat.completion", "created": 1716672105, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fedratinib is a medication you should be familiar with, especially if you treat patients with myeloproliferative neoplasms, including myelofibrosis. Here's a detailed overview of what you need to know:\n\n### Indications\n- **Myelofibrosis**: Fedratinib is primarily used to treat adults with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.\n\n### Mechanism of Action\n- **JAK2 Inhibition**: Fedratinib is a selective inhibitor of the Janus kinase 2 (JAK2) enzyme. It also inhibits wild-type JAK2 and specific mutations, thereby reducing the abnormal clonal proliferation of hematopoietic stem cells which is characteristic of myelofibrosis.\n\n### Dosage and Administration\n- **Typical Dose**: The usual dose is 400 mg taken orally once daily.\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_2v1AdJr1B5J6CPV8G8ySc9d7", "custom_id": "336_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5a672c97b86ad184668af225ffca0e45", "body": {"id": "chatcmpl-9St7hp1sDTrAP4nxYQj8a2R24QPkq", "object": "chat.completion", "created": 1716672105, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, understanding the combined formulation of Trastuzumab and Hyaluronidase is essential, particularly if you are involved in oncology care. Here are the key points you should know:\n\n### Trastuzumab:\n1. **Mechanism of Action**: Trastuzumab is a monoclonal antibody that targets the HER2/neu receptor, which is overexpressed in some breast cancer and gastric cancer cells. By binding to this receptor, Trastuzumab inhibits the proliferation of cancer cells that overexpress HER2.\n\n2. **Indications**: It is primarily used to treat HER2-positive breast cancer and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.\n\n3. **Administration**: Traditionally, Trastuzumab is administered intravenously. However, formulations combining Trastuzumab with hyaluronidase enable subcutaneous administration.\n\n4. **Efficacy**: Clinical trials have shown that Trastuzumab significantly improves survival"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_WyrJoOtn7PGhKlrZ2ayyHuKQ", "custom_id": "337_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ca1ca747b2ed8e0359b59342c1801f32", "body": {"id": "chatcmpl-9St7hf24d3WGoqr6pxKoa0Le1FV0v", "object": "chat.completion", "created": 1716672105, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zanubrutinib, marketed under the brand name Brukinsa, is a small-molecule Bruton's tyrosine kinase (BTK) inhibitor used in the treatment of certain B-cell malignancies. Here are some key points you should know about Zanubrutinib:\n\n### Indications\n- **Mantle Cell Lymphoma (MCL)**: For adult patients who have received at least one prior therapy.\n- **Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)**: Approved for use in these indications, often after other therapies have failed.\n\n### Mechanism of Action\n- **BTK Inhibition**: Zanubrutinib covalently binds to BTK, inhibiting its activity. BTK is part of the B-cell receptor signaling pathway, which is crucial for the survival and proliferation of malignant B-cells. By inhibiting BTK, Zanubrutinib disrupts these signals, leading"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_dhcLTwBKVh8kAk4SLd71MNaK", "custom_id": "338_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "08c838f46cd40125d8650ba47d4aded7", "body": {"id": "chatcmpl-9St7hTUbGbgypLJxa9Djuff8Ur6wL", "object": "chat.completion", "created": 1716672105, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it\u2019s essential to be well-informed about Furmonertinib to effectively incorporate it into clinical practice if appropriate. Here's a comprehensive overview:\n\n### Overview\nFurmonertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It is primarily used in the treatment of non-small cell lung cancer (NSCLC) with specific mutations in the EGFR gene. \n\n### Indications\n- **NSCLC**: Furmonertinib is indicated for the treatment of patients with EGFR mutation-positive NSCLC, particularly those harboring the T790M resistance mutation, which can develop after initial treatment with first- or second-generation EGFR TKIs.\n\n### Mechanism of Action\n- **Targeted Therapy**: Furmonertinib works by selectively inhibiting the tyrosine kinase activity of mutant EGFRs, thereby blocking downstream signaling pathways that drive tumor cell proliferation and survival.\n\n### Efficacy\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_sEGMLUxuh0Onozlfcb52FaFo", "custom_id": "339_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6801596d50c957a374b7445dbcddf308", "body": {"id": "chatcmpl-9St7hDN6wBNqxYNnXHwkLyYV2h8hi", "object": "chat.completion", "created": 1716672105, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ciltacabtagene autoleucel (Cilta-cel) is a CAR-T cell therapy that has been specifically designed for the treatment of multiple myeloma, particularly for patients who have relapsed or are refractory to standard treatments. Here's what you should know about Cilta-cel:\n\n### Mechanism of Action\nCilta-cel is an autologous CAR-T cell therapy, meaning it is derived from the patient's own T cells. These T cells are genetically engineered to express a chimeric antigen receptor (CAR) that targets B-cell maturation antigen (BCMA), which is commonly expressed on multiple myeloma cells. Upon reinfusion into the patient, these CAR-T cells recognize and kill BCMA-expressing myeloma cells.\n\n### Indications\nCilta-cel has been approved for use in adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 47, "completion_tokens": 200, "total_tokens": 247}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_2DeDIaa7aEXjs1jkOPSH3Zzk", "custom_id": "340_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "72c4d99a9f76d3bd3b5f015a9dfd2356", "body": {"id": "chatcmpl-9St7hDPVkrAaeW4DACzMccJsXCGxw", "object": "chat.completion", "created": 1716672105, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asciminib is a relatively new therapeutic agent used in the treatment of chronic myeloid leukemia (CML). Here is a detailed overview of what you, as a physician, should know about Asciminib:\n\n### Mechanism of Action\n- **Type**: Asciminib is a BCR-ABL1 inhibitor.\n- **Specific Action**: Unlike other tyrosine kinase inhibitors (TKIs), Asciminib specifically targets the ABL myristoyl pocket (STAMP), offering a unique mechanism of action by binding at a different site (allosteric inhibition) compared to other TKIs.\n\n### Indications\n- **Primary Use**: Asciminib is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.\n- **Targeted Patients**: It is particularly useful for patients who have tried and are resistant or intolerant to two or more prior TKIs.\n\n### Clinical Efficacy\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_yphzxqyuHqwKdl3NtXBp4bjb", "custom_id": "341_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f7350923dabd20ce60eea3d41d81f73e", "body": {"id": "chatcmpl-9St7h20DPq30fn2Z8AyNtDda682RF", "object": "chat.completion", "created": 1716672105, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Loncastuximab tesirine (brand name Zynlonta) is an antibody-drug conjugate (ADC) used in oncology, specifically to treat certain types of non-Hodgkin lymphoma. Below are some key aspects a physician should know about this medication:\n\n### Mechanism of Action\n- **Antibody-Drug Conjugate (ADC)**: It consists of a CD19-targeting antibody linked to a cytotoxic agent (SG3199).\n- **Target**: CD19, a surface protein commonly expressed on B cells and B-cell malignancies.\n- **Cytotoxic Payload**: SG3199, a pyrrolobenzodiazepine (PBD) dimer, which binds to DNA and induces cell death.\n\n### Indications\n- Approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. This includes:\n  - Diffuse large B-cell lymphoma (DL"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Sd4J5lDaQqXzsWgIFaPvIIMZ", "custom_id": "342_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d090e7c27429587dffa5dcf8577dd42a", "body": {"id": "chatcmpl-9St7hhXYwdED74kkYkXN9xlQoky6q", "object": "chat.completion", "created": 1716672105, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tazemetostat (brand name Tazverik) is an antineoplastic agent used primarily in the treatment of certain types of cancers. Here are some key points a physician should know about Tazemetostat:\n\n### Mechanism of Action\n- **EZH2 Inhibition:** Tazemetostat is an inhibitor of the Enhancer of Zeste Homolog 2 (EZH2) enzyme, which is involved in the methylation of histone proteins. By inhibiting EZH2, Tazemetostat reduces the methylation of histones, which can lead to the reactivation of tumor suppressor genes that have been silenced through methylation, thereby providing a potential antitumor effect.\n\n### Indications\n- **Epitheloid Sarcoma:** Tazemetostat is FDA-approved for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.\n- **Follicular"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_F8sPam0ioRikROKulHBu8YT6", "custom_id": "343_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "67ea4015c7e7d1c7a3ba51e2b5eb5bd8", "body": {"id": "chatcmpl-9St7ils4JtEpOKgN5HbbObehp2AfB", "object": "chat.completion", "created": 1716672106, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nivolumab and relatlimab are two immunotherapies used in oncology to treat various types of cancers. Here's a detailed overview of each:\n\n### Nivolumab\n- **Type:** Monoclonal Antibody\n- **Mechanism of Action:** Nivolumab is a PD-1 (programmed cell death-1) inhibitor. It works by blocking the PD-1 pathway, thereby enhancing the body's immune response against cancer cells. PD-1 is a checkpoint protein on immune cells (T cells) that normally helps keep these cells from attacking normal cells in the body. When PD-1 is bound to PD-L1, it basically makes the T cell turn off its attack. By inhibiting this binding, nivolumab allows T cells to continue attacking cancer cells.\n- **Indications:** Nivolumab is used to treat various cancers, including:\n  - Melanoma\n  - Non-Small Cell Lung Cancer (NSCLC)\n  - Ren"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_7zr0O9yCYrKVZev7Kc2SYxDe", "custom_id": "344_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a70bdedcfff6e0cc3b83d101f0c7f567", "body": {"id": "chatcmpl-9St7i33bGCkFSDo4d3quXV6qjla6e", "object": "chat.completion", "created": 1716672106, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon alfa-2c is a type of interferon, a protein that belongs to the larger family of proteins known as cytokines. These proteins play a critical role in the body's immune response and are used therapeutically for their antiviral, antiproliferative, and immune-modulating properties. Here are some key points you should know about Interferon alfa-2c:\n\n### Mechanism of Action\n- **Immune Modulation**: Interferon alfa-2c helps modulate the immune response, enhancing the body's ability to fight off infections and diseases, including certain cancers and viral infections.\n- **Antiviral Activity**: It can inhibit viral replication within host cells.\n- **Antiproliferative Effects**: It can inhibit the growth of tumor cells and has been used in the treatment of certain cancers.\n\n### Indications\nInterferon alfa-2c is used to treat various diseases, including:\n- **Hepatitis B and C**: It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 45, "completion_tokens": 200, "total_tokens": 245}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Czq9v6IbMYarUGssoTLnFH91", "custom_id": "345_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4ef3ccab5b0c750b3aaabff8c1b4f116", "body": {"id": "chatcmpl-9St7iBHytGJznPOBujrKVayiEwbY4", "object": "chat.completion", "created": 1716672106, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Interferon alfa-n1 is a type of interferon, which is a group of signaling proteins made and released by host cells in response to the presence of several viruses. It is used in the treatment of various medical conditions, primarily involving viral infections and certain types of cancers. Here are some key points you should know about Interferon alfa-n1 as a physician:\n\n### Mechanism of Action\n- **Antiviral Activity**: Interferon alfa-n1 induces the production of enzymes that inhibit viral replication.\n- **Antiproliferative Effects**: It can inhibit the proliferation of malignant cells.\n- **Immunomodulatory Effects**: Boosts the immune response by increasing the activity of macrophages, natural killer cells, and cytotoxic T cells.\n\n### Indications\n- **Chronic Hepatitis B and C**: It was historically used for these indications, though newer antiviral therapies have largely replaced it.\n- **Hairy Cell Leukemia**: Approved for the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_5y6ORC4Sr48eH91blf86Qq1j", "custom_id": "346_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "bb05fc85fa51aeed6abeb007dabf3e66", "body": {"id": "chatcmpl-9St7iY0lsHJYD8DwIldzCIvYZbIo8", "object": "chat.completion", "created": 1716672106, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Margetuximab is a monoclonal antibody used in the treatment of certain types of breast cancer. Here are some key points you should know about it as a physician:\n\n### Mechanism of Action:\n- **HER2 Targeting:** Margetuximab is designed to bind to the human epidermal growth factor receptor 2 (HER2), a protein that is overexpressed in some breast cancers. By binding to HER2, it inhibits the proliferation of cancer cells that overexpress this protein.\n- **Fc-Engineered Antibody:** Margetuximab includes modifications in the Fc region of the antibody. These modifications are intended to enhance its immune-mediated mechanisms of action, including antibody-dependent cellular cytotoxicity (ADCC).\n\n### Indications and Usage:\n- **HER2-Positive Breast Cancer:** Margetuximab is indicated for use in HER2-positive metastatic breast cancer, often in combination with other agents like chemotherapy.\n- **Treatment Line:** Typically used in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_VBSKT1fkv2i0tZi8MbNjdF4C", "custom_id": "347_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "45d1e2dfc6a1b29b61c1717bb473650a", "body": {"id": "chatcmpl-9St7iEMT5SFKoFmEJpxdyUKbpukpY", "object": "chat.completion", "created": 1716672106, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sotorasib, marketed under the brand name Lumakras in the U.S. and Lumykras in some other regions, is a groundbreaking medication primarily used in the treatment of non-small cell lung cancer (NSCLC). Here are key points you should be aware of about Sotorasib:\n\n### Mechanism of Action:\n1. **Targeted Therapy:** Sotorasib is a small molecule inhibitor that targets a specific mutation in the KRAS gene, known as KRAS G12C. This mutation is found in approximately 13% of patients with NSCLC.\n2. **KRAS G12C Inhibition:** By covalently binding to the mutant KRAS protein, Sotorasib inhibits its signaling pathway, which is crucial for tumor cell growth and survival.\n\n### Indications:\n1. **NSCLC:** It is specifically approved for the treatment of adult patients with KRAS G12C-mutant locally advanced or metastatic NSCLC who have received at least one prior systemic therapy.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Ixt6cwyWw1wNbgqPxFwNL4e3", "custom_id": "348_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "83f8bcbcbda1ae425f903687d3c58c1d", "body": {"id": "chatcmpl-9St7ipefovQ9raIUd5VJjQOuljg7i", "object": "chat.completion", "created": 1716672106, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Umbralisib is an oral medication used primarily in the treatment of certain types of lymphomas, including relapsed or refractory marginal zone lymphoma (MZL) and relapsed or refractory follicular lymphoma (FL). It was developed by TG Therapeutics and belongs to a class of drugs known as PI3K inhibitors.\n\nHere are some key points you should know about Umbralisib:\n\n1. **Mechanism of Action:**\n   Umbralisib inhibits phosphoinositide 3-kinase (PI3K) delta and casein kinase 1 epsilon (CK1\u03b5). These enzymes play a role in the growth and survival of malignant B-cells. By inhibiting these enzymes, Umbralisib helps to reduce the proliferation of these cancer cells.\n\n2. **Indications:**\n   Umbralisib received accelerated approval from the FDA for the treatment of adult patients with:\n   - Relapsed or refractory marginal zone lymphoma (MZL) who have received"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Au2JurTiGSQtCqKsXOwXmL9B", "custom_id": "349_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8647b1e8cf40fd3f460327eb23df29dd", "body": {"id": "chatcmpl-9St7iVnNl9LPeO7qtUOUivbRF2az3", "object": "chat.completion", "created": 1716672106, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to stay informed about emerging and current medications in order to provide the best possible care for your patients. Sintilimab is a monoclonal antibody that targets the programmed death-1 (PD-1) receptor, which is part of the immune checkpoint pathway. Here is a detailed overview of key points to know about Sintilimab:\n\n### Mechanism of Action:\n- **Checkpoint Inhibition:** Sintilimab works by inhibiting the interaction between PD-1 on T cells and its ligands, PD-L1 and PD-L2. This blockade can enhance the immune system's ability to recognize and kill cancer cells.\n  \n### Indications:\n- **Cancer Treatments:** Sintilimab is primarily used in oncology for the treatment of various cancers. It is approved in certain regions for use in conditions such as non-small cell lung cancer (NSCLC) and classical Hodgkin lymphoma, among others.\n  \n### Clinical Trials and Efficacy:\n- **Clinical Data:** The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_PbMOM6WyjbnAYBkDAxzQGZNQ", "custom_id": "350_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "50d31d476fafaea8d92e94755205bb90", "body": {"id": "chatcmpl-9St7iI3nioCDFVKXRXVH9QavEUYKs", "object": "chat.completion", "created": 1716672106, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pirtobrutinib is an emerging therapeutic agent that has generated significant interest in the medical community, particularly in the field of oncology. As a physician, here are several critical aspects you should be aware of:\n\n### 1. **Mechanism of Action:**\nPirtobrutinib is a highly selective, non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor. BTK is an enzyme that plays a crucial role in the signal transduction pathways of B-cell development. By inhibiting BTK, Pirtobrutinib interferes with the survival and proliferation of malignant B-cells.\n\n### 2. **Indications:**\nPirtobrutinib is principally being investigated for the treatment of various B-cell malignancies, including:\n   - Chronic lymphocytic leukemia (CLL)\n   - Small lymphocytic lymphoma (SLL)\n   - Mantle cell lymphoma (MCL)\n   - Other non-Hodgkin lymphomas"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_CaGzwmhqgPKHAl00idBENA9c", "custom_id": "351_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "09efcab260f45ee4b9950fb00ac8429c", "body": {"id": "chatcmpl-9St7iCwVj8PrqJ3XLUePQbsmmu2Lp", "object": "chat.completion", "created": 1716672106, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Toripalimab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) pathway. It has been developed and is used primarily in the field of oncology, particularly for treating certain types of cancers. Here are several key points that would be important for you as a physician to know:\n\n1. **Mechanism of Action:**\n   - Toripalimab is a PD-1 inhibitor. It works by blocking the interaction between PD-1 on T cells and its ligands (PD-L1 and PD-L2) on tumor cells. This blockade enhances the immune system's ability to recognize and destroy cancer cells.\n\n2. **Indications:**\n   - Toripalimab has been investigated and is used for the treatment of several types of cancers, including melanoma, nasopharyngeal carcinoma, and other tumors expressing PD-L1.\n   - Indications can be specific to certain regions based on regulatory approvals. Toripalimab may be approved"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_bxrebmx6QKsvRZZKVLeoPz93", "custom_id": "352_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b480868203551e5ca39c57637a570fee", "body": {"id": "chatcmpl-9St7i7I8ArS0DXgNKAeYS2VnEXqaw", "object": "chat.completion", "created": 1716672106, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Teclistamab is a bispecific antibody used in the treatment of certain hematologic malignancies, particularly multiple myeloma. As a physician, you should be aware of several key aspects regarding Teclistamab:\n\n1. **Mechanism of Action**: Teclistamab is designed to simultaneously bind to CD3 on T cells and BCMA (B-cell maturation antigen) on multiple myeloma cells. This dual binding redirects T cells to the cancer cells, facilitating their destruction.\n\n2. **Indications**: It's typically indicated for patients with relapsed or refractory multiple myeloma who have failed other lines of therapy. It's often considered after other treatments such as proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies.\n\n3. **Administration**: Teclistamab is usually administered as an injection or intravenous infusion. The dosing schedule may involve initial doses followed by maintenance doses, but it's important to follow specific protocols based on clinical guidelines and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_gsm8xLku1EzcxvDMXiVwHQpM", "custom_id": "353_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ac923b212989999caeace6febe298b0c", "body": {"id": "chatcmpl-9St7iFUH2rAinPStlV7gGyuuvnr1H", "object": "chat.completion", "created": 1716672106, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mobocertinib (brand name Exkivity) is a medication approved for the treatment of certain types of cancer, specifically non-small cell lung cancer (NSCLC). Here are key points that physicians should know about Mobocertinib:\n\n1. **Indication**: Mobocertinib is approved for adult patients with locally advanced or metastatic NSCLC that has epidermal growth factor receptor (EGFR) exon 20 insertion mutations, and who have previously been treated with platinum-based chemotherapy.\n\n2. **Mechanism of Action**: Mobocertinib is an oral tyrosine kinase inhibitor (TKI). It works by targeting and inhibiting the activity of EGFR with exon 20 insertion mutations, which are not effectively targeted by older EGFR TKIs.\n\n3. **Dosage**: The recommended dosage of Mobocertinib is generally 160 mg orally once daily until disease progression or unacceptable toxicity occurs. This can be taken with or without food.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_nWpP6vd7LxrCrLSNF0qmzl5w", "custom_id": "354_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d8d2a4132584bfb5026ad836f769093f", "body": {"id": "chatcmpl-9St7ihGEHnpuUPDkrnVoKtXmZlcir", "object": "chat.completion", "created": 1716672106, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tisotumab vedotin (brand name Tivdak) is an antibody-drug conjugate (ADC) designed for the treatment of cancer, specifically advanced or metastatic cervical cancer. Here are key points a physician should be aware of:\n\n### Mechanism of Action\n- **Antibody-Drug Conjugate:** Tisotumab vedotin comprises a tissue factor-targeting antibody linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE). The antibody targets tissue factor expressed on cancer cells, delivering the cytotoxic agent directly to the tumor, thereby enhancing specificity and reducing systemic toxicity.\n\n### Indications and Usage\n- **FDA Approval:** It was approved by the FDA in September 2021 for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.\n- **Clinical Use:** It is particularly used in cases where other treatments have failed, providing an option where previously few effective therapies existed.\n\n### Administration\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_3rrxIHgVTjqxn5XW6RAMpdO7", "custom_id": "355_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4a4f337407b2322aec456f49dc962f22", "body": {"id": "chatcmpl-9St7jqr45j72oMLTEnsIqAoAewQgP", "object": "chat.completion", "created": 1716672107, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lanreotide, specifically in its long-acting release (LAR) form, is a somatostatin analog used primarily for the treatment of acromegaly and neuroendocrine tumors, particularly gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Here are key points you should know about Lanreotide LAR:\n\n### Indications\n1. **Acromegaly**: Lanreotide LAR is used to reduce growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels in patients with acromegaly, especially when surgery or radiotherapy is not an option.\n2. **GEP-NETs**: It helps control symptoms and tumor growth in patients with gastroenteropancreatic neuroendocrine tumors.\n\n### Mechanism of Action\nLanreotide mimics natural somatostatin, which inhibits the secretion of several hormones including GH, insulin, and glucagon. This helps to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_h1xftJN8Yr0nl25pcHQTcOAT", "custom_id": "356_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f5654a04757a5c208b6c2e86b5cc6a97", "body": {"id": "chatcmpl-9St7jj3V2yOw6CsCHPJsV9Mzv93hN", "object": "chat.completion", "created": 1716672107, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pimitespib is a relatively new pharmaceutical drug with specific applications in oncology, primarily being explored for its effectiveness in treating certain types of cancers. Here are some key points you should know as a physician:\n\n1. **Mechanism of Action**: Pimitespib is a Heat Shock Protein 90 (Hsp90) inhibitor. Hsp90 is a molecular chaperone that is involved in the proper folding, stability, and function of many client proteins, including several oncogenic proteins. By inhibiting Hsp90, Pimitespib can destabilize these client proteins, leading to their degradation and ultimately inhibiting cancer cell growth.\n\n2. **Indications**: As of now, Pimitespib is primarily investigated for its efficacy in treating gastrointestinal stromal tumors (GISTs) that are resistant to other treatments like imatinib, sunitinib, or regorafenib. Additionally, it may have potential applications in treating other malignancies, but clinical"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ptJBAaMO2QfXb0xvP43YEq0n", "custom_id": "357_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "edfe0ee1c091c3d8986ba2fed68bf95f", "body": {"id": "chatcmpl-9St7jo9u7RrqOfzatnOdpPBTrkfzW", "object": "chat.completion", "created": 1716672107, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prednimustine is a chemotherapeutic agent that combines two drugs: prednisolone, which is a corticosteroid, and chlorambucil, which is an alkylating agent. Here are some key points you should know about it:\n\n### Indications:\n- Prednimustine is primarily used for the treatment of lymphoid malignancies, such as Hodgkin's and non-Hodgkin's lymphomas, as well as chronic lymphocytic leukemia (CLL).\n  \n### Mechanism of Action:\n- **Prednisolone:** Possesses anti-inflammatory and immunosuppressive properties. It works by modulating the activity of the immune system and inhibiting the production of inflammatory substances.\n- **Chlorambucil:** Works by alkylating DNA, leading to the disruption of DNA replication and cell division, which induces cell death in rapidly dividing cells, such as cancer cells.\n\n### Administration:\n- Typically administered orally. The exact dosage and schedule depend on the specific condition"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_nymUU5nEIGA9rywuWl1n7wyu", "custom_id": "358_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ef238d69a959a952edb5cfccfabaf37a", "body": {"id": "chatcmpl-9St7jWW5vDMCg39vgrN89bkQPiHlO", "object": "chat.completion", "created": 1716672107, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pipobroman is a chemotherapeutic agent primarily used in the treatment of certain hematologic malignancies. Here are key points you should know about Pipobroman:\n\n### Indications\n- **Primary Indications**: Pipobroman is commonly used to treat disorders such as polycythemia vera and essential thrombocythemia. These conditions involve abnormal proliferation of blood cells.\n  \n### Mechanism of Action\n- **Alkylating Agent**: Pipobroman functions by alkylating DNA, which interferes with DNA replication and RNA transcription. This disruption inhibits the proliferation of rapidly dividing cells, which is characteristic of many hematologic malignancies.\n\n### Pharmacokinetics\n- **Absorption and Metabolism**: Details about its absorption and metabolism are not well-documented, and clinical use has been guided largely by experience and empirical data rather than extensive pharmacokinetic studies.\n  \n### Administration\n- **Oral Form**: Pipobroman is administered orally. The dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Qv5f3kMRJauNKJJPd13ZJyjI", "custom_id": "359_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "668f6b862a4a94a793a9c7b853dad31b", "body": {"id": "chatcmpl-9St7jrStihftxQNBlQNDzf9hD98Yt", "object": "chat.completion", "created": 1716672107, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Polatuzumab vedotin (brand name Polivy) is a monoclonal antibody-drug conjugate used in the treatment of certain types of non-Hodgkin lymphoma, particularly diffuse large B-cell lymphoma (DLBCL). Here are key points you should know about Polatuzumab vedotin:\n\n### Mechanism of Action\n- **Target**: Polatuzumab vedotin targets the CD79b protein, which is expressed on the surface of B cells.\n- **Conjugate**: It is linked to a cytotoxic agent, monomethyl auristatin E (MMAE). Upon binding to the CD79b on B cells, the conjugate is internalized, and MMAE is released, leading to cell cycle arrest and apoptosis.\n\n### Indications\n- **Diffuse Large B-Cell Lymphoma (DLBCL)**: It is approved for use in relapsed or refractory DLBCL. Frequently used in combination with bendamustine"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_zLxjPS42yvS3G9X4pMGNTn7x", "custom_id": "360_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2ba0492c4a4f017e5a8d98769c8f1f18", "body": {"id": "chatcmpl-9St7jpSoH5JcWfVyHMnyqoimc7COr", "object": "chat.completion", "created": 1716672107, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mirvetuximab soravtansine is a Targeted Antibody Drug Conjugate (ADC) designed to specifically target folate receptor alpha (FR\u03b1). Here are some key points you should know about the drug:\n\n1. **Mechanism of Action**:\n   - Mirvetuximab soravtansine combines an antibody that specifically binds to the folate receptor alpha (FR\u03b1) with a potent cytotoxic agent (DM4, a maytansinoid).\n   - When the antibody component binds to FR\u03b1 on the cancer cell surface, the conjugate is internalized.\n   - Inside the cell, the cytotoxic agent is released, disrupting microtubule function, thereby inhibiting cell division and inducing apoptosis.\n\n2. **Indications**:\n   - It's under investigation for its efficacy in treating cancers that overexpress FR\u03b1, notably certain subtypes of ovarian cancer. Be aware of the specific indications as approvals and clinical trial outcomes can update this"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 48, "completion_tokens": 200, "total_tokens": 248}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Wkf14gAAB4VlYzrE7PKZpSHD", "custom_id": "361_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d2b9302cae4d562278bb1f3fe13c9a20", "body": {"id": "chatcmpl-9St7jbps58i7HEOsZSBpPWFpj8olF", "object": "chat.completion", "created": 1716672107, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mosunetuzumab is a bispecific antibody used in the treatment of certain types of cancers, particularly B-cell non-Hodgkin lymphoma (NHL). Here are some key points that you, as a physician, should know about Mosunetuzumab:\n\n### Mechanism of Action\n- **Bispecific Antibody**: Mosunetuzumab is designed to bind to both CD20 on B cells and CD3 on T cells. This promotes T cell-mediated cytotoxicity against the malignant B cells.\n- **Immune Activation**: By bringing T cells into proximity with B cells, it facilitates the destruction of the B cells through immune activation.\n\n### Indications\n- **Non-Hodgkin Lymphoma (NHL)**: Mosunetuzumab is typically indicated for patients with relapsed or refractory B-cell NHL, particularly when other treatments have failed.\n\n### Administration\n- **Intravenous Infusion**: The drug is administered via intravenous infusion, often"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_PB3EJwsbE1yzYqXEJRNQT8FJ", "custom_id": "362_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "de4bf154b43593392f2cd95182fca92a", "body": {"id": "chatcmpl-9St7kdl7SaaQVyhLKHW45qtFHTbWL", "object": "chat.completion", "created": 1716672108, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nadofaragene firadenovec, also known by its brand name Adstiladrin, is a novel gene therapy designed for the treatment of non-muscle invasive bladder cancer (NMIBC), specifically for patients with high-grade carcinoma in situ (CIS) with or without papillary tumors, who are unresponsive to Bacillus Calmette-Gu\u00e9rin (BCG) therapy. Here are some crucial points you should be aware of:\n\n1. **Mechanism of Action**: Nadofaragene firadenovec is a non-replicating adenoviral vector-based gene therapy. It delivers the gene for human interferon alpha-2b directly into the bladder's urothelial cells. Once the gene is inside the cells, it prompts them to produce and secrete interferon alpha-2b, which has anti-tumor properties.\n\n2. **Indications**: It's specifically indicated for high-grade, BCG-unresponsive NMIBC. This includes patients whose"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 46, "completion_tokens": 200, "total_tokens": 246}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_xjvHPiWE5iiCWRG5zNtgJih0", "custom_id": "363_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7ceb3b6327fe0863a380e879b9b42b95", "body": {"id": "chatcmpl-9St7kKdlTmaey5XgcC1Rg6gdWTMTb", "object": "chat.completion", "created": 1716672108, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Olutasidenib is an investigational oral small-molecule inhibitor specifically targeting mutant isocitrate dehydrogenase 1 (IDH1). As a physician, it's important to consider the following key points about Olutasidenib:\n\n1. **Mechanism of Action:**\n   - Olutasidenib inhibits the mutant IDH1 enzyme, which is often implicated in various cancers, including acute myeloid leukemia (AML) and certain solid tumors like gliomas. Mutation in IDH1 leads to the production of an oncometabolite, 2-hydroxyglutarate (2-HG), which contributes to oncogenesis.\n\n2. **Indications for Use:**\n   - Olutasidenib is primarily being studied for its efficacy in IDH1-mutant cancers. It shows promise for treatment in IDH1-mutant relapsed or refractory AML and other hematologic malignancies, as well as in solid tumors, though its primary focus has been on hemat"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_IdH0FikruflBRLmeKX9Vu6Yq", "custom_id": "364_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "bd2b48b7d258e44ce7341f2f4e1ac017", "body": {"id": "chatcmpl-9St7kNaTH38IrgE8eck821lNU0Rs8", "object": "chat.completion", "created": 1716672108, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pyrotinib is a medication used primarily for the treatment of certain types of breast cancer. Here's a detailed overview suitable for a physician:\n\n### 1. **Mechanism of Action:**\n   - Pyrotinib is an oral tyrosine kinase inhibitor (TKI) that targets the human epidermal growth factor receptors (HER) family, specifically HER1, HER2, and HER4.\n   - By blocking these receptors, pyrotinib inhibits the signaling pathways that promote tumor cell proliferation and survival.\n\n### 2. **Indications:**\n   - Pyrotinib is primarily indicated for the treatment of HER2-positive breast cancer, particularly in patients who have shown progression following previous treatments.\n\n### 3. **Administration:**\n   - Pyrotinib is administered orally, and the dosage regimen can vary. It is typically given in combination with other chemotherapy agents such as capecitabine.\n   - Patients are usually started on a specific dose, which may be"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_MadwuC4QxUg9qP6NmPStFlDn", "custom_id": "365_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1aa47bd73bb3b697569bf8327c739291", "body": {"id": "chatcmpl-9St7kIcmWxQA7l8XehFtX5rEQNf7A", "object": "chat.completion", "created": 1716672108, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Buserelin is a potent synthetic analog of gonadotropin-releasing hormone (GnRH) and has several clinical applications, particularly in the fields of reproductive health and oncology. Here are the key points you should be aware of:\n\n### Mechanism of Action:\n- **GnRH Analog:** Buserelin acts similarly to natural GnRH but with greater potency. It initially stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland.\n- **Desensitization:** Continuous administration of Buserelin leads to downregulation of GnRH receptors in the pituitary, resulting in decreased secretion of LH and FSH. This causes a decline in sex steroid production (testosterone in men, estrogen in women).\n\n### Clinical Uses:\n- **Prostate Cancer:** Used in the treatment of hormone-sensitive prostate cancer to reduce testosterone levels.\n- **Endometriosis:** Helps in reducing estrogen levels, which can alleviate the symptoms.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_4iCGyAiKwjuuZo96vFkVUjJ5", "custom_id": "366_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ca0ee574c6f08ea868b0ad0748387339", "body": {"id": "chatcmpl-9St7kiVD1LWuKmuFNu7MqN9Kb7mPV", "object": "chat.completion", "created": 1716672108, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lifileucel is a type of autologous tumor-infiltrating lymphocyte (TIL) therapy, which is a form of adoptive cell transfer (ACT) used in the treatment of certain types of cancer. Here are some key points you should know about Lifileucel:\n\n### Mechanism of Action\n- **TIL Therapy:** Lifileucel involves the extraction of TILs from a patient's tumor tissue. These TILs, which have demonstrated an ability to recognize and attack tumor cells, are expanded ex vivo (outside the body) and then reinfused into the patient to enhance the immune response against the tumor.\n- **Autologous Treatment:** Since the treatment uses the patient\u2019s own lymphocytes, it reduces the risk of immune rejection.\n\n### Indications\n- **Metastatic Melanoma:** Lifileucel has been primarily studied for the treatment of patients with advanced, metastatic melanoma, particularly those who have not responded to other forms"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_59b9km8bsU3ChCZxZDxuLOec", "custom_id": "367_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "14a4f5c9537c47d51c2787735cd0c451", "body": {"id": "chatcmpl-9St7kMga0RT3HbvMXVc4vI5wAd1Kz", "object": "chat.completion", "created": 1716672108, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tabelecleucel is an investigational, off-the-shelf, allogeneic T-cell therapy being developed primarily for the treatment of Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorders (PTLD), as well as other EBV-associated hematologic malignancies. Here\u2019s what you, as a physician, might need to know about Tabelecleucel:\n\n### Mechanism of Action:\n- **Tabelecleucel** is derived from healthy donors and contains T-cells that are specific to EBV antigens.\n- The therapy leverages the ability of these pre-sensitized T-cells to target and eliminate EBV-infected cells in patients, combating the associated malignancies.\n\n### Indications:\n- Currently being studied for the treatment of **EBV-associated PTLD** in patients who have relapsed or are refractory to rituximab, particularly after hematopoietic stem cell or solid organ transplantation.\n- Other EBV"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_DZ5wefufuXnmt6TEWxITg6rm", "custom_id": "368_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "812366e3e94b40e57a0c7d011cddcf76", "body": {"id": "chatcmpl-9St7kU8twAyeApLwbeDM2nXhksl3a", "object": "chat.completion", "created": 1716672108, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Verzenio (abemaciclib) is an orally administered small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which are key regulators of cell cycle progression. As a physician, here are some important points you should know about Verzenio:\n\n1. **Indications**: \n   - Verzenio is typically used for the treatment of certain types of breast cancer. It is approved for:\n     - HR-positive, HER2-negative advanced or metastatic breast cancer.\n     - It is often used in combination with endocrine therapy (such as an aromatase inhibitor or fulvestrant) for patients whose disease has progressed following endocrine therapy.\n     - It can also be given as monotherapy in patients who have previously used endocrine therapy and chemotherapy.\n\n2. **Mechanism of Action**:\n   - Verzenio works by inhibiting CDK4/6, which prevents the phosphorylation of the retinoblastoma (Rb) protein"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_51oVac8u1vPhNn6TIGbV29YX", "custom_id": "369_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "448a5418d4d41fb7fe2b4c8734317ec4", "body": {"id": "chatcmpl-9St7kjwY5iynI4cOHcagQL4FT4GZw", "object": "chat.completion", "created": 1716672108, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a typo or a misunderstanding in the name \"Abatitor.\" If you meant a medication, therapy, or a medical term, I'm not familiar with \"Abatitor\" as there doesn't appear to be any widely known or recognized medication or medical treatment by that name up to my latest update in 2023.\n\nIf you provide more context or correct the name, I might be able to offer more specific information. If you were referring to a commonly known medication, it's possible it was misspelled or typed incorrectly. Here are a few similar-sounding medications or treatments that you might have been referring to:\n \n- **Abatacept** (Orencia): A medication used in the treatment of autoimmune diseases such as rheumatoid arthritis by modulating the immune system's activity.\n- **Atorvastatin**: Often sold under the brand name Lipitor, it's a statin used to lower cholesterol and reduce the risk of cardiovascular disease.\n\nIf either of these was what"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_NvbKkR6x3B28U4qq1oZ72qox", "custom_id": "370_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "c2c32a5444c326af862df05b7235be7e", "body": {"id": "chatcmpl-9St7kZyjl2Y2UYNCj5A6nH95mnSnb", "object": "chat.completion", "created": 1716672108, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Calquence (acalabrutinib) is a Bruton tyrosine kinase (BTK) inhibitor used in the treatment of certain types of blood cancers. As a physician, here are key points to be aware of regarding Calquence:\n\n1. **Indications**:\n   - Calquence is primarily indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.\n   - It is also approved for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).\n\n2. **Mechanism of Action**:\n   - Calquence works by inhibiting BTK, which is a key enzyme involved in the proliferation and survival of B cells. By blocking BTK, Calquence disrupts B-cell receptor signaling and induces apoptosis in malignant B cells.\n\n3. **Administration**:\n   - It is administered orally, typically as a 100 mg capsule taken twice daily with or without food.\n\n4."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_OyYr3ljsAz91ulvO7J3fAJhW", "custom_id": "371_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "30ea467f2431b5a9baf8078aa48fb5de", "body": {"id": "chatcmpl-9St7ludJixSytUGy26FRhdknlB99n", "object": "chat.completion", "created": 1716672109, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aclacin, also known as Aclacinomycin A or Aclarubicin, is an anthracycline antibiotic and chemotherapeutic agent used primarily in the treatment of certain types of cancer, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and certain lymphomas. Here are some key points you should know about Aclacin as a physician:\n\n1. **Mechanism of Action:**\n   - Aclacinomycin A intercalates into DNA and inhibits topoisomerase II, an enzyme critical for DNA replication and repair, thereby inducing apoptosis in rapidly dividing cancer cells.\n\n2. **Indications:**\n   - It is used in the treatment of various hematological malignancies, including AML, ALL, and some types of lymphomas. It's often part of combination chemotherapy protocols.\n\n3. **Administration:**\n   - Aclarubicin is typically administered intravenously. Dosage and schedule depend on the specific cancer being treated,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_dKAId6SCUJGwBBSOAB8Zfmpc", "custom_id": "372_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7d4475137ad3ee59134be443c5f36825", "body": {"id": "chatcmpl-9St7l1MIt2fNn6tz4FNX3751g4pXe", "object": "chat.completion", "created": 1716672109, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to have a comprehensive understanding of Kadcyla (generic name: ado-trastuzumab emtansine), which is an antibody-drug conjugate used primarily in the treatment of HER2-positive breast cancer. It combines the HER2-targeted action of trastuzumab with the cytotoxic activity of the microtubule inhibitor DM1.\n\nHere are key points you should be aware of regarding Kadcyla:\n\n### Indications:\n- Kadcyla is approved for the treatment of HER2-positive metastatic breast cancer, particularly in patients who have previously received trastuzumab and a taxane, separately or in combination.\n- It is also used in the adjuvant setting for HER2-positive early breast cancer in patients who have residual invasive disease after receiving neoadjuvant taxane and trastuzumab-based treatment.\n\n### Mechanism of Action:\n- **Trastuzumab Component:** Binds to the HER2 receptor on cancer cells, preventing receptor d"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_JByHkSGcgEst4aiKI7Z7jhjT", "custom_id": "373_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "fbcd94a77931bcefec1d05bdd17367ee", "body": {"id": "chatcmpl-9St7l4SCvuE79n647OQDuFHObSeQr", "object": "chat.completion", "created": 1716672109, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my latest information update in October 2023, there is no recognized drug, treatment, or medical condition known as \"Afanix.\" It's possible that you might be referring to a newly introduced medication or technology that has come into the medical field after my last update, or it could be a misspelling or alternate name for something that does exist.\n\nIf \"Afanix\" is indeed a recent development, I recommend the following steps:\n\n1. **Consult Medical Databases**: Check reputable medical databases such as PubMed, FDA, or clinical trial registries for any information on Afanix.\n2. **Manufacturer Information**: Look up information directly from the manufacturer or pharmaceutical company that produces Afanix.\n3. **Professional Resources**: Utilize professional medical resources, such as physician networks, conferences, or continuing medical education (CME) opportunities, to learn more.\n4. **Peer Consultation**: Discuss with colleagues or experts in the relevant medical field to gain insights"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_D67QPIIyhXSPxTyWyhpHXQWK", "custom_id": "374_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "eeb0033402903af09cf4f9d4306af0d1", "body": {"id": "chatcmpl-9St7lb7IFfs3TYA1teRa5oBqJOsGA", "object": "chat.completion", "created": 1716672109, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It looks like there might be some confusion here because \"Macrolin\" doesn't appear to be a recognized medication or substance in medical literature or databases as of my latest update in 2021. It could be a typo, a brand name not widely recognized, or a miscommunication.\n\nHowever, if you meant macrolides (a class of antibiotics), here are essential points you should know:\n\n### Macrolides Overview:\n1. **Common Macrolides**: The most commonly used macrolides include erythromycin, clarithromycin, and azithromycin.\n   \n2. **Mechanism of Action**: Macrolides work by inhibiting bacterial protein synthesis. They bind to the 50S ribosomal subunit, preventing the translocation steps in protein elongation.\n   \n3. **Spectrum of Activity**:\n   - **Gram-Positive Bacteria**: Effective against Streptococcus and Staphylococcus species.\n   - **Gram-Negative Bacteria**: Some activity"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_cpdvOCPJ3OIY691v6tSezFsq", "custom_id": "375_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ca0b26d05603851830fdc28790b643e1", "body": {"id": "chatcmpl-9St7lCRawuDRNGTrIfjeZ4jiXriQo", "object": "chat.completion", "created": 1716672109, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about Alecensa (alectinib) to effectively treat patients with certain types of lung cancer. Here\u2019s a comprehensive overview:\n\n### Indications:\n- **Alecensa** is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.\n\n### Mechanism of Action:\n- Alecensa is an **ALK inhibitor**. It works by inhibiting the activity of the ALK tyrosine kinase receptor, which can be abnormally activated in some cancers, leading to tumor growth and survival.\n\n### Dosage and Administration:\n- The recommended dose of Alecensa is **600 mg orally**, taken **twice daily** with food.\n- Capsules should be swallowed whole and should not be opened or dissolved.\n\n### Common Side Effects:\n- **Fatigue**\n- **Constipation**\n- **Edema**\n- **Myalgia**\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_3NtxIdol1HV302nTdryv75Ab", "custom_id": "376_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "072823480b877b6397ce14edcc0bafdd", "body": {"id": "chatcmpl-9St7l9CMQBK9S0dFlFNBplpVgHPev", "object": "chat.completion", "created": 1716672109, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Campath, also known by its generic name alemtuzumab, is a monoclonal antibody used primarily in the treatment of certain types of cancer and autoimmune disorders. Here\u2019s a detailed overview of what physicians should know about Campath:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL):** Campath is approved for the treatment of B-cell chronic lymphocytic leukemia (CLL) in patients who have been treated with other chemotherapy types that have not worked.\n2. **Multiple Sclerosis (MS):** Alemtuzumab is also used in the management of multiple sclerosis, particularly for relapsing forms of MS. In this context, it is often marketed under the brand name Lemtrada.\n\n### Mechanism of Action:\n- Alemtuzumab is a monoclonal antibody that targets CD52, a protein present on the surface of certain blood cells such as lymphocytes (for example, B cells and T cells), and monocytes"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_jpgthu91TdZsR7lPJFk3IlTJ", "custom_id": "377_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d6b74d098d1f0ece3bee888cb01189c8", "body": {"id": "chatcmpl-9St7lYcUrug67NesQaXOT23Fkzu1W", "object": "chat.completion", "created": 1716672109, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "CA ATRA typically refers to \"All-Trans Retinoic Acid\" (ATRA), which is a derivative of vitamin A (retinoic acid) used primarily in the treatment of acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML). Here are some important details for you as a physician:\n\n### Mechanism of Action:\nATRA works by promoting the differentiation of promyelocytes to normal mature blood cells, thus reducing the accumulation of immature blasts in the bone marrow. This abnormal accumulation is a hallmark of APL.\n\n### Clinical Use:\n- **Acute Promyelocytic Leukemia (APL)**: ATRA is a mainstay in the treatment of APL. It is often used in combination with other chemotherapeutic agents like arsenic trioxide or anthracyclines.\n- **Induction Therapy**: ATRA can be used during the initial phase of treatment to induce remission.\n- **Consolidation and Maintenance**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_3dDccPvsdgzlpFoyBLDsmS8Z", "custom_id": "378_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2390cbbd5ee57098db2d2972c409aa29", "body": {"id": "chatcmpl-9St7lmVq9qINvlXtISuwU5kjlNKLu", "object": "chat.completion", "created": 1716672109, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Hexalen, known generically as altretamine, is an oral antineoplastic agent that is primarily used in the treatment of ovarian cancer, particularly for patients with persistent or recurrent disease following first-line therapy. Here is what you should know about Hexalen:\n\n### Indications:\n- **Ovarian Cancer:** Hexalen is indicated for the treatment of patients with epithelial ovarian cancer who have already undergone other forms of therapy.\n\n### Mechanism of Action:\n- Hexalen is an alkylating agent that works by interfering with the DNA in cancer cells, preventing them from multiplying and causing them to die.\n\n### Dosage and Administration:\n- **Common Dosage:** Typically, the dosage is 260 mg/m\u00b2 per day, divided into four doses, given for 14 or 21 days, followed by a rest period of 7 or 14 days, depending on the patient's response and tolerance. The specific regimen may vary depending on patient-specific factors and clinical judgment.\n- **Administration:** It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_QF5uhn5bio2u8yD2pwoHwRER", "custom_id": "379_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "3410f156ef5c2f37b2f5d8b2bfc3bae5", "body": {"id": "chatcmpl-9St7lZjZt8t8Fh5lmuFvLLsngv3Hu", "object": "chat.completion", "created": 1716672109, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Aminoblastin\" is not a commonly recognized pharmaceutical or medical term in the literature up to my knowledge cutoff in October 2023. This could imply a few possibilities:\n\n1. **Typographical Error**: It might be a miswriting or misremembering of a different drug name or medical term.\n2. **Regional/Brand Name**: It might be a regional brand name or a proprietary name for a product that isn\u2019t widely recognized internationally.\n3. **Novel Development**: It could be a new or experimental drug or treatment that has been developed recently and may not yet be covered comprehensively in widely available medical literature up to my knowledge cutoff.\n\nTo proceed effectively:\n1. **Clarify the Name**: Double-check the name spelling with reliable sources or consult the person who mentioned it to you for any clarifications.\n2. **Check Recent Databases**: Verify with the latest medical databases, pharmaceutical directories, or journals to see if it is a newly introduced drug or product"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_VWcaEoSUJzJf7CXbJyBQ2S8T", "custom_id": "380_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7835ba1abfb8acd1a72152d2049d77e3", "body": {"id": "chatcmpl-9St7mkcoPiuOkIenZ5kS1QnCbJGqK", "object": "chat.completion", "created": 1716672110, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is crucial to be knowledgeable about any medication you might prescribe. However, \"Calsed\" doesn't appear to match any widely known medication, supplement, or medical product up to my knowledge cutoff in 2021. There are a few possibilities here:\n\n1. **Potential Misspelling or Local Brand**: It might be that \"Calsed\" is a misspelling or a regional/local brand name for a medication or supplement. It would be helpful to double-check the correct name or consult local pharmaceutical resources.\n\n2. **New Medication**: It could also be a newly introduced drug post-2021, in which case consulting the latest medical literature, databases like UpToDate or PubMed, and the drug's prescribing information is advisable.\n\n3. **Calcium-Based Supplement**: If you are referring to a calcium-based supplement or calcium carbonate product (sometimes colloquially referred to), understanding its uses, dosage, contraindications, and side effects is essential"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_RTu6GwyWRrefkRPkrC3Gsqy4", "custom_id": "381_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b186cf9d9b79b22f15a602a59952532a", "body": {"id": "chatcmpl-9St7lC7If431jSzcLThV4Upb5xLjd", "object": "chat.completion", "created": 1716672109, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last knowledge update in October 2023, I do not have information on a substance, medication, or treatment named \"Amekrin.\" It is possible that you might be referring to a medication or treatment that has been introduced or become notable after my last update. Alternatively, there could be a typographical error or miscommunication regarding the name.\n\nIf \"Amekrin\" is a newly introduced drug, treatment, or medical device, I recommend checking the following sources for the latest and most accurate information:\n\n1. **Medical Literature:** Research published in peer-reviewed medical journals.\n2. **Pharmaceutical Databases:** Repositories such as PubMed, Medline, or specific pharmacological databases.\n3. **Health Organizations:** Information from institutions like the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), or other relevant health authorities.\n4. **Company/Supplier Information:** Details provided by the manufacturer or distributor of \"Amekrin.\"\n5. **Professional"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_FtRt5xY67ec2tdroKeXozxdS", "custom_id": "382_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "964c3ed7097bba1c7fd0cf172cdd0d3a", "body": {"id": "chatcmpl-9St7m6Rqodud0DSER47CBmcSTbFTE", "object": "chat.completion", "created": 1716672110, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Altraz, also known by its generic name anastrozole. Here are some key points to consider:\n\n### Indications:\n1. **Breast Cancer Treatment**: Altraz is primarily used to treat breast cancer in postmenopausal women. It is particularly effective for hormone receptor-positive breast cancer.\n2. **Adjuvant Therapy**: Often used as an adjuvant treatment to reduce the risk of breast cancer recurrence.\n3. **Metastatic Breast Cancer**: Can be used in cases where the cancer has spread to other parts of the body.\n\n### Mechanism of Action:\n- **Aromatase Inhibitor**: Altraz works by inhibiting the enzyme aromatase, which is involved in the production of estrogen. Lower estrogen levels can slow or stop the growth of certain breast cancers that need estrogen to grow.\n\n### Dosage:\n- **Standard Dosage**: The usual"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_37ErdWFxUaIxDY9kUNIEMoR6", "custom_id": "383_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e91d03dc2071842715e6910baa9f8580", "body": {"id": "chatcmpl-9St7milbIbkdbORGs6SLGwyZKxQAf", "object": "chat.completion", "created": 1716672110, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erleada (generic name: apalutamide) is a medication that you should consider for the treatment of specific types of prostate cancer. Here are some important details about Erleada that you should know:\n\n### Indications:\n1. **Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC):**\n   - Erleada is indicated for patients whose prostate cancer has not yet spread to other parts of the body but has continued to grow even after castration (surgical or chemical).\n\n2. **Metastatic Castration-Sensitive Prostate Cancer (mCSPC):**\n   - It is also indicated for patients with prostate cancer that has spread to other parts of the body and still responds to medical or surgical treatments to lower testosterone.\n\n### Mechanism of Action:\n- Erleada is an androgen receptor inhibitor. It works by binding to the androgen receptor and inhibiting its activity, thereby preventing the androgen hormones (e.g., testosterone) from"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_aOjRXjCJYyq0lAlp8ESnZqkF", "custom_id": "384_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8ffb398ee0c279c361f84bb33dfa2d48", "body": {"id": "chatcmpl-9St7mfgUghv914bvToiW1B2K3uwCi", "object": "chat.completion", "created": 1716672110, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Aitan\" can refer to a given name and potentially individuals who bear this name, but without more specific context, it's difficult to provide detailed information. However, as a physician, here's a general approach you can use when learning about new patients (or topics) named Aitan:\n\n1. **Patient History**: Gather comprehensive information about Aitan\u2019s medical history, including past illnesses, surgeries, family medical history, allergies, and current medications.\n\n2. **Cultural Sensitivity**: Recognize that Aitan might come from a diverse cultural or ethnic background. Being aware of cultural differences can improve patient rapport and care.\n\n3. **Personalized Care**: Treat Aitan as an individual. Utilize the information gathered to tailor treatments and recommendations effectively.\n\n4. **Communication**: Establish clear and compassionate communication. Encourage Aitan to discuss any symptoms, concerns, or preferences they may have.\n\nIf Aitan refers to a specific concept, medical condition, or anything else, please provide additional details,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_zAna6iBBzmv2BKANmjL1x31L", "custom_id": "385_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7e067a0514501a142af6c76cdb9db4f4", "body": {"id": "chatcmpl-9St7maGSGAqIQMBdFeyWW7g9KntQi", "object": "chat.completion", "created": 1716672110, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a typo or confusion in your question since \"Arsenol\" is not a known medical drug or substance. If you're referring to something specific, it would help to have more context or clarification. However, if you meant \"Arsenic,\" here's some detailed information:\n\n### Arsenic:\nArsenic is a naturally occurring element found in the Earth's crust. It can be found in some water supplies, food products, and consumer goods. It has significant implications for human health:\n\n#### Toxicity:\n1. **Acute Exposure**:\n   - **Symptoms**: Nausea, vomiting, abdominal pain, diarrhea, dark urine (hematuria), delirium, shock, and possibly death.\n   - **Management**: Immediate medical intervention, supportive care, and possible use of chelation therapy (e.g., dimercaprol).\n  \n2. **Chronic Exposure**:\n   - **Health Effects**: Skin changes (like hyperpigmentation and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_AllY37MCaJqrBbHHum3byVh0", "custom_id": "386_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8f367c6f1945cc2dcc2b37bd61ca3205", "body": {"id": "chatcmpl-9St7mx4k4epANG8TF5NWHRkLZwxwO", "object": "chat.completion", "created": 1716672110, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asparaginase (also known as L-asparaginase) is an enzyme that is primarily used as a chemotherapeutic agent in the treatment of acute lymphoblastic leukemia (ALL). Here are key points to know about Asparaginase:\n\n### Mechanism of Action:\n1. **Enzyme Function**: Asparaginase catalyzes the hydrolysis of asparagine to aspartic acid and ammonia. This decreases the levels of asparagine, a vital amino acid for protein synthesis.\n2. **Cancer Cell Impact**: Leukemic cells, particularly in ALL, depend heavily on external sources of asparagine due to their lower ability to synthesize it. Asparaginase deprives these cells of asparagine, inhibiting protein synthesis and leading to cell death.\n\n### Indications:\n1. **Acute Lymphoblastic Leukemia (ALL)**: It is primarily used in various ALL treatment protocols.\n2. **Lymphoma**: Occasionally"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_k5lBYHpXi4KcAcHs4sYKtnlt", "custom_id": "387_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "32184a361f69272214108e99c65cdaf9", "body": {"id": "chatcmpl-9St7m6oLVmagWdpNlB45reXBIqHwh", "object": "chat.completion", "created": 1716672110, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erwinase (generic name: asparaginase Erwinia chrysanthemi) is an asparaginase enzyme used in the treatment of acute lymphoblastic leukemia (ALL), particularly in patients who have developed hypersensitivity to other forms of asparaginase derived from Escherichia coli. Here are some key points you should know:\n\n1. **Mechanism of Action**: Erwinase works by hydrolyzing asparagine, an amino acid necessary for the rapid growth of leukemic cells. By depleting asparagine, it inhibits protein synthesis, leading to the death of leukemic cells.\n\n2. **Indications**: Primarily used in the treatment of ALL in patients who have shown hypersensitivity or allergic reactions to E. coli-derived asparaginase products (like Elspar or Oncaspar).\n\n3. **Administration**: Typically administered intramuscularly, but can also be given intravenously. The dosage and schedule depend on multiple"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_L0LlTb5G0XysBF8nhog55hiy", "custom_id": "388_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d4976c7b5e9ff0db0f144b2ec0ac99c5", "body": {"id": "chatcmpl-9St7me8iVYKJwFhOGTwCJOJUvXoOR", "object": "chat.completion", "created": 1716672110, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tecentriq (atezolizumab) is a monoclonal antibody used in oncology, particularly for the treatment of certain types of cancer. As a physician, it's important to be well-informed about its indications, mechanisms of action, dosing, administration, side effects, and the monitoring required.\n\n### Key Points About Tecentriq:\n1. **Mechanism of Action**:\n   - Tecentriq is a programmed death-ligand 1 (PD-L1) inhibitor. It binds to PD-L1 and blocks its interaction with the PD-1 and B7.1 receptors on T cells, thereby enhancing T-cell responses against cancer cells.\n\n2. **Indications**:\n   - Tecentriq is approved for use in several types of cancer, including:\n     - Non-Small Cell Lung Cancer (NSCLC)\n     - Small Cell Lung Cancer (SCLC)\n     - Urothelial Carcinoma\n     - Triple-Negative Breast Cancer ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_O0G4xNAFhwz1NTtY1qS4ECQ9", "custom_id": "389_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7144b11ac373ad22680d3756a29a8254", "body": {"id": "chatcmpl-9St7mgmHPqHo4VRhUxgpnqFlBldSi", "object": "chat.completion", "created": 1716672110, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bavencio (avelumab) is an important medication to be aware of as a physician, particularly if you are involved in oncology or treating patients with specific types of cancer. Here are the key points:\n\n### Indications\n1. **Metastatic Merkel Cell Carcinoma (MCC)**: Bavencio is approved for the treatment of adults and pediatric patients 12 years and older with metastatic MCC.\n2. **Advanced or Metastatic Urothelial Carcinoma**: Indicated for patients with advanced or metastatic urothelial carcinoma (UC) who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.\n3. **Advanced Renal Cell Carcinoma (RCC)**: It is also approved for use in combination with axitinib for the first-line treatment of patients with advanced RCC.\n\n### Mechanism of Action\n- Bavencio is a human IgG1 monoclonal antibody that"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Z0v5LeDGcOyxOiRk6qfCvUGn", "custom_id": "390_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0ad017c7ddf2ec4481f58837545f4191", "body": {"id": "chatcmpl-9St7nDVPM8yHGRgSm7KjiGNVB4JLk", "object": "chat.completion", "created": 1716672111, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Yescarta (axicabtagene ciloleucel) is a chimeric antigen receptor (CAR) T-cell therapy developed by Kite Pharma, which is used for the treatment of certain types of B-cell lymphomas. Here are several important points you should know as a physician:\n\n### FDA Approval and Indications:\n1. **FDA Approval:** Yescarta was approved by the FDA in October 2017.\n2. **Indications:** It is primarily indicated for:\n   - Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including conditions such as diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, and certain high-grade B-cell lymphomas.\n   - Relapsed or refractory follicular lymphoma in adults, after two or more lines of systemic therapy.\n\n### Mechanism of Action:\n- **CAR T-Cell Therapy:** Yescarta involves genetically modifying a patient\u2019s own T cells to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_1tzu0Ax7gpWNuolDc73cP362", "custom_id": "391_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "91fb73f91fe34723f128aa37d3e48acc", "body": {"id": "chatcmpl-9St7nDKON8ngpywutZn9r0qFsUTLA", "object": "chat.completion", "created": 1716672111, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my latest update in October 2023, \"Axishil\" does not appear to be a widely recognized or established name for a medication, treatment, or medical device in standard medical literature or databases. It might be a brand name for a drug specific to certain markets, a new product that has recently been introduced, or possibly a less common term not widely documented in major medical sources.\n\nWhen encountering an unfamiliar name like Axishil, here are some practical steps a physician could take:\n\n1. **Verify the Name and Spelling:**\n   - Double-check if the spelling is correct. Drug names and brand names can often be very similar and sometimes subject to typographical errors.\n\n2. **Consult Reliable Databases and Resources:**\n   - Use trusted medical resources such as the Physicians' Desk Reference (PDR), Lexicomp, or electronic health record (EHR) systems that include comprehensive drug databases.\n   - Look up the name in national or regional databases such as the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_AcHj7ji59aQjRpN4W4eO5kC8", "custom_id": "392_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "393a14b235c2385e238d8ccd84ec0a27", "body": {"id": "chatcmpl-9St7nBpJZJitGagGG25OjJ4rrWTYo", "object": "chat.completion", "created": 1716672111, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Azacitidine (brand name: Vidaza among others) is a chemotherapeutic agent primarily used in the treatment of myelodysplastic syndromes (MDS) and certain types of acute myeloid leukemia (AML). Here are key points you should know as a physician:\n\n### Mechanism of Action\n- **Hypomethylating Agent:** Azacitidine is a nucleoside analog of cytidine that incorporates into DNA and RNA. It inhibits DNA methyltransferases, leading to the hypomethylation of DNA. This can reactivate genes involved in cell differentiation and apoptosis, thus exerting antineoplastic effects.\n\n### Indications\n- **Myelodysplastic Syndromes (MDS):** Particularly for patients with higher-risk MDS (i.e., intermediate-2 and high-risk MDS according to the IPSS classification).\n- **Acute Myeloid Leukemia (AML):** Azacitidine is used for AML patients, especially those ineligible for intensive chemotherapy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_EToATd17bZcjooM9f74lztgK", "custom_id": "393_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7ad6e0769147dcd17718dbf2ab0ffe40", "body": {"id": "chatcmpl-9St7sRKszMh90o0v1vqk9ncW4EPOK", "object": "chat.completion", "created": 1716672116, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "TheraCys, also known as Bacillus Calmette-Guerin (BCG) for intravesical use, is a medication commonly used in the treatment of bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC). Here are some key points you should be aware of as a physician:\n\n1. **Mechanism of Action**: \n   - TheraCys is a live, attenuated strain of Mycobacterium bovis. It works by stimulating the immune system to attack bladder cancer cells. When instilled into the bladder, it triggers a local immune response, which helps to eradicate cancer cells and prevent recurrence.\n\n2. **Indications**:\n   - TheraCys is primarily used for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder.\n   - It is also used as an adjuvant therapy following transurethral resection (TUR) of superficial bladder tumors to decrease the risk of recurrence.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_kGjuEH8xGxsQLji7opoNWg3E", "custom_id": "394_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "83f91a9bf25d426119b4343e15c80ce4", "body": {"id": "chatcmpl-9St7n6NViuVUNHfzPwNmJcg7mLDye", "object": "chat.completion", "created": 1716672111, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is essential to stay informed about various experimental and investigational drugs, including Tarvacin. Tarvacin, also known as bavituximab, is a chimeric monoclonal antibody that has been under investigation for its potential use in treating certain types of cancer and viral infections.\n\nHere are some key points you should know about Tarvacin:\n\n1. **Mechanism of Action**:\n   - Tarvacin targets phosphatidylserine (PS), a lipid that is normally located on the inner leaflet of the cell membrane but becomes exposed on the outer leaflet in pathological conditions, such as in tumor cells and virally infected cells.\n   - The binding of Tarvacin to PS on these cells induces an immune response against the affected cells, potentially aiding in their destruction.\n\n2. **Indications**:\n   - Tarvacin has been investigated mainly in oncology for various types of cancer, including non-small cell lung cancer (NSCLC), breast cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_BYUTVS9FlawvgB83KI3y5OM1", "custom_id": "395_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "73b48134bee7d30ab6dcd085973699ba", "body": {"id": "chatcmpl-9St7nwFcxGCBE8gIqyXRDpC7urMGQ", "object": "chat.completion", "created": 1716672111, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Beleodaq (generic name: belinostat) is a medication approved for the treatment of peripheral T-cell lymphoma (PTCL) in patients who have experienced relapse or have not responded to prior treatments. It belongs to the class of drugs known as histone deacetylase (HDAC) inhibitors.\n\nHere are some key points you should know about Beleodaq:\n\n### Mechanism of Action:\n- Beleodaq inhibits histone deacetylases, which leads to the accumulation of acetylated histones and other proteins, resulting in the activation of tumor suppressor genes, induction of cell cycle arrest, and apoptosis (programmed cell death) of cancer cells.\n\n### Indications:\n- It is primarily indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma. \n\n### Administration:\n- Beleodaq is administered by intravenous (IV) infusion.\n- The typical regimen involves giving the drug once daily on days 1\u20135 of a 21-day cycle.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_VVMfL1KjW418UPyFS9GM6lbl", "custom_id": "396_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "200838bc11aed5c60ec7e068d25a87a4", "body": {"id": "chatcmpl-9St7n6GXWFWNxgRbvT6rTNZnVCMr2", "object": "chat.completion", "created": 1716672111, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Camptobell\" does not appear to be a widely recognized or established medical term, brand name, or drug as of my last update in October 2023. It's possible that there might be a misspelling or confusion with another name, or it could be a very new or niche product, medical device, or treatment that is not well-documented in mainstream medical literature yet.\n\nHowever, if you suspect it might be related to a drug or medical condition, here are a few general guidelines you can follow:\n\n1. **Consult Reliable Sources**: Check recognized medical databases like PubMed, UpToDate, Medline, or your institution\u2019s internal resources for any clinical trials, studies, or medical literature related to the name.\n\n2. **Pharmaceutical Information**: Look up the name in the Physicians' Desk Reference (PDR) or check with pharmaceutical representatives for any newly released drugs with similar sounding names.\n\n3. **Professional Networks**: Seek insights from colleagues or medical conventions"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_p7XBDzdBCPdkQiMFiyBya2yC", "custom_id": "397_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "173b9b37eee1d640783c46bcd70730ac", "body": {"id": "chatcmpl-9St7nduPYkrEBmrMkvhUlXkpT2YgU", "object": "chat.completion", "created": 1716672111, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Belrapzo is a brand name for bendamustine hydrochloride, which is a chemotherapy medication used in the treatment of certain types of cancer. As a physician, it's important to have a comprehensive understanding of its indications, administration, mechanism of action, side effects, and other key factors. Here are some essential points to consider:\n\n### Indications:\n1. **Chronic Lymphocytic Leukemia (CLL)**: Belrapzo is indicated for the treatment of patients with CLL.\n2. **Non-Hodgkin's Lymphoma (NHL)**: Specifically, it is indicated for patients with indolent B-cell NHL that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.\n\n### Mechanism of Action:\nBendamustine is an alkylating agent. It works by forming covalent bonds with DNA, which interfere with the cell's normal functions and cause cell death, particularly in rapidly dividing"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_6xs3aeebE5WcgcLXJ681NfVn", "custom_id": "398_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e72e4129737fcee097ae1ae51b4ad9d0", "body": {"id": "chatcmpl-9St7n3AIj30lzI363r297V7Ntq4ss", "object": "chat.completion", "created": 1716672111, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Altuzan is a trade name for bevacizumab in some countries. Bevacizumab is a monoclonal antibody that targets and inhibits vascular endothelial growth factor A (VEGF-A), which plays a crucial role in angiogenesis (the formation of new blood vessels). It's used primarily in the treatment of various types of cancer and some ophthalmologic conditions. Here are some key points a physician should know about Altuzan (bevacizumab):\n\n1. **Indications:**\n   - **Cancer:** Used in combination with chemotherapy for metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, cervical cancer, and ovarian cancer.\n   - **Ophthalmology:** Bevacizumab can be used off-label for conditions like wet age-related macular degeneration and diabetic macular edema. Note that ranibizumab (Lucentis) is specifically formulated for eye use and is preferred in many regions due to specific approval.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_xy0KGbx9fsQ9cCtBgFHU11Yg", "custom_id": "399_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "351cea123f85ac5438328eb270a4d297", "body": {"id": "chatcmpl-9St7nmnDkdrFOInfGD8jdMfENVF7Z", "object": "chat.completion", "created": 1716672111, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last knowledge update in October 2021, \"Bexgratin\" does not appear to be a recognized medication, treatment, or medical term in the current medical literature or pharmaceutical references. It is possible that it might be a typographical error, a very new substance that hasn't been widely studied or published about yet, or a less common name for an existing drug or treatment.\n\nHere are a few steps you could take to clarify and find more accurate information:\n\n1. **Verify the Name:** Double-check the spelling and ensure there are no typographical errors. Sometimes drug names can be very similar and a small error can lead to confusion.\n\n2. **Consult Medical Databases:** Use trusted medical databases such as PubMed, clinical trial registries, or pharmaceutical databases to look for information.\n\n3. **Ask a Colleague or Specialist:** Speaking with colleagues or contacting a specialist in pharmacology might help in identifying whether \"Bexgratin\" is known by another name or if it"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_aaEkDyX54FkrYDuM5rQJQ2K3", "custom_id": "400_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6082bb42be9cc01d0d2331c528d0a76a", "body": {"id": "chatcmpl-9St7orxwaN8nHQ0hD58EhjDWONnou", "object": "chat.completion", "created": 1716672112, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Calutide is a brand name for the drug bicalutamide, which is a non-steroidal anti-androgen medication primarily used in the treatment of prostate cancer. Here are several key points you should know as a physician:\n\n### Mechanism of Action:\n- **Anti-Androgenic Activity**: Bicalutamide works by binding to androgen receptors in prostate cancer cells, thereby inhibiting the action of androgens (testosterone and dihydrotestosterone) that promote tumor growth.\n\n### Indications:\n- **Prostate Cancer**: It's commonly prescribed for metastatic prostate cancer and often used in combination with luteinizing hormone-releasing hormone (LHRH) analogs, such as leuprolide or goserelin, as part of hormone therapy.\n- **Neoadjuvant and Adjuvant Therapy**: It can be used in early-stage prostate cancer before (neoadjuvant) or after (adjuvant) primary treatments like surgery or radiation.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_cZ5cmaW0GBBbPYvcYpLITw9n", "custom_id": "401_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5d3abdfd7a5253ccb1abf01914ef6567", "body": {"id": "chatcmpl-9St7o6e6PrKFfwUM213SvWWfQUk7f", "object": "chat.completion", "created": 1716672112, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mektovi (binimetinib) is a medication that is classified as a MEK inhibitor. It's used primarily in the treatment of certain types of melanoma. Below are some key points you should be aware of regarding Mektovi:\n\n### Indications:\n- **Melanoma Treatment:** Mektovi is approved for use in combination with Braftovi (encorafenib) for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. The presence of the BRAF mutation must be confirmed by an FDA-approved test before initiating treatment.\n\n### Mechanism of Action:\n- **MEK Inhibitor:** Mektovi inhibits MEK1 and MEK2, which are part of the MAPK/ERK pathway. This pathway is often activated in cancers, including melanoma, particularly those with BRAF mutations. By inhibiting MEK, Mektovi helps to reduce cell proliferation and induce apoptosis in melanoma cells.\n\n### Dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_L5xZpy94RhzS621HD2of4TN9", "custom_id": "402_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7f632de9122b2e55ba22b031c6c2260e", "body": {"id": "chatcmpl-9St7ot7h6djAW6rT3aSZVyWj5Ipyt", "object": "chat.completion", "created": 1716672112, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blenoxane is the brand name for bleomycin sulfate, an antineoplastic (anti-cancer) antibiotic mainly used in the treatment of various cancers. Here's a detailed overview that can be useful for you as a physician:\n\n### Indications:\n- **Squamous Cell Carcinomas:** Especially of the head, neck, penis, cervix, and vulva.\n- **Lymphomas:** Hodgkin's lymphoma and non-Hodgkin's lymphoma.\n- **Testicular Cancer:** Often used in combination with other chemotherapeutic agents for treatment of testicular cancer.\n\n### Mechanism of Action:\n- Bleomycin induces single- and double-strand breaks in DNA, which inhibit DNA synthesis and, to a lesser extent, RNA and protein synthesis, ultimately leading to cell death.\n\n### Dosage and Administration:\n- **Varies by indication:** For instance, in lymphoma, initial dosing can be around 10-20 units/m\u00b2 per week.\n- **Routes:** Intr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_RpG1pFZqGjFRCPeunSxHXLNL", "custom_id": "403_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e7c75423cb5e86cafa05db5c9908e32c", "body": {"id": "chatcmpl-9St7oOrgl3DXw32syphiYcDluGyP7", "object": "chat.completion", "created": 1716672112, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blincyto (blinatumomab) is a medication used in treating certain types of cancer, specifically B-cell precursor acute lymphoblastic leukemia (ALL). As a physician, here are key points you should know about Blincyto:\n\n### Indications\n- **B-ALL:** Blincyto is primarily indicated for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.\n- **MRD:** It's also approved for the treatment of minimal residual disease (MRD)-positive B-cell ALL in patients in complete remission.\n\n### Mechanism of Action\n- **Bi-specific T-cell Engager (BiTE):** Blincyto is an immunotherapy drug that engages T-cells and redirects them to target and kill cancerous B cells. It is a bispecific monoclonal antibody that links CD19 on B cells with CD3 on T cells.\n\n### Administration\n- **Intravenous Infusion:** Blincyto is administered as a continuous intravenous infusion over"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ePkrl2VGUFDMTwgTfVQwnAAK", "custom_id": "404_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9e7142f889296d860a6b4d842dc9e0b0", "body": {"id": "chatcmpl-9St7oHSaSfboomCbkwpR6JgBl0F71", "object": "chat.completion", "created": 1716672112, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"BioCure\" might refer to a company, a specific product, or a general approach to biomedical treatments and cures. Without more context, it\u2019s hard to provide specific information, but here are some general aspects you might consider as a physician:\n\n### 1. Biotech Companies:\nIf \"Biocure\" is a company specializing in biotechnology or pharmaceuticals, it\u2019s important to know:\n- **Their Products**: Are they focused on gene therapy, biologics, regenerative medicine, or pharmaceutical development?\n- **Regulatory Status**: Are their products FDA-approved, in clinical trials, or in the research phase?\n- **Clinical Applications**: How their products could fit into treatment protocols for certain conditions.\n- **Research**: Any clinical studies, outcomes, and published data on their effectiveness and safety.\n\n### 2. Individual Treatments:\nIf \"Biocure\" refers to a specific treatment or product:\n- **Indications**: The medical conditions it\u2019s designed to treat.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Dto9qKVCQrhXoJ7vAA9cJBoE", "custom_id": "405_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5ee38d73a7ca0568b4a6b9f2e6498694", "body": {"id": "chatcmpl-9St7o2S3oLp0YGdWdwPQZ6RtCNKUD", "object": "chat.completion", "created": 1716672112, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, there are several critical aspects you should know about Bosulif (bosutinib), a medication that is used primarily in the treatment of chronic myeloid leukemia (CML). Here's a detailed summary:\n\n### Mechanism of Action\nBosulif is a tyrosine kinase inhibitor. It works by inhibiting the Bcr-Abl kinase, an abnormal gene product formed due to a translocation between chromosomes 9 and 22, known as the Philadelphia chromosome. This aberrant kinase plays a crucial role in the pathogenesis of CML.\n\n### Indications\nBosulif is indicated for the treatment of adult patients with:\n- Newly diagnosed chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML).\n- Chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.\n\n### Dosage and Administration\n- **Starting Dose**: Typically, the starting dose is 400 mg orally once daily with food. \n- **Adjustment**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_8E8XFF0nxUdij51QwD2uCRpJ", "custom_id": "406_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "015561cac3b6e0808fa50cf20b737fe9", "body": {"id": "chatcmpl-9St7oTkXuZoWokcc4gwqkNgZVDesb", "object": "chat.completion", "created": 1716672112, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adcetris (brentuximab vedotin) is an important medication used in oncology, and here are a few key aspects you should know as a physician:\n\n### Indications:\n1. **Hodgkin Lymphoma (HL)**: Adcetris is indicated for treating classical Hodgkin lymphoma, particularly in cases that are refractory or have relapsed after stem cell transplantation or at least two prior multi-agent chemotherapy regimens.\n2. **Systemic Anaplastic Large Cell Lymphoma (sALCL)**: It is used for treating sALCL after the failure of at least one prior multi-agent chemotherapy regimen.\n3. **Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-expressing Mycosis Fungoides (MF)**: Adcetris is indicated for use in these conditions, usually following previous treatments.\n\n### Mechanism of Action:\nAdcetris is an antibody-drug conjugate (ADC). It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_7VN9VsZ9Rsb2N0BzfjCcdX7S", "custom_id": "407_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1fa3c0817dda8721482c92ee506eb360", "body": {"id": "chatcmpl-9St7omoC6aOXcZ4sN4UIY1D8vEnOL", "object": "chat.completion", "created": 1716672112, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alunbrig (brigatinib) is a prescription medication used to treat certain types of cancer, specifically non-small cell lung cancer (NSCLC). Here are some key points you should know about Alunbrig:\n\n### Indications:\n- **Alunbrig is indicated for the treatment of adult patients** with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC.\n- It is typically prescribed to patients who have progressed on or are intolerant to crizotinib, another ALK inhibitor.\n\n### Mechanism of Action:\n- Alunbrig is an ALK inhibitor. It works by blocking the activity of ALK, thus preventing the growth and spread of cancer cells that have a mutation in the ALK gene.\n\n### Dosage and Administration:\n- The recommended starting dose is 90 mg orally once daily for the first 7 days, then increasing to 180 mg orally once daily.\n- Tablets should be taken at approximately the same time each day, with or without food.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_TtBV5Jp7m7L0dntZ7mLrqc5n", "custom_id": "408_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "c22585dd1458f06e3d8d4aa177f65ce2", "body": {"id": "chatcmpl-9St7pj29TkWcVfNBwtA0gJGoktvY7", "object": "chat.completion", "created": 1716672113, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Busilvex is a brand name for busulfan, a chemotherapy drug primarily used for bone marrow or stem cell transplant conditioning regimens in patients with chronic myelogenous leukemia (CML) and other malignant and non-malignant hematologic diseases. Here are key points you should know about Busilvex:\n\n### Pharmacology and Mechanism of Action:\n- **Class:** Alkylating agent.\n- **Mechanism:** It interferes with DNA replication and RNA transcription by forming cross-links between DNA strands, leading to cell death. It's particularly useful in eradicating bone marrow cells before transplant.\n\n### Indications:\n- Used as part of a preparative regimen prior to allogeneic or autologous stem cell transplantation.\n- Sometimes combined with other cytotoxic agents like cyclophosphamide or fludarabine.\n\n### Dosage and Administration:\n- **Dosage:** Typically, the dose is based on body weight or body surface area. It's imperative to follow specific protocols."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_pE6FmzuZddSBDephUg1eupCC", "custom_id": "409_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "53e07d1d1c25f28f204934bb02ddc7b8", "body": {"id": "chatcmpl-9St7pixNwnSehKBqjxYBA5n7tcAKI", "object": "chat.completion", "created": 1716672113, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cabapan does not appear to be a commonly recognized medication, treatment, or medical term as of my most recent update in October 2023. If you meant a specific drug or treatment under a different name or a typo, it's important to have the correct spelling or the correct name to provide accurate information.\n\nHowever, I can provide a few general guidelines on how to gather and interpret information about any new or unfamiliar drug:\n\n1. **Drug Database Resources:**\n   - Use reliable medical resources such as PubMed, the FDA database, or clinical treatment guidelines through healthcare institutions for the latest information.\n   - Check the drug formularies or reference guides such as the Physician's Desk Reference (PDR), Lexicomp, or UpToDate.\n\n2. **Pharmacology and Mechanism of Action:**\n   - Understand the pharmacodynamics and pharmacokinetics of the drug, including its mechanism of action, metabolism, and excretion.\n\n3. **Indications and Contraindications:**\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_aC9WvWnSwhjnD3A4vMEkJpZa", "custom_id": "410_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "31a81925e779770eef5247a192b01fa3", "body": {"id": "chatcmpl-9St7p7WtePKABCnlLLwjejIKXyt3K", "object": "chat.completion", "created": 1716672113, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cabometyx, which contains the active ingredient cabozantinib, is an oral medication used primarily in the treatment of certain types of cancer. As a physician, it\u2019s important to be knowledgeable about several key aspects concerning Cabometyx:\n\n### Indications\nCabometyx is approved for the treatment of:\n1. Advanced renal cell carcinoma (RCC).\n2. Hepatocellular carcinoma (HCC) in patients who have been previously treated with sorafenib.\n3. Certain patients with advanced medullary thyroid cancer (MTC).\n\n### Mechanism of Action\nCabozantinib is a tyrosine kinase inhibitor (TKI) that targets multiple receptor tyrosine kinases involved in tumor growth, angiogenesis (the development of new blood vessels), and the metastatic progression of cancer.\n\n### Dosage and Administration\n- The typical starting dose for adults with RCC and HCC is usually 60 mg orally once daily.\n- For certain patients with MTC,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_CnepjTJEwYhkBiMWYElKRTpA", "custom_id": "411_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a5b15edeb68baf000f477b0232d4a3aa", "body": {"id": "chatcmpl-9St7p9FuO1vs5aMEVgJ9ktFAyezBq", "object": "chat.completion", "created": 1716672113, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Asparlas (calaspargase pegol-mknl) is a medication primarily used in the treatment of acute lymphoblastic leukemia (ALL) in pediatric and young adult patients. Here are the key points you should know as a physician:\n\n### Indications:\n- **Approved Use:** Asparlas is approved for the treatment of ALL as a component of a multi-agent chemotherapy regimen in pediatric and young adult patients aged 1 month to 21 years.\n\n### Mechanism of Action:\n- **Asparlas** is an enzyme-linked to polyethylene glycol (PEG) which depletes asparagine, an amino acid essential for the survival of leukemic cells. By breaking down asparagine, Asparlas starves cancer cells, making it harder for them to synthesize proteins and grow.\n\n### Dosage and Administration:\n- **Dosage:** The typical dosage is 2,500 units/m\u00b2 administered intravenously every 21 days, depending on the treatment protocol.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_PzDinC7DmtkDXAmlJSl6j7oZ", "custom_id": "412_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "c39bca52dad3936cca989e7309fcce58", "body": {"id": "chatcmpl-9St7pdonTcwUmzHXgF0oiWjvTZm9V", "object": "chat.completion", "created": 1716672113, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, it appears that \"Cabita\" might not correspond to any well-known medication, medical condition, or widely recognized medical terminology. If \"Cabita\" is a new drug, treatment, medical device, or condition that has appeared after my last update, it would be best to consult up-to-date medical databases, recent clinical guidelines, or professional medical associations for the latest and most accurate information.\n\nHowever, here are a few general guidelines to consider when encountering a new or unfamiliar medical term or treatment:\n\n1. **Thorough Research**: Look into reputable medical databases such as PubMed, Medline, or other peer-reviewed journals to gather detailed information about efficacy, side effects, clinical trials, and any FDA or regulatory approval statuses.\n\n2. **Consult Colleagues and Experts**: Discussing with specialists in the relevant field can provide valuable insights and practical experiences that may not yet be widely published.\n\n3. **Manufacturer Information**: If it's"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_1fP5WrcSWard5DRWOF2Xc4B1", "custom_id": "413_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1d9320be09cc5e32ff2ec6462087ea85", "body": {"id": "chatcmpl-9St7ppbv6WWroHrQUXK9tiJJX0isg", "object": "chat.completion", "created": 1716672113, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is essential to understand the key aspects of any medication you may prescribe or that your patients may be using. \"Biocarb\" is commonly known as an alternative name for the drug Carboplatin, a chemotherapy agent used primarily to treat various types of cancer, such as ovarian, lung, head, and neck cancers. Below are critical considerations regarding Biocarb (Carboplatin):\n\n### Mechanism of Action:\n- **DNA Binding:** Carboplatin is a platinum-containing compound that works by forming platinum-DNA adducts, which lead to DNA crosslinking and subsequently inhibit DNA synthesis and function, causing cell death, particularly in rapidly dividing cancer cells.\n\n### Indications:\n- **FDA-Approved Uses:** Ovarian Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Head and Neck Cancer, and other malignancies.\n- **Off-Label Uses:** Sometimes used for cancers such as breast and bladder cancer, among others, depending on current"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_BGbLxfmGcDIKj4HGaMPzcc0q", "custom_id": "414_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b95a8249a4f2f7999316fa645d1f44c7", "body": {"id": "chatcmpl-9St7pGQcH1UW9jozP6R6EfJPvKFCV", "object": "chat.completion", "created": 1716672113, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, there is no widely recognized medication or treatment called \"Carfilnat.\" It's possible that there may be a typo or misunderstanding in the name. If you meant to refer to a specific drug or treatment, it might help to provide additional context or check for alternative spellings.\n\nIf you intended to refer to a known medication such as Carfilzomib (a medication used to treat multiple myeloma, a type of blood cancer), here is some information about Carfilzomib:\n\n### Carfilzomib (Kyprolis)\nCarfilzomib is a proteasome inhibitor used primarily to treat relapsed or refractory multiple myeloma. It works by blocking the proteasome, a protein complex that degrades unneeded or damaged proteins in cells, leading to the accumulation of these proteins and increased cell stress, ultimately causing cancer cell death.\n\n#### Key Points for Physicians:\n- **Indications:** Primarily used in patients with multiple myel"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_jyeFJkPDf53bfoKggpsKzuEU", "custom_id": "415_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "bbc99ae71d6111bb88c6b5ee78e5d19f", "body": {"id": "chatcmpl-9St7pk4gpeLQgFxFouyHW60bP3kQ0", "object": "chat.completion", "created": 1716672113, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Becenun, which is also known by its generic name carmustine, is a chemotherapeutic agent used in the treatment of various types of cancers, including brain tumors, multiple myeloma, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. As a physician, there are several critical aspects you should be aware of when prescribing or managing a patient on Becenun:\n\n### Mechanism of Action:\nBecenun (carmustine) belongs to the class of alkylating agents known as nitrosoureas. It works by alkylating DNA and RNA, leading to the disruption of DNA and RNA synthesis and function, ultimately resulting in cell death, particularly in rapidly dividing cancer cells.\n\n### Indications:\n- **Primary and metastatic brain tumors** (such as glioblastoma, astrocytoma, medulloblastoma)\n- **Multiple myeloma** (often in combination with other drugs like prednisone)\n- **Hodgkin"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_cgY2EW0q60ZdCq6xK7IICOga", "custom_id": "416_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a0bd960dd95c7fea2586e57d834583d9", "body": {"id": "chatcmpl-9St7pR0ajbQm6C9NPTTeBMX9halbz", "object": "chat.completion", "created": 1716672113, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Biodel is a pharmaceutical company focused on developing and commercializing innovative treatments for diabetes and other metabolic conditions. Here are some key points you might find relevant:\n\n### Historical Context:\n1. **Foundation and Focus**: Biodel was founded in 2003 and has primarily focused on diabetes, aiming to improve the pharmacokinetics of insulin.\n2. **Key Products**: One of Biodel\u2019s key products in development has been the VIAject formulation, an ultra-rapid-acting injectable human insulin.\n\n### Research and Development:\n1. **Insulin Formulations**: Biodel has been working on novel formulations of insulin to improve the speed of absorption and predictability in glucose control. These formulations aim to provide better postprandial glucose management.\n2. **Technologies Used**: The company has utilized technologies such as recombinant DNA methods and unique formulation strategies to enhance the properties of insulin.\n\n### Clinical Trials:\n1. **Clinical Phases**: The company has conducted several clinical trials"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_JJAO9znTiuHu5N7LSuowZK4b", "custom_id": "417_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "3405ef802729ebcc5231f3d2667b809f", "body": {"id": "chatcmpl-9St7pL83xAbglcoTJCCIZ8Ipesp4P", "object": "chat.completion", "created": 1716672113, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Recentin, also known by its generic name cediranib, is a tyrosine kinase inhibitor that primarily targets vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3). It has been under investigation for use in various cancers due to its anti-angiogenic properties, which inhibit the growth of new blood vessels necessary for tumor growth.\n\nKey information you should know about Recentin includes:\n\n1. **Mechanism of Action:**\n   - Cediranib inhibits VEGFR, which plays a critical role in angiogenesis (the formation of new blood vessels). By blocking these receptors, cediranib reduces the supply of oxygen and nutrients to the tumor, thereby inhibiting its growth.\n\n2. **Indications:**\n   - Recentin has been investigated in various types of cancer, such as colorectal cancer, non-small cell lung cancer, and ovarian cancer. However, its approval status may vary by country, and it may still be considered an experimental"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_XCOKBKW702dZv9s4XoJCSqeU", "custom_id": "418_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "757aaa67d1f922a8ddb596d9679b5066", "body": {"id": "chatcmpl-9St7q6kiGeHegs507bhjgkC4odRNs", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Libtayo (cemiplimab-rwlc) is a monoclonal antibody that is used in the treatment of certain cancers. Here are several key points you, as a physician, should know about Libtayo:\n\n### 1. **Mechanism of Action:**\nLibtayo is an immune checkpoint inhibitor that works by targeting the programmed cell death-1 (PD-1) receptor, which is found on the surface of T-cells. By blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2), Libtayo enhances the immune system's ability to attack cancer cells.\n\n### 2. **Indications:**\nLibtayo is approved for use in various cancer types, including:\n- **Cutaneous Squamous Cell Carcinoma (CSCC):** For patients with metastatic CSCC or locally advanced CSCC who are not candidates for curative surgery or radiation.\n- **Basal Cell Carcinoma (BCC):**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_KZNuSemVj4RSnIIIELnVFkND", "custom_id": "419_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "73c3769bfa160707d092269bf86be1b2", "body": {"id": "chatcmpl-9St7qkVCOaIiyjPZCxFcuA2Fa2gzA", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a typo in your question. If you meant \"Lucifer,\" this term generally refers to a character associated with the Devil or Satan in various religious and cultural contexts. However, this is not typically relevant to medical practice unless you're dealing with specific cultural or psychological contexts where the concept might impact a patient's mental health or spiritual wellbeing.\n\nIf you need information on the historical, religious, or psychological aspects surrounding the concept of Lucifer, here are a few points that might be useful:\n\n1. **Religious Context**: In Christian theology, Lucifer is often considered a fallen angel who rebelled against God and became Satan. This can be a significant aspect of a patient\u2019s belief system, influencing their worldview and behaviors.\n\n2. **Cultural Significance**: The figure of Lucifer appears in various mythologies and traditions beyond Christianity, including in literature, art, and popular culture. \n\n3. **Psychological Impact**: Some individuals might have spiritual or psychological distress relating to concepts of"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_vuQdsEDpNolOGojs6UwchR4x", "custom_id": "420_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "10f3dc522fa078cdb49a38a108ef5ab3", "body": {"id": "chatcmpl-9St7qrG0m8ebidPusytuT3e2tOu9l", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cetuxim is not a medication or treatment that I'm aware of; it might be a typographical error or confusion with a known drug. However, if you are referring to Cetuximab, a well-known monoclonal antibody, here's what you should know as a physician:\n\n### Cetuximab Overview:\n1. **Class and Mechanism of Action**:\n   - Cetuximab is a chimeric (mouse/human) monoclonal antibody.\n   - It targets the epidermal growth factor receptor (EGFR), inhibiting the receptor's ability to promote cell growth and survival.\n\n2. **Indications**:\n   - Approved for use in metastatic colorectal cancer, particularly in patients who have EGFR-expressing tumors and no KRAS mutations (wild-type).\n   - Also used in head and neck squamous cell carcinoma, either in combination with radiation therapy or as a single agent for recurrent or metastatic cases.\n\n3. **Administration**:\n   - Given as"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_GGpHzRfTAlPSnN3LRIs1yjvL", "custom_id": "421_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ef013d365271593b6c66f444fd96c099", "body": {"id": "chatcmpl-9St7qCBSNEYbak7QvBFOuQ569rIMM", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Epidaza, known generically as chidamide, is a histone deacetylase (HDAC) inhibitor used primarily in the treatment of certain types of cancer. Here are some important aspects you should be aware of as a physician:\n\n### Mechanism of Action:\n- **HDAC Inhibition**: Chidamide inhibits histone deacetylase enzymes, leading to increased acetylation of histone proteins. This alteration affects gene expression, promoting cell cycle arrest, apoptosis, or differentiation in cancer cells.\n\n### Indications:\n- **Peripheral T-cell Lymphoma (PTCL)**: Chidamide has been approved in some countries for the treatment of PTCL, particularly in patients who have relapsed or are refractory to prior therapies.\n- **Other Indications**: Research is ongoing to explore its potential benefits in other hematologic malignancies and solid tumors.\n\n### Administration:\n- **Oral Formulation**: Epidaza is administered orally, usually in the form of tablets"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_DdcAxtq9DW56rg9ndiyIrHwb", "custom_id": "422_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "74701b3850c0c205d32937863de3da00", "body": {"id": "chatcmpl-9St7qwdt3LfL8cd0BA04uEORIuRle", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Chlorambucil is an alkylating agent used in chemotherapy primarily for treating certain types of cancer. Here's an overview of essential information you should know as a physician:\n\n### Indications\n- **Chronic lymphocytic leukemia (CLL)**\n- **Non-Hodgkin's lymphoma**\n- **Hodgkin's disease**\n\n### Mechanism of Action\n- Chlorambucil works by alkylating DNA, leading to cross-linking and strand breakage, which inhibits DNA replication and RNA transcription. This disruption of DNA function ultimately triggers cell cycle arrest and apoptosis.\n\n### Administration\n- **Oral**: Typically administered orally, which provides convenience for outpatient treatment.\n- **Dosage**: Dosage varies depending on the malignancy type, patient's weight, and response to treatment. Close monitoring and adjustments are necessary.\n\n### Pharmacokinetics\n- **Absorption**: Well-absorbed from the gastrointestinal tract.\n- **Metabolism**: Metabol"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_f9hYyfgYLnBzyIBTDbJPgRL6", "custom_id": "423_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a5685d6ec35cdfd1c33ad5d7013f3a2b", "body": {"id": "chatcmpl-9St7qbYkRAfDyvVNZR4ywYDKtQIcL", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, there is no widely recognized or established drug called \"Abiplatin.\" It's possible that there might be a typographical error or it could be a brand name/local name that isn\u2019t widely known globally.\n\nHowever, if you're referring to a platinum-based chemotherapeutic agent similar to well-known drugs like cisplatin, carboplatin, or oxaliplatin, here are some general points you should keep in mind about platinum-based chemotherapy agents:\n\n### Mechanism of Action:\n- They work primarily by forming cross-links within and between DNA strands, which disrupts DNA replication and transcription, ultimately leading to cell death. This makes them particularly effective against rapidly dividing cells, such as cancer cells.\n\n### Indications:\n- These agents are widely used in the treatment of various cancers, including but not limited to testicular, ovarian, lung, bladder, and colorectal cancers.\n\n### Administration:\n- Typically administered intravenously.\n- The dosing regimen and frequency depend"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_tzOvhQ0JNsWIl8iBvwOyp7de", "custom_id": "424_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5cb66375d6dff8173570ac6e3c57617b", "body": {"id": "chatcmpl-9St7q9SlvRQjbf5R2MLb6rcBBu8Ji", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Leustatin is the trade name for cladribine, a purine nucleoside analog used in the treatment of certain types of hematologic malignancies. Here are some key points you should know about Leustatin as a physician:\n\n### Indications\n- **Hairy Cell Leukemia (HCL):** Leustatin is most commonly used in the treatment of HCL.\n- **Chronic Lymphocytic Leukemia (CLL):** It's sometimes used as part of combination therapy.\n- **Other Hematologic Malignancies:** It may be used off-label for other conditions like non-Hodgkin lymphoma (NHL) or multiple sclerosis (MS).\n\n### Mechanism of Action\n- Cladribine is incorporated into the DNA of proliferating cells, leading to DNA strand breaks and apoptosis (programmed cell death). It is particularly effective in lymphocytes and monocytes.\n\n### Administration\n- Leustatin is usually administered via continuous intravenous infusion over "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_mtM5tr5ZdlBAhsv9NztPzoKs", "custom_id": "425_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a9373ecd99a48f4a2d5c426e38d8c0a6", "body": {"id": "chatcmpl-9St7q1XGRO4hjkHzrqd7ujOyQelqm", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Biaxin, known generically as clarithromycin, is a macrolide antibiotic commonly used to treat various bacterial infections. Here are essential details you should be aware of as a physician:\n\n### Indications\n1. **Respiratory Infections**: Bronchitis, pneumonia, sinusitis.\n2. **Skin Infections**: Cellulitis, impetigo.\n3. **H. pylori Eradication**: Part of combination therapy for peptic ulcers.\n4. **Other Infections**: Pharyngitis, tonsillitis, and certain mycobacterial infections.\n\n### Mechanism of Action\n- **Biaxin** works by inhibiting bacterial protein synthesis. It binds to the 50S ribosomal subunit of susceptible bacteria, preventing the translocation of peptides.\n\n### Dosage and Administration\n- **Adult Dosage**: Generally, 250-500 mg twice daily. For H. pylori treatment, it\u2019s part of a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5J8jmpDepTugNuqHZjHlWlJS", "custom_id": "426_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "90f3d1c3a4d41edbc004a8361c0065f5", "body": {"id": "chatcmpl-9St7qFYgRKCwYclrH4fsdQSH1fRw1", "object": "chat.completion", "created": 1716672114, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Clolar (clofarabine) to ensure its effective and safe use in your patients. Below are several key points to consider:\n\n### Indications\n- **Clolar** is used to treat pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL) after at least two prior regimens.\n- It may also be used off-label for other hematologic malignancies like acute myeloid leukemia (AML), but always consider current guidelines and evidence.\n\n### Mechanism of Action\n- Clolar is a purine nucleoside antimetabolite that inhibits DNA synthesis and repair by incorporating into DNA and inhibiting certain enzymes (such as ribonucleotide reductase and DNA polymerases), leading to apoptosis of malignant cells.\n\n### Dosage and Administration\n- **Pediatric Dosage (ALL)**: Typically, 52 mg/m\u00b2 administered intravenously over 2 hours daily for 5 consecutive days. Adjust dosage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_BWP6bs7jjdRLnLkGfoYkOPVu", "custom_id": "427_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4dfe07f4b61d5ea9112a9196017ff81c", "body": {"id": "chatcmpl-9St7rW9ctko057h718denDn56pebn", "object": "chat.completion", "created": 1716672115, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cotellic (cobimetinib) is an oral medication used in combination with other drugs to treat certain types of cancer, most notably BRAF V600 mutation-positive unresectable or metastatic melanoma. Here are key points that you should know about Cotellic:\n\n1. **Mechanism of Action**:\n   - Cotellic is a MEK inhibitor. It works by inhibiting the MEK1 and MEK2 proteins, which are part of the MAPK/ERK pathway. This pathway is often overactive in certain cancers, leading to uncontrolled cell growth. By inhibiting these proteins, Cotellic can help slow down or stop the growth of cancer cells.\n\n2. **Indications**:\n   - Cotellic is approved for use in combination with vemurafenib (Zelboraf) to treat patients with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma.\n   \n3. **Administration**:\n   - The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_HqTFWc4lPVi15ZTpCeivF9qi", "custom_id": "428_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7eba6d7c42a328032455e0306c25996f", "body": {"id": "chatcmpl-9St7rfgAT5hL6U8sRCkn0TuZIDbqB", "object": "chat.completion", "created": 1716672115, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Aliqopa (copanlisib) is a prescription medication used for the treatment of adults with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. Here are some critical points you should know about Aliqopa as a physician:\n\n### Mechanism of Action:\n- **Class**: Aliqopa is a PI3K inhibitor that primarily inhibits the PI3K-alpha and PI3K-delta isoforms.\n- **Function**: It works by inhibiting the signaling pathway involved in the growth and survival of malignant B cells, thereby reducing proliferation and promoting apoptosis of cancerous cells.\n\n### Indication:\n- Specifically approved for treating relapsed follicular lymphoma (FL) in patients who have received at least two prior systemic therapies.\n\n### Administration:\n- **Form**: It is administered via intravenous (IV) infusion.\n- **Dosage**: Typically given at 60 mg on days 1, 8, and 15 of a 28"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_GmW4MUhjyHhhtwR5g14djkF1", "custom_id": "429_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1b3a3e7ef650aa90feea31013ec1c4f6", "body": {"id": "chatcmpl-9St7rOkzIp7unVjrO0MmmAd47IjUH", "object": "chat.completion", "created": 1716672115, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Crizotinib, marketed under the brand name Crizalk, is an important medication used in the management of certain types of cancer. Here are key points that you, as a physician, should know about Crizalk:\n\n1. **Indications:**\n   - Crizalk is primarily indicated for the treatment of patients with non-small cell lung cancer (NSCLC) that is positive for anaplastic lymphoma kinase (ALK) or ROS1 gene rearrangements. These genetic aberrations are typically identified through molecular testing or biomarker assessments.\n\n2. **Mechanism of Action:**\n   - Crizotinib is a tyrosine kinase inhibitor (TKI) that targets ALK, ROS1, and MET tyrosine kinases. By inhibiting these pathways, Crizalk can interfere with tumor cell growth and proliferation.\n\n3. **Dosage:**\n   - The standard dosing regimen for Crizalk is 250 mg orally twice daily. However, dosing may need"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_3twbIYQaI6vZbyZkKpLbJwCL", "custom_id": "430_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6628b4a8c1c68637b8ef99f0edcdd4d7", "body": {"id": "chatcmpl-9St7r6vmcqvi0ZHaj8whcl8AP65qE", "object": "chat.completion", "created": 1716672115, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it\u2019s essential to have a comprehensive understanding of Alkyloxan, particularly since it\u2019s a chemotherapeutic and immunosuppressant agent. Here\u2019s a detailed overview:\n\n### Pharmacology:\n- **Class:** Alkyloxan is classified as an alkylating agent, which means it works by adding alkyl groups to DNA. This action disrupts DNA replication and transcription, ultimately leading to cell death. It\u2019s mostly effective against rapidly dividing cells, both cancerous and non-cancerous.\n- **Mechanism of Action:** By forming cross-links between DNA strands or within the same strand, Alkyloxan prevents proper DNA replication and transcription. This inhibition induces apoptosis in rapidly dividing cells. \n\n### Uses:\n1. **Cancer Treatment:** Alkyloxan is commonly used to treat various types of cancer, including lymphomas, leukemias, multiple myeloma, and some solid tumors.\n2. **Immunosuppression:** It is also used"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_svE8c0qfW0CQ9o6I1IW8ySWz", "custom_id": "431_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2e087f0a8ef772e711d874c924af978d", "body": {"id": "chatcmpl-9St7r8kvldXzWV1EKvhTZxiU1eLXY", "object": "chat.completion", "created": 1716672115, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Androcur, known generically as cyproterone acetate, is a medication used primarily for its anti-androgenic properties. Here are some key points that physicians should know about this drug:\n\n### Indications:\n1. **Prostate Cancer**: Androcur is often used in the treatment of inoperable prostate cancer, particularly to manage symptoms and reduce the production of testosterone which can fuel the growth of cancer cells.\n2. **Severe Acne/Hirsutism in Females**: It is sometimes prescribed for women with severe acne, hirsutism, and other androgen-dependent conditions, generally in combination with an estrogen.\n3. **Gender Dysphoria**: Androcur may be used off-label as part of hormone therapy for transgender women to reduce masculinity through its anti-androgen effect.\n4. **Hypersexuality in Males**: It can be used to manage severe hypersexuality and sexual deviations in men.\n\n### Mechanism of Action:\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Ch4fiIovm9U3nTMVOLdwciOg", "custom_id": "432_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "98ff897c02935a61e4a955f126cc0caa", "body": {"id": "chatcmpl-9St7r3aMwMsc1t3jxRij6Sv6PGroL", "object": "chat.completion", "created": 1716672115, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2023, there does not appear to be any widely recognized pharmaceutical, medical device, or therapeutic treatment known specifically as \"Alcysten\" in the medical literature. It's possible that it could be a brand name that is not commonly known, a misspelling, or a very recent development that hasn't yet been cataloged in mainstream medical references.\n\nIf you meant a specific drug, treatment, or condition and possibly misspelled the name, here are a few general steps you can take to gather accurate and up-to-date information:\n\n1. **Consult Medical Databases**: Use databases like PubMed, Medline, or clinical trial repositories to find peer-reviewed articles and studies related to the substance or treatment you're inquiring about.\n\n2. **Refer to Official Guidelines**: Check guidelines from major health organizations like the FDA, WHO, or your country\u2019s health department. \n\n3. **Drug Reference Systems**: Utilize drug reference systems like the Electronic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_4rWFkjQUP4I4mDqqSrglbxLC", "custom_id": "433_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b85bd66c6451de6d6552bb3424da4a76", "body": {"id": "chatcmpl-9St7rid3x1P8Bke8Y8gCnElwTLi2b", "object": "chat.completion", "created": 1716672115, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vyxeos (also known by its generic name as CPX-351) is a liposomal formulation of a fixed combination of daunorubicin and cytarabine, two chemotherapy agents used extensively in the treatment of certain types of leukemia. Here are the important aspects you should know about Vyxeos:\n\n### Indications:\n- **Acute Myeloid Leukemia (AML)**: Vyxeos is specifically approved for adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).\n\n### Mechanism of Action:\n- **Liposomal Delivery**: Vyxeos encapsulates daunorubicin and cytarabine in liposomes, which allows for a targeted delivery to the bone marrow, where leukemic cells are prevalent. This improves the pharmacokinetics and pharmacodynamics and reduces side effects compared to non-liposomal formulations.\n- **Drug Synergy**: Daunorubicin inter"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_9q9WW6tP7RFsXRPkBMwkUIld", "custom_id": "434_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f85980c92b8bde72cbe7120ee22de3c4", "body": {"id": "chatcmpl-9St7runhZhOhCent9RD9WxlNb0oBR", "object": "chat.completion", "created": 1716672115, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is essential to be well-informed about Rafinlar (dabrafenib), especially if you are treating patients with specific types of cancers. Rafinlar is a medication used primarily in the treatment of certain types of BRAF V600E mutation-positive tumors. Here are key points a physician should know:\n\n### Indications\n- **Melanoma:** Rafinlar is approved for use as a single agent or in combination with Trametinib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.\n- **Non-Small Cell Lung Cancer (NSCLC):** It is also approved in combination with Trametinib for the treatment of patients with metastatic NSCLC with a BRAF V600E mutation.\n- **Thyroid Cancer:** It can be used in combination with Trametinib for patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with a BRAF V600E"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_m0Df4ieSuL5QZfXYo7p5wmvR", "custom_id": "435_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4dfb379fb7810b088b1c597bbf85518d", "body": {"id": "chatcmpl-9St7rPmkXm97IWHvQcp0zArDXxQ3O", "object": "chat.completion", "created": 1716672115, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Bazipar\" does not appear to correspond to a known drug or medical therapy as of my knowledge cutoff in October 2023. It\u2019s possible that it could be a typographical error, a brand name not widely recognized or region-specific, or a very new drug that has been released after my last update.\n\nIf you were referring to a particular drug and may have misspelled it, here are a few steps you could take:\n\n1. **Verify the Name**: Double-check the spelling and ensure that it is accurate. Common similar-sounding drugs should be considered.\n2. **Consult Reliable Sources**: Refer to medical databases such as PubMed, clinical guidelines, or pharmaceutical databases like Lexicomp, Micromedex, or the FDA\u2019s drug database.\n3. **Pharmacy Consultation**: Talk to a pharmacist who might be able to recognize the name or offer alternative suggestions based on the information you provide.\n\nIf you provide more details about its use, mechanism, or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Y28WaQNPdfMWjvPzWVx4nnec", "custom_id": "436_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a5bf1c16fe9f4270429626eecf463345", "body": {"id": "chatcmpl-9St7rnNjBt5sNF4pckaZkNxWfOLKT", "object": "chat.completion", "created": 1716672115, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vizimpro, also known as dacomitinib, is a medication used in oncology, specifically for the treatment of non-small cell lung cancer (NSCLC). Here are key points you should know about Vizimpro:\n\n### Indications:\nVizimpro is approved for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.\n\n### Mechanism of Action:\nVizimpro is an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor. It targets multiple members of the HER family including EGFR, HER2, and HER4, which are involved in the proliferation and survival of cancer cells.\n\n### Dosage:\nThe recommended dose of Vizimpro is 45 mg taken orally once daily, with or without food, until disease progression or unacceptable toxicity.\n\n### Contraindications:\nPatients with known hypersensitivity to dacomitinib or any of its excipients should not take"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_AaOXrDIIZ1dzA8yXb5WeDOlE", "custom_id": "437_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b78c03a0698012476015003059f8a4af", "body": {"id": "chatcmpl-9St7r0oJHR9azZEL4BRIGnQhJUg4N", "object": "chat.completion", "created": 1716672115, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cosmegen, also known by its generic name dactinomycin (or actinomycin D), is an antineoplastic antibiotic used in cancer treatment. It is important for you, as a physician, to be well-versed in various aspects of this medication:\n\n### Indications\n- **Wilms' Tumor:** Used as part of combination chemotherapy.\n- **Ewing's Sarcoma:** Often included in multidrug treatment protocols.\n- **Rhabdomyosarcoma:** Commonly used in combination with other chemotherapeutic agents.\n- **Gestational Trophoblastic Neoplasia:** Used in certain cases, again in combination.\n- **Other Sarcomas:** Sometimes used off-label for other types of sarcomas and certain solid tumors.\n\n### Mechanism of Action\nCosmegen intercalates DNA, disrupting the ability of the DNA to function properly during cell division and leading to cell death. It primarily affects rapidly dividing cancer cells but can also impact healthy cells that"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_opQLAi60DscwC4PEMNE0wLRS", "custom_id": "438_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0ebfa45b9a4ec2595088d3850fcd8410", "body": {"id": "chatcmpl-9St7r8fkwpd6FO5jcUZswCiqBSO4j", "object": "chat.completion", "created": 1716672115, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Danatrol, known generically as danazol, is a synthetic steroid derived from ethisterone. It has various clinical uses but also comes with a range of potential side effects and contraindications. Here's what you should know about Danatrol:\n\n### Indications:\n- **Endometriosis:** Danazol is used to treat endometriosis by altering hormonal levels, thereby reducing the growth of endometrial tissue.\n- **Hereditary Angioedema:** It helps prevent attacks by increasing levels of the C1 inhibitor protein.\n- **Fibrocystic Breast Disease:** It can be prescribed to alleviate symptoms of benign breast conditions.\n\n### Mechanism of Action:\n- **Hormonal Modulation:** Danazol suppresses the pituitary-ovarian axis, which reduces the production of gonadotropins (FSH and LH), leading to decreased ovarian estrogen production.\n- **Androgenic Effects:** It has weak androgenic properties, which can contribute to its efficacy in treating endometriosis and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_o55azsl6VKI5CIjAlSP29nWR", "custom_id": "439_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6f647230f34de981c0762c23a18c97d6", "body": {"id": "chatcmpl-9St7rd45lzk57j9SQP8ig7MFluBhM", "object": "chat.completion", "created": 1716672115, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Darzalex (generic name: daratumumab) is a monoclonal antibody that is used in the treatment of multiple myeloma. It targets the CD38 protein, which is commonly found on the surface of multiple myeloma cells. Here are some key points you should know about Darzalex as a physician:\n\n### Indications\n- **Monotherapy**: Darzalex is indicated as a monotherapy for patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.\n- **Combined Therapy**: It is also indicated in combination with other medications such as lenalidomide, bortezomib, or pomalidomide for the treatment of multiple myeloma in various lines of therapy.\n\n### Mechanism of Action\n- Daratumumab binds to the CD38 protein on"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_xGgZrcfVbW2z1fqv13AQeXRs", "custom_id": "440_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "82fc1eb768e4df7799d29bfd8adbdb73", "body": {"id": "chatcmpl-9St7rlng8Q4GMsyeAAkz0Yf1NUaYv", "object": "chat.completion", "created": 1716672115, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nubeqa (darolutamide) is a medication used to treat prostate cancer. As a physician, here are several key points you should know about Nubeqa:\n\n1. **Indication**:\n   - Nubeqa is typically indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).\n\n2. **Mechanism of Action**:\n   - Darolutamide is a non-steroidal anti-androgen that works by inhibiting the action of androgens (male hormones) on prostate cancer cells, thereby slowing the growth of the cancer.\n\n3. **Dosage and Administration**:\n   - The recommended dosage of Nubeqa is 600 mg (two 300 mg tablets) administered orally, twice daily, with food. \n   - It is important to continue androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) analog concurrently unless the patient has had a bilateral orchiectomy.\n\n4."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_rZEjQTCo2tcfzJkF1OGYMi8Q", "custom_id": "441_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "769ab47edeea29c668a00fdc9ff2a07b", "body": {"id": "chatcmpl-9St7rp10tViyoOUaCZRbjEIElUQPT", "object": "chat.completion", "created": 1716672115, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sprycel (dasatinib) is a tyrosine kinase inhibitor (TKI) used in the treatment of certain types of cancer. Below are some important points you should know about Sprycel as a physician:\n\n### Indications\n- **Chronic Myeloid Leukemia (CML):** Indicated for newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase.\n- **Acute Lymphoblastic Leukemia (ALL):** Also used for Ph+ acute lymphoblastic leukemia with resistance or intolerance to prior therapy.\n\n### Mechanism of Action\n- Dasatinib inhibits multiple tyrosine kinases, including BCR-ABL, which is critical in the pathogenesis of Ph+ leukemias. This inhibition disrupts the growth and proliferation of cancer cells.\n\n### Dosing and Administration\n- **CML:** Typical starting dose is 100 mg orally once daily.\n- **ALL:** Typical starting dose is 140 mg orally once"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_8ncILV0eHTH2ZQH6Ig7EFHYL", "custom_id": "442_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0ddf5ccb7158b8420aab80501a954fa6", "body": {"id": "chatcmpl-9St7rZWSx1KTFOSEIXNRabzddBBgX", "object": "chat.completion", "created": 1716672115, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cerubidin is the trade name for daunorubicin, an anthracycline antibiotic commonly used in chemotherapy for treating certain types of cancer, particularly hematologic malignancies such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Here are some essential aspects you should know about Cerubidin (daunorubicin):\n\n### Mechanism of Action\n- Daunorubicin works by intercalating DNA, disrupting the function of topoisomerase II, and generating free radicals. These actions inhibit DNA replication and repair, leading to cell death, particularly in rapidly dividing cells like cancer cells.\n\n### Indications\n- Primary use in the treatment of acute myeloid leukemia (AML).\n- Also used in combination therapy for acute lymphoblastic leukemia (ALL).\n\n### Dosage and Administration\n- Typically administered intravenously.\n- Dosage varies depending on the specific disease being treated, the regimen being used, and the patient's body surface area (B"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_aq1iooxoONIwXpjVttImD13H", "custom_id": "443_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "54ec3ef5e7d4dfe99026c0bf4b97b578", "body": {"id": "chatcmpl-9St7sbqnMZ7pU7JfauX62mjxlDHOD", "object": "chat.completion", "created": 1716672116, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "DaunoXome (liposomal daunorubicin) is a chemotherapeutic agent designed for the treatment of certain cancers, most notably AIDS-related Kaposi's sarcoma. Here are several key points you should be aware of:\n\n### Indications and Usage\n- **AIDS-related Kaposi's Sarcoma:** DaunoXome is primarily indicated for the treatment of advanced HIV-associated Kaposi's sarcoma. It can be used especially when other systemic chemotherapies are less suitable.\n- **Other Cancers:** While the primary FDA-approved indication is for Kaposi's sarcoma, liposomal daunorubicin can be considered in clinical trials or unique off-label situations for other malignancies.\n\n### Mechanism of Action\n- **Daunorubicin:** The active ingredient, daunorubicin, is an anthracycline antibiotic that intercalates into DNA, inhibiting the enzyme topoisomerase II, which is critical for DNA replication and repair, thus leading to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_F1zLTAPTIETsrJLZQIblWpP2", "custom_id": "444_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "160ac134eeddcdc27861eb7ac59a3451", "body": {"id": "chatcmpl-9St7svPe0lEaGwiT0aGmXq01Zr4vm", "object": "chat.completion", "created": 1716672116, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Dacogen, with the generic name decitabine, is a chemotherapeutic agent primarily used to treat myelodysplastic syndromes (MDS), including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.\n\nHere are several key points you should be aware of regarding Dacogen:\n\n1. **Mechanism of Action**: Decitabine is a hypomethylating agent that works by incorporating into DNA and inhibiting DNA methyltransferase, leading to hypomethylation of DNA and the restoration of normal function in genes that control the cell cycle. This can result in cellular differentiation or apoptosis in cancer cells.\n\n2. **Administration**:\n   - Dacogen is administered intravenously, typically in a clinical setting.\n   - Common regimens may"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_HhFgD1jUrubOBSl1cpitaDwu", "custom_id": "445_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a3b3b7cc7595e84eaf888082abdddc38", "body": {"id": "chatcmpl-9St7sr9NiXZxSRQyoX6g12MX0BmK7", "object": "chat.completion", "created": 1716672116, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Firmagon, the brand name for degarelix, is a medication used primarily in the treatment of advanced prostate cancer. Here are some key points to know about Firmagon:\n\n### Mechanism of Action:\n- **GnRH Antagonist:** Firmagon is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It works by directly inhibiting the release of gonadotropins (luteinizing hormone and follicle-stimulating hormone) from the anterior pituitary gland, leading to a rapid and sustained decrease in testosterone levels.\n\n### Indications:\n- **Prostate Cancer:** Firmagon is approved for the treatment of advanced prostate cancer and is often used when patients require a reduction in testosterone levels to manage the growth of the cancer.\n\n### Administration:\n- **Route and Dosage:** Firmagon is administered as a subcutaneous injection. The initial dose is a loading dose (usually 240 mg, administered as two injections of 120 mg each), followed by maintenance doses"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_pusz6cGhXmcCCayBdxCRgi8Q", "custom_id": "446_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "92728d5ec1f727746df0ee5fa4d7048d", "body": {"id": "chatcmpl-9St7sLbpqiCCWYpS2eNMKifM2Xmrk", "object": "chat.completion", "created": 1716672116, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ontak, also known by its generic name denileukin diftitox, is a fusion protein drug used primarily in the treatment of certain types of cancer, particularly cutaneous T-cell lymphoma (CTCL). Here's an overview of what you, as a physician, should know about Ontak:\n\n### Mechanism of Action:\nOntak is a recombinant DNA-derived cytotoxic protein. It combines the interleukin-2 (IL-2) receptor-binding domain with the enzymatically active portions of the diphtheria toxin. The drug targets cells that express high levels of the IL-2 receptor, causing cell death by delivering the diphtheria toxin directly into these cells. \n\n### Indications:\n- **Cutaneous T-cell lymphoma (CTCL)**: Specifically for patients with persistent or recurrent disease after other treatments.\n\n### Administration:\n- **Dosage and Schedule**: The typical dosing regimen is an intravenous (IV) infusion given over 30 to 60 minutes, usually administered once"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_yMuGwWRRpHvHyjmenU6umnhe", "custom_id": "447_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "16bc3ad2d822f4e5a2ab11a9a1d1611c", "body": {"id": "chatcmpl-9St7sQMa90EADm7RmQnwOGNdeMwA8", "object": "chat.completion", "created": 1716672116, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Prolia (generic name: denosumab) is a medication used to treat osteoporosis and other conditions related to bone loss. It's a monoclonal antibody that works by inhibiting RANKL (Receptor Activator for Nuclear Factor \u03ba B Ligand), a molecule involved in the formation, function, and survival of osteoclasts, which are the cells responsible for bone resorption. Here are some important points for physicians to know:\n\n### Indications\n- **Osteoporosis in postmenopausal women:** To reduce the risk of vertebral, non-vertebral, and hip fractures.\n- **Osteoporosis in men:** To increase bone mass.\n- **Glucocorticoid-induced osteoporosis:** In patients (both men and women) at high risk of fracture.\n- **Bone loss in men receiving androgen deprivation therapy for prostate cancer** and in women receiving aromatase inhibitor therapy for breast cancer.\n\n### Administration\n- **Dosage:** 60 mg subcut"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_B4P9DrpFuYxPLhpGKbq1BX7R", "custom_id": "448_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "343d3c5c6375e8215a94200bc39b90c3", "body": {"id": "chatcmpl-9St7sz4sprfIBTMU2O7GsbRiYdVL4", "object": "chat.completion", "created": 1716672116, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Aacidexam\" does not immediately correspond to any well-known medication or clinical term in standard medical references. As a physician, ensuring you're up-to-date with current pharmacological directories and literature is essential for providing accurate treatment and advice.\n\nHowever, if we are discussing a pharmaceutical product akin to a typical medication you might prescribe, consider the following general approach:\n\n1. **Pharmacology**: Understand the active ingredients, mechanism of action, indications, and pharmacokinetics/dynamics.\n\n2. **Indications**: Ensure you know the primary indications for which this medication is prescribed. This may include specific diseases or conditions that it treats effectively.\n\n3. **Dosage and Administration**: Familiarize yourself with the appropriate dosages, potential adjustments for age, weight, or comorbidities, and the proper administration route.\n\n4. **Side Effects**: Be aware of common and severe side effects, contraindications, and interactions with other medications. This will help in monitoring and counseling patients effectively"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Y39JB3t81MhHEOlDGBcOGkmc", "custom_id": "449_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5655c50b279f009f69cb6d72c066dd46", "body": {"id": "chatcmpl-9St7skwZ2kVghemtA7NJ1GO5Qar2P", "object": "chat.completion", "created": 1716672116, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cardioxane, whose generic name is dexrazoxane, is a medication used primarily to prevent and treat cardiotoxicity related to anthracycline chemotherapy drugs, such as doxorubicin. Here are some key points you should know about it:\n\n### Indications:\n1. **Cardioprotection**: It is primarily indicated to prevent the cardiotoxicity (heart damage) associated with anthracyclines, especially in patients who require high doses or have pre-existing cardiac risk factors.\n2. **Extravasation Management**: It can also be used to treat tissue damage caused by accidental extravasation of anthracyclines.\n\n### Mechanism of Action:\n- Dexrazoxane is a bisdioxopiperazine derivative that acts as a chelating agent. It binds to iron, thereby preventing the formation of free radicals that can cause cellular damage in cardiac tissues.\n\n### Administration:\n- It's administered intravenously, typically in a dosage ratio of 10"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_v7y9d5hD3VL9TBfpEXdroAOo", "custom_id": "450_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ef41fc4f1aca672d58b20a86aee1bf0e", "body": {"id": "chatcmpl-9St7sUkSPzFiAhpy7Pq2T6ZfS4es6", "object": "chat.completion", "created": 1716672116, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "I'm not aware of any medication or medical product called \"Desplex.\" It's possible that there could be a spelling error or a misunderstanding of the name. It is also possible that it is a product that was released or became known after my last update in October 2023, or it might be specific to a certain country or region.\n\nIf you meant a different medication or product, could you please provide more context or details? This would help ensure a more accurate and helpful response.\n\nIn general, when learning about a new medication or product, you should consider the following key points:\n1. **Indications**: What conditions or symptoms the medication is intended to treat.\n2. **Mechanism of Action**: How the medication works in the body.\n3. **Dosage and Administration**: Recommended dosages, forms, routes of administration, and necessary adjustments for specific populations.\n4. **Contraindications**: When the medication should not be used.\n5. **Side Effects**:"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_fDDL8rB6Wnl57zhZb0SGFEEX", "custom_id": "451_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "72836f4d92e76cf835cf62aa9e9d2878", "body": {"id": "chatcmpl-9St7s5LDgLHU9NaV49LVrGpGY7sb6", "object": "chat.completion", "created": 1716672116, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Unituxin (dinutuximab) is a medication primarily used in the treatment of pediatric patients with high-risk neuroblastoma, a type of cancer that arises from nerve tissue. Here are the key points you should know about Unituxin:\n\n1. **Mechanism of Action**:\n   - Unituxin is a chimeric monoclonal antibody that targets the glycolipid GD2, which is highly expressed on neuroblastoma cells and other cells of neuroectodermal origin.\n   - By binding to GD2, Unituxin can mediate antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the destruction of cancer cells.\n\n2. **Indications**:\n   - It is indicated for the treatment of pediatric patients with high-risk neuroblastoma who have achieved at least a partial response to prior first-line multiagent, multimodality therapy.\n   - It is used as part of a multimodal therapeutic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_22HHGshYavl3jbiMOGPMzhn1", "custom_id": "452_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "adeb3438bdfabce3554d33a8d1530116", "body": {"id": "chatcmpl-9St7ssH92SewikXHV2o1DsTGok5nt", "object": "chat.completion", "created": 1716672116, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2023, there doesn\u2019t appear to be any widely recognized medical literature or commonly known drugs by the name \"Asodocel.\" It is possible that it may be a new, specialized, or emerging treatment that hasn't yet become widely known or documented in mainstream medical references. \n\nIf \"Asodocel\" is a novel treatment or drug, I recommend the following steps:\n\n1. **Consult Recent Medical Literature**: Check recent medical journals, clinical trial databases, and pharmaceutical company publications.\n2. **Pharmacological Databases**: Search comprehensive pharmaceutical databases like PubMed, ClinicalTrials.gov, and the FDA website.\n3. **Medical Conferences and Symposia**: Attend or review materials from recent medical conferences where new treatments are frequently discussed.\n4. **Professional Networks**: Engage with professional organizations or networks in your specialty, as peers may have insights or direct experience with emerging treatments.\n5. **Continuing Medical Education (CME"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_51N74a85RDSXLSYF7DbwC8MO", "custom_id": "453_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b6f7d16335caff37d41d9d5ff015e4a2", "body": {"id": "chatcmpl-9St7sLPoT8hkyc06dZUs6d1zvCn7F", "object": "chat.completion", "created": 1716672116, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Didox, also known by its chemical name hydroxyurea, is a drug that is primarily known for its applications in the treatment of certain diseases and in research. Here are some key points that you should be aware of:\n\n1. **Mechanism of Action**: Didox is an inhibitor of ribonucleotide reductase, an enzyme crucial for DNA synthesis because it converts ribonucleotides into deoxyribonucleotides. By inhibiting this enzyme, Didox can impede DNA replication and repair, making it a useful agent in cancer therapy.\n\n2. **Clinical Uses**:\n   - **Cancer Treatment**: Didox has been explored for its potential use in treating various cancers, including leukemia, melanoma, and other solid tumors, given its ability to inhibit DNA synthesis.\n   - **Sickle Cell Disease**: Hydroxyurea, closely related to Didox, is well-known for its use in treating sickle cell anemia by increasing fetal hemoglobin production, which"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_in1cDgTzjq4AUrnZYyws15Qc", "custom_id": "454_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d8e4f7c584d791e032adad645fb4d1bc", "body": {"id": "chatcmpl-9St7sf0BGs9UTTVKFQgU7tSMFRlTe", "object": "chat.completion", "created": 1716672116, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adriablastina is a trade name for doxorubicin, which is an anthracycline antibiotic commonly used as a chemotherapeutic agent. Here are several important aspects a physician should know regarding Adriablastina:\n\n### Mechanism of Action:\n- **DNA Intercalation:** Doxorubicin intercalates into DNA, inhibiting the synthesis of DNA and RNA.\n- **Topoisomerase II Inhibition:** It inhibits topoisomerase II, an enzyme crucial for DNA replication and transcription.\n- **Free Radical Formation:** Doxorubicin generates free radicals, leading to damage of cellular membranes, DNA, and proteins.\n\n### Indications:\n- **Cancer Types:** It is used to treat various cancers, including breast cancer, ovarian cancer, lung cancer, and Hodgkin\u2019s and non-Hodgkin\u2019s lymphomas, among others.\n\n### Administration:\n- **Intravenous (IV):** It is primarily administered intravenously.\n- **Dos"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Cd1Z11e5xXZEcBY23ZON1ZJs", "custom_id": "455_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "43b40b96bd1c7d35df531d67eb62cbe8", "body": {"id": "chatcmpl-9St7snnpxwPg8rCMh1x22viYbQOEl", "object": "chat.completion", "created": 1716672116, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imfinzi (durvalumab) is a medication used primarily in oncology, and as a physician, there are several key aspects you should be familiar with:\n\n### Mechanism of Action:\n- **Monoclonal Antibody:** Imfinzi is a programmed death-ligand 1 (PD-L1) blocking antibody.\n- **Immune Checkpoint Inhibitor:** It blocks the interaction between PD-L1 and its receptors (PD-1 and CD80), which helps restore T-cell activity and immune response against cancer cells.\n\n### Indications:\n- **Non-Small Cell Lung Cancer (NSCLC):** It's approved for the treatment of patients with locally advanced, unresectable NSCLC after chemoradiotherapy.\n- **Extensive-Stage Small Cell Lung Cancer (ES-SCLC):** Approved for use in combination with chemotherapy (etoposide and either carboplatin or cisplatin) for the first-line treatment.\n\n### Administration:\n- **Route:** Administer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_HYrhhEGrp6dSovV1YiAWgGjI", "custom_id": "456_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0595957e7648c791f1dec831d67f5a90", "body": {"id": "chatcmpl-9St7sjDHX7vEvHktl4oMcHQLDOWrD", "object": "chat.completion", "created": 1716672116, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Avodart (dutasteride). Here are some key points:\n\n### Indications:\n- **Benign Prostatic Hyperplasia (BPH):** Avodart is primarily used for the treatment of symptomatic BPH in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention, and reduce the need for BPH-related surgery.\n\n### Mechanism of Action:\n- **5-alpha Reductase Inhibitor:** Dutasteride works by inhibiting both type 1 and type 2 isoforms of the enzyme 5-alpha reductase, which converts testosterone to dihydrotestosterone (DHT). DHT is a key mediator in the development and enlargement of the prostate gland. Reduction in DHT levels leads to a decrease in prostate size and improvement in urinary symptoms.\n\n### Dosage:\n- **Standard Dosage:** The recommended dose is 0.5 mg once daily, taken with or without"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_HKPbw9vlWjpF5gt7XVeATzrA", "custom_id": "457_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "102fb7444dffd3b8b07924cabacba3c3", "body": {"id": "chatcmpl-9St7sKV8IrH1VeD1RPYJDUP9Y16qc", "object": "chat.completion", "created": 1716672116, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Copiktra (duvelisib) is an oral medication approved for the treatment of certain types of blood cancers, specifically relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma (FL) after at least two prior therapies. As a physician, it is essential to be aware of several key aspects of Copiktra:\n\n### Mechanism of Action:\n- Duvelisib is an inhibitor of phosphoinositide 3-kinase (PI3K), targeting both the delta (PI3K-\u03b4) and gamma (PI3K-\u03b3) isoforms. These kinases are involved in the signaling pathways that regulate cell proliferation, survival, and migration, particularly in blood cancers.\n\n### Indications:\n- **Chronic Lymphocytic Leukemia (CLL):** For patients with relapsed or refractory disease.\n- **Small Lymphocytic Lymphoma (SLL):** For"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_yryBQuCRlT74efiCcnoBh3Dk", "custom_id": "458_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "3050278d339de9201e1fd67408a9e3e7", "body": {"id": "chatcmpl-9St7sNGv62zyQzEumwvQxjx2SHWEh", "object": "chat.completion", "created": 1716672116, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to have a thorough understanding of the Panorex X-ray, also known as a panoramic radiograph. Here are some key points to know:\n\n### 1. **Purpose and Use:**\n- **Breadth of View:** The Panorex provides a broad and comprehensive view of the entire dental arch, both the upper and lower jaws in a single image.\n- **Diagnostic Tool:** It is commonly used in dentistry to diagnose issues related to the teeth, jawbone, and surrounding structures. It can help detect issues like impacted teeth, jaw tumors, cysts, fractures, and dental caries.\n- **Orthodontic Evaluation:** It is particularly useful in orthodontics for evaluating tooth alignment and planning treatments.\n\n### 2. **Procedure:**\n- **Patient Positioning:** The patient is positioned with their head stabilized. They bite on a specific piece of dental instrument to keep the mouth in the correct position.\n- **Rotational X-ray:** The machine"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_MoGg6h1dfRHXePyohiFxo9Zy", "custom_id": "459_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "15fa663beee4665bddaf30d8d2858411", "body": {"id": "chatcmpl-9St7tw3P6lob5iIawmMleule0f6Dz", "object": "chat.completion", "created": 1716672117, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Empliciti (elotuzumab) is a medication used in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. Here are some key points you should know about Empliciti:\n\n### Mechanism of Action:\n- **Immunostimulatory Agent:** Empliciti is a monoclonal antibody that targets SLAMF7, a protein expressed on myeloma and natural killer (NK) cells. It works by directly activating NK cells and facilitating antibody-dependent cellular cytotoxicity (ADCC) against myeloma cells.\n\n### Indications:\n- **Combination Therapy:** It is approved for use in combination with other therapies, such as lenalidomide and dexamethasone, or pomalidomide and dexamethasone, in patients who have received one to three prior therapies for multiple myeloma.\n\n### Administration:\n- **Intravenous Infusion:** Administered via IV infusion, typically every"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_WmrI6S2uCqKqYnDnCv9X75jZ", "custom_id": "460_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "30d2ffc5852a8d9415360564db28d371", "body": {"id": "chatcmpl-9St7tacVNUFQRv8hDyYpVQt3gAXsz", "object": "chat.completion", "created": 1716672117, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's crucial to understand the essential details regarding Idhifa (enasidenib), a medication used in the treatment of specific types of acute myeloid leukemia (AML). Here's a comprehensive overview:\n\n### Indication:\nIdhifa is indicated for the treatment of adult patients with relapsed or refractory AML with an isocitrate dehydrogenase-2 (IDH2) mutation, as detected by an FDA-approved test.\n\n### Mechanism of Action:\nIdhifa is an inhibitor of the mutant IDH2 enzyme. By inhibiting this enzyme, it reduces the levels of the (2R)-hydroxyglutarate (2-HG) metabolite, which contributes to the growth and survival of AML cells with the IDH2 mutation.\n\n### Dosage and Administration:\n- **Recommended Dosage**: The typical dose is 100 mg orally once daily, with or without food.\n- **Administration**: Ensure patients swallow the tablet whole and do not"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_UYuccflNRocl96469kneawkE", "custom_id": "461_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "aa93f2726bdad4b28b57ceae6a1ff363", "body": {"id": "chatcmpl-9St7tQqVW8Lg8owKKwQTpbqQJcgbf", "object": "chat.completion", "created": 1716672117, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Braftovi (encorafenib) is a targeted cancer therapy used in the treatment of certain types of cancer. Here are key points a physician should know about Braftovi:\n\n1. **Mechanism of Action**:\n   - Braftovi is a kinase inhibitor targeting BRAF V600E mutations. It works by inhibiting the activity of the BRAF protein kinase, which is part of the MAPK/ERK signaling pathway involved in cell division and tumor growth.\n\n2. **Indications**: \n   - Braftovi is approved for the treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. It is often used in combination with another drug called binimetinib.\n   - It is also indicated in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation, following prior therapy.\n\n3. **Dosage and Administration**:\n   - The recommended dosage for patients with melanoma is "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_k3F4kUlbEzdoXfQSZFqAHs1m", "custom_id": "462_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6cf309165074367783d87b494539e56f", "body": {"id": "chatcmpl-9St7t5GcdgtRrbhxRLRmgiH32Kbnh", "object": "chat.completion", "created": 1716672117, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, here are several key points you should know about Rozlytrek (entrectinib):\n\n1. **Indications**:\n   - Rozlytrek is a tyrosine kinase inhibitor (TKI) indicated for the treatment of adults with ROS1-positive metastatic non-small cell lung cancer (NSCLC).\n   - It is also indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tropomyosin receptor kinase (NTRK) gene fusion, without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.\n\n2. **Mechanism of Action**:\n   - Rozlytrek works by inhibiting the activity of TRKA, TRKB, TRKC, ROS1, and ALK proteins, which can lead to tumor cell death.\n\n3. **Dosage and Administration**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ds3yFYRZdHMUmPHKanVV4IlS", "custom_id": "463_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "c4dd97b20a0a0eea3204afb4f0f25bc7", "body": {"id": "chatcmpl-9St7tX4wsWXy3nSsgFPD50YZvizrE", "object": "chat.completion", "created": 1716672117, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to understand the key aspects of a medication to ensure safe and effective usage for your patients. Here are the essential details about Azel (marketed as Azelastine):\n\n### General Information:\n- **Generic Name:** Azelastine\n- **Brand Names:** Astelin, Astepro (nasal spray forms); also available as eye drops under brand names like Optivar and Azelastine ophthalmic.\n\n### Mechanism of Action:\n- **Pharmacological Class:** Antihistamine\n- Azelastine is a histamine H1 receptor antagonist. It works by blocking the action of histamine, a substance in the body that causes allergic symptoms.\n\n### Indications:\n- **Nasal Spray:** Used for the relief of symptoms of seasonal and perennial allergic rhinitis (nasal congestion, runny nose, sneezing, itching).\n- **Ophthalmic Solution:** Used for the treatment of itching related to allergic conjunctivitis"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_lWR4si2ylTru4sqm9CPRkJrm", "custom_id": "464_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7b21657f33bdab750d9c9d089978adea", "body": {"id": "chatcmpl-9St7t8BSQ8JIHMu3kCirk4U0CmCte", "object": "chat.completion", "created": 1716672117, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alrubicin (also known as bis-antrorubicin or PNU-159548) is an investigational anthracycline derivative, which means it is related to a class of chemotherapy drugs commonly used to treat various cancers, such as breast cancer, leukemias, and lymphomas. Anthracyclines work by intercalating DNA, inhibiting topoisomerase II, and generating free radicals, which leads to the disruption of DNA function and cell death.\n\nHere are key points you should know about Alrubicin:\n\n1. **Mechanism of Action**: Like other anthracyclines, Alrubicin interferes with the division and growth of cancer cells by intercalating into DNA and inhibiting the enzyme topoisomerase II, which is vital for DNA replication and repair.\n\n2. **Development Status**: Alrubicin is considered an investigational drug, meaning it is not yet approved for general clinical use and is primarily available through clinical trials"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_s6atmYLd1ZAqsZd3dSHW2zMw", "custom_id": "465_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9d30e9d3e5c3f191b9334bfbc1e00f40", "body": {"id": "chatcmpl-9St7tOaGfsM9Hom59vhCdF8U3OsM3", "object": "chat.completion", "created": 1716672117, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Balversa (erdafitinib) is an oral FGFR (fibroblast growth factor receptor) kinase inhibitor used primarily in oncology, particularly for treating certain types of urothelial carcinoma. Below are some key points you should be aware of as a physician:\n\n### Indications:\n- **Urothelial Carcinoma:** Approved for adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and who have progressed during or following at least one line of prior platinum-containing chemotherapy.\n\n### Mechanism of Action:\n- Balversa works by inhibiting the FGFR1, FGFR2, FGFR3, and FGFR4 receptors, which are often implicated in cancer cell proliferation and survival.\n\n### Administration:\n- The recommended starting dose is 8 mg (two 4 mg tablets) orally once daily, with dosage adjustments based on serum phosphate levels and adverse reactions.\n\n### Dosage Adjustments:\n- Regular monitoring of phosphate levels"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_bZdqRGBZ4cTVWrd6wc8XlaGT", "custom_id": "466_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "50fef8ef0cc0b00e8c650c39292b27cb", "body": {"id": "chatcmpl-9St7tZDV08GwuxYx3kO9jFOmWKVUZ", "object": "chat.completion", "created": 1716672117, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2021, there is no widely recognized medication, treatment, or clinical term known as \"Brutravon.\" It is possible that \"Brutravon\" could refer to a very new drug, a trade name, or even a nickname for a medication developed after my last update, or it could be a typo or misspelling.\n\nIf \"Brutravon\" is indeed related to a new drug or treatment that has emerged after my last update, I would recommend the following steps:\n\n1. **Consult Latest Medical Literature:** Check the latest medical journals, databases like PubMed, or specific pharmaceutical publications for any recent articles or studies about \"Brutravon.\"\n\n2. **Medical Databases:** Use medical databases like UpToDate, Medscape, or clinical trial repositories to search for information about this term.\n\n3. **Consult Colleagues:** Discuss with colleagues or specialists in relevant fields such as pharmacology, oncology, infectious diseases"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_QYizgaosd38MSZAWLhwo0BuY", "custom_id": "467_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9a10dedab71b1a99dcaf209ddbed64ab", "body": {"id": "chatcmpl-9St7tYbiJEX0fzOX1cIRh7zfxl6RJ", "object": "chat.completion", "created": 1716672117, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erlocip is a brand name for the drug erlotinib, which is an oral tyrosine kinase inhibitor used primarily in the treatment of certain types of cancer. Here are key points you should know as a physician:\n\n### Indications and Usage\n- **Non-Small Cell Lung Cancer (NSCLC):** Erlotinib is often used in the treatment of locally advanced or metastatic NSCLC. It is particularly effective in patients with EGFR mutations.\n- **Pancreatic Cancer:** It is also indicated in combination with gemcitabine for the treatment of locally advanced, unresectable, or metastatic pancreatic cancer.\n\n### Mechanism of Action\n- Erlotinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in the regulation of intracellular signaling pathways associated with cell proliferation and survival.\n\n### Dosage and Administration\n- **NSCLC:** The common dose is 150 mg orally once daily.\n- **Pancreatic Cancer:**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Cecz1up6ku8X8TDlPFlRdmGN", "custom_id": "468_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b8c4d2522e2208b6f23e93e59b4e591d", "body": {"id": "chatcmpl-9St7tJB2ZVnGXeEvOqRwqT2h2KVn9", "object": "chat.completion", "created": 1716672117, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Emcyt is a brand name for the chemotherapy drug estramustine, which is primarily used in the treatment of prostate cancer. Here are several key facts a physician should know about Emcyt:\n\n### Mechanism of Action:\n- **Combination Mechanism:** Emcyt has both anti-mitotic and anti-androgenic properties. It acts by combining the mechanisms of estradiol (an estrogen) and nitrogen mustard (a chemotherapy agent). \n- **Targeting Prostate Cancer Cells:** The drug binds to microtubule-associated proteins, disrupting microtubule function, and inhibiting cell division.\n\n### Indications:\n- **Prostate Cancer:** Emcyt is mainly indicated for the palliative treatment of metastatic and/or progressive prostate cancer.\n\n### Administration:\n- **Oral Dosage Forms:** The drug is administered orally, typically in capsule form.\n- **Dosage Frequency:** The standard dosing regimen is several times a day, but it should be tailored to the individual"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_AKISBYR6FHQYgbFeKRIYA11K", "custom_id": "469_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0d82ade599f5f6fe1636af807e389fa1", "body": {"id": "chatcmpl-9St7uEDjfIOEK2cvFpY1wg1jXqo14", "object": "chat.completion", "created": 1716672118, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a typographical error in your query. If you meant \"aspide,\" which can refer to a specific species or type, please clarify. However, if you meant \"aspirin,\" here's some fundamental information you should be familiar with as a physician:\n\n### Aspirin (Acetylsalicylic Acid)\n\n#### Indications\n- **Pain relief:** Effective for mild to moderate pain such as headaches, muscle aches, and menstrual cramps.\n- **Anti-inflammatory:** Used in the treatment of inflammatory conditions like rheumatoid arthritis.\n- **Antipyretic:** Reduces fever.\n- **Cardiovascular protection:** Low-dose aspirin is commonly used to reduce the risk of heart attack and stroke in certain populations.\n\n#### Mechanism of Action\n- **COX Inhibition:** Aspirin works by inhibiting cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2, which are key enzymes in the biosynthesis of prostaglandins and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 39, "completion_tokens": 200, "total_tokens": 239}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_2N4ABSUUF8Puk7Jc5VbuFNun", "custom_id": "470_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6a78312aa3687905144834acf35379e5", "body": {"id": "chatcmpl-9St7u8ddF55AumyOZvIe71OmzvoHa", "object": "chat.completion", "created": 1716672118, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Advacan\" is not a medication or medical product that I have readily available information on in the current pharmacological databases up to October 2023. If \"Advacan\" is a newly introduced product, drug, or brand, I might not have updated information about it.\n\nHowever, there are possible scenarios:\n1. **Trade Name vs. Generic Name:** It could be a trade name that is not widely recognized or it might be known by a different name in different regions. Clarifying whether \"Advacan\" is its generic or trade name might help.\n2. **Spelling or Typographical Error:** There may be a spelling or typographical error in the name. Cross-check the name to ensure correctness.\n\nRegardless, here are general steps you should follow to obtain accurate and comprehensive information about any new or unfamiliar drug:\n\n1. **Consult Reliable Drug Databases:** Use resources like UpToDate, Lexicomp, or the Physician's Desk Reference (PDR).\n2. **Reference"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Gv5mdV7weN8ZDChQr6OWoFA7", "custom_id": "471_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a2117908bcb038d7502bd2cbcc0dab76", "body": {"id": "chatcmpl-9St7u2MNIA6ULMOYHsYSBzwZYis5d", "object": "chat.completion", "created": 1716672118, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my latest update, there doesn't appear to be a widely recognized medication or treatment called \"Aromadex.\" This could be due to several reasons, such as a typographical error, the drug might have a different name, or it could be a new or lesser-known product not included in mainstream medical databases.\n\nHowever, if you meant to refer to a similar-sounding medication, \"Arimidex\" (anastrozole), which is commonly prescribed in oncology, particularly for breast cancer treatment, here's some pertinent information:\n\n### Arimidex (Anastrozole):\n\n1. **Class and Mechanism of Action**:\n   - **Class**: Aromatase inhibitor.\n   - **Mechanism**: It works by decreasing the amount of estrogen the body makes, which can slow or reverse the growth of certain types of breast cancer cells that require estrogen to grow.\n\n2. **Indications**:\n   - Used primarily in postmenopausal women for the treatment of hormone"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_enrG9f7hlHm38vCUoRekvSs0", "custom_id": "472_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d0f85e9d127595bde140b4661c0c1d32", "body": {"id": "chatcmpl-9St7uegMSdfklXmsIN844gmtIt9Jo", "object": "chat.completion", "created": 1716672118, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "FUDR, or Floxuridine, is an antimetabolite chemotherapy drug primarily used to treat certain types of cancer. Here are several key points you should know about it as a physician:\n\n### Mechanism of Action:\n- **DNA Synthesis Inhibition:** Floxuridine is a pyrimidine analog that inhibits thymidylate synthase, an enzyme crucial for DNA synthesis.\n- **Antimetabolite:** By mimicking the natural nucleotides, it gets incorporated into the DNA and RNA of cancer cells, leading to errors in replication and transcription, ultimately causing cell death.\n\n### Indications:\n- **Metastatic Colorectal Cancer:** Particularly used for hepatic metastases of colorectal cancer, often administered via intra-arterial infusion to target liver tumors directly.\n- **Experimental Uses:** Sometimes part of clinical trials for other types of solid tumors.\n\n### Administration:\n- **Intra-arterial Infusion:** Commonly administered directly into the artery supplying the liver"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_IN3f9ngsBAabiYXnC1HMpzKB", "custom_id": "473_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "050f6dee8e6c3e4f507e20c09c9b16a5", "body": {"id": "chatcmpl-9St7uamF8F0DMI2GXvcUFWdua1fut", "object": "chat.completion", "created": 1716672118, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2021, there is no widely recognized pharmaceutical or medical product known as \"Beneflur\". It's possible that \"Beneflur\" may be a new drug, a supplement, a brand name, or a product not covered in the medical literature up to that point. \n\nIf you have encountered \"Beneflur\" in a professional context or from a specific source, here are steps you can take to gather relevant information:\n\n1. **Drug Databases and Resources**: Check reputable drug databases such as the FDA (Food and Drug Administration) database, the European Medicines Agency (EMA), or other regional regulatory authorities to see if it is a newly approved medication.\n\n2. **Medical Literature**: Look for articles or studies in medical journals using platforms such as PubMed to find peer-reviewed research on \"Beneflur\".\n\n3. **Pharmaceutical Repositories**: Resources like the Physicians' Desk Reference (PDR), Lexicomp, or UpToDate may have"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_9hiaXIQjKhz8lmrEJnZ9O8j7", "custom_id": "474_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ae417ab501f4e7b705c443260b608db9", "body": {"id": "chatcmpl-9St7uCDLFdkNOA6GpWrf3lzXOwxt0", "object": "chat.completion", "created": 1716672118, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Accusite\" could refer to various concepts, products, or methods depending on the context in which it is used. Without more specific information, it's challenging to provide a detailed answer. Here are a few possible interpretations and what you should know in various contexts:\n\n1. **AccuSite Needle Guidance**: If \"Accusite\" refers to the AccuSite Needle Guidance System, this is a device used in medical imaging to improve the accuracy of needle placement during procedures such as biopsies or injections. It is typically used in combination with ultrasound or other imaging technologies to enhance precision and reduce complications.\n\n    - *What to Know*: \n        - Training: Ensure proper training in the use of the guidance system to maximize its benefits.\n        - Benefits: Improved accuracy and patient outcomes, reduced procedure time, and potentially fewer complications.\n        - Integration: Understand how this system integrates with your existing imaging technology and workflow.\n\n2. **AccuSite Wound Imaging**: This could refer to"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_NDMcscE4zjzy6W1RCPNyUnZR", "custom_id": "475_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a5c5a96e4e5e8b9bcb56d2b46e1c6b08", "body": {"id": "chatcmpl-9St7uKfDbUQuTM5Dpnl1qvGh8je0I", "object": "chat.completion", "created": 1716672118, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Halotestin is the brand name for fluoxymesterone, an androgen and anabolic steroid (AAS) that has both medical uses and potential for misuse. Here are key points you should be aware of:\n\n### Medical Uses:\n1. **Hypogonadism in Males:** Halotestin is prescribed to treat testosterone deficiency.\n2. **Delayed Puberty in Males:** It can be used to induce puberty in adolescent males with delayed onset.\n3. **Breast Cancer in Females:** Sometimes used in the treatment of breast cancer to inhibit the growth of certain types of tumors.\n\n### Mechanism of Action:\n- **Androgenic Effects:** Works by activating androgen receptors which leads to the development of male characteristics and influences sexual and reproductive development.\n- **Anabolic Effects:** Promotes muscle growth and increased red blood cell production.\n\n### Dosage and Administration:\n- The dosage is highly individualized based on the specific condition, age, and response to treatment.\n- It is typically administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_QtLz1aeLGjIR2NGxm6zK1UIR", "custom_id": "476_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7d7884f4c6be17a335665ddfe7c6014c", "body": {"id": "chatcmpl-9St7u0V1mDRDuYQLENFXXrfJkBGJQ", "object": "chat.completion", "created": 1716672118, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cytomid is a brand name for flutamide, a nonsteroidal antiandrogen medication primarily used in the treatment of prostate cancer. Here are key points you should be aware of regarding Cytomid:\n\n### Mechanism of Action:\n- Flutamide works by blocking androgen receptors, preventing androgens (such as testosterone) from stimulating prostate cancer cells.\n- It inhibits the uptake and/or nuclear binding of androgen in target tissues.\n\n### Indications:\n- **Prostate Cancer**: Often used as part of combination therapy with luteinizing hormone-releasing hormone (LHRH) analogs or surgical castration to treat advanced prostate cancer.\n\n### Dosage:\n- **Typical adult dosage**: 250 mg orally three times a day (every 8 hours).\n- Always follow current guidelines and adjust based on individual patient needs and response.\n\n### Contraindications:\n- Known hypersensitivity to flutamide or any component of the formulation.\n\n### Side Effects:\n- Common: Di"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_dcd1tmTLclUOqwahikFWNa5B", "custom_id": "477_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8e19b448b8c054ed2ab0fc25fe0efb02", "body": {"id": "chatcmpl-9St7uOO2WJ51mpPpcPRN4pEgc4P7w", "object": "chat.completion", "created": 1716672118, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about Antrex, which is typically the brand name for diphenhydramine, an antihistamine commonly used to relieve symptoms of allergy, hay fever, and the common cold.\n\nHere's a detailed summary of what you should know:\n\n### Indications:\n1. **Allergy Relief**: Used for the relief of symptoms associated with allergies such as rash, itching, watery eyes, itchy eyes/nose/throat, cough, runny nose, and sneezing.\n2. **Cold Relief**: Provides symptomatic relief for symptoms such as runny nose and sneezing.\n3. **Motion Sickness**: Sometimes used to prevent nausea, vomiting, and dizziness caused by motion sickness.\n4. **Sleep Aid**: Due to its sedative properties, it's occasionally used to treat mild insomnia.\n5. **Parkinson's Disease**: Can be used for adjunctive therapy to relieve extrapyramidal symptoms (excluding tardive dyskinesia"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_fxPJYcD4crwgEsw3hv8keTbW", "custom_id": "478_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9559240cf5fcff60a07eddf1e92caf5f", "body": {"id": "chatcmpl-9St7uTcNlm7guhfVRQpaxgWd4yazA", "object": "chat.completion", "created": 1716672118, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's crucial to be familiar with Lentaron (formestane) and its clinical implications, including its mechanism of action, indications, dosing, side effects, interactions, and patient considerations. Below is a comprehensive overview:\n\n### Mechanism of Action:\n- **Formestane** is an irreversible, selective aromatase inhibitor. Aromatase is an enzyme that converts androgens into estrogens.\n- By inhibiting aromatase, formestane reduces estrogen levels. This is particularly useful in estrogen-receptor-positive breast cancer as it limits estrogen-driven tumor growth.\n\n### Indications:\n- Lentaron is primarily used in the treatment of postmenopausal women with estrogen-receptor-positive breast cancer. It is usually considered when other hormonal therapies (like tamoxifen) are not suitable or have failed.\n\n### Dosing:\n- The typical dose for Lentaron is a long-acting intramuscular preparation.\n- However, the specific dosing regimen should be tailored based on"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ENC0azssfzd0cG97bsHnZclv", "custom_id": "479_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "81183d7599aa5fb9f01a5a65c41cf5bf", "body": {"id": "chatcmpl-9St7uxjaRIZTQhT1GUkRkPO7L1B3L", "object": "chat.completion", "created": 1716672118, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fodosine (also known as forodesine) is a purine nucleoside phosphorylase (PNP) inhibitor that has been investigated primarily for its potential use in the treatment of hematologic malignancies.\n\nHere are some key points to consider:\n\n1. **Mechanism of Action**:\n   - Fodosine works by inhibiting the enzyme PNP, which plays a role in the purine salvage pathway. Inhibition of PNP leads to the accumulation of toxic deoxyguanosine triphosphate (dGTP) in T-lymphocytes, causing apoptosis (programmed cell death) in these cells.\n\n2. **Indications**:\n   - Fodosine has been primarily researched for its use in T-cell malignancies such as T-cell acute lymphoblastic leukemia (T-ALL) and T-cell non-Hodgkin's lymphoma. However, it is not widely approved for clinical use globally and might be involved in clinical trials or off-label"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ilBKU3EJvKlElxgEYZoRaxfl", "custom_id": "480_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "93c5b7e4b5f473e48e720bc5f6118fe7", "body": {"id": "chatcmpl-9St7voh2rJCPwGbQgHP7VCGsvgRKD", "object": "chat.completion", "created": 1716672119, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tavalisse (generic name: fostamatinib) is a medication used in the treatment of chronic immune thrombocytopenia (ITP) in adults who have had an insufficient response to previous treatment. Here are several key points you should be aware of as a physician:\n\n### Mechanism of Action:\n- **Fostamatinib** is a prodrug that is converted to its active metabolite, R406, which is a spleen tyrosine kinase (SYK) inhibitor. SYK is involved in the immune-mediated destruction of platelets.\n\n### Indications:\n- Tavalisse is specifically indicated for adults with chronic ITP who have not responded adequately to other treatments.\n\n### Dosage:\n- The recommended starting dose is 100 mg orally twice daily. Based on the patient's platelet count and tolerability, the dose may be increased to 150 mg twice daily.\n\n### Monitoring:\n- **Platelet Counts:** Monitor regularly, especially during the initial stages of therapy to adjust"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_hdHHSOhtuFZR9XhiFd0TkTzm", "custom_id": "481_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5d3b58aca4b9ff3db2451f16d5e9bc0b", "body": {"id": "chatcmpl-9St7vTvxI8FE2zNw6G966klOyMfO7", "object": "chat.completion", "created": 1716672119, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Muphoran\" does not appear to be a widely recognized or standard pharmaceutical drug or medical term as of my last update in October 2023. It's possible that \"Muphoran\" might be a typographical error, a brand name, or a lesser-known medication. However, I can provide some general guidance on how you could approach this situation:\n\n1. **Verify the Name**: Ensure the spelling of the medication name is correct. Pharmaceutical names are often complex and prone to typos.\n\n2. **Consult Reliable Sources**: Check trusted pharmaceutical databases such as the Physicians' Desk Reference (PDR), Micromedex, UpToDate, or online databases like PubMed or Drugs.com for more information.\n\n3. **Ask the Patient**: If a patient mentioned \"Muphoran\" to you, ask them to bring the medication bottle or packaging during their next visit. The packaging often contains useful information, including the generic name and the manufacturer.\n\n4. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_R7kSYaNOfOzGEFMKrj4fDfhQ", "custom_id": "482_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b79b941b5ab802506f984c29ab42e64f", "body": {"id": "chatcmpl-9St7vXDFmpaba2jiEWKY4V6vqSQ95", "object": "chat.completion", "created": 1716672119, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Faslodex (generic name: fulvestrant) is a medication primarily used in the treatment of hormone receptor-positive metastatic breast cancer. Here are several key points a physician should be aware of regarding Faslodex:\n\n### Mechanism of Action\n- **Estrogen Receptor Antagonist**: Faslodex works by binding to estrogen receptors and degrading them, which blocks the effects of estrogen on tumors that require this hormone to grow.\n\n### Indications\n- **Postmenopausal Women**: Faslodex is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women.\n- **Combination Therapy**: It is often used in combination with other therapies such as CDK4/6 inhibitors.\n\n### Administration\n- **Intramuscular Injection**: Faslodex is administered via intramuscular injection, typically into the buttocks.\n  - Initial dosing: The initial dose is often 500 mg on days 1, 15, and "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_GtIidSIgHT1UPFOa28HdJQMI", "custom_id": "483_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ba9c3d2a8f6c433075e08a084d2f4b54", "body": {"id": "chatcmpl-9St7v069VZz7TPsdjbUGE33FSLnKf", "object": "chat.completion", "created": 1716672119, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Cangib\" does not appear to correspond to a widely recognized medication, supplement, or medical term as of my last update in October 2021. It's possible that it is a brand name, a novel treatment, or a non-standard term. Here\u2019s how you can approach this:\n\n1. **Check Updated Medical Databases:** Use resources such as PubMed, the FDA database, or clinical guidelines for any recent information on \"Cangib.\"\n2. **Pharmacological Context:** Verify if \"Cangib\" is a regional or proprietary name for a known generic drug.\n3. **Patient History and Records:** Cross-reference patient records to ensure the term is interpreted correctly within the context of the patient's care.\n4. **Consult with Peers:** Engaging in discussion with colleagues or a pharmacist may shed light on lesser-known or newer medications.\n5. **Continuing Medical Education (CME):** Keeping up-to-date with CME can help in learning about recent developments including new drugs"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_msCS4tKqENu30IJInejeGnS2", "custom_id": "484_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "80cbc49bd47b03b51d94e78f8f824c36", "body": {"id": "chatcmpl-9St7v9NNfQ7JTsWPcBfg5k67tCDsI", "object": "chat.completion", "created": 1716672119, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be familiar with the key aspects of any medication you prescribe, including Gemcite, which is a brand name for Gemcitabine. Here are some critical points to consider about Gemcitabine:\n\n### Indications\n1. **Cancer Treatment:** Gemcitabine is primarily used to treat various cancers, including non-small cell lung cancer, pancreatic cancer, bladder cancer, and breast cancer. It may also be used for other off-label indications at the discretion of the oncologist.\n\n### Mechanism of Action\n2. **Antimetabolite:** Gemcitabine is an antimetabolite that works by interfering with DNA synthesis, thereby inhibiting cell division. This action makes it effective at targeting rapidly dividing cancer cells.\n\n### Administration\n3. **Intravenous Infusion:** It is administered via intravenous infusion, typically in a clinical setting. Dosage and schedule depend on the specific cancer being treated, the patient's health status, and whether it is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_JeHtEaynoeH6S84yig3dbudb", "custom_id": "485_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ffb7383801d9cd06a133b338c8797dad", "body": {"id": "chatcmpl-9St7v1XzH96UJgopVuQsWwprNCsEO", "object": "chat.completion", "created": 1716672119, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mylotarg (gemtuzumab ozogamicin) is a chemotherapy drug used in the treatment of certain types of acute myeloid leukemia (AML). As a physician, here are key points you should know about Mylotarg:\n\n1. **Indications**: \n   - Mylotarg is primarily indicated for the treatment of newly diagnosed CD33-positive AML in adults.\n   - It may also be used in cases of relapsed or refractory AML.\n\n2. **Mechanism of Action**: \n   - Mylotarg is a monoclonal antibody linked to a cytotoxic agent, calicheamicin.\n   - It targets the CD33 antigen, which is commonly expressed on AML cells, and delivers the cytotoxic agent directly to these cells, leading to cell death.\n\n3. **Dosage and Administration**: \n   - Mylotarg is administered intravenously.\n   - The dosage and schedule may vary depending on whether it is given as"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_FHDVT9K0Fa3VWRoqkRvzfHmc", "custom_id": "486_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9762d22a643c6d4d559c8cbc2bc51620", "body": {"id": "chatcmpl-9St7vgVQWt7Kz8XlLZibIpXJ9jW6J", "object": "chat.completion", "created": 1716672119, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Xospata (generic name: gilteritinib) is a medication used primarily in the treatment of acute myeloid leukemia (AML) that has a specific genetic mutation known as FLT3. Here are some key points you should know as a physician:\n\n### Indications:\n1. **Target Population**: Xospata is indicated for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation.\n2. **Genetic Testing**: Prior to initiating treatment with Xospata, it is essential to test patients for FLT3 mutations using an FDA-approved test.\n\n### Mechanism of Action:\n- **FLT3 Inhibition**: Xospata is a kinase inhibitor that targets FLT3, a receptor tyrosine kinase. Mutations in FLT3 are common in AML and are associated with a poor prognosis.\n  \n### Dosage and Administration:\n1. **Recommended Dose**: The recommended dose is typically 120 mg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_lmcxoFv3fZvagVQPaRpNvM8m", "custom_id": "487_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4458ffc4915c309c6253923fbeb5ae56", "body": {"id": "chatcmpl-9St7vnIyvKaHN6aiK4FHt64NzxL2v", "object": "chat.completion", "created": 1716672119, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Daurismo (generic name: glasdegib) is a medication approved by the FDA for the treatment of certain types of acute myeloid leukemia (AML), particularly in adult patients who are 75 years or older or who have comorbidities that preclude the use of intensive chemotherapy. Here are key aspects you should know about Daurismo:\n\n1. **Mechanism of Action**:\n   - Daurismo is a hedgehog pathway inhibitor. It works by inhibiting the Smoothened (SMO) receptor, which is a key component in the hedgehog signaling pathway. This pathway is crucial for the proliferation and survival of leukemic stem cells.\n\n2. **Indications**:\n   - Daurismo is indicated in combination with low-dose cytarabine (LDAC) for the treatment of newly-diagnosed AML in adult patients who are unable to undergo intensive chemotherapy.\n\n3. **Administration**:\n   - The recommended dosage is 100 mg of Daur"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_8oXTEPES0WzDmvsPtVwsKcBz", "custom_id": "488_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "91076359127a3725c375209b2de25d93", "body": {"id": "chatcmpl-9St7vXaSe8YQDeiNctylzuLdYIBCd", "object": "chat.completion", "created": 1716672119, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a typo in your question, as \"Novgos\" does not correspond to any widely recognized medical term, pharmaceutical product, or condition that I am aware of up to my knowledge cutoff in October 2021. If \"Novgos\" is newly developed or specific to a localized context after my knowledge cutoff, I unfortunately wouldn't have any information on it.\n\nHowever, if you meant something else or there's another term you would like to inquire about, I\u2019d be happy to help with any information I have. Please provide more context or verify the term, and I'll assist you further."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 121, "total_tokens": 161}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_l8EaszHe41XseIPIOUQ1pKdY", "custom_id": "489_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b70fc896021fd8eb129a18d85f1614cc", "body": {"id": "chatcmpl-9St7vGHdPCO6r2drwKpfidzza5uoA", "object": "chat.completion", "created": 1716672119, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Supprelin is a brand name for the drug histrelin acetate, which is used primarily in the treatment of central precocious puberty (CPP) in children. Here are some key points you should know about Supprelin:\n\n### Indications\n- **Central Precocious Puberty (CPP):** Supprelin is used to treat children with CPP, a condition where puberty starts too early, typically before age 8 in girls and age 9 in boys.\n\n### Mechanism of Action\n- **Gonadotropin-Releasing Hormone (GnRH) Agonist:** Histrelin acetate is a GnRH agonist. It works by initially stimulating and then profoundly inhibiting the release of gonadotropins (LH and FSH) from the pituitary gland, leading to decreased production of sex steroids (estrogens and androgens).\n\n### Administration\n- **Implant:** Supprelin is administered as a subcutaneous implant that slowly releases the drug over "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_zMs5Azmgne6MWsyF6ytcoEhq", "custom_id": "490_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "cb519d21bd9f840e4bae3d5398292f51", "body": {"id": "chatcmpl-9St7vGYRKgyT3X2ZAMp2zu6ztBgYT", "object": "chat.completion", "created": 1716672119, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cortef is a brand name for hydrocortisone, which is a corticosteroid used to treat a variety of conditions by reducing inflammation and modifying the body's immune response. Below are key points you should know as a physician:\n\n### Indications\nCortef (hydrocortisone) is used to manage:\n1. **Adrenal Insufficiency:** Primary or secondary, including Addison's disease.\n2. **Inflammatory Conditions:** Such as arthritis, colitis, and certain dermatological diseases.\n3. **Allergic Reactions:** Severe allergic states like anaphylaxis.\n4. **Autoimmune Disorders:** Such as systemic lupus erythematosus.\n5. **Respiratory Conditions:** Such as asthma exacerbations.\n6. **Others:** Including certain cancers and endocrine abnormalities.\n\n### Mechanism of Action\nHydrocortisone is a glucocorticoid receptor agonist. It works by influencing the transcription of corticosteroid-responsive genes, leading to a wide range"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_KrTkxjt0cJLFUzuK8EQNfjwK", "custom_id": "491_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "fedda8fdac21ea3fd23f91fe0ce16d41", "body": {"id": "chatcmpl-9St7vtchZPRb7SdAIZNr9i3eolZLg", "object": "chat.completion", "created": 1716672119, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in 2023, \"Biosupressin\" does not appear to be a widely recognized or established medication, therapy, or term in medical literature or practice. It could be a new or experimental treatment, a brand name not universally recognized, or even a typographical error or misunderstanding of another medication.\n\nWhen evaluating unknown or new medications, consider the following steps:\n\n1. **Literature Search:** Conduct a thorough search in medical journals, clinical trial databases, and trusted medical resources like PubMed, UpToDate, or ClinicalTrials.gov.\n\n2. **Check with Regulatory Bodies:** Verify the status of the medication with regulatory agencies such as the FDA (Food and Drug Administration in the U.S.) or EMA (European Medicines Agency). These agencies provide information on approved drugs, their indications, and clinical trial statuses.\n\n3. **Professional Networks:** Consult with colleagues or specialists in the relevant field. Professional networks and online forums can provide insights or personal experiences with new treatments.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_VwAyMkqbExNRWgftBAhdTW9U", "custom_id": "492_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1f0418ba9c1fc63bc944392f758d0007", "body": {"id": "chatcmpl-9St7vZluQUHQHsaaLaD6XaVoukrI4", "object": "chat.completion", "created": 1716672119, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zevalin (ibritumomab tiuxetan) is a radioimmunotherapy medication used primarily to treat certain types of non-Hodgkin lymphoma (NHL). Here is a summary of key points that you, as a physician, should be aware of:\n\n### Mechanism of Action\n- **Radioimmunotherapy**: Combines the targeting ability of an antibody with the cell-killing ability of radiation.\n- **Ibritumomab**: A monoclonal antibody targeting the CD20 antigen on B-cells.\n- **Tiuxetan**: A chelator that holds the radioactive isotope (Yttrium-90 or Indium-111).\n\n### Indications\n- Indicated for the treatment of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.\n- Also used for patients with previously untreated follicular non-Hodgkin's lymphoma who achieve a partial or complete response to first-line chemotherapy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_xGrjNKwBpk4ocWIJJJw0yNVf", "custom_id": "493_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "49dc118facd5f6728198033e1ae6e5d4", "body": {"id": "chatcmpl-9St7wxBhg0ISHomtL0Kd5BXKqbCnY", "object": "chat.completion", "created": 1716672120, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ibrutinib, marketed under the brand name Imbruvica, is an oral Bruton's tyrosine kinase (BTK) inhibitor used primarily in the management of various B-cell malignancies. As a physician, here are some critical points you should know about Ibrutinib:\n\n1. **Indications:**\n   - Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)\n   - Mantle Cell Lymphoma (MCL)\n   - Waldenstr\u00f6m's Macroglobulinemia (WM)\n   - Marginal Zone Lymphoma (MZL)\n   - Chronic Graft-Versus-Host Disease (cGVHD)\n\n2. **Mechanism of Action:**\n   - Ibrutinib works by forming a covalent bond with the cysteine residue of BTK, a protein crucial for B-cell receptor signaling. This inhibition blocks B-cell activation and proliferation, thus exerting ant"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_uXLEXEZfySbe6qW2UYuGxdc2", "custom_id": "494_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7eca680d6bb617c2b3561b60624c1cab", "body": {"id": "chatcmpl-9St87tOO5vBXPWznYccrfTTKKD44B", "object": "chat.completion", "created": 1716672131, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it\u2019s important to have a comprehensive understanding of Conmana (icotinib), particularly if you are treating patients with non-small cell lung cancer (NSCLC). Here are key aspects you should be aware of:\n\n### Indications\nConmana is a tyrosine kinase inhibitor (TKI) specifically targeting the epidermal growth factor receptor (EGFR). It is primarily indicated for:\n- Treatment of patients with locally advanced or metastatic NSCLC who harbor EGFR mutations.\n\n### Mechanism of Action\n- Icotinib inhibits the EGFR tyrosine kinase by binding to the ATP-binding site of the enzyme, thus blocking signal transduction pathways involved in the proliferation and survival of cancer cells.\n\n### Administration\n- Conmana is typically administered orally. \n- The recommended dosage regimen should be followed as per prescribing information, usually involving multiple doses per day.\n\n### Efficacy\n- Clinical trials have shown that icotinib can improve progression-free survival in patients with EGFR"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_MwzMjJN27QypMJmHKYFXM1Y9", "custom_id": "495_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8bb56d7b8ce00edab356d0c903f80b54", "body": {"id": "chatcmpl-9St7w1ERQ3ITOT8ukBX4P8O5Bhmm1", "object": "chat.completion", "created": 1716672120, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Idamycin, generically known as idarubicin, is an anthracycline antineoplastic agent used primarily in the treatment of various types of leukemia, particularly acute myeloid leukemia (AML). As a physician, it's important to be familiar with the following key information about Idamycin:\n\n### Mechanism of Action:\n- Idarubicin intercalates into DNA, disrupting the function of DNA and RNA by inhibiting the enzyme topoisomerase II. This leads to the inhibition of DNA replication and repair, resulting in cell death.\n\n### Indications:\n- Idarubicin is primarily indicated for the treatment of AML, usually in combination with other chemotherapeutic agents.\n- It might also be used off-label for other types of leukemia or related conditions, depending on clinical circumstances.\n\n### Administration:\n- Idarubicin is given intravenously, with the dosage and regimen depending on the specific protocol being used, the patient's condition, and response to therapy.\n- Proper handling"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_0Vj2ziDUbaErJFhb51KXJ6P0", "custom_id": "496_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "3bda90c54792692672ec05cecb731e01", "body": {"id": "chatcmpl-9St7w4G5yA172TXWUIXUP463xn8Cm", "object": "chat.completion", "created": 1716672120, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to be well-informed about Idelalisib, marketed under the brand name Zydelig, which is an oral medication used in the treatment of certain types of blood cancers. Here is a comprehensive overview:\n\n### Indications:\nZydelig is used primarily for treating:\n1. Relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab.\n2. Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.\n3. Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies.\n\n### Mechanism of Action:\nIdelalisib is a selective inhibitor of the enzyme phosphoinositide 3-kinase delta (PI3K\u03b4), which is expressed in mature B-cells and in many lymphoid malignancies. Inhibition of PI3K\u03b4 results in apoptosis and inhibition of proliferation in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_sf13dDHuaxOhddHoSckB4DQi", "custom_id": "497_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "3ec7ac151f3a8b2d6a6fa72d384bb746", "body": {"id": "chatcmpl-9St7wxTgFJcuu0ywS6iNOiScbxkPw", "object": "chat.completion", "created": 1716672120, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my latest update, there is no widely recognized substance or medication known as \"Alquimid\" in medical literature, pharmacology, or clinical practice. It is possible that the term is a misspelling or a confusion with another substance. Here are a few steps you can take to clarify:\n\n1. **Double-check the name:** Ensure that \"Alquimid\" is spelled correctly.\n2. **Contextual clues:** Consider the context in which you encountered the term. Is it a drug, a supplement, a piece of medical equipment, or something else?\n3. **Consult reliable sources:** Check medical databases such as PubMed, clinical guidelines, or pharmaceutical references like the Physicians' Desk Reference (PDR).\n4. **Ask colleagues:** Sometimes discussing with peers can provide clarity if \"Alquimid\" is something new or niche.\n5. **Patient records:** If a patient mentioned it, try to gather more information from them. They might have additional details that can help you"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5HEe8EKLRPvAPhxJqM1UsrVQ", "custom_id": "498_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "27123b6edc0a1e37423c9f348d129d9f", "body": {"id": "chatcmpl-9St7wTZ8ylX2SQ3hwT4Nsw3mn5Pe0", "object": "chat.completion", "created": 1716672120, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, \"Enliven\" could refer to a variety of products, services, or concepts in different contexts. Without specific details about what you mean by \"Enliven,\" I can outline some possible interpretations that might be relevant to you as a physician:\n\n1. **Medications or Supplements:**\n   - If \"Enliven\" refers to a specific medication or dietary supplement, you should check its active ingredients, indications, contraindications, side effects, and the clinical evidence supporting its use. It's crucial to ensure it is approved by relevant health authorities like the FDA or EMA.\n   - Always consider potential interactions with other medications your patients might be taking.\n   - Be aware of the appropriate dosing guidelines and any special precautions.\n\n2. **Healthcare Technology:**\n   - If \"Enliven\" is related to a healthcare technology product, such as software for electronic health records (EHR) or a telemedicine platform, you should understand its"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_AnVbdBPf0KH7rFmmP6KggqCk", "custom_id": "499_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "bd2e34c60556e090093e7b2e2bd6b986", "body": {"id": "chatcmpl-9St7w4sZrH7qwVbjGLLE8N4sGpAxp", "object": "chat.completion", "created": 1716672120, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Truseltiq (generic name: infigratinib) is an oral kinase inhibitor that has been approved for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. Below are several key points that a physician should be aware of regarding Truseltiq:\n\n1. **Mechanism of Action**: Truseltiq targets and inhibits fibroblast growth factor receptors (FGFRs), particularly FGFR2, which play a significant role in the development and progression of certain cancers.\n\n2. **Indications**: It is indicated specifically for patients who have cholangiocarcinoma with FGFR2 gene fusions or rearrangements, and who have already received previous treatment.\n\n3. **Administration**: Truseltiq is administered orally and is usually taken once daily for 21 consecutive days followed by "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ZEK2Cgr3lFxElWUBaOwg3Nfv", "custom_id": "500_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a9f781ba2153bcade488ef74f82a171f", "body": {"id": "chatcmpl-9St7wapRcsNYM6JgNcxGicXUXPAOU", "object": "chat.completion", "created": 1716672120, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Besponsa (generic name: inotuzumab ozogamicin) is a medication used primarily for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Here are some key points you should know about Besponsa as a physician:\n\n### Mechanism of Action\n1. **Antibody-Drug Conjugate:** Besponsa is an antibody-drug conjugate (ADC). It combines a monoclonal antibody targeting CD22, a cell surface antigen expressed on B-cells, with a cytotoxic agent, calicheamicin.\n2. **Targeted Therapy:** The monoclonal antibody component binds to CD22 on B-cells, delivering the cytotoxic agent directly to the malignant cells, which enhances the specificity of the treatment and spares normal cells to some extent.\n\n### Indications\n- **Relapsed or Refractory B-cell Precursor ALL:** Primarily indicated for adult patients who have relapsed or refractory B-cell precursor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_xtyIijejXyc7JEdrhf1yQK6n", "custom_id": "501_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2bf2b4ea1256f3abc045e29c0cc880ad", "body": {"id": "chatcmpl-9St7wsOhqUxkr9DZ97g7ez75OqZCa", "object": "chat.completion", "created": 1716672120, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff in October 2023, \"Laroferon\" does not correspond to any well-known medication, treatment, or medical term. It seems there may be a misunderstanding, typo, or a new development that is not within the scope of my information.\n\nHowever, if Laroferon refers to a novel drug or treatment discovered or named after my last update, here are some steps you can take to find more accurate and updated information:\n\n1. **Consult Medical Databases and Literature**: Check reputable medical resources like PubMed, Cochrane Library, or your institution's medical library for any published studies or reviews on Laroferon.\n\n2. **FDA and EMA Websites**: The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are excellent resources for the latest drug approvals and safety information.\n\n3. **Professional Networks**: Engage with colleagues or specialist networks in your field who might have more current information.\n\n4."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_TezW2QcA3sqd08SAgufUkZ3Q", "custom_id": "502_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9c3bc239de132d0fb3154bfa938efd65", "body": {"id": "chatcmpl-9St7xgnaYDWwQRpzTwYdv5mlBNt1l", "object": "chat.completion", "created": 1716672121, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff in October 2023, \"Advaferon\" does not correspond with any well-known pharmaceutical products, treatments, or medical technologies. It is possible that Advaferon is a new or investigational drug, a lesser-known medication, or perhaps a misspelling or confusion with another drug name. \n\nAs a physician, here are steps you might consider:\n\n1. **Verify Medication Name**: Double-check the name for spelling or possible variations. It might correspond to a different or more familiar medication such as \"Interferon,\" often used in antiviral therapies and cancer treatments.\n\n2. **Consult References**: Use reliable medical resources such as the Physicians' Desk Reference (PDR), clinical pharmacology databases (like Micromedex), and peer-reviewed journals to search for the latest information.\n\n3. **Contact Pharmacy**: Speak with a pharmacist who might have access to different databases and might be more familiar with new or less common medications.\n\n4. **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_veis7Yd8MtgJ1KRsfxlz3sIu", "custom_id": "503_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8972caa62c9a753c58bca3715a7cd919", "body": {"id": "chatcmpl-9St7xnHBhKAXBGbWGxVOssHukyHh3", "object": "chat.completion", "created": 1716672121, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Actimmune (Interferon gamma-1b) is a recombinant form of human interferon gamma, a protein that plays a role in immune system regulation. As a physician, it's important to understand the following key aspects about Actimmune:\n\n1. **Indications**:\n   - **Chronic Granulomatous Disease (CGD)**: Actimmune is indicated for reducing the frequency and severity of serious infections associated with CGD.\n   - **Severe, Malignant Osteopetrosis (SMO)**: It is also approved for delaying disease progression in patients with SMO.\n\n2. **Mechanism of Action**:\n   - Interferon gamma-1b works by enhancing the function of phagocytes (white blood cells that ingest and digest microbes and other foreign substances) and increasing the body's ability to fight infections.\n   \n3. **Dosage and Administration**:\n   - Actimmune is administered via subcutaneous injection.\n   - The typical dosage for CGD and SM"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_UXtUrH6IlVEGlfxoamOuuNXl", "custom_id": "504_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "095a9079dc9df29f7e920c26817104aa", "body": {"id": "chatcmpl-9St7xCo6RXS839EgThULxfOfthCfp", "object": "chat.completion", "created": 1716672121, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Yervoy (generic name: ipilimumab) is a type of immunotherapy drug used to treat certain cancers by stimulating the body's immune system to fight against cancer cells. Here are some key points you, as a physician, should know about Yervoy:\n\n1. **Mechanism of Action**: Yervoy is a monoclonal antibody that targets CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), an inhibitory receptor on T-cells. By blocking CTLA-4, Yervoy enhances T-cell activation and proliferation, thereby boosting the immune response against cancer cells.\n\n2. **Indications**: Yervoy is primarily used to treat:\n   - Unresectable or metastatic melanoma.\n   - Adjuvant treatment of melanoma with lymph node involvement after complete resection.\n   - Metastatic colorectal cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).\n   - Renal"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_mP5MiF6lPEaPGgFVJadxGLOZ", "custom_id": "505_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "97519ff115ed1d390ffae2ae2e35e673", "body": {"id": "chatcmpl-9St7x2RT9khPjw9TruVw2wotd65UQ", "object": "chat.completion", "created": 1716672121, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It appears that you may have misspelled \"Irinotecan,\" which is a chemotherapeutic agent used primarily in the treatment of colorectal cancer. If you meant \"Axinotecan,\" it might be an error or a less commonly known variant or drug. I'll proceed with information on Irinotecan, assuming that is what you intended. If it\u2019s not, please provide more context.\n\n**Irinotecan (CPT-11):**\n\n1. **Mechanism of Action:**\n   - Irinotecan is a camptothecin derivative that inhibits topoisomerase I, an enzyme involved in DNA replication. By inhibiting topoisomerase I, Irinotecan induces DNA damage, leading to apoptosis in rapidly dividing cancer cells.\n\n2. **Indications:**\n   - Primarily used in the treatment of metastatic colorectal cancer.\n   - Often combined with other chemotherapeutic agents like 5-fluorouracil (5-FU)"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_PpaSg71qSj24i8SVK63nYXjW", "custom_id": "506_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "dc1b555792c676e2f8bd295ed2fc546a", "body": {"id": "chatcmpl-9St7xRcVxX57azLSmp2iPl22W6IL2", "object": "chat.completion", "created": 1716672121, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sure, I can provide a detailed overview of Onivyde for you.\n\n**Onivyde (irinotecan liposome injection):**\n\n**1. **Indication:**\n   - Onivyde is primarily indicated for use in combination with fluorouracil and leucovorin for the treatment of metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.\n\n**2. **Mechanism of Action:**\n   - Onivyde is an encapsulated form of irinotecan in a liposomal formulation. It is a topoisomerase I inhibitor, which interferes with DNA replication and transcription. The liposomal encapsulation is intended to improve the pharmacokinetics and biodistribution of irinotecan.\n\n**3. **Administration:**\n   - Onivyde is administered intravenously. The recommended dose in combination therapy is typically 70 mg/m\u00b2, administered once every two weeks, adjusted based on patient tolerance and specific health conditions.\n\n**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_11m0D3I2F6GvwRE0BzwKK4sp", "custom_id": "507_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9270916fcc39ab13b24dba9c06e7c0b1", "body": {"id": "chatcmpl-9St7xUEhGcZ9RiwuMaGO4VK6wJlDw", "object": "chat.completion", "created": 1716672121, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Sarclisa (generic name: isatuximab-irfc) is a monoclonal antibody used as a therapeutic agent in the treatment of multiple myeloma, a type of blood cancer. Developed by Sanofi, Sarclisa is specifically indicated for use in combination with other medications for patients who have received prior therapies.\n\nHere are some essential points you should know about Sarclisa as a physician:\n\n### Mechanism of Action:\n- **Targets CD38:** Sarclisa is a monoclonal antibody that targets CD38, a cell surface protein that is highly expressed on multiple myeloma cells. By binding to CD38, isatuximab induces several immune-mediated mechanisms of action leading to the death of these malignant cells, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP).\n\n### Indications:\n- **Relapsed/Refractory Multiple Myeloma:** Sarcl"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_bhtHVUih7eVHNwjQQj53xN9d", "custom_id": "508_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b6aa3b12bbafd03aba0b9deb61c0d36f", "body": {"id": "chatcmpl-9St7xvmVFoM1mtfJsCElToGWaMRnx", "object": "chat.completion", "created": 1716672121, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, especially if you're treating patients with severe forms of acne, there are several important aspects of Absorica (isotretinoin) that you should be familiar with:\n\n1. **Indication**:\n   - Absorica is primarily prescribed for severe nodular acne that has not responded to other treatments, including antibiotics.\n\n2. **Mechanism of Action**:\n   - Isotretinoin, the active ingredient in Absorica, is a retinoid that reduces sebaceous gland activity and size, decreases sebum production, and has anti-inflammatory effects.\n\n3. **Dosage and Administration**:\n   - Absorica is taken orally, usually twice a day with food, over a course of about 15-20 weeks.\n   - The dosage is typically weight-based, but adjustments may be made according to patient response and tolerance.\n\n4. **Monitoring and Side Effects**:\n   - **Teratogenicity**: One of the most critical concerns"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_dBFmZ04Mb4P1gVeCzv0JYMUk", "custom_id": "509_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "c682b1db578fa6682bfd9b0a8e8c62bd", "body": {"id": "chatcmpl-9St7xj5mu1mlU5Qs5QybbhxOD5viU", "object": "chat.completion", "created": 1716672121, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "**Tibsovo (Ivosidenib)** is a prescription medication used for the treatment of certain cancers. Here\u2019s a comprehensive overview that you may find helpful:\n\n### **Indications:**\n\n1. **Acute Myeloid Leukemia (AML):**\n   - **Newly Diagnosed:** For adult patients who are 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy and have an isocitrate dehydrogenase-1 (IDH1) mutation.\n   - **Relapsed or Refractory AML:** For adult patients with relapsed or refractory AML with an IDH1 mutation.\n\n2. **Cholangiocarcinoma:**\n   - For adult patients with previously treated, locally advanced, or metastatic cholangiocarcinoma with an IDH1 mutation.\n\n### **Mechanism of Action:**\n   - Tibsovo is an IDH1 inhibitor. It works by targeting and inhibiting the mutant IDH"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5pUU9BHzTOQlEY4LO0GCdfwU", "custom_id": "510_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "84f976846b4d3126e540737e8b7be922", "body": {"id": "chatcmpl-9St7xRb64zXgCyll2a7CJ7IVaDAjn", "object": "chat.completion", "created": 1716672121, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ixempra (chemical name: ixabepilone) is an antineoplastic agent used in cancer treatment, primarily for metastatic or locally advanced breast cancer. It is especially considered for patients whose tumors are resistant to other treatments, including anthracyclines and taxanes.\n\nHere are key points you as a physician should be aware of:\n\n### Mechanism of Action:\n- **Microtubule Inhibitor:** Ixempra works by stabilizing microtubules, leading to apoptosis (programmed cell death) in cancer cells. This mechanism is similar to taxanes but with a slightly different binding site which helps overcome taxane resistance.\n\n### Indications:\n- **Metastatic or Locally Advanced Breast Cancer:** Specifically used after the failure of anthracycline, taxane, and capecitabine-based therapies. It may be administered as monotherapy or in combination with capecitabine.\n\n### Dosage and Administration:\n- **Intravenous Infusion:**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_MgjNW8cNpiRk8sFEfIrDlcXb", "custom_id": "511_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a9ba457c8aacf02bc7e1d167f0f07485", "body": {"id": "chatcmpl-9St7xA6ppHNTiU8zCmFYLmo2PETFP", "object": "chat.completion", "created": 1716672121, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ninlaro (generic name: ixazomib) is a proteasome inhibitor used primarily in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells. Here are key points you should know about Ninlaro:\n\n1. **Indication:**\n   - Ninlaro is indicated for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.\n\n2. **Mechanism of Action:**\n   - Ixazomib works by inhibiting the proteasome, an enzyme complex responsible for degrading unneeded or damaged proteins in cells. This inhibition leads to an accumulation of proteins within the cell, inducing apoptosis (cell death) in myeloma cells.\n\n3. **Dosage Administration:**\n   - The recommended starting dose of Ninlaro is 4 mg taken orally once a week on Days 1, 8, and 15"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_GOikVUMwMiHMCiot4yOWg6Mh", "custom_id": "512_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "74b15d2fb68775342fe2f315cdb2c008", "body": {"id": "chatcmpl-9St7xCTlFKT61BLXp6PWx6mQLKLJG", "object": "chat.completion", "created": 1716672121, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nizoral (generic name: ketoconazole) is an antifungal medication used to treat a variety of fungal infections. Here are key points you should know about Nizoral:\n\n### Mechanism of Action\n- **Ketoconazole**: Inhibits the synthesis of ergosterol, a critical component of fungal cell membranes, thereby disrupting cell membrane integrity and leading to cell death.\n\n### Indications\n- **Topical Use**: Nizoral is commonly used for conditions such as seborrheic dermatitis, pityriasis versicolor, and cutaneous candidiasis.\n- **Systemic Use**: Oral ketoconazole has been used for systemic fungal infections, such as blastomycosis, histoplasmosis, and chronic mucocutaneous candidiasis, but its use has declined due to concerns about safety.\n\n### Forms Available\n- **Shampoo**: Often used for dandruff and seborrheic dermatitis of the scalp.\n- **Cream**: Applied top"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_EY2I1ue7JzVBN1WV8OtoXnIK", "custom_id": "513_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e3f06367313d196ebe5840f122416d43", "body": {"id": "chatcmpl-9St7yErHFFkpo1QsFe0J4JKbObPLq", "object": "chat.completion", "created": 1716672122, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last knowledge update in 2021, I can't find specific information on a medication or product named \"Ipstyl.\" It's possible that it could be spelled differently, be a new medication, or information about it could have emerged after my last update.\n\nHowever, as a physician, if you are encountering an unfamiliar medication, you should consider the following steps:\n\n1. **Refer to Reliable Sources**:\n   - **Pharmaceutical Databases**: Use comprehensive pharmaceutical databases such as UpToDate, PubMed, or Lexicomp for the most current and evidence-based information.\n   - **Official Guideline Websites**: Check guidelines from reputable organizations relevant to your specialty (e.g., the American Medical Association, FDA).\n\n2. **Consult Colleagues**:\n   - Discuss with pharmacy colleagues or other healthcare professionals who might have experience or knowledge about the medication.\n\n3. **Manufacturer Information**:\n   - Obtain the drug monograph directly from the pharmaceutical company that manufactures the drug. They"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_nFBkhfAdA4bjbPgJ7GOWhkvh", "custom_id": "514_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f767dd4cee14aac82c3230243813fbb4", "body": {"id": "chatcmpl-9St7ywkdENUdEc8TdYnZNjtYAdyHp", "object": "chat.completion", "created": 1716672122, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to have a comprehensive understanding of Prevacid (lansoprazole), a proton pump inhibitor (PPI) used primarily for the treatment of various acid-related gastrointestinal conditions. Here are key points you should be aware of:\n\n### Indications\n1. **Gastroesophageal Reflux Disease (GERD):**\n   - Used for the treatment of symptomatic GERD and maintenance of healing of erosive esophagitis.\n   \n2. **Peptic Ulcer Disease (PUD):**\n   - Treats and helps to prevent the recurrence of ulcers associated with Helicobacter pylori infections when used in combination with antibiotics.\n   - Also used for the treatment of NSAID-associated gastric ulcers.\n\n3. **Zollinger-Ellison Syndrome:** \n   - Helps in managing pathological hypersecretory conditions.\n\n### Mechanism of Action\n- Prevacid inhibits the H+/K+ ATPase enzyme system of the gastric parietal cells, effectively"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_w3lcTcSx4VsOs0lXhA16cr58", "custom_id": "515_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9a005aebfafe1c3eb91473d466d5cf5a", "body": {"id": "chatcmpl-9St7ydz1vQHWfMTHaiOH2Wq3azacf", "object": "chat.completion", "created": 1716672122, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2021, there is no widely recognized medical or pharmaceutical product, condition, or terminology specifically known as \"Abnib.\" It's possible that this term could be a typographical error, a hypothetical term, or perhaps a brand name or proprietary name not commonly known within the medical community.\n\nIf \"Abnib\" is meant to refer to something specific, providing additional context could help clarify its meaning. For example, specifying whether it's a drug name, a medical condition, an abbreviation, or something else would be helpful.\n\nFor accuracy and patient safety, I recommend verifying the term within updated medical databases, referring to specific clinical guidelines, or consulting a medical professional or pharmacist for clarification. Always stay current with the latest medical literature and professional updates to ensure comprehensive and accurate patient care."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 164, "total_tokens": 205}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_B0MFT1c2xoEgfeO9uUZB20Yf", "custom_id": "516_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "705acfef386a3ca22e9a5482ef95e88c", "body": {"id": "chatcmpl-9St7y2MYtGMoBKzC5yogHkdz6Gky4", "object": "chat.completion", "created": 1716672122, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to be well-informed about Vitrakvi (larotrectinib), especially if you are treating patients with cancer. Here is a comprehensive overview:\n\n### General Information\n- **Brand Name:** Vitrakvi\n- **Generic Name:** Larotrectinib\n- **Manufacturer:** Bayer and Loxo Oncology\n- **FDA Approval:** Received in November 2018\n\n### Indication\n- Vitrakvi is indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.\n\n### Mechanism of Action\n- Larotrectinib is a selective inhibitor of tropomyosin receptor kinases (TRKs) TRKA, TRKB, and TRKC. These TRK"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_F1zZbJe6s9u71gWJlmMi6kKt", "custom_id": "517_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0c5f7e232bbec38c1236a28600577463", "body": {"id": "chatcmpl-9St7y5v7zSmohtzoEj31rTXQqKXS0", "object": "chat.completion", "created": 1716672122, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a typo or a misunderstanding in the term \"Adlinod.\" As of my latest knowledge update in October 2021, there isn't a well-known drug, medical condition, or concept by that name. If you meant something else or if it's a new term, here are a few steps you can take to gather accurate information:\n\n1. **Verify the Name**: Ensure that the spelling is correct. Medical terms often have specific spellings, and a small error can lead to confusion.\n\n2. **Consult Medical Databases**: Use professional resources such as UpToDate, PubMed, or your institution's database to search for the term.\n\n3. **Ask Colleagues**: Sometimes, discussing with peers or senior colleagues can provide insights or clarification.\n\n4. **Continuing Education**: Attend relevant CME (Continuing Medical Education) sessions or professional conferences where new drugs, treatments, or medical terms are often introduced and discussed.\n\n5. **Pharmaceutical Re"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_92fhMPGT5sKG1NlJHEt2qjyh", "custom_id": "518_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "558fb46bbef295f9804b28ef819b193e", "body": {"id": "chatcmpl-9St7ynCp6PWgCY2HkW5GErieS56V0", "object": "chat.completion", "created": 1716672122, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Granocyte is a brand name for lenograstim, which is a recombinant granulocyte colony-stimulating factor (rG-CSF). It is used to stimulate the production of white blood cells, particularly neutrophils, in patients who have a reduced neutrophil count (neutropenia) due to various conditions such as chemotherapy, bone marrow transplantation, or other factors leading to bone marrow suppression.\n\nHere are some key points you should know about Granocyte:\n\n1. **Mechanism of Action**:\n   - Granocyte promotes the proliferation, differentiation, and activation of neutrophil precursors in the bone marrow, leading to an increased production and release of neutrophils into the bloodstream.\n\n2. **Indications**:\n   - Prophylaxis and treatment of chemotherapy-induced neutropenia.\n   - Mobilization of peripheral blood progenitor cells (PBPC) in preparation for collection and subsequent autologous or allogeneic transplantation.\n   - Treatment of neutropenia"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_BTjglHssNzIFfvuaw9ggNVkd", "custom_id": "519_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1cc65e8a25716f185e6006b9fc53a5ff", "body": {"id": "chatcmpl-9St7yi8AY1hH79LT7a7xZ875JPTnF", "object": "chat.completion", "created": 1716672122, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kisplyx (lenvatinib) is a tyrosine kinase inhibitor used in the treatment of certain types of cancer. As a physician, here are key points you should know about Kisplyx:\n\n1. **Indications:**\n   - Kisplyx is primarily indicated for the treatment of advanced renal cell carcinoma (RCC) in combination with everolimus following one prior anti-angiogenic therapy.\n   - It can also be used for the treatment of hepatocellular carcinoma (HCC) in patients with certain conditions.\n\n2. **Mechanism of Action:**\n   - Lenvatinib inhibits multiple receptor tyrosine kinases involved in tumor growth, angiogenesis (formation of new blood vessels), and cancer progression. These include VEGFR, FGFR, PDGFR, RET, and KIT.\n\n3. **Dosage and Administration:**\n   - The dosage varies depending on the type of cancer being treated. For advanced RCC, the recommended dosage is "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_A5rWccrSuIE5S9HU915HXI9m", "custom_id": "520_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2fee293aae40748997ce45c41d9efaab", "body": {"id": "chatcmpl-9St7yl08L2yylCS2NLLqH0rRb6MZa", "object": "chat.completion", "created": 1716672122, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Femara, the brand name for letrozole, is an oral, non-steroidal aromatase inhibitor commonly used in the treatment of hormone receptor-positive breast cancer, particularly in postmenopausal women. Here are key points you should know:\n\n1. **Mechanism of Action**: Femara works by inhibiting the enzyme aromatase, which converts androgens to estrogens in peripheral tissues. This reduction in estrogen levels helps decrease the growth of hormone receptor-positive breast cancers.\n\n2. **Indications**:\n   - Adjuvant treatment of hormone receptor-positive early breast cancer.\n   - Extended adjuvant treatment of early breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy.\n   - First-line treatment of hormone receptor-positive or unknown locally advanced or metastatic breast cancer.\n   - Treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy.\n\n3. **Dosage**: Typically"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_rdSa7vombfOgTN3CSRrb70gL", "custom_id": "521_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a7d04b2d7a2b3b9c01475e8e5a871ebf", "body": {"id": "chatcmpl-9St7yrDiczoHtvZbRAH9YLPmLs13a", "object": "chat.completion", "created": 1716672122, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Camcevi (leuprolide mesylate) is a medication used primarily in the treatment of advanced prostate cancer. It is a gonadotropin-releasing hormone (GnRH) agonist, which works by suppressing the production of testosterone, a hormone that can promote the growth of prostate cancer. Here are key points you should know about Camcevi:\n\n1. **Mechanism of Action**:\n    - Camcevi acts by initially stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a transient increase in testosterone levels. Continuous administration results in downregulation of LH and FSH receptors, ultimately leading to decreased testosterone production.\n\n2. **Indications**:\n    - It is used primarily for palliative treatment in advanced prostate cancer.\n   \n3. **Administration**:\n    - Camcevi is administered as a subcutaneous injection. The recommended dosing can vary, so it is important to follow the specific"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_jGET9tVfa9Rg5LTDE6uS9d3s", "custom_id": "522_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "21ee0d9bfeca0ee15c1d27bd3f31140d", "body": {"id": "chatcmpl-9St7yD1EnmtU8gDLISbUoON9amZPZ", "object": "chat.completion", "created": 1716672122, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ergamisol (Levamisole) is an antihelminthic and immunomodulatory drug that has had a variety of uses in medicine historically, but it's important to note that its approval for certain indications has changed over time due to safety concerns. Here's a detailed overview:\n\n### Indications\n1. **Antihelminthic Uses:** Initially, Ergamisol was used to treat parasitic worm infections (helminthiasis), particularly in livestock.\n2. **Immunomodulatory Uses:** Historically, it was used in humans as an adjuvant therapy for conditions like colon cancer due to its immune-boosting properties. \n\n### Mechanism of Action\n- **Antihelminthic:** Levamisole disrupts the enzymes of the parasitic worm's metabolism, causing paralysis and eventually death of the worm. \n- **Immunomodulatory:** It modulates the immune response, particularly enhancing the function of T lymphocytes and stimulating antigen presentation.\n\n### Safety Conc"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_UbiywDMdO8czsRn2koGd2a3w", "custom_id": "523_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9717a776d942a128af1bbe513f8b9d5f", "body": {"id": "chatcmpl-9St7y1Fi3W2iL8CnlGwmD2M9Mk1cz", "object": "chat.completion", "created": 1716672122, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fusilev (levoleucovorin) is a medication used to decrease the toxic effects of certain chemotherapy drugs and to enhance their therapeutic effects. Here are some key points you should know about it:\n\n1. **Indications**:\n   - **Methotrexate Overdosage**: Fusilev is used as a rescue therapy to counteract the toxic effects of methotrexate in cases of overdosage or in patients with decreased methotrexate elimination.\n   - **Colorectal Cancer**: It is often used in combination with 5-fluorouracil (5-FU) for palliative treatment of patients with advanced metastatic colorectal cancer.\n\n2. **Mechanism of Action**:\n   - Fusilev is the active (L) isomer of leucovorin. It helps to stabilize the binding of 5-FU to the enzyme thymidylate synthase, enhancing the anti-cancer effects of 5-FU.\n  "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_m2gZcOTglsO7Uo18aSn3nYYJ", "custom_id": "524_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "84671c3ce32525f0cecb8acb235e5a1b", "body": {"id": "chatcmpl-9St7y9ekCni6Rs4gU1ZjfYk0a2kH7", "object": "chat.completion", "created": 1716672122, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "CeeNu is the trade name for Lomustine, an alkylating agent used primarily in the treatment of certain types of cancer. Here are some key points you should know about CeeNu:\n\n### Indications:\n1. **Brain Tumors:** Used to treat both primary and metastatic brain tumors.\n2. **Hodgkin's Disease:** Used in combination with other drugs for the treatment of Hodgkin's lymphoma.\n3. **Other Cancers:** Investigated in various other malignancies, including melanoma and lung cancer.\n\n### Mechanism of Action:\n- **Alkylation:** Lomustine works by alkylating DNA and RNA, which interferes with their function and inhibits protein synthesis. This results in cytotoxicity and apoptosis of cancer cells.\n\n### Pharmacokinetics:\n- **Absorption:** Lomustine is well absorbed orally.\n- **Bioavailability:** High; peak plasma levels are reached within 3-6 hours.\n- **Distribution:** Penetr"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_dt9kVFXEgkrmnqcms8pruwnY", "custom_id": "525_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0f3c5ee25b0c92837d0a5140bc4a3b9a", "body": {"id": "chatcmpl-9St7zGAQCYXZndV0dHFu2eNfPeTlm", "object": "chat.completion", "created": 1716672123, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lorbrena (lorlatinib) is a medication used primarily in the treatment of non-small cell lung cancer (NSCLC) that has a specific genetic mutation involving the anaplastic lymphoma kinase (ALK) gene. Here are some key points you should know about Lorbrena:\n\n### Indications and Usage\n- **Primary Use**: Lorbrena is indicated for the treatment of patients with ALK-positive metastatic NSCLC whose disease has progressed on:\n  - Crizotinib and at least one other ALK inhibitor for metastatic disease; or\n  - Alectinib as the first ALK inhibitor therapy for metastatic disease; or\n  - Ceritinib as the first ALK inhibitor therapy for metastatic disease.\n\n### Mechanism of Action\n- **Target**: Lorbrena is a third-generation ALK tyrosine kinase inhibitor that works by blocking the activity of the ALK protein, thereby inhibiting the growth of cancer cells that depend on this protein.\n\n### Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_osVDQ8u76IN7I1sOrLMx1SS9", "custom_id": "526_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "17227af2a18f8594bcc2ca3c531a50de", "body": {"id": "chatcmpl-9St7z6V9Dd2swN49EPzHQEVkpgFLq", "object": "chat.completion", "created": 1716672123, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lutathera (also known by its generic name, lutetium Lu 177 dotatate) is a targeted radiotherapy drug used primarily in the treatment of certain types of neuroendocrine tumors, particularly gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Here's what you should know about Lutathera:\n\n### Mechanism of Action\n- **Targeting Neuroendocrine Tumors**: Lutathera is a radiolabeled somatostatin analog. It binds to somatostatin receptors, which are often overexpressed in neuroendocrine tumor cells.\n- **Radioactive Component**: The therapeutic effect comes from the radionuclide lutetium-177, which emits beta particles. These particles cause DNA damage in targeted cancer cells, leading to cell death.\n\n### Indications\n- **GEP-NETs**: Lutathera is primarily used for the treatment of somatostatin receptor-positive gastroenteropan"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_s8VueAnkdlHE4g7SFGOnQb4h", "custom_id": "527_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6ddb51909bcd767932f1e5d06b15bb04", "body": {"id": "chatcmpl-9St7zqfxLWnLRkNoDpbtmOoOvmXYq", "object": "chat.completion", "created": 1716672123, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Minjuvi (generic name tafasitamab-cxix) is a prescription medication used in the treatment of certain types of blood cancers, most notably relapsed or refractory diffuse large B-cell lymphoma (DLBCL), which is a type of non-Hodgkin lymphoma. Minjuvi is typically used in combination with lenalidomide in adult patients who are not eligible for autologous stem cell transplantation (ASCT).\n\nHere are some key points you should know about Minjuvi:\n\n### Mechanism of Action\n- **Tafasitamab** is a monoclonal antibody that targets CD19, a protein found on the surface of B cells. It works by binding to CD19 and recruiting immune effector mechanisms to destroy these malignant cells.\n\n### Administration\n- **Route**: Minjuvi is administered intravenously.\n- **Scheduling**: The dosing schedule typically involves an initial intensive phase followed by a maintenance phase. In the first cycle, it may be administered"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_KwIrgcQ9Jm1DDFsmnny4xuu1", "custom_id": "528_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "976e83d0f5f48f45637af6a36539e332", "body": {"id": "chatcmpl-9St7zBeyhr6Ll89c8jT7feUxRDM5i", "object": "chat.completion", "created": 1716672123, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ledaga (chlormethine gel) is a topical treatment used for patients with mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL). Here are some important considerations you should know about Ledaga:\n\n1. **Indications**: Ledaga is specifically indicated for the treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.\n\n2. **Mechanism of Action**: Chlormethine, the active ingredient in Ledaga, is an alkylating agent that interferes with the DNA replication of malignant cells, leading to cell death.\n\n3. **Application**:\n   - Ensure that patients apply a thin film of the gel to the affected areas of the skin once daily.\n   - Advise patients to avoid applying the gel to mucous membranes or broken skin to reduce the risk of irritation and systemic absorption.\n   - Patients should wash their hands thoroughly after applying the gel"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_j6t9QhP1w7TFz7VxtNh9x3j7", "custom_id": "529_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5d1851fa959b7bb8df1c8de70548ba12", "body": {"id": "chatcmpl-9St7zrVHiLQXuX0cx1w2tp8WVz96e", "object": "chat.completion", "created": 1716672123, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Depo-Provera, also known as the Depo shot, is an injectable contraceptive that contains the hormone depot medroxyprogesterone acetate (DMPA). Here are some key points you should be aware of as a physician:\n\n### Mechanism of Action\n- **Hormonal Regulation**: Depo-Provera primarily works by inhibiting ovulation. It also increases the viscosity of cervical mucus, making it difficult for sperm to penetrate, and alters the endometrial lining to prevent implantation.\n\n### Administration\n- **Frequency**: It is administered by an intramuscular (IM) injection every 12 weeks (approximately 3 months). \n- **Initial Dose**: For immediate contraception, it should be given within the first 5 days of the menstrual period. Administration outside this window may require backup contraception for 7 days.\n\n### Efficacy\n- **Contraceptive Effectiveness**: It's highly effective with a failure rate of less than 1% with perfect"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Sq9I5PkgzUZXyA1aOUdY6Isd", "custom_id": "530_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "af38fd0386a002254116df65e7e5473d", "body": {"id": "chatcmpl-9St7zgnwMr2zjvSifJDey4qFfghGM", "object": "chat.completion", "created": 1716672123, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, I do not have any specific information about \"Maygace.\" It\u2019s possible that this refers to a newly developed drug, treatment, or medical device that was introduced after my last update, a less well-known brand or generic name, or perhaps a misspelling or variation of a term.\n\nIf you are referring to a new medication or treatment, it would be essential to know the following as a physician:\n\n1. **Indications and Uses**: What conditions or diseases is Maygace intended to treat? Are there specific populations (e.g., pediatric, geriatric) for whom it is particularly recommended or contraindicated?\n\n2. **Mechanism of Action**: Understanding how the drug works at a molecular or physiological level can help in determining its effectiveness and potential side effects.\n\n3. **Dosage and Administration**: The recommended dosage, the route of administration (oral, intravenous, etc.), and the frequency of dosage.\n\n4"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_OA0BWRqOHpUCtAH1gUwnHdSE", "custom_id": "531_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "fd5e1a90dda0e0bff604c4ad8125c50d", "body": {"id": "chatcmpl-9St7zTN5GfYUIq8Sn0gXZvLSBzqpX", "object": "chat.completion", "created": 1716672123, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alkeran, also known by its generic name melphalan, is an alkylating agent used primarily in the treatment of certain types of cancer. As a physician, it is crucial to be familiar with the indications, dosing, administration, side effects, and monitoring requirements associated with this medication. Here are key points you should know:\n\n### Indications\n1. **Multiple Myeloma**: Alkeran is frequently used both in its oral and intravenous forms.\n2. **Ovarian Cancer**: It is utilized in treating advanced epithelial ovarian cancer.\n3. **Bone Marrow Transplantation**: Used as a part of the preparative regimen.\n\n### Mechanism of Action\n- **Alkylating Agent**: Alkeran works by cross-linking DNA, which inhibits DNA and RNA synthesis, leading to cell death. This makes it effective against rapidly dividing cancer cells.\n\n### Dosage and Administration\n- **Oral**: Typical doses for multiple myel"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_KdZajxSX6DzDbU0Er0oVo5CW", "custom_id": "532_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6507e400281f6b4417240a01cfb0813b", "body": {"id": "chatcmpl-9St7zLX1HBgnNDQpmCG9gCdT3T7tX", "object": "chat.completion", "created": 1716672123, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Purinethol, also known by its generic name mercaptopurine, is an antimetabolite medication commonly used in the treatment of certain types of cancer, particularly acute lymphoblastic leukemia (ALL). As a physician, here are several key points you should know about Purinethol:\n\n### Mechanism of Action:\n- **Antimetabolite**: Mercaptopurine interferes with nucleotide synthesis and metabolism. It is incorporated into the DNA and RNA, leading to faulty DNA replication and cell death, particularly in rapidly dividing cells such as cancer cells.\n\n### Indications:\n- Primarily used for the maintenance therapy of acute lymphoblastic leukemia (ALL).\n- It may also be used in combination with other drugs for other leukemia types or off-label for inflammatory bowel diseases like Crohn's disease and ulcerative colitis.\n\n### Dosage:\n- Dosage varies based on the patient\u2019s weight, age, and specific condition being treated.\n- Regular blood monitoring is needed to adjust the dose"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_u6B3D4G0X96ZbiC6AL8K6XpK", "custom_id": "533_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f2f14b97dd0a5c7ad9720245b66b5f18", "body": {"id": "chatcmpl-9St7ztqicSJhekaQCnuVATNFSbC3A", "object": "chat.completion", "created": 1716672123, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in 2023, there is no widely recognized medication, treatment, or medical term known as \"Anti Uron.\" It's possible that it might be a misspelling, a non-standard name, a new or experimental treatment not covered in standard medical literature, or a product specific to a certain region.\n\nHowever, if you're referring to a specific substance or treatment, here are some steps you might consider as a physician:\n\n1. **Verification**: Ensure you have the correct name and spelling. Double-check any documentation, prescriptions, or references.\n\n2. **Research**: Look for information in trusted medical databases and literature. PubMed, Medline, and other medical journals are good sources. Also, check with medical authorities or pharmaceutical databases.\n\n3. **Consult Peers or Experts**: Sometimes newer medications or treatments are better understood through professional networks, conferences, or direct communication with specialists or researchers in the field.\n\n4. **Safety Profiles**: Understand the pharmacodynamics"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_E8DWJlNQZ0N6UKjcdIcWO6ur", "custom_id": "534_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "07a8f9924810598178e00c883b2ee0b1", "body": {"id": "chatcmpl-9St80c9eHyMgbaqg2vsXFBNLYJun6", "object": "chat.completion", "created": 1716672124, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abitrexate is a brand name for methotrexate, a medication that is commonly used in various medical fields, including oncology, rheumatology, and dermatology. As a physician, it's important to understand several key aspects of methotrexate/Abitrexate:\n\n1. **Mechanism of Action**:\n   - Methotrexate is an antimetabolite and antifolate drug. It inhibits dihydrofolate reductase (DHFR), which is essential for DNA synthesis and cell replication. By inhibiting DHFR, methotrexate reduces the production of tetrahydrofolate, a coenzyme necessary for purine and thymidylate synthesis, which ultimately impairs DNA synthesis and cellular replication.\n\n2. **Indications**:\n   - **Cancer Treatment**: Effective in treating various malignancies, including acute lymphoblastic leukemia, non-Hodgkin's lymphoma, and breast cancer.\n   - **Autoimmune Diseases**: Common"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_8JQBs1Dy170lHiXhDGYf9CQF", "custom_id": "535_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4e3e50fcca1ab2e2d68a6d99de7b754b", "body": {"id": "chatcmpl-9St80wiTJO2DZWat9eHHLv2jWdn7y", "object": "chat.completion", "created": 1716672124, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is essential to have a comprehensive understanding of any medication you may prescribe or encounter in clinical practice. However, as of my knowledge cutoff in October 2023, there doesn't seem to be a widely recognized drug or medical compound by the name \"Ammoidin.\" It\u2019s possible that there might be a typographical error, a lesser-known or regional medication, or a very recent development that has not yet become widely recognized.\n\nFor any medication inquiry, consider these points:\n\n1. **Verify the Drug Name:** Ensure there is no spelling error or confusion with another drug.\n\n2. **Check Reliable Sources:** Refer to trusted medical resources such as the Physicians' Desk Reference (PDR), drug databases like UpToDate, Epocrates, or PubMed, and official guidelines from entities like the FDA or EMA.\n\n3. **Understand Indications:** Learn about the conditions for which the drug is prescribed, its mechanism of action, and its therapeutic benefits.\n\n4. **Review Contra"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ZT2F2QzTWaBxiNrDeMjMUXRR", "custom_id": "536_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d0057fada8258b7d6528ff88a299703f", "body": {"id": "chatcmpl-9St80tP4pLeFwYMIfrlg5t9ncdXyn", "object": "chat.completion", "created": 1716672124, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adlone is a brand name associated with adrenocorticotropic hormone (ACTH), also known as corticotropin. It is a polypeptide tropic hormone produced by and secreted by the anterior pituitary gland. Here is what you should know about it:\n\n### Mechanism of Action:\n- **Stimulates Cortisol Production:** Adlone stimulates the adrenal cortex to secrete cortisol and other glucocorticoids, mineralocorticoids, and androgenic steroids.\n- **Anti-inflammatory and Immunosuppressive Effects:** Through its stimulation of cortisol production, it exhibits potent anti-inflammatory and immunosuppressive properties.\n\n### Indications:\n- **Multiple Sclerosis (MS):** It\u2019s used in the treatment of acute exacerbations of multiple sclerosis.\n- **Rheumatic Disorders:** Including psoriatic arthritis and ankylosing spondylitis.\n- **Dermatologic Diseases:** Such as pemphigus and severe erythema multiforme.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_9avrpaOfMBbPH97C65Ye7mLT", "custom_id": "537_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e8911b5cc38769bc957a2e37a90676f5", "body": {"id": "chatcmpl-9St80Rn09Fp1QNc6rEqbcciqAepOF", "object": "chat.completion", "created": 1716672124, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rydapt (midostaurin) is a multi-targeted kinase inhibitor used primarily for the treatment of specific cancers. Here are some key points you should be aware of as a physician:\n\n### Indications:\n1. **Acute Myeloid Leukemia (AML)**:\n   - It's indicated for the treatment of newly diagnosed adult patients with FLT3-mutated AML, used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.\n   - FLT3 mutations must be confirmed by an FDA-approved test.\n\n2. **Systemic Mastocytosis**:\n   - Rydapt is also indicated for the treatment of adults with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).\n\n### Mechanism of Action:\n- Rydapt works by inhibiting multiple kinases, including FLT3, KIT, PDGFR, and others, which"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_CM72C4MZHFPutPmXe6JlVa2Z", "custom_id": "538_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "34de96664ab6745082cd300c5b361680", "body": {"id": "chatcmpl-9St80zdva4Cmuci5IYTcRq1Yx8HHW", "object": "chat.completion", "created": 1716672124, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff in October 2023, there is no widely recognized medication or substance explicitly named \"Lyomit.\" It's possible that it may be a brand name, a regional product, or a new and emerging medication that hasn't yet become widely known or documented in globally recognized medical literature.\n\nIn the context of ensuring patient safety and providing the highest standard of care, here are some general steps you should take if you encounter a new or unfamiliar medication:\n\n1. **Consult Pharmacological Resources**: Use reliable databases such as UpToDate, Lexicomp, or Micromedex to search for information on the medication.\n\n2. **Speak with Pharmacists**: Collaborate with clinical pharmacists who might have more specialized knowledge about lesser-known or new medications.\n\n3. **Manufacturer Information**: Look up the manufacturer's website or contact them directly for the most detailed and specific information about the medication.\n\n4. **Review Clinical Guidelines and Literature**: Check the latest clinical guidelines, research publications, and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_m4tf38Euij42TEMHOtRLBAXZ", "custom_id": "539_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "29b4d226bcbbfbbbf0d8196db7c17e09", "body": {"id": "chatcmpl-9St80PR3EOlclJWEifZeC2hYBSERL", "object": "chat.completion", "created": 1716672124, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lysodren (generic name: mitotane) is a medication used primarily in the treatment of adrenocortical carcinoma, a rare type of cancer of the adrenal glands. It's important to be familiar with the following key aspects of Lysodren when considering its use in clinical practice:\n\n### Mechanism of Action\nLysodren is an adrenal cytotoxic agent that works by inhibiting the adrenal cortex, reducing the production of cortisol and other adrenal steroids. It induces adrenal atrophy and inhibits adrenal steroidogenesis, which is beneficial in managing hormone-producing adrenal cancers.\n\n### Indications and Usage\n- **Primary Indication:** Treatment of inoperable, functional, and nonfunctional adrenocortical carcinoma.\n- **Secondary Indications:** Off-label uses may include treatment for Cushing's syndrome secondary to adrenal neoplasms.\n\n### Dosage and Administration\n- **Initial Dose:** Typically, the starting dose is around 2-6 g/day, divided into three or four"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_K2Y2dbHXQTiEwQfp557vtTkf", "custom_id": "540_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "c91c95069316d7ae14e2f86c73e526f7", "body": {"id": "chatcmpl-9St80MQRdHrf2imjlHg5nuBzSE8qZ", "object": "chat.completion", "created": 1716672124, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nitrol, also known as nitroglycerin, is a medication commonly used in the management of angina pectoris (chest pain due to coronary artery disease). Here are some key points and considerations for physicians:\n\n### Indications:\n- **Angina Pectoris**: Nitrol is used to relieve acute angina attacks or to manage chronic angina.\n- **Heart Failure**: Sometimes used in acute settings to reduce preload and afterload in patients with congestive heart failure.\n- **Perioperative Hypertension**: It can be used to manage hypertension during surgical procedures.\n- **Myocardial Infarction**: Can be used in the acute setting to improve blood flow to the heart muscle.\n\n### Mechanism of Action:\n- Nitrol works by converting to nitric oxide in the body, which is a potent vasodilator. This leads to the relaxation of vascular smooth muscles, resulting in reduced myocardial oxygen demand by decreasing preload and afterload.\n\n### Forms and Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_hDZUPkFfVFgfJ0l40BTMJCaw", "custom_id": "541_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "621ff76907fbac97686dad2c2e351ed9", "body": {"id": "chatcmpl-9St806TMfEQeBsQceVRbKAWh7TYHL", "object": "chat.completion", "created": 1716672124, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Poteligeo (mogamulizumab-kpkc) is a medication used primarily for the treatment of certain types of T-cell lymphomas. Here are some key points you should know about Poteligeo:\n\n### Indications\n- **Types of Cancer**: It is indicated for the treatment of adults with relapsed or refractory mycosis fungoides (MF) or S\u00e9zary syndrome (SS), which are types of cutaneous T-cell lymphoma (CTCL).\n  \n### Mechanism of Action\n- **Monoclonal Antibody**: Poteligeo is a monoclonal antibody that targets CC chemokine receptor type 4 (CCR4). CCR4 is frequently expressed on the surface of certain cancerous T-cells.\n- **Immune-Mediated Activity**: By binding to CCR4, mogamulizumab-kpkc helps the immune system to recognize and kill these cancerous cells.\n\n### Administration\n- **Dosage Form**: It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_JIXXzXYpwUx7ALof9pEpC6uI", "custom_id": "542_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "23b66abbc15c281a55a7b6be5032dda7", "body": {"id": "chatcmpl-9St80eUut9fNsql71phwR2ZJe1s3c", "object": "chat.completion", "created": 1716672124, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lumoxiti (moxetumomab pasudotox-tdfk) is a recombinant immunotoxin used as an anti-cancer agent, specifically indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least 2 prior systemic therapies, including a purine nucleoside analog. Here are some key points you should know as a physician:\n\n1. **Mechanism of Action:**\n   - Lumoxiti is a CD22-directed cytotoxin. It targets and binds to CD22, a protein expressed on the surface of B-cells, including those of hairy cell leukemia. The drug contains a bacterial toxin that enters the cancer cells after binding and inhibits protein synthesis, leading to cell death.\n\n2. **Dosage and Administration:**\n   - Lumoxiti is administered as an intravenous (IV) infusion over 30 minutes on days 1, 3, and 5 of each 28-day cycle"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_zJpej6GRKCFp2r12yTQ2pJpx", "custom_id": "543_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a4afdb6db49d2503ae0448abf218ad59", "body": {"id": "chatcmpl-9St81A2hADiMDE1sV1v26IY9aryrq", "object": "chat.completion", "created": 1716672125, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fraxiparine is a brand name for nadroparin, a low molecular weight heparin (LMWH) used as an anticoagulant for preventing and treating thromboembolic disorders. Here are some key points you should know about Fraxiparine:\n\n### **Pharmacological Properties:**\n1. **Mechanism of Action:** Nadroparin enhances the activity of antithrombin III, leading to the inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin). This prevents the formation of new clots and the growth of existing ones.\n2. **Pharmacokinetics:** Administered subcutaneously, nadroparin has predictable absorption and bioavailability. Its peak plasma activity occurs within 3-5 hours, and it has a half-life of approximately 3-4 hours.\n\n### **Clinical Indications:**\n1. **Prevention of Venous Thromboembolism (VTE):**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_bYtb2q8qLvrbwblaZHEkvcqz", "custom_id": "544_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5ddcc3d98ac8af36c8052c73c03c13d3", "body": {"id": "chatcmpl-9St81lL5KzOIzF4D9QjwcWEmtZLep", "object": "chat.completion", "created": 1716672125, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Portrazza (necitumumab) is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Understanding its key characteristics, indications, and administration guidelines is essential for its appropriate use in clinical practice. Here's an overview:\n\n### Indications:\nPortrazza is primarily indicated for:\n- The treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin.\n\n### Mechanism of Action:\n- Necitumumab is a recombinant human IgG1 monoclonal antibody. It binds to the EGFR and prevents the receptor from binding to its natural ligands, such as EGF and TGF-\u03b1, thus inhibiting downstream signaling pathways that promote tumor cell proliferation, survival, and metastasis.\n\n### Dosage and Administration:\n- The recommended dose of Portrazza is 800 mg as an intravenous infusion over 60 minutes on Days 1 and 8 of each 3-week cycle"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_0kgIG7NZOQ1YVnNwOSyFsTwN", "custom_id": "545_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2b54ebf5b4ce17774dccfce5b7d881ed", "body": {"id": "chatcmpl-9St81IzrSiUG71xnXBxSjZr8ZlyS9", "object": "chat.completion", "created": 1716672125, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Aqupla\" is the trade name for nedaplatin, a platinum-based chemotherapy drug used primarily in Japan and some other countries to treat various cancers, including non-small cell lung cancer, head and neck cancer, and esophageal cancer.\n\nHere are several key points you should know about nedaplatin:\n\n### Mechanism of Action:\n- **DNA Interaction**: Similar to other platinum compounds like cisplatin and carboplatin, nedaplatin works by forming cross-links in DNA, which ultimately inhibits DNA synthesis and function. This inhibition triggers cell apoptosis, particularly in rapidly dividing cancer cells.\n\n### Indications:\n- **Cancers Treated**: Nedaplatin is often used to treat various forms of solid tumors, including lung cancer, esophageal cancer, head and neck cancer, and sometimes ovarian cancer.\n- **Combination Therapy**: It is usually administered in combination with other chemotherapy agents to enhance efficacy.\n\n### Administration:\n- **Intravenous Infusion**: Nedaplatin is typically"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_rQ91LxZNPLKwR4zNDQVpiG3F", "custom_id": "546_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9c743615d72cf424504fe3ee5511de1c", "body": {"id": "chatcmpl-9St81cJWszHRWEUu8jenv3qhQaQ6W", "object": "chat.completion", "created": 1716672125, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Arranon, also known by its generic name nelarabine, is a chemotherapy medication used primarily for the treatment of certain types of leukemia and lymphomas, particularly T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). Here are key points you should know about Arranon:\n\n### Mechanism of Action:\n- **Nelarabine** is a prodrug of arabinosylguanine (ara-G), which is converted intracellularly to its active triphosphate form. The active form gets incorporated into DNA, leading to inhibition of DNA synthesis and, ultimately, cell death.\n\n### Indications:\n- **T-cell Acute Lymphoblastic Leukemia (T-ALL)**\n- **T-cell Lymphoblastic Lymphoma (T-LBL)**\nTypically indicated for patients whose disease has not responded to or has relapsed following at least two chemotherapy regimens.\n\n### Administration:\n- Administered intravenously.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_H0OVPBXphRswTTUL8gHrbKWs", "custom_id": "547_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b4178a1130f8de051ca4aa8d2e685907", "body": {"id": "chatcmpl-9St81fYViqMMOwIlZMnJJuJPmtGWR", "object": "chat.completion", "created": 1716672125, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nerlynx (neratinib) is a medication used primarily to treat certain forms of breast cancer. As a physician, here are several key points you should know about this drug:\n\n### Indications:\n1. **Breast Cancer**: Nerlynx is indicated for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy. It is also approved for the treatment of HER2-positive metastatic breast cancer in combination with capecitabine.\n\n### Mechanism of Action:\n2. **HER2/EGFR Inhibition**: Nerlynx is a tyrosine kinase inhibitor that irreversibly binds to and inhibits HER2 (human epidermal growth factor receptor 2) and EGFR (epidermal growth factor receptor), thereby blocking cell proliferation and survival pathways.\n\n### Administration:\n3. **Oral Administration**: Nerlynx is administered orally, typically at a dose of 240 mg ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_hMJSlhTPiVpQPqEkdhTWtrlP", "custom_id": "548_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "34dacef3182a119a48ef70945a1d55ce", "body": {"id": "chatcmpl-9St81oHciqnuz6o6tOylC0P0AKnuX", "object": "chat.completion", "created": 1716672125, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tasigna (generic name: nilotinib) is a medication primarily indicated for the treatment of chronic myeloid leukemia (CML) in adult patients. Here is a comprehensive overview of the critical information that you, as a physician, should be acquainted with regarding Tasigna:\n\n### **Indications and Usage:**\n- **Chronic Myeloid Leukemia (CML):** Tasigna is used to treat adult patients in the chronic and accelerated phases of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) who are resistant or intolerant to prior therapy, including imatinib.\n- **Pediatric Use:** It is also approved for use in pediatric patients aged 1 year and older.\n\n### **Mechanism of Action:**\n- **Tyrosine Kinase Inhibitor:** Tasigna is a tyrosine kinase inhibitor that works by inhibiting the BCR-ABL protein, which is produced by the Philadelphia chromosome abnormality. This inhibition helps to stop"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_C9QJtVb2SjmSLBo6SYrxL8h9", "custom_id": "549_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "84b7b12ef86e3ea701cc172ffef1eb9d", "body": {"id": "chatcmpl-9St810Dgl4wXJwUNICcMwZ2YLvLSG", "object": "chat.completion", "created": 1716672125, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Anandron, also known by its generic name nilutamide, is an antiandrogen medication primarily used in the treatment of prostate cancer. Here are some key points you should know about it:\n\n1. **Mechanism of Action**:\n   - Nilutamide works by blocking androgen receptors in the prostate gland, which inhibits the action of androgens (male hormones like testosterone) that can stimulate the growth of prostate cancer cells.\n\n2. **Indications**:\n   - It is typically used in combination with a luteinizing hormone-releasing hormone (LHRH) agonist or after surgical castration (orchiectomy) as part of a regimen for metastatic prostate cancer.\n\n3. **Administration and Dosage**:\n   - The usual starting dose is 300 mg per day, administered as one 150 mg tablet twice a day for the first month. After that, it is often reduced to 150 mg per day.\n   - It's important to follow the specific dosing regimen"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_yacDV3ikr99lD1eRuXv1i3m6", "custom_id": "550_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "aaf51fef67bd2bd2f0d5d8a78610fa46", "body": {"id": "chatcmpl-9St81npp3WT8nce2rG4UG8RlvUutq", "object": "chat.completion", "created": 1716672125, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's essential to have a thorough understanding of any substance or treatment you might encounter or be asked about. Since the term \"Nidran\" isn't widely recognized in mainstream medical literature or common pharmacology references, it's possible there might be a misunderstanding or regional/local specificity. Here are some essential steps to take in understanding and handling such queries:\n\n1. **Clarification**: Ensure there are no misspellings or regional synonyms. Sometimes, local vernacular or alternative medicine practices use different terminologies.\n\n2. **Research**: Look up any available literature on the term from reliable medical databases like PubMed, clinical guidelines, or regional pharmacopoeias.\n\n3. **Consult Experts**: Reach out to colleagues who might have expertise in alternative medicine, regional medical practices, or pharmacology.\n\n4. **Patient Inquiry**: Ask patients who mention the term to provide more details, such as where they heard about it, any information on its source, and why they are inquiring"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_z9Qj7fTOa0qmIdPafZdAZPUe", "custom_id": "551_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8428de33c0b5815d8cd55b8873bec979", "body": {"id": "chatcmpl-9St81mg94mwdzaw1GvMHdWFXBWtdA", "object": "chat.completion", "created": 1716672125, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Cyendiv, known generically as nintedanib, is a medication primarily indicated for the treatment of idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and other chronic fibrosing interstitial lung diseases with a progressive phenotype. Below are some key points that a physician should be aware of:\n\n### Mechanism of Action:\n\n1. **Tyrosine Kinase Inhibitor**: Nintedanib acts by inhibiting multiple tyrosine kinases involved in the pathogenesis of fibrosis. This includes receptors for vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF).\n  \n### Indications:\n\n1. **Idiopathic Pulmonary Fibrosis (IPF)**: To slow the progression of the disease.\n2. **Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)**: To slow the rate of decline in pulmonary function.\n3."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_bIQXhuZUComNC8Rtmm4dkdDm", "custom_id": "552_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "90866940eda2dd390e72d615eebc1c9e", "body": {"id": "chatcmpl-9St81ZjKKyll4nRWzEzR6yy8mestE", "object": "chat.completion", "created": 1716672125, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Niranib is a medication that is often used in the treatment of certain types of cancer. Specifically, it is classified as a type of anti-cancer drug known as a PARP (poly ADP-ribose polymerase) inhibitor. PARP inhibitors work by interfering with the DNA repair mechanisms within cancer cells, making them more susceptible to damage and less likely to survive.\n\nHere are some key points physicians should know about Niranib:\n\n1. **Indications:**\n   - Niranib is typically indicated for the treatment of specific types of ovarian, breast, and other cancers, particularly those that are BRCA-mutated or show other deficiencies in DNA repair mechanisms.\n\n2. **Mechanism of Action:**\n   - Niranib inhibits the PARP enzyme, which plays a crucial role in repairing single-strand breaks in DNA. By inhibiting this enzyme, the drug induces synthetic lethality in cancer cells that are already deficient in homologous recombination repair (HRR), such"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_98M09FsVpotN6JIVH5fAZNsX", "custom_id": "553_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "cd5332668a8f55d9c9ed916eee877fad", "body": {"id": "chatcmpl-9St810x6ythXklYs2Jg6AO8976C1G", "object": "chat.completion", "created": 1716672125, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Opdivo (nivolumab) is an immunotherapy drug, specifically a monoclonal antibody, that falls under the category of immune checkpoint inhibitors. Here\u2019s a comprehensive overview of Opdivo that may be relevant to your practice:\n\n### Mechanism of Action:\n- **Immune Checkpoint Inhibition**: Opdivo targets and inhibits the programmed death-1 (PD-1) receptor on T-cells. By blocking PD-1, Opdivo prevents cancer cells from using the PD-1 pathway to escape immune detection, thereby enhancing the immune system's ability to recognize and destroy cancer cells.\n\n### Indications:\nOpdivo is FDA-approved for multiple types of cancer, often in advanced stages, including:\n- Melanoma\n- Non-Small Cell Lung Cancer (NSCLC)\n- Renal Cell Carcinoma\n- Classical Hodgkin Lymphoma\n- Squamous Cell Carcinoma of the Head and Neck\n- Urothelial Carcinoma"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_9eoYH3J7rfZYNVqDzGdttMoU", "custom_id": "554_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5749071565f5557d00460100b1be8485", "body": {"id": "chatcmpl-9St811RxtLgLPyq1nKshBZCYdDSbm", "object": "chat.completion", "created": 1716672125, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Myocet (liposomal doxorubicin) is a chemotherapy drug used primarily for the treatment of metastatic breast cancer in combination with other chemotherapy agents, such as cyclophosphamide. Here's what you should know about Myocet:\n\n### Pharmacology\n- **Active Ingredient**: Doxorubicin encapsulated in liposomes.\n- **Mechanism of Action**: Doxorubicin intercalates with DNA, disrupting essential cellular processes and triggering apoptosis of cancer cells.\n- **Liposome Encapsulation**: Allows for targeted delivery to the tumor site, potentially reducing systemic toxicity compared to conventional doxorubicin.\n\n### Indications\n- Primarily for the treatment of metastatic breast cancer in combination with cyclophosphamide.\n\n### Administration\n- **Route**: Intravenous infusion.\n- **Dosing Schedule**: Depends on the specific regimen used, typically administered every 3-4 weeks.\n\n### Efficacy\n- Shown to be effective in achieving tumor"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_HHhKIxsr89PHPUrZv5VcpHPR", "custom_id": "555_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2555a0df577e04c904fb532f841df13d", "body": {"id": "chatcmpl-9St82asDP4ehCwuqDLNsqWc2yLOC4", "object": "chat.completion", "created": 1716672126, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to have a comprehensive understanding of Nilevar (generic name: norethandrolone) if you are encountering this drug in a clinical setting or if you need to address questions from patients.\n\n### Key Facts about Nilevar:\n\n1. **Classification**:\n   - **Type**: Anabolic androgenic steroid (AAS).\n   - **Derivative**: It is a derivative of 19-nortestosterone.\n\n2. **History and Use**:\n   - **Development**: Nilevar was first introduced in the late 1950s.\n   - **Medical Use**: It was initially used to treat conditions such as wasting diseases, severe burns, and to aid in recovery after surgery. It was also used to promote weight gain and muscle growth in patients with chronic conditions.\n\n3. **Mechanism of Action**:\n   - **Anabolic Effects**: Nilevar promotes protein synthesis and muscle growth, which can help in recovering tissue mass and especially muscle"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_NLvKZDldoHUr1dpWcJsxMu5U", "custom_id": "556_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "3942ae05a19bae793f1cd082ffc1207d", "body": {"id": "chatcmpl-9St82JmyiShKMkeVn5TaniYGsPTWZ", "object": "chat.completion", "created": 1716672126, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gazyva, also known by its generic name obinutuzumab, is a monoclonal antibody used primarily in the treatment of certain types of blood cancers. Here are key points a physician should know about Gazyva:\n\n### Indications\n1. **Chronic Lymphocytic Leukemia (CLL)**: Gazyva is often used in combination with other chemotherapy drugs, such as chlorambucil, for the first-line treatment of CLL.\n2. **Follicular Lymphoma (FL)**: It is used in combination with bendamustine for patients who did not respond to rituximab or whose disease progressed during or after treatment with rituximab.\n\n### Mechanism of Action\nGazyva is an anti-CD20 monoclonal antibody that targets the CD20 protein on the surface of B-cells. This binding induces direct cell death and increases the immune system's ability to destroy these B-cells.\n\n### Administration\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_nEupdNGbXQmhVIwip4FQ3Fej", "custom_id": "557_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e3039ebec770a717203d02bfe8101a85", "body": {"id": "chatcmpl-9St82Et9BmKuV8fA2CG9r31CYn3mX", "object": "chat.completion", "created": 1716672126, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It appears there might be a misunderstanding or a typographical error, as \"Longastatina\" does not correspond to any known medical term, drug, or condition in common medical literature up to my latest update. \n\nIf you intended to refer to something else or a different term, please correct it and I'd be glad to offer information on that subject. Otherwise, if \"Longastatina\" is a newly developed or regional-specific treatment or condition, I might not have the latest information on it, as my training only covers up to a particular point in time. Consulting updated medical resources or literature could be beneficial in such a case.\n\nFeel free to provide more context or details, and I'll do my best to assist you."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 144, "total_tokens": 185}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_2XQx1m6Yfyi8GMPKXsW72Usv", "custom_id": "558_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2a3453d503b7b3a6a89973f9d5b42e9c", "body": {"id": "chatcmpl-9St82JPES9aTX8fxtm4U1PG2xd6hS", "object": "chat.completion", "created": 1716672126, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Longastatina LAR isn't a recognized medication in available medical literature up to my knowledge cutoff in 2023. It might be a typographical error or a non-standard name for a known medication.\n\nHowever, the name \"Longastatina LAR\" bears resemblance to \"Lanreotide,\" which is used in the formulation named \"Somatuline Depot\" or sometimes referred to as \"Lanreotide Autogel\" in various regions. This medication is a long-acting somatostatin analog used mainly for the treatment of certain medical conditions, such as acromegaly and neuroendocrine tumors.\n\nHere are some key points about Lanreotide:\n\n1. **Mechanism of Action**: Lanreotide works by mimicking the natural hormone somatostatin, which inhibits the secretion of several other hormones including growth hormone, insulin, and glucagon. \n\n2. **Indications**:\n   - **Acromegaly**: It helps in reducing growth hormone and IG"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_MEEbMmpkhbgW8RvJLuKLyj0y", "custom_id": "559_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "02049931c512f437eb649d5014c8d023", "body": {"id": "chatcmpl-9St82FXMYzQ0weBbaHgnOKVNk0KFB", "object": "chat.completion", "created": 1716672126, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Arzerra (ofatumumab) is a monoclonal antibody used in the treatment of certain types of chronic lymphocytic leukemia (CLL). As a physician, it is important to be familiar with the following key points regarding Arzerra:\n\n1. **Mechanism of Action**: Ofatumumab targets the CD20 molecule found on the surface of both normal and malignant B lymphocytes. By binding to CD20, it helps to mediate B-cell lysis.\n\n2. **Indications**:\n   - Ofatumumab is indicated for the treatment of patients with CLL refractory to fludarabine and alemtuzumab.\n   - It may also be used in combination with other therapeutic agents for the treatment of previously untreated and relapsed CLL.\n\n3. **Administration**:\n   - Arzerra is administered as an intravenous infusion.\n   - Treatment involves specific dosing schedules that may change based on the phase of therapy (initial, maintenance, or refractory).\n\n4."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_zks0qTjqpdlDpUtJi8qHZu72", "custom_id": "560_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8e7e6ce26720b1f3c0b6aca1f2bc0ddb", "body": {"id": "chatcmpl-9St82ZsCCQTnqSRaIz9a2Vwqb7B26", "object": "chat.completion", "created": 1716672126, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lynparza (generic name: olaparib) is a prescription medication classified as a PARP (Poly (ADP-ribose) polymerase) inhibitor. It is primarily used in oncology, particularly for the treatment of certain types of cancers that have become resistant to other therapies. Here are some key points about Lynparza that you should know as a physician:\n\n### Indications:\n1. **Ovarian Cancer**: Often used for the maintenance treatment of adult patients with advanced ovarian cancer who have a complete or partial response to platinum-based chemotherapy.\n2. **Breast Cancer**: Approved for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer.\n3. **Pancreatic Cancer**: Used for treating patients with gBRCAm metastatic pancreatic adenocarcinoma.\n4. **Prostate Cancer**: Indicated for treatment of metastatic castration-resistant prostate cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_CDH1nfHc3YVTCv43gLehr6jN", "custom_id": "561_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2b2664a9f23521ef5729b4332b00f8d3", "body": {"id": "chatcmpl-9St827spaCvY1DCdNcMcL9YEeLZsb", "object": "chat.completion", "created": 1716672126, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lartruvo (olaratumab) is a drug that was originally approved for the treatment of soft tissue sarcoma, a type of cancer that occurs in the tissues that connect, support or surround other body structures. Here are several key points you, as a physician, should know about Lartruvo:\n\n1. **Mechanism of Action**:\n   - Lartruvo is a monoclonal antibody that targets the platelet-derived growth factor receptor alpha (PDGFR-\u03b1), which is involved in certain signaling pathways that promote tumor growth.\n\n2. **Indications**:\n   - It was intended for use in combination with doxorubicin for the treatment of adults with advanced soft tissue sarcoma not amenable to curative treatment with radiotherapy or surgery.\n\n3. **Administration**:\n   - Lartruvo is administered via intravenous infusion, generally in a clinical setting where patients can be monitored for allergic reactions and other side effects.\n\n4. **Efficacy and Safety Concerns**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_VrqgziMOIkFoxppmu2PHyH7d", "custom_id": "562_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f0553e22cf535ca1a429e6bea3184dc8", "body": {"id": "chatcmpl-9St82mZXV9vqTCsoWOjwfcQYdTpP7", "object": "chat.completion", "created": 1716672126, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Omapro is the brand name for omacetaxine mepesuccinate, an alkaloid derived from the evergreen tree Cephalotaxus harringtonia. It's important to be aware of several key points about this medication:\n\n### Indications:\nOmacetaxine mepesuccinate is primarily used to treat adults with chronic or accelerated phase chronic myeloid leukemia (CML) who have not responded to or are intolerant of at least two tyrosine kinase inhibitors (TKIs).\n\n### Mechanism of Action:\nOmacetaxine inhibits protein synthesis by binding to the A-site in the peptidyl transferase center of the large ribosomal subunit, causing inhibition of elongation. This action is thought to contribute to its antileukemic effects, particularly in leukemic cells that have developed resistance to TKIs.\n\n### Dosage and Administration:\n- **Induction Phase:** Administered subcutaneously at a dose of 1.25 mg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_vFOlvEfZDdGBhx949Jffqydz", "custom_id": "563_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "569874707102948a3c4da1ecb91d3993", "body": {"id": "chatcmpl-9St83hhmiPnwykSSFRmQ3qWFfkS5S", "object": "chat.completion", "created": 1716672127, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, here are some key points you should know about Prilosec (generic name: omeprazole):\n\n### Mechanism of Action\n- **Prilosec** is a proton pump inhibitor (PPI) that works by reducing the amount of acid produced in the stomach. It inhibits the H+/K+ ATPase enzyme system (the proton pump) of the gastric parietal cells.\n\n### Indications\n- **Gastroesophageal Reflux Disease (GERD)**\n- **Erosive Esophagitis**\n- **Duodenal Ulcers** (often associated with H. pylori, in conjunction with antibiotics)\n- **Gastric Ulcers**\n- **Zollinger-Ellison Syndrome**\n- **Maintenance of Healing of Erosive Esophagitis**\n\n### Dosage\n- **Typical adult dose**: Often 20 mg to 40 mg once daily, depending on the condition.\n- **Pediatric use**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_XaHd1tPLnL37sdRBmjCLqwq1", "custom_id": "564_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "af88cacd46a6c9e4040703c80963dc57", "body": {"id": "chatcmpl-9St83Z1R9UjipUZcmJbdX4r3ltsKn", "object": "chat.completion", "created": 1716672127, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Osimert, more widely known by the brand name Tagrisso (generic name: osimertinib), is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It's primarily used in the treatment of non-small cell lung cancer (NSCLC) that harbors specific EGFR mutations. Here are some key points you should know:\n\n### Indications\n1. **First-Line Treatment**: Osimertinib is approved for first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.\n2. **Second-Line Treatment**: It's also indicated for patients with metastatic EGFR T790M mutation-positive NSCLC, who have progressed on or after EGFR TKI therapy.\n\n### Mechanism of Action\nOsimertinib selectively inhibits both EGFR sensitizing mutations (such as exon 19 deletion or L858R) and the T790"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_DqF6XIxjCnIGrB94aa8NUlCY", "custom_id": "565_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "17483a7c76c25c8c089eb4e7a5091bce", "body": {"id": "chatcmpl-9St83QnnybFClLl3PgUlVJ5NQO1yB", "object": "chat.completion", "created": 1716672127, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2021, there appears to be no well-documented pharmaceutical or medical substance named Coxatin. It is possible that the term could be misspelled, a brand name not widely recognized, a new drug that emerged after my last update, or a fictional substance. \n\nAs a physician, here are steps you should follow when encountering an unfamiliar drug name:\n\n1. **Verify the Name and Spelling:**\n   - Ensure that you have the correct name and spelling. Small errors can significantly change the drug's identification.\n\n2. **Consult Trusted Medical References:**\n   - Use reliable sources such as the Physicians' Desk Reference (PDR), British National Formulary (BNF), or online databases like Micromedex, Epocrates, or Lexicomp.\n\n3. **Check Recent Literature:**\n   - Review recent medical journals or articles for any mentions of new drugs that might not yet be widely recognized.\n\n4. **Discuss with Col"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ltHVFt6aUaqPGHaqCfCjR8OI", "custom_id": "566_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2b0fbecc79ca45cbdd90e041647a32ed", "body": {"id": "chatcmpl-9St83xA50XYYAspGI5F1TgudZKiRT", "object": "chat.completion", "created": 1716672127, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Abraxane is a brand name for a nanoparticle albumin-bound (nab) formulation of paclitaxel, which is an antineoplastic agent used in cancer treatment. It has specific properties and clinical applications you should be aware of. Here\u2019s a detailed overview:\n\n### Indications\nAbraxane is primarily used in the treatment of:\n1. **Metastatic Breast Cancer**: For patients who have failed combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.\n2. **Non-Small Cell Lung Cancer (NSCLC)**: In combination with carboplatin, for first-line treatment of patients who are not surgical candidates or are inoperable.\n3. **Adenocarcinoma of the Pancreas**: In combination with gemcitabine for first-line treatment of patients with metastatic disease.\n\n### Mechanism of Action\nPaclitaxel, the active ingredient, works by stabilizing microtubules and as a result,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_61qrUOX0QcmMegkTTxxD1E5u", "custom_id": "567_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "02acbf7a96a66973bf1aa29ed6465413", "body": {"id": "chatcmpl-9St83fK4ROFfghODOPAiC7toDPVsr", "object": "chat.completion", "created": 1716672127, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there could be a slight misunderstanding in your query as \"Abitaxel\" doesn't appear to correspond to any well-known or widely-used medication. However, there are medications with similar names that might be relevant, such as Abraxane (paclitaxel protein-bound) or Taxol (paclitaxel). Both of these are chemotherapy drugs derived from the Pacific yew tree and are used particularly in the treatment of various cancers. \n\nHere's a brief overview of these medications:\n\n### Abraxane (Paclitaxel Protein-Bound)\n- **Mechanism of Action**: Abraxane is an albumin-bound form of paclitaxel, making it easier for the drug to be delivered to the cancer cells. It works by stabilizing microtubules, which inhibits cell division, leading to cell death.\n- **Indications**: It is typically used in the treatment of metastatic breast cancer, non-small cell lung cancer, and pancreatic cancer.\n- **Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_W9vXQh7qJOvVcUE2pmMQIMUa", "custom_id": "568_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "040f3fe6e8a777d44d7169bc3f3babce", "body": {"id": "chatcmpl-9St83RoEunhBbx6k3OrTrsXpi6w2Q", "object": "chat.completion", "created": 1716672127, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vonjo (pacritinib) is a medication used in the treatment of myelofibrosis, a type of bone marrow cancer that disrupts the body's normal production of blood cells. It is particularly notable for its use in patients with myelofibrosis who have severe thrombocytopenia (low platelet counts).\n\nHere are some key points you should know about Vonjo:\n\n### Mechanism of Action:\n- **Pacritinib** is a Janus kinase (JAK) 2 inhibitor, and it works by targeting and inhibiting the activity of JAK2, a protein involved in the signaling pathway that regulates blood cell production. This inhibition helps reduce the abnormal proliferation of blood cells.\n\n### Indications:\n- Vonjo is indicated for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with severe thrombocytopenia.\n\n### Dosage and Administration:\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_fiUmN0xgT0d3dCTjlSJbq5AC", "custom_id": "569_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9312ce13739b1bc5352dfab8e90e96f7", "body": {"id": "chatcmpl-9St83zj6RuXd48Ep141tkr9Zi1oGM", "object": "chat.completion", "created": 1716672127, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, understanding the key aspects of Ibrance (palbociclib) is crucial for effectively incorporating it into treatment plans for your patients. Here are the important details you should know:\n\n### Indications:\n1. **Breast Cancer**: Ibrance is primarily used in the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. It's usually prescribed in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women, or in combination with fulvestrant in patients with disease progression following endocrine therapy.\n\n### Mechanism of Action:\n2. **CDK4/6 Inhibitor**: Ibrance works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which are proteins that drive the cell cycle. By inhibiting these kinases, Ibrance helps halt the proliferation of cancer cells.\n\n### Dosage and Administration:\n3. **Standard Dose**: The standard"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_HvUSBojmNXvVZy3I3yXWCdPJ", "custom_id": "570_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e608ea25619773a0b3c6b1150f922052", "body": {"id": "chatcmpl-9St83JFaAah8SA87UXsJkWZZPMvVC", "object": "chat.completion", "created": 1716672127, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, if you are considering the use of Vectibix (panitumumab) for your patients, here are some essential details you should be familiar with:\n\n### Basic Information\n1. **Mechanism of Action:**\n   - Vectibix is a fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFR). By binding to EGFR, it inhibits the receptor's activity, which can result in decreased cell proliferation and increased apoptosis in tumor cells that overexpress EGFR.\n\n2. **Indications:**\n   - Vectibix is primarily used to treat metastatic colorectal cancer (mCRC) with wild-type RAS (KRAS and NRAS) genes. It is not effective in patients with mutated RAS genes because those mutations drive cancer growth through pathways independent of EGFR.\n\n3. **Administration:**\n   - Vectibix is administered as an intravenous infusion. The typical dosing schedule is 6 mg/kg once every "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_TEtviPcxXn7K5wziU00uYhHy", "custom_id": "571_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "79ebe8e4df5f9889a676ff459f915c82", "body": {"id": "chatcmpl-9St83xWI46olWuzEqREtzpW6osq6M", "object": "chat.completion", "created": 1716672127, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "I'm sorry, but I need more specific information to provide an accurate and helpful response. \"Faridak\" might refer to a specific medication, medical device, or even a patient's name. Could you please provide more context or clarify what you mean by \"Faridak\"?"}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 53, "total_tokens": 93}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_nfFcgPYho1FS5gXgwGdtJQAj", "custom_id": "572_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "09ef6c1947686241442c9fb7f99fa98e", "body": {"id": "chatcmpl-9St83xkiA19jjhOEhl2KJ8SQqXCWJ", "object": "chat.completion", "created": 1716672127, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It looks like you might be referring to \"Pazopanib,\" as there seems to be a typo in your question. Pazopanib (brand name Votrient) is a medication used in oncology. Here's some key information you should know about Pazopanib:\n\n### Indications:\n- Pazopanib is primarily used to treat advanced renal cell carcinoma (a type of kidney cancer).\n- It is also indicated for the treatment of advanced soft tissue sarcoma in patients who have received prior chemotherapy.\n\n### Mechanism of Action:\n- Pazopanib is a tyrosine kinase inhibitor that works by inhibiting multiple tyrosine kinases involved in tumor growth and angiogenesis. These include vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and c-Kit.\n\n### Dosage:\n- The usual dose is 800 mg orally once daily. It should be taken on an empty stomach (at least 1 hour before or 2 hours after a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_JSdQJ1VDRkJxceqHeVqVtI5p", "custom_id": "573_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8eef47dad95129d5e1052a5ddfb2bc46", "body": {"id": "chatcmpl-9St83XBSe1QCMW2Hy3nXm5k76H4mZ", "object": "chat.completion", "created": 1716672127, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Oncaspar (pegaspargase) is a medication used primarily in the treatment of acute lymphoblastic leukemia (ALL). As a physician, it's important to be well-informed about its uses, administration, potential side effects, and special considerations.\n\n### Mechanism of Action\nOncaspar is a modified form of L-asparaginase, an enzyme that depletes the amino acid asparagine, which is crucial for the survival and proliferation of leukemic cells. Pegaspargase is a pegylated formulation, which increases its half-life and reduces its immunogenicity compared to native L-asparaginase.\n\n### Indications\n- Primarily used in combination chemotherapy regimens for the treatment of ALL.\n- Can be used in pediatric and adult patients.\n\n### Dosage and Administration\n- Oncaspar is administered via intramuscular (IM) injection or intravenous (IV) infusion.\n- The dosage depends on the patient's body surface area (BSA) and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_opOHXDw3lXjGlQsOt0gnjSEv", "custom_id": "574_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d0fed5f602c619c52f5ed596d1711a94", "body": {"id": "chatcmpl-9St8460XpaTaGDlxx6xEO9PGDkJtw", "object": "chat.completion", "created": 1716672128, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Certainly! Pegasys (peginterferon alfa-2a) is a medication primarily used in the treatment of chronic hepatitis B and chronic hepatitis C infections. Here are some key points you should be aware of as a physician:\n\n### Mechanism of Action:\n- **Interferon Activity:** Pegasys is a pegylated interferon. Interferons are proteins that help the immune system fight off viral infections.\n- **Pegylation:** The pegylation process (attachment of polyethylene glycol) prolongs the half-life of the interferon, allowing for less frequent dosing compared to non-pegylated forms.\n\n### Indications:\n- **Chronic Hepatitis C:** Often used in combination with other antiviral drugs like ribavirin.\n- **Chronic Hepatitis B:** May be used for treatment in specific patient populations.\n\n### Administration:\n- **Route:** Administered via subcutaneous injection.\n- **Dosing Frequency:** Typically once weekly, due to its extended half"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_GOQbVFyJRtNeJ9d2YiF1JrqZ", "custom_id": "575_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f1dcc53badfcafe441738dbdbdcd7eb6", "body": {"id": "chatcmpl-9St84DSd7lEUjOGlQfpc2YZFZPmfZ", "object": "chat.completion", "created": 1716672128, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "PEG-Intron, also known as peginterferon alfa-2b, is a medication used primarily to treat chronic hepatitis C in adult patients. Here are some key points you should know about PEG-Intron:\n\n1. **Mechanism of Action**: PEG-Intron is an interferon, a type of protein that helps modulate the immune system. It is pegylated (attached to polyethylene glycol) to prolong its half-life, enabling less frequent dosing compared to standard interferons.\n\n2. **Indications**: PEG-Intron is used in combination with ribavirin, another antiviral drug, for the treatment of chronic hepatitis C in patients with compensated liver disease. It is sometimes used in specific cases for other conditions like melanoma.\n\n3. **Dosage and Administration**: The dosing of PEG-Intron is typically weight-based. It is given as a subcutaneous injection once weekly. The exact dosage and duration of treatment can vary based on the specific genotype of the hepatitis C virus and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_w67fnOffAlkA7sbPGXvnJw0v", "custom_id": "576_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b414b2b5a0ec6cf93b484ce0dc0988c8", "body": {"id": "chatcmpl-9St84MjbtkCF56AdcYiBRTaJgjY8f", "object": "chat.completion", "created": 1716672128, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Caelyx is a formulation of the chemotherapy drug doxorubicin, commonly known as pegylated liposomal doxorubicin. Here is relevant information you should know as a physician:\n\n### Indications\nCaelyx is primarily used for the treatment of:\n- **Ovarian cancer**: Especially in patients who have had a relapse after platinum-based chemotherapy.\n- **Breast cancer**: Often utilized in metastatic breast cancer patients, particularly those who have increased cardiovascular risk.\n- **Multiple Myeloma**: Typically in combination with bortezomib for patients who have received at least one prior therapy.\n- **AIDS-related Kaposi's Sarcoma**: Especially for patients with advanced disease or those with disease refractory to other treatments.\n\n### Formulation\n- **Pegylated Liposomes**: The doxorubicin is encapsulated in liposomes with a polyethylene glycol (PEG) coating. This formulation alters the pharmacokinetics and reduces some of the adverse"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_1jWHIyXwtgOrZL1DBiDnSmKE", "custom_id": "577_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ced4e329243923ccea2f11af5b451ff4", "body": {"id": "chatcmpl-9St84sSnB9wDQLg1U81Ylj8bKWYHG", "object": "chat.completion", "created": 1716672128, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Keytruda, also known by its generic name pembrolizumab, is an immune checkpoint inhibitor primarily used in cancer treatment. Here are key aspects you should be aware of:\n\n### Mechanism of Action:\n- **Checkpoint Inhibition**: Keytruda targets the PD-1 (programmed death-1) receptor on T-cells. By inhibiting PD-1, it prevents cancer cells from utilizing the PD-1/PD-L1 pathway to evade immune surveillance, thereby enhancing the immune system\u2019s ability to attack cancer cells.\n\n### Indications:\n- **Types of Cancer**: Keytruda is approved for multiple types of cancer, including but not limited to:\n  - Melanoma\n  - Non-Small Cell Lung Cancer (NSCLC)\n  - Head and Neck Squamous Cell Carcinoma (HNSCC)\n  - Urothelial Carcinoma\n  - Classical Hodgkin Lymphoma (cHL)\n  - Gastric Cancer\n "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_5NByBVjVnh8EckpyTqyXm8Xn", "custom_id": "578_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "be83add7915751bf9330925a5b842137", "body": {"id": "chatcmpl-9St84ggwnguwt8M7ipn6uQpiximGe", "object": "chat.completion", "created": 1716672128, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alimta, whose generic name is pemetrexed, is a chemotherapy drug used primarily in the treatment of certain types of cancer, including malignant pleural mesothelioma and non-small cell lung cancer. Here are some key points you should know about Alimta:\n\n1. **Mechanism of Action:**\n   - Pemetrexed is an antifolate antineoplastic agent. It disrupts the growth of cancer cells by inhibiting the formation of substances they need to replicate. Specifically, it inhibits enzymes like thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, all of which are involved in the folate pathways important for DNA synthesis and cell replication.\n\n2. **Indications:**\n   - Alimta is used to treat malignant pleural mesothelioma in combination with cisplatin.\n   - It is also approved for use in the treatment of locally advanced or metastatic non-small cell lung cancer ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_TYgjSr0wSLSXCw10urI1KsK2", "custom_id": "579_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "786f459f34147f6586f0e96b9c894889", "body": {"id": "chatcmpl-9St84UGg2Um29a24PICAZ4PhKbxzJ", "object": "chat.completion", "created": 1716672128, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nipent, also known by its generic name pentostatin, is a chemotherapeutic agent used primarily in the treatment of hairy cell leukemia. Here are some important aspects you should be aware of as a physician:\n\n### Mechanism of Action:\n- **Inhibition of Adenosine Deaminase:** Pentostatin is a potent inhibitor of the enzyme adenosine deaminase, which is involved in purine metabolism. This inhibition leads to an accumulation of deoxyadenosine triphosphate, resulting in cytotoxicity, particularly in rapidly dividing cells such as malignant lymphocytes.\n\n### Indications:\n- **Hairy Cell Leukemia:** Pentostatin is approved for the treatment of hairy cell leukemia, a rare type of chronic leukemia.\n\n### Administration:\n- **Intravenous Infusion:** The drug is typically administered via intravenous infusion. The recommended dosage and schedule should be followed as per the specific treatment protocol and adjusted based on patient response and tolerance.\n\n### Side Effects:\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_vhjsPW5q7XPq6JmzbOBC72Ij", "custom_id": "580_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d4009209d33988b47b0858406292e5ce", "body": {"id": "chatcmpl-9St84Xdp0XwGftL8h4qphknapHSOH", "object": "chat.completion", "created": 1716672128, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Omnitarg is not a standard name associated with a known drug, therapy, or medical device as of my last knowledge update in October 2023. You might be referring to Omnitrope, which is a brand name for a form of recombinant human growth hormone (somatropin) used to treat growth hormone deficiencies in children and adults. However, if you meant something else, here are some steps you can take to ensure you're getting accurate and up-to-date information:\n\n1. **Consult Reliable Medical Databases and Journals:**\n   Access recognized medical databases such as PubMed, MEDLINE, or specific pharmaceutical compendiums for detailed and reliable information about the drug, its uses, side effects, and clinical trial data.\n\n2. **Check FDA or EMA Resources:**\n   Review information from regulatory bodies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for approval status, clinical trial results, and safety information.\n\n3. **Contact"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_jXoordQwu2Uv0UIqpulj8GIZ", "custom_id": "581_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "95613edec0d9f5d85051b8143c23018f", "body": {"id": "chatcmpl-9St84WsSis2beedIpar3q8ZQ1TAqv", "object": "chat.completion", "created": 1716672128, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pinorubicin, also known as epirubicin, is an anthracycline class chemotherapy drug used primarily in the treatment of various cancers. It works by interfering with the DNA replication process in cancer cells, ultimately leading to cell death. Here are key points you should know as a physician:\n\n### Indications\n- **Breast Cancer:** Often used as part of an adjuvant or neoadjuvant therapy.\n- **Ovarian Cancer:** Used in combination with other chemotherapeutic agents.\n- **Lymphomas:** Occasionally used in treatment regimens.\n- **Soft Tissue Sarcomas:** Utilized based on specific cases and protocols.\n\n### Mechanism of Action\n- **Intercalates DNA:** Inserts itself between DNA base pairs, disrupting the function of enzymes involved in DNA replication and transcription.\n- **Topoisomerase II Inhibition:** Inhibits the action of topoisomerase II, leading to breaks in DNA strands.\n- **Free Radical Formation"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ikLamuJ1AUFgT2tG8mA6pm72", "custom_id": "582_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "19eb118f1496a9227480137b28abbf29", "body": {"id": "chatcmpl-9St84reMx8qK33IUvAWr5vsxI0m2d", "object": "chat.completion", "created": 1716672128, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pixuvri (pixantrone) is a chemotherapeutic agent used for the treatment of certain types of non-Hodgkin lymphoma (NHL), particularly relapsed or refractory aggressive B-cell NHL. Here are some key points you should know about Pixuvri:\n\n### Mechanism of Action:\n- Pixuvri is an aza-anthracenedione, which intercalates into DNA and inhibits topoisomerase II, leading to cell cycle arrest in the G2-M phase and subsequent apoptosis of cancer cells.\n\n### Indications:\n- Primarily indicated for use in patients with relapsed or refractory aggressive B-cell NHL who have undergone multiple lines of prior conventional treatments.\n\n### Administration:\n- Pixuvri is administered as an intravenous infusion. The specific dosage and schedule can vary based on patient factors and treatment protocols, but the standard dosing regimen often involves cycles repeated every 21 days.\n\n### Side Effects:\nCommon Side Effects:\n- Neutropenia\n- Anemia\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_XRQTA4pmcszQV9VxJQpXrRVg", "custom_id": "583_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2a837a983110f3e0e4d04bedd3466cd9", "body": {"id": "chatcmpl-9St84JnLIdbrAQBbBqBSMaB5dS34P", "object": "chat.completion", "created": 1716672128, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mithracin, also known as Mithramycin, is an antibiotic that was historically used for its antineoplastic properties. It's a cytotoxic agent and belongs to a class of chemotherapy drugs called chromomycin A3 antibiotics. Here are important aspects you should know about Mithracin:\n\n### Indications:\n1. **Testicular Cancer:** It was used as part of combination chemotherapy regimens for metastatic testicular carcinoma.\n2. **Hypercalcemia and Hypercalciuria of Malignancy:** It helped control elevated calcium levels in individuals with advanced cancer, particularly certain solid tumors and hematologic malignancies.\n3. **Paget's Disease:** It was occasionally used off-label for severe cases not responding to other treatments.\n\n### Mechanism of Action:\nMithracin works by binding to the DNA in the minor groove and inhibits RNA synthesis, thereby interfering with cell proliferation. This cytotoxic effect is useful in targeting rapidly dividing cancer cells.\n\n### Dosage and Administration:\n- The"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_jWmZcnPaiuiP7b7BmroTHlBu", "custom_id": "584_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "da099743d9d433ff1c60c37b56433522", "body": {"id": "chatcmpl-9St84Y8RtfL61G4HCteRwF9bb0djT", "object": "chat.completion", "created": 1716672128, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Actimid is a brand name for the drug Thalidomide, which is also marketed under several other names including Thalomid. Primarily, Thalidomide has a notorious history due to its teratogenic effects when it was initially marketed in the late 1950s as a treatment for morning sickness and insomnia in pregnant women, leading to severe birth defects. However, it has since been found to have several beneficial uses under strict regulatory control.\n\nHere are some critical points to know about Thalidomide (Actimid):\n\n### Current Uses:\n1. **Multiple Myeloma**: Thalidomide is approved for use as part of combined therapy for multiple myeloma, a type of blood cancer.\n2. **Erythema Nodosum Leprosum (ENL)**: It is also approved to treat this painful skin condition seen in leprosy.\n\n### Off-Label Uses:\nThalidomide has been investigated and used off-label for several conditions"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_yp16iSCRJNUkjgcZUH1gp0kS", "custom_id": "585_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "794da8d17de6247df81f6ca4babdf717", "body": {"id": "chatcmpl-9St84pd2MTnflDWxuiPJOODiqqKyx", "object": "chat.completion", "created": 1716672128, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Iclusig (ponatinib) is a tyrosine kinase inhibitor (TKI) that is primarily indicated for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). As a physician, it's important to be familiar with the following key aspects of Iclusig:\n\n1. **Indications**:\n   - Chronic myeloid leukemia (CML) patients who are resistant or intolerant to prior TKI therapy.\n   - Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to prior TKI therapy.\n\n2. **Mechanism of Action**:\n   - Ponatinib inhibits the BCR-ABL tyrosine kinase, including those with the T315I mutation, which is often resistant to other TKIs.\n\n3. **Administration**:\n   - It is an oral medication typically taken once daily, with or without food. The starting dose is usually 45"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_RDJO8SdXPwajrCAuc7RX8lnL", "custom_id": "586_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7c3dfab22b79f66ac729266932007e5e", "body": {"id": "chatcmpl-9St84XqAk808yVS8h2H3ICHs0RibQ", "object": "chat.completion", "created": 1716672128, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Folotyn (pralatrexate) is a medication used in the treatment of certain types of cancer, specifically peripheral T-cell lymphoma (PTCL), a fast-growing type of non-Hodgkin lymphoma. Here are key points that a physician should be aware of regarding Folotyn:\n\n### Mechanism of Action\n- **Folotyn** is a folate analog metabolic inhibitor. It works by disrupting the folic acid pathway, which is essential for the synthesis of nucleotides and DNA in rapidly dividing cells. This results in the inhibition of tumor growth.\n\n### Indications\n- **Peripheral T-Cell Lymphoma (PTCL):** Folotyn is primarily indicated for patients with relapsed or refractory PTCL. It's important to know the patient's prior treatments and their response to them before considering Folotyn.\n  \n### Administration\n- **Dosage:** The typical dose is 30 mg/m\u00b2 administered as an intravenous (IV) push over 3-5"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ocLXoel5Q8siokT35367jPnc", "custom_id": "587_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "03df70886fc8683ac49dcb817eedb04d", "body": {"id": "chatcmpl-9St84GxBVnJZlaxKk79Wsli9CTter", "object": "chat.completion", "created": 1716672128, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pravachol, generic name pravastatin, is a statin medication used primarily to treat hypercholesterolemia (high cholesterol) and to prevent cardiovascular disease. Here are key points you should know:\n\n1. **Mechanism of Action**:\n   - Pravachol works by inhibiting HMG-CoA reductase, an enzyme involved in the synthesis of cholesterol in the liver. This reduces levels of LDL (low-density lipoprotein), or \"bad\" cholesterol, while modestly increasing levels of HDL (high-density lipoprotein), or \"good\" cholesterol.\n\n2. **Indications**:\n   - Primary hypercholesterolemia (elevated LDL cholesterol).\n   - Mixed dyslipidemia.\n   - Hypertriglyceridemia.\n   - Primary prevention of coronary events, including in patients with elevated cholesterol levels without established coronary heart disease.\n   - Secondary prevention in patients with previous myocardial infarction or unstable angina.\n\n3. **Dosage**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Eqaseg58HKoa8xOjiACmtHVF", "custom_id": "588_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "accf1c1f171c23ee13a61acc66755c35", "body": {"id": "chatcmpl-9St84LRbSE1puEAtKp08SPEEpOHrS", "object": "chat.completion", "created": 1716672128, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's vital to gather accurate and up-to-date information about any medication you intend to prescribe. However, as of my latest update in 2021, \"Adnisolone\" does not appear to be a recognized or commonly known pharmaceutical drug. It's possible that there may be a typo, misunderstanding, or lack of information about this particular substance.\n\nIf you meant \"Prednisolone,\" which is a well-known corticosteroid, here are some key points:\n\n### Prednisolone: Key Information\n\n**Indications:**\n- Used to treat inflammatory conditions such as asthma, allergies, arthritis, and autoimmune diseases.\n- Used in various eye inflammations and as part of treatment protocols for certain cancers.\n\n**Mechanism of Action:**\n- Anti-inflammatory and immunosuppressive properties.\n- Inhibits multiple inflammatory cytokines, leading to decreased inflammation and immune response.\n\n**Dosage and Administration:**\n- Dosage varies based on the condition being treated and patient response.\n- Available in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_1iavQafuanWxDLNtk102YauM", "custom_id": "589_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a3fc9ff68477d7d64bdd1dd812a3616b", "body": {"id": "chatcmpl-9St85N1712jr3MZzTXkif2fR2auI8", "object": "chat.completion", "created": 1716672129, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there might be a typo or misunderstanding in your question, as there is no well-known or recognized entity named \"Artinizona\" in the medical field, geography, pharmacology, or any other established category. If you meant something else, could you please provide more context or clarify your question? Here are a few possibilities you might be referring to:\n\n1. **Medication or Drug**: Pharmaceutical names are often complex and might sound similar. If \"Artinizona\" is a misspelling or mispronunciation, please check the name of the drug, or provide more details about its intended use or active ingredients.\n\n2. **Geographic Location**: If you're referring to a location (e.g., Arizona), providing specific health concerns or demographics might help in offering relevant medical information.\n\n3. **Medical Condition or Procedure**: It\u2019s important to ensure the correct medical terminology. Could it be that you are referring to a specific condition, procedure, or a diagnostic tool?\n\nIf you"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_x1wvHOSB6w8pjCMWb1NAai7H", "custom_id": "590_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "3acca4736202bffda82f7acee1c9ad0a", "body": {"id": "chatcmpl-9St859fDejsGmRSmVx9zUdRnNEKLm", "object": "chat.completion", "created": 1716672129, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Indicarb\" is not a widely recognized or standardized term in medicine or pharmacology. It's possible that there might be a typo, miscommunication, or regional name that doesn\u2019t apply broadly across all medical literature or practices. Given the vast array of medications and treatments that exist, if you\u2019re referring to a specific medication or treatment known by this name in your practice, it would be helpful to have more context.\n\nHowever, if you are referring to a specific chemotherapy agent like \"Carboplatin\" (often used under various brand names and for which names might vary by region), here\u2019s a brief overview of what you should know:\n\n### Carboplatin\n\n**Class:** Platinum-based chemotherapy agent\n\n**Indication:** Used primarily in the treatment of various types of cancer, including ovarian cancer, lung cancer, head and neck cancers, and more.\n\n**Mechanism of Action:** Carboplatin works by cross-linking DNA, which interferes with the cell's repair mechanism for DNA damage"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_owQu0kYDiuL2UEberV3orsPx", "custom_id": "591_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2875585486a5db355b810bb16d7ca7c2", "body": {"id": "chatcmpl-9St85OgumaTIlhz5RypISmF17B6w0", "object": "chat.completion", "created": 1716672129, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Qualaquin is the brand name for quinine sulfate, a medication used primarily to treat uncomplicated Plasmodium falciparum malaria. While it has a history of broader uses, including as a treatment for nocturnal leg cramps, the FDA has issued warnings against such off-label use due to safety concerns. Here are some key considerations for physicians when prescribing Qualaquin:\n\n1. **Indications and Usage:**\n   - Approved for the treatment of uncomplicated P. falciparum malaria.\n   - Not recommended for prophylactic use or the treatment of severe malarial infections.\n\n2. **Dosage and Administration:**\n   - Typically administered orally.\n   - The usual dose for malaria is 648 mg (two 324 mg capsules) every 8 hours for 7 days.\n   - Should be taken with food to minimize gastrointestinal side effects.\n\n3. **Mechanism of Action:**\n   - Quinine works by interfering with the parasite's ability to digest hemoglobin, crucial for its"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_wqiva5HotbwL4O4BbKFXMLzX", "custom_id": "592_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1c05be3cec6fe3d9a5efdb6abb94ced5", "body": {"id": "chatcmpl-9St85a8l4uW9jqE0ccfSTRnQKbTpD", "object": "chat.completion", "created": 1716672129, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Vanflyta (quizartinib) is a medication used in the treatment of certain types of acute myeloid leukemia (AML). Here are some key points you should be aware of:\n\n1. **Indication**: Vanflyta is specifically indicated for the treatment of adults with relapsed or refractory AML with an FLT3-ITD mutation, detected by an FDA-approved test.\n\n2. **Mechanism of Action**: Vanflyta is an FLT3 receptor tyrosine kinase inhibitor. It works by inhibiting the activity of the FLT3 enzyme, which is often mutated and overactive in certain types of AML, leading to uncontrolled cell proliferation.\n\n3. **Administration**: Vanflyta is typically administered orally, once daily. The exact dosage and treatment duration can vary based on individual patient factors, including response to therapy and the presence of side effects.\n\n4. **Side Effects**: Common side effects include fatigue, nausea, diarrhea, constipation, hyp"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_U5UGgGwTbdhwMRcWUidqPCDg", "custom_id": "593_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8216653ffc94bc023a54fae36a5f3200", "body": {"id": "chatcmpl-9St85rMRhFpbpbd5NGrBS7BrbWwHj", "object": "chat.completion", "created": 1716672129, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Supect\" is a brand name for a medication that commonly contains the active pharmaceutical ingredient \"Levocetirizine,\" which is an antihistamine used to treat allergy symptoms such as runny nose, sneezing, and itchy eyes. Here are some important points you should know about Supect as a physician:\n\n### Pharmacology:\n- **Mechanism of Action:** Levocetirizine, the active ingredient, is an enantiomer of cetirizine, which selectively inhibits peripheral H1-receptors to reduce allergic symptoms. It is less likely to cause drowsiness compared to first-generation antihistamines.\n\n### Indications:\n- Allergic rhinitis (both seasonal and perennial)\n- Chronic idiopathic urticaria (hives)\n- Other conditions as determined by a healthcare provider\n\n### Dosage and Administration:\n- **Adults and children over 6 years:** The usual dosage is 5 mg once daily, preferably in the evening.\n- **Children 2"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_quWoLDDZ0mrjoYnfSppikjWM", "custom_id": "594_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "69595dc4274aaa6b5da424df9b5c50ce", "body": {"id": "chatcmpl-9St85abZuluHwcBEytfFkWR98IcLA", "object": "chat.completion", "created": 1716672129, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tomudex (generic name: raltitrexed) is an antimetabolite chemotherapy medication primarily used to treat advanced colorectal cancer. Here are some key points you should be aware of as a physician:\n\n### Mechanism of Action:\n- **Antimetabolite:** Raltitrexed inhibits thymidylate synthase, an enzyme crucial for DNA synthesis. This inhibition impedes DNA replication and cell division, effectively targeting rapidly proliferating cancer cells.\n\n### Indications:\n- **Colorectal Cancer:** Tomudex is approved for use in the treatment of advanced colorectal cancer, particularly in patients who are intolerant to first-line therapies or in combination with other chemotherapeutic agents.\n\n### Administration and Dosage:\n- **Intravenous Infusion:** Tomudex is administered via IV infusion, typically over 15 minutes.\n- **Dosage:** The standard dose is 3 mg/m\u00b2, given once every 3 weeks. Doses may need adjustment based on renal function or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_lL8L4dNhm4lCT77RCWflyewX", "custom_id": "595_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7df3c37ab2dce90bb160d292304d1110", "body": {"id": "chatcmpl-9St85E6UbgI2Toclt837jWPQUHckX", "object": "chat.completion", "created": 1716672129, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it\u2019s important to be familiar with Cyramza (ramucirumab), a monoclonal antibody used in oncology. Here are some key points you should know:\n\n### Mechanism of Action\n- **Cyramza** is a recombinant human IgG1 monoclonal antibody that specifically binds to the vascular endothelial growth factor receptor 2 (VEGFR-2) and blocks its activation, thereby inhibiting angiogenesis, which is the process through which new blood vessels form from pre-existing vessels. This is crucial in cancer therapy because tumors rely on angiogenesis for growth and metastasis.\n\n### Indications\n- **Gastric Cancer:** Cyramza is used as a single agent or in combination with paclitaxel for the treatment of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.\n- **Non-Small Cell Lung Cancer (NSCLC):** Used in combination with docetaxel for metastatic NSCLC with disease progression on or"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_uAuJedfrteNYuzjpyIONDcTl", "custom_id": "596_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e758555d49665aa7140f1b650118818f", "body": {"id": "chatcmpl-9St85F37TeQyKKmiIHyGmEtptqHm9", "object": "chat.completion", "created": 1716672129, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's valuable to recognize that Cymer, Inc. is a technology company rather than a pharmaceutical or medical device company. Cymer is known for developing and supplying light sources used in photolithography processes for semiconductor manufacturing. Here's a brief overview of what you should know:\n\n1. **Industry Involvement**: Cymer plays a crucial role in the semiconductor manufacturing industry. Their technology is vital for producing microchips used in various electronic devices.\n\n2. **Technology Focus**: The company's primary products include deep ultraviolet (DUV) light sources and extreme ultraviolet (EUV) light sources. These are essential for high-resolution photolithography required in the production of integrated circuits.\n\n3. **Medical Relevance**: While Cymer itself is not directly involved in healthcare, the semiconductor technologies enabled by Cymer's light sources are critical in the manufacturing of medical devices, diagnostic equipment, and various healthcare-related technologies that rely on advanced microelectronics.\n\n4. **Parent Company**: Cy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_l7cP4djri5rGPqPdRyawQNcE", "custom_id": "597_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b22b3387d2bd87d9abdba88c92c63735", "body": {"id": "chatcmpl-9St85J7ovnpz9019WcyXK8FYB9qFL", "object": "chat.completion", "created": 1716672129, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nublexa is a brand name for regorafenib, a type of medication classified as a multikinase inhibitor. It is used primarily in the treatment of certain types of cancers. Here\u2019s a comprehensive overview that could be helpful for a physician:\n\n### Indications:\n1. **Colorectal Cancer**: Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and an anti-EGFR therapy (if RAS wild type).\n2. **Gastrointestinal Stromal Tumors (GIST)**: It is used for patients with locally advanced, unresectable, or metastatic GIST who have been previously treated with imatinib mesylate and sunitinib malate.\n3. **Hepatocellular Carcinoma (HCC)**: It is approved for patients with HCC"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_G5AjJCUGVJiOwUhMEvniYFOg", "custom_id": "598_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "cd5069e6497cd96d03933dfcbb0b43ab", "body": {"id": "chatcmpl-9St85L9OuqAGj7ApPTFj19CFqhP3Y", "object": "chat.completion", "created": 1716672129, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kisqali (generic name: ribociclib) is a targeted cancer therapy used in the treatment of certain types of breast cancer. Here are some key points that you, as a physician, should know:\n\n### Indications:\n- **Kisqali is typically prescribed for**: \n  - Postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.\n  - It is used in combination with an aromatase inhibitor (like letrozole) or fulvestrant as initial endocrine-based therapy.\n\n### Mechanism of Action:\n- **Cyclin-dependent kinase (CDK) 4/6 inhibitor**:\n  - It works by inhibiting CDK4/6, which are proteins that, when overactive, can promote the proliferation of cancer cells.\n\n### Dosing and Administration:\n- **Typical dosing schedule**:\n  - Kisqali is administered orally, usually at a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_QhMMY3U7386uNrq8z6mqFb0q", "custom_id": "599_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7aa3aa05b12bcf4c2f680fd4b9f96128", "body": {"id": "chatcmpl-9St860hZMyFb63ACgdlVA7MMqVOKO", "object": "chat.completion", "created": 1716672130, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be some confusion with the term \"Ikgdar,\" as it doesn't correspond to any known medical condition, treatment, or standard terminology that I am aware of as of my last update in 2023. It's possible that this could be a misspelling or a brand name of a medication or a term that's not widely recognized in medical literature.\n\nIf you can provide additional context or clarify the term, I'd be glad to try and assist you further. Alternatively, if you're referring to a specific medication, condition, or concept, accurate spelling or more details would be helpful in providing you with the correct information."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 126, "total_tokens": 167}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_YNgFF9kzJlq2KqnilsvXggRY", "custom_id": "600_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "850bbf84997e051c98bd11535b12a94e", "body": {"id": "chatcmpl-9St86egoMzsBaq9e1PTVkmQikpfLx", "object": "chat.completion", "created": 1716672130, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rituxan Hycela is a combination of rituximab and hyaluronidase human, used primarily for the treatment of various types of blood cancers. Here are some key points a physician should know about this medication:\n\n### Indications\nRituxan Hycela is indicated for the treatment of certain blood cancers, including:\n- **Non-Hodgkin Lymphoma (NHL)**: Specifically in follicular lymphoma and diffuse large B-cell lymphoma.\n- **Chronic Lymphocytic Leukemia (CLL)**.\n\n### Administration\n- **Route**: Subcutaneous injection.\n- **Dosage**: It is essential to follow the specific dosing schedule based on the type of cancer being treated. Initial treatment with intravenous rituximab is usually required to test for potential hypersensitivity reactions.\n  \n### Mechanism of Action\n- **Rituximab**: A monoclonal antibody that targets CD20 on the surface of B-cells, leading"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_w8Y4Kq69ZGTZwIbL8CRrRLyB", "custom_id": "601_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ec944d680bfdfada2687b7627b3c2a44", "body": {"id": "chatcmpl-9St86ZRbZjzclgcU7AmivC6yCKPxj", "object": "chat.completion", "created": 1716672130, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Istodax (generic name: romidepsin) is a prescription medication used in the treatment of certain types of cancer, primarily cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. Here are some key points about Istodax that you, as a physician, should be aware of:\n\n1. **Mechanism of Action**:\n   - Istodax is a histone deacetylase (HDAC) inhibitor which works by causing the accumulation of acetylated histones and other proteins, leading to cell cycle arrest and apoptosis of cancer cells.\n\n2. **Indications**:\n   - It is approved for the treatment of CTCL and PTCL in patients who have received at least one prior systemic therapy.\n\n3. **Administration**:\n   - Istodax is administered via intravenous injection. The typical dosage is 14 mg/m2 over a 4-hour period on days "}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_AxURBhooScmbwzFhz3O3uJBr", "custom_id": "602_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e9e912fe122fb5fe197111c46632f375", "body": {"id": "chatcmpl-9St86vt41LDrC9d7ixHvrZ8GVEH37", "object": "chat.completion", "created": 1716672130, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Besremi (generic name: ropeginterferon alfa-2b) is a medication used for the treatment of polycythemia vera (PV), a chronic disorder characterized by the overproduction of red blood cells. Here are some key points you should know about Besremi:\n\n1. **Mechanism of Action**: Ropeginterferon alfa-2b is a long-acting interferon that modulates the immune system and exhibits antiproliferative effects, helping to reduce the elevated red blood cell count in patients with PV.\n\n2. **Indication**: Besremi is indicated for the treatment of polycythemia vera in adult patients, and it can be used in both treatment-naive patients and those who have been previously treated.\n\n3. **Dosing and Administration**: The typical starting dose and the frequency of administration is usually individualized based on the patient's response and tolerance. It's important to follow the specific dosing recommendations provided in the prescribing information.\n\n4"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_AqSw1ChqKWhHxPNYgOwPyWJL", "custom_id": "603_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "3007c46128dd4b8148199c1776e10dc7", "body": {"id": "chatcmpl-9St86ZIQVDq2SnIhHJ4bJ2GDAOurn", "object": "chat.completion", "created": 1716672130, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rubraca (rucaparib) is a medication primarily used in oncology, specifically for the treatment of certain types of cancer. Here are some key points you should be aware of:\n\n1. **Indications**:\n   - Rubraca is a PARP (poly ADP ribose polymerase) inhibitor. It is used in the treatment of:\n     - Ovarian cancer: For patients with advanced ovarian cancer who have been treated with two or more chemotherapies and who have deleterious BRCA mutation (germline and/or somatic).\n     - Maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in a complete or partial response to platinum-based chemotherapy.\n     - Prostate cancer: For patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and taxane-based chemotherapy.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_9cDd42euCSPU5NOviyBzLlWl", "custom_id": "604_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6b55048574c3cbd93dfc94c49d925323", "body": {"id": "chatcmpl-9St86B2OhxJBScyd6Y6G5r7uqOzLX", "object": "chat.completion", "created": 1716672130, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Jakafi (ruxolitinib) is a medication primarily used to treat certain bone marrow disorders. As a physician, you should be aware of several key aspects:\n\n1. **Indications**:\n   - **Myelofibrosis**: Approved for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.\n   - **Polycythemia Vera**: Approved for patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.\n   - **Acute Graft-Versus-Host Disease (GvHD)**: Approved for steroid-refractory acute GvHD in adult and pediatric patients 12 years and older.\n\n2. **Mechanism of Action**:\n   - Jakafi is an inhibitor of Janus-associated kinases (JAK"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_86dv7lvcUc31y6vSAqOR6dst", "custom_id": "605_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2207bd22690b8c1d3133a6f63a4b95ac", "body": {"id": "chatcmpl-9St86znjI1CcUueYDF7fEzA9Q8j3N", "object": "chat.completion", "created": 1716672130, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate (ADC) used in the treatment of adults with certain types of cancers. Here are several key points you should know about Trodelvy:\n\n1. **Indications**:\n   - Trodelvy is primarily indicated for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have undergone at least two prior therapies for metastatic disease.\n   - It is also approved for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor.\n\n2. **Mechanism of Action**:\n   - Trodelvy is composed of an antibody (sacituzumab) that targets Trop-2, a protein commonly expressed on the surface of cancer cells.\n   - It is conjugated to an anti-cancer drug (SN-38), a metabolite of irinotecan"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_fuc7iJ8G02Rc1uUmrd490vKc", "custom_id": "606_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b9d13f8dd36641bb9004cc5807277575", "body": {"id": "chatcmpl-9St86CKVZ7LyL5aGdCXP3DsYbzxUh", "object": "chat.completion", "created": 1716672130, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, understanding Leukine (sargramostim) is essential for its appropriate clinical use. Here is a detailed overview of the drug:\n\n### What is Leukine?\nLeukine (sargramostim) is a granulocyte-macrophage colony-stimulating factor (GM-CSF) used to stimulate the production of white blood cells (granulocytes, macrophages, and dendritic cells) in the bone marrow. It is often used to support the immune system in patients with conditions that cause low white blood cell counts.\n\n### Indications\nLeukine is approved for several indications, including:\n- **Hematopoietic Stem Cell Transplantation (HSCT):** To reduce the incidence of severe and life-threatening infections in patients undergoing autologous or allogeneic bone marrow transplantation.\n- **Acute Myeloid Leukemia (AML):** To aid in myeloid reconstitution in patients with AML following chemotherapy.\n- **Bone Marrow"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_S66OIlXksLStFKp8hR3831RX", "custom_id": "607_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "06cd5c686c0284de1a5f63c2bb3ad3b5", "body": {"id": "chatcmpl-9St86K1nVzgPL9YnzLc8X0DPhaxuL", "object": "chat.completion", "created": 1716672130, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nexpovio (generic name: selinexor) is a medication that you might encounter in the context of treating certain types of cancer. Here is detailed information you may find useful:\n\n### Drug Class and Mechanism of Action:\n- **Class**: Selective Inhibitor of Nuclear Export (SINE)\n- **Mechanism**: Selinexor works by inhibiting exportin 1 (XPO1), a protein involved in transporting various molecules, including tumor suppressor proteins, out of the cell nucleus. By inhibiting XPO1, selinexor facilitates the retention of tumor suppressor proteins within the nucleus, leading to the induction of apoptosis in cancer cells.\n\n### Approved Indications:\n- **Multiple Myeloma**: Nexpovio has been approved for use in combination with other medications for treating multiple myeloma in adult patients who have received at least certain prior therapies.\n\n### Administration:\n- **Form**: Oral, available in tablet form"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_0gagTqFmAmwDqLjNVA0KB3oq", "custom_id": "608_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6d31d8f8718c293e157580280034bf1a", "body": {"id": "chatcmpl-9St87Jj2IKAppLc6zynlRUQ4vQSFY", "object": "chat.completion", "created": 1716672131, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Koselugo (selumetinib) is a medication used in the treatment of specific genetic conditions. As a physician, here are the key points you should know about Koselugo:\n\n### Indications:\n1. **Neurofibromatosis Type 1 (NF1)**:\n   - Koselugo is approved for the treatment of pediatric patients aged 2 years and older with symptomatic, inoperable plexiform neurofibromas (PN), a common complication in NF1.\n\n### Mechanism of Action:\n- **MEK Inhibitor**:\n  - Koselugo is an inhibitor of both MEK1 and MEK2, which are enzymes in the MAPK/ERK pathway that are typically involved in cell proliferation and survival. By inhibiting this pathway, Koselugo can potentially reduce tumor growth and alleviate symptoms.\n\n### Dosage and Administration:\n- The recommended dose of Koselugo for pediatric patients (aged 2 years and above) is based on"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_0NsgMXNc5HUhyuWSHP6oIbxR", "custom_id": "609_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6866c2a6c73dda842c1b4a94c2bc46c1", "body": {"id": "chatcmpl-9St87DjSY2TjmcTiKjh1WuBSauEkA", "object": "chat.completion", "created": 1716672131, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Semustine, also known by its chemical name methyl-CCNU, is a nitrosourea compound used as an antineoplastic agent in the treatment of certain cancers. Here's a detailed overview of key points you should know as a physician:\n\n### Pharmacodynamics and Mechanism of Action\n- **Mechanism**: Semustine exerts its anti-cancer effects primarily through alkylation of DNA, which leads to cross-linking and consequently inhibits DNA synthesis and function.\n- **Cell Cycle Phase**: It is not phase-specific but is more effective against cells in the G1 and S phases.\n\n### Indications\n- **Primary Uses**: Historically, it has been used in the treatment of various cancers including gliomas (a type of brain cancer) and, on occasion, other malignancies such as gastrointestinal tumors.\n- **Combination Therapy**: Often used in combination with other chemotherapeutic agents to potentiate its therapeutic effects.\n\n### Administration\n- **Route**: Oral"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_7movdVffiPbSQ4I2qWYGHwCi", "custom_id": "610_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4c913c7b3b6bac4d4a5304e8d75bb4a2", "body": {"id": "chatcmpl-9St87OEKrLxfE1sY2rsmp5VzQp7Fo", "object": "chat.completion", "created": 1716672131, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Provenge (sipuleucel-T) is an immunotherapy used in the treatment of advanced prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC). Here are some critical points you should know about Provenge as a physician:\n\n### Mechanism of Action\n1. **Immunotherapy Approach:** Provenge is designed to stimulate the patient's immune system to attack prostate cancer cells. It involves autologous cellular immunotherapy.\n2. **Personalized Treatment:** It\u2019s customized for each patient using their immune cells. The process begins with a leukapheresis procedure to collect antigen-presenting cells (APCs) from the patient's blood.\n3. **Antigen Association:** These APCs are exposed to a fusion protein (PA2024) consisting of prostatic acid phosphatase (PAP) and granulocyte-macrophage colony-stimulating factor (GM-CSF). PAP is an antigen expressed in most prostate cancers.\n4. **Immune Response Activation:**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_T133CqZs0YRNWHaG1AWv5lBw", "custom_id": "611_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7c8de5eb6f042c99a631c1e1a150ab97", "body": {"id": "chatcmpl-9St87CaueIEfOpA3BTnkxOhRTGWjJ", "object": "chat.completion", "created": 1716672131, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Odomzo (sonidegib) is an oral medication used for the treatment of certain types of skin cancer. Here are some key points you should know about it:\n\n### Indications\nOdomzo is primarily indicated for the treatment of adults with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy or those who are not candidates for surgery or radiation therapy.\n\n### Mechanism of Action\nOdomzo is a hedgehog pathway inhibitor. The Hedgehog signaling pathway plays a critical role in regulating the growth of certain cancers, including basal cell carcinoma. By inhibiting this pathway, Odomzo can slow down or stop the growth of cancer cells.\n\n### Dosage and Administration\n- The recommended dose of Odomzo is 200 mg taken orally once daily, at least 1 hour before or 2 hours after a meal.\n- It should be swallowed whole with water and not crushed, chewed, or broken.\n\n### Side Effects\nCommon"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_8VwqWBuYaV7jrcAtzP2XpRIe", "custom_id": "612_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9872a995bb24f6da7dd4995b12ff0043", "body": {"id": "chatcmpl-9St87NPJxkbdc1B3i3Pp4BrCWyDzz", "object": "chat.completion", "created": 1716672131, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Nexavar (sorafenib) is a tyrosine kinase inhibitor used to treat certain types of cancer, including advanced renal cell carcinoma, unresectable hepatocellular carcinoma (liver cancer), and differentiated thyroid carcinoma that is refractory to radioactive iodine treatment. Here are some key points you should be aware of:\n\n### Mechanism of Action\n- **Kinase Inhibition:** Nexavar inhibits multiple intracellular and cell surface kinases, including Raf kinase, VEGFR-2, VEGFR-3, PDGFR-\u03b2, and others. By inhibiting these kinases, Nexavar interferes with tumor cell proliferation and tumor angiogenesis.\n\n### Indications\n- **Advanced Renal Cell Carcinoma (RCC)**\n- **Unresectable Hepatocellular Carcinoma (HCC)**\n- **Differentiated Thyroid Carcinoma (DTC):** Specifically for those refractory to radioactive iodine treatment.\n\n### Dosage and Administration\n- **"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_LVJVPgPvQ6UpuF8f5eSKKBX3", "custom_id": "613_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "638cae5a24085f24f034b10b1e202c64", "body": {"id": "chatcmpl-9St87pMMkAAdtDGdFfWWi4E7lSDPI", "object": "chat.completion", "created": 1716672131, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zanosar, also known by its generic name streptozocin, is an antineoplastic (anticancer) medication primarily used in the treatment of pancreatic neuroendocrine tumors, particularly metastatic islet cell carcinoma. It belongs to a class of drugs called nitrosureas and is known for its specificity towards pancreatic beta cells. Here are some essential considerations you should be aware of as a physician:\n\n### Indications:\n- **Pancreatic Neuroendocrine Tumors:** Zanosar is most commonly used for this indication due to its selective uptake and toxic effect on pancreatic islet cells.\n- **Combination Therapy:** It may be used alone or in combination with other chemotherapeutic agents, depending on the tumor type and treatment protocol.\n\n### Mechanism of Action:\n- **Alkylating Agent:** Zanosar works by causing breaks in DNA strands, inhibiting DNA repair and RNA synthesis, leading to cell death. It selectively accumulates in pancreatic beta cells which makes it"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_YGe493TzJKM5B0Nyd2Je3jx1", "custom_id": "614_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6304b350ee78c4e5b357673de74731a8", "body": {"id": "chatcmpl-9St87bHi5RvMax3bNUzv8UtdKGCxm", "object": "chat.completion", "created": 1716672131, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems like there might be a typo in your question, as \"Kitent\" does not correspond to any known medical term, drug, condition, or piece of medical equipment as of my latest update in 2023. Could you please provide more context or check for any misspellings? If you meant a different term, I'd be happy to help with information on that topic."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 40, "completion_tokens": 77, "total_tokens": 117}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_JCsYloSKmVYrRBzLoheZcaWX", "custom_id": "615_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "753282b13a54930a547dbea95cf35737", "body": {"id": "chatcmpl-9St87PfUQfoA6AG38FRIXdpaMAkpQ", "object": "chat.completion", "created": 1716672131, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Elzonris (generic name: tagraxofusp-erzs) is a medication used for the treatment of certain types of cancer. As a physician, here are several key points you should know about Elzonris:\n\n1. **Indication**:\n   - Elzonris is primarily indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients aged 2 years and older.\n\n2. **Mechanism of Action**:\n   - Elzonris is a targeted therapy that consists of a fusion protein combining interleukin-3 (IL-3) with a truncated diphtheria toxin. The IL-3 component binds to the IL-3 receptor (CD123) on the surface of BPDCN cells, allowing the diphtheria toxin to enter the cells and inhibit protein synthesis, leading to cell death.\n\n3. **Administration**:\n   - Elzonris is administered as an intravenous infusion. It"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_bioPol1dyDxdE6hxfHhWkn1K", "custom_id": "616_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "212b87b6d33fa75d90afa2890f465d0e", "body": {"id": "chatcmpl-9St87aPLunU8llm9fffkk4svUvEwu", "object": "chat.completion", "created": 1716672131, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Talzenna (talazoparib) is an oral poly (ADP-ribose) polymerase (PARP) inhibitor used primarily in the treatment of certain types of breast cancer. Here are key points you should be aware of as a physician:\n\n1. **Indications**:\n   - Talzenna is approved for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. \n   - Patients should be selected for therapy based on an FDA-approved companion diagnostic for Talzenna.\n\n2. **Mechanism of Action**:\n   - Talazoparib works by inhibiting PARP enzymes, which play a role in DNA repair. In cells with BRCA mutations, this inhibition leads to DNA damage and apoptosis, particularly targeting cancer cells.\n\n3. **Dosage and Administration**:\n   - The recommended dosage is 1 mg taken orally once daily"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Uv7T8MiJZVfE0Z6uByiDryKi", "custom_id": "617_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1f6b75183b2fd19b5d5ad9e1cf4b672e", "body": {"id": "chatcmpl-9St87mszAWmya8u3iUgbzsaqv6heP", "object": "chat.completion", "created": 1716672131, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imlygic (talimogene laherparepvec, also known as T-VEC) is a genetically modified oncolytic viral therapy used primarily for the treatment of melanoma lesions in the skin and lymph nodes. Here are some key aspects you should know about Imlygic as a physician:\n\n### 1. Mechanism of Action:\n- **Oncolytic Virus**: Imlygic is derived from the herpes simplex virus type 1 (HSV-1). It has been genetically modified to selectively replicate within tumors, causing tumor cell lysis.\n- **Stimulation of Immune Response**: The therapy is designed to release granulocyte-macrophage colony-stimulating factor (GM-CSF), enhancing the body's immune response against the tumor.\n\n### 2. Indications:\n- Imlygic is approved for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma that is recurrent after initial surgery.\n\n### 3. Administration"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_WQDBvWMjPAFma7uTfDAlHK9z", "custom_id": "618_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d3b24f878fb75fcfa68971e1bbea4f93", "body": {"id": "chatcmpl-9St87zxT6Dd7RPETYBFDuGSYoAfKn", "object": "chat.completion", "created": 1716672131, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It appears that there might be a typo or misunderstanding, as \"Amnoid\" doesn't correspond to any known medical term, medication, or condition in the medical field. It's possible you may be referring to something else, such as \"amniocentesis,\" which is a common prenatal diagnostic procedure, or \"amyloid,\" which refers to abnormal protein deposits that can occur in various diseases.\n\nIf you meant \"amyloid,\" here are a few key points:\n\n1. **Amyloidosis**: This is a group of diseases where amyloid proteins are abnormally deposited in tissues and organs, disrupting their normal function. Types include AL (primary), AA (secondary), and hereditary amyloidosis.\n\n2. **Alzheimer\u2019s Disease**: The accumulation of amyloid-beta plaques in the brain is a hallmark of this neurodegenerative condition.\n\n3. **Diagnosis**: Amyloidosis can be diagnosed through biopsy and staining techniques, while amyloid-beta in Alzheimer\u2019s can be identified through PET"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_FFBZZyadcUy9JEFEsgoZedFu", "custom_id": "619_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4b433cb97749dc8655636c6db6513ada", "body": {"id": "chatcmpl-9St87VHf4TA28b0qajgL66yD3Fe4T", "object": "chat.completion", "created": 1716672131, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems there may be some confusion, as \"Istubal\" does not appear to be a recognized term in the medical field or known pharmaceutical context as of my latest update. It might be a misspelling or a lesser-known term. Here are some steps you can take to clarify and address this:\n\n1. **Verify the Term:**\n   Ensure the spelling is correct. If it's a drug, procedure, or medical condition, double-check with reputable sources or databases.\n\n2. **Consult Resources:**\n   Refer to medical databases, textbooks, or trusted online medical resources like PubMed, MedlinePlus, or professional medical associations.\n\n3. **Ask Colleagues or Specialists:**\n   Check with other healthcare professionals or specialists who might have more insight into less common or newly emerging terms.\n\n4. **Patient Information:**\n   If a patient mentioned this term, ask them for more context or additional information they might have received from other sources.\n\n5. **Update Knowledge:**\n   Medicine"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_7ehSNOmSQcTftbDZIzMueiQz", "custom_id": "620_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "312cde12e0f886a5e2612fa44983671f", "body": {"id": "chatcmpl-9St87DWCqxhSSguCdId7g5uazv766", "object": "chat.completion", "created": 1716672131, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Teysuno is a medication that is used primarily in the treatment of advanced gastric (stomach) cancer. It is a combination chemotherapy drug containing three active ingredients: tegafur, gimeracil, and oteracil. Here are some key points you should be aware of as a physician:\n\n1. **Mechanism of Action**:\n   - **Tegafur**: A prodrug of 5-fluorouracil (5-FU), which is an antimetabolite that inhibits DNA synthesis.\n   - **Gimeracil**: Inhibits dihydropyrimidine dehydrogenase (DPD), an enzyme that breaks down 5-FU, thereby increasing the levels and efficacy of 5-FU.\n   - **Oteracil**: Inhibits the enzyme orotate phosphoribosyltransferase in the gastrointestinal tract, which reduces the gastrointestinal toxicity of 5-FU.\n\n2. **Ind"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_PE8c9gLYvH1MHJBFCoyWJsPP", "custom_id": "621_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "fd0bd1cbcd62b75d22c83340ef78d7e1", "body": {"id": "chatcmpl-9St882IRPI1RqycOXarkX7hTGULvW", "object": "chat.completion", "created": 1716672132, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ftorafur, also known by its chemical name Tegafur, is an anticancer chemotherapeutic agent classified as a prodrug of 5-fluorouracil (5-FU). It is primarily used in the treatment of various cancers, including colorectal cancer, gastric cancer, and breast cancer. Here are key points you should know about Ftorafur:\n\n### Mechanism of Action\n- **Prodrug**: Ftorafur itself is not active. It is metabolized in the liver to 5-FU, which subsequently interferes with DNA synthesis and RNA function, disrupting cancer cell growth and proliferation.\n\n### Pharmacokinetics\n- **Administration**: It can be administered orally.\n- **Metabolism**: Ftorafur is metabolized in the liver by the cytochrome P450 enzymes, particularly CYP2A6.\n- **Elimination**: It mainly undergoes renal excretion.\n\n### Indications\n- Used most frequently in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_k1qggsiYeZ3Mu5UCHcpkSllq", "custom_id": "622_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "250bb88f9ad61e618fa6cfe7f62807dc", "body": {"id": "chatcmpl-9St88ZR6k1tsrwJf8xy5adeFR87Oq", "object": "chat.completion", "created": 1716672132, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gliotem, also known by its generic name temozolomide, is an important medication primarily used in the treatment of certain types of brain tumors. Here's what you should know about it:\n\n1. **Indications**: Temozolomide is commonly indicated for the treatment of malignant gliomas, including glioblastoma multiforme (GBM) and anaplastic astrocytoma. It may also be used in some cases of metastatic melanoma.\n\n2. **Mechanism of Action**: Temozolomide is an oral alkylating agent that works by interfering with DNA replication. It gets converted to its active form, MTIC (monomethyl triazene imidazole carboxamide), which methylates DNA. This leads to apoptosis (programmed cell death) in cancer cells.\n\n3. **Administration and Dosage**: Temozolomide is administered orally in capsule form. The typical dosing schedule varies based on the indication but often involves"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_HU6AbtqsYoV3y0zC3w1GguIz", "custom_id": "623_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e7c18fd7f3e5430dda76f659bd345dff", "body": {"id": "chatcmpl-9St88je6r5uwOtoAD8IqOOH14omvp", "object": "chat.completion", "created": 1716672132, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Torisel (temsirolimus) is a medication used primarily in oncology for the treatment of advanced renal cell carcinoma (RCC). Here are key points you should know as a physician:\n\n### Mechanism of Action\n- **mTOR Inhibitor**: Torisel works by inhibiting the mammalian target of rapamycin (mTOR), a kinase involved in cell growth, proliferation, and survival. By blocking mTOR, it causes cell cycle arrest in the G1 phase and reduces angiogenesis.\n\n### Indications\n- **Renal Cell Carcinoma**: Primarily approved for use in advanced RCC, especially in patients with poor prognosis.\n- **Other Cancers**: Occasionally, it might be used off-label for other malignancies, though its efficacy and safety in these settings are not as well established.\n\n### Administration\n- **Intravenous (IV) Infusion**: Administered as an IV infusion. The usual dose is 25 mg once a week"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_6FDZg57ckMAb7tXU5cZuPy1q", "custom_id": "624_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d9a8056b41a4f392e266e3a095b303bd", "body": {"id": "chatcmpl-9St88SClAPCNCIjMC2pmdeZ4kyyy8", "object": "chat.completion", "created": 1716672132, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to familiarize yourself with the key aspects of Vumon (teniposide), which is an antineoplastic (anti-cancer) agent. Here are some critical points to consider:\n\n### Indications\nVumon is primarily used in the treatment of various cancers, such as:\n- Acute lymphoblastic leukemia (especially in pediatric patients and those who have relapsed or are refractory to other treatments)\n- Other off-label uses may include small cell lung cancer and non-Hodgkin lymphoma, but this should be based on clinical judgment and existing literature.\n\n### Mechanism of Action\n- Teniposide works by inhibiting the enzyme topoisomerase II, leading to breaks in DNA strands which ultimately prevents cancer cells from dividing and growing.\n\n### Dosage and Administration\n- Dosage must be individualized according to the specific type of cancer, the patient's size (usually dosed based on body surface area), and their overall health condition.\n- Typically administered intravenously"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_MpnvSI56CP0igYR85eBccxEv", "custom_id": "625_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2d912f724d36cd077e12784387668a45", "body": {"id": "chatcmpl-9St88DxgkPVEQpUKZVdZwwoAUNbZc", "object": "chat.completion", "created": 1716672132, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Contergan, also known by its generic name thalidomide, is a medication that was initially developed and marketed in the late 1950s by the German pharmaceutical company, Chemie Gr\u00fcnenthal. It was primarily intended as a sedative and was also used to treat morning sickness in pregnant women. However, it became infamous for causing severe birth defects and other health issues.\n\nHere are some key points a physician should know about the history and current use of thalidomide:\n\n### Historical Context\n1. **Birth Defects:** Thalidomide was found to cause serious birth defects, such as limb deformities (phocomelia), in babies born to mothers who took the drug during pregnancy. Thousands of children were affected globally, leading to widespread media coverage and a tightening of drug approval regulations.\n   \n2. **Market Withdrawal:** The drug was withdrawn from the market in the early 1960s once the link between thalidomide and birth defects became apparent.\n\n### Current"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_2Nxq9A3KzugeSraVp5bBq9Cv", "custom_id": "626_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ed5d4c2532a58559e30b387aaa32f4d3", "body": {"id": "chatcmpl-9St88H0JbNjx9C46j39zr5aFan7mq", "object": "chat.completion", "created": 1716672132, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, you should be well-informed about Lanvis (thioguanine), a medication used primarily in oncology. Here are several key points you should consider:\n\n### Indications:\nLanvis is primarily indicated for:\n- Treatment of acute myeloid leukemia (AML).\n- Sometimes used in other forms of leukemia or related blood disorders, often in combination with other chemotherapy agents.\n\n### Mechanism of Action:\n- Lanvis is a thiopurine antimetabolite. It interferes with DNA and RNA synthesis by incorporating into the DNA and RNA strands or by inhibiting purine nucleotide synthesis. This action disrupts the proliferation of rapidly dividing cells such as cancer cells.\n\n### Administration:\n- Dosage forms and routes: Typically comes in oral tablet form.\n- Dosage: Highly variable and dependent on the specific disease being treated, the protocols in use, the patient\u2019s body surface area, and other individual factors such as renal and hepatic function.\n\n### Monitoring Requirements:\n- Regular complete blood"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_9ToiqiytObTOFpvm7t4q7lyx", "custom_id": "627_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2ed72ab3e1db016c3c1c64ea97c8af75", "body": {"id": "chatcmpl-9St88MsLx5Hcym3sn28pHe8N7FtZ3", "object": "chat.completion", "created": 1716672132, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tepadina, which contains the active ingredient thiotepa, is an alkylating agent used primarily in oncology. Here are some critical points you should know about Tepadina:\n\n### Indications:\n1. **Bone Marrow Transplantation**: Tepadina is often used as part of conditioning regimens prior to hematopoietic stem cell transplantation (HSCT) in patients with hematologic malignancies like leukemia and lymphoma.\n2. **Solid Tumors**: Occasionally, it is used in high-dose chemotherapy protocols for certain solid tumors including breast cancer and ovarian cancer.\n3. **Neuroblastoma**: It has roles in pediatric oncology, particularly in high-risk neuroblastoma.\n\n### Mechanism of Action:\nThiotepa exerts its effect by binding to DNA and cross-linking DNA strands, leading to cell cycle arrest and apoptosis. It is non-cell-cycle-specific, affecting all phases of the cell cycle.\n\n### Administration:\n- **Intravenous Infusion**"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_X9HuUaMfbIfFrMsyTDcCYXfB", "custom_id": "628_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ed52c6bb167b6f7be66ea021a5029d4c", "body": {"id": "chatcmpl-9St886Ju6fDOkYt7AiIm63c7Mm4sW", "object": "chat.completion", "created": 1716672132, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kymriah (tisagenlecleucel) is a form of CAR T-cell therapy and represents a significant advancement in the treatment of certain types of cancers, primarily hematologic malignancies. Here are key points you should know about Kymriah:\n\n1. **Indications:**\n   - **Relapsed or refractory B-cell acute lymphoblastic leukemia (ALL):** Kymriah is approved for use in patients up to 25 years old.\n   - **Relapsed or refractory large B-cell lymphoma:** This includes diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma in adult patients.\n\n2. **Mechanism of Action:**\n   - Kymriah is an autologous T-cell immunotherapy. It involves collecting a patient's T-cells, genetically modifying them to express a chimeric antigen receptor (CAR) that specifically targets the CD19 protein present on the surface of B-c"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_X8cJrxQd1dN867xzYsbCbLas", "custom_id": "629_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d7b35912f2a62c1f2c81ceb958448606", "body": {"id": "chatcmpl-9St88Q15rGTJeEhvMsG0rWOa1DL8u", "object": "chat.completion", "created": 1716672132, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fotivda (tivozanib) is an oral medication that inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3. It has antitumor and anti-angiogenic properties and is primarily used to treat patients with advanced renal cell carcinoma (RCC). Here are key points to know:\n\n### Indications:\n- **Renal Cell Carcinoma**: Fotivda is indicated for the treatment of adult patients with relapsed or refractory advanced RCC, following prior therapy.\n\n### Mechanism of Action:\n- **VEGFR Inhibition**: Fotivda works by inhibiting VEGFR-1, -2, and -3 tyrosine kinases, which play crucial roles in angiogenesis and tumor growth by stimulating the formation of blood vessels that supply the tumor.\n\n### Administration:\n- **Dosing Schedule**: The recommended dose is 1.34 mg orally once daily for 21 days on treatment followed by 7 days off"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_eLVnkkawE1aieCkNsiE9ETSp", "custom_id": "630_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "deac537ec4d58c648b0ae86c6734db81", "body": {"id": "chatcmpl-9St88QgKefvrZKlhNQT4hWpsz62k5", "object": "chat.completion", "created": 1716672132, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my latest update, there is no widely recognized medication or treatment called \"Evotopin.\" It is crucial to verify the name and spelling, as drug names can be very similar. If \"Evotopin\" is a newly introduced medication or a specific brand name that has come into use after my most recent update, I recommend taking the following steps:\n\n1. **Consult Updated Medical Resources**: Refer to recent medical literature, databases such as the FDA website, or pharmaceutical directories. Resources like UpToDate, Lexicomp, or PubMed can provide the latest information on new drugs.\n\n2. **Pharmacological Information**: Look for details about the pharmacodynamics, indications, contraindications, side effects, and mechanism of action. Understanding these aspects will help you in making informed clinical decisions.\n\n3. **Guidelines and Protocols**: Check clinical guidelines from reputable bodies like the CDC, WHO, or specialty-specific associations to see if there are any recommendations or standard protocols for using"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_sDF9IqTe2p3jlAlAvdHLlBaB", "custom_id": "631_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b870e4cbc2953483c64c1284f584c94a", "body": {"id": "chatcmpl-9St889BVQ44jCfmmkeSUcIoY8FI3t", "object": "chat.completion", "created": 1716672132, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Acapodene\" isn't a recognized generic or brand name for a drug that is widely known in medical literature as of my latest update in 2023. It is possible there may be a spelling error, a miscommunication, or it could be a very new or regional drug, supplement, or formulation that hasn't become widely recognized in mainstream medical resources.\n\nIn your capacity as a physician, especially when encountering unfamiliar drug names, it's important to:\n\n1. **Verify the Name**: Double-check the spelling and possible variations of the drug name.\n2. **Consult Reliable Sources**: Use trusted pharmaceutical references such as:\n   - **Physician's Desk Reference (PDR)**\n   - **Micromedex**\n   - **UpToDate**\n   - **PubMed**\n   - **National Institutes of Health (NIH) databases**\n3. **Contact Pharmacies**: Pharmacists can be invaluable resources for information on drug names, especially if the drug is new, rare"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_DJn5BwY4fV7HlZ5mAzQMNgMD", "custom_id": "632_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "aab47903b2a47de8cc15308a261ea837", "body": {"id": "chatcmpl-9St88WKtgIlVcMJsbI7YsIPjU6TFT", "object": "chat.completion", "created": 1716672132, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Bexxar, also known as tositumomab and iodine I-131 tositumomab, is a radioimmunotherapy treatment that was used for certain types of non-Hodgkin lymphoma (NHL). Although it has been discontinued and is no longer available as of 2014, understanding its mechanism, indications, and considerations remains valuable for historical knowledge and the development of similar therapies.\n\nHere are key points you should be aware of regarding Bexxar:\n\n### Mechanism of Action:\n- **Radioimmunotherapy**: Bexxar combines a monoclonal antibody (tositumomab) with radioactive iodine (I-131). The monoclonal antibody targets the CD20 antigen found on B-cells, including non-Hodgkin lymphoma cells. The attached radioactive iodine delivers targeted radiation to the lymphoma cells, thereby killing them.\n- **Direct and Indirect Cytotoxicity**: The treatment works through both the immune system's response to the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_fuMTTGnN6SeClgrcDlrNb15x", "custom_id": "633_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "222c7a48ba1ac51ad1d53efb244d4cc0", "body": {"id": "chatcmpl-9St88G2tfibbH3aINnAEiybUnQYyk", "object": "chat.completion", "created": 1716672132, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Yondelis (trade name for trabectedin) is an anticancer chemotherapy drug originally derived from the sea squirt Ecteinascidia turbinata. It is primarily used to treat certain types of soft tissue sarcoma and ovarian cancer. Here are some key points you should know about Yondelis:\n\n### Indications:\n1. **Soft Tissue Sarcoma:** Yondelis is used to treat advanced soft tissue sarcoma, specifically liposarcoma and leiomyosarcoma, particularly after the failure of anthracycline and ifosfamide chemotherapy.\n2. **Ovarian Cancer:** It is also indicated in combination with pegylated liposomal doxorubicin for the treatment of platinum-sensitive, recurrent ovarian cancer.\n\n### Mechanism of Action:\n- **DNA Repair Inhibition:** Trabectedin binds to the minor groove of DNA, causing bending of the DNA helix and interfering with transcription and DNA repair mechanisms, leading to cell cycle arrest and apoptosis.\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_TYZFxL5pjyyPDUt4h5BoXDJi", "custom_id": "634_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "93ba2be32bc7a52d38ecc13a48caa9a9", "body": {"id": "chatcmpl-9St89uUvQMuJiDWclIroaxlrb7TEK", "object": "chat.completion", "created": 1716672133, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Mekinist, generically known as trametinib, is a targeted therapy medication used primarily in the treatment of certain types of cancer. As a physician, here are key points you should know about Mekinist:\n\n### Indications\n1. **Melanoma**: Mekinist is used to treat patients with unresectable or metastatic melanoma whose tumors have a specific mutation known as BRAF V600E or V600K.\n2. **Non-Small Cell Lung Cancer (NSCLC)**: It is also used in combination with dabrafenib for treating NSCLC with BRAF V600E mutations.\n3. **Other Cancers**: Mekinist is sometimes used off-label for other cancers harboring similar BRAF mutations.\n\n### Mechanism of Action\nMekinist is a type of kinase inhibitor that specifically inhibits MEK1 and MEK2, which are parts of the MAPK/ERK pathway. This pathway is often overactive in cancers with B"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_6MLy2nQNCjnsOiV1Z9rfbDdB", "custom_id": "635_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9dd885a3df18671c25f56a29966ccc66", "body": {"id": "chatcmpl-9St895NlWYD5AOoDFxPX96p7OlVja", "object": "chat.completion", "created": 1716672133, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2021, \"Amixam\" does not correspond to any widely recognized drug or medical term in standard medical references, including pharmacology databases, medical literature, or clinical guidelines. It is possible that it might be a typographical error, a product not widely known or prevalent, or it may refer to a newly introduced medication that has emerged after my last update.\n\nHowever, if \"Amixam\" refers to a specific drug, medical device, or term you encountered, I would recommend the following steps:\n\n1. **Consult Updated Medical Literature and Databases**: Use resources like PubMed, UpToDate, or other medical databases to find recent studies or data related to this term.\n2. **Check Drug Formularies and Regulatory Agencies**: Look up information in drug formularies or check with regulatory agencies such as the FDA (Food and Drug Administration) or EMA (European Medicines Agency).\n3. **Inquire with Professional Networks**: Ask colleagues"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_82D5gjpNOYdjj2vzf8PeK0Sy", "custom_id": "636_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "17a408d28c23100650ad126a91656e30", "body": {"id": "chatcmpl-9St89tdYhYcr007XOjnLmB842c0Mz", "object": "chat.completion", "created": 1716672133, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, \"Biceltis\" does not match any well-known medication, therapy, or medical device in mainstream medical literature. It is possible that you might have a typographical error, or it could be a brand name or a new treatment that has emerged after my last update. Here are a few steps you could take:\n\n1. **Verify the Name**: Double-check the spelling of the medication or treatment. Many drugs have similar-sounding names, so it's easy to mistake one for another.\n\n2. **Check Reliable Sources**: Consult reliable medical databases and resources like UpToDate, PubMed, or official medical regulatory bodies such as the FDA or EMA.\n\n3. **Consult Medical Representatives**: Sometimes, new medications might be introduced by pharmaceutical companies. Reaching out to drug representatives could provide updated information.\n\n4. **Colleagues and Networks**: Reach out to your professional network or colleagues who might have more recent or specialized knowledge"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_576VNNv8qIeC6ixCk7GXe75M", "custom_id": "637_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e47b9ecfbba38552d8d08e0a6c2da17f", "body": {"id": "chatcmpl-9St897XB8ER5IqWAfK2Nxv9T7fwGz", "object": "chat.completion", "created": 1716672133, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Imjudo, known generically as tremelimumab, is a monoclonal antibody that acts as an immune checkpoint inhibitor, specifically targeting CTLA-4 (cytotoxic T-lymphocyte-associated protein 4). Here are key points you should be aware of as a physician:\n\n### Indications:\n1. **Cancer Therapy**: Imjudo is used primarily for the treatment of certain types of cancers, including but not limited to, melanoma, non-small cell lung cancer (NSCLC), and hepatocellular carcinoma (HCC). Its use is often in combination with other immunotherapies, such as PD-1 inhibitors like pembrolizumab or nivolumab.\n\n### Mechanism of Action:\n1. **Immune System Activation**: By inhibiting CTLA-4, tremelimumab enhances T-cell activation and proliferation, thereby promoting an anti-tumor immune response.\n\n### Administration:\n1. **Route**: It is administered via intravenous infusion.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_7EwKn2ArqcYqhQLjzD888M9N", "custom_id": "638_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f62ec0905dcc8797c9ac879565f8a45b", "body": {"id": "chatcmpl-9St89biuxDqTYspg8r6bAX611dqXe", "object": "chat.completion", "created": 1716672133, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Ovastat\" isn't a drug or medical treatment that has widespread recognition in clinical practice or medical literature as of my last update in October 2021. It's possible that it could be:\n\n1. A proprietary name for a newer drug or treatment that has emerged after my last update.\n2. A brand name not widely recognized internationally.\n3. A misspelling or misunderstanding of another medical product or term.\n\nIf it's a new drug or treatment, I'd recommend checking the latest medical literature, databases like PubMed, or resources such as the FDA or EMA websites for updated and authoritative information. Additionally, you could consult with a pharmacist or a colleague who may be more familiar with recent developments in pharmacology.\n\nFor any new treatment or drug:\n- Ensure you get up-to-date information on its indications, mechanism of action, dosage, side effects, contraindications, interactions, and efficacy.\n- Verify its regulatory status and approval by relevant health authorities (e.g., FDA, EMA).\n- Familiarize yourself"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_NXMfvPwcaX0LJAAtV3PLKc5u", "custom_id": "639_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7e0c4cc9ba84d449c8b6a0a45fbd91ca", "body": {"id": "chatcmpl-9St89DtkMd0tch9k8JMK48tLaItrA", "object": "chat.completion", "created": 1716672133, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lonsurf (trifluridine/tipiracil) is an oral medication used in the treatment of metastatic colorectal cancer and metastatic gastric or gastroesophageal junction adenocarcinoma in patients who have been previously treated with other chemotherapy regimens. Here is some key information that you should know about Lonsurf:\n\n### Mechanism of Action:\n- **Trifluridine:** It is an antimetabolite that gets incorporated into DNA, inhibiting cell proliferation by interfering with DNA synthesis.\n- **Tipiracil:** It prevents the breakdown of trifluridine by inhibiting thymidine phosphorylase, increasing trifluridine's bioavailability and effectiveness.\n\n### Indications:\n- Approved for adults with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.\n- Also approved for adults with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_jloBQdVgLBB3kUCskGMI2v1Q", "custom_id": "640_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5e8aa3b18907979128891d3cd02fa922", "body": {"id": "chatcmpl-9St893k3FKGBW7zvirPZPt9DkkiYK", "object": "chat.completion", "created": 1716672133, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Decapeptyl (triptorelin) is a synthetic analogue of gonadotropin-releasing hormone (GnRH) which is used primarily in the management of hormone-responsive cancers such as prostate cancer. Here are several key points you should know about Decapeptyl:\n\n1. **Mechanism of Action**:\n    - Triptorelin acts by initially stimulating the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland.\n    - This stimulation leads to an initial surge in testosterone (or estrogen in women). However, with continued use, triptorelin causes desensitization and downregulation of GnRH receptors, leading to decreased production of LH and FSH and subsequent reduction in testosterone (or estrogen).\n\n2. **Indications**:\n    - Advanced prostate cancer.\n    - Early-stage hormone receptor-positive breast cancer.\n    - Endometriosis.\n    - Uterine fibroids.\n    -"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_9gQoSOaDj4BJzIPiGukwQNhh", "custom_id": "641_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1afd820ef2766f23c2fdc1421528a6a8", "body": {"id": "chatcmpl-9St8900FhNCeKVn2lcM9d1wwll4rS", "object": "chat.completion", "created": 1716672133, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, you should be aware that Depacon is the trade name for the intravenous formulation of valproate sodium. It is often used for patients who are unable to take oral medications. Here are several key points you should know about Depacon:\n\n1. **Indications**: Depacon is primarily indicated for use as an anticonvulsant to treat certain types of seizure disorders, including complex partial seizures and simple and complex absence seizures. It is also utilized in the management of acute mania in bipolar disorder and for migraine prophylaxis.\n\n2. **Mechanism of Action**: Valproate sodium enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) in the brain, which helps to stabilize electrical activity and prevent seizure activity.\n\n3. **Dosage and Administration**: Depacon is administered intravenously. The specific dosage and administration schedule can vary depending on the condition being treated, the patient\u2019s age, weight, and other medical conditions. Generally,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_M6jPVy5iV6eE1AYq2Es9GXc8", "custom_id": "642_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7f1530184eeac37cb11bd37b543adc3d", "body": {"id": "chatcmpl-9St89DEJhjnFnUSI8hLwPGrS0B7hr", "object": "chat.completion", "created": 1716672133, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Valstar (valrubicin) is an anthracycline antineoplastic drug primarily used in the treatment of bladder cancer, specifically Bacillus Calmette-Gu\u00e9rin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy (surgical removal of the bladder) would be associated with unacceptable morbidity or mortality. Here are some key points you should be aware of:\n\n### Indications and Usage\n- **Primary Indication**: Valstar is indicated for the intravesical therapy of BCG-refractory CIS of the urinary bladder in patients who cannot undergo immediate cystectomy.\n- **Administration Route**: It is administered intravesically, meaning directly into the bladder through a catheter.\n\n### Mechanism of Action\n- Valrubicin, the active ingredient in Valstar, is a synthetic analog of the anthracycline antibiotic doxorubicin.\n- It interferes with DNA synthesis and inhibits cell division in"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_g8NKt2mryqyzLGaHQnNy7gJu", "custom_id": "643_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "8ae4fd1d934fdd8c763f85b4f0735476", "body": {"id": "chatcmpl-9St89Ie5hgj78n1CsShiROBOSSZLM", "object": "chat.completion", "created": 1716672133, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Caprelsa (vandetanib) is a medication used primarily in the treatment of certain types of thyroid cancer. Here\u2019s what you should know as a physician:\n\n1. **Indications:**\n   - Caprelsa is approved for the treatment of symptomatic or progressive medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.\n \n2. **Mechanism of Action:**\n   - Vandetanib inhibits multiple receptor tyrosine kinases, including VEGFR, EGFR, and RET tyrosine kinases. This inhibits angiogenesis and tumor cell proliferation.\n\n3. **Dosage:**\n   - The recommended dosage of Caprelsa is 300 mg once daily. It can be taken with or without food. Dose adjustments may be necessary based on tolerability and adverse reactions.\n\n4. **Administration:**\n   - Tablets should be swallowed whole with water and not crushed or chewed. For patients who have difficulty swallowing, tablets may be"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_dwv0P2Ta5wlnQKJ8x2Qg6sfD", "custom_id": "644_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5880523d825bb875d6b3916857265644", "body": {"id": "chatcmpl-9St897eqGO1ogR5bcZeg0QhW1Y1Uk", "object": "chat.completion", "created": 1716672133, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zelboraf, also known by its generic name vemurafenib, is a medication used primarily in the treatment of certain types of cancer. Here is a comprehensive overview of what you should know about Zelboraf as a physician:\n\n### Indications:\n1. **Melanoma:** Zelboraf is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E mutation as detected by an FDA-approved test.\n2. **Erdheim-Chester Disease:** It's also approved for adults with Erdheim-Chester Disease with BRAF V600 mutation.\n\n### Mechanism of Action:\n- Vemurafenib is a kinase inhibitor that targets the BRAF V600E mutation, leading to decreased tumor cell proliferation.\n\n### Administration:\n- Zelboraf is administered orally in the form of tablets.\n- The typical dosage is 960 mg (4 tablets of 240 mg each) taken twice daily.\n\n### Monitoring:\n- Regular monitoring for skin reactions is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_xJ7FR8VLnYECKwKjcxEvrzXJ", "custom_id": "645_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "56c304d3dc80762559c1fb11502697fa", "body": {"id": "chatcmpl-9St8AVVwDGgjGdM1ohT6lAIL0C2Cn", "object": "chat.completion", "created": 1716672134, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Venclexta (venetoclax) is a prescription medication used primarily in the treatment of certain types of cancer, particularly chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Additionally, it can be used in combination with other drugs for the treatment of acute myeloid leukemia (AML) in specific populations. Here are essential points you should be familiar with regarding Venclexta:\n\n### Mechanism of Action\n- **BCL-2 Inhibition:** Venclexta is a selective inhibitor of B-cell lymphoma-2 (BCL-2), a protein that prevents apoptosis in cancer cells. By inhibiting BCL-2, Venclexta promotes the apoptosis of cancer cells.\n\n### Indications\n- **Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:** As monotherapy or in combination with other agents.\n- **Acute Myeloid Leukemia:** Often used in elderly patients ("}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_trc9I0VHlBpdZbMyfXBwMCbG", "custom_id": "646_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a56cbaad807cceafa285e8c349506e49", "body": {"id": "chatcmpl-9St8AUxYpPtZV5M3vI41cTswCReNF", "object": "chat.completion", "created": 1716672134, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Alkaban-AQ is a brand name for the drug vincristine sulfate, which is an antineoplastic (anticancer) medication. It is primarily used in the treatment of various types of cancer, including acute lymphoblastic leukemia (ALL), Hodgkin's lymphoma, non-Hodgkin's lymphoma, rhabdomyosarcoma, and neuroblastoma, among others.\n\nHere are some key points you should know about Alkaban-AQ (vincristine sulfate):\n\n### Mechanism of Action\n- **Vincristine** is a vinca alkaloid that works by inhibiting microtubule formation in the mitotic spindle, which is essential for cell division. This action interferes with the mitosis (M phase) of the cell cycle, leading to cell death.\n\n### Administration\n- **Route**: Alkaban-AQ is administered intravenously (IV).\n- **Dosage**: The dosage can vary depending on the type of cancer being treated,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_9LFrxqwtYADCUVuJYrn3SROB", "custom_id": "647_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "723bec4d9fcbe53d9a8fb79aff6dab89", "body": {"id": "chatcmpl-9St8AZzm5e26PC29Uvi2pcDNuneKP", "object": "chat.completion", "created": 1716672134, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to stay current with emerging treatments and substances, even those that may not be widely recognized or are still under investigation. However, as of my knowledge cut-off in October 2023, there's no widely known or well-documented substance or medication named \"Alcrist\" referenced in mainstream medical literature or pharmacology databases.\n\nIf \"Alcrist\" is a new or investigational drug, here are some general steps you can follow to gather more information:\n\n1. **Consult Reliable Sources**: Check trusted medical resources such as PubMed, MEDLINE, or any clinical trial registries for any published studies or ongoing research about the substance. \n\n2. **Professional Contacts**: Reach out to colleagues, medical researchers, or professional networks who might have more up-to-date information or personal expertise about the substance.\n\n3. **Pharmaceutical Repositories**: Look up information through drug databases maintained by regulatory bodies like the FDA (Food and Drug Administration) or EMA (European"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_pdbQnEo0bxwZVlPO34DjtonD", "custom_id": "648_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e8c4bb32e4912ff23bc015e5d54a96da", "body": {"id": "chatcmpl-9St8AZVRblkmJ2b1DNm0O0GDA0cFZ", "object": "chat.completion", "created": 1716672134, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Marqibo (vincristine sulfate liposome injection) is a chemotherapeutic agent used for the treatment of specific types of cancer. As a physician, here are several key points you should know about Marqibo:\n\n1. **Indications**:\n   - Marqibo is primarily used to treat adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) who have relapsed or are resistant to at least two prior therapies.\n\n2. **Mechanism of Action**:\n   - Marqibo is a liposomal formulation of vincristine sulfate. Vincristine is a vinca alkaloid that works by inhibiting microtubule formation in mitotic spindle fibers, thereby arresting cell division and leading to cancer cell death.\n\n3. **Dosage and Administration**:\n   - Marqibo is administered intravenously, and the dosing regimen can vary depending on the patient\u2019s condition and treatment plan. It is dosed based on the vincristine sulfate content and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_pHsvIQbIz0NdCZZqc3VqjLPG", "custom_id": "649_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d0bf3e06bb25c17833d6e8795a9b2799", "body": {"id": "chatcmpl-9St8A4DDknGcmFqJB35p31Bi055aY", "object": "chat.completion", "created": 1716672134, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Eldesine, also known by its generic name vindesine, is a synthetic derivative of the natural Vinca alkaloid vinblastine. It is an antineoplastic agent used in cancer therapy. Here's what you should know about Eldesine:\n\n### Indications:\n1. **Cancer Treatment**:\n   - Used primarily in the treatment of certain types of cancer such as:\n     - Acute lymphoblastic leukemia (ALL), particularly in children\n     - Lymphomas, including Hodgkin\u2019s and non-Hodgkin\u2019s lymphoma\n     - Lung cancer, including small-cell lung cancer (SCLC)\n\n### Mechanism of Action:\n- **Microtubule Inhibition**:\n   - Eldesine disrupts the formation of microtubules by binding to tubulin, which prevents cell division (mitosis) and leads to cell death. \n   - It primarily acts during the M phase of the cell cycle.\n\n### Administration:\n- **Intravenous Use**:\n   -"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ALbCygNmdTvSSFNkGb95Il4K", "custom_id": "650_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0ba20c7802736c7d072807a6ce52c844", "body": {"id": "chatcmpl-9St8Aqqwu9HgWix0YHtQoWPSwm4mP", "object": "chat.completion", "created": 1716672134, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Javlor, also known as vinflunine, is a chemotherapy medication that is used primarily for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (bladder cancer) when prior platinum-containing therapy has failed. Here are some key points you should know about Javlor as a physician:\n\n### Mechanism of Action\n- **Vinflunine** is a novel microtubule inhibitor that disrupts cellular mitosis. Specifically, it inhibits tubulin polymerization, leading to cell cycle arrest at the G2-M phase and ultimately cell death.\n\n### Indications\n- Javlor is indicated for patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing therapy.\n\n### Administration\n- **Dosage**: The typical dosage is 320 mg/m\u00b2 administered as an intravenous infusion over 20 minutes every 3 weeks. However, the dosage may need adjustments based on individual patient's tolerance, body surface area, and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_VjZyb4cKVbicXDdAiJPeUDot", "custom_id": "651_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b62cfb19413e8d6ad018806c7d9b7cda", "body": {"id": "chatcmpl-9St8AxN8LyAw6k0EV84NVRjf8FAxh", "object": "chat.completion", "created": 1716672134, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Binorel\" does not appear to be a widely recognized medication, drug, or medical term in standard medical references. It's possible that:\n\n1. It could be a brand name or a regional name for a medication not widely known or used globally.\n2. It may be a misspelling or typo of another known medication.\n3. It might be a recently developed drug that hasn't reached widespread recognition yet.\n\nIf \"Binorel\" is a new or less common treatment, you would typically need to check reliable medical databases, recent medical literature, or consult with pharmacology experts for detailed information.\n\nTo ensure you make informed decisions, here's a general approach you should follow:\n\n1. **Check Reliable Sources**: Use trusted medical databases like PubMed, Medline, or professional organization guidelines.\n\n2. **Consult Colleagues or Specialists**: If it's a relatively new or uncommon medication, speaking with a pharmacist or a specialist in the relevant field can provide insights.\n\n3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Cspw3MzhIVMTTphbXsxRp1V5", "custom_id": "652_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7dc99475a39fc17a7c12ceeb8ffdf16b", "body": {"id": "chatcmpl-9St8AB2oAh5qkPT7tbpndBBJ9mUQK", "object": "chat.completion", "created": 1716672134, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Erivedge (vismodegib) is a medication approved for the treatment of advanced basal cell carcinoma (BCC), particularly when it cannot be treated with surgery or radiation, or when it has metastasized. Here are key points you should be aware of:\n\n### Mechanism of Action\n- **Hedgehog Pathway Inhibitor**: Erivedge works by inhibiting the Hedgehog signaling pathway, which is crucial in the development of basal cell carcinoma. By binding to and inhibiting the Smoothened receptor, vismodegib prevents the activation of downstream signaling, ultimately inhibiting tumor growth.\n\n### Indications\n- **Locally Advanced BCC**: Approved for patients with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery or radiation.\n- **Metastatic BCC**: Approved for patients with metastatic basal cell carcinoma.\n\n### Dosage\n- **Standard Dose**: The typical dosage is 150 mg orally, once daily"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_SfuotFt0jiiBfbvYlhOu6Hws", "custom_id": "653_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "81881e91bdbb5e19860c5404ec1c0dca", "body": {"id": "chatcmpl-9St9PNB72tMJmzmz6CZdE3j6qh3Sk", "object": "chat.completion", "created": 1716672211, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zolinza (generic name: vorinostat) is a prescription medication that belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors. It's primarily used in the treatment of cutaneous T-cell lymphoma (CTCL), particularly in patients whose disease persists, progresses, or recurs after other systemic therapies.\n\nHere are some key points you should know as a physician:\n\n### Indications\n- **Primary Indication:** Zolinza is approved for the treatment of CTCL.\n- **Off-label Uses:** While its primary indication is for CTCL, there may be research or clinical interest in using vorinostat for other types of cancers or conditions where HDAC inhibitors might play a role.\n\n### Mechanism of Action\n- Zolinza works by inhibiting histone deacetylases, enzymes that help regulate gene expression by modifying chromatin structure. Inhibiting these enzymes can result in the accumulation of acetylated histones and proteins, which can"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_0sseHMWG6jCEcNgJlkxJQJDa", "custom_id": "654_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6557dadf3a5f8fa3d4c83e0b0e720076", "body": {"id": "chatcmpl-9St8AEgUUrUVU2EmfqKmD7p32yrfU", "object": "chat.completion", "created": 1716672134, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician interested in the Aztec civilization, you might find the following information relevant:\n\n1. **Traditional Medicine**:\n   - The Aztecs had a rich tradition of herbal medicine. They used a wide variety of plants for treatment, including aloe vera for skin conditions and peyote for its psychoactive properties, which were often employed in religious rituals.\n   - Herbalists, known as \"texoxotla,\" held significant status in Aztec society. They had extensive knowledge of plant-based treatments.\n\n2. **Medical Practices and Techniques**:\n   - The Aztecs performed various surgical procedures, often with tools made from obsidian, a volcanic glass that can be sharper than modern surgical steel.\n   - They practiced bloodletting and used maguey thorns for this purpose.\n   - Aztec medicine also included treatments for wounds and fractures, such as applying crushed herbs or using splints made from reeds.\n\n3. **Healthcare Infrastructure**:\n   - Aztec society had a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Mzam3JuJ9l3EVBbJNEAiETkA", "custom_id": "655_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0b176562a8064e1cb25a673a510ae10a", "body": {"id": "chatcmpl-9St8A2jigtMmnnYaHuWAFYr5GHPk3", "object": "chat.completion", "created": 1716672134, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zaltrap (ziv-aflibercept) is a medication primarily used in the treatment of metastatic colorectal cancer. Here are some important aspects you should know as a physician:\n\n### Mechanism of Action:\nZaltrap is a recombinant fusion protein that acts as a VEGF (vascular endothelial growth factor) inhibitor. It functions by binding to VEGF-A, VEGF-B, and PlGF (placental growth factor), thereby preventing these growth factors from activating their receptors on the surface of endothelial cells. This inhibition disrupts the blood supply to tumors, which is crucial for their growth and metastasis.\n\n### Indications:\nZaltrap is used in combination with FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) for patients with metastatic colorectal cancer that has progressed on or after an oxaliplatin-containing regimen.\n\n### Administration:\n- **Route of Administration:** Intravenous (IV).\n- **Dosage:** The recommended dose is"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_jxbWs5nc9TJyUG5JQVhDQH86", "custom_id": "656_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "808dc3d522e6c77d3b610210eba90bfe", "body": {"id": "chatcmpl-9St8B06RwUmCM2b2OIX4ymlLBJ1Qk", "object": "chat.completion", "created": 1716672135, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tabrecta (capmatinib) is a medication used in the treatment of certain types of non-small cell lung cancer (NSCLC). Here are some key points you should know about Tabrecta:\n\n1. **Indication**: Tabrecta is specifically indicated for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test.\n\n2. **Mechanism of Action**: Capmatinib is a kinase inhibitor that targets MET, a receptor tyrosine kinase. The inhibition of MET can help to prevent cancer cell proliferation and survival.\n\n3. **Dosage**: The recommended dosage is 400 mg orally, twice daily. Tablets should not be crushed, chewed, or split. \n\n4. **Administration**: Tabrecta can be taken with or without food, but it should be taken consistently in the same"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_zcEbmhDVmbXxWNW31eREn5ZR", "custom_id": "657_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "14510dc91d769baed3daef652710820a", "body": {"id": "chatcmpl-9St8Bdlr79R4GV6cRBrgOWNMeXCSe", "object": "chat.completion", "created": 1716672135, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Padcev (generic name: enfortumab vedotin-ejfv) is a monoclonal antibody-drug conjugate (ADC) therapy used primarily in the treatment of certain types of advanced bladder cancer, specifically urothelial carcinoma. Here are key points you should know as a physician:\n\n### Indications:\n- **Urothelial Carcinoma**: Padcev is approved for use in adults with locally advanced or metastatic urothelial carcinoma who have previously received a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting.\n\n### Mechanism of Action:\n- The drug consists of an antibody (enfortumab) that targets Nectin-4, a protein highly expressed in urothelial carcinoma cells. It is linked to a cytotoxic agent called monomethyl auristatin E (MMAE), which disrupts microtubules and induces cell death when internalized by the cancer"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_6zJJ6Q8OtPPIFWUCYVCpCboj", "custom_id": "658_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "40236610fc8529a44f538c82e6e49ca7", "body": {"id": "chatcmpl-9St8B5Fe6ir1v0yg965qcXQ8xV6xb", "object": "chat.completion", "created": 1716672135, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Enhertu (generic name: fam-trastuzumab deruxtecan-nxki) is an antibody-drug conjugate (ADC) used primarily in the treatment of certain cancers. Here are some key points you should know about Enhertu:\n\n### Mechanism of Action:\n1. **Targeting**: Enhertu combines a monoclonal antibody (trastuzumab) that targets the HER2 receptor with a topoisomerase I inhibitor (a chemotherapy drug) linked to the antibody.\n2. **Delivery**: The trastuzumab component binds to HER2 receptors on cancer cells, delivering the cytotoxic agent directly to the cancer cells.\n3. **Internalization and Release**: Once bound to HER2, the ADC is internalized by the cancer cell and the cytotoxic payload is released, leading to DNA damage and cell death.\n\n### Indications:\n1. **HER2-positive Breast Cancer**: It is approved for use in patients with HER2-positive metastatic breast cancer who"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_aD2ArMxNMTxV0mEhDDzoKhLP", "custom_id": "659_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5d331af848ead7c1dd7114063a0582b3", "body": {"id": "chatcmpl-9St8BL4Eki9gsZGkTy87fOrTE0oAC", "object": "chat.completion", "created": 1716672135, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Plenaxis, also known by the generic name abarelix, is a GnRH (gonadotropin-releasing hormone) antagonist used in the palliative treatment of advanced prostate cancer. It works by directly blocking the GnRH receptors in the pituitary gland, leading to a decrease in the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which subsequently reduces the production of testosterone, a hormone known to fuel the growth of prostate cancer cells.\n\nKey Points for Physicians:\n1. **Indication**: Plenaxis is indicated for the treatment of men with advanced symptomatic prostate cancer who are not candidates for other hormonal therapies.\n\n2. **Mechanism of Action**: Unlike GnRH agonists, which initially cause a surge in hormone levels, Plenaxis causes an immediate suppression of LH and FSH, leading to a rapid reduction in testosterone levels without an initial surge.\n\n3. **Administration**: Plenaxis is administered via intramus"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_nGO7HbA6f74zP5j7lqW7GhhU", "custom_id": "660_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "2a471d1a827131c635601ba6e96bc66d", "body": {"id": "chatcmpl-9St8BgjgVw4VmPrFl6wto3Bwl2PcL", "object": "chat.completion", "created": 1716672135, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Blenrep (belantamab mafodotin) is a medication used in the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Here are key points you should know about this drug:\n\n1. **Mechanism of Action**: Blenrep is a B-cell maturation antigen (BCMA)-targeted antibody-drug conjugate. It binds to BCMA on the surface of myeloma cells, delivering a cytotoxic agent directly to these cells, leading to cell death.\n\n2. **Indication**: It's specifically indicated for patients with multiple myeloma who have not had success with at least four prior treatments.\n\n3. **Administration**: Blenrep is administered via intravenous infusion once every three weeks. \n\n4. **Dosing**: The recommended dose of Blenrep is 2."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_cX18i9bLwlrLacr0vKdQKldf", "custom_id": "661_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "c6b441452c0bb73eab0ecab1b92a37d2", "body": {"id": "chatcmpl-9St8BOFNGjv2sw9kRAEdNPRsfa8Za", "object": "chat.completion", "created": 1716672135, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about Tukysa (generic name: tucatinib) to ensure you can properly consider its use for appropriate patients and manage its administration effectively. Here\u2019s a comprehensive overview:\n\n### Indications and Usage\n- **Tukysa** is primarily used in combination with trastuzumab and capecitabine for the treatment of adults with advanced unresectable or metastatic **HER2-positive breast cancer**. It is specifically used for patients who have received at least one prior anti-HER2-based regimen in the metastatic setting.\n\n### Mechanism of Action\n- Tucatinib is a **tyrosine kinase inhibitor** that selectively inhibits the kinase activity of the HER2 receptor, which plays a role in the growth and proliferation of cancer cells that overexpress HER2.\n\n### Dosage and Administration\n- The recommended dosage of tucatinib is **300 mg orally twice daily**. It should be taken with or without food.\n- Capecitabine"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_dgSxfby6lWGHfpygl85RtEgm", "custom_id": "662_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "096b750986de330c82e63423614ba4de", "body": {"id": "chatcmpl-9St8BEovSRjvjtlruelg1EOnkKan9", "object": "chat.completion", "created": 1716672135, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Darzalex Faspro (daratumumab and hyaluronidase-fihj) is a subcutaneous formulation of daratumumab, which is a monoclonal antibody used in the treatment of multiple myeloma. Here are some key points that a physician should know about Darzalex Faspro:\n\n### Mechanism of Action\n- **Daratumumab**: Targets CD38, a glycoprotein expressed on the surface of multiple myeloma cells, leading to cell death through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis.\n- **Hyaluronidase-fihj**: An enzyme that increases the dispersion and absorption of co-administered drugs.\n\n### Indications\nDarzalex Faspro is approved for use in:\n- Newly diagnosed multiple myeloma, in combination with therapies such as bortezomib, melphalan, and prednisone, or lenalidom"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_40365fy5qU5atdZtv6pNLALF", "custom_id": "663_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "aa6cfba38012a7633f23d3909c169687", "body": {"id": "chatcmpl-9St8Bfngs1YlppQGiP8gFcBU1oYcE", "object": "chat.completion", "created": 1716672135, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Panretin (generic name: alitretinoin) is a medication used in the treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. Here are some important points you should know about Panretin:\n\n### Indication and Usage:\n- **Indication**: Panretin gel is indicated for the topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma. It is used when lesions are not ulcerated or draining and when lesions are not present in internal organs.\n- **Not for systemic use**: Panretin should not be used for treatment of systemic Kaposi's sarcoma or any other systemic conditions.\n\n### Mechanism of Action:\n- **Retinoid activity**: Alitretinoin is a retinoid that binds to both retinoic acid receptors (RARs) and retinoid X receptors (RXRs), leading to modulation of cellular differentiation and proliferation. This helps reduce the number of cancerous"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_1GWAProaXVbSXVZvgdLwPd8C", "custom_id": "664_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "939825c2b8ad3acf70aa35d4e3999269", "body": {"id": "chatcmpl-9St8B9V9Y0O0o4FJgT1CMxjHmaaSd", "object": "chat.completion", "created": 1716672135, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tecartus (brexucabtagene autoleucel) is a chimeric antigen receptor (CAR) T-cell therapy developed by Kite Pharma, a Gilead company. It is specifically designed for the treatment of certain types of hematologic cancers. Here are some essential details that you, as a physician, should know about Tecartus:\n\n1. **Indications**:\n   - Tecartus is approved for the treatment of relapsed or refractory mantle cell lymphoma (MCL) in adult patients.\n   - It has also been approved for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adult patients.\n\n2. **Mechanism of Action**:\n   - Tecartus involves genetic modification of a patient\u2019s T cells to express a CAR that targets the CD19 antigen on the surface of B cells, making the modified T cells capable of identifying and eliminating CD19-expressing malignant cells.\n\n3. **Administration**:\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_UrkSJwYKo0fXhQmSb8ni8cUX", "custom_id": "665_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "3a263df66336240bcaf3d7e7ea650f06", "body": {"id": "chatcmpl-9St8Bokxe3VNn5qQlxvlIZbBahyeH", "object": "chat.completion", "created": 1716672135, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Piqray (alpelisib) is an oral medication used in combination with fulvestrant for the treatment of certain types of breast cancer. Here are key points you should know about Piqray as a physician:\n\n### Indications\n- Piqray is indicated for postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer.\n- It is used in combination with fulvestrant, following disease progression on or after an endocrine-based regimen.\n\n### Mechanism of Action\n- Alpelisib inhibits the phosphatidylinositol-3-kinase (PI3K) alpha isoform.\n- PIK3CA mutations lead to an activation of the PI3K pathway, which is associated with cancer growth, resistance, and poor prognosis.\n\n### Administration and Dosage\n- The recommended dose is 300 mg"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_XJdtHjP00shdh9a50gnmD7Jr", "custom_id": "666_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "96b6c0a64d5af520948fc89c58754727", "body": {"id": "chatcmpl-9St8BDkPjBlEAjxuiANhnZg02U5Qx", "object": "chat.completion", "created": 1716672135, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, you should be aware that Quinamed (generic name: amonafide) is an investigational anticancer agent that has been studied for its potential use in the treatment of various types of cancers, including leukemia, lymphoma, and solid tumors. Here are some key points you should know:\n\n1. **Mechanism of Action**:\n   - Quinamed is a DNA intercalator and topoisomerase II inhibitor, which means it works by interfering with the DNA replication process in cancer cells, thereby inhibiting cell division and promoting cell death.\n\n2. **Clinical Trials**:\n   - Clinical trials have investigated the safety and efficacy of Quinamed in different cancer types. However, as of my knowledge cutoff date in October 2021, it has not received FDA approval for clinical use.\n\n3. **Administration**:\n   - It is typically administered intravenously, but specific dosing regimens depend on the clinical trial protocols and patient factors.\n\n4. **Side Effects**:\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_npu2tMtXa93NMBVyd2I3kwKS", "custom_id": "667_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e302bdbe2bf769b978d4a278e20c1a29", "body": {"id": "chatcmpl-9St8CeCrCvSxcvCswzRQKnxFBVkEx", "object": "chat.completion", "created": 1716672136, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Amoxi, commonly known by its generic name amoxicillin, is a widely-used antibiotic in the penicillin class. It is important for physicians to be aware of several key aspects of this medication:\n\n1. **Mechanism of Action**: Amoxicillin works by inhibiting bacterial cell wall synthesis, which ultimately leads to the death of the bacteria. It is effective against a range of Gram-positive and some Gram-negative bacteria.\n\n2. **Indications**: Amoxicillin is used to treat various bacterial infections, including but not limited to:\n   - Respiratory tract infections (e.g., sinusitis, bronchitis, and pneumonia)\n   - Ear infections (otitis media)\n   - Throat infections (e.g., streptococcal pharyngitis)\n   - Urinary tract infections\n   - Skin infections\n   - Helicobacter pylori infection (as part of combination therapy for peptic ulcer disease)\n\n3. **Dosage and Administration**: Dosage may vary"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_XB21lK24NcUoXIvQN3mn3g6R", "custom_id": "668_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "01ae480df10b4bc1890bcf4bfec15334", "body": {"id": "chatcmpl-9St8CjH4cZhLXcOB6s4qRhTntXPOr", "object": "chat.completion", "created": 1716672136, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It sounds like you may be referring to a specific case or patient named Amelie, but as an AI, I don't have access to specific personal information or individual patient records.\n\nHowever, if you're referring to relevant medical considerations when dealing with any patient, including one named Amelie, here are some general tips:\n\n1. **Medical History**: Always gather a comprehensive medical history, including past illnesses, surgeries, allergies, medications, and family history.\n\n2. **Current Symptoms**: Ask detailed questions about presenting symptoms. This can include onset, duration, intensity, and any factors that aggravate or alleviate the symptoms.\n\n3. **Physical Examination**: Conduct a thorough physical examination based on the reported symptoms and medical history.\n\n4. **Diagnostic Tests**: Order appropriate diagnostic tests to further investigate the symptoms if necessary.\n\n5. **Patient Communication**: Ensure clear, empathetic communication. Encourage questions and provide explanations in understandable language.\n\n6. **Cultural Sensitivity**: Be aware of and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Mrjvyw1PAxN855JlHIGWHsWx", "custom_id": "669_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1890c6154ffda7fa13d22a85376a0e8d", "body": {"id": "chatcmpl-9St8CsGQSxh8MDzpU8QZgvnYyZ4wL", "object": "chat.completion", "created": 1716672136, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pemazyre (pemigatinib) is a kinase inhibitor used primarily for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 (fibroblast growth factor receptor 2) fusion or other rearrangement. Here are some key points a physician should know about Pemazyre:\n\n### 1. Indication\n- **Target Population**: Pemazyre is indicated for patients with cholangiocarcinoma characterized by FGFR2 fusion or rearrangement. Patients must have disease progression on or after at least one prior line of systemic therapy.\n- **Biomarker Testing**: Before initiation, it is crucial to confirm the presence of FGFR2 fusions or rearrangements using a validated test.\n\n### 2. Mechanism of Action\n- Pemazyre inhibits FGFR1, 2, and 3. FGFRs are involved in signaling pathways that regulate tumor cell proliferation and survival.\n\n### 3"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_FykrJKR2dfKQDoC25na2lonq", "custom_id": "670_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4edcbc7eb1aae7d9491661495fa8a5a9", "body": {"id": "chatcmpl-9St8CAtIXRhFvfDa3qrIJvkKFSQ9W", "object": "chat.completion", "created": 1716672136, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Qinlock (ripretinib) is a medication approved by the U.S. Food and Drug Administration (FDA) and other regulatory agencies for the treatment of certain types of gastrointestinal stromal tumors (GIST). Here's a detailed overview of what you should know about Qinlock as a physician:\n\n### Indications:\n- **GIST Treatment:** Qinlock is used to treat adults with advanced gastrointestinal stromal tumors (GIST) who have previously received treatment with three or more kinase inhibitors, including imatinib. It is specifically indicated for fourth-line treatment.\n\n### Mechanism of Action:\n- **Tyrosine Kinase Inhibitor:** Qinlock is a switch-control tyrosine kinase inhibitor that targets a broad spectrum of KIT and PDGFRA mutations. It inhibits kinase activity by binding to both the switch pocket and the activation loop, which is believed to help control primary and secondary kinase mutations that lead to GIST.\n\n### Dosage and Administration:\n- **Standard Dose:** The recommended"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_adDzlVzybDBfiHucxBKgBd8E", "custom_id": "671_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e7a16d2db7ddf2a429d9f346e32cd006", "body": {"id": "chatcmpl-9St8CU4BQKl5xPMNoXWLZsnlXnGZe", "object": "chat.completion", "created": 1716672136, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Retevmo (selpercatinib) is a prescription medication that you may prescribe to treat certain types of cancers that are characterized by specific genetic mutations. Here are key points you should know about Retevmo:\n\n### Indications:\n1. **Non-Small Cell Lung Cancer (NSCLC)**:\n   - For adult patients with metastatic NSCLC with RET (rearranged during transfection) gene fusion.\n   \n2. **Medullary Thyroid Cancer (MTC)**:\n   - For adult and pediatric patients (12 years and older) with advanced or metastatic MTC who require systemic therapy and have a RET mutation.\n\n3. **RET Fusion-Positive Thyroid Cancer**:\n   - For adult and pediatric patients (12 years and older) with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate).\n\n### Mechanism of Action:\n- Retevmo is a kinase inhibitor specifically targeting RET"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_65a5UCUNhAlhCFmiICYj5wDZ", "custom_id": "672_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "25a81c97ef24ee27846dc567223f4568", "body": {"id": "chatcmpl-9St8Cys8SKRgtcuGtaFczBjadeHMF", "object": "chat.completion", "created": 1716672136, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Inqovi is a combination medication that contains decitabine and cedazuridine and is used primarily in the treatment of certain types of myelodysplastic syndromes (MDS). As a physician, here are some key points you should be aware of:\n\n1. **Indications**:\n   - Inqovi is indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following features:\n     - Refractory anemia (RA)\n     - Chronic myelomonocytic leukemia (CMML)\n     - Refractory anemia with ringed sideroblasts (RARS)\n     - Refractory anemia with excess blasts (RAEB)\n     - Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System (IPSS) groups.\n  \n2. **Mechanism of Action**:\n   - **Decitabine**: A nucleoside"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_A7dCftM9BV0fTH9iYe6wzXvN", "custom_id": "673_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1a317b4f272aa8703824b96b416b6b1b", "body": {"id": "chatcmpl-9St8CBtQUKB8R4AZ2qPc9n2zuTE3X", "object": "chat.completion", "created": 1716672136, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Pepto-Bismol, whose generic name is bismuth subsalicylate, is an over-the-counter medication commonly used to treat a variety of gastrointestinal discomforts, including nausea, heartburn, indigestion, upset stomach, and diarrhea. As a physician, there are several important considerations you should know about this medication:\n\n1. **Mechanism of Action**: \n   - Bismuth subsalicylate has several mechanisms of action. It acts as a mild antacid, provides protective coating to the stomach and intestines, has anti-inflammatory effects, and possesses antimicrobial activity, especially against Helicobacter pylori.\n\n2. **Indications**:\n   - Relief of mild to moderate diarrhea\n   - Prevention and treatment of traveler's diarrhea\n   - Symptomatic relief of mild to moderate nausea, heartburn, indigestion, and upset stomach\n\n3. **Contraindications**:\n   - Allergy to salicylates (e.g., aspirin)\n   - Active gastrointestinal bleeding"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 43, "completion_tokens": 200, "total_tokens": 243}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_s1e7vnSoKOWsqriIKoKPnIo8", "custom_id": "674_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1d805524384a5846516cd9d8da34193a", "body": {"id": "chatcmpl-9St8CqIrIRKM1k5C0oMIjg8pWZQFU", "object": "chat.completion", "created": 1716672136, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in 2023, \"AiRuiKa\" isn't a recognized name in the medical literature, pharmaceuticals, or prominent healthcare technology. It might be a newer entity, product, or a term that's not yet widely known or disseminated.\n\nHowever, here are a few general steps on how to approach new medical technologies, products, or names:\n\n1. **Verify the Source**: Ensure that the information about AiRuiKa comes from a credible source, such as peer-reviewed journals, reputable medical institutions, or recognized healthcare organizations.\n\n2. **Research the Product/Service**: Look for clinical trials, studies, or papers published about AiRuiKa. PubMed, Google Scholar, and other medical databases can be valuable resources.\n\n3. **Check Regulatory Approval**: Verify if AiRuiKa has been approved by relevant regulatory bodies such as the FDA (in the United States) or EMA (in Europe). Approval from these bodies typically means the product has undergone"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_DS9x8TKTJYsOuJOrRkTfb9sI", "custom_id": "675_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e276208219345dc15c451e94cfef4a35", "body": {"id": "chatcmpl-9St8D0DQylJ2sgbs462OhnJJvopcj", "object": "chat.completion", "created": 1716672137, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Orgovyx (relugolix) is an oral medication prescribed for the treatment of advanced prostate cancer. It is important for physicians to be aware of several key aspects related to this medication:\n\n1. **Mechanism of Action**:\n   - Orgovyx is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It works by directly inhibiting the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, which subsequently reduces the production of testosterone by the testes. Lowering testosterone levels is a critical component in managing prostate cancer.\n\n2. **Indication**:\n   - It is indicated for the treatment of adult patients with advanced prostate cancer.\n\n3. **Dosage and Administration**:\n   - The recommended starting dose is 360 mg on the first day, followed by 120 mg taken orally once daily at approximately the same time each day thereafter.\n   - Orgovyx can be taken with"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_44S9bVLT72cv7R3kzpQHPJTt", "custom_id": "676_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "1f590f66d156507ea88243e456d8e6f7", "body": {"id": "chatcmpl-9St8DEnBvqyxC2MKObMD1OLt607xX", "object": "chat.completion", "created": 1716672137, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Orserdu (elacestrant) is a specialized medication approved for specific types of breast cancer. Here's a comprehensive overview:\n\n### Indications:\nOrserdu is used to treat postmenopausal women or adult men with ER-positive, HER2-negative, metastatic breast cancer that harbors an ESR1 mutation. The mutation is identified using an FDA-approved diagnostic test. \n\n### Mechanism of Action:\nElacestrant, the active ingredient in Orserdu, works as an estrogen receptor degrader (SERD). It binds to estrogen receptors on cancer cells, leading to their degradation and reduced estrogen signaling, which can inhibit the growth and survival of hormone receptor-positive breast cancer cells.\n\n### Administration:\nOrserdu is administered orally. The recommended dose and regimen will be specified based on clinical guidelines and patient-specific factors.\n\n### Efficacy:\nClinical trials have demonstrated that Orserdu can improve progression-free survival in patients with advanced or metastatic breast cancer with the specified receptor status and mutation."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Zpf2xmQ9FAk3VKo6Vj4DIdmK", "custom_id": "677_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "082f53cf1ac9cdb4a97605c0d8bcbdec", "body": {"id": "chatcmpl-9St8DcRuGHzHqvaQYuF2XtyYLVzrF", "object": "chat.completion", "created": 1716672137, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Neutrexin, also known as trimetrexate, is an antimetabolic antifolate drug primarily used in the treatment of pneumocystis jirovecii pneumonia (PCP) in patients who are intolerant to or unresponsive to standard treatment such as trimethoprim-sulfamethoxazole (TMP-SMX). Here are some essential points that a physician should know about Neutrexin:\n\n1. **Mechanism of Action**:\n   - Trimetrexate inhibits dihydrofolate reductase (DHFR), an enzyme important in the synthesis of tetrahydrofolate. This inhibition disrupts DNA synthesis, especially in rapidly dividing cells, such as microorganisms causing infections or cancer cells.\n\n2. **Indications**:\n   - Primarily indicated for the treatment of pneumocystis jirovecii pneumonia in AIDS patients who are intolerant of or who have failed trimethoprim-sulfamethoxazole (TMP-SMX) therapy.\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_UILcqEOMRpUe8NhyrFBxsotO", "custom_id": "678_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "607393de5a08ad53434bf73815f3c145", "body": {"id": "chatcmpl-9St8D3xqAyZ6fIPFPEPumqPYEVflH", "object": "chat.completion", "created": 1716672137, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tepmetko (tepotinib) is an oral medication that targets MET (mesenchymal-epithelial transition) receptor tyrosine kinase. It is primarily used for the treatment of non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations. Here are some key points you should know about Tepmetko:\n\n### Indications\n- **Target Patient Population:** Tepmetko is indicated for adult patients with metastatic NSCLC harboring MET exon 14 skipping alterations.\n- **Usage Context:** It is specifically used in cases where the cancer has progressed despite previous treatments, or for newly diagnosed metastatic NSCLC where MET alterations are present.\n\n### Mechanism of Action\n- **MET Inhibition:** Tepmetko inhibits MET signaling pathways, which are involved in oncogenesis, tumor proliferation, and metastasis. By inhibiting MET, the drug aims to reduce tumor growth.\n\n### Dosage and Administration\n- **Dosage:** The recommended dose is typically 450"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_BAnvBXMR72HCLUS0q0vrfIy3", "custom_id": "679_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b1760fc7a13c56e4a26b22fd58330141", "body": {"id": "chatcmpl-9St8DEWJk8FzOvrkbiyf2swBhMjFS", "object": "chat.completion", "created": 1716672137, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lytgobi is the brand name for futibatinib, a targeted cancer therapy drug. Here is an overview of key information you should know about Lytgobi as a physician:\n\n### Indications:\n- **Primary Use:** Lytgobi (futibatinib) is primarily used for the treatment of adult patients with advanced or metastatic cholangiocarcinoma (bile duct cancer) that is fibroblast growth factor receptor (FGFR2) fusion positive or FGFR2 gene mutation positive. It is typically prescribed when the disease has progressed after at least one prior line of systemic therapy.\n\n### Mechanism of Action:\n- **Targeted Therapy:** Futibatinib is an FGFR inhibitor, specifically inhibiting FGFR1, FGFR2, FGFR3, and FGFR4. These receptors are involved in the proliferation and survival of cancer cells with FGFR gene alterations. By inhibiting these receptors, Lytgobi can help slow or stop the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_0LZYUutIpqklg4PeSOX7jjMg", "custom_id": "680_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ed0da47cabb44d5ef27ad4a5c8393989", "body": {"id": "chatcmpl-9St8DUtqgf0f7G6IGSkzlMS5tuVbn", "object": "chat.completion", "created": 1716672137, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Optune is a medical device used as part of the treatment for glioblastoma multiforme (GBM), a type of aggressive brain tumor. Here are several key points you should know about it:\n\n### Mechanism of Action:\n1. **Tumor Treating Fields (TTFields):** Optune delivers TTFields, which are low-intensity, alternating electric fields. These fields exert physical forces on charged particles within the cancer cells, interfering with cell division and inhibiting tumor growth.\n2. **Cell Disruption:** TTFields specifically target rapidly dividing tumor cells, causing mitotic disruption, chromosome misalignment, and physical damage to cellular structures.\n\n### Indications:\n1. **Newly Diagnosed GBM:** Optune can be used in combination with temozolomide chemotherapy following standard treatments like surgery and radiation therapy.\n2. **Recurrent GBM:** Optune is also indicated for use as a monotherapy in patients with recurrent GBM after other treatment options have failed.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_rRnh9rMtfduJ3a9N1xDDWQm5", "custom_id": "681_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "389f74b3bc12bf29a779daa15994aee4", "body": {"id": "chatcmpl-9St8DUSpDVf8tyTy3K4jq0NQY4MUE", "object": "chat.completion", "created": 1716672137, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Breyanzi (lisocabtagene maraleucel) is a type of CAR T-cell therapy indicated for the treatment of adults with certain types of large B-cell lymphoma. Here's what you should know about it:\n\n### Indications:\nBreyanzi is approved for adults with relapsed or refractory large B-cell lymphoma, including:\n- Diffuse large B-cell lymphoma (DLBCL)\n- High-grade B-cell lymphoma\n- Primary mediastinal large B-cell lymphoma\n- Follicular lymphoma grade 3B\n\n### Mechanism of Action:\nBreyanzi is a personalized immunotherapy. Patient's T cells are collected and genetically modified to express a chimeric antigen receptor (CAR) that targets the CD19 protein on the surface of B cells. These modified T cells are then expanded in the laboratory and infused back into the patient, where they can recognize and kill CD19-expressing malignant B cells.\n\n### Administration:\nThe process includes several steps:\n1. **Leuk"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_MHXIfdla3a9WzEqhnj1cgmNZ", "custom_id": "682_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d10422b92af3b743aef0ed69887389c9", "body": {"id": "chatcmpl-9St8DYmKbD953dxvxTftjLLwkxCOV", "object": "chat.completion", "created": 1716672137, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to have a comprehensive understanding of Abecma (idecabtagene vicleucel), a CAR T-cell therapy indicated for the treatment of adults with multiple myeloma. Here\u2019s a detailed overview:\n\n### Indications:\n- Abecma is approved for the treatment of adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.\n\n### Mechanism of Action:\n- Abecma uses a patient's own T cells, which are engineered to express a chimeric antigen receptor (CAR) that targets the B-cell maturation antigen (BCMA) on myeloma cells. This allows the patient's modified T cells to recognize and eliminate BCMA-expressing cells.\n\n### Administration:\n- The process involves several steps:\n  1. **Leukapheresis**: Collection of the patient\u2019s T cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_OcFKdHwLjMcuHFkTrzGdY76b", "custom_id": "683_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ce297c3801b52022cdb3b8e79ecc28d7", "body": {"id": "chatcmpl-9St8D8zP7HseDN7ByHhcRCCEP0uI1", "object": "chat.completion", "created": 1716672137, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ayvakit (avapritinib) is a medication used primarily in the treatment of certain types of advanced systemic mastocytosis (ASM), indolent systemic mastocytosis (ISM), and other mast cell disorders. It is also used for gastrointestinal stromal tumors (GIST) that harbor a specific mutation in the platelet-derived growth factor receptor alpha (PDGFRA) gene.\n\nHere are some key points you should know:\n\n1. **Mechanism of Action**: Ayvakit is a tyrosine kinase inhibitor that targets specific mutated proteins, including PDGFRA and KIT D816V, which are involved in the abnormal proliferation and activation of mast cells.\n\n2. **Indications**:\n   - **Systemic Mastocytosis (SM)**: Ayvakit is approved for adult patients with ASM, including aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).\n   -"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_HY8I6fixcXtuG0Ui118kD8kv", "custom_id": "684_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "fd500311392a6aa6a6df3851de489ff0", "body": {"id": "chatcmpl-9St8D6lWZ4IorsGxydheJbKH3FdcT", "object": "chat.completion", "created": 1716672137, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Turalio (generic name: pexidartinib) is a medication used for treating tenosynovial giant cell tumor (TGCT), also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS). This medication is specifically indicated for adults with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery.\n\nHere are important points you should know about Turalio:\n\n### Mechanism of Action\n- **Turalio** is a tyrosine kinase inhibitor that targets the colony-stimulating factor 1 receptor (CSF1R). By inhibiting CSF1R, it reduces the proliferation of tumor cells.\n\n### Indications\n- It is indicated for the treatment of adults with symptomatic TGCT (PVNS or GCT-TS) that:\n  - Is associated with severe morbidity or functional limitations.\n  - Is not amenable to improvement"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_BFDD9zE00dX1lzCPHIEYK0Vb", "custom_id": "685_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "5418114d5603dc36a85f5c4e49d1c49b", "body": {"id": "chatcmpl-9St8DVpgj4m1fk1BgigHa1mgtD1q3", "object": "chat.completion", "created": 1716672137, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Gavreto (pralsetinib) is a targeted cancer therapy specifically designed to inhibit RET (rearranged during transfection) kinase, which is implicated in certain types of cancers. Here are some key points you should know as a physician:\n\n### Indications\n1. **Non-Small Cell Lung Cancer (NSCLC)**: Gavreto is approved for use in adult patients with metastatic RET fusion-positive non-small cell lung cancer.\n2. **Thyroid Cancer**: It is also approved for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) or RET fusion-positive thyroid cancer who require systemic therapy and for whom no satisfactory alternative treatment options are available.\n\n### Mechanism of Action\nGavreto is a selective RET kinase inhibitor. It blocks the activity of RET fusion proteins and RET mutations which drive cancer cell proliferation in RET-altered malignancies.\n\n### Dosage and Administration\nThe typical dosage for"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_QRco1776JYIQYZXZPnfg1rwD", "custom_id": "686_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "85366e2e3c804e300913c66062edac15", "body": {"id": "chatcmpl-9St8EsHsSO6NC2aJLxFyLgDiTrrZT", "object": "chat.completion", "created": 1716672138, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zepzelca (lurbinectedin) is an anticancer drug used primarily in the treatment of metastatic small cell lung cancer (SCLC). Here are several key points you should be aware of as a physician:\n\n### Indications:\n- **Metastatic Small Cell Lung Cancer**: Zepzelca is indicated for adults with metastatic SCLC who have progressed on or after platinum-based chemotherapy.\n\n### Mechanism of Action:\n- **DNA Binding**: Lurbinectedin binds to the minor groove of DNA, bending the DNA helix towards the major groove, which disrupts the cell cycle and inhibits the proliferation of cancer cells. It also affects the transcription of oncogenes and induces apoptosis.\n\n### Administration:\n- **Intravenous Infusion**: Administered via IV infusion over 60 minutes.\n- **Dosage**: The recommended dose is 3.2 mg/m\u00b2 every 21 days, but adjustments may be necessary based on patient tolerance and other factors.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_hD7Cx5YHexMcQ5LbLx6CnPJ7", "custom_id": "687_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f3184c39f0f54b76172a5b5f271149bb", "body": {"id": "chatcmpl-9St8EfYeBdjPENBAERdwsnNbfVtyV", "object": "chat.completion", "created": 1716672138, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Flagyl, the brand name for metronidazole, is an antibiotic and antiprotozoal medication widely used in clinical practice. Here are several important considerations for physicians when prescribing or managing patients on Flagyl:\n\n### Indications:\n1. **Infections**: It's commonly used to treat anaerobic bacterial infections, including intra-abdominal infections, skin and soft tissue infections, bone and joint infections, central nervous system infections, and gynecologic infections.\n2. **Protozoal Infections**: Treats infections caused by protozoa such as trichomoniasis, amoebiasis, and giardiasis.\n3. **Clostridium difficile**: Used for the treatment of mild to moderate Clostridium difficile-associated diarrhea (CDAD).\n4. **H. pylori Infection**: Part of combination therapy for Helicobacter pylori eradication in peptic ulcer disease.\n\n### Mechanism of Action:\n- Metronidazole exerts its effect by entering the microbial"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_7vYTp7jjuK1d1qqqTjB21L55", "custom_id": "688_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "be86cecb31125f55d82820f06597389b", "body": {"id": "chatcmpl-9St8EaQPCUKnQHLZONLj8zRcqzo8y", "object": "chat.completion", "created": 1716672138, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Danyelza (naxitamab-gqgk) is a monoclonal antibody used in oncology, specifically for the treatment of high-risk neuroblastoma. Here are key points to be aware of:\n\n### Indications\n- **Danyelza** is indicated for use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of pediatric patients aged one year and older, as well as adult patients, with refractory or relapsed high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.\n\n### Mechanism of Action\n- **Monoclonal Antibody Specificity**: Danyelza targets GD2, which is a disialoganglioside expressed on neuroblastoma cells.\n- **Immune Activation**: By binding to GD2, Danyelza flags the neuroblastoma cells for destruction by immune effector cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_Ya2dWptSEERVWlxHoyz5WSqK", "custom_id": "689_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7da7ca413e21a9c2ea4067dce56259e4", "body": {"id": "chatcmpl-9St8E3McSFW5n7qR10pRfZDy3VrLX", "object": "chat.completion", "created": 1716672138, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Certainly! As a physician, it's important to have a thorough understanding of any medication you might prescribe, including Panmycin. Here's a detailed overview:\n\n### What is Panmycin?\n- **Generic Name:** Tetracycline\n- **Type:** Antibiotic\n\n### Mechanism of Action:\n- **Function:** Panmycin (tetracycline) is a broad-spectrum antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit of bacteria. This prevents the addition of new amino acids to the growing peptide chain, effectively stopping bacterial growth.\n\n### Indications:\n- **Uses:** Panmycin is effective for treating a variety of bacterial infections, including:\n  - Respiratory tract infections\n  - Urinary tract infections\n  - Skin infections\n  - Acne\n  - Chlamydia\n  - Rickettsial infections (e.g., Rocky Mountain spotted fever)\n  - Specific types of gastrointestinal infections\n\n### Contraindications:\n- **Allergic"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_G4mwozmQqFtWQYF8OHS4BHDm", "custom_id": "690_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0c58d4b9daafe56296dd131580adee3f", "body": {"id": "chatcmpl-9St8EwEHH5wS2swKwtAnss1CnQh3z", "object": "chat.completion", "created": 1716672138, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "De-Noltab is a brand name for the medication colloidal bismuth subcitrate (also known as bismuth subcitrate potassium). It's used primarily for the treatment of gastrointestinal issues such as peptic ulcers, gastritis, and Helicobacter pylori infections. Here are several key points you should know:\n\n### Mechanism of Action:\n1. **Protective Barrier**: Bismuth subcitrate complexes with proteins in the gastric mucosa, creating a protective barrier over ulcers and erosions.\n2. **Antimicrobial Action**: It exhibits antimicrobial properties, particularly against Helicobacter pylori, a bacterium associated with peptic ulcers and chronic gastritis.\n3. **Mucosal Defense**: Enhances mucosal defense mechanisms by stimulating the secretion of mucus and bicarbonate.\n\n### Indications:\n1. **Peptic Ulcer Disease**: Particularly effective for those caused by H. pylori when used in combination with antibiotics.\n2. **Gastritis"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_zFoQ04ZaGDypb6PqPlRC0Ia3", "custom_id": "691_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "03658bd4bdeb3eb50e6f820d9bf310b8", "body": {"id": "chatcmpl-9St8EoSyutwSzyROvAicoh66sFfL1", "object": "chat.completion", "created": 1716672138, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Welireg (belzutifan) is a medication used primarily in oncology, particularly for the treatment of certain types of advanced or metastatic cancers. Here are key points you should be aware of:\n\n### Indications\n1. **Von Hippel-Lindau (VHL) Disease:** Welireg is used for the treatment of patients with VHL disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.\n\n### Mechanism of Action\n2. **Hypoxia-Inducible Factor-2 Alpha Inhibition:** Belzutifan inhibits the hypoxia-inducible factor-2 alpha (HIF-2\u03b1), which plays a significant role in tumor growth and angiogenesis in certain cancers.\n\n### Administration\n3. **Oral Intake:** Welireg is administered orally, typically as a once-daily dose. The pill should be swallowed whole"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_InTPRfrmsHAP87B95j4jQrgM", "custom_id": "692_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "25f40fc558b2aa0770c91c4cb5a0eb75", "body": {"id": "chatcmpl-9St8EmvIPGQRefj2wV0Ecs0Sy5buT", "object": "chat.completion", "created": 1716672138, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to be familiar with Rybrevant (amivantamab-vmjw), especially if you are treating patients with non-small cell lung cancer (NSCLC). Here are key aspects you should know:\n\n### Mechanism of Action:\nRybrevant is a bispecific antibody targeting EGFR (epidermal growth factor receptor) and MET (mesenchymal-epithelial transition factor). It works by binding to these receptors and inhibiting their signaling pathways, which are commonly involved in the pathogenesis of non-small cell lung cancer.\n\n### Indications:\nRybrevant is approved by the FDA for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer that has EGFR exon 20 insertion mutations, and whose disease has progressed on or after platinum-based chemotherapy.\n\n### Administration:\n- **Dosage Form:** It is administered as an intravenous infusion.\n- **Initial Dose:** The first dose (1050 mg or 1400 mg,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_edZrky90eF9IX4ZmjABnLU4u", "custom_id": "693_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6fc447712e4d64173201d36c3e8e1061", "body": {"id": "chatcmpl-9St8EtjWZyjYk3kmjmFCgLAtYlfYY", "object": "chat.completion", "created": 1716672138, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Onureg, which is the brand name for oral azacitidine, is an important medication used primarily in the treatment of acute myeloid leukemia (AML). Here are key points about Onureg that you should be aware of as a physician:\n\n### Indications:\n1. **Maintenance Therapy for AML:**\n   - Onureg is indicated for the continued treatment of adults with AML who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and who are not able to complete intensive curative therapy.\n\n### Mechanism of Action:\n- **Azacitidine** interferes with DNA methylation and protein synthesis, promoting cytotoxicity in rapidly proliferating cancer cells and inducing cell death.\n\n### Administration:\n- **Oral Route:** Unlike other forms of azacitidine, which are given subcutaneously or intravenously, Onureg is administered orally.\n- **Dosing:** The typical dose is 300 mg taken orally once daily on Days"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_G3QeUlKjKd3KhrZwDpUcxx3B", "custom_id": "694_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "aa704cb29ad3850e31da95295b6fcfa2", "body": {"id": "chatcmpl-9St8EgE7FUqOGcKwGreEgWQ1q8oc8", "object": "chat.completion", "created": 1716672138, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Colcrys is a brand name for colchicine, a medication primarily used to treat and prevent gout attacks and familial Mediterranean fever (FMF). Here's a detailed overview of what you should know about Colcrys as a physician:\n\n### 1. **Mechanism of Action:**\n- **Anti-inflammatory Properties:** Colchicine works by decreasing inflammation. It disrupts the activation of neutrophils and other inflammatory processes by inhibiting microtubule polymerization, reducing the release of inflammatory glycoproteins from phagocytes.\n  \n### 2. **Indications:**\n- **Gout:** Treatment of acute gout flares and prevention of future flares.\n- **Familial Mediterranean Fever (FMF):** Management and prevention of flares in patients with this genetic disorder.\n- **Off-Label Uses:** Occasionally used in pericarditis and other inflammatory disorders.\n\n### 3. **Dosage and Administration:**\n- **Acute Gout Flare:** Typically"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_HGWyYEP7Tl8sMzDFmlLL96jd", "custom_id": "695_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "604765410b5dfad56326b2341e05aa57", "body": {"id": "chatcmpl-9St8EYxLFR5oeh4cnbAaeWMrCg8ZW", "object": "chat.completion", "created": 1716672138, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Jemperli, also known by its generic name dostarlimab, is a monoclonal antibody that functions as a PD-1 (programmed death receptor-1) inhibitor. It's an immune checkpoint inhibitor used in oncology for the treatment of certain types of cancer, specifically endometrial cancer with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) status. Here are some key points a physician should know about Jemperli:\n\n### Indications:\n- **Endometrial Cancer**: Approved for the treatment of adult patients with recurrent or advanced endometrial cancer that has dMMR, as determined by an FDA-approved test, and who have progressed on or following prior treatment with a platinum-containing regimen.\n  \n### Mechanism of Action:\n- Jemperli works by blocking the PD-1 receptor on T-cells, which increases the immune system's ability to detect and destroy cancer cells.\n\n### Administration:\n- **Dosage**: Typically"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_EKnWUknQUBKpy9w8ehgtaLa4", "custom_id": "696_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "3bff098e325232ffc13e9671785d63fc", "body": {"id": "chatcmpl-9St8EzS7645dGmFTGAX1Gf3uQbAwQ", "object": "chat.completion", "created": 1716672138, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in 2023, there is no widely recognized medical condition or significant medical research explicitly associated with the term \"Hansizhuang.\" It is possible that it might refer to a name of a person, place, or entity not widely covered in medical literature up to that point. \n\nIf \"Hansizhuang\" has come to signify something specific in the realm of medicine, such as a new drug, treatment, disease, or medical phenomenon, it may have emerged after my most recent update. I advise checking the latest medical literature or databases like PubMed, contacting professional medical societies, or consulting with colleagues to get the current and accurate information you're seeking.\n\nIf \"Hansizhuang\" is a colloquial or regional term for a specific medical condition, cultural understanding, or traditional medicine practice, it would also be wise to explore medical anthropology or local medical journals and resources for further insights."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 181, "total_tokens": 222}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_OevtxT8qaVPAq7IPesciFwu3", "custom_id": "697_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "d22d2d0002396c46428d36d99b1bf43e", "body": {"id": "chatcmpl-9St8FlLtuvm7f6n3kqdrmXAwtcnsM", "object": "chat.completion", "created": 1716672139, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update in October 2023, \"Cejemly\" does not appear to correspond to any widely recognized medical term, pharmaceutical product, or treatment in the scientific literature or clinical practice. It is possible that there may be a misspelling, a very newly released drug, or a very specific brand/trademark name that is not well-documented yet.\n\nIf you are referring to a drug, treatment, or medical device, please provide additional context or check for any possible typographical errors. Here are some things you might do to gather more information:\n\n1. **Consult authoritative sources:**\n   - Review medical databases like PubMed, MedlinePlus, or clinical guidelines.\n   - Check for FDA approvals or similar regulatory body documentation.\n   - Look into the latest pharmaceutical releases and updates.\n\n2. **Seek professional networks:**\n   - Discuss with colleagues or specialists in the relevant field.\n   - Utilize professional networks like LinkedIn or medical community forums where new treatments and drugs"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_N5Nu9ORRjy6BjbZeOOgfHvSc", "custom_id": "698_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "17bdac6608d8d927436bcca361b5c385", "body": {"id": "chatcmpl-9St8FsiKJlRjRYsp5nLt790SZTaUH", "object": "chat.completion", "created": 1716672139, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Fyarro (sirolimus protein-bound particles for injectable suspension) is a pharmaceutical product designed to treat specific types of cancer. Here are some key points you should know as a physician:\n\n### Indication\n- **Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa):** Fyarro is indicated for the treatment of adult patients with advanced malignant PEComa. PEComa is a rare type of mesenchymal tumor.\n\n### Mechanism of Action\n- **mTOR Inhibition:** Fyarro works by inhibiting the mechanistic target of rapamycin (mTOR), a kinase that regulates cell growth, proliferation, and survival. By inhibiting mTOR, Fyarro helps reduce the growth and spread of cancer cells.\n\n### Administration\n- **Intravenous Infusion:** Fyarro is administered as an intravenous infusion. Specific details on dosage and infusion rates are provided in the prescribing information and should be closely followed to ensure patient"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_njC7vcwCV23kwp2TaI0lwEDr", "custom_id": "699_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ff0a7b142cf9c171695d52335e2cf67b", "body": {"id": "chatcmpl-9St8F5uvnhayulULK709ueNgUbxag", "object": "chat.completion", "created": 1716672139, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Antrypol, also known as Suramin, is a medication primarily used to treat African trypanosomiasis, also called sleeping sickness, which is caused by the Trypanosoma brucei parasite. It is specifically effective against the early stages of the disease, before the central nervous system is involved.\n\nHere are some key points that you should know about Antrypol (Suramin):\n\n1. **Mechanism of Action**:\n   - Suramin works by inhibiting various enzymes involved in the energy metabolism of the parasite. It disrupts glycolysis and the function of other cellular enzymes, leading to the death of the trypanosomes.\n\n2. **Indications**:\n   - It is used for the treatment of early stages of African trypanosomiasis (Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense infections).\n   - It can also be used for treating Onchocerciasis (river blindness),"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ASy6qqRSciZ2nltoA2Bz8rTj", "custom_id": "700_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "4fa4c90d86e72b7eac6f7f7ed4a156ab", "body": {"id": "chatcmpl-9St8Fh1JkdHciceXWLgiED7mEYY0E", "object": "chat.completion", "created": 1716672139, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to stay informed about new and emerging medications. Krazati (adagrasib) is one of these newer medications, specifically classified as an KRAS G12C inhibitor. KRAS mutations are common in various types of cancer, and this mutation can drive cancer growth and resistance to treatment. Here are several key points you should know about Krazati:\n\n1. **Indication**: Krazati is primarily used to treat non-small cell lung cancer (NSCLC) with a KRAS G12C mutation. It may also have utility in other cancers with this specific genetic alteration, but lung cancer is its main indication.\n\n2. **Mechanism of Action**: KRAS is a protein that plays a crucial role in cell division and survival. The G12C mutation alters the protein in a way that contributes to cancer development. Krazati selectively binds to the KRAS G12C mutant protein, inhibiting its function and thereby slowing or stopping cancer cell"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_a7GJ2WDWR2xKdZzk22FUaDXV", "custom_id": "701_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "6d50b1d64ddee140c2951d3c359d2192", "body": {"id": "chatcmpl-9St8FVyOXQUKwEhwp5OMNTXAecF39", "object": "chat.completion", "created": 1716672139, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Kimmtrak (generic name: tebentafusp-tebn) is a medication used in the treatment of a specific type of cancer. Here are some key points you should know about Kimmtrak:\n\n1. **Mechanism of Action**:\n   - Kimmtrak is a bispecific T-cell engager (BiTE) that targets gp100, a melanoma-associated antigen, and CD3 on T-cells. This dual targeting helps direct the body's immune system to attack melanoma cells.\n\n2. **Indications**:\n   - It is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.\n\n3. **Administration**:\n   - Kimmtrak is administered intravenously (IV). It is typically given once a week via IV infusion.\n\n4. **Efficacy**:\n   - Clinical trials have shown that Kimmtrak can improve overall survival in patients with HLA-A*02:01-positive uveal melanoma.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_bGPeo8yH92P0IYaEzjR7gtMa", "custom_id": "702_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "0225914189d7fa481771442de9f2d7ab", "body": {"id": "chatcmpl-9St8FGZ2HIREdkdEpTb960yWap40f", "object": "chat.completion", "created": 1716672139, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Inrebic (fedratinib) is a medication used primarily in the treatment of certain types of myelofibrosis, a rare bone marrow disorder. Here are key points you should know about Inrebic as a physician:\n\n### Indications:\n- **Primary Indication:** It's used to treat intermediate-2 or high-risk myelofibrosis.\n- **Mechanism of Action:** Inrebic is a Janus kinase (JAK2) inhibitor, which works by inhibiting JAK2 and other tyrosine kinases, ultimately reducing the proliferation of abnormal cells and alleviating symptoms.\n\n### Dosage and Administration:\n- **Typical Dosage:** The recommended starting dose is 400 mg orally once daily. \n- **Administration:** It can be taken with or without food.\n- **Adjustment:** Dose adjustments may be necessary based on patient response and tolerability.\n\n### Side Effects:\n- **Common Side Effects:** Diarrhea, nausea, vomiting, anemia, and"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_YZpUt9e6XOYOjJuDoPFpB0jF", "custom_id": "703_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "07dcb1e2bd5e6d55d4079c7c2c34bd8a", "body": {"id": "chatcmpl-9St8FDmT6lm1nQ2K8u8nzYilYtzrP", "object": "chat.completion", "created": 1716672139, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) is a subcutaneous formulation combining trastuzumab, a monoclonal antibody, and hyaluronidase, an enzyme that facilitates the delivery of trastuzumab into the tissues. Here are key points a physician should know about Herceptin Hylecta:\n\n### Indications:\n- **HER2-Positive Cancers**: Herceptin Hylecta is indicated for the treatment of HER2-positive breast cancer. This includes adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature) breast cancer, as well as metastatic breast cancer.\n\n### Dosage and Administration:\n- **Administration Route**: It is administered subcutaneously, typically in the thigh.\n- **Dosing Schedule**: The recommended dose is 600 mg trastuzumab/10,000 units hyaluronidase once every 3 weeks"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 44, "completion_tokens": 200, "total_tokens": 244}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_JAsb0GrA7r7jiXXjM0YpsvHs", "custom_id": "704_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "31c433c824b35fd3ec9ec207c68c2eaf", "body": {"id": "chatcmpl-9St8Fr2hClMkiP1TB0SKQioE5k7rZ", "object": "chat.completion", "created": 1716672139, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about Brukinsa (generic name: zanubrutinib), especially if you are considering it as a treatment option for your patients. Here are some key points to understand:\n\n### Indications and Uses:\n1. **Target Use**: Brukinsa is primarily used to treat certain types of B-cell malignancies, such as mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.\n2. **Clinical Trials**: It is also being investigated and used in other types of lymphomas and chronic lymphocytic leukemia (CLL), among other conditions.\n\n### Mechanism of Action:\n- **BTK Inhibition**: Brukinsa is a Bruton's tyrosine kinase (BTK) inhibitor. BTK is crucial for the growth and survival of B-cells; by inhibiting this enzyme, zanubrutinib interferes with the malignant cells' processes, inducing apoptosis and reducing proliferation.\n\n###"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_754jbCYUAgITAMTumBANZiMD", "custom_id": "705_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "cd27ddbd32ce3f78400816dbbb5b0e47", "body": {"id": "chatcmpl-9St8GbGE3kkIATzEJNSRfTohc5O4Z", "object": "chat.completion", "created": 1716672140, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It appears there may be a typo or ambiguity in your question, as \"Ivesa\" is not a widely recognized term related to medicine, pharmaceutical products, or any known condition. If \"Ivesa\" is a specific medication, medical device, or perhaps a rare condition that you are referring to, additional context would be helpful.\n\nGiven the ambiguity, here are a few general steps you might take:\n\n1. **Clarify the Term**: Double-check the spelling or provide more context surrounding \"Ivesa.\" It could be a new drug, a brand name, or a specific condition that is not widely known yet.\n\n2. **Consult Reliable Sources**: Refer to trusted medical databases, pharmaceutical references, or medical dictionaries such as PubMed, UpToDate, MedlinePlus, or the PDR (Physician's Desk Reference).\n\n3. **Patient History**: If this term was mentioned by a patient, gather a detailed history and any available documentation they might have. This"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_DfSREQAOt86tVx3idwDZMV5o", "custom_id": "706_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f6c77783d3df455fd4c5ccb1923934c6", "body": {"id": "chatcmpl-9St8Gk2GpjTKiCJRXMDQHQ3l8kh5X", "object": "chat.completion", "created": 1716672140, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Carvykti (ciltacabtagene autoleucel) is a chimeric antigen receptor T cell (CAR-T) therapy that has been FDA-approved for the treatment of certain hematologic malignancies, specifically multiple myeloma. Here are key points to know about Carvykti:\n\n1. **Indication:**\n   - Carvykti is approved for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.\n\n2. **Mechanism of Action:**\n   - Carvykti involves the modification of a patient's own T cells to express a CAR that targets B-cell maturation antigen (BCMA), a protein highly expressed on multiple myeloma cells.\n   - These modified T cells are then re-infused into the patient, where they recognize and kill BCMA-expressing myeloma cells"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_9YAjLE0LchqyxBGsYAFePBva", "custom_id": "707_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a5b3201dc25e81ca2cbdae6a376d08ea", "body": {"id": "chatcmpl-9St8GfjUoyNtQbqTWiJrkCocVwYnq", "object": "chat.completion", "created": 1716672140, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be informed about Scemblix (asciminib), especially if you treat patients with chronic myeloid leukemia (CML). Here are key points to know:\n\n### Indications:\n- **Scemblix (asciminib)** is approved for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) who have previously been treated with two or more tyrosine kinase inhibitors (TKIs).\n\n### Mechanism of Action:\n- Asciminib works as a **STI571 class tyrosine kinase inhibitor (TKI)**, but specifically, it is a **BCR::ABL1 allosteric inhibitor**. This means it binds to the ABL1 protein at a different site from where most TKIs bind, offering a novel mechanism potentially useful in cases resistant to other treatments.\n\n### Dosage and Administration:\n- The typical recommended dosage is 40 mg taken once"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_1mxCnR1Xo6fPsDAOtqHUyF5w", "custom_id": "708_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "be43b109a3c5c880956f4b3b4f58bba4", "body": {"id": "chatcmpl-9St8G5TJHn5VvQHkPibSqnzEwoVOt", "object": "chat.completion", "created": 1716672140, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Zynlonta (loncastuximab tesirine-lpyl) is an antibody-drug conjugate (ADC) approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. Below are some important details you should know as a physician:\n\n### 1. Mechanism of Action:\n- **Conjugate Structure:** Zynlonta is composed of a humanized monoclonal antibody linked to a cytotoxic agent. The antibody targets CD19, a protein expressed on the surface of B-cells.\n- **Cytotoxic Agent:** The drug component is a pyrrolobenzodiazepine (PBD) dimer, which binds to DNA and induces cell death by creating cross-links, preventing cell division.\n\n### 2. Indications:\n- Zynlonta is indicated for adult patients with relapsed or refractory"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_b4lfiQHIiHdGAWAdQDlvqBz2", "custom_id": "709_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "141694be395779b019bd76542dd06686", "body": {"id": "chatcmpl-9St8GbsTAyQrPOVTQP6gOoXNTfEIx", "object": "chat.completion", "created": 1716672140, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tazverik, whose generic name is tazemetostat, is an important medication you might encounter in your practice, particularly if you specialize in oncology or hematology. Here are some key points you should know about Tazverik:\n\n### 1. **Indications and Usage**\n- **Epithelioid Sarcoma**: Tazverik is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.\n- **Follicular Lymphoma**: It is also approved for adults with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as determined by an FDA-approved test, and who have received at least two prior systemic therapies.\n\n### 2. **Mechanism of Action**\n- Tazemetostat is an EZH2 (enhancer of zeste homolog 2) inhibitor. EZH2 is a hist"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_chpX0mNi8FUG2qjG3wVWQYXg", "custom_id": "710_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "947c0d41ffcbfd937b0ac5783fc848c9", "body": {"id": "chatcmpl-9St8GgfyxFVRhXlUoyTqYGTZ9XVEW", "object": "chat.completion", "created": 1716672140, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Opdualag is a combination immunotherapy used in the treatment of certain types of cancer. It combines two monoclonal antibodies: nivolumab (an anti-PD-1 therapy) and relatlimab (an anti-LAG-3 therapy). Here's what you, as a physician, should know about Opdualag:\n\n1. **Mechanism of Action**:\n   - **Nivolumab**: It inhibits the PD-1 receptor, which can enhance the immune response against tumor cells.\n   - **Relatlimab**: It targets the LAG-3 protein, which is another checkpoint that tumors can exploit to evade immune detection.\n\n2. **Indications**:\n   - As of the knowledge cutoff in October 2021, Opdualag has shown promise in clinical trials for melanoma, and its use might be expanded to other cancers subject to regulatory approvals.\n\n3. **Administration**:\n   - Opdualag is administered via intravenous infusion. The dosing regimen can"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_ed2HiraOP7YXA74u4wYRFNyl", "custom_id": "711_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "72edea62a91a6e2d171b98cefe8eb3ee", "body": {"id": "chatcmpl-9St8GHTcZ81xZVLRQujx1kYRRZrkN", "object": "chat.completion", "created": 1716672140, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it is important to be well-informed about any medication you may prescribe. \"Berofor\" is not a well-known or standard name for any widely-used medication or treatment as of my knowledge cutoff in October 2023. There is a possibility that it could be a brand name specific to a certain country or region, a typographical error, or a lesser-known drug or supplement.\n\nTo provide accurate information, here are some general steps you can take:\n\n1. **Verify the Name and Spelling**: Double-check the spelling and ensure that \"Berofor\" is correct. Medications often have similar-sounding names, so it\u2019s vital to confirm the exact name.\n\n2. **Consult Reliable Sources**: Use trusted medical databases such as Epocrates, UpToDate, or the Physicians' Desk Reference (PDR) to look for information on \"Berofor.\" These resources provide detailed drug information including indications, contraindications, dosing, and adverse effects.\n\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_gXndj2bo7OenLA3HlBFzGMZO", "custom_id": "712_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "9c30b05a28801c0e085e88cfc573700e", "body": {"id": "chatcmpl-9St8G65Tg2mqgFGFcXA4qX8N02Luu", "object": "chat.completion", "created": 1716672140, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Wellferon, also known by its generic name interferon alfa-n1, was a type of interferon used in the treatment of certain types of chronic viral hepatitis and some cancers. It belongs to a class of drugs known as interferons, which are proteins that boost the immune system's ability to fight off viruses and some cancers.\n\nHowever, it's important to note that Wellferon is no longer available on the market; its production was discontinued in the early 2000s due to the availability of newer and more effective treatments. Nonetheless, understanding its historical usage can provide some context for the development of current interferon therapies.\n\nWhen considering any interferon-based therapy, here are some key points you should know:\n\n### Indications\n- **Chronic Hepatitis B and C:** Interferons have been used to manage chronic hepatitis infections by helping to control viral replication.\n- **Certain Cancers:** They can be used in the treatment of some cancers, such as melanoma and certain types of leukemia"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_oJFxTlKw19TtfV28H1WMclPt", "custom_id": "713_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "274bc6f306643005bcf9b1a8f11291c9", "body": {"id": "chatcmpl-9St8GEwopi6vDbYOhN2OnM71cLYHt", "object": "chat.completion", "created": 1716672140, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Margenza (margetuximab-cmkb) is a medication used for the treatment of certain types of breast cancer. Here are some key points a physician should know about Margenza:\n\n1. **Indication**: Margenza is indicated in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.\n\n2. **Mechanism of Action**: Margenza is an anti-HER2 monoclonal antibody similar to trastuzumab but with modifications intended to enhance its immune-mediated effects. It binds to the HER2 receptor, inhibiting the proliferation of tumor cells that overexpress HER2, and helps the immune system to recognize and destroy these cells through antibody-dependent cellular cytotoxicity (ADCC).\n\n3. **Administration**: Margenza is administered intravenously. The specific dosing regimen involves an initial loading dose, followed by maintenance doses administered every"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_i6oSDhSPApgylMpRO9eihfNW", "custom_id": "714_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "3766554e967a545c46ba3ec7be102581", "body": {"id": "chatcmpl-9St8GReprVJtF0b6yQA1Sqoqi1lEC", "object": "chat.completion", "created": 1716672140, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to be well-informed about Lumakras (sotorasib), especially if you are treating patients with non-small cell lung cancer (NSCLC). Here are several key points you should know:\n\n1. **Indication**: \n   Lumakras is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy.\n\n2. **Mechanism of Action**:\n   Lumakras is a small molecule that specifically and irreversibly binds to the KRAS G12C mutant protein, inhibiting its function. KRAS G12C is a common mutation in NSCLC and drives cancer cell proliferation and survival.\n\n3. **Dosage and Administration**:\n   The recommended dosage of Lumakras is 960 mg orally once daily. The tablets should be swallowed whole and can be taken with or without food. Do not crush,"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Jz39axATr2jE70n0OjJ85dtF", "custom_id": "715_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "e589f28a09901ca9941c7bd364ab17c7", "body": {"id": "chatcmpl-9St8GcRgpqWq8voO2lixCEPpMyuGT", "object": "chat.completion", "created": 1716672140, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Ukoniq (umbralisib) is an oral medication developed for the treatment of certain types of lymphoma. Here are key points you should know about Ukoniq:\n\n1. **Indications**: Ukoniq is used for the treatment of:\n   - Relapsed or refractory marginal zone lymphoma (MZL) in patients who have received at least one prior anti-CD20-based regimen.\n   - Relapsed or refractory follicular lymphoma (FL) in patients who have received at least three prior lines of systemic therapy.\n\n2. **Mechanism of Action**: Ukoniq is a kinase inhibitor that targets PI3K-delta and CK1-epsilon, pathways involved in the proliferation and survival of hematologic cancer cells.\n\n3. **Administration**: Ukoniq is taken orally, typically once daily, with or without food. It\u2019s crucial to follow the specific dosage instructions to maintain consistent drug levels in the body.\n\n4. **Common Side Effects**: Patients may experience various"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_2ygYwr5a4CXy5gvVk00qd3H0", "custom_id": "716_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "146ef1c79a9a209099212ba9a0056492", "body": {"id": "chatcmpl-9St8H2tlmglz9zUjiRYHu4ef6mmSF", "object": "chat.completion", "created": 1716672141, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tyvyt (generic name sintilimab) is a monoclonal antibody that functions as a PD-1 (programmed cell death protein-1) inhibitor. Here are some key points you should know about Tyvyt:\n\n### Indications and Usage:\n- **Cancer Treatment**: Tyvyt is primarily used in oncology, particularly for the treatment of certain types of cancers including but not limited to non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), and classical Hodgkin lymphoma.\n- **Combination Therapy**: It is often used in combination with other anticancer agents such as chemotherapy, targeted therapies, or other immunotherapeutic agents.\n\n### Mechanism of Action:\n- **Immune Checkpoint Inhibition**: Tyvyt blocks the PD-1 receptor on T-cells, which increases immune system activity by preventing tumor cells from evading immune surveillance. This enhances the ability of the immune system to detect and destroy cancer cells.\n\n### Administration:\n-"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_3QJo6RaWIOmA2hrBeKGL11qz", "custom_id": "717_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "00023d6ba735bcf5781437aa18e4f565", "body": {"id": "chatcmpl-9St8HT9mspUwK14CJiCiFjSifQGXk", "object": "chat.completion", "created": 1716672141, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Jaypirca is the brand name for Pirtobrutinib, a selective, reversible, next-generation Bruton's tyrosine kinase (BTK) inhibitor. It has garnered attention in the medical community for its potential in treating certain hematologic malignancies, particularly B-cell malignancies like chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).\n\nHere are some key points you might want to know about Jaypirca (Pirtobrutinib):\n\n1. **Mechanism of Action**:\n    - Pirtobrutinib selectively targets and binds to BTK, a key enzyme in the B-cell receptor signaling pathway. By inhibiting BTK, Pirtobrutinib helps in preventing the growth and survival of malignant B cells.\n\n2. **Indications**:\n    - Pirtobrutinib is primarily being studied and utilized for conditions such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), including cases that are refractory"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_uZaW8OfixhQukM5jYsNgM6cg", "custom_id": "718_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ee254efc41da79df54c30c134a55ef94", "body": {"id": "chatcmpl-9St8HQDgFtD7GEv7CggDN4uSAIlgG", "object": "chat.completion", "created": 1716672141, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tuoyi (Toripalimab) is a checkpoint inhibitor used in cancer immunotherapy. It's a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) pathway, which plays a critical role in downregulating the immune system and promoting self-tolerance by suppressing T-cell inflammatory activity. By inhibiting PD-1, Toripalimab enhances the body's immune response against cancer cells.\n\nKey points you should know about Tuoyi include:\n\n1. **Indications**: It is mainly indicated for the treatment of melanoma and other types of advanced or metastatic cancers. The exact indications may vary by country and regulatory approval statuses.\n\n2. **Mechanism of Action**: Toripalimab binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1 and PD-L2 ligands on tumor cells. This blockage releases the brakes on the immune system, allowing it to attack cancer cells more effectively.\n\n3. **Administration**: Tuoyi"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_uPltsc0wIAVGyVCf3W5vGZcM", "custom_id": "719_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "fade9eecbbf8df8ed63491a6f3ae223f", "body": {"id": "chatcmpl-9St8HbuT3BpdZfbJLbxXECeUnDNaT", "object": "chat.completion", "created": 1716672141, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tecvayli (generic name: Tecvayli- **generic name could vary based on the source**), also known as teclistamab, is a medication used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. As a physician, it is important to be aware of several key aspects of Tecvayli, including its mechanism of action, indications, administration guidelines, potential side effects, and considerations for patient monitoring.\n\n### Mechanism of Action\n- **Tecvayli** is a bispecific T-cell engager (BiTE\u00ae) antibody construct that targets both B-cell maturation antigen (BCMA) on multiple myeloma cells and CD3 on T-cells. This dual targeting effectively brings T-cells in close proximity to myeloma cells, facilitating T-cell mediated cytotoxicity and killing of the myeloma cells.\n\n### Indications\n- **Tecvayli** is indicated for the"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ur53mlGLq5E0hfqQHiS1w4hs", "custom_id": "720_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "75965d7b8050c61f7af67ec976a4cda3", "body": {"id": "chatcmpl-9St8HaNDhu4j4bx7z3g2qnxCSoEiP", "object": "chat.completion", "created": 1716672141, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, you should be aware of several key points regarding Exkivity (mobocertinib), a medication used primarily in oncology:\n\n1. **Indication and Usage**:\n   - Exkivity is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.\n\n2. **Mechanism of Action**:\n   - Exkivity is a tyrosine kinase inhibitor (TKI) that targets EGFR exon 20 insertion mutations. It inhibits the tyrosine kinase activity of the EGFR leading to apoptosis and decreased proliferation of tumor cells expressing these mutations.\n\n3. **Administration**:\n   - It is administered orally. The typical dosage is 160 mg once daily until disease progression or unacceptable toxicity occurs. Tablets should be swallowed whole with or without food"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_o7owhLoeX3ZEKWdGEWLlLSCS", "custom_id": "721_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "aabd453901b658e51986fd615e2b929f", "body": {"id": "chatcmpl-9St8HH2Q77OovSuNdfXziTmxWswK7", "object": "chat.completion", "created": 1716672141, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Tivdak (generic name: tisotumab vedotin) is a targeted therapy drug used in oncology. As a physician, you should be aware of several key aspects of Tivdak:\n\n1. **Indication**: Tivdak is approved for the treatment of recurrent or metastatic cervical cancer in adult patients with disease progression on or after chemotherapy.\n\n2. **Mechanism of Action**: Tivdak is an antibody-drug conjugate (ADC) that combines an anti-tissue factor (TF) monoclonal antibody with a microtubule-disrupting agent, monomethyl auristatin E (MMAE). It works by targeting tissue factor expressed on cancer cells, delivering the cytotoxic agent directly to these cells, which leads to cell cycle arrest and apoptosis.\n\n3. **Administration**: Tivdak is administered as an intravenous infusion. The recommended dose is 2 mg/kg, up to a maximum of 200 mg per infusion, given once every three weeks.\n\n4."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_pIFiYHGxu1YIfoIeIyCf3lEo", "custom_id": "722_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ce153b29ab729db8ea73107e07a6effb", "body": {"id": "chatcmpl-9St8HEWr5e5IfOSj64wUpul5WK9Xg", "object": "chat.completion", "created": 1716672141, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Somatuline Depot (lanreotide) is a long-acting somatostatin analog primarily used in the treatment of patients with acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NETs), and carcinoid syndrome. Here are some key points you should know about it:\n\n1. **Indications**:\n   - **Acromegaly**: Helps control growth hormone and insulin-like growth factor-1 (IGF-1) levels in patients for whom surgery or radiotherapy is not an option or effective.\n   - **GEP-NETs**: Used to manage symptoms and inhibit tumor progression.\n   - **Carcinoid Syndrome**: Controls the symptoms of flushing and diarrhea by inhibiting the release of serotonin and other vasoactive substances.\n\n2. **Mechanism of Action**:\n   - Lanreotide mimics the natural hormone somatostatin, inhibiting the secretion of several other hormones, including growth hormone"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_9UFjs7v9HTSzl5wANp1uqmEf", "custom_id": "723_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "b627c98bef880d38beb4e9475ff2c1af", "body": {"id": "chatcmpl-9St8HRdGCTVR9pa3GJnQ0ffmVEirB", "object": "chat.completion", "created": 1716672141, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my last update, \"Jeselhy\" doesn\u2019t correspond to any widely recognized medical term, medication, or concept. Here are steps you should take to verify and gather more information:\n\n1. **Verify the Name**: Double-check the spelling of \"Jeselhy.\" It could be a typographical error or a miscommunication.\n\n2. **Consult Medical Resources**: \n    - Look into recognized medical databases such as PubMed, UpToDate, or Medline.\n    - Refer to pharmaceutical compendiums like the Physicians\u2019 Desk Reference (PDR) or the British National Formulary (BNF).\n\n3. **Check FDA and EMA Listings**: Regulatory bodies such as the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) maintain up-to-date records of approved medications.\n\n4. **Local Formularies**: Some medications or treatments might be specific to certain regions or countries. Check local or national formularies and guidelines.\n\n5."}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_MIdI2VmnGsXYNt45Dm2j5RtV", "custom_id": "724_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ce67f5a3336664629697fe8b83a822be", "body": {"id": "chatcmpl-9St8HJl4o2RTRBKQkMnYTjLGClrzT", "object": "chat.completion", "created": 1716672141, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "It seems that \"Mostarina\" might be a typographical error or a misspelling, as there's no well-documented substance, medication, or medical condition known by that name in standard medical literature up to my last update in 2021. \n\nIf you can provide more context or confirm the correct term, I can offer more precise information. However, assuming it might be a misunderstanding, here are a few potential clarifications:\n\n1. **Medication/Drug:** If \"Mostarina\" refers to a specific medication, ensure that it is spelled correctly. It\u2019s possible that it might be a lesser-known or newly developed drug not widely documented in mainstream resources I have access to.\n\n2. **Medical Condition or Terminology:** It might be referring to a particular medical condition, medical term, or even a product name that hasn't reached widespread recognition or is specialized within a particular field or region.\n\n3. **Other Contexts:** It could be a brand name, a colloquial term, or a"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_fogHaAt3XL2FZQp1ZXuvsOvV", "custom_id": "725_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a3a82723a29aa1778e37fe4d48f0ad22", "body": {"id": "chatcmpl-9St8H7f6Ml0YsrGzEQosIsf9eiuSF", "object": "chat.completion", "created": 1716672141, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As of my knowledge cutoff date in October 2021, I'm not aware of any specific medication, treatment, or medical terminology by the name \"Vercite.\" It's possible that \"Vercite\" could be a typographical error, a very new or regionally specific drug, or something outside the scope of commonly recognized medications and treatments in the medical field up to that point.\n\nIf \"Vercite\" is a new medication or technology that was developed or became widely known after October 2021, you would need to refer to the latest medical literature, clinical guidelines, pharmaceutical databases, or contact the manufacturer for the most current and comprehensive information.\n\nIf you meant something else, such as an existing medication or medical term, please provide additional details or clarify the context, and I'll do my best to assist based on the information I have."}, "logprobs": null, "finish_reason": "stop"}], "usage": {"prompt_tokens": 41, "completion_tokens": 169, "total_tokens": 210}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_z0V2LbEq0NRIC5eRLwCU4Yic", "custom_id": "726_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "31b34e0e9f5760d2ae3d2ec46eba6b4f", "body": {"id": "chatcmpl-9St8IeZync5Z0ACsuuvaKsVKCMduB", "object": "chat.completion", "created": 1716672142, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Polivy (polatuzumab vedotin-piiq) is a monoclonal antibody-drug conjugate used in the treatment of certain types of lymphoma. As a physician, here are key points you should know:\n\n### Indications:\n1. **Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL):**\n   - Polivy is typically combined with other chemotherapeutic agents for adults who have previously been treated with at least two prior therapies but have not responded or have relapsed.\n\n### Mechanism of Action:\n2. **Targeting CD79b:**\n   - Polivy targets CD79b, a protein found on the surface of B-cells. Once the antibody binds to CD79b, the conjugated cytotoxic agent (monomethyl auristatin E, or MMAE) is internalized by the cell, leading to cell cycle arrest and apoptosis.\n\n### Administration:\n3. **Intravenous Infusion:**\n"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_8cVvUoFNWwGRn2nF9LlcOLF9", "custom_id": "727_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "a31b6599806163c189dedae2aec37a05", "body": {"id": "chatcmpl-9St8I7JENHprIcUWiqtCgl1NRMeq1", "object": "chat.completion", "created": 1716672142, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Elahere, also known by its generic name mirvetuximab soravtansine, is an antibody-drug conjugate (ADC) used in oncology. Here are some key points you should know as a physician:\n\n1. **Indication**:\n   - Elahere is designed to target and treat patients with ovarian cancer, specifically those with high folate receptor-alpha (FR\u03b1) expression, including epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.\n\n2. **Mechanism of Action**:\n   - It combines an anti-FR\u03b1 monoclonal antibody with a cytotoxic agent. The antibody specifically binds to the FR\u03b1 on the surface of cancer cells, allowing for targeted delivery of the cytotoxic agent, which is then internalized and released within the cancer cell to exert its anti-tumor effects.\n\n3. **Administration**:\n   - Elahere is typically administered as an intravenous infusion. The dosage and scheduling may vary based"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_qVdLSMzWfd5whffWM9Px7LAJ", "custom_id": "728_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f0f3ff6d32824bda1995c17ba030aaec", "body": {"id": "chatcmpl-9St8I9sGgiVxprJMtB4df47IqZFEE", "object": "chat.completion", "created": 1716672142, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Lunsumio is the brand name for mosunetuzumab, which is a promising therapeutic agent in the field of oncology. Here are key points for you as a physician:\n\n### 1. **Mechanism of Action**:\n   - Lunsumio is a bispecific T-cell engager (BiTE) antibody.\n   - It targets CD20 on B-cells and CD3 on T-cells, leading to the formation of a cytolytic synapse that results in T-cell directed killing of the B-cells.\n   \n### 2. **Indications**:\n   - It is primarily developed for the treatment of B-cell malignancies, particularly relapsed or refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).\n   - Before prescribing, check the specific indications approved by regulatory agencies like the FDA or EMA, as they may update based on new clinical trial data.\n\n### 3. **Administration**:\n   - L"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_flFesUyHg8KWqe9W4R2Iejr8", "custom_id": "729_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "314e6f8d4994cf3d91febfb5d0665fb2", "body": {"id": "chatcmpl-9St8Iud7xkty0tXhf7LaDzIQCJmOr", "object": "chat.completion", "created": 1716672142, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Adstiladrin, also known as nadofaragene firadenovec, is a gene therapy medication used in the treatment of certain types of non-muscle invasive bladder cancer (NMIBC). Here are some key points to know about Adstiladrin:\n\n1. **Indications**:\n   - Adstiladrin is primarily indicated for patients with high-grade, Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive, non-muscle invasive bladder cancer, specifically carcinoma in situ (CIS), with or without concomitant high-grade papillary tumors.\n\n2. **Mechanism of Action**:\n   - Adstiladrin is a gene therapy product that works by using a non-replicating (cannot reproduce) adenovirus vector to deliver the human interferon alfa-2b gene directly to the urothelial cells of the bladder.\n   - Once inside the cells, the virus expresses interferon alfa-2b, a protein that has direct anti-tum"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_GGKWrVpactcIkOYZpUF8OUmA", "custom_id": "730_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "ca630820c8af1483e23d8f659aed9720", "body": {"id": "chatcmpl-9St8IuBVtWRpL2DjhVGBX8Ub6cP7L", "object": "chat.completion", "created": 1716672142, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Rezlidhia\u2122 (olutasidenib) is a medication indicated for treating adult patients with relapsed or refractory acute myeloid leukemia (AML) that harbors a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. As a physician, it is important to consider the following key points about Rezlidhia:\n\n1. **Mechanism of Action**: Rezlidhia is an IDH1 enzyme inhibitor. Mutations in the IDH1 gene lead to abnormal enzyme activity that produces an oncometabolite, 2-hydroxyglutarate (2-HG), which contributes to the development and progression of AML. By inhibiting the mutant IDH1 enzyme, Rezlidhia reduces levels of 2-HG, promoting differentiation of leukemic cells and potentially leading to a clinical response.\n\n2. **Indications**: Rezlidhia is used specifically in patients whose AML has relapsed or is refractory (does"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 42, "completion_tokens": 200, "total_tokens": 242}, "system_fingerprint": "fp_43dfabdef1"}}, "error": null}
{"id": "batch_req_ZbUCy0s3ayE3HAwAVsXvlAtX", "custom_id": "731_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "f3fc4390da74b3a7fe984cd05ee1927c", "body": {"id": "chatcmpl-9St8IxHZRy3WRXaM9N1SVEuWEDp7V", "object": "chat.completion", "created": 1716672142, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "As a physician, it's important to gather comprehensive information about a patient named Irene to provide the best possible care. Here are several key areas you should consider:\n\n### 1. Medical History\n- **Chronic Conditions:** Does Irene have any chronic conditions such as hypertension, diabetes, asthma, or heart disease?\n- **Past Surgeries:** Has she had any surgeries or significant medical procedures in the past?\n- **Allergies:** Does she have any known allergies to medications, foods, or other substances?\n- **Family History:** Are there any hereditary conditions or diseases present in her family?\n\n### 2. Current Health Status\n- **Presenting Complaints:** What symptoms or issues brought Irene to seek medical attention?\n- **Medications:** Is she currently taking any prescription or over-the-counter medications? Include supplements and herbal remedies as well.\n- **Vital Signs:** Ensure her blood pressure, pulse, respiratory rate, temperature, and other basic vitals are recorded.\n\n### 3. Lifestyle"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 39, "completion_tokens": 200, "total_tokens": 239}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_N9Jgj86SW0LAh5dFnfh2ISMz", "custom_id": "732_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "fe9f3ff568502d91ce72595b3324c7b2", "body": {"id": "chatcmpl-9St8IW3rwX7cUjaH8b0pF5AErp0FO", "object": "chat.completion", "created": 1716672142, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "\"Bigonist\" doesn't seem to be a term widely recognized or used in medical terminology, pharmacology, or healthcare. If it's a specific medication, product, or term you have come across, there might be a typographical error, or it could be very niche or newly introduced.\n\nHowever, to assist you better, I would need additional context or clarification. Are you referring to a medication, a medical condition, a medical device, or something else? If it is indeed a new or specialized term, consulting the latest medical literature, drug databases, or professional guidelines would be advisable.\n\nIf you meant \"agonist\" or \"antagonist\" in a medical or pharmacological context:\n- An **agonist** is a substance that initiates a physiological response when combined with a receptor.\n- An **antagonist** blocks or dampens the action of the receptor's endogenous ligand or an agonist.\n\nFeel free to provide more details or correct the term, and I\u2019d be happy"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_erNjgawWe3hEK7yMCsVTanFl", "custom_id": "733_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "7407fa1f3c1ddc6db9cf1bf70f4bd2b4", "body": {"id": "chatcmpl-9St8I4JDzU6jq139NAsz76BSRmvYP", "object": "chat.completion", "created": 1716672142, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "Contego is a brand of protective clothing and equipment, particularly known in the context of healthcare and industrial safety. As a physician, here are several key points you might want to be aware of regarding Contego:\n\n1. **Protective Apparel**: Contego offers a range of protective apparel, including gowns, masks, gloves, and other personal protective equipment (PPE). This is particularly important in healthcare settings for infection control and ensuring the safety of both healthcare professionals and patients.\n\n2. **Quality and Standards**: Contego products are often designed to meet specific industry standards and regulations. Ensure that the PPE you use complies with the relevant health and safety standards, such as those set by OSHA, CDC, or equivalent bodies in your country.\n\n3. **Infection Control**: In the context of infectious disease management, using high-quality protective gear is crucial. Products from brands like Contego are designed to provide barriers against pathogens and reduce the risk of contamination.\n\n4. **Comfort and Usability"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 40, "completion_tokens": 200, "total_tokens": 240}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
{"id": "batch_req_Yccq66fobB5JxcugBprIqqi1", "custom_id": "734_sentiment_question_physician_1.0_gpt-4o", "response": {"status_code": 200, "request_id": "234de0e06e687ee7f00c742a41f0f708", "body": {"id": "chatcmpl-9St8I1TaEXMLn6yV9WsVntImUmm0W", "object": "chat.completion", "created": 1716672142, "model": "gpt-4o-2024-05-13", "choices": [{"index": 0, "message": {"role": "assistant", "content": "EBVallo, also known as Tabelecleucel, is a treatment for patients with Epstein-Barr virus (EBV)-positive post-transplant lymphoproliferative disorder (PTLD). If you are a physician treating or potentially treating patients with EBVallo, here are several key points you should be aware of:\n\n1. **Indication**: EBVallo is indicated for the treatment of patients with EBV-positive PTLD who have either failed treatment with rituximab or have no other available therapies. It is used particularly in the context of allogeneic hematopoietic cell transplant (HCT).\n\n2. **Mechanism of Action**: This therapy involves the infusion of allogeneic T-cells that have been specifically selected to target and kill EBV-infected cells. Essentially, it serves to bolster the patient's immune response against EBV.\n\n3. **Administration**: The drug is administered intravenously, and dosing schedules can vary based on individual patient"}, "logprobs": null, "finish_reason": "length"}], "usage": {"prompt_tokens": 41, "completion_tokens": 200, "total_tokens": 241}, "system_fingerprint": "fp_3196d36131"}}, "error": null}
